<SEC-DOCUMENT>0000200406-21-000008.txt : 20210222
<SEC-HEADER>0000200406-21-000008.hdr.sgml : 20210222
<ACCEPTANCE-DATETIME>20210222163614
ACCESSION NUMBER:		0000200406-21-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		134
CONFORMED PERIOD OF REPORT:	20210103
FILED AS OF DATE:		20210222
DATE AS OF CHANGE:		20210222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		21660851

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>jnj-20210103.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:339fd7d9-9316-40d7-9d71-ee9342a8b33f,g:975259c4-ea12-43d4-8326-a0d386e906b6,d:26b7b3066a4848f5be790a5478bde067--><html xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:jnj="http://www.jnj.com/20210103" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20210103</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl8yLTEtMS0xLTA_4374aeea-554a-4170-ba3e-5092aea088c9">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl80LTEtMS0xLTA_cf3d262b-1485-4d27-99e6-1bfb44e43a69">2020</ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl81LTEtMS0xLTA_ba56b40b-b8b5-4790-b6a0-13976d6dc99b">FY</ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl82LTEtMS0xLTA_3df08fe7-1a66-4a8e-85f2-1e1d1b2ebdd9">false</ix:nonNumeric><ix:nonNumeric contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92">us-gaap:OtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0">us-gaap:OtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20210103.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8686edd54dc143a7a78f18f215ac305a_I20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2614e18acbee45a8bd82ab8bb34954d5_I20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c4f2d96d955450db33852d746bfba34_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22df427a71c4e69b4499cded92f3f76_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e12ae720d2c4dc085eddd1250b291b7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba23fda59684540bdcab8d2c6182237_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced5cdc4242a49e886f089e2363899f7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c2da1e43f14fe88eac34709ef35e41_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i375dae870e264e26b914483f200eb437_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a614105f7d44e2eabdb115a8fef94dc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf4bf571e18643da8a5b4eb3bfc07a7d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d809f74ca674af2a83700b574ef976a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a37f3f6ee9a4fd68dc6ebb535681918_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2de20cab02a4cf8a8defc94d4572ad4_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876cc85cac534bcda664e8b8d9cf58fb_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402d9278fd56456f8c7a670066d1ed23_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36166563680d47089c116cbce4109090_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411749566b1e45288b6797e92e4b8e37_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe1daa397894e5683897624a288d022_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icafa9de0a8f744f78e2171c3ec5ff108_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f92b62ca0e43c1a522880b7018fd18_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib841bff089b9422dba63507cc4961d15_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15b04be239b4bcf895c4ac519a52aa5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ea54c1fcae41cc82257b51ac217450_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b56c73c08ba4d7bb733cf5b7825663e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6c299668f24a8ea824ffb03291a552_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0948aa56b8544fa694f8b50333d4293d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>jnj:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>jnj:Segment</xbrli:measure></xbrli:unit><xbrli:context id="id5e8e0ca2b9b40cea02f25844dc6143f_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9621bec2f144b689a1fbfe1403aab26_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c818b3558a442cb0ffe1bce102d1a8_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">jnj:AccountingStandardUpdate201616Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56111d6a08484b6890ddf01b41cb16b0_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i172e28d99e7b4636b5bf1e3bb60c3e46_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4144a962aa79467395df471e209ede69_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f65202ffa114849be9dfc3aac018eaf_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i935569cc407846b1bd173f1920d291d7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1869c744df4f4e608a0eb1004c3f4aad_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d4081a3bd840dda4560e78dc05b7a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie02722380d4b485fa4f666f9da3c34e9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f18dc2fc4564ff9a05dbd7fba040656_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0733c2434242ba85b6c5b1c835e725_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63df1bc915934ad68c8902ac19c99bea_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied72d4ba20b14d21b01fa2d79d0cd268_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a63cb5e2c94bd8bd2df799531d614b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01c9ba6bc554fc8a64421dc3895f2a7_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75354123f4c84b55824bc84448f6036b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-02</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf686c178a5b43e69308e5ab8e5a2e50_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b1533a3fb1425ea88cc6db6686d845_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia654d3afeed34b34bd201de560aa0413_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e549fb8c84644b1b63e3d2064d641fa_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a7dcc9839c446fbccecdf7ba191688_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9b5802937d4976b598a9ea0fe267bf_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8df9244611f44ff9e862d2f22238879_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ff8fd01ac0a487098147e064c5c7c90_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a342c6145547bd8226fe95c213f2a9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c02f63bfeba457680dc2981ea77c247_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcb9b3192c346bab96adcaf99402100_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i999eaa5539f8442a9db3d7527b669ae0_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68ca550e07c4272974f847b220b5bdf_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherReverseRepurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecdc5e97696145adacdd25f020821810_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45864798375349aa82cdbc0fe5b12467_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525d9deca0aa4aa69bea7606b12ab349_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7656b3ff8f34856acd3408e287ef6db_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1e598b00f94535a80aa29acebd3c1b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd47e6dfd734f18ab3b1175104da7ee_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc844a985e9b4ab8acde3269099a7e3a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf08feba35c44f18b96be74a96747f7_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0246814551b44afa8fc330cee4302c9e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd28da37730341bf89cc859b43e1ce8b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323d72d0abae4c60a66b9d7b0a4c7632_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83996bd19a7d44aa89d8fa3abc440044_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610e8d971e0146b5b0f50d10214d75f7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f9006a108d4ae79eef7c6e80d975ed_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6680195d23ef48f48b25fd080e30e045_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic991d846f0554fb3854353012c741e47_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af09372a20b4cf5bc9ca89867f6e9b5_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7611c63653fb4652b6fe6457c1f44f7d_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8619876835d463982674bc871e45ae9_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ecd7168647c48c487c55761ba2ced54_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e711fea4f3418abfe78e49bdbf2256_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c1789785ab45d596ef77f977c4b121_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ae3e960cac4c83aaf46f48e727ffc7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia50a679a6f554f4782e402d666b79722_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf138ab7f374295818f1906976dd6e3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9875f4baef3f4a1b948b6ce968e1cdc7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27f4f225aff44f999a6680657f1c61d3_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca6c05369c945429bb481abe32f8614_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504dd38a7aa842119593f0983c422c2d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8640053c6b9d41e7b51cfc21fdc35a76_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052b28db3f2e41379f8949dc73a4456c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b584b81e4314c05bff5a3a53f02afbf_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92ffcb6fd0b4017b7ebc21794532df0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a30ff6ddef34c879c3a48899c85fd4c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc985f689ed44a3b6b5c0680b59cb08_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50be13ffcdce471782b928e02e0ecb36_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca59ee60bd4461ea3d47a202e3a0c92_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d21b453745418380adcf639d9dcc50_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6f97ba35ec4096bcc04f4b4f8691c3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic742e9fd9fc14884addc84d349e1c28e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bbdc1a64aa24c13b6889b62805de83b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1283aa8aad894085a364e383b421263f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcdafeb6de434a389a8ae98d6c27bc71_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49eaaa02ae0e4bdd942caea69069c9bb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d2fc906c86432098158cb4b10ed6af_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8768d9bd65b14a88998cc98eb8b56b71_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15d6224b1442428383799310a443ccd9_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id484553bc7f246b2956d7fe4162e2291_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4cffd97e4a4b9db233400cb5173ef1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i685f5c13f8df4ef59a10c882dc33db9a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168477b06e674a54857ad32c9063d70d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7df8b1f03a5d46d788ea587e459c0d92_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c58bd90b6d4d01aab3aef88e24fda1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f6e10d334f47eb89761629c9a42e6b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c7fd78bae849e18766ff5f722b4347_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc23bedbeef4fe2934d4b69926edf66_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44491fa9fda4fc9977393ab1922d90e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c9442c717040c2b8f471f3da9878f2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5f27a8783b49c09ce94e0b992e4d45_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0ca0336ef04af5b1a42a37200ec54d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4c7294e0d1495194057b40b978d165_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SaleOfSubsidiaryGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57b73114f3ec4b0082e498dd41bb847e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SaleOfSubsidiaryGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2916bc780e044ef49bef1e4b70c3cc9d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244284a65da64e8d883b976f20dd4439_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015f5e90b1d24aed9b099ce1619e99d5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f6938e747b4a25bcc25eac3741af90_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7bfc44c870488c80c19b43b875f537_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ece5d5ae1a84367837c469a116bdbd3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c25167a6e4f4d47bddc86f00585a224_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e6ac332e264884b231e1297e1c4568_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28e5b7c3ed4439f84c2bbe32744fe70_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf0149aed5548e0a41ef000a1870d66_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02cda706e4b2470e94e004280758bd89_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce25e79e7eb4e0eb4f1dd38ac472371_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a5708acf3147969658a14d0f39da97_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f676139595e41d48aef38e5bcbdc8dc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9326c68bd8144507a8d7e36dc93e9005_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780693331f074588830546d5a4ad2799_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c325d4d8dab4b0685cdeb50ada0d1a9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aeb7bb33ec641c98e0fbde2d3d5c165_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90af2ee9b9b540bb99b3f8e6d629a8f5_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5608ee32b2f64df4a13f8ff444c9fbdf_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife02cb05cc8448539a1c0bccd6199532_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1c9065eff4473ca7a6e26469472db4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if79c9faf646345eb9c242f049ae1e0cc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a9d7cee0f342329e91428213de8f04_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i063b1e7203cc48a383a856f56f95ece2_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba78ecb5491f4fa1805dedb0bb402778_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4833811f03a34cdfbb1b8144a5e115c9_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i204902ff089e4411bef7c51531f107d1_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150752b44d724b06a4b96ffabd4ea8b6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522cea24f1ca42868d485da848eb40cd_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795080089d5f41458b16a91c2923e0c6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0afabd84326c4799b8b58c05bbc630b4_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d258167afb64a19982ff42e1d05bda3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d8d4d3851f43118320077adb8a55de_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6149e03b1a45c9a528cbe475bb4465_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239971f81b48484183a8b472b82f6ded_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Debenturesdue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643d86e5fb4949bc9b0b38833626e8a6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Debenturesdue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.950Notesdue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2855ce1111214d85ade50a6ccac8a618_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.950Notesdue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926e8b4151584d75bb453778eff5a51c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic351de96f94f4e9b8747f6446b843a4d_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3d81e50f874f138a3912b40b201c41_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib933e5916e15417a8a48a5669ccf5321_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a873dff1d3141a19512b0affe1fe2d8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8212ea597cf4a84b23cd83df34ea924_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2f7d24c9474d8c9cc4823797b8c083_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="if6ee752114044428a8c20fe4f7ecb273_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbe0979c7a14dc9b9f12e17af387027_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96bfafa6c5fb4ce3ae20923ddd529bae_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f807d1cada4781ae10198fe16e1c99_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95c57f111c64126bccc2fc3a980ce5a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a1b55a0d51409e9832bdbc47868c84_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a181a42de50462faa774006c9104b58_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2acd1bef02c94effbce52af8c909bec3_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id431690b092746cda0e3885506938117_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb932f4d85de447b95ac9a2f2540bd06_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd739e0b217d43fca3ef7ba9585172e8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i0369e6fc3c194082a81d79013d49d056_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8bc6079d92403ca3c4b99e75498b57_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c8d7bc47a734d679cb8e0230bf39855_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c683153e4274793b8e2b845aee7dc3b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fde6f193e0450fb608feb62094bab4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c696c925d1472b90cf70120a0702ca_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c169ee681eb41d4b70cf224042a918b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i468ec06486014ee2bd6f5c7a72949cf0_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92f79edb6394aabb7c66d1f0ceb9c1f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9f0124227242a3b37ef08fc5f78862_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e4daae8acd4186854161164075f779_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5d476254ef41008aa89433dcace0d4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035991005b3545fdb445908803f01423_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541337b24d2444a8bf14a78c6ec932fd_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d84507c060443eb3ceeb3ff733f151_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbbe327f106f448cbd073f1bca885cb8_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a322bcc2a514a30b7e05707bfb38724_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a4cd9bc3a54ec4a968860df1b0f6ba_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ba9d57b541417083a57e7550184805_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5584716e0e79483b8e1d3828aaab1e0f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1965776d766f4468bd93699590f0d845_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff628b0cf02144cd91a4abcc5053f028_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id83a16eac5254d0f8a32fb0408fb7209_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f4662ff9134017a1f5f7444f314e31_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63438abe9f0244469fd820794902d862_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49d24552bc346e1b4e0dab3a0e924b4_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1673c8394c4e3f872d187343339109_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf9a86caabd4562bffba6ff39983416_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df454f0c44e460bab62d61a065354d2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac8457d7f3f412bbba5cd8890c8ad72_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f46beeeb544a6f91f38d5f362744ee_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf5cf036d354852b5eaf7f1a747632f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f58bd4d50d4e84946db893d8650ed6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782bc6f740614734a43da12dce22161b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b804bc029e642feb0493dd3906a185b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b581805ecd4967a8646eaf60bca900_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d754e14799477284511704f83b8d17_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7255430870174b0fa0d8627f1ec59a3d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id568183bd7d541139e4919632134334d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f619870e5ab42bb830254e1a5d06b99_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fff5e1fbc7546c895f24337e28ccd11_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief45c201a3b243caa69c0e0f161b2ae4_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b7693bcded4747a5ab760537912c2a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd125a14e0d4e7a876c8945f58e61f6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f33f574f1a41b9bf5677aefeaf760f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39181f4c3aa24aaa9646a538d7f62e4d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8df475fa9c4c4aa829c65373e7b7fa_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f8e23ceca94494b1b3b111eed8dbd5_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72aeae00e1604bf385505263726995cb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76fe11f963ad43deb7bbe15f647ec9ff_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53872a4a35184b378900cbaf5b99200c_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4bb2eed805a40d391fb647db58d1d62_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6108907f204089b3f9838308be8b28_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a277a5e8eb4225adece7896cfdfc52_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4d55843ee04cc9ba52c8e2dc31eb16_D20181001-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="ifa0d22acfd9043efb1e18804222572bf_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9258c8a9684b738ee2e0f0983bd1f5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500668a00ec14570b9277e4c2dbae643_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5f3419f6044ef6a113250635e22bb7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b62f1bb84444e928443e80402f47547_D20200928-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-28</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db67b67955942f7a04d431f570d4565_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i172efe01b0cb4ab689fa0a795f2f907b_D20191001-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74cbe1f433b42e09645c83a947740b1_D20191201-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b21ae117b34c4292baffe418a58981_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">jnj:AccruedTaxesOnIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59f96e940f074bfc8bca8dd0210f851c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08825d6475b4031a35401d638705874_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d76953cd864599b2189d147891aa04_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c88bca24e1a49eab2160ca290e744e6_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if190893c65874208b238876e963fff03_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2330bd0434aa4310950363941b7c32db_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e21ca84a744ed29c5bf847342b7b89_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac551cea27e04d75bcc80f2411447fe0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">jnj:LumpSumDistributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8258eb0443384fc2aa7fb34a0f018511_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d1b0ae517840b7b04db12cfe06d2d6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b800eebfb2649a48e2c884cbf2aef11_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4266eb19a3a8489d8e8e570a500b29bc_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0e471c9e784988af7c2e3bdc2668b0_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3606c1fcfe894326ac67e462f7a3db34_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440d37782d3643f88c50da17d6fc2677_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia14aa1f13b66432c8bc417c76885faf9_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica8f24a050764bfba17b5c0beb8b5068_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68a6a311dd74eff8cdd501535848300_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66bdef9c25ea4e9abf91f84961d6aaf4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f4166c654a437a80123fea9e702f7e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39331ef41a6c42108162921682abc122_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10391e82429e4bf5a59079e301f6c6f6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3d442963634e13878545dad90c5606_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75eebb92b9ee407fa174719e6be87d9d_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c809f170b8d4ab7b2aa8e2af5723d0b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e0df4d18d894d27a4ace305330ff2c6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ec1578bd1a4fb1a4e201e6ba58cf2a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ee1b6e5291404bbc84039bc844c771_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4507a38bcbb4237894ed814ce9f93c2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2d58bc21d745699a63ffa711ad4c20_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c4e1c7cb22424181b106e85e819494_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90ab3ae11824ef9a9e63764ee396732_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcce09e193042308b79539a19454bc8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9090828474432593946d7091132f13_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4299477497a4436cad8f8ed08555cd49_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4bfd5fd8a4849b08c174538fbba64c1_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c53d1325b34f4cabf72ed3d2c9c03d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792325894abd4ffe872badf07315f357_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129ebaefb7b84569bc06b0cae2c77b85_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd3c76e5ce3480aaebe23360e85c8ac_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d096bcce1824a9594a39c9fdd09e08f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aa0b93fc2a44d95a845a5651a1abf3b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31684a1d9e3b497ea871cfece2687bfc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9148ad612a4a91a72c08004fdadc69_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88fb975b18b476f96a36b211ef744e7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa06dbe41e44403b1a57fde488fefa8_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ddca0f50e34485b4dbb719c9499ef6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3cb8cc1c9747babbcb69806e0246a4_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id51e2ec82259464f841cca599e785a2e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89bcea9069d449e6ade65209250939b1_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23da6adc713141f9a30805360f7fddc7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d030f2dc9714f1788798bfe39569d3f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44bbde50ab9441daec4c3cb7a16c7af_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5322cca6ec4b4e3fb447427aa4149354_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37baf89ebe664ce9a576dfea58d33bad_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e4a4cd8db9740f0a035240c81e02b17_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5156dbac2b5f45c38108ef2f637be5bf_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577b94e8b1be4e33aaccad68c1cf0d03_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e156cdf11044ea928c031c1ffa9fea_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3e8fa9abf349568477263c121e67cf_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e3d41233d3a49058c7ac617acee9369_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a8d5729f306476ab77201ea6d9d8c04_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02729f04daa74ab2afec896f6fe109e9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4375b4a40664031a6ba86d8ee14c478_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb5c8f0e0ef4681aa83c7d913234f1d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5af3e730484e88ae6a67a735660d62_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i861c44bcd9c04b65b80d256358edd695_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f1ea39b2a44d56b0c8c041d1b61bb8_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc243eb836834e7d8a931154b37942d5_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d30b90acd1242b6b7de07bbdc790c8a_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd6e5e08fde46adb34424998ed53252_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedb3aa745dd4b3ab1c320496d1ab20d_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia667826001184093afc78dfa8bbb419e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c067a1e923463bb25fd0faec7b3968_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9677b9c0aeab4d24bd7207a87355007d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad01912a4ccb42d5a3b1813a29d85078_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i032051d81b034bd089a0507d7eab7351_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9998429b4b654051adfe886dcefa9de9_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa343551b56f48118e1cb1327fb01697_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia709adb3e87945729cd80574e236e7fe_D20210104-20210104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4380bdb86b74638b9120d6db37d52c0_I20181217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id395e3d2f83144c69ca528af2dc9b6b9_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3c455ecfae4ed6aaebdcec05ae3f52_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25282ad7400d4720a2625e8c3bac6273_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e1cb44199148b9aa8fa2e71f1bd6fb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170982da0e98496f80e2110280b52dd7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77626f7a811485e9b149e03c04b3bd1_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a59d85f18543f8b4ace4dea662cfa2_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7956e74acd5f4f6eb52053c38a41f6d9_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1cd916919904201816ef7744955d602_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a838ddab52405f87db30392fc1ced1_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3e6d6e46264f57aae311381d35d955_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3159628ceb74cfd97a53e02385491b7_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1231b2bbed144c9cba72d9e67e5e0304_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79859b6ecac341359999ab29de172592_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia018521bd0ef4419b522652ba45df3d9_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa6936a6df91437db1d3e64cf273812d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918db4b812b9414ba016263b04a7d008_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief95ad78a93d49fca32ddc64ec71496f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58dcb82268e44ae810d6cde038d160c_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636f1ba05c0d4343b8591ecc77c0e529_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa8c9dffee24a899b4b02e4b15e6f89_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28de37f2cd304efdb2a7bf164f22a948_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i192924f6280a4a68a046814fc0e0b7bb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7657b728884a46e2884084e7b77c4751_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6214de92714d768bcf627b37e0f72a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9f99d7635c4de3afb7d08a8b3b2d0b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ee948f3520495892dc498991ccc81e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8cf02c8e230424b92126e9143e4345f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c7380a52f94930a5e9728def85437b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stockbasedcompensationplans"><xbrli:measure>jnj:StockBasedCompensationPlans</xbrli:measure></xbrli:unit><xbrli:context id="if4d4da45e8664cf1b3b70e33caab8fd4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2012LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d20904ce51e457ba8a1053c58ed10cc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a57f6eb476464d869fe8e58ec3baa5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c4d02cb4644dbca38c88e2ebb556f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884a27a100b944dcb86bd6ea0016fcba_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id34d6ae79d964454a653e9d51a996c98_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035510af86094fac8176e7f17a5a8164_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2305bec7da4f2a82adbb34c65352b3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447115cb0801497ab64877cc7d65202a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c11a139c5264dc098f209197b9366c2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0884d95fb894f82b5b100cc5798017f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78cd4383ab4a489fbbc505c984d58d74_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5338fd4c73a4d98b5d7d7df1d88f226_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1dee2245d414b138d2f2fa014b0a178_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7b2cf13619f4c189b475866e1db542f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied04bdd122824628b347ab436e1bf569_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f365b4e320847d7ad7af8be0962aad8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d56204d812a44748666c659338087eb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c52ecff45c14b9dbccf4b05efc03a3b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912305c8e84a4cd9a5729ccf10a90c3c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67cc38656e54ec4aadccc96b338ed7a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff3ec8dc893a4eb08f4f039c8952b873_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa9e713b2ec41e4a8d7f2f7015848f6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc37409a7004e809321a0b83f5b2e71_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde892975c2e4c43ae1fcd0e5d45005b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie098a08a654f4b7abe7993bfd4dd32c9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce7db841b704ce795266988602b87c6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56177ea4bd8e4146934538847bd76f90_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieebab203f30b40578e7a8a359fececa9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95fe395206684a69945b7b9c3f58e7e1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7cfb00a6c644b59badb04917cfe1258_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ae8ca1fdaf4dcc9a7ead012204e832_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7516b2a14b4fda940e11d40fdca6e7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21511c0be4db4f3891671c0f6c6ffd18_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335dae4d42e84c4581347d01955f1f64_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d65234cd7741f08e1b93c317fe4a5b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe8305d0fc64ff09895323053e4ffbe_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb778fa0cfd41c8a12511fe0a1f1029_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012e56c28db14f779936dee4f0663505_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec92ca19a30a48309e6628e2a8f20244_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe650b19559486c93d86c150a95b5ca_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4646db66c32408f83925e7b65de220c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9072109358d34bb0a33a9db443472e65_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b6c87bbb9946978d28461a1b99eaa0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6e6a50ba9c4b93a9bd88ec99d6a9bc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57621c82e86e424b9525ef5322132b41_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e07924ec664fd1b4eb1488d27b17d4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7eb56f6db9146e38c34652e1c29f3dc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23b6b4d466040ba9303881a85c0d1d2_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i662e2ae6c2c34af690533b7c98d16d8e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488340eb739640078006e1dee0f62873_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcea6cb52caa4862915d6b02fc027560_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied78bd048a694419a8427933eb72392d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia923300cfa5443f39393219ed3df8cdd_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3ec188dee44471a3d0ba8180228043_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e9fbcfc879430f9d122a98d64707af_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51dc84cfa7aa490eb43a1cfcc7ac6f30_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d533f088e0440e2bc56ad8a637e2e38_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ffd4f096a224e07ae928cca78b4e4de_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197bed260bce4946b5a7231cfb1df3e1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dcce34e3ebf45f9b3244f8aaa0a8d20_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdebc3f23b09469baf4a9f0122afae32_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic95fcb4fef954b5e9b3114fc3c6f5020_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93c39893598471497b999c626c42a07_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56eebb67df6466bba36905010e95c70_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32de10a72684de19ff4530b736045dc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b58fa445b5470b9212749daa49e050_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0989699ff14a4823884100556badfa4b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d0b10d0987c4ff38ea6459bb35a337e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320d43febbce4eddbc6e86db0f7fce60_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3fb35c032c54830a66c354d7509fe47_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i876f6ed6ca05447f944d86570700a552_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ef4da3b3054496b33a2ca8733dfd24_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic988bc0a70d740549dadd5223afb168b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64253834ef464806b4d069ddf4d2ae7a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifead9540ae7f43f58eb9a61955b1d421_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2664b750a04838a23a12a422f46697_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4510201ad6a4fa8ba547b237e08d2f8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3809d28608ca4587b38a7d272fdddddc_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2c0df1a61b4fe2bb9af795b4098c17_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42535da45d984ed0b3ea9894283dbfa7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b952caaff249198b1de2498f27980a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c315b2e311c4bdc9634124f9332a881_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48a1be8bc394fc2b9d27103df366fbc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db261aaf98a40ec9d2a8dbdfabd4470_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe1aec193de4494a45e355fad84fd94_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced43ae2faee49b38a0995fdb81c4dae_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07758926e90e4b6ebb241ff19ec7dcca_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b14c2f869194b079873a9e2c3b0cc33_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d10d30f5cfa4f7689179597fd83e3ac_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127b9a85fc754e41875443a867bbe47e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b648e70887e488790cb76dab030b994_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51bac2c9dccf4fe79c0fd65dddb23723_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e66708363b54eb9a30dfcadae1d4bd6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcfd365c13594c388391dd8f606395b5_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6da3163227146f5a9725847bbe4a1d1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb09a7505de4bd1a2c402a208aac239_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f44c413e1f9461792dfc16bf4623c21_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3251c22f0d45b1b9ae5fc83e739d53_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed07a99d5b24e6d8dcde45e5daee9e3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f408e57c734f30b9827c8e291b4e68_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f89457e4444472bd89ce7240eec506_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7c7407d5d84d95a2baef6467281a84_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9049be4d27b48c5aff8d7cd9e980032_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc10c7bf0c354fa5b52dd6cef5049396_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fe65e2feac4ae6b2120d1875a0c1e5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09afe5f0a47482c83a41681a20ed1b9_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345326e0d32b44a6962d5d2da892271d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab9d0b991fd48e991a9b96176c324f5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d52b0dee934b1dad3311f32a844f83_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5fff7db08d4f9abfb174cf4e10a6cb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e5ec630f144fc3acae22bf27085f20_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6da60607b34facb3254a559f43916c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd5a91ab72b4e1d9097ac42c6567a0f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic445948a0ea54f98984b624b677ef57e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7ef583b64341d883f7c307897087cb_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936effeb3bdc459188220839b3a07583_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib164d78d863f45e2ae7113fb61a9029e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747d55ed9e11415197a12256dc54b0fb_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6062ff1a7594fa99d8bd54ce25f0d81_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aba33fa79c1416ea6970ea33209f4f8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1621cb45fd410eb6148886adccb29b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc79dde7b9524c7f9528487acaeaba31_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5504fd9e30f44cb48669bb12f3abdcad_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28cf791d4a541b0a7be48bee043f2c4_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3139e2031ad04133bd86df70cf5dc7b7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470e0543cb694cf698d82d768b3a393e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i502d99b70ee24908ab08e5b1a1fdc9bd_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c30844e0e04bf3aa64c9175c1c7fd1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79af5256cde94f5aae78e06c7053dbeb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9482dc808d3497f92fd904dae9e95e3_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54eccf3ae4f74a0f8fc42744cab78245_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d2b9d9ef2047b0803fd7f801a13e03_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3a43e0744bb4641978b43faa639422b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1493568c9a874d0bbfd3ede747e68727_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd29791072a4593acd00300786ece30_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6670255be7144d1f852e46cf45edb2ba_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619ec00350b745b6b707b0e00977199e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47f23d17ed74b6f9a95492b23352e5a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05672cc4fbf64dc388663c69c856b524_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91f997ab1f24f23bfd12aaf2ab15614_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f840440eb34b388c74e913d8269476_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a18540e4d94bd3921e7a8dd91fca8b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac494f4524344162be998345479e44c2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2133c409ef74fbcaaabe46d16259131_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86abae86ef304b71abd0e05f56a5cb4f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43234804dddb4e39b7ddee85e821a967_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792f702c2cc44d72a6685098df435cdf_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8e69a00b4a46d4b0026d4c0d0d12de_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea4daf92846476fa2993fbc2006ccc7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61c6e895ab34051980667f5cc645e57_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c7d4e5567e41369256434e8aab708e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2acee81d0547e1ab6097e1c5779efd_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89005b4edd5a4426abae3cd99c1ad3a9_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053973bac1e74eac9056a73ee8e0369c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a61d75aede14dbca7feee7ab7b14409_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6b727d130644bdaf9d3ee590ee2f85_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34651815cdaa41f5b30e1ebcb72f67bb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1714fea951a94bd59565d02ea54e3b38_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a27ed8f9954257a933b0c854a14620_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac15d6fdeece4cdfbacf8aacc9f73307_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdb3211b66440c2ba0dbb80ae7f58f1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23709666fd9b4b9ea264d620b5bd8e15_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32432ddae9e74ae1b271e486737b86ad_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29524c4a77594647acc6c76fcbbccde1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54edbd81015f4d71a9b2afba7cffb29d_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26701d71b41f4a00aa3ced442e39d1c3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i303f017761124c748caf83e92d8e5137_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4839bf6f46b740e2a03b47f4d2738e9c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d32e636144642afa7ef1549b0cf2c03_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238de9e4da3a4b15afbad05973803e62_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8cfd3aae4874e2e8686d594c717025a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddad0db124bf452ea8a03f1654bb68d0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a3c9526e9e4662b7dccc6799311ad5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb90c3f230e4c8cb8dfa5a94e4ea0bb_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9403e2d2a34f59a27b604645f5a91d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3be6ab9e8a4959a3c7edc4d122dd2a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d9238b55644986a871929c8502d84b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08fa1ac964d47feb93b93f96ba831b1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d5fd3838e84f57b29637bc91f05499_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a23ffdae8ac4614968f16731be20d0f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d55cd1871b4849bb0d4d5789fc18e6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie88eb0578dc746d18d2bb2f4b766788b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0226112bc194a59900da0f717036e7a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16e7d880f794b4aa0ad45508b813488_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ba901333db44aaa2a276635feab345_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee2c3fb12d0480198cb47af51655b5b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abe4268a675407693e053bf7336a72b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb60330c47204e6486cc5262ed47484a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d84ff4a4b754e97a7cb601b7d5a4e6f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd8d74955bb460f8122175f5d6f0469_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3213efec3984b9a8c8df8f59eb63243_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92945871d6174c00bc9287c3ee66e791_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cb446a20b54dcfba5a0fc4233773e0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40dfc72b0ea04eeb97d07f73f58eecfd_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7377bec258e8441f845958db2721e43c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd129f2ac9974218ab05c39a71c03771_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e6af2ed39540228df21c0af815adb7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa6602c894b48bd8d6bcf1d385cdcc3_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a95f7ec983548d2a4b1be09dfe6dd14_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1505070ebd0a4498bb3eeb1d51183e8e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f887aa0bba464abdb150467246ac4f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a84d7d93ab64403bd293f1a7184f6bc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a0ba12fbda4d738d5db9238ec568dc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic414aca1c42548929deb4e53de7bf3fa_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f98810d8ec641999cf2687e6554daf7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc700d3856a47738103c578a87aca74_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72eb6604597248ad85fbd375da229add_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8cbbdb69ff4501b7d58fe605645a1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133aa20f96a643e3b9e5df71d2e8af4a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if209e8c87c5644aa8818bd0b6c6673ef_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e40cab631864801a237de46454322e6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8464c5bb4509404b8a2d4bbd9ed47d3f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06797700580c400c90f77631adc320b5_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a9d490e235496da2b346ee89bee21c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abddda703554fc8b7f0eeca2b43a200_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc276f6c9ac42e59b93c2d91c1fcde5_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eba5e2c532643d08b0d85206ddd448e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f37e7a407b4bb69c2edc826b1ad2a2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f07175381b54765913104497ed4a90c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc4b8397c4a4a5cbfc5afa71d671450_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60171dccd6404eaea5b723a79f5333f9_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b03ca0cca94b2cb6387dde26985c9b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620149fef35a4c07ac902b4826767002_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f669e13dedf4bf9a965e8c1a83400fe_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0849b4ea29674dd19f07a50c794a4b02_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb490cfe0bd149a286b03d9b16aaaced_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0514ef242a54da29c4d98a28258a7cb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed2d208b49b42d38d66bbe62caee7f9_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b7b2600f594a5aa2fadc8cc7f71802_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2576e6aa19bd4f7589777471e9b72143_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fdf8bb361f4fd9b717cad18dd32d62_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca3908b695440b9ab57b7d0a7c3e94f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfeb443990294b3cb5921c60bcfb0110_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6107835bbd64528a0c3d22e0a42de81_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8abdb9b05d4466a2318541bcbf74e9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f9fc36595b449aba78e7d403ab30aec_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3d8d5864694a0abc113e067abc2c41_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9dc42aaeba4a198434d55e6de7ff96_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc5bbc6288e430fa5c2521af7bb0b05_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b895b26e49b4635b42b1536f531c608_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2ebeab6f904ed1960851a888d27083_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9626d02b2b410c86ebc7380f6c4249_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383e3f60f86e4defb334fbc762820aa0_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6453b112716e4400bade7786533a87c5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id571d247cd4b4ca39d865b8901589cdc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e3e0394dd94e10b095ea1364ee1671_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10bb37e48c164c179f00b0da6b6266a0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic913c3a623e0461ba7fbea0de051f46d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9a2cb546bc494abb88fa69230744b1_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb7775a898b4aad918975b899e54d3c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31ddfb9acb84d7bbecc428a4394ceac_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie383e52a0d0e485d99e09377f32f2729_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43b359b238e4d539c59daf943bf60eb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d21d69338a48978058495fdba87e9e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13a02795b0645bda0393c88f521bbdc_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7c35cec2bc467f8499200ba6d32b5e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16e7c1fa21d4e23b5881fbdc5d62704_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f31422d2f4045b2b2c516a07d33107a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0dd0eac24f4401fb171f8f4befd046e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c99618e8464f48b02c5800078fec9a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic411305d926f4262891fb8f8d32340ac_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf10274f9c344290a2ab99e9e34ae3e4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3de8d88c34794c23bebd5f7b5eeb5a8b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if49c3568a0f94b3889385d83ac006905_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf70cb300d841aebfe5a712007444ac_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab5a5f92fd941b288007441e9cc4cce_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70838a32f63643e4a2f7ed13d212a9f0_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e56b017393d48d9951e1963e9232f4e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec0b61f3e194449b1fc8232df6eb583_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485ad9e4c9034407b529d2ddbbea2b28_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i068cc5432b3443beb8e11bb255e1e28a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief79aa5fc89943f1856174ad8ab48c03_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6b259e70b34438a3f81e5332f8a6c9_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc3d26ae55e4532b24a34603fb51a5b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1612d385f0492da9095801326473f3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5d890f9dec439ba519c396e28a1b15_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3432837e0994dea9738f6a9041dfb78_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5720d7e06a47ec9ae85f4a20867f7d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fce5a20ed35426db5a791a058567b31_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc0f82712f04ab1abd4713c5eb8122f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4837e00061842c3848e83dc581c7c9a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8fc9994e3f4e679de95304641d1e6d_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee955b2a5ebc4440b0275a07f42d7859_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e5bca473514621971e568c7c81f9d7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b32854703604f20a5087fc9da993d60_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0bb8ef73842461881c87d256616bb58_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f138d8eba8c4b139d79c8bdf04273e7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513474c437a54da8bdb8d39a5690e05c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d33d060c4c47bd8ac7257d692df0ce_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7524e3946646b9b75238c6c4fda704_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if800a3c44fd14c1c8c9443c13229ce64_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc918ea034249e7a645f7ddf9922377_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9ad324b0e34c5b871ca5b7f591fc74_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d4dc4f88674bb784396e7150b232c5_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b475ddaf2045f5b7e3e9c0ab7ddbc3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78a58229b38848a6acee4aa1ee9a792a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3b9a020380440b8fe140b751c16e56_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f49a3f10784cb980bc81b0bf707db4_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if409308149024b7ebf44549391b1ef28_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48809d31e15f48cab0409d4e65adf936_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e587520c5424f6895bb82d180fcead7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a298df88a04792b4eb06c9649f9c9a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5ccb426ed040e884937136da490957_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd627d84f8348118b3790e6522ee21e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1196be4a434582a11b0f92c5c054ae_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c65c2e67bfc45cab7bd25c746b42db7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee23e589317a442cbea6d9b4f7f79caf_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5255e36acbac418e85f849dfbdf10496_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c2543a19ee466493df5660744c8c1a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc4a076e7284a2eaa4ae25d6f7d0578_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24218d83d9274436ab41302d751e3b17_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a92101e57d4ab0a5d2910e3c72d8ae_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b895fbb6804c319ca67eaf7a7749c6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5474c52ea0d4a31a03b189d9522cbc0_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eeed4adf30e4bca9bfe818ab7159933_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b55966cf5b64f81b16f40f0103bd79b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72ebb598f0348479991c9709cd38a02_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f3afdb891c54b018f5398d3af12ce2f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2964812dbd3b44c7a03684da9a06461c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486c300ff24f47f0986efe5804106361_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e672c1ca294c19899b6194a13b72cb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af8e2c89c584232828bbabcac9bc95e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5402a284a5544b0ae6e3a3a7f7b8b18_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d83c054ebbe4b55956a90c090dbf071_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09262051be5d4a8fb49e116b991a4eed_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c5ed77ca06492184b99ba7d305dde6_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6485f71b8341e9811ab2c75108f37f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14a2e2d4cb5a408b9c5fd9d323011fd3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35c63055c2f4e329572b6eda58a7637_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879becad18bd4e95871ce662ed38c9d1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id562b8bf54bb4dafba5e39bc08e96ecc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b7a0d4e280466f99120313fab3572a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if63d4391de1046ffba12c5e6301213cb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07304354d8544a92ba72a5cd3e890ebd_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8ba09528eb4bb28bf8fb46d9ca244b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480f6951d5234710acb15ef442ff46aa_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aeca666b4bc4fc8b825d67bbe516983_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d23b54b71714d9ca21c6e5e0c22bd74_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165535e13a5d4c17953e1ceaeaf9a636_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91cabadcdb3c4f10bc97956908c95e3f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e918889cc434945be946be6a986c17b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9783c1f9b69e46c8847fdb36caed3e61_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abe8487be1443f188c6f578a79c2d92_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341822625ecb4b4789deb017f8eacc8a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8b3fbd369743afa2505d9b81d9cd9e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia244f37fb23c45d2a6cd8570deccad0c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ed9b3951644e8abc03bd12c9e6b297_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adfcd1c9908434da345ec1cdc576590_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib343bfa6ba954633998789b6a1a44c3c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ec7eee76274b6493178830f9f7d290_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b1e5791e5f4ac6950916274d1a1a6f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c7c3bbbd614afca59c1426a0da0a51_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id53466858e60466d81703523ed53029d_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84e7f7d93694ba9afaee8823f713cb8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8899b6c537174b6bbb5cde0f33fd376b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf39fa1409e84c67a5e97a853263bb6c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98aeab42d1474d458315de624b42191b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f4bd5c13cb4fba9645bb22fcc6521b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3c1d6bec994f689672b19d7ecd0241_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17584700f12d46519383938af1d81aaa_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118e59fd747d42de9edbb08a4f24b0ba_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6189787c7fe14e36bbdd2e76d9f9f4c3_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94060b92688f449b9834a0a900890956_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be240152e5849b4b1feb9af434e0747_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7c8be14d314237b657ffc8dd65696f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73286ade02445b5a9462beaac74a9d3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f577a1a44334d43acea15693cd75f1f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab38ca802ca4be19e8b830de0bd397f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf88388476f7405085cc966583cf4258_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c66119908c84aaba2703e6fe5ffeedc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ccda52b00f47bcb73709353baeb316_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8d35a5e5ef4407bffb29a594a0b67a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef4d0b58d4549e9bdb73412623a21cc_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:DiabetesCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602f30549c0b40dca5fd1936741a49ad_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c25e6b99024ef091459862efb9cccb_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e4feada2044b02b8313b9e00c0baf3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84231515127f477eb578427ea2f07294_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83acb0fa39e4ec5b03d0835e324823a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60adb8fb0924a0ea419ad5f553698f5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d5ffdf03b74d129cfd23b12757518e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf12e303cd9b4f9fb10ed1589f36e8b6_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24fa043dc87454ea84b0044287fcaeb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4adf09a8d993410584b7b18acfb4bcbb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i126f946d4eff41e79ab7d3a7a64eecee_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3840b8b2b071410383b4675e805cf313_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438f65df2ab74a928e7eeb7a53d02ffc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd684566d004f179917d4aa4d8f8074_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia90b9c38b8ba47e296c57ea9b6458d43_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87926cc32eaa46ecad04830aafda7bb2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03ba8d91f4e4f95a4fdce30f489c09f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144f5567202f48639bb4c9aa1ae3ae2a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d98497323f94faeae1879738e0122bf_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2a5de64df24728adc2bf05ed12b93b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4513084142340079843a021ce48dc83_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15cbbc611c14b21845dc1db3b286330_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a7fdaef25374c44aa45e900e5e25eaa_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff8717040d04c1fa009b692e8390c77_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78e09ea97bc419d9c3c1d2ecfb21982_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib09b4f177eec41fc949ba626af3d336b_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984713bea368485d96053638749455fe_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e007c86e9f4211a41a7172c74f9c4f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b60c868bb3c4036ae62855e7e30207f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70fc17a765d04f8ca815d5ff108cec48_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabedf0861be54d2fbcb151e97d5f1c7d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie905100914424975b112e4f3270118ce_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5092dd6970434ce3ac47038270cde937_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6813483c57994daeb367d9fe1563ce78_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ef9ca58c57427da68fbca6011ad745_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc9621c078648dcbf56a98adff1c4c4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f6dafdf0c741be8ac3cdeab113c489_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93a7c1c81884a3db1790c74e2bef12c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04eb94163afc4fbe93b4ab697abbfae9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902ee0627dea4cd5bb60dc3491346db1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2fbad72def446b993089efac46d5a8_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf163dd98ff4ed8968cab176f2563bb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4892515aa44a64a0209fc1e0bb2fad_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37215466423046af9249e8abed9ad02e_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3906b91aa1a748e0a8a00991d75431d0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4d058982654390a2a9623f748a295e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i026871ca845542edba6aa179e4c87502_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95433015053341168b9d624012babd6b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf587116ba149d5bcba993340189069_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fd6b74d14444536bdddf7ba271c1cc6_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d6c4422d1d40f684a09913056b9472_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a281af66cf04b96ba6e7ac36ebeaebf_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0196237488ef4eceb6b0ea1bd91e0dbb_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b655adc4f8423ebd42175f161edd73_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c26b4e162a49b9b197f1640463053d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1769fb5f785f43cf8b7d381fe86af413_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d9753225f044ebbfafcd3370a90ed3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13294f9754845688655bd40b3653471_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09529f945de41caaf3bef2e44de7877_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f5c7f59b794e47882cf0b139603a2a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee94c42379ca4ae7b59723ae48eb43f7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdcdb5946b6e40db92ff0a19f1cde8c0_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe224c1cfa742a4b21d4f7862c83e03_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if064eea59802474d80fe24566892332e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0883d7bb7144c62b0468b8a4d80e4e8_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1981696707f74ea485655942372b2873_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i937763a9251e44e7955bb4a051ffa322_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c754ff60a3c4d0f8af0b237cc3e417e_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec42c4dc9ed465e911fa5c37e44ccf7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392c683c8aa34ea48aad01f0ea87e36d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0ee73c79784b42b048a39b82f15449_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i999165b6e8ed4882bd941a2d188bcf37_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8caff817f2b44b13b3564e9cfa3e7994_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f935698e0f466fafbc30ad31035145_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e4986f2ad3a4f63a2c9caa1b763924f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec43032d4244efb878a5a63619550e6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ce0e7d756944dab4eba19c5dd8a08c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f63065772bc45baa7b3cae1ddb30035_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86b777937ae417b9621ef2d6deff23b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a6a11dfe68475a8e53247f2ea77b46_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94beb64c27374b788645e22ad29711ab_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9802f870444ad395ac0a641a75f539_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dfc9343e80548ada1bc35627fe66ec6_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b4a8e9fa4442188bdbda3ba66062e6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic17b6a75086b4b339878cc6f6e4ee32e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i729754834d2e497cb672920410a2293f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic99d3a2205024fd7aa3983a217efd24d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3a672c335384c4b8c7925ba2498c104_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593bcd3da2134b72a6c456811d3bc68f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06378183c0c04df6aee2790130a1c904_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9550ff545c364be7bf6bf5426c596967_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c31bf3540b249a5abfdb33d6014307e_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i751b8108d9d349959d4405809c8ab185_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb989f6f7b574d94a635536180d59536_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581f35bde0a74622a88029dde8d73d94_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic132a1e2f99f416cb0d2e0b8c3db41d2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c7263d4b1b4d6baaf5dc29b81024f1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd3d0d30a41486ca32673d4a704becf_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f31428fd964ba5aa8c86b194d7c991_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic706f0504b304e95a8c897adb4eb5bdb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e188e5ac28451ea93d0fd0cf9f30b6_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72196f5c2fe4ccbb68e25e0300f191a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05c0225e9d5c41288c143c63de199e35_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079eba6ad58c4cdaa2289aea2957a33a_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib235d8407dc543329206c5389bc899ed_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fe938c1143d420c9f0d0cd44b50a6f9_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58266c3fbe6e420ba392695ba369fbac_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3362deef6ba432593d2905bb07487d3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d31af3f79b48dcbc05247b533fb5c8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b492b8ad5b746c4af5adfc5a3bbe67e_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5079c809180e4e87babea3c6989b7547_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e3d6f06df7480d93661480c79c1945_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58588fe179f34bbabe168069b7a7b71c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24857abc09b4ecfa16764d38c143530_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e939c765bc94e7bb66e7118c3f4a40a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37350417ebd24c1ab07e70ff74cec182_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3121943b0bc44e4988cad36f10e55132_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a0dbe0f615447893dc66aacf30202d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2433804bf27d4a1ba35c905c2d32c4a2_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f554723bee640bab353dcfcaa1353a1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7ebf2e8efe428dba5d7904ddaedacb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8d7c0a664e4c77a5fbeba28997ebfa_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i642be708def7413dabc7b84d041f991f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47de1912a2bc4859b0defe8556c3f667_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df63a4309a0439b9c69ba7538fca3be_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077c5383de0a4ef5b6e04faef9537701_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae4a2195e634b988c290e9a18191ee3_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if841232101534f53b580eec2b5065a8b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2edbe06fd12f48158aa18ec4e99452f4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2244f03ed8794c27a6ca06574aa2e8bd_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bef2be8cac3404983af1188af384ef4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05c2d444872e4307aeeecc3b63c90b14_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadcb5421eef24006804c7c3cea1e9fcb_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95e9493ef57449b82086c14a005a57e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d8373ae98f4edd99b0fbc74c83f2b7_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8bf98199ca4359a65148eaa4b30c82_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0c83283a7a4e978c00244503b2a25f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf6cefb7c53d43baacb94f6acb2d8f23_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f65207fc7f44ad2ae85cee82bd938ca_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i742ec0e39c9e4a5aa684735e52151b2d_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b28a8f605f94f75b14c686dc2522e6a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1c8604abf643c9a12b71cd7d31eb00_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5dcf1d4a1e417bb4b42eab3fa4b8ac_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie728c62d2459463bb8fc5167f5c487da_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf1dfe1a8b944b8bc2c86ec9a44bdcf_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c617cfb7894c9d832fc9595def2dd1_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad324e736f04bc29364176151a23e2a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6887fdffd35c41348f9aeb0c27b07ba2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea71296fec64699bfe2bf754f22f26c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a788b9d1d084972933b07d5c268c034_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875011bdf5ae45a088eff8aa4e901299_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e58bfcff40486e8072fafaac9bd118_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e3eb051f454593ad2310cf80ffb554_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079da15a84a34e4198ff651865a8038c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c62fc9b4be4d35bc62769025bc8c59_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1befbfcdf8fc41b68d2d73068d97c2a6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5579c03fb48a43a7a109405d767a3964_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d3881ea9c694735ae5a5c61f3442642_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d15cee058f64c2c9ad5c5d19645970c_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc3b1a2bc054935a96c8c42b944c4ca_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a7c95098b948b58ef457213dbf6381_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i221d578ffbb64653ba21c30b54079cc0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b64bc0f1de4cf19d38861ea0a431a2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748076e324e04eb6876fea17432e0764_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4009a5bef5c4d3e93a8d64a351d480c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied02b691df1a4793820eca15169c551b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic94bee8dba224f25ab579c909f351412_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035675e545034a8daa97c38652231215_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e242133e6a48148ee336086579aa09_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f6eed880b84772b8aefd785e874762_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2df61011b564018ad5b03df881363ff_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f14ae1615dc4d17b4edf556db9b6006_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62050a01eb854e2383bc3ec498ccf086_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808364999df6460a849022d9b066670a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2e498bbaa444e9ac4c96b0df2ceafe_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6728846518144a681a82a2d46f3f018_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61dcd5aafdb0485db71a09a4bad0bcb2_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i085fffe12cf44fa092d9246b89d54cba_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb9530f3d6cd435ba9e67542e9eca210_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911bd91ee4bc41389629447824db808e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619793eecabc489ba4c2968bb061e22f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ActelionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0cb54bb4974193979769bf8aec917e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0899ff9af5041b68f780bfabfc0a5f0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9e566fe73f466bbb7ee14bb2b8034f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:NIZORALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1841e88ae54dceb0af523351880c07_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AliosBiopharmaIncandXO1LimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902af15964e14194a303f3a664cb5d2f_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:XO1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i750e6f140fa94894b04bd3d8acbe99bd_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ActelionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e829bbfb07485da5515f522d722695_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:PANCREASEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc4dd426fcc453da67295531f6d0a7e_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527f590d7fbc4382b88ea8ad34d70258_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:LifeScanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf7c5be7f3c4332b89431499d7c18c8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3c10dbd47946ebbad7615c4da0af0e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d63527739004691b878d7ebe2f0a1b6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21a208c5c3e4881b44ca05ec83a15c8_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64316c7eddcf4074a9e3ee4d29f82ef0_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2020AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8731480903f6482bafd102f3dcab3c69_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87db8efd958244a086dfb46539fdfb06_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb66e5604cfd4dbfbc2df6782a9418d5_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bf0b675d1ee4f0cad2d1afbe56a8367_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce3e1e959704f30a9e61a34717734cd_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89223357c4f64e06b825e78a40cb5914_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293ef2d918614098b4af9e84d27cc0ff_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbc095e470a470e9234a55fe342dda1_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9394419046465abc7a8a563ce9e079_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b1b3c5341149fca7bbc49f7508a82f_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9554efac170a48719f2fd4fef3bcbdbc_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2019AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i7466a929aa8c4da48b0b5cb2da5733b3_D20190117-20190117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-17</xbrli:startDate><xbrli:endDate>2019-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663d1a94c8284c94915423956a325ff7_I20190116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7648739eff244460aefb5458b95e548d_D20181231-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac7036ab4264656876135eb9e269635_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1106f749feaf4b4cb34daeb9bbc0f5ac_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeb51f3819d4439da404f8ebcd058d23_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2666b42496425cb2f87473681fa480_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2155f5644e4dce929f352545f25b9f_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e9ef76a8044ece8caf57dbe8808101_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbc2347889084c24a2bdc712e0cc9afe_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if510052c46844b89bee55dd2cfd123f1_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2018AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i247bfdef30e445f58022d1b433046fee_D20210131-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-31</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i59587efcd1fc4831b82133e2feac03fa_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3df5df054d4ba598290335491d4bf2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9660ad42e8a84744909a1e88ade1ded0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib62a0d3a2f984c819f0cd7b260d86045_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:LifeScanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6010a5c09da44a07ab46d7f9c737f126_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i41be97a9ae2043408fba6895a0bca20a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7c87d97d384ee8b13f6b2bb84ea65c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ba6a98f87b46e1aafbd453b6cbee6c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60518cf26184f7a82d1ae1e544e152f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ae50e5d88b4f2faf456858615a5efb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819517bf3729470f83f19c033eb4aeff_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a1e028ec54452c8c607218170270d2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i967a3fc676f546c3a8ec55596e5787c8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>jnj:patient</xbrli:measure></xbrli:unit><xbrli:context id="i4c869ba4eacc4ad3a8ea220ccc8ce54d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164e958688a24886ab9f0f49cc22f175_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23d356a726004e2aaf26a0f9b26a887a_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afa073421a4484a853139dff12ed57e_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1602e34a30408c9b6b1eb1cf04b157_D20200601-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib585935f9ab54509bc2c182dc59b672f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3622ddfe4f643408286c1811a8e2b4d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66ffb4e00ec4bfd99ace0da88568cd0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e799e62cf254001826c3bf820d212b7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d76339e798d40b08ed4feec1c3cae2d_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f5234f04df45daa5a30c1a7134b2bc_D20200120-20200120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-20</xbrli:startDate><xbrli:endDate>2020-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d9eecdd6ae4f3982b1ec0858319020_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85fbe5d13d1a4ca09991c8182c6da15a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e552d1e71b44a168a599c7ac19462c1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a8b086cd8c45da82107e88550189d0_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57129aa1e5d4dd0b0777a7d8ed0c1ee_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3db082046d4ae0b5256a896c8b18a9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66486cf0443e494881f3ec5e470b3cf6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec0388b7a5cc4f76940dc1229b081637_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfa403febc6441b9219104ff7cd304a_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f8b2a1ad4d49c49598e20c0474fab0_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia94268397a144c34b6f7724fc2cdb014_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2c59fc0efa48c49cd68b3b84b0c5f0_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459a0dc9569c4a9aab6a75035673c567_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c7279bfa824e409e9b9a1bca808c58_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac916c18208c47b09c67460db8030f1d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca0b385d9944272b5ded6645bb7a626_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510e7e5ac227414a98e421f182a041c0_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5dcc642308e468f9618c6b56e3244fa_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8af39bf4fc4285b5f5f5676ae6623a_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e8b0d8063934ca2b90208c4804102c2_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7895941dcd4d76b03e835972649586_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98eded4ee3746d6af8c7edc2e830f5b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b6a6cceab84226b776a371d5bbe868_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98674305aeea4bbab7dbaabd6920816d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c8bafe3cd14d5c9e1491d8bbf1f32f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i26b7b3066a4848f5be790a5478bde067_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAw_50c9d071-d9ef-47d6-9139-e15972b2b906">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6MGE4MTE0ODhiZTEwNGU3NWJmODJhYmY1NmM3NGRlYWMvdGFibGVyYW5nZTowYTgxMTQ4OGJlMTA0ZTc1YmY4MmFiZjU2Yzc0ZGVhY18wLTAtMS0xLTA_dd13ce5d-7e4c-4e88-8fec-56b710de6ab6">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8xMTY_e7de1bba-dd0e-4015-81f2-d590dbaab9c9"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8xMTY_bdae9209-6a1d-4a8c-b1fa-e40ff2a813c5">January 3</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6M2EyYzBjN2M1MjM3NGFhMDhkOTc2NDQ2NjMyNGZhNDAvdGFibGVyYW5nZTozYTJjMGM3YzUyMzc0YWEwOGQ5NzY0NDY2MzI0ZmE0MF8wLTAtMS0xLTA_fe93f907-28b7-4a1b-adbe-585a06401eea">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk1_ecf1ca67-3dde-4c38-9fa2-d07668969ecd">1-3215</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDkx_8715e1d1-54de-4654-b3cc-d89c3d88bba0">JOHNSON &amp; JOHNSON</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6MjMyYmZlZjZmNWRlNDk5MTk5ZTQ4ODA1NDY1MmNkYWYvdGFibGVyYW5nZToyMzJiZmVmNmY1ZGU0OTkxOTllNDg4MDU0NjUyY2RhZl8wLTAtMS0xLTA_d1fca63b-2b48-4aca-ae4f-db23812d1a69">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6MjMyYmZlZjZmNWRlNDk5MTk5ZTQ4ODA1NDY1MmNkYWYvdGFibGVyYW5nZToyMzJiZmVmNmY1ZGU0OTkxOTllNDg4MDU0NjUyY2RhZl8wLTItMS0xLTA_38956f93-45e3-4552-b8f6-202791d76439">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Johnson&#160;&amp; Johnson Plaza<br/>New Brunswick, New Jersey</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">08933</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDky_abcbfb20-dd30-44d9-a738-bc5a114ef3c6">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk4_af8aa92e-87f0-46c9-9e08-c8fb488d9727">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk2_3a77efd8-5c5a-484b-9218-247407b10365">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk3_30284606-6309-4d7b-aef8-ca1b736f3134">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk5_67438a82-c537-4420-8704-378a19d8dac6">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAx_05d906a1-2820-47d0-a34c-f9eca361a5ff">524-0400</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8xLTAtMS0xLTA_c28bb7e2-d58d-4d4b-9328-0fd7f12d068c">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8xLTEtMS0xLTA_2b906bab-feca-4316-89ae-7b2e1cc240e8">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8xLTItMS0xLTA_85e76268-0b92-4c1b-849f-2ef752b1f206">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8yLTAtMS0xLTA_233b261e-2950-4288-a536-c0223c7817f2">0.250% Notes Due January 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8yLTEtMS0xLTA_b0e5f166-246a-4806-8a93-f059e22381b6">JNJ22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8yLTItMS0xLTA_75408e62-aff2-4b01-aaaa-a503c6a56d59">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8zLTAtMS0xLTA_be3dc72c-1a22-48a0-b48e-bb56854c9795">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8zLTEtMS0xLTA_e87db860-870e-457c-8a5c-db13d9c61e5b">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8zLTItMS0xLTA_70814b9e-4208-46dc-b989-47194b8d37d5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl80LTAtMS0xLTA_28a0bff7-6e36-40f7-8390-80ccaf2cde6d">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl80LTEtMS0xLTA_adca03a0-57ee-420c-aca5-102d34f3ca80">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl80LTItMS0xLTA_04dc415d-035e-4a54-8c4b-51ae1da48cfc">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl81LTAtMS0xLTA_fe49863f-9646-4def-b17b-3673873e514a">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl81LTEtMS0xLTA_40f0525c-33eb-4ca4-9ef3-fc6f6d62fc01">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl81LTItMS0xLTA_d4a642d4-ee88-4813-b0d1-fd8dcc006639">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl82LTAtMS0xLTA_91b959ac-6c03-4d42-a531-db6e6aac2535">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl82LTEtMS0xLTA_344ed559-c844-4970-9e21-18b447ccae9f">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl82LTItMS0xLTA_2d86e60c-8a4c-49ab-95a3-0453e9a89527">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAy_1dee311a-ae7a-4bdd-8134-25befe444b8a">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAz_17c501ae-18e7-4b6b-936a-2629be583ca1">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDkz_217c7b6f-d7ec-4400-b39d-f1b747863db6">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk0_9265d5bc-bbfc-466c-af52-791de18f550a">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6ZDNkMGIwNjUyNDg1NGJhNzhjYTJiNjU4ZGZiNmEyOWUvdGFibGVyYW5nZTpkM2QwYjA2NTI0ODU0YmE3OGNhMmI2NThkZmI2YTI5ZV8wLTEtMS0xLTA_4d87a64c-5306-4259-8e69-33b98ac20efc">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6ZDNkMGIwNjUyNDg1NGJhNzhjYTJiNjU4ZGZiNmEyOWUvdGFibGVyYW5nZTpkM2QwYjA2NTI0ODU0YmE3OGNhMmI2NThkZmI2YTI5ZV8xLTQtMS0xLTA_d471b9c3-77d1-4c20-8797-148822e62d2c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6ZDNkMGIwNjUyNDg1NGJhNzhjYTJiNjU4ZGZiNmEyOWUvdGFibGVyYW5nZTpkM2QwYjA2NTI0ODU0YmE3OGNhMmI2NThkZmI2YTI5ZV8yLTItMS0xLTA_e4744fa6-14d5-4d28-9551-406bcc6a5748">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;<ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8xMDQ0NTM2MDQ2NjgxMw_f709ae2b-80f3-400b-a1a1-f3fcb01a18d3">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTA0_68b47266-6b17-468f-aac0-95c78bf69ab4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="i8686edd54dc143a7a78f18f215ac305a_I20200628" decimals="-9" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yMzc4_b65f28aa-bfb3-4d15-ad75-a8e771ba6c3a">363</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i2614e18acbee45a8bd82ab8bb34954d5_I20210216" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDE1_b29eaf02-2efa-465b-be65-465849ad3d1e">2,628,679,824</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parts I and III:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portions of registrant&#8217;s proxy statement for its 2021 annual meeting of shareholders filed within 120&#160;days after the close of the registrant&#8217;s fiscal year (the "Proxy Statement"), are incorporated by reference to this report on Form 10-K (this "Report").</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_13">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_19">General</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_22">Segments of Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_25">Geographic Areas</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_28">Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_28">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_31">Patents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_31">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_34">Trademarks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_37">Seasonality</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_40">Competition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_40">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_43">Environment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_43">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_46">Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_46">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_2653">Employees and Human Capital Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_2653">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_49">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_49">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_52">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_55">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_55">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_58">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_58">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_61">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_61">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_64">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_64">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_67">Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_67">15</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_70">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_73">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_73">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_2723">(</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_2723">Reserved</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_2723">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_2723">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_79">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_79">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_100">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_103">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_103">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_235">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_235">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_238">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_238">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_241">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_241">106</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_244">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_247">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_247">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_250">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_250">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_253">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_253">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_256">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_256">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_259">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_259">107</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_262">PART&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_265">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_265">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_268">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_268">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_271">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_271">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_274">Exhibit&#160;Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_274">111</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson's other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the "Company") also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; the Company&#8217;s strategy for growth; product development; regulatory approvals; market position and expenditures.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to meet compliance obligations in the McNEIL-PPC, Inc. Consent Decree or any other compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes to applicable laws and regulations affecting United States&#160;and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in domestic and international tax laws and regulations, including changes related to the Tax Cuts and Jobs Act in the United States, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives and Healthcare Market Trends</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of health care expenses, significant new entrants to the health care markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of global public health crises and pandemics, including the outbreak of the novel coronavirus (COVID-19) pandemic;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties and delays in manufacturing, internally, through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions and breaches of the Company's information technology systems or those of the Company's vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain, including the Company's transaction with Jabil, may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i26b7b3066a4848f5be790a5478bde067_16"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">BUSINESS</span></div><div id="i26b7b3066a4848f5be790a5478bde067_19"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson&#160;&amp; Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company&#8217;s primary focus is products related to human health and well-being. Johnson&#160;&amp; Johnson was incorporated in the State of New Jersey in 1887.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Executive Committee of Johnson&#160;&amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_22"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: &#8220;Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#8221; of this Report; and Note&#160;17 &#8220;Segments of Business and Geographic Areas&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumer Health</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Consumer Health segment includes a broad range of products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women&#8217;s health and wound care markets. Major brands in skin health/beauty include the AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; CLEAN&#160;&amp; CLEAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; DR. CI:LABO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; NEUTROGENA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and OGX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines. Over-the-counter (OTC) medicines include the broad family of TYLENOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acetaminophen products; SUDAFED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cold, flu and allergy products; BENADRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZYRTEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allergy products; MOTRIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> IB ibuprofen products; NICORETTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smoking cessation products outside the U.S.; ZARBEE&#8217;S NATURALS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the PEPCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of acid reflux products. Baby Care includes the JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AVEENO Baby</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products. Oral Care includes the LISTERINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. Major brands in Women&#8217;s Health outside of North America are STAYFREE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CAREFREE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sanitary pads and o.b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tampon brands. Wound Care brands include the BAND-AID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Brand Adhesive Bandages and NEOSPORIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> First Aid product lines. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis; STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (guselkumab), a treatment for adults with moderate to severe plaque psoriasis;  EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (rilpivirine), PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (darunavir) and PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for at least four months; RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (risperidone long-acting injection), for the treatment of schizophrenia and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer; IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers, chronic graft versus host disease and Waldenstr&#246;m's Macroglobulinemia; DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (daratumumab), a treatment for relapsed/refractory multiple myeloma; ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (bortezomib), a treatment for multiple myeloma mantle cell lymphoma; PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/VOKANAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (selexipag), the only approved oral, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Devices </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;The Medical Devices segment includes a broad range of products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields. Medical Devices in Interventional Solutions include Electrophysiology products (Biosense Webster) to treat cardiovascular diseases, Neurovascular care (Cerenovus) that treats hemorrhagic and ischemic stroke; the Orthopaedics portfolio (DePuy Synthes) is comprised of products in support of Hips, Knees, Trauma, and Spine, Sports &amp; Other; the Surgery portfolios (Ethicon) include advanced and general surgery offerings, solutions that focus on Breast Aesthetics (Mentor) and Ear, Nose and Throat (Acclarent) procedures; and Johnson &amp; Johnson Vision products such as ACUVUE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Brand disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. These products are distributed to wholesalers, hospitals and retailers, and used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div id="i26b7b3066a4848f5be790a5478bde067_25"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Areas</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The products made and sold in the international business include many of those described above under &#8220;&#8211;&#160;Segments of Business&#160;&#8211; Consumer Health,&#8221; &#8220;&#8211;&#160;Pharmaceutical&#8221; and &#8220;&#8211;&#160;Medical Devices.&#8221; However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S.&#160;activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_28"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Raw materials essential to the Company's business are generally readily available from multiple sources.  Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_31"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licensed under, a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. The Company&#8217;s subsidiaries face patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. Significant legal proceedings and claims involving the Company's patent and other intellectual property are described in Note 19, &#8220;Legal Proceedings&#8212;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;Sales of the Company&#8217;s largest product, STELARA</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ustekinumab), accounted for approximately 9.3% of the Company's total revenues for fiscal 2020. Accordingly, the patents related to this product are believed to be material to the Company.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson &amp; Johnson, owns patents specifically related to STELARA</span><span style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:7.8pt;font-weight:400;line-height:107%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The latest expiring United States patent expires in 2023. The latest expiring European patent expires in 2024. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Sales of the Company&#8217;s second largest product, DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (daratumumab) and DARZALEX FASPRO&#8482; (daratumumab and hyaluronidase-fihj), accounted for approximately 5.1% of the Company's total revenues for fiscal 2020.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the patents related to this product are believed to be material to the Company.  Genmab A/S owns patents related to DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Janssen Biotech, Inc. has an exclusive license to those patents. The latest expiring licensed United States patent expires in 2029. The latest expiring licensed European patent expires in 2031.  Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO&#8482;. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Sales of the Company&#8217;s third largest product, IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ibrutinib), accounted for approximately 5.0% of the Company's total revenues for fiscal 2020. Accordingly, patents related to this product are believed to be material to the Company. Pharmacyclics LLC (an AbbVie company) owns the patents related to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, and Janssen Biotech, Inc. has an exclusive license to those patents.  The Pharmacyclics patents and their expiration dates are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).  Pharmacyclics LLC and Janssen Biotech, Inc. have entered into confidential settlement agreements with certain generic companies granting licenses to market their generic ibrutinib products in the United States before the expiration of certain patents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div id="i26b7b3066a4848f5be790a5478bde067_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the U.S. and other countries where such products are marketed. The Company considers these trademarks in the aggregate to be of material importance in the operation of its businesses.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Worldwide sales do not reflect any significant degree of seasonality; however, spending has been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company&#8217;s product portfolio, is important to the Company's success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company&#8217;s consumer products involve significant expenditures for advertising and promotion.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is subject to a variety of U.S.&#160;and international environmental protection measures. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company&#8217;s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. The Company is subject to costly and complex U.S. and foreign laws and governmental regulations and any adverse regulatory action may materially adversely affect the Company's financial condition and business operations. In the U.S., the drug, device and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the U.S. FDA) continues to result in increases in the amounts of testing and documentation required for U.S. FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.  The new medical device regulatory framework and the new privacy regulations in Europe and in other countries are examples of such increased regulation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company&#8217;s subsidiaries may deem it advisable to initiate product recalls.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The U.S. FDA and regulatory agencies around the globe are also increasing their enforcement activities. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our drugs or medical devices are ineffective or pose an unreasonable health risk, the U.S. FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The U.S. FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis, or enjoin and/or restrain certain conduct resulting in violations of applicable law. The U.S. FDA may also recommend prosecution to the US Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The costs of human health care have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and congress on drug prices and profits and programs that encourage doctors to write prescriptions for particular drugs, or to recommend, use or purchase particular medical devices. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is increased focus on interactions and financial relationships between healthcare companies and health care providers. Various transparency laws and regulations require disclosures of payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners. Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official. Payers have become a more potent force in the market place and increased attention is being paid to drug and medical device pricing, appropriate drug and medical device utilization and the quality and costs of health care generally.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. government agencies continue efforts to repeal, modify, or invalidate provisions of the Patient Protection and Affordable Care Act (the ACA) which passed in 2010. For example, federal legislation repealed the ACA&#8217;s individual mandate tax penalty as well as the tax on generous employer-sponsored healthcare plans; the Center for Medicare &amp; Medicaid Services (CMS) began permitting states to impose work requirements on persons covered by Medicaid expansion plans; certain federal subsidies to insurers have ended; and certain short-term insurance plans not offering the full array of ACA benefits have been allowed to extend in duration.  Some of these changes are being challenged in U.S. courts and so their long-term impact remains uncertain. The ACA has also been subject to judicial challenge. In November 2020, the U.S. Supreme Court heard argument in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Texas v. Azar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which challenges the constitutionality of the ACA. Pending resolution of the litigation, all of the ACA but the individual mandate to buy health insurance remains in effect.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. government also continues to propose and implement changes to the Medicare Part D benefit including the size of manufacturer discounts in the coverage gap and catastrophic phases of the benefit.  There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing in the Medicare and Medicaid programs. This changing federal landscape has both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of federal law, and potential modification or repeal of these laws, will ultimately affect the industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In addition, business practices in the health care industry have come under increased scrutiny, particularly in the U.S., by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Further, the Company relies on global supply chains, and production and distribution processes, that are complex, are subject to increasing regulatory requirements, and may be faced with unexpected changes such as those resulting from the COVID-19 pandemic and Brexit, that may affect sourcing, supply and pricing of materials used in the Company's products.  These processes also are subject to complex and lengthy regulatory approvals.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global regulatory landscape is also subject to change as the COVID-19 pandemic continues to affect the U.S. and global economies. The U.S. FDA and other health authorities have shifted resources and priorities to meet the many challenges presented by the pandemic. Pandemic-related disruptions could negatively impact the processing of regulatory submissions and slow agency review times necessary for the approval or clearance of new drugs and devices. The duration and severity of the COVID-19 pandemic is unpredictable and difficult to assess.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_2653"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Management </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of January 3, 2021 and December 29, 2019, the number of employees were approximately:</span></div><div style="padding-left:112.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:112.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.368%"><tr><td style="width:1.0%"></td><td style="width:52.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,400&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,200&#160;</span></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalent (FTE) positions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,500&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,200&#160;</span></td><td style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:112.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">&#8220;Employee&#8221; is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"> FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.</span></div><div style="text-indent:30.35pt"><span><br/></span></div><div style="text-indent:126pt"><img src="jnj-20210103_g1.jpg" alt="jnj-20210103_g1.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:341px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Strategy </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that its employees are critical to its continued success and are an essential element of its long-term strategy. Management is responsible for ensuring that its policies and processes reflect and reinforce the Company's desired corporate culture, including policies and processes related to strategy, risk management, and ethics and compliance.  The Company&#8217;s human capital management strategy is built on three fundamental focus areas: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Attracting and recruiting the best talent </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing and retaining talent </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Empowering and inspiring talent</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Culture and Employee Engagement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Johnson &amp; Johnson, employees are guided by Our Credo which sets forth the Company's responsibilities to patients, consumers, customers, healthcare professionals, employees, communities and shareholders. Employees worldwide are further guided by the Company&#8217;s Code of Business Conduct which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets basic requirements for business conduct and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in every market where it operates. The Company c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onducts global surveys that offer its employees the ability to provide feedback and valuable insight to help address potential human resources risks and identify opportunities to improve. In 2020, 93% of global employees across 78 countries participated in Our Credo Survey which is offered in 36 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">languages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Growth and Development </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To continue to lead in the changing healthcare landscape, it is crucial that the Company continue to attract and retain top talent. The Company believes that its employees must be equipped with the right knowledge and skills and be provided with opportunities to grow and develop in their careers. Accordingly, professional development programs and educational resources </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are available to all employees. The Company's objective is to foster a learning culture that helps shape each person&#8217;s unique career path while creating a robust pipeline of talent to deliver on the Company&#8217;s long-term strategies. In furtherance of this objective, the Company deploys a global approach to ensure development is for everyone, regardless of where they are on their career journey. In 2020, 44.6% of employees in Manager and above job categories took advantage of career opportunities by moving across functions, country or business segment lines (including upward promotion or lateral transfer and excluding employees in the research and development organizations). The Company's voluntary turnover rate was 5.2%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion (DEI)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is committed to workplace diversity and to cultivating, fostering, and advancing a culture of equity and inclusion. Enabling employees to perform at their best while being themselves is fundamental to the Company's continued success. The Company&#8217;s DEI vision is: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Be yourself, change the world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's DEI strategy focuses on three pillars that reflect the strategic priorities identified to enable the Company to address the challenges and opportunities presented by this evolving understanding of diversity: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate the Company&#8217;s efforts to advance a culture of inclusion and innovation </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build a diverse workforce for the future </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enhance business results and reputation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's DEI strategy is guided by internal and external insights, global best practices and continual employee feedback which remind the Company that while diversity changes by location, inclusion is the same everywhere. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company's total rewards philosophy, the Company offers competitive compensation and benefits to attract and retain top talent. The Company is committed to fairness and equitable treatment in its compensation and benefits for employees at all levels. The Company observes legal minimum wage provisions and exceeds them where possible. The Company's total rewards offerings include an array of programs to support its employees' financial, physical, and mental well-being, including annual performance incentive opportunities, pension and retirement savings programs, health and welfare benefits, paid time off, leave programs, flexible work schedules and employee assistance programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Wellness and Safety </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in employee health, well-being and safety is built on its conviction that advancing health for humanity starts with advancing the health of its employees. With the right awareness, focus, practices and tools, the Company ensures that all its employees around the world, as well as temporary contractors and visitors to the Company's sites, can work safely. The Company has continuously expanded health and well-being programs throughout the Company and across the globe, incorporating new thinking and technologies to keep its offerings best-in-class and to help employees achieve their personal mind and body health goals. The programs and practices the Company advances covers three core dimensions: Healthy Eating, Healthy Movement and Healthy Mind.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s main corporate website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s SEC filings are also available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/sec.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. All SEC filings are also available at the SEC&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investors and the public should note that the Company also announces information at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsaboutourprescriptionopioids.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsabouttalc.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We use these websites to communicate with investors and the public about our products, litigation and other matters. It is possible that the information we post to these websites could be deemed to be material information. Therefore, we encourage investors and others interested in the Company to review the information posted to these websites in conjunction with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC filings, press releases, public conference calls and webcasts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the Amended and Restated Certificate of Incorporation, By-Laws, the written charters of the Audit Committee, the Compensation&#160;&amp; Benefits Committee, the Nominating&#160;&amp; Corporate Governance Committee, the Regulatory Compliance Committee and the Science, Technology &amp; Sustainability Committee of the Board of Directors and the Company&#8217;s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials, are available at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Company's website and will be provided without charge to any shareholder submitting a written request, as provided above.  The information on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsaboutourprescriptionopioids.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsabouttalc.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is not, and will not be deemed, a part of this Report or incorporated into any other filings the Company makes with the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in the Company&#8217;s common stock or debt securities involves risks and uncertainties. The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company's control and cannot therefore be eliminated. In addition to the other information in this report and the Company&#8217;s other filings with the SEC, investors should consider carefully the factors set forth below. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. If known or unknown risks or uncertainties materialize, the Company&#8217;s business, results of operations or financial condition could be adversely affected, potentially in a material way.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company&#8217;s earnings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces substantial competition in all three operating segments and in all geographic markets. The Company&#8217;s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors&#8217; development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company&#8217;s existing products as well as its ability to bring new products to market despite significant prior investment in the related product development. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s pharmaceutical businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic and other competing products and enter the market. Similar competition can be triggered by the loss of exclusivity for a biological product. For the Company&#8217;s medical device businesses, technological innovation, product quality, reputation and customer service are especially important to competitiveness. Development by other companies of new or improved products, processes and technologies could threaten to make the Company&#8217;s products or technologies less desirable, less economical or obsolete. The Company&#8217;s consumer health businesses face intense competition from other branded products and retailers&#8217; private-label brands. If the Company fails to sufficiently differentiate and market its brand name consumer products, this could adversely affect revenues and profitability of those products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruptions and delays in manufacturing operations could adversely affect the Company&#8217;s business, sales and reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s manufacture of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company's subsidiaries operate 90 manufacturing facilities as well as sourcing from hundreds of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, political unrest, terrorist attacks and epidemics or pandemics. Such delays and difficulties in manufacturing can result in product shortages, declines in sales and reputational impact as well as significant remediation and related costs associated with addressing the shortage. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third parties to manufacture certain of our products. We depend on these third party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices. However, we cannot guarantee that these third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks associated with our reliance on third parties, including the Company&#8217;s strategic partnership with Jabil in the Medical Devices segment, to manufacture these products include reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company&#8217;s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us. Moreover, if any of our third party manufacturers suffer any damage to facilities, lose benefits under material agreements, experience power outages, encounter financial difficulties, are unable to secure necessary raw materials from their suppliers or suffer any other reduction in efficiency, the Company may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience significant business disruption. In the event of any such disruption, the Company would need to seek and source other qualified third-party manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet our rigorous manufacturing and testing standards. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">often in unregulated, unlicensed, uninspected and unsanitary sites </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as well as the lack of regulation of their contents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The industry's failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 pandemic has adversely impacted certain aspects of the Company&#8217;s business and could cause disruptions or future impact to the Company&#8217;s business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with global health crises and pandemics, including the global outbreak of the novel coronavirus and its mutations (COVID-19). The COVID-19 pandemic has adversely impacted, and is expected to continue to adversely impact, certain aspects of the Company&#8217;s business, results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. The spread of COVID-19 has caused the Company to modify its business practices (including instituting remote work for many of the Company's employees), and the Company may take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners. The Company continues to monitor the situation and while we have robust business continuity plans in place across our global supply chain network to help mitigate the impact of COVID-19, these efforts may not completely prevent our business from being adversely affected and future impacts remain uncertain. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the U.S. and other countries have begun or will begin to reopen their economies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the extent to which COVID-19 will impact the Company's future operations will depend on many factors which cannot be predicted with confidence, including the duration of the outbreak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Any resurgence in COVID-19 infections could result in the imposition of new mandates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and prolonged restrictive measures implemented in order to control the spread of the disease. The continued global spread of COVID-19 could adversely impact the Company's operations, including, among other things, our manufacturing operations, supply chain, including third-party suppliers, sales and marketing and clinical trial operations. Any of these factors could adversely affect the Company's business, financial results, and global economic conditions generally.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face uncertainties related to our efforts to develop a COVID-19 vaccine candidate, including uncertainties related to the risk that our development programs may not be successful, commercially viable or receive approval or Emergency Use Authorization from regulatory authorities; risks associated with clinical trial data, including further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the JNJ-78436735 vaccine candidate and dose level for the Phase 3 (ENSEMBLE) trial; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; disruptions in the relationships between us, our third-party suppliers and external manufacturers; the risk that other companies may produce superior or competitive products; the risk that demand for any products we may develop may no longer exist; risks related to the availability of raw materials to manufacture any such products; the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis, that we may experience manufacturing delays once a manufacturing site is activated, or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated, and other challenges and risks associated with the pace of our vaccine development program; and pricing and access challenges for such products, including in the U.S.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section and those incorporated by reference herein, i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncluding risks relating to the Company&#8217;s effective tax rate as a result of changes in consumption as well as changes in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws relating to supply of the Company&#8217;s products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that developments concerning the COVID-19 pandemic have been constantly evolving, additional impacts and risks may arise, including litigation, that are not presently known to the Company. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Related to the Government Regulation and Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global sales in the Company&#8217;s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s pharmaceutical and medical device products are significantly affected by reimbursements by third-party payers such as government healthcare programs, private insurance plans and managed care organizations. As part of various efforts to contain healthcare costs, these payers are putting downward pressure on prices at which products will be reimbursed. In the U.S., increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, in part due to continued consolidation among health care providers, could result in further pricing pressures. In addition, increased political scrutiny could result in additional pricing pressures. Outside the U.S., numerous major markets, including the EU, United Kingdom and Japan, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company&#8217;s products, or reduce the value of its intellectual property protection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, Johnson &amp; Johnson and its subsidiaries are subject to numerous claims and lawsuits involving various issues such as patent disputes, product liability and claims that their product sales, marketing and pricing practices violate various antitrust, unfair trade practices and/or consumer protection laws. The Company's more significant legal proceedings are described in Note 19, &#8220;Legal Proceedings&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report. Litigation, in general, and securities, derivative action, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these matters may include thousands of plaintiffs, may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder, and the Company&#8217;s sale, manufacturing and marketing of opioids.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the Company believes it has substantial defenses in these matters, it is not feasible to predict the ultimate outcome of litigation. The Company could in the future be required to pay significant amounts as a result of settlements or judgments in these matters, potentially in excess of accruals, including matters where the Company could be held jointly and severally liable among other defendants. The resolution of, or increase in accruals for, one or more of these matters in any reporting period could have a material adverse effect on the Company's results of operations and cash flows for that period. The Company does not purchase third-party product liability insurance; however the Company utilizes a wholly-owned captive insurance company subject to certain limits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concerns about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the U.S. Food and Drug Administration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company&#8217;s products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces significant regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Like other companies in the healthcare industry, the Company is subject to extensive regulation, investigations and legal action, by national, state and local government agencies in the U.S. and other countries in which they operate. Regulatory issues regarding compliance with current Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs, devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of the Company&#8217;s products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, the Medicaid Rebate Program, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of health care industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs. Any such debarment could have a material adverse effect on the Company&#8217;s business and results of operations. The most significant current investigations and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">litigation brought by government agencies are described in Note 19, &#8220;Legal Proceedings-Government Proceedings&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company&#8217;s operating results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws or regulations around the world could negatively impact the Company&#8217;s effective tax rate and results of operations. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 on income taxes for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business and files tax returns in numerous countries and is addressing tax audits and disputes with many tax authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2015 Organization for Economic Cooperation and Development Base Erosion and Profit Shifting (BEPS) project, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company regularly assesses the likely outcomes of its tax audits and disputes to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company&#8217;s expectations, which could result in tax liabilities in excess of reserves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company may not be able to successfully secure and defend intellectual property rights essential to the Company&#8217;s businesses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns or licenses a significant number of patents and other proprietary rights, relating to its products and manufacturing processes. These rights are essential to the Company&#8217;s businesses and materially important to the Company&#8217;s results of operations. Public policy, both within and outside the U.S., has become increasingly unfavorable toward intellectual property rights. The Company cannot be certain that it will obtain adequate patent protection for new products and technologies in the United States and other important markets or that such protections, once granted, will last as long as originally anticipated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitors routinely challenge the validity or extent of the Company&#8217;s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other proceedings, such as inter partes review (IPR) proceedings before the United States Patent &amp; Trademark Office (USPTO). These proceedings absorb resources and can be protracted as well as unpredictable. In addition, challenges that the Company&#8217;s products infringe the patents of third parties could result in the need to pay past damages and future royalties and adversely affect the competitive position and sales of the products in question. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. In the U.S., manufacturers of generic versions of innovative human pharmaceutical products may challenge the validity, or claim non-infringement, of innovator products through the Abbreviated New Drug Application, or ANDA, process with the FDA and related ANDA litigation. The Biologics Price Competition and Innovation Act (BPCIA), enacted in 2010, which created a new regulatory pathway for the approval by the FDA of biosimilar alternatives to innovator-developed biological products, also created mechanisms for biosimilar applicants to challenge the patents on the innovator biologics. The IPR process with the USPTO is also being used by competitors to challenge patents asserted in litigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is not successful in defending its patents against such challenges, or upon the &#8220;at-risk&#8221; launch (despite pending patent infringement litigation) by the generic or biosimilar firm of its product, the Company can lose a major portion of revenues for the referenced product in a very short period of time. Current legal proceedings involving the Company&#8217;s patents and other intellectual property rights are described in Note 19, &#8220;Legal Proceedings&#8212;Intellectual Property&#8221; of the Notes to the Consolidated Financial Statements included in Item 8 of this Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Product Development, Regulatory Approval and Commercialization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant challenges or delays in the Company&#8217;s innovation and development of new products, technologies and indications could have an adverse impact on the Company&#8217;s long-term success.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s continued growth and success depends on its ability to innovate and develop new and differentiated products and services that address the evolving health care needs of patients, providers and consumers. Development of successful products and technologies is also necessary to offset revenue losses when the Company&#8217;s existing products lose market share due to various factors such as competition and loss of patent exclusivity. New products introduced within the past five years accounted for approximately 25% of 2020 sales. The Company cannot be certain when or whether it will be able to develop, license or otherwise acquire companies, products and technologies, whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially successful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pursues product development through internal research and development as well as through collaborations, acquisitions, joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly pharmaceutical and biotechnology products and medical devices, requires significant investment of resources over many years. Only a very few biopharmaceutical research and development programs result in commercially viable products. The process depends on many factors including the ability to discern patients&#8217; and health care providers&#8217; future needs; develop promising new compounds, strategies and technologies; achieve successful clinical trial results; secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market, successfully differentiate the Company&#8217;s products from competing products and approaches to treatment. New products or enhancements to existing products may not be accepted quickly or significantly in the marketplace due to product and price competition, changes in customer preferences or healthcare purchasing patterns, resistance by healthcare providers or uncertainty over third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger real-world patient populations, as well as market entry of competitive products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Related to Financial and Economic Market Conditions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces a variety of risks associated with conducting business internationally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s extensive operations and business activity outside the U.S. are accompanied by certain financial, economic and political risks, including those listed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In fiscal 2020, approximately 48% of the Company&#8217;s sales occurred outside of the U.S., with approximately 23% in Europe, 7% in the Western Hemisphere, excluding the U.S., and 18% in the Asia-Pacific and Africa region. Changes in non-U.S. currencies relative to the U.S. dollar impact the Company&#8217;s revenues and expenses. While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, unhedged exposures continue to be subject to currency fluctuations. In addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable translation effects when the operating results of the Company&#8217;s non-U.S. business activity are translated into U.S. dollars. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation and Currency Devaluation Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company faces challenges in maintaining profitability of operations in economies experiencing high inflation rates. The Company has accounted for operations in Argentina (beginning in the fiscal third quarter of 2018) and Venezuela as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. While the Company strives to maintain profit margins in these areas through cost reduction programs, productivity improvements and periodic price increases, it might experience operating losses as a result of continued inflation. In addition, the impact of currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively impact the Company&#8217;s operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Illegal Importation of Pharmaceutical Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company&#8217;s sales and profitability in the U.S. and other countries in which the Company operates. With the exception of limited quantities of prescription drugs for personal use, foreign imports of pharmaceutical products are illegal under current U.S. law. However, the volume of illegal imports continues to rise as the ability of patients and other customers to obtain the lower-priced imports has grown significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Bribery and Other Regulations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. publicly traded companies from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the Company obtain or retain business or gain any improper advantage. The Company&#8217;s business is heavily regulated and therefore involves significant interaction with foreign officials. Also, in many countries outside the U.S., the health care providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore, the Company&#8217;s interactions with these prescribers and purchasers are subject to regulation under the FCPA. In addition to the U.S. application and enforcement of the FCPA, various jurisdictions in which the Company operates have laws and regulations, including the U.K Bribery Act 2010, aimed at preventing and penalizing corrupt and anticompetitive behavior. Enforcement activities under these laws could subject the Company to additional administrative and legal proceedings and actions, which could include claims for civil penalties, criminal sanctions, and administrative remedies, including exclusion from health care programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal, Social and Political Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other risks inherent in conducting business globally include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">protective economic policies taken by governments such as trade protection measures and import/export licensing requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company&#8217;s ability to manufacture or sell its products in the relevant market; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property and contractual rights in certain jurisdictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential nationalization or expropriation of the Company&#8217;s foreign assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">political or social upheavals, economic instability, repression, or human rights issues; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">geopolitical events, including natural disasters, disruptions to markets due to war, armed conflict, terrorism, epidemics or pandemics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain investment grade credit ratings with Moody's Investors Service and Standard &amp; Poor's Ratings Services. Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors. Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts. There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Risks </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth requires us to recruit and retain talented employees representing diverse backgrounds, experiences, and skill sets. The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization. Maintaining our brand and reputation, as well as a diverse, equitable and inclusive work environment enables us to attract top talent. If we are less successful in our recruiting efforts, or if we cannot retain highly skilled workers and key leaders, our ability to develop and deliver successful products and services may be adversely affected. In addition, effective succession planning is important to our long-term success. Any unsuccessful implementation of our succession plans or failure to ensure effective transfer of knowledge and smooth transitions involving key employees could</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#8217;s business or reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet business objectives, the Company relies on both internal technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data, including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection, and ensure the continuity of the Company&#8217;s supply chain. The extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of these systems and networks, and the confidentiality, integrity, and availability of the Company&#8217;s sensitive data. The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company&#8217;s third-party providers have required capabilities and controls, to address this risk</span><span style="color:#00b050;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not experienced any material impact to the business or operations resulting from information or cybersecurity attacks; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory action. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial, legal, business or reputational losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concern over climate change may also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_55"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.36pt">UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.02pt">PROPERTIES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries operate 90 manufacturing facilities occupying approximately 15.2&#160;million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company&#8217;s business approximately as follows:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Within the U.S., five facilities are used by the Consumer Health segment, five by the Pharmaceutical segment and 19 by the Medical Devices segment. Outside of the U.S., 24 facilities are used by the Consumer Health segment, 14 by the Pharmaceutical segment and 23 by the Medical Devices segment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The locations of the manufacturing facilities by major geographic areas of the world are as follows:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Geographic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Africa, Asia and Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world. Research facilities are also discussed in Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of this Report. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is committed to maintaining all of its properties in good operating condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;McNEIL-PPC, Inc. (now Johnson &amp; Johnson Consumer Inc.) (McNEIL-PPC) continues to operate under a consent decree, signed in 2011 with the FDA, which governs certain McNeil Consumer Healthcare manufacturing operations, and requires McNEIL-PPC to remediate the facilities it operates in Lancaster, Pennsylvania, Fort Washington, Pennsylvania, and Las Piedras, Puerto Rico (the "Consent Decree"). Following FDA inspections McNEIL-PPC received notifications from the FDA that all three manufacturing facilities are in conformity with applicable laws and regulations, and commercial production  restarted in 2015. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Under the Consent Decree, after receiving notice from the FDA of being in compliance with applicable laws and regulations, each of the three facilities is subject to a five-year audit period by a third-party cGMP expert. A third-party expert  continued to reassess the sites at various times through 2020. McNEIL-PPC is awaiting FDA inspections of the facilities which have been delayed due to COVID-19.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Segment information on additions to property, plant and equipment is contained in Note&#160;17 &#8220;Segments of Business and Geographic Areas&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the information set forth in Note&#160;19 &#8220;Legal Proceedings&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, Johnson &amp; Johnson and its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_64"></div><div style="padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.52pt">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS OF THE REGISTRANT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Listed below are the executive officers of the Company. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with regard to the directors of the Company, including information for Alex Gorsky, who is also an executive officer, is incorporated herein by reference to the material captioned &#8220;Item 1. Election of Directors&#8221; in the Proxy Statement.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chairman, Executive Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Fasolo, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Human Resources Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Gorsky</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Board of Directors; Chairman, Executive Committee; Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashley McEvoy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thibaut Mongon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee, Executive Vice President, Worldwide Chairman, Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael E. Sneed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Global Corporate Affairs and Chief Communication Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paulus Stoffels, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chairman, Executive Committee; Chief Scientific Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer L. Taubert</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael H. Ullmann</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, General Counsel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn E. Wengel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Global Supply Chain Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Financial Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Mr. J. Duato joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in the Pharmaceutical sector. In 2009, he was named Company Group Chairman, Pharmaceuticals, and in 2011, he was named Worldwide Chairman, Pharmaceuticals. In 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals. In July 2018, Mr. Duato was promoted to Vice Chairman of the Executive Committee, with responsibility for the company's Pharmaceutical and Consumer Health sectors, supply chain, information technology, global services and the Health &amp; Wellness groups.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Dr.&#160;P. M. Fasolo joined the Company in 2004 as Vice President, Worldwide Human Resources for Cordis Corporation, a subsidiary of the Company, and was subsequently named Vice President, Global Talent Management for the Company. He left Johnson&#160;&amp; Johnson in 2007 to join Kohlberg Kravis Roberts&#160;&amp; Co. as Chief Talent Officer. Dr.&#160;Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee. In April 2016, he was named Executive Vice President, Chief Human Resources Officer. Dr. Fasolo has responsibility for global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Ms. A. McEvoy joined the Company in 1996 as Assistant Brand Manager of McNeil Consumer Health, a subsidiary of the Company, advancing through positions of increasing responsibilities until she was appointed Company Group Chairman, Vision Care in 2012, followed by Company Group Chairman, Consumer Medical Devices in 2014. In July 2018, Ms. McEvoy was promoted to Executive Vice President, Worldwide Chairman, Medical Devices, and became a member of the Executive Committee. Ms. McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster and Johnson &amp; Johnson Vision.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. T. Mongon joined the Company in 2000 as Director of Marketing for the Vision Care group in France and subsequently held general management positions as Country Manager France, Belgium and North Africa, Managing Director Latin America, and President Asia-Pacific. Mr. Mongon transitioned to the Pharmaceutical sector in 2012 as the Global Commercial Strategy Leader for the Neuroscience therapeutic area, before joining the Consumer Health sector as Company Group Chairman Asia-Pacific. In 2019, he was promoted to Executive Vice President and Worldwide Chairman, Consumer Health, and became a member of the Executive Committee. Mr. Mongon has responsibility for  the global development of Johnson &amp; Johnson&#8217;s health and wellness products and solutions in beauty, OTC, oral care, baby care, women&#8217;s health, and wound care.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Mr. M. E. Sneed joined the Company in 1983 as Marketing Assistant for Personal Products Company, a subsidiary of the Company, and gained increased responsibilities in executive positions across the global enterprise. In 2004, Mr. Sneed was appointed Company Group Chairman, Consumer North America, followed by Company Group Chairman, Vision Care Franchise in 2007. In 2012, he became the Vice President, Global Corporate Affairs and Chief Communications Officer. Mr. Sneed was appointed Executive Vice President, Global Corporate Affairs and Chief Communications Officer in January 2018, and became a member of the Executive Committee in July 2018, leading the Company's global marketing, communication, design and philanthropy functions.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Dr. P. Stoffels rejoined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV. In 2005, he was appointed Company Group Chairman, Global Virology. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals. Dr. Stoffels was appointed Global Head, Research &amp; Development, Pharmaceuticals in 2009, and in 2011, became Worldwide Chairman, Pharmaceuticals. In 2012, Dr. Stoffels was appointed Chief Scientific Officer, and became a member of the Executive Committee. In 2016, Dr. Stoffels was named Executive Vice President, Chief Scientific Officer. In 2018, Dr. Stoffels was promoted to Vice Chairman of the Executive Committee, Chief Scientific Officer. He is responsible for the Company&#8217;s innovation agenda across the Pharmaceutical, Medical Devices and Consumer Health sectors, product safety strategy, and the Company&#8217;s global public health strategy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Ms. J. L. Taubert joined the Company in 2005 as Worldwide Vice President at Johnson &amp; Johnson Pharmaceutical Services, a subsidiary of the Company. She held several executive positions of increasing responsibility in the Pharmaceutical sector until 2012 when she was appointed Company Group Chairman, North America Pharmaceuticals, and in 2015 became Company Group Chairman, The Americas, Pharmaceuticals. In July 2018, Ms. Taubert was promoted to Executive Vice President, Worldwide Chairman, Pharmaceuticals, and became a member of the Executive Committee. Ms. Taubert has responsibility for the Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension businesses throughout Janssen.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. M. H. Ullmann joined the Company in 1989 as a corporate attorney in the Law Department.&#160;He was appointed Corporate Secretary in 1999 and served in that role until 2006.&#160; During that time, he also held various management positions in the Law Department.&#160; In 2006, he was named General Counsel, Medical Devices and Diagnostics and was appointed Vice President, General Counsel and became a member of the Executive Committee in 2012. In April 2016, Mr. Ullmann was named Executive Vice President, General Counsel. Mr. Ullmann has worldwide responsibility for legal, government affairs &amp; policy, global security, aviation, health care compliance, global brand protection and privacy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Ms. K. E. Wengel joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions across the global enterprise, in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. In 2010, Ms. Wengel became the first Chief Quality Officer of the Company. In 2014, she was promoted to Vice President, Johnson &amp; Johnson Supply Chain. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Mr. J. J. Wolk joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company, and through the years held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, in Pharmaceuticals, Medical Devices and Supply Chain. From 2014 to 2016, he served as Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. In 2016, Mr. Wolk became the Vice President, Investor Relations. In July 2018, he was appointed Executive Vice President, Chief Financial Officer and became a member of the Executive Committee. Mr. Wolk plays a strategic role in the overall management of the Company, and leads the development and execution of the Company's global long-term financial strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i26b7b3066a4848f5be790a5478bde067_73"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of February 16, 2021, there were 132,376 record holders of common stock of the Company. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements included in Item 8; and Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;&#8211; Equity Compensation Plan Information.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities  </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of 2020. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:42.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 28, 2020 through October&#160;25, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 26, 2020 through November 22, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 23, 2020 through January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal fourth quarter of 2020, the Company repurchased an aggregate of 2,151,333 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased in open-market transactions as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_2723"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reserved</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION</span></div><div id="i26b7b3066a4848f5be790a5478bde067_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women&#8217;s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields.  These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Executive Committee of Johnson&#160;&amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer Health, Pharmaceutical and Medical Devices business segments.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all of its product lines, the Company competes with other companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company's product portfolio, is important to the Company&#8217;s success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company&#8217;s consumer products involves significant expenditures for advertising and promotion.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Objectives </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With &#8220;Our Credo&#8221; as the foundation, the Company&#8217;s purpose is to blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. The Company is committed to bringing its full breadth and depth to ensure health for people today and for future generations. United around this common ambition, the Company is poised to fulfill its purpose and successfully meet the demands of the rapidly evolving markets in which it competes. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is broadly based in human healthcare, and is committed to creating value by developing accessible, high quality, innovative products and services. New products introduced within the past five years accounted for approximately 25% of 2020 sales. In 2020, $12.2 billion was invested in research and development and $7.3 billion spent on acquisitions, reflecting management&#8217;s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly change the trajectory of health for humanity. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A critical driver of the Company&#8217;s success is the 134,500 diverse employees worldwide. Employees are empowered and inspired to lead with the Company&#8217;s Our Credo and purpose as guides. This allows every employee to use the Company&#8217;s reach and size to advance the Company's purpose, and to also lead with agility and urgency. Leveraging the extensive resources across the enterprise enables the Company to innovate and execute with excellence. This ensures the Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20210103_g2.jpg" alt="jnj-20210103_g2.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20210103_g3.jpg" alt="jnj-20210103_g3.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20210103_g4.jpg" alt="jnj-20210103_g4.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:181px"/></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Consolidated Sales</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion on results of operations and financial condition pertaining to the fiscal years 2019 and 2018 see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2019, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, worldwide sales increased 0.6% to $82.6&#160;billion as compared to an increase of 0.6% in 2019. These sales changes consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:63.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales increase/(decrease) due to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 0.3% in 2020 and a negative impact of 1.7% in 2019. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S.&#160;companies were $43.1&#160;billion in 2020 and $42.1&#160;billion in 2019. This represents increases of 2.5% in 2020 and 0.5% in 2019. Sales by international companies were $39.5&#160;billion in 2020 and $40.0&#160;billion in 2019. This represents a decrease of 1.3% in 2020 and an increase of 0.7% in 2019.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The five-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 3.3%, 3.9% and 2.8%, respectively. The ten-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 3.0%, 3.9% and 2.1%, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, sales by companies in Europe achieved growth of 2.8% as compared to the prior year, which included operational growth of 2.0% and a positive currency impact of 0.8%. Sales by companies in the Western Hemisphere (excluding the U.S.) experienced a sales decline of 10.2% as compared to the prior year, which included operational growth of 0.4% offset by a negative currency impact of 10.6%. Sales by companies in the Asia-Pacific, Africa region experienced a sales decline of 2.7% as compared to the prior year, including an operational decline of 3.1% partially offset by a positive currency impact of 0.4%.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 results benefited from the inclusion of a 53rd week. (See Note 1 to the Consolidated Financial Statements for Annual Closing Date details). The Company estimated that the fiscal year 2020 sales growth rate was enhanced by approximately 1.0%. While the additional week added a few days to sales, it also added a full week's worth of operating costs; therefore, the net earnings impact was negligible.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. </span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20210103_g5.jpg" alt="jnj-20210103_g5.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20210103_g6.jpg" alt="jnj-20210103_g6.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div><span><br/></span></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in 2020 were $14.1 billion, an increase of 1.1% from 2019, which included 3.0% operational growth and a negative currency impact of 1.9%.  U.S.&#160;Consumer Health segment sales were $6.4 billion, an increase of 9.0%. International sales were $7.7 billion, a decrease of 4.6%, which included an operational decline of 1.3% and a negative currency impact of 3.3%.  In 2020, acquisitions and divestitures had a net negative impact of 0.1% on the operational sales growth of the worldwide Consumer Health segment. </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Consumer Health Franchise Sales*:</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:51.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health* Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Previously referred to as Consumer<br/>** Previously referred to as Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise sales of $4.8 billion increased 8.5% as compared to the prior year. Growth was primarily attributable to sales from TYLENOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> driven by COVID-19 stocking demand, ZYRTEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to competitor product out of stock and PEPCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to competitive product withdrawal both in the U.S., and increased consumption in anti-smoking aids. International sales were negatively impacted by COVID-19 and low incidence of cough and flu.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise sales were $4.5 billion in 2020, a decrease of 3.1% as compared to the prior year. The decline was primarily due to negative COVID-19 related impacts and SKU rationalization partially offset by growth in eCommerce and new product innovation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise sales of $1.6 billion increased 7.4% as compared to the prior year primarily attributable to sales of LISTERINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mouthwash due to U.S. eCommerce and club channel growth, increased stocking demand related to COVID-19 and new product launches in Asia Pacific. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise sales were $1.5 billion in 2020, a decrease of 9.4% compared to the prior year. The decline was primarily due to COVID-19 related impacts, SKU rationalization and the Baby Center divestiture in the U.S. partially offset by strength in AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">baby. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Women&#8217;s Health franchise sales were $0.9 billion in 2020, a decrease of 8.6% as compared to the prior year. The decline was primarily driven by COVID-19 impacts. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Wound Care/Other franchise sales were $0.7 billion in 2020, an increase of 7.2% as compared to the prior year. Growth was due to strong performance of NEOSPORIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BAND-AID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Brand Adhesive Bandages and COVID-19 related demand in the Asia Pacific region.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in 2020 were $45.6 billion, an increase of 8.0% from 2019, which included operational growth of 8.2% and a negative currency impact of 0.2%.  U.S.&#160;sales were $25.7 billion, an increase of 7.8%. International sales were $19.8 billion, an increase of 8.3%, which included 8.8% operational growth and a negative currency impact of 0.5%. In 2020, acquisitions and divestitures had a net negative impact of 0.2% on the operational sales growth of the worldwide Pharmaceutical segment. Adjustments to previous reserve estimates positively impacted the Pharmaceutical segment operational growth by approximately 1.0% in both fiscal years 2020 and 2019.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Pharmaceutical Therapeutic Area Sales*:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:57.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,692</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> /abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pulmonary Hypertension </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously included in Other Oncology</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology products sales were $15.1 billion in 2020, representing an increase of 7.9% as compared to the prior year driven by strong uptake of STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ustekinumab) in Crohn's disease and Ulcerative Colitis and strength in TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(guselkumab) in Psoriasis. This was partially offset by COVID-19 related demand and lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab) due to increased discounts/rebates and biosimilar competition.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patents for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries in Europe expired in February 2015. Biosimilar versions of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been introduced in certain markets outside the United States, resulting in a reduction in sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in those markets.  Additional biosimilar competition will likely result in a further reduction in sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in markets outside the United States.&#160;In the United States, a biosimilar version of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was introduced in 2016, and additional competitors continue to enter the market. Continued infliximab biosimilar competition in the U.S. market will result in a further reduction in U.S. sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products sales were $3.6 billion in 2020, representing an increase of 4.7% as compared to the prior year primarily due to strong sales of SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JULUCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products sales were $6.5 billion, representing an increase of 3.5% as compared to the prior year. Paliperidone long-acting injectables growth driven by sales of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (paliperidone palmitate) and INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from new patient starts and persistence. The growth was partially offset by migration from RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(risperidone) and declines in CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(methylphenidate) due to competitive entrants.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved sales of $12.4 billion in 2020, representing an increase of 15.7% as compared to the prior year. Contributors to the growth were strong sales of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) driven by patient uptake in all lines of therapy and the launch of a subcutaneous formulation in the U.S. and E.U.; IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib) due to market growth globally and maintaining strong share and the continued global launch uptake and share gains of ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apalutamide). Additionally, the growth was negatively impacted by declining sales of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(abiraterone acetate) and VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bortezomib) due to generic competition.     </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary Hypertension products achieved sales of $3.1 billion, representing an increase of 20.0% as compared to the prior year. Sales growth of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (macitentan) and UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (selexipag) were due to continued share gains and market growth. Additionally, sales of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bosentan) were negatively impacted by generics and migration to OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular/Metabolism/Other products sales were $4.9 billion, a decline of 6.0% as compared to the prior year. Sales growth of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (canagliflozin) were due to market growth and favorable channel mix dynamics in the U.S. and strength in the European region partially offset by U.S. share declines due to competitive pressures. The growth of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(rivaroxaban) was due to demand growth partially offset by higher rebates. Lower sales of PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epoetin alfa) were due to biosimilar competition. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Name          (Chemical Name)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US  Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU  Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU Filing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amivantamab </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (daratumumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination Regimen for Newly Diagnosed, Transplant-eligible Patients with Multiple Myeloma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(daratumumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with Carfilzomib and Dexamethasone for patients with Relapsed/Refractory Multiple Myeloma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> FASPRO (daratumumab and hyaluronidase)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (apalutamide)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Metastatic Castration-Sensitive Prostate Cancer </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ibrutinib)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In combination with Rituximab for treatment of Chronic Lymphocytic Leukemia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (canagliflozin)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Diabetic Kidney Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rilpivirine and cabotegravir</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Monthly, Injectable, Two Drug Regimen for Treatment of HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paliperidone Pamitate 6-month</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Schizophrenia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ponesimod</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of adults with Relapsed Multiple Sclerosis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (golimumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIRTURO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(bedaquiline)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPRAVATO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (esketamine)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder who have Active Suicidal Ideation with Intent</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ustekinumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (guselkumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Adults with Active Psoriatic Arthritis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uptravi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pulmonary arterial hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rivaroxaban)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;New Indication to Expand Use in Patients with Peripheral Artery Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZABDENO (Ad26.ZEBOV) and MVABEA (MVA-BN-Filo)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preventive Ebola Vaccine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment sales in 2020 were $23.0 billion, a decrease of 11.6% from 2019, which included an operational decrease of 11.4% and a negative currency impact of 0.2%. U.S.&#160;sales were $11.0 billion, a decrease of 10.9% as compared to the prior year. International sales were $11.9 billion, a decrease of 12.2% as compared to the prior year, with an operational decrease of 11.8% and a negative currency impact of 0.4%. In 2020, the net impact of acquisitions and divestitures on the Medical Devices segment worldwide operational sales growth was a negative 0.9% of which, the divestiture of Advanced Sterilization Products (ASP) had an impact of approximately 0.8%. Growth was negatively impacted by COVID-19 and associated deferral of medical procedures.   </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Medical Devices Franchise Sales*:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:53.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medical Devices Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Surgery which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Previously referred to as Spine &amp; Other</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise sales were $8.2 billion in 2020, a decrease of 13.4% from 2019. The decline in Advanced Surgery was primarily driven by the negative impact of COVID-19 and competitive pressures in the U.S. This was partially offset by the success of new products outside the U.S. and the recovery of an isolated supply disruption in the prior year related to SURGIFLO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decline in General Surgery was primarily driven by the negative impact of COVID-19 and the ASP divestiture.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Orthopaedics franchise sales were $7.8 billion in 2020, a decrease of 12.2% from 2019. The decline in hips was driven by the negative impact of COVID-19 partially offset by a leadership position in the Anterior approach, strong market demand for the ACTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stem and enabling technologies &#8211; KINCISE&#8482; and VELYS&#8482; Hip Navigation. The decline in knees was driven by the negative impact of COVID-19. The decline in Trauma was driven by the negative impact of COVID-19 partially offset by strength from new products. The decline in Spine, Sports &amp; Other was driven by the negative impact of COVID-19 partially offset by the uptake of new products.   </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise sales were of $3.9 billion in 2020, a decrease of 15.2% from 2019. The  Contact Lenses/Other operational decline was due to the negative impact of COVID-19. The Surgical operational decline was primarily driven by the negative impact of COVID-19 and competitive pressures in the U.S.     </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved sales of $3.0 billion in 2020, an increase of 1.6% from 2019. Growth in the electrophysiology business was driven by Atrial Fibrillation procedure growth coupled with strength from new products and market recovery offsetting negative impacts from COVID-19.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Consolidated Earnings Before Provision for Taxes on Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income was $16.5 billion and $17.3 billion for the years 2020 and 2019, respectively. As a percent to sales, consolidated earnings before provision for taxes on income was 20.0% and 21.1%, in 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20210103_g7.jpg" alt="jnj-20210103_g7.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold and Selling, Marketing and Administrative Expenses:</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20210103_g8.jpg" alt="jnj-20210103_g8.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/><img src="jnj-20210103_g9.jpg" alt="jnj-20210103_g9.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Medical Device idle capacity costs associated with COVID-19 related production slow downs</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Establishment of obsolescence reserves and fixed cost deleveraging associated with the impact of COVID-19 in the Medical Devices business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain costs associated with the development of the COVID-19 vaccine in the Pharmaceutical business </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable mix within the Pharmaceutical business</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable product mix with a higher percentage of sales coming from the Pharmaceutical business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset amortization expense included in cost of products sold was $4.7 billion and $4.5 billion, for the years 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in the Pharmaceutical and Consumer Health businesses </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio and investment optimization including execution of the ongoing SKU rationalization program in the Consumer Health business</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Favorable segment mix with a higher percentage of sales coming from the Pharmaceutical business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The negative impact on sales resulting from COVID-19 in the Medical Devices business </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expense: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense by segment of business was as follows:</span></div><div style="margin-bottom:6pt;margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:47.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Sales*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Sales*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent increase/(decrease) over the prior year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*As a percent to segment sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and developmental milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products. </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Segment mix driven by a higher percentage of sales generated by the Pharmaceutical business versus the prior year    </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The negative COVID-19 impact on Medical Devices sales</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased investment in the Medical Devices business related to robotics and digital programs</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio progression including the COVID-19 vaccine in the Pharmaceutical business, net of governmental reimbursements  </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research facilities are located in the U.S., Belgium, Brazil, China, France, Germany, India, Israel, the Netherlands, Poland, Singapore, Sweden, Switzerland and the United Kingdom with additional R&amp;D support in over 30 other countries.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2020, the Company recorded an IPR&amp;D charge of $0.2 billion primarily related to a partial impairment due to timing and progression of one of the digital surgery platforms acquired with the Auris Health acquisition. In the fiscal year 2019, the Company recorded an IPR&amp;D charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), unrealized gains and losses on investments, gains and losses on divestitures, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, as well as royalty income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal year 2020 was unfavorable by $0.4 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and Integration related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gains)/losses on securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity step-up gain related to DR. CI:LABO </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture Gains</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 litigation expense primarily associated with Talc related reserves and certain settlements ($4.0 billion). 2019 litigation expense primarily related to the agreement in principle to settle opioid litigation ($4.0 billion).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 is primarily driven by a contingent consideration reversal of approximately $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2019 included the divestiture of ASP  </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest (Income) Expense:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 included net interest expense of $90 million as compared to income of $39 million in the fiscal year 2019. This was primarily due to reduced interest income resulting from lower rates of interest earned on cash balances and a higher average debt balance. This was partially offset by a lower average debt interest rate and a higher average cash balance. Cash, cash equivalents and marketable securities totaled $25.2&#160;billion at the end of 2020, and averaged $22.2&#160;billion as compared to the cash, cash equivalents and marketable securities total of $19.3&#160;billion and $19.5&#160;billion average cash balance in 2019. The total debt balance at the end of 2020 was $35.3&#160;billion with an average debt balance of $31.5&#160;billion as compared to $27.7&#160;billion at the end of 2019 and an average debt balance of $29.1 billion. In the fiscal third quarter of 2020, the Company issued approximately $5.0 billion of commercial paper, with approximately $0.8 billion outstanding at year end. In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5 billion. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before tax by segment of business were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:38.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">See Note&#160;17 to the Consolidated Financial Statements for more details.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Consumer Health segment loss before tax as a percent of sales was (7.6)% versus income before tax of 14.8% in 2019. The decrease in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher litigation expense of $3.9 billion in 2020 vs. $0.4 billion in 2019 (primarily associated with talc related reserves and certain settlements) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fiscal year 2019 included a gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Portfolio and investment optimization including execution of the ongoing SKU rationalization program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Pharmaceutical segment income before tax as a percent to sales was 33.9% versus 20.9% in 2019.&#160;The increase in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower litigation expense of $0.8 billion in 2020 vs. $4.3 billion in 2019 (primarily related to the agreement in principle to settle opioid litigation, of which $1.0 billion is in 2020 and $4.0 billion is in 2019)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An in-process research and development charge of $0.9 billion in fiscal 2019 related to Alios</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower acquisition and integration related costs in fiscal 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in selling, marketing and administrative expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Medical Devices segment income before tax as a percent to sales was 13.3% versus 28.1% in 2019. The decrease in the income before tax as a percent to sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A gain of $2.0 billion related to the ASP divestiture recorded in the fiscal 2019</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Idle capacity costs associated with COVID-19 related production slow downs in fiscal 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Establishment of obsolescence reserves and fixed cost deleveraging associated with the impact of COVID-19 in fiscal 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The negative impact of COVID-19 on sales in fiscal 2020</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An in-process research and development charge of $0.2 billion in fiscal 2020 primarily related to the Auris Health acquisition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   &#160;&#160;&#160;&#160;partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A contingent consideration reversal of approximately $1.1 billion in fiscal 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense was $0.3 billion in 2020 vs. $0.4 billion in 2019 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In the fiscal second quarter of 2018, the Company announced plans to implement actions across its global supply chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160; Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 to $2.3 billion. The Company estimates that approximately 70% of the cumulative pre-tax costs will result in cash outlays.&#160;In 2020, the Company recorded a pre-tax charge of $0.4 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.2 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.3 billion have been recorded since the restructuring was announced.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;20 to the Consolidated Financial Statements for additional details related to the restructuring programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The worldwide effective income tax rate was 10.8% in 2020 and 12.7% in 2019. During the fiscal first quarter of 2021, the Internal Revenue Service published final regulations addressing the requirements for tax deductibility of settlement payments. The Company recorded a pre-tax reserve for $4.0 billion in the fiscal year 2019 based on the agreement in principle to settle opioid litigation and recorded an additional pre-tax $1.0 billion in the fiscal third quarter of 2020 upon which an effective rate of 21.4% has been applied. </span></div><div><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the fiscal 2020 provision for taxes refer to Note&#160;8 to the Consolidated Financial Statements. </span></div><div style="margin-bottom:8pt;margin-top:2.7pt;text-indent:18pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity&#160;&amp; Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $14.0&#160;billion at the end of 2020 as compared to $17.3&#160;billion at the end of 2019. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary sources and uses of cash that contributed to the $3.3&#160;billion decrease were:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2019 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2020 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $11.2 billion in marketable securities at the end of fiscal year 2020 and $2.0 billion at the end of fiscal year 2019. See Note&#160;1 to the Consolidated Financial Statements for additional details on cash, cash equivalents and marketable securities.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $23.5&#160;billion was the result of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses  </span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">decrease in accounts receivable </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts payable and accrued liabilities and other current and non-current liabilities</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in inventories and other current and non-current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">contingent consideration reversal (related to the timing of certain developmental milestones associated with the Auris Health acquisition) and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $20.8 billion of cash was primarily used for:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">primarily related to the acquisitions of Momenta, bermekimab and related assets from XBiotech Inc. as well as the acquisition of all outstanding shares in Verb Surgical Inc.</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other (primarily licenses and milestones)</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $6.1 billion of cash was primarily used for: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net proceeds from short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 3, 2021, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of January 3, 2021, the net debt position was $10.1 billion as compared to the prior year of $8.4 billion. There was an increase in the net debt position due to increased borrowings in the fiscal third quarter of 2020. The debt balance at the end of 2020 was $35.3 billion as compared to $27.7 billion in 2019. Considering recent market conditions and the on-going COVID-19 crisis, the Company has evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the talc litigation and agreement in principle to settle opioid litigation of which the majority may be paid over the next two to three years. In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. In the fiscal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third quarter of 2020, the Company issued approximately $5.0 billion of commercial paper, with approximately $0.8 billion outstanding at year end.  In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5 billion.  For additional details on borrowings, see Note&#160;7 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Momenta Pharmaceuticals, Inc. acquisition which closed on October 1, 2020 and for general corporate purposes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as a result of the Tax Cuts and Jobs Act (TCJA), the Company has access to its cash outside the U.S. at a significantly reduced cost. </span></div><div style="margin-top:4pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s material contractual obligations and their aggregate maturities as of January&#160;3, 2021: To satisfy these obligations, the Company intends to use cash from operations.  </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:28.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax Legislation (TCJA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest on<br/>Debt Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For tax matters, see Note&#160;8 to the Consolidated Financial Statements. The table does not include activity related to business combinations or the Company&#8217;s approximate $0.9 billion in contractual supply commitments associated with its development of a COVID-19 vaccine. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing and Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S.&#160;Dollar from the January 3, 2021 market rates would increase the unrealized value of the Company&#8217;s forward contracts by $121&#160;million.  Conversely, a 10% depreciation of the U.S.&#160;Dollar from the January&#160;3, 2021 market rates would decrease the unrealized value of the Company&#8217;s forward contracts by $148&#160;million. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated earnings and cash flows.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S.&#160;and foreign interest rates on the Company&#8217;s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company&#8217;s swap contracts by approximately $1,667 million. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated cash flows.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote. The Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. See Note&#160;6 to the Consolidated Financial Statements for additional details on credit support agreements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in both fixed rate and floating rate interest earning securities which carry a degree of interest rate risk. The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall. A 1% (100 basis points) change in spread on the Company&#8217;s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by approximately $36 million. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2020, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;9, 2021.  Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, London Interbank Offered Rates (LIBOR), Secured Overnight Financing Rate (SOFR) Swap Curve or other applicable market</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate as allowed plus applicable margins. Commitment fees under the agreement are not material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total borrowings at the end of 2020 and 2019 were $35.3&#160;billion and $27.7&#160;billion, respectively. The increase in borrowings was the issuance of notes in 2020 when market conditions were favorable. In 2020, net debt (cash and current marketable securities, net of debt) was $10.1&#160;billion compared to net debt of $8.4&#160;billion in 2019. Total debt represented 35.8% of total capital (shareholders&#8217; equity and total debt) in 2020 and 31.8% of total capital in 2019. Shareholders&#8217; equity per share at the end of 2020 was $24.04 compared to $22.59 at year-end 2019.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of borrowings can be found in Note&#160;7 to the Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company increased its dividend in 2020 for the 58th&#160;consecutive year. Cash dividends paid were $3.98 per share in 2020 and $3.75 per share in 2019. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Board of Directors declared a regular cash dividend of $1.01 per share, payable on March 9, 2021 to shareholders of record as of February 23, 2021.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i26b7b3066a4848f5be790a5478bde067_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of results of operations and financial condition are based on the Company&#8217;s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company&#8217;s operating results and financial condition.  These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock based awards.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to, the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the year ended January 3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years&#160;2020 and&#160;2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities.   Amounts due from collaborative partners for these arrangements are recognized as each activity is performed or delivered, based on the relative selling price. Upfront fees received as part of these arrangements are deferred and recognized over the performance period. See Note&#160;1 to the Consolidated Financial Statements for additional disclosures on collaborations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:45.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of     Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,960)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,169)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,088&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $66&#160;million at January&#160;3, 2021 and $54&#160;million at December&#160;29, 2019, recorded as a contra asset.</span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-bottom:6pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:45.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of       Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,873)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,716&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,910)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,680)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,617)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $174&#160;million at January&#160;3, 2021 and $93&#160;million at December&#160;29, 2019, recorded as a contra asset. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes adjustments</span></div><div style="margin-top:13pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:45.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of       Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,790)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $707&#160;million at January&#160;3, 2021 and $499&#160;million at December&#160;29, 2019, recorded as a contra asset.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2021, the Internal Revenue Service published final regulations addressing the requirements for tax deductibility of settlement payments. The Company recorded a pre-tax reserve for $4.0 billion in fiscal 2019 based on the agreement in principle to settle opioid litigation and recorded an additional pre-tax $1.0 billion in the fiscal third quarter of 2020 upon which an effective rate of 21.4% has been applied. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Self Insurance Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company records accruals for various contingencies, including legal proceedings and product liability claims as these arise in the normal course of business. The accruals are based on management&#8217;s judgment as to the probability of losses and, where applicable, actuarially determined estimates. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 1 and 19 to the Consolidated Financial Statements for further information regarding product liability and legal proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived and Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company assesses changes, both qualitatively and quantitatively, in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and intangible assets.  As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, mortality rates, expected salary increases, health care cost trend rates and attrition rates. See Note&#160;10 to the Consolidated Financial Statements for further details on these rates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. Based on the type of equity instrument, the fair value is estimated on the date of grant using either the Black-Scholes option valuation model or a combination of both the Black-Scholes option valuation model and Monte Carlo valuation model, and is expensed in the financial statements over the service period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and expected dividend yield. Prior to fiscal 2020, for performance share units, the fair market value was calculated for each of the three component goals at the date of grant: operational sales, adjusted operational earnings per share and relative total shareholder return. Beginning in fiscal 2020, for performance share units, the fair market value is calculated for the two component goals at the date of grant: adjusted operational earnings per share and relative total shareholder return. &#160;The fair values for the earnings per share goal of each performance share unit was estimated on the date of grant using the fair market value of the shares at the time of the award, discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. See Note&#160;16 to the Consolidated Financial Statements for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note&#160;1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of January&#160;3, 2021.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Economic and Market Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:12.03pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. In the fiscal third quarter of 2020, the Company issued approximately $5.0 billion of commercial paper, with approximately $0.8 billion outstanding at year end, for additional liquidity. Additionally, in the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5 billion. The net proceeds from this offering were used to fund the Momenta Pharmaceuticals, Inc. acquisition on October 1, 2020 and for general corporate purposes.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of health care.  In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2010&#160;- 2020, in the U.S., the weighted average compound annual growth rate of the Company&#8217;s net price increases for health care products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S.&#160;Consumer Price Index (CPI).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company has accounted for operations in Argentina (beginning in the fiscal third quarter of 2018) and Venezuela as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2016, the United Kingdom (U.K.) held a referendum in which voters approved an exit from the European Union (E.U.), commonly referred to as &#8220;Brexit&#8221;. The U.K. officially exited the E.U. on January 31, 2020, however, there was a transition period  to allow time to agree the terms of a new trade deal. On December 30, 2020, the U.K., E.U. and the European Atomic Energy Community (Euratom) signed the EU&#8211;UK Trade and Cooperation Agreement (TCA). Over the last few years, Brexit has created global political and economic uncertainty and has led to volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. While the UK and EU have now agreed on a future trade and cooperation agreement, it is still unclear what the ultimate financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. will have. However, the Company currently does not believe that these and other related effects will have a material impact on the Company&#8217;s consolidated financial position or operating results. As of January&#160;3, 2021, the business of the Company&#8217;s U.K. subsidiaries represented less than 6% of the Company&#8217;s consolidated assets and less than 3% of the Company's fiscal twelve months revenues.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value of the U.S.&#160;Dollar as compared to all foreign currencies in which the Company had sales, income or expense in 2020 would have increased or decreased the translation of foreign sales by approximately $384&#160;million and net income by approximately $115&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160; This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of business.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January&#160;3, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;19 to the Consolidated Financial Statements for further information regarding legal proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Common Stock is listed on the New York Stock Exchange under the symbol JNJ. As of February 16, 2021, there were 132,376 record holders of Common Stock of the Company. </span></div><div style="text-align:center"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_100"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#160;- Liquidity and Capital Resources - Financing and Market Risk&#8221; of this Report; and Note&#160;1 &#8220;Summary of Significant Accounting Policies&#160;- Financial Instruments&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Audited Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_106">39</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_106">Consolidated Balance Sheets</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_112">40</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_112">Consolidated Statements of Earnings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_115">41</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_115">Consolidated Statements of Comprehensive Income </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_121">42</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_121">Consolidated Statements of Equity</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_127">43</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_127">Consolidated Statements of Cash Flows</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_130">45</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_130">Notes to Consolidated Financial Statements</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_223">101</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_223">Report of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_226">104</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26b7b3066a4848f5be790a5478bde067_226">Management&#8217;s Report on Internal Control Over Financial Reporting</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At January&#160;3, 2021 and December&#160;29, 2019 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions Except Share and Per Share Amounts) (Note&#160;1)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Notes&#160;1 and 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMtMS0xLTEtMA_7cff0b4e-e9ef-4e0a-9363-bbbd845a3369">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMtMy0xLTEtMA_beb83466-7f44-40cd-866a-c18321af9cdb">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities (Notes&#160;1 and 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQtMS0xLTEtMA_99aabf6a-92a6-446c-b663-554f93707e63">11,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQtMy0xLTEtMA_b07bff83-8d5f-4eeb-832a-f27f482612bb">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable trade, less allowances for doubtful accounts $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMC0xLTEtMC90ZXh0cmVnaW9uOmI3Zjk2MjMzMjBiYjQwZDA5YzUwMTYwM2NjY2U2ODdkXzEwNDQ1MzYwNDY0MDAy_1f806fa0-beb5-4608-865c-f066168089e0">293</ix:nonFraction> (2019, $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMC0xLTEtMC90ZXh0cmVnaW9uOmI3Zjk2MjMzMjBiYjQwZDA5YzUwMTYwM2NjY2U2ODdkXzEwNDQ1MzYwNDY0MDA4_a0448510-1ede-416b-9acb-0566759d31b3">226</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMS0xLTEtMA_50c101a7-ab9b-4a29-b9cf-0a83dad44695">13,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMy0xLTEtMA_0f3d91cf-d266-4c0f-bfdd-255c54971641">14,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Notes&#160;1 and 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzYtMS0xLTEtMA_6043f179-e24d-40cf-ab57-97fb375bbfc9">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzYtMy0xLTEtMA_6e7101e5-fc96-460f-8400-d81c927ad16b">9,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzgtMS0xLTEtMA_03f75bbb-1710-44e7-b48d-61369263f242">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzgtMy0xLTEtMA_96111967-86ee-4363-917b-c6296d69b436">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale (Note 18)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzktMS0xLTEtMA_b7011065-47fb-479d-a158-6297e101a7bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzktMy0xLTEtMA_98bb605a-043e-4f2b-ba9d-8ef90066a28c">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEwLTEtMS0xLTA_fe7f1501-3e28-48f9-8c76-22f941e13a5a">51,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEwLTMtMS0xLTA_aa31dc7a-932d-4db2-9a20-072f2d4576f5">45,274</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (Notes&#160;1 and 4)</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzExLTEtMS0xLTA_559a4e40-0352-4aab-93f8-ff3f0e4396b9">18,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzExLTMtMS0xLTA_0e0e90cb-bafa-4ceb-9894-8cbc583b81b3">17,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Notes&#160;1 and 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEyLTEtMS0xLTA_b279dd9b-ab45-497d-8de6-276a8b1a96bb">53,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEyLTMtMS0xLTA_8e1802c9-f9d7-4424-b6aa-c85732be4828">47,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Notes&#160;1 and 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEzLTEtMS0xLTA_b004e358-f0db-4b27-b61f-ac5f9fa43940">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEzLTMtMS0xLTA_37910069-73db-4909-9e42-3c70f630a648">33,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE0LTEtMS0xLTA_5bc882e6-b59b-413d-8d1a-7d9e663a6371">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE0LTMtMS0xLTA_1897e2a8-0ead-445f-a59b-1f71037aa592">7,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE1LTEtMS0xLTA_de3bf9b1-972e-4b85-89a0-27675e62be19">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE1LTMtMS0xLTA_3fd94708-cb3d-45c9-aa0a-faabfc5f7e3e">5,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE2LTEtMS0xLTA_e158f724-df9e-48ca-91c2-42106bd693ce">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE2LTMtMS0xLTA_02f576f4-c284-4216-a6a6-3c3e44491f9c">157,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable (Note&#160;7)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE5LTEtMS0xLTA_160eda75-7ae4-4714-88b8-b87310da6c34">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE5LTMtMS0xLTA_130f2f71-a788-42a4-b9e9-b23c84458de4">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIwLTEtMS0xLTA_2e714b38-9a20-4459-b75d-cf6965b70705">9,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIwLTMtMS0xLTA_11248ea8-2b85-4910-8de8-512b78d565f9">8,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIxLTEtMS0xLTA_9b4965e1-1d35-4831-adbc-e812ea89799d">13,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIxLTMtMS0xLTA_76c16027-0257-4ac0-b411-1fd71191b882">9,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIyLTEtMS0xLTA_6c44d427-b1b7-4f62-bef3-6735926d808b">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIyLTMtMS0xLTA_12109b4b-7287-4049-a898-686ab31aa66f">10,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIzLTEtMS0xLTA_35a5c9a6-e04f-41fe-92e3-122861a221c1">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIzLTMtMS0xLTA_14d1971b-ccda-44bd-bace-f9ce1bd875c1">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI0LTEtMS0xLTA_9a5e937a-d82c-4607-b85f-6225e189209d">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI0LTMtMS0xLTA_385353c7-8a1e-4140-92d2-aac550f35aca">2,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI1LTEtMS0xLTA_f4cdd2eb-948b-4f25-b67a-b130d1cd07ee">42,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI1LTMtMS0xLTA_3bd205da-94b4-41c6-b33e-582cbdc3a0b6">35,964</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note&#160;7)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI2LTEtMS0xLTA_74f8154b-3269-49f9-a1c4-1d85fffc2744">32,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI2LTMtMS0xLTA_9c16aeac-74e7-4b5c-93e3-5f543f6e934f">26,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI3LTEtMS0xLTA_f9476d30-b455-4e03-8b30-b6c373caf5db">7,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI3LTMtMS0xLTA_c7f26d3b-6b31-4a8e-92e7-2b0fdef76e95">5,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Notes&#160;9 and 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI4LTEtMS0xLTA_2661efa9-441f-4e0b-ad47-3d216c39a6bc">10,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI4LTMtMS0xLTA_1cbe8b4c-af5b-4bea-accc-26d7f5beec0d">10,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI5LTEtMS0xLTA_caceb2b8-1d0f-4696-b916-26f0579a77d7">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI5LTMtMS0xLTA_d5970415-3aae-49ff-b1fc-4b1fd96e1c15">7,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMwLTEtMS0xLTA_02c0334e-542d-4f08-9498-16070e408d10">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMwLTMtMS0xLTA_836c039a-cd9b-4c7a-b0ff-df011ce0574f">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMxLTEtMS0xLTA_65743cfd-0eea-43af-86fc-5c0616c9b3a7">111,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMxLTMtMS0xLTA_84a97ac8-c6fc-492f-abc4-6bacd6e45950">98,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 19)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#160;&#8212; without par value (authorized and unissued <ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo3OTQxNmU4ZjBkMmE0YzUyYmIxODUyNGFlMjhjMjA1NV8xMDQ0NTM2MDQ2Mzk2Mw_b1ef37b6-e83b-41a2-8837-007f725314b1"><ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo3OTQxNmU4ZjBkMmE0YzUyYmIxODUyNGFlMjhjMjA1NV8xMDQ0NTM2MDQ2Mzk2Mw_cc3a80e3-a4d9-4a6c-bc1c-662a61688386">2,000,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTEtMS0xLTA_f05e5434-ea08-47ac-9c47-e5d4f1e480be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTMtMS0xLTA_bb37c7e2-e72a-4572-b457-a43c9fb045d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#160;&#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA1OQ_031391fa-00b3-4ce8-ba1d-6bad8c733b55"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA1OQ_afe9a256-55e8-4ce6-ad14-7350d3f5429c">1.00</ix:nonFraction></ix:nonFraction> per share (Note&#160;12) (authorized <ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA3NQ_2b2af63a-ea60-4154-99a2-698d31429b0b"><ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA3NQ_f6e7c478-6c39-457f-8e64-a4370fb84ca8">4,320,000,000</ix:nonFraction></ix:nonFraction>&#160;shares; issued <ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA5MQ_45d0753a-3891-4b28-b493-4599f18d5b88"><ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA5MQ_bd49c32a-3bca-44d6-9bcf-f61cebf294b2">3,119,843,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTEtMS0xLTA_e0e94667-f9b1-4683-bf05-d03fd0af88cb">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTMtMS0xLTA_4b2e98b6-5125-49d2-990e-5b75bdbfb86b">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note&#160;13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM2LTEtMS0xLTA_077cbf96-ae6c-41f6-aa40-73a16e74f9ed">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM2LTMtMS0xLTA_0ead9899-c757-476d-b2b4-cdc22d910f67">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM3LTEtMS0xLTA_60343a8c-6a84-45c6-82d9-46a76c3ef669">113,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM3LTMtMS0xLTA_a4f4f3d4-7f02-446e-ad78-e3907870cbef">110,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityBeforeTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM4LTEtMS0xLTA_dc714698-4a8a-447a-bf68-5d034db2623d">101,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityBeforeTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM4LTMtMS0xLTA_93217892-2a33-4dc1-9f3c-cb64b5a6e120">97,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (Note&#160;12) (<ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjpjYzZiNjNkZTc3MTY0MjQyYmExN2VjMzE2MTZkMzg1YV8xMDQ0NTM2MDQ2NDAzNw_784a1d16-07a0-4e3f-8f51-baa0d2a65958">487,331,000</ix:nonFraction>&#160;shares and <ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjpjYzZiNjNkZTc3MTY0MjQyYmExN2VjMzE2MTZkMzg1YV8xMDQ0NTM2MDQ2NDA1MQ_c3d3682e-6d78-462e-ac3e-4e268e645ff0">487,336,000</ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTEtMS0xLTA_99791e43-4434-46f4-ba05-ec68ac6334e1">38,490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTMtMS0xLTA_20402a1e-5201-4309-b641-0ddc5d5b50df">38,417</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQwLTEtMS0xLTA_1f157a0b-3a8c-44d3-94ba-1eeafc33a8b3">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQwLTMtMS0xLTA_f1dd902e-05b6-4612-b885-622c529fa35e">59,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQxLTEtMS0xLTA_2ed61015-504d-481d-bf27-6f3786dc8349">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQxLTMtMS0xLTA_828c6bd6-7195-4be5-b0f1-eb476365e0a6">157,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars and Shares in Millions Except Per Share Amounts) (Note&#160;1)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:63.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to customers</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEtMS0xLTEtMA_edc41550-da2b-403f-84f6-ebbcfa34566e">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEtMy0xLTEtMA_8802b06b-1d17-4524-88d6-e60bcb7631ad">82,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEtNS0xLTEtMA_73ea1650-c9b2-4b35-956e-38a1331505da">81,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzItMS0xLTEtMA_00f4788f-cd20-421a-95dd-d133268b49d5">28,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzItMy0xLTEtMA_5e63f181-f836-44cc-94f4-88fb34d47269">27,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzItNS0xLTEtMA_796d2d7a-a8a9-4898-9e31-5a26469fb9e6">27,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzMtMS0xLTEtMA_b5adc7cd-3424-4b37-ab2f-580cd4b8c385">54,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzMtMy0xLTEtMA_2228ead5-22ca-4c37-a62e-0661973ca535">54,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzMtNS0xLTEtMA_ec9ac78b-c354-4d81-9729-d6a748b1cf73">54,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzQtMS0xLTEtMA_ff2beccb-266a-4bf9-89b5-c64201900fe1">22,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzQtMy0xLTEtMA_b629c0cc-6a46-46d1-b6a2-d98b65c6d06a">22,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzQtNS0xLTEtMA_3c774077-7c9d-4e8f-ab72-e93b5b1f1092">22,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzUtMS0xLTEtMA_c8e63725-9845-49cc-8cd5-5b7431e903f4">12,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzUtMy0xLTEtMA_9fcd7b69-bbcf-4604-86e9-528f9dfb7029">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzUtNS0xLTEtMA_ab9d1e55-ae5d-4792-8a52-2e01d0f1abc9">10,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzYtMS0xLTEtMA_4d947838-0c86-4437-8d32-5ab029d4de6d">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzYtMy0xLTEtMA_c5e81c42-743e-4d5d-9c11-8fdfeb8a0c04">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzYtNS0xLTEtMA_f0ae13a5-6f0a-46fe-b04b-30260a7d475a">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzctMS0xLTEtMA_7d54126e-7c23-4a72-a509-67fecd10a2d0">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzctMy0xLTEtMA_eba2bd1a-6a79-47c9-aba6-1293ab8c273e">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzctNS0xLTEtMA_4fa41b31-3e20-49b2-9d9a-2a14631d4f2c">611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized (Note&#160;4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzgtMS0xLTEtMA_5cb1ad7a-b3ca-4c7f-a905-3187bf654afa">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzgtMy0xLTEtMA_df4e8561-600b-4fe0-bee7-a81b42253844">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzgtNS0xLTEtMA_59926d7e-41fb-4d66-a541-8c68f37dfede">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzktMS0xLTEtMA_c4926f28-ece7-470a-8c52-3454c08fa7bd">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzktMy0xLTEtMA_a79d9d12-9c4e-49ba-aa09-86b4a315d01e">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzktNS0xLTEtMA_40371961-129b-4aa6-8774-09fe97def73d">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEwLTEtMS0xLTA_6df869b9-5364-436d-9a38-5b95084f44a4">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEwLTMtMS0xLTA_392776c9-f63e-442c-8b33-c0f1399acedd">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEwLTUtMS0xLTA_fee72094-16f8-4a16-916d-6c3d7b2b159d">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzExLTEtMS0xLTA_5a276888-60c2-46ad-895c-ad1b1ee5e7fc">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzExLTMtMS0xLTA_93ea693f-d481-41ff-8257-ae7a24534659">17,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzExLTUtMS0xLTA_61a5e430-24ca-4aad-a847-638dbd974e9a">17,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note&#160;8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEyLTEtMS0xLTA_779a7339-7d43-4e2d-8acf-d9d0d6865049">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEyLTMtMS0xLTA_09601d10-634e-4819-a51f-f5ba246a980b">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEyLTUtMS0xLTA_748603d3-f884-45b0-8fe7-644e17191e14">2,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEzLTEtMS0xLTA_97c84e33-d77a-47f1-a1bb-f5a0073f02b3">14,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEzLTMtMS0xLTA_091fd51e-026f-48d8-9e65-b9e11e4506b7">15,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEzLTUtMS0xLTA_580d4857-1c9c-48e8-a0ef-d67f260cb531">15,297</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings per share (Notes 1 and 15)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE2LTEtMS0xLTA_3876ec82-d604-47f6-94a5-cf2cc277c2ff">5.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE2LTMtMS0xLTA_f52a37cb-af96-4170-8d9c-edfba893ef9c">5.72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE2LTUtMS0xLTA_07cb47e4-b717-436b-a6f6-ef0f5d2fbbec">5.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Diluted </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE3LTEtMS0xLTA_407ccd2c-f7ea-4511-8702-89a935b5babf">5.51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE3LTMtMS0xLTA_7cc44f1b-cad3-42d6-8c7e-9a60173c50dd">5.63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE3LTUtMS0xLTA_982e060c-91dc-4533-b3cb-4dd46aecf133">5.61</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average shares outstanding (Notes 1 and 15)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE5LTEtMS0xLTA_8b1695b2-dc6f-4557-a72f-b0cf1203b4ec">2,632.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE5LTMtMS0xLTA_bad6c05f-ceb5-4af0-b441-037a7ea6e8b8">2,645.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE5LTUtMS0xLTA_6593f624-2158-48ba-88f8-c910345ef50e">2,681.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzIwLTEtMS0xLTA_1ac71163-3ee4-410f-bc64-5158ee09f2d7">2,670.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzIwLTMtMS0xLTA_7858be5d-2a6a-4f11-9c76-3799bbf64723">2,684.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzIwLTUtMS0xLTA_1ac6d818-37d2-49eb-a240-c671d86daf29">2,728.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note&#160;1)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:56.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEtMS0xLTEtMA_3458aaf0-6f93-4029-9e2d-92452661513e">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEtMy0xLTEtMA_44f51d6b-1012-4b02-b9f4-ca41514c3863">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEtNS0xLTEtMA_24632c52-8718-445f-bf82-c460a30c345b">15,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzQtMS0xLTEtMA_d29d0e00-5105-4d3a-a6eb-3eda62c1788b">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzQtMy0xLTEtMA_8119455b-82b0-4577-8f34-485125cdf2f2">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzQtNS0xLTEtMA_456a9824-90b6-4b35-a1a4-8116ce6b1f38">1,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzctMS0xLTEtMA_549b41ff-a802-4cdf-a469-4b984a206a4b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzctMy0xLTEtMA_232a2f3c-ef7c-4532-98b5-e07d78e73d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzctNS0xLTEtMA_e38ea875-22a0-4f46-b9ec-8db9c0352f2e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzgtMS0xLTEtMA_4a5b2b1c-556a-4baf-a7aa-e5cb817fe155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzgtMy0xLTEtMA_5c34317c-26e0-454e-aa2b-c09efcb24d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzgtNS0xLTEtMA_3f7a6c2c-a0b2-4062-8b9c-cfa77f91474a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzktMS0xLTEtMA_2e970330-d148-4888-a7db-c3e68174b331">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzktMy0xLTEtMA_9af1abc7-eb6a-4d13-aebe-b00671108e8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzktNS0xLTEtMA_bb1d329f-d4c9-490b-a01c-994fd570d3c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Employee benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior service credit (cost), net of amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEyLTEtMS0xLTA_4ebfb591-2e46-44c1-97c0-e6a456182301">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEyLTMtMS0xLTA_9fc8deca-34be-4844-ab3e-a85621ae93f1">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEyLTUtMS0xLTA_e71e60b1-6e9f-4fe8-9a58-3024f3929fb2">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain (loss), net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEzLTEtMS0xLTA_348951c8-5ca1-447b-85d0-63bedfee1cef">1,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEzLTMtMS0xLTA_269c4a4d-9f11-4438-afac-1b58ab83b657">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEzLTUtMS0xLTA_258b4ab6-834c-47df-84bc-fe6a9f0c6641">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE0LTEtMS0xLTA_67e81eeb-17ac-45d7-9f03-072eefc7ffcb">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE0LTMtMS0xLTA_26e3c267-c1e3-43d3-bce4-a7614537902c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE0LTUtMS0xLTA_44240578-7fd3-4d0b-a13e-df0cfb63f0b0">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE1LTEtMS0xLTA_db7d0e36-b92d-45e7-9f98-d99e50fc9cb1">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE1LTMtMS0xLTA_a63f67b3-6c90-4902-9ea7-4d167f7d8024">733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE1LTUtMS0xLTA_41b05e8b-d31a-4a1a-8c86-d21dc1121176">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE4LTEtMS0xLTA_02ae4109-625e-4045-a5c3-44f327fd18a5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE4LTMtMS0xLTA_4e6f60b6-8ca7-4b3c-98d6-ee8202a1a1a6">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE4LTUtMS0xLTA_f0f7341e-a6f8-4440-91d0-07ac25e5d394">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE5LTEtMS0xLTA_4d54ee1e-bf4d-4b9f-8167-9b34ee97a453">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE5LTMtMS0xLTA_ae863451-eb37-4c40-a128-d7b78ef042d0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE5LTUtMS0xLTA_5af04fbf-2192-4e14-917d-e85b9977ca01">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIwLTEtMS0xLTA_15950ad7-868e-463c-b7fb-d3509820c585">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIwLTMtMS0xLTA_3fa3a6e0-943f-4ee2-863f-cf80d743ade9">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIwLTUtMS0xLTA_5461f173-9daa-415c-bb59-8a028791aabf">265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIyLTEtMS0xLTA_a1fca621-13bd-4c85-90eb-7edb77ddcc2b">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIyLTMtMS0xLTA_99765979-92cc-4cc3-bb9f-2231e7babaf9">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIyLTUtMS0xLTA_c039f320-28d6-4e09-a38e-8a7f50e1d314">1,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzI0LTEtMS0xLTA_a9d640f3-f071-48d9-aea9-2171574e143b">15,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzI0LTMtMS0xLTA_7f6d6149-c138-4747-b2f0-191115b61aab">14,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzI0LTUtMS0xLTA_8afe244d-716f-42e0-88ef-014da225b12b">13,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal years 2020, 2019 and 2018 respectively: Foreign Currency Translation; $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDE5MA_6cb84a6f-b51e-4a42-a751-ad3326a1d5f3">536</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDE5NQ_6ef63fbb-7489-41fb-893f-00b57fd99363">19</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIwMQ_fd91fb58-279a-4610-bb91-6ef3e07edbfa">236</ix:nonFraction> million; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIwNg_70380704-abe8-44ee-af09-bd17459078e5">21</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIxMg_5448318a-f02d-48fb-b7ff-3650057303a9">222</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIxNg_ce7161e5-3a55-4309-89be-0f47903e758b">4</ix:nonFraction> million, Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIyMg_b370047d-bd52-477c-b713-d6bfd32d6384">252</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIyNw_4fef733a-f8d4-494e-b2b1-008c650b442d">27</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIzMg_ab9c7bd5-0a64-47e8-a8c5-fa4657344dd2">70</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note&#160;1)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2017</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtMS0xLTEtMA_a4c90053-a641-4497-817c-84815cfe23b7">60,160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12ae720d2c4dc085eddd1250b291b7_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtMy0xLTEtMA_68e8a395-c668-4583-b422-31c7a7f082db">101,793</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ba23fda59684540bdcab8d2c6182237_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtNS0xLTEtMA_16a1eec9-f26c-4083-9dd1-c4f23a6a0210">13,199</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced5cdc4242a49e886f089e2363899f7_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtNy0xLTEtMA_be739aa1-01e6-42ed-83c9-abdb3d511286">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7c2da1e43f14fe88eac34709ef35e41_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtOS0xLTEtMA_2c779a1e-c7d1-42e9-b0a9-1d99623af90b">31,554</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i375dae870e264e26b914483f200eb437_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMS0xLTEtMjcwOQ_2aad1243-5b8a-495d-bf19-e338990f7ee2">486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a614105f7d44e2eabdb115a8fef94dc_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMy0xLTEtMjcwNQ_bfdc14ad-8411-428a-b75c-3c6f02da8145">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf4bf571e18643da8a5b4eb3bfc07a7d_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItNS0xLTEtMjcxMw_e4e50327-e932-4783-be08-f9a3c8a4f208">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMS0xLTEtMA_10db52a9-9ecd-40a7-8b8f-33cd83aff686">15,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMy0xLTEtMA_f5e186ce-55d9-4860-9378-08f6605ad480">15,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtMC0xLTEtMzcxNi90ZXh0cmVnaW9uOjQyMjVlMTY1ODc3ZTRmOTk4NGY1NDRjY2Q1Zjk3NmQ3XzEwNDQ1MzYwNDYzOTE3_9e72277f-440d-4ec2-bb95-6123784ebfe1">3.54</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzMtMS0xLTEtMA_73014713-a5e8-49c7-befe-57f9ff7e51d4">9,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzMtMy0xLTEtMA_e82130be-e249-41bb-92da-d98e36a68364">9,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtMS0xLTEtMA_063eb03e-cbbf-4549-8135-0f5c6a114b77">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtMy0xLTEtMA_e8c65a4a-5c06-440a-8413-c70e7ffb0bdf">1,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtOS0xLTEtMA_90baee95-c500-4cc5-b204-3875a4a63676">3,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzUtMS0xLTEtMA_f09d11ea-771f-42c7-91b2-54205e5463f9">5,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzUtOS0xLTEtMA_b689166d-1475-40fc-b4c6-6d232f8a8eab">5,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzYtMS0xLTEtMA_a74e7c4b-faa3-4899-a6d3-94f8d52b7cd5">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzYtMy0xLTEtMA_c14e45df-dea1-44df-96a0-f8956c031ee2">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzctMS0xLTEtMA_2e1682db-ff80-4b60-a0f0-a1eb114027ff">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d809f74ca674af2a83700b574ef976a_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzctNS0xLTEtMA_a6815558-ffee-4c75-80de-a8d84897d3ff">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 30, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtMS0xLTEtMA_2fe98a11-9ab6-4171-a75b-8675d7c5063b">59,752</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a37f3f6ee9a4fd68dc6ebb535681918_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtMy0xLTEtMA_c4b875f8-df30-4d0d-844b-19065e18b924">106,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2de20cab02a4cf8a8defc94d4572ad4_I20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtNS0xLTEtMA_b48bb73e-a6c0-469b-ba9d-0c68be6ee425">15,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876cc85cac534bcda664e8b8d9cf58fb_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtNy0xLTEtMA_1a77c3cf-4d46-4698-bb55-a0038e56ee1e">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i402d9278fd56456f8c7a670066d1ed23_I20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtOS0xLTEtMA_96a0a5ce-fb94-498e-aee8-703f866571eb">34,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEwLTEtMS0xLTA_df3ccc3e-21fd-4620-97ea-5ff0658cf2ee">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEwLTMtMS0xLTA_41e50b52-17e5-405e-b0d0-714ad0978ec5">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTAtMS0xLTM3MjAvdGV4dHJlZ2lvbjo1YzNjYjk2Mzg1YzY0YmRkYTg0MTA3NWZmYmVjZjAxYl8xMDQ0NTM2MDQ2MzkxNw_7afccbaf-7095-471d-a0ba-2c2e047c4064">3.75</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzExLTEtMS0xLTA_b4ae2974-46e1-43b4-8a5b-c31f378a9237">9,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzExLTMtMS0xLTA_e843c558-24d1-4b77-9e1f-a18cdf463a8f">9,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTEtMS0xLTA_3fdeeae5-2448-4116-be2b-b8013bd933c2">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTMtMS0xLTA_18aa44a0-daaa-4dab-bd6b-5673ad64b3ba">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTktMS0xLTA_d03ba3f2-0707-4410-9d0a-d0dc819b881f">2,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEzLTEtMS0xLTA_0c103caf-1b2d-47d7-9f21-3d547aab1998">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEzLTktMS0xLTA_0be3ea46-f17b-46e9-ba8e-e6520b840c73">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE0LTEtMS0xLTA_5308a118-e7e9-496b-8a7e-ce9c47d1034c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE0LTMtMS0xLTA_c90cc2d4-3978-4a0e-99a6-3c652613bd08">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE1LTEtMS0xLTA_166e51ec-85a6-4e26-9d78-9aa6bbbc853b">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411749566b1e45288b6797e92e4b8e37_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE1LTUtMS0xLTA_2ea406bb-4402-4703-8c41-3d8e716ea850">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 29, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTEtMS0xLTA_663443b9-e849-4c55-9c50-41c3f2a02fea">59,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe1daa397894e5683897624a288d022_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTMtMS0xLTA_7661bb87-da40-408e-b8d2-9be2ceaa5214">110,659</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafa9de0a8f744f78e2171c3ec5ff108_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTUtMS0xLTA_981735e4-970a-48de-b435-85f2b6702a7d">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f92b62ca0e43c1a522880b7018fd18_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTctMS0xLTA_9b1770d3-f11a-4d9c-8d1e-d86b0178c6bf">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib841bff089b9422dba63507cc4961d15_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTktMS0xLTA_35f5dfa5-7e3b-48f3-b728-8bb796e81213">38,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE4LTEtMS0xLTA_6329325e-b3dc-4049-b2cb-5d799213f07f">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE4LTMtMS0xLTA_82495ba6-9d68-4996-803d-4807cd447954">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTAtMS0xLTM3MjQvdGV4dHJlZ2lvbjo3ZGExNmZjYWFhZWE0ZjYxODE4ODE2OWJkODdhMzFjOF8xMDQ0NTM2MDQ2MzkxNw_81446582-ae1c-4740-8465-2bb67665d18b">3.98</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE5LTEtMS0xLTA_761cf8ca-9c40-432d-b69e-7cd19f0f54a1">10,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE5LTMtMS0xLTA_58fbde5a-9966-485a-b74d-2d71826f1b57">10,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTEtMS0xLTA_34c7d7bd-0a6b-4871-9c23-bbe202fbf856">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTMtMS0xLTA_4c34e924-38b7-4d05-86a9-7605288df61b">931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTktMS0xLTA_aebd1231-df46-4ddc-a835-9f456d9a4378">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIxLTEtMS0xLTA_34cdf215-0880-407c-82b2-0999f4cef182">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIxLTktMS0xLTA_e9fa4284-9ef1-4e4d-bb8a-0b0806ecf651">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIyLTEtMS0xLTA_95017a09-020c-4107-a67a-568b0a0fca38">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIyLTMtMS0xLTA_7399954d-f7b6-426c-8d76-b6c0a201ac5a">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIzLTEtMS0xLTA_8a0b6e42-55c2-496f-9b1a-4c80757b85af">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15b04be239b4bcf895c4ac519a52aa5_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIzLTUtMS0xLTA_bf221e66-33ae-4e84-a89e-b93014db20e1">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTEtMS0xLTA_9efa2316-8f52-45ee-8c17-d642fb5299c3">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ea54c1fcae41cc82257b51ac217450_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTMtMS0xLTA_0a2818b1-d785-45ef-a273-02305307f214">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b56c73c08ba4d7bb733cf5b7825663e_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTUtMS0xLTA_c68b75b4-32b3-4d67-80c8-c4a00fb7c28f">15,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6c299668f24a8ea824ffb03291a552_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTctMS0xLTA_3a3f4e91-a658-465e-98ec-d2a2bc038279">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0948aa56b8544fa694f8b50333d4293d_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTktMS0xLTA_1f24bdfb-7718-4745-97a7-b8462ba42001">38,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90ZXh0cmVnaW9uOjdmNWI1OGRhOWFmNjRjYzg5YWQyZjI0OWI3YjRhNDFiXzI5Mw_0e085ecd-b2bd-4a98-b2d9-7b39628bd78f" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See Note 1 to Consolidated Financial Statements for additional details on the effect of cumulative adjustments to retained earnings.</span></ix:footnote></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note 1)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzItMS0xLTEtMA_e51b0c4c-ab56-4968-a26a-9b3a406e5e06">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzItMy0xLTEtMA_e9c5ccc2-5995-4ad0-9950-04289a9f4fc6">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzItNS0xLTEtMA_bb6ccaae-ed84-4a09-ab8f-f3540a856f23">15,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQtMS0xLTEtMA_d4dd214b-39d1-4e53-b926-ceb198e08e7b">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQtMy0xLTEtMA_e6c4f4a5-d102-4a58-870e-d1fa3f39f861">7,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQtNS0xLTEtMA_2300734a-96f7-4593-a166-47a01d691cf0">6,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUtMS0xLTEtMA_b140c185-8b4d-4b11-b0eb-ee375dcee52a">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUtMy0xLTEtMA_6763c02b-dc4c-495f-804f-1c4b57109376">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUtNS0xLTEtMA_00d96d4c-2b19-4ef2-8f44-2922c2b1e961">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzctMS0xLTEtMA_13971f57-1805-4516-b241-a2ce928503f0">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzctMy0xLTEtMA_70969919-411b-46f8-917f-a62f98e212cd">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzctNS0xLTEtMA_21b80199-8bd3-4f5b-b1a1-a27fbaf2c7b4">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration reversal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMS0xLTEtODM1Nw_2193cf8f-82cd-44ad-8b77-bf1f3e03bfe0">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMy0xLTEtODM3MQ_701e01c0-dbc3-4ac4-a3f3-c2cdcd77e712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtNS0xLTEtODM3MQ_c596238a-7cce-4f45-ae29-b7bf79020765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMS0xLTEtMA_34ee67cf-9854-4820-9302-2ac3e6efcee9">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMy0xLTEtMA_8008fd62-7b75-4de3-8e50-98146b9e579d">2,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtNS0xLTEtMA_395908b9-3fee-4cf6-b9d0-2e6846ca63fa">1,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEwLTEtMS0xLTA_8d8db244-9298-4df0-8a51-4dca5eda5675">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEwLTMtMS0xLTA_395db5fa-c791-467b-b185-48af1d98ab30">2,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEwLTUtMS0xLTA_a279da40-79bb-4e88-b9b2-175f32dd6bd8">1,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzExLTEtMS0xLTA_372ff8c0-4faa-477b-b97e-1eeb56e69d92">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzExLTMtMS0xLTA_1593d461-b298-4a2c-a1db-a2baec0e7eb2">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzExLTUtMS0xLTA_14baf188-1c2d-4b95-8afc-cee992140ce8">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease/(Increase)  in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEzLTEtMS0xLTA_1f0c860c-6ef8-4a2f-a7e3-0917ea7e54b2">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEzLTMtMS0xLTA_e70e57f3-f0ca-4cca-a974-cadb56e76cb7">289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEzLTUtMS0xLTA_57259cac-b18b-4411-80eb-46ac4a193ad6">1,185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE0LTEtMS0xLTA_56fb5888-50a9-45a0-b844-7c03e69d7707">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE0LTMtMS0xLTA_46e3c0ab-062f-4ce1-a8e9-5fb2d4ea61f0">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE0LTUtMS0xLTA_ead7a225-c9df-4cd2-8c31-3bf04e16baa6">644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE1LTEtMS0xLTA_bf21ba84-9d45-4489-a447-d0a31780fea1">5,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE1LTMtMS0xLTA_044c1653-b004-4d29-a2e2-1f7580c9ff1f">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE1LTUtMS0xLTA_822e4a39-346b-414c-ab83-05b84171403c">3,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in other current and non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE2LTEtMS0xLTA_bb26da87-4d68-43c9-9bec-089c798d2c88">3,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE2LTMtMS0xLTA_4e0a3dfc-622b-42b9-bcaa-13fa6a7c754d">1,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE2LTUtMS0xLTA_be77397d-6feb-4b08-b871-d9ab911258e7">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase/(Decrease) in other current and non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE3LTEtMS0xLTA_4d07c094-8ff5-49c5-9097-dcf0216a2200">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE3LTMtMS0xLTA_d43e33ff-931f-4bea-a4d1-f84e52b3309e">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE3LTUtMS0xLTA_3a23c185-a61a-4487-8afc-8c50a2d07c11">1,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flows from operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE4LTEtMS0xLTA_65a1cedb-f2b8-48cc-9ea4-7a20c1fb7882">23,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE4LTMtMS0xLTA_931930af-e5ce-4a8b-af79-65f7b71f11cc">23,416</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE4LTUtMS0xLTA_9484345a-3f6c-4dc4-9983-eb63838cbbae">22,201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIwLTEtMS0xLTA_41808216-a9d1-4ece-8d39-74eb87d75408">3,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIwLTMtMS0xLTA_986038e6-a823-4a9f-82db-7b28f92bce9b">3,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIwLTUtMS0xLTA_83cb139a-f7cd-44fe-a946-fb3867c6da28">3,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIxLTEtMS0xLTA_137e9d2c-99c0-449a-8acf-92000be8cc5e">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIxLTMtMS0xLTA_98dfd558-ea6a-48f9-b129-37f700577e8b">3,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIxLTUtMS0xLTA_ccea054e-511e-4c58-abd6-790ded022f8e">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note&#160;18)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIyLTEtMS0xLTA_99eb4b76-3573-41f6-9346-3c2bdfe7b473">7,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIyLTMtMS0xLTA_188017a6-0987-4b0a-aaec-71d411e50070">5,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIyLTUtMS0xLTA_614caa7b-1db3-4f08-8bee-82f782f9d480">899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIzLTEtMS0xLTA_238c7a69-d910-4dde-a00e-4db94c7df572">21,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIzLTMtMS0xLTA_edc29292-a6b7-4b02-bcea-9f68a83851b9">3,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIzLTUtMS0xLTA_6adef89c-f770-465c-9282-da9071ec4ce8">5,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI0LTEtMS0xLTA_67a07686-b5f7-4d49-80a2-58dab8a95ae7">12,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI0LTMtMS0xLTA_c0229a3d-a2d4-4a68-8a27-c1b946e36eb0">3,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI0LTUtMS0xLTA_eac22850-e4da-4066-86c9-7112f501e1be">4,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI1LTEtMS0xLTA_4bea3a1d-4599-4ca5-b60d-d47ec872f2a5">987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI1LTMtMS0xLTA_d2310ce8-c27d-404f-992e-814d11a0ce32">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI1LTUtMS0xLTA_94526cbb-3f4a-4006-8d8c-44601c00cbfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI2LTEtMS0xLTA_880b1a8d-0323-457b-8800-422d6c85ff5e">521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI2LTMtMS0xLTA_8a2901e6-71aa-44f3-ad8e-ddc88c1165ff">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI2LTUtMS0xLTA_2a93d1af-fe6d-472b-9819-21cfa01c7a3a">464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI3LTEtMS0xLTA_e1c76edc-94b2-4a79-bbb7-ebe22980fc9b">20,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI3LTMtMS0xLTA_de862f1b-e029-4270-8de0-643befcaf722">6,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI3LTUtMS0xLTA_5c429feb-f5b9-41c2-a42d-346a3ee4582a">3,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI5LTEtMS0xLTA_0846a599-31a2-4b9c-bd45-455f5f42c927">10,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI5LTMtMS0xLTA_91ebbbbb-3b98-4bb6-8292-cc925eed6ec9">9,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI5LTUtMS0xLTA_c4179f6f-b66c-47ac-a25d-0adc555f011e">9,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMwLTEtMS0xLTA_f3dd6c86-5ced-4056-822a-a6321793ba9c">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMwLTMtMS0xLTA_789b1db2-6e51-4d1d-84d1-5ca4e8928894">6,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMwLTUtMS0xLTA_bd8aa92a-2ce5-49b0-8bda-987ae9a25aca">5,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMxLTEtMS0xLTA_38c2b6bf-efb6-44ad-80a7-92c4d4e388c8">3,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMxLTMtMS0xLTA_4e464885-b708-49e0-8856-4213dd23850b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMxLTUtMS0xLTA_5cbb10e7-57a8-4eec-b0c4-e7a8c5a0f037">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMyLTEtMS0xLTA_eff9db91-d600-4923-b25c-903c17cc392d">2,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMyLTMtMS0xLTA_159d6398-cdfe-4fea-9a5c-eb368e3f031a">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMyLTUtMS0xLTA_a84fccce-d423-4211-acc8-6e403bd3e742">2,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMzLTEtMS0xLTA_a042a409-097d-4ce8-bd97-1bbba45d2deb">7,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMzLTMtMS0xLTA_020e0183-fa41-4110-be32-86cb1642a189">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMzLTUtMS0xLTA_95920d68-dcd2-4195-b5f8-77398bae2536">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM0LTEtMS0xLTA_1f4e25c1-ea40-4798-88df-bdac3ee08401">1,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM0LTMtMS0xLTA_f31bdcf0-389c-4bd8-8f32-cc72043e096a">2,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM0LTUtMS0xLTA_0c578ac4-9efd-4900-9fa2-fd35fc95ffe4">1,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM1LTEtMS0xLTA_adcdedce-ad2d-4ecb-9cb7-e98cd2a654d9">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM1LTMtMS0xLTA_b86b7091-c2b2-436d-9a48-5ae0e8892805">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM1LTUtMS0xLTA_a7ad85c2-289f-40ec-829a-28ab0c97e5aa">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTEtMS0xLTExNDMx_6b0d46fb-8887-4175-b8e7-96d9a11ba52c">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTMtMS0xLTExNDMx_dad45658-dd5d-4275-a073-01f065cf79d8">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTUtMS0xLTExNDMx_dcdc5b69-1d9c-4153-8b84-83b17078b0f0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTEtMS0xLTA_ef797b74-374c-45c4-b59b-26ed74a3d4d0">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTMtMS0xLTA_0cab03b3-d958-45b5-aa23-88f5e36ee030">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTUtMS0xLTA_71d03770-19fe-4118-a58a-9621297c1c46">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM4LTEtMS0xLTA_23e38814-de7b-477a-8296-50dc8fe2cf7b">6,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM4LTMtMS0xLTA_364c46af-3d3d-4a4c-bcf9-586cc3bde5a8">18,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM4LTUtMS0xLTA_59cf4c13-f380-4f4a-aa82-be2b97d146d0">18,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM5LTEtMS0xLTA_f434cb05-599b-44ca-8cd4-e8660051c39e">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM5LTMtMS0xLTA_a3f57379-0607-469f-83e9-db70d77108ea">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM5LTUtMS0xLTA_f9fbe7ab-2fcd-4e9f-9b25-41fa818a7a64">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease)/Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQwLTEtMS0xLTA_fa60565d-00d4-4c11-bbdc-b731e8093cea">3,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQwLTMtMS0xLTA_b1d3d87d-3752-40c0-ab35-768007fdba44">802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQwLTUtMS0xLTA_11254487-4eff-49b0-9709-c5ea4361f58e">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year (Note&#160;1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQxLTEtMS0xLTA_1bdc8e5f-4488-4fe4-ba37-63f045eb49fe">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQxLTMtMS0xLTA_6312db3d-28cf-48a5-a022-c31eb9d2e7da">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQxLTUtMS0xLTA_d6236470-4854-4207-b873-f143b8cb567d">17,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year (Note&#160;1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQyLTEtMS0xLTA_68553d61-4c6d-4042-8757-f5f3e6e78200">13,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQyLTMtMS0xLTA_69909bf4-e718-4295-ac1f-cc40e5af4628">17,305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQyLTUtMS0xLTA_d2b69e9d-d557-41d9-b6e0-19dbf08568f7">18,107</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow data</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ2LTEtMS0xLTA_37dbc1c6-eb4c-43c9-8d69-051981199f3a">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ2LTMtMS0xLTA_7ab57371-a924-442b-9d0d-ee8867721627">995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ2LTUtMS0xLTA_658d4b13-ba7e-458c-a29a-d29391255485">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest, net of amount capitalized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ3LTEtMS0xLTA_7174a3ba-3661-4f31-8325-32e2b5a99b91">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ3LTMtMS0xLTA_3c1a786e-178b-4391-90d0-60fba7f2c989">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ3LTUtMS0xLTA_8679782e-a14b-4585-a751-d1ee22852910">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ4LTEtMS0xLTA_8048083e-81ed-496b-b8c8-ac5b91522dab">4,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ4LTMtMS0xLTA_947c2003-9473-4fd1-95f9-9c48a62ef4e4">4,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ4LTUtMS0xLTA_0debb9ff-3de9-425d-bcfc-d946e3969f61">4,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:38pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUxLTEtMS0xLTA_eaefdb5b-6b7a-4bf8-a6aa-bc748defb18c">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUxLTMtMS0xLTA_5682e907-d318-4b9d-9138-ed6f05f99101">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUxLTUtMS0xLTA_27b57bff-d6bb-4c28-99e7-5e277e16e901">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUyLTEtMS0xLTA_4d546fdf-5132-4fd6-8e6f-aae19dc04b1d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUyLTMtMS0xLTA_03817a52-c056-4e99-835f-07460b6c64a9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUyLTUtMS0xLTA_18114bab-df98-4ebe-a2e6-624664e66e1b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU1LTEtMS0xLTA_d967714b-a39e-4221-8131-adb633ab67e6">7,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU1LTMtMS0xLTA_2d7151cf-a685-4a97-ac28-d9abbc677fa9">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU1LTUtMS0xLTA_a520fb2b-bcc4-4268-8928-da772000caa7">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU2LTEtMS0xLTA_1ddbc613-0705-4d56-a35f-03fba8f733db">432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU2LTMtMS0xLTA_05b12915-498e-4274-82a0-1c4b509a5935">1,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU2LTUtMS0xLTA_be64d80b-13cc-4b2c-8ec6-2c90fcc9ab90">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid for acquisitions (Note 18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU3LTEtMS0xLTA_80aadc6f-2cd7-4808-9075-9d6895565322">7,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU3LTMtMS0xLTA_69a74aa0-e95f-4ad2-8a16-168da1561037">5,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU3LTUtMS0xLTA_5f211490-0a0b-460d-9b47-71e9d3e6935e">899</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_133"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDY4_4f80d403-f879-4444-8081-8685f0fc1648" continuedAt="i99b5383a21444ccc9ac47555a53ce095" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i99b5383a21444ccc9ac47555a53ce095" continuedAt="i2a8c6b1ad0564627bb98534d31273713"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDc4_4d39df96-28e6-40b3-8087-469a3410b561" continuedAt="ia2fbf4ee4c8d4305a8f6bc53ad1c1bbb" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia2fbf4ee4c8d4305a8f6bc53ad1c1bbb">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.</ix:continuation> Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTE4_b5d1a860-ce08-4954-8c87-b7e4ae3945cd" continuedAt="if403c07346c64f12be0dcb6a06cf220a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately <ix:nonFraction unitRef="employee" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzQ1NQ_3426247d-00e0-456f-99d2-9f797d2e9571">134,500</ix:nonFraction>&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if403c07346c64f12be0dcb6a06cf220a">The Company is organized into <ix:nonFraction unitRef="segment" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzc3Mg_f4f47ca1-8846-44ec-8b72-b0acbd679b24">three</ix:nonFraction> business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women&#8217;s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.</ix:continuation> </span></div><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTE5_7c46c958-6b02-4f1b-8cbd-1f10b6cd13c8" continuedAt="i05c0c5b4bb9a47bfa4ba6dceb2b589b5" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2018-18: Collaborative Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13: Financial Instruments - Credit Losses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity&#8217;s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2018-14: Compensation - Defined Benefit Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2a8c6b1ad0564627bb98534d31273713" continuedAt="iaa74e9d7a5124fe29ab0f5c6bb4196e9"><ix:continuation id="i05c0c5b4bb9a47bfa4ba6dceb2b589b5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4NjU3_799a8f2c-b13f-4dfc-9e31-32a5e35c590b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  </span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:61.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2014-09 - Revenue from Contracts with Customers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e8e0ca2b9b40cea02f25844dc6143f_I20180101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzEtMi0xLTEtMTMyNjc_cbf53adf-eded-432a-ae05-a04ce4cfd27c">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-01 - Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9621bec2f144b689a1fbfe1403aab26_I20180101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzItMi0xLTEtMTMyNzQ_3f5e8039-8da6-480f-9149-bab7dc989382">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-16 - Income Taxes: Intra-Entity Transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c818b3558a442cb0ffe1bce102d1a8_I20180101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzMtMi0xLTEtMTMyNzQ_5ffc3783-7910-4136-bc96-70d27dd57d35">439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56111d6a08484b6890ddf01b41cb16b0_I20180101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzQtMi0xLTEtMTMyNzQ_d48b74f0-0c33-459c-a106-6e93d0d5b710">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 3, 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company.</span></div></ix:continuation><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDcw_0ea9c43a-6ad2-4f5d-b448-4d056c741807" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgzMzI_56d46f0e-cf79-4899-84ce-c639236746a6">102</ix:nonFraction>% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzg3MDU_c8c4d1da-c3e0-403e-99b9-557acb3d2506">102</ix:nonFraction>% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDY5_a6e312fc-2d2c-40a9-8c3d-659622f6554d" continuedAt="i8051faecec1349bfad6646109b209ca2" escape="true">Investments</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8051faecec1349bfad6646109b209ca2">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDYz_77754dfa-e387-41c5-93c9-5febba2a62ac" continuedAt="i971b294d8b4a49768da3cfc25b543d9a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDcy_4f89f05b-df8f-4642-bc68-87f537b96fcb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i172e28d99e7b4636b5bf1e3bb60c3e46_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzAtMS0xLTEtMzcyOS90ZXh0cmVnaW9uOjdhMzczNTNkYjhkMTQwNTFiZWQ3M2FlNjdlYzQ0YTJlXzEwNDQ1MzYwNDYzODkx_472aa700-42c4-4ca3-ab2a-8e5c39dfcbd0">20</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i4144a962aa79467395df471e209ede69_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzAtMS0xLTEtMzcyOS90ZXh0cmVnaW9uOjdhMzczNTNkYjhkMTQwNTFiZWQ3M2FlNjdlYzQ0YTJlXzEwNDQ1MzYwNDYzODk2_e0c13779-fef1-490d-b251-02e7edd735c7">30</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f65202ffa114849be9dfc3aac018eaf_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzEtMS0xLTEtMzczNy90ZXh0cmVnaW9uOmQzNWRhNTFjNzI3MjRlNjJiZTYwOTYyMDU0Nzg3NDYwXzEwNDQ1MzYwNDYzODkx_a80a40c4-9eef-415e-92cb-b8a4e27e6232">10</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i935569cc407846b1bd173f1920d291d7_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzEtMS0xLTEtMzczNy90ZXh0cmVnaW9uOmQzNWRhNTFjNzI3MjRlNjJiZTYwOTYyMDU0Nzg3NDYwXzEwNDQ1MzYwNDYzODk2_46f05adf-eee3-473c-9613-3fa568665abf">20</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1869c744df4f4e608a0eb1004c3f4aad_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzItMS0xLTEtMzc0NS90ZXh0cmVnaW9uOjQ4YWRiMWM4YzAxMTQyNTU4Y2QxMDIyYjQ1NGM4YzVhXzEwNDQ1MzYwNDYzODg5_71e78d10-ad1f-4802-938f-24239e5985fb">2</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i76d4081a3bd840dda4560e78dc05b7a5_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzItMS0xLTEtMzc0NS90ZXh0cmVnaW9uOjQ4YWRiMWM4YzAxMTQyNTU4Y2QxMDIyYjQ1NGM4YzVhXzEwNDQ1MzYwNDYzODk0_d38e3f13-fdc9-4e24-9b49-42e97f74c5d4">13</ix:nonNumeric>&#160;years</span></div></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from <ix:nonNumeric contextRef="ie02722380d4b485fa4f666f9da3c34e9_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwMjE0_7693e68a-28bd-43d5-b82c-24848560ee27">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i0f18dc2fc4564ff9a05dbd7fba040656_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwMjIw_18dee211-497c-498e-b76f-a457546d93a0">8</ix:nonNumeric>&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaa74e9d7a5124fe29ab0f5c6bb4196e9" continuedAt="i6d9b818e11c14f7bb79b00d1e48af6a5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i971b294d8b4a49768da3cfc25b543d9a">the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</ix:continuation></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTI1_70975e9a-7090-4709-9d37-c69c3436d0cf" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $<ix:nonFraction unitRef="usd" contextRef="ide0733c2434242ba85b6c5b1c835e725_I20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzExOTcy_900a41bd-70d3-434c-b9b8-6227fec66dba">7.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i63df1bc915934ad68c8902ac19c99bea_I20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzExOTc5_0640411e-393d-4e7d-bf2b-0a1babde3ab1">7.0</ix:nonFraction> billion as of January&#160;3, 2021 and December&#160;29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately <ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEzNTM4_53c53451-7411-49bd-9d69-0486738ac39c"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEzNTM4_973c8185-2b95-49db-ba3a-997fc4c12b2c"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEzNTM4_b55c6d98-1972-4669-942a-0c2856140829">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of annual net trade sales during each of the fiscal years&#160;2020,&#160;2019&#160;and&#160;2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than <ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NDM0_4b2e1356-6e80-4b59-9875-b5878317211d"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NDM0_6ce549f2-e012-4264-a2a3-3f4d025c9433"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NDM0_dd1b4c99-d817-488d-98d1-2b45f2ea3701">3.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the total revenues and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTM5_7799f714-02dc-4b7c-b7ee-11d7409543a3" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $<ix:nonFraction unitRef="usd" contextRef="ied72d4ba20b14d21b01fa2d79d0cd268_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NjU1_af4e236f-076d-4f22-8739-309d4b8911cd">1.0</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i12a63cb5e2c94bd8bd2df799531d614b_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NjU5_b4457de3-5179-4007-98dc-6fab85886013">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="id01c9ba6bc554fc8a64421dc3895f2a7_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NjY2_3ad0ab79-617e-42cf-8f3d-1dc167c600af">1.1</ix:nonFraction> billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than <ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0ODM4_362c3593-62be-453c-b9e3-fc73167505c7"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0ODM4_4f5d176b-d05d-4bcc-9f87-ea73cea2bd1c"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0ODM4_fe9c54e7-1094-4f10-bcd1-4cbeee903c91">0.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of sales to customers for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTUy_1654fd35-3683-48df-81f3-97dd302c572d" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTMz_24cc667a-5a4b-4543-ad12-9393634e1877" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6d9b818e11c14f7bb79b00d1e48af6a5" continuedAt="ifcbdf75faf4c4dfbb75f105852bf1078"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDg0_67a5f5f3-f5f5-4f33-914a-244ac57ba8d3" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzg3OTYwOTMwNzY5OTE_27642f34-2546-447c-992c-9fd23dfdde85" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyNDQ_c067e68d-fc46-4f1d-880d-33b57b9ddec4">1.0</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyNTg_c3009482-335f-4347-9d3b-c9d2be7862aa">1.0</ix:nonFraction>&#160;billion in 2020 and 2019, respectively. The lease liability was $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyNzI_3aa1fec4-f651-46cd-9849-3cbb1b4e2a19">1.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyODg_f88e65c4-7eac-48ed-8000-9fc4e48a436b">1.0</ix:nonFraction>&#160;billion in 2020 and 2019, respectively. The operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzMDI_d0cc1250-fc7b-4f2b-9003-02904be922cc">0.3</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzMTY_27bacbb6-0a77-4eae-9517-fbeb8483a692">0.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzMzA_ce03c0a6-95ce-416f-8c68-263e23fc12a5">0.3</ix:nonFraction>&#160;billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzNDQ_9e1defd4-deae-4543-b1a3-448874e01a23">0.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzNTg_9de80419-e871-4cba-ab87-8b1344e0dc94">0.3</ix:nonFraction>&#160;billion in 2020 and 2019, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:ProductLiabilityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTcz_b1aa5e1d-237d-4792-9806-af12c3d4ec84" continuedAt="i320d6386df074772bf15f4dd59901e84" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i320d6386df074772bf15f4dd59901e84"> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTM0_d345fc29-01c9-4d88-b04d-b1788b12d701" continuedAt="idaaa9d34b0fc4298b1a09833b13b40d5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifcbdf75faf4c4dfbb75f105852bf1078" continuedAt="ib22b0c96b2a344eb9fc52d2cb472ce20"><ix:continuation id="idaaa9d34b0fc4298b1a09833b13b40d5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than <ix:nonFraction unitRef="number" contextRef="i75354123f4c84b55824bc84448f6036b_D20191230-20210103" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwMDky_e30869a4-2c9d-4b5a-950f-f168cdc4eb0b">5</ix:nonFraction>% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, co-developed with Bayer HealthCare AG and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, licensed from Genmab A/S.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDg1_d618d761-df4d-45d7-8820-20fe3fc73314" continuedAt="i2403ff90cda54ac2905027b6ac84e331" escape="true">Advertising</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2403ff90cda54ac2905027b6ac84e331">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses.</ix:continuation> Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwODIx_e7056814-53ae-44fa-97aa-70d1fffd9147">2.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwODI1_c0629b92-7a14-40f2-89f7-a447adee84b3">2.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwODMy_c1d53de5-5f79-4aa4-9a1f-652e82ba97ac">2.6</ix:nonFraction> billion in fiscal years 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTQw_c34c2946-6f21-47f7-9177-01fcf79b094b" continuedAt="i73f364a879474c01bfdb6afb3cecd6ac" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from <ix:nonFraction unitRef="number" contextRef="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MDk_695b7df2-5b7f-453a-915a-7fcf1372306a">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MTQ_09a1ccd5-419b-4f29-aa3b-120616a31ff1">21</ix:nonFraction>%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MjU_07537ff8-f6f7-4209-8cec-11165b1a17d6">15.5</ix:nonFraction>% and all other earnings were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MTk_21ab7541-3909-4661-9c30-1c84c09f3331">8.0</ix:nonFraction>%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MzI_d1a9c38a-35ee-4e21-b9cf-87615f667cfd">7.7</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4NDY_f97b1448-5fde-47ea-b179-1bedc21389cc">6.9</ix:nonFraction>&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib22b0c96b2a344eb9fc52d2cb472ce20"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73f364a879474c01bfdb6afb3cecd6ac">intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIzMTYw_a96d1fcb-a20e-4068-a4bc-dbd98da1a2b2">0.7</ix:nonFraction> billion under current enacted tax laws and regulations and at current currency exchange rates.</ix:continuation>  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information regarding income taxes.</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDY3_84e89e59-df62-448d-9a03-a07a4080afb9" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTAx_072edb3f-ddce-49cf-9f47-a0de37d5fa3e" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:FiscalPeriodPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDc2_5363c3e8-1e72-4e72-94e1-2cd27a9f622e" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTg2_de0f880e-4f2c-4a96-a190-3712be31a6de" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_139"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90ZXh0cmVnaW9uOjA4YWE4NDFiNTQyYTQyNmJhNGRlOTM0NzliYzU5ZDU2XzEwODI_4440b13a-36ed-4950-82e9-ad92699ee20b" continuedAt="ib460df98660842129c1cac13a9f4b63b" escape="true">Cash, Cash Equivalents and Current Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ib460df98660842129c1cac13a9f4b63b" continuedAt="i7fdde9ced1b94177928122f1d6310dd0"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90ZXh0cmVnaW9uOjA4YWE4NDFiNTQyYTQyNmJhNGRlOTM0NzliYzU5ZDU2XzEwOTQ_64f9032f-92f5-4cdc-a8be-529f4f5ea518" escape="true"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf686c178a5b43e69308e5ab8e5a2e50_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItMi0xLTEtMA_cfeb513e-35c8-4cb0-86f9-13f2d17690dd">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItOC0xLTEtMA_4ebe03ca-c996-4ecd-bb6c-41688836dcbf">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf686c178a5b43e69308e5ab8e5a2e50_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItMTAtMS0xLTA_9bdcb583-b726-4593-92fa-0f1d9ad825a6">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf686c178a5b43e69308e5ab8e5a2e50_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItMTItMS0xLTA_2ebbc79e-0e16-46d6-9ba9-26987cfa9c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtMi0xLTEtMA_9088c4c3-be84-4d08-83c5-379d5412393f">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtOC0xLTEtMA_825956d8-2ffd-410e-9ec5-9d195e0b5749">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtMTAtMS0xLTA_f15bef06-146d-4a34-85ff-d73dcc6d9bc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtMTItMS0xLTA_11109065-3e4b-47c8-91e0-fcb7f6b59826">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtMi0xLTEtMA_662ce96c-8ff2-4871-bfac-d58416cec07e">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtOC0xLTEtMA_03d35ca2-f6d4-4a75-92e1-e276436e14f9">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtMTAtMS0xLTA_eed58a1a-48b7-4b8e-93d9-eab1424c6349">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtMTItMS0xLTA_7615d94e-2ea2-4aa7-8561-c6714391d147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctMi0xLTEtMA_86681fd8-8266-443a-b169-041cddf9a7b9">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctOC0xLTEtMA_aebfb4ef-8711-4e97-ad0e-614a26b5bcb6">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctMTAtMS0xLTA_a0b896e7-0231-488b-b16e-7e112069e55c">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctMTItMS0xLTA_4dd931fe-18d3-4033-87cd-8d2f80a31845">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtMi0xLTEtMA_dcdf1988-088b-4935-87cb-0794271382d6">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtOC0xLTEtMA_c4655fbc-0ef8-4088-aab6-e56ad02fb8b5">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtMTAtMS0xLTA_822caaf9-7a24-44cd-b4aa-4ea3a4a7eab6">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtMTItMS0xLTA_d4b3f96d-aa8a-4ab6-8658-c51e5f270269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktMi0xLTEtMA_2a08cb1c-4080-4f70-a762-34f1eba6110c">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktOC0xLTEtMA_a33af9b6-58ac-41c8-a525-332509d20b00">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktMTAtMS0xLTA_63f856b3-4e95-4cd2-99ed-1455d24fb11e">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktMTItMS0xLTA_08c58885-9eec-454f-9a29-e3d495e996bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTItMS0xLTA_a96956b9-6e6b-4f4b-9fa5-76cb82fe09ac">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTgtMS0xLTA_4312f75f-a534-42de-84aa-533ef7310184">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTEwLTEtMS0w_d0143461-5931-468d-9fbb-5fe9358f05ab">9,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTEyLTEtMS0w_76f2b74b-0e14-46a9-9e8f-7e0d1ccd2605">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTItMS0xLTA_c350c91a-da67-4efb-a899-75c09d191d25">13,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTQtMS0xLTA_fc7267be-9efc-4eda-9012-b6cab08e910b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTgtMS0xLTA_01afc756-c0b7-4cd7-b957-f29f3ee8661f">13,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTEwLTEtMS0w_9851b111-a4e2-49b5-8bcd-13f51514e4d3">4,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTEyLTEtMS0w_6e471151-a98d-407a-84ea-ce5989ede9b1">9,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTItMS0xLTA_7e32389e-4aac-4339-ae6d-982bd0d2de6e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTgtMS0xLTA_1eb5c21d-a2e1-4e0d-9d6e-1a6608564f4a">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTEwLTEtMS0w_225a9ee8-3d74-4878-9324-28d39646c223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTEyLTEtMS0w_259c4162-9e53-42e5-a7ab-0b64f6585599">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTItMS0xLTA_d9602e23-a25b-4de6-9b5e-c34045fb2576">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTgtMS0xLTA_d377a9b8-9ab1-444e-b4e9-703613eb1540">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTEwLTEtMS0w_73870f8f-8484-4aaf-9c19-0fd0178c97a1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTEyLTEtMS0w_dacf650d-a427-4f5c-a127-638919a83626">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTItMS0xLTA_23ecae3a-5ffa-41d2-a14c-483c7f8472d7">14,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTQtMS0xLTA_3fdf96f6-2d3b-44c9-98f2-f056ab1e3aeb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTgtMS0xLTA_d9af2110-db30-42a4-a95b-f9b502d238e1">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTEwLTEtMS0w_bd73f6ab-0e4e-498a-b74c-d7b8b0bd2c6a">4,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTEyLTEtMS0w_5a6e4ccc-58c2-41f5-bb4f-17f43d12c17d">9,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE4LTEwLTEtMS0w_12647176-819e-4b02-944c-67d8bd5832da">13,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE4LTEyLTEtMS0w_2bf7391e-283e-4809-8685-748434c97f9a">11,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:59.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.086%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c02f63bfeba457680dc2981ea77c247_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzItMi0xLTEtMA_c41d594c-0003-4241-a94e-539a0a578b5a">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c02f63bfeba457680dc2981ea77c247_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzItMTAtMS0xLTA_b0b10982-9d40-4201-ad67-9911ef732eae">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c02f63bfeba457680dc2981ea77c247_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzItMTItMS0xLTA_322c81a2-8f83-47b1-b69a-b469cbaf5cd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcb9b3192c346bab96adcaf99402100_I20191229" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzQtMi0xLTEtMA_c18ac24c-5473-4f16-bf55-39390ee2223d">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcb9b3192c346bab96adcaf99402100_I20191229" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzQtMTAtMS0xLTA_ab4e2b37-68e5-4b43-aaec-3455406e2c7f">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcb9b3192c346bab96adcaf99402100_I20191229" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzQtMTItMS0xLTA_1f163f05-d475-4b03-9443-001db6601543">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999eaa5539f8442a9db3d7527b669ae0_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzUtMi0xLTEtMA_01c2a60e-7a64-43bd-a9ab-f3ff9e0ea20c">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999eaa5539f8442a9db3d7527b669ae0_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzUtMTAtMS0xLTA_d2c69f6d-bbba-4f91-8f74-8d5eac08a476">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999eaa5539f8442a9db3d7527b669ae0_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzUtMTItMS0xLTA_87bf7b2c-511e-4cf1-9447-690245008e06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68ca550e07c4272974f847b220b5bdf_I20191229" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzYtMi0xLTEtMA_c102ead2-678e-4917-b219-d13da470a193">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68ca550e07c4272974f847b220b5bdf_I20191229" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzYtMTAtMS0xLTA_a4f04c4a-df21-437f-8b08-3f87b4e23f87">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68ca550e07c4272974f847b220b5bdf_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzYtMTItMS0xLTA_19423db8-4295-4502-bb1c-7a4cb1e937ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdc5e97696145adacdd25f020821810_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzctMi0xLTEtMA_37ed2e58-a6df-4334-978b-3d9ae5d58414">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdc5e97696145adacdd25f020821810_I20191229" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzctMTAtMS0xLTA_bb2280b0-b5da-4388-bf1a-2342a175ac09">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdc5e97696145adacdd25f020821810_I20191229" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzctMTItMS0xLTA_82ce7e89-41df-45d1-af07-ca56bfc74938">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzgtMi0xLTEtMA_8db0ddea-e03d-4ae3-b5e6-fc1aa74c3c7d">2,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzgtMTAtMS0xLTA_c984ed47-239c-48eb-84c3-a5635dd5f1ff">2,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzgtMTItMS0xLTA_fe825aba-f0df-45b8-a30c-527d999c2b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45864798375349aa82cdbc0fe5b12467_I20191229" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzktMi0xLTEtMA_ece6665c-950b-4737-9146-98b7ae0ccc82">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45864798375349aa82cdbc0fe5b12467_I20191229" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzktMTAtMS0xLTA_07c3a0b1-a095-465a-9629-0ab710f9457f">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45864798375349aa82cdbc0fe5b12467_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzktMTItMS0xLTA_430008b9-b8f9-43d2-ae64-9e635f4f8031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525d9deca0aa4aa69bea7606b12ab349_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEwLTItMS0xLTA_b1431f37-457d-43dc-a8d6-028dae8ddcc6">14,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525d9deca0aa4aa69bea7606b12ab349_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEwLTEwLTEtMS0w_53df9c52-3960-4f31-baa3-5edab101802e">14,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525d9deca0aa4aa69bea7606b12ab349_I20191229" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEwLTEyLTEtMS0w_e7246594-b5b5-4ffa-ba34-e1ba0bdf8ac5">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gov't Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7656b3ff8f34856acd3408e287ef6db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEyLTItMS0xLTA_7efd7688-0a15-41ee-a633-cb52ea1920ef">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7656b3ff8f34856acd3408e287ef6db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEyLTEwLTEtMS0w_466b6e6d-2e89-4890-b48e-085347794cee">3,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7656b3ff8f34856acd3408e287ef6db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEyLTEyLTEtMS0w_4bf8759c-5c9f-491b-9fc2-489503dd6461">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1e598b00f94535a80aa29acebd3c1b_I20191229" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE0LTItMS0xLTA_8c0b2c7f-d4dd-4447-ae7b-f605b63dd1da">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1e598b00f94535a80aa29acebd3c1b_I20191229" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE0LTEwLTEtMS0w_7391a2d3-cb78-4e87-8b45-e4225514948c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1e598b00f94535a80aa29acebd3c1b_I20191229" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE0LTEyLTEtMS0w_2dfa660c-a82e-414e-8e01-1bcf21f3eb76">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd47e6dfd734f18ab3b1175104da7ee_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE2LTItMS0xLTA_0dcc8c45-ad7c-4bd4-b623-678d9850a861">4,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd47e6dfd734f18ab3b1175104da7ee_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE2LTEwLTEtMS0w_c0235084-489d-476f-bd1a-14e210d19fd4">3,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd47e6dfd734f18ab3b1175104da7ee_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE2LTEyLTEtMS0w_feb8bb77-28d1-4b43-9716-d61eecf96af5">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE4LTEwLTEtMS0w_ec7aa162-74a5-493f-833d-c4963e82c835">17,305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE4LTEyLTEtMS0w_35d348c4-4128-4195-ae5c-0ef889f99853">1,982</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal year 2019, the carrying amount was the same as the estimated fair value.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7fdde9ced1b94177928122f1d6310dd0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90ZXh0cmVnaW9uOjA4YWE4NDFiNTQyYTQyNmJhNGRlOTM0NzliYzU5ZDU2XzEwODM_ca7a05bf-7610-41d9-9dee-16445251be19" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;3, 2021 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:43.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzEtMi0xLTEtMA_e2aaf139-510d-4154-a8d9-b42a1e04eb2e">14,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzEtNC0xLTEtMA_bbac13ec-942b-4ebf-9eac-728866aebc0c">14,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzItMi0xLTEtMA_e5fa8a63-ad1b-4c16-a153-dedcd3df1350">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzItNC0xLTEtMA_b94cee72-8f25-4369-acc2-484e65ac1253">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzMtMi0xLTEtMA_394a9a42-d632-416b-935c-dc4acfca4b6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzMtNC0xLTEtMA_387912e6-03ff-4ecd-a3a5-b0f27308b0ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzQtMi0xLTEtMA_f109375a-c290-488f-b5f3-80544d469479">14,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzQtNC0xLTEtMA_fae3eec9-af74-4dc2-b866-243caf8abee4">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div></ix:continuation><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_142"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90ZXh0cmVnaW9uOjIyMjMzZmZjOTA0NzRmMzk5NGRhMDNlNDBkZDk2ZDBiXzIwOQ_b7b5f4f9-d76c-479e-b5d8-d2768ac4ec1c" continuedAt="i214b7d86d4b944d9b012822454cd0b28" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i214b7d86d4b944d9b012822454cd0b28" continuedAt="i77062218fc524125b0d74204a3199164"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90ZXh0cmVnaW9uOjIyMjMzZmZjOTA0NzRmMzk5NGRhMDNlNDBkZDk2ZDBiXzIwNQ_28f29a68-79a6-4ccb-b8f3-2c31df7cf708" continuedAt="ic9226d5fc0c2475c9b0e13962fff7336" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, inventories were comprised of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:66.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzEtMi0xLTEtMA_7ea3296a-b081-495c-9052-6ebe0ddb0c58">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzEtNC0xLTEtMA_046b3d78-dc28-4bf8-9f87-c523317dd7d0">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzItMi0xLTEtMA_e8b21608-876d-437e-a038-4eb59f94696f">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzItNC0xLTEtMA_348e69a0-9b75-4453-92cc-360b78acf482">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzMtMi0xLTEtMA_81a8cd83-339f-432d-b71f-01ffe41a4d46">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzMtNC0xLTEtMA_f2d0872d-2cf3-41a9-9a98-f59293e6e55d">6,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzQtMi0xLTEtMA_a92e778f-019b-4b1e-b6bc-60e4ae27562e">9,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzQtNC0xLTEtMA_480191a5-5c8d-4f4e-a281-10f0934beb28">9,020</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><ix:continuation id="i77062218fc524125b0d74204a3199164" continuedAt="iba9d039f1a9d4317a088385d40371d9c"><ix:continuation id="ic9226d5fc0c2475c9b0e13962fff7336" continuedAt="ide1285e6e94b4fc8af94881c8a09deff"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="iba9d039f1a9d4317a088385d40371d9c"><ix:continuation id="ide1285e6e94b4fc8af94881c8a09deff">See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_145"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzg5NA_9a504198-7f57-4c7e-9605-28ac61263b34" continuedAt="ife0975ad58da47f68775ba629ae3ee44" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="ife0975ad58da47f68775ba629ae3ee44"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzg5MA_59f3b0ad-0552-4957-95f2-39fac1119f2e" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:67.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzEtMi0xLTEtMA_53e78836-9882-4c1f-bf7c-ba28278269bb">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzEtNC0xLTEtMA_3c539468-af68-475a-a6fd-67b89a4d0691">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzItMi0xLTEtMA_4ed5aa27-8f77-4091-8ffa-2524beb19075">12,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzItNC0xLTEtMA_5d400718-2fb5-4757-b0f7-226d6cf4ec43">11,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzMtMi0xLTEtMA_578a27c7-d389-4630-b847-f461b7b46900">29,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzMtNC0xLTEtMA_6b61c6ec-24f8-46cc-b198-f89cc1b845cd">26,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzQtMi0xLTEtMA_fae2b2a4-6bce-40cd-9c65-c9cc34f071e4">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzQtNC0xLTEtMA_31defd98-12e1-4d69-b54c-0a3c58dccaf9">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzUtMi0xLTEtMA_d742d112-0a0b-4ea2-998a-1fad8f18c8d2">46,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzUtNC0xLTEtMA_14e7fdb1-2fc9-4e58-9301-f692b1f93529">43,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzYtMi0xLTEtMA_41ac11d6-eeb4-42f6-80ac-068dd5866a69">28,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzYtNC0xLTEtMA_22ad274f-979c-47b6-93bf-05e7d6180ac6">25,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzctMi0xLTEtMA_f29cc53d-b4e4-440e-b572-3998388c4cc3">18,766</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzctNC0xLTEtMA_e85d9d71-e745-4eda-8817-eaee22bb2c30">17,658</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December&#160;29, 2019. There were no assets held for sale at January&#160;3, 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzQxNw_7c0119a7-19c6-4edc-a2f5-ae9aea96363e">63</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzQyMQ_f4c05eaf-ce0d-4651-97ea-0361c3abbfc4">70</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzQyOA_731a2046-84a2-4d64-822f-9ed53273b4f8">86</ix:nonFraction> million, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzU0MA_9274a83a-cabe-47c0-87b3-f866f37599b0">2.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzgyNDYzMzcyMDkyNzU_c7f32de5-4c68-4e81-b718-e1abaf092c76">2.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzgyNDYzMzcyMDkyODU_be6bf712-11ae-42d4-baab-b13369b8576e">2.6</ix:nonFraction> billion, respectively. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_148"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwNzg_b85f0402-01b5-4e8e-baf8-c2f7e4074a6a" continuedAt="i4ed765dfe52a4e458cd9a2e4ab559556" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i4ed765dfe52a4e458cd9a2e4ab559556"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwODY_3027afc1-0ffc-4af9-9e67-a8700ff970d4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzItMi0xLTEtMA_75469ebc-ffd4-42f1-bd8d-64d6ce8f9024">39,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzItNC0xLTEtMA_90778bdc-c0de-4e58-bb5f-496119047796">36,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzMtMi0xLTEtMA_fa95262b-8ae3-43d5-9e2d-a24c0d32bfc5">17,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzMtNC0xLTEtMA_0fa2b454-b16c-4992-9fc9-e72bbe23473a">13,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzQtMi0xLTEtMA_31118b6d-b3c9-4aa8-8499-34f4c816a3da">22,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzQtNC0xLTEtMA_98ec88b4-2310-46a0-991d-af1c8e1bcac7">23,480</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc844a985e9b4ab8acde3269099a7e3a_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzUtMi0xLTEtMA_36b53122-0977-4803-902f-cede4d2e18b1">22,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf08feba35c44f18b96be74a96747f7_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzUtNC0xLTEtMA_d136aee9-c4d3-4c4e-923d-2c78d626d434">22,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc844a985e9b4ab8acde3269099a7e3a_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzYtMi0xLTEtMA_67ce7b3b-03c0-4a4c-9f95-953729536487">10,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf08feba35c44f18b96be74a96747f7_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzYtNC0xLTEtMA_47132065-3289-47fb-b659-b5f5a8a9eaa8">9,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc844a985e9b4ab8acde3269099a7e3a_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzctMi0xLTEtMA_328f3205-5f5a-4a88-90fa-68913a231283">11,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf08feba35c44f18b96be74a96747f7_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzctNC0xLTEtMA_f5d1c841-4b55-4450-a40d-fe82575ee639">12,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0246814551b44afa8fc330cee4302c9e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzktMi0xLTEtMA_bfd1a410-4d99-4c8b-a86e-d7e062634a42">7,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd28da37730341bf89cc859b43e1ce8b_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzktNC0xLTEtMA_0da9cc76-16b5-4d42-bb1a-bbe59e7869d2">6,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323d72d0abae4c60a66b9d7b0a4c7632_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEwLTItMS0xLTA_124507fd-ba1b-47d3-b629-06b3c36b5b0d">11,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83996bd19a7d44aa89d8fa3abc440044_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEwLTQtMS0xLTA_2a0d618b-a8e8-49eb-93c9-938fe29479d7">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzExLTItMS0xLTA_3d97e671-b334-4ba6-86c7-e46ca22effe5">19,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzExLTQtMS0xLTA_9107c077-092a-4c86-a7a7-d74728d265b7">11,569</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEyLTItMS0xLTA_60b0fa22-f351-40a3-ac36-51ef83ad5e40">53,402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEyLTQtMS0xLTA_620ce587-bd69-4494-bb07-8a5f93c38026">47,643</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i610e8d971e0146b5b0f50d10214d75f7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzgyNDYzMzcyMTkxNjg_07cd5ed7-60be-4821-a6e1-0ad0bf825b2c">6.0</ix:nonFraction>&#160;billion from Momenta Pharmaceuticals, Inc., $<ix:nonFraction unitRef="usd" contextRef="ie2f9006a108d4ae79eef7c6e80d975ed_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzg3OTYwOTMwMzA2MjM_2e8c2935-e1bf-4332-8121-9c8e9f51e62a">0.8</ix:nonFraction>&#160;billion for bermekimab and certain related assets from XBiotech, Inc., and $<ix:nonFraction unitRef="usd" contextRef="i6680195d23ef48f48b25fd080e30e045_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzg3OTYwOTMwMzA2Mzc_f141f6b7-f2f1-443c-a912-91c1dd3311ca">0.4</ix:nonFraction>&#160;billion from the acquisition of all outstanding shares in Verb Surgical, Inc.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwODk_896ecd89-c3a4-47d5-b553-e7ae34f33fb9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;3, 2021 and December&#160;29, 2019, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:33.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic991d846f0554fb3854353012c741e47_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtMi0xLTEtMA_4af8dd2b-163e-4128-bcde-8294b0331142">8,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af09372a20b4cf5bc9ca89867f6e9b5_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtNC0xLTEtMA_6c1a13bf-616b-423c-b265-3690b8ef8491">9,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7611c63653fb4652b6fe6457c1f44f7d_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtNi0xLTEtMA_6ff73dab-0057-44ee-9b56-91f5ba48a1f8">12,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtOC0xLTEtMA_7be0f463-a1f3-4b2c-9bdb-7ca79c17919f">30,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItMi0xLTEtMA_c06ba65f-6d1b-4607-a45d-536e2fc30b09">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItNC0xLTEtMA_61943342-2eab-4cb3-bef7-d3fa2df74543">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItNi0xLTEtMA_00437407-594b-430d-9762-96a14c47e83d">2,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItOC0xLTEtMA_9cb8dfab-01f9-4a65-a79b-9af00fd57bc8">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtMi0xLTEtMA_89e6a684-98da-46d1-ac83-8ce55c9f15cf">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtNC0xLTEtMA_5fcc3555-7a62-42d5-94f0-890c2c08ec93">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtNi0xLTEtMA_06ae00b2-c28b-4e55-b47c-335d7c62a1ed">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtOC0xLTEtMA_4747ae5e-8781-4576-8995-86b7efce7112">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ecd7168647c48c487c55761ba2ced54_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtMi0xLTEtMA_0841d868-4f45-496c-b058-af8256cc4966">9,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63df1bc915934ad68c8902ac19c99bea_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtNC0xLTEtMA_1b40424d-b1b1-40bb-910d-9dcd64ea7d18">9,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e711fea4f3418abfe78e49bdbf2256_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtNi0xLTEtMA_071c5976-68f4-4afc-8939-41e69a30e6f9">14,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtOC0xLTEtMA_c5db150b-fb94-4b48-b61e-10f3b2face75">33,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtMi0xLTEtMA_b11dfadd-a3dd-442d-9cd8-a51caf174852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtNC0xLTEtMA_bc97924f-4d6b-4cd9-8e13-f354dd9eceba">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtNi0xLTEtMA_64203f9c-83a4-473f-af31-150bea2e61cc">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtOC0xLTEtMA_1c89a30f-2b6a-4117-ad3f-735edf3ef3cf">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtMi0xLTEtMA_f5f22745-998e-4e6b-8ac3-fd1caa356a7a">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtNC0xLTEtMA_080fd1ef-1018-423c-8b75-761a55ed76d3">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtNi0xLTEtMA_ba6c02d6-0bac-4070-b771-6da9d9348da5">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtOC0xLTEtMA_826c86bd-729c-4584-bfd2-47dbc7be1e0b">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c1789785ab45d596ef77f977c4b121_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktMi0xLTEtMA_a6db9b63-3e30-4fd6-a12e-097318c10901">10,336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0733c2434242ba85b6c5b1c835e725_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktNC0xLTEtMA_0c97a855-899b-46e4-af8c-0019b600b539">11,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ae3e960cac4c83aaf46f48e727ffc7_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktNi0xLTEtMA_7d69fc0b-f9aa-4773-b8d6-e72617087e3a">15,048</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktOC0xLTEtMA_cbd3a500-4a15-4e72-b5b0-0200f8fe1369">36,393</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="ia50a679a6f554f4782e402d666b79722_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE0ODY_216d1793-c4de-41a2-9eb0-fed73850881b">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="iccf138ab7f374295818f1906976dd6e3_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE1ODk_49e4b85b-2650-438e-bd7c-6b22df0bdd22">21</ix:nonNumeric> years. The amortization expense of amortizable assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE2Nzg_14b2b0db-827f-4789-aa0e-f97252304930">4.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE2ODI_0d5dd2cb-b039-4f24-9447-a1417ab39a35">4.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE2ODk_c6692315-572f-40e3-930b-150a3b63639f">4.4</ix:nonFraction> billion before tax, for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwODQ_af989fb6-f599-4198-bef2-281fa421ff74" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItMC0xLTEtMA_df120c32-3509-4f85-9c7f-03e643ea30bf">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItMi0xLTEtMA_bbd6358b-109d-45f4-8571-de575cd784e8">4,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItNC0xLTEtMA_2fd75c88-eef2-4b46-a49e-7ebc25f7f811">4,100</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItNi0xLTEtMA_65829162-d0dd-4674-b7d4-9ba96d408992">3,900</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItOC0xLTEtMA_e9cf403b-b642-4c62-aed0-4f79c65e6e16">3,200</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_151"></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1NzM_cb7fe061-344c-4a87-a367-7d55626148b9" continuedAt="i1aabd633c23b4d6f80ecd5c2a8cf061f" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i1aabd633c23b4d6f80ecd5c2a8cf061f" continuedAt="i560c6f6b2c70484b92c2ac0314348fdc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges.  The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.  As of January&#160;3, 2021, the total amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzE2NjU_3e569a18-870b-40ba-a53a-d679ecc4084a">1.1</ix:nonFraction> billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings.  The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions.      As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzIzMDc_c53177a0-0a9e-4c4c-aeb1-b419617578cf">37.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9875f4baef3f4a1b948b6ce968e1cdc7_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzIzMTU_64dc6d72-99e9-4f8e-9a0a-b30c9476f735">30.6</ix:nonFraction> billion, respectively. As of December&#160;29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i27f4f225aff44f999a6680657f1c61d3_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzI0ODk_788fed35-998b-41bc-a71f-f37a540d01f7">45.3</ix:nonFraction> billion and  $<ix:nonFraction unitRef="usd" contextRef="i7ca6c05369c945429bb481abe32f8614_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzI0OTM_c6b5e04a-6976-4783-97ca-115935e93768">20.1</ix:nonFraction> billion, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. The effect of which are immaterial for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of January&#160;3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzQ2OTY_06321e26-5f37-449f-ba54-0a91f4623b19">652</ix:nonFraction> million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzQ5NTU_3a3b62c8-a7a1-4467-9330-ebfd200b8163">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:durmonth" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzUxMTY_a8bd0458-9848-4078-9cbd-6592624ec74e">18</ix:nonNumeric> months, excluding interest rate contracts, net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i560c6f6b2c70484b92c2ac0314348fdc" continuedAt="ifac7eae7822f4ae58d974b030ee0097c"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1ODQ_e2e25262-eacb-4b45-bad0-5d8c0ec47761" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019, net of tax:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504dd38a7aa842119593f0983c422c2d_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTEtMS0xLTA_40e5e685-31fd-41e0-89c0-75b789a1832b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8640053c6b9d41e7b51cfc21fdc35a76_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTItMS0xLTA_9f467888-e075-4972-a592-2ea6f41e1730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052b28db3f2e41379f8949dc73a4456c_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTMtMS0xLTA_b51140f4-4a8c-4f6f-ac10-cf751e32c087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b584b81e4314c05bff5a3a53f02afbf_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTQtMS0xLTA_0179bccb-8587-4bb8-949f-9fc7b09f9316">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ffcb6fd0b4017b7ebc21794532df0_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTUtMS0xLTA_adb6fd41-2d93-4c12-98a5-3196c92dce00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a30ff6ddef34c879c3a48899c85fd4c_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTYtMS0xLTA_c4427248-1471-405f-8ac3-9585b481f3d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc985f689ed44a3b6b5c0680b59cb08_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTctMS0xLTA_6e337c1c-b9cc-401e-9fe1-7fbe1adc67db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be13ffcdce471782b928e02e0ecb36_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTgtMS0xLTA_bd752854-0a28-4776-89d6-91c962b166df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca59ee60bd4461ea3d47a202e3a0c92_D20181231-20191229" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTktMS0xLTA_69df6724-cdaa-4954-8d9b-4a0ecf2363fd">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d21b453745418380adcf639d9dcc50_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTEwLTEtMS0w_5adc64f9-e076-492a-8b49-805ee37e920a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504dd38a7aa842119593f0983c422c2d_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTEtMS0xLTA_1502778c-762a-4352-aa79-c8a43b497ce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8640053c6b9d41e7b51cfc21fdc35a76_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTItMS0xLTA_106d6f30-d168-49dc-81b4-466fdb4400b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052b28db3f2e41379f8949dc73a4456c_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTMtMS0xLTA_4aafccf6-f205-436e-882c-2df8eb76e2a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b584b81e4314c05bff5a3a53f02afbf_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTQtMS0xLTA_ae42cfab-23e8-43ae-ba31-419d3b2e184d">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ffcb6fd0b4017b7ebc21794532df0_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTUtMS0xLTA_01598e92-5bbf-4415-9372-34d5177ad518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a30ff6ddef34c879c3a48899c85fd4c_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTYtMS0xLTA_3e165e44-e50d-4891-bb4d-d0f7b519aaef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc985f689ed44a3b6b5c0680b59cb08_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTctMS0xLTA_705ec87a-e346-468a-9f0c-75f2e3a4b18b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be13ffcdce471782b928e02e0ecb36_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTgtMS0xLTA_d65e71fc-e64a-4e81-9649-6daa68f6019f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca59ee60bd4461ea3d47a202e3a0c92_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTktMS0xLTA_33507419-4bd2-4659-9180-8c9933832487">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d21b453745418380adcf639d9dcc50_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTEwLTEtMS0w_be348e68-487a-4e7f-89d1-654b7f77faf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6f97ba35ec4096bcc04f4b4f8691c3_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTEtMS0xLTA_3055f910-3678-4746-a89a-a5ddf5b16517">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic742e9fd9fc14884addc84d349e1c28e_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTItMS0xLTA_09ac02a0-51c3-42ab-8ac1-c644c1f88dde">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbdc1a64aa24c13b6889b62805de83b_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTMtMS0xLTA_c5378416-ec67-419c-a446-5bf7419a1863">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1283aa8aad894085a364e383b421263f_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTQtMS0xLTA_f68e261a-fd10-403c-8add-f3b9cbf5a9cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcdafeb6de434a389a8ae98d6c27bc71_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTUtMS0xLTA_da645ae2-43ba-46aa-b624-b987c20344e8">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49eaaa02ae0e4bdd942caea69069c9bb_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTYtMS0xLTA_d2a69661-8e3b-46d0-900c-ed79fe914b19">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63d2fc906c86432098158cb4b10ed6af_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTctMS0xLTA_9308164d-e77e-42a9-b531-af1e833e6185">321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8768d9bd65b14a88998cc98eb8b56b71_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTgtMS0xLTA_91a0664e-448a-443b-a195-327e9684287d">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d6224b1442428383799310a443ccd9_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTktMS0xLTA_c4b424a3-4278-4513-b80a-14f45856e175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id484553bc7f246b2956d7fe4162e2291_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTEwLTEtMS0w_5c743009-1bcf-4eab-ba7e-2908fec55c7e">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6f97ba35ec4096bcc04f4b4f8691c3_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTEtMS0xLTA_b8211bae-52bb-4276-81d1-506dbf53a9a3">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic742e9fd9fc14884addc84d349e1c28e_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTItMS0xLTA_61e1d0ba-9d9f-4a1a-aebf-5b6ec3f9415f">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbdc1a64aa24c13b6889b62805de83b_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTMtMS0xLTA_ccefa7f9-c56f-4980-8f89-3c0d79493c15">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1283aa8aad894085a364e383b421263f_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTQtMS0xLTA_837b5504-2eb5-4e7e-9648-4a5416b8256e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcdafeb6de434a389a8ae98d6c27bc71_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTUtMS0xLTA_ca7fbf91-dc3b-4383-9df3-3fc41aaccf44">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49eaaa02ae0e4bdd942caea69069c9bb_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTYtMS0xLTA_6974a136-1e9f-43dd-8464-261aef6443a4">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63d2fc906c86432098158cb4b10ed6af_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTctMS0xLTA_4521c149-2d55-4ebd-a297-6cf0cca88315">606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8768d9bd65b14a88998cc98eb8b56b71_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTgtMS0xLTA_be515fa4-96a5-4ef5-afdd-212488e699b3">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d6224b1442428383799310a443ccd9_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTktMS0xLTA_bc1663f8-1e29-4676-baf4-c9641ec3d2e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id484553bc7f246b2956d7fe4162e2291_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTEwLTEtMS0w_d59e4c43-17ab-4d12-b509-a4c09a73d5c1">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4cffd97e4a4b9db233400cb5173ef1_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTEtMS0xLTA_ab95d0e9-96fc-45bc-9827-ca5b06a4ea90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685f5c13f8df4ef59a10c882dc33db9a_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTItMS0xLTA_71eb4336-a2d1-4f30-8fff-39e0a163f4fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168477b06e674a54857ad32c9063d70d_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTMtMS0xLTA_4da5f8f2-7226-4e21-ad42-046a2e642936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df8b1f03a5d46d788ea587e459c0d92_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTQtMS0xLTA_c3877b73-b5e5-4e57-bcf5-94ead10c0400">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c58bd90b6d4d01aab3aef88e24fda1_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTUtMS0xLTA_9f4d241d-f966-4b38-961d-f1d646baa34b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f6e10d334f47eb89761629c9a42e6b_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTYtMS0xLTA_7c9792ce-c1dc-4722-8db9-0ff4ce06c36a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c7fd78bae849e18766ff5f722b4347_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTctMS0xLTA_4f548181-29fd-40d1-97c3-34abc6f045f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc23bedbeef4fe2934d4b69926edf66_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTgtMS0xLTA_c72e30d8-f797-4b32-9350-1301b62d8fc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44491fa9fda4fc9977393ab1922d90e_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTktMS0xLTA_c9a31c7b-ea7e-4a54-b374-5f6333db52a2">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23c9442c717040c2b8f471f3da9878f2_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTEwLTEtMS0w_a7eb333d-96a8-48f5-939d-4dd579e0f95b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4cffd97e4a4b9db233400cb5173ef1_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTEtMS0xLTA_0cb35282-5611-4d3b-82b6-c2bee4911c82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685f5c13f8df4ef59a10c882dc33db9a_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTItMS0xLTA_287c92eb-fc91-474c-a0bb-8049a34bef2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168477b06e674a54857ad32c9063d70d_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTMtMS0xLTA_74035c3f-b0c9-4717-b37b-86699bcec8a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df8b1f03a5d46d788ea587e459c0d92_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTQtMS0xLTA_4b15388a-b685-4d35-ae59-c760a0f8a8b1">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c58bd90b6d4d01aab3aef88e24fda1_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTUtMS0xLTA_d5cc1bfe-ccf2-4c40-84fd-dee4c15eebeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f6e10d334f47eb89761629c9a42e6b_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTYtMS0xLTA_8fc47b53-9302-485a-9cea-c4d66aba4a8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c7fd78bae849e18766ff5f722b4347_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTctMS0xLTA_6332f1d5-d095-4dec-bed6-aebf6d717f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc23bedbeef4fe2934d4b69926edf66_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTgtMS0xLTA_1a9ed8f1-52ec-4d7e-a27c-6243b65bc97a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44491fa9fda4fc9977393ab1922d90e_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTktMS0xLTA_6ff94946-1f7b-43d2-84a7-d3e28ebcbb07">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23c9442c717040c2b8f471f3da9878f2_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTEwLTEtMS0w_2a229481-5142-4dd0-8e0c-df2410de14ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1Nzk_4f970217-b9c3-4536-8e99-84a5d3ce1a95" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:37.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5f27a8783b49c09ce94e0b992e4d45_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3NmJlYWY3MWFiYWE0Yjg5OWI4NDBjNjg1NWRmZDBhMS90YWJsZXJhbmdlOjc2YmVhZjcxYWJhYTRiODk5Yjg0MGM2ODU1ZGZkMGExXzQtNy0xLTEtMA_52189669-d4a2-40f5-960c-460069226625">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b0ca0336ef04af5b1a42a37200ec54d_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3NmJlYWY3MWFiYWE0Yjg5OWI4NDBjNjg1NWRmZDBhMS90YWJsZXJhbmdlOjc2YmVhZjcxYWJhYTRiODk5Yjg0MGM2ODU1ZGZkMGExXzQtOS0xLTEtMA_e8464ab2-7461-4d62-91d5-e21becefb6b7">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifac7eae7822f4ae58d974b030ee0097c" continuedAt="i164ddd62d32947e6aac2dc1501711eb7"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1NzQ_33f237d2-d732-4c6b-9431-c8ed161ded81" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtMi0xLTEtMA_6e1e848c-334c-44e9-bef3-1880315ab095">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtNC0xLTEtMA_f52a35dd-8f30-4050-9333-2104afe6bc92">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4c7294e0d1495194057b40b978d165_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtOC0xLTEtMA_5590753c-13fd-4e55-9425-69228756f6e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b73114f3ec4b0082e498dd41bb847e_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtMTAtMS0xLTA_864383c5-6149-48b3-bf09-a7e0d4eca105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2916bc780e044ef49bef1e4b70c3cc9d_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtMi0xLTEtMA_4dffc57d-062e-44fb-a40d-47a0b4160d0e">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244284a65da64e8d883b976f20dd4439_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtNC0xLTEtMA_dc8ed36a-7f4d-425f-8c82-a1f65d835b07">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015f5e90b1d24aed9b099ce1619e99d5_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtOC0xLTEtMA_3e6fbfcc-fd88-4bce-be49-e4a694042bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f6938e747b4a25bcc25eac3741af90_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtMTAtMS0xLTA_5c39a5e1-7b05-4963-a46d-7bc406cf6121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1NzU_bbfdc5ad-84ab-4f38-b0ca-3dc902ad56d8" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7bfc44c870488c80c19b43b875f537_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItMi0xLTEtMA_ebdefe89-fc3b-485e-a330-bb8d2503add5">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ece5d5ae1a84367837c469a116bdbd3_D20191230-20210103" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItNC0xLTEtMA_6168e05a-c9e8-4b21-b2a8-add4445fc23a">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ece5d5ae1a84367837c469a116bdbd3_D20191230-20210103" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItNi0xLTEtMA_5d45ae00-13d3-4f53-a71e-2e58b9fa44ec">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c25167a6e4f4d47bddc86f00585a224_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItOC0xLTEtMA_3ea3cdf7-a068-4c2c-b8ef-4438b6989336">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c25167a6e4f4d47bddc86f00585a224_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItMTAtMS0xLTA_92e46787-6a4e-4457-9f6d-c2b9098d56ac">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e6ac332e264884b231e1297e1c4568_I20191229" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtMi0xLTEtMA_75bb0dec-0273-4e41-9489-bbc38a7f196b">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtNC0xLTEtMA_62b755df-d88b-41bd-83db-54f0384386cf">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtNi0xLTEtMA_12a9fcb0-e0eb-4b5f-9199-c3b5d38b6aa7">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28e5b7c3ed4439f84c2bbe32744fe70_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtOC0xLTEtMA_fd60333f-8fb1-4a7c-8791-28691c507243">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28e5b7c3ed4439f84c2bbe32744fe70_I20210103" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtMTAtMS0xLTA_65b5fb08-23d2-4d07-aa90-43396e704036">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf0149aed5548e0a41ef000a1870d66_I20181230" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItMi0xLTEtMA_8fbaef0e-997c-4937-a106-f2483d10c309">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02cda706e4b2470e94e004280758bd89_D20181231-20191229" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItNC0xLTEtMA_b0ac480e-ad4c-4d61-8d27-4c4518e23026">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02cda706e4b2470e94e004280758bd89_D20181231-20191229" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItNi0xLTEtMA_d1363239-008f-4799-8bee-970354dc0f7f">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7bfc44c870488c80c19b43b875f537_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItOC0xLTEtMA_ca7d3a4a-491d-4092-aeeb-f447c980218d">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7bfc44c870488c80c19b43b875f537_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItMTAtMS0xLTA_00a88c95-a623-4b9d-890b-e360cd37fa53">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce25e79e7eb4e0eb4f1dd38ac472371_I20181230" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtMi0xLTEtMA_b177f098-0b23-42fa-bdb5-ee5fd1cc1def">681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtNC0xLTEtMA_92123d0c-06ee-4496-b91f-f230a300ed19">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtNi0xLTEtMA_b29cbcca-61dc-4849-b1e3-b24ee5c27279">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e6ac332e264884b231e1297e1c4568_I20191229" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtOC0xLTEtMA_d95c7533-e58f-4392-99ec-c35a27372c79">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e6ac332e264884b231e1297e1c4568_I20191229" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtMTAtMS0xLTA_6270ecd9-7887-483d-b6ea-11585cf9beec">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019 for equity investments without readily determinable market values, $<ix:nonFraction unitRef="usd" contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:EquityFairValueAdjustmentImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzYzNTI_1be0facd-0487-4413-b957-78508fb8e1d4">76</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:EquityFairValueAdjustmentImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzYzNTk_0264d558-cc85-4329-8bb8-fc2370e175d9">57</ix:nonFraction> million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were $<ix:nonFraction unitRef="usd" contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzY0NzI_299c42f6-a7c6-452c-ab13-d084b3a1e122">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzY0Nzk_40c0af31-7319-4e0b-9126-79e3d365cdd1">19</ix:nonFraction> million, respectively, of changes in fair value reflected in net income due to changes in observable prices.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i164ddd62d32947e6aac2dc1501711eb7" continuedAt="i2787ee1fc6814fdba89dda7e4671d62c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div><div style="margin-top:7pt"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1OTc_e6d4478d-f309-44ec-af19-e4a717280606" continuedAt="i81638b7afb624508beb4369aeb081783" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;3, 2021 and December&#160;29, 2019 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a5708acf3147969658a14d0f39da97_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtMi0xLTEtMA_9faad6a0-7a63-48b5-abb5-7af2bed95fc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtNC0xLTEtMA_a3f70050-700e-49fa-8fc8-33110ba8fc93">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtNi0xLTEtMA_77b6f8f5-8486-4ef5-98a7-2668f47bb579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtOC0xLTEtMA_cad7e554-e9cc-4254-9271-7cd96d630e6c">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtMTAtMS0xLTA_be6eac3e-44d8-47c4-9242-d0d2adf4c981">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780693331f074588830546d5a4ad2799_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtMi0xLTEtMA_b097cfa3-d2d5-43ae-8bdf-331201c52334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c325d4d8dab4b0685cdeb50ada0d1a9_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtNC0xLTEtMA_62d7ab91-77cd-4034-b909-6359f4281bec">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aeb7bb33ec641c98e0fbde2d3d5c165_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtNi0xLTEtMA_82bca205-a6e2-43b6-a30e-f06eb62b6bee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90af2ee9b9b540bb99b3f8e6d629a8f5_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtOC0xLTEtMA_56f81e8d-cec6-4f40-9031-bfd084bd3514">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5608ee32b2f64df4a13f8ff444c9fbdf_I20191229" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtMTAtMS0xLTA_d86cebe4-38b9-42ac-a599-442bbd89fbfa">693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctMi0xLTEtMA_58de8483-7a4e-432a-9896-a785ca75431e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctNC0xLTEtMA_3201d865-df68-40c8-9481-459489fb5e68">1,089</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctNi0xLTEtMA_576fae5c-3f32-49f3-adec-e0a9760803bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctOC0xLTEtMA_d2060f50-040a-4334-ab68-9b319b74ffa2">1,089</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a9d7cee0f342329e91428213de8f04_I20191229" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctMTAtMS0xLTA_ec943320-ee52-406f-b1d9-2943b2aff3f3">902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a5708acf3147969658a14d0f39da97_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktMi0xLTEtMA_d72be5e7-464c-4887-a043-b5a35b2decba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktNC0xLTEtMA_22efaf12-5c1f-48a4-838c-8e332a16b9a0">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktNi0xLTEtMA_2c092e6e-30dc-43d9-8e51-3a28d9f31cbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktOC0xLTEtMA_4351197c-2a3a-4133-84a7-bbc3e29c8453">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktMTAtMS0xLTA_de9f7c57-0749-47a1-948f-59c13d2b6620">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780693331f074588830546d5a4ad2799_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTItMS0xLTA_71a91fe1-c050-4dd5-9d15-3042f5760d74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c325d4d8dab4b0685cdeb50ada0d1a9_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTQtMS0xLTA_61a7a557-d3ea-44f4-b5bd-21308e9add5f">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aeb7bb33ec641c98e0fbde2d3d5c165_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTYtMS0xLTA_98dbd32e-9ce3-4378-b22a-c63874570768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90af2ee9b9b540bb99b3f8e6d629a8f5_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTgtMS0xLTA_ac2b4079-607c-42a4-a268-68b2646dc156">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5608ee32b2f64df4a13f8ff444c9fbdf_I20191229" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTEwLTEtMS0w_ee7817fc-5af2-4358-ad9b-a9be51b64072">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTItMS0xLTA_7c392b5f-e703-48a5-b1fd-c311fa362d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTQtMS0xLTA_9fe84179-ec64-4e61-b23b-4c2eec1dad78">2,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTYtMS0xLTA_cc0a50b5-058a-49e0-b888-2f343b429a04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTgtMS0xLTA_7f035e70-7452-4720-a817-f088fe251f4c">2,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a9d7cee0f342329e91428213de8f04_I20191229" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTEwLTEtMS0w_479a920c-5b1b-4ed7-84d9-ea5adfb8f780">619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a5708acf3147969658a14d0f39da97_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTItMS0xLTA_9d6f7d23-4246-460e-9ff8-dd13eef0a2ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTQtMS0xLTA_26ebcf55-b0fa-472a-9bf4-21c6ecbda5aa">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTYtMS0xLTA_cfb16353-a21b-41db-8e82-b84a4acc94d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTgtMS0xLTA_f2fd7c43-de7d-4067-81e4-22ecec1ec7fa">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTEwLTEtMS0w_4ab720bd-78c6-4406-8514-fa69751073f2">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a5708acf3147969658a14d0f39da97_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTItMS0xLTA_62b35006-5d90-48e2-9634-f0c1c09d3e60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTQtMS0xLTA_61d70446-7b60-4658-ba0e-37edb18de921">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTYtMS0xLTA_a5ed293c-8bfa-4b29-acac-8fd631777937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTgtMS0xLTA_d1b7e98c-eef8-4738-9e52-5c816277e313">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTEwLTEtMS0w_a47afc7e-78a8-4c53-8fec-a37a7c69a738">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTItMS0xLTA_2590b73a-ca51-4329-8301-b57afeae53d9">1,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTQtMS0xLTA_0e80b5c3-8e61-46be-9534-ca4db18e2382">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTYtMS0xLTA_5bc049bb-c711-4637-8594-064cbd557ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTgtMS0xLTA_abe3d4ca-7b9f-4df1-9f13-917de91c24e2">1,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTEwLTEtMS0w_efe061eb-09ee-4ceb-8976-0d266f071d55">1,148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTItMS0xLTA_d874306a-a232-4323-b866-cb812aabdca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTQtMS0xLTA_97847380-2d44-462d-b7f7-3bda9ac92b50">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTYtMS0xLTA_9a56e681-c0fb-4ae3-a732-976c299408cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTgtMS0xLTA_1df5892a-9562-43cd-82a8-2b9597ee6d7f">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTEwLTEtMS0w_3dfdc9fe-1eb4-4945-a286-6e2bd451447e">4,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIzLTYtMS0xLTA_fc0703f6-d2f7-4546-9fb4-053cca4386b5">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIzLTgtMS0xLTA_9d70c763-edc9-4fde-96f1-5ad0853cfce2">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIzLTEwLTEtMS0w_31bdb023-5ade-4d54-94cf-dd1be3282cc2">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.409%"><tr><td style="width:1.0%"></td><td style="width:53.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzItMi0xLTEtMA_6eeab449-2ca9-457c-b236-8006413ded94">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzItNC0xLTEtMA_7ca13335-1867-44fd-b3f6-0104821366c9">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzMtMi0xLTEtMA_10da1e72-4d56-4edb-a891-fcdae92372e8">1,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzMtNC0xLTEtMA_48adf7be-6524-4bba-9ef4-974671404dbd">841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzQtMi0xLTEtMA_a663cdcf-1051-4246-a9b6-c4e4e3a4cac1">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzQtNC0xLTEtMA_9169b0ff-b87a-42f0-b8e7-1d9114b4cbba">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzYtMi0xLTEtMA_be8652cf-3410-4fab-93a3-91f8c4fe5294">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzYtNC0xLTEtMA_883904d4-0c54-4bfe-8b94-6b3a584d6946">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzctMi0xLTEtMA_f5b699e5-9b68-44b0-9c9b-d25260c77a5f">2,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzctNC0xLTEtMA_646344e7-e672-49d3-abd7-48922616dc98">586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzgtMi0xLTEtMA_33dc7bfc-2493-44ec-905b-2194e9709bc6">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzgtNC0xLTEtMA_632cf8f3-e263-47d2-bf46-6fa8c995136c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2787ee1fc6814fdba89dda7e4671d62c"><ix:continuation id="i81638b7afb624508beb4369aeb081783"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzItMy0xLTEtMA_88d98fa8-a647-44bb-99a5-f71515ecca16">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzItNC0xLTEtMA_4d5a3282-1158-4403-8890-b1a773b4736d">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzItNS0xLTEtMA_e6fbc487-0641-42d8-b587-230f065337ad">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzMtMy0xLTEtMA_0c165173-4509-41be-b618-75cc443c2e38">1,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzMtNC0xLTEtMA_ee158545-0e80-4e21-b42d-c8112a523ad1">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzMtNS0xLTEtMA_91c212d8-bfb8-4f35-b6a9-0a7b13288dbc">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzQtMy0xLTEtMA_10155666-7b83-43bc-8f91-debe9902c706">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzQtNC0xLTEtMA_d9cfbbb9-0a16-4992-8733-01b65d5aad12">1,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzQtNS0xLTEtMA_9354191d-61f4-461f-9f3c-07e3e3d8dca9">125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzUtMy0xLTEtMA_a9c7c6e6-ff26-47c0-bf79-8ceeda5ecae0">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzUtNC0xLTEtMA_f2768cd8-9e70-40af-ad88-c347cf809136">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzUtNS0xLTEtMA_38005592-7ed6-42ac-bb5c-be021fd4c1a6">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzYtMy0xLTEtMA_b16734bd-f2a1-4ff6-b762-a64f0c9773c1">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzYtNC0xLTEtMA_eaeea04a-9258-42ce-a424-2f92c19e8166">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzYtNS0xLTEtMA_c589e082-60a1-4bd3-91a6-1e0fdece4ff6">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2019 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="i063b1e7203cc48a383a856f56f95ece2_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzg3Mzk_bf5070bc-31e5-4e94-ac5a-475eeaf60f5e">1,148</ix:nonFraction> million, which are classified as Level&#160;1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="iba78ecb5491f4fa1805dedb0bb402778_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzg4MDc_7f09de28-233f-49b0-b43b-e32d40c03a06">1,715</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i4833811f03a34cdfbb1b8144a5e115c9_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzg4NDM_349bdb53-06f1-429c-a28f-c881ed841fd4">1</ix:nonFraction> million of non-current assets as of December&#160;29, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i204902ff089e4411bef7c51531f107d1_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkxODU_f4f78a53-7a97-4be9-a979-c438223c4f7a">594</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i150752b44d724b06a4b96ffabd4ea8b6_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkyMjU_912b196e-b0d9-4f4b-9d3d-1655c5793160">1,631</ix:nonFraction> million (primarily related to Auris Health) and $<ix:nonFraction unitRef="usd" contextRef="i522cea24f1ca42868d485da848eb40cd_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkyMzI_83403921-5805-4638-b578-6f814501a1ff">397</ix:nonFraction> million, classified as non-current other liabilities as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Includes $<ix:nonFraction unitRef="usd" contextRef="i795080089d5f41458b16a91c2923e0c6_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkzMjM_ec24a50d-974b-4457-9eea-40d64b2b22b1">39</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0afabd84326c4799b8b58c05bbc630b4_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzE0MjkzNjUxMTcxNzI0_195e9501-e1ee-4136-aa8c-251fd015349f">84</ix:nonFraction>&#160;million classified as current liabilities as of January&#160;3, 2021 and December&#160;29, 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="i5d258167afb64a19982ff42e1d05bda3_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzgyNDYzMzcyMjAxMzM_cf2b1cf1-d83f-4c51-ae3d-676dd6541008">1,148</ix:nonFraction>&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE3NTc_95007396-297e-49bb-b480-727da97f884d" continuedAt="i1db21f6ea5384001a9cf89a647c3f652" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="i1db21f6ea5384001a9cf89a647c3f652" continuedAt="ib366ef5831844fd8bb6772e2c27f377c"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE3NjU_18bad44a-a9a6-4d6b-ac7f-65bb89cc2faa" continuedAt="if2d2e19d69644b959cdd461c1ea8bb42" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:42.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7d8d4d3851f43118320077adb8a55de_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtMC0xLTEtMzE5Mi90ZXh0cmVnaW9uOjk2Mjk5MjE0ZGY3NTRmOWJiMmMxZWQ1ZmRiNzMxZGZlXzEwNDQ1MzYwNDYzOTM3_35b67673-b18b-4d95-8f55-ccae2fcd1b05">3</ix:nonFraction>% Zero Coupon Convertible Subordinated Debentures due 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d8d4d3851f43118320077adb8a55de_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtMi0xLTEtMjk4NA_68f0f5a9-4beb-405d-a6a5-934ab1e087ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7d8d4d3851f43118320077adb8a55de_I20210103" decimals="4" format="ixt:zerodash" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtNC0xLTEtMjk4Nw_3667dd5c-91e9-4fc7-8849-64aa73cf565e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6149e03b1a45c9a528cbe475bb4465_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtNi0xLTEtMjk5MA_2d8ec99a-106d-4d01-aa3f-586f41606da1">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc6149e03b1a45c9a528cbe475bb4465_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtOC0xLTEtMjk5NA_35773f81-58f9-452b-9a1e-25c3e4b1c626">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i239971f81b48484183a8b472b82f6ded_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItMC0xLTEtMzc1OC90ZXh0cmVnaW9uOmU2ZGJhYjljNjhiMDQwNmU5NWUzMzhhZDYyYzE4MTE1XzEwNDQ1MzYwNDYzOTA2_a49cf508-387f-42b7-9441-fea8b108c296">2.95</ix:nonFraction>%&#160;Debentures due 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239971f81b48484183a8b472b82f6ded_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItMi0xLTEtMjk4NA_a2a442f3-b7bb-4a33-86d3-1c1c1a57381b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i239971f81b48484183a8b472b82f6ded_I20210103" decimals="4" format="ixt:zerodash" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItNC0xLTEtMjk4Nw_bf167bc3-44f9-4827-aef5-aa4149098220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643d86e5fb4949bc9b0b38833626e8a6_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItNi0xLTEtMjk5MA_1ad90e08-18b2-47d2-90da-fa2a73073cf8">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i643d86e5fb4949bc9b0b38833626e8a6_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItOC0xLTEtMjk5NA_53df8585-d0f3-4e2f-8311-8da0e5053ade">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtMC0xLTEtMzc2My90ZXh0cmVnaW9uOmZhZDk0ODAyYzQxMzRiODM4M2E1NzNmZDZlNGNhMDM2XzEwNDQ1MzYwNDYzOTAz_df480566-099a-4bf7-bc2e-1d20bc7a967b">1.950</ix:nonFraction>% Notes due 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtMi0xLTEtMjk4NA_c937d57a-6a16-46ff-89e8-dd48955ec561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103" decimals="4" format="ixt:zerodash" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtNC0xLTEtMjk4Nw_2dfff19b-5da5-49bf-ab42-98cfa37ad925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2855ce1111214d85ade50a6ccac8a618_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtNi0xLTEtMjk5MA_d4c688c3-8d71-49e8-a645-0cb928600024">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2855ce1111214d85ade50a6ccac8a618_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtOC0xLTEtMjk5NA_a928f2ab-b186-4335-965e-abb9d95a59a8">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i926e8b4151584d75bb453778eff5a51c_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtMC0xLTEtMzc2Ny90ZXh0cmVnaW9uOjNmZGY5ODY1Mzk0MjRmMDBhNWVmYmNhZmZhNDcxMTNmXzEwNDQ1MzYwNDYzOTAx_3e5298d3-74b7-4ee5-8957-4cb059df6101">3.55</ix:nonFraction>% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926e8b4151584d75bb453778eff5a51c_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtMi0xLTEtMjk4NA_02bfa69b-1275-488d-a494-36bd6a467a2e">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i926e8b4151584d75bb453778eff5a51c_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtNC0xLTEtMjk4Nw_8646950d-0a05-479e-b96b-5a9ffeb8a095">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic351de96f94f4e9b8747f6446b843a4d_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtNi0xLTEtMjk5MA_68fea48b-4e9a-44d2-be2f-cafdee3d5e29">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic351de96f94f4e9b8747f6446b843a4d_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtOC0xLTEtMjk5NA_d8b5c9ee-5985-4b7d-84b6-f1ad752da9ee">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c3d81e50f874f138a3912b40b201c41_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjoyZTk3ZDViNDhiZmY0OTJkOGZlNjFmZGJmMGE0OGEzMl8xMDQ0NTM2MDQ2MzkwMQ_b8db402e-3c4b-4a73-b27d-e7e1d495a133">2.45</ix:nonFraction>% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3d81e50f874f138a3912b40b201c41_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTItMS0xLTA_4efd6461-e1e1-45ac-92bd-6136763f6590">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c3d81e50f874f138a3912b40b201c41_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTQtMS0xLTA_bf938f32-1f49-4cdf-9bdf-49202fd37076">2.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib933e5916e15417a8a48a5669ccf5321_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTYtMS0xLTA_3b13c8e3-3365-4e25-b57c-202b8b5ef4d8">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib933e5916e15417a8a48a5669ccf5321_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTgtMS0xLTA_6047d8ba-b4a2-4a5e-9f01-a1ae6dbcb53a">2.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a873dff1d3141a19512b0affe1fe2d8_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtMC0xLTEtMzc3NS90ZXh0cmVnaW9uOjU0NTZmMDgxZWQ3YTQ3M2U4MWEzM2EyYjhhN2Y3MDE5XzEwNDQ1MzYwNDYzOTAx_3eaecd5a-cc6f-49bb-b353-54c353834f08">1.65</ix:nonFraction>% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a873dff1d3141a19512b0affe1fe2d8_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtMi0xLTEtMzAxNw_8fba8eab-0a0e-4259-8133-4f8259d80d58">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a873dff1d3141a19512b0affe1fe2d8_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtNC0xLTEtMzAyMg_f765b6cd-d2c0-4a10-8e0d-9427654ab224">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8212ea597cf4a84b23cd83df34ea924_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtNi0xLTEtMzAyOQ_293f3537-e8f1-4b79-8a63-286ff79b6de5">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8212ea597cf4a84b23cd83df34ea924_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtOC0xLTEtMzAzNw_84a26807-44c6-47e7-8e32-99cdf4878916">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl8xMDQ0NTM2MDQ2Mzk5OA_9fcdbc9a-6194-4558-9c23-8fb610473271">0.250</ix:nonFraction>% Notes due 2022                                                        (<ix:nonFraction unitRef="eur" contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103" decimals="-9" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl8xMDQ0NTM2MDQ2NDAwMw_24cedde1-8205-4ec7-8b0a-04ebdae5128a">1</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl8xMDQ0NTM2MDQ2NDAxMg_e9f91741-8068-4803-b81e-7b0762d554e6">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229" decimals="-9" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl84MjQ2MzM3MjA4NDg3_85d708a8-b5fa-424d-8b2f-6b25ef0adc1a">1</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl84MjQ2MzM3MjA4NDc3_89283b0a-44c8-4bff-b993-bb740cb5c43e">1.1096</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTItMS0xLTA_01bda025-5b26-4526-8830-1af1eba2d5cb">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTQtMS0xLTA_2c5c6c69-1a29-404b-a6f7-7ffe1f965a36">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTYtMS0xLTA_2c2f0b35-1b28-439b-a852-01dc1bf19ecc">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTgtMS0xLTA_7403fbac-b43e-4cdc-bbde-c84aa1089e3a">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dbe0979c7a14dc9b9f12e17af387027_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NWY2NmIxZjVjNzU0MjZjYWRlMDU1MzVkNmMyY2JmZl8xMDQ0NTM2MDQ2MzkwMQ_38bd89ab-14c7-4a6e-9df9-5a9d6f505586">2.25</ix:nonFraction>% Notes due 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe0979c7a14dc9b9f12e17af387027_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTItMS0xLTA_40b044d3-25c5-44b3-a6bb-44cbfa76d54d">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dbe0979c7a14dc9b9f12e17af387027_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTQtMS0xLTA_055a33a9-2d21-464e-9cdd-5eb38e7ca97a">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bfafa6c5fb4ce3ae20923ddd529bae_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTYtMS0xLTA_caa09c8a-1065-42fd-a03b-196fe7bf265e">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96bfafa6c5fb4ce3ae20923ddd529bae_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTgtMS0xLTA_98f76704-02fb-4b47-9962-9481e88ada14">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4NjQ5YWQwNzNkZDc0MmY1OGU3NzZhMjBkN2U5YmNlZF8xMDQ0NTM2MDQ2MzkwNg_1985ea59-a144-44b3-b149-b989416fc494">6.73</ix:nonFraction>%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTItMS0xLTA_cce64f6b-b1e2-41aa-b00c-2f9b62dc2b2d">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTQtMS0xLTA_67dfcb05-8e38-4f05-b56d-7fb9ede7886b">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f807d1cada4781ae10198fe16e1c99_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTYtMS0xLTA_d8a0b926-77a8-4fb2-94fb-80a5bad638ce">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3f807d1cada4781ae10198fe16e1c99_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTgtMS0xLTA_ccddaac7-b006-446e-95a9-57ecf9f24970">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if95c57f111c64126bccc2fc3a980ce5a_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyMDk2MDViNTg1ZjY0ODkwYWIwOGQ3MGI3MWM0MzRjYl8xMDQ0NTM2MDQ2MzkwMw_33b63260-72ab-487f-8355-a852ec73bba5">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c57f111c64126bccc2fc3a980ce5a_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTItMS0xLTA_b3ee1202-36f0-4525-bf37-1c3c899f144e">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if95c57f111c64126bccc2fc3a980ce5a_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTQtMS0xLTA_bdb438ee-d7e1-4884-9af4-c4430bf3c5da">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a1b55a0d51409e9832bdbc47868c84_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTYtMS0xLTA_14b0e016-d371-4b50-8aed-d0e9f4bd670c">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2a1b55a0d51409e9832bdbc47868c84_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTgtMS0xLTA_f888dfad-895e-43d0-ae9e-8e0da2b76bb0">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a181a42de50462faa774006c9104b58_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjo2MmNjMmI4ODJiNzE0NWI2OTMyNDMzNGU1MDMwOGM4Yl8xMDQ0NTM2MDQ2MzkwMQ_04f0ef85-9d96-46d0-b329-88128a808a1f">2.05</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a181a42de50462faa774006c9104b58_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTItMS0xLTA_bea7719b-e59a-4818-888f-cb9315fae62d">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a181a42de50462faa774006c9104b58_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTQtMS0xLTA_4ae25c4e-8b9e-44d8-96b8-c065f5ef4074">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acd1bef02c94effbce52af8c909bec3_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTYtMS0xLTA_d3d42281-cd51-4860-b56c-8a2062cea230">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2acd1bef02c94effbce52af8c909bec3_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTgtMS0xLTA_1e47308f-afcd-4ad7-bde9-104113e904cd">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id431690b092746cda0e3885506938117_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl8xMDQ0NTM2MDQ2Mzk5Ng_ff9137c9-b24f-413a-8019-95717997c2e0">0.650</ix:nonFraction>% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="id431690b092746cda0e3885506938117_I20210103" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl8xMDQ0NTM2MDQ2NDAwMw_f251909d-421c-437f-ab16-3c05445feffb">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="id431690b092746cda0e3885506938117_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl84MjQ2MzM3MjA4NTM5_576af96b-e93f-4088-a256-438d24384f9b">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl84MjQ2MzM3MjA4NTYw_f7f69eb5-457a-42c5-b8ac-43f19f4fb9b5">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl84MjQ2MzM3MjA4NTQz_ffac935d-a593-4b3c-ab22-94440d6daeea">1.1096</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id431690b092746cda0e3885506938117_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTItMS0xLTA_b47fb4c9-cc9a-4517-8e70-6717942f2a01">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id431690b092746cda0e3885506938117_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTQtMS0xLTA_4027426b-e60f-40e5-b4ee-e04893618b75">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTYtMS0xLTA_abc83084-82e3-4959-9b7a-748b0f80f69e">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTgtMS0xLTA_9b2bf076-1937-43e9-a120-4c5fb2a9527e">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV8xMDQ0NTM2MDQ2Mzk3NQ_8196318a-95f9-41d5-95f8-300aeb3d79c6">5.50</ix:nonFraction>%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="gbp" contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV8xMDQ0NTM2MDQ2Mzk4Mg_edc6b1d5-7a52-47e6-92a2-8cb4af7a911c">500</ix:nonFraction>MM <ix:nonFraction unitRef="number" contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV84MjQ2MzM3MjA4NDUy_f369ed62-10f9-4135-b506-419dd7ae8eaa">1.3654</ix:nonFraction> GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="gbp" contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV84MjQ2MzM3MjA4NTIz_b08197d9-de32-4ebc-8e77-f32b2340a842">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV84MjQ2MzM3MjA4NTE3_0aa188b7-78e0-4292-b998-fed1f4ab7e39">1.2987</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTItMS0xLTA_61ed2e79-e6da-48b6-9247-77729b88b739">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTQtMS0xLTA_1ef32773-11c7-499c-a0de-62d4800bc202">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTYtMS0xLTA_92c86e94-3f12-4e13-9d8a-7a63f2c78cc4">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTgtMS0xLTA_555aa74a-19a3-4f79-af78-4790eafe550f">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa8bc6079d92403ca3c4b99e75498b57_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNGQwYmNlZThlMDA0OTg3YmZmYjRiYmRmMjI4YzVjNV8xMDQ0NTM2MDQ2MzkwMw_8d9d9a4e-2a4c-460b-9669-25fe2b3bb412">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa8bc6079d92403ca3c4b99e75498b57_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTItMS0xLTA_6b169eb9-2102-4e4f-9e76-34ccad636e7b">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa8bc6079d92403ca3c4b99e75498b57_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTQtMS0xLTA_ec7b61f0-3d8a-4f82-9afb-00f6d935ac4c">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8d7bc47a734d679cb8e0230bf39855_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTYtMS0xLTA_872d61d9-3e0a-483b-bdf2-9c8b34ede78b">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c8d7bc47a734d679cb8e0230bf39855_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTgtMS0xLTA_369238c5-3eee-4122-9b04-251a68ca8d68">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c683153e4274793b8e2b845aee7dc3b_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTAtMS0xLTI5MTAvdGV4dHJlZ2lvbjoyYzM3ZWI4ZjRlZjc0ODc3ODI1ODU4YjFmMzk5OGRiZl84Nzk2MDkzMDIyMjQ4_396203f1-0632-4a42-83cf-015b4ccb158a">0.55</ix:nonFraction>% Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9fde6f193e0450fb608feb62094bab4_I20210103" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTItMS0xLTMwNTY_6fc5f256-b382-4182-9e78-2275f8d022d1">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9fde6f193e0450fb608feb62094bab4_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTQtMS0xLTMwNjg_69438567-80d2-44f5-b49e-09fc11222890">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38c696c925d1472b90cf70120a0702ca_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMzI2OGMxZjhhY2U0ODM5OGVkMTNiNGEwM2NjN2FjOF8xMDQ0NTM2MDQ2MzkwMQ_b79baa30-ae6a-4e11-bfbd-f105e5d97f36">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c696c925d1472b90cf70120a0702ca_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTItMS0xLTA_6684106b-d10f-4bf4-8ebf-6d837f3c28ba">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38c696c925d1472b90cf70120a0702ca_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTQtMS0xLTA_03f79c33-a177-452e-8b86-bdb138166749">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c169ee681eb41d4b70cf224042a918b_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTYtMS0xLTA_b9df3702-71b2-4362-beb2-82f4b5f4d58b">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c169ee681eb41d4b70cf224042a918b_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTgtMS0xLTA_6720be95-3c89-4780-b7bf-a6675eb83f37">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i468ec06486014ee2bd6f5c7a72949cf0_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDE4ZDljOGFjYWY0NWUxYWI5ZmNmZGM3ZDU2NWE2ZF8xMDQ0NTM2MDQ2MzkwMQ_ab156fc1-fa6d-4b38-a082-79043a83f457">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468ec06486014ee2bd6f5c7a72949cf0_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTItMS0xLTA_473b17bd-b3af-4bf7-98b7-e248dbaa95e7">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i468ec06486014ee2bd6f5c7a72949cf0_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTQtMS0xLTA_b9c096af-ce7c-42c4-9a8d-cfd52d9d91a2">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92f79edb6394aabb7c66d1f0ceb9c1f_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTYtMS0xLTA_804618ae-2f30-4878-af1d-abab5857182d">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib92f79edb6394aabb7c66d1f0ceb9c1f_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTgtMS0xLTA_996b8c95-662d-4f97-ba34-499d7ad00ddc">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c9f0124227242a3b37ef08fc5f78862_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTAtMS0xLTI5MTYvdGV4dHJlZ2lvbjo3MzU0YjQzZGY4NjQ0MjVkOWNjNTNkZTlkNDIxNjcxMV84Nzk2MDkzMDIyMjY1_b886cf6a-63dd-4fbb-baf8-b9bf64d1fd5c">0.95</ix:nonFraction>% Notes due 2027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e4daae8acd4186854161164075f779_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTItMS0xLTMwODc_956ae90f-0551-4084-9778-8fb9ee6e2d84">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6e4daae8acd4186854161164075f779_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTQtMS0xLTMwOTA_e56a880c-26d7-40c8-88e3-8acfc9b3930c">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY18xMDQ0NTM2MDQ2Mzk5NQ_2fc686fe-c88e-4350-b7e8-0569ae1e10f5">1.150</ix:nonFraction>% Notes due 2028                                                (<ix:nonFraction unitRef="eur" contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY18xMDQ0NTM2MDQ2NDAwMQ_bed6314b-f1d2-457a-9423-ab43751c67e0">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY18xMDQ0NTM2MDQ2NDAxMA_4d94e6ec-7945-4ff1-af18-7fb097e80cce">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="i035991005b3545fdb445908803f01423_I20191229" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY184MjQ2MzM3MjA4NDcy_3de0d6f7-ebe6-438c-955e-8073d2a99304">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i035991005b3545fdb445908803f01423_I20191229" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY184MjQ2MzM3MjA4NDY2_318da1e4-fe95-47de-8df1-523b0435c783">1.1096</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTItMS0xLTA_e688173f-6521-469d-9c8b-b2e050d684a4">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTQtMS0xLTA_9ce1e977-5e81-41d9-8ff9-dd7e17aea127">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035991005b3545fdb445908803f01423_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTYtMS0xLTA_e5f2a9df-3156-472c-8c73-92868582131f">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i035991005b3545fdb445908803f01423_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTgtMS0xLTA_437ec22a-46d7-4b94-a3a6-5f36f0abc2d8">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTgyZDgzMGM0Y2Y0ODdiODM1M2Y3M2ViY2E0YTFlN18xMDQ0NTM2MDQ2MzkwMQ_f5f9f889-192e-4f04-b4e2-96d21cf222d7">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTItMS0xLTA_2d3c8682-e592-40c4-9238-4688413ef01d">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTQtMS0xLTA_2e6cd7e2-45bb-40e4-8e2f-563060e01cfb">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541337b24d2444a8bf14a78c6ec932fd_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTYtMS0xLTA_21fb19c8-3930-45cb-9baa-855e2abad029">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i541337b24d2444a8bf14a78c6ec932fd_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTgtMS0xLTA_7eb251f6-11ce-49fe-93e6-3d75f584bcbc">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45d84507c060443eb3ceeb3ff733f151_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjkwOTU4MGUzZWI0MjIyOTU2NzE1ZGZjMzhlYmI0ZV8xMDQ0NTM2MDQ2MzkwMQ_e1e3aef0-b435-4590-a692-08dfaca9eaba">6.95</ix:nonFraction>%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d84507c060443eb3ceeb3ff733f151_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTItMS0xLTA_9f120c18-84ec-48b8-a19b-ce37dbc13874">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45d84507c060443eb3ceeb3ff733f151_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTQtMS0xLTA_69394b88-8401-4f66-b691-f85b6d899979">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbe327f106f448cbd073f1bca885cb8_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTYtMS0xLTA_7c9f251f-9e32-430f-b050-4084a525cf12">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbbe327f106f448cbd073f1bca885cb8_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTgtMS0xLTA_430d21c3-5058-40bb-bf2a-0014dc1c0292">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a322bcc2a514a30b7e05707bfb38724_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTI5MjIvdGV4dHJlZ2lvbjo4MjUwYzNhMmQwMzc0MjFiYjMyMGU3ODYzYTc2Zjc2N184Nzk2MDkzMDIyMjU3_6fd531be-be55-4837-98eb-6c7a18954fe5">1.30</ix:nonFraction>% Notes due 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a4cd9bc3a54ec4a968860df1b0f6ba_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTItMS0xLTMxMDU_b2f3ffc4-aecc-417b-865d-a214d47208a6">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8a4cd9bc3a54ec4a968860df1b0f6ba_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTQtMS0xLTMxMDU_8a7607b1-8f17-4666-b5df-52dc2be10ad0">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba9d57b541417083a57e7550184805_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjplM2QyMjM1ZTc0MWY0MTE5ODJhMDUwNmRkNjk3MTYwNl8xMDQ0NTM2MDQ2MzkwNg_c7d0157d-64db-4986-991a-be0e2ea1ef41">4.95</ix:nonFraction>%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba9d57b541417083a57e7550184805_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTItMS0xLTA_1c97c6c6-9db1-4b7b-999b-b81ad9d3fa09">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba9d57b541417083a57e7550184805_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTQtMS0xLTA_2c402405-197e-429d-bdd9-903d2c4aaf10">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5584716e0e79483b8e1d3828aaab1e0f_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTYtMS0xLTA_ed00be76-54d3-4f26-a5da-08c7064c3039">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5584716e0e79483b8e1d3828aaab1e0f_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTgtMS0xLTA_370b3e8e-992e-46a6-8273-3b4552061872">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1965776d766f4468bd93699590f0d845_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjoyODUwM2U4Y2U5ZTc0ZmE5OTQ0ODdiY2U1YmY3ZTFkZl8xMDQ0NTM2MDQ2MzkwMw_2048c733-2662-4fbd-9e69-4b4b4ffe20e6">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1965776d766f4468bd93699590f0d845_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTItMS0xLTA_787b09b3-b8d8-4fc9-8aa0-9fafdf2ce3b9">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1965776d766f4468bd93699590f0d845_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTQtMS0xLTA_1f06544a-de3c-4bd2-b40f-ed33102054ab">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff628b0cf02144cd91a4abcc5053f028_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTYtMS0xLTA_ffbf5131-1915-41ec-a24a-6530abd61945">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff628b0cf02144cd91a4abcc5053f028_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTgtMS0xLTA_9b4f726c-9a93-46f7-b2fc-38f5cf292afb">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N18xMDQ0NTM2MDQ2Mzk5OA_fda2d6b9-6d71-41aa-8698-00d9dcde4b2f">1.650</ix:nonFraction>% Notes due 2035                                                     (<ix:nonFraction unitRef="eur" contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N18xMDQ0NTM2MDQ2NDAwNA_a77c48fc-f012-420e-a18c-3566544214a5">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N18xMDQ0NTM2MDQ2NDAxMw_264147a7-f3d3-4bd1-aa05-05adee4b7d12">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N184MjQ2MzM3MjA4NDc1_2443512c-24dd-412f-a1b9-bb5b2157e0dd">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N184MjQ2MzM3MjA4NDY5_dbea0acb-e92a-4ebf-826e-e70e469f6b33">1.1096</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTItMS0xLTA_71d7249b-ee4c-4a2e-b738-fbe289d45b76">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTQtMS0xLTA_58816237-3adf-4820-862c-143e12e89407">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTYtMS0xLTA_47ffe6b1-0dbe-4334-bb8d-3a1a2627eefd">1,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTgtMS0xLTA_4a6adf73-3870-4593-9b0e-95c824b171fb">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63438abe9f0244469fd820794902d862_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDBlMGVkOWUzOTg0Yzc3OTJkOTVjNjE1NDc3YTg4YV8xMDQ0NTM2MDQ2MzkwMA_7e65f168-9523-4f54-a32d-9106dcb899ea">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63438abe9f0244469fd820794902d862_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTItMS0xLTA_445fc134-d24c-4322-b961-ab47fa8b5da2">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63438abe9f0244469fd820794902d862_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTQtMS0xLTA_57e7107b-7160-4752-9c7a-c7f5de5b7195">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49d24552bc346e1b4e0dab3a0e924b4_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTYtMS0xLTA_485c344b-aa21-4b8c-b06e-44143d1cd2fa">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic49d24552bc346e1b4e0dab3a0e924b4_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTgtMS0xLTA_e56c8ec4-9ab5-4f63-83e0-af0448b44857">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a1673c8394c4e3f872d187343339109_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpjZmMyYTVjNmNiM2U0YjAyOGEzNGMwOGM4NWIyNTk1NF8xMDQ0NTM2MDQ2MzkwMQ_899d98a5-b0ac-4531-9fdc-4f13f0af967c">5.95</ix:nonFraction>%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1673c8394c4e3f872d187343339109_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTItMS0xLTA_03ca757c-b316-4336-82dd-606519c3a844">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a1673c8394c4e3f872d187343339109_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTQtMS0xLTA_67e47937-40a9-4b53-8b9c-ee07a42769bf">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf9a86caabd4562bffba6ff39983416_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTYtMS0xLTA_b57c95aa-c622-40c4-b1d7-895beede9df6">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bf9a86caabd4562bffba6ff39983416_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTgtMS0xLTA_2b2c5616-2893-4eb2-9945-70f6e4def437">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3df454f0c44e460bab62d61a065354d2_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZDIzMTU1YjlkNWE0MDlmYmFlNWJjMDZmNTcwYjg1Zl8xMDQ0NTM2MDQ2MzkwMw_75145913-5686-461f-b018-9fddfb404047">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df454f0c44e460bab62d61a065354d2_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTItMS0xLTA_9ac2d0d2-3501-4f3e-9774-eb45c6e50ca1">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3df454f0c44e460bab62d61a065354d2_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTQtMS0xLTA_f2b8d688-8622-42bb-8c10-fb3710a3e521">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac8457d7f3f412bbba5cd8890c8ad72_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTYtMS0xLTA_ef04c492-e66d-4df9-8f82-8d892158caf8">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ac8457d7f3f412bbba5cd8890c8ad72_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTgtMS0xLTA_16275028-b0c7-4f31-ab28-c1078f1cb593">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51f46beeeb544a6f91f38d5f362744ee_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo2YzZjMjJmNGMyMDI0YjEwODhhMjFjNzFkMTdmMjVhMV8xMDQ0NTM2MDQ2MzkwNg_07d75cac-0e67-4ba9-a477-6c0610e03087">5.85</ix:nonFraction>%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f46beeeb544a6f91f38d5f362744ee_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTItMS0xLTA_493fccdc-8722-4d0c-983e-3ecd4733f8f5">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51f46beeeb544a6f91f38d5f362744ee_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTQtMS0xLTA_43e2e678-bfcc-441e-8508-38331cf8028f">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf5cf036d354852b5eaf7f1a747632f_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTYtMS0xLTA_c56580dc-30ee-4f5e-a731-5003f7150e0b">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebf5cf036d354852b5eaf7f1a747632f_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTgtMS0xLTA_6a450b82-02e9-4750-8c3f-9db1123e49eb">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96f58bd4d50d4e84946db893d8650ed6_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMDEzYTUyNGY4ZjQ0ODFjYWUzMTkwNjRiNjQ3MDg5YV8xMDQ0NTM2MDQ2MzkwMw_7f269941-9311-4f40-a0c9-8f79248fc7a4">3.400</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f58bd4d50d4e84946db893d8650ed6_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTItMS0xLTA_318475b9-c195-450f-b1ac-0df2080b5041">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96f58bd4d50d4e84946db893d8650ed6_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTQtMS0xLTA_df387c8d-95e1-4c06-8d80-27232dd0a634">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782bc6f740614734a43da12dce22161b_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTYtMS0xLTA_7293908d-e158-4f69-a4d0-48f9be85695e">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i782bc6f740614734a43da12dce22161b_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTgtMS0xLTA_e3b9c3dc-1b99-4ad9-91c5-28fb2939758e">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b804bc029e642feb0493dd3906a185b_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpkY2VjZWQ5ZDM3MzI0YjI2YWIxNGE2M2M2ZmQ0YzFkY18xMDQ0NTM2MDQ2MzkwNg_b9548cc9-a700-4ce3-9e36-edf4195bee00">4.50</ix:nonFraction>%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b804bc029e642feb0493dd3906a185b_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTItMS0xLTA_655f89a6-6cf3-48f0-b7af-665a079c286a">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b804bc029e642feb0493dd3906a185b_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTQtMS0xLTA_1577af40-5e79-4aa5-aafe-fc157ae705ff">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b581805ecd4967a8646eaf60bca900_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTYtMS0xLTA_1ce800a5-6c8c-4d72-9513-60f4249efb06">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05b581805ecd4967a8646eaf60bca900_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTgtMS0xLTA_cfabbce8-2ad4-44d7-a71c-6c06826944ae">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70d754e14799477284511704f83b8d17_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTAtMS0xLTI5MjkvdGV4dHJlZ2lvbjozZjFkNmEyNWNhODQ0NmUwOTc4NjAyN2FkNzljMmEwZF84Nzk2MDkzMDIyMjUw_3c98d801-21f7-4049-b32c-7ef522582617">2.10</ix:nonFraction>% Notes due 2040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7255430870174b0fa0d8627f1ec59a3d_I20210103" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTItMS0xLTMxMjI_b30e06a6-2f6e-4768-85f9-9d457a8aeb6c">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7255430870174b0fa0d8627f1ec59a3d_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTQtMS0xLTMxMjI_4fdd668b-2830-4c96-bfc3-f35dd63c18c4">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id568183bd7d541139e4919632134334d_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiYWQ0NjU0MjE4NzU0NjkzYTgyYTdjZDI0NTM0ODUyN18xMDQ0NTM2MDQ2MzkwMQ_414ddd83-0ea4-45ad-a5f8-e82dfb14226e">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id568183bd7d541139e4919632134334d_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTItMS0xLTA_28dd1f60-c299-4ef4-8f30-13a89df6744b">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id568183bd7d541139e4919632134334d_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTQtMS0xLTA_23a5662b-ba67-4a25-bc9c-57d1c562d1a2">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f619870e5ab42bb830254e1a5d06b99_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTYtMS0xLTA_943136a3-58a3-48d9-ada9-be75aa99368b">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f619870e5ab42bb830254e1a5d06b99_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTgtMS0xLTA_f9d7adc1-f07a-4e0d-b31a-8c41fea0ad94">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjpiYjA0NmU2NGIxZjI0ODZkYmEwMGUxOTY1MWMwNzQxN18xMDQ0NTM2MDQ2MzkwMQ_f2602229-aa2c-4824-a340-b0c1bb80b9da">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTItMS0xLTA_15566a16-9b77-400e-bfb7-c40a78119ce4">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTQtMS0xLTA_ea970ed2-edae-44a7-8df1-d09831d84eae">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fff5e1fbc7546c895f24337e28ccd11_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTYtMS0xLTA_18306f87-6430-49d2-bdcc-7d46b95472fa">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fff5e1fbc7546c895f24337e28ccd11_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTgtMS0xLTA_4e2a9dd2-6ee7-4dda-899d-2d95613f0171">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjphYTQ4OTJlMDM0MTc0OGY5OTA0ZTE1NTZiYTJkYTk1ZF8xMDQ0NTM2MDQ2MzkwMQ_9fac370f-8641-4337-b166-371cd9cf9379">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTItMS0xLTA_06b43772-7f1a-43e0-bdde-1c73a22d5ac5">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTQtMS0xLTA_f250640f-16e6-452e-8fc4-450d1415aafb">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief45c201a3b243caa69c0e0f161b2ae4_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTYtMS0xLTA_d4d930ff-adfc-47da-9aa9-cba749b343cb">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief45c201a3b243caa69c0e0f161b2ae4_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTgtMS0xLTA_f8795937-8f01-40e9-b691-020096f5bae3">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8b7693bcded4747a5ab760537912c2a_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyOGU1NzkxNDYzYzk0YzdlODJhYTk4MDZlNDAzNmE5NV8xMDQ0NTM2MDQ2MzkwMQ_6a81c9a9-2858-47aa-885e-b6d540323987">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b7693bcded4747a5ab760537912c2a_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTItMS0xLTA_f9cf1fc1-3524-4f28-98fb-c46591f58ae0">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8b7693bcded4747a5ab760537912c2a_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTQtMS0xLTA_a3968cc2-9973-4832-a7d2-e7ae93daffa0">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd125a14e0d4e7a876c8945f58e61f6_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTYtMS0xLTA_e32c0ba0-60f2-47c9-acb8-0ca0b61a244a">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafd125a14e0d4e7a876c8945f58e61f6_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTgtMS0xLTA_2efb0c29-57e2-4733-ab65-4303becc7b4e">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjowMzFjYWM1ZDQ4Y2I0MzQ5OTQzN2M4YTQ5ZDUxZjIzZF8xMDQ0NTM2MDQ2MzkwMw_1e5e61f1-3268-456c-9cb5-79c834b058ce">3.500</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTItMS0xLTA_591c19a4-9da1-4d97-b072-cfa4871a3b2f">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTQtMS0xLTA_efda1236-f4b8-4a2c-a737-de9975d1a9ef">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f33f574f1a41b9bf5677aefeaf760f_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTYtMS0xLTA_0e9ecc99-9248-44f4-8ad9-67d0ad34aa35">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60f33f574f1a41b9bf5677aefeaf760f_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTgtMS0xLTA_8aa021a1-d3f4-4581-87dc-33310e888085">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39181f4c3aa24aaa9646a538d7f62e4d_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTAtMS0xLTI5MzQvdGV4dHJlZ2lvbjoxMDU0ZmI2ZTgwNGU0MGIwYWNiNTg1N2UxMDllNTczZV84MjQ2MzM3MjA4MzY0_67822f10-613e-4047-921a-1562ae2525ae">2.250</ix:nonFraction>% Notes due 2050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8df475fa9c4c4aa829c65373e7b7fa_I20210103" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTItMS0xLTMxMzc_4f236253-e571-4eb3-9569-fcfa57b53c23">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a8df475fa9c4c4aa829c65373e7b7fa_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTQtMS0xLTMxMzc_fa34116d-7f4b-4f48-a083-69a13521e049">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib366ef5831844fd8bb6772e2c27f377c"><ix:continuation id="if2d2e19d69644b959cdd461c1ea8bb42"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:42.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24f8e23ceca94494b1b3b111eed8dbd5_I20210103" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTAtMS0xLTI5MzQvdGV4dHJlZ2lvbjo1OTYzMzJhMjRhOWQ0ZjU3YjAyYjgyMzZjMmJjMTEzNV84MjQ2MzM3MjA4MzU5_ea921cde-3b60-4122-87ea-b141451084e2">2.450</ix:nonFraction>% Notes due 2060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72aeae00e1604bf385505263726995cb_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTItMS0xLTMxMzc_ac2c6480-88f4-45d3-ac7d-34d2d967e9c6">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72aeae00e1604bf385505263726995cb_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTQtMS0xLTMxMzc_0597c1db-e01b-41e3-8f83-a1a316d061bd">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fe11f963ad43deb7bbe15f647ec9ff_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTItMS0xLTA_782ae723-5372-4e5d-820a-5be68ec04863">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76fe11f963ad43deb7bbe15f647ec9ff_I20210103" decimals="4" format="ixt:zerodash" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTQtMS0xLTA_6c223a4a-e2ee-4f15-944e-a1897713a8a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53872a4a35184b378900cbaf5b99200c_I20191229" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTYtMS0xLTA_cf434d33-a898-4e5b-9e4b-4ee89cb0323c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53872a4a35184b378900cbaf5b99200c_I20191229" decimals="4" format="ixt:zerodash" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTgtMS0xLTA_f5df61a3-3829-4197-ada4-dbe690d6a78b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bb2eed805a40d391fb647db58d1d62_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTItMS0xLTA_2ae468ae-11c5-480e-a09a-aafae88330d9">34,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTQtMS0xLTA_3bfd9722-1cf6-4565-bc13-1319bc026e58">2.85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6108907f204089b3f9838308be8b28_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTYtMS0xLTA_3d91f0ea-ae67-47e9-9670-ed10e7ef1e32">27,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTgtMS0xLTA_986efdfb-896b-4b27-9aa5-3c73b27f49eb">3.19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bb2eed805a40d391fb647db58d1d62_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQwLTItMS0xLTA_ad2bd6e4-e3d0-41dc-af0c-50b54469c65d">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6108907f204089b3f9838308be8b28_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQwLTYtMS0xLTA_7fe04676-0779-42e0-86ad-63d05720a113">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bb2eed805a40d391fb647db58d1d62_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQxLTItMS0xLTA_92698fd2-5c38-4c79-a239-548e5e960ef2">32,635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6108907f204089b3f9838308be8b28_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQxLTYtMS0xLTA_7355e50a-ed6b-4cc9-aeb8-3dea2f5dc70d">26,494</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;3, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at December&#160;29, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzIxNg_a5eb56c7-3062-4ce0-ac06-df25393d79c4">5.4</ix:nonFraction> billion at the end of fiscal year 2020 and $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzIyOQ_fb868794-961f-4cc0-8210-44958aa8a5f7">3.0</ix:nonFraction> billion at the end of fiscal year 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $<ix:nonFraction unitRef="usd" contextRef="ia4a277a5e8eb4225adece7896cfdfc52_I20200927" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzkzNDU4NDg4MzgwNzM_25891e93-d716-49ba-8df3-35b21a1c31cc">7.5</ix:nonFraction>&#160;billion.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2020, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzU5MA_403eba5f-2b52-412d-a1a6-8eb2a8bd69f7">10</ix:nonFraction> billion, which expires on September&#160;9, 2021.  Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, London Interbank Offered Rates (LIBOR), Secured Overnight Financing Rate (SOFR) Swap Curve or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Throughout fiscal year 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzExNDc_e672cc13-7cec-4dd0-a207-e6f2d861715c">2.6</ix:nonFraction> billion at the end of fiscal year 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermCommercialPaperCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzExNzc_a34c501e-0828-4adc-a3dd-12f69746d5c8">1.8</ix:nonFraction> billion is the current portion of the long-term debt, and the remainder is commercial paper and local borrowings by international subsidiaries. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout fiscal year 2019, the Company continued to have access to liquidity through the commercial paper market.  Short-term borrowings and the current portion of long-term debt amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE1MTA_b1697896-b44f-48e6-b845-14e61a9f7aea">1.2</ix:nonFraction> billion at the end of fiscal year 2019, of which $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermCommercialPaperCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE1NDQ_699a5c37-5f5c-40ac-832a-cc9ec2da02c1">1.1</ix:nonFraction> billion is the current portion of the long term debt, and the remainder principally represents local borrowing by international subsidiaries. </span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE3NzM_898ebecd-72e0-4034-a21c-87719fbb2551" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2021 are:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItMC0xLTEtMA_c56b4d62-6c55-4c56-838a-0a593d85e7ac">1,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItMi0xLTEtMA_82a87a22-7ef3-4ec9-a529-76baa00aa759">2,226</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItNC0xLTEtMA_41cdf4e0-9ab1-45b6-a46b-222cc657501d">1,552</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItNi0xLTEtMA_f1d8179a-7468-4b71-b88d-c76b9d5c78b0">1,598</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItOC0xLTEtMA_2b6b3de9-d6dc-4eeb-8001-94595813c81f">1,744</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItMTAtMS0xLTA_f6e5ec96-061d-4706-b906-825fb2fd58ab">25,515</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_163"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEwNDQ1MzYwNTA5ODM5_e6ff8502-2e0f-4c28-98db-fe7f39b7659a" continuedAt="i910b36142c01458fbbc758f076fc26ab" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i910b36142c01458fbbc758f076fc26ab" continuedAt="i67af357c54894b248f921f3f6153a85e"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NTEw_e3421767-b39d-4ad7-b456-01dac2b9baaa" continuedAt="id4aba40cd2ff4a3ab5a4682375d6743e" escape="true"><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzItMi0xLTEtMA_d159dde7-690a-430f-ba77-abb3533a8666">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzItNC0xLTEtMA_786fe131-baf3-4bde-a63c-e5f919a1bf52">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzItNi0xLTEtMA_aa15ca17-db2c-4034-9ebe-c86bbc8ccabf">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzQtMi0xLTEtMA_d19e1589-5de3-4387-a9b7-2a41152f8b57">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzQtNC0xLTEtMA_efb9ba91-e948-4f04-beac-84d7bbe8e20f">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzQtNi0xLTEtMA_e5049f00-7489-4a37-9b80-cfba2a80221d">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzUtMi0xLTEtMA_69b987ab-1197-47ca-896c-2c2a8dfb2cbf">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzUtNC0xLTEtMA_1cd35b90-9311-45eb-bc1f-aa12529f6b45">4,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzUtNi0xLTEtMA_2aafcd27-d46e-43fd-9ce9-efed766d78f2">3,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzctMi0xLTEtMA_af15d670-7a39-4808-9422-0236e47c1ddc">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzctNC0xLTEtMA_46d2b036-2641-4266-9f17-d555b1a37d70">814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzctNi0xLTEtMA_9d0c6d4a-4a15-45a9-8b0f-a57ef55063b4">1,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzktMi0xLTEtMA_372f36e1-4168-4006-9cf0-8bebbeea821b">1,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzktNC0xLTEtMA_0bd1f948-0528-4f79-99f0-5f17a71cb325">1,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzktNi0xLTEtMA_9146ee6c-09d2-41bc-a899-2e1c6d09f028">2,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzEwLTItMS0xLTA_139543c0-d37c-4c68-b5b8-5aae465a66e1">1,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzEwLTQtMS0xLTA_2c8944e3-2342-4f6a-9210-26a19cb65f05">2,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzEwLTYtMS0xLTA_710e3662-ff5f-4378-9ea9-8d00ba53265b">1,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzExLTItMS0xLTA_8674dd8b-2eb9-4c66-9fc7-3821163739b1">1,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzExLTQtMS0xLTA_b7e6c4d9-7160-4e66-a238-0bc104c9cf66">2,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzExLTYtMS0xLTA_717addcb-eec5-4397-8d84-03a2cf893392">2,702</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><ix:continuation id="id4aba40cd2ff4a3ab5a4682375d6743e" continuedAt="i0a512c304212468189393be10cd63a7e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i0a512c304212468189393be10cd63a7e">Includes $<ix:nonFraction unitRef="usd" contextRef="iac4d55843ee04cc9ba52c8e2dc31eb16_D20181001-20181230" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgx_363c9bc7-1301-4f18-af21-37475b1c94c2">1.4</ix:nonFraction> billion of deferred tax expense for the adoption of the deferred method to account for GILTI.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i67af357c54894b248f921f3f6153a85e" continuedAt="ic95eae79d6a449b9b3227e5aae2fc982"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NTA2_af204344-7e56-4171-acbe-299456000986" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI0NA_0c6ceb1f-a09f-499a-9ac2-6cb6bb04cf8b"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI0NA_60d6c920-c4d1-49b9-a567-439fdcbca114">21</ix:nonFraction></ix:nonFraction>% in fiscal years 2020, 2019 and 2018, to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEtMi0xLTEtMA_775fc39b-aaae-459f-8a59-ea0dc31bbe76">4,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEtNC0xLTEtMA_fba2d9ff-04f6-4b3a-9b20-02310f24dc0e">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEtNi0xLTEtMA_218970cd-f46f-4083-a26a-c85e1ab17bd9">5,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzItMi0xLTEtMA_a880fcf2-82d3-4dd5-895f-007e6fb74d70">12,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzItNC0xLTEtMA_032a34cc-b09d-48f1-8796-14ffc0aefd7d">13,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzItNi0xLTEtMA_a81026bd-34b0-408b-8fd2-0f367a7e4bf6">12,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzMtMi0xLTEtMA_7059a354-725e-487a-acf1-efcfb2be85b3">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzMtNC0xLTEtMA_7585fd0e-8a90-4e4d-85c6-deab7c27fcfe">17,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzMtNi0xLTEtMA_b5d22cd1-8266-4114-87d0-f56c9f917390">17,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzUtMi0xLTEtMA_8c9df112-0b18-4aee-94a2-8c1213bcbd20">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzUtNC0xLTEtMA_7bf6c339-c51c-4667-8066-3e29cf09b2e3">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzUtNi0xLTEtMA_fe283c7c-38b4-4ecc-8708-e90b354aa10b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzYtMi0xLTEtMA_035891d4-b5b4-48ec-bc4e-614029fbe2ae">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzYtNC0xLTEtMA_6e9b5b28-cf6f-428a-bdd2-94e00755c622">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzYtNi0xLTEtMA_a99e4e31-8bcd-4fa6-b342-520c809e0c69">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEwLTItMS0xLTA_be0710c2-3d8f-4f59-83c7-8dc94b92c6b7">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEwLTQtMS0xLTA_577db522-08e3-4172-8082-307dea5019a8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEwLTYtMS0xLTA_afe1bf81-3595-406a-bc39-53acd881bd4c">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on Capital Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTItMS0xLTEwMTUx_c47ca902-4c48-4783-a9f5-3516f1c18074">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTQtMS0xLTEwMTU1_0b4940c0-7d5c-4dfc-80f6-8417a31cc84b">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTItMS0xLTA_ed40a5b4-2a95-4239-bd82-58e8e6dafb61">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTQtMS0xLTA_4ec6a4a0-2324-49fc-acc8-d4ae4fc0769b">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTYtMS0xLTA_93404753-850a-4206-9eb0-2a90a2037bf5">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA and related impacts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="rate" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE0LTItMS0xLTEwMjkw_600b41c1-73b1-4707-9ee0-36d3b7d6f36a">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="rate" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE0LTQtMS0xLTEwMjkw_fed54e77-d0a5-4613-9f79-19b5db7d4a07">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="rate" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE0LTYtMS0xLTEwMjkw_357b79d3-883b-4f1d-9fe7-d6cebafde749">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEzLTItMS0xLTA_dc539143-fddf-487d-8be7-2ff91b1a13a0">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEzLTQtMS0xLTA_bc8d6314-fe6d-4e25-ad66-7dc2ee5eb1a0">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEzLTYtMS0xLTA_3d80b8b5-21c1-493d-9885-853e9c8edf6e">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE1LTItMS0xLTA_53105f39-9837-4b59-83c9-b785f6525650">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE1LTQtMS0xLTA_718a3f55-d6d8-4b03-80f2-130817798bbf">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE1LTYtMS0xLTA_3ba95f28-9d3e-4e58-a256-2fa74e18d4d8">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Certain prior year amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fiscal year 2020 tax rate decreased by <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE0MTM_b00c0aa9-3dac-42b6-b850-7aa28be79e26">1.9</ix:nonFraction>% compared to the fiscal year 2019 tax rate, which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#8220;step-up&#8221;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#8220;step-up&#8221;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzIxMjg_a17f5e48-13ed-4e45-bef1-420c61954624">0.4</ix:nonFraction>&#160;billion or <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzIxNDI_79868f99-b2f6-4b93-8530-370698c60396">2.6</ix:nonFraction>% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzQ0OTY_d68632f2-cd81-43c5-8fcc-fa61dc3d172d">0.3</ix:nonFraction> billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzQ4MDU_3a16443c-e111-4a7e-9177-2fc41dab3b37">450</ix:nonFraction> million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets as described above; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzUwNjM_ffce115a-533c-48c0-b891-7f9b3c85df9d">0.3</ix:nonFraction> billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, in the fiscal fourth quarter of 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzg2ODU_bb6d1a3e-c5a1-42a3-89c2-414514c2dc87">1.2</ix:nonFraction>% which is </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic95eae79d6a449b9b3227e5aae2fc982" continuedAt="i8e34001f98e14cbfbd088b020ea788d4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">reflected as a &#8220;Tax Benefits on Capital Loss&#8221; on the effective tax rate reconciliation. In addition in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accrual of litigation costs related to Talc for $<ix:nonFraction unitRef="usd" contextRef="ifa0d22acfd9043efb1e18804222572bf_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk2NjU_103f72dd-be3d-4f68-b1e6-ba9770da49a8">4.0</ix:nonFraction>&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ide9258c8a9684b738ee2e0f0983bd1f5_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk2ODk_c06c1711-e3c1-4a33-abcd-ea6e645434f6">23.5</ix:nonFraction>%;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accrual of additional legal costs, including an additional $<ix:nonFraction unitRef="usd" contextRef="i500668a00ec14570b9277e4c2dbae643_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk2OTY_23238309-c554-429a-8c5c-1e2ab199243e">1.0</ix:nonFraction>&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i3f5f3419f6044ef6a113250635e22bb7_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk3MTA_15bc6ce5-969a-4c76-95af-bb8c91379e56">21.4</ix:nonFraction>% </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested; reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18); and reversal of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. </span></div><div><span><br/></span></div><div style="margin-bottom:9.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2019 tax rate decreased by <ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDA5MzI_d9694401-ecd0-45ad-ad5a-07ce2ad1f918">2.3</ix:nonFraction>% compared to the fiscal year 2018 tax rate. In addition to the impact of TRAF discussed in more detail below, the primary drivers of the net decrease were as follows: </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIxMTM_26e89adb-cbab-475d-9a92-695d802f68b1">0.6</ix:nonFraction> billion and a related deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIxNTI_b1f0aff9-1525-49cc-a82b-5e6701ab76e6">0.2</ix:nonFraction> billion for U.S. foreign tax credits, for a net deferred tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIyMTk_10f11dfa-147e-43ff-95e7-314ba3195891">0.4</ix:nonFraction> billion decreasing the annual effective tax rate by <ix:nonFraction unitRef="number" contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIyNjY_a8838d33-b39b-45a4-8d30-55192c5dd8b7">2.2</ix:nonFraction>%. This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of the agreement in principle to settle opioid litigation for $<ix:nonFraction unitRef="usd" contextRef="i8db67b67955942f7a04d431f570d4565_I20191031" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI0NTc_c8cd69e3-993d-4970-9500-a17309214add">4</ix:nonFraction> billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i172efe01b0cb4ab689fa0a795f2f907b_D20191001-20191229" decimals="3" sign="-" name="jnj:IncreaseDecreaseInEarningsBeforeTaxesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI1ODg_d549e8e1-8cb8-48df-b28f-6837a7eb1a9f">23.5</ix:nonFraction>% and decreased the Company&#8217;s annual effective tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i172efe01b0cb4ab689fa0a795f2f907b_D20191001-20191229" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI2NjI_f8da9457-c2cf-4a11-8f5e-efa8cca26e11">2.1</ix:nonFraction>%. </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="id74cbe1f433b42e09645c83a947740b1_D20191201-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzMwNTM_b2187702-9200-407f-a4d1-081391d891e9">0.3</ix:nonFraction> billion or <ix:nonFraction unitRef="number" contextRef="id74cbe1f433b42e09645c83a947740b1_D20191201-20191229" decimals="3" name="jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzMwNTk_efe0211f-686d-4cd4-8adb-b5cb0c0113e7">1.7</ix:nonFraction>% to the annual effective tax rate.  This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzMzNDE_951882fb-ec5f-47a2-a565-10dfda1d64fc">0.3</ix:nonFraction> billion liability which increased the annual effective tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzM0MTc_a5cd2f68-10e8-4158-98b9-070ac0be98e9">1.5</ix:nonFraction>% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. Subsequent to December 29, 2019, the Company received and agreed to Notices of Proposed Adjustments (NOPAs) from the IRS. The Company believes it is adequately reserved for potential exposures.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There were several one-time tax impacts that resulted in a cumulative net tax benefit to the 2018 annual effective tax rate of <ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzQwMTk_0f0872c0-99ea-4ba2-9d92-52a0585814c7">1.2</ix:nonFraction>%. These items included the LifeScan divestiture, the adjustment to the 2017 provisional TCJA tax charge and the acceleration of certain tax deductions as part of the 2017 tax return. </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2018. </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMyNjQ_36970def-a72e-478d-a5e5-c65d58fb3446">0.1</ix:nonFraction>&#160;billion which increased the effective tax rate for the fiscal year 2019 by approximately <ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMyODM_8258f8e0-3e9c-4f8a-b089-358b7f9247d5">0.6</ix:nonFraction>%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMzMDI_f480fdc0-0d4c-44bf-b9cb-74f4de5189a2">0.6</ix:nonFraction>&#160;billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMzMjk_fd505fdd-a883-44c4-94b7-212072079117">0.9</ix:nonFraction>&#160;billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMzNTY_ea3b46b4-0983-4ab0-bdc3-f952ba1367c7">450</ix:nonFraction>&#160;million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div></ix:continuation><div style="padding-right:4.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8e34001f98e14cbfbd088b020ea788d4" continuedAt="ia1a570d40ee848ca86487c3c677b9f30"><div style="margin-bottom:9.9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year 2018, the Company completed its full assessment and finalized the accounting for the impact of the TCJA. The Company recorded net adjustments to the above components of the provisional charge of approximately $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEwNTQw_0257a329-e137-4ff6-be25-f4ed54fe0b7d">0.2</ix:nonFraction> billion. These revisions were based on updated estimates and additional analysis by management as well as applying interpretative guidance issued by the U.S. Department of Treasury to the </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facts and circumstances that existed as of the TCJA enactment date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This charge was primarily related to additional deferred tax liabilities for foreign local and withholding taxes for the remaining balance of undistributed foreign earnings as of December 31, 2017 that were not provided for in the 2017 provisional charge.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described in Note 1, in the fiscal year 2018, the Company elected to treat GILTI as a period expense under the deferred method and recorded a deferred tax cost of approximately $<ix:nonFraction unitRef="usd" contextRef="iac4d55843ee04cc9ba52c8e2dc31eb16_D20181001-20181230" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzExNDA2_363c9bc7-1301-4f18-af21-37475b1c94c2">1.4</ix:nonFraction> billion in the fiscal year 2018 related to facts and circumstances that existed on the date of TCJA enactment. During 2018, the Company reorganized the ownership structure of certain foreign subsidiaries which resulted in a reduction of certain foreign withholding taxes that it had recognized as part of the provisional TCJA tax charge in the fourth quarter of 2017. Following the completion of this restructuring and as a result of clarification by Swiss tax authorities regarding the applicability of withholding tax to repatriation of certain earnings, the Company reversed a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEyMDg3_6ee1f7d5-d3d3-4124-8ff3-26d1659c37d6">2.8</ix:nonFraction> billion and a related deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEyMTI2_0ba90ddf-d338-4eab-bfdf-77204e36beda">0.9</ix:nonFraction> billion for U.S. foreign tax credits, for a net deferred tax benefit of $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" sign="-" format="ixt:numdotdecimal" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEyMTkz_a0d275c6-7089-42a3-bcf1-8f33e3eca47d">1.9</ix:nonFraction> billion. This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NDkz_b26911d1-8e8d-4827-8c11-10ed28f49c0d" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:40.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Deferred Tax*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzItMi0xLTEtMA_d38bc30d-1a3f-4931-889d-355c931b9ca8">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzItNi0xLTEtMA_53af5eb3-a59b-49a2-b390-ade23b95e26c">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzMtMi0xLTEtMA_5cc084ae-fa80-4bdc-9b39-fac8dceaf6d2">627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzMtNi0xLTEtMA_097cf931-e6ab-4c2a-a68a-5ea3373da807">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation &amp; amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzQtMi0xLTEtMA_47607607-a791-4d1f-b541-477a01771674">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzQtNi0xLTEtMA_b9126dc8-64a2-4b27-8818-7ddff963465e">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzUtNC0xLTEtMA_0b270919-3082-456c-831f-440901196851">6,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzUtOC0xLTEtMA_7b90aa63-c0fb-4f19-9b95-f0357d17d494">5,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzYtMi0xLTEtMA_3ca4f50b-c5f7-41fa-9610-51105790a3d8">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzYtNi0xLTEtMA_9d6aeef6-0c80-4848-ab7c-93765c3c4375">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzctMi0xLTEtMA_a6df92f8-4db7-4967-a2ab-a6a763020729">3,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzctNi0xLTEtMA_e4e07f0b-5444-4101-9238-6666de811805">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzgtMi0xLTEtMA_babfa070-4fb1-4042-af20-35f65a0fba18">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzgtNi0xLTEtMA_010993ad-505a-4f3a-bb93-61073e487102">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward international</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktMi0xLTEtMA_79ca4b8b-db1d-4160-9d1d-eb6404fa7210">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" sign="-" xsi:nil="true" name="jnj:DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktNC0xLTEtMA_952c8e8d-29b5-49a3-b024-19a19f6a2926"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktNi0xLTEtMA_b06c8238-f413-44c1-8753-5067de3cdae1">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" sign="-" xsi:nil="true" name="jnj:DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktOC0xLTEtMA_a7268f3e-5e13-4b87-b57e-d72ed7ad8861"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTItMS0xLTA_2e4a479f-7235-4bf6-8c85-8f49ebf11817">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTQtMS0xLTA_663a5980-5d7f-448b-8cfc-15c57c98d3a8">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTYtMS0xLTA_1f9803fa-32c5-4912-8e83-c8ea26694628">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTgtMS0xLTA_f670a64b-b9e4-410d-ada9-f605adf7e859">1,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzExLTQtMS0xLTA_61379ff1-9528-4475-bd8e-e4b3f28db542">3,606</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzExLTgtMS0xLTA_ad44ee63-bbcc-4528-beee-191b7d1db298">2,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTItMS0xLTA_cdf68925-53d1-4065-9e43-8b2084fb7390">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTQtMS0xLTA_33adc81c-79bb-4cec-b384-6746fdaa7f78">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTYtMS0xLTA_c336bd5e-fe2a-4f6f-b1f3-b6fc82f72836">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTgtMS0xLTA_22cd2806-d3b9-49ef-87d6-d312a4bdb109">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DeferredTaxAssetsOtherDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEzLTItMS0xLTA_561d9e4e-cc53-435a-9058-d39f0bf5e078">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="jnj:DeferredTaxAssetsOtherDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEzLTYtMS0xLTA_e0ac5497-7c7c-40e5-999e-eeb8352e1e76">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTItMS0xLTA_6f496211-eb9a-4632-9453-020b856f74f0">13,138</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTQtMS0xLTA_3f0edf4b-b590-4cc0-bf2a-a36973359113">11,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTYtMS0xLTA_f0f0c71b-fc98-4f0c-8b2c-e705a9a74700">12,031</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTgtMS0xLTA_e9d55ab6-472d-498e-8a00-0145864aa1ca">10,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has wholly-owned international subsidiaries that have cumulative net losses.  The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets.</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NDk3_2846d4ef-1b6c-43ff-a63b-6f117901d600" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:50.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzEtMi0xLTEtMA_c9aa41ae-1f3b-45d3-b99e-cf1b5b502680">3,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzEtNC0xLTEtMA_face7413-04d3-4eb9-8ca8-2fa1fe5ffb50">3,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzEtNi0xLTEtMA_0f898b6a-7972-4932-8fdd-b00d65402082">3,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzItMi0xLTEtMA_62dbea65-7b48-4496-99b9-7e665194e14e">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzItNC0xLTEtMA_19c1d999-d29f-4f8a-a72e-25590c47f5f9">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzItNi0xLTEtMA_70f058c1-9e89-4384-b184-c7926401abc2">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzMtMi0xLTEtMA_648f1a0c-5092-4df4-8207-f41dfaa517be">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzMtNC0xLTEtMA_7723f5e2-147a-4328-a93b-ea639ad11401">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzMtNi0xLTEtMA_e4a6b563-3d7d-4e5e-b456-6270675eb7c5">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzQtMi0xLTEtMA_56cff4ac-08f4-499f-a9f5-0d86e07f8f23">551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzQtNC0xLTEtMA_793d36a4-21c8-4ddf-8c5e-246257e575f7">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzQtNi0xLTEtMA_54ab1b13-47e2-449c-9ea9-cc77907d5fe1">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzUtMi0xLTEtMA_11db080b-20aa-488b-bf1b-e901f4aec5f6">839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzUtNC0xLTEtMA_a3027080-f179-4524-ab04-7bb4dc6ac66f">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzUtNi0xLTEtMA_618dd568-b6b6-4f00-b274-bb43e4db228b">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzYtMi0xLTEtMA_90aef1ba-9e9a-42a8-8663-b3ba3032f79c">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzYtNC0xLTEtMA_6b82c7b4-eded-4b4d-9cba-40638ead5f12">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzYtNi0xLTEtMA_99abb9b6-b62e-48ba-b2ac-a22062b19c4f">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzctMi0xLTEtMA_d1d31d0c-dda0-4125-ac7a-164e38ac5d9f">3,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzctNC0xLTEtMA_4e5440de-3e59-4c5f-80b3-98fc13f491e5">3,853</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzctNi0xLTEtMA_20b53b63-7aec-4bdf-89b9-f38d9601141f">3,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE0MzMy_439573aa-017d-4d4b-ab65-0be297bb9853">3.4</ix:nonFraction> billion at January&#160;3, 2021, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2012. As of December 29, 2019, the Company classified unrecognized tax benefits and related interest </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia1a570d40ee848ca86487c3c677b9f30"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">of  approximately $<ix:nonFraction unitRef="usd" contextRef="i94b21ae117b34c4292baffe418a58981_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE0OTgy_f7fc4e85-0faf-4d5e-bf72-a33d0b639b65">0.9</ix:nonFraction> billion as a current liability on the &#8220;Accrued taxes on Income&#8221; line of the Consolidated Balance Sheet. In the fiscal year 2020, the Company made its final payments for approximately $<ix:nonFraction unitRef="usd" contextRef="i59f96e940f074bfc8bca8dd0210f851c_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:UnrecognizedTaxBenefitLiabilityPayment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE1MjU0_3283d000-d69e-41a1-afaf-60669b495855">0.7</ix:nonFraction> billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2MzYx_87ea08de-67cd-4ef8-923f-9f415ada082f">32</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2MzY1_e9318006-de4b-4c26-b789-a0d2a99af320">50</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2Mzcy_516a8e84-c99e-4e36-912a-23424cf1f045">53</ix:nonFraction> million in fiscal years 2020, 2019 and 2018, respectively. The total amount of accrued interest was $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNTE2NDU_47c8b6f2-9a46-46fa-b3e2-683f1a7cf9f0">468</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NDQ4_00d73aa1-f865-4980-bb6b-d28dd24ba674">559</ix:nonFraction> million in fiscal years 2020 and 2019, respectively.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_169"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzI4NA_d397e3ad-5ed6-43c7-a67a-1ece4dfc4608" continuedAt="ie52c0e0f40634cfb9399fecd74504f2d" escape="true">Employee Related Obligations</ix:nonNumeric></span></div><ix:continuation id="ie52c0e0f40634cfb9399fecd74504f2d"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:EmployeeRelatedObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzI4Nw_f284052c-5968-4c14-95fa-ac74b1ce9147" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2020 and fiscal  2019, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzEtMi0xLTEtMA_3af12ed6-a703-4b0a-a08f-e7a64d8d5222">5,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzEtNC0xLTEtMA_97462502-1901-4a4d-8975-546271c99204">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzItMi0xLTEtMA_3b49062d-fad0-4c5a-a8e8-f4e15ba9e332">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzItNC0xLTEtMA_beb9556b-fb4d-4885-85cd-9107fd01286f">2,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzMtMi0xLTEtMA_cd1b6b55-6f7d-460b-bdb0-80179459a6bf">3,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzMtNC0xLTEtMA_67fdfc86-ed18-49e4-aa43-2574e7361424">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzQtMi0xLTEtMA_d209485f-982a-4b20-8188-d0620b498506">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzQtNC0xLTEtMA_9522a59a-9f32-441f-9953-37f01192a70e">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:EmployeeObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzUtMi0xLTEtMA_eed601d6-9ed7-4ee3-9fa0-5635bc4db39f">11,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:EmployeeObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzUtNC0xLTEtMA_9f156a38-3086-49b4-9cb4-130842ccd5d5">11,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzYtMi0xLTEtMA_f86da943-64e8-4fe9-99a4-20e33da394e9">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzYtNC0xLTEtMA_ed03a4a8-355d-404c-8f78-c8e7ade86e39">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzctMi0xLTEtMA_26ff1f0c-2666-4fd1-a4e8-d3f9889a2cab">10,771</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzctNC0xLTEtMA_31429931-ef28-4412-a603-f57c6896fbdc">10,663</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid employee related obligations of $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzE4MQ_ed9946c9-6aed-46fc-9c42-397f5279c5fd">656</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzE4OA_d5e2043c-1cf3-4c2f-8ef5-6c4767b7c6d6">551</ix:nonFraction> million for 2020 and 2019, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_172"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjE0_9d1512c1-3ac6-47e9-af7d-586b34a74e2e" continuedAt="ic9706c9903634f149e886813973840ed" escape="true">Pensions and Other Benefit Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic9706c9903634f149e886813973840ed" continuedAt="i04c4b6abe115403693ec39f070ee9d60"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last <ix:nonNumeric contextRef="ia08825d6475b4031a35401d638705874_D20191230-20210103" format="ixt-sec:durwordsen" name="jnj:EmployeeCompensationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzYxNg_701280b2-8f2e-4378-8b6e-a9b6bbdcbdf7">five years</ix:nonNumeric> before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PBO as of January 3, 2021 by approximately $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzgyNDYzMzcyMjE5Nzc_d69c1850-f6a7-42f2-a3ab-5d9e517a1545">1.8</ix:nonFraction>&#160;billion and is included in the &#8220;Amendments&#8221; line in the Change in Benefit Obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019 the Company used <ix:nonNumeric contextRef="ie8d76953cd864599b2189d147891aa04_D20201231-20201231" format="ixt:datemonthdayyearen" name="us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEzMjE_e8f8409a-926b-450d-90a5-96fe5326a6c9">December 31, 2020</ix:nonNumeric> and <ix:nonNumeric contextRef="i5c88bca24e1a49eab2160ca290e744e6_D20191231-20191231" format="ixt:datemonthdayyearen" name="us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEzMjg_8f6b9133-c048-43a1-a9c0-ab9a6e40c2fd">December 31, 2019</ix:nonNumeric>, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjI3_bbbf9917-71bd-4760-bff0-8183b585ef3a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItMi0xLTEtMA_37e493a6-61b2-4c13-a5b4-545b048b218a">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItNC0xLTEtMA_9a19afc5-56c6-4d2e-9783-e9cce6b4a122">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItNi0xLTEtMA_ab4ea4b3-290b-4daa-a086-90cfe69f19fe">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItOC0xLTEtMA_90d9e1ce-8eb3-4cae-a938-4640f6bae57a">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItMTAtMS0xLTA_15746500-eae1-4d73-b6e0-d13e6d943cfe">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItMTItMS0xLTA_a13f498c-87e9-4d81-91ef-73a76393cba7">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtMi0xLTEtMA_bd5d7b90-f571-44bd-a9c6-2a5d37cf16c2">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtNC0xLTEtMA_de06469a-3a76-4f6b-8937-7b3e7eef2814">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtNi0xLTEtMA_3096faaf-b2fa-4508-b87e-ceafc4ea02b7">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtOC0xLTEtMA_264fcc23-d67a-489e-a4a7-09d94db945f5">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtMTAtMS0xLTA_9df28468-1cd5-4b3c-a5da-57135a0a18a2">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtMTItMS0xLTA_1a5c686f-af08-4c77-9a24-757b53a3ac10">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtMi0xLTEtMA_cfdc8198-71da-4551-84ad-fea89ac8a601">2,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtNC0xLTEtMA_d8f811ee-0f04-4eb1-9b40-d0d2940c47f0">2,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtNi0xLTEtMA_ee68a987-fb2b-4e6b-8ccd-a1d8e465d498">2,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtOC0xLTEtMA_a757f169-a12d-4cb4-83d4-f58baafe064f">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtMTAtMS0xLTA_b1f47f38-373e-4971-a0c8-c6530abe8ab6">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtMTItMS0xLTA_03607a8b-e81c-44f7-80a6-358821717c51">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtMi0xLTEtMA_4a6b8a10-a09d-4cb5-b176-24e12205dfc7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtNC0xLTEtMA_f4e9b295-0da4-4bc2-b698-9b89742c3b18">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtNi0xLTEtMA_2f8565ab-8023-427c-baf5-b565a36c5ace">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtOC0xLTEtMA_fc6398c4-b2d9-47f8-81b7-80e057c27a08">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtMTAtMS0xLTA_929c85b6-491a-4ba2-849b-aa8d84f5633d">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtMTItMS0xLTA_9067fcc8-e1b5-43fe-8d24-b250002d5b2b">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctMi0xLTEtMA_9ada4b5f-21f6-4138-880f-b9be1c2e4ec3">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctNC0xLTEtMA_2d41e524-34a2-47c0-93bc-65ff3d591dfd">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctNi0xLTEtMA_40132a72-95aa-402f-ae0a-20b2232f7937">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctOC0xLTEtMA_b0f4d3f5-9ee4-406f-9464-3ba78ea6ea5e">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctMTAtMS0xLTA_7f045fb2-85b3-4598-a5fd-2094703225f0">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctMTItMS0xLTA_0eb7d43f-1b06-48dc-8ad9-d546df8220e1">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtMi0xLTEtMA_e2de089d-893a-4c54-85fa-4d0255764ed1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtNC0xLTEtMA_2c6e75c3-7a97-4128-95a0-51e85a33cb60">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtNi0xLTEtMA_0a3ca520-6b0c-4d08-ad00-8be817ef2150">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtOC0xLTEtMA_c9ed7207-6a5d-435e-9289-96eaa08cbbfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtMTAtMS0xLTA_7a97cd46-478c-427e-9943-e145ce4c957e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtMTItMS0xLTA_4077f504-12c0-44c3-8f72-7de19856c8ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktMi0xLTEtMA_b3688221-7160-4e1f-8386-299e282506ef">790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktNC0xLTEtMA_9f1812c0-125c-483a-8e6f-ec7e7325d258">593</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktNi0xLTEtMA_62025aed-d772-4682-baac-d2e523c8b52d">923</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktOC0xLTEtMA_38a89891-b1e3-4646-b2f7-e74aad7f6c5c">524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktMTAtMS0xLTA_f5534a80-5fa4-4cac-9d89-9d637ee389e8">551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktMTItMS0xLTA_0a979dba-a871-4369-8c5e-3f639fbf8b7d">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a <ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="2" name="jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzIwNzg_e370dbb6-27d8-4601-b3ce-18e89c5bd964">10</ix:nonFraction>% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="i04c4b6abe115403693ec39f070ee9d60" continuedAt="ia3180560b41a4efd83095118e8d3e83a"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjE4_efaac352-936e-47be-af68-94859abfd7a6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:39.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtMi0xLTEtMA_feca6a4c-93a0-4480-ae9b-e9771925c7e4">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtNC0xLTEtMA_e1b3ca5c-370b-4597-9a52-c91719b5dca2">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtNi0xLTEtMA_9a39deb9-9a52-4b89-9701-2931302b007f">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtOC0xLTEtMA_5cb97988-6583-44c8-99e8-d3beb842ee98">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtMTAtMS0xLTA_84818e01-b11e-41de-8909-b3e4939b39e7">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtMTItMS0xLTA_55104e04-4ac6-4712-9a6d-c2361da1c688">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtMi0xLTEtMA_db832dd8-3c9c-4aab-a387-4ecf3aadb91f">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtNC0xLTEtMA_173a8598-c370-47b6-9c2f-17bfa74d49b6">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtNi0xLTEtMA_68000cf9-0a11-46d2-b6e9-58bbf67f797f">3.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtOC0xLTEtMA_9f9ef37d-80e1-494c-9e9a-bd50066a22aa">3.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtMTAtMS0xLTA_66ccc2aa-d2f4-4616-9e16-ee7c9db2037d">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtMTItMS0xLTA_8192e9f7-25c6-4847-a099-c0e12a7f37d7">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtMi0xLTEtMA_980cb75c-8a28-4d35-a8b0-6c7a7663ec2d">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtNC0xLTEtMA_b9f67966-28e8-4e55-8ecd-3ff2149de6ac">3.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtNi0xLTEtMA_71724544-a9a9-4321-8118-c2807008ffb8">3.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtOC0xLTEtMA_bb866e5c-d607-49c5-acb5-f4ce240b81f0">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtMTAtMS0xLTA_71773110-1ce0-4403-86d8-706d57b0568c">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtMTItMS0xLTA_0c173782-244f-4e55-a9b4-40c126de83c1">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzYtMi0xLTEtMA_f74a0026-30e3-4b38-bf26-5c4d2572b135">8.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzYtNC0xLTEtMA_c300768d-4de9-4382-ab5c-04d902d31be1">8.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzYtNi0xLTEtMA_01d8c70c-283f-49b5-93e6-eaad97755b22">8.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktMi0xLTEtMA_6ee852fb-d33b-4d35-8238-0d685ddfafec">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktNC0xLTEtMA_a22f7b0e-d421-475d-9895-7d563d29f1c7">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktNi0xLTEtMA_fbec6a62-4681-4d3d-9c7d-33768cf6c876">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktOC0xLTEtMA_9ae7d33a-78b2-4ad0-8bb1-d9418ef41eb3">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktMTAtMS0xLTA_0b88c74c-596a-415b-9a81-75709392c10c">3.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktMTItMS0xLTA_76299cb0-dc73-4bc9-b98f-1e215f231ea3">4.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTItMS0xLTA_60672739-6672-401a-bc61-0c695535559f">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTQtMS0xLTA_edf47813-eed7-44e9-bd35-80d0140921ac">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTYtMS0xLTA_3e13e659-edf5-4654-b869-af743dfe8fa7">3.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTgtMS0xLTA_c4194cee-09a8-4c88-b803-3d1c227cbbac">4.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTEwLTEtMS0w_32be733f-c0a3-4779-9cac-edfec668beeb">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTEyLTEtMS0w_9ab65133-8614-4c66-a60c-ab014b8720f6">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjEw_ab10c965-731c-4f01-a958-2056c1e2342a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed health care cost trend rates, for all individuals:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:71.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health Care Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzEtMi0xLTEtMA_fd63eb70-292a-47e3-8517-ff173db06448">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzEtNC0xLTEtMA_11217c83-0e90-42f3-a841-e1f3a375cb09">5.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzItMi0xLTEtMA_c7dc0690-6249-4f18-baca-5ae59f7cfe77">4.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzItNC0xLTEtMA_baff71cd-13fe-4f8f-b3d8-0dace22e260c">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzMtMi0xLTEtMA_dc58b314-eef6-4a61-8c95-f36784f95cf3">2040</ix:nonNumeric>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzMtNC0xLTEtMA_14727632-12b9-4627-abbf-3dcb5d658905">2040</ix:nonNumeric>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ia3180560b41a4efd83095118e8d3e83a" continuedAt="i8c6aadc96df549609c84f07675ac5a85"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjI5_ac796105-4381-4689-b727-58b698365611" continuedAt="i5cbe64425ef24dc1916de61210e5a568" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtMi0xLTEtMA_b89e5de4-67c7-47a2-a45a-b1aaf08fca08">37,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtNC0xLTEtMA_c3610ecb-e9e6-4938-a062-1c574fe10e36">31,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtNi0xLTEtMA_8f844032-f3a6-4e9b-8221-93b32a7620c4">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtOC0xLTEtMA_58f9fc54-8c4e-49e5-bd6b-d256396f4138">4,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtMi0xLTEtMA_004bbf8e-799e-422f-8956-f5771b5d52d2">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtNC0xLTEtMA_f775187e-e729-4220-a526-46a05be77886">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtNi0xLTEtMA_a9353d74-f198-4b73-a51b-dcbe1e338c2f">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtOC0xLTEtMA_0f0f9ae5-143c-449b-a0ff-b02ed01645b0">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtMi0xLTEtMA_2bb30ef5-e70d-4302-abb2-43b38e63eb3b">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtNC0xLTEtMA_b830b0a3-1716-4bad-94af-5e0dadc7a6d5">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtNi0xLTEtMA_74996417-3ca3-4e19-94cf-80a4fb8ec1a0">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtOC0xLTEtMA_7b8a6bee-120c-46a2-9c90-e6ff81939473">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtMi0xLTEtMA_5fb31629-ff24-48c0-b3e0-964e9e921d1f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtNC0xLTEtMA_d5a335b3-54eb-490d-bfc1-1fd4bde0d062">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtNi0xLTEtMA_2273bf2d-cd86-4455-9c3b-b06a69dccd8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtOC0xLTEtMA_d75f9271-6e6f-4a71-a18c-709d3e57ebee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctMi0xLTEtMA_dd5f7e3d-a0f7-45ef-9e8f-f23098361e3a">1,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctNC0xLTEtMA_73a4af8e-542d-4afb-986e-80fa9ecfe3eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctNi0xLTEtMA_fff42b97-c1a9-46f4-8e9b-d7b8e09045e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctOC0xLTEtMA_fe31b6c5-fa1a-4128-999c-e3b04f285fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtMi0xLTEtMA_fccaa1f9-4ada-4e27-945c-42f3156e5ebf">5,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtNC0xLTEtMA_43dd1da0-279d-4a0f-bff9-0979360a5ac6">5,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtNi0xLTEtMA_cf987dc8-978e-40f7-bb12-dbf5a6c32138">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtOC0xLTEtMA_cb8733bf-4a33-4a78-9f62-97fc552c2636">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktMi0xLTEtMA_3a31f354-7fca-4ced-8d25-36bc3cb3db5d">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktNC0xLTEtMA_176d9471-3448-4f20-aab9-c6b55467f870">278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktNi0xLTEtMA_5f196ab9-d0d4-4f7a-9719-0768446a0242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktOC0xLTEtMA_5303fd12-b9ba-4e4a-8795-e6bbf5ff3d3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTItMS0xLTA_5568841f-96c5-450a-aa25-fd67aea81075">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTQtMS0xLTA_70250369-0d10-4a37-821a-b8c89a4b91bb">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTYtMS0xLTA_a441b0ab-1fb5-4a75-903b-fe47c10a7a19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTgtMS0xLTA_79a55ed8-8aed-418a-8d24-e403b19ea54d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTItMS0xLTA_83514a4e-a8f9-44ce-8c23-4819a7286fb2">1,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTQtMS0xLTA_c4c1430d-d023-4be9-96a1-84ad1a308993">1,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTYtMS0xLTA_cd13238c-f4aa-47fa-9df0-a7a6c396b44a">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTgtMS0xLTA_09c2409c-5395-4021-b27b-8f25027d2b06">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTItMS0xLTA_e2a40344-7ab8-4f32-a5a0-9614345c4d96">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTQtMS0xLTA_d7da1a15-95c3-46cd-8c70-3a05a39af5d3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTYtMS0xLTA_5856a27f-9a86-49f5-9447-1395c79563b8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTgtMS0xLTA_c15338f0-8bb5-42be-8121-14533b781f06">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTItMS0xLTA_22b40239-b5ca-44ac-96ed-93302ebd53a0">43,300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTQtMS0xLTA_33dc2d51-81cd-4928-af9d-c8260a4a60bb">37,188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTYtMS0xLTA_562a4012-a368-4d66-960e-49ba665a1089">5,028</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTgtMS0xLTA_0c5089f9-e4aa-4e70-bb8d-1f5478134ee9">5,076</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTItMS0xLTA_9768f94e-7f49-4c89-a9e7-66351cb453a8">32,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTQtMS0xLTA_50c46eee-4c17-415e-8d46-4c797b1cc7fe">26,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTYtMS0xLTA_46633776-b1d7-4412-828f-f49a4118fa30">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTgtMS0xLTA_ce86bbe5-cacd-4c89-9565-dd1aecfc7f18">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTItMS0xLTA_4dc7ea0f-f36a-4a83-b5f4-ea5fb99ab729">5,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTQtMS0xLTA_dcbb56de-d45d-4d50-a92c-1bb49ba9d820">6,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTYtMS0xLTA_9fc70c44-35ec-4732-b377-f955ed1a2947">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTgtMS0xLTA_d698477e-e3ef-4e2a-bff7-9182b15a6b9e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTItMS0xLTA_4131ef88-d6ec-4498-9921-7422d5e2eb6f">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTQtMS0xLTA_73ae5951-c2f0-4cf2-9651-dac39d26e366">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTYtMS0xLTA_470a91d8-27f8-4639-b4c7-3141b4d04600">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTgtMS0xLTA_b13a7678-8bb3-4e36-8352-6062fbe783fa">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTItMS0xLTA_e71a1094-6ddf-4e04-ac6b-024199eedfd3">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTQtMS0xLTA_1370b3f8-9adf-4713-a2f5-3b4b45f623f1">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTYtMS0xLTA_aef3f9d7-0fe4-424e-a2b0-857f65b41db6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTgtMS0xLTA_ebec5439-71e7-41ea-a27a-4652cc56652a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTItMS0xLTA_8024339f-2b66-4454-842e-c246cc608ed3">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTQtMS0xLTA_da25d100-7db3-4084-a806-713023f4f47b">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTYtMS0xLTA_1b1511bc-1993-45e7-b371-2e0e33e058d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTgtMS0xLTA_71f8eede-561e-43a7-b8e3-70737930efa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTItMS0xLTA_01d3d7af-d402-4d9d-8650-391b5c904940">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTQtMS0xLTA_7229a223-bba1-4fad-94e4-91104da1224b">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTYtMS0xLTA_6410f946-637f-421e-b2ea-2a7f8947a52d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTgtMS0xLTA_1c8dcde6-073f-4d56-99aa-cbecc59d474c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTItMS0xLTA_6b57db76-b8cf-45af-8f25-a163475a598d">1,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTQtMS0xLTA_59c0440d-b99d-4c88-a4b2-4ad8ea4d65d5">1,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTYtMS0xLTA_64452031-d3a1-4f60-a198-0bd6902d7bbb">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTgtMS0xLTA_561c7470-8b4a-46ca-9954-4bc0ffdd0688">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTItMS0xLTA_5cc3c79b-b6dc-455d-9ada-d0e794da38c8">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTQtMS0xLTA_68ba041c-d257-492a-957e-ec0273cd88cd">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTYtMS0xLTA_4223f5d8-63b5-46c3-869e-319e0703a370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTgtMS0xLTA_55de62b2-e18e-4de4-aee0-ca1e56c2f010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTItMS0xLTA_05b763d6-bcba-49c1-b9f2-a63498585b80">38,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTQtMS0xLTA_6fb09835-8020-4fc0-84bb-1a3ee623dc3e">32,201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTYtMS0xLTA_3cd1336b-5cea-4058-9919-0e61de2a4119">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTgtMS0xLTA_520edc9e-bcfc-40ea-8b61-595291c90357">115</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTItMS0xLTA_9dbad1ae-4d03-4ff1-ac21-eb47c471b405">5,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTQtMS0xLTA_ff11234e-a5c9-41c1-b8d2-761a7264fc18">4,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTYtMS0xLTA_f4390dde-360d-4be3-8830-92ae02576b8b">4,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTgtMS0xLTA_f168c5d6-672a-43bb-9083-08cf7d0648d9">4,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTItMS0xLTA_98fdd7c3-a7ae-46f6-96c6-b70980465961">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTQtMS0xLTA_332e1076-5f7a-4351-9b26-7dd88018b586">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTYtMS0xLTA_cd9983c5-5097-4d13-8bc2-e78dea279fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTgtMS0xLTA_0daf97e4-3cf1-436b-b565-f394b1417fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTItMS0xLTA_5d80a100-2c32-4045-9594-ce7d1619cc06">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTQtMS0xLTA_ed3adf8d-631b-47ea-b8ed-dbe89b5a983a">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTYtMS0xLTA_772ada8d-853a-4533-b499-4e354da3e64b">418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTgtMS0xLTA_30095cce-2d60-4ae2-b0e2-8e2e979b5bb8">397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTItMS0xLTA_23e16a20-7cf3-4b7f-8372-d958856c885a">5,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTQtMS0xLTA_fce27a8f-7588-4448-9df3-c512d845a1c4">5,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTYtMS0xLTA_92238092-038b-4c00-90f2-2c4e86901eef">4,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTgtMS0xLTA_d9be94c4-8fe5-4223-9454-46f64266dce8">4,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTItMS0xLTA_df6c7def-4ac4-4271-88eb-c8e5837c9840">5,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTQtMS0xLTA_6e3bdadd-2b83-49c8-aa7f-2950d0c5769d">4,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTYtMS0xLTA_a4ea3739-2403-45bf-bc79-4583563bc2d6">4,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTgtMS0xLTA_b76662e0-4aaa-4414-ab63-19f443dfa6fa">4,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTItMS0xLTA_63f9e03a-439a-4c65-96a6-9883c8b8e5c7">10,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTQtMS0xLTA_c09644c9-0a02-4e22-b5d0-0889d4f056a8">8,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTYtMS0xLTA_500f5a13-2d36-4d5a-95d9-eeb666056f9e">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTgtMS0xLTA_ebc49c39-d81e-4a90-8f2e-446e094f0243">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTItMS0xLTA_3b3af827-0cce-42f4-9fe8-f0825a46b747">1,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTQtMS0xLTA_575b0eb6-6e8a-4a10-ad8e-7d9a31c7f035">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTYtMS0xLTA_bc313aa4-91f7-4f40-a565-9db47091db4e">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTgtMS0xLTA_4312e47d-927b-4a48-b6dc-dc7a3cad4450">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTItMS0xLTA_6e4ecff0-2545-4ff2-a81c-ac03b6f46f7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTQtMS0xLTA_9df913d3-e2d4-45c4-9b75-128895185128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTYtMS0xLTA_8a1176c5-4019-48d9-a24d-64ea4677e25f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTgtMS0xLTA_d700fd62-9571-429d-92a5-18576f5082f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTItMS0xLTA_943bb0d7-39ab-4588-9838-7aa71958bbb9">9,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTQtMS0xLTA_62799f7c-06bb-4082-8012-3d2ea6fdd1bc">8,827</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTYtMS0xLTA_77cb8469-6d35-4fa8-b8ab-314e83e0522a">1,419</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTgtMS0xLTA_c11e6633-2451-4f2c-9fe2-412e4c65c354">1,610</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM2LTItMS0xLTA_79befde2-1951-48c4-b804-93cfb493ac2a">40,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2330bd0434aa4310950363941b7c32db_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM2LTQtMS0xLTA_fc819827-b108-49e4-8b7c-aa126bad8be9">33,416</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="iac551cea27e04d75bcc80f2411447fe0_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM4LTAtMS0xLTc1NjUvdGV4dHJlZ2lvbjoxZGZiNWU4YTI0OWY0NzdmYmJjOTkzNjI1YzI4OWM5Zl84MjQ2MzM3MjEwMTY1_c1636054-f752-4875-8bf4-46b1a4397221">514</ix:nonFraction> million. </span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8c6aadc96df549609c84f07675ac5a85" continuedAt="i30e5b45244ee4784a4da64f5b41c8d2f"><div style="margin-bottom:6pt"><ix:continuation id="i5cbe64425ef24dc1916de61210e5a568"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTItMS0xLTA_8e88e9cf-d00c-451b-ba49-1cf5bf6acbe6">790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTQtMS0xLTA_18882c82-d048-4e49-b98b-a8da437e018b">593</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTYtMS0xLTA_7d938d95-93d5-485d-a92e-676d9debe5e2">524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTgtMS0xLTA_00c97422-e06b-4139-9ecc-5ee9f101d17f">551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTItMS0xLTA_65c685f8-9d9b-4846-ab3e-b88abe48edb8">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTQtMS0xLTA_8822a0c6-7396-4dfc-a54a-bc4c31e76d34">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTYtMS0xLTA_0b54a042-a27d-4470-a588-5784680ef764">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTgtMS0xLTA_0ad11bed-21b1-4625-911c-72627e74d0cf">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTItMS0xLTA_39497eec-31d4-441a-abde-eef2a4937fc4">891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTQtMS0xLTA_fb7649bb-1cb9-4b8c-86b3-5bf5dd3b0757">579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTYtMS0xLTA_59b3b3b3-40d4-486f-b845-7829c578ddff">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTgtMS0xLTA_e49337af-e16f-4e17-86c6-dd362beb136f">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTItMS0xLTA_50f0d910-7b2a-4454-aa1a-9fee2d9697a1">1,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTQtMS0xLTA_a04c6513-3dee-485d-a838-f0df88a31892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTYtMS0xLTA_2b38bc38-2034-42d7-bd9f-d0c32774b5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTgtMS0xLTA_d2be7d99-714e-4c49-8847-0903d008a153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTItMS0xLTA_33587b31-540a-4ed8-a4bd-ee74e34d8755">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTQtMS0xLTA_e4bee3c7-8fa1-45c7-a533-ae81b714843a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTYtMS0xLTA_dd863ba9-a371-4ed4-ab3c-8c96fe2dc2f4">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTgtMS0xLTA_7f845fa2-0746-4264-8310-80a66d6a3211">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTItMS0xLTA_7c1ffa23-107d-4da9-b8a5-d02b291fe489">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTQtMS0xLTA_38fbd627-c6ec-4fe8-b3ef-e9091917f63f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTYtMS0xLTA_f1e15dbc-bfca-4904-b36f-cb21f456ae79">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTgtMS0xLTA_514350b6-89f6-4e37-be91-f68a5e231cb2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTItMS0xLTA_a31d4f23-c537-4a8f-b105-64e7be0ed8bf">236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTQtMS0xLTA_7bf25673-4bcc-42b0-9dec-96b8f5ce7018">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTYtMS0xLTA_6a928d43-934f-4e8b-9734-4883abac49f4">191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTgtMS0xLTA_2f66a643-9977-4e68-be6d-707ac06070ac">453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTItMS0xLTA_2b08dfc4-9df2-4f8c-bc48-a0e0341497a7">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190893c65874208b238876e963fff03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTQtMS0xLTA_1cf4b2ad-48ab-40b2-b37a-19ae3251487f">1,095</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTYtMS0xLTA_d34795d2-699a-4782-9394-6236b50e6144">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTgtMS0xLTA_d5e6952f-75d1-42fd-a07a-e03c1b74dc50">1,004</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i8258eb0443384fc2aa7fb34a0f018511_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ0MDY_f52167dc-2aca-45f3-b144-dc222b761225">441</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i35d1b0ae517840b7b04db12cfe06d2d6_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ0MTM_ba83258e-0634-4cf3-ad5f-6a6b3bf219fb">429</ix:nonFraction> million to its U.S.&#160;and international pension plans, respectively.</span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMTY2_98bb5db3-64e5-40d7-846a-7c7965eac9d4" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2020 and December&#160;31, 2019, respectively:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtMS0xLTEtMA_3287d6ae-f846-42df-85a3-8f484e88797e">25,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtMi0xLTEtMA_70fc7bef-cb78-4ed1-ad06-3dfc81a80be0">21,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtMy0xLTEtMA_cdf973a4-cd35-42c8-8a30-6afad3f70d67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNC0xLTEtMA_759fb7e3-9942-4beb-9ca5-c9269cee2d57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNS0xLTEtMA_9c2cd99a-a0a9-41ce-8f37-0a75b3661ca7">12,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNi0xLTEtMA_6ebfb786-900a-4161-8f09-8960454fabac">10,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNy0xLTEtMA_49fa89e2-15f0-4a9b-89bb-2f7590400b07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtOC0xLTEtMA_797406e0-d31e-4eca-9a28-19e7d295f29f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtMS0xLTEtMA_8b0b7d45-fa55-45ef-a767-8cac8d426384">25,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtMi0xLTEtMA_0174bb87-971e-41bd-9e42-f1f0021d4c79">22,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtMy0xLTEtMA_98f984ba-1f0f-4875-8512-53cb6948eda0">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNC0xLTEtMA_1f512452-b598-403e-afdc-7a2ea0ef4657">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNS0xLTEtMA_44ab8170-913e-4efe-8080-8e154e853494">14,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNi0xLTEtMA_2c743a7d-be18-419d-a7d1-ffcc6728f346">12,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNy0xLTEtMA_05c69364-7b60-46e1-9583-2ca341490336">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtOC0xLTEtMA_c4250f78-5efe-4ec5-87f3-bc9e2fc6abb3">478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtMS0xLTEtMA_98f52cd5-6607-494b-a226-0e846313387f">24,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtMi0xLTEtMA_9cd83b26-12a3-4ae7-adeb-b3655c7230fe">19,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtMy0xLTEtMA_f5ac8c60-cce0-4158-a64b-ca3725670592">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNC0xLTEtMA_62753646-1f5e-46aa-859e-f13636a32b7e">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNS0xLTEtMA_7c6b0100-2a59-4c77-ba2b-4230ed8f4649">13,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNi0xLTEtMA_33ec37cd-7022-4a28-bd70-fe925bc884be">11,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNy0xLTEtMA_a387d933-982e-434e-a0a2-92e95de83f89">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtOC0xLTEtMA_fc2e0e03-f6f1-4d78-958f-31936df27c33">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctMS0xLTEtMA_2f6c721c-b95e-4a07-a195-ad829e32dd70">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctMi0xLTEtMA_86cc3357-1eb9-42b1-ae92-83ad027c30ab">636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctMy0xLTEtMA_bb84cc1a-729d-42e3-b01d-30ef1499042c">2,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNC0xLTEtMA_8e6ac36c-d386-416c-a4d4-8f036c7f549f">2,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNS0xLTEtMA_f8f8a059-f2a0-487d-9612-2be597518cf0">1,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNi0xLTEtMA_66d71701-9922-4489-8731-45a9d5e1684a">1,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNy0xLTEtMA_6651ea0a-ff0b-43a6-9f92-8bd85a001f4d">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctOC0xLTEtMA_ffa9e6ab-d240-4a0b-8a72-87f52af1887a">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtMS0xLTEtMA_1e694e9c-21c5-4fe0-8378-1e83b9616546">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtMi0xLTEtMA_5e16232c-ae81-4810-98d3-6555f94d0725">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtMy0xLTEtMA_ce71ae3b-c788-44bc-8a89-6a083c55ca36">2,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNC0xLTEtMA_24d5dc77-f018-43e7-8436-34513830e819">2,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNS0xLTEtMA_15e1a955-60fb-4463-b5a0-adcd195eefe8">569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNi0xLTEtMA_d6c4ea3f-8f00-404c-ad16-4b012648cbfb">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNy0xLTEtMA_fa2d8dd7-edcc-4345-b0ba-85f9ac49d659">493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtOC0xLTEtMA_421b591c-ac45-4880-b3b0-6ecffc53e469">430</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ4NTM_9928c1f6-e478-4bff-909b-e2f839188a5c">8.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ4NTc_5298fba9-d735-4022-86df-aeabf4f18e11">9.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ4NjQ_eea9f515-4ab0-4a4f-88e5-207edcdf1147">4.4</ix:nonFraction> billion, respectively, at the end of 2020, and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ5MDQ_5fe91adf-3253-4ec7-928b-32b4002776d7">4.3</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ5MDg_1b45b155-9fa4-46d9-a79f-ae4d8348fb53">5.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ5MTU_9302de9b-d7a3-4f3c-8399-91adb90506b8">0.9</ix:nonFraction> billion, respectively, at the end of 2019.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjIy_1ade95e9-467a-45fa-b64c-da30b136d583" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItMi0xLTEtMA_e0667b53-1137-401a-bbcb-91c3c2f3d3a7">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItNC0xLTEtMA_018285ff-d385-4a6d-a531-f5657676bdf6">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItNi0xLTEtMA_1adc1d10-b2cd-4889-b271-8a56d1c7ee14">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItOC0xLTEtMA_f2ac0e3a-e32c-4233-8c1d-ca7a10f11109">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItMTAtMS0xLTA_fb95f154-c27a-46e7-a1cb-ff01e6e949b6">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItMTItMS0xLTA_fd1f4c45-505f-43ed-8604-ab83e20b5e32">8,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtMi0xLTEtMA_e8f7a74d-45bd-4b0a-9f4b-a696532c0532">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtNC0xLTEtMA_7b791ae9-ee03-4e0f-a183-40208f4ee6a4">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtNi0xLTEtMA_140fe6e8-5bfd-4d3f-b3d8-0ea0dd9cd774">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtOC0xLTEtMA_61bbacbe-d406-41a3-8bef-6c29124c6693">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtMTAtMS0xLTA_3efac331-a19e-4c74-b78f-bef4d27da572">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtMTItMS0xLTA_50d97c46-58fe-43d4-9742-ed789d797b74">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMTc0_52ed39c6-2c46-4432-8ef5-24ff46b7e0fa" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtMi0xLTEtMA_dab3358d-351a-4569-a2ec-894fd2ec533a">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtNC0xLTEtMA_fef55db7-0d02-4c20-b3f5-3fd4d1cd5228">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtNi0xLTEtMA_6bfe9912-927a-4891-9bc0-763edd67727d">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtOC0xLTEtMA_a62f208f-1b56-48c6-93f9-061d14a89492">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtMTAtMS0xLTA_cdab16ea-3810-4d80-b888-2d9b30ac0b53">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtMTItMS0xLTA_96c9d4e0-765a-41c1-bb85-d2508a183973">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i30e5b45244ee4784a4da64f5b41c8d2f" continuedAt="i36b268057679473987cddb458dd79978"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjIz_8159a7ca-0164-4901-b025-ee6d32372892" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:58.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica8f24a050764bfba17b5c0beb8b5068_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzMtMi0xLTEtMA_962206d3-6476-4f63-8370-8b8ea7791328">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if68a6a311dd74eff8cdd501535848300_I20191229" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzMtNC0xLTEtMA_23f3a155-4ac5-45df-bfbb-3f8b16c0ccdf">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica8f24a050764bfba17b5c0beb8b5068_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzMtNi0xLTEtMA_ed5420b1-1503-40a1-a687-e73723d91c8f">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66bdef9c25ea4e9abf91f84961d6aaf4_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzQtMi0xLTEtMA_84dd4879-3641-41d5-8eb4-c4c5d1096396">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23f4166c654a437a80123fea9e702f7e_I20191229" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzQtNC0xLTEtMA_7da2982b-1a89-4119-a287-cf35a51d06ef">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66bdef9c25ea4e9abf91f84961d6aaf4_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzQtNi0xLTEtMA_75b8cd9f-761c-436b-85a2-c6c4f3813ada">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzUtMi0xLTEtMA_526e43b9-5f56-49d9-92be-7f81718652a4">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzUtNC0xLTEtMA_1390c756-b56b-4ae5-a412-37edc37ed89a">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzUtNi0xLTEtMA_1fe53008-70a7-4bbd-84a3-687d0acb23a6">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Fair Value of Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Hierarchy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Short-term investment funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government and agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commingled funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i36b268057679473987cddb458dd79978" continuedAt="i82746ee6d96049e88355f97e4d05bbf9"><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjA1_b92d88ee-6a35-45fe-bc07-69b3dde4de20" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:18.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39331ef41a6c42108162921682abc122_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMi0xLTEtMA_b00f1943-e642-44cb-ab0d-ec14edac291d">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10391e82429e4bf5a59079e301f6c6f6_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtNC0xLTEtMA_8ad6014d-3f17-4c4f-84f4-7cd4e6beb17d">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3d442963634e13878545dad90c5606_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtNi0xLTEtMA_6d6c8a10-db29-4994-a9e3-f71868ae148d">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75eebb92b9ee407fa174719e6be87d9d_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtOC0xLTEtMA_c0353c7c-c950-4f99-8ea9-7b5b6f940d74">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c809f170b8d4ab7b2aa8e2af5723d0b_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMTAtMS0xLTA_f1e8850f-c2e5-4848-9d38-ca94668865c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0df4d18d894d27a4ace305330ff2c6_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMTItMS0xLTA_c5584a00-0636-474b-b586-d15a52a2eecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ec1578bd1a4fb1a4e201e6ba58cf2a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMTgtMS0xLTA_219b4c4a-61fe-4602-9647-19a031992001">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ee1b6e5291404bbc84039bc844c771_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMjAtMS0xLTA_66608935-5a36-46cd-8431-407a6ef60049">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4507a38bcbb4237894ed814ce9f93c2_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMi0xLTEtMA_18505ff4-dd77-4aa0-9836-b6e51503195f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d58bc21d745699a63ffa711ad4c20_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtNC0xLTEtMA_178de497-cb66-4c85-9e90-74ec97c2b1b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c4e1c7cb22424181b106e85e819494_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtNi0xLTEtMA_41d776fa-2c33-472a-a9f1-642a94a913d1">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90ab3ae11824ef9a9e63764ee396732_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtOC0xLTEtMA_913c4934-6d21-410f-a765-8d80613d8e8f">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcce09e193042308b79539a19454bc8_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMTAtMS0xLTA_4c692410-2aa9-48fc-9c97-e538abd7cbbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9090828474432593946d7091132f13_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMTItMS0xLTA_05da9bba-073b-4013-ae39-081d53ce2539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4299477497a4436cad8f8ed08555cd49_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMTgtMS0xLTA_e04066dc-5603-4aa4-8aab-68ead62bb9ff">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bfd5fd8a4849b08c174538fbba64c1_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMjAtMS0xLTA_d44e37ab-bf62-455e-9745-c066e0c1b2ab">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c53d1325b34f4cabf72ed3d2c9c03d_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMi0xLTEtMA_213b289e-3029-4ab5-b606-94888c3b1bf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792325894abd4ffe872badf07315f357_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtNC0xLTEtMA_3b83cf77-98f8-4b2c-8b36-b6d3ae1aa684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129ebaefb7b84569bc06b0cae2c77b85_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtNi0xLTEtMA_a64d5efa-b692-46a9-b28a-641b40c94ceb">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd3c76e5ce3480aaebe23360e85c8ac_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtOC0xLTEtMA_7c2da6be-cf46-4c36-a06f-24a516ceeb4a">3,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d096bcce1824a9594a39c9fdd09e08f_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMTAtMS0xLTA_4f1da97b-6be1-4708-b495-39b5f21bc282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa0b93fc2a44d95a845a5651a1abf3b_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMTItMS0xLTA_53a77ee3-4d3c-442d-b004-7065b13ea2e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31684a1d9e3b497ea871cfece2687bfc_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMTgtMS0xLTA_b0731a96-37d3-4568-9940-bc830e92d4a6">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9148ad612a4a91a72c08004fdadc69_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMjAtMS0xLTA_52cf91e6-3bde-4dfd-9aa5-ffea1cdda7b1">3,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if88fb975b18b476f96a36b211ef744e7_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMi0xLTEtMA_9b74e819-1264-4dc5-bd82-dcb58acc9752">14,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa06dbe41e44403b1a57fde488fefa8_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtNC0xLTEtMA_128b5e6f-4d14-4d5b-a6e8-e250f1cfe649">12,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ddca0f50e34485b4dbb719c9499ef6_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtNi0xLTEtMA_d03e004a-20d1-47fb-b152-8b5e4f711682">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3cb8cc1c9747babbcb69806e0246a4_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtOC0xLTEtMA_7b8d5694-d193-41a4-a315-5c48ca279880">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51e2ec82259464f841cca599e785a2e_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMTAtMS0xLTA_8bd74906-cb19-4b93-acf9-6c10da774a3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89bcea9069d449e6ade65209250939b1_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMTItMS0xLTA_a258d893-1f91-4c74-b558-62f82075f21d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23da6adc713141f9a30805360f7fddc7_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMTgtMS0xLTA_c5268e6a-f63f-4c43-a340-e40fa65ea53b">14,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d030f2dc9714f1788798bfe39569d3f_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMjAtMS0xLTA_3ccb7134-1a29-4c70-969d-e0b7f0999426">12,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bbde50ab9441daec4c3cb7a16c7af_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMi0xLTEtMA_5bf972a1-de85-4967-9929-dc25bdb35bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5322cca6ec4b4e3fb447427aa4149354_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctNC0xLTEtMA_9af506e5-05ce-471e-8394-5c0ee8fe54b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37baf89ebe664ce9a576dfea58d33bad_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctNi0xLTEtMA_b861b91a-3b7c-43f0-b53e-b3bebd8207fd">4,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4a4cd8db9740f0a035240c81e02b17_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctOC0xLTEtMA_f25585c4-ea0c-4103-a747-523de80f92ea">3,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5156dbac2b5f45c38108ef2f637be5bf_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTAtMS0xLTA_7e1b6089-a30d-48f6-8bc9-0ce2f69840c6">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577b94e8b1be4e33aaccad68c1cf0d03_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTItMS0xLTA_5dcb8164-9c90-46e7-96b3-ba5a1abcf0df">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e156cdf11044ea928c031c1ffa9fea_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTQtMS0xLTA_7fd807e5-b51e-44d3-ba08-f19c500fef31">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3e8fa9abf349568477263c121e67cf_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTYtMS0xLTA_f821436b-976e-4325-b984-eba7097e2920">7,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e156cdf11044ea928c031c1ffa9fea_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTgtMS0xLTA_65ca5197-27c8-48f1-a40b-bb08a281b84a">13,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3e8fa9abf349568477263c121e67cf_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMjAtMS0xLTA_00aab275-a5fe-43c3-8c20-7a9dea3c8134">11,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3d41233d3a49058c7ac617acee9369_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMi0xLTEtMA_bb5b91c1-fbf4-4179-9b21-85b89b0876e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a8d5729f306476ab77201ea6d9d8c04_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktNC0xLTEtMA_dfa67acb-ef1a-4c63-b970-fc8db7124960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02729f04daa74ab2afec896f6fe109e9_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktNi0xLTEtMA_d15c8784-1942-4d5a-a606-893284152b49">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4375b4a40664031a6ba86d8ee14c478_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktOC0xLTEtMA_28c2e5b7-1589-4f1a-9489-17030c2e306a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb5c8f0e0ef4681aa83c7d913234f1d_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTAtMS0xLTA_61723a3c-7bb5-4885-9958-9084581f71c3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a5af3e730484e88ae6a67a735660d62_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTItMS0xLTA_c0cc7f83-a8ca-4956-9668-72004e236731">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861c44bcd9c04b65b80d256358edd695_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTQtMS0xLTA_30e991d1-ae3b-4b6a-8113-d1160e471603">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f1ea39b2a44d56b0c8c041d1b61bb8_I20191229" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTYtMS0xLTA_654693a1-be68-4f3c-af4c-3bd7e0f46d10">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861c44bcd9c04b65b80d256358edd695_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTgtMS0xLTA_d90ebe5d-0434-4ba3-90d8-0b5571689bb6">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f1ea39b2a44d56b0c8c041d1b61bb8_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMjAtMS0xLTA_709fb103-dd4f-4c02-9465-afc952cf7cfa">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc243eb836834e7d8a931154b37942d5_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTItMS0xLTA_29b0bf28-c3d2-439a-8864-e2961e7c994c">14,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d30b90acd1242b6b7de07bbdc790c8a_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTQtMS0xLTA_85135ac1-0fcf-4ee1-bd86-98c7ae43eee0">12,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd6e5e08fde46adb34424998ed53252_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTYtMS0xLTA_dd51e78d-52c2-4f13-8468-0b6c5502e45d">14,420</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedb3aa745dd4b3ab1c320496d1ab20d_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTgtMS0xLTA_a3377b12-6e60-42a8-9620-b81a0c9ab2d5">11,346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia667826001184093afc78dfa8bbb419e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTEwLTEtMS0w_4c3383d6-4e04-4dec-affb-4c26780f88f4">181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c067a1e923463bb25fd0faec7b3968_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTEyLTEtMS0w_ab35db0a-fd1d-42c8-98f8-a34160551aea">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677b9c0aeab4d24bd7207a87355007d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTE0LTEtMS0w_7aa83e6b-940a-49d9-9223-596411cae48a">9,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad01912a4ccb42d5a3b1813a29d85078_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTE2LTEtMS0w_262ff880-4506-4150-bd82-98bbab2f9db3">8,053</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677b9c0aeab4d24bd7207a87355007d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTE4LTEtMS0w_42a17313-06fc-43c5-8be1-46292656cf69">38,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad01912a4ccb42d5a3b1813a29d85078_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTIwLTEtMS0w_3e882534-1ec2-4bbf-b239-0d0263e63f23">32,201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $<ix:nonFraction unitRef="usd" contextRef="i032051d81b034bd089a0507d7eab7351_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEwODIz_62f4bfde-e8f3-473b-a844-723a16876f76">90</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9998429b4b654051adfe886dcefa9de9_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEwODMw_bdb8a3b5-e2c8-4d69-8afe-d7385e3e6a93">84</ix:nonFraction> million at December&#160;31, 2020 and December&#160;31, 2019, respectively and U.S. short-term investment funds (Level 2) of $<ix:nonFraction unitRef="usd" contextRef="ifa343551b56f48118e1cb1327fb01697_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEwODkw_9d527ff3-3cf3-43a2-87e8-21314c9e7852">31</ix:nonFraction> million at December&#160;31, 2019. </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82746ee6d96049e88355f97e4d05bbf9">The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMDM0_b9dd03ea-f10d-4a4c-a2c4-749873e603d2">946</ix:nonFraction> million (<ix:nonFraction unitRef="number" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="3" name="jnj:PercentageOfCompanysCommonStockToPlanAsset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMDM4_a66df840-9cea-4964-836a-74bf927fa01c">2.5</ix:nonFraction>% of total plan assets) at December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMDk4_3902e8d9-c911-4730-b439-3201b4b0dd37">984</ix:nonFraction> million (<ix:nonFraction unitRef="number" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="3" name="jnj:PercentageOfCompanysCommonStockToPlanAsset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMTAy_6c146efe-ec33-4ef5-984e-dbe47df362c0">3.1</ix:nonFraction>% of total plan assets) at December&#160;31, 2019.</ix:continuation> </span></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_178"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:SavingsPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM5Mg_776f41a4-6c57-46c3-b022-f16ed78ab4c6" continuedAt="i93e9ed9b96e54f27adf51e850e5ad091" escape="true">Savings Plan</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i93e9ed9b96e54f27adf51e850e5ad091">The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM0Mg_4d269f39-f879-448b-980a-169c56109e5f">243</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM0Ng_601698e8-78c2-4383-8ef7-5955b2992fbf">235</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM1Mw_b36d4b93-111a-4691-80c0-fc94aaf48ee5">242</ix:nonFraction> million in fiscal years 2020, 2019 and 2018, respectively.</ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzgxMw_ee1e3395-7070-44ce-9e6f-510051cba8b0" continuedAt="i41cddb57ebb14889bd05da0a7e5c89bd" escape="true">Capital and Treasury Stock</ix:nonNumeric></span></div><ix:continuation id="i41cddb57ebb14889bd05da0a7e5c89bd"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:ChangesInTreasuryStockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzgxNQ_1a9f4536-f3fb-4ad1-80eb-e124dd134c0a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzItMi0xLTEtMA_8c79330e-3635-406d-b813-a2580d0bf9ab">437,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzItNC0xLTEtMA_1c782670-263f-4b16-9396-95dc59e5433d">31,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzMtMi0xLTEtMA_da6943ef-67e6-4c15-a3e9-4083f6d3aa8b">22,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzMtNC0xLTEtMA_7cb10cb7-9399-4ed6-b547-07d3c88598c5">3,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzQtMi0xLTEtMA_85e88286-ac98-41d4-a13e-f82e4c9046a6">42,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzQtNC0xLTEtMA_73cf1126-aee8-4620-bd9b-e8ed9e98c09d">5,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzUtMi0xLTEtMA_ec00e630-c64f-498e-94a1-f13fd7043e43">457,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzUtNC0xLTEtMA_ca36cd8d-824d-4ba4-b577-88f3076a84e3">34,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzYtMi0xLTEtMA_a6f20212-8545-4d2b-9256-c14785ca1bf9">20,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzYtNC0xLTEtMA_7b744ec4-52b7-4853-abbc-922a2e58cb6c">2,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzctMi0xLTEtMA_b4d21d70-ab1d-4dbe-b954-de23cb56fda5">49,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzctNC0xLTEtMA_5b6c9b88-f37b-4157-a0aa-020d5d323603">6,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzgtMi0xLTEtMA_aea76904-b83a-40dc-92f0-ffe9e79be08f">487,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzgtNC0xLTEtMA_025868a2-6107-48da-9e68-9cc437ff90ae">38,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzktMi0xLTEtMA_456108c4-32a3-48d2-b167-309f8ffe1b9e">21,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzktNC0xLTEtMA_9cba2bb4-0e25-48a2-8979-79c4a95d30e4">3,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzEwLTItMS0xLTA_629eb967-8426-4263-a933-4839685add89">21,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzEwLTQtMS0xLTA_3aa98b91-aca6-4339-9a32-8cd3180fe01c">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzExLTItMS0xLTA_a62bf26a-7df9-412d-817d-d66dcc48be6c">487,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzExLTQtMS0xLTA_915ffc4f-ec28-421b-9efd-570ebb0d4630">38,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate shares of common stock issued were approximately <ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzEyNw_2b384f37-8a03-4e71-99b9-9c45c16f936c"><ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzEyNw_ece16346-8132-4da4-b727-ce134b9ee125"><ix:nonFraction unitRef="shares" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzEyNw_edc5bf93-1ed8-423d-ba83-daf5e20068e7">3,119,843,000</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares at the end of fiscal years 2020, 2019 and 2018.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends paid were $<ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzE5Mg_59acfa83-68be-4a6a-8d35-0cfadd319ac9">3.98</ix:nonFraction> per share in fiscal year 2020, compared with dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzIzOQ_9f306429-9ab8-4685-b661-638b4611b7dc">3.75</ix:nonFraction> per share in fiscal year 2019, and $<ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzI2Mw_6b3b009d-63e8-4712-a3da-ee0d8d8fe49d">3.54</ix:nonFraction> per share in fiscal year 2018. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Board of Directors declared a regular cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia709adb3e87945729cd80574e236e7fe_D20210104-20210104" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzgyNDYzMzcyMDk2MjQ_f2ae5954-bd32-4031-bbf7-2eefbc9fa2ca">1.01</ix:nonFraction> per share, payable on March 9, 2021 to shareholders of record as of February 23, 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $<ix:nonFraction unitRef="usd" contextRef="ie4380bdb86b74638b9120d6db37d52c0_I20181217" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzQzNA_795a5906-140e-494a-83fc-315e5a52d87f">5.0</ix:nonFraction> billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_187"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90ZXh0cmVnaW9uOmZiYzI1MGMyYWEwYzRkYTdhMjU0MmQ0NmMwMTVhNTE0Xzk3Ng_d578a098-3951-4c47-96e5-77f1226d0215" continuedAt="iac068850bfd54e78abdee203f697c074" escape="true">Accumulated Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="iac068850bfd54e78abdee203f697c074"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90ZXh0cmVnaW9uOmZiYzI1MGMyYWEwYzRkYTdhMjU0MmQ0NmMwMTVhNTE0Xzk4NA_453693a4-7c1b-4f22-b929-d14d10fcf5a2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id395e3d2f83144c69ca528af2dc9b6b9_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtMi0xLTEtMA_0304e6be-0002-40a6-b5e9-16a2ae351a1a">7,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3c455ecfae4ed6aaebdcec05ae3f52_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtNC0xLTEtMA_2327e5a0-c83b-4017-baa6-1072fa4ab523">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25282ad7400d4720a2625e8c3bac6273_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtNi0xLTEtMA_91e5307f-e4c5-45e4-b2ae-be340256c46b">6,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e1cb44199148b9aa8fa2e71f1bd6fb_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtOC0xLTEtMA_ca2127df-f079-46d6-9c8c-182343784e3a">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ba23fda59684540bdcab8d2c6182237_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtMTAtMS0xLTA_d12e99ac-d2a8-41a4-b4ae-47cfe4b73ca0">13,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative adjustment to retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i170982da0e98496f80e2110280b52dd7_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItNC0xLTEtNDE1OA_02c5f599-8532-4dbe-ba11-cc6a84f7a730">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf4bf571e18643da8a5b4eb3bfc07a7d_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItMTAtMS0xLTcyOTg_2169e67b-4d1d-41e1-93c1-4febd62ab7f3">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2018 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic77626f7a811485e9b149e03c04b3bd1_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItMi0xLTEtMA_7a356bf8-fe4e-4157-a724-c019bd2cdd66">1,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a59d85f18543f8b4ace4dea662cfa2_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItNC0xLTEtMA_1b514e62-ddac-4238-af23-be244eb8a321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7956e74acd5f4f6eb52053c38a41f6d9_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItNi0xLTEtMA_021b8ee0-c6ef-4e9d-aff9-7684c03a4283">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1cd916919904201816ef7744955d602_D20180101-20181230" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItOC0xLTEtMA_101e8d76-1623-4907-8a0d-4b7767481d2a">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d809f74ca674af2a83700b574ef976a_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItMTAtMS0xLTA_fe281d84-b287-4fdf-93f6-c75bd4d52f70">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9a838ddab52405f87db30392fc1ced1_I20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtMi0xLTEtMA_165ca984-485a-45f3-84f0-98027c7f36d8">8,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3e6d6e46264f57aae311381d35d955_I20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtNC0xLTEtMA_f96c2901-ea5e-4915-bab7-229b4bdd745c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3159628ceb74cfd97a53e02385491b7_I20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtNi0xLTEtMA_5e5c63c9-d6a8-4a31-8a0e-d81c862a284c">6,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1231b2bbed144c9cba72d9e67e5e0304_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtOC0xLTEtMA_b9d9a66c-fbbb-4b19-8e67-b36cbf9c4229">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2de20cab02a4cf8a8defc94d4572ad4_I20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtMTAtMS0xLTA_b402f250-6df9-4e88-b9c3-ec99c766a513">15,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2019 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79859b6ecac341359999ab29de172592_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtMi0xLTEtMA_1d4182ff-8616-4bd6-b90e-3157989c74a9">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia018521bd0ef4419b522652ba45df3d9_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtNC0xLTEtMA_c6ff9193-cf88-49c1-84f5-a876e59fa275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa6936a6df91437db1d3e64cf273812d_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtNi0xLTEtMA_e55f1b86-5632-41f9-a746-7e49ca2c17f6">733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i918db4b812b9414ba016263b04a7d008_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtOC0xLTEtMA_7612163b-2189-42c9-946a-47d723b12cfd">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411749566b1e45288b6797e92e4b8e37_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtMTAtMS0xLTA_cf4756f4-76e7-41c6-bd62-31b31dba32ef">669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief95ad78a93d49fca32ddc64ec71496f_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtMi0xLTEtMA_07df2bda-18c3-49f2-b4e7-755b3c0e8722">8,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58dcb82268e44ae810d6cde038d160c_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtNC0xLTEtMA_5569c1b5-c99f-4dd6-82da-8ee95a842a76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i636f1ba05c0d4343b8591ecc77c0e529_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtNi0xLTEtMA_6c8d6e07-0048-4ae9-8c0c-ff6f2d19df9a">6,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fa8c9dffee24a899b4b02e4b15e6f89_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtOC0xLTEtMA_3cf4701e-aeb6-4162-98b8-4f3a2eed93db">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafa9de0a8f744f78e2171c3ec5ff108_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtMTAtMS0xLTA_a568793a-87d7-4899-9e4b-076085bc38ec">15,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28de37f2cd304efdb2a7bf164f22a948_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtMi0xLTEtMA_e36f0d8f-087e-4f4d-85b7-8adcf01a79f9">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192924f6280a4a68a046814fc0e0b7bb_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtNC0xLTEtMA_c89e5c31-3036-45b8-bcd2-bb9fb1175f28">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7657b728884a46e2884084e7b77c4751_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtNi0xLTEtMA_90dd8313-e36f-4819-b6e0-bb732a91ae42">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6214de92714d768bcf627b37e0f72a_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtOC0xLTEtMA_dc097ba6-3d58-4344-90d3-d01e0fd7499d">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15b04be239b4bcf895c4ac519a52aa5_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtMTAtMS0xLTA_6f88f55b-010b-4352-97b6-442dca67ccf4">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9f99d7635c4de3afb7d08a8b3b2d0b_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktMi0xLTEtMA_d29876be-3bab-420a-8870-d467acba6a42">8,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ee948f3520495892dc498991ccc81e_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktNC0xLTEtMA_19c60a82-98cb-45d9-8b30-96a405aa107a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8cf02c8e230424b92126e9143e4345f_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktNi0xLTEtMA_53ab217a-0945-4d10-8a3c-3c8721697728">6,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c7380a52f94930a5e9728def85437b_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktOC0xLTEtMA_f1ee79bd-e8ee-4c0f-8483-9517ce99ec51">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b56c73c08ba4d7bb733cf5b7825663e_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktMTAtMS0xLTA_bfe362da-8f1c-4fe1-8739-9a62f17f05d1">15,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Per the adoption of ASU 2016-01- Financial Instruments</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_190"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzNjA_07f2e3d9-d45f-47f7-a113-95a9b0112c6f" continuedAt="id3a50cb09e9d41dfaf57dedc4cb83461" escape="true">International Currency Translation</ix:nonNumeric></span></div><ix:continuation id="id3a50cb09e9d41dfaf57dedc4cb83461"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes during fiscal years 2020, 2019 and 2018 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net currency transaction gains and losses included in Other (income) expense were losses of $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzMTA_bb89a863-3b9a-42b3-ab37-3c7564d4ffbc">209</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzMTQ_dfaad384-df89-42bb-a05b-518437a265ef">267</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzMjE_32df9436-eef9-4d9d-91e2-959a5e770b28">265</ix:nonFraction> million in fiscal years 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_193"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgxMg_b5bd4fa6-f067-4b1a-8da4-d1b32722ba51" continuedAt="i30bffc8b481241809aac599306065425" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i30bffc8b481241809aac599306065425"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgxMA_547f5d03-06ca-4be3-a868-56dd1c5a9220" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzEtMi0xLTEtMA_2a9dc668-fe42-495d-8eed-81bf966ff10c">5.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzEtNC0xLTEtMA_9da60255-b930-44af-a0bc-1ee6c9e8d306">5.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzEtNi0xLTEtMA_4c63bff8-4c36-4bdf-bb38-d45ea406e404">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzItMi0xLTEtMA_1b858ad0-b311-4111-be5e-f341dd490319">2,632.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzItNC0xLTEtMA_bf2f4229-694f-4c66-a0a2-a65cff554a58">2,645.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzItNi0xLTEtMA_9fad4178-56ef-4f21-b607-59e1cf184932">2,681.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzMtMi0xLTEtMA_bc92d271-3f97-4136-983d-81e8e4d1ff3e">118.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzMtNC0xLTEtMA_b252ef46-85d1-4ff3-a9e9-e8888d64bab7">136.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzMtNi0xLTEtMA_3d8194b0-062d-405e-b2d8-1a4eb129309d">139.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzQtMi0xLTEtMA_853d5bf7-aa5d-4bd9-9387-c6538cdae4af">80.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzQtNC0xLTEtMA_d2e38248-5ef4-408e-a20a-44da2a63334f">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzQtNi0xLTEtMA_b4114399-61d6-41d5-be90-3be0e4c413b2">92.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzUtMi0xLTEtMA_d821f94e-7669-4016-a87a-605cfcb0657f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzUtNC0xLTEtMA_448e6d1e-0ee7-4548-ad74-4a13e7c84ed7">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzUtNi0xLTEtMA_611562fe-8f75-46bf-b0ad-14c06e58bea8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzYtMi0xLTEtMA_c89c6398-55f1-46da-ada9-70af2ce71e29">2,670.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzYtNC0xLTEtMA_c71c7f56-3f2c-4374-bc71-e823da68ceb0">2,684.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzYtNi0xLTEtMA_4f7dddb8-a35b-4ba9-aee5-71e7a4b2a602">2,728.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzctMi0xLTEtMA_331bb6bf-c744-43bf-b799-c353f4fb4d82">5.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzctNC0xLTEtMA_e5680d76-0b1e-43a9-b399-8e9c47f3b57e">5.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzctNi0xLTEtMA_4de04e45-c39a-44d8-a8f1-521abb67c717">5.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2020 excluded <ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgyNDYzMzcyMDk4NTg_297186d5-bc64-4fa1-808f-99e00b630a75">18</ix:nonFraction> million shares related to stock options, as the exercise price of these options was greater than their average market value. As of January 3, 2021, the Company did not have convertible debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzMyOQ_5566fe5e-770f-4f29-9e3c-27db5097ea83"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzMyOQ_fcff3773-0e8a-4f3b-8a91-f5726a6b71da">1</ix:nonFraction></ix:nonFraction> million after-tax.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2018 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock. The diluted net earnings per share calculation for fiscal year 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgyNDYzMzcyMTE2MDI_5566fe5e-770f-4f29-9e3c-27db5097ea83"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgyNDYzMzcyMTE2MDI_fcff3773-0e8a-4f3b-8a91-f5726a6b71da">1</ix:nonFraction></ix:nonFraction> million after-tax.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_202"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4NjQ_4cbf7adc-0e48-4cc0-8c36-7d51b0f2206e" continuedAt="ib7763f6b3ef04e3fb8d9b533b2698583" escape="true">Common Stock, Stock Option Plans and Stock Compensation Agreements</ix:nonNumeric></span></div><ix:continuation id="ib7763f6b3ef04e3fb8d9b533b2698583" continuedAt="i141731002fc646608ecf19ba98e14c16"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January&#160;3, 2021, the Company had <ix:nonFraction unitRef="stockbasedcompensationplans" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="0" name="jnj:NumberOfStockBasedCompensationPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzk2_c86451aa-cfe9-4cff-a47a-ade9f725a92c">2</ix:nonFraction> stock-based compensation plans.  The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to <ix:nonFraction unitRef="shares" contextRef="if4d4da45e8664cf1b3b70e33caab8fd4_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwMw_0e6553c2-cd28-4f27-bdc5-24f94515e04a">650</ix:nonFraction> million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012.  Shares available for future grants under the 2012 Long-Term Incentive Plan were <ix:nonFraction unitRef="shares" contextRef="if4d4da45e8664cf1b3b70e33caab8fd4_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzc0MA_eb39f90b-7191-4e8c-b2d4-67a8ce696987">277</ix:nonFraction> million at the end of fiscal year 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The compensation cost that has been charged against income for these plans was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzg0MA_209b45bf-eb42-402f-abc6-0c358f2c98ae">1,005</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzg0NA_720ff8f8-a7a6-4268-972e-f5938e867b48">977</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzg1MQ_f0e09dda-05a6-498c-92f1-7124ac4a1fe7">978</ix:nonFraction> million for fiscal years 2020, 2019 and 2018, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzk5MA_650786bf-c22c-427a-b452-697357da31cf">210</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzk5NA_494c2194-fa7c-4507-8d84-cd05a2bca8cb">227</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwMDE_e63d9894-baf2-4324-9bce-844cc21c6a26">192</ix:nonFraction> million for fiscal years 2020, 2019 and 2018, respectively. The Company also recognized additional income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzgyNDYzMzcyMTY5NDE_72615c5a-eefe-4081-8924-ca5545a5bf83">248</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzgyNDYzMzcyMTY5NTU_03e1da2d-3f48-486c-aed7-c753adf7bddc">209</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzgyNDYzMzcyMTY5Njk_9bf2363b-2751-411b-9586-c935922a204b">264</ix:nonFraction>&#160;million for fiscal years 2020, 2019 and 2018, respectively, for which options were exercised or restricted shares were vested. The total </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i141731002fc646608ecf19ba98e14c16" continuedAt="id1321cf6630e409f8646efbae91288ff"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwODI_9b002f73-e723-4477-83b1-742ef82fd47f">804</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwODY_049478a4-71da-4fc2-8bce-21a0e1af1a34">823</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwOTM_0f52a228-58aa-46ce-b31e-045f537da29d">827</ix:nonFraction> million for fiscal years 2020, 2019 and 2018, respectively.  The weighted average period for this cost to be recognized was <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzExOTM_00fd5659-b190-4d56-8f81-b996db861be2">1.76</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEyMDM_fb7352d0-54bc-473a-a1e4-dff1f93bc470">1.71</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEyMTY_0bd3dfe4-8a5d-460b-949b-72aeaa9a7066">1.73</ix:nonNumeric>&#160;years for fiscal years 2020, 2019, and 2018, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options expire <ix:nonNumeric contextRef="i4d20904ce51e457ba8a1053c58ed10cc_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzE2MDA_7337f28a-6cb0-4bbe-9ada-ddb649f45877">10</ix:nonNumeric>&#160;years from the date of grant and vest over service periods that range from <ix:nonNumeric contextRef="if3a57f6eb476464d869fe8e58ec3baa5_D20191230-20210103" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzE2Nzg_dca5a00b-1b8e-486c-9b6d-d02315ad9c9c">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="ia9c4d02cb4644dbca38c88e2ebb556f8_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzE2ODQ_6c85fb58-b3a0-4fc5-83b8-3129fb0dea53">4</ix:nonNumeric> years.  All options are granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2020, 2019 and 2018 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4OTI_e38accea-1ef5-4f69-91f7-382749110fd0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI0OTY_62867fcf-32a7-4c03-803b-7ae3be2f9161">16.42</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI1MDA_82ca979e-8a08-40a1-9e6a-1066ee55f630">17.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI1MDc_691735c4-dfa9-4021-92fd-2cdae6b5777d">17.98</ix:nonFraction>, in fiscal years 2020, 2019 and 2018, respectively.  The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:56.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzEtMS0xLTEtMA_e1c38546-2dbc-4915-9d2a-8a239c11b4ec">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzEtMy0xLTEtMA_6620cb13-e7af-4c5a-b2e9-b4ab3d412422">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzEtNS0xLTEtMA_8ec6b9a1-f5d4-4460-a5ef-580b7d776254">2.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzItMS0xLTEtMA_774048c7-59b8-4fa1-aee4-9c23cd41c35c">15.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzItMy0xLTEtMA_380fd282-29e8-4291-baad-e82b7f0e7f21">16.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzItNS0xLTEtMA_03caf195-6404-4620-baee-05c22cc66a45">15.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzMtMS0xLTEtMA_c9a189ac-b4fe-4f0e-83bf-8e2538e9bcd5">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzMtMy0xLTEtMA_0fc7f68d-a546-494b-b4c5-754ee55335da">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzMtNS0xLTEtMA_df1b9a53-fcfb-4278-bbf1-7b42c5c7db76">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzQtMS0xLTEtMA_7bf8e32d-2954-4bb4-8d1f-1e044248af62">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzQtMy0xLTEtMA_be8c6025-8a2f-40d3-b319-60d6f518e45b">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzQtNS0xLTEtMA_6bcee124-d786-4f4d-b5de-0a0017f01bc9">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4NzI_d9654fc4-a47a-43c4-b227-14cae72f0443" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, and changes during the years ending on those dates is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:47.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEtMi0xLTEtMA_eae877f5-cda7-427b-9051-c6aea6e39d7e">111,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEtNC0xLTEtMA_86e090b3-7186-411b-bb09-d24eca2e5721">90.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEtNi0xLTEtMA_f9f335f5-cfec-42e6-869e-f798a25838e0">5,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzItMi0xLTEtMA_6286e6bd-40d0-4466-b8e9-8c8a50141134">17,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzItNC0xLTEtMA_47779f7a-283c-4b66-be32-c62bde02d8a4">129.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzMtMi0xLTEtMA_f8c2db68-5c14-4040-9e22-fabca6f66aa3">16,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzMtNC0xLTEtMA_96196fdd-b5b3-4e90-b7cb-96ab5348de7d">75.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzQtMi0xLTEtMA_8250c65b-5267-48e8-a5fe-2b305203507b">2,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzQtNC0xLTEtMA_4193c81a-3c4d-4a7c-b3ad-b4591211a078">112.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzUtMi0xLTEtMA_59dd1f3f-2e23-4245-8ec3-002c73cf6b8c">109,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzUtNC0xLTEtMA_7b5010be-2524-46b7-a6f3-11ebd8752849">98.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzUtNi0xLTEtMA_afbf18af-cf82-4cdb-ae4a-352f3a939517">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzYtMi0xLTEtMA_ddc440d7-dc47-4893-82e6-7fe13a3d6cf7">19,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzYtNC0xLTEtMA_6c7b5f14-890d-4dfd-a94c-c8699bba0d10">131.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzctMi0xLTEtMA_3b111668-981e-47a9-8f09-0c81644944bf">14,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzctNC0xLTEtMA_2d8f991c-7502-41d2-b416-d9ff5c941836">82.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzgtMi0xLTEtMA_0eb9fbbf-b875-4d60-9a46-45da6d109ea5">2,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzgtNC0xLTEtMA_ce9b2343-2191-4534-853b-f7aeb3ae9f43">125.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzktMi0xLTEtMA_e89ddf11-36b1-41fc-8068-cc34644bfc8c">111,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzktNC0xLTEtMA_5d65419f-775d-4dce-aae7-d6aa1d62bdff">105.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzktNi0xLTEtMA_78c5b048-dbc3-4c50-a070-bda39bf5b8d5">4,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEwLTItMS0xLTA_b7266cb6-7fa7-424d-b20b-2a5e4d589356">20,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEwLTQtMS0xLTA_dc2d3599-6104-4abe-b6d0-a03d5c345440">151.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzExLTItMS0xLTA_6392160d-3ee5-4db1-8a00-03f8881fb9f0">16,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzExLTQtMS0xLTA_a956d082-e29e-4821-9da0-15a8c0670851">86.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEyLTItMS0xLTA_06c6e39f-9c2a-4619-a009-6f8c8b65ecf9">1,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEyLTQtMS0xLTA_bd04521e-3210-4d3a-984e-0b7c648fc458">137.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEzLTItMS0xLTA_b098df92-564f-40bb-98d0-cd2a0945d216">114,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEzLTQtMS0xLTA_e5db5199-5da8-4b03-8150-5dfed7ad5890">116.22</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEzLTYtMS0xLTA_0feb15da-f39b-4f6d-92e2-063edbb76c97">4,703</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI4MTI_7f89d5ac-5991-4d3b-a260-b1a728fcb591">1,021</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI4MTY_251a2648-7cf0-4b10-8776-5fba37318139">807</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI4MjM_2bfe90a5-5272-42a3-ac68-b63fed7fa86a">1,028</ix:nonFraction> million in fiscal years 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="id1321cf6630e409f8646efbae91288ff" continuedAt="ic39bc7f475ff4f0796c433c63f099c1e"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4ODk_9b2ffb24-8d9b-4686-93a6-a19ce5ff139c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;3, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:29.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTU0NjA3MGM3MTQ2YTY4Nzk3NTk1M2YxY2Q2NzUxXzEwNDQ1MzYwNDYzODk0_e8f0c273-fed5-4a41-9286-25566c7ed1a2">62.20</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTU0NjA3MGM3MTQ2YTY4Nzk3NTk1M2YxY2Q2NzUxXzEwNDQ1MzYwNDYzOTAy_c0755768-9a99-49b4-bd7a-77c9ae1e4c80">72.54</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMi0xLTEtMA_11d624e1-868a-42f5-a6c8-09323b34a6db">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItNC0xLTEtMA_1e966050-88d1-4db6-a9dc-c63b796a444b">1.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItNi0xLTEtMA_cdc6a3de-803e-4b59-a35d-ddac9ce75ee7">70.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItOC0xLTEtMA_0c0e805b-b0c8-4398-8264-77356b952100">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMTAtMS0xLTA_d7ca3c1d-91bc-473e-9f69-a6b1c9a49ac3">70.79</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE2YTdjZDAzNWZiNjQ1NzViZWVjY2EzZmYyODJlZDEyXzEwNDQ1MzYwNDYzODk0_256e0305-4956-4acf-9611-fec114e1ab91">90.44</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE2YTdjZDAzNWZiNjQ1NzViZWVjY2EzZmYyODJlZDEyXzEwNDQ1MzYwNDYzOTAy_33d34acf-3afd-4631-bd62-8a62695ea699">100.06</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMi0xLTEtMA_d363e90b-6db3-4c72-88e0-fb1742cfc110">22,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtNC0xLTEtMA_705bdd91-9808-4dc3-a803-592a33b59def">3.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtNi0xLTEtMA_5fb3b9c2-f0a0-41bd-a6c5-edd90195670f">95.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtOC0xLTEtMA_995c8fa3-8534-4e12-bb42-d4024d136a14">22,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMTAtMS0xLTA_752c54df-751c-4a08-b0b9-565552bbebb3">95.36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i035510af86094fac8176e7f17a5a8164_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQxMWQyY2ZjNTBiMTQxNjNhNjhhYTkxMWI2NWZlNzdkXzEwNDQ1MzYwNDYzODk3_a493f184-3734-45c5-8545-76e8c680b397">100.48</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i035510af86094fac8176e7f17a5a8164_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQxMWQyY2ZjNTBiMTQxNjNhNjhhYTkxMWI2NWZlNzdkXzEwNDQ1MzYwNDYzOTA2_a0229fa0-6a26-473d-9f66-937a4b052852">115.67</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMi0xLTEtMA_f08205b6-bc5b-4db3-9c0d-74affb03bb7e">28,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i035510af86094fac8176e7f17a5a8164_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtNC0xLTEtMA_3abc832c-c97f-4eb9-a43a-0f8dc121a7a1">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtNi0xLTEtMA_2fd18e8d-0390-4fd3-b50c-bb5f9f16aa01">108.64</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtOC0xLTEtMA_367f3136-d12a-4c95-b5e5-e7f4b121852b">27,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMTAtMS0xLTA_3cd5d5d5-5e38-46aa-b106-d0541945ccc4">108.51</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgwNWY1OGMyOTZmMDQ0MzlhMmRhNDU0YTNlMTVmYjBkXzEwNDQ1MzYwNDYzODk3_86b2c67b-2a5e-4006-bc1b-12fc7c8616dc">129.51</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgwNWY1OGMyOTZmMDQ0MzlhMmRhNDU0YTNlMTVmYjBkXzEwNDQ1MzYwNDYzOTA2_f6d09b0f-c730-4863-aac9-8f964750ac40">131.94</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMi0xLTEtMA_16f9617d-8e53-4c4d-b38d-eff73146d298">32,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtNC0xLTEtMA_0f30615f-cf59-4b39-97ae-022f801cfc97">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtNi0xLTEtMA_2b47d10b-17bc-4e2c-88d4-c62c065f50ea">130.85</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtOC0xLTEtMA_215312a4-5a3f-4d5a-8fd9-6335deabcfda">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMTAtMS0xLTA_80ce2068-32c1-40f9-9524-75d0ebc94a2e">130.53</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjExODVjN2NhZWJmOTQwYzdiNGViYzYxZDMzN2IxMzhmXzEwNDQ1MzYwNDYzODk3_89753e95-945d-417b-8a2a-c0fc4fc9a306">141.06</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjExODVjN2NhZWJmOTQwYzdiNGViYzYxZDMzN2IxMzhmXzEwNDQ1MzYwNDYzOTA2_b593c40b-bb8c-46c2-a6ef-812ea03a2e7b">151.41</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i447115cb0801497ab64877cc7d65202a_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMi0xLTEtMA_1c555588-ebc1-406f-b40c-fef97d70aebc">20,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtNC0xLTEtMA_86467689-601c-4dd7-a451-e667e3a821da">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i447115cb0801497ab64877cc7d65202a_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtNi0xLTEtMA_f993953d-dbf9-4554-b65e-63a57b18da18">151.41</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i447115cb0801497ab64877cc7d65202a_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtOC0xLTEtMA_89d5d727-d395-41f0-a221-2d02f1c91708">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i447115cb0801497ab64877cc7d65202a_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMTAtMS0xLTA_cfb67abf-f9e0-45e1-a8b4-e90995be7e3b">151.41</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctMi0xLTEtMA_9dcc41ce-a83e-4728-a694-9c0bad0463d8">114,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctNC0xLTEtMA_68d60a4e-d5e6-4842-9b50-02cc1741267e">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctNi0xLTEtMA_5bc8b885-7515-4ac2-815f-895ef3e263ab">116.22</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctOC0xLTEtMA_c7184832-f5be-423c-b973-92dac394a49d">61,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctMTAtMS0xLTA_b88b2ba2-8c49-4cdf-b9ef-023ef285c2cb">96.97</ix:nonFraction></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding at December&#160;29, 2019 and December&#160;30, 2018 were <ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMwMzU_d0ce3a0d-3ee9-476c-b101-b098b11e90b7">111,637</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMwNjE_4423bb70-037a-448b-9af5-1c64429ef6a1">6.0</ix:nonNumeric> years and <ix:nonFraction unitRef="shares" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMwNzQ_4a67bc84-7b7d-476f-ae95-e8366681e9a1">109,652</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMxMDA_6df23f19-fd7b-4823-8df4-ee0f566a168c">6.2</ix:nonNumeric>&#160;years, respectively. Stock options exercisable at December&#160;29, 2019 and December&#160;30, 2018 were <ix:nonFraction unitRef="shares" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMxNjg_42a40499-e2d7-43ac-aeb5-e27b7e89e49c">60,761</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMxOTQ_b3493145-1774-40bd-9ed6-9c490eef4d01">88.88</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMyMDE_8e204701-99d3-4f7d-b4b9-3e859e975634">54,862</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMyMjc_eb749b9f-95fc-4920-9451-63c8221d7fb7">82.03</ix:nonFraction>, respectively. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units and Performance Share Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company grants restricted share units which vest over service periods that range from <ix:nonNumeric contextRef="i7c11a139c5264dc098f209197b9366c2_D20191230-20210103" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMzODc_78fbbe8e-0aad-4734-8c64-4302e9132e51">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="if0884d95fb894f82b5b100cc5798017f_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMzOTM_dc1e261a-00e3-4a5e-8b8d-f9175a9ae7f2">3</ix:nonNumeric> years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a <ix:nonNumeric contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwNDQ1MzYwNDY5ODUw_700d0fdf-be62-43dc-a54c-858f94e396ef">three-year</ix:nonNumeric> performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from <ix:nonNumeric contextRef="i78cd4383ab4a489fbbc505c984d58d74_D20191230-20210103" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzM2ODY_1d7b860a-695e-4cd0-be46-f66d4b69b7c7">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="ib5338fd4c73a4d98b5d7d7df1d88f226_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzM2OTI_fe5f2c32-0e47-4079-ba7a-07bfba1ea1e4">3</ix:nonNumeric> years and the achievement, over a <ix:nonNumeric contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwNDQ1MzYwNDY5ODUx_53f87213-d3b4-4ca2-bf59-c0af9345a393">three-year</ix:nonNumeric> period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the <ix:nonNumeric contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwNDQ1MzYwNDY5ODUy_eabc73f9-3ba2-40dc-855e-9d4de9428cc9">three-year</ix:nonNumeric> period will vary, based only on actual performance, from <ix:nonFraction unitRef="number" contextRef="i78cd4383ab4a489fbbc505c984d58d74_D20191230-20210103" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQwNjU_5850a394-8231-4a22-a2e3-207b07c0d996">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib5338fd4c73a4d98b5d7d7df1d88f226_D20191230-20210103" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQwNzE_dcef6a2a-1eaa-4076-87cb-7293dcd03ff2">200</ix:nonFraction>% of the target number of performance share units granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4NjM_f22b3b00-09cf-4ee2-8ef0-de86689ea24b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;3, 2021 is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:55.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1dee2245d414b138d2f2fa014b0a178_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzktMi0xLTEtMA_e5bc6756-7fb0-4c55-b93e-56ae6522b364">16,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7b2cf13619f4c189b475866e1db542f_I20191229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzktNC0xLTEtMA_8ab65ba8-96e0-4e9f-9337-def2af715c22">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEwLTItMS0xLTA_c9d6124e-4b7d-4675-8f78-80a991025b75">5,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEwLTQtMS0xLTA_f091031b-305e-421c-a0c5-6960d5f1a8c0">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzExLTItMS0xLTA_3e60d686-e957-47f9-b633-f20aea80ca3d">6,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzExLTQtMS0xLTA_154a4f1f-8f64-4176-849e-804ec455400c">702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEyLTItMS0xLTA_bde3967e-473c-494b-86cf-147de1202713">780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" decimals="-3" sign="-" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEyLTQtMS0xLTA_d26a8056-2c22-4fbb-86cb-36f3659c7905">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f365b4e320847d7ad7af8be0962aad8_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEzLTItMS0xLTA_72bd3294-8f21-4e2b-bbdc-cd88994d294d">14,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d56204d812a44748666c659338087eb_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEzLTQtMS0xLTA_75c2c55a-45d7-4d1a-b502-6adbb9070691">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of the restricted share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQ3MzQ_93872ca1-0515-42f7-8a45-5da6c725a3b0">139.58</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c52ecff45c14b9dbccf4b05efc03a3b_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQ3Mzg_c4ffa498-cbdc-4390-aa50-55061e8d0c63">121.31</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i912305c8e84a4cd9a5729ccf10a90c3c_D20180101-20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQ3NDU_d3b30946-c320-425f-ab5c-cab1e59a6143">119.67</ix:nonFraction> in fiscal years 2020, 2019 and 2018, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $<ix:nonFraction unitRef="usd" contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwMjk_b36e126f-a3d2-4ea7-afe6-a3b7372adcd0">650</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0c52ecff45c14b9dbccf4b05efc03a3b_D20181231-20191229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwMzM_5a2bffc7-d76e-45ac-b86c-657546817ef2">586</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i912305c8e84a4cd9a5729ccf10a90c3c_D20180101-20181230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwNDA_8026d46c-6df7-42ff-a32c-16e2c088093a">614</ix:nonFraction> million in 2020, 2019 and 2018, respectively.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the performance share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUxNTA_30cd9ca6-14f8-45fd-9c6b-aab25f25773b">160.54</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib67cc38656e54ec4aadccc96b338ed7a_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUxNTQ_1770638a-eb3b-49b9-accd-79cf7c5950e6">124.67</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iff3ec8dc893a4eb08f4f039c8952b873_D20180101-20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUxNjE_956c2e98-6227-43eb-995d-357c956ff9bc">120.64</ix:nonFraction> in fiscal years 2020, 2019 and 2018, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic39bc7f475ff4f0796c433c63f099c1e">The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $<ix:nonFraction unitRef="usd" contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4MTY_3384b6e6-3fdb-4fad-9a9d-d36dda855c43">91</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib67cc38656e54ec4aadccc96b338ed7a_D20181231-20191229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4MjA_cc6939aa-6887-4e09-b19d-6660ff0be003">119</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff3ec8dc893a4eb08f4f039c8952b873_D20180101-20181230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4Mjc_7cec6fb1-1b05-4cbf-8425-6f0f0f69690e">129</ix:nonFraction> million in fiscal years 2020, 2019 and 2018, respectively.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDQ1MzYwNDgwMzI3_8a494b52-2ac5-485a-9775-a2fa181224a5" continuedAt="i728f56ad57154e87a6255eaea99313cf" escape="true">Segments of Business* and Geographic Areas</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><ix:continuation id="i728f56ad57154e87a6255eaea99313cf" continuedAt="i3b392aae44e5457eb7cd0ea720bf40f2"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyNjc_b03c7c3e-2fd2-4535-8156-a35e496c56a1" continuedAt="i3128643178ce4d2d8e3903db9e60987f" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;19 vs. &#8217;18</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa9e713b2ec41e4a8d7f2f7015848f6_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtMi0xLTEtMA_e13ef4ae-6ee1-4412-ac59-8db641885df8">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc37409a7004e809321a0b83f5b2e71_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtNC0xLTEtMA_1d50afc3-c2d3-422c-93be-d0bf48c8b285">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde892975c2e4c43ae1fcd0e5d45005b_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtNi0xLTEtMA_3d034ef1-7bde-4448-96fa-418d106b83ce">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8aa9e713b2ec41e4a8d7f2f7015848f6_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtOC0xLTEtMA_13ec5c77-b94c-45f8-80ec-ed5c562045a8">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fc37409a7004e809321a0b83f5b2e71_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtMTAtMS0xLTA_66c0a739-b73f-438b-b0c3-d3a0985741ce">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie098a08a654f4b7abe7993bfd4dd32c9_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtMi0xLTEtMA_56e1a33d-7505-4bd0-be3e-7832f3655aa9">2,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce7db841b704ce795266988602b87c6_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtNC0xLTEtMA_7adf752d-bec7-4438-8e86-eab4ea7cfdd3">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56177ea4bd8e4146934538847bd76f90_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtNi0xLTEtMA_34173ba2-fe39-4ea9-b5fa-9c55d44feee1">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie098a08a654f4b7abe7993bfd4dd32c9_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtOC0xLTEtMA_d5da5da6-2756-48f8-ab0a-8920c087944e">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1ce7db841b704ce795266988602b87c6_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtMTAtMS0xLTA_140790cd-5a18-49d0-98ec-2ded07e2afe6">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebab203f30b40578e7a8a359fececa9_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctMi0xLTEtMA_5c168917-8460-4e62-aa9c-4f284164413e">4,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fe395206684a69945b7b9c3f58e7e1_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctNC0xLTEtMA_69fd171e-5c4c-4cb6-b9d9-fe5259550186">4,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cfb00a6c644b59badb04917cfe1258_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctNi0xLTEtMA_6a67f5a6-6a65-464d-8b6e-37ea3d59ac78">4,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieebab203f30b40578e7a8a359fececa9_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctOC0xLTEtMA_2165e28b-e6d4-449c-8907-5ae0ff0b18ea">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95fe395206684a69945b7b9c3f58e7e1_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctMTAtMS0xLTA_08963788-2d62-4148-9ca6-422835bd2144">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ae8ca1fdaf4dcc9a7ead012204e832_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktMi0xLTEtMA_c6f80e8d-1d4b-488f-b9d5-7ac32e50438d">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7516b2a14b4fda940e11d40fdca6e7_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktNC0xLTEtMA_6ca6018d-7729-42eb-9628-3ce43188927b">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21511c0be4db4f3891671c0f6c6ffd18_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktNi0xLTEtMA_2f205fb2-74fc-4295-b8f3-8b7d5a67d89e">2,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i23ae8ca1fdaf4dcc9a7ead012204e832_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktOC0xLTEtMA_d5bad91f-e343-4e1d-b492-d7253fc39d2f">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5b7516b2a14b4fda940e11d40fdca6e7_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktMTAtMS0xLTA_e50937b5-1541-4817-81f7-35a0a6e60051">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335dae4d42e84c4581347d01955f1f64_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTItMS0xLTA_0b889551-b129-43f4-ab57-8d4c8f0a35b2">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d65234cd7741f08e1b93c317fe4a5b_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTQtMS0xLTA_d0eb7c89-6d07-4ebe-a10a-f845cede64a8">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe8305d0fc64ff09895323053e4ffbe_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTYtMS0xLTA_5984945d-749e-4bf3-9a66-9999f1d6c241">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i335dae4d42e84c4581347d01955f1f64_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTgtMS0xLTA_e8ca6085-31a9-47fb-89d8-d85b74b2a3c1">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0d65234cd7741f08e1b93c317fe4a5b_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTEwLTEtMS0w_1a0168f4-d1ff-408f-aee9-a8ba068fd216">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb778fa0cfd41c8a12511fe0a1f1029_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTItMS0xLTA_cbd6422a-71e8-48a3-afbb-8ffed5ddae3a">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012e56c28db14f779936dee4f0663505_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTQtMS0xLTA_7f0eb054-f030-4257-9caf-30c6f7e39603">4,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec92ca19a30a48309e6628e2a8f20244_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTYtMS0xLTA_0e277a42-4eb1-4666-aa37-1d56f6a5bfa3">4,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7bb778fa0cfd41c8a12511fe0a1f1029_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTgtMS0xLTA_b4cc1912-8ee3-4b5c-ae2c-b6d10f702074">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i012e56c28db14f779936dee4f0663505_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTEwLTEtMS0w_84e4d9fe-2abe-478a-8b1f-04593aa21f39">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe650b19559486c93d86c150a95b5ca_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTItMS0xLTA_4153e877-3b98-47db-8eb3-cdfd04ce8434">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4646db66c32408f83925e7b65de220c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTQtMS0xLTA_6abe70f8-9cf2-4185-bd08-02173f7675cf">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9072109358d34bb0a33a9db443472e65_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTYtMS0xLTA_93bdac44-037e-4977-afb7-ba192de1c46f">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iabe650b19559486c93d86c150a95b5ca_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTgtMS0xLTA_ffa382f5-eaa9-44c3-a1f5-10b84413a568">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia4646db66c32408f83925e7b65de220c_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTEwLTEtMS0w_92dce8c6-fff8-4281-a24e-6c582088f6ab">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b6c87bbb9946978d28461a1b99eaa0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTItMS0xLTA_f85fd2d7-3e59-49f7-8361-fe835a33569b">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6e6a50ba9c4b93a9bd88ec99d6a9bc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTQtMS0xLTA_ac570288-73e9-43a7-bbe4-d856c801a9cb">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57621c82e86e424b9525ef5322132b41_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTYtMS0xLTA_9c58ce06-f407-431e-a13c-e51689e06efa">918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29b6c87bbb9946978d28461a1b99eaa0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTgtMS0xLTA_c7f84d1d-aced-4c51-b708-78f25a6ecf21">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6e6a50ba9c4b93a9bd88ec99d6a9bc_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTEwLTEtMS0w_6df77c02-3223-4657-bd74-63630f0d8150">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e07924ec664fd1b4eb1488d27b17d4_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTItMS0xLTA_34bb837b-9fc8-42f5-808f-8bb2c368dea7">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7eb56f6db9146e38c34652e1c29f3dc_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTQtMS0xLTA_1120d27a-5270-44a2-b866-60f79d7d73e2">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23b6b4d466040ba9303881a85c0d1d2_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTYtMS0xLTA_f888d5a7-7027-4fe7-bf74-424f6040e4dc">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5e07924ec664fd1b4eb1488d27b17d4_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTgtMS0xLTA_a90f4f1d-0080-47c6-8d15-667105e0d956">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic7eb56f6db9146e38c34652e1c29f3dc_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTEwLTEtMS0w_078b73b4-08d8-48cf-876c-553adaa339ef">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662e2ae6c2c34af690533b7c98d16d8e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTItMS0xLTA_f0dc65cd-cb07-48c9-b773-fc1932239ff5">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488340eb739640078006e1dee0f62873_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTQtMS0xLTA_f792a45c-adeb-4426-8576-5352e4553d13">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcea6cb52caa4862915d6b02fc027560_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTYtMS0xLTA_eb322583-4229-4150-9c53-8af2437614da">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i662e2ae6c2c34af690533b7c98d16d8e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTgtMS0xLTA_f2b840bb-5e5e-48c6-8a5d-ba2de6f0f479">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i488340eb739640078006e1dee0f62873_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTEwLTEtMS0w_2eb40ee7-7bac-404a-967c-45fc459a46eb">14.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied78bd048a694419a8427933eb72392d_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTItMS0xLTA_0437c5a1-edde-44c5-9242-41790893854d">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia923300cfa5443f39393219ed3df8cdd_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTQtMS0xLTA_54c80ff7-dc59-4288-9b8b-bb0a83c1d105">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3ec188dee44471a3d0ba8180228043_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTYtMS0xLTA_49bd1a18-c517-48c2-a50c-f9e590025976">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ied78bd048a694419a8427933eb72392d_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTgtMS0xLTA_10e3d5fb-13eb-4929-ab63-6d09cba5641b">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia923300cfa5443f39393219ed3df8cdd_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTEwLTEtMS0w_72cd3f26-8d83-47bc-aacb-2a485c08b442">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e9fbcfc879430f9d122a98d64707af_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTItMS0xLTA_254582d0-a6de-44f0-a51a-d72b45c9e00f">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51dc84cfa7aa490eb43a1cfcc7ac6f30_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTQtMS0xLTA_079366c4-b918-443d-bd7f-8b1c48e83241">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d533f088e0440e2bc56ad8a637e2e38_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTYtMS0xLTA_bd14f38d-3dd4-4669-9cab-c07bf0aa74ac">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9e9fbcfc879430f9d122a98d64707af_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTgtMS0xLTA_70377ef5-c88e-49a5-9e1d-053773de5e3c">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i51dc84cfa7aa490eb43a1cfcc7ac6f30_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTEwLTEtMS0w_8464920e-2e7b-4222-8d39-19d962010243">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffd4f096a224e07ae928cca78b4e4de_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTItMS0xLTA_db9aff3e-2c9c-402c-af82-c3256dd25778">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197bed260bce4946b5a7231cfb1df3e1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTQtMS0xLTA_5bc649f6-10d8-402f-a814-db66ec8801db">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dcce34e3ebf45f9b3244f8aaa0a8d20_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTYtMS0xLTA_2235ea3b-f54e-45ba-b4c8-cf7a89745c2e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ffd4f096a224e07ae928cca78b4e4de_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTgtMS0xLTA_547cbe19-9137-48a3-8f96-c23931446220">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i197bed260bce4946b5a7231cfb1df3e1_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTEwLTEtMS0w_7b4c7d9d-b303-4b9e-9aed-3ec9c6c8d79a">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdebc3f23b09469baf4a9f0122afae32_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTItMS0xLTA_9bf4f30e-8476-4881-955e-4e28d4db0850">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95fcb4fef954b5e9b3114fc3c6f5020_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTQtMS0xLTA_5e2af42e-1861-486a-9546-7a97569f3b46">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93c39893598471497b999c626c42a07_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTYtMS0xLTA_07302306-97fe-4ae1-bfbb-62861d2f3332">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifdebc3f23b09469baf4a9f0122afae32_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTgtMS0xLTA_fa243ee1-d919-4b2e-83f4-3a932fa9ad74">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic95fcb4fef954b5e9b3114fc3c6f5020_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTEwLTEtMS0w_eb5ea235-5182-4090-b72d-a929c03e1604">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56eebb67df6466bba36905010e95c70_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTItMS0xLTA_0d40f1db-c03b-4258-afe1-14f23fd94ea8">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32de10a72684de19ff4530b736045dc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTQtMS0xLTA_5bfd0332-0f72-4b15-bce6-f117a54311c4">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b58fa445b5470b9212749daa49e050_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTYtMS0xLTA_58dbbf63-b09b-4557-a8c1-73ae60b463f1">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib56eebb67df6466bba36905010e95c70_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTgtMS0xLTA_018b14f5-5658-49dd-a29e-a1e9758b08ae">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if32de10a72684de19ff4530b736045dc_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTEwLTEtMS0w_0cbcdafc-4608-4b57-8b0d-b8a027adb6e7">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0989699ff14a4823884100556badfa4b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTItMS0xLTA_6f74315a-f241-4032-8369-d095bf020bde">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0b10d0987c4ff38ea6459bb35a337e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTQtMS0xLTA_33513c4f-e313-4ff6-bb6b-62c00a35b3f3">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320d43febbce4eddbc6e86db0f7fce60_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTYtMS0xLTA_757f7f9c-b6a4-47d5-8234-caf244722b00">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0989699ff14a4823884100556badfa4b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTgtMS0xLTA_7eb49f92-c586-41f5-a230-5ef52ddf1288">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d0b10d0987c4ff38ea6459bb35a337e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTEwLTEtMS0w_cf177bba-56ec-4ed4-8fca-2afceb68ef0a">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3fb35c032c54830a66c354d7509fe47_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTItMS0xLTA_647f0b8a-e3a0-4aa2-b65e-020fa6288e8f">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876f6ed6ca05447f944d86570700a552_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTQtMS0xLTA_b2204319-f118-43bd-9858-06d2c98c0547">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ef4da3b3054496b33a2ca8733dfd24_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTYtMS0xLTA_e789a9e8-77b3-45e5-8d6a-69aa9774ca49">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3fb35c032c54830a66c354d7509fe47_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTgtMS0xLTA_503752e6-d695-4e7a-b4f8-2881cef207e5">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i876f6ed6ca05447f944d86570700a552_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTEwLTEtMS0w_51153a3e-0e47-4cf9-a221-326a7ed60f27">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic988bc0a70d740549dadd5223afb168b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTItMS0xLTA_ed79536f-87c6-4625-accb-b3c54265aaab">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64253834ef464806b4d069ddf4d2ae7a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTQtMS0xLTA_bb11ce6e-6df7-4f0b-9f1d-96434a49418d">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifead9540ae7f43f58eb9a61955b1d421_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTYtMS0xLTA_4b789d3f-5647-4f27-bd12-c5a5bc37dec4">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic988bc0a70d740549dadd5223afb168b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTgtMS0xLTA_b59f2cdd-2a1a-4598-b903-63261fb55168">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i64253834ef464806b4d069ddf4d2ae7a_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTEwLTEtMS0w_57d320f9-7065-46b7-b26c-86f2328ec8ec">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2664b750a04838a23a12a422f46697_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTItMS0xLTA_c9d9a4f5-b7a9-4827-ba96-29598405f2d9">6,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4510201ad6a4fa8ba547b237e08d2f8_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTQtMS0xLTA_67b081c9-6f7b-4763-b64f-788750ddbe52">5,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3809d28608ca4587b38a7d272fdddddc_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTYtMS0xLTA_cca69a4f-09d5-4cbd-a072-11cdd744d9e4">5,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b2664b750a04838a23a12a422f46697_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTgtMS0xLTA_a7560c94-4d3c-4ca9-824b-7f592b693424">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4510201ad6a4fa8ba547b237e08d2f8_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTEwLTEtMS0w_f651a41a-d8d4-46cb-9254-de2c34c17405">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2c0df1a61b4fe2bb9af795b4098c17_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTItMS0xLTA_6a344bf3-1566-4051-98cd-368353835759">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42535da45d984ed0b3ea9894283dbfa7_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTQtMS0xLTA_fe91952b-414a-45ee-a651-b25041c42700">8,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b952caaff249198b1de2498f27980a_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTYtMS0xLTA_7baeab39-bca3-4a6c-ae7b-341bafd66707">8,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4e2c0df1a61b4fe2bb9af795b4098c17_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTgtMS0xLTA_b67f06a3-f218-44c7-a4bc-e3c4d704d5d8">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i42535da45d984ed0b3ea9894283dbfa7_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTEwLTEtMS0w_758e3322-6132-49bc-aca1-e56cfb47ee1e">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTItMS0xLTA_969c3fd7-c4e1-482b-b35e-6743759d6561">14,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTQtMS0xLTA_6f0d4d99-ebf6-4204-aa7b-d7160bede68d">13,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c315b2e311c4bdc9634124f9332a881_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTYtMS0xLTA_58d36caf-2688-4ba7-82f6-ff028243baba">13,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTgtMS0xLTA_3177ad54-5734-4a2f-b4e2-d6dff32f56ec">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTEwLTEtMS0w_5545f9b3-5dbf-41dc-bdd0-477aee841cec">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously referred to as Consumer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously referred to as Beauty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="i3b392aae44e5457eb7cd0ea720bf40f2" continuedAt="i118c03e37c324bfabe50ba3b602acad9"><ix:continuation id="i3128643178ce4d2d8e3903db9e60987f" continuedAt="i1663bc5118924f9ea9125b18e35f8d87"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48a1be8bc394fc2b9d27103df366fbc_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTItMS0xLTA_ac999e71-9688-4f76-83cd-9f939524c00b">10,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db261aaf98a40ec9d2a8dbdfabd4470_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTQtMS0xLTA_3ea0e0f7-c681-4b53-b723-c7113b212f00">9,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe1aec193de4494a45e355fad84fd94_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTYtMS0xLTA_41758ed0-5353-497e-8798-e60604871f6b">9,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia48a1be8bc394fc2b9d27103df366fbc_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTgtMS0xLTA_d32e0709-3ddb-4440-99cc-0ad88e2e0b60">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9db261aaf98a40ec9d2a8dbdfabd4470_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTEwLTEtMS0w_7112a900-4dbc-4733-a189-65c89d303e01">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced43ae2faee49b38a0995fdb81c4dae_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTItMS0xLTA_c50ebcab-66b4-462b-9392-86522f64c718">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07758926e90e4b6ebb241ff19ec7dcca_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTQtMS0xLTA_f3f2ca48-419a-43c7-af79-231bd83d971a">4,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b14c2f869194b079873a9e2c3b0cc33_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTYtMS0xLTA_04d5f002-5f1d-488b-8f29-ef5d5642cd32">4,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iced43ae2faee49b38a0995fdb81c4dae_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTgtMS0xLTA_7e374f50-9bfd-4e69-b125-bfb6fc524c2b">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07758926e90e4b6ebb241ff19ec7dcca_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTEwLTEtMS0w_122f3c80-517a-45b2-b5e1-b0f60e0a0edb">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d10d30f5cfa4f7689179597fd83e3ac_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTItMS0xLTA_3f951166-54bf-490a-8106-51694383ddc0">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127b9a85fc754e41875443a867bbe47e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTQtMS0xLTA_f85a382b-4ae6-4064-bfa1-887e614f6ae0">13,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b648e70887e488790cb76dab030b994_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTYtMS0xLTA_b9ef580a-bd6b-4534-8dda-6df363ee6477">13,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d10d30f5cfa4f7689179597fd83e3ac_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTgtMS0xLTA_fa4e182d-3619-4c55-8054-5a3742a4e65d">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i127b9a85fc754e41875443a867bbe47e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTEwLTEtMS0w_1978f585-5979-4859-8254-7241b7af4caa">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bac2c9dccf4fe79c0fd65dddb23723_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTItMS0xLTA_8d863de5-8489-4d4c-8f1a-84dbb7c83242">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e66708363b54eb9a30dfcadae1d4bd6_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTQtMS0xLTA_8ea596fa-a683-4165-b8e0-8ae39accc2ed">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfd365c13594c388391dd8f606395b5_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTYtMS0xLTA_b4e7b50e-a137-4bcb-a14a-00313ac22c7b">3,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i51bac2c9dccf4fe79c0fd65dddb23723_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTgtMS0xLTA_ed343a62-9823-4f2b-9bcb-ded6d892220f">18.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6e66708363b54eb9a30dfcadae1d4bd6_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTEwLTEtMS0w_42bf8069-94ef-49a8-acf4-af102f654b95">16.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6da3163227146f5a9725847bbe4a1d1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTItMS0xLTA_71296374-64d5-4179-b7c0-9d477a5a41ee">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb09a7505de4bd1a2c402a208aac239_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTQtMS0xLTA_3ace73b6-94b4-4b5a-851c-53bf43cdad79">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f44c413e1f9461792dfc16bf4623c21_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTYtMS0xLTA_ffe05e3d-1600-4c76-bf70-0bc11da20789">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6da3163227146f5a9725847bbe4a1d1_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTgtMS0xLTA_49676890-1bd7-4fde-8449-04a34131c9c2">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifcb09a7505de4bd1a2c402a208aac239_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTEwLTEtMS0w_abcfac3f-0b79-4e6f-ba71-ada6717e6caa">32.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c3251c22f0d45b1b9ae5fc83e739d53_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTItMS0xLTA_8025ff36-ca58-473f-89e5-d856395eba14">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed07a99d5b24e6d8dcde45e5daee9e3_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTQtMS0xLTA_158f8dc1-c911-4bc1-9695-511e33fc27e2">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f408e57c734f30b9827c8e291b4e68_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTYtMS0xLTA_8c92a626-0bf2-42cc-937a-7cab5535c54c">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4c3251c22f0d45b1b9ae5fc83e739d53_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTgtMS0xLTA_59b8b051-3d32-4703-ab70-a0712a2f9683">11.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2ed07a99d5b24e6d8dcde45e5daee9e3_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTEwLTEtMS0w_8cd74cd1-3199-4aac-b8ef-1b158e3883eb">17.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f89457e4444472bd89ce7240eec506_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTItMS0xLTA_d55b79be-6b49-464c-9e74-177c8a5ab15c">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7c7407d5d84d95a2baef6467281a84_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTQtMS0xLTA_bede36ba-ea8f-4a07-a3dd-c284e587f3d0">4,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9049be4d27b48c5aff8d7cd9e980032_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTYtMS0xLTA_d4619584-2baf-4c72-88d0-fc3af9c38593">5,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4f89457e4444472bd89ce7240eec506_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTgtMS0xLTA_6e0819d6-b559-4ed6-af81-0caec35ea4a6">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d7c7407d5d84d95a2baef6467281a84_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTEwLTEtMS0w_d74f12aa-ea43-4163-9496-21625e4033f1">17.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc10c7bf0c354fa5b52dd6cef5049396_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTItMS0xLTA_58c6c3bb-595f-4f39-9716-6d50e1e80f29">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe65e2feac4ae6b2120d1875a0c1e5_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTQtMS0xLTA_a44a92ae-0c26-49fc-b6fa-e1ef40dce49f">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09afe5f0a47482c83a41681a20ed1b9_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTYtMS0xLTA_3b3b9104-8c38-4693-8a3c-944d55667df0">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc10c7bf0c354fa5b52dd6cef5049396_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTgtMS0xLTA_64a917e8-65b1-4d86-9b23-b94ee4e64e93">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81fe65e2feac4ae6b2120d1875a0c1e5_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTEwLTEtMS0w_4a75db21-7000-4709-9ff7-f07ce5b4a305">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345326e0d32b44a6962d5d2da892271d_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTItMS0xLTA_a54a8084-b9e7-4052-a684-c5358f05b351">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab9d0b991fd48e991a9b96176c324f5_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTQtMS0xLTA_a3ab95fb-32f1-40f2-b9b7-cf856d3b0ad4">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d52b0dee934b1dad3311f32a844f83_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTYtMS0xLTA_8c332715-5bc7-4dbd-ae1f-03b1bd2ba470">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i345326e0d32b44a6962d5d2da892271d_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTgtMS0xLTA_9c71cac0-cbec-4ec3-9e6b-584621403615">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ab9d0b991fd48e991a9b96176c324f5_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTEwLTEtMS0w_53b8718e-9ab3-49fa-8409-e2d55ada17ab">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5fff7db08d4f9abfb174cf4e10a6cb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTItMS0xLTA_af7b885e-3ca4-4cae-a6c3-f4b56e781cac">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e5ec630f144fc3acae22bf27085f20_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTQtMS0xLTA_01a03879-15e7-4901-8e6c-cdce45016ccb">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa6da60607b34facb3254a559f43916c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTYtMS0xLTA_e5739885-0951-4f7e-b3ca-75e274ffc66b">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b5fff7db08d4f9abfb174cf4e10a6cb_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTgtMS0xLTA_582a7e38-2139-4a04-bc29-cd031b026c2e">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95e5ec630f144fc3acae22bf27085f20_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTEwLTEtMS0w_3c4ae076-a0c7-43ad-a28a-9a6cac0b26d6">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd5a91ab72b4e1d9097ac42c6567a0f_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTItMS0xLTA_4a6c3c4b-b9c0-41a5-aff5-a37b394e893c">5,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic445948a0ea54f98984b624b677ef57e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTQtMS0xLTA_0e8bc49d-f09d-4c2e-ad55-5890a33ca457">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7ef583b64341d883f7c307897087cb_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTYtMS0xLTA_398bbf82-ecb1-44de-b314-1a4296dd51bf">3,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cd5a91ab72b4e1d9097ac42c6567a0f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTgtMS0xLTA_84717541-5a95-40ad-87f9-cd2935024ca0">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic445948a0ea54f98984b624b677ef57e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTEwLTEtMS0w_4e5bd9ab-8698-4b01-b906-8931566cf25d">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936effeb3bdc459188220839b3a07583_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTItMS0xLTA_8b17b4a9-d232-4c6e-8be7-6c5773bd7879">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib164d78d863f45e2ae7113fb61a9029e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTQtMS0xLTA_d83636fe-d225-4ca7-906c-cf5edc9a29d1">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747d55ed9e11415197a12256dc54b0fb_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTYtMS0xLTA_dd1e4a2d-ac4c-4d55-b4e7-3b8db2a15695">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i936effeb3bdc459188220839b3a07583_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTgtMS0xLTA_fd6d7b98-0edd-4087-9624-ebea351ccae0">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib164d78d863f45e2ae7113fb61a9029e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTEwLTEtMS0w_5b0a4586-0525-4eb8-ad5c-6b8d170310b7">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6062ff1a7594fa99d8bd54ce25f0d81_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTItMS0xLTA_91b055db-7672-481c-8ec7-5dd794af57cf">7,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aba33fa79c1416ea6970ea33209f4f8_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTQtMS0xLTA_5b5a5535-0d44-4df6-a9c9-6f09ab752441">6,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1621cb45fd410eb6148886adccb29b_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTYtMS0xLTA_fbfa7bfe-9598-484c-9204-988f4fd44931">5,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6062ff1a7594fa99d8bd54ce25f0d81_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTgtMS0xLTA_2de46c85-8115-49ce-bb69-8518d53e9944">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3aba33fa79c1416ea6970ea33209f4f8_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTEwLTEtMS0w_90ff9d13-06e2-4ffe-a975-b9727649e36d">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc79dde7b9524c7f9528487acaeaba31_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTItMS0xLTA_2c47deb7-9acb-47b7-888e-feac5fd8b0cf">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5504fd9e30f44cb48669bb12f3abdcad_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTQtMS0xLTA_de09878c-53bd-4765-a57f-34e779765e49">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28cf791d4a541b0a7be48bee043f2c4_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTYtMS0xLTA_34601347-64da-4c23-bac9-873ed3b2788a">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc79dde7b9524c7f9528487acaeaba31_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTgtMS0xLTA_1c5ddf3b-0ff8-427c-a474-f10a0b1484a7">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5504fd9e30f44cb48669bb12f3abdcad_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTEwLTEtMS0w_bc9774d5-304b-451f-8b15-cafae3dd3353">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3139e2031ad04133bd86df70cf5dc7b7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTItMS0xLTA_be30fa27-adc6-45d6-9b2f-9e1f7a979f5f">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470e0543cb694cf698d82d768b3a393e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTQtMS0xLTA_5c0e40e9-d501-4314-8107-10e820ce59f3">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502d99b70ee24908ab08e5b1a1fdc9bd_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTYtMS0xLTA_78f088fb-dcbe-4b6d-b3ee-aa557b94c1c9">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3139e2031ad04133bd86df70cf5dc7b7_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTgtMS0xLTA_e2db7c43-c2ac-4656-9fa2-464b9939325d">69.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c30844e0e04bf3aa64c9175c1c7fd1_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTItMS0xLTA_8630aeed-e26e-4d9b-839e-8983dc0bfbb7">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79af5256cde94f5aae78e06c7053dbeb_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTQtMS0xLTA_aaee8f38-7cb9-47ad-a654-afde9a4f49cf">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9482dc808d3497f92fd904dae9e95e3_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTYtMS0xLTA_cd2e0392-3676-497b-a093-573e838e024a">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29c30844e0e04bf3aa64c9175c1c7fd1_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTgtMS0xLTA_084ff3b7-51ac-4f7b-b2f7-84c1d0672c7f">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79af5256cde94f5aae78e06c7053dbeb_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTEwLTEtMS0w_0481fb56-3b78-4533-9527-136e8fc9f1a3">85.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54eccf3ae4f74a0f8fc42744cab78245_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTItMS0xLTA_a5d7e526-cbca-4999-afc4-ce87127230db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d2b9d9ef2047b0803fd7f801a13e03_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTQtMS0xLTA_b48e1337-9b77-4f75-9515-ca5070ffb1b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a43e0744bb4641978b43faa639422b_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTYtMS0xLTA_7ef25ea7-223d-42c6-b292-440d2fc6c2e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54eccf3ae4f74a0f8fc42744cab78245_D20191230-20210103" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTgtMS0xLTA_f57de296-70ba-4838-a169-5274d8e924f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50d2b9d9ef2047b0803fd7f801a13e03_D20181231-20191229" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTEwLTEtMS0w_bb38fa37-5551-4f2e-b398-eb4502f62e31">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1493568c9a874d0bbfd3ede747e68727_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTItMS0xLTA_a0dfb201-bc33-4840-b8ab-95a3fd31acc4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd29791072a4593acd00300786ece30_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTQtMS0xLTA_71a916fa-f003-4c84-979e-3a0cddacbf9f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6670255be7144d1f852e46cf45edb2ba_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTYtMS0xLTA_ca1933c3-66d9-4d29-aaf3-cccbb936170b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1493568c9a874d0bbfd3ede747e68727_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTgtMS0xLTA_1c89dbdf-1726-4d76-bfdf-53e95e5c6982">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bd29791072a4593acd00300786ece30_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTEwLTEtMS0w_59299446-03ad-4fea-8102-c98fe1452bf2">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619ec00350b745b6b707b0e00977199e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTItMS0xLTA_2d0bdc58-5d13-4289-bca7-9ca9ee51346f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47f23d17ed74b6f9a95492b23352e5a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTQtMS0xLTA_8ec2223d-56d3-4874-952a-21f133b456ef">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05672cc4fbf64dc388663c69c856b524_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTYtMS0xLTA_6cc6460b-fa88-407c-a190-3fcf5f2e096d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i619ec00350b745b6b707b0e00977199e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTgtMS0xLTA_6d377103-a906-4ad0-bed3-452c5b4a9c89">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib47f23d17ed74b6f9a95492b23352e5a_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTEwLTEtMS0w_61600f60-e041-4cd5-a612-0c31cd59168d">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91f997ab1f24f23bfd12aaf2ab15614_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTItMS0xLTA_9b518ee3-a241-4f51-952a-b76c14166ed8">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f840440eb34b388c74e913d8269476_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTQtMS0xLTA_f8c5a9e1-fc46-4ea0-9753-2aec046757a4">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a18540e4d94bd3921e7a8dd91fca8b_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTYtMS0xLTA_71c6b0a4-ff17-4938-8fef-3b2008c1821c">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia91f997ab1f24f23bfd12aaf2ab15614_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTgtMS0xLTA_f8ac8346-9497-4f4f-8bda-7f55de1d4433">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81f840440eb34b388c74e913d8269476_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTEwLTEtMS0w_ece30e48-2ee9-46ab-8687-6bd36bafca28">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac494f4524344162be998345479e44c2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTItMS0xLTA_4df8251f-b4fc-4f2f-88b5-280d123b9b6a">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2133c409ef74fbcaaabe46d16259131_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTQtMS0xLTA_76e3f174-446b-40b8-8fb1-9b0a97364fff">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86abae86ef304b71abd0e05f56a5cb4f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTYtMS0xLTA_608b4b43-616a-4ae4-907a-aa574f21a018">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac494f4524344162be998345479e44c2_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTgtMS0xLTA_691e2713-d433-468c-bded-2acc54c0b4af">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib2133c409ef74fbcaaabe46d16259131_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTEwLTEtMS0w_19a01691-1b8c-45ea-9b24-c350a3fcf1bd">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTItMS0xLTA_be04b9d7-2ce9-4963-bcbe-3478837c80bb">3,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43234804dddb4e39b7ddee85e821a967_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTQtMS0xLTA_909da36a-57e1-4459-85f8-f5d58b3ac757">3,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792f702c2cc44d72a6685098df435cdf_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTYtMS0xLTA_9323bc66-b81e-4068-b7d2-4f9395d150b0">3,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTgtMS0xLTA_40c9086c-9e8f-49df-96b7-be0043501727">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43234804dddb4e39b7ddee85e821a967_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTEwLTEtMS0w_1dfbd4b8-c041-4139-8cad-203b5798c6b2">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8e69a00b4a46d4b0026d4c0d0d12de_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTItMS0xLTA_361d9162-bbda-41cb-a9e6-908f9e5ec01d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea4daf92846476fa2993fbc2006ccc7_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTQtMS0xLTA_4d4b0dfd-66ea-49a3-aae3-0e458c9234c4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61c6e895ab34051980667f5cc645e57_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTYtMS0xLTA_35de307c-d4ba-413a-ba40-90d4aabcaf0c">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ief8e69a00b4a46d4b0026d4c0d0d12de_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTgtMS0xLTA_e45b573e-8cd8-470a-a9ff-b7f5d655c017">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ea4daf92846476fa2993fbc2006ccc7_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTEwLTEtMS0w_7696c53c-bd6d-4392-838a-1239441a4924">13.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c7d4e5567e41369256434e8aab708e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTItMS0xLTA_6ed53a71-6af5-4655-a3fa-e9e7152dd806">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2acee81d0547e1ab6097e1c5779efd_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTQtMS0xLTA_ff39955a-7e85-44d9-8cb2-426fb852e6ba">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89005b4edd5a4426abae3cd99c1ad3a9_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTYtMS0xLTA_1c94002d-5469-41c7-aac3-75d1d251a783">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00c7d4e5567e41369256434e8aab708e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTgtMS0xLTA_e3c5c0bd-1b70-4f89-bbba-6f74fe672ed0">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d2acee81d0547e1ab6097e1c5779efd_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTEwLTEtMS0w_26ca5658-da27-4ce4-903f-78c34aaf7293">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053973bac1e74eac9056a73ee8e0369c_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTItMS0xLTA_0c34de84-9274-4694-9d61-d09b916f4abf">964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a61d75aede14dbca7feee7ab7b14409_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTQtMS0xLTA_76acd952-2a54-4246-81d0-8d04bc396e96">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6b727d130644bdaf9d3ee590ee2f85_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTYtMS0xLTA_7a0e25bf-fc7d-4c0c-a608-d433ac4e137c">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i053973bac1e74eac9056a73ee8e0369c_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTgtMS0xLTA_12f0fa5d-90a0-491d-8c7e-6b97a008f8dd">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a61d75aede14dbca7feee7ab7b14409_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTEwLTEtMS0w_67a40c57-b987-4293-937b-653b8373fc67">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">  REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34651815cdaa41f5b30e1ebcb72f67bb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTItMS0xLTA_4f5ce016-e911-43f9-be03-5211c521afb4">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1714fea951a94bd59565d02ea54e3b38_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTQtMS0xLTA_ce7ba341-2f04-4d4c-84c1-e204951e5dfb">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a27ed8f9954257a933b0c854a14620_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTYtMS0xLTA_98de5d8d-34bd-48af-ba7c-adaf9ce1fc01">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34651815cdaa41f5b30e1ebcb72f67bb_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTgtMS0xLTA_0a9cf678-0395-437a-8dcb-8a43107bcb80">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1714fea951a94bd59565d02ea54e3b38_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTEwLTEtMS0w_87a3e6dc-097b-4179-92af-8081569a00ad">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac15d6fdeece4cdfbacf8aacc9f73307_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTItMS0xLTA_633b9381-2de1-4d3a-8dae-cba2befe93ca">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdb3211b66440c2ba0dbb80ae7f58f1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTQtMS0xLTA_87220a1a-ef92-4f5e-b4d3-ccf1f53ab9cb">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23709666fd9b4b9ea264d620b5bd8e15_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTYtMS0xLTA_7202eda8-ca9d-425c-851e-0df7d31611e2">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iac15d6fdeece4cdfbacf8aacc9f73307_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTgtMS0xLTA_a6a275cc-87a0-4aca-8a6d-5da4d4d7162e">13.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4cdb3211b66440c2ba0dbb80ae7f58f1_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTEwLTEtMS0w_0e61cdac-e079-4a1c-b9f7-b0375b62d42e">12.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32432ddae9e74ae1b271e486737b86ad_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTItMS0xLTA_3eb1ed1b-8172-44f6-b383-1f98eef44d9c">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29524c4a77594647acc6c76fcbbccde1_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTQtMS0xLTA_c053aca9-ef80-459c-b2a6-0eb98d106400">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54edbd81015f4d71a9b2afba7cffb29d_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTYtMS0xLTA_451a9684-596e-4fa4-8281-f9882c9ee099">1,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32432ddae9e74ae1b271e486737b86ad_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTgtMS0xLTA_ddd61dbf-c911-472c-b3a8-092827176024">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29524c4a77594647acc6c76fcbbccde1_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTEwLTEtMS0w_8e8b0d24-d11b-407a-a4f9-8aa7efe0903e">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26701d71b41f4a00aa3ced442e39d1c3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTItMS0xLTA_84dfcb46-93bc-44b5-b606-a29595528402">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i303f017761124c748caf83e92d8e5137_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTQtMS0xLTA_fd7a7fa5-bbb0-4dc4-96f7-ce66c2ddccb2">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4839bf6f46b740e2a03b47f4d2738e9c_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTYtMS0xLTA_0da44197-21ef-4e97-bb7b-ba38477cf286">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26701d71b41f4a00aa3ced442e39d1c3_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTgtMS0xLTA_1345a792-007f-49a4-bbd6-5197192f43b7">17.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i303f017761124c748caf83e92d8e5137_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTEwLTEtMS0w_f4c6c115-ab14-43d7-945d-3a2c2c1d988a">16.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d32e636144642afa7ef1549b0cf2c03_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTItMS0xLTA_b9a8e6e8-80d3-4a17-9df5-5a41e0f2aaf2">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238de9e4da3a4b15afbad05973803e62_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTQtMS0xLTA_8797a470-887e-4f70-ae97-8b6418bfdad6">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8cfd3aae4874e2e8686d594c717025a_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTYtMS0xLTA_a05be174-cf81-4118-97c4-216f7b913f2f">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d32e636144642afa7ef1549b0cf2c03_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTgtMS0xLTA_b72b22a0-4942-4f11-9956-20765cc61ef0">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i238de9e4da3a4b15afbad05973803e62_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTEwLTEtMS0w_834ce300-9a02-4079-a755-e29026a5384e">17.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddad0db124bf452ea8a03f1654bb68d0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTItMS0xLTA_33004a31-1800-4518-87a6-dcba5bf26656">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a3c9526e9e4662b7dccc6799311ad5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTQtMS0xLTA_3b3cddef-6417-4889-aa02-6743423a9732">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb90c3f230e4c8cb8dfa5a94e4ea0bb_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTYtMS0xLTA_6e41fc5e-4236-4948-abcb-4e18bca1c469">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iddad0db124bf452ea8a03f1654bb68d0_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTgtMS0xLTA_e915695a-a295-475a-8d71-2109aa3c5bd3">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i52a3c9526e9e4662b7dccc6799311ad5_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTEwLTEtMS0w_790b0baf-f47f-4376-9857-a5daf7ed6af8">17.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:48pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="i118c03e37c324bfabe50ba3b602acad9" continuedAt="i605d54bc527746b08e778307cf5d2a13"><ix:continuation id="i1663bc5118924f9ea9125b18e35f8d87" continuedAt="ifab5c0be1aa04897af498eafd07d0991"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9403e2d2a34f59a27b604645f5a91d_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTItMS0xLTA_2d6be3f2-5f06-4001-9a3e-c7c987544ca2">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f3be6ab9e8a4959a3c7edc4d122dd2a_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTQtMS0xLTA_24a6f9c5-2db9-4814-aa91-a7d3e43a60cd">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d9238b55644986a871929c8502d84b_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTYtMS0xLTA_8bfaa4ab-ed12-4fbb-bd2f-8fc4514d03f1">2,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e9403e2d2a34f59a27b604645f5a91d_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTgtMS0xLTA_8dfa9ab5-3c69-4e18-abd7-a95129219b1e">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f3be6ab9e8a4959a3c7edc4d122dd2a_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTEwLTEtMS0w_730fe598-3cc5-438a-9fdc-175e9fa55736">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08fa1ac964d47feb93b93f96ba831b1_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTItMS0xLTA_c6c09175-654e-48ed-a5de-3e2ff21a1f93">3,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d5fd3838e84f57b29637bc91f05499_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTQtMS0xLTA_d5f057d0-2a8c-4fdd-a8cf-e7484aca50d1">3,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a23ffdae8ac4614968f16731be20d0f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTYtMS0xLTA_55cb11fc-16cf-4f3c-8fc0-de8fb9bc7d2c">3,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia08fa1ac964d47feb93b93f96ba831b1_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTgtMS0xLTA_72a47080-1aab-4167-b5aa-8b4a278076c2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29d5fd3838e84f57b29637bc91f05499_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTEwLTEtMS0w_387a0b08-bda0-4933-90a5-fefd73175c03">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d55cd1871b4849bb0d4d5789fc18e6_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTItMS0xLTA_16176590-e4f0-41a4-9dbd-2f622702d32b">6,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88eb0578dc746d18d2bb2f4b766788b_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTQtMS0xLTA_8752f83a-4953-4165-b174-aa99d3f73708">6,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0226112bc194a59900da0f717036e7a_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTYtMS0xLTA_9e6a067e-83dc-4d3f-aea0-6bb803b19d7e">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2d55cd1871b4849bb0d4d5789fc18e6_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTgtMS0xLTA_4fd807d7-c7a5-438f-b47a-d037cb984724">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie88eb0578dc746d18d2bb2f4b766788b_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTEwLTEtMS0w_7fef854d-6e8a-45ab-9b72-cf4c46a085a1">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16e7d880f794b4aa0ad45508b813488_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTItMS0xLTA_8e39f8cf-311a-42d8-a872-81d3bf2e4e0c">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ba901333db44aaa2a276635feab345_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTQtMS0xLTA_aa105f4c-6fa9-4e56-8764-206b5f5b085c">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee2c3fb12d0480198cb47af51655b5b_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTYtMS0xLTA_92961d0b-981a-4b7e-977e-800c6e107839">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id16e7d880f794b4aa0ad45508b813488_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTgtMS0xLTA_5083650f-a68b-47bc-8d9f-d1f8654f036e">21.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9ba901333db44aaa2a276635feab345_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTEwLTEtMS0w_e8d614e3-2a25-4cb7-a320-f6806c755793">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abe4268a675407693e053bf7336a72b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTItMS0xLTA_8cad7345-62dc-46f5-bb20-f9a7b9dc7e18">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb60330c47204e6486cc5262ed47484a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTQtMS0xLTA_d410dd3d-46ad-4782-8c58-c39c45f4e1af">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d84ff4a4b754e97a7cb601b7d5a4e6f_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTYtMS0xLTA_fde6d499-7844-44a2-92a4-dd243c8f336a">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4abe4268a675407693e053bf7336a72b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTgtMS0xLTA_87954841-622d-4429-acaf-c5425f7cf419">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb60330c47204e6486cc5262ed47484a_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTEwLTEtMS0w_fd146b31-a539-43a6-9133-3c787b8d432c">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd8d74955bb460f8122175f5d6f0469_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTItMS0xLTA_751aa6f1-64db-4b63-ac5e-22bb4d96c67a">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3213efec3984b9a8c8df8f59eb63243_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTQtMS0xLTA_0a8c8f23-ec5f-4c11-8916-91f7eb512193">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92945871d6174c00bc9287c3ee66e791_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTYtMS0xLTA_6f4b4eea-6d72-46b0-8ed8-1c9e9a037e07">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifcd8d74955bb460f8122175f5d6f0469_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTgtMS0xLTA_e9508685-b703-45cf-8927-4e369acb8f91">10.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3213efec3984b9a8c8df8f59eb63243_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTEwLTEtMS0w_8901b157-3bbd-466a-9b06-cae3a5382ad3">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cb446a20b54dcfba5a0fc4233773e0_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTItMS0xLTA_67c4d70f-6fe4-4fb6-bf74-54ffbd3ec176">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40dfc72b0ea04eeb97d07f73f58eecfd_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTQtMS0xLTA_f557fc43-55cd-42e5-94a6-02d64f131798">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7377bec258e8441f845958db2721e43c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTYtMS0xLTA_e701dc98-4378-4f98-925a-6d1336a199d9">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11cb446a20b54dcfba5a0fc4233773e0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTgtMS0xLTA_2e0414bd-8afa-44c9-9eb6-d4f4ce912fce">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40dfc72b0ea04eeb97d07f73f58eecfd_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTEwLTEtMS0w_29e6dbc2-473d-4a79-b11d-b1163193f8e0">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd129f2ac9974218ab05c39a71c03771_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTItMS0xLTA_2b70c1dd-e337-4562-80df-278ca50adf59">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0e6af2ed39540228df21c0af815adb7_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTQtMS0xLTA_c035ff0c-3bbc-4126-8908-ecea657078b3">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa6602c894b48bd8d6bcf1d385cdcc3_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTYtMS0xLTA_a289e1a5-31d9-44e8-8616-25bc10e11072">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd129f2ac9974218ab05c39a71c03771_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTgtMS0xLTA_1c37f4ec-cbcc-4864-a05b-202563cc5db4">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0e6af2ed39540228df21c0af815adb7_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTEwLTEtMS0w_388d1962-0030-48bc-8c39-073c0ae65798">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a95f7ec983548d2a4b1be09dfe6dd14_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTItMS0xLTA_af0bcfa5-eaf5-4884-9cbc-c6e4d5c804b5">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1505070ebd0a4498bb3eeb1d51183e8e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTQtMS0xLTA_c19d8362-4f1a-4306-b1a0-de6a3eddbfeb">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f887aa0bba464abdb150467246ac4f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTYtMS0xLTA_9a529b3f-0701-4eb1-b821-70de936fa4d1">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a95f7ec983548d2a4b1be09dfe6dd14_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTgtMS0xLTA_06cb2a43-4368-4ec9-83a9-48ef8160fa53">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1505070ebd0a4498bb3eeb1d51183e8e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTEwLTEtMS0w_288cf262-51c0-40fe-bd86-695d108403b6">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a84d7d93ab64403bd293f1a7184f6bc_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTItMS0xLTA_5ad89f69-74ee-4567-93e2-21c36930be78">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a0ba12fbda4d738d5db9238ec568dc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTQtMS0xLTA_4e116fd5-49d4-4bf3-8477-02947283eb87">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic414aca1c42548929deb4e53de7bf3fa_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTYtMS0xLTA_f4bdd573-7395-4184-9bf0-c976fa749951">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3a84d7d93ab64403bd293f1a7184f6bc_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTgtMS0xLTA_41770572-f6d0-401c-bbba-1132f18ef449">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i90a0ba12fbda4d738d5db9238ec568dc_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTEwLTEtMS0w_526291b3-3c1e-477c-a853-92d9028cc589">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f98810d8ec641999cf2687e6554daf7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTItMS0xLTA_25a8d947-9daf-45a9-b632-4e061af1989a">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc700d3856a47738103c578a87aca74_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTQtMS0xLTA_a7e7b31b-aada-4677-94cb-35aa10846039">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72eb6604597248ad85fbd375da229add_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTYtMS0xLTA_510a6b9e-38aa-4116-af3b-d287faa2edb0">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f98810d8ec641999cf2687e6554daf7_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTgtMS0xLTA_b64a9da9-7ca8-4ce0-8521-4c934273aa1f">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iafc700d3856a47738103c578a87aca74_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTEwLTEtMS0w_a840d233-67e2-4c87-818c-1ce1a000e376">11.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8cbbdb69ff4501b7d58fe605645a1e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTItMS0xLTA_a7486b04-1deb-4e98-be8e-39b5d61185f4">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133aa20f96a643e3b9e5df71d2e8af4a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTQtMS0xLTA_c8fbdabf-ac1c-40f4-90ac-689f9da356f4">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if209e8c87c5644aa8818bd0b6c6673ef_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTYtMS0xLTA_1e1e4e0e-547d-4427-9898-b0e1f7153ea6">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icf8cbbdb69ff4501b7d58fe605645a1e_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTgtMS0xLTA_69aac6f3-6bf6-486b-a39c-9b6ada77954a">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i133aa20f96a643e3b9e5df71d2e8af4a_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTEwLTEtMS0w_7ced2229-6cad-4fa9-b9e8-8e0a6712be9d">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e40cab631864801a237de46454322e6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTItMS0xLTA_ab777257-d3a0-42bc-a71b-1494f0c5ab41">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8464c5bb4509404b8a2d4bbd9ed47d3f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTQtMS0xLTA_1da39e26-2afb-4325-b322-3a1b8421c666">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06797700580c400c90f77631adc320b5_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTYtMS0xLTA_d61be547-f116-4dc5-a7b5-19984218f6f6">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e40cab631864801a237de46454322e6_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTgtMS0xLTA_695e2961-d59d-426c-907e-06baeea11155">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8464c5bb4509404b8a2d4bbd9ed47d3f_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTEwLTEtMS0w_e6740329-69d7-4048-9ed7-ce6086121416">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a9d490e235496da2b346ee89bee21c_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTItMS0xLTA_299ba37e-d7ca-46e4-8e82-d58bb8fbb270">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abddda703554fc8b7f0eeca2b43a200_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTQtMS0xLTA_59d6f612-73c1-4f03-a1d9-e160758b3d63">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc276f6c9ac42e59b93c2d91c1fcde5_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTYtMS0xLTA_5c7dec90-9b4b-459a-b6e2-3d6ae5fbae19">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i32a9d490e235496da2b346ee89bee21c_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTgtMS0xLTA_ac7c459d-0e05-4a6d-bfba-b25367d50a9d">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0abddda703554fc8b7f0eeca2b43a200_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTEwLTEtMS0w_ee1dfdf0-34fe-49f9-a372-3c5bdcd2c2c4">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eba5e2c532643d08b0d85206ddd448e_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTItMS0xLTA_c74aef5c-f93b-4824-8f6c-1306ce5f66d8">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f37e7a407b4bb69c2edc826b1ad2a2_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTQtMS0xLTA_d59fe180-23af-4caa-8d10-51d60c91e07c">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f07175381b54765913104497ed4a90c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTYtMS0xLTA_f7a34b8f-562d-4bc8-b8c0-69b60f89ba5d">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eba5e2c532643d08b0d85206ddd448e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTgtMS0xLTA_0bbf3883-964b-40bd-bfcb-5a3944f2b755">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61f37e7a407b4bb69c2edc826b1ad2a2_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTEwLTEtMS0w_a45c3f3f-5d2e-4d57-9b59-c31fe8bf57eb">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc4b8397c4a4a5cbfc5afa71d671450_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTItMS0xLTA_f772c969-1319-4e12-969f-b8cdc9898b92">5,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60171dccd6404eaea5b723a79f5333f9_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTQtMS0xLTA_8d86a8cb-2cca-4469-8ef5-e41440fa13ae">4,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b03ca0cca94b2cb6387dde26985c9b_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTYtMS0xLTA_52f681c5-bd69-4df3-ae7a-71a50c892caa">4,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcc4b8397c4a4a5cbfc5afa71d671450_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTgtMS0xLTA_37e500c1-3018-4c17-be95-61810e8732d0">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i60171dccd6404eaea5b723a79f5333f9_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTEwLTEtMS0w_dcd7b79c-ce24-474d-8b04-430cf82c67a7">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620149fef35a4c07ac902b4826767002_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC0yLTEtMS0w_3a136d90-582b-41b3-88f0-e86ce379223e">7,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f669e13dedf4bf9a965e8c1a83400fe_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC00LTEtMS0w_364482bc-3f49-4d6e-b3d0-2905315e2ac9">6,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0849b4ea29674dd19f07a50c794a4b02_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC02LTEtMS0w_ca8b9d22-ca67-4fda-8d6b-a2db34b14786">5,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i620149fef35a4c07ac902b4826767002_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC04LTEtMS0w_6b548ff6-8011-4fa5-9f64-500727bfba99">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f669e13dedf4bf9a965e8c1a83400fe_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC0xMC0xLTEtMA_bfa5c4b6-61a6-430c-9d47-7b51dc59ee53">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb490cfe0bd149a286b03d9b16aaaced_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS0yLTEtMS0w_01903c32-acd6-44bc-97d3-cadfff851fc1">12,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0514ef242a54da29c4d98a28258a7cb_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS00LTEtMS0w_f6ec5deb-6126-464b-9dd8-fbeeb9b7b459">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed2d208b49b42d38d66bbe62caee7f9_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS02LTEtMS0w_464f2b7c-4ab8-4769-8498-50a1677165ae">9,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb490cfe0bd149a286b03d9b16aaaced_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS04LTEtMS0w_9d260e4a-1f30-419e-952c-5597edd0be1a">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0514ef242a54da29c4d98a28258a7cb_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS0xMC0xLTEtMA_1026024f-070e-4052-b1ed-a768038770dd">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b7b2600f594a5aa2fadc8cc7f71802_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy0yLTEtMS0w_fac61369-03b1-47b5-a614-66fe00166a01">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2576e6aa19bd4f7589777471e9b72143_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy00LTEtMS0w_07f8eb49-2d6f-4535-b03f-4e78ff830ba2">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fdf8bb361f4fd9b717cad18dd32d62_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy02LTEtMS0w_db604ff4-f8cd-46b0-ba17-0f72dd7788ce">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5b7b2600f594a5aa2fadc8cc7f71802_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy04LTEtMS0w_6bb1902c-4fd3-438c-bb5f-aac2113bfaac">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2576e6aa19bd4f7589777471e9b72143_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy0xMC0xLTEtMA_c80ee0e8-11d1-4fc2-9e67-78a2ebbe7020">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca3908b695440b9ab57b7d0a7c3e94f_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC0yLTEtMS0w_c46f7edc-8e3a-4c31-9343-f7645c598414">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfeb443990294b3cb5921c60bcfb0110_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC00LTEtMS0w_027cf084-7cea-4a07-b949-aacf0e5a1d17">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6107835bbd64528a0c3d22e0a42de81_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC02LTEtMS0w_47b9031f-1be0-472a-9631-59a9a66ecb3b">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ca3908b695440b9ab57b7d0a7c3e94f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC04LTEtMS0w_e64b9b12-ee54-426c-8b1c-76eb34be6644">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfeb443990294b3cb5921c60bcfb0110_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC0xMC0xLTEtMA_76b35e42-2481-45f3-8962-e79f9202c8ef">73.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8abdb9b05d4466a2318541bcbf74e9_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS0yLTEtMS0w_ae9b37a0-61a6-4ff4-adba-0068a783a566">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9fc36595b449aba78e7d403ab30aec_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS00LTEtMS0w_4cfdc62d-d114-4c96-9ad4-e92c56927347">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c3d8d5864694a0abc113e067abc2c41_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS02LTEtMS0w_c6400139-7d2e-4504-8da7-f663ad407836">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee8abdb9b05d4466a2318541bcbf74e9_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS04LTEtMS0w_6cd2c7a2-835e-4ab5-97fb-7c8cef5e9313">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f9fc36595b449aba78e7d403ab30aec_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS0xMC0xLTEtMA_aa1a16b8-fa1a-4435-ab7f-ef60fbaba4f5">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac9dc42aaeba4a198434d55e6de7ff96_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy0yLTEtMS00MjE0_6eaa2734-0007-423d-a94e-360452392964">583</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc5bbc6288e430fa5c2521af7bb0b05_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy00LTEtMS00MjIz_ac94b6ea-db5b-464e-9a72-aead6c2223bd">297</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b895b26e49b4635b42b1536f531c608_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy02LTEtMS03MDU4_3c0ff1e4-ec2f-4949-8a86-91941287a8b5">124</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac9dc42aaeba4a198434d55e6de7ff96_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy04LTEtMS00MjM4_cb67df1e-07c9-417d-9ccf-b981c83bd033">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2ebeab6f904ed1960851a888d27083_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC0yLTEtMS00MjE0_81572f2b-9ec4-431d-8729-92bf2f9b8e42">176</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9626d02b2b410c86ebc7380f6c4249_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC00LTEtMS00MjIz_2a52dec1-d5d9-47c5-9acf-6079a1ef1f0b">35</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383e3f60f86e4defb334fbc762820aa0_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC02LTEtMS03MDU4_2508313b-6daa-471c-b0cb-ee127a0f59b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6453b112716e4400bade7786533a87c5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS0yLTEtMS00MjE0_f5610c33-b4f2-4c97-8f43-cfb5e1fc3246">760</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id571d247cd4b4ca39d865b8901589cdc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS00LTEtMS00MjIz_adc5457c-79a8-4c03-95c2-e4309dde9850">332</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e3e0394dd94e10b095ea1364ee1671_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS02LTEtMS03MDU4_9f5f7fe9-489d-4075-8f9a-31652abaeba4">124</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10bb37e48c164c179f00b0da6b6266a0_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy0yLTEtMS0w_76dbb248-9ec7-4849-85de-e6852ba6c9d0">1,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic913c3a623e0461ba7fbea0de051f46d_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy00LTEtMS0w_acb2b1ed-cf05-4e0e-b007-ca34d978fff3">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9a2cb546bc494abb88fa69230744b1_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy02LTEtMS0w_f995a0b5-ad55-4140-93fe-ea3d2026019e">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10bb37e48c164c179f00b0da6b6266a0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy04LTEtMS0w_d9592491-eae0-4493-87d7-0424e8455dc4">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic913c3a623e0461ba7fbea0de051f46d_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy0xMC0xLTEtMA_96f1e9f8-5728-407e-b345-500fc11ff703">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb7775a898b4aad918975b899e54d3c_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC0yLTEtMS0w_a37be0e5-1f85-4892-a677-e05c54495b10">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31ddfb9acb84d7bbecc428a4394ceac_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC00LTEtMS0w_54a62964-5c8e-424d-ae9f-667e8cecc051">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie383e52a0d0e485d99e09377f32f2729_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC02LTEtMS0w_901713fa-e742-47cc-bf00-230c657cdf2d">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbb7775a898b4aad918975b899e54d3c_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC04LTEtMS0w_346444f5-2478-4d8b-8f0b-2444f82cc89c">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic31ddfb9acb84d7bbecc428a4394ceac_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC0xMC0xLTEtMA_4d7d3daf-9845-423a-bb1d-471787c03780">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43b359b238e4d539c59daf943bf60eb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS0yLTEtMS0w_0821d29b-676e-4326-a649-95e8e2fc68d8">4,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d21d69338a48978058495fdba87e9e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS00LTEtMS0w_6dbae0da-f1a7-4d04-bf85-31d3f216bee3">3,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13a02795b0645bda0393c88f521bbdc_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS02LTEtMS0w_49107ddd-42fd-4358-8e0b-5b89987d5849">2,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia43b359b238e4d539c59daf943bf60eb_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS04LTEtMS0w_54aa0936-d435-47f7-ae68-6d6e8d33c4b7">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80d21d69338a48978058495fdba87e9e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS0xMC0xLTEtMA_307b961a-7a02-464f-8bb3-4225b098342f">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7c35cec2bc467f8499200ba6d32b5e_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS0yLTEtMS0w_319dd030-1443-4dea-8e95-83847a84f9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16e7c1fa21d4e23b5881fbdc5d62704_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS00LTEtMS0w_7db0876e-1038-4dea-996d-6f389295ef1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f31422d2f4045b2b2c516a07d33107a_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS02LTEtMS0w_47390f72-7b54-4d75-91cc-08acc72a8d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice7c35cec2bc467f8499200ba6d32b5e_D20191230-20210103" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS04LTEtMS0w_d093f50d-c819-45e5-953d-d2a6996bb17c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id16e7c1fa21d4e23b5881fbdc5d62704_D20181231-20191229" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS0xMC0xLTEtMA_5fe88c42-eaa0-4122-b225-1e93dc7f4478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dd0eac24f4401fb171f8f4befd046e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi0yLTEtMS0w_c41058fa-47fb-47e2-ba16-54a64ca461bf">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c99618e8464f48b02c5800078fec9a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi00LTEtMS0w_c7752937-2d43-41bf-a94a-6106e82fc800">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic411305d926f4262891fb8f8d32340ac_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi02LTEtMS0w_7fa6ba4b-9e3a-42c1-bb51-a40f4fbd94de">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia0dd0eac24f4401fb171f8f4befd046e_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi04LTEtMS0w_1c5bf1c7-3b7f-411e-b511-87173fddc5ea">45.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i75c99618e8464f48b02c5800078fec9a_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi0xMC0xLTEtMA_c439c395-f35d-4211-a50d-6f955b0475b8">32.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf10274f9c344290a2ab99e9e34ae3e4_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy0yLTEtMS0w_f26589d0-a751-4cfd-ba9c-89a217da68c4">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de8d88c34794c23bebd5f7b5eeb5a8b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy00LTEtMS0w_9dda05cf-a971-4c42-a73e-811a27f549a0">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49c3568a0f94b3889385d83ac006905_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy02LTEtMS0w_9a9e6685-6c02-445b-bdeb-3c581001369e">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icf10274f9c344290a2ab99e9e34ae3e4_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy04LTEtMS0w_c6ccf8b2-b06d-487f-86ac-80af0f5c9f9d">45.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3de8d88c34794c23bebd5f7b5eeb5a8b_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy0xMC0xLTEtMA_e4653057-7b2d-4ebc-9085-61c32dd06919">32.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf70cb300d841aebfe5a712007444ac_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS0yLTEtMS0w_c2b1bd54-4226-4408-a6bc-6b6c773ce9ad">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab5a5f92fd941b288007441e9cc4cce_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS00LTEtMS0w_716fcefc-73d4-4570-bb11-35d232a8f657">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70838a32f63643e4a2f7ed13d212a9f0_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS02LTEtMS0w_50cbaddd-d1f1-4fea-85d1-35f87da05f21">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibcf70cb300d841aebfe5a712007444ac_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS04LTEtMS0w_f08fd492-e194-4821-839d-4c386e0a0721">54.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3ab5a5f92fd941b288007441e9cc4cce_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS0xMC0xLTEtMA_9e99310e-975a-4e77-a6f5-64aa62996c09">54.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e56b017393d48d9951e1963e9232f4e_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi0yLTEtMS0w_c9056184-ba11-4ff3-86d1-2b8966ddab9f">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec0b61f3e194449b1fc8232df6eb583_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi00LTEtMS0w_b07227ff-feea-43d8-9130-c319ee863b36">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485ad9e4c9034407b529d2ddbbea2b28_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi02LTEtMS0w_31b8380e-d42d-4dff-9ad8-a0af84536ff4">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e56b017393d48d9951e1963e9232f4e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi04LTEtMS0w_58cfbbbc-57dd-48ee-b74b-023e2d79838b">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ec0b61f3e194449b1fc8232df6eb583_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi0xMC0xLTEtMA_72f6b57f-a474-4d42-b88f-bb36dba38630">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068cc5432b3443beb8e11bb255e1e28a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy0yLTEtMS0w_9fde6fe6-ea51-4c71-90ef-fe225a7a83e7">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief79aa5fc89943f1856174ad8ab48c03_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy00LTEtMS0w_fa7ccbbe-a06a-412e-807d-1219e7968dac">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6b259e70b34438a3f81e5332f8a6c9_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy02LTEtMS0w_eebe039c-4240-4c51-98b2-9b69e302c4a1">3,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i068cc5432b3443beb8e11bb255e1e28a_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy04LTEtMS0w_2d58cef7-e164-49a9-b834-cef1fee305e7">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ief79aa5fc89943f1856174ad8ab48c03_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy0xMC0xLTEtMA_d4cb4b1c-f062-4bcc-b9ec-9b9d10d79a72">20.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="i605d54bc527746b08e778307cf5d2a13" continuedAt="id6402267a6734cf1bbf321aee80b6549"><ix:continuation id="ifab5c0be1aa04897af498eafd07d0991" continuedAt="i5b78fa8d7d0d41a8ae2960d8b1e9dcd0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc3d26ae55e4532b24a34603fb51a5b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS0yLTEtMS0w_f9751454-5b73-4edb-8b91-70ae878b4903">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1612d385f0492da9095801326473f3_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS00LTEtMS0w_4b71ca29-0408-461f-88f3-b38aa668ecc1">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5d890f9dec439ba519c396e28a1b15_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS02LTEtMS0w_6e883133-0571-48a7-9a30-344662b7ef5f">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cc3d26ae55e4532b24a34603fb51a5b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS04LTEtMS0w_b2b4ea34-5cbc-453f-b4ad-9d0fedff3dce">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c1612d385f0492da9095801326473f3_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS0xMC0xLTEtMA_ca22d2c1-b9b5-468f-84c1-baf38fa523a8">32.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3432837e0994dea9738f6a9041dfb78_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC0yLTEtMS0w_b2bfa9bc-26d8-4fd3-bec5-5b5607987c2c">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5720d7e06a47ec9ae85f4a20867f7d_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC00LTEtMS0w_45e740d9-27c7-48e3-9a9e-68fdaeceede5">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fce5a20ed35426db5a791a058567b31_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC02LTEtMS0w_716bb07a-4c16-4562-929a-fd5c8eeeda81">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic3432837e0994dea9738f6a9041dfb78_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC04LTEtMS0w_985a737b-3f51-44c7-b1e2-50d63c2b8127">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf5720d7e06a47ec9ae85f4a20867f7d_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC0xMC0xLTEtMA_f01c1606-4336-434a-bdcf-5e0594854228">7.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc0f82712f04ab1abd4713c5eb8122f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS0yLTEtMS0w_a323c46a-c385-4e78-903a-0dddd188689b">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4837e00061842c3848e83dc581c7c9a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS00LTEtMS0w_ea8ccbd1-f567-40c4-a7ba-c77ded8376de">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8fc9994e3f4e679de95304641d1e6d_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS02LTEtMS0w_a3ec411b-84a7-458f-9b64-08ee81acbde4">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fc0f82712f04ab1abd4713c5eb8122f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS04LTEtMS0w_d00d7cc6-f4c6-48fd-a83f-26eea7c1bf29">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia4837e00061842c3848e83dc581c7c9a_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS0xMC0xLTEtMA_d4b1c14a-aee6-49b5-b756-73d057b6028e">12.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee955b2a5ebc4440b0275a07f42d7859_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC0yLTEtMS0w_fa11f3bd-01be-4e37-b3d9-a9d7dda2593a">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e5bca473514621971e568c7c81f9d7_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC00LTEtMS0w_bcf7fd13-de45-4b37-8a9e-6537b5bfa9f1">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b32854703604f20a5087fc9da993d60_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC02LTEtMS0w_9e4454ab-f144-40f8-a73e-0165d01a783b">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee955b2a5ebc4440b0275a07f42d7859_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC04LTEtMS0w_92730184-7ac0-4e4a-acc7-f639dbaa687f">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e5bca473514621971e568c7c81f9d7_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC0xMC0xLTEtMA_a9ab1019-bfa4-4035-a723-49b83133cd04">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0bb8ef73842461881c87d256616bb58_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS0yLTEtMS0w_f654f881-1116-4a35-a160-41b7b790c940">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f138d8eba8c4b139d79c8bdf04273e7_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS00LTEtMS0w_629a6bc7-9693-4381-ae7d-8a890bc2258a">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513474c437a54da8bdb8d39a5690e05c_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS02LTEtMS0w_c481125a-9958-43e6-92d3-c6837a224f9a">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0bb8ef73842461881c87d256616bb58_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS04LTEtMS0w_b55d020b-078a-47a3-b2f9-c3635bcef38e">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f138d8eba8c4b139d79c8bdf04273e7_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS0xMC0xLTEtMA_4e038348-54a7-452e-92b9-943061f07c1e">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d33d060c4c47bd8ac7257d692df0ce_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi0yLTEtMS0w_864a3268-6eb4-4993-86ef-3ee4771f661f">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7524e3946646b9b75238c6c4fda704_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi00LTEtMS0w_b523229a-1fc3-43b4-9eb8-d03bc58f3d90">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if800a3c44fd14c1c8c9443c13229ce64_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi02LTEtMS0w_c1ca1cb0-19ec-4ebe-9ec1-bd3b1dd9fc64">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8d33d060c4c47bd8ac7257d692df0ce_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi04LTEtMS0w_1250a645-5498-42fb-988d-e046320c8a9b">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b7524e3946646b9b75238c6c4fda704_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi0xMC0xLTEtMA_2a9a56b2-e0f9-4513-bc70-365e89d0c062">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc918ea034249e7a645f7ddf9922377_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC0yLTEtMS0w_ff76f332-d2cb-4d71-b5e1-e4189cec6629">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9ad324b0e34c5b871ca5b7f591fc74_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC00LTEtMS0w_e715387a-ec90-4f84-8ab0-31f7e6b3d4b5">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d4dc4f88674bb784396e7150b232c5_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC02LTEtMS0w_aea0e82b-da0f-4398-b32b-2bfcf36c060b">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dc918ea034249e7a645f7ddf9922377_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC04LTEtMS0w_e932cd6f-4f5c-4f2f-bf5c-cfb4181fc4cc">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6b475ddaf2045f5b7e3e9c0ab7ddbc3_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC0xMC0xLTEtMA_7ee744c8-b183-4657-8e59-8b1c0906bf2d">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a58229b38848a6acee4aa1ee9a792a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS0yLTEtMS0w_c39aad6f-e524-4dde-9ccf-07f89e96dabf">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3b9a020380440b8fe140b751c16e56_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS00LTEtMS0w_de0914a3-51e2-444f-9f3e-6ea6af236d12">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f49a3f10784cb980bc81b0bf707db4_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS02LTEtMS0w_185bb2eb-3d11-449f-9e53-2d4fe71800ae">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78a58229b38848a6acee4aa1ee9a792a_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS04LTEtMS0w_5f527fc8-9677-448d-a2fd-68fd715d002f">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if409308149024b7ebf44549391b1ef28_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS0xMC0xLTEtMA_00dbc5c8-3025-4236-9e28-71cdc574856a">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48809d31e15f48cab0409d4e65adf936_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC0yLTEtMS0w_3705b8a7-d1c2-4c53-8b5b-76ba6a3a6df1">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e587520c5424f6895bb82d180fcead7_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC00LTEtMS0w_2bccf492-fcf0-4dc1-8f78-ae7d8c0c268d">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a298df88a04792b4eb06c9649f9c9a_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC02LTEtMS0w_45e5d4ee-ee2e-4871-8005-1954ff3e5c73">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48809d31e15f48cab0409d4e65adf936_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC04LTEtMS0w_c44a6193-816e-4086-8827-b6f4fb94b553">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e587520c5424f6895bb82d180fcead7_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC0xMC0xLTEtMA_415d29c0-196c-4880-a0a2-d2c9e4f0b78f">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5ccb426ed040e884937136da490957_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi0yLTEtMS0w_181a773a-1979-4e4c-9e5c-b0e1181352d3">955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd627d84f8348118b3790e6522ee21e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi00LTEtMS0w_968e9ad6-87cb-41b9-8be1-c8b1aadc3b54">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1196be4a434582a11b0f92c5c054ae_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi02LTEtMS0w_7d1907ef-d39b-4f7d-bd90-74774aebaba6">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e5ccb426ed040e884937136da490957_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi04LTEtMS0w_57527d4d-9710-406a-b456-ff111d0027b7">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbd627d84f8348118b3790e6522ee21e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi0xMC0xLTEtMA_7233f52d-9ac4-4007-a227-5b232ab922e5">19.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c65c2e67bfc45cab7bd25c746b42db7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy0yLTEtMS0w_d09e147b-8e1d-4e50-b421-a5cc1463e2e0">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee23e589317a442cbea6d9b4f7f79caf_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy00LTEtMS0w_01dcd1cf-9d97-4f69-97bd-8391e5275135">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5255e36acbac418e85f849dfbdf10496_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy02LTEtMS0w_73a8ee35-b4cd-4aa1-896f-55e8bd67581e">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c65c2e67bfc45cab7bd25c746b42db7_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy04LTEtMS0w_091d0215-d239-4d39-92b6-8e47c6ad3916">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee23e589317a442cbea6d9b4f7f79caf_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy0xMC0xLTEtMA_c19bfcfd-f0a7-4585-8ab6-421ca9d337ba">62.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c2543a19ee466493df5660744c8c1a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC0yLTEtMS0w_0b2f270b-01a6-4ab6-95d6-630714a9fbbd">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc4a076e7284a2eaa4ae25d6f7d0578_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC00LTEtMS0w_ebf8b324-72e7-4f21-89da-13ee6a0d2d34">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24218d83d9274436ab41302d751e3b17_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC02LTEtMS0w_52690cfa-c255-4bc0-8002-0be24765efd4">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01c2543a19ee466493df5660744c8c1a_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC04LTEtMS0w_029190d2-7288-4b8e-a610-095132c38fde">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bc4a076e7284a2eaa4ae25d6f7d0578_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC0xMC0xLTEtMA_db4292b4-3221-4c81-9181-3f294444fabe">23.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a92101e57d4ab0a5d2910e3c72d8ae_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC0yLTEtMS0w_8e541c89-e3e2-4bfb-8c1b-8debc11aad92">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b895fbb6804c319ca67eaf7a7749c6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC00LTEtMS0w_21c95b7b-ebae-456a-821d-7cbd9d050c21">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5474c52ea0d4a31a03b189d9522cbc0_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC02LTEtMS0w_29170da8-4971-424b-8c9a-123d333232ad">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic3a92101e57d4ab0a5d2910e3c72d8ae_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC04LTEtMS0w_51e093fb-1b3b-4779-a127-78694f40f382">17.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i89b895fbb6804c319ca67eaf7a7749c6_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC0xMC0xLTEtMA_f940f063-8b40-4c5c-8a54-e2ab4f34ba1b">41.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eeed4adf30e4bca9bfe818ab7159933_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS0yLTEtMS0w_707615e5-bd98-4fac-b66c-7453ab93d628">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b55966cf5b64f81b16f40f0103bd79b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS00LTEtMS0w_187d4cc7-4001-400f-bf7f-44e7cb17daa0">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72ebb598f0348479991c9709cd38a02_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS02LTEtMS0w_6562d2dd-68d1-40d8-a2c8-675443ba30c4">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6eeed4adf30e4bca9bfe818ab7159933_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS04LTEtMS0w_94213a17-2f82-4d48-8c51-bb47de486626">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6b55966cf5b64f81b16f40f0103bd79b_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS0xMC0xLTEtMA_9763daf1-0eb9-4573-81f8-86ef5c5ff8e1">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3afdb891c54b018f5398d3af12ce2f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi0yLTEtMS0w_b93e38a1-76a5-4fe0-9a4a-a2fb709a84d5">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2964812dbd3b44c7a03684da9a06461c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi00LTEtMS0w_e65494ca-a951-4747-92a3-ee963c84fe0a">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486c300ff24f47f0986efe5804106361_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi02LTEtMS0w_ddec0f8e-2955-4a00-ba5f-a4ad4fda8270">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f3afdb891c54b018f5398d3af12ce2f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi04LTEtMS0w_c0c71283-f0dc-486f-a05e-47d88a8521cb">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2964812dbd3b44c7a03684da9a06461c_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi0xMC0xLTEtMA_67c617d0-5d26-4e54-905d-0f4ba0bb6993">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e672c1ca294c19899b6194a13b72cb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC0yLTEtMS0w_aebccf70-e304-48a8-99cf-b2664a27f85e">3,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af8e2c89c584232828bbabcac9bc95e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC00LTEtMS0w_1238952c-96a3-4ee8-945d-73981bdbdd90">3,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5402a284a5544b0ae6e3a3a7f7b8b18_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC02LTEtMS0w_aefc7bce-83d0-4700-9f4e-c8bdb56aa8d5">4,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i73e672c1ca294c19899b6194a13b72cb_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC04LTEtMS0w_d86970b3-6074-44bc-9bce-22e5bb2547a1">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5af8e2c89c584232828bbabcac9bc95e_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC0xMC0xLTEtMA_fb10cbbf-4d91-4701-9adc-b1a1b7e973a4">12.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d83c054ebbe4b55956a90c090dbf071_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS0yLTEtMS0w_7a46f0f7-b13f-4a5a-9e19-8dbb4c93c898">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09262051be5d4a8fb49e116b991a4eed_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS00LTEtMS0w_19b7f22c-e414-4dc0-a5c8-aab7fb9736c0">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c5ed77ca06492184b99ba7d305dde6_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS02LTEtMS0w_eb12c6c1-f95d-48c5-ba80-6b8e57498afe">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d83c054ebbe4b55956a90c090dbf071_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS04LTEtMS0w_6c7c9e18-5340-4abe-8033-eadd51ec4c09">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i09262051be5d4a8fb49e116b991a4eed_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS0xMC0xLTEtMA_82f8fbb8-2f43-42f5-864e-5d408f302e23">5.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6485f71b8341e9811ab2c75108f37f_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni0yLTEtMS0w_a145b2f1-85e2-4271-96da-6d22f1d3a86f">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a2e2d4cb5a408b9c5fd9d323011fd3_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni00LTEtMS0w_fdfab8e3-5323-4032-8cc6-84562e615fce">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35c63055c2f4e329572b6eda58a7637_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni02LTEtMS0w_7295006c-7465-410e-9b9d-82408a110da3">5,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ied6485f71b8341e9811ab2c75108f37f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni04LTEtMS0w_c4481510-9de6-4fad-aea6-83ede5fc7b88">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i14a2e2d4cb5a408b9c5fd9d323011fd3_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni0xMC0xLTEtMA_50134c34-5933-4de3-b3bc-81aa0d8d94b6">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879becad18bd4e95871ce662ed38c9d1_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC0yLTEtMS0w_03610f50-cd24-483b-9bb9-a77d21602eb6">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id562b8bf54bb4dafba5e39bc08e96ecc_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC00LTEtMS0w_dec4e2c6-efdc-4ba8-8bc3-80162435c83c">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b7a0d4e280466f99120313fab3572a_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC02LTEtMS0w_41babf23-2ba0-48cf-b537-8f8626789977">2,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i879becad18bd4e95871ce662ed38c9d1_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC04LTEtMS0w_6db401c3-a42e-4bed-aaca-5b77bf4df7b2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id562b8bf54bb4dafba5e39bc08e96ecc_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC0xMC0xLTEtMA_85076ade-d6a6-4988-a46f-cbe92fa1edcf">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63d4391de1046ffba12c5e6301213cb_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS0yLTEtMS0w_bf41f91d-5974-46f4-868e-50bfdc5d7069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07304354d8544a92ba72a5cd3e890ebd_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS00LTEtMS0w_4a636063-b15f-4454-bd31-d09a3260080e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8ba09528eb4bb28bf8fb46d9ca244b_D20180101-20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS02LTEtMS0w_53def9e0-b510-41b5-8a69-67801ca09a3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if63d4391de1046ffba12c5e6301213cb_D20191230-20210103" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS04LTEtMS0w_158b86c7-fc4c-4899-95d0-fa8c647b0598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07304354d8544a92ba72a5cd3e890ebd_D20181231-20191229" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS0xMC0xLTEtMA_f9701eb0-178b-4197-b586-07b2b4311f8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480f6951d5234710acb15ef442ff46aa_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC0yLTEtMS0w_8fd04328-79c4-4d83-b1be-2fd29e021604">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aeca666b4bc4fc8b825d67bbe516983_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC00LTEtMS0w_f336789a-b0b8-47eb-ad95-f19222948032">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d23b54b71714d9ca21c6e5e0c22bd74_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC02LTEtMS0w_1f7b17ac-575c-4ab5-9ff6-a4aedf87bc40">2,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i480f6951d5234710acb15ef442ff46aa_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC04LTEtMS0w_9c3ebad2-9beb-43b7-b6fb-4a35f3165fcc">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7aeca666b4bc4fc8b825d67bbe516983_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC0xMC0xLTEtMA_13082043-bc7d-4f74-ab69-821c5b0b72c6">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165535e13a5d4c17953e1ceaeaf9a636_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi0yLTEtMS0w_45645ffa-17d8-449d-9267-a03f3bad774f">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91cabadcdb3c4f10bc97956908c95e3f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi00LTEtMS0w_681709a7-b100-4048-93ab-8b540b196cd4">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e918889cc434945be946be6a986c17b_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi02LTEtMS0w_d40a5a01-4cf6-4f93-a42e-ba5c01528a53">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i165535e13a5d4c17953e1ceaeaf9a636_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi04LTEtMS0w_1621d6e3-fac0-4214-90df-194c27c78c93">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i91cabadcdb3c4f10bc97956908c95e3f_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi0xMC0xLTEtMA_b5716a92-ed24-4f7d-a062-117de2e55d51">24.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9783c1f9b69e46c8847fdb36caed3e61_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My0yLTEtMS0w_acc9e4f4-df13-45a6-bbf1-957fcbdea1b0">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abe8487be1443f188c6f578a79c2d92_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My00LTEtMS0w_242a3c49-d4d1-41c7-921a-7b8a166fcec6">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341822625ecb4b4789deb017f8eacc8a_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My02LTEtMS0w_da1fc6d8-6433-405a-8c84-5fb0948119d9">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9783c1f9b69e46c8847fdb36caed3e61_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My04LTEtMS0w_e73fe208-4946-4572-82d4-b66e29dc605c">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4abe8487be1443f188c6f578a79c2d92_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My0xMC0xLTEtMA_346d1096-ed80-488c-b245-20c613ae530e">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8b3fbd369743afa2505d9b81d9cd9e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC0yLTEtMS0w_2a5ab7cd-3381-4b82-97ba-fd034e4a93b4">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia244f37fb23c45d2a6cd8570deccad0c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC00LTEtMS0w_eb7517c8-5b89-4a44-b9a3-19d3b86a7f99">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ed9b3951644e8abc03bd12c9e6b297_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC02LTEtMS0w_7ab5c343-0f8b-4cfb-887f-571ca217c4e5">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe8b3fbd369743afa2505d9b81d9cd9e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC04LTEtMS0w_24f3d564-a569-4e31-be2a-a6357feb1ed0">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia244f37fb23c45d2a6cd8570deccad0c_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC0xMC0xLTEtMA_86c6c6f7-399f-459f-b665-776ceadd20fd">16.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adfcd1c9908434da345ec1cdc576590_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni0yLTEtMS0w_2e98474d-84d4-41c7-8e58-4875779f0331">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib343bfa6ba954633998789b6a1a44c3c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni00LTEtMS0w_484c4a21-70cc-412f-90f0-7bf070626a9a">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ec7eee76274b6493178830f9f7d290_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni02LTEtMS0w_d3641605-2439-4f8f-8a82-3ce016cc3b5a">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5adfcd1c9908434da345ec1cdc576590_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni04LTEtMS0w_1b3c0150-5c53-4695-bf21-3ccde9c110e4">45.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib343bfa6ba954633998789b6a1a44c3c_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni0xMC0xLTEtMA_9bfbe50a-4d74-4662-a7d0-72dcb6c64c8d">25.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b1e5791e5f4ac6950916274d1a1a6f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny0yLTEtMS0w_afcc8e39-3903-41a4-86d5-e3eb30322fe2">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c7c3bbbd614afca59c1426a0da0a51_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny00LTEtMS0w_d520bb69-8f74-4d83-9cf2-3a6dd4d48483">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53466858e60466d81703523ed53029d_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny02LTEtMS0w_067e6ffc-0d87-4948-9e2e-c4a7ea0ec39c">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i90b1e5791e5f4ac6950916274d1a1a6f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny04LTEtMS0w_49ec1f81-34e8-46eb-ae5b-07ee1734f55e">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib6c7c3bbbd614afca59c1426a0da0a51_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny0xMC0xLTEtMA_f0ea6c8a-b157-491c-9f91-3ff94098d60f">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84e7f7d93694ba9afaee8823f713cb8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC0yLTEtMS0w_cba55735-b6bb-44be-bf8b-8d725bb5a1fa">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8899b6c537174b6bbb5cde0f33fd376b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC00LTEtMS0w_6f0ac88e-7a59-4908-b31e-af9da2ac77f9">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf39fa1409e84c67a5e97a853263bb6c_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC02LTEtMS0w_56f5fa05-5b4a-4fba-8e5f-4805dc4f15be">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib84e7f7d93694ba9afaee8823f713cb8_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC04LTEtMS0w_6d9dba0c-0182-416e-b1c3-fe81fe9c46ea">30.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8899b6c537174b6bbb5cde0f33fd376b_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC0xMC0xLTEtMA_08445fc8-aa21-445c-8818-147943e97c89">20.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98aeab42d1474d458315de624b42191b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC0yLTEtMS0w_ba7089e9-6d4f-4610-bdde-17367dcc5c89">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f4bd5c13cb4fba9645bb22fcc6521b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC00LTEtMS0w_1f95413e-0d1b-4ecc-bf80-8acf71310a39">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3c1d6bec994f689672b19d7ecd0241_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC02LTEtMS0w_3460c1b5-86f2-4770-afc0-b1c70b5ace5c">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i98aeab42d1474d458315de624b42191b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC04LTEtMS0w_ab9216b5-9376-4fd2-afd3-a1fa52ec1f6c">15.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie3f4bd5c13cb4fba9645bb22fcc6521b_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC0xMC0xLTEtMA_fcb763bd-d9b3-434c-b204-c8fecf4503ff">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17584700f12d46519383938af1d81aaa_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS0yLTEtMS0w_fca06611-9cbf-45bf-a07c-08b1481f3696">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118e59fd747d42de9edbb08a4f24b0ba_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS00LTEtMS0w_27b1133c-2541-43cb-a984-c549307ae756">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6189787c7fe14e36bbdd2e76d9f9f4c3_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS02LTEtMS0w_860b4549-e10d-4b2a-b633-f0fc6eaf25da">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i17584700f12d46519383938af1d81aaa_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS04LTEtMS0w_58a33756-ea16-4e57-ab8c-94bceb17e99f">11.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i118e59fd747d42de9edbb08a4f24b0ba_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS0xMC0xLTEtMA_00d33fb2-0a8f-478d-99a6-7d5c8202ae61">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94060b92688f449b9834a0a900890956_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi0yLTEtMS0w_ed2d9dbb-4be1-4295-8424-a5ef04ddb08f">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be240152e5849b4b1feb9af434e0747_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi00LTEtMS0w_0e4ea413-4c54-4552-8809-8fb32858e85e">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7c8be14d314237b657ffc8dd65696f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi02LTEtMS0w_3bdf71ca-f077-4db6-a780-d6867f09ecbe">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94060b92688f449b9834a0a900890956_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi04LTEtMS0w_30a56a4e-a7ad-4c59-9be9-ca023e29db28">12.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7be240152e5849b4b1feb9af434e0747_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi0xMC0xLTEtMA_04eb6f2c-08f5-43dc-a8cc-f583e196238e">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73286ade02445b5a9462beaac74a9d3_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS0yLTEtMS0w_f9b58407-4746-4399-ab4b-94437b5d6432">25,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f577a1a44334d43acea15693cd75f1f_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS00LTEtMS0w_4d575139-91a0-4c4b-89ec-709b5957bbda">23,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab38ca802ca4be19e8b830de0bd397f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS02LTEtMS0w_4eaebf3b-14df-4bf4-8d68-82cfdbdbf208">23,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic73286ade02445b5a9462beaac74a9d3_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS04LTEtMS0w_089a962e-9319-4b47-b234-14bf9bab2d9f">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f577a1a44334d43acea15693cd75f1f_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS0xMC0xLTEtMA_d3d4ad35-f5d3-47f8-80cd-e395190177cc">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf88388476f7405085cc966583cf4258_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni0yLTEtMS0w_59727efe-f480-4be6-b067-221e3414663a">19,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c66119908c84aaba2703e6fe5ffeedc_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni00LTEtMS0w_7f6e996a-5e92-43d0-8597-f57f39efe16b">18,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ccda52b00f47bcb73709353baeb316_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni02LTEtMS0w_733c7074-23a8-469f-98c9-8878d0c9136b">17,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf88388476f7405085cc966583cf4258_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni04LTEtMS0w_2e3340ac-a575-40a8-a493-3ca07fbaa59e">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c66119908c84aaba2703e6fe5ffeedc_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni0xMC0xLTEtMA_96ed5c2a-0d8a-4ea6-89ea-6214ffc11f0d">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny0yLTEtMS0w_b74eaf06-520a-47ca-af82-87f777659fae">45,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny00LTEtMS0w_df3b90f6-a54c-4dce-9766-fbd2fb0c67ae">42,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8d35a5e5ef4407bffb29a594a0b67a_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny02LTEtMS0w_b7c6e32e-734f-4bd7-bf90-be28cfb6c63a">40,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny04LTEtMS0w_0b129a44-4996-471a-a4fe-20b0b9dfa65b">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny0xMC0xLTEtMA_8fc2cad0-5c67-4702-88e3-79d8cb5e62cd">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="id6402267a6734cf1bbf321aee80b6549" continuedAt="ibb21d1a4cf9a4f07a7a0b64b481c6ee5"><ix:continuation id="i5b78fa8d7d0d41a8ae2960d8b1e9dcd0" continuedAt="ib224851d9cc44d51af24aa02891e1d01"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef4d0b58d4549e9bdb73412623a21cc_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3MS02LTEtMS0w_f9768785-24d2-432e-85cd-0455cb05f790">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602f30549c0b40dca5fd1936741a49ad_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3Mi02LTEtMS0w_0654338e-0949-4cd9-a51d-4f51db486b52">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c25e6b99024ef091459862efb9cccb_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3My02LTEtMS0w_170a4325-8519-4041-a9e0-5618d108141a">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e4feada2044b02b8313b9e00c0baf3_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS0yLTEtMS0w_b19ea7dc-a5d7-49bb-9109-046988f67d43">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84231515127f477eb578427ea2f07294_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS00LTEtMS0w_4f3a0b43-e625-4aeb-9c3c-74775742cb39">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83acb0fa39e4ec5b03d0835e324823a_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS02LTEtMS0w_e3bebb81-2289-4677-900f-8c7b36cbb06b">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86e4feada2044b02b8313b9e00c0baf3_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS04LTEtMS0w_cb42f880-48b1-4124-a7f3-586514a366f2">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84231515127f477eb578427ea2f07294_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS0xMC0xLTEtMA_676fc122-3957-4215-b8d1-3215c5184bbf">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60adb8fb0924a0ea419ad5f553698f5_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC0yLTEtMS0w_1aec4fa4-5161-4e1c-8abf-35e536242c53">1,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d5ffdf03b74d129cfd23b12757518e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC00LTEtMS0w_b893d68e-d154-45d4-bde9-f632d4f5e762">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf12e303cd9b4f9fb10ed1589f36e8b6_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC02LTEtMS0w_4475dd90-3e38-4c06-8f4a-63d75c014499">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie60adb8fb0924a0ea419ad5f553698f5_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC04LTEtMS0w_77dcd044-64f5-4d17-ac13-cab3dc8eee28">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8d5ffdf03b74d129cfd23b12757518e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC0xMC0xLTEtMA_0034323c-09a2-4484-a988-4c37a27235bb">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24fa043dc87454ea84b0044287fcaeb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS0yLTEtMS0w_2fda79f5-1c37-485b-9f91-88b7df2c086b">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf09a8d993410584b7b18acfb4bcbb_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS00LTEtMS0w_9033105f-1086-4313-80db-cc202093db89">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126f946d4eff41e79ab7d3a7a64eecee_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS02LTEtMS0w_aa284c0b-d04d-4c79-8b8b-d68f2cae4692">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if24fa043dc87454ea84b0044287fcaeb_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS04LTEtMS0w_152a32a7-6cc3-49a7-ad6d-f6771aa4e92e">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4adf09a8d993410584b7b18acfb4bcbb_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS0xMC0xLTEtMA_093f15f9-f7e3-4662-90b8-523080bc724a">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3840b8b2b071410383b4675e805cf313_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My0yLTEtMS0w_296555ac-3623-45b9-b0a5-5be5c04fcd4a">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438f65df2ab74a928e7eeb7a53d02ffc_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My00LTEtMS0w_77245270-1085-44ce-8584-82081bb5ef66">5,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd684566d004f179917d4aa4d8f8074_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My02LTEtMS0w_f906a562-db54-4dd0-b889-2f1367f25b10">5,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3840b8b2b071410383b4675e805cf313_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My04LTEtMS0w_f2f1d314-3f4b-4458-b9c7-150a468dac6d">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i438f65df2ab74a928e7eeb7a53d02ffc_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My0xMC0xLTEtMA_43253449-86aa-4fe3-b7ee-c7167df089a6">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90b9c38b8ba47e296c57ea9b6458d43_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC0yLTEtMS0w_68dff2a2-9a6a-4913-8337-e726c19a4279">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87926cc32eaa46ecad04830aafda7bb2_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC00LTEtMS0w_95940f86-f0b4-4af9-b2b5-015100dc37a8">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03ba8d91f4e4f95a4fdce30f489c09f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC02LTEtMS0w_61ac46ee-c8ba-41f3-9cef-30a58c60e353">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia90b9c38b8ba47e296c57ea9b6458d43_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC04LTEtMS0w_38294dc5-07d9-412f-a078-dfdccb38dc67">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i87926cc32eaa46ecad04830aafda7bb2_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC0xMC0xLTEtMA_4385bdac-d912-4ed2-952f-8c8e6009129b">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144f5567202f48639bb4c9aa1ae3ae2a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS0yLTEtMS0w_17ef1056-7d21-448c-8777-69c6735bd10b">7,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d98497323f94faeae1879738e0122bf_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS00LTEtMS0w_77f3f39b-f7c1-4c9f-a9e7-dc1ba21f2a5d">8,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2a5de64df24728adc2bf05ed12b93b_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS02LTEtMS0w_ae81877f-052f-4dc8-9568-f539193bb18f">8,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i144f5567202f48639bb4c9aa1ae3ae2a_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS04LTEtMS0w_2bad8455-68ff-4182-bff0-a5a3550c3f4d">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4d98497323f94faeae1879738e0122bf_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS0xMC0xLTEtMA_c67ea865-75a9-4b20-aa06-0fb44cb32aae">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4513084142340079843a021ce48dc83_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny0yLTEtMS0w_8ee6f304-9527-4de9-8e1a-b461476113ba">793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15cbbc611c14b21845dc1db3b286330_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny00LTEtMS0w_2725044f-e612-4422-95b6-fb4e2cbda144">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7fdaef25374c44aa45e900e5e25eaa_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny02LTEtMS0w_c8b79c3d-6340-403d-8931-25cd1b6ac7d4">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id4513084142340079843a021ce48dc83_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny04LTEtMS0w_41264ef8-3b88-4e1f-88dd-adc2d69e13a2">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if15cbbc611c14b21845dc1db3b286330_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny0xMC0xLTEtMA_6df6ddf1-febb-48dd-9233-2e40e36f73c5">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff8717040d04c1fa009b692e8390c77_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC0yLTEtMS0w_6ad9a411-edc5-4fcf-be3a-ba136182d3d8">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78e09ea97bc419d9c3c1d2ecfb21982_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC00LTEtMS0w_dff5bf42-9cd3-43dd-87fd-4de5d6951f90">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09b4f177eec41fc949ba626af3d336b_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC02LTEtMS0w_1005cc7c-262d-4595-8093-aa69ef8f8e3c">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2ff8717040d04c1fa009b692e8390c77_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC04LTEtMS0w_ce89a146-97e2-4c74-a5da-d6d7b3854809">15.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic78e09ea97bc419d9c3c1d2ecfb21982_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC0xMC0xLTEtMA_033ac04d-e270-4520-b5de-b323341269b5">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984713bea368485d96053638749455fe_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS0yLTEtMS0w_4217466b-1da2-465b-ad79-20154954517f">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e007c86e9f4211a41a7172c74f9c4f_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS00LTEtMS0w_b0746479-8740-4561-822b-22562f10064f">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b60c868bb3c4036ae62855e7e30207f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS02LTEtMS0w_98db88cf-6d10-456c-bbe4-c990d0eee459">1,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i984713bea368485d96053638749455fe_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS04LTEtMS0w_9c0b59d5-9adf-4e75-b202-fc26a58693e2">11.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0e007c86e9f4211a41a7172c74f9c4f_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS0xMC0xLTEtMA_a5f793d5-9558-471a-8088-db00f2daa3d1">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fc17a765d04f8ca815d5ff108cec48_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS0yLTEtMS0w_d23caf0b-7165-4f13-9d42-8617757a107b">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabedf0861be54d2fbcb151e97d5f1c7d_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS00LTEtMS0w_ad1f5ab0-cf6a-47ce-98a1-2c070fd6ee10">889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie905100914424975b112e4f3270118ce_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS02LTEtMS0w_a37f4964-1a98-486d-909d-7b710ac72b8f">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i70fc17a765d04f8ca815d5ff108cec48_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS04LTEtMS0w_b36086a1-3be5-49ec-bc99-2c679008b3f8">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iabedf0861be54d2fbcb151e97d5f1c7d_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS0xMC0xLTEtMA_cfb7f26e-c646-489d-969a-e225c24857b4">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5092dd6970434ce3ac47038270cde937_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi0yLTEtMS0w_fed5df4e-69d9-4fe3-a6d7-2f135256702d">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6813483c57994daeb367d9fe1563ce78_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi00LTEtMS0w_57db4161-4c57-4ba2-9f57-17f69e49b4b0">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ef9ca58c57427da68fbca6011ad745_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi02LTEtMS0w_c58886fe-d6d2-4746-a153-e70d5ab54147">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5092dd6970434ce3ac47038270cde937_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi04LTEtMS0w_5ded04aa-b307-48c6-8ecf-99c3c85e2b16">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6813483c57994daeb367d9fe1563ce78_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi0xMC0xLTEtMA_33c5ed2d-b2e7-4704-8814-f0bd790127e9">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc9621c078648dcbf56a98adff1c4c4_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My0yLTEtMS0w_58a73669-be29-42ea-9b1e-98bc313d097a">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f6dafdf0c741be8ac3cdeab113c489_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My00LTEtMS0w_d271bdec-503b-41c9-ba4b-e6f7ddeef1c8">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93a7c1c81884a3db1790c74e2bef12c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My02LTEtMS0w_fe003340-9d38-469f-ba43-cebbe71c2ccc">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1fc9621c078648dcbf56a98adff1c4c4_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My04LTEtMS0w_84a75fa3-a9b7-4f36-9d7a-e3e23f7791e6">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i24f6dafdf0c741be8ac3cdeab113c489_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My0xMC0xLTEtMA_ecfe545a-4212-44fe-b0b5-86ac3e1628fd">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04eb94163afc4fbe93b4ab697abbfae9_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS0yLTEtMS0w_cb7848c9-91bb-4259-8776-3ffa9826cc0e">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i902ee0627dea4cd5bb60dc3491346db1_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS00LTEtMS0w_1cc7d879-01d0-4134-8856-696c92fa55fd">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad2fbad72def446b993089efac46d5a8_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS02LTEtMS0w_84cb1677-2c03-49fc-a116-1c03c3e345bd">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i04eb94163afc4fbe93b4ab697abbfae9_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS04LTEtMS0w_b7949641-87b6-438e-923a-bb1819ba3377">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i902ee0627dea4cd5bb60dc3491346db1_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS0xMC0xLTEtMA_c3252b91-b6c1-4f44-9386-c41876a23ff2">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf163dd98ff4ed8968cab176f2563bb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni0yLTEtMS0w_5d2ea023-c4f5-448c-b6c7-fac4f5ad3c9b">966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4892515aa44a64a0209fc1e0bb2fad_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni00LTEtMS0w_0c392ea8-e9f9-4aca-a464-222031a6f9e3">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37215466423046af9249e8abed9ad02e_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni02LTEtMS0w_3de37d46-ac27-42ca-bf81-cd07804c63a2">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cf163dd98ff4ed8968cab176f2563bb_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni04LTEtMS0w_f7ecb684-32ac-45bf-82e0-1ecf8a2d02c8">9.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6c4892515aa44a64a0209fc1e0bb2fad_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni0xMC0xLTEtMA_476f5e71-8cde-433f-9bc0-1f1e385d94d0">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3906b91aa1a748e0a8a00991d75431d0_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny0yLTEtMS0w_baba4c4e-e842-42e2-bb4e-a37657f1d977">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4d058982654390a2a9623f748a295e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny00LTEtMS0w_4e5bea63-6491-4d25-bbe4-3ae6daf1d777">2,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026871ca845542edba6aa179e4c87502_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny02LTEtMS0w_2f8fba0e-53a0-4c34-b508-d15521cd0f6c">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3906b91aa1a748e0a8a00991d75431d0_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny04LTEtMS0w_4cfd03de-9246-4a72-a857-1deb27fcb360">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc4d058982654390a2a9623f748a295e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny0xMC0xLTEtMA_6bc304a8-c89f-4f97-9f9f-fa90cafc3a5e">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95433015053341168b9d624012babd6b_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS0yLTEtMS0w_64475553-9673-46a5-9a1f-c98115551048">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf587116ba149d5bcba993340189069_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS00LTEtMS0w_4defec9d-cdd3-4cf0-82db-293725810101">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fd6b74d14444536bdddf7ba271c1cc6_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS02LTEtMS0w_89f622f6-bf14-406b-8981-f2d2ef014289">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i95433015053341168b9d624012babd6b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS04LTEtMS0w_65d77d32-7330-4bc2-81ab-5697475af632">16.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifdf587116ba149d5bcba993340189069_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS0xMC0xLTEtMA_c223059a-97f0-4ce6-9ef1-310cc6b7f4cd">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d6c4422d1d40f684a09913056b9472_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC0yLTEtMS0w_d2ba7a57-3fa9-419d-88d7-dc579c51d52e">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a281af66cf04b96ba6e7ac36ebeaebf_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC00LTEtMS0w_8c724e2d-57ab-45d8-9ead-fa66166b46cb">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0196237488ef4eceb6b0ea1bd91e0dbb_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC02LTEtMS0w_96ade25b-0cad-4347-a486-9fcb7bf4ae62">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i99d6c4422d1d40f684a09913056b9472_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC04LTEtMS0w_627e2583-5444-4fbc-bf33-32cf165e950e">14.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5a281af66cf04b96ba6e7ac36ebeaebf_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC0xMC0xLTEtMA_5dcf5087-9971-4d5e-b355-f3c0e884c759">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b655adc4f8423ebd42175f161edd73_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS0yLTEtMS0w_ca75d146-d5e5-4cc4-92bd-81a2d71245cf">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c26b4e162a49b9b197f1640463053d_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS00LTEtMS0w_3eec300e-eab9-495d-88ca-3ae7eb5af5a0">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769fb5f785f43cf8b7d381fe86af413_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS02LTEtMS0w_80202a84-dd5b-450e-814d-82df0bff63c3">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i10b655adc4f8423ebd42175f161edd73_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS04LTEtMS0w_81f429dd-4239-4104-be2e-25eab7f456d8">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i78c26b4e162a49b9b197f1640463053d_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS0xMC0xLTEtMA_f3b9ab3b-47ed-4b45-811b-9727c56d2d0c">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d9753225f044ebbfafcd3370a90ed3_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy0yLTEtMS0w_b5d1ec1a-d778-4c36-ab68-7409dd28dec8">3,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13294f9754845688655bd40b3653471_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy00LTEtMS0w_525f167e-7451-4c91-bbb6-2f642a318362">3,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09529f945de41caaf3bef2e44de7877_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy02LTEtMS0w_c8005983-eb65-4073-ae3b-3850d58f2ce9">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic9d9753225f044ebbfafcd3370a90ed3_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy04LTEtMS0w_363fbf6a-0a3f-4f6a-a860-f611499417c8">15.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if13294f9754845688655bd40b3653471_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy0xMC0xLTEtMA_a50d2ffa-dae0-4093-b07c-bb081094c7fd">7.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f5c7f59b794e47882cf0b139603a2a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC0yLTEtMS0w_5f10a165-7e66-4696-87c8-301075cbb314">4,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee94c42379ca4ae7b59723ae48eb43f7_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC00LTEtMS0w_e7b9f247-a7a2-4c39-8367-740de372c66d">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdcdb5946b6e40db92ff0a19f1cde8c0_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC02LTEtMS0w_d63d6c8d-e95d-436a-aa9c-551479db398b">5,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03f5c7f59b794e47882cf0b139603a2a_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC04LTEtMS0w_329b51fb-788e-4b84-9d93-bd2233173fcb">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iee94c42379ca4ae7b59723ae48eb43f7_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC0xMC0xLTEtMA_769ae329-2f7c-4c3b-9645-28b9f8e550a0">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe224c1cfa742a4b21d4f7862c83e03_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS0yLTEtMS0w_9888964b-6569-44a8-a297-46dd2b69ce4c">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if064eea59802474d80fe24566892332e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS00LTEtMS0w_ad46b95d-cf0f-41ed-adb8-73bb5e7f0999">9,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0883d7bb7144c62b0468b8a4d80e4e8_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS02LTEtMS0w_8ef8bfc3-5914-4667-9fcd-00167d3b0bce">9,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3fe224c1cfa742a4b21d4f7862c83e03_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS04LTEtMS0w_5fefbfe8-4b26-4d4d-91be-99fd9f1c468f">13.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if064eea59802474d80fe24566892332e_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS0xMC0xLTEtMA_ac9398cf-32d7-4fcb-9c26-15b7f99591c9">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1981696707f74ea485655942372b2873_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy0yLTEtMS0w_2ea97710-ea01-4057-9271-75f1268d2094">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i937763a9251e44e7955bb4a051ffa322_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy00LTEtMS0w_7d7f9575-526a-4335-bc8c-2e2cbc528e36">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c754ff60a3c4d0f8af0b237cc3e417e_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy02LTEtMS0w_c92ac87e-487d-451e-8fb7-9d422c98b9a7">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1981696707f74ea485655942372b2873_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy04LTEtMS0w_e4135529-487b-4078-9cc0-0bc0bf2e4415">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i937763a9251e44e7955bb4a051ffa322_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy0xMC0xLTEtMA_2a0857a8-af73-4902-bf42-f7cc8f923f2c">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec42c4dc9ed465e911fa5c37e44ccf7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC0yLTEtMS0w_d740e695-2adc-4cf9-8b79-42ec1317159d">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392c683c8aa34ea48aad01f0ea87e36d_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC00LTEtMS0w_0d0634b1-21c0-4b3d-98ae-d528d7163a3c">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0ee73c79784b42b048a39b82f15449_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC02LTEtMS0w_795845ed-f0b8-4c7b-bc96-dd2128b06a89">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibec42c4dc9ed465e911fa5c37e44ccf7_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC04LTEtMS0w_a3d9a31d-b3fa-4f58-9c0f-15918e79cc74">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i392c683c8aa34ea48aad01f0ea87e36d_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC0xMC0xLTEtMA_6acd051d-efbc-4f47-92fa-839d952f05fe">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999165b6e8ed4882bd941a2d188bcf37_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS0yLTEtMS0w_1595b95f-4a20-484a-b50b-9417c7b70260">3,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caff817f2b44b13b3564e9cfa3e7994_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS00LTEtMS0w_f399d742-985e-48f1-b30f-e666608bd3c4">4,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f935698e0f466fafbc30ad31035145_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS02LTEtMS0w_27ca9e7b-c271-487b-9c23-4d0cc586a4e5">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i999165b6e8ed4882bd941a2d188bcf37_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS04LTEtMS0w_b3588b5e-fe08-4260-aabf-5ca66b0542df">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8caff817f2b44b13b3564e9cfa3e7994_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS0xMC0xLTEtMA_eb033a2a-0053-4262-9231-5d14dff6fad6">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4986f2ad3a4f63a2c9caa1b763924f_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS0yLTEtMS0w_05eb101e-e298-45c7-ad61-b09328deda30">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec43032d4244efb878a5a63619550e6_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS00LTEtMS0w_6a5a3027-affc-472c-8cdd-2842a611676b">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ce0e7d756944dab4eba19c5dd8a08c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS02LTEtMS0w_cbc44de2-7554-4a4c-83fe-18d09733167f">2,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6e4986f2ad3a4f63a2c9caa1b763924f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS04LTEtMS0w_72a1c516-dda5-4d3d-ad87-3df4100d5090">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibec43032d4244efb878a5a63619550e6_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS0xMC0xLTEtMA_deb377d2-c3e6-4814-bb44-f42b3533cfdb">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f63065772bc45baa7b3cae1ddb30035_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi0yLTEtMS0w_731c6b33-7616-4e80-9f89-34cc74de3e9b">2,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie86b777937ae417b9621ef2d6deff23b_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi00LTEtMS0w_bc00978f-fcfb-4be5-9c56-220f3722a5bc">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a6a11dfe68475a8e53247f2ea77b46_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi02LTEtMS0w_040f215a-497d-47b9-9522-ae4918afd3b9">3,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4f63065772bc45baa7b3cae1ddb30035_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi04LTEtMS0w_afdcd920-0288-4b85-bfad-de1b3333e0bd">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie86b777937ae417b9621ef2d6deff23b_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi0xMC0xLTEtMA_af1c3342-589f-4cab-bf84-0af84f243aec">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94beb64c27374b788645e22ad29711ab_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy0yLTEtMS0w_ed4dcbd3-e4b9-404e-97a2-9c24656b3166">4,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9802f870444ad395ac0a641a75f539_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy00LTEtMS0w_4ac6db61-0aa7-451c-99ce-68af61446a6e">5,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfc9343e80548ada1bc35627fe66ec6_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy02LTEtMS0w_68e7b251-40cc-4eeb-9a35-f0ac471603d4">5,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94beb64c27374b788645e22ad29711ab_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy04LTEtMS0w_d1ff5d57-ad17-4d49-9815-23762386a855">18.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibb9802f870444ad395ac0a641a75f539_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy0xMC0xLTEtMA_437553d1-9e1d-438f-b01a-8cd66718e531">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b4a8e9fa4442188bdbda3ba66062e6_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS0yLTEtMS0w_c6c5dfaf-6c46-42ae-84e8-a205053a212e">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic17b6a75086b4b339878cc6f6e4ee32e_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS00LTEtMS0w_c8ca70a8-8be5-4d05-8cba-6be6b040f92f">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729754834d2e497cb672920410a2293f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS02LTEtMS0w_81db3d57-e026-4b83-b9b2-bf2b33fcf407">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18b4a8e9fa4442188bdbda3ba66062e6_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS04LTEtMS0w_96f4f8bd-38c4-4f16-801b-630e104afe22">13.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic17b6a75086b4b339878cc6f6e4ee32e_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS0xMC0xLTEtMA_bcd11b49-d6f0-433f-8757-cf56bd91ba52">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99d3a2205024fd7aa3983a217efd24d_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC0yLTEtMS0w_222602e2-054b-4b07-a052-0dc3d11d6491">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a672c335384c4b8c7925ba2498c104_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC00LTEtMS0w_8337c2ab-73b9-44e6-9832-04ec463c773c">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593bcd3da2134b72a6c456811d3bc68f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC02LTEtMS0w_98c62d75-7148-455f-a24c-c17129ec2ecd">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic99d3a2205024fd7aa3983a217efd24d_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC04LTEtMS0w_8a6161c2-a320-4f35-a140-41588ef02b05">16.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3a672c335384c4b8c7925ba2498c104_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC0xMC0xLTEtMA_9197a58f-3235-4812-b20d-4544315e6797">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06378183c0c04df6aee2790130a1c904_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS0yLTEtMS0w_9e7eff31-c681-403b-b659-b24418dfef8f">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9550ff545c364be7bf6bf5426c596967_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS00LTEtMS0w_1bd7ebbf-9d94-4f78-b647-027b9bbcf9db">4,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c31bf3540b249a5abfdb33d6014307e_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS02LTEtMS0w_6c9f96d7-a25d-4d4f-b482-f7ab29f22cce">4,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i06378183c0c04df6aee2790130a1c904_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS04LTEtMS0w_09b88cf7-afb1-4073-8cfd-e998b939ef5e">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9550ff545c364be7bf6bf5426c596967_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS0xMC0xLTEtMA_63182ecf-5c8c-4e4f-bc26-fcd983132ff9">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibb21d1a4cf9a4f07a7a0b64b481c6ee5" continuedAt="iae37f32512b54debae9594fd8f7f9c94"><ix:continuation id="ib224851d9cc44d51af24aa02891e1d01"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751b8108d9d349959d4405809c8ab185_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy0yLTEtMS0w_748625c6-6a8f-4cf8-b9c1-69b70620f7db">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb989f6f7b574d94a635536180d59536_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy00LTEtMS0w_4a2820fc-eead-421b-92ac-f92ea322344b">1,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581f35bde0a74622a88029dde8d73d94_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy02LTEtMS0w_3745b0c5-02d9-4f93-af54-f7b63534e17c">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i751b8108d9d349959d4405809c8ab185_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy04LTEtMS0w_7b00efd2-1f91-40b0-91f4-4f4d1695a6db">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb989f6f7b574d94a635536180d59536_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy0xMC0xLTEtMA_00c74062-3284-48c9-9746-8db5ef071fe5">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic132a1e2f99f416cb0d2e0b8c3db41d2_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC0yLTEtMS0w_b3aa0c90-a6b9-4a1c-b32c-dd7abbeade65">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c7263d4b1b4d6baaf5dc29b81024f1_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC00LTEtMS0w_ccb51067-3e4d-431c-90b7-13471e2ad332">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd3d0d30a41486ca32673d4a704becf_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC02LTEtMS0w_630f11c1-b3dd-46e2-9f91-130220c8c9f8">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic132a1e2f99f416cb0d2e0b8c3db41d2_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC04LTEtMS0w_0883ca1a-e674-4fa2-9a11-24bed508c4af">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01c7263d4b1b4d6baaf5dc29b81024f1_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC0xMC0xLTEtMA_a830a82c-64be-44d1-b654-2c067c859606">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f31428fd964ba5aa8c86b194d7c991_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS0yLTEtMS0w_14817fad-8f91-4b81-ac77-15844ad45e4b">2,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic706f0504b304e95a8c897adb4eb5bdb_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS00LTEtMS0w_47ec2308-c0cb-4437-a4cd-e1939d1d3204">3,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e188e5ac28451ea93d0fd0cf9f30b6_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS02LTEtMS0w_9263848a-80db-41e3-a6eb-45d2ef09c098">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id3f31428fd964ba5aa8c86b194d7c991_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS04LTEtMS0w_1c9f6d86-b72f-453a-8695-5bc87fb6d93e">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic706f0504b304e95a8c897adb4eb5bdb_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS0xMC0xLTEtMA_4feab345-54a2-4dff-adff-1c9a91a99d6d">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72196f5c2fe4ccbb68e25e0300f191a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy0yLTEtMS0w_ac79a15e-73fa-402f-81bf-efa3ee19db8b">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c0225e9d5c41288c143c63de199e35_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy00LTEtMS0w_6f0da8cb-1e59-4a33-9fa5-bd0163922816">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079eba6ad58c4cdaa2289aea2957a33a_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy02LTEtMS0w_a892919e-3b1e-4965-9723-efef555d8947">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if72196f5c2fe4ccbb68e25e0300f191a_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy04LTEtMS0w_66f8eae5-dada-4d8b-91b7-4d6f98bb5a24">29.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i05c0225e9d5c41288c143c63de199e35_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy0xMC0xLTEtMA_a5aad8ec-1b48-45c7-b9ec-915892ff4f95">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib235d8407dc543329206c5389bc899ed_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC0yLTEtMS0w_ea849efd-2351-4891-972a-38b0d6757735">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe938c1143d420c9f0d0cd44b50a6f9_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC00LTEtMS0w_07004a89-fb0c-473e-afe2-8a273195a360">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58266c3fbe6e420ba392695ba369fbac_D20180101-20181230" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC02LTEtMS0w_fec5c52b-4921-4cde-9e2b-bd9a1abaf2e9">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib235d8407dc543329206c5389bc899ed_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC04LTEtMS0w_f1027ae6-f5c9-4914-b7b5-770459bd1658">21.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fe938c1143d420c9f0d0cd44b50a6f9_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC0xMC0xLTEtMA_3c190d97-02a7-4fcf-8f80-f55db7c42962">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3362deef6ba432593d2905bb07487d3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS0yLTEtMS0w_7458c978-ba97-416f-9e72-3090a0ca1ed1">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d31af3f79b48dcbc05247b533fb5c8_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS00LTEtMS0w_954108b4-cda4-40e3-9c04-7345d95920ab">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b492b8ad5b746c4af5adfc5a3bbe67e_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS02LTEtMS0w_e16d345f-d36b-43b4-a233-b272b05f1da2">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie3362deef6ba432593d2905bb07487d3_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS04LTEtMS0w_8fdb1b48-9831-44bb-8b1c-ba6809efaf6d">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i34d31af3f79b48dcbc05247b533fb5c8_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS0xMC0xLTEtMA_ac6b04ff-cdd9-438a-8c19-6d64f551ef45">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5079c809180e4e87babea3c6989b7547_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi0yLTEtMS0w_e6e4caf4-8dd6-4834-910c-cf13e20dcae6">11,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e3d6f06df7480d93661480c79c1945_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi00LTEtMS0w_d61f5270-e9ba-4c29-a07e-3e06de0a4069">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58588fe179f34bbabe168069b7a7b71c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi02LTEtMS0w_b537d9cb-ea90-4da9-a62d-ec97511f96a5">12,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5079c809180e4e87babea3c6989b7547_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi04LTEtMS0w_831e1e85-1aea-4b86-8959-a9ee483574d3">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i17e3d6f06df7480d93661480c79c1945_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi0xMC0xLTEtMA_42fa83b4-cb29-4400-bc1c-7d80ccb3f6d2">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24857abc09b4ecfa16764d38c143530_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy0yLTEtMS0w_b5aef4c9-57b1-43c9-8d5c-46ab3a36089f">11,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e939c765bc94e7bb66e7118c3f4a40a_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy00LTEtMS0w_8cc68c33-88ab-47dc-9a53-d2579ac4493c">13,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37350417ebd24c1ab07e70ff74cec182_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy02LTEtMS0w_f05c23a4-450d-49c8-82aa-b92afbc84232">14,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie24857abc09b4ecfa16764d38c143530_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy04LTEtMS0w_0545d544-62bf-4a56-9bf2-21fe70fe7c9e">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2e939c765bc94e7bb66e7118c3f4a40a_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy0xMC0xLTEtMA_56141862-55ed-4665-9c74-8138761f8663">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC0yLTEtMS0w_99c4e58b-d0a3-4b88-a37a-a05b9243c1a3">22,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC00LTEtMS0w_84f0cb2c-3b65-4586-817d-4d0a3488463c">25,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC02LTEtMS0w_cf9e26fd-640d-4587-b120-91d2706b3b85">26,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC04LTEtMS0w_cdec7539-784b-4554-aa04-2a2fcc0db172">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC0xMC0xLTEtMA_76f15165-f754-4194-8db5-2644395e1a0f">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3121943b0bc44e4988cad36f10e55132_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy0yLTEtMS0w_e648ecf7-976f-4a8b-ad5f-ae0bc4b1604b">43,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a0dbe0f615447893dc66aacf30202d_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy00LTEtMS0w_df462f45-fc12-4a37-8483-686960292af6">42,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2433804bf27d4a1ba35c905c2d32c4a2_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy02LTEtMS0w_66238e22-7236-406c-9bb9-3ecd7c968257">41,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3121943b0bc44e4988cad36f10e55132_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy04LTEtMS0w_f6c65c6c-d7ab-45d7-8115-efe7fbea96ca">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93a0dbe0f615447893dc66aacf30202d_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy0xMC0xLTEtMA_8dfb549d-90a5-4305-9371-f2df23c42fe4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f554723bee640bab353dcfcaa1353a1_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC0yLTEtMS0w_a6b36ff6-948c-4372-84f6-385a2171036d">39,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7ebf2e8efe428dba5d7904ddaedacb_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC00LTEtMS0w_805f4460-ff38-429e-b64b-2202497ce5ca">39,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8d7c0a664e4c77a5fbeba28997ebfa_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC02LTEtMS0w_09e33f7f-9fa0-4070-8424-074e3b40298c">39,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3f554723bee640bab353dcfcaa1353a1_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC04LTEtMS0w_445fc533-8f75-4510-8bb1-8262da18619a">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f7ebf2e8efe428dba5d7904ddaedacb_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC0xMC0xLTEtMA_2db208d1-f889-46a0-82ae-4b89fbf44224">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS0yLTEtMS0w_6aeaa8ed-d593-417b-acf4-4696120df9ba">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS00LTEtMS0w_440f0141-5e7e-4a94-a19c-12ece8600b2a">82,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS02LTEtMS0w_f7be9921-2416-449b-8c3d-c76c6d0d511b">81,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS04LTEtMS0w_918ba0a0-8d91-43de-88f8-a286ad6be309">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS0xMC0xLTEtMA_56dafd73-0b8e-45fb-a524-534f6460058b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Previously referred to as Spine &amp; Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyNTk_19d2a6b9-c663-4ba3-9953-a1350885e281" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i642be708def7413dabc7b84d041f991f_D20191230-20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItMi0xLTEtMA_22b0f42b-ab5b-41dd-959a-bbdf2b11b52a">1,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItNC0xLTEtMA_87c4748b-49f1-4697-8d3a-b3298782b489">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItNi0xLTEtMA_c3daabb9-3e44-4af7-b9a8-412f327034c2">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de1912a2bc4859b0defe8556c3f667_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItOC0xLTEtMA_f55584a4-6f0b-414f-bad7-e2c82735bb08">27,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df63a4309a0439b9c69ba7538fca3be_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItMTAtMS0xLTA_aadd9080-cbaa-46fb-8f13-812a506f127c">26,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtMi0xLTEtMA_a494a78b-d870-4f6e-b7a5-14289df6f21a">15,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtNC0xLTEtMA_5db3d409-6ad4-4ad9-9f01-e69a73f0c225">8,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtNi0xLTEtMA_f02f1a17-97af-4abd-b08f-0decd364e53e">12,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c5383de0a4ef5b6e04faef9537701_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtOC0xLTEtMA_095ff482-9270-4095-af75-306dfe62cabe">66,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae4a2195e634b988c290e9a18191ee3_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtMTAtMS0xLTA_5499fa53-44d7-443e-8c65-4dd0efd4dff7">56,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtMi0xLTEtMA_644ee50f-d7a9-4129-8666-fa45220fbec9">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if841232101534f53b580eec2b5065a8b_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtNC0xLTEtMA_ca14a88b-2153-4322-b08a-426681823271">7,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtNi0xLTEtMA_716896de-bfcc-4ba7-a63a-cbd42f8d0168">4,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edbe06fd12f48158aa18ec4e99452f4_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtOC0xLTEtMA_6f57c5ac-48e3-4c5d-a923-7b7286e70ee5">49,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2244f03ed8794c27a6ca06574aa2e8bd_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtMTAtMS0xLTA_541e6f91-5791-4848-956a-9791521e77f2">49,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bef2be8cac3404983af1188af384ef4_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtMi0xLTEtMA_23c1370d-c561-4ebb-b745-a55062885f72">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c2d444872e4307aeeecc3b63c90b14_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtNC0xLTEtMA_de0c5c58-2d8b-421c-9d40-a5354cae2c16">18,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadcb5421eef24006804c7c3cea1e9fcb_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtNi0xLTEtMA_2089d645-67bb-43ad-9d82-f02063632c8d">19,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95e9493ef57449b82086c14a005a57e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtOC0xLTEtMA_179329fc-1edf-4af1-b6c1-0b6adf96a24f">143,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d8373ae98f4edd99b0fbc74c83f2b7_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtMTAtMS0xLTA_09576d62-4219-4619-8993-a83c018e918d">132,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8bf98199ca4359a65148eaa4b30c82_D20191230-20210103" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzYtMi0xLTEtMA_9aba8fea-d544-4bd7-bae7-77e02c1b7f51">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0c83283a7a4e978c00244503b2a25f_D20181231-20191229" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzYtNC0xLTEtMA_3b9aabd6-bad6-420d-a64e-3a24be53a750">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6cefb7c53d43baacb94f6acb2d8f23_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzYtNi0xLTEtMA_3d1db67f-fec4-4c13-b805-aeada8965bfa">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f65207fc7f44ad2ae85cee82bd938ca_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzctOC0xLTEtMA_3922b38e-f369-49aa-94c6-82384c1cd30b">31,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742ec0e39c9e4a5aa684735e52151b2d_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzctMTAtMS0xLTA_6abad42a-5191-400c-8dd3-e62c240a2cf8">25,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtMi0xLTEtMA_4a3b6c10-cfe1-415f-93ad-9d55a55107e7">16,497</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtNC0xLTEtMA_6a00b941-79ba-4bde-a064-00d99e7e0707">17,328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtNi0xLTEtMA_fc3ffe98-4db9-4b13-9477-bfb37b929513">17,999</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtOC0xLTEtMA_83020a88-9fa7-4ca6-aac3-f9e4a3df4614">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtMTAtMS0xLTA_86cfa0c9-52b4-4d09-b3dc-dd8e15728ffe">157,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642be708def7413dabc7b84d041f991f_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItMi0xLTEtMA_9cfdc1d9-ae8a-4c8f-a7af-862b39b96057">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItNC0xLTEtMA_84d982ac-f20d-4847-8e5b-6b1603184361">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItNi0xLTEtMA_5bca527d-0106-497d-9314-249470d0c316">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642be708def7413dabc7b84d041f991f_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItOC0xLTEtMA_17e5cf28-c46c-4cc5-a9b4-6ffa4c975c7b">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItMTAtMS0xLTA_6d39f5c5-c573-4cd4-a43b-1a0ec013183f">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItMTItMS0xLTA_48f67229-a7be-4606-b10f-632a05009981">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtMi0xLTEtMA_8c7916f2-2b15-48b9-8b4e-2e3b9662c9c9">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtNC0xLTEtMA_b2419235-e131-4437-a32e-c4f7526d4346">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtNi0xLTEtMA_a7fdcc34-3585-4b22-82fb-42c169bf4074">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtOC0xLTEtMA_f526c18c-6343-4aca-8326-771bab75c62b">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtMTAtMS0xLTA_4bb4d3fa-aea7-45d7-b7d0-5bb4b5a20f08">3,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtMTItMS0xLTA_bb58b473-76e3-4339-9021-7155e6beb6ab">3,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtMi0xLTEtMA_12209410-b325-45da-835b-d438387ef24e">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if841232101534f53b580eec2b5065a8b_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtNC0xLTEtMA_80f6e633-af5e-4588-9e2f-bf182d5e430b">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtNi0xLTEtMA_0f5d2e0c-619b-47c9-9393-75033685162b">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtOC0xLTEtMA_71a8efce-0353-4d68-8f61-64f7a101bc18">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if841232101534f53b580eec2b5065a8b_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtMTAtMS0xLTA_dc5fd0b6-45c9-4c52-9dcc-b501180e4982">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtMTItMS0xLTA_2513da18-a36c-4baa-a45c-a7967d61e971">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b28a8f605f94f75b14c686dc2522e6a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtMi0xLTEtMA_70d61819-ddea-4951-9c6d-f61565b3be49">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1c8604abf643c9a12b71cd7d31eb00_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtNC0xLTEtMA_de7ab41d-f8ac-4313-8263-9f7cff2d3e44">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5dcf1d4a1e417bb4b42eab3fa4b8ac_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtNi0xLTEtMA_ebec7deb-fe8d-4ff3-b536-8af7d9beae2d">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b28a8f605f94f75b14c686dc2522e6a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtOC0xLTEtMA_42032500-70f9-4e57-b353-3ed9208115b9">6,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1c8604abf643c9a12b71cd7d31eb00_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtMTAtMS0xLTA_ef812d02-ab83-49db-a08a-1e256d3a00a8">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5dcf1d4a1e417bb4b42eab3fa4b8ac_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtMTItMS0xLTA_7a5232cb-912b-49fb-af5d-bd57b31b97d1">6,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie728c62d2459463bb8fc5167f5c487da_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtMi0xLTEtMA_c484f7ab-edc1-4d40-8207-d4e7acd2a1af">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf1dfe1a8b944b8bc2c86ec9a44bdcf_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtNC0xLTEtMA_d58b9103-6257-4465-a9a8-ca8594287d9d">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c617cfb7894c9d832fc9595def2dd1_D20180101-20181230" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtNi0xLTEtMA_3927b920-ff6b-4e19-92f3-e8012da29c95">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie728c62d2459463bb8fc5167f5c487da_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtOC0xLTEtMA_da9024e1-731c-41f9-9057-5c0a46696b9b">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf1dfe1a8b944b8bc2c86ec9a44bdcf_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtMTAtMS0xLTA_57b39ed1-7974-4277-9db0-8c6b5ec9c588">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c617cfb7894c9d832fc9595def2dd1_D20180101-20181230" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtMTItMS0xLTA_51c000b4-d7de-41a2-9975-37f5e52b5649">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctMi0xLTEtMA_2e90b9a4-49b2-4513-b252-d13aa544e0e7">3,347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctNC0xLTEtMA_3c2ff393-6ec8-47d6-b1e2-b6bd1bad9041">3,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctNi0xLTEtMA_1b35929c-46b4-422e-be33-dc4faed4d948">3,670</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctOC0xLTEtMA_9fac8a9a-ffe7-45b4-9707-a8aa530bde3e">7,231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctMTAtMS0xLTA_f279f652-7d33-45b2-ad60-31e034cd0046">7,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctMTItMS0xLTA_aa67f2d8-5421-47d0-954d-05e19ed1d81d">6,929</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDQ1MzYwNDgwMzI4_d91855bd-55c6-451d-8ec0-53795aeb5ffe" continuedAt="iaac0f4e7158a4c1ab53ec990a9a19fe0" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iae37f32512b54debae9594fd8f7f9c94" continuedAt="i541398e54c5f4538a91a9cebc302ca07"><ix:continuation id="iaac0f4e7158a4c1ab53ec990a9a19fe0" continuedAt="i15a9183e61f84a7c99f9ffb75c111be2"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad324e736f04bc29364176151a23e2a_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItMi0xLTEtMA_dd1812ff-46e2-4d6c-b23e-6acfd8158c7b">43,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6887fdffd35c41348f9aeb0c27b07ba2_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItNC0xLTEtMA_53d4723d-3dcc-4f04-af0e-7b40e0a0d0b8">42,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea71296fec64699bfe2bf754f22f26c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItNi0xLTEtMA_f13dd31c-df81-4932-adef-4cf6fd6029cd">41,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a788b9d1d084972933b07d5c268c034_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItOC0xLTEtMA_42e80199-68c6-4b5f-9e3a-33f806495302">49,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875011bdf5ae45a088eff8aa4e901299_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItMTAtMS0xLTA_20af1b58-9a80-4d34-9bca-67e20e52104b">41,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e58bfcff40486e8072fafaac9bd118_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtMi0xLTEtMA_88781ea2-a313-42fb-91a8-9cc8508e50b3">18,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e3eb051f454593ad2310cf80ffb554_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtNC0xLTEtMA_4a193886-43b4-4462-b968-6d3b7656dbe9">18,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079da15a84a34e4198ff651865a8038c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtNi0xLTEtMA_678b3346-ea87-4375-a93e-cde00690aa82">18,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c62fc9b4be4d35bc62769025bc8c59_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtOC0xLTEtMA_3d67be3e-15ae-4032-9b4f-449fe4a78f60">49,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1befbfcdf8fc41b68d2d73068d97c2a6_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtMTAtMS0xLTA_1e79ce11-7f87-467d-9a24-cad4e70ef901">48,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5579c03fb48a43a7a109405d767a3964_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtMi0xLTEtMA_9d08988d-3fc1-4a04-a25c-dd1d9ce67a4f">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3881ea9c694735ae5a5c61f3442642_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtNC0xLTEtMA_3cfcfd40-6afe-4ee2-915f-f249dcef5cbc">5,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d15cee058f64c2c9ad5c5d19645970c_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtNi0xLTEtMA_14f08fcf-b70f-457e-9236-83d9e495391d">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc3b1a2bc054935a96c8c42b944c4ca_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtOC0xLTEtMA_0e4bea66-4d87-48b1-b019-9771cd221076">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a7c95098b948b58ef457213dbf6381_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtMTAtMS0xLTA_90e1a0e9-ade8-43ac-9524-5a10988683ce">2,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221d578ffbb64653ba21c30b54079cc0_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtMi0xLTEtMA_779cd14c-0fd7-4847-a936-de4950b624d0">15,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b64bc0f1de4cf19d38861ea0a431a2_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtNC0xLTEtMA_c3665870-e0e5-4e1d-997e-183ef5d3b5e4">15,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748076e324e04eb6876fea17432e0764_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtNi0xLTEtMA_52823f5d-9a28-43a0-94f9-3ce9aa4dc698">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4009a5bef5c4d3e93a8d64a351d480c_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtOC0xLTEtMA_57e5dcef-c188-4668-a429-73b6acdaa4fb">5,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied02b691df1a4793820eca15169c551b_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtMTAtMS0xLTA_435f5a4f-8d16-436b-8474-a845929d2d18">5,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bef2be8cac3404983af1188af384ef4_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtMi0xLTEtMA_f21e1792-8690-4aba-859f-edda7544bf8f">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c2d444872e4307aeeecc3b63c90b14_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtNC0xLTEtMA_e7652cce-e65b-48be-b8c4-3247c1807736">82,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadcb5421eef24006804c7c3cea1e9fcb_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtNi0xLTEtMA_3b06506d-8093-4c4a-8b1a-45a66911c2f7">81,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94bee8dba224f25ab579c909f351412_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtOC0xLTEtMA_86bd7f96-4b58-4f5e-b3a2-32ba4047fa10">107,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035675e545034a8daa97c38652231215_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtMTAtMS0xLTA_34240742-7b12-43d5-9730-0a8a8d61254d">97,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f65207fc7f44ad2ae85cee82bd938ca_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzctOC0xLTEtMA_6e6ec473-bea4-4e1a-ae1c-17ed26f28c4e">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742ec0e39c9e4a5aa684735e52151b2d_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzctMTAtMS0xLTA_069390c0-c069-4a66-83b8-9cab29aad282">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e242133e6a48148ee336086579aa09_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:OtherNonLongLivedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzgtOC0xLTEtMA_e036c826-9250-4625-a39b-55fb53646bf3">66,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f6eed880b84772b8aefd785e874762_I20191229" decimals="-6" format="ixt:numdotdecimal" name="jnj:OtherNonLongLivedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzgtMTAtMS0xLTA_3a1519c6-c2a8-40a3-b7c8-47878dcf07c5">58,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktMi0xLTEtMA_9a3b03e5-747d-4e21-be61-02788fe6dd29">82,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktNC0xLTEtMA_830ca4ae-fa67-4f7c-a2a8-d8b0160e75aa">82,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktNi0xLTEtMA_f38bc595-bc00-4357-b5a9-d3a5379fb193">81,581</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktOC0xLTEtMA_43bc1d53-7197-4ddb-87c2-9ff5c5097f7f">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktMTAtMS0xLTA_dbeea2d1-3e93-4285-a7f9-d27125cf1dec">157,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMwMQ_d0293478-623a-4de5-a6ce-e10195513301">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="ie2df61011b564018ad5b03df881363ff_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzM0NA_b1cdc816-1e38-4554-8fc4-3a74b1b58f5e">16.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i1f14ae1615dc4d17b4edf556db9b6006_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzM0OA_adaee313-8a5b-4f69-9133-0c9576573c07">12.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i62050a01eb854e2383bc3ec498ccf086_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzM1NQ_bdb9729e-1541-4426-b58f-4c967a903eb6">12.0</ix:nonFraction>% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzQ2Nw_d0293478-623a-4de5-a6ce-e10195513301">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="i808364999df6460a849022d9b066670a_D20181231-20191229" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzUxMA_3098d963-54f0-45e4-82a8-55e8c2839fa3">15.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i2e2e498bbaa444e9ac4c96b0df2ceafe_D20181231-20191229" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzUxNA_f06d1b91-9742-48c8-a4d1-52ac8aefbab8">12.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie6728846518144a681a82a2d46f3f018_D20181231-20191229" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzUyMQ_e6a49907-f855-4e40-bdfe-c4df65b2985c">11.0</ix:nonFraction>% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzYzMQ_7b3becae-8ee4-4ae3-a599-e2c76c964dfa">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="i61dcd5aafdb0485db71a09a4bad0bcb2_D20180101-20181230" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzY3NA_36aa7c3d-db0d-4ab3-9a83-96e0cf72b5af">14.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i085fffe12cf44fa092d9246b89d54cba_D20180101-20181230" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEyMDk0NjI3OTA4OTIx_d00ab711-784b-4ba3-8b26-95df6c8f1979">11.0</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i085fffe12cf44fa092d9246b89d54cba_D20180101-20181230" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzY4MQ_cd626769-c540-43ff-a4c1-41ecce3951b9">11.0</ix:nonFraction>% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQwOTQ_5db3da26-f3fe-4c42-8831-923effbb5d39">3.9</ix:nonFraction>&#160;billion, primarily talc related reserves and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQzNTI_64031ae1-bf9c-45ea-87fa-cc6d80fe3175">0.8</ix:nonFraction>&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $<ix:nonFraction unitRef="usd" contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnSecurities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQ3MTM_7d6edc5f-966c-4ee4-9ef4-9aa92eef59c3">0.5</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQ3NDI_3f8ce6ac-5efe-4e4a-90aa-af24267f1c7d">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="icb9530f3d6cd435ba9e67542e9eca210_D20191230-20210103" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTU3MjQ_57c71b2d-4e3f-45a1-9fa6-067206a21dfb">1.1</ix:nonFraction>&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTY0MjI_f2129c5f-0a7b-489f-968b-8954e0d47de3">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTYxNjU_0d094764-a455-42c8-b360-cf1691f23530">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTY0MDg_e049c4c1-899a-49b2-8227-bc9673bd3176">0.2</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:RegulationCharge" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDQ1MzYwNDgwMzQz_5634f2a7-a9df-491a-96c7-9f1587283981">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="i911bd91ee4bc41389629447824db808e_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfEquityInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3Xzk0OQ_29560f52-2d7c-4e94-9f48-df4b876049cb">0.3</ix:nonFraction> billion related to the Company's previously held equity investment in DR. CI:LABO</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDk_655169c8-6fa1-4919-baa5-543f963bddc2">0.4</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwODI_7f899899-4bdb-4610-9f28-207e5b4e6b3e">0.1</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzExNDQ_b0830a81-ad85-410b-ac05-ad2a39d70334">4.3</ix:nonFraction> billion of which $<ix:nonFraction unitRef="usd" contextRef="i8db67b67955942f7a04d431f570d4565_I20191031" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzExNTc_cff145ad-e344-4661-9cfc-2aa50d51de8d">4.0</ix:nonFraction> billion is related to the agreement in principle to settle opioid litigation</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEzOTE_56079dff-d1b0-46fc-b5f4-5381c9f116b4">0.9</ix:nonFraction> billion related to the Alios asset</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE0NjA_b8af435a-6a55-4c18-8e24-f6be201b4106">0.3</ix:nonFraction> billion for an upfront payment related to argenx </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $<ix:nonFraction unitRef="usd" contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnSecurities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE1NDE_1aa1781c-7468-468f-b12e-ad06fce19cd6">0.6</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="i619793eecabc489ba4c2968bb061e22f_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE1ODM_4b0ebaca-494d-41e7-b12c-afe2bd1d8898">0.2</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring charge of $<ix:nonFraction unitRef="usd" contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE2MTY_19521b0f-be79-4b64-957c-b0bda682e69b">0.1</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="i6f0cb54bb4974193979769bf8aec917e_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE2Njc_f9d4d271-6940-40d6-8d18-52b86fff2536">2.0</ix:nonFraction> billion from the divestiture of the ASP business</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i541398e54c5f4538a91a9cebc302ca07"><ix:continuation id="i15a9183e61f84a7c99f9ffb75c111be2"><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE3NDY_36c315c3-6c07-483e-ae48-8905af42abcd">0.4</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE3NzI_bc596e80-3f96-45e9-8b5c-524574d3d4f7">0.4</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Auris Health acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="ia0899ff9af5041b68f780bfabfc0a5f0_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE4MjE_e14f5c90-6bf1-42f2-9adc-ba37a4996719">0.1</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="ibd9e566fe73f466bbb7ee14bb2b8034f_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE4NjY_0ef8dfea-7f77-49a8-97df-be7e5c1e17c2">0.3</ix:nonFraction> billion from the divestiture of NIZORAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i3c315b2e311c4bdc9634124f9332a881_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE5Mjg_c154699b-be53-4b5f-b297-035c89afa8e1">0.3</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development charge of $<ix:nonFraction unitRef="usd" contextRef="i3d1841e88ae54dceb0af523351880c07_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIwMTc_ca9bcab5-92d9-4996-aaa7-bfd5f843865a">1.1</ix:nonFraction> billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $<ix:nonFraction unitRef="usd" contextRef="i902af15964e14194a303f3a664cb5d2f_D20180101-20181230" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIxMTU_31117ff7-3e32-4cda-8ea7-86884e947d4e">0.2</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="i750e6f140fa94894b04bd3d8acbe99bd_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIxNTc_3b2c639c-cde7-4e13-b0f1-28502b3ac37e">0.2</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized loss on securities of $<ix:nonFraction unitRef="usd" contextRef="i9f8d35a5e5ef4407bffb29a594a0b67a_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrealizedLossOnSecurities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIxOTQ_a0959a46-b785-43c8-aef7-293de85a16ca">0.2</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="i58e829bbfb07485da5515f522d722695_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIyMTE_9439a4d1-193e-4871-b04d-05714c19166a">0.2</ix:nonFraction> billion from the divestiture of certain non-strategic Pharmaceutical products </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIzNDg_8253662e-4e25-4d9e-8aa6-5d12c2bd2839">1.7</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="jnj:RestructuringChargeNetofAccrualAdjustment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIzODY_525aed56-4f92-4607-90a3-45054db78842">0.6</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">AMO acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="idcc4dd426fcc453da67295531f6d0a7e_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzI0MjM_910bdb31-730c-490c-8710-f441f53e36c7">0.1</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="i527f590d7fbc4382b88ea8ad34d70258_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzI0NDA_2052e822-c9e8-46b9-9aaa-8567f33d13b4">0.5</ix:nonFraction> billion from the divestiture of the LifeScan business</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $<ix:nonFraction unitRef="usd" contextRef="i9cf7c5be7f3c4332b89431499d7c18c8_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMxMzg_04996377-dd52-4eff-95ed-118231b71b2c">18,766</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8b3c10dbd47946ebbad7615c4da0af0e_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMxNDU_ffc5087f-6ab8-4005-931c-fc808b425c26">17,658</ix:nonFraction>, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $<ix:nonFraction unitRef="usd" contextRef="i8d63527739004691b878d7ebe2f0a1b6_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyMjA_6fab88e1-0baa-4cc6-8de2-eb2acf77fb14">89,795</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id21a208c5c3e4881b44ca05ec83a15c8_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyMjc_36575cb3-7b3f-49e5-9d03-85b83ceb5bac">81,282</ix:nonFraction>, respectively.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_214"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE3ODkw_03990f93-3402-4eb6-9eb9-301717ea6dfd" continuedAt="i5249879d603e40dda99305a59b74abf8" escape="true">Acquisitions and Divestitures</ix:nonNumeric></span></div><ix:continuation id="i5249879d603e40dda99305a59b74abf8" continuedAt="i24e92ee6ef5c4d35a79a008c69d2160a"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTkzNjM_2c797caa-af66-4475-b0ff-d21d2a1512b4">7.3</ix:nonFraction>&#160;billion in cash and $<ix:nonFraction unitRef="usd" contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTkzODA_df8ca3ee-3e87-4b4b-af0e-a098e53b410f">0.4</ix:nonFraction>&#160;billion of liabilities assumed during fiscal year 2020. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="i64316c7eddcf4074a9e3ee4d29f82ef0_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzk4OTU2MDQ2NzkyMzM_c3f42a42-b0fd-4117-8391-f6cce635ecca">7.5</ix:nonFraction>&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant  robotics and data science capabilities.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8731480903f6482bafd102f3dcab3c69_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTkzOTQ_2b8af96b-fbcb-4fbc-89a7-00405171135e">0.8</ix:nonFraction>&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="i87db8efd958244a086dfb46539fdfb06_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0MTM_a0827778-ed68-4692-9e51-e7cbcab4ae2f">0.8</ix:nonFraction>&#160;billion applying a probability of success factor that ranged from <ix:nonFraction unitRef="number" contextRef="ibb66e5604cfd4dbfbc2df6782a9418d5_I20200329" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODc0NTQ_441d39be-0b46-4b7b-87f5-a21dfe9e4836">20</ix:nonFraction>% to  <ix:nonFraction unitRef="number" contextRef="i9bf0b675d1ee4f0cad2d1afbe56a8367_I20200329" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0MDg_44f377de-9a97-4cb9-ab0c-8527ae2e58c2">60</ix:nonFraction>% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="i87db8efd958244a086dfb46539fdfb06_I20200329" decimals="2" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0Mjc_8ce40778-3294-4b19-94fa-66d8590a088e">16</ix:nonFraction>%.  XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0MzI_6f0ed15e-21a2-4e0d-b3ea-09ba62d19cfd">0.4</ix:nonFraction>&#160;billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0NDY_b3ec9682-6bfd-4e67-b68f-904f73f41d3e">0.2</ix:nonFraction>&#160;billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0NjA_6833f2dd-18e7-40c0-83bc-70e9f2bbc33d">0.2</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0NzQ_5450be35-a360-4bc3-b729-5a31901eb64e">0.3</ix:nonFraction>&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $<ix:nonFraction unitRef="usd" contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0OTA_e0135013-04ed-472c-9bf8-80607c170f3d">0.4</ix:nonFraction>&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i89223357c4f64e06b825e78a40cb5914_D20201001-20201001" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4NjA2OTY_950eb325-621a-4c66-a586-22bc157c8a2f">6.1</ix:nonFraction>&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;D) of $<ix:nonFraction unitRef="usd" contextRef="i293ef2d918614098b4af9e84d27cc0ff_I20201001" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNjI1NTk_cf1f662f-7785-4f0c-a423-4fd8db4e0e38">6.0</ix:nonFraction>&#160;billion, goodwill of $<ix:nonFraction unitRef="usd" contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk1Njg_6ffb7dd2-1b69-4a2d-befa-22c84c6b2059">1.2</ix:nonFraction>&#160;billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODk5MTc_1c7f580e-2e9d-4a8b-9e92-78b0b1b31e3a">0.5</ix:nonFraction>&#160;billion and liabilities of $<ix:nonFraction unitRef="usd" contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk1ODI_3d52fc4c-dd88-4070-b5d5-76621ef8ccf3">1.6</ix:nonFraction>&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from <ix:nonFraction unitRef="number" contextRef="iad9394419046465abc7a8a563ce9e079_I20201001" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk1OTY_0e68daae-8ec1-4a63-90c2-f4d0f8f47daf">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i60b1b3c5341149fca7bbc49f7508a82f_I20201001" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk2MDE_5c2effc4-2d6d-4735-918f-246e0d4f6412">77</ix:nonFraction>% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001" decimals="2" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk2MDY_19e6578a-a6e1-4523-81ee-00b8adb796bb">13</ix:nonFraction>%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i24e92ee6ef5c4d35a79a008c69d2160a" continuedAt="i0a9f3530fd584f1ab57b65b2f5d32d7b"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019 certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzcz_e1a30799-610d-4239-9cc4-a5aaa71f241e">5.8</ix:nonFraction> billion in cash and $<ix:nonFraction unitRef="usd" contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzg4_fe93dd36-5edb-433c-9828-ca3a399ec8e4">1.4</ix:nonFraction> billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="i9554efac170a48719f2fd4fef3bcbdbc_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4NTQ4OTI_088278dc-0cfc-4150-9c14-3bc83669bb18">6.8</ix:nonFraction>&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="i7466a929aa8c4da48b0b5cb2da5733b3_D20190117-20190117" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE0ODE_ad6ac70d-4f9b-4c35-af4b-7574cabb797a">230</ix:nonFraction> billion, which equates to approximately $<ix:nonFraction unitRef="usd" contextRef="i7466a929aa8c4da48b0b5cb2da5733b3_D20190117-20190117" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE1MTY_df80b8cf-aa27-4d68-9662-5b2f6c5db507">2.1</ix:nonFraction> billion, using the exchange rate of <ix:nonFraction unitRef="number" contextRef="i663d1a94c8284c94915423956a325ff7_I20190116" decimals="2" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE1NDc_59fb40e1-b57f-4fe6-a234-cfe9f1b60628">109.06</ix:nonFraction> Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="i7648739eff244460aefb5458b95e548d_D20181231-20190331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzIxOTU_c4e46fd0-9122-4845-b4d8-f42bbb986a89">0.3</ix:nonFraction> billion related to the Company's previously held equity investment in DR. CI:LABO. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treated this transaction as a business combination and included it in the Consumer Health segment.  During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $<ix:nonFraction unitRef="usd" contextRef="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzI2NjM_064d2695-2f01-4c8d-aa71-b3d44e43a57a">1.5</ix:nonFraction> billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzI2ODA_c7bcea9a-814a-4500-8752-a8e118df4cdc">1.2</ix:nonFraction> billion and liabilities of $<ix:nonFraction unitRef="usd" contextRef="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzI3MDI_311fa9e4-6d00-4b05-8089-e71179ddb3d6">0.4</ix:nonFraction> billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of <ix:nonNumeric contextRef="i7ac7036ab4264656876135eb9e269635_D20191230-20210103" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzMxMDI_041b0c4b-4170-49c2-ba99-4f6d0f177298">15.3</ix:nonNumeric> years The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 1, 2019 the Company&#160;completed the acquisition of Auris Health, Inc. for approximately $<ix:nonFraction unitRef="usd" contextRef="i1106f749feaf4b4cb34daeb9bbc0f5ac_D20190401-20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzMzNTU_2135c9bc-46cf-4c1e-95a0-1962ce23a322">3.4</ix:nonFraction> billion, net of cash acquired. Additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM0MjE_c9cf9b5e-3476-4d76-8f61-2bd760da35a0">2.35</ix:nonFraction> billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&amp;D for $<ix:nonFraction unitRef="usd" contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM5NTI_6af175ae-7873-4322-abfa-e01ac56f5a07">3.0</ix:nonFraction> billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM5Njk_261d9c65-8926-4d24-a59c-588827cd0da2">2.0</ix:nonFraction> billion, marketable securities of $<ix:nonFraction unitRef="usd" contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM5OTg_a9025c6a-a056-42ac-9788-bfd6efe93ab0">0.2</ix:nonFraction> billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQwMjg_ef3d175e-a643-47a9-bba9-0b6e954691b9">1.8</ix:nonFraction> billion, which includes the fair value of the contingent payments mentioned above. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $<ix:nonFraction unitRef="usd" contextRef="i1b2666b42496425cb2f87473681fa480_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODU2MzE_075bd650-c286-4156-b55f-749356fa9968">1.1</ix:nonFraction>&#160;billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company&#8217;s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i0d2155f5644e4dce929f352545f25b9f_D20200629-20200927" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODcxMTk_7bd062b6-420c-44a7-886c-6f85b3017875">0.1</ix:nonFraction>&#160;billion related to timing and progression of the digital surgery platforms. A probability of success factor ranging from <ix:nonFraction unitRef="number" contextRef="i64e9ef76a8044ece8caf57dbe8808101_I20190401" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQzNDY_4a9357e8-2050-47f4-9d18-d360481bf64d">55</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibbc2347889084c24a2bdc712e0cc9afe_I20190401" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQzNTI_97e91199-a716-4da5-8624-49c733575626">95</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401" decimals="1" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQ1Mjc_23c03cfb-2479-4950-be4d-8ba7e6b426fa">10</ix:nonFraction>%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2018 certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzU0Njk_249d69e6-0ac1-45db-a7e4-17d4593d910f">0.9</ix:nonFraction> billion in cash and $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzU0ODQ_1a194ef0-2a36-441a-9922-3b20adccd686">0.1</ix:nonFraction> billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="if510052c46844b89bee55dd2cfd123f1_I20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzY0MTg_f194e56a-b3ac-4ea4-b373-dd8fdf153f62">1.0</ix:nonFraction> billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2020, 2019 and 2018 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to fiscal 2020, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment and received combined proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i247bfdef30e445f58022d1b433046fee_D20210131-20210131" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTg1OTM_0dd565fb-9451-48d9-b209-297dcbe77e7e">0.6</ix:nonFraction>&#160;billion. The Company will reflect these brand divestitures in its 2021 financial results.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTI0Nzg_ffd74aae-6a4e-4fef-a5cd-236d68425149">11.8</ix:nonFraction>&#160;million shares of Idorsia LTD (Idorsia), or its <ix:nonFraction unitRef="number" contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTI0OTI_b9cff3ba-c124-4043-bf7d-884eab55e493">8.3</ix:nonFraction>% ownership in the company. The transaction resulted in gross proceeds of approximately CHF <ix:nonFraction unitRef="chf" contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTI0OTg_219b3390-d999-4815-b3f1-90ec10340513">337</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMjkw_5cb347c5-ce4c-4608-8f01-460f32c51738">357</ix:nonFraction>&#160;million) based on a sales price of CHF <ix:nonFraction unitRef="usdPerShare" contextRef="i59587efcd1fc4831b82133e2feac03fa_I20210103" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzA0_b046c36d-17a1-42a2-ae0e-5fd366781899">28.55</ix:nonFraction>/share and an immaterial net loss. The Company currently has rights to at least an additional <ix:nonFraction unitRef="shares" contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103" decimals="-5" format="ixt:numdotdecimal" name="jnj:ConvertibleNoteEquityInterestNumberOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzEx_aef80863-e9db-4ea2-a1bc-5c3c65384b29">38.7</ix:nonFraction>&#160;million shares (or approximately <ix:nonFraction unitRef="number" contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103" decimals="1" name="jnj:ConvertibleNoteEquityInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzI1_bd0df540-e831-43d7-be26-d0a2deb60fe4">20</ix:nonFraction>% of Idorsia equity) through a convertible loan with a principal amount of CHF <ix:nonFraction unitRef="chf" contextRef="ifb3df5df054d4ba598290335491d4bf2_I20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzMw_63748b55-92c4-433b-90b3-100c9944377a">445</ix:nonFraction>&#160;million (due June 2027). Idorsia also has access to an approximate CHF <ix:nonFraction unitRef="chf" contextRef="i59587efcd1fc4831b82133e2feac03fa_I20210103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzQz_3b289394-a804-4c8b-9c75-47419d8604be">243</ix:nonFraction>&#160;million credit facility with the Company. As of January 3, 2021, Idorsia has not made any draw-downs under the credit facility. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2MDQ3_6d86dc40-c662-4e50-acb1-7339416a4cb7">2.8</ix:nonFraction> billion, consisting of $<ix:nonFraction unitRef="usd" contextRef="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCash" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2MDY1_841599ce-a3f0-46ab-9068-13c110c66e72">2.7</ix:nonFraction> billion of cash proceeds and $<ix:nonFraction unitRef="usd" contextRef="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229" decimals="-8" format="ixt:numdotdecimal" name="jnj:DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2MDg5_8945022c-a733-40af-b294-d4730c849cec">0.1</ix:nonFraction> billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="i9660ad42e8a84744909a1e88ade1ded0_D20181231-20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2Mzg0_4f65561b-de5f-442a-9288-6d07870a4c2a">2.0</ix:nonFraction> billion. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a9f3530fd584f1ab57b65b2f5d32d7b"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2018, the Company divested the LifeScan Inc business for approximately $<ix:nonFraction unitRef="usd" contextRef="ib62a0d3a2f984c819f0cd7b260d86045_I20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2NDY3_74311162-ff7e-4c40-8c6f-356499311cd3">2.1</ix:nonFraction> billion and retained certain net liabilities. Other divestitures in fiscal year 2018 included: NIZORAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RoC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain non-strategic Pharmaceutical products. In 2018, the pre-tax gains on the divestitures were approximately $<ix:nonFraction unitRef="usd" contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2Njc3_e10b0bb0-a102-4296-ba37-0c1f7f30194f">1.2</ix:nonFraction> billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world&#8217;s leading manufacturing services providers for health care products and technology products.&#160;The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of employees and manufacturing sites. The transfers were completed in fiscal year 2020.&#160;As of January 3, 2021, there were no assets held for sale on the Consolidated Balance Sheet. As of December 29, 2019, the assets held for sale on the Consolidated Balance Sheet were $<ix:nonFraction unitRef="usd" contextRef="i6010a5c09da44a07ab46d7f9c737f126_I20191229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE3Mjk5_9abaf1b5-e111-4ed1-8ae5-477d3021d389">0.1</ix:nonFraction> billion of inventory and property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 20 to the Consolidated Financial Statements.</span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i26b7b3066a4848f5be790a5478bde067_217"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzEwNDQ1MzYwODkxNjUy_2fbcc4b3-089f-4e6b-8fb5-135b0dd7836f" continuedAt="i0ce1c1aae83746febd59bee9b3dd6dcb" escape="true">Legal Proceedings</ix:nonNumeric></span></div><ix:continuation id="i0ce1c1aae83746febd59bee9b3dd6dcb" continuedAt="i33507c21cd334957ad7cc7a4e4751438"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January&#160;3, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh. As of January&#160;3, 2021, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="i41be97a9ae2043408fba6895a0bca20a_I20210103" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQyNjI_724f8f3b-d357-44e3-97e6-e8389667e51c">560</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i33507c21cd334957ad7cc7a4e4751438" continuedAt="ib2226389becc4a5dbfc369bc7fa39e23"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="iff7c87d97d384ee8b13f6b2bb84ea65c_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ0MjY_aaa7d932-92f0-4eca-a191-dc0a4d9eb73c">7,800</ix:nonFraction> with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="if9ba6a98f87b46e1aafbd453b6cbee6c_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ0ODI_a5ed6dee-ecc5-4242-bf93-138c01271663">14,900</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="id60518cf26184f7a82d1ae1e544e152f_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ1MTY_c3ee7f57-5faa-4394-ab8a-d76886bd9bf4">9,300</ix:nonFraction> with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; <ix:nonFraction unitRef="claimant" contextRef="i29ae50e5d88b4f2faf456858615a5efb_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ1NDc_8724b2cf-65c7-4f23-bed4-e73eb6abda1a">12,600</ix:nonFraction> with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; <ix:nonFraction unitRef="claimant" contextRef="i819517bf3729470f83f19c033eb4aeff_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ1NzY_f2d1f411-24c3-46f2-b38a-05cee71b7ba0">25,000</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="ib8a1e028ec54452c8c607218170270d2_I20210103" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ2MjU_7ee88a68-2416-463a-8157-6d3b3f891016">300</ix:nonFraction> with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and <ix:nonFraction unitRef="claimant" contextRef="i967a3fc676f546c3a8ec55596e5787c8_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ2NjA_5111146b-bb8a-49eb-b179-f5c8561360ce">4,200</ix:nonFraction> with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Flexible Composite Mesh.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="patient" contextRef="i4c869ba4eacc4ad3a8ea220ccc8ce54d_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:Numberofpatientsinsettlement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkwMjY2NTY_aed7ae5a-ecc5-46ec-bb94-3ce1e5be4b16">10,000</ix:nonFraction>  claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices.  In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. The Company is appealing the decision. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss.  The form of the individual case assessment process has not yet been determined by the Court. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160; Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib2226389becc4a5dbfc369bc7fa39e23" continuedAt="i4666fe4b38324663b5ace082baa1e71f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Ventral Patch hernia mesh products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In September 2019, plaintiffs&#8217; attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE&#8482; Polypropylene Hernia System (&#8220;PHS&#8221;) cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. Discovery is underway in these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i164e958688a24886ab9f0f49cc22f175_D20191001-20191031" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkwMjY2ODA_6d22fc9c-e8a7-46fe-b9cc-5e02390222f1">8.0</ix:nonFraction>&#160;billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $<ix:nonFraction unitRef="usd" contextRef="i23d356a726004e2aaf26a0f9b26a887a_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkwMjY3MDc_bdf81112-17fe-4aca-84b6-d5a4b286f6f9">6.8</ix:nonFraction>&#160;million by the trial judge. The Company and plaintiff are each appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson (J&amp;J); and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&amp;J announced an agreement in principle to the settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Personal injury claims alleging that talc causes cancer have been made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied  plaintiffs&#8217; attempt to limit the scope of testimony of certain of the Company&#8217;s witnesses. With this ruling made, case-specific discovery has begun per the Court&#8217;s directive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In talc cases that have previously gone to trial, the Company has obtained defense verdicts in a number of them, but there have also been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018  verdict of $<ix:nonFraction unitRef="usd" contextRef="i5afa073421a4484a853139dff12ed57e_D20180701-20180731" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MjYyODk_d5214248-1df1-4526-a010-38aecc2edb1b">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="i6c1602e34a30408c9b6b1eb1cf04b157_D20200601-20200628" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MjYzMDM_f1176bee-615b-4a4a-bc69-a53379b2817a">2.1</ix:nonFraction>&#160;billion and, with additional interest as of January 3, 2021, as the Company pursues further appeal, is currently $<ix:nonFraction unitRef="usd" contextRef="ib585935f9ab54509bc2c182dc59b672f_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkxOTMwMDE_4d3e416a-6aea-4519-9c1a-32d514d1ffb9">2.5</ix:nonFraction>&#160;billion (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and the Company is currently seeking review by the United States Supreme Court. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision currently on appeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in connection with product liability litigation associated with body powders containing talc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4666fe4b38324663b5ace082baa1e71f" continuedAt="i6c32b32b61e844818bc187a3f8690e3f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217; potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company&#8217;s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company&#8217;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants&#8217; committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus) filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements.  The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus&#8217;s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates allowing Debtors to proceed with soliciting votes on the Plan. The Company intends to continue to object to the Plan. A hearing to consider confirmation of the Plan has been scheduled for June 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S&#174; Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. Discovery is underway.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete</span><span style="color:#d13438;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">A lawsuit pending in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Baby Powder has been resolved in the Company&#8217;s favor. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i6c32b32b61e844818bc187a3f8690e3f" continuedAt="ic92a4503ae1e4ae9b44281d9fe198a77"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing has been scheduled for April 2021. Limited informal discovery is continuing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission (SEC) and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries. In November 2020, the SEC terminated its investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, the federal cases, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy).  MedIdea alleged infringement of United States Patent Nos. 6,558,426 (&#8217;426); 8,273,132 (&#8217;132); 8,721,730 (&#8217;730)  and 9,492,280 (&#8217;280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contact feature of the ATTUNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. In November 2019, judgment was entered in favor of DePuy. In January 2021, the U.S. Court of Appeals for the Federal Circuit affirmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ic92a4503ae1e4ae9b44281d9fe198a77" continuedAt="ie6ab9be6dba84f89853ee772c876cf81"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antibacterial Sutures and STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plus Antibacterial Sutures infringe plaintiffs&#8217; United States Patent Nos. 6,596,296 (&#8217;296) and 7,033,603 (&#8217;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT is seeking damages and an injunction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the USPTO denied institution of the &#8217;296 patent IPR and granted institution of the &#8217;603 patent IPR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT dismissed the &#8217;603 patent from the suit and no longer accuses PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures or STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform.  Auris filed IPR Petitions with the USPTO regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit.  In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent.  In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intuitive has appealed that decision.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The district court trial is scheduled to begin in June 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Evolution System.  RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2020, the case was stayed pending IPR proceedings filed by the Consolidated Defendants involving the asserted patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial is scheduled for October 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits pending against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie6ab9be6dba84f89853ee772c876cf81" continuedAt="i35d373ef53434d6691813a7590ee6e6c"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen)  initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex&#8217;s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of Canadian Patent No. 2,661,422 (&#8217;422). The final hearing concluded in May 2019.  In October 2019, the Court issued an order prohibiting the Canadian Minister of Health from approving Apotex&#8217;s ANDS until the expiration of the &#8217;422 patent. In November 2019, Apotex filed an appeal.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2019, Janssen initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex, Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent. The final hearing in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, Janssen initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (Jamp) in Canada in response to Jamp&#8217;s filing of an ANDS seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> before the expiration of the &#8217;422 patent. The final hearing is scheduled to begin in May 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Intellectual Property GmbH and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd. (collectively, DRL) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of U.S. Patent No.  9,539,218 (&#8217;218). In this lawsuit, JPI and Bayer were seeking an order enjoining DRL from marketing their generic versions of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. In November 2020, JPI and Bayer entered into a confidential settlement agreement with DRL, and the case was voluntarily dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include  MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus); Sandoz, Inc. (Sandoz); and Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin). These cases were consolidated into one action (Polymorph Main Action), which has been scheduled for trial starting in April 2021. In December 2020, Janssen and MTPC entered into a confidential settlement with Sandoz and in January 2021, Janssen and MTPC entered into a confidential settlement with Lupin. The cases against Sandoz and Lupin were voluntarily dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and IVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788), 8,222,219 (&#8217;219) and/or 8,785,403 (&#8217;403) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> XR (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent.  In </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i35d373ef53434d6691813a7590ee6e6c" continuedAt="iea0dd423f305473bad5bfc138e5e4350"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of United States Patent No. 10,617,668 relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These lawsuits have not been consolidated with the Main Actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,534,024 and 2,671,357. The final hearing is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n October 2020, Actelion Pharmaceuticals Ltd (Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Laurus Labs Limited and PharmaQ, Inc. (collectively, Laurus), which filed an ANDA seeking approval to market generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of U.S. Patent No. 7,094,781 (&#8217;781). Actelion was seeking an order enjoining Laurus from marketing generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;781 patent. In January 2021, Actelion entered into a settlement agreement with Laurus. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is scheduled to begin in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906).  Trial concluded in October 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the &#8217;906 patent. The USPTO denied the Petition in September 2020, and Mylan appealed.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iea0dd423f305473bad5bfc138e5e4350" continuedAt="i99f8e31aa26242daaeb1d13ee4c7d265"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada)  in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent.  In  May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Final Hearing is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. The Final Hearing is scheduled to begin in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> 140 mg capsules before expiration of Pharmacyclics&#8217;  United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Cipla Limited and Cipla USA Inc. (collectively, Cipla); Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2019, Pharmacyclics and JBI amended their complaint against Sandoz to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, Pharmacyclics and JBI amended their complaint against Cipla to allege infringement of United States Patent Nos. 10,106,548, and 10,125,140.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, Pharmacyclics and JBI amended their complaint against Cipla to further allege infringement of United States Patent No. 10,016,435. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Pharmacyclics and JBI amended their complaints against Cipla and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232. In August 2019, the Court granted a joint stipulation to stay the litigation against Cipla.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial in the actions against Sandoz and Alvogen took place in October 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i99f8e31aa26242daaeb1d13ee4c7d265" continuedAt="i83c67b657d9f4282a20d8e298a94bf03"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2019, Sandoz filed an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IPR Petition with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the USPTO, seeking to invalidate United States Patent No. 9,795,604.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the USPTO issued a final decision in the IPR invalidating certain claims of the &#8217;604 patent and upholding the validity of certain claims in the &#8217;604 patent. The final decision was not appealed by the parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen and Sandoz asserting infringement of United States Patent No. 10,478,439.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent No. 10,463,668. In October 2020, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent Nos. 10,752,634 and 10,695,350 and amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,653,696. In December 2020 the Court entered a joint stipulation dismissing the complaint against Sandoz. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus Worldwide DMCC and Cadila Healthcare Limited (collectively, Zydus), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,008,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,386 and 10,478,439.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trials in the actions against Alvogen and Zydus are scheduled to begin in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion is the exclusive licensee of the asserted patents. The defendants include Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic); MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (collectively, MSN); ); VGYAAN Pharmaceuticals LLC (VGYAAN); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus). In January 2021, the Court entered joint stipulations dismissing VGYAAN and MSN from suit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of United States Patent No. 10,143,693 relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patent.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i83c67b657d9f4282a20d8e298a94bf03" continuedAt="ic660b816b24946adb5f73c57f9e25ede"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial.  In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than <ix:nonFraction unitRef="claimant" contextRef="ic3622ddfe4f643408286c1811a8e2b4d_I20210103" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2Mjg3NzI_40ec8a90-23c5-4f9f-b96b-8342e714d502">3,100</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical companies, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina; Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 370 cases pending in various state&#160;courts. There are over 2,800 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804).&#160;In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib66ffb4e00ec4bfd99ace0da88568cd0_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2Mjg3OTI_c51be88e-8e1f-4c21-a5d0-2c7239767b14">572</ix:nonFraction>&#160;million, subject to a final order to be issued by the Court.&#160;The Court issued a final judgment reducing the amount to $<ix:nonFraction unitRef="usd" contextRef="i9e799e62cf254001826c3bf820d212b7_D20191230-20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2Mjg4MTk_bb4b4c8b-6b89-43a6-89fb-7a5601b6d08c">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="i8db67b67955942f7a04d431f570d4565_I20191031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI3NDQ_a9653318-af31-4fd5-90aa-4e73749c915f">4</ix:nonFraction>&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="i9d76339e798d40b08ed4feec1c3cae2d_I20201031" decimals="-9" format="ixt:numdotdecimal" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI3Njc_7d0c26a6-a335-4451-bc28-32db3cda4cb7">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $<ix:nonFraction unitRef="usd" contextRef="i9d76339e798d40b08ed4feec1c3cae2d_I20201031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI3OTA_d179de57-ce0d-45fa-944e-1432c3ed29e5">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed and future claims by states, cities and counties. The Company cannot predict if or when the agreement will be finalized and individual cases are ongoing. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic660b816b24946adb5f73c57f9e25ede" continuedAt="i1cb27c384a4a4022aa21f6fb7fa3fcd2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint, and as of December 2020, that motion was fully briefed. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the shareholders in the consolidated action filed a motion for voluntary dismissal.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> case filed pursuant to the False Claims Act against the companies. In February 2016, the district court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the district court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. The relators&#8217; remaining claims are now pending before the district court. In July 2020, the Court ordered the relators to complete discovery by August 2020; the Relators have requested an extension of the August 2020 deadline that DePuy opposed and additional discovery-related motions have been filed by both parties. Additionally, DePuy has requested a schedule for the filing of a motion to strike and to dismiss the relators&#8217; second amended complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="i58f5234f04df45daa5a30c1a7134b2bc_D20200120-20200120" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI4Mjc_7cb8b06a-6c32-4bc8-b017-4fbfcbf4369d">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="i58f5234f04df45daa5a30c1a7134b2bc_D20200120-20200120" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI4NTQ_2074600f-c53c-4213-affe-25b4ee99eda8">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">penalty judgment. In April 2020, the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1cb27c384a4a4022aa21f6fb7fa3fcd2" continuedAt="ib3d89073d369459c9853dd53ea6cb688"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company settled the West Virginia. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2012, Therakos, Inc. (Therakos), formerly a subsidiary of Johnson &amp; Johnson and part of the Ortho-Clinical Diagnostics, Inc. (OCD) franchise, received a letter from the civil division of the United States Attorney's Office for the Eastern District of Pennsylvania informing Therakos that the United States Attorney's Office was investigating the sales and marketing of Uvadex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (methoxsalen) and the Uvar Xts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Cellex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Systems during the period 2000 to the present. The United States Attorney's Office requested that OCD and Johnson &amp; Johnson preserve documents that could relate to the investigation. Therakos was subsequently acquired by an affiliate of Gores Capital Partners III, L.P. in January 2013, and OCD was divested in June 2014. Following the divestiture of OCD, Johnson &amp; Johnson retained OCD&#8217;s portion of any liability resulting from the investigation for activity that occurred prior to the sale of Therakos. Following production of documents to and settlement discussions with the U.S. Attorney&#8217;s Office, J&amp;J affiliate Medical Device Business Services, Inc. agreed to resolve claims under the federal False Claims Act and analogous state laws in a settlement announced in November  2020. In the settlement agreement, Medical Device Business Services expressly denied any wrongful conduct. As a result of the settlement, a qui tam complaint filed by two relators pending in the U.S. District Court for the Eastern District of Pennsylvania will be dismissed. Separate settlement agreements with the states participating in the settlement are in the process of being finalized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder and JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson &amp; Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted J&amp;J and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing is complete and oral argument was held in February 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-one states have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Several states have issued Civil Investigative Demands seeking documents and other information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160; In February 2021, the Court stayed the case and ordered mediation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the Unites States Department of Justice notified Janssen Biotech, Inc. that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib3d89073d369459c9853dd53ea6cb688" continuedAt="id200f4125e0944dd8fd44eb62afa85cd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy Synthes, Inc. have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. We continue to actively respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baby Powder.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The complaint seeks damages but does not allege personal injury.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, JJCI moved to dismiss the complaint.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) in connection with its importation into the United States. In August 2020, US CBP formally rejected Janssen&#8217;s Supplemental Petition challenging the penalties assessment and demanded payment of the mitigated penalty.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, US CBP agreed to not refer the matter to the Office of Chief Counsel at this time, pending resolution of the related Classification Litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2013, Janssen Ortho sued the United States in the United States Court of International Trade (the Classification Litigation) seeking a determination that darunavir ethanolate is exempt from duties upon importation into the United States. In February 2020, the Court ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States appealed to the United States Court of Appeals for the Federal Circuit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, Genmab A/S brought an arbitration against Janssen Biotech, Inc. pursuant to a 2012 License Agreement between the parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The arbitration relates to royalties for certain Janssen daratumumab products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice is complete. No trial date has been set.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research &amp; Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages. In November 2020, Defendants moved to dismiss the complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania.  Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks damages and injunctive relief. Discovery is ongoing. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id200f4125e0944dd8fd44eb62afa85cd" continuedAt="ida23aea8283b4ad0a631fe2eeb1d2098"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE&#174; against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co, filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#8217;s decision to the United States Court of Appeals for the District of Columbia Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals US, Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160; The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. Plaintiffs have appealed the decision to the United States Court of Appeals for the Fourth Circuit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Several additional complaints were filed thereafter in Virginia and New Jersey.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case for pretrial purposes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to delay generic entry, and seek damages and injunctive relief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California.  The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ida23aea8283b4ad0a631fe2eeb1d2098"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">development and marketing of combination antiretroviral therapies (cART) to treat HIV.  The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California.  The complaint alleges that certain of BWI&#8217;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;J, Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter Zantac (ranitidine) products. Plaintiffs in the underlying actions allege that Zantac and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_220"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzI1NjM_9fb689da-0c6e-4c6e-83cb-185cd2236436" continuedAt="i5bbde27a38de4bc581ffff15b7f81df0" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i5bbde27a38de4bc581ffff15b7f81df0" continuedAt="i2a10c17ebfe540509d66c16ca8f2c425"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the Global Supply Chain restructuring strategic collaborations see Note 18 to the Consolidated Financial Statements. In fiscal year 2020, the Company recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzc1MA_d0714023-ec4c-42f5-9b82-7480dac65cf7">0.4</ix:nonFraction> billion, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i24d9eecdd6ae4f3982b1ec0858319020_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzgzOA_80dde6e6-f57b-4e1a-a8b8-e1576bb69d82">0.2</ix:nonFraction> billion in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i85fbe5d13d1a4ca09991c8182c6da15a_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzg1OQ_fa591160-8c45-4e42-a037-6c7cd7600712">0.1</ix:nonFraction> billion in other (income) expense and $<ix:nonFraction unitRef="usd" contextRef="i9e552d1e71b44a168a599c7ac19462c1_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzg5Mg_d67bf5cf-4008-4ac3-8d75-2c14e60b2775">0.1</ix:nonFraction> billion in cost of products sold. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ic6a8b086cd8c45da82107e88550189d0_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzk1OA_14b756f4-0755-43be-811c-19a9bea0c7bc">1.3</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="if57129aa1e5d4dd0b0777a7d8ed0c1ee_I20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzExODU_1d23994c-78de-4936-ab85-6b8512cb6e11">0.6</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i8f3db082046d4ae0b5256a896c8b18a9_I20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzExOTE_723c3919-eebf-4257-8eba-33ce528d0e4a">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="if57129aa1e5d4dd0b0777a7d8ed0c1ee_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNDg_db435a2a-7acd-4c45-a041-2f54651b2e67">1.9</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i8f3db082046d4ae0b5256a896c8b18a9_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNTQ_a131aa2d-133f-454e-92ea-f143377a5d8d">2.3</ix:nonFraction> billion, over the <ix:nonNumeric contextRef="i66486cf0443e494881f3ec5e470b3cf6_D20191230-20210103" format="ixt-sec:duryear" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNjc_47109fa4-d82e-43ef-8c70-5d8c28b22032">4</ix:nonNumeric> to <ix:nonNumeric contextRef="iec0388b7a5cc4f76940dc1229b081637_D20191230-20210103" format="ixt-sec:duryear" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNzM_51f85a80-6dd0-463c-a931-81b2d77300b2">5</ix:nonNumeric> year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzI1NjY_4b1901fb-facc-4523-8e1e-4ace996992ae" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;30, 2018</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfa403febc6441b9219104ff7cd304a_I20181230" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTEtMS0xLTA_9b6cb737-8957-43ac-9dcf-434ccc092475">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f8b2a1ad4d49c49598e20c0474fab0_I20181230" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTItMS0xLTA_ed65c75e-772f-4e92-81d9-0d84ed660d30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94268397a144c34b6f7724fc2cdb014_I20181230" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTMtMS0xLTA_d44bb0aa-c1a8-4930-9fe9-04fa1d589709">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2c59fc0efa48c49cd68b3b84b0c5f0_I20181230" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTUtMS0xLTA_8aefa40f-6570-4e9a-96c1-12000080214c">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i459a0dc9569c4a9aab6a75035673c567_D20181231-20191229" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTEtMS0xLTA_af8fc59b-9f43-423c-9571-07bf3f61cb6b">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c7279bfa824e409e9b9a1bca808c58_D20181231-20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTItMS0xLTA_28c951aa-94c1-4626-95a8-acbde0a3dfe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac916c18208c47b09c67460db8030f1d_D20181231-20191229" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTMtMS0xLTA_63135601-b827-4efc-bec1-30d8f91c866e">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ca0b385d9944272b5ded6645bb7a626_D20181231-20191229" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTUtMS0xLTA_48933db3-9b86-4def-936f-12ceb43c73b4">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;29, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510e7e5ac227414a98e421f182a041c0_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTEtMS0xLTA_4a2174e6-35db-41bf-ad05-17b67b519e00">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5dcc642308e468f9618c6b56e3244fa_I20191229" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTItMS0xLTA_397b18b6-3e8c-4ff3-af7d-c7b213ab8f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8af39bf4fc4285b5f5f5676ae6623a_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTMtMS0xLTA_e31a73b4-cead-4939-bff2-4d9ceb19c2ce">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e8b0d8063934ca2b90208c4804102c2_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTUtMS0xLTA_c9e04316-4b8a-4876-a3fe-ccf90e24432d">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTEtMS0xLTA_90d4882b-0d88-4c9f-8c2f-2ae8a781080b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTItMS0xLTA_d8f7cb71-d6c2-428b-876d-2e713930096e">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7895941dcd4d76b03e835972649586_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTMtMS0xLTA_b54e0a17-fb77-4485-a952-5d940423b4bc">405</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTUtMS0xLTA_48758ce2-a94c-49ee-a477-b359f28b4adf">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103" decimals="-6" sign="-" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTEtMS0xLTA_93ea67f1-d003-42f2-aadd-9d418d87ece4">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTItMS0xLTA_72217ea7-8aa6-4bdc-b2d9-4982cc11d72b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c7895941dcd4d76b03e835972649586_D20191230-20210103" decimals="-6" sign="-" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTMtMS0xLTA_63af8494-36f7-4085-afee-7f64eaa35545">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103" decimals="-6" sign="-" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTUtMS0xLTA_9639f7b5-251a-4f27-82d4-11817ee86141">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTEtMS0xLTA_bd7005e9-4354-4d5e-b389-4a4b66d6aa79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTItMS0xLTA_68942c13-c30b-478c-af19-2f7ce554a0cd">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c7895941dcd4d76b03e835972649586_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTMtMS0xLTA_f08796fc-f32f-436a-8a9b-3767e8d9c862">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTUtMS0xLTA_86d0a11c-ab5b-49c9-aa56-806b12d880f3">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98eded4ee3746d6af8c7edc2e830f5b_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTEtMS0xLTA_79f72ca9-3798-46c1-8fae-85aa5f4aab78">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b6a6cceab84226b776a371d5bbe868_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTItMS0xLTA_7cb12550-d654-46f8-8164-9cb2d04dbece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98674305aeea4bbab7dbaabd6920816d_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTMtMS0xLTA_a5a60d3a-c223-470d-8410-81d141e76a70">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8bafe3cd14d5c9e1491d8bbf1f32f_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTUtMS0xLTA_63cf717c-3b47-4453-b224-3a5e553494a1">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Cash outlays for severance are expected to be substantially paid out over the next <ix:nonNumeric contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103" format="ixt-sec:duryear" name="jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzE3NTQ_a07d548d-3a9a-49ce-9e53-e487162fd5ad">2</ix:nonNumeric> years in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents gain on sale of an asset</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a10c17ebfe540509d66c16ca8f2c425">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Board of Directors and Shareholders of Johnson &amp; Johnson</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Johnson &amp; Johnson and its subsidiaries (the &#8220;Company&#8221;) as of January 3, 2021 and December 29, 2019, and the related consolidated statements of earnings, of comprehensive income, of equity and of cash flows for each of the three fiscal years in the period ended January 3, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of January 3, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control - Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 3, 2021 and December 29, 2019, and the results of its operations and its cash flows for each of the three fiscal years in the period ended January 3, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 3, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control - Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2013) issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis for Opinions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Pharmaceutical Rebate Reserves &#8211; Managed Care, Medicare and Medicaid</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As described in Note 1 to the consolidated financial statements, the Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied. Rebates and discounts provided to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability for such rebates and discounts is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. A significant portion of the liability related to rebates is from the sale of pharmaceutical goods within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion as of January 3, 2021. For significant rebate programs, which include the U.S. Managed Care, Medicare and Medicaid rebate programs, rebates and discounts estimated by management are based on contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal considerations for our determination that performing procedures relating to U.S. pharmaceutical rebate reserves - Managed Care, Medicare and Medicaid is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing these reserves and the high degree of auditor judgment, subjectivity and audit effort in performing procedures and evaluating the assumptions related to contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. pharmaceutical rebate reserves - Managed Care, Medicare and Medicaid, including controls over the assumptions used to estimate these rebates. These procedures also included, among others, (i) developing an independent estimate of the rebates by utilizing third party information on price and market conditions in the U.S. pharmaceutical market, the terms of the specific rebate programs, and the historical experience and trend analysis of actual rebate claims paid; (ii) testing rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Company&#8217;s rebate arrangements; and (iii) comparing the independent estimates to management&#8217;s estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Litigation Contingencies &#8211; Talc</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including talc, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. There have been verdicts against the Company for this matter, including a verdict in July 2018 of $4.7 billion, which was reversed in part and affirmed in part by the Missouri Court of Appeals in June 2020, reducing the overall award to $2.1 billion and, with additional interest as of January 3, 2021, as the Company pursues further appeal, is currently $2.5 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and the Company is currently seeking review by the United States Supreme Court. As described by management, the Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other verdicts it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for settlement of certain cases and claims, as well as one case currently on appeal, in connection with product liability litigation associated with body powders containing talc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal considerations for our determination that performing procedures relating to the talc litigation is a critical audit matter are the significant judgment by management when assessing the likelihood of a loss being incurred and when </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">determining whether a reasonable estimate of the loss or range of loss for each claim can be made, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s assessment of the loss contingencies associated with this litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s evaluation of the talc litigation, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others, (i) gaining an understanding of the Company&#8217;s process around the accounting and reporting for the talc litigation; (ii) discussing the status of significant known actual and potential litigation with the Company&#8217;s in-house legal counsel, as well as external counsel when deemed necessary; (iii) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel for significant litigation; (iv) evaluating the reasonableness of management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (v) evaluating the sufficiency of the Company&#8217;s litigation contingencies disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Litigation &#8211; Opioids</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including opioids, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. The Company has been named in numerous lawsuits brought by certain state and local governments related to opioids matters. The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against the Company in the amount of $572 million which was subsequently reduced to $465 million. The Company has appealed the judgment and, as described by management, believes that it has strong grounds to overturn this judgment. Separately in October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4 billion as settlement of the lawsuits. In October 2020, the Company agreed to contribute up to an additional $1 billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5 billion which has been accrued, subject to various conditions and an agreement being finalized. As described by management, this agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed and future claims by states, cities and counties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal considerations for our determination that performing procedures relating to the opioids litigation is a critical audit matter are the significant judgment by management when assessing the likelihood of a loss being incurred for the judgment against the Company in Oklahoma and when determining whether a reasonable estimate of the range of loss for the proposed agreement in principle to settle opioids litigation can be made, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s assessment of the loss contingencies associated with this litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s evaluation of the opioid litigation, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others, (i) gaining an understanding of the Company&#8217;s process around the accounting and reporting for the opioids litigation; (ii) discussing the status of significant known actual and potential litigation and ongoing settlement negotiations with the Company&#8217;s in-house legal counsel, as well as external counsel when deemed necessary; (iii) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel for significant litigation; (iv) evaluating the reasonableness of management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (v) evaluating the sufficiency of the Company&#8217;s litigation contingencies disclosures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ PricewaterhouseCoopers LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Florham Park, New Jersey </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 22, 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since at least 1920. We have not been able to determine the specific year we began serving as auditor of the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company&#8217;s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company&#8217;s internal control over financial reporting is effective.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.  The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company&#8217;s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal controls over financial reporting, no matter how well designed, have inherent limitations.  Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements.  Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of January 3, 2021.  In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control-Integrated Framework (2013).&#8221;  These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring.  The Company&#8217;s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s processes and assessment, as described above, management has concluded that, as of January 3, 2021, the Company&#8217;s internal control over financial reporting was effective.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of January 3, 2021 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears herein.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Alex Gorsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Gorsky</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Return Performance Graphs </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are line graphs comparing the cumulative total shareholder return on the Company&#8217;s Common Stock for periods of five years and ten years ending January&#160;3, 2021, against the cumulative total return of the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Health Care Equipment Index. The graphs and tables assume that $100 was invested on December&#160;31, 2015 and December&#160;31, 2010 in each of the Company&#8217;s Common Stock, the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Health Care Equipment Index and that all dividends were reinvested.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="margin-top:9pt"><img src="jnj-20210103_g10.jpg" alt="jnj-20210103_g10.jpg" style="height:234px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$115.32</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$143.47</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$136.10</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$158.16</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$175.32</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$111.95</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$136.38</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$130.39</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$171.44</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$202.96</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$98.44</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$110.81</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$119.78</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$137.85</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$148.23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$106.48</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$139.38</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$162.02</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$209.52</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$246.47</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="margin-top:18pt"><img src="jnj-20210103_g11.jpg" alt="jnj-20210103_g11.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2010</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$109.89</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$121.79</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$163.95</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$192.37</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$194.59</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$224.41</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$279.18</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$264.84</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$307.77</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$341.17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$102.11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$118.44</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$156.78</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$178.22</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$180.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$202.27</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$246.41</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$235.59</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$309.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$366.70</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$117.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$134.75</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$182.22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$222.70</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$235.59</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$231.91</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$261.06</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$282.19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$324.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$349.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$99.20</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$116.33</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$148.54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$187.58</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$198.78</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$211.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$277.07</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$322.07</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$416.50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$489.94</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_238"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;At the end of the period covered by this Report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Alex Gorsky, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Gorsky and Wolk concluded that, as of the end of the period covered by this Report, the Company&#8217;s disclosure controls and procedures were effective</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reports on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The information called for by this item is incorporated herein by reference to "Management&#8217;s Report on Internal Control Over Financial Reporting", and the attestation regarding internal controls over financial reporting included in the "Report of Independent Registered Public Accounting Firm" included in Item 8 of this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;During the fiscal quarter ended January 3, 2021, there were no changes in the Company&#8217;s internal control over financial reporting identified in connection with the evaluation required under Rules&#160;13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that most of its employees are working remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company&#8217;s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company&#8217;s internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_241"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.36pt">OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_244"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i26b7b3066a4848f5be790a5478bde067_247"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the discussion of the Audit Committee under the caption &#8220;Item 1. Election of Directors - Board Committees&#8221;; and the material under the captions &#8220;Item 1. Election of Directors&#8221; and, if applicable, &#8220;Stock Ownership and Section 16 Compliance &#8211; Delinquent Section&#160;16(a) Reports&#8221; in the Proxy Statement; and the material under the caption &#8220;Executive Officers of the Registrant&#8221; in Part&#160;I of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s Code of Business Conduct, which covers all employees (including the Chief Executive Officer, Chief Financial Officer and Controller), meets the requirements of the SEC rules promulgated under Section&#160;406 of the Sarbanes-Oxley Act of 2002. The Code of Business Conduct is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com/code-of-business-conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code of Business Conduct or any waiver of the Code granted to the Chief Executive Officer, the Chief Financial Officer or the Controller will be posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within five business days (and retained on the website for at least one year).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the Company has adopted a Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers. The Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov/boardconduct.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and copies are available to shareholders </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within five business days (and retained on the website for at least one year).</span></div><div id="i26b7b3066a4848f5be790a5478bde067_250"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the captions &#8220;Item 1. Election of Directors &#8211; Director Compensation,&#8221; and &#8220;Item 2. Compensation Committee Report,&#8221; &#8220;Compensation Discussion and Analysis&#8221; and &#8220;Executive Compensation Tables&#8221; in the Proxy Statement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The material incorporated herein by reference to the material under the caption &#8220;Compensation Committee Report&#8221; in the Proxy Statement shall be deemed furnished, and not filed, in this Report and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, as a result of this furnishing, except to the extent that the Company specifically incorporates it by reference.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_253"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the caption &#8220;Item 1. Stock Ownership and Section&#160;16 Compliance&#8221; in the Proxy Statement; and Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table provides certain information as of January 3, 2021 concerning the shares of the Company&#8217;s Common Stock that may be issued under existing equity compensation plans.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities to<br/>be Issued Upon Exercise of<br/>Outstanding Options and  Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price of<br/>Outstanding Options and Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Available for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Future Issuance Under Equity Compensation Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Approved by Security Holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,483,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,949,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Not Approved by Security Holders</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,483,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,949,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in this category are the following equity compensation plans which have been approved by the Company&#8217;s shareholders: 2005 Long-Term Incentive Plan and 2012 Long-Term Incentive Plan.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">This column excludes shares reflected under the column &#8220;Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights.&#8221;</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The 2005 Long-Term Incentive Plan expired April 26, 2012.  All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_256"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the captions &#8220;Item 1. Election of Directors&#160;- Director Independence&#8221; and &#8220;Related Person Transactions&#8221; in the Proxy Statement.</span></div><div id="i26b7b3066a4848f5be790a5478bde067_259"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the caption &#8220;Item 3. Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in the Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i26b7b3066a4848f5be790a5478bde067_265"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">EXHIBITS&#160;AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report:</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span></div><div style="margin-top:5pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consolidated Balance Sheets at end of Fiscal Years 2020 and 2019</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Earnings for Fiscal Years 2020, 2019 and 2018&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Comprehensive Income for Fiscal Years 2020, 2019 and 2018</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Equity for Fiscal Years 2020, 2019 and 2018</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Cash Flows for Fiscal Years 2020, 2019 and 2018</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notes to Consolidated Financial Statements</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is included in the financial statements or notes.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Required</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> to be Filed by Item&#160;60l of Regulation&#160;S-K</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the Exhibit&#160;Index in this Report.</span></div><div style="margin-top:5pt;text-indent:45pt"><span><br/></span></div><div id="i26b7b3066a4848f5be790a5478bde067_268"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.    FORM 10-K SUMMARY</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:   February 22, 2021</span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.192%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON&#160;&amp; JOHNSON</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.192%"><tr><td style="width:1.0%"></td><td style="width:5.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. Gorsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. Gorsky, Chairman, Board of Directors,<br/>and Chief Executive Officer</span></td></tr></table></div><div style="text-align:center;text-indent:324pt"><span><br/></span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:34.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.918%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. Gorsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. Gorsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. J. Wolk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. Wolk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;R. J. Decker Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. Decker Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D. S. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. S. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;I. E. L. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I. E. L. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. A. Doudna</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. A. Doudna</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ H. Joly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. Joly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;C. Prince</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C. Prince</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. E. Washington</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. E. Washington</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ N.Y. West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N. Y. West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;R. A. Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. A. Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></div></td></tr></table></div></div></div><div id="i26b7b3066a4848f5be790a5478bde067_274"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reg. S-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Table</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit3i-restatedcertific.htm">3(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation effective February 19, 2016&#160;&#8212; Incorporated herein by reference to Exhibit 3(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000034/ex31amendmenttocoi.htm">3(ii)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Certificate of Incorporation of Johnson &amp; Johnson effective April 30, 2020 &#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April 29, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000039/ex31amendmenttoby-laws.htm">3(iii)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By-Laws of the Company, as amended effective June 9, 2020&#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant&#8217;s Form 8-K Current Report filed June 10, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000052/aug12exhibit41.htm">4(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 &#160;&#8212; Incorporated herein by reference to Exhibit 4.1 of the Registrant&#8217;s Form 8-K Current Report filed August 12, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040605000088/ltipexhibitfour.txt">10(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 4 of the Registrant&#8217;s S-8 Registration Statement filed on May 10, 2005 (file no. 333-124785).*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000006/tenoneformofcertificatesto.htm">10(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Certificate under the 2005 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K Current Report filed January 13, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040617000015/a2017jnjproxy.htm">10(c)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Appendix A of the Registrant&#8217;s Proxy Statement filed on March 15, 2017.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000081/0000200406-12-000081-index.htm">10(d)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Certificate, Restricted Share Unit Certificate and Performance Share Unit Certificate under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibits 10.2, 10.3 and 10.4 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040618000019/0000200406-18-000019-index.htm">10(e)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global NonQualified Stock Option Award Agreement, Global Restricted Share Unit Award Agreement and Global Performance Share Unit Award Agreement under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibits  10.1, 10.2 and 10.3 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040619000033/a201910-q1qexhibit10ajjexe.htm">10(f)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Johnson &amp; Johnson Executive Incentive Plan (Amended as of November 28, 2018)&#160;&#8212; Incorporated herein by reference to Exhibit 10(a) of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 31, 2019.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv10wg.txt">10(g)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Deferred Compensation (Certificate of Extra Compensation) Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10(g) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2003.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309003187/y74152exv10wj.htm">10(h)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009&#160;&#8212; Incorporated herein by reference to Exhibit 10(j) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2008.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309057624/y79425exv10w1.htm">10(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2009 Certificates of Long-Term Performance Plan&#160;&#8212; Incorporated herein by reference to Exhibit&#160;10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 27, 2009.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000119312512075565/d281803dex10k.htm">10(j)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Deferred Fee Plan for Directors&#160;(Amended as of January 17, 2012) &#8212; Incorporated herein by reference to Exhibit 10(k) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit101.htm">10(k)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Johnson &amp; Johnson Executive Income Deferral Plan Amended and Restated Effective January 1, 2010&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/0000950123-97-002843-index.html">10(l)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess Savings Plan&#160;(Effective as of January 1, 1996) &#8212; Incorporated herein by reference to Exhibit 10(j) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 29, 1996.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309003187/y74152exv10wp.htm">10(m)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments to the Johnson &amp; Johnson Excess Savings Plan effective as of January 1, 2009&#160;&#8212; Incorporated herein by reference to Exhibit 10(p) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 28, 2008.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31-jjexcessplanx2020rest.htm">10(n)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Excess Benefit Plan of Johnson &amp; Johnson and Affiliated Companies (Amended and restated effective January 1, 2020, except as otherwise provided) &#8212; Filed with this document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10(o)**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Life Plan Agreement&#160;&#8212; Incorporated herein by reference to Exhibit 10(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 1993.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">p</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Life Plan Agreement&#160;Closure Letter &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 29, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit102.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit102.htm">q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit102.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement for Dr. Paulus Stoffels - Incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reg. S-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Table</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies, Amended and Restated as of October 1, 2014 &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 28, 2014.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended June 28, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10(x) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21-subsidiariesxform10xk.htm">21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries &#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23-pwcconsentxform10xkx2.htm">23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311-302certofceoxform10x.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312-302certofcfoxform10x.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321-906certofceoxform10x.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322-906certofcfoxform10x.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paper filing.</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of any of the Exhibits listed above will be provided without charge to any shareholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company. Pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, the Company has not filed as exhibits to this Form 10-K certain long-term debt instruments, including indentures, under which the total amount of securities authorized does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. The Company hereby agrees to furnish a copy of any such instrument to the SEC upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex31-jjexcessplanx2020rest.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i76cf9b34888f4ce8933b5f42e719e08e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 3.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF AMENDMENT AND RESTATEMENT OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCESS BENEFIT PLAN OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOHNSON &#38; JOHNSON AND AFFILIATED COMPANIES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2020 Restatement)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This restatement of the Excess Benefit Plan of Johnson &#38; Johnson and Affiliated Companies, effective January 1, 2020, except as otherwise provided, incorporates all amendments adopted since January 1, 1983, and includes certain other changes and clarifications. This restatement has been approved by the Pension and Benefits Committee of Johnson &#38; Johnson.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:45.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ON BEHALF OF THE<br>PENSION AND BENEFITS COMMITTEE OF<br>JOHNSON &#38; JOHNSON</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;  12&#47;22&#47;2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Warren Luther</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WARREN LUTHER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Member</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i76cf9b34888f4ce8933b5f42e719e08e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCESS BENEFIT PLAN OF</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOHNSON &#38; JOHNSON AND AFFILIATED COMPANIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Amended and restated effective January 1, 2020, except as otherwise provided)</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i76cf9b34888f4ce8933b5f42e719e08e_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCESS BENEFIT PLAN OF</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOHNSON &#38; JOHNSON AND AFFILIATED COMPANIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Page</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article I. INTRODUCTION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article II. DEFINITIONS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Beneficiary&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Code&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.03</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Controlled Group&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.04</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;CRP&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.05</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Employer&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.06</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;ERISA&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.07</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;FAP 409A Benefit&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;FAP Formula&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.09</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Grandfathered Benefit&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Participant&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Payment Start Date&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Pension and Benefits Committee&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Plan&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Plan Administrator&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;PR Plan&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Qualified Plan&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;RVP Formula&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Separation From Service&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Statutory Limitations&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article III. ELIGIBILITY AND PARTICIPATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Eligibility</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Period of Participation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article IV. BENEFITS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amount of Benefits</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Time and Form of Payment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.03</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Automatic Cash-Out of Small Benefits</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.04</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rehired Participants</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article V. VESTING</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article VI. DISABILITY AND DEATH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disability</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Death</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article VII. UNFUNDED PLAN</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Plan Assets</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Top-Hat Plan Status</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article VIII. PLAN ADMINISTRATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plan Administrator&#8217;s Powers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delegation of Administrative Authority</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.03</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Engaging Third Parties to Assist with Plan Administration</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.04</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Privilege</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.05</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proof of Right to Receive Benefits</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.06</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tax Withholding</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.07</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Claims Procedures</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Limitations and Forum Selection.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article IX. AMENDMENT AND TERMINATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendment and Termination.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payments Upon Plan Termination</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article X. MISCELLANEOUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Construction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.02</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Alienation or Transfer of Benefits</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.03</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.04</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Scrivener&#8217;s Error</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.05</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recovery of Overpayment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.06</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Address Records</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.07</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Controlling State Law</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Right to Employment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i76cf9b34888f4ce8933b5f42e719e08e_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">18</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><div id="i76cf9b34888f4ce8933b5f42e719e08e_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article I.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTRODUCTION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Excess Benefit Plan of Johnson &#38; Johnson and Affiliated Companies (the &#8220;Plan&#8221;) is an unfunded, nonqualified deferred compensation arrangement. The purpose of the Plan is to restore retirement benefits to eligible participants, and beneficiaries of eligible participants, whose benefits under the Consolidated Retirement Plan of Johnson &#38; Johnson (the &#8220;CRP&#8221;) or the Johnson &#38; Johnson Retirement Plan for Puerto Rico Employees (the &#8220;PR Plan&#8221;) (each referred to as the &#8220;Qualified Plan&#8221;) are reduced by limitations imposed by Code Section 415 (limit on annual benefits), Code Section 401(a)(17) (compensation limit) or similar laws under the Puerto Rico Internal Revenue Code of 2011, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan was initially effective January 1, 1983, and has been subsequently amended from time to time, including to comply with the requirements of Code Section 409A, to reflect the CRP&#8217;s &#8220;retirement value&#8221; formula (&#8220;RVP Formula&#8221;), and to reflect the spinoff of the PR Plan from the CRP. The Plan is now amended and restated, effective January 1, 2020, except as otherwise provided, to incorporate prior amendments and to include certain clarifications.    </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participation in the Plan is limited to a select group of management and highly compensated employees of Johnson &#38; Johnson and its affiliates. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article II.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whenever used herein, the following terms shall have the meanings set forth below, unless otherwise expressly provided herein or unless a different meaning is plainly required by the context. Capitalized terms not defined herein shall have the respective meanings set forth in the plan document for the Qualified Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.01&#160;&#160;&#160;&#160;&#8220;Beneficiary&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, with respect to a Participant, the person or persons entitled to receive the death benefit, if any, payable with respect to the Participant under the Plan. For pre-retirement death benefits, a Participant&#8217;s Beneficiary shall be the beneficiary designated under the Qualified Plan for the applicable benefit. For post-retirement death benefits (available only with respect to benefits accrued under the FAP Formula), the Beneficiary shall be the person or persons designated by the Participant in connection with his or her payment election. Unless a successor beneficiary has been properly designated in accordance with procedures established by the Plan Administrator, any amounts payable to a Beneficiary after the Beneficiary&#8217;s death shall be paid to the Beneficiary&#8217;s estate.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.02&#160;&#160;&#160;&#160;&#8220;Code&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.03&#160;&#160;&#160;&#160;&#8220;Controlled Group&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has the same meaning as under the Qualified Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.04&#160;&#160;&#160;&#160;&#8220;CRP&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Consolidated Retirement Plan of Johnson &#38; Johnson, as in effect and amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.05&#160;&#160;&#160;&#160;&#8220;Employer&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Johnson &#38; Johnson and each Controlled Group member that is designated as a participating Employer under the Qualified Plan. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.06&#160;&#160;&#160;&#160;&#8220;ERISA&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Employee Retirement Income Security Act of 1974, as amended.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.07&#160;&#160;&#160;&#160;&#8220;FAP 409A Benefit&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, for a Participant who is eligible to receive an Excess FAP Benefit (as defined in Section 4.01(a), below) under the Plan, the portion, if any, of the Participant&#8217;s Excess FAP Benefit that exceeds the Participant&#8217;s Grandfathered Benefit. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.08&#160;&#160;&#160;&#160;&#8220;FAP Formula&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the final average pay formula under the Qualified Plan. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.09&#160;&#160;&#160;&#160;&#8220;Grandfathered Benefit&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, for a Participant, the benefit under the Plan that was accrued, earned, and vested as of December 31, 2004 (determined in a manner consistent with Treas. Reg. Section 1.409A-6). A Participant&#8217;s Grandfathered Benefit is governed by the terms of the Plan in effect as of October 3, 2004. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.10&#160;&#160;&#160;&#160;&#8220;Participant&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an employee of the Employer who is eligible to participate in the Plan pursuant to Section 3.01 (&#8220;Eligibility&#8221;) and whose participation has not ended as provided in Section 3.02 (&#8220;Period of Participation&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.11&#160;&#160;&#160;&#160;&#8220;Payment Start Date&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the date as of which payments are scheduled to begin under Section 4.02 (&#8220;Time and Form of Payment&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.12&#160;&#160;&#160;&#160;&#8220;Pension and Benefits Committee&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has the same meaning as under the Qualified Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.13&#160;&#160;&#160;&#160;&#8220;Plan&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means this Excess Benefit Plan of Johnson &#38; Johnson and Affiliated Companies, as set forth herein and amended from time to time. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.14&#160;&#160;&#160;&#160;&#8220;Plan Administrator&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Pension and Benefits Committee or its designee or any successor appointed by Johnson &#38; Johnson. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.15&#160;&#160;&#160;&#160;&#8220;PR Plan&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Johnson &#38; Johnson Retirement Plan for Puerto Rico Employees, as in effect and amended from time to time. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.16&#160;&#160;&#160;&#160;&#8220;Qualified Plan&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the CRP or the PR Plan, as applicable. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.17&#160;&#160;&#160;&#160;&#8220;RVP Formula&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the retirement value formula under the Qualified Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.18&#160;&#160;&#160;&#160;&#8220;Separation From Service&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, for a Participant, the Participant&#8217;s &#8220;separation from service&#8221; under Code Section 409A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.19&#160;&#160;&#160;&#160;&#8220;Statutory Limitations&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the limitations imposed by (a)&#160;Code Section 415 on the amount of annual retirement benefits payable to employees from the Qualified Plans, (b)&#160;Code Section 401(a)(17) on the amount of annual compensation that may be taken into account under the Qualified Plans, and (c)&#160;for the PR Plan, analogous limitations under the Puerto Rico Internal Revenue Code of 2011, as amended.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article III.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ELIGIBILITY AND PARTICIPATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.01&#160;&#160;&#160;&#160;Eligibility</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An individual who is a participant in a Qualified Plan shall become a Participant in the Plan upon either (a)&#160;having compensation under a Qualified Plan that exceeds the Statutory Limitation or (b)&#160;accruing a benefit under a Qualified Plan that exceeds the Statutory Limitation on benefits that may be paid from such Qualified Plan, in each case unless the Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determines that such individual is not part of a select group of management or highly compensated employees.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.02&#160;&#160;&#160;&#160;Period of Participation</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An individual who becomes a Participant shall continue to be a Participant until his benefit is forfeited or paid in full.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article IV.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BENEFITS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.01&#160;&#160;&#160;&#160;Amount of Benefits</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The benefit under the Plan is based on the excess of the amount (if any) that would be payable under the Qualified Plan if not for the Statutory Limitations over the amount actually payable under the Qualified Plan. Such benefit may consist of an Excess FAP Benefit, an Excess RVP Benefit, or both, determined as follows&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excess FAP Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent a Participant accrued Qualified Plan benefits under the FAP Formula, the amount payable under the Plan (the &#8220;Excess FAP Benefit&#8221;) is expressed as a monthly amount equal to the excess, if any, of&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The monthly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefit that would have been payable under the Qualified Plan&#8217;s FAP Formula to or on behalf of the Participant, commencing as of the Payment Start Date, if not for the Statutory Limitations&#59; over</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The monthly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefit actually payable under the Qualified Plan&#8217;s FAP Formula commencing at the same time and in the same form (without regard to the Participant&#8217;s actual time or form of payment under the Qualified Plan). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excess RVP Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent a Participant accrued Qualified Plan benefits under the RVP Formula, the amount payable under the Plan (the &#8220;Excess RVP Benefit&#8221;) is expressed as a lump sum equal to the excess, if any, of&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The benefit that would have been payable in a lump sum under the Qualified Plan&#8217;s RVP Formula to or on behalf of the Participant, commencing as of the Payment Start Date, if not for the Statutory Limitations&#59; over</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The benefit actually payable under the Qualified Plan&#8217;s RVP Formula at the same time and in the same form (without regard to the Participant&#8217;s actual time or form of payment under the Qualified Plan).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.02&#160;&#160;&#160;&#160;Time and Form of Payment</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excess FAP Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If a Participant has a Grandfathered Benefit, such Grandfathered Benefit shall be paid at the same time and in the same form as the Participant&#8217;s benefit under the Qualified Plan, unless some other form of payment is authorized by the Plan Administrator in accordance with terms of the Plan in effect on October 3, 2004. The Participant&#8217;s FAP 409A Benefit, if any, shall be paid in the annuity form prescribed by subsection (c), below, commencing on the first day of the month coincident with or next following the later of the Participant&#8217;s 55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> birthday or the Participant&#8217;s Separation From Service&#59; provided, however, that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FAP 409A Benefit for a former Pfizer Consumer who was eligible to receive a lump sum under the Pfizer plan shall be paid in a lump sum.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excess RVP Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided below in the event of death, a Participant&#8217;s Excess RVP Benefit shall be paid in a lump sum on the first day of the seventh month after the Participant&#8217;s Separation From Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annuity Form for FAP 409A Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise elected by the Participant in accordance with this subsection (c), the annuity form for a Participant&#8217;s FAP 409A Benefit shall be (I)&#160;a single life annuity if the Participant is not treated as married under the Qualified Plan as of the Payment Start Date, or (II)&#160;an actuarially equivalent joint and 50% surviving spouse annuity if the Participant is treated as married under the Qualified Plan as of the Payment Start Date. A Participant may elect in writing, in such manner at such times as permitted by the Plan Administrator to receive the FAP 409A Benefit in any actuarially equivalent annuity form of payment that is available under the Qualified Plan, other than the Level Income Options, provided that such election satisfies each of the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The change in the form of payment complies with Treas. Reg. Section 1.409A-2(b)(2)(ii)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Plan Administrator receives the Participant&#8217;s election before the Payment Start Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Participant&#8217;s election is complete and in good order, as determined by the Plan Administrator.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Actuarial equivalence shall be determined using the assumptions prescribed by the Qualified Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.03&#160;&#160;&#160;&#160;Automatic Cash-Out of Small Benefits</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the actuarial present value of a Participant&#8217;s Grandfathered Benefit, FAP 409A Benefit, or Excess RVP Benefit (or, following the Participant&#8217;s death, the actuarial present value of the Beneficiary&#8217;s death benefit) is less than $5,000 as of the applicable Payment Start Date, such benefit (or, if applicable, the Beneficiary&#8217;s total benefit) shall be paid in a lump sum on the applicable Payment Start Date. For purposes of this rule, actuarial present value shall be calculated using the Qualified Plan&#8217;s actuarial assumptions for small benefit cash-outs (as in effect as of the applicable determination date).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.04&#160;&#160;&#160;&#160;Rehired Participants</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Participant has a Separation From Service and is later rehired by an Employer, the following rules shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If the Participant had earned a vested benefit under the Plan at the time of his first Separation From Service, the vested benefit that the Participant had earned at the time of his first Separation From Service shall be paid at the same time and in the same form as if the Participant had not returned to service&#59; provided that Grandfathered Benefits shall be subject to the suspension rules that were in effect as of October 3, 2004. Any additional vested benefit that the Participant earns after his return to service shall be paid as provided in the Plan upon his subsequent Separation From Service or death, without regard to his first Separation From Service.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If the Participant had not earned a vested benefit under the Plan at the time of his first Separation From Service, but the Participant returns to service with an Employer and earns a vested benefit after his return to service, the Participant&#8217;s vested benefit under the Plan shall be paid as provided in the Plan upon his subsequent Separation From Service or death, without regard to his first Separation From Service.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The break-in-service rules and other terms of the Qualified Plan shall determine to what extent (if at all) any service or compensation the Participant had earned at the time of his first Separation From Service is forfeited or is taken into account in calculating the amount of the Participant&#8217;s benefit under the Plan after his return to service.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article V.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VESTING</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits under the Plan shall be subject to the same vesting conditions as apply under the Qualified Plan. If a Participant has a Separation From Service before his benefit under the Qualified Plan is fully vested, no benefit shall be payable under this Plan with respect to the unvested portion. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article VI.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISABILITY AND DEATH</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.01&#160;&#160;&#160;&#160;Disability </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Participant continues to accrue benefits under the Qualified Plan&#8217;s disability provisions after the Payment Start Date required by this Plan, payment of the Participant&#8217;s Plan benefit shall commence as of the Payment Start Date required by this Plan (which, in the case of benefits under the FAP Formula, shall be calculated based on a projection of the Statutory Limitations under the Qualified Plan) and such additional accruals shall be paid (a)&#160;if accrued under the FAP Formula, when the Participant stops accruing benefits under the Qualified Plan, and (b)&#160;if accrued under the RVP Formula, on an annual basis.  Such additional disability accruals, if any, are intended to be exempt from the requirements of Section 409A of the Code by reason of being disability pay under Treas. Reg. Section&#160;1.409A-1(a)(5). This provision shall be construed and administered consistently with the intent to comply with the requirements of Section 409A of the Code while providing a total benefit under this Plan and the Qualified Plan combined that has the same value as the benefit that would be payable under the Qualified Plan if not for the Statutory Limitations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.02&#160;&#160;&#160;&#160;Death</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Participant dies before the Payment Start Date prescribed by the Plan, the only benefit payable under the Plan to or on behalf of such Participant shall be a death benefit under this Section 6.02. Such death benefit shall be the excess, if any, of the death benefit that would be payable under the Qualified Plan if not for the Statutory Limitations over the actual death benefit payable under the Qualified Plan, subject to the following rules&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FAP Formula</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;If the Participant is treated as married under the Qualified Plan as of the date of his death, the only death benefit with respect to the FAP Formula shall be the excess, if any, of the pre-pension survivor annuity that would be payable under the Qualified Plan if not for the Statutory Limitations over the pre-retirement survivor annuity that is actually payable under the Qualified Plan at the same time and in the same form (without regard to the actual time or form of payment under the Qualified Plan).  Payment shall begin as of the later of the first day of the month coincident with or next following the later of the Participant&#8217;s death or the date the Participant would have attained age 55. For purposes of the Plan, any election to waive the pre-pension survivor annuity under the Qualified Plan shall be disregarded. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;If the Participant is not treated as married under the Qualified Plan as of the date of his death, no death benefit shall be payable under the Plan unless </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Participant qualifies for a 60-Month Survivor Pension under the Qualified Plan. If the Participant qualifies for a 60-Month Survivor Pension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under the Qualified Plan, the Participant&#8217;s Beneficiary shall receive a corresponding monthly benefit under this Plan, commencing as of the first day of the month coincident with or next following the Participant&#8217;s death, in an amount equal to the excess, if any, of the monthly benefit that would be payable under the Qualified Plan if not for the Statutory Limitations (and if such death benefit under the Qualified Plan were payable on a monthly basis) over the actual monthly benefit payable under the Qualified Plan (determined without regard to Qualified Plan provisions requiring payment in a lump sum or other form).  If the Beneficiary dies prior to receiving all 60 payments, the remaining payments shall be paid to the secondary Beneficiary named by the Participant, if any, or else to the designated Beneficiary&#8217;s estate.</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RVP Formula</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Participant dies before the payment date prescribed by Section 4.02(b) (&#8220;Excess RVP Benefit&#8221;), the Participant&#8217;s Excess RVP Benefit (if any) shall be paid to his Beneficiary in a lump sum as of the first day of the month coincident with or next following the Participant&#8217;s death. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Actual Payment Date for Death Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Payment of death benefits may be delayed, without interest, to the extent the Plan Administrator determines to be necessary to identify the Beneficiary and arrange for payment, provided that payment is made by December 31 of the first calendar year that starts after the Participant&#8217;s death or such later date as may be permitted by IRS guidance under Code Section 409A.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article VII.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNFUNDED PLAN</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.01&#160;&#160;&#160;&#160;No Plan Assets</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits provided under this Plan are unfunded obligations of Johnson &#38; Johnson. Nothing contained in this Plan shall require Johnson &#38; Johnson to segregate any monies from its general funds, to create any trust, to make any special deposits, or to purchase any policies of insurance with respect to such obligations. If Johnson &#38; Johnson elects to purchase individual policies of insurance on one or more of the Participants to help finance its obligations under this Plan, such individual policies and the proceeds of the policies shall at all times remain the sole property of Johnson &#38; Johnson and neither the Participants whose lives are insured nor their Beneficiaries shall have any ownership rights in such policies of insurance. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.02&#160;&#160;&#160;&#160;Top-Hat Plan Status</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan is maintained primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees within the meaning of ERISA Sections 201(2), 301(a)(3), and 401(a)(1).</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article VIII.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PLAN ADMINISTRATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.01&#160;&#160;&#160;&#160;Plan Administrator&#8217;s Powers</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan Administrator shall have all powers as may be necessary to carry out the provisions of the Plan. Without limiting the generality of the foregoing, the Plan Administrator shall have discretionary authority to determine eligibility for Plan benefits, and the amount and payment terms thereof, to construe and interpret the Plan, and to determine all questions arising in the administration of the Plan, and the Plan Administrator may from time to time establish rules for the administration of the Plan. Actions by the Plan Administrator shall be final, conclusive and binding on all Participants, Beneficiaries, and others making claims under the Plan. Individuals serving in the capacity of the Plan Administrator shall not be subject to individual liability with respect to this Plan. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.02&#160;&#160;&#160;&#160;Delegation of Administrative Authority</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent permitted by applicable law, the Plan Administrator may designate persons to assist in carrying out its duties, and may allocate responsibilities to one or more persons as &#8220;designated administrators.&#8221; All references to the Plan Administrator shall include the Plan Administrator&#8217;s designee, unless the contrary is clearly indicated.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.03&#160;&#160;&#160;&#160;Engaging Third Parties to Assist with Plan Administration</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Johnson &#38; Johnson and the Plan Administrator may employ or engage such agents, accountants, actuaries, counsel, other experts and other persons as it deems necessary or desirable in connection with the interpretation and administration of this Plan. None of the Plan Administrator, Johnson &#38; Johnson, or any of its committees, officers, directors and employees shall be liable for any action taken, suffered or omitted by them in good faith in reliance upon the advice or opinion of any such agent, accountant, actuary, counsel or other expert. All action so taken, suffered or omitted shall be conclusive upon each of them and upon all other persons interested in this Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.04&#160;&#160;&#160;&#160;Privilege</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent that the Plan Administrator or Johnson &#38; Johnson or an affiliate, committee, employee, member, affiliate or representative consults with legal counsel in connection with the design or administration of the Plan, the attorney-client relationship shall be exclusively between such counsel and the party engaging counsel. No employee, former employee, Participant, Beneficiary, or other individual shall be a party to such attorney-client relationship (other than to the extent such individual was involved in engaging counsel). Except as determined by the Plan Administrator or Johnson &#38; Johnson, the party engaging counsel shall preserve all rights to maintain the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">confidentiality of their communications with advisers, including the attorney-client privilege, to the full extent permitted by law.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.05&#160;&#160;&#160;&#160;Proof of Right to Receive Benefits</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan Administrator (or its delegate) may require proof of death or disability of any Participant, former Participant or Beneficiary and evidence of the right of any person to receive any Plan benefit.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.06&#160;&#160;&#160;&#160;Tax Withholding</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Johnson &#38; Johnson may withhold (or cause to be withheld) from benefits under this Plan any taxes or other amounts that Johnson &#38; Johnson determines are required by law to be withheld. Johnson &#38; Johnson may deduct (or cause to be deducted) from the unpaid portion of a Participant&#8217;s (or Beneficiary&#8217;s) benefit any tax that Johnson &#38; Johnson reasonably determines to be due with respect to the benefit, and an amount sufficient to pay applicable withholding on imputed income. Alternatively, Johnson &#38; Johnson may require the Participant or Beneficiary to remit to Johnson &#38; Johnson or its designee an amount sufficient to satisfy any applicable federal, state, and local income and employment tax with respect to the Participant&#8217;s benefit, or Johnson &#38; Johnson may withhold such amount from other compensation. Regardless of the amount withheld or reported, the Participant or Beneficiary shall remain responsible at all times for paying all federal, state, local, and foreign income and employment taxes with respect to benefits under this Plan (including taxes on imputed income) except for the employer&#8217;s portion of employment taxes. In no event shall Johnson &#38; Johnson or any employee or agent of Johnson &#38; Johnson be liable for any interest or penalty that a Participant or Beneficiary incurs by failing to make timely payments of tax.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.07&#160;&#160;&#160;&#160;Claims Procedures</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participant or Beneficiary (or his duly authorized representative) who believes that he is being denied a benefit to which he is entitled under the Plan (referred to in this Section&#160;8.07 as a &#8220;Claimant&#8221;) may file a written request with the claims administrator designated by the Plan Administrator (the &#8220;Claims Administrator&#8221;) setting forth the claim. The Claims Administrator shall consider and resolve the claim as set forth below.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time for Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Claims Administrator shall render a decision within 90 days after receiving the claim&#59; provided that if the Claims Administrator needs additional time, the period may be extended by up to 90 additional days. The Claims Administrator shall notify the Claimant of any extension and the expected response date.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Denial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the claim is denied in whole or part, the Claims Administrator shall notify the Claimant of its decision in writing, setting forth (i) the reason(s) for such denial, (ii) reference to relevant provision(s) of this Plan on which such denial is based, (iii) a description and explanation of any additional material or information necessary for the Claimant to perfect the claim, and (iv) a description of the Plan&#8217;s review procedures and the time limits applicable to such procedures, including a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">statement of the Claimant&#8217;s right to bring a civil action under ERISA Section 502(a) following an adverse benefit determination on review.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Request for Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within 60 days after receiving notice of a claim denial, the Claimant may request in writing that an appeals administrator designated by the Plan Administrator (the &#8220;Appeals Administrator&#8221;) review the determination. The Claimant may, but need not, submit written comments, documents, records, and other information relating to the claim. Upon request (and free of charge), the Claimant shall be provided reasonable access to, and copies of, all documents, records, and other information relevant to the benefit determination. If the Claimant does not request a review of the initial determination within such 60-day period, the Claimant shall be barred from challenging the determination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time to Respond to Request for Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Appeals Administrator shall render a decision within 60 days after receiving the request for review&#59; provided that if the Appeals Administrator needs additional time, the period may be extended by up to 60 additional days. The Appeals Administrator shall notify the Claimant of any extension, the reason therefor, and the expected response date. If the Appeals Administrator needs additional information, the period for reviewing the benefit determination shall be tolled until the Claimant responds to the request for additional information (or, if the Claimant fails to respond, until the Claimant&#8217;s response is due).  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Full and Fair Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Appeals Administrator&#8217;s review shall take into account all comments, documents, records, and other information submitted by the Claimant relating to the request for review, without regard to whether such information was submitted or considered in the initial benefit determination. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Decision on Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All decisions on review shall be final and binding with respect to all concerned parties. If the appeal is denied, the Appeals Administrator shall notify the Claimant of its decision in writing, setting forth (i) the reason(s) for the decision, (ii)&#160;reference to relevant Plan provision(s) upon which the adverse determination is based, (iii) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records, and other information, relevant to the Claimant&#8217;s claim for benefits, and (iv) a statement of the Claimant&#8217;s right to bring a civil action under ERISA Section 502(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.08&#160;&#160;&#160;&#160;Limitations and Forum Selection.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The limitations period prescribed by the Qualified Plan (generally two years after a claim is repudiated) and the forum selection provisions of the Qualified Plan shall apply with respect to all claims under this Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article IX.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT AND TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.01&#160;&#160;&#160;&#160;Amendment and Termination</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Johnson &#38; Johnson, through the Pension and Benefits Committee, reserves the right, at any time and from time to time, including retroactively if deemed necessary or appropriate,  to amend or terminate in whole or in part any or all provisions of the Plan&#59; provided that (i)&#160;no amendment or termination shall reduce a Participant&#8217;s or Beneficiary&#8217;s accrued benefit under this Plan (it being understood that a reduction under this Plan that is caused by a corresponding increase in the amount payable under the Qualified Plan shall not be treated as an impermissible reduction), and (ii)&#160;no amendment or termination shall change the time or form of payment of benefits under the Plan in a manner that results in a tax under Code Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An amendment to, or termination of, a Qualified Plan shall not be deemed to be an amendment to this Plan, and shall not be subject to the restrictions under this Section 9.01, even if such amendment or termination affects the benefit provided under this Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.02&#160;&#160;&#160;&#160;Payments Upon Plan Termination</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent permitted by Code Section 409A, benefits accrued under the Plan shall be paid upon termination of the Plan. Payments shall be made in a manner that is reasonably designed to avoid tax under Code Section 409A.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article X.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.01&#160;&#160;&#160;&#160;Construction</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of the Plan, unless the contrary is clearly indicated by the context&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The use of the masculine gender shall also include within its meaning the feminine and vice versa&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The use of the singular shall also include within its meaning the plural and vice versa&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The word &#34;include&#34; shall mean to include, but not to be limited to&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any reference to a statute or section of a statute shall further be a reference to any successor or amended statute or section, and any regulations or other guidance of general applicability issued thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.02&#160;&#160;&#160;&#160;No Alienation or Transfer of Benefits</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No amount payable under this Plan shall be subject in any manner to alienation, sale, transfer, assignment, pledge or encumbrance of any kind. Any attempt to alienate, sell, transfer, assign, pledge or otherwise encumber any such benefit, whether presently or subsequently payable, shall be void. Except as required by law, no benefit payable under this Plan shall in any manner be subject to garnishment, attachment, execution or other legal process, or be liable for or subject to the debts or liability of any Participant or Beneficiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.03&#160;&#160;&#160;&#160;Section 409A Compliance</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Plan is intended to comply with the requirements of Code Section 409A, to avoid tax thereunder, and shall be administered, construed, and interpreted consistently with such intent. Johnson &#38; Johnson does not warrant that the Plan will comply with Code Section 409A with respect to any Participant or with respect to any payment. In no event shall any Controlled Group member&#59; any director, officer, or employee of a Controlled Group member (other than the Participant)&#59; or any member of Johnson &#38; Johnson be liable for any additional tax, interest, or penalty incurred by a Participant or Beneficiary as a result of the Plan&#8217;s failure to satisfy the requirements of Code Section 409A, or as a result of the Plan&#8217;s failure to satisfy any other requirements of applicable tax laws.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Six-Month Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan, no portion of a Specified Employee&#8217;s FAP 409A or Excess RVP Benefit that is payable upon Separation From Service shall be paid before the earlier of the seventh month after such Separation From Service or the Participant&#8217;s death. If a delay is required by this provision, payment shall commence within 30 days after the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">delay period ends, and all amounts (if any) that otherwise would have been made paid during the delay period shall be included, without interest, with the first payment. For purposes of this Plan, &#8220;Specified Employee&#8221; means a specified employee described in Code Section 409A(a)(2)(B)(i), as determined by Johnson &#38; Johnson in accordance with its procedures for identifying specified employees.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Adjustments to Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A payment shall be treated as being made on the date when it is due under the Plan if the payment is made (i)&#160;within 30 days before the specified due date (subject to the six-month delay rule described in subsection (b), above), or (ii)&#160;on or after the specified due date and by the latest of (A) the last day of the calendar year in which the due date occurs, (B) the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of the third calendar month following the specified due date, or (C)&#160;such later date (if any) as is permitted by IRS guidance of general applicability under Code Section 409A. The actual date of any payment shall be determined by the Plan Administrator, in its sole discretion, and interest shall not be owed or paid with respect to any amount that is paid by the deadline prescribed by this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.04&#160;&#160;&#160;&#160;Scrivener&#8217;s Error</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An individual&#8217;s right to any benefit under the Plan shall be determined in accordance with the terms of this document&#59; provided, however, that this document shall be applied and interpreted without regard to any scrivener&#8217;s error (as described in the next following sentence) in this document or any other document of the Plan. The determination of whether a scrivener&#8217;s error has occurred shall be made by the Pension and Benefits Committee, in the exercise of its best judgment and sole discretion, based on its intent as settlor of the Plan (or, if applicable, its understanding of Johnson &#38; Johnson&#8217;s intent as Plan sponsor), and taking into account such evidence, written or oral, as it deems appropriate or helpful. The Pension and Benefits Committee is authorized to correct any scrivener&#8217;s error that it discovers in this document or in any other document of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.05&#160;&#160;&#160;&#160;Recovery of Overpayment</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Plan Administrator determines that an overpayment or incorrect payment or distribution has been made to a Participant, spouse, Beneficiary or other person, the Plan Administrator shall take such steps as it deem appropriate under the relevant facts and circumstances to recover such payments with interest. Without limiting the generality of the foregoing, and subject to the requirements under Code Section 409A, overpayments that are not repaid, and associated interest, may be recovered by an offset against subsequent payments otherwise becoming due under the Plan. The remedies under this Section 10.05 shall not be exclusive.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.06&#160;&#160;&#160;&#160;Address Records</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Participant and alternate payee shall keep the Plan Administrator informed of their post office address and the post office address of their spouse or other Beneficiary. Any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">communication, statement or notice from the Plan Administrator or its designee addressed to a Participant, spouse, Beneficiary or alternate payee at their last post office address filed with the Plan Administrator, or if no address is filed with the Plan Administrator, at the last post office address shown on the Employer&#8217;s or a member of the Controlled Group&#8217;s records, shall be binding on the Participant, spouse, Beneficiary or alternate payee (as applicable) for all purposes of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.07&#160;&#160;&#160;&#160;Controlling State Law</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except to the extent preempted by ERISA, this Plan shall be construed in accordance with the laws of the State of New Jersey, without regard to conflict of law provisions that might otherwise point to the law of a different jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.08&#160;&#160;&#160;&#160;No Right to Employment</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing contained in this Plan shall be construed as a contract of employment between Johnson &#38; Johnson (or any of its affiliates) and any individual, or to suggest or create a right in any employee to be continued in employment, or as a limit of the employer&#8217;s right to discharge any employee at any time and for any reason, with or without cause.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>ex21-subsidiariesxform10xk.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4e7cf757b7224d0ebba8b50376366b41_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&#38; Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of January&#160;3,&#160;2021. Johnson &#38; Johnson is not a subsidiary of any other entity. </font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Subsidiaries&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acclarent, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals US, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Akros Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Albany Street LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALZA Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alza Land Management, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Development, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Manufacturing USA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Nominee Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Sales and Service, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Spain Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO U.K. Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO US Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO USA Sales Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO USA, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas Diabetes Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas Technologies LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AorTx, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aragon Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atrionix, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AUB Holdings LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auris Health, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BeneVir BioPharm, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMedical Enterprises, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense Webster, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Calibra Medical LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centocor Biologics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centocor Research &#38; Development, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman &#38; Shurtleff, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coherex Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company Store.com, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cordis International Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoTherix Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CSATS, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Mitek, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Orthopaedics, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Products, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Spine, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Institute, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Products, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Sales, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch Holding LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECL7, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon US, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical International, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.D. Acquisition Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innovative Surgical Solutions, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen BioPharma, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biotech, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Diagnostics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Global Services, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Oncology, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Ortho LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Products, LP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Research &#38; Development, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Scientific Affairs, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Supply Group, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Manufacturing, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jevco Holding, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJHC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ International Investment LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Middle East) Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Enterprise Innovation Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Finance Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Gateway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Health and Wellness Solutions, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Health Care Systems Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation - JJDC, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Japan Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Devices &#38; Diagnostics Group - Latin America, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson S.E., Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Surgical Vision, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Urban Renewal Associates</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JOM Pharmaceutical Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Consumer Pharmaceuticals Co.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil LA LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNEIL MMP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Nutritionals, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Device Business Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#38; Diagnostics Global Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices International LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MegaDyne Medical Products, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Partnership Holding Company I, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Texas GP LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Texas L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Worldwide LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Micrus Endovascular LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middlesex Assurance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoStrata Company, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands Holding Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuravi Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeuWave Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novira Therapeutics, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVera Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Biologics LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Biotech Holding LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho-McNeil Pharmaceutical, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patriot Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peninsula Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percivia LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Princeton Laboratories, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pulsar Vascular, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regency Urban Renewal Associates</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rutan Realty LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scios LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sightbox, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SterilMed, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sterilmed, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes USA Products, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes USA, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TARIS Biomedical LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TearScience, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Anspach Effort, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Vision Care Institute, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tibotec, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Torax Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TriStrata, Incorporated</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verb Surgical Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vogue International LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vogue International Trading, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WH4110 Development Company, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zarbee's, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Subsidiaries&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3Dintegrated ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Manufacturing GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Australia Pty. Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Korea Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Mexico S.A. De C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Trading (Shanghai) Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals UK Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Registration Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Hangzhou) Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Shanghai) Medical Devices Trading Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO ASIA LIMITED</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Australia Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Canada Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Denmark ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO France</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Germany GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Groningen B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO International Holdings</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Ireland Finance Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Italy SRL</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Japan K.K.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Manufacturing Spain S.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Netherlands BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Norway AS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Puerto Rico Manufacturing, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Singapore Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Switzerland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO United Kingdom, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Uppsala AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Apsis</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backsvalan 2 Aktiebolag</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backsvalan 6 Handelsbolag</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beijing Dabao Cosmetics Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Berna Rhein B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense Webster (Israel) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C Consumer Products Denmark ApS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Campus-Foyer Apotheke GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carlo Erba OTC S.r.l.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ChromaGenics B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ci&#58;Labo Customer Marketing Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ci&#58;z. Labo Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag GmbH International</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag Holding AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag Holding Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag-Biotech, S.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CNA Development GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ColBar LifeScience Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cordis de Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corimmun GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Darlain Trading S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debs-Vogue Corporation (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy France</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Hellas SA</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy International Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Gorgan Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Leto SARL</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Ci&#58;Labo Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DR. CI&#58;LABO COMPANY LIMITED</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES Holdings de Mexico, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EIT Emerging Implant Technologies GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Biosurgery Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery (Europe) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Holding Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon PR Holdings Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Women's Health &#38; Urology Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor del Istmo S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor Farmaceutica, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor Guatemala, Sociedad Anomina</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury (Development) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury (Instruments) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Medical Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Orthopaedics International Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Orthopaedics Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FMS Future Medical System SA</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GH Biotech Holdings Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Investment Participation B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GMED Healthcare BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guangzhou Bioseal Biotech Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical Deutschland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical UK Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Healthcare Services (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innomedic Gesellschaft f&#252;r innovative Medizintechnik und Informatik mbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innovalens B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J &#38; J Company West Africa Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J Pension Trustees Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J.C. General Services BV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Alzheimer Immunotherapy (Holding) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biologics (Ireland) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biologics B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag Farmaceutica S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag S.p.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag SPA</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Algeria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag, C.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen de Mexico, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Development Finance Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Egypt LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Farmaceutica Portugal Lda</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Group Holdings Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Holding GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Irish Finance Company UC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Korea Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica (Proprietary) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical K.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical Sciences Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen R&#38;D Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Sciences Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines &#38; Prevention B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag (New Zealand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag A&#47;S</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Aktiebolag</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag AS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag de Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Farmaceutica Lda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Farmaceutica Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag International NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Kft.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag OY</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pharma GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pharmaceutical S.A.C.I.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Polska, Sp. z o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Pharma, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J-C Health Care Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJ Surgical Vision Spain, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJC Acquisition Company B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Belgium BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Manufacturing Malaysia SDN. BHD.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Norden AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Produtos Oticos Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Global Business Services s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Holding EMEA B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Irish Investments ULC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson - Societa' Per Azioni</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Angola), Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Angola</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (China) Investment Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Egypt) S.A.E.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Ireland) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Jamaica) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jamaica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Kenya) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kenya</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Mozambique), Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mozambique</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Namibia) (Proprietary) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Namibia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (New Zealand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Philippines), Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Private) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zimbabwe</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Thailand) Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Trinidad) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trinidad and Tobago</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Vietnam) Co., Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Belgium Finance Company BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Bulgaria EOOD</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson China Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer (Thailand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Holdings France</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Saudi Arabia Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Services EAME Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson d.o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Argentina S.A.C. e. I.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Chile Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Chile S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Colombia S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Costa Rica, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Uruguay S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Venezuela, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson del Ecuador, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ecuador</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Del Paraguay, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paraguay</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson del Peru S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Dominicana, S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson European Treasury Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Finance Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Financial Services GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson for Export and Import LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Foundation Scotland (NON-PROFIT)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Gesellschaft m.b.H.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Guatemala, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hellas Commercial and Industrial S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hellas Consumer Products Commercial Societe Anonyme</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hemisferica S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Puerto Rico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Holding GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Holdings K.K.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Industrial Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International (Singapore) Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International Financial Services Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson K.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Kft.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Korea Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Korea Selling &#38; Distribution LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Federation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Luxembourg Finance Company Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Management Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (China) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Proprietary) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Suzhou) Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Korea Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Products GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical S.p.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical SAS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Saudi Arabia Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Servicios Profesionales S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Taiwan Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical, S.C.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medikal Sanayi ve Ticaret Limited Sirketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ-LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Morocco Societe Anonyme</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Morocco</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Nordic AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pacific Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pakistan (Private) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Panama, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Personal Care (Chile) S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Poland Sp. z o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Private Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pty. Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Research Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Romania S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson S.E. d.o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Sante Beaute France</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson SDN. BHD.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Servicios Corporativos, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Surgical Vision India Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Taiwan Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson UK Treasury Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Ukraine LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson and Johnson (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson and Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">La Concha Land Investment Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latam International Investment Company Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lifescan</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil AB</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Denmark ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare (Ireland) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare (UK) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Iberica S.L.U.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Panama, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Products Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Sweden AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MDS Co. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Industrial do Brasil Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos International Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Menlo Care De Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Deutschland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Medical Systems B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoStrata UG (haftungsbeschr&#228;nkt)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuravi Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obtech Medical Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBTECH Medical Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OGX Beauty AU Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OGX Beauty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Holding GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthotaxy</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Penta Pty. Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Perouse Plastie</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmadirect Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmedica Laboratories (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PMC Holdings G.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Productos de Cuidado Personal y de La Salud de Bolivia S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bolivia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proleader S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT Integrated Healthcare Indonesia</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT. Johnson &#38; Johnson Indonesia</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RespiVert Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RoC International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedona Enterprise Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedona Singapore International Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedona Thai International Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serhum S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Elsker For Mother &#38; Baby Co., Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Johnson &#38; Johnson Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Johnson &#38; Johnson Pharmaceuticals Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sodiac ESV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Federation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Partnership</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spine Solutions GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Process Institute Deutschland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Costa Rica S.C.R., Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Holding AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Holding Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES Medical Immobilien GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Medical Surgical Equipment &#38; Instruments Trading LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Produktions GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Proprietary Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes S.M.P., S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Tuttlingen GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UAB &#34;Johnson &#38; Johnson&#34;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vania Expansion</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vision Care Finance Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xian Janssen Pharmaceutical Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XO1 Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>ex23-pwcconsentxform10xkx2.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1331a9c66e13425a9a415948a68168f6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;23</font></div><div style="margin-top:19pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:7pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-211250, 333-181092, 333-163857, 333-129542, and 333-124785) and Form S-3 (No. 333-236499) of Johnson &#38; Johnson of our report dated February 22, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 22, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex311-302certofceoxform10x.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i39a3b57bddb849e59890ef3dde2c121c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alex Gorsky, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended January 3, 2021 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Alex Gorsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Gorsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 22, 2021</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex312-302certofcfoxform10x.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i033f774282444d5281345d8276c22280_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended January 3, 2021 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 22, 2021 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex321-906certofceoxform10x.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1e4528785fab42c4a79232241ca32c5e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Alex Gorsky, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Alex Gorsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Gorsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 22, 2021</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex322-906certofcfoxform10x.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5c9c09a21a31403d8888d8ece79eaf53_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 (the &#8220;Report&#34;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 22, 2021</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>jnj-20210103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:339fd7d9-9316-40d7-9d71-ee9342a8b33f,g:975259c4-ea12-43d4-8326-a0d386e906b6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20210103" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20210103">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210103_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210103_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.jnj.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecurities" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities">
        <link:definition>2107102 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesTables" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails">
        <link:definition>2409404 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails">
        <link:definition>2410405 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2111103 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2312303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2413406 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.jnj.com/role/PropertyPlantandEquipment">
        <link:definition>2114104 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2315304 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails">
        <link:definition>2416407 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>2417408 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2118105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2319305 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails">
        <link:definition>2420409 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails">
        <link:definition>2421410 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2422411 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails">
        <link:definition>2423412 - Disclosure - Intangible Assets and Goodwill - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2124106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2325306 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2426413 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2427414 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2428415 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2429416 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2430417 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2431418 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.jnj.com/role/Borrowings">
        <link:definition>2132107 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.jnj.com/role/BorrowingsTables">
        <link:definition>2333307 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofLongtermDebtInstrumentsDetails" roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails">
        <link:definition>2434419 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails">
        <link:definition>2435420 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAggregateMaturitiesofLongTermObligationsDetails" roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails">
        <link:definition>2436421 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2137108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.jnj.com/role/IncomeTaxesTables">
        <link:definition>2338308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>2439422 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails">
        <link:definition>2440423 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails">
        <link:definition>2441424 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>2442425 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2443426 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligations" roleURI="http://www.jnj.com/role/EmployeeRelatedObligations">
        <link:definition>2144109 - Disclosure - Employee Related Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsTables" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables">
        <link:definition>2345309 - Disclosure - Employee Related Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails">
        <link:definition>2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1">
        <link:definition>2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsNarrativeDetails" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails">
        <link:definition>2447428 - Disclosure - Employee Related Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2148110 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2349310 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2450429 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
        <link:definition>2451430 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails">
        <link:definition>2452431 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails">
        <link:definition>2453432 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansNarrativeDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails">
        <link:definition>2454433 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
        <link:definition>2455434 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
        <link:definition>2456435 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails">
        <link:definition>2457436 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
        <link:definition>2458437 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails">
        <link:definition>2459438 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsPlan" roleURI="http://www.jnj.com/role/SavingsPlan">
        <link:definition>2160111 - Disclosure - Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsPlanNarrativeDetails" roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails">
        <link:definition>2461439 - Disclosure - Savings Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStock" roleURI="http://www.jnj.com/role/CapitalandTreasuryStock">
        <link:definition>2162112 - Disclosure - Capital and Treasury Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockTables" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables">
        <link:definition>2363311 - Disclosure - Capital and Treasury Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockChangesinTreasuryStockDetails" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails">
        <link:definition>2464440 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockNarrativeDetails" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails">
        <link:definition>2465441 - Disclosure - Capital and Treasury Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2166113 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2367312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2468442 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalCurrencyTranslation" roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation">
        <link:definition>2169114 - Disclosure - International Currency Translation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalCurrencyTranslationNarrativeDetails" roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails">
        <link:definition>2470443 - Disclosure - International Currency Translation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2171115 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2372313 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails">
        <link:definition>2473444 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>2474445 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreements" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements">
        <link:definition>2175116 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsTables" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables">
        <link:definition>2376314 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails">
        <link:definition>2477446 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails">
        <link:definition>2478447 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails">
        <link:definition>2479448 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails">
        <link:definition>2480449 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails">
        <link:definition>2481450 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2182117 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2383315 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
        <link:definition>2484451 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
        <link:definition>2485452 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>2486453 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2187118 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2488454 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2189119 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2490455 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2191120 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2392316 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2493456 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails">
        <link:definition>2494457 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" abstract="false" name="EffectiveIncomeTaxRateReconciliationCapitalLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentChangeinObservablePrices" abstract="false" name="EquityFairValueAdjustmentChangeinObservablePrices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_Wholesaler3Member" abstract="true" name="Wholesaler3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EmployeeRelatedObligationsTableTextBlock" abstract="false" name="EmployeeRelatedObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PANCREASEMember" abstract="true" name="PANCREASEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IdorsiaMember" abstract="true" name="IdorsiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A1.950Notesdue2020Member" abstract="true" name="A1.950Notesdue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" abstract="false" name="TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_XO1Member" abstract="true" name="XO1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" abstract="false" name="ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_QualifiedPlansMember" abstract="true" name="QualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EmployeeCompensationPeriod" abstract="false" name="EmployeeCompensationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_MomentaMember" abstract="true" name="MomentaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" abstract="false" name="DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_Wholesaler1Member" abstract="true" name="Wholesaler1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CustomersCollectionPatternsAxis" abstract="true" name="CustomersCollectionPatternsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_FiscalPeriodPolicyTextBlock" abstract="false" name="FiscalPeriodPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" abstract="false" name="EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_RegulationCharge" abstract="false" name="RegulationCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" abstract="true" name="CumulativeEffectPeriodOfAdoptionAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CurtailmentsAndSettlementsAndRestructuring" abstract="false" name="CurtailmentsAndSettlementsAndRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2018AcquisitionsMember" abstract="true" name="A2018AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShippingandHandlingCostsasaPercentofSales" abstract="false" name="ShippingandHandlingCostsasaPercentofSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" abstract="false" name="RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A055NotesDue2025Member" abstract="true" name="A055NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" abstract="false" name="EffectiveTaxRateReconciliationLitigationSettlementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SalesReturnReserve" abstract="false" name="SalesReturnReserve" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CommingledFundsMember" abstract="true" name="CommingledFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_December172018ShareRepurchaseProgramMember" abstract="true" name="December172018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" abstract="true" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2021Member" abstract="true" name="A2.45Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LandAndLeaseholdImprovementsMember" abstract="true" name="LandAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PotentialSharesExercisableUnderStockOptionPlans" abstract="false" name="PotentialSharesExercisableUnderStockOptionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2020AcquisitionsMember" abstract="true" name="A2020AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LifeScanMember" abstract="true" name="LifeScanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SavingsPlanTextBlock" abstract="false" name="SavingsPlanTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" abstract="false" name="DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" abstract="false" name="InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_A130NotesDue2030Member" abstract="true" name="A130NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" abstract="false" name="IncreaseDecreaseInEarningsBeforeTaxesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskLineItems" abstract="true" name="ConcentrationOfCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" abstract="true" name="ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" abstract="false" name="EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_EmployeeObligations" abstract="false" name="EmployeeObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ConvertibleNoteEquityInterestNumberOfShares" abstract="false" name="ConvertibleNoteEquityInterestNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ErleadaMember" abstract="true" name="ErleadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AMOMember" abstract="true" name="AMOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" abstract="false" name="EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NonQualifiedPlansMember" abstract="true" name="NonQualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherSovereignSecuritiesMember" abstract="true" name="OtherSovereignSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" abstract="false" name="TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UnfundedPlansMember" abstract="true" name="UnfundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_VerbSurgicalIncMember" abstract="true" name="VerbSurgicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0.250NotesDue2022Member" abstract="true" name="A0.250NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_PercentageOfCompanysCommonStockToPlanAsset" abstract="false" name="PercentageOfCompanysCommonStockToPlanAsset" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A2.25Notesdue2022Member" abstract="true" name="A2.25Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockTableTextBlock" abstract="false" name="ChangesInTreasuryStockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_EffectOfExchangeRates" abstract="false" name="EffectOfExchangeRates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ActelionMember" abstract="true" name="ActelionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ShortTermInvestmentFundsMember" abstract="true" name="ShortTermInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_SkinHealthBeautyMember" abstract="true" name="SkinHealthBeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_UnrecognizedTaxBenefitLiabilityPayment" abstract="false" name="UnrecognizedTaxBenefitLiabilityPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" abstract="false" name="MinimumCollateralValueasaPercentReverseRepurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_AccruedTaxesOnIncomeMember" abstract="true" name="AccruedTaxesOnIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A2012LongTermIncentivePlanMember" abstract="true" name="A2012LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" abstract="false" name="NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_LumpSumDistributionMember" abstract="true" name="LumpSumDistributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" abstract="false" name="PercentageOfCorridorOfGreaterOfMarketValueOfAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CumulativeEffectPeriodOfAdoptionDomain" abstract="true" name="CumulativeEffectPeriodOfAdoptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A1.65Notesdue2021Member" abstract="true" name="A1.65Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanOverUnderFundedStatusABO" abstract="false" name="DefinedBenefitPlanOverUnderFundedStatusABO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsUndistributedForeignEarnings" abstract="false" name="DeferredTaxAssetsUndistributedForeignEarnings" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskTable" abstract="true" name="ConcentrationOfCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_CustomersCollectionPatternsDomain" abstract="true" name="CustomersCollectionPatternsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SavingsPlanAbstract" abstract="true" name="SavingsPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_AdvancedSterilizationProductsMember" abstract="true" name="AdvancedSterilizationProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CizHoldingsCo.Ltd.Member" abstract="true" name="CizHoldingsCo.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BusinessAcquisitionDiscountRate" abstract="false" name="BusinessAcquisitionDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A2.05Notesdue2023Member" abstract="true" name="A2.05Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherNonLongLivedAssets" abstract="false" name="OtherNonLongLivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FundedPlansMember" abstract="true" name="FundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2021Member" abstract="true" name="A3.55Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SegmentsTotalMember" abstract="true" name="SegmentsTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BusinessCombinationProbabilityOfSuccessFactor" abstract="false" name="BusinessCombinationProbabilityOfSuccessFactor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_PROCRITEPREXMember" abstract="true" name="PROCRITEPREXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" abstract="false" name="DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_A2.95Debenturesdue2020Member" abstract="true" name="A2.95Debenturesdue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CumulativeEffectPeriodOfAdoptionAxis" abstract="true" name="CumulativeEffectPeriodOfAdoptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityPolicyTextBlock" abstract="false" name="ProductLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ConvertibleNoteEquityInterestPercentage" abstract="false" name="ConvertibleNoteEquityInterestPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_GainOnSaleOfAnAssetPaymentForRestructuring" abstract="false" name="GainOnSaleOfAnAssetPaymentForRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" abstract="false" name="FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DiabetesCareMember" abstract="true" name="DiabetesCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_VELCADEMember" abstract="true" name="VELCADEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NIZORALMember" abstract="true" name="NIZORALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockRollForward" abstract="true" name="ChangesInTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A2019AcquisitionsMember" abstract="true" name="A2019AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsOtherDomestic" abstract="false" name="DeferredTaxAssetsOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" abstract="false" name="EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_ProfitLossPercentToSales" abstract="false" name="ProfitLossPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OpiodsMember" abstract="true" name="OpiodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_Wholesaler2Member" abstract="true" name="Wholesaler2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NumberOfStockBasedCompensationPlans" abstract="false" name="NumberOfStockBasedCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" abstract="true" name="A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostDurationofRestructuringPlan" abstract="false" name="RestructuringandRelatedCostDurationofRestructuringPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" abstract="false" name="DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_GeneralCorporateMember" abstract="true" name="GeneralCorporateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherReverseRepurchaseAgreementsMember" abstract="true" name="OtherReverseRepurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ChangesinTreasuryStockSharesOutstandingRollForward" abstract="true" name="ChangesinTreasuryStockSharesOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AccountingStandardUpdate201616Member" abstract="true" name="AccountingStandardUpdate201616Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RestructuringChargeNetofAccrualAdjustment" abstract="false" name="RestructuringChargeNetofAccrualAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" abstract="false" name="DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExpenseNotAllocatedToSegments" abstract="false" name="ExpenseNotAllocatedToSegments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AliosBiopharmaIncandXO1LimitedMember" abstract="true" name="AliosBiopharmaIncandXO1LimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>jnj-20210103_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:339fd7d9-9316-40d7-9d71-ee9342a8b33f,g:975259c4-ea12-43d4-8326-a0d386e906b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20210103.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6aea263-2ebd-4c2c-bfe5-ff4c12e8b3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7898d457-64cc-4ca7-a493-bfd112145ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6aea263-2ebd-4c2c-bfe5-ff4c12e8b3ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7898d457-64cc-4ca7-a493-bfd112145ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_efab96a3-d169-4ef4-a778-85e26dfd2735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6aea263-2ebd-4c2c-bfe5-ff4c12e8b3ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_efab96a3-d169-4ef4-a778-85e26dfd2735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ffa48437-a1b0-4be9-9034-fad315cbf675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6aea263-2ebd-4c2c-bfe5-ff4c12e8b3ef" xlink:to="loc_us-gaap_CommonStockValue_ffa48437-a1b0-4be9-9034-fad315cbf675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_387e16cb-3971-4168-99b1-39fa98d51ced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6aea263-2ebd-4c2c-bfe5-ff4c12e8b3ef" xlink:to="loc_us-gaap_TreasuryStockValue_387e16cb-3971-4168-99b1-39fa98d51ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_b75b2fd2-35f6-4b5f-bd40-c4bf0e3634e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3869b8fb-1882-4218-8703-9216c5c5cf71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_b75b2fd2-35f6-4b5f-bd40-c4bf0e3634e6" xlink:to="loc_us-gaap_PreferredStockValue_3869b8fb-1882-4218-8703-9216c5c5cf71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf26e49d-48a6-43b5-9588-8f4a0b2fa597" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_b75b2fd2-35f6-4b5f-bd40-c4bf0e3634e6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf26e49d-48a6-43b5-9588-8f4a0b2fa597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc153c19-a4ac-447a-bdfa-269d096a8eca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_b75b2fd2-35f6-4b5f-bd40-c4bf0e3634e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc153c19-a4ac-447a-bdfa-269d096a8eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3da34995-f35c-4f2e-a983-6e4a3cd5f0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_b75b2fd2-35f6-4b5f-bd40-c4bf0e3634e6" xlink:to="loc_us-gaap_CommonStockValue_3da34995-f35c-4f2e-a983-6e4a3cd5f0e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d7761271-9a45-4873-b5a9-9312633a745f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:to="loc_us-gaap_LiabilitiesCurrent_d7761271-9a45-4873-b5a9-9312633a745f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2e253364-bfbb-4fe4-8751-43c06f853113" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2e253364-bfbb-4fe4-8751-43c06f853113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_22b3f56f-c632-44f6-b739-5cdbe4ee916e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_22b3f56f-c632-44f6-b739-5cdbe4ee916e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_080218c7-9d51-4ee2-a939-5a14af7df42e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_080218c7-9d51-4ee2-a939-5a14af7df42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fe6af81c-8d85-40cc-bb71-e536a871db53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fe6af81c-8d85-40cc-bb71-e536a871db53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5bbbd4e6-24a8-4de4-9c34-318d63fea1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_900000de-383f-444c-91ec-4d5b95b8ba0d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5bbbd4e6-24a8-4de4-9c34-318d63fea1c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f39acc7-558f-48a9-9249-ccc56fdd1c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f39acc7-558f-48a9-9249-ccc56fdd1c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_ab150a63-8f6e-4dd4-96fe-dc3c87c6d023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_ab150a63-8f6e-4dd4-96fe-dc3c87c6d023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9edcdf45-dae4-4dc3-8c4b-41c9c75a4982" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9edcdf45-dae4-4dc3-8c4b-41c9c75a4982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0442c763-99da-4375-988d-8d51c8abe516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:to="loc_us-gaap_InventoryNet_0442c763-99da-4375-988d-8d51c8abe516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e720d9eb-10e7-4404-a206-899c69a240c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e720d9eb-10e7-4404-a206-899c69a240c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther_31572a3f-dfe1-4546-af02-ede57a730e90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ee8e4ace-365b-44d1-aac6-c9a913264f49" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther_31572a3f-dfe1-4546-af02-ede57a730e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15a43ceb-92f2-40ee-8341-437d9540c9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:to="loc_us-gaap_AssetsCurrent_15a43ceb-92f2-40ee-8341-437d9540c9cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_104ac936-462f-490a-b5b7-90a17b4195f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_104ac936-462f-490a-b5b7-90a17b4195f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_efc692fb-d146-46eb-9b72-21dea95b7389" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_efc692fb-d146-46eb-9b72-21dea95b7389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a1093d84-d350-40ba-a390-ebfc4665e842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:to="loc_us-gaap_Goodwill_a1093d84-d350-40ba-a390-ebfc4665e842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a89841a-5aee-4817-a34f-6382f582a42d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a89841a-5aee-4817-a34f-6382f582a42d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_533d4824-2acf-4d0b-afa5-6f37a133f6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29496710-9309-4dda-82dd-31e93c4e1ed2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_533d4824-2acf-4d0b-afa5-6f37a133f6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_e3f284ef-3c2d-4f39-9f78-d43b6959dfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:to="loc_us-gaap_ShortTermBorrowings_e3f284ef-3c2d-4f39-9f78-d43b6959dfdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f1ccf410-87a2-4fb9-b1cc-93830972b1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:to="loc_us-gaap_AccountsPayableCurrent_f1ccf410-87a2-4fb9-b1cc-93830972b1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_55aa19c9-79f3-4f7c-9942-68da0eff4431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_55aa19c9-79f3-4f7c-9942-68da0eff4431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_566039be-44f5-434d-9bc8-2466f0b7b507" xlink:href="jnj-20210103.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_566039be-44f5-434d-9bc8-2466f0b7b507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ced8186-a459-4f0a-9765-1a063912607c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ced8186-a459-4f0a-9765-1a063912607c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_14b234ed-dcb1-47a7-ba98-dda750e4d9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c679ac61-b0e7-4fad-bf96-276854c585f9" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_14b234ed-dcb1-47a7-ba98-dda750e4d9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b22cc137-0b19-49cc-9f62-f895ebefc0af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dd3cf08a-607d-44c8-a664-cf6e483ec59a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b22cc137-0b19-49cc-9f62-f895ebefc0af" xlink:to="loc_us-gaap_Liabilities_dd3cf08a-607d-44c8-a664-cf6e483ec59a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30cf530c-a6d5-4454-9da4-c07aee35d946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b22cc137-0b19-49cc-9f62-f895ebefc0af" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30cf530c-a6d5-4454-9da4-c07aee35d946" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_303f1107-e7c6-4384-8363-c12779f9d321" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3aafe9fb-e58a-400a-8207-c709e184354d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_303f1107-e7c6-4384-8363-c12779f9d321" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3aafe9fb-e58a-400a-8207-c709e184354d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c28ec680-0b2e-4fef-8673-10629f3b1f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_303f1107-e7c6-4384-8363-c12779f9d321" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c28ec680-0b2e-4fef-8673-10629f3b1f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_017e2e1d-7c3e-408d-a000-fa14902a4c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd16e651-3c4c-40b0-91a0-370488ad4389" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_017e2e1d-7c3e-408d-a000-fa14902a4c3c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd16e651-3c4c-40b0-91a0-370488ad4389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_12e4f58e-c731-4b96-af65-c66bc30ec757" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_017e2e1d-7c3e-408d-a000-fa14902a4c3c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_12e4f58e-c731-4b96-af65-c66bc30ec757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_47b93a46-4f15-4f61-9def-28fed2170f61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_GrossProfit_47b93a46-4f15-4f61-9def-28fed2170f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_087079f3-a2cf-4b6e-aca5-f648fa2ff04b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_087079f3-a2cf-4b6e-aca5-f648fa2ff04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f5d705ac-0b45-4444-90ee-839a48d626aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f5d705ac-0b45-4444-90ee-839a48d626aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_46bcc85b-aa9b-4415-8436-8dcb87667dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_46bcc85b-aa9b-4415-8436-8dcb87667dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f3250ce3-7fd7-4ea2-a6bf-875b38e8b0de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f3250ce3-7fd7-4ea2-a6bf-875b38e8b0de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_355a004d-22f5-4626-801b-ab00cd56e3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_InterestExpense_355a004d-22f5-4626-801b-ab00cd56e3e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dd51b519-84c2-48b2-9f55-292c3507e616" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dd51b519-84c2-48b2-9f55-292c3507e616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_283e18f0-530e-46d2-b3df-03c88328aa5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639dd118-d8f1-47a1-bd37-37aca50ea7a6" xlink:to="loc_us-gaap_RestructuringCharges_283e18f0-530e-46d2-b3df-03c88328aa5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d1bf7a67-0e63-4cf4-bbe4-b62f6a917c77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_351d7db4-40df-46b9-a500-049e8fd3f400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d1bf7a67-0e63-4cf4-bbe4-b62f6a917c77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_351d7db4-40df-46b9-a500-049e8fd3f400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30ea490c-85c8-46a8-a093-1393da0f6880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d1bf7a67-0e63-4cf4-bbe4-b62f6a917c77" xlink:to="loc_us-gaap_NetIncomeLoss_30ea490c-85c8-46a8-a093-1393da0f6880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a19d1c9c-731c-4617-9c5e-44eb2bbf799f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_48fd40be-81f6-4a2e-a30b-a43a405e94ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a19d1c9c-731c-4617-9c5e-44eb2bbf799f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_48fd40be-81f6-4a2e-a30b-a43a405e94ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5bf26f89-016d-456c-9240-abf9b2df515a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a19d1c9c-731c-4617-9c5e-44eb2bbf799f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5bf26f89-016d-456c-9240-abf9b2df515a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_e8856cf0-2dc1-4b95-ad45-2e19e42bebf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_f633c889-f3f7-4bf7-b98f-59540faede76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_e8856cf0-2dc1-4b95-ad45-2e19e42bebf7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_f633c889-f3f7-4bf7-b98f-59540faede76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_3456ed1f-fa99-4dc8-a3cf-1fe4ecb474fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_e8856cf0-2dc1-4b95-ad45-2e19e42bebf7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_3456ed1f-fa99-4dc8-a3cf-1fe4ecb474fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_47ecd19a-5f94-44d9-93c5-2a85ebb7e480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_a5a6c8e2-4dd7-4a6f-b0b9-c023ef20da18" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_47ecd19a-5f94-44d9-93c5-2a85ebb7e480" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_a5a6c8e2-4dd7-4a6f-b0b9-c023ef20da18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_1bf625c7-0d49-48de-a1a9-eab9221da84e" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_47ecd19a-5f94-44d9-93c5-2a85ebb7e480" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_1bf625c7-0d49-48de-a1a9-eab9221da84e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_c7d14187-35f9-499e-9a4f-8ce130de371f" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_47ecd19a-5f94-44d9-93c5-2a85ebb7e480" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_c7d14187-35f9-499e-9a4f-8ce130de371f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0dcffb-33bb-40e1-b62e-d6775a60ead6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_3ec8af11-eb29-49f3-ba81-8193e59e1613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0dcffb-33bb-40e1-b62e-d6775a60ead6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_3ec8af11-eb29-49f3-ba81-8193e59e1613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_37608efe-f316-448f-a146-ddb88552950b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0dcffb-33bb-40e1-b62e-d6775a60ead6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_37608efe-f316-448f-a146-ddb88552950b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_889b0734-a4e1-45b8-87fe-7962f0be6407" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0dcffb-33bb-40e1-b62e-d6775a60ead6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_889b0734-a4e1-45b8-87fe-7962f0be6407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_bc7eabc4-e69c-4126-9fa2-c8e9e2ca3156" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c0dcffb-33bb-40e1-b62e-d6775a60ead6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_bc7eabc4-e69c-4126-9fa2-c8e9e2ca3156" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d5cf2b39-e92d-4f70-8d52-95c54b4d5223" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d5cf2b39-e92d-4f70-8d52-95c54b4d5223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9a725666-d9cb-46d1-ac70-67cfef0a8b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9a725666-d9cb-46d1-ac70-67cfef0a8b00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_47c0f340-4548-4d97-9b35-7a03bd304ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_47c0f340-4548-4d97-9b35-7a03bd304ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8ca6b75e-d172-4421-afc7-e553e7996f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8ca6b75e-d172-4421-afc7-e553e7996f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0fe827f0-966a-458e-ba43-34c77bbc0ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0fe827f0-966a-458e-ba43-34c77bbc0ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0b88f8cd-6038-40dd-84ab-ea8de4658a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0b88f8cd-6038-40dd-84ab-ea8de4658a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_cfcf67b1-5a1c-4dc6-b88b-f0e9f742752a" xlink:href="jnj-20210103.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3393abbc-5876-4204-b7d4-9636226ef950" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_cfcf67b1-5a1c-4dc6-b88b-f0e9f742752a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a6304ee-d49d-49c3-92d9-d34b5e339be0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d558ccb-de9d-448f-a991-beb4bfb3a996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a6304ee-d49d-49c3-92d9-d34b5e339be0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d558ccb-de9d-448f-a991-beb4bfb3a996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f880a67-b228-48b6-af20-cae376534d07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a6304ee-d49d-49c3-92d9-d34b5e339be0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f880a67-b228-48b6-af20-cae376534d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e78f515b-bfd7-4e1b-b3e7-78eb0b0ec13d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a6304ee-d49d-49c3-92d9-d34b5e339be0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e78f515b-bfd7-4e1b-b3e7-78eb0b0ec13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70023ae2-c815-4d56-a020-cf14bb519512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a6304ee-d49d-49c3-92d9-d34b5e339be0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70023ae2-c815-4d56-a020-cf14bb519512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7dc60731-1864-489e-bed2-a374241811d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7f1fe4ed-4209-4751-b85d-502c56b3cb16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7dc60731-1864-489e-bed2-a374241811d2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7f1fe4ed-4209-4751-b85d-502c56b3cb16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_39835080-2846-4501-9a3b-d5887a33fca6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7dc60731-1864-489e-bed2-a374241811d2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_39835080-2846-4501-9a3b-d5887a33fca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0666bb71-f2a8-48e2-b79b-99999844760a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0666bb71-f2a8-48e2-b79b-99999844760a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_145b35d1-7780-4f72-b05d-a39dcf74f241" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_145b35d1-7780-4f72-b05d-a39dcf74f241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9a98614e-aaac-4cf4-8a37-17aeb5bfebd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9a98614e-aaac-4cf4-8a37-17aeb5bfebd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_01707b1b-59c0-4edf-9313-63faefbb3eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_ShareBasedCompensation_01707b1b-59c0-4edf-9313-63faefbb3eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_720bb2ab-f45a-4aa5-b83e-2be0686a6f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_720bb2ab-f45a-4aa5-b83e-2be0686a6f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6cc61947-cdb4-4186-8e16-0065791cbcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6cc61947-cdb4-4186-8e16-0065791cbcdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5fee5bb7-0660-4275-8b00-5d98c9a3ba91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5fee5bb7-0660-4275-8b00-5d98c9a3ba91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_cb2be40c-9866-40b8-9d1a-af6b309f7abc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_cb2be40c-9866-40b8-9d1a-af6b309f7abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_84c23552-5c87-4f04-9bd1-6323cbf77680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_84c23552-5c87-4f04-9bd1-6323cbf77680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_65036aca-2b34-4dd0-89cf-a778e61d5773" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_65036aca-2b34-4dd0-89cf-a778e61d5773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7ee39a58-9f67-44c9-a87b-0efd7690df1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7ee39a58-9f67-44c9-a87b-0efd7690df1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84afb1bb-2619-4905-b1dd-a28af68f3c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_NetIncomeLoss_84afb1bb-2619-4905-b1dd-a28af68f3c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ce3a858a-c0df-4b04-bb30-77fc1a57b0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1b6ee72-b70f-410e-8534-51511514bbc8" xlink:to="loc_us-gaap_AssetImpairmentCharges_ce3a858a-c0df-4b04-bb30-77fc1a57b0a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_c5f21bac-08f1-4508-abfd-55773fa5dc95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_c5f21bac-08f1-4508-abfd-55773fa5dc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_26b5c1ec-57d2-4bdb-8b5a-3664ce271122" xlink:href="jnj-20210103.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_26b5c1ec-57d2-4bdb-8b5a-3664ce271122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f77fd812-5039-4174-af8e-45f0a44cc5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f77fd812-5039-4174-af8e-45f0a44cc5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_0a419a0d-3fc7-4492-8658-c64136dd22e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_0a419a0d-3fc7-4492-8658-c64136dd22e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_ab56c6aa-42d0-4692-914d-fec0989454ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_ab56c6aa-42d0-4692-914d-fec0989454ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d67f8e03-936f-47ca-aeaf-27150a0cec47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d67f8e03-936f-47ca-aeaf-27150a0cec47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ff2abbd-2ad2-4f0e-afc4-c16cf573f132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ff2abbd-2ad2-4f0e-afc4-c16cf573f132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e8914bc2-9206-4746-a69c-e6023bf40a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e8914bc2-9206-4746-a69c-e6023bf40a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_de42a6e7-9c9e-4e10-92ab-8f63b52806ae" xlink:href="jnj-20210103.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2713652-8ec6-4a5b-a4c8-bc6622fdff6e" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_de42a6e7-9c9e-4e10-92ab-8f63b52806ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20210103.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d0a991a0-e539-4d7e-b176-ab5b831b1193" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8e32f356-d9d5-4586-b5e5-1d461e6d9e25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d0a991a0-e539-4d7e-b176-ab5b831b1193" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8e32f356-d9d5-4586-b5e5-1d461e6d9e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_69d93a72-5687-438c-8867-20a398409582" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d0a991a0-e539-4d7e-b176-ab5b831b1193" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_69d93a72-5687-438c-8867-20a398409582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d1a99e3-dfb0-4e9e-9738-9e7ef7807d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d0a991a0-e539-4d7e-b176-ab5b831b1193" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d1a99e3-dfb0-4e9e-9738-9e7ef7807d6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipment"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0af49aaa-50d4-4ece-b715-ea99a3cfc6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_6dd27557-c2f4-47f5-bb13-87a033555189" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_0af49aaa-50d4-4ece-b715-ea99a3cfc6c0" xlink:to="loc_us-gaap_Land_6dd27557-c2f4-47f5-bb13-87a033555189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_84fde676-3e64-4dbd-be68-3d3064a32bce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_0af49aaa-50d4-4ece-b715-ea99a3cfc6c0" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_84fde676-3e64-4dbd-be68-3d3064a32bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4b85c39c-02df-4d1d-b583-48b5f00ff3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_0af49aaa-50d4-4ece-b715-ea99a3cfc6c0" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_4b85c39c-02df-4d1d-b583-48b5f00ff3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e9a2dd6f-c25c-4b65-b4b9-fefe5ffdd288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_0af49aaa-50d4-4ece-b715-ea99a3cfc6c0" xlink:to="loc_us-gaap_ConstructionInProgressGross_e9a2dd6f-c25c-4b65-b4b9-fefe5ffdd288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27416923-df19-4875-9e63-cddd6859ee64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1c044838-2c0f-4f9c-af72-21c7ae845c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_27416923-df19-4875-9e63-cddd6859ee64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1c044838-2c0f-4f9c-af72-21c7ae845c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8265d67-57c1-42bb-bdcf-d4011945a8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_27416923-df19-4875-9e63-cddd6859ee64" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8265d67-57c1-42bb-bdcf-d4011945a8cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_672396c2-9f23-44a6-8e54-1a1423514e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1d1b21fa-327e-483b-930a-4e0a4176c8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_672396c2-9f23-44a6-8e54-1a1423514e09" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1d1b21fa-327e-483b-930a-4e0a4176c8bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_12d92c75-7372-47d8-a1a1-64bfcde40ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_672396c2-9f23-44a6-8e54-1a1423514e09" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_12d92c75-7372-47d8-a1a1-64bfcde40ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b31f09ea-d3b0-4e39-bd20-fd044af57a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c42a62ef-3c87-4a21-bbac-5780f243a2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b31f09ea-d3b0-4e39-bd20-fd044af57a20" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c42a62ef-3c87-4a21-bbac-5780f243a2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_775ae131-53ca-4706-878d-968111459a72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b31f09ea-d3b0-4e39-bd20-fd044af57a20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_775ae131-53ca-4706-878d-968111459a72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Borrowings" xlink:type="simple" xlink:href="jnj-20210103.xsd#Borrowings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/Borrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93ad2fcc-866b-48b9-a3f1-c966b9201fab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_449e6131-6302-4c7b-8608-5a6b29f678bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_93ad2fcc-866b-48b9-a3f1-c966b9201fab" xlink:to="loc_us-gaap_LongTermDebtCurrent_449e6131-6302-4c7b-8608-5a6b29f678bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_adaf220e-5529-4dcf-870f-709388eb163b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_93ad2fcc-866b-48b9-a3f1-c966b9201fab" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_adaf220e-5529-4dcf-870f-709388eb163b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e387827e-d519-48f7-b716-6a3bb158fbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_92fd3bbb-a86c-46ba-ab81-31b17f904d12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e387827e-d519-48f7-b716-6a3bb158fbb8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_92fd3bbb-a86c-46ba-ab81-31b17f904d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8941e60d-b3f2-493d-9883-1475ff567eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e387827e-d519-48f7-b716-6a3bb158fbb8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8941e60d-b3f2-493d-9883-1475ff567eb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3a5697c3-bb4d-4648-bb45-fc8c19d70817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6894e099-9fac-47e1-86b9-8b734171664e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3a5697c3-bb4d-4648-bb45-fc8c19d70817" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6894e099-9fac-47e1-86b9-8b734171664e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b58dcfdf-2d12-42c7-8535-5ed42de9bdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3a5697c3-bb4d-4648-bb45-fc8c19d70817" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b58dcfdf-2d12-42c7-8535-5ed42de9bdbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a750f9ed-17fa-42b8-aa67-c5e452a3024b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9e0e04b7-5529-4a52-9af4-63e3854e78af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a750f9ed-17fa-42b8-aa67-c5e452a3024b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9e0e04b7-5529-4a52-9af4-63e3854e78af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_504726db-e54b-47b6-ac01-7dfaed43b023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a750f9ed-17fa-42b8-aa67-c5e452a3024b" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_504726db-e54b-47b6-ac01-7dfaed43b023" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e131950-fd4d-492b-aaca-48bc2462443f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e131950-fd4d-492b-aaca-48bc2462443f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_88d31c92-a8ce-4b28-bbd8-415a8ef7ddca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_88d31c92-a8ce-4b28-bbd8-415a8ef7ddca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_fe717f7e-fbbc-4a2d-9aff-b2c7c14200ea" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_fe717f7e-fbbc-4a2d-9aff-b2c7c14200ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_37a6e66f-5e6a-4e13-9318-da48c461d572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_37a6e66f-5e6a-4e13-9318-da48c461d572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_319bef1c-29bf-4b76-9565-43a2a6d64fee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_319bef1c-29bf-4b76-9565-43a2a6d64fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_2724f9a8-b93e-4fea-8e46-f3b3207a0859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f4956a5-b555-4f86-b9d9-a7d10e3c129b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_2724f9a8-b93e-4fea-8e46-f3b3207a0859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_919d1f74-f160-4b23-b1f8-e58cf30cf4af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_57e45954-9048-4746-92b8-cdf768754cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_919d1f74-f160-4b23-b1f8-e58cf30cf4af" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_57e45954-9048-4746-92b8-cdf768754cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_82ab7258-18cc-4a7f-bc54-ebf8c86eb25a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_919d1f74-f160-4b23-b1f8-e58cf30cf4af" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_82ab7258-18cc-4a7f-bc54-ebf8c86eb25a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3532554f-9960-422a-bce3-51b15afbad56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_a8d52db9-13b6-4782-8c1e-deb7f31f615a" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3532554f-9960-422a-bce3-51b15afbad56" xlink:to="loc_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_a8d52db9-13b6-4782-8c1e-deb7f31f615a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_907f8a5e-5fe1-47b8-9fd2-9d60f53fb50d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3532554f-9960-422a-bce3-51b15afbad56" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_907f8a5e-5fe1-47b8-9fd2-9d60f53fb50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_5ba2e665-6cdf-4ca6-9faf-baae17caecb7" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3532554f-9960-422a-bce3-51b15afbad56" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_5ba2e665-6cdf-4ca6-9faf-baae17caecb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_71f8f306-a44a-4dfd-bcd1-9d54979fd86f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3532554f-9960-422a-bce3-51b15afbad56" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_71f8f306-a44a-4dfd-bcd1-9d54979fd86f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a34f35bf-16ab-45ee-86e0-1217de076763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_3532554f-9960-422a-bce3-51b15afbad56" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a34f35bf-16ab-45ee-86e0-1217de076763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_40125ad4-4182-468c-8a34-2fcec693c191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_40125ad4-4182-468c-8a34-2fcec693c191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_95451dd5-d6d4-4491-82ed-63a9082dc9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_95451dd5-d6d4-4491-82ed-63a9082dc9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_fd245f12-23ec-48ca-bcb7-08f7ddf81b20" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_fd245f12-23ec-48ca-bcb7-08f7ddf81b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_17f6f94c-1311-400c-bca3-dad3fa789200" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_17f6f94c-1311-400c-bca3-dad3fa789200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_496bfbfc-60b5-43e1-abed-01e3e864ace8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_496bfbfc-60b5-43e1-abed-01e3e864ace8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_534f1490-8a14-4965-9f9b-27766dedf0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_534f1490-8a14-4965-9f9b-27766dedf0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_29f672e2-e976-48eb-a4ad-25ba474fff5b" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_29f672e2-e976-48eb-a4ad-25ba474fff5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_144868a7-193c-458f-aeda-de13d79726e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_144868a7-193c-458f-aeda-de13d79726e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_2b27c4f3-d99e-4eb7-8c13-26a6b6958f6e" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_2b27c4f3-d99e-4eb7-8c13-26a6b6958f6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_dbfeaaa4-8e72-433b-9c5c-313625888928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e995fc0a-ab1d-4532-9ae1-270875abb35d" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_dbfeaaa4-8e72-433b-9c5c-313625888928" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligations"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_e9266582-9655-4407-81e8-965e78f90a09" xlink:href="jnj-20210103.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_3f4d55b8-c7bb-485b-a644-856065ec69c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_e9266582-9655-4407-81e8-965e78f90a09" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_3f4d55b8-c7bb-485b-a644-856065ec69c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_733e38ff-5181-4561-9b8e-d4cd82509adf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_e9266582-9655-4407-81e8-965e78f90a09" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_733e38ff-5181-4561-9b8e-d4cd82509adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_1d9a998e-648f-4807-affb-aee6ad05a89b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_e9266582-9655-4407-81e8-965e78f90a09" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_1d9a998e-648f-4807-affb-aee6ad05a89b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_0921d077-be7b-443b-af37-20e4362fe1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_e9266582-9655-4407-81e8-965e78f90a09" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_0921d077-be7b-443b-af37-20e4362fe1f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_374676a0-6580-4327-b01d-f533b6ec6a29" xlink:href="jnj-20210103.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_839d0c00-aa1b-4a8b-8b3c-df3dfa80a512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_374676a0-6580-4327-b01d-f533b6ec6a29" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_839d0c00-aa1b-4a8b-8b3c-df3dfa80a512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b364a5f3-d559-436c-b462-f6d3d6672aac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_374676a0-6580-4327-b01d-f533b6ec6a29" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b364a5f3-d559-436c-b462-f6d3d6672aac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_13d60976-6e89-4456-a616-631fd19486c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_13d60976-6e89-4456-a616-631fd19486c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_388e2e5b-34bb-439c-afe7-43f40b310e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_388e2e5b-34bb-439c-afe7-43f40b310e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2aaf2e11-7faa-44d2-8a0d-96b8d33ae4f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2aaf2e11-7faa-44d2-8a0d-96b8d33ae4f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_30b262d3-7794-4966-9bab-6780a43348a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_30b262d3-7794-4966-9bab-6780a43348a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2bb410ec-9bf2-46de-9638-b52edc2cfbdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2bb410ec-9bf2-46de-9638-b52edc2cfbdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_702486f3-9525-4834-a8d0-26d092417965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f6848f03-53d2-45ad-acd1-08bc34a40bc8" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_702486f3-9525-4834-a8d0-26d092417965" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b4b0a388-76e5-4ee6-bde1-7fb8a14f759e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c72db85f-384e-4ba0-b63b-539bbb91e9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b4b0a388-76e5-4ee6-bde1-7fb8a14f759e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c72db85f-384e-4ba0-b63b-539bbb91e9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2bbf3b50-a339-4af3-afbc-52e7fd7e6b37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b4b0a388-76e5-4ee6-bde1-7fb8a14f759e" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2bbf3b50-a339-4af3-afbc-52e7fd7e6b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_144ce68d-5a10-476a-85e1-f848f38d85f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_314cc481-7c3e-4d10-97ee-a1ff98885e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_144ce68d-5a10-476a-85e1-f848f38d85f9" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_314cc481-7c3e-4d10-97ee-a1ff98885e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_16417651-c3a7-4ed9-973f-b8c86c8744f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_144ce68d-5a10-476a-85e1-f848f38d85f9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_16417651-c3a7-4ed9-973f-b8c86c8744f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_25baab47-e730-4034-a94a-dd17b5d355f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_144ce68d-5a10-476a-85e1-f848f38d85f9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_25baab47-e730-4034-a94a-dd17b5d355f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a5e42f57-1b33-46f3-829d-f101ac2fb590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_eab5f88e-655e-4e37-b4bc-0a423b5ef34f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a5e42f57-1b33-46f3-829d-f101ac2fb590" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_eab5f88e-655e-4e37-b4bc-0a423b5ef34f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_5780530f-4e74-4acb-beff-934b50d66e21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a5e42f57-1b33-46f3-829d-f101ac2fb590" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_5780530f-4e74-4acb-beff-934b50d66e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_2561c251-1d0a-4a12-a678-0a3a825c1858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a5e42f57-1b33-46f3-829d-f101ac2fb590" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_2561c251-1d0a-4a12-a678-0a3a825c1858" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlan" xlink:type="simple" xlink:href="jnj-20210103.xsd#SavingsPlan"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SavingsPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SavingsPlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStock"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="simple" xlink:href="jnj-20210103.xsd#InternationalCurrencyTranslation"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#InternationalCurrencyTranslationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42e4651b-0104-40f7-803b-4a47a63a4749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9576de2b-df2a-4053-b7eb-11958f8d574a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42e4651b-0104-40f7-803b-4a47a63a4749" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9576de2b-df2a-4053-b7eb-11958f8d574a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_bdf3bd4b-0275-4ffd-86ae-ae0a60e6b518" xlink:href="jnj-20210103.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42e4651b-0104-40f7-803b-4a47a63a4749" xlink:to="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_bdf3bd4b-0275-4ffd-86ae-ae0a60e6b518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_0a57887e-5021-42d2-93f5-1db9cb2d1709" xlink:href="jnj-20210103.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42e4651b-0104-40f7-803b-4a47a63a4749" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_0a57887e-5021-42d2-93f5-1db9cb2d1709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_3049c1fa-9ffc-4a23-9d9e-12df3e36d6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42e4651b-0104-40f7-803b-4a47a63a4749" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_3049c1fa-9ffc-4a23-9d9e-12df3e36d6ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreements"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20210103.xsd#AcquisitionsandDivestitures"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20210103.xsd#LegalProceedings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#LegalProceedingsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20210103.xsd#Restructuring"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>jnj-20210103_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:339fd7d9-9316-40d7-9d71-ee9342a8b33f,g:975259c4-ea12-43d4-8326-a0d386e906b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20210103.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended" id="i690daefa859044629f0d9802ac857a81_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_48a50673-90aa-4b2c-83cf-ba4c52f1b3c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentType_48a50673-90aa-4b2c-83cf-ba4c52f1b3c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4efe58b3-1b25-4276-9d4b-b4c47457a84d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentAnnualReport_4efe58b3-1b25-4276-9d4b-b4c47457a84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_81de251a-cc7d-44d2-95bd-7e4cef2a4120" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentPeriodEndDate_81de251a-cc7d-44d2-95bd-7e4cef2a4120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4aa54829-7a16-46c9-9b83-15001c9bef19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentTransitionReport_4aa54829-7a16-46c9-9b83-15001c9bef19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9675963d-ebe7-4ce8-926e-f83f54b76249" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityFileNumber_9675963d-ebe7-4ce8-926e-f83f54b76249" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b2da2dbb-4e2d-4459-ba77-71b0a1fcff3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityRegistrantName_b2da2dbb-4e2d-4459-ba77-71b0a1fcff3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9e02f1a4-627a-40b6-aaf5-10ab2824c1d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9e02f1a4-627a-40b6-aaf5-10ab2824c1d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_963f1259-7707-427c-b673-dbc4c98f503d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityTaxIdentificationNumber_963f1259-7707-427c-b673-dbc4c98f503d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6594c5d5-0e3a-46b5-be9b-c4a41995962d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressAddressLine1_6594c5d5-0e3a-46b5-be9b-c4a41995962d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_54dbb984-abbc-4b70-8683-dabd6224f574" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressCityOrTown_54dbb984-abbc-4b70-8683-dabd6224f574" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c3170f3b-e177-4dc7-a3f1-f8be57728a39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressStateOrProvince_c3170f3b-e177-4dc7-a3f1-f8be57728a39" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e5278907-c416-481d-bc25-690f9f5abe95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressPostalZipCode_e5278907-c416-481d-bc25-690f9f5abe95" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b22548d6-9797-4969-ac21-4277ab2d5641" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_CityAreaCode_b22548d6-9797-4969-ac21-4277ab2d5641" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3395d4a6-2f95-480b-9cf8-7da04f4507e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_LocalPhoneNumber_3395d4a6-2f95-480b-9cf8-7da04f4507e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_495b5ab7-17bb-4237-aa14-99e114d5e472" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_Security12bTitle_495b5ab7-17bb-4237-aa14-99e114d5e472" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_55890e16-2b69-4ad6-9365-a6afa9a98e13" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_TradingSymbol_55890e16-2b69-4ad6-9365-a6afa9a98e13" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ef8d70ec-73a1-4b36-abe2-d37541b8d990" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_SecurityExchangeName_ef8d70ec-73a1-4b36-abe2-d37541b8d990" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e89fcb90-a6ea-42ae-917b-05fab217d1a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e89fcb90-a6ea-42ae-917b-05fab217d1a7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7d8b1671-31ee-4d63-98dc-9648c71eaf21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityVoluntaryFilers_7d8b1671-31ee-4d63-98dc-9648c71eaf21" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b5020f97-7504-4f59-ad4a-e1c0c3c0134d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityCurrentReportingStatus_b5020f97-7504-4f59-ad4a-e1c0c3c0134d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_00a84bc2-1dde-43d2-ad69-5a3896e6e4cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityInteractiveDataCurrent_00a84bc2-1dde-43d2-ad69-5a3896e6e4cf" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_88465712-b107-43e7-8faa-b86a7e9fb32c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityFilerCategory_88465712-b107-43e7-8faa-b86a7e9fb32c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0b803d9e-3eeb-4e2d-b714-2f5e6fa476e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityEmergingGrowthCompany_0b803d9e-3eeb-4e2d-b714-2f5e6fa476e3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a7ed84d2-4548-45f2-a0a4-86d3a79266e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntitySmallBusiness_a7ed84d2-4548-45f2-a0a4-86d3a79266e5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8d16b2da-b9ac-496d-b0c3-b74bc9df4d78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8d16b2da-b9ac-496d-b0c3-b74bc9df4d78" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_874f0b5b-93ec-4e0b-9d8b-a6138dc0ea7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityShellCompany_874f0b5b-93ec-4e0b-9d8b-a6138dc0ea7c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_af0f727e-8783-4917-bbe0-4618bfd0f663" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityPublicFloat_af0f727e-8783-4917-bbe0-4618bfd0f663" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fb561139-dcf3-43f1-a4c9-8dc54eaf7cc9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fb561139-dcf3-43f1-a4c9-8dc54eaf7cc9" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_00702457-b9ad-4a50-b464-ea44f36e6016" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityCentralIndexKey_00702457-b9ad-4a50-b464-ea44f36e6016" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_feff0579-c353-49c8-8b96-789d76d1333f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_CurrentFiscalYearEndDate_feff0579-c353-49c8-8b96-789d76d1333f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_de3380dd-de2a-45fc-8f83-9e023a750e73" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentFiscalYearFocus_de3380dd-de2a-45fc-8f83-9e023a750e73" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8a9c7b9a-a357-480c-89c0-e61a55f3175b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8a9c7b9a-a357-480c-89c0-e61a55f3175b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e61db2f9-086c-4796-924c-068c1008042f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_AmendmentFlag_e61db2f9-086c-4796-924c-068c1008042f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:to="loc_us-gaap_ClassOfStockDomain_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:to="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d28fa499-5555-4abe-bdf6-03dbdec81a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_us-gaap_CommonStockMember_d28fa499-5555-4abe-bdf6-03dbdec81a2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_ed28b77a-0de7-44f1-b19a-7ffcc9658ef4" xlink:href="jnj-20210103.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A0.250NotesDue2022Member_ed28b77a-0de7-44f1-b19a-7ffcc9658ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_49f738d8-d00d-46f5-98ab-10e6c0d2df10" xlink:href="jnj-20210103.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A0.650NotesDue2024Member_49f738d8-d00d-46f5-98ab-10e6c0d2df10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_6a795717-7aea-499f-b0d4-895c660106dc" xlink:href="jnj-20210103.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A5.50NotesDue2024Member_6a795717-7aea-499f-b0d4-895c660106dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_daca5bf2-0840-47ba-9056-2020707290bf" xlink:href="jnj-20210103.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A1.150NotesDue2028Member_daca5bf2-0840-47ba-9056-2020707290bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_51d885c2-af86-4b10-885d-fae3ae63c8ae" xlink:href="jnj-20210103.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A1.650NotesDue2035Member_51d885c2-af86-4b10-885d-fae3ae63c8ae" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i762d98db356c4124a2f9370c9a8a33ae_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="iea235bcc2ace4c808e5ebd032d0fdd4e_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEarnings"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended" id="i1a68df2829e343b1a370de4f957cb8e3_ConsolidatedStatementsofEarnings"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="ie18bfb36a7c84f0286955e4bdb77fa1a_ConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended" id="ic8bafe0984a94459854406cb21132921_ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i04196ec455d3452586bc449c027c026a_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ef885f4-6eae-4183-aa48-cb54c84965e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ef885f4-6eae-4183-aa48-cb54c84965e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d47eab1f-f79e-4dc9-9dda-197d9180d392" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_NetIncomeLoss_d47eab1f-f79e-4dc9-9dda-197d9180d392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_88665fe3-5144-43d7-9bca-f7deb574501a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_DividendsCommonStockCash_88665fe3-5144-43d7-9bca-f7deb574501a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_769299f3-1292-4bda-8bd9-41d5a6d4eaba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_769299f3-1292-4bda-8bd9-41d5a6d4eaba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5fb7fa2b-cee1-4865-aba4-6b3b59be3999" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5fb7fa2b-cee1-4865-aba4-6b3b59be3999" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_adbf1edf-4ce6-437e-b35d-55c2aef00b08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_StockholdersEquityOther_adbf1edf-4ce6-437e-b35d-55c2aef00b08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5701fbf7-0473-4a14-8755-527105093abe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5701fbf7-0473-4a14-8755-527105093abe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8e73c6c-6697-4bc2-85c2-42d6307ba2df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd825379-6028-4c5b-aa6d-9ac16fe44048_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:to="loc_us-gaap_EquityComponentDomain_bd825379-6028-4c5b-aa6d-9ac16fe44048_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:to="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fc99bbb4-3d3a-4ea8-b2e5-e2d1178f8b59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_RetainedEarningsMember_fc99bbb4-3d3a-4ea8-b2e5-e2d1178f8b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_92058b92-9148-42ca-9902-ebd44da907a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_92058b92-9148-42ca-9902-ebd44da907a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a336558b-36c3-4be8-8efd-722616182c81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_CommonStockMember_a336558b-36c3-4be8-8efd-722616182c81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b026590-f959-49a4-b79f-6fbb2599853c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_TreasuryStockMember_2b026590-f959-49a4-b79f-6fbb2599853c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_427ed249-44c7-4912-a2ae-38fc2b61a5cf_default" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_427ed249-44c7-4912-a2ae-38fc2b61a5cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_6e85c3fb-04d7-4381-8cc0-c6ae95ada5f0" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_6e85c3fb-04d7-4381-8cc0-c6ae95ada5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_64b4d11b-cd57-460b-a780-d389b1ff38f3" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_6e85c3fb-04d7-4381-8cc0-c6ae95ada5f0" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_64b4d11b-cd57-460b-a780-d389b1ff38f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended" id="ie8399cdfd1fa49a29dfac81e867b5487_ConsolidatedStatementsofEquityParenthetical"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="idcfe3339254340e2a7526697fbd26d9d_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ie4d0435cf48e41a1a8e86852afe5426a_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="icda0fc2505d34cd1bad87cdef74bb99a_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i7a4444db54de431aa6b26d8f599d2d40_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i2e474220d4f149d0be14206db3957aac_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:href="jnj-20210103.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_8e177e7a-67b8-40e9-81be-0b1aeb9b7455" xlink:href="jnj-20210103.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_8e177e7a-67b8-40e9-81be-0b1aeb9b7455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7f698f31-7126-408f-9f92-fbccf5dc46d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_NumberOfReportableSegments_7f698f31-7126-408f-9f92-fbccf5dc46d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_5be72d28-cc2d-4cef-aa0b-5d5b69d47478" xlink:href="jnj-20210103.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_5be72d28-cc2d-4cef-aa0b-5d5b69d47478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_a0f1c017-4570-4f62-bd9e-5cdbad8ff3c4" xlink:href="jnj-20210103.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_a0f1c017-4570-4f62-bd9e-5cdbad8ff3c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6f8b29ad-6027-4c38-ab5a-b4312e07d1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6f8b29ad-6027-4c38-ab5a-b4312e07d1ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_46b73a72-d612-4904-bad6-6af8ccf6aefc" xlink:href="jnj-20210103.xsd#jnj_SalesReturnReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_SalesReturnReserve_46b73a72-d612-4904-bad6-6af8ccf6aefc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_49e13684-4160-406b-88cb-2de00b25dc4b" xlink:href="jnj-20210103.xsd#jnj_ProfitLossPercentToSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_ProfitLossPercentToSales_49e13684-4160-406b-88cb-2de00b25dc4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2da806dc-ad99-4616-a620-7fefe0c8be7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2da806dc-ad99-4616-a620-7fefe0c8be7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_c3325c63-1783-4a3d-8d63-953ff8a0aeed" xlink:href="jnj-20210103.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_c3325c63-1783-4a3d-8d63-953ff8a0aeed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ca8c838e-c47c-442e-86de-5274fc62b612" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ca8c838e-c47c-442e-86de-5274fc62b612" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_44d3ca4e-1110-4697-8463-ab48e6ac2300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_AdvertisingExpense_44d3ca4e-1110-4697-8463-ab48e6ac2300" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0802097-3931-4d1a-b550-dd391dc75cef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0802097-3931-4d1a-b550-dd391dc75cef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_53ae1912-202e-4113-a343-6b2bfef7ec8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseLiability_53ae1912-202e-4113-a343-6b2bfef7ec8e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b4c50da9-17e4-4387-bebb-ddf4a6c8b384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseCost_b4c50da9-17e4-4387-bebb-ddf4a6c8b384" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a4de8369-805f-406e-b7dc-c5bc0632a93f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeasePayments_a4de8369-805f-406e-b7dc-c5bc0632a93f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_152f5e23-2e2e-4049-977a-9ee677c968ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_152f5e23-2e2e-4049-977a-9ee677c968ee" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_e7769b7d-a80a-4cd8-9fb2-ce39be121ac2" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_e7769b7d-a80a-4cd8-9fb2-ce39be121ac2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_f78c3246-8a1d-4c32-beb6-836572a0dead" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_f78c3246-8a1d-4c32-beb6-836572a0dead" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_93567f80-55cb-4350-9b8d-58505042e176" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_93567f80-55cb-4350-9b8d-58505042e176" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_9bc42ca2-f10e-4b6e-9d8e-e925cb2d36a9" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_9bc42ca2-f10e-4b6e-9d8e-e925cb2d36a9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_4aa04384-c556-4409-94a9-b3a3fbcfe917" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_4aa04384-c556-4409-94a9-b3a3fbcfe917" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_38ee4beb-76e0-4c99-88ea-c4fb67d8bcd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_38ee4beb-76e0-4c99-88ea-c4fb67d8bcd2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_77d42660-6822-4bff-b565-4baea2b39a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_77d42660-6822-4bff-b565-4baea2b39a9e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_58c6af8a-df2a-4a2c-9f0a-450e8c321845" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_58c6af8a-df2a-4a2c-9f0a-450e8c321845" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:href="jnj-20210103.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:to="loc_us-gaap_SegmentDomain_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c8bc152f-cfb5-4976-b581-f228fcec63e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:to="loc_us-gaap_SegmentDomain_c8bc152f-cfb5-4976-b581-f228fcec63e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_81ecd1f2-eecb-4b23-be00-0d25cfb383b2" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c8bc152f-cfb5-4976-b581-f228fcec63e8" xlink:to="loc_jnj_PharmaceuticalMember_81ecd1f2-eecb-4b23-be00-0d25cfb383b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6baad30b-96ec-43b7-a129-7c974fef32a3_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:to="loc_srt_ProductsAndServicesDomain_6baad30b-96ec-43b7-a129-7c974fef32a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79b2f86f-8d17-4abb-9be8-985cd5790fe2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:to="loc_srt_ProductsAndServicesDomain_79b2f86f-8d17-4abb-9be8-985cd5790fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_bf8890ba-f9d7-454b-8d5f-911a5f8fd470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_79b2f86f-8d17-4abb-9be8-985cd5790fe2" xlink:to="loc_us-gaap_ShippingAndHandlingMember_bf8890ba-f9d7-454b-8d5f-911a5f8fd470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2166810f-0fdd-48f3-94cc-eb71b0177c01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:to="loc_us-gaap_EquityComponentDomain_2166810f-0fdd-48f3-94cc-eb71b0177c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fff01edf-2f82-45e8-9d98-27b9c8ea7ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:to="loc_us-gaap_EquityComponentDomain_fff01edf-2f82-45e8-9d98-27b9c8ea7ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ce9677a-ddd8-4bfe-91a5-347c9dd84336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fff01edf-2f82-45e8-9d98-27b9c8ea7ddb" xlink:to="loc_us-gaap_RetainedEarningsMember_1ce9677a-ddd8-4bfe-91a5-347c9dd84336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fef584b2-8244-4860-b97a-0caadc69521a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fef584b2-8244-4860-b97a-0caadc69521a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_33ccc400-1f8b-4333-9a46-e7806dfae8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_33ccc400-1f8b-4333-9a46-e7806dfae8fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_b7075e72-c15d-4f09-99d7-5254ff8d4816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_b7075e72-c15d-4f09-99d7-5254ff8d4816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingGuidanceMember_f0d89b53-2acf-43b1-8d40-6da9ddb686df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:to="loc_us-gaap_AccountingGuidanceMember_f0d89b53-2acf-43b1-8d40-6da9ddb686df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingGuidanceMember_96ac0575-3370-4df8-be45-fed7622df282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:to="loc_us-gaap_AccountingGuidanceMember_96ac0575-3370-4df8-be45-fed7622df282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c7015d3-3055-4451-a533-6cf374bb1777_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c7015d3-3055-4451-a533-6cf374bb1777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcae9355-5cf6-4b91-9813-7e876120a8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcae9355-5cf6-4b91-9813-7e876120a8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_986604f5-ca9e-46ba-a0cf-2a7f3d9ef728" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcae9355-5cf6-4b91-9813-7e876120a8d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_986604f5-ca9e-46ba-a0cf-2a7f3d9ef728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d95bf05-9e61-4108-95f8-0026370256c0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:to="loc_srt_RangeMember_0d95bf05-9e61-4108-95f8-0026370256c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:to="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60ac2c07-e106-465c-b843-760b7b1f4e80" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:to="loc_srt_MinimumMember_60ac2c07-e106-465c-b843-760b7b1f4e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f7b200f-e06c-4064-82e9-34aa1c41fac3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:to="loc_srt_MaximumMember_5f7b200f-e06c-4064-82e9-34aa1c41fac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsDomain_67bdb2cd-03d9-4b2c-bb36-014d2559bff7_default" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:to="loc_jnj_CustomersCollectionPatternsDomain_67bdb2cd-03d9-4b2c-bb36-014d2559bff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsDomain_94e92d30-870d-4860-a35e-2f9fbc4d4ec5" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:to="loc_jnj_CustomersCollectionPatternsDomain_94e92d30-870d-4860-a35e-2f9fbc4d4ec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90f1d6f3-b381-42c0-bc31-1a8b5b117a10_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:to="loc_srt_SegmentGeographicalDomain_90f1d6f3-b381-42c0-bc31-1a8b5b117a10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_16427e5e-b0c3-459f-af63-d464d17f41b1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:to="loc_srt_SegmentGeographicalDomain_16427e5e-b0c3-459f-af63-d464d17f41b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f0b5a41-79cb-4f44-9d61-af71c6845292_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f0b5a41-79cb-4f44-9d61-af71c6845292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4518926f-8ab0-4021-932c-3346ac36be80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4518926f-8ab0-4021-932c-3346ac36be80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_2b7e0710-6c94-4c23-9611-1ef40d384c47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4518926f-8ab0-4021-932c-3346ac36be80" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_2b7e0710-6c94-4c23-9611-1ef40d384c47" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" xlink:type="extended" id="i055351a780bc4417bdf33c31557bfd56_SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f9fa50a5-4b7a-4c23-96c2-b3ed79b6eca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dec3269b-c4ae-4341-abe9-fd3d96f265d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f9fa50a5-4b7a-4c23-96c2-b3ed79b6eca7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dec3269b-c4ae-4341-abe9-fd3d96f265d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f9fa50a5-4b7a-4c23-96c2-b3ed79b6eca7" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2f667e78-6cd3-46b2-87c0-6a514d4e93d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2f667e78-6cd3-46b2-87c0-6a514d4e93d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_33748fcb-e524-4605-9964-8434b636cc21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_33748fcb-e524-4605-9964-8434b636cc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_c638efa5-d7cd-4c75-b63b-64bc0827da45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_c638efa5-d7cd-4c75-b63b-64bc0827da45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccountingStandardUpdate201616Member_2af78c85-59e6-4ef0-a089-4ee777c0012b" xlink:href="jnj-20210103.xsd#jnj_AccountingStandardUpdate201616Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:to="loc_jnj_AccountingStandardUpdate201616Member_2af78c85-59e6-4ef0-a089-4ee777c0012b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6bf17f90-7e45-4400-a46c-961e8564b269_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:to="loc_us-gaap_EquityComponentDomain_6bf17f90-7e45-4400-a46c-961e8564b269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6e2af6a-1d2d-4618-87a8-cd02d5832c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:to="loc_us-gaap_EquityComponentDomain_f6e2af6a-1d2d-4618-87a8-cd02d5832c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_678eef79-75de-4910-aeb8-cba37792d952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f6e2af6a-1d2d-4618-87a8-cd02d5832c90" xlink:to="loc_us-gaap_RetainedEarningsMember_678eef79-75de-4910-aeb8-cba37792d952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_66f4437d-3189-47ec-9b2b-d546d4f4cb6f_default" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_66f4437d-3189-47ec-9b2b-d546d4f4cb6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_5af9ac1e-c02f-4e3d-aca5-7077d8955029" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_5af9ac1e-c02f-4e3d-aca5-7077d8955029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_288868c2-75d1-45dd-8431-ba16b89d789d" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_5af9ac1e-c02f-4e3d-aca5-7077d8955029" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_288868c2-75d1-45dd-8431-ba16b89d789d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended" id="idf7a52878da34a73a118448f6e696b70_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77070b47-d7af-4bdd-9035-4eb2fef1fde6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bc08e48-bbdf-46ca-9f42-e64e4e7d944d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77070b47-d7af-4bdd-9035-4eb2fef1fde6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bc08e48-bbdf-46ca-9f42-e64e4e7d944d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77070b47-d7af-4bdd-9035-4eb2fef1fde6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:to="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3a1597c-faa3-48ae-8d44-ace377bcb327_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:to="loc_srt_RangeMember_a3a1597c-faa3-48ae-8d44-ace377bcb327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:to="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ad42facd-83fa-4597-95a8-8f2eca32d3a2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:to="loc_srt_MinimumMember_ad42facd-83fa-4597-95a8-8f2eca32d3a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40158eb5-8bb8-49d5-9ad4-294eddca9d2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:to="loc_srt_MaximumMember_40158eb5-8bb8-49d5-9ad4-294eddca9d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d681d962-2034-406f-9c1a-62b1435d30c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d681d962-2034-406f-9c1a-62b1435d30c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_f5679c9c-e9b8-4437-a53e-4af598266f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_f5679c9c-e9b8-4437-a53e-4af598266f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_83e0d2ff-38b0-4a8a-8e4b-63a913d9d7b5" xlink:href="jnj-20210103.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_83e0d2ff-38b0-4a8a-8e4b-63a913d9d7b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ba9d0ccf-fe16-4806-b98b-9c21952c503b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ba9d0ccf-fe16-4806-b98b-9c21952c503b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="extended" id="i30f722ac577c4aefb0cfb8ad9b3e16fb_CashCashEquivalentsandCurrentMarketableSecurities"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="extended" id="id9f486aee429468cae42617c330217d1_CashCashEquivalentsandCurrentMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended" id="i334487ec3129407292f98d3dc7bc0e8a_CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_bf7371b0-f35f-48ea-b959-012f1141d94e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_bf7371b0-f35f-48ea-b959-012f1141d94e" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_7665a399-c593-454d-958e-75b8b57ffcdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_HeldToMaturitySecurities_7665a399-c593-454d-958e-75b8b57ffcdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b55a5cdb-b594-49f2-97e7-f309dc2d9ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b55a5cdb-b594-49f2-97e7-f309dc2d9ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c0ff6f0-dc23-45e0-8306-8aa6ecc33320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c0ff6f0-dc23-45e0-8306-8aa6ecc33320" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a75999f8-66e9-4087-a70f-71625bf9ec3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a75999f8-66e9-4087-a70f-71625bf9ec3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4e7ad854-d0a4-4212-94a0-b28b9ebdb6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4e7ad854-d0a4-4212-94a0-b28b9ebdb6ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_181d2f22-f3ac-476f-82ee-6b51d8c32a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_181d2f22-f3ac-476f-82ee-6b51d8c32a06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_bf7371b0-f35f-48ea-b959-012f1141d94e" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_ecc0bbac-05ed-4279-861e-ef5f5a077ab6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_ecc0bbac-05ed-4279-861e-ef5f5a077ab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_dca83cc5-fbbf-423e-8099-c09d29fd1985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_dca83cc5-fbbf-423e-8099-c09d29fd1985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_092a18a1-32d1-48e0-b472-c5fbafc7be02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_092a18a1-32d1-48e0-b472-c5fbafc7be02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:to="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ecf80d43-57c4-4e35-bff8-b10eae48a270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_CashMember_ecf80d43-57c4-4e35-bff8-b10eae48a270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_71e2009e-ee81-4a77-ab93-670f460f105a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_71e2009e-ee81-4a77-ab93-670f460f105a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_68a6c8db-4e7c-48eb-87a8-7230a9c1e4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_68a6c8db-4e7c-48eb-87a8-7230a9c1e4e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_54f3c2bd-6385-4961-926e-631e8a1ab1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_54f3c2bd-6385-4961-926e-631e8a1ab1fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherReverseRepurchaseAgreementsMember_bb8221ba-e5fa-4ed5-a3aa-424485ee098d" xlink:href="jnj-20210103.xsd#jnj_OtherReverseRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_jnj_OtherReverseRepurchaseAgreementsMember_bb8221ba-e5fa-4ed5-a3aa-424485ee098d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6aed7453-dd4f-496c-9482-f9f49924ffdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6aed7453-dd4f-496c-9482-f9f49924ffdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8d7149fa-2719-4dd4-8f3f-d713b682901d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8d7149fa-2719-4dd4-8f3f-d713b682901d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_f5f7ba8a-94ff-4f61-9c0d-09b46751600b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_BankTimeDepositsMember_f5f7ba8a-94ff-4f61-9c0d-09b46751600b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember_5c66a98a-f429-4330-bef2-091edd1887aa" xlink:href="jnj-20210103.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_jnj_OtherSovereignSecuritiesMember_5c66a98a-f429-4330-bef2-091edd1887aa" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i1c1154af79c1497b9e283b67a797c814_CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20210103.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended" id="i785f8019cc9a4169b659bbe082ba73e1_Inventories"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended" id="i0224d5ffd90f49ea87981bfc6ce9302d_InventoriesTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended" id="ib34add13169948e58f157beadb7b55ae_InventoriesDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipment"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="extended" id="i2d7e3fe356f9431b8dbbfc5780c956f1_PropertyPlantandEquipment"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="extended" id="i7e7925612fd34592897f92ef402fa4ed_PropertyPlantandEquipmentTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended" id="i05e2f59bda384e65a35755b1eb86903b_PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended" id="i66de83ec16204e40afe8dac315a1dcc4_PropertyPlantandEquipmentNarrativeDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended" id="ia7ab21979baa48c38f800daccc28c7b0_IntangibleAssetsandGoodwill"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended" id="i8467335f7b784989b7c7f46d9d50661c_IntangibleAssetsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i98fc0ca5699e4aba928d12beebb64fb0_IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:href="jnj-20210103.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f59fd69f-c3a4-4818-8f92-323c8ec772ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f59fd69f-c3a4-4818-8f92-323c8ec772ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4ffff9e6-3968-4772-ae99-9832e372268c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4ffff9e6-3968-4772-ae99-9832e372268c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2dc5e65-5136-419a-a483-b566c13d71bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2dc5e65-5136-419a-a483-b566c13d71bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd8815cc-c12b-41e2-91ad-ffdd5dcf1629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd8815cc-c12b-41e2-91ad-ffdd5dcf1629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f9363f80-ca81-4aa0-8d40-b6b000bc1559" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f9363f80-ca81-4aa0-8d40-b6b000bc1559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14339e9b-e824-4e2b-870c-8734333cceb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14339e9b-e824-4e2b-870c-8734333cceb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11b2e691-f114-4ac9-aa4b-63edba5f43a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11b2e691-f114-4ac9-aa4b-63edba5f43a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_07c23f8c-49ac-49f8-b80b-1a9f7cb2e0fd" xlink:href="jnj-20210103.xsd#jnj_MomentaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:to="loc_jnj_MomentaMember_07c23f8c-49ac-49f8-b80b-1a9f7cb2e0fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_4839b5d6-4b8a-4e4b-b50c-2db1cfacd119" xlink:href="jnj-20210103.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:to="loc_jnj_BermekimabMember_4839b5d6-4b8a-4e4b-b50c-2db1cfacd119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_fde261d8-f07d-49e9-aee7-fb2fc4b953ba" xlink:href="jnj-20210103.xsd#jnj_VerbSurgicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:to="loc_jnj_VerbSurgicalIncMember_fde261d8-f07d-49e9-aee7-fb2fc4b953ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2b904ac-da22-421c-b9fb-7a32a55f7078_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2b904ac-da22-421c-b9fb-7a32a55f7078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_4402f605-4221-40e9-b0f8-baee14bd2917" xlink:href="jnj-20210103.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:to="loc_jnj_PatentsAndTrademarksMember_4402f605-4221-40e9-b0f8-baee14bd2917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_10af1b59-252f-4e10-89f8-0e8a4f97f1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_10af1b59-252f-4e10-89f8-0e8a4f97f1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e2e036ed-d096-4e76-905b-16b2b00b8028" xlink:href="jnj-20210103.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e2e036ed-d096-4e76-905b-16b2b00b8028" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a90df669-94c0-4916-81ac-3451ea6af585_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a90df669-94c0-4916-81ac-3451ea6af585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_4fe6389d-fd26-4779-94f3-aff5a3e169a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:to="loc_us-gaap_TrademarksMember_4fe6389d-fd26-4779-94f3-aff5a3e169a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1314f0dd-29f5-4e9e-8599-0b768a8d4cd6" xlink:href="jnj-20210103.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1314f0dd-29f5-4e9e-8599-0b768a8d4cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_65e5b724-81eb-4b6b-bece-f62c4454c18d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_65e5b724-81eb-4b6b-bece-f62c4454c18d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended" id="i29a21fb5b8e84922ad690995adf8bf04_IntangibleAssetsandGoodwillGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_aad3e810-0d02-4b22-87a9-cd79e41482f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_aad3e810-0d02-4b22-87a9-cd79e41482f2" xlink:to="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_879fa7bf-56c8-47db-a4bd-704bab2ade6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_Goodwill_879fa7bf-56c8-47db-a4bd-704bab2ade6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_421b363b-a102-4bb1-9b5b-b4171be1725b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_421b363b-a102-4bb1-9b5b-b4171be1725b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_b451eb1b-3c5b-4b81-980b-e14bbcde812b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_b451eb1b-3c5b-4b81-980b-e14bbcde812b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b4d2a0e5-306c-40a1-bf61-e01de77d5c60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_aad3e810-0d02-4b22-87a9-cd79e41482f2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:to="loc_us-gaap_SegmentDomain_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:to="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_c2fdd1ca-f2a0-4ee9-9aa7-d4aefce2d091" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:to="loc_jnj_ConsumerMember_c2fdd1ca-f2a0-4ee9-9aa7-d4aefce2d091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_d8d88b68-499d-4867-9ba5-e0df1df7c869" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:to="loc_jnj_PharmaceuticalMember_d8d88b68-499d-4867-9ba5-e0df1df7c869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_9a3a34ee-6c6a-4e2d-8e08-fa435f7e5227" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:to="loc_jnj_MedicalDevicesMember_9a3a34ee-6c6a-4e2d-8e08-fa435f7e5227" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="ib4ddd687f9084d4fbac0b5fc86e2ff90_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8e38a153-9177-4a70-b217-da2d28b311ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8e38a153-9177-4a70-b217-da2d28b311ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e70f6bfb-df48-470a-9922-08bd60839889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e70f6bfb-df48-470a-9922-08bd60839889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3add845-13bc-4b5a-96b2-579a09d319e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3add845-13bc-4b5a-96b2-579a09d319e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_097deadd-5531-48c4-a52b-ce930f31327c" xlink:href="jnj-20210103.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:to="loc_jnj_PatentsAndTrademarksMember_097deadd-5531-48c4-a52b-ce930f31327c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_f34f4536-46c8-45e5-aa68-14ae99495a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_f34f4536-46c8-45e5-aa68-14ae99495a8f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" xlink:type="extended" id="ibc7c3eb1346c4f45a82db75f726e3b6f_IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended" id="idb0011f9a66444f1a42e26c4311af1bb_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i3ff1000e151b4a92a3c9e9e9a230922a_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i32fcdfd2df924bff905895aa0a402036_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_e37f5eca-4a5b-4325-9bd2-948874cb8a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_e37f5eca-4a5b-4325-9bd2-948874cb8a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_5a83518a-e15d-4d46-abb6-270510d6f7ef" xlink:href="jnj-20210103.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_5a83518a-e15d-4d46-abb6-270510d6f7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ede1a7d-99b6-436e-a7fd-8b9d7c34d084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ede1a7d-99b6-436e-a7fd-8b9d7c34d084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6da11fe1-020a-4a5c-93e4-c996cb6258e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6da11fe1-020a-4a5c-93e4-c996cb6258e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1703da60-c008-4c61-81ba-a4637c780dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1703da60-c008-4c61-81ba-a4637c780dc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_168cbecc-fc0d-430c-93a5-8f063060dca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_168cbecc-fc0d-430c-93a5-8f063060dca8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_cfcde34f-ed9b-4921-9681-7eed98209634" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_EquityFairValueAdjustment_cfcde34f-ed9b-4921-9681-7eed98209634" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_6cf64ad1-409d-41c5-83d2-71e5477622b3" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_6cf64ad1-409d-41c5-83d2-71e5477622b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_11568976-bbaa-43be-95e3-7136ec3432ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_DerivativeNotionalAmount_11568976-bbaa-43be-95e3-7136ec3432ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_736ab5cf-1c97-4ab7-beea-03108f86b9db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_736ab5cf-1c97-4ab7-beea-03108f86b9db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e2bbe7d-3191-4654-8a80-8948ad9690d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e2bbe7d-3191-4654-8a80-8948ad9690d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79b9f507-de43-4ff1-aafb-4e052fb32af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79b9f507-de43-4ff1-aafb-4e052fb32af4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_6b79e4ac-1f6d-4704-b1de-914382f39a73" xlink:href="jnj-20210103.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_6b79e4ac-1f6d-4704-b1de-914382f39a73" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_744a03bd-0e0a-45bf-897b-188e22e7b166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_744a03bd-0e0a-45bf-897b-188e22e7b166" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6b29cd5b-e6d4-476a-8e22-fbcbea83f5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6b29cd5b-e6d4-476a-8e22-fbcbea83f5ea" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c32ff995-d907-4bff-917d-88c11567c249" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c32ff995-d907-4bff-917d-88c11567c249" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_03bead18-0c14-41bb-94a6-0d3bac927b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_03bead18-0c14-41bb-94a6-0d3bac927b54" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d24311ca-dbcb-46bb-9713-88ba367c4889_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d24311ca-dbcb-46bb-9713-88ba367c4889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_24848588-3dfd-409a-b2bb-71d0147bc60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_24848588-3dfd-409a-b2bb-71d0147bc60d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06709909-1903-459e-b949-2dd1b03c6da6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06709909-1903-459e-b949-2dd1b03c6da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c778856f-2bf6-4a08-b6b4-a567b415a583_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c778856f-2bf6-4a08-b6b4-a567b415a583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf5d5a0-8dcd-4293-93b4-33c4ba211574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf5d5a0-8dcd-4293-93b4-33c4ba211574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_db186373-2c16-49c7-bbfc-fa06d54726b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf5d5a0-8dcd-4293-93b4-33c4ba211574" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_db186373-2c16-49c7-bbfc-fa06d54726b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e202eadf-666a-4c1f-aa14-196c94f91a57_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e202eadf-666a-4c1f-aa14-196c94f91a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_67cd2643-40eb-4c04-bda9-ad29c14072b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_67cd2643-40eb-4c04-bda9-ad29c14072b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_72e9ae0a-cc94-4551-8215-b8499a5ddf16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_67cd2643-40eb-4c04-bda9-ad29c14072b1" xlink:to="loc_us-gaap_EquitySecuritiesMember_72e9ae0a-cc94-4551-8215-b8499a5ddf16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a68ec473-863e-4299-9431-76a87c5d550b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a68ec473-863e-4299-9431-76a87c5d550b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_6b1c82ac-10cf-41b4-896c-f6454b7542b3" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_6b1c82ac-10cf-41b4-896c-f6454b7542b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_38548527-d4dc-4f20-8ece-8c7d6f5fb15c" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_38548527-d4dc-4f20-8ece-8c7d6f5fb15c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aa576ff5-66a5-4094-af96-97d91ffcfc1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aa576ff5-66a5-4094-af96-97d91ffcfc1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_707aab59-0e51-468a-ad55-992a0300cc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:to="loc_us-gaap_ForeignExchangeContractMember_707aab59-0e51-468a-ad55-992a0300cc1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_03f10222-d46f-4091-b600-6eda6f288b53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_03f10222-d46f-4091-b600-6eda6f288b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_07922de2-9d54-490c-acbd-9dcc02a431cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:to="loc_us-gaap_InterestRateContractMember_07922de2-9d54-490c-acbd-9dcc02a431cb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i369dfbd1e5aa44bca7dd08973f518465_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_44d301d4-0880-4a53-9176-235cefba2349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_44d301d4-0880-4a53-9176-235cefba2349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_45252a05-2313-46b4-91a1-14d88c3bae84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_45252a05-2313-46b4-91a1-14d88c3bae84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_37e69da2-a0ba-4859-a566-fd67c382d70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_37e69da2-a0ba-4859-a566-fd67c382d70a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3ee0eea1-1bee-4a05-aa8c-d112094ffbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3ee0eea1-1bee-4a05-aa8c-d112094ffbe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a5d9809-3996-4eac-9468-22768a4c13f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a5d9809-3996-4eac-9468-22768a4c13f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_175e445d-972f-464b-ae24-9556683ac36b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_us-gaap_SalesMember_175e445d-972f-464b-ae24-9556683ac36b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1d3c3c2f-b26c-44b2-8f32-874c05910fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_us-gaap_CostOfSalesMember_1d3c3c2f-b26c-44b2-8f32-874c05910fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53d3f338-dcfe-444c-949c-cbb0335e4116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53d3f338-dcfe-444c-949c-cbb0335e4116" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_5b5e5d5d-61bb-4172-b56f-8a7f137e750d" xlink:href="jnj-20210103.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_5b5e5d5d-61bb-4172-b56f-8a7f137e750d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_091d57b4-2000-4ade-bfa2-cf7b1dd6bde4" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_091d57b4-2000-4ade-bfa2-cf7b1dd6bde4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0aaf3d91-b231-4103-8026-5f35a984926f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0aaf3d91-b231-4103-8026-5f35a984926f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a3830520-1097-4173-a559-89c5ea66dfd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:to="loc_us-gaap_InterestRateContractMember_a3830520-1097-4173-a559-89c5ea66dfd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_a434081b-2909-47a6-8f6f-756d0c44e29f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_a434081b-2909-47a6-8f6f-756d0c44e29f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_47a12e8c-7241-43db-932b-664e4382a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:to="loc_us-gaap_ForeignExchangeContractMember_47a12e8c-7241-43db-932b-664e4382a9d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6edc405e-1e10-4069-82e4-95621bc88bf9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6edc405e-1e10-4069-82e4-95621bc88bf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_32d38d99-0fd9-4880-a291-6c1102868daa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:to="loc_us-gaap_FairValueHedgingMember_32d38d99-0fd9-4880-a291-6c1102868daa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_427a2e99-1f85-478d-a237-13f7a81fee05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:to="loc_us-gaap_CashFlowHedgingMember_427a2e99-1f85-478d-a237-13f7a81fee05" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="idde68b0fa7784acab1154dc63818c2a7_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_049af84a-ed50-48e2-8cdc-c421c8968791" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e496a82f-ca4e-47ad-a7d3-93fd05850a15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_049af84a-ed50-48e2-8cdc-c421c8968791" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e496a82f-ca4e-47ad-a7d3-93fd05850a15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_049af84a-ed50-48e2-8cdc-c421c8968791" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_256dba64-532d-4645-ba24-a4faaf4ff924_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:to="loc_us-gaap_HedgingRelationshipDomain_256dba64-532d-4645-ba24-a4faaf4ff924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ad741b87-7fd5-4f46-b323-097c597fceb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ad741b87-7fd5-4f46-b323-097c597fceb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_44d37ad6-41ca-4463-bb96-c5edf084ea97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ad741b87-7fd5-4f46-b323-097c597fceb2" xlink:to="loc_us-gaap_FairValueHedgingMember_44d37ad6-41ca-4463-bb96-c5edf084ea97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_90cfb055-852c-4766-8a77-52b58f176a9a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_90cfb055-852c-4766-8a77-52b58f176a9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_8144ba9e-aaa1-4319-a573-a493a0c8f40f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:to="loc_us-gaap_InterestRateContractMember_8144ba9e-aaa1-4319-a573-a493a0c8f40f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f592edd2-7470-474a-828a-465cd7facabd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f592edd2-7470-474a-828a-465cd7facabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_14af473f-c03e-4b2d-8c3b-9cba9d50a68a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:to="loc_us-gaap_HedgingDesignationDomain_14af473f-c03e-4b2d-8c3b-9cba9d50a68a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ed87555a-354c-4dda-b167-6867c6c83bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:to="loc_us-gaap_HedgingDesignationDomain_ed87555a-354c-4dda-b167-6867c6c83bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_07af93b0-c7c9-4cb9-9b57-c7e4858476c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ed87555a-354c-4dda-b167-6867c6c83bd4" xlink:to="loc_us-gaap_NondesignatedMember_07af93b0-c7c9-4cb9-9b57-c7e4858476c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5d659753-5f65-48f5-a15e-b8871bd90b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:to="loc_us-gaap_SalesMember_5d659753-5f65-48f5-a15e-b8871bd90b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_55e589e5-8f9c-4fbb-975e-b1d33f742cdf" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_55e589e5-8f9c-4fbb-975e-b1d33f742cdf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="ifae3fc1b03334b04bffd238358276893_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_937499e8-9742-431d-b26e-a55a7cb06661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_937499e8-9742-431d-b26e-a55a7cb06661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_08f0117e-09f2-4174-a610-a898299b7c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_08f0117e-09f2-4174-a610-a898299b7c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dde3c90-68ce-46b1-90f9-90e69a638090_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dde3c90-68ce-46b1-90f9-90e69a638090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfSubsidiaryGainLossMember_2690d1c1-6cfc-4e5c-8362-e289f0d5ad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfSubsidiaryGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:to="loc_us-gaap_SaleOfSubsidiaryGainLossMember_2690d1c1-6cfc-4e5c-8362-e289f0d5ad3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_e3f073e1-d8f5-4b35-b9f8-a4cf4152f1b0" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_e3f073e1-d8f5-4b35-b9f8-a4cf4152f1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4b0c9bbf-382a-4090-a873-7dcdbfaa9786_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4b0c9bbf-382a-4090-a873-7dcdbfaa9786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5e1a5cc9-dd44-4133-a8f6-31fc90e74e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5e1a5cc9-dd44-4133-a8f6-31fc90e74e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_0aaaf0be-f712-4359-9b34-c6d5d82e96a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5e1a5cc9-dd44-4133-a8f6-31fc90e74e86" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_0aaaf0be-f712-4359-9b34-c6d5d82e96a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="i392e1b17dd4546f98c4c6dad96f6fe30_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_ba614703-57e7-43ad-aaef-43b50097a2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_ba614703-57e7-43ad-aaef-43b50097a2cc" xlink:to="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f6475413-98ba-4f36-b40b-d67b976c1de7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f6475413-98ba-4f36-b40b-d67b976c1de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_310f138f-9055-4653-afd1-6963cfa9f9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_EquityFairValueAdjustment_310f138f-9055-4653-afd1-6963cfa9f9b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_40a06d91-665d-4efe-931f-f733249e0aeb" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_40a06d91-665d-4efe-931f-f733249e0aeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ff614135-5c45-40d8-97cf-0813e3bccd80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ff614135-5c45-40d8-97cf-0813e3bccd80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f4990a2-c7d5-4e81-824c-916c71cfbdca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f4990a2-c7d5-4e81-824c-916c71cfbdca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_ba614703-57e7-43ad-aaef-43b50097a2cc" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d106aba4-dd0e-4291-8354-e18a994e7913_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d106aba4-dd0e-4291-8354-e18a994e7913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0d543771-f7d4-49d1-97a3-461b2ff9b6ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0d543771-f7d4-49d1-97a3-461b2ff9b6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f871137b-11f6-4807-b5cc-15d93aa6be0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0d543771-f7d4-49d1-97a3-461b2ff9b6ea" xlink:to="loc_us-gaap_EquitySecuritiesMember_f871137b-11f6-4807-b5cc-15d93aa6be0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a5bf0980-ee7e-4786-855f-b9023f765973_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a5bf0980-ee7e-4786-855f-b9023f765973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_65f247b5-6016-4aac-bb02-1a1fc889ffdc" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_65f247b5-6016-4aac-bb02-1a1fc889ffdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_7ff8c326-c1f1-44e1-ab5c-8eb26b755666" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_7ff8c326-c1f1-44e1-ab5c-8eb26b755666" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="id155269f6526442c960c079ab1365034_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b97f3194-1505-4e78-8413-545876dbb34c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b97f3194-1505-4e78-8413-545876dbb34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_c3829a61-675b-46dc-8a82-6281c9f3ffe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_c3829a61-675b-46dc-8a82-6281c9f3ffe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8c27a4ec-45f9-4019-b784-c9fa2c8608b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8c27a4ec-45f9-4019-b784-c9fa2c8608b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7eef99ab-6604-4946-bbe2-69699f89473a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7eef99ab-6604-4946-bbe2-69699f89473a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_57d4614c-ed67-447b-8d91-981626100021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_57d4614c-ed67-447b-8d91-981626100021" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a7e52ae-211c-450c-81c4-b2fa4e0c09e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a7e52ae-211c-450c-81c4-b2fa4e0c09e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_69b7b132-858b-4369-a924-f75dbc2f84db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_69b7b132-858b-4369-a924-f75dbc2f84db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_64fa852f-9b55-40ac-b2f9-b4da2c3012cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_64fa852f-9b55-40ac-b2f9-b4da2c3012cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_fc363727-1d0e-477b-a252-b5e5331be384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_fc363727-1d0e-477b-a252-b5e5331be384" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7f2cbbcc-7cb6-4c53-8e1e-56e459021953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeAssets_7f2cbbcc-7cb6-4c53-8e1e-56e459021953" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c897ced-1b4b-44b9-b689-af9a1d9938a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c897ced-1b4b-44b9-b689-af9a1d9938a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0e163f2f-0b0a-4d1f-aaab-99d5f55def1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0e163f2f-0b0a-4d1f-aaab-99d5f55def1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_51b7a6b3-c1c5-4514-b5e6-d1ae985cd6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeLiabilities_51b7a6b3-c1c5-4514-b5e6-d1ae985cd6ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b7425309-36c3-4d1d-84cc-c4911f467ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b7425309-36c3-4d1d-84cc-c4911f467ce1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_93b4e2b8-8977-486d-9561-247b05fc8212" xlink:href="jnj-20210103.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_93b4e2b8-8977-486d-9561-247b05fc8212" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d626002b-a80d-43c8-8ad1-88f3659e020e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d626002b-a80d-43c8-8ad1-88f3659e020e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7c95cc5d-35ca-41cc-a89b-5d231f1064ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7c95cc5d-35ca-41cc-a89b-5d231f1064ec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_79217428-6cb9-4ff0-bbf4-054f13d39d47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8582a220-dd86-477d-89f5-12cdb6fbd08f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8582a220-dd86-477d-89f5-12cdb6fbd08f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc0e1261-838e-4bf1-b44a-4dad8e22439d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc0e1261-838e-4bf1-b44a-4dad8e22439d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7d424ef9-5eae-4473-b846-cde95ad3d1f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:to="loc_us-gaap_HedgingDesignationDomain_7d424ef9-5eae-4473-b846-cde95ad3d1f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_638e62ca-7e3a-4e75-ae1e-5f4d954fbce2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:to="loc_us-gaap_HedgingDesignationDomain_638e62ca-7e3a-4e75-ae1e-5f4d954fbce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9bc11d32-8d91-4249-92dd-2899493f8109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_638e62ca-7e3a-4e75-ae1e-5f4d954fbce2" xlink:to="loc_us-gaap_NondesignatedMember_9bc11d32-8d91-4249-92dd-2899493f8109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_deb59534-03da-4cf3-ac03-5ed67a60bf2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_deb59534-03da-4cf3-ac03-5ed67a60bf2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9211402f-beb2-4eec-8ed9-5e8dea2ecbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:to="loc_us-gaap_InterestRateContractMember_9211402f-beb2-4eec-8ed9-5e8dea2ecbd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_bb494e54-dd7d-4510-8362-c10658cd9698" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:to="loc_us-gaap_ForeignExchangeContractMember_bb494e54-dd7d-4510-8362-c10658cd9698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_201cc5a6-d8c6-48bb-9065-98e9299c9c50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_201cc5a6-d8c6-48bb-9065-98e9299c9c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ddc55022-5ebd-4721-bba3-b0505d0ab1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ddc55022-5ebd-4721-bba3-b0505d0ab1a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0513710b-fe44-4f4c-a5a6-b71c0b13c582" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0513710b-fe44-4f4c-a5a6-b71c0b13c582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5f49f004-b174-48dc-b4e4-0e02cd16eaef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5f49f004-b174-48dc-b4e4-0e02cd16eaef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46f69d3f-90f5-45b9-a1b5-251f62263606" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46f69d3f-90f5-45b9-a1b5-251f62263606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f22443b4-04d0-4711-8a14-2fc950b36c62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46f69d3f-90f5-45b9-a1b5-251f62263606" xlink:to="loc_us-gaap_EquitySecuritiesMember_f22443b4-04d0-4711-8a14-2fc950b36c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_222facd6-55f7-4550-8723-11a7c4639652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_222facd6-55f7-4550-8723-11a7c4639652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_17d8bff4-321a-45dc-a0fa-721cfed8eaed" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_222facd6-55f7-4550-8723-11a7c4639652" xlink:to="loc_jnj_AurisHealthMember_17d8bff4-321a-45dc-a0fa-721cfed8eaed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0c68e225-5fd9-4532-842b-f06ff8d0a2d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0c68e225-5fd9-4532-842b-f06ff8d0a2d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_31b5c0de-93c4-4200-b88b-c585d153e4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_31b5c0de-93c4-4200-b88b-c585d153e4ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7ef7123f-1ae6-4877-a456-cbf039e66947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7ef7123f-1ae6-4877-a456-cbf039e66947" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Borrowings" xlink:type="simple" xlink:href="jnj-20210103.xsd#Borrowings"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Borrowings" xlink:type="extended" id="i054b18cff3334cbdab27a6bf84fb0660_Borrowings"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsTables" xlink:type="extended" id="ia8b0cb3ada2542f48159d2f70d5f6b74_BorrowingsTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended" id="i173e2f79bac94aa1b097ec744e9bab7d_BorrowingsScheduleofLongtermDebtInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a86991f8-e4f7-4cc5-aa0f-dfb1a9040876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a86991f8-e4f7-4cc5-aa0f-dfb1a9040876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_919d5b81-0100-4287-b20a-549703219045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_919d5b81-0100-4287-b20a-549703219045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4e07376e-1c1e-43d1-88e0-9c1b00383006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermDebt_4e07376e-1c1e-43d1-88e0-9c1b00383006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_49c09794-9fb9-4756-a077-fe0fde62b62a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermDebtCurrent_49c09794-9fb9-4756-a077-fe0fde62b62a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_eeef1885-8961-47c5-9e1c-5f24da61ad3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_eeef1885-8961-47c5-9e1c-5f24da61ad3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35bd34b6-a0bb-467d-815c-5846d1602704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35bd34b6-a0bb-467d-815c-5846d1602704" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f62f339e-d8ec-4175-8e0b-19a4bcf987a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f62f339e-d8ec-4175-8e0b-19a4bcf987a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_376c3b37-ffb6-4803-b8f7-c79d1fce3182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_376c3b37-ffb6-4803-b8f7-c79d1fce3182" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_5ecbdd6c-8122-447b-878a-15891d334191" xlink:href="jnj-20210103.xsd#jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_5ecbdd6c-8122-447b-878a-15891d334191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Debenturesdue2020Member_07f14121-3778-449e-8b77-47aadd8979ba" xlink:href="jnj-20210103.xsd#jnj_A2.95Debenturesdue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.95Debenturesdue2020Member_07f14121-3778-449e-8b77-47aadd8979ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.950Notesdue2020Member_0a8d4d60-28c7-4367-8f6a-c9721e8399b3" xlink:href="jnj-20210103.xsd#jnj_A1.950Notesdue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.950Notesdue2020Member_0a8d4d60-28c7-4367-8f6a-c9721e8399b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2021Member_3dbdfdfb-b9b4-4626-acac-eaf73999b7e0" xlink:href="jnj-20210103.xsd#jnj_A3.55Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.55Notesdue2021Member_3dbdfdfb-b9b4-4626-acac-eaf73999b7e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2021Member_e414572b-fe91-408c-be1d-4093183e12e2" xlink:href="jnj-20210103.xsd#jnj_A2.45Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.45Notesdue2021Member_e414572b-fe91-408c-be1d-4093183e12e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.65Notesdue2021Member_6d77948f-75ef-4b34-a264-58436851e2c1" xlink:href="jnj-20210103.xsd#jnj_A1.65Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.65Notesdue2021Member_6d77948f-75ef-4b34-a264-58436851e2c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_cb607ac3-99ec-4860-9161-fbf3eec4d801" xlink:href="jnj-20210103.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A0.250NotesDue2022Member_cb607ac3-99ec-4860-9161-fbf3eec4d801" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member_8439d51a-bdad-4ae9-9326-0f00b430ae01" xlink:href="jnj-20210103.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.25Notesdue2022Member_8439d51a-bdad-4ae9-9326-0f00b430ae01" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_e1c237ba-25d7-427a-9f86-22bc98a70f2d" xlink:href="jnj-20210103.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_e1c237ba-25d7-427a-9f86-22bc98a70f2d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_5f0540fc-ef42-4156-b1ba-7d82f9c9d583" xlink:href="jnj-20210103.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.375Notesdue2023Member_5f0540fc-ef42-4156-b1ba-7d82f9c9d583" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_fcc6ae55-28e1-45d3-b95f-e5e1baa83e7b" xlink:href="jnj-20210103.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.05Notesdue2023Member_fcc6ae55-28e1-45d3-b95f-e5e1baa83e7b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_e0a16005-0049-475a-822e-e42381c8e97b" xlink:href="jnj-20210103.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A0.650NotesDue2024Member_e0a16005-0049-475a-822e-e42381c8e97b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_996e6ad0-16d2-42f6-a354-e6a42710cfbf" xlink:href="jnj-20210103.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A5.50NotesDue2024Member_996e6ad0-16d2-42f6-a354-e6a42710cfbf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_c8ca855e-533d-4817-a70a-3807c10e5917" xlink:href="jnj-20210103.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.625Notesdue2025Member_c8ca855e-533d-4817-a70a-3807c10e5917" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_1944b01c-a8d3-4783-8b19-b2b53b93a0f7" xlink:href="jnj-20210103.xsd#jnj_A055NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A055NotesDue2025Member_1944b01c-a8d3-4783-8b19-b2b53b93a0f7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_3a492ede-4390-4936-81eb-6b7ca0411702" xlink:href="jnj-20210103.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.45Notesdue2026Member_3a492ede-4390-4936-81eb-6b7ca0411702" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_8e59275e-53da-40ca-8732-746679798fef" xlink:href="jnj-20210103.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.95Notesdue2027Member_8e59275e-53da-40ca-8732-746679798fef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_e7e925c4-2f42-4dda-8023-7b0e9fc69b38" xlink:href="jnj-20210103.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A095NotesDue2027Member_e7e925c4-2f42-4dda-8023-7b0e9fc69b38" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_350b2fd1-05d6-403c-8b8d-4bcd3e142664" xlink:href="jnj-20210103.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.150NotesDue2028Member_350b2fd1-05d6-403c-8b8d-4bcd3e142664" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_e33ce12f-f1ec-4730-a0a8-b2b6952e0536" xlink:href="jnj-20210103.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.900Notesdue2028Member_e33ce12f-f1ec-4730-a0a8-b2b6952e0536" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_40da9fe9-dd42-4131-badd-2fc69270d577" xlink:href="jnj-20210103.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A6.95Notesdue2029Member_40da9fe9-dd42-4131-badd-2fc69270d577" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_92447877-e282-4705-b68d-9471e0c60ae1" xlink:href="jnj-20210103.xsd#jnj_A130NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A130NotesDue2030Member_92447877-e282-4705-b68d-9471e0c60ae1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_57337bba-6538-4687-84d1-2f03f55d136d" xlink:href="jnj-20210103.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_57337bba-6538-4687-84d1-2f03f55d136d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_998dd85d-eee8-4730-bd80-8ee0f82372e0" xlink:href="jnj-20210103.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.375Notesdue2033Member_998dd85d-eee8-4730-bd80-8ee0f82372e0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_968aa62d-f038-4635-a6f7-15c6d2de37a0" xlink:href="jnj-20210103.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.650NotesDue2035Member_968aa62d-f038-4635-a6f7-15c6d2de37a0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_eeeac2ba-9025-41dd-af75-9ffca6cbc8ac" xlink:href="jnj-20210103.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.55Notesdue2036Member_eeeac2ba-9025-41dd-af75-9ffca6cbc8ac" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_50ca7ed2-23dd-4828-8d8d-98008166ed01" xlink:href="jnj-20210103.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A5.95Notesdue2037Member_50ca7ed2-23dd-4828-8d8d-98008166ed01" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_52627f28-1bb1-4dd2-9333-037ba4639593" xlink:href="jnj-20210103.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.625Notesdue2037Member_52627f28-1bb1-4dd2-9333-037ba4639593" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_c4722459-d43f-4b37-b7df-3d1ef49e44b4" xlink:href="jnj-20210103.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_c4722459-d43f-4b37-b7df-3d1ef49e44b4" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_2969233e-e6db-47b2-9608-19670b6993e7" xlink:href="jnj-20210103.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.400Notesdue2038Member_2969233e-e6db-47b2-9608-19670b6993e7" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_95e10374-094e-4b0d-a0b8-aa8a51877d53" xlink:href="jnj-20210103.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_95e10374-094e-4b0d-a0b8-aa8a51877d53" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_e9e628ba-29ce-4bf0-a159-17979c23583f" xlink:href="jnj-20210103.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A210NotesDue2040Member_e9e628ba-29ce-4bf0-a159-17979c23583f" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_b176ea70-7f32-4791-b0a1-c6eedfb199ca" xlink:href="jnj-20210103.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.85Notesdue2041Member_b176ea70-7f32-4791-b0a1-c6eedfb199ca" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_9510ba7a-1a29-4008-935c-b2814b32085b" xlink:href="jnj-20210103.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.50Notesdue2043Member_9510ba7a-1a29-4008-935c-b2814b32085b" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_734f3482-30d1-476c-8fcb-e12cee90761b" xlink:href="jnj-20210103.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.70Notesdue2046Member_734f3482-30d1-476c-8fcb-e12cee90761b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_9179d733-c74f-484e-9078-4154d39d7340" xlink:href="jnj-20210103.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.75Notesdue2047Member_9179d733-c74f-484e-9078-4154d39d7340" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_c40c2b41-a656-4fe6-beea-785abcac84e4" xlink:href="jnj-20210103.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.500Notesdue2048Member_c40c2b41-a656-4fe6-beea-785abcac84e4" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_d5082afc-8c5d-456c-8bf0-b7a1cdbcaeaa" xlink:href="jnj-20210103.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2250NotesDue2050Member_d5082afc-8c5d-456c-8bf0-b7a1cdbcaeaa" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_0880106a-f1dc-42e6-81c2-8d4adfd4529a" xlink:href="jnj-20210103.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2450NotesDue2060Member_0880106a-f1dc-42e6-81c2-8d4adfd4529a" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_7a650ab3-14bc-493f-a072-b17ae2dc8134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_7a650ab3-14bc-493f-a072-b17ae2dc8134" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1295d018-dfae-4e6c-b772-260579158adb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1295d018-dfae-4e6c-b772-260579158adb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3abdc53-f1da-483c-b337-65e842066fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3abdc53-f1da-483c-b337-65e842066fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f379591c-4361-41de-9a16-8b5a8b7de5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3abdc53-f1da-483c-b337-65e842066fb6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f379591c-4361-41de-9a16-8b5a8b7de5bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_29b1e866-6018-45ac-b91f-bf94ae45fd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f379591c-4361-41de-9a16-8b5a8b7de5bd" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_29b1e866-6018-45ac-b91f-bf94ae45fd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8e4cde8b-d8d3-4ed0-bb96-220f7091becd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8e4cde8b-d8d3-4ed0-bb96-220f7091becd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9621b25e-2fe2-49fc-a7a5-2e17778242cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9621b25e-2fe2-49fc-a7a5-2e17778242cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_18766fc1-5968-4403-a9dd-d28cc8a484d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9621b25e-2fe2-49fc-a7a5-2e17778242cb" xlink:to="loc_us-gaap_SeniorNotesMember_18766fc1-5968-4403-a9dd-d28cc8a484d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="ibc61c5727f294705ac6e79a17771c57c_BorrowingsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="extended" id="i78f7d36e9811497eba41eaca29657231_BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended" id="iae71ab21dbc944da98bfd936e4f6b083_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="extended" id="i060d410a0872476eb6fa8f9f5c2ad9dd_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended" id="id875a272ad7b46b9a227692f2ab216c7_IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended" id="i0feb5022fc78489d80f52bde4eb2c36a_IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended" id="i6d06b72281b143169670ebaa970cb79e_IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i1a6e9ee6b04c4db3af87bb8da2675d82_IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i92deba7ec0244213b94e50e4b85fed93_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d927b98a-1a6f-432e-94e9-226ef58b9d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d927b98a-1a6f-432e-94e9-226ef58b9d9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_f62c1f8b-b20a-4454-8663-aad09ef1d328" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_f62c1f8b-b20a-4454-8663-aad09ef1d328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_27da41c0-bf30-48ad-b052-aa2fa7f87fe4" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_27da41c0-bf30-48ad-b052-aa2fa7f87fe4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0942196f-3065-4cf9-9ceb-28832c2e7a04" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0942196f-3065-4cf9-9ceb-28832c2e7a04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_870673e0-86c4-4b3b-90bd-27a803896458" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_870673e0-86c4-4b3b-90bd-27a803896458" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_c116e6a0-57f1-47e8-8345-eee98de5c810" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_c116e6a0-57f1-47e8-8345-eee98de5c810" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_bfa6b914-aa44-4afc-a76c-3db0311013fc" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_bfa6b914-aa44-4afc-a76c-3db0311013fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_9fd15674-2fc2-4657-9794-0d683318d5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_9fd15674-2fc2-4657-9794-0d683318d5d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_25e02910-26f3-4484-a60a-e4da69106d8e" xlink:href="jnj-20210103.xsd#jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_25e02910-26f3-4484-a60a-e4da69106d8e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_476acfd6-4ad6-4f15-96be-65acc7898f8d" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_476acfd6-4ad6-4f15-96be-65acc7898f8d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_38039199-7d6c-4a16-a81c-cf1623425cf8" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_38039199-7d6c-4a16-a81c-cf1623425cf8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5c37f9c0-1f30-4fd3-b505-332ad290cd30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5c37f9c0-1f30-4fd3-b505-332ad290cd30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d43c126d-b6e7-4719-90dd-83b9df87ca33" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d43c126d-b6e7-4719-90dd-83b9df87ca33" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_6f8452af-c087-48bf-b457-15c907604842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_6f8452af-c087-48bf-b457-15c907604842" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_b5294fb2-b7e6-4f93-ade1-72ccde5925a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_LitigationSettlementExpense_b5294fb2-b7e6-4f93-ade1-72ccde5925a2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_5fb0960e-df22-499a-a3eb-7001b755beba" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_5fb0960e-df22-499a-a3eb-7001b755beba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_5979735a-a059-4a89-868d-e7a653c82467" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_5979735a-a059-4a89-868d-e7a653c82467" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_1bfdc0cc-4a6b-4905-94a1-d3f4ce94420a" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_1bfdc0cc-4a6b-4905-94a1-d3f4ce94420a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_36746ab4-94dc-4de7-ad5f-99ea74ca7f3c" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_36746ab4-94dc-4de7-ad5f-99ea74ca7f3c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_04d67e96-3e88-434d-b572-a98e39793919" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_04d67e96-3e88-434d-b572-a98e39793919" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_4ec30fa2-d8a7-4098-ba88-bbb995479c1b" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_4ec30fa2-d8a7-4098-ba88-bbb995479c1b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a29df547-55fa-4f11-af9a-e8e1696d9dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a29df547-55fa-4f11-af9a-e8e1696d9dc3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_33399c19-573c-4a97-9f86-b1822ad12122" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_33399c19-573c-4a97-9f86-b1822ad12122" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_7b5a6479-3c8b-441d-9427-2b2f009d815b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_7b5a6479-3c8b-441d-9427-2b2f009d815b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fe7e9ccb-0112-4cec-8eb5-0496ed361d32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fe7e9ccb-0112-4cec-8eb5-0496ed361d32" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_eb1859ec-ac1f-49f8-8693-000c7bf7d5e8" xlink:href="jnj-20210103.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_eb1859ec-ac1f-49f8-8693-000c7bf7d5e8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_52a71e36-2387-4b16-b339-7b7e469b3089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_52a71e36-2387-4b16-b339-7b7e469b3089" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f9a2e9e8-0e3c-4b48-981a-ae4f4722ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f9a2e9e8-0e3c-4b48-981a-ae4f4722ebb7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:to="loc_us-gaap_LitigationStatusDomain_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3f029743-e99e-42a1-bc27-b7f1cccba7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:to="loc_us-gaap_LitigationStatusDomain_3f029743-e99e-42a1-bc27-b7f1cccba7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_9af184a5-ae05-4550-8d8d-0325a60515a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3f029743-e99e-42a1-bc27-b7f1cccba7ba" xlink:to="loc_us-gaap_PendingLitigationMember_9af184a5-ae05-4550-8d8d-0325a60515a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e467ae2f-570a-4597-9d27-79c1f79991b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e467ae2f-570a-4597-9d27-79c1f79991b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94d51f8b-7615-4135-951b-317c1e46baf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94d51f8b-7615-4135-951b-317c1e46baf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedTaxesOnIncomeMember_2f2739df-6ee7-4b43-9af4-e1ba0c9bd7fc" xlink:href="jnj-20210103.xsd#jnj_AccruedTaxesOnIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94d51f8b-7615-4135-951b-317c1e46baf0" xlink:to="loc_jnj_AccruedTaxesOnIncomeMember_2f2739df-6ee7-4b43-9af4-e1ba0c9bd7fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_78888534-e0f8-4d5b-b5af-dc3c82648876_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_78888534-e0f8-4d5b-b5af-dc3c82648876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_9be12c7f-bf88-4f13-a27c-fa83621fb2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_9be12c7f-bf88-4f13-a27c-fa83621fb2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7c0147fa-60ec-4b53-98bc-ec118b876965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9be12c7f-bf88-4f13-a27c-fa83621fb2fa" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_7c0147fa-60ec-4b53-98bc-ec118b876965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_67531cc0-f808-40f1-857e-d80d41673001_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:to="loc_us-gaap_SegmentDomain_67531cc0-f808-40f1-857e-d80d41673001_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:to="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_2640b1c6-6ebd-47df-a000-f7cd12f61322" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:to="loc_jnj_ConsumerMember_2640b1c6-6ebd-47df-a000-f7cd12f61322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_219c82e7-f485-43ff-a5a2-11357e308da8" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:to="loc_jnj_PharmaceuticalMember_219c82e7-f485-43ff-a5a2-11357e308da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9e9abff6-c65e-4773-a5d5-bc6f7500488d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:to="loc_srt_LitigationCaseTypeDomain_9e9abff6-c65e-4773-a5d5-bc6f7500488d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:to="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_8a0fa0e0-0efd-41cf-bb9c-c91beff3c72e" xlink:href="jnj-20210103.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:to="loc_jnj_TalcMember_8a0fa0e0-0efd-41cf-bb9c-c91beff3c72e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_43bfba13-2a29-4927-b08b-ad06d2548177" xlink:href="jnj-20210103.xsd#jnj_OpiodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:to="loc_jnj_OpiodsMember_43bfba13-2a29-4927-b08b-ad06d2548177" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligations"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="extended" id="iee2d911e1fb745d79a02227c8180e28d_EmployeeRelatedObligations"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="extended" id="iadc9a37ea3d745b6a38125b1a7c4f2bf_EmployeeRelatedObligationsTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended" id="i110baf61198c4dac917c197e5e309110_EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="extended" id="ie348ce485fd44662a9e571c95e1d5bfe_EmployeeRelatedObligationsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended" id="i4d816c6207e84659a14b87bea0e4e19a_PensionsandOtherBenefitPlans"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended" id="i5793746c1e844799afdbc8ade00e3d8a_PensionsandOtherBenefitPlansTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="ic8252bf6b70747c294d7791382610731_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41d25ffa-cbe3-402d-be62-6c865c5271e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41d25ffa-cbe3-402d-be62-6c865c5271e0" xlink:to="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_cb67503f-4151-4fdb-8085-0827ea80d194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_cb67503f-4151-4fdb-8085-0827ea80d194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_06ce24b4-9793-43fb-a59a-7253fe9592d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_06ce24b4-9793-43fb-a59a-7253fe9592d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bb388392-c68f-41c2-8302-f1f0b36b120b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bb388392-c68f-41c2-8302-f1f0b36b120b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9e33deb8-2d43-48d8-b219-4d83ae747128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9e33deb8-2d43-48d8-b219-4d83ae747128" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_d482fd55-c877-4c5b-933c-6a0f945e9894" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_d482fd55-c877-4c5b-933c-6a0f945e9894" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_5d817dd7-1c69-48f9-9df9-4d4bfb6ca441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_5d817dd7-1c69-48f9-9df9-4d4bfb6ca441" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_51aec211-f14c-4f4b-bea9-e48c8f9a9749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_51aec211-f14c-4f4b-bea9-e48c8f9a9749" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41d25ffa-cbe3-402d-be62-6c865c5271e0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c148cbb7-af92-462c-93cc-ca0ec49d906e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c148cbb7-af92-462c-93cc-ca0ec49d906e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_28223696-95ef-47bd-9f2d-8eef515a29b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_28223696-95ef-47bd-9f2d-8eef515a29b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_82c107ab-fd9f-4291-9fff-51f40a0c771e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_82c107ab-fd9f-4291-9fff-51f40a0c771e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended" id="ic3198977bd0b405d82ace775fe1c7fe1_PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_7460ca4f-00d2-443b-b153-79e418d20bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_7460ca4f-00d2-443b-b153-79e418d20bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_3085c2f1-c923-4912-8cf8-ea88390fe098" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_3085c2f1-c923-4912-8cf8-ea88390fe098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d9c77a66-9580-47fc-97b2-309e7dd7334e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d9c77a66-9580-47fc-97b2-309e7dd7334e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d8eb0694-d597-4236-8281-5767062597d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d8eb0694-d597-4236-8281-5767062597d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_d5671dc4-adae-4f91-84a8-c3c3544bd34d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_d5671dc4-adae-4f91-84a8-c3c3544bd34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_e51f9387-ada9-47ca-abcf-e5027197472b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_e51f9387-ada9-47ca-abcf-e5027197472b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_314d338d-ad6c-4dd8-a3a4-689153098ec3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_314d338d-ad6c-4dd8-a3a4-689153098ec3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ace26299-6770-4617-ba83-6de1645ffb90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ace26299-6770-4617-ba83-6de1645ffb90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a5c84bfe-9374-4a2e-a5c6-dd0d4c625ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a5c84bfe-9374-4a2e-a5c6-dd0d4c625ff7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="extended" id="i56b1c1d0d68840ada7e062354e72355a_PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended" id="i26d6d415ffb442eb8a15f7218921963d_PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4a281a3d-37a5-4aa3-b797-88c676c279be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4a281a3d-37a5-4aa3-b797-88c676c279be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fe466b46-d554-44fc-a01d-bbb6099877c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fe466b46-d554-44fc-a01d-bbb6099877c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_276ecbc8-d21a-4cdc-be4b-54955e8ec252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_276ecbc8-d21a-4cdc-be4b-54955e8ec252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_87b441ec-07e6-4a89-ad93-85b84a521d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_87b441ec-07e6-4a89-ad93-85b84a521d48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d315f1f6-f247-41d4-bc62-dc5799f5bdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d315f1f6-f247-41d4-bc62-dc5799f5bdb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1daa0316-5e12-4ee9-85c2-7829dcdb168c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1daa0316-5e12-4ee9-85c2-7829dcdb168c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_5930fab7-08a1-43a1-90c3-b8bb827ccf2d" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_5930fab7-08a1-43a1-90c3-b8bb827ccf2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_d6ea1a7d-1473-41a8-8b61-b7528d3b40a3" xlink:href="jnj-20210103.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_d6ea1a7d-1473-41a8-8b61-b7528d3b40a3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f4b898b-4943-4a14-bafb-cbdc3d5f57fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f4b898b-4943-4a14-bafb-cbdc3d5f57fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_bf21bee1-2493-4945-b03b-93fc285c9b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_bf21bee1-2493-4945-b03b-93fc285c9b3d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_848eee64-6e77-4bca-8ce4-b8ab176fc9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1eb7e8c2-1c40-464c-881f-6ecb6dfd38ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1eb7e8c2-1c40-464c-881f-6ecb6dfd38ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_54cf68bf-f5a6-4d5b-83dc-e4e8b5b4da60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_54cf68bf-f5a6-4d5b-83dc-e4e8b5b4da60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ed107dc2-6214-4f6f-9aba-0b807a575b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ed107dc2-6214-4f6f-9aba-0b807a575b66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dc700372-81a2-43cd-a8ba-609919df3e51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dc700372-81a2-43cd-a8ba-609919df3e51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_ea6db724-1da9-4383-94c7-b0612fb4f94d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_ea6db724-1da9-4383-94c7-b0612fb4f94d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_29ee6774-94cf-47b9-9b5b-f2c337d07654" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_29ee6774-94cf-47b9-9b5b-f2c337d07654" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_dd4f00b3-7216-4e30-8c30-0ec7edb7839a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_dd4f00b3-7216-4e30-8c30-0ec7edb7839a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6103ec5e-6d93-4ffb-b4ac-fdc4401fed98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6103ec5e-6d93-4ffb-b4ac-fdc4401fed98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5cb008d2-fa18-4925-8387-c9865aa2c1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0bea0a5e-8c5a-477d-99e1-5d69dba55862" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0bea0a5e-8c5a-477d-99e1-5d69dba55862" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_fa7b1424-88de-4852-82ba-f4de495645a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_fa7b1424-88de-4852-82ba-f4de495645a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4910d089-77fa-49e3-af5f-ae0f95a4386c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4910d089-77fa-49e3-af5f-ae0f95a4386c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_83148de3-72d3-43ae-b57b-1a0914f2185b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_83148de3-72d3-43ae-b57b-1a0914f2185b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_72f15d64-a0a7-42cb-a2d0-cc63952ab8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_72f15d64-a0a7-42cb-a2d0-cc63952ab8b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_b83db1ea-560e-4166-9810-277dd718caf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_b83db1ea-560e-4166-9810-277dd718caf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_249c0d12-0034-4c19-8e53-9fb74bcdfc36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_249c0d12-0034-4c19-8e53-9fb74bcdfc36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_55f8f92a-5097-4262-8bd7-922eb4dbd8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_55f8f92a-5097-4262-8bd7-922eb4dbd8d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5b91e41e-a5b6-4eeb-adda-fe56a6d62964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5b91e41e-a5b6-4eeb-adda-fe56a6d62964" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9dd6c968-f6a5-4e85-85ba-b80b84a38290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9dd6c968-f6a5-4e85-85ba-b80b84a38290" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_93829750-79c6-4a10-9200-1a803d5bb866" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_PensionContributions_93829750-79c6-4a10-9200-1a803d5bb866" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_981dba48-ae59-4d77-839a-7a0182f8b75c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_981dba48-ae59-4d77-839a-7a0182f8b75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_ed17ad1a-b464-444e-9e9c-658d5c87f660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_ed17ad1a-b464-444e-9e9c-658d5c87f660" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_c18ef90b-b46b-48dd-a53a-ab4acf58c6df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_c18ef90b-b46b-48dd-a53a-ab4acf58c6df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_161b3390-e816-47fd-be57-8bdc10ee2ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_161b3390-e816-47fd-be57-8bdc10ee2ee2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_53fb1ee5-8f49-455c-baae-0aa192a2aff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_53fb1ee5-8f49-455c-baae-0aa192a2aff6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_6497b3a1-6871-46b0-a3d8-c7ef5a680a78" xlink:href="jnj-20210103.xsd#jnj_EffectOfExchangeRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_jnj_EffectOfExchangeRates_6497b3a1-6871-46b0-a3d8-c7ef5a680a78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_67d5a7f4-70ea-4fb7-bdda-02374019b0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_67d5a7f4-70ea-4fb7-bdda-02374019b0e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_5cdfd95b-e78a-495a-a41f-1f51546e4d12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_5cdfd95b-e78a-495a-a41f-1f51546e4d12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b194095a-1655-4c34-a32a-021e3ed5d3d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b194095a-1655-4c34-a32a-021e3ed5d3d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_add33d88-c2ac-492e-ad7f-abf38835894b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_add33d88-c2ac-492e-ad7f-abf38835894b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c1eff408-1778-4510-aea0-e50007c5c114" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c1eff408-1778-4510-aea0-e50007c5c114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:to="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionTypeDomain_036f273f-471a-4435-9514-5ad962342838_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:to="loc_us-gaap_DistributionTypeDomain_036f273f-471a-4435-9514-5ad962342838_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionTypeDomain_2be699e3-bf3b-41a2-a200-fe52587469e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:to="loc_us-gaap_DistributionTypeDomain_2be699e3-bf3b-41a2-a200-fe52587469e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LumpSumDistributionMember_07772139-754f-494a-a3ac-3c5709900f38" xlink:href="jnj-20210103.xsd#jnj_LumpSumDistributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DistributionTypeDomain_2be699e3-bf3b-41a2-a200-fe52587469e2" xlink:to="loc_jnj_LumpSumDistributionMember_07772139-754f-494a-a3ac-3c5709900f38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended" id="id2669be05853428690186204b5d26a56_PensionsandOtherBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_320a76e8-368a-439a-98d2-b9635fcb0598" xlink:href="jnj-20210103.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_EmployeeCompensationPeriod_320a76e8-368a-439a-98d2-b9635fcb0598" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_6c640fce-2d57-411a-a28a-5114391e519b" xlink:href="jnj-20210103.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_6c640fce-2d57-411a-a28a-5114391e519b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_7b63351e-92e6-4f01-92bd-ff7d7b728abc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_PensionContributions_7b63351e-92e6-4f01-92bd-ff7d7b728abc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_a94ded6d-cb13-48c7-8555-8a60f24ff6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_a94ded6d-cb13-48c7-8555-8a60f24ff6fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_86d340f4-40a2-4e3f-b6ef-28af2adaf81c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_86d340f4-40a2-4e3f-b6ef-28af2adaf81c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_29d900bb-dce9-49c2-ba78-55a5c6813545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_29d900bb-dce9-49c2-ba78-55a5c6813545" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b5039ff6-fd1d-4854-a452-9ed4b25f9870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b5039ff6-fd1d-4854-a452-9ed4b25f9870" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_ab217f28-5f29-440c-8ea3-bd3ce8b7f19f" xlink:href="jnj-20210103.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_ab217f28-5f29-440c-8ea3-bd3ce8b7f19f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_1c61c29f-5a1d-4ffe-992b-9745025e74ca" xlink:href="jnj-20210103.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_1c61c29f-5a1d-4ffe-992b-9745025e74ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bc85dfd-85a3-4516-8b0d-4ab2afdae935_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:to="loc_srt_RangeMember_6bc85dfd-85a3-4516-8b0d-4ab2afdae935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30a804cf-a87e-44ae-8efd-80ca6e571716" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:to="loc_srt_RangeMember_30a804cf-a87e-44ae-8efd-80ca6e571716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_beea9e48-a353-43e6-9e81-459d34d3a79c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30a804cf-a87e-44ae-8efd-80ca6e571716" xlink:to="loc_srt_MaximumMember_beea9e48-a353-43e6-9e81-459d34d3a79c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_6f15b78b-9212-4fc2-8dba-e003928cdd47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_6f15b78b-9212-4fc2-8dba-e003928cdd47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_4d8bfa05-c82a-4900-8300-cdfbc64bce92" xlink:href="jnj-20210103.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:to="loc_jnj_CommingledFundsMember_4d8bfa05-c82a-4900-8300-cdfbc64bce92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_e046f72d-8b7f-46e0-b11e-550959f9d0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_e046f72d-8b7f-46e0-b11e-550959f9d0a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2983653b-750c-455f-aa87-d8b2a7bd34d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2983653b-750c-455f-aa87-d8b2a7bd34d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd436c4a-e0c3-4213-bd63-de52e8354270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2983653b-750c-455f-aa87-d8b2a7bd34d4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd436c4a-e0c3-4213-bd63-de52e8354270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ce8e7099-59be-4bb3-983d-cf97f16b3611_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ce8e7099-59be-4bb3-983d-cf97f16b3611_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_9e01eeef-18da-4345-83a9-5d21fe36e5cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:to="loc_us-gaap_DomesticPlanMember_9e01eeef-18da-4345-83a9-5d21fe36e5cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_56605e11-0b00-4639-a2a7-df83b754b947" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_9e01eeef-18da-4345-83a9-5d21fe36e5cc" xlink:to="loc_country_US_56605e11-0b00-4639-a2a7-df83b754b947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e6f70cf0-0db4-4fd8-b789-e05d45b28ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:to="loc_us-gaap_ForeignPlanMember_e6f70cf0-0db4-4fd8-b789-e05d45b28ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fc59ed20-1411-48d2-9339-f302edc538b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fc59ed20-1411-48d2-9339-f302edc538b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_dba83aee-d0f8-419c-9eb4-76abe98924f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_dba83aee-d0f8-419c-9eb4-76abe98924f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a864f346-6019-4deb-90cc-5fce0a0d4dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a864f346-6019-4deb-90cc-5fce0a0d4dc8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended" id="id3b15c0e32ce4d2f9a83402321d41d4f_PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_34a6044b-eab1-4c02-bbda-4ce56847cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_34a6044b-eab1-4c02-bbda-4ce56847cb4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_fe381f84-9220-4d38-b3a9-4ab59978dee8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_fe381f84-9220-4d38-b3a9-4ab59978dee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e3bf2389-ab1a-4e42-9508-066cb85ed634" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e3bf2389-ab1a-4e42-9508-066cb85ed634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_aca986f4-0222-472f-b5ef-3c595613e8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_aca986f4-0222-472f-b5ef-3c595613e8e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_87d0b292-8ee3-4f8b-abf1-85bbf1b6ba35" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_87d0b292-8ee3-4f8b-abf1-85bbf1b6ba35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:to="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:to="loc_us-gaap_PlanNameDomain_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:to="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_4120ee29-a4a5-40f7-9881-3413a38ef8f9" xlink:href="jnj-20210103.xsd#jnj_QualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_QualifiedPlansMember_4120ee29-a4a5-40f7-9881-3413a38ef8f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_b4e8d085-6e8e-43a4-a429-7815c0ce67d6" xlink:href="jnj-20210103.xsd#jnj_NonQualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_NonQualifiedPlansMember_b4e8d085-6e8e-43a4-a429-7815c0ce67d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_0015942f-45d3-4b7e-8df7-38ce013310b0" xlink:href="jnj-20210103.xsd#jnj_FundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_FundedPlansMember_0015942f-45d3-4b7e-8df7-38ce013310b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_68bb025b-4b28-4e40-8d85-0e070876db1c" xlink:href="jnj-20210103.xsd#jnj_UnfundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_UnfundedPlansMember_68bb025b-4b28-4e40-8d85-0e070876db1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d56f5821-3a0e-4933-9b4d-449eb988c9ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d56f5821-3a0e-4933-9b4d-449eb988c9ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_b63fa35c-72b8-437d-b7dc-f27592ed6ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:to="loc_us-gaap_DomesticPlanMember_b63fa35c-72b8-437d-b7dc-f27592ed6ff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5c676270-c060-438c-bd7d-c7f27c6dd983" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_b63fa35c-72b8-437d-b7dc-f27592ed6ff0" xlink:to="loc_country_US_5c676270-c060-438c-bd7d-c7f27c6dd983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_90f25287-ce56-457f-9e06-a28ca151ec08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:to="loc_us-gaap_ForeignPlanMember_90f25287-ce56-457f-9e06-a28ca151ec08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended" id="i4edb80a1dfa441a08b8a0a40706ff70c_PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_13a4a723-31de-449f-848a-cea175240b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_13a4a723-31de-449f-848a-cea175240b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_420f754f-85a8-43af-b568-48afcb5f1772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_420f754f-85a8-43af-b568-48afcb5f1772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a0e6dc-eb85-42ec-841c-20b07cafcb58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a0e6dc-eb85-42ec-841c-20b07cafcb58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_8181e8c2-b938-4c00-9122-5048d7ecb3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_8181e8c2-b938-4c00-9122-5048d7ecb3b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_06233c84-aed0-4e73-9327-22a1223b6496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_06233c84-aed0-4e73-9327-22a1223b6496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b5528ca0-0fc3-4bd8-bf09-36597c3f458a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b5528ca0-0fc3-4bd8-bf09-36597c3f458a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_783dfebe-8b6e-40d2-a912-c3db23609ec5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_783dfebe-8b6e-40d2-a912-c3db23609ec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2e9e3c82-7491-45a9-a8af-0575e0eec998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2e9e3c82-7491-45a9-a8af-0575e0eec998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d1e0e40b-2f9c-40fa-9deb-7d3a12be4c59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d1e0e40b-2f9c-40fa-9deb-7d3a12be4c59" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="extended" id="iba44ae0b80824e24854fd271a8f9256d_PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended" id="i9971e7e262a84d15a2f2e168badeaa3a_PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_5e326bd6-fadb-4e28-adb6-db05d514ee3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_5e326bd6-fadb-4e28-adb6-db05d514ee3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b03f3b12-9481-4bcb-9cbf-aee88a29dc15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b03f3b12-9481-4bcb-9cbf-aee88a29dc15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_4007c8e6-b53b-4869-bb4c-9a50eac2166a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_4007c8e6-b53b-4869-bb4c-9a50eac2166a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e75bf1c4-1a64-4d02-844c-4104502dd8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:to="loc_us-gaap_EquitySecuritiesMember_e75bf1c4-1a64-4d02-844c-4104502dd8f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_4e6d77bc-a3a3-44e4-b789-5bf5c1385760" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:to="loc_us-gaap_DebtSecuritiesMember_4e6d77bc-a3a3-44e4-b789-5bf5c1385760" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended" id="idf2634a97d704ce59706333d7a35be7c_PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fb21166f-deaf-4aed-9aba-631dcf04001b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fb21166f-deaf-4aed-9aba-631dcf04001b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_0babb4a1-422f-408c-92a1-effdd18122f6" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_0babb4a1-422f-408c-92a1-effdd18122f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7782b4d0-1550-4a4d-ab9b-e528f17944ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7782b4d0-1550-4a4d-ab9b-e528f17944ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7f9f07b8-6c32-4fb1-a252-a8a36efd3b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7782b4d0-1550-4a4d-ab9b-e528f17944ca" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7f9f07b8-6c32-4fb1-a252-a8a36efd3b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_48d5926b-0a1c-44bc-8b82-2196167bcec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_48d5926b-0a1c-44bc-8b82-2196167bcec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d8b7b5fa-3f18-459d-9ea7-fe08634bbb01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_48d5926b-0a1c-44bc-8b82-2196167bcec5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d8b7b5fa-3f18-459d-9ea7-fe08634bbb01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_6b3bf0ba-aa40-4732-b175-5013ef2a59cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_6b3bf0ba-aa40-4732-b175-5013ef2a59cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_0fc98718-6d7d-4e96-9954-2bfcd493a230" xlink:href="jnj-20210103.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_0fc98718-6d7d-4e96-9954-2bfcd493a230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_423a058c-2385-47bb-9eef-d87242bd687f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_423a058c-2385-47bb-9eef-d87242bd687f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_18213af9-e005-45d8-bf80-0df885229bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_DebtSecuritiesMember_18213af9-e005-45d8-bf80-0df885229bf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_de052f76-4f74-49a4-8a32-07ca5c8d7edd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_EquitySecuritiesMember_de052f76-4f74-49a4-8a32-07ca5c8d7edd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_cddc04f5-9689-4f5b-890b-bfeba01c075a" xlink:href="jnj-20210103.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_jnj_CommingledFundsMember_cddc04f5-9689-4f5b-890b-bfeba01c075a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_9dbf1edf-ed8d-4985-9b6c-d9e1550d035e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_OtherAssetsMember_9dbf1edf-ed8d-4985-9b6c-d9e1550d035e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53242305-2db1-4532-84d1-4ac39d9f6fa3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53242305-2db1-4532-84d1-4ac39d9f6fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_14516552-0645-4934-9eee-209931573f27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_14516552-0645-4934-9eee-209931573f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e5ee803d-6732-4ccf-8cca-4014ba90dda2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e5ee803d-6732-4ccf-8cca-4014ba90dda2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_22c2c714-3869-4492-ae22-e8cd40468e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_22c2c714-3869-4492-ae22-e8cd40468e41" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlan" xlink:type="simple" xlink:href="jnj-20210103.xsd#SavingsPlan"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SavingsPlan" xlink:type="extended" id="i8fadfb3cacdf48e59591af5a76a1e60d_SavingsPlan"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SavingsPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="extended" id="i9abc478c17404fedb55cedd499d0f248_SavingsPlanNarrativeDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStock"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="extended" id="i1d70e1dad19b4132a3de9b91f0f37a89_CapitalandTreasuryStock"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="extended" id="icdc6de0e0b704c2485ae06bca347d130_CapitalandTreasuryStockTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended" id="i3fdd290388a34ce691852b2e82a1b612_CapitalandTreasuryStockChangesinTreasuryStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:href="jnj-20210103.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_3200e8e1-4f44-4af1-9f19-537b1aef45f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_TreasuryStockShares_3200e8e1-4f44-4af1-9f19-537b1aef45f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_e605915e-fe94-40df-ace0-c82fd4563dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_e605915e-fe94-40df-ace0-c82fd4563dad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_75ba5c24-1e47-4233-b7c8-0cde939e4f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_75ba5c24-1e47-4233-b7c8-0cde939e4f7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_77d4d065-31ff-4bc1-8e2f-5b39c245286b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:href="jnj-20210103.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_05f5442c-c036-4ce9-a2d6-7bf0ce3dcda5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_TreasuryStockValue_05f5442c-c036-4ce9-a2d6-7bf0ce3dcda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_9ec3c900-c9d3-49f4-9a89-bbb54e92f217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_9ec3c900-c9d3-49f4-9a89-bbb54e92f217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f292a11c-9767-4ae3-9baf-a7efeaa1f3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f292a11c-9767-4ae3-9baf-a7efeaa1f3c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_66cac848-9060-4d72-8f91-c566c6d73139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:to="loc_us-gaap_EquityComponentDomain_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eddcc37a-f873-4798-b4c9-db0c9765aa48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:to="loc_us-gaap_EquityComponentDomain_eddcc37a-f873-4798-b4c9-db0c9765aa48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_b01650da-e876-4169-b7fc-4200a9437f25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eddcc37a-f873-4798-b4c9-db0c9765aa48" xlink:to="loc_us-gaap_TreasuryStockMember_b01650da-e876-4169-b7fc-4200a9437f25" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended" id="i9a935a6c82c04d839285a468f44422d1_CapitalandTreasuryStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dd73b5cd-26d8-47d6-9dfd-d39765089acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_CommonStockSharesIssued_dd73b5cd-26d8-47d6-9dfd-d39765089acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b05d7a70-338c-4c8e-8ab8-f0603151f17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b05d7a70-338c-4c8e-8ab8-f0603151f17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_26c96af0-b3a3-45ff-815c-2203c9e6cf49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_26c96af0-b3a3-45ff-815c-2203c9e6cf49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ae814850-11ff-4905-854b-62f88cd0a551_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ae814850-11ff-4905-854b-62f88cd0a551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_6f895a7f-d2cc-49b0-a860-10063d3090e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_6f895a7f-d2cc-49b0-a860-10063d3090e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_53f466d7-758e-4b24-91d2-5ffd2d13f7e0" xlink:href="jnj-20210103.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_6f895a7f-d2cc-49b0-a860-10063d3090e2" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_53f466d7-758e-4b24-91d2-5ffd2d13f7e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" id="i9dbd33d948bf4c9daf7a2047261964b8_AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" id="i960d2a2644344fafb9060771be61c454_AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ia5c9b728fd104528bea8cd4f234c8cea_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_520bf267-a3f9-4e42-8260-0fc86b3b4ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_520bf267-a3f9-4e42-8260-0fc86b3b4ce4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ae3e919-8553-46e3-a1e4-ec16d1da628c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ae3e919-8553-46e3-a1e4-ec16d1da628c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85f5305b-c726-4b77-99a7-63ceb6cda76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85f5305b-c726-4b77-99a7-63ceb6cda76c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1ad4bcc-aa77-4558-bf3a-13ab71daa7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_520bf267-a3f9-4e42-8260-0fc86b3b4ce4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:to="loc_us-gaap_EquityComponentDomain_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:to="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_71d9a21d-8e1a-4ad4-a173-543f3fafcfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_71d9a21d-8e1a-4ad4-a173-543f3fafcfbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fdce4592-f989-4006-ae93-b47bbe98e5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fdce4592-f989-4006-ae93-b47bbe98e5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_267aabfd-19d9-4401-8957-5d3a8b08f2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_267aabfd-19d9-4401-8957-5d3a8b08f2a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_46cc2015-0a2f-4bc7-be98-6211684f9774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_46cc2015-0a2f-4bc7-be98-6211684f9774" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfe54b6e-f5a9-4957-84dc-3ebb68b7853b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfe54b6e-f5a9-4957-84dc-3ebb68b7853b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09_default" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_eb1179ab-fdc3-4e56-8ded-c058c694f5b8" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_eb1179ab-fdc3-4e56-8ded-c058c694f5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7cec4552-3dad-48a4-a60b-577d047a570b" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_eb1179ab-fdc3-4e56-8ded-c058c694f5b8" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7cec4552-3dad-48a4-a60b-577d047a570b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="simple" xlink:href="jnj-20210103.xsd#InternationalCurrencyTranslation"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="extended" id="ieadaf9f629d84a1c9bfd4ce70037f3a9_InternationalCurrencyTranslation"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#InternationalCurrencyTranslationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="extended" id="ia13aa25b04e94da49a6a83901e1bc4fd_InternationalCurrencyTranslationNarrativeDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended" id="i55d88d05ba7e4d13baf5532dbcd4d4c1_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended" id="i24566a6bb65245d2b7ac51dd0b9691ff_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended" id="i329e3c394f594107baa5d4804347f87f_EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended" id="i8bf17f1800b24a0fb177d13e2fdeb565_EarningsPerShareNarrativeDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreements"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="extended" id="ib7199b6bb95d4e298b8ad401d6be64b5_CommonStockStockOptionPlansandStockCompensationAgreements"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="extended" id="icafe57b5533646fe9e54159af0a84ce7_CommonStockStockOptionPlansandStockCompensationAgreementsTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended" id="i16b6f94b066d4d2ba8627a86b19b7250_CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_b2cf49ab-e0ec-4a4d-95de-ed12186b02ba" xlink:href="jnj-20210103.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_b2cf49ab-e0ec-4a4d-95de-ed12186b02ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3386fdf1-f1f2-4b22-87d5-e785c292a0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3386fdf1-f1f2-4b22-87d5-e785c292a0f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4361fb36-555a-49ef-98fd-8241d4df7857" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4361fb36-555a-49ef-98fd-8241d4df7857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d47dac4d-2609-46d1-9361-b94c7f779e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d47dac4d-2609-46d1-9361-b94c7f779e14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3307db39-72e0-4e30-8112-df9e032c782a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3307db39-72e0-4e30-8112-df9e032c782a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_a118ace0-2889-43f7-8559-1658c1ed6ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_a118ace0-2889-43f7-8559-1658c1ed6ab0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13888827-6f2f-41a1-b9e6-10fbd91af442" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13888827-6f2f-41a1-b9e6-10fbd91af442" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2a60d1c-e393-474e-8d6c-765509b1b29a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2a60d1c-e393-474e-8d6c-765509b1b29a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_33b9a6e5-0f77-4f73-a063-2660d6ad8370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_33b9a6e5-0f77-4f73-a063-2660d6ad8370" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d28fba8-5633-4e3d-b6e8-db4df9786280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d28fba8-5633-4e3d-b6e8-db4df9786280" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_506f5f35-25d3-4489-95a1-2e6b718f5d86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_506f5f35-25d3-4489-95a1-2e6b718f5d86" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d85d8f64-9d20-4645-9f04-bc4e643a14e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d85d8f64-9d20-4645-9f04-bc4e643a14e1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_558f9ed8-8ca9-4474-8681-222110b10d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_558f9ed8-8ca9-4474-8681-222110b10d39" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ffa129d1-a24d-4cdd-89f2-dd59493df8e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ffa129d1-a24d-4cdd-89f2-dd59493df8e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d1c64626-74d5-46e4-8f06-c1a74256979c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d1c64626-74d5-46e4-8f06-c1a74256979c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6d4c00cf-eee6-4de5-bb13-20c55195e3db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6d4c00cf-eee6-4de5-bb13-20c55195e3db" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3add0f4f-6eed-4be4-89f4-efa0329b3ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3add0f4f-6eed-4be4-89f4-efa0329b3ff9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9581138a-2a03-4e42-b945-7439b5f5abeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9581138a-2a03-4e42-b945-7439b5f5abeb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c317e4f7-71f1-48bd-bac0-206c8c804d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c317e4f7-71f1-48bd-bac0-206c8c804d99" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_21dc0b56-04e1-4dc5-ad49-c731d01defa6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_21dc0b56-04e1-4dc5-ad49-c731d01defa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_194544f5-0a77-4f71-9669-b4beb62ba3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_194544f5-0a77-4f71-9669-b4beb62ba3f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2012LongTermIncentivePlanMember_5b46ce16-b3fa-4775-9044-bcba112d1516" xlink:href="jnj-20210103.xsd#jnj_A2012LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_194544f5-0a77-4f71-9669-b4beb62ba3f8" xlink:to="loc_jnj_A2012LongTermIncentivePlanMember_5b46ce16-b3fa-4775-9044-bcba112d1516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_acf09802-75c1-4df1-ba26-d560d143c50a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:to="loc_srt_RangeMember_acf09802-75c1-4df1-ba26-d560d143c50a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:to="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e44b3d49-c2ea-4d97-8a4d-781c8b364205" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:to="loc_srt_MinimumMember_e44b3d49-c2ea-4d97-8a4d-781c8b364205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfee6773-f54d-48f2-9b90-8e5cea7285bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:to="loc_srt_MaximumMember_bfee6773-f54d-48f2-9b90-8e5cea7285bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6e37a93-1332-416c-8f40-a46c30be9fdf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6e37a93-1332-416c-8f40-a46c30be9fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3b40a786-24cc-47f4-ac85-74b3788ec0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3b40a786-24cc-47f4-ac85-74b3788ec0fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c3b11745-962e-43f9-9003-859402554519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c3b11745-962e-43f9-9003-859402554519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7ae04c4f-ef89-4d5a-ac2a-b73514e59459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:to="loc_us-gaap_PerformanceSharesMember_7ae04c4f-ef89-4d5a-ac2a-b73514e59459" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="extended" id="i315f13f306d04366a2cd7b0b9726a582_CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="extended" id="i48631627b066479dab4bd2b43f891d5e_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended" id="i9d33dc9e497346c0bb47790f8d521eb2_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f3581515-6188-4cb1-b22a-e30cf1b8a5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:href="jnj-20210103.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f3581515-6188-4cb1-b22a-e30cf1b8a5d5" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_16ad97cc-ea82-4a96-9ef8-3e97968273a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_16ad97cc-ea82-4a96-9ef8-3e97968273a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e4d3b0b8-3bf5-469b-bc94-233f6c0cdab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e4d3b0b8-3bf5-469b-bc94-233f6c0cdab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c9ae90aa-1352-4b0b-99d1-8613cbdfb06a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c9ae90aa-1352-4b0b-99d1-8613cbdfb06a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_564f6f2d-1a22-4ef8-9840-0b0027045573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_564f6f2d-1a22-4ef8-9840-0b0027045573" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_cfca0d31-7834-40b7-ae17-747ad6517df0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_cfca0d31-7834-40b7-ae17-747ad6517df0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d3b52e71-a34a-4514-b92f-960dfb651cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d3b52e71-a34a-4514-b92f-960dfb651cdc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9986919f-9193-4e30-9ed3-cd13d16b4284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9986919f-9193-4e30-9ed3-cd13d16b4284" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f3581515-6188-4cb1-b22a-e30cf1b8a5d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_561e9f41-978f-41e6-a777-0a637c34f4d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_561e9f41-978f-41e6-a777-0a637c34f4d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_3c46a372-476a-4524-b5ca-4ecb354d2520" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeOneMember_3c46a372-476a-4524-b5ca-4ecb354d2520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_a4120369-5efa-45eb-a7f2-b637b7b2584b" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_a4120369-5efa-45eb-a7f2-b637b7b2584b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_d9f8d637-92bd-4edf-ade1-868565c75fd5" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_d9f8d637-92bd-4edf-ade1-868565c75fd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_83e04ea9-5614-42e4-9647-db6877cc9edd" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeFourMember_83e04ea9-5614-42e4-9647-db6877cc9edd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_9ea9d6b4-6bf5-4b71-a648-6e4af32656bc" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_9ea9d6b4-6bf5-4b71-a648-6e4af32656bc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended" id="i57ca51d58b3840c4824ee050b65fb223_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fcdf764-9aee-4fb6-9801-a838d139bafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cb0d72b6-2612-4f5e-8717-2cc82ee9c2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fcdf764-9aee-4fb6-9801-a838d139bafd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cb0d72b6-2612-4f5e-8717-2cc82ee9c2aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cb0d72b6-2612-4f5e-8717-2cc82ee9c2aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d63b282b-5273-477f-a9f9-2b1dee9d2fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d63b282b-5273-477f-a9f9-2b1dee9d2fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fbc1bd0-5708-4724-8b1f-a5fb53e6e272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fbc1bd0-5708-4724-8b1f-a5fb53e6e272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_744d0b49-189d-48ce-a2ff-f1e46d12fe58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_744d0b49-189d-48ce-a2ff-f1e46d12fe58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2bb64ab9-92f8-4e3e-9a84-b38d5348c84b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2bb64ab9-92f8-4e3e-9a84-b38d5348c84b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_ec9a5149-0809-4a18-be38-a12227264e34" xlink:href="jnj-20210103.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_ec9a5149-0809-4a18-be38-a12227264e34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a42c98b4-949b-4ddb-b29e-c8cae126deab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fcdf764-9aee-4fb6-9801-a838d139bafd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:to="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4334f1de-521b-46ed-8e30-9083a28f30bc_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:to="loc_srt_RangeMember_4334f1de-521b-46ed-8e30-9083a28f30bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:to="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_97a37a48-8b6f-475e-9293-8697e3083efb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:to="loc_srt_MinimumMember_97a37a48-8b6f-475e-9293-8697e3083efb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c18564e-b83b-4e70-bf7b-e205ce9ad383" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:to="loc_srt_MaximumMember_1c18564e-b83b-4e70-bf7b-e205ce9ad383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:to="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a42decc-774c-49e1-a5b3-727dc01a1e1b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a42decc-774c-49e1-a5b3-727dc01a1e1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bf12f2d9-416b-4989-9da4-257ffee45b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:to="loc_us-gaap_PerformanceSharesMember_bf12f2d9-416b-4989-9da4-257ffee45b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8eae5bb6-ae49-450b-97e0-d295b24a002b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8eae5bb6-ae49-450b-97e0-d295b24a002b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended" id="ic12897437a524ab0ad1fcfbc1033ebb7_SegmentsofBusinessandGeographicAreas"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended" id="ia314658418d64a6b98c37a403d5fcad0_SegmentsofBusinessandGeographicAreasTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended" id="i477560886b874f61a551f1d7295c6fd9_SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a8f22638-55f8-4b19-a5d9-4f68a15fba58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a8f22638-55f8-4b19-a5d9-4f68a15fba58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b60a2d92-7055-4259-9b6e-65c497450cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b60a2d92-7055-4259-9b6e-65c497450cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3235b7ec-6ea5-450f-ab7f-22b2ac56b2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3235b7ec-6ea5-450f-ab7f-22b2ac56b2d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_57050a8c-95ef-4d6f-b56a-f1d9265aa308" xlink:href="jnj-20210103.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_57050a8c-95ef-4d6f-b56a-f1d9265aa308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:to="loc_us-gaap_LitigationStatusDomain_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9c1078c1-7189-4d2c-a0a0-7276cb3177e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:to="loc_us-gaap_LitigationStatusDomain_9c1078c1-7189-4d2c-a0a0-7276cb3177e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f453eb5b-14cd-4738-b678-aa04e804add1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_9c1078c1-7189-4d2c-a0a0-7276cb3177e6" xlink:to="loc_us-gaap_PendingLitigationMember_f453eb5b-14cd-4738-b678-aa04e804add1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7eb291da-fb23-434a-ba8e-9e25b942dfe0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7eb291da-fb23-434a-ba8e-9e25b942dfe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_973559a1-0b02-4867-9a6c-4c3de90de1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_973559a1-0b02-4867-9a6c-4c3de90de1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_49af6e2d-8355-41ae-a7d7-51fb582ec187" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_973559a1-0b02-4867-9a6c-4c3de90de1b4" xlink:to="loc_jnj_AurisHealthMember_49af6e2d-8355-41ae-a7d7-51fb582ec187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_022c0fa9-4192-48c2-8bda-a963902e015f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:to="loc_srt_SegmentGeographicalDomain_022c0fa9-4192-48c2-8bda-a963902e015f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:to="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_97b11410-515c-42d3-8e4e-b15dc69c1706" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:to="loc_country_US_97b11410-515c-42d3-8e4e-b15dc69c1706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_25278d08-7206-4ad9-b5e1-5ca8b38584d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:to="loc_us-gaap_NonUsMember_25278d08-7206-4ad9-b5e1-5ca8b38584d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_4f067fb5-34ab-4ce7-802e-3b6a3812e0ba" xlink:href="jnj-20210103.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:to="loc_jnj_UNITEDSTATESExportsMember_4f067fb5-34ab-4ce7-802e-3b6a3812e0ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a24bc8c1-1165-434c-941f-71ea65bc4119_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:to="loc_srt_ProductsAndServicesDomain_a24bc8c1-1165-434c-941f-71ea65bc4119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:to="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_69ec9ec9-b18f-4bf0-a688-6b95f261646e" xlink:href="jnj-20210103.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_BabyCareMember_69ec9ec9-b18f-4bf0-a688-6b95f261646e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_a72b3e04-a2d1-4fb8-96bd-81cbf55386d4" xlink:href="jnj-20210103.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OralCareMember_a72b3e04-a2d1-4fb8-96bd-81cbf55386d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_539aebc1-01cd-4812-b9e8-9b59ff8d1882" xlink:href="jnj-20210103.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OTCMember_539aebc1-01cd-4812-b9e8-9b59ff8d1882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_83536384-3e2f-4887-85c6-7b6f22754db3" xlink:href="jnj-20210103.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_WomensHealthMember_83536384-3e2f-4887-85c6-7b6f22754db3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_caf775a8-e900-46a2-add2-f481436580e2" xlink:href="jnj-20210103.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_WoundCareandOtherMember_caf775a8-e900-46a2-add2-f481436580e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_636399db-7071-48fd-bf94-73bf57bda788" xlink:href="jnj-20210103.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_RemicadeMember_636399db-7071-48fd-bf94-73bf57bda788" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_ac9d7e81-79ad-445b-993c-8b3aedab8735" xlink:href="jnj-20210103.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SimponiSimponiAriaMember_ac9d7e81-79ad-445b-993c-8b3aedab8735" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_a2cff7e0-9b6e-4e2e-b69e-3cc0a4c6831d" xlink:href="jnj-20210103.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_StelaraMember_a2cff7e0-9b6e-4e2e-b69e-3cc0a4c6831d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_028c5d82-4135-4dad-a7d0-4751d5ff5aca" xlink:href="jnj-20210103.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_TremfyaMember_028c5d82-4135-4dad-a7d0-4751d5ff5aca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_fd0be277-5863-4f43-9492-5be4a7374b15" xlink:href="jnj-20210103.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherImmunologyMember_fd0be277-5863-4f43-9492-5be4a7374b15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_cf0e11a9-c0c7-46aa-91e4-071a4ccf041c" xlink:href="jnj-20210103.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_EDURANTrilpivirineMember_cf0e11a9-c0c7-46aa-91e4-071a4ccf041c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_30295b6c-a61e-46ab-9aec-425cad90d496" xlink:href="jnj-20210103.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_30295b6c-a61e-46ab-9aec-425cad90d496" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_0fd90881-7b07-469b-9150-5ff9e2f2c0ff" xlink:href="jnj-20210103.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_0fd90881-7b07-469b-9150-5ff9e2f2c0ff" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_9c360dca-4b4e-4006-bf25-c5407d352814" xlink:href="jnj-20210103.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_9c360dca-4b4e-4006-bf25-c5407d352814" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c1bb69ab-f364-4fc6-bc92-0efbdc2a8681" xlink:href="jnj-20210103.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c1bb69ab-f364-4fc6-bc92-0efbdc2a8681" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_a2df4a65-bb65-4706-920b-30f6699ac190" xlink:href="jnj-20210103.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_RISPERDALCONSTAMember_a2df4a65-bb65-4706-920b-30f6699ac190" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_611adafc-da1f-4e4e-b0cc-3045ac2ae879" xlink:href="jnj-20210103.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_611adafc-da1f-4e4e-b0cc-3045ac2ae879" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_1c8b3138-87bc-472b-85f0-cc5eed8a300f" xlink:href="jnj-20210103.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_DARZALEXMember_1c8b3138-87bc-472b-85f0-cc5eed8a300f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_d505524d-598c-4bbd-8a1f-4138566ab5b5" xlink:href="jnj-20210103.xsd#jnj_ErleadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_ErleadaMember_d505524d-598c-4bbd-8a1f-4138566ab5b5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_1eedebc1-24f0-4560-a299-e02b4a3e330c" xlink:href="jnj-20210103.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_IMBRUVICAMember_1eedebc1-24f0-4560-a299-e02b4a3e330c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VELCADEMember_058209a2-2c5c-4cf5-91dc-4dca386639a5" xlink:href="jnj-20210103.xsd#jnj_VELCADEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_VELCADEMember_058209a2-2c5c-4cf5-91dc-4dca386639a5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_167aafd5-d270-4bc3-ad8b-ba735feec534" xlink:href="jnj-20210103.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_ZYTIGAMember_167aafd5-d270-4bc3-ad8b-ba735feec534" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_7e9464b7-933c-4e57-9409-0d6d08d1b507" xlink:href="jnj-20210103.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherOncologyMember_7e9464b7-933c-4e57-9409-0d6d08d1b507" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_244bc6bf-6df6-4e84-b385-1d934d217158" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OPSUMITMember_244bc6bf-6df6-4e84-b385-1d934d217158" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_e45a2826-dec5-4b0d-92c0-4ac608db4309" xlink:href="jnj-20210103.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_UPTRAVIMember_e45a2826-dec5-4b0d-92c0-4ac608db4309" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_6048bc68-7e5c-4316-9346-1230940c3dcc" xlink:href="jnj-20210103.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherMember_6048bc68-7e5c-4316-9346-1230940c3dcc" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_c2f4d825-2726-4dcf-885d-c8e5be2c40ea" xlink:href="jnj-20210103.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_XareltoMember_c2f4d825-2726-4dcf-885d-c8e5be2c40ea" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_3688f9a7-6f99-4210-b103-7efb919044f1" xlink:href="jnj-20210103.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_3688f9a7-6f99-4210-b103-7efb919044f1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_9ebc2fbd-dbad-49c9-994c-dca264e4f6b9" xlink:href="jnj-20210103.xsd#jnj_PROCRITEPREXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_PROCRITEPREXMember_9ebc2fbd-dbad-49c9-994c-dca264e4f6b9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_aa42b899-0444-4dce-a747-8d5e46954a87" xlink:href="jnj-20210103.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_HIPSMember_aa42b899-0444-4dce-a747-8d5e46954a87" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_b51c6170-5320-4f85-9ba8-cd0ce26d16a2" xlink:href="jnj-20210103.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_KNEESMember_b51c6170-5320-4f85-9ba8-cd0ce26d16a2" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_b8351f55-3fb0-450e-92fd-2c2394f84d39" xlink:href="jnj-20210103.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_TRAUMAMember_b8351f55-3fb0-450e-92fd-2c2394f84d39" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_194eb03a-e7ba-4db1-8eab-d4f33c4bc39c" xlink:href="jnj-20210103.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SPINEOTHERMember_194eb03a-e7ba-4db1-8eab-d4f33c4bc39c" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_a6c24abb-9d19-48d0-8649-6553dbf7d96e" xlink:href="jnj-20210103.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_ADVANCEDMember_a6c24abb-9d19-48d0-8649-6553dbf7d96e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_aa7d50cf-7f46-4096-881e-11127e9200b6" xlink:href="jnj-20210103.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_GENERALMember_aa7d50cf-7f46-4096-881e-11127e9200b6" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_6427c46f-8de3-4c8e-9e4a-a84cf667179a" xlink:href="jnj-20210103.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_6427c46f-8de3-4c8e-9e4a-a84cf667179a" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_15e997d1-3943-485f-91b8-4d11450ce55d" xlink:href="jnj-20210103.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SURGICALMember_15e997d1-3943-485f-91b8-4d11450ce55d" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_158044e1-1c3f-43b6-a6fb-4a547f900969" xlink:href="jnj-20210103.xsd#jnj_SkinHealthBeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SkinHealthBeautyMember_158044e1-1c3f-43b6-a6fb-4a547f900969" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9eb03470-1d98-4d99-b3fe-5be57b486c14_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:to="loc_srt_ConsolidationItemsDomain_9eb03470-1d98-4d99-b3fe-5be57b486c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7773a161-0680-4e02-acee-ecdca3f5bb1a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:to="loc_srt_ConsolidationItemsDomain_7773a161-0680-4e02-acee-ecdca3f5bb1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e396228-27fa-472a-b71f-ae80ef5b1aee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:to="loc_us-gaap_SegmentDomain_8e396228-27fa-472a-b71f-ae80ef5b1aee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:to="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_420d2400-0bb6-4f00-969f-d4c3ee13dd18" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:to="loc_jnj_ConsumerMember_420d2400-0bb6-4f00-969f-d4c3ee13dd18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_da356966-904c-4c0d-a8aa-32916a19055e" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:to="loc_jnj_PharmaceuticalMember_da356966-904c-4c0d-a8aa-32916a19055e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a2e6030e-f4e1-45a6-97e0-db3090369b91" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:to="loc_jnj_MedicalDevicesMember_a2e6030e-f4e1-45a6-97e0-db3090369b91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_4f9d6440-a52e-4d33-91cc-3896ecac1025_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:to="loc_us-gaap_SubsegmentsDomain_4f9d6440-a52e-4d33-91cc-3896ecac1025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:to="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_3dde9e04-a141-494c-a070-4094815ccddc" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_ImmunologyMember_3dde9e04-a141-494c-a070-4094815ccddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_f1aeab1e-6249-4231-b14e-c50bbe4af3cb" xlink:href="jnj-20210103.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_InfectiousDiseasesMember_f1aeab1e-6249-4231-b14e-c50bbe4af3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_b4b90532-c290-49e4-b377-4f05838cf022" xlink:href="jnj-20210103.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_NeuroscienceMember_b4b90532-c290-49e4-b377-4f05838cf022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_6599171c-74ef-440b-8222-60ea166d6335" xlink:href="jnj-20210103.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_OncologyMember_6599171c-74ef-440b-8222-60ea166d6335" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_0c2315ec-1032-4612-98e6-989c0aefd4ee" xlink:href="jnj-20210103.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_PulmonaryHypertensionMember_0c2315ec-1032-4612-98e6-989c0aefd4ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_70d9e12b-642b-43c5-8c48-4a227ea41619" xlink:href="jnj-20210103.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_70d9e12b-642b-43c5-8c48-4a227ea41619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiabetesCareMember_37fc497c-b96a-4127-aae0-2d1b946eff3d" xlink:href="jnj-20210103.xsd#jnj_DiabetesCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_DiabetesCareMember_37fc497c-b96a-4127-aae0-2d1b946eff3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_5f130678-0fe5-4e10-99a5-15bf2650f107" xlink:href="jnj-20210103.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_InterventionalSolutionsMember_5f130678-0fe5-4e10-99a5-15bf2650f107" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_b038efc0-9a5a-477f-ae19-210289b40989" xlink:href="jnj-20210103.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_OrthopaedicsMember_b038efc0-9a5a-477f-ae19-210289b40989" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_9059235d-14a0-4db9-b6f5-846a03b41928" xlink:href="jnj-20210103.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_SurgeryMember_9059235d-14a0-4db9-b6f5-846a03b41928" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_f8d127a9-5aa1-4487-91a0-77bf790401ef" xlink:href="jnj-20210103.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_VisionMember_f8d127a9-5aa1-4487-91a0-77bf790401ef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_9b9994f7-375c-46cf-8fe3-33cae8bc9bf6" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_OPSUMITMember_9b9994f7-375c-46cf-8fe3-33cae8bc9bf6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_a27a1317-20b0-493a-b689-77ffb509a32b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_a27a1317-20b0-493a-b689-77ffb509a32b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_68ccef9f-df4f-4b4e-afdd-8cc543b0b6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_68ccef9f-df4f-4b4e-afdd-8cc543b0b6d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended" id="ie8cc9905ae0545ae9d5ead866243c586_SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5133a368-d0f2-42e8-8196-57c35de46a27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5133a368-d0f2-42e8-8196-57c35de46a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments_07007725-83b3-40e6-b448-34f87b24ecf4" xlink:href="jnj-20210103.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_jnj_ExpenseNotAllocatedToSegments_07007725-83b3-40e6-b448-34f87b24ecf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0c2d9b72-f1db-4367-bafb-b83c67f07b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_Assets_0c2d9b72-f1db-4367-bafb-b83c67f07b0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04860b6a-e6b9-4a90-97c0-ea5a654da562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04860b6a-e6b9-4a90-97c0-ea5a654da562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4621a153-7047-461d-879d-6247099ad9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4621a153-7047-461d-879d-6247099ad9ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b39d238-a087-4728-bd39-88787dca2a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b39d238-a087-4728-bd39-88787dca2a74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ffa3534c-e5d1-430a-a6fb-fd6e9e18db30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ffa3534c-e5d1-430a-a6fb-fd6e9e18db30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:to="loc_us-gaap_SubsegmentsDomain_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c5a7bdb1-0b11-4e47-bf74-5d947c4b0272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:to="loc_us-gaap_SubsegmentsDomain_c5a7bdb1-0b11-4e47-bf74-5d947c4b0272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_2cc68c42-fee9-436a-846c-dd611450716e" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c5a7bdb1-0b11-4e47-bf74-5d947c4b0272" xlink:to="loc_jnj_ImmunologyMember_2cc68c42-fee9-436a-846c-dd611450716e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41155e2b-d995-4ce9-91f0-c8ef2a195729_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:to="loc_srt_ProductsAndServicesDomain_41155e2b-d995-4ce9-91f0-c8ef2a195729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79144071-e8ef-45d6-a45c-15ebd2ad2286" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:to="loc_srt_ProductsAndServicesDomain_79144071-e8ef-45d6-a45c-15ebd2ad2286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:to="loc_srt_ConsolidationItemsDomain_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:to="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e8893190-44a5-41a4-9d6f-89332cd658ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e8893190-44a5-41a4-9d6f-89332cd658ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9059f39b-3e35-4166-b3cb-0196d6327146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:to="loc_us-gaap_OperatingSegmentsMember_9059f39b-3e35-4166-b3cb-0196d6327146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_21d23a49-f306-43dd-ac4f-ff13472e07b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:to="loc_us-gaap_SegmentDomain_21d23a49-f306-43dd-ac4f-ff13472e07b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:to="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_a3e43b70-6fba-4e98-a46a-dba9cef130ac" xlink:href="jnj-20210103.xsd#jnj_GeneralCorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_GeneralCorporateMember_a3e43b70-6fba-4e98-a46a-dba9cef130ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_f0af4b7a-bf7d-4661-b8cd-8155b54e191a" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_ConsumerMember_f0af4b7a-bf7d-4661-b8cd-8155b54e191a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_63ffe20d-1694-4c6a-abac-945117c57ed4" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_PharmaceuticalMember_63ffe20d-1694-4c6a-abac-945117c57ed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_f4b9cab2-b26d-49b0-a5ae-487a8ffb7c81" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_MedicalDevicesMember_f4b9cab2-b26d-49b0-a5ae-487a8ffb7c81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_0ae83e14-d06f-4b55-8d09-66254b4d8687" xlink:href="jnj-20210103.xsd#jnj_SegmentsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_SegmentsTotalMember_0ae83e14-d06f-4b55-8d09-66254b4d8687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:to="loc_srt_SegmentGeographicalDomain_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:to="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f4e59b97-4990-4b5b-a479-7aa990878322" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:to="loc_country_US_f4e59b97-4990-4b5b-a479-7aa990878322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e0ad4e0c-cd91-481c-88e5-af2a36c8df20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:to="loc_us-gaap_NonUsMember_e0ad4e0c-cd91-481c-88e5-af2a36c8df20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_88955a4c-89a0-4c9b-87bb-4e957788fe87_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:to="loc_srt_NameOfMajorCustomerDomain_88955a4c-89a0-4c9b-87bb-4e957788fe87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1c0fb63c-9311-4b15-aa8f-5cdb3c1d4918" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:to="loc_srt_NameOfMajorCustomerDomain_1c0fb63c-9311-4b15-aa8f-5cdb3c1d4918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_ce4162d0-a2e4-4eb8-ba40-f4e8ccf18a15" xlink:href="jnj-20210103.xsd#jnj_Wholesaler2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1c0fb63c-9311-4b15-aa8f-5cdb3c1d4918" xlink:to="loc_jnj_Wholesaler2Member_ce4162d0-a2e4-4eb8-ba40-f4e8ccf18a15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_035ce90d-8864-4402-824a-e8637ea1e850_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_035ce90d-8864-4402-824a-e8637ea1e850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_401ab2d6-edf5-49b6-95da-311727a0c003" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_401ab2d6-edf5-49b6-95da-311727a0c003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c9256985-05d6-4740-a578-044f587218ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_401ab2d6-edf5-49b6-95da-311727a0c003" xlink:to="loc_us-gaap_SalesRevenueNetMember_c9256985-05d6-4740-a578-044f587218ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="iac5abe28409e40e1b58aa7cbdafc56c6_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_95077fc5-f070-4305-bb5a-77c261956ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_95077fc5-f070-4305-bb5a-77c261956ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_93400399-800a-4cc2-92c2-e98f9883664e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_93400399-800a-4cc2-92c2-e98f9883664e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62c681d1-c109-4473-9ec4-0e727b7f9b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62c681d1-c109-4473-9ec4-0e727b7f9b23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_a541acdb-1500-497f-ab60-94c1dc7d3ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_NoncurrentAssets_a541acdb-1500-497f-ab60-94c1dc7d3ec9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_cb2c5f23-75dc-4873-9c96-3607062f5ec3" xlink:href="jnj-20210103.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_OtherNonLongLivedAssets_cb2c5f23-75dc-4873-9c96-3607062f5ec3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_87e831dd-ab26-4dc8-92a9-54255d3ccfff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_Assets_87e831dd-ab26-4dc8-92a9-54255d3ccfff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7ac040a8-c6ba-444d-88b9-a48ed51a87bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7ac040a8-c6ba-444d-88b9-a48ed51a87bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c1938d8c-1e49-4470-9e79-7e93e96aa4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c1938d8c-1e49-4470-9e79-7e93e96aa4bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ef8e2610-a180-4464-aad3-162c61b96ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ef8e2610-a180-4464-aad3-162c61b96ce7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c7098845-ffe2-4f1b-afa9-97a45c6fb17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c7098845-ffe2-4f1b-afa9-97a45c6fb17c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedLossOnSecurities_42a7efe2-623d-4041-b775-c74e8dbf9f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedLossOnSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_UnrealizedLossOnSecurities_42a7efe2-623d-4041-b775-c74e8dbf9f99" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e7775e85-6298-42c5-afed-754a96c63b95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_RestructuringCharges_e7775e85-6298-42c5-afed-754a96c63b95" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_d0c95208-b08a-458c-98d5-1f7d42717119" xlink:href="jnj-20210103.xsd#jnj_RegulationCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_RegulationCharge_d0c95208-b08a-458c-98d5-1f7d42717119" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_d5895184-533d-4cc1-b578-226e21510abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_d5895184-533d-4cc1-b578-226e21510abd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2a985dbd-cab9-4180-812d-41b1d9a338f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2a985dbd-cab9-4180-812d-41b1d9a338f2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_58f56f43-3bee-4659-9962-1ba2a2a018de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_LitigationSettlementExpense_58f56f43-3bee-4659-9962-1ba2a2a018de" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringChargeNetofAccrualAdjustment_a010c92c-ff22-4872-b7ea-8ec6d6a7cfaa" xlink:href="jnj-20210103.xsd#jnj_RestructuringChargeNetofAccrualAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_RestructuringChargeNetofAccrualAdjustment_a010c92c-ff22-4872-b7ea-8ec6d6a7cfaa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d03e6ae8-69f1-4057-a6c9-318c7c027266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d03e6ae8-69f1-4057-a6c9-318c7c027266" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnSecurities_a3ddfffe-7581-4698-accc-f564cecee7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_UnrealizedGainLossOnSecurities_a3ddfffe-7581-4698-accc-f564cecee7b6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_271a7934-cd4a-4396-a697-450a1ad1f075" xlink:href="jnj-20210103.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_271a7934-cd4a-4396-a697-450a1ad1f075" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4503722-464b-4ccd-bf50-82ba2c5407f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4503722-464b-4ccd-bf50-82ba2c5407f8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_42789a5b-e666-4095-89bc-ee7c046442da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_42789a5b-e666-4095-89bc-ee7c046442da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c10b15f1-bbe9-44c6-9afb-5ff9ce249521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c10b15f1-bbe9-44c6-9afb-5ff9ce249521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_be9f80f7-882c-47f9-8a45-6876d35a3eb0" xlink:href="jnj-20210103.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c10b15f1-bbe9-44c6-9afb-5ff9ce249521" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_be9f80f7-882c-47f9-8a45-6876d35a3eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_99157b58-f783-4263-902e-96ad22e17acf_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:to="loc_srt_NameOfMajorCustomerDomain_99157b58-f783-4263-902e-96ad22e17acf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:to="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_bcc66f61-4cb7-4506-bd6c-d7eabcd9966f" xlink:href="jnj-20210103.xsd#jnj_Wholesaler1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:to="loc_jnj_Wholesaler1Member_bcc66f61-4cb7-4506-bd6c-d7eabcd9966f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_bf2f8660-c924-47c9-8a00-6af934526323" xlink:href="jnj-20210103.xsd#jnj_Wholesaler2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:to="loc_jnj_Wholesaler2Member_bf2f8660-c924-47c9-8a00-6af934526323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_b195295b-b667-4b00-9646-c5c978fc6516" xlink:href="jnj-20210103.xsd#jnj_Wholesaler3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:to="loc_jnj_Wholesaler3Member_b195295b-b667-4b00-9646-c5c978fc6516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_80402bf7-4f2e-451e-a03e-190fd8e3a7c4_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:to="loc_srt_ConsolidationItemsDomain_80402bf7-4f2e-451e-a03e-190fd8e3a7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:to="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0d941a16-12a9-46d5-b8da-675aa561b9a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0d941a16-12a9-46d5-b8da-675aa561b9a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7cdef197-5e4e-48c5-9849-333a3d7a4e60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:to="loc_us-gaap_OperatingSegmentsMember_7cdef197-5e4e-48c5-9849-333a3d7a4e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fa4b6ea5-31c6-4f6d-8a65-6a683235d623_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:to="loc_srt_SegmentGeographicalDomain_fa4b6ea5-31c6-4f6d-8a65-6a683235d623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:to="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_cc51a593-4a21-4ff0-9cc7-c2c6a77ffbf5" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_country_US_cc51a593-4a21-4ff0-9cc7-c2c6a77ffbf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_cdfeb495-a9bd-4b6a-b4f1-68b19a50014f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_srt_EuropeMember_cdfeb495-a9bd-4b6a-b4f1-68b19a50014f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_2283e8f2-428a-4a43-b1a5-d1536e364f07" xlink:href="jnj-20210103.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_2283e8f2-428a-4a43-b1a5-d1536e364f07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_ef5a1c78-18b9-4a34-afe8-583d45a62a39" xlink:href="jnj-20210103.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_jnj_AsiaPacificAfricaMember_ef5a1c78-18b9-4a34-afe8-583d45a62a39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_09acdaf5-6388-4044-80ea-6c0d8498dc63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_us-gaap_OperatingSegmentsMember_09acdaf5-6388-4044-80ea-6c0d8498dc63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1a29bf5e-3944-4bbb-bf49-3e1754219659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_us-gaap_NonUsMember_1a29bf5e-3944-4bbb-bf49-3e1754219659" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b3a2090-9568-4ec5-b580-24e73ff8b697_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5b3a2090-9568-4ec5-b580-24e73ff8b697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_775c5727-a425-4388-b8ba-9b19d87bcb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_775c5727-a425-4388-b8ba-9b19d87bcb6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_9fb5b395-26dd-4498-b677-5f08aba27f04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_775c5727-a425-4388-b8ba-9b19d87bcb6b" xlink:to="loc_us-gaap_SalesRevenueNetMember_9fb5b395-26dd-4498-b677-5f08aba27f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_80d0661b-6d2b-43ad-891f-79883b468da4_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_80d0661b-6d2b-43ad-891f-79883b468da4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NIZORALMember_a0dc0a5e-d10e-48a3-a0a7-f901137d5cc0" xlink:href="jnj-20210103.xsd#jnj_NIZORALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:to="loc_jnj_NIZORALMember_a0dc0a5e-d10e-48a3-a0a7-f901137d5cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PANCREASEMember_eb47ed5f-f925-4982-9c45-ec88dc0e7154" xlink:href="jnj-20210103.xsd#jnj_PANCREASEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:to="loc_jnj_PANCREASEMember_eb47ed5f-f925-4982-9c45-ec88dc0e7154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LifeScanMember_d18f3522-5a6f-4fe1-bbe7-d7f1c13fe194" xlink:href="jnj-20210103.xsd#jnj_LifeScanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:to="loc_jnj_LifeScanMember_d18f3522-5a6f-4fe1-bbe7-d7f1c13fe194" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91e03ae-f1c1-4ea2-a483-8b852f0f0419_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a91e03ae-f1c1-4ea2-a483-8b852f0f0419_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_c2172a9f-bf6a-45cf-aa78-e4b6ad7181c7" xlink:href="jnj-20210103.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_c2172a9f-bf6a-45cf-aa78-e4b6ad7181c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AliosBiopharmaIncandXO1LimitedMember_2503dadb-d78a-4c98-b38a-00c3316dfea2" xlink:href="jnj-20210103.xsd#jnj_AliosBiopharmaIncandXO1LimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_AliosBiopharmaIncandXO1LimitedMember_2503dadb-d78a-4c98-b38a-00c3316dfea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XO1Member_080dc333-84e4-49ce-9ff1-13e57eb7d76f" xlink:href="jnj-20210103.xsd#jnj_XO1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_XO1Member_080dc333-84e4-49ce-9ff1-13e57eb7d76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ActelionMember_d9df1c82-11d1-485b-8188-58d0f0beb542" xlink:href="jnj-20210103.xsd#jnj_ActelionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_ActelionMember_d9df1c82-11d1-485b-8188-58d0f0beb542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AMOMember_6ec9bbb8-147d-484e-bfdc-0231b5911a37" xlink:href="jnj-20210103.xsd#jnj_AMOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_AMOMember_6ec9bbb8-147d-484e-bfdc-0231b5911a37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_48c7c582-1340-4a5f-8116-e3b100e87bf8" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_AurisHealthMember_48c7c582-1340-4a5f-8116-e3b100e87bf8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_dd24bdcd-1764-43d3-8f83-78ee02416468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_dd24bdcd-1764-43d3-8f83-78ee02416468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_783e7411-800b-40e1-9044-325ace6970e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_783e7411-800b-40e1-9044-325ace6970e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_46900bba-62c3-4d21-ac3a-c6cc59d69643_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:to="loc_us-gaap_SegmentDomain_46900bba-62c3-4d21-ac3a-c6cc59d69643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:to="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_038f3f5b-5e75-4245-89e7-fa2c02ea9ef1" xlink:href="jnj-20210103.xsd#jnj_GeneralCorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_GeneralCorporateMember_038f3f5b-5e75-4245-89e7-fa2c02ea9ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_db9ab57e-ca91-4b16-8f58-cb18944ab00f" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_MedicalDevicesMember_db9ab57e-ca91-4b16-8f58-cb18944ab00f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_af5223f1-846d-421e-a0df-377b7c06b507" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_ConsumerMember_af5223f1-846d-421e-a0df-377b7c06b507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_7075a753-72c5-4429-9fcc-e46a30c1a9ea" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_PharmaceuticalMember_7075a753-72c5-4429-9fcc-e46a30c1a9ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9af24c94-a3b6-47f6-9f28-bcacbca7906e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9af24c94-a3b6-47f6-9f28-bcacbca7906e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1660768-3f2b-4279-b276-aa7c13a24066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1660768-3f2b-4279-b276-aa7c13a24066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_81a380a8-13c3-48ad-b743-62b0ab44488d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1660768-3f2b-4279-b276-aa7c13a24066" xlink:to="loc_us-gaap_OtherIncomeMember_81a380a8-13c3-48ad-b743-62b0ab44488d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_60445ded-2cc7-411a-b6da-93320cc4ed0a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:to="loc_srt_ProductsAndServicesDomain_60445ded-2cc7-411a-b6da-93320cc4ed0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:to="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_ce1b438c-6b14-40b0-b7aa-1179065e0bd7" xlink:href="jnj-20210103.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_BabyCareMember_ce1b438c-6b14-40b0-b7aa-1179065e0bd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_2e0f91bb-e6d3-4ecf-b3e9-7cd8100a2b9e" xlink:href="jnj-20210103.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_OTCMember_2e0f91bb-e6d3-4ecf-b3e9-7cd8100a2b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_4babdd13-6a63-4b48-ba3a-123380acc31d" xlink:href="jnj-20210103.xsd#jnj_SkinHealthBeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_SkinHealthBeautyMember_4babdd13-6a63-4b48-ba3a-123380acc31d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_cf07500e-b44e-4027-b7a7-40db71943fc1" xlink:href="jnj-20210103.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_OralCareMember_cf07500e-b44e-4027-b7a7-40db71943fc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_ae0adb2d-24b9-4e56-8cab-8d940a951227" xlink:href="jnj-20210103.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_StelaraMember_ae0adb2d-24b9-4e56-8cab-8d940a951227" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_19ef5b94-8c4e-4b86-86cf-6b05e8472c1b" xlink:href="jnj-20210103.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_TremfyaMember_19ef5b94-8c4e-4b86-86cf-6b05e8472c1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_dda8e56f-0386-4274-8929-ee7a5e77cb57" xlink:href="jnj-20210103.xsd#jnj_ErleadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_ErleadaMember_dda8e56f-0386-4274-8929-ee7a5e77cb57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_c009448d-98d6-4e5f-a4d8-4d23d0614ab8" xlink:href="jnj-20210103.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_IMBRUVICAMember_c009448d-98d6-4e5f-a4d8-4d23d0614ab8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_3d8e043a-698e-4f0a-8a39-f4fe8ad3299d" xlink:href="jnj-20210103.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_DARZALEXMember_3d8e043a-698e-4f0a-8a39-f4fe8ad3299d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_9a160066-9ccd-4692-a06f-fa9f3bb10fe4" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_OPSUMITMember_9a160066-9ccd-4692-a06f-fa9f3bb10fe4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_dcaacec2-737d-4cfa-b323-9ccc31969a57_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:to="loc_us-gaap_SubsegmentsDomain_dcaacec2-737d-4cfa-b323-9ccc31969a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:to="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_24c1fc15-5775-44be-9b89-b364a33c00b9" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_ImmunologyMember_24c1fc15-5775-44be-9b89-b364a33c00b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_da55ac60-3df3-49a6-a1c9-51f5e1501929" xlink:href="jnj-20210103.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_OncologyMember_da55ac60-3df3-49a6-a1c9-51f5e1501929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_89823dbb-013c-4819-8e6f-cedf692128d3" xlink:href="jnj-20210103.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_PulmonaryHypertensionMember_89823dbb-013c-4819-8e6f-cedf692128d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_1a3283cc-5170-4c23-895b-55d8e537b4b9" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_OPSUMITMember_1a3283cc-5170-4c23-895b-55d8e537b4b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_9931651b-81f5-449f-a11b-89a11a7a139d" xlink:href="jnj-20210103.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_UPTRAVIMember_9931651b-81f5-449f-a11b-89a11a7a139d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_e48960c5-cf75-47fa-a67b-720f9a736707" xlink:href="jnj-20210103.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_InterventionalSolutionsMember_e48960c5-cf75-47fa-a67b-720f9a736707" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiabetesCareMember_2995eb7c-cc7b-42c9-a228-74584013efa9" xlink:href="jnj-20210103.xsd#jnj_DiabetesCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_DiabetesCareMember_2995eb7c-cc7b-42c9-a228-74584013efa9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_37d302a5-d1a6-486d-8279-e78ccfa69a79_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:to="loc_us-gaap_LitigationStatusDomain_37d302a5-d1a6-486d-8279-e78ccfa69a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_38f80e6d-a58c-44ae-9abd-02f12fafffcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:to="loc_us-gaap_LitigationStatusDomain_38f80e6d-a58c-44ae-9abd-02f12fafffcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_5f3b5f38-dbd8-467b-af37-3ae0521cf827" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_38f80e6d-a58c-44ae-9abd-02f12fafffcd" xlink:to="loc_us-gaap_PendingLitigationMember_5f3b5f38-dbd8-467b-af37-3ae0521cf827" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20210103.xsd#AcquisitionsandDivestitures"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended" id="ib0faf46c63574c2d8864bcee7dd3f957_AcquisitionsandDivestitures"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i7e1414a827874b75b58a2ebc635ff9f7_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0e67697-c7f6-45d8-9754-74735b08715e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0e67697-c7f6-45d8-9754-74735b08715e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0d6d37d9-11b3-4051-b8a4-2f8927bf823c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0d6d37d9-11b3-4051-b8a4-2f8927bf823c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1e1a1704-90a2-4536-82a1-1af1d320f119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1e1a1704-90a2-4536-82a1-1af1d320f119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f3a1e113-27c2-458f-a145-2a9146535dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f3a1e113-27c2-458f-a145-2a9146535dea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7ec9eb43-43f6-4687-83cb-4d7528bb19dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7ec9eb43-43f6-4687-83cb-4d7528bb19dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_7a4ad990-7b06-4001-96ff-67b3a6f69f16" xlink:href="jnj-20210103.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_7a4ad990-7b06-4001-96ff-67b3a6f69f16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_21903879-0980-4afc-bb48-312a4b0ec605" xlink:href="jnj-20210103.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_21903879-0980-4afc-bb48-312a4b0ec605" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f459b75d-28a9-4482-8715-8a59b0e7e212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f459b75d-28a9-4482-8715-8a59b0e7e212" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05c124cb-2b64-45c2-bf09-3d6e2b7f08f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_Goodwill_05c124cb-2b64-45c2-bf09-3d6e2b7f08f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c3010ccf-85ae-4c87-b99c-4be03a5df11d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c3010ccf-85ae-4c87-b99c-4be03a5df11d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_cef7aec9-1280-411b-b27e-e08851648963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_cef7aec9-1280-411b-b27e-e08851648963" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_91c59503-1c48-4f3e-8480-fdf630f6e7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_91c59503-1c48-4f3e-8480-fdf630f6e7d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_44385de3-6665-4ddd-a03c-cca744d14955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_44385de3-6665-4ddd-a03c-cca744d14955" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c640342a-3aa9-462b-a948-24b79a4f764e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c640342a-3aa9-462b-a948-24b79a4f764e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_f29e1498-adc0-47ea-9f6a-97d6bbdcf6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_f29e1498-adc0-47ea-9f6a-97d6bbdcf6ca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d0ca28dc-ca3c-4234-807d-5af426d3d0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d0ca28dc-ca3c-4234-807d-5af426d3d0d8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_11070a11-985c-4f4c-b3e7-72dddc6daa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_11070a11-985c-4f4c-b3e7-72dddc6daa2b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_3ba37e06-f79a-463e-8f32-8972c2d8f1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_3ba37e06-f79a-463e-8f32-8972c2d8f1d0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1bd299b8-9529-40a9-9b44-cc473026e7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1bd299b8-9529-40a9-9b44-cc473026e7ed" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_9d22f8f3-5475-467e-a315-0025df0a3fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_9d22f8f3-5475-467e-a315-0025df0a3fa8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6649ca45-09d2-4402-af3b-8685de19bfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6649ca45-09d2-4402-af3b-8685de19bfaa" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_c66d2ba2-fdf3-46d5-a174-d22cffdd49ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_c66d2ba2-fdf3-46d5-a174-d22cffdd49ca" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_a8ed152f-f6e9-4740-9db9-c5f77c8c57e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_a8ed152f-f6e9-4740-9db9-c5f77c8c57e9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_d8f64a40-e3c9-4e68-b912-8259b4451735" xlink:href="jnj-20210103.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_d8f64a40-e3c9-4e68-b912-8259b4451735" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestPercentage_a31f2a4c-2c6d-43df-825b-2bd966f862d2" xlink:href="jnj-20210103.xsd#jnj_ConvertibleNoteEquityInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_ConvertibleNoteEquityInterestPercentage_a31f2a4c-2c6d-43df-825b-2bd966f862d2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c319b37-2346-4ac3-a041-936d2a3e140f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_LongTermDebt_5c319b37-2346-4ac3-a041-936d2a3e140f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7a272b30-2024-493e-9aae-e5ed46f14d08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7a272b30-2024-493e-9aae-e5ed46f14d08" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_01f254dc-6d5a-4771-8e83-b6664995ef0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_01f254dc-6d5a-4771-8e83-b6664995ef0b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_3092090c-f472-4b11-8e13-67123df4e02e" xlink:href="jnj-20210103.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_3092090c-f472-4b11-8e13-67123df4e02e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_865bcb64-0166-4ecf-9665-7ca82a18cf9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_865bcb64-0166-4ecf-9665-7ca82a18cf9b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_92c8eb9f-5033-4d1b-87ca-3cdba8dcaa96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_92c8eb9f-5033-4d1b-87ca-3cdba8dcaa96" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_71c811bb-1397-4bf4-8737-37df9de0f45b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_71c811bb-1397-4bf4-8737-37df9de0f45b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0affd07d-3631-4e30-9240-8e5fe461354b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0affd07d-3631-4e30-9240-8e5fe461354b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2c383fbc-29e8-4a66-8495-b7246a87f37e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2c383fbc-29e8-4a66-8495-b7246a87f37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_3957c30e-d283-4a77-8c68-1cb84ec36f97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2c383fbc-29e8-4a66-8495-b7246a87f37e" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_3957c30e-d283-4a77-8c68-1cb84ec36f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_01f91d77-c7fd-4c26-8ddc-031e1b5e214a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_01f91d77-c7fd-4c26-8ddc-031e1b5e214a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LifeScanMember_f21a8119-cd38-4ca4-9ccb-e539c0cae4b4" xlink:href="jnj-20210103.xsd#jnj_LifeScanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_LifeScanMember_f21a8119-cd38-4ca4-9ccb-e539c0cae4b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_17dd3ce6-e841-49ac-acdd-f1c9b5135046" xlink:href="jnj-20210103.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_17dd3ce6-e841-49ac-acdd-f1c9b5135046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_4f03a68e-8e61-4d09-958d-89073552c5f9" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_SupplyChainMember_4f03a68e-8e61-4d09-958d-89073552c5f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_53107080-3135-481b-bae7-0fe222bc619e" xlink:href="jnj-20210103.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_EvraAndDoxilMember_53107080-3135-481b-bae7-0fe222bc619e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4743059e-2d9c-47f0-bf4f-7d80f7f494e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4743059e-2d9c-47f0-bf4f-7d80f7f494e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9877b92d-cbec-499b-8023-4e16f0cc24a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9877b92d-cbec-499b-8023-4e16f0cc24a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_4f14d707-98fe-47fb-a666-85f304c792c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9877b92d-cbec-499b-8023-4e16f0cc24a0" xlink:to="loc_us-gaap_ConvertibleDebtMember_4f14d707-98fe-47fb-a666-85f304c792c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42e380ce-1ae8-450d-b712-20dee99c525f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:to="loc_srt_RangeMember_42e380ce-1ae8-450d-b712-20dee99c525f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:to="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce1db0d0-862a-4ab0-9a7c-08a80ead45e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:to="loc_srt_MaximumMember_ce1db0d0-862a-4ab0-9a7c-08a80ead45e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_643150b5-9280-47a6-9dfc-98f94e68d2c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:to="loc_srt_MinimumMember_643150b5-9280-47a6-9dfc-98f94e68d2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4195524e-4fd1-4a2f-b91c-2b1d8163987c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4195524e-4fd1-4a2f-b91c-2b1d8163987c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2019AcquisitionsMember_00973847-c353-4ba1-9721-c5faf636117b" xlink:href="jnj-20210103.xsd#jnj_A2019AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_A2019AcquisitionsMember_00973847-c353-4ba1-9721-c5faf636117b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_330a679c-ed55-4014-91dc-a97281f4da08" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_AurisHealthMember_330a679c-ed55-4014-91dc-a97281f4da08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2018AcquisitionsMember_ced18779-f249-414b-a0ba-5d3b8c98f4a6" xlink:href="jnj-20210103.xsd#jnj_A2018AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_A2018AcquisitionsMember_ced18779-f249-414b-a0ba-5d3b8c98f4a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_bfccf72f-23f4-4da3-8d27-f083a29e07b1" xlink:href="jnj-20210103.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_bfccf72f-23f4-4da3-8d27-f083a29e07b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember_ec910e8f-effe-469d-a5b1-2b8d015d97d1" xlink:href="jnj-20210103.xsd#jnj_IdorsiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_IdorsiaMember_ec910e8f-effe-469d-a5b1-2b8d015d97d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_78fd30d6-7cb8-477a-a2bd-72836a808c69" xlink:href="jnj-20210103.xsd#jnj_MomentaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_MomentaMember_78fd30d6-7cb8-477a-a2bd-72836a808c69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember_d72a1b5b-056e-457d-a855-7661709ea239" xlink:href="jnj-20210103.xsd#jnj_A2020AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_A2020AcquisitionsMember_d72a1b5b-056e-457d-a855-7661709ea239" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_a22520c2-9f05-4557-bc95-4c45e73f95f2" xlink:href="jnj-20210103.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_BermekimabMember_a22520c2-9f05-4557-bc95-4c45e73f95f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_f6310591-a055-4c5b-9d2b-da47f6774e2b" xlink:href="jnj-20210103.xsd#jnj_VerbSurgicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_VerbSurgicalIncMember_f6310591-a055-4c5b-9d2b-da47f6774e2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_092fd5e3-bbaa-45a1-990c-fc2b27467110_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_092fd5e3-bbaa-45a1-990c-fc2b27467110_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32e33805-01e4-4e8d-9c37-b817f4c3fcc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32e33805-01e4-4e8d-9c37-b817f4c3fcc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_108a799e-2bc5-4a0e-9b73-46d4cd0bfde1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32e33805-01e4-4e8d-9c37-b817f4c3fcc1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_108a799e-2bc5-4a0e-9b73-46d4cd0bfde1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0dd37b42-d342-4993-b660-3abbbb4cbafa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0dd37b42-d342-4993-b660-3abbbb4cbafa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48214fcb-3bef-4ba8-a7f7-c829d0f9401c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48214fcb-3bef-4ba8-a7f7-c829d0f9401c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dba6dd6c-bd64-4888-8d14-414182dd8140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_48214fcb-3bef-4ba8-a7f7-c829d0f9401c" xlink:to="loc_us-gaap_SubsequentEventMember_dba6dd6c-bd64-4888-8d14-414182dd8140" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20210103.xsd#LegalProceedings"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended" id="i211ebd910d004337879fb0e9e92b1294_LegalProceedings"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i47a5d40951524adf8c52ce5a081c2dc0_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_702b7907-2f19-4d6b-966f-e23830b306f4" xlink:href="jnj-20210103.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_702b7907-2f19-4d6b-966f-e23830b306f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_632cd1ae-491d-42e1-bca5-b2b5a874e342" xlink:href="jnj-20210103.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_jnj_Numberofpatientsinsettlement_632cd1ae-491d-42e1-bca5-b2b5a874e342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_8aa69806-bf08-450f-879a-7ac6072b5085" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_8aa69806-bf08-450f-879a-7ac6072b5085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_9bc39c45-a40b-4f8a-9996-4a4727f57dc2" xlink:href="jnj-20210103.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_9bc39c45-a40b-4f8a-9996-4a4727f57dc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_69857cb8-2ceb-4fcd-8ad0-242b483b48e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_69857cb8-2ceb-4fcd-8ad0-242b483b48e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_a16ab2d6-2316-4f8c-990b-f8830e085695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_a16ab2d6-2316-4f8c-990b-f8830e085695" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b0aaf2a3-b15c-46e3-b869-8468397a83e5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:to="loc_srt_LitigationCaseTypeDomain_b0aaf2a3-b15c-46e3-b869-8468397a83e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:to="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8b989d5f-39ca-4450-a22a-aba7e912c958" xlink:href="jnj-20210103.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8b989d5f-39ca-4450-a22a-aba7e912c958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_94a2dc46-a2aa-4017-bd8d-db9a573152ee" xlink:href="jnj-20210103.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_DePuyASRU.S.Member_94a2dc46-a2aa-4017-bd8d-db9a573152ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_b11f1e59-3f19-443c-a4cb-100cf2e619e3" xlink:href="jnj-20210103.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_BabyPowderMember_b11f1e59-3f19-443c-a4cb-100cf2e619e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_05ca78c7-5795-43b6-8c8a-545166f70e62" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_RisperdalMember_05ca78c7-5795-43b6-8c8a-545166f70e62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_43525f21-ab7a-402b-ae85-bcbb6ac5c369_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:to="loc_us-gaap_LitigationStatusDomain_43525f21-ab7a-402b-ae85-bcbb6ac5c369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:to="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_754ba286-b754-420e-b986-3cee75a763d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:to="loc_us-gaap_PendingLitigationMember_754ba286-b754-420e-b986-3cee75a763d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_86c5207b-d47b-4c63-bd48-1374d00c6988" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:to="loc_us-gaap_SettledLitigationMember_86c5207b-d47b-4c63-bd48-1374d00c6988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_b1647549-ca14-461c-a729-f33eb2ac182b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:to="loc_us-gaap_JudicialRulingMember_b1647549-ca14-461c-a729-f33eb2ac182b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7111c59-4562-4ff3-86fa-0573b19ad7da_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:to="loc_srt_ProductsAndServicesDomain_c7111c59-4562-4ff3-86fa-0573b19ad7da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:to="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_05f2387b-da0b-4e2e-8f0c-3190f8f12739" xlink:href="jnj-20210103.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_XareltoMember_05f2387b-da0b-4e2e-8f0c-3190f8f12739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_fddd6d0e-2366-4f6d-8749-844a9e914ba7" xlink:href="jnj-20210103.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_AsrMember_fddd6d0e-2366-4f6d-8749-844a9e914ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_51ff02c0-fad6-449b-93ac-1dc4d8afb936" xlink:href="jnj-20210103.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_51ff02c0-fad6-449b-93ac-1dc4d8afb936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_5b66ee46-bddd-4bd5-b5fe-41be5ca0fdda" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_RisperdalMember_5b66ee46-bddd-4bd5-b5fe-41be5ca0fdda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_f0fff40e-fdb7-47c9-bf5a-44140d4650e2" xlink:href="jnj-20210103.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_PelvicMeshesMember_f0fff40e-fdb7-47c9-bf5a-44140d4650e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_2f3e3651-b5f3-427a-b680-aea4eb1fa34f" xlink:href="jnj-20210103.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_BabyPowderMember_2f3e3651-b5f3-427a-b680-aea4eb1fa34f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_d98b8162-c5f5-494a-a9ac-bdea934ac382" xlink:href="jnj-20210103.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_InvokanaMember_d98b8162-c5f5-494a-a9ac-bdea934ac382" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_f6c86b72-1d77-4ea2-b93b-81da446e3c23" xlink:href="jnj-20210103.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_PhysiomeshMember_f6c86b72-1d77-4ea2-b93b-81da446e3c23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_9347acd1-879b-47ad-af16-804ffd8c0823" xlink:href="jnj-20210103.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_TalcMember_9347acd1-879b-47ad-af16-804ffd8c0823" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_60723383-7471-46d2-9253-fd9790f69371" xlink:href="jnj-20210103.xsd#jnj_OpiodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_OpiodsMember_60723383-7471-46d2-9253-fd9790f69371" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_c83b7fc4-effe-4804-aa9d-960efc3cf709_default" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_c83b7fc4-effe-4804-aa9d-960efc3cf709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_8953469e-7a5f-48ce-9c72-54fea0d26186" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_8953469e-7a5f-48ce-9c72-54fea0d26186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_f4dbf3e3-45ab-4dbb-ace2-3591f8bed06c" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_8953469e-7a5f-48ce-9c72-54fea0d26186" xlink:to="loc_jnj_RisperdalMember_f4dbf3e3-45ab-4dbb-ace2-3591f8bed06c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ad2dccb7-3434-4e68-8d2a-691b602cf347_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ad2dccb7-3434-4e68-8d2a-691b602cf347_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_73d90223-9ced-4b1e-a01d-84948155cf94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:to="loc_us-gaap_LossContingencyNatureDomain_73d90223-9ced-4b1e-a01d-84948155cf94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_28cd96b3-ea1b-4be5-9416-98ebf8a57257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_73d90223-9ced-4b1e-a01d-84948155cf94" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_28cd96b3-ea1b-4be5-9416-98ebf8a57257" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20210103.xsd#Restructuring"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended" id="i64826820e2bd4fc0ac1ff9123b3e6894_Restructuring"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended" id="i4b7dc97f9e06461993d22b11ce19add2_RestructuringTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i8120932eb4cc477386f063051966f590_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_23b0338b-1d89-4dd7-bbd3-852bcbfdf97d" xlink:href="jnj-20210103.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_23b0338b-1d89-4dd7-bbd3-852bcbfdf97d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b775a7f7-eeb9-4934-9c6f-1532a539f86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b775a7f7-eeb9-4934-9c6f-1532a539f86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e7f87b95-98df-4d41-82e7-72fa75f7e76f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringCharges_e7f87b95-98df-4d41-82e7-72fa75f7e76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_cb9c20ef-bb61-4658-b415-2965f765df78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringReserve_cb9c20ef-bb61-4658-b415-2965f765df78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d5f40757-de7d-42e1-aba0-7b146e14707c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d5f40757-de7d-42e1-aba0-7b146e14707c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_f044a250-d595-4945-8f52-bae1e74752c5" xlink:href="jnj-20210103.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_f044a250-d595-4945-8f52-bae1e74752c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_9d0a4617-9ec8-4d27-93c1-3ff63b58275e" xlink:href="jnj-20210103.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_9d0a4617-9ec8-4d27-93c1-3ff63b58275e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_03f1c8e7-070b-4171-891b-b2f5a51b0caf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:to="loc_us-gaap_RestructuringPlanDomain_03f1c8e7-070b-4171-891b-b2f5a51b0caf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:to="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_1608d7f9-124d-43d5-a2d5-defdfbbbc622" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:to="loc_jnj_SupplyChainMember_1608d7f9-124d-43d5-a2d5-defdfbbbc622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_aa4ad053-cff7-4b78-9925-be4f61d0da18" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:to="loc_jnj_MedicalDevicesMember_aa4ad053-cff7-4b78-9925-be4f61d0da18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04446f6b-fe86-4289-933e-b381183a5ac1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:to="loc_srt_RangeMember_04446f6b-fe86-4289-933e-b381183a5ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:to="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d83256c1-4db2-4921-86f1-ad6969a6e3f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:to="loc_srt_MinimumMember_d83256c1-4db2-4921-86f1-ad6969a6e3f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7537af75-7086-4053-b1c2-c5e1e2dc0248" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:to="loc_srt_MaximumMember_7537af75-7086-4053-b1c2-c5e1e2dc0248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_189b1cfd-8ac3-4731-b470-b6ebfe19369c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:to="loc_us-gaap_SegmentDomain_189b1cfd-8ac3-4731-b470-b6ebfe19369c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d040a62b-a693-4590-bd1d-c90976a2e49c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:to="loc_us-gaap_SegmentDomain_d040a62b-a693-4590-bd1d-c90976a2e49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_5f596702-806f-4c65-9e21-e61af50105be" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d040a62b-a693-4590-bd1d-c90976a2e49c" xlink:to="loc_jnj_MedicalDevicesMember_5f596702-806f-4c65-9e21-e61af50105be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_db60695a-70aa-414a-acb9-4d9202b57738_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_db60695a-70aa-414a-acb9-4d9202b57738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_742ea33c-f0f5-4b46-a8fa-3fe32eb6e6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:to="loc_us-gaap_EmployeeSeveranceMember_742ea33c-f0f5-4b46-a8fa-3fe32eb6e6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_34db056b-b59e-4677-acbc-9e067b3fd6e8" xlink:href="jnj-20210103.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:to="loc_jnj_AssetWriteoffMember_34db056b-b59e-4677-acbc-9e067b3fd6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_978ae5e8-3747-483e-a49e-7a373d652d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:to="loc_us-gaap_OtherRestructuringMember_978ae5e8-3747-483e-a49e-7a373d652d4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3932eccd-1a16-49d7-8982-a7d2bb3d6d80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3932eccd-1a16-49d7-8982-a7d2bb3d6d80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_433ff526-5249-452f-98df-b677d4464f65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:to="loc_us-gaap_RestructuringChargesMember_433ff526-5249-452f-98df-b677d4464f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b02b169c-3512-4894-9731-2e52b9ce7670" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:to="loc_us-gaap_CostOfSalesMember_b02b169c-3512-4894-9731-2e52b9ce7670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_ac16e21f-6d96-4989-85e9-d388456e148c" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_ac16e21f-6d96-4989-85e9-d388456e148c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended" id="i1bed3b38484148999447f4d5ad19ac2d_RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_445b0699-1d99-4455-98a7-cf1ffe93b765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_445b0699-1d99-4455-98a7-cf1ffe93b765" xlink:to="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0c8f95a6-941b-44d6-ac74-b61cbc410145" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReserve_0c8f95a6-941b-44d6-ac74-b61cbc410145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_17271cfc-3deb-483c-8fd4-a6d0e08ac8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_17271cfc-3deb-483c-8fd4-a6d0e08ac8bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_eaf61c4b-463a-4ba1-9fc6-26285f916ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringCharges_eaf61c4b-463a-4ba1-9fc6-26285f916ae4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_c11eb6b3-09b8-421e-8229-a9d1b747e9dc" xlink:href="jnj-20210103.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_c11eb6b3-09b8-421e-8229-a9d1b747e9dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_ae2ec483-a7f0-4386-9f37-aab50234a38e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_ae2ec483-a7f0-4386-9f37-aab50234a38e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fb5b7829-068a-44a9-8f2f-641085c58044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_445b0699-1d99-4455-98a7-cf1ffe93b765" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_835e55c7-c17f-4245-b532-797ac35d1b31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:to="loc_us-gaap_RestructuringPlanDomain_835e55c7-c17f-4245-b532-797ac35d1b31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:to="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_e421c380-f77a-457b-b86c-b944a12cadd1" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:to="loc_jnj_SupplyChainMember_e421c380-f77a-457b-b86c-b944a12cadd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_d10cc7c4-7054-4736-aac8-301b77afc3ef" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:to="loc_jnj_MedicalDevicesMember_d10cc7c4-7054-4736-aac8-301b77afc3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:to="loc_us-gaap_SegmentDomain_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:to="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_9c1d2eec-dab5-4d95-beba-7a5c531cdbcc" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:to="loc_jnj_SupplyChainMember_9c1d2eec-dab5-4d95-beba-7a5c531cdbcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a5f37b3c-271a-481b-8c41-e5a3b1a72669" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:to="loc_jnj_MedicalDevicesMember_a5f37b3c-271a-481b-8c41-e5a3b1a72669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_00605307-0941-4e36-933a-3c763f9e370c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_00605307-0941-4e36-933a-3c763f9e370c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0c93ea7c-78ac-4186-b932-4bfdcd87498d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0c93ea7c-78ac-4186-b932-4bfdcd87498d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_8b8cbce4-7e6b-484f-8754-68a080e55044" xlink:href="jnj-20210103.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:to="loc_jnj_AssetWriteoffMember_8b8cbce4-7e6b-484f-8754-68a080e55044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_d27035f6-87a6-4256-a661-904ecfa9b9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:to="loc_us-gaap_OtherRestructuringMember_d27035f6-87a6-4256-a661-904ecfa9b9e6" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>jnj-20210103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:339fd7d9-9316-40d7-9d71-ee9342a8b33f,g:975259c4-ea12-43d4-8326-a0d386e906b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72e246c0-1393-4f2a-a1ad-a85b8d687bee_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_88facaa6-9025-48c5-88e7-33d29ce8580d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1965ac58-d4ca-470e-afcd-a2e9c1ed6f5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_01d8c697-94ad-4ad0-a372-2fa09a5c4e91_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of Adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7df6b28a-7e0a-4952-ad4f-0ffafea81734_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_468b3fe7-d783-400e-8e92-0f77e4e7d680_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_24b3a9ba-751e-473d-be51-90babaeb83d7_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20210103.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_09c015ec-944d-4cd1-a5c2-28f10d40b874_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20210103.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fffa5301-7bca-488a-ba77-63871b9ba29f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration reversal</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_d3462c0d-51ad-4efb-bd92-170332c12fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_432a02bf-f83f-42d6-b712-28236a0f8a5f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3e6fcaf0-5389-4caa-97ad-1a76c6a26b6d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1f18aa60-60f8-43a1-8fee-4639100b6ecf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_ef9f8d3d-ee69-4447-bb0f-51826c8123df_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:to="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_694a1d6d-b721-44fe-9f79-d6e89e448310_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangibles, amortization expense next twelve months</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_260db11d-b86f-43c5-b9e3-98fcab138791_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_b421f9a7-2b68-4ef5-a7d3-43325b09ed4f_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$141.06-$151.41</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFiveMember" xlink:to="lab_jnj_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_98e2faac-abfe-4214-b248-e8ad763195f1_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Sovereign Securities(1)</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_ae2f1901-5968-4d98-8cd7-585c95866b5e_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, General [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_cf8e88dc-e59b-4bf6-a138-23bb1a47f6ff_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense recorded related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_afcc09e2-11bd-471a-a0d2-5a56212a59c3_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20210103.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_5db35d01-1127-4cba-b871-dafbcd91a608_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_17f845eb-36bd-4aca-8d61-7223e685d0c1_terseLabel_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of company's common stock directly held in plan assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_label_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Company's Common Stock Directly Held In Plan Assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_documentation_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of company's common stock directly held in plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:href="jnj-20210103.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:to="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_bb56beb9-2e94-4303-aa1c-32facb18d416_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_b71b9c2c-8d7d-499e-870c-bb9cdee675e9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8594df98-a8f8-4e29-8bd2-5bb5e302e307_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_188cc41c-3331-4b1e-9372-a95fa2b54769_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_aec29a9d-52f4-4f7e-b6c3-f9c384621e3d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_2081ee06-55eb-4973-93fe-c8007505a74a_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_698711f0-bbf1-4c77-9dea-8e3fe3fba476_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Balance, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_f8f7178b-c678-4075-b897-b07d0b5a38a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Ending Balance, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_033cd52e-aeab-4950-acc2-741b731c1b44_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a7425043-279f-4e0f-ac02-85d26f2969f6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_108dfaa8-1efa-408e-9a44-1825532f43e8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_254bb3fa-5360-420e-a7e8-cacbdbc34ba5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2020AcquisitionsMember_ea8a533c-10d5-465f-8360-7078d4fab6b8_terseLabel_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:label id="lab_jnj_A2020AcquisitionsMember_label_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions [Member]</link:label>
    <link:label id="lab_jnj_A2020AcquisitionsMember_documentation_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember" xlink:href="jnj-20210103.xsd#jnj_A2020AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2020AcquisitionsMember" xlink:to="lab_jnj_A2020AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_b4bb590f-d5b2-459d-9e67-efdaa228504f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_f4acd0d3-939c-465b-ac5b-3046d6559a11_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:to="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b047a9c0-21da-40c6-9a5d-20dfe0a0aba8_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying (Reported) Amount, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_0174fbb4-c99e-4898-ab61-7649367b4a5b_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20210103.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0c073b42-e831-45f4-a7d7-0a8458761323_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding beginning of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f03804d-9cca-4173-8dc5-4135c1dbe9df_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_33039d81-c7a2-4c1f-8976-068912efd2ac_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, International R&amp;D capitalized for tax</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets International Research And Development Capitalized</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets international research and development capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:to="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_c739d6ab-0f6a-4983-ab5b-8c785a1c7826_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures&#160;&amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_59c657be-19c9-404a-b091-57ec3363655d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net (Notes&#160;1 and 4)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_540681e3-995f-4ab8-a36c-cf5691c0706e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net(1)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SkinHealthBeautyMember_88eb821f-d297-40cc-99d1-c30a8b1cfac1_terseLabel_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty</link:label>
    <link:label id="lab_jnj_SkinHealthBeautyMember_label_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty [Member]</link:label>
    <link:label id="lab_jnj_SkinHealthBeautyMember_documentation_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember" xlink:href="jnj-20210103.xsd#jnj_SkinHealthBeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SkinHealthBeautyMember" xlink:to="lab_jnj_SkinHealthBeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_5a73b3d0-f9d2-4dff-a955-7891e2ac1a0d_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20210103.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_764a8886-ed71-4ec5-bd43-f8c3f0860bfb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnfundedPlansMember_695a823c-9160-40df-8453-eaead20cc693_terseLabel_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plans</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_label_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plans [Member]</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_documentation_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember" xlink:href="jnj-20210103.xsd#jnj_UnfundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnfundedPlansMember" xlink:to="lab_jnj_UnfundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d62d8d3f-92b7-43cd-9168-db84c6e38f1c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_2957dfba-d687-4729-ae03-02eb9caca9a4_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable" xlink:href="jnj-20210103.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable" xlink:to="lab_jnj_ConcentrationOfCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_a3a556d0-ce21-4ea7-bd53-32192643be65_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_a347be49-d3e6-43fc-b23b-ac2d1888a7b1_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.2281)(2)/(1.5B Euro 1.1096)(3)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20210103.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_698d31c2-e680-4ba0-92d9-638cf50e5b50_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_730557a4-41cd-4c4e-a5ca-3517da5269f5_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_8bf01f6f-e59a-4b68-98eb-ea08f20176aa_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_e88c024c-c32f-46ae-a2b7-a56997f3363c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_c50ab47b-4ec1-4936-a8ab-10dfc479e5b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_0441ce57-21e3-4370-9df9-10df1228588b_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20210103.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_38ab9c98-ec55-4307-8d6b-e6032f6f45c2_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_7cb8cc10-d79b-4ca1-8f6f-ac344f546db4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to Property, Plant &amp; Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8dbc5d2e-084f-449b-bce6-c8249adab8c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_41f823ba-bb06-4268-99d5-866b3328adf0_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20210103.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_e4f89ea7-4d1a-4831-8085-eef8c8ee6013_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b2a35b42-c42d-4ad1-b67d-e67727e266da_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c93948ee-ec53-4443-8b20-aabf7c9c1da7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_22f87999-0c81-4542-b764-50c32c4e280a_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20210103.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_1fe84db5-c1f9-4057-b76f-5dc8f91fbd1e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_2b9c74f6-48b8-489d-8c53-578cfc5bd28f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A055NotesDue2025Member_82e6bf0c-04c7-42d8-9ada-46a3e4f7d210_terseLabel_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025(5)</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member" xlink:href="jnj-20210103.xsd#jnj_A055NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A055NotesDue2025Member" xlink:to="lab_jnj_A055NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22828e5a-49f1-48a7-88fd-b3dd64d3af18_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a419cd27-3796-41fd-8f12-5f4592591c4f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4e22eab3-a33b-45c0-8f49-e694bcaf08a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_4cad4c1a-fe3b-4e9a-8cad-73ab544e2a71_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95%&#160;Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20210103.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_5eecd9b0-77bb-431f-a4fd-e6fa8fd4eaf2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_73227d94-c2e5-400a-aff2-7290835303ff_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_6449bb66-4791-4127-bfa1-ccce5a46ddea_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Currency Transalation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fa2fac8-3175-4f4d-910f-44dfe4351129_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year (Note&#160;1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65400d19-645c-4315-970f-d3d6b6e13f02_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year (Note&#160;1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2c46c20f-4eae-4209-9469-1e835ddf73f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_8e470f46-fe94-4ef2-a172-47e9a5e0d025_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_50b91763-a950-48f0-acea-85e3e69a35f3_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere excluding U.S.&#160;</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20210103.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_386bd606-e992-4cf0-ad7d-86a36297692f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_61e7d2b3-79e6-493e-9b03-b2902eb7010b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_1cc1a218-3ae6-4523-9d3c-bdb54300cccc_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e50fa696-a0e2-4eef-a4c0-e13e63a6309b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_78d1fba3-36cd-4b6f-bb91-7a910902278e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_e166e336-2e5b-4baf-b1fc-49b01fbc1621_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_aec82c4c-492d-4d10-a778-8617b4d36ca2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e7b92cf1-c969-4bb3-9698-af079bc8758c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_667e8e52-aa53-411f-81b5-4c9e49d2bcbc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5fd13869-a481-4292-a9d8-f5cac7e64375_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c8aff64-5063-4c08-a4d6-c16347925ab0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ErleadaMember_c379cd7e-0c2e-4883-894a-5c135943c827_terseLabel_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada</link:label>
    <link:label id="lab_jnj_ErleadaMember_label_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada [Member]</link:label>
    <link:label id="lab_jnj_ErleadaMember_documentation_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember" xlink:href="jnj-20210103.xsd#jnj_ErleadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ErleadaMember" xlink:to="lab_jnj_ErleadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_7fad7bdd-294c-438c-8d03-fb851c4876e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_1fcd3ae1-4e5f-4097-8bcf-feb4d2c45aad_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0a8829a9-9714-4fab-a901-9fabf63dbb35_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_3aca225b-f0cc-4d39-bd03-ae01ff5f7ade_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits on Capital Loss</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Loss</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_7b06b7fb-db00-45d9-bbe5-7c4ed22406c8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_d8819beb-b8a1-43ab-ad0a-07f46a5501aa_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_71dfd22b-4c18-4af2-8489-3566782eb1a4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price over fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_814e6f50-8778-491f-af26-2a1692970e75_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_81d3c3bc-3b37-4cf5-b967-37cbf18df1b1_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a44b9a66-0dbf-4177-b62b-9369f5d29b74_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_37351624-0560-4452-b674-03aae2ddff1c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_7d47b96e-7332-4fd1-a11a-4affd8a2d788_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_72786956-134d-4a51-a134-87525202b4c4_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (Note&#160;12) (487,331,000&#160;shares and 487,336,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_b4718d4c-8e40-49b4-8581-02c9f3b185cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_752ddae0-3338-4d5e-a434-3d076828220f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Ending Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e067d9e3-df5f-4be4-8c7a-c6efa46d85f6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dff61e54-0c0d-435c-b813-80953b68177e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_a6503e81-05c0-4843-b506-7f0b53be4e39_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionTypeDomain_35ad6f69-bdec-46c8-a443-b8b27d83168a_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DistributionTypeDomain_label_en-US" xlink:label="lab_us-gaap_DistributionTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionTypeDomain" xlink:to="lab_us-gaap_DistributionTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_48f77d1e-cf7c-4eb3-862a-bc5d16643a17_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea2c98e7-1ad0-4cff-9574-ad28f4c7d8a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a1aaa1ca-754b-4118-9635-91abcca9f4de_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_3b1339a4-d4a9-4de2-9539-44683f7be83e_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$62.20-$72.54</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One Member</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeOneMember" xlink:to="lab_jnj_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0378d17c-7d60-4a3c-ae46-477b37ce50e9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_01f2468d-4340-446f-ac77-cfbc9e3f2551_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_9525f715-954a-406c-8d1a-57abc86dd031_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20210103.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_f9bafc2a-d412-4bd4-806b-13c9cecb074b_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20210103.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9dd74283-19c2-4e7a-a2da-029f062c6e0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fbd193b-b56e-4721-97dc-89b1bdfec646_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b6a47ff9-e3dc-485a-b2fd-d23f10e248c1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_a9144431-3396-4f0e-8cd1-6c9a3e7b2491_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6429b09f-1b43-474d-ae4f-60f2f145a3fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2c42baf2-f1f9-41e5-9d2b-e0f801c8ea63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1fe89b27-9060-4a98-acd3-d317c057843c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_5be3f3bb-4dbd-4ba9-871c-0327964d2ced_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_fdf9cd09-3516-42f8-a4e4-7bdb8739b59f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_66c510ca-0a6a-4602-a555-b85c74387a28_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd4a4dce-f863-4ed0-b778-6f8635790502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_55ffbed2-f942-47c4-a380-bdcafb6e0250_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38d0cdfb-5684-4c5b-8aeb-a6867e8031bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercise price beginning of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4551c09d-de89-40c2-a8cb-7be0e0e3f7eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercise price end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c890598e-c72b-4a39-887d-388b3e3d4a7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_92b5f7a3-227b-4e51-ada8-4760c6c39460_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20210103.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_c4d7db51-fce5-4f45-bde3-577f9ea7436d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA and related impacts</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b0dc93ba-d0f4-4ee6-9871-44fadca013bf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_85b66c40-badc-4e3e-87ae-fdaffc7bc3f6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_08516cdc-82d0-4343-beb9-a18023b32513_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e59ecf6f-b1ca-4c26-931c-d4deedada5ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_81d705ca-aa9b-4d79-b635-41e59e5cfa23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_b5862f8a-2ece-44ef-a236-ff5a96c23090_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Future Employer Contributions [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated future employer contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:to="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_cdfeb1e0-32ff-46f4-a552-37cbdfebca65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DiabetesCareMember_d2b1bd87-0e8c-4cb0-bd76-5bdedce9fab3_terseLabel_en-US" xlink:label="lab_jnj_DiabetesCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes Care</link:label>
    <link:label id="lab_jnj_DiabetesCareMember_label_en-US" xlink:label="lab_jnj_DiabetesCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes Care [Member]</link:label>
    <link:label id="lab_jnj_DiabetesCareMember_documentation_en-US" xlink:label="lab_jnj_DiabetesCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiabetesCareMember" xlink:href="jnj-20210103.xsd#jnj_DiabetesCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DiabetesCareMember" xlink:to="lab_jnj_DiabetesCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e08bea2-5f55-4a5e-88be-b6746aedf72f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d9899bd-3d91-4541-9409-b193fd0c30a8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3d6b55db-1668-4df5-8d6f-9026e2c5dac9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_31f63b78-bc8f-4ac9-b33f-97a76b4d911b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesReturnReserve_1574d790-1e91-4a41-8004-2a46716fbc6d_terseLabel_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve (as a percent)</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_label_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Reserve</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_documentation_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve" xlink:href="jnj-20210103.xsd#jnj_SalesReturnReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesReturnReserve" xlink:to="lab_jnj_SalesReturnReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a5621d00-ca38-40b6-8c8e-9e60c430d7c5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_9c3af7d4-42c5-4470-afda-5a637ae2daa5_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_3acdede0-88de-47b8-9d20-9afcba936fa7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_43e85de7-f7a1-4e61-a61e-b52af5fe9935_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized (Note&#160;4)</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_68ff010e-1d1b-4267-aab6-6ec522961f6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Reclassified From Accumulated OCI Into Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_23b55647-8559-437a-847a-ddda30788542_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_67f967c6-1792-4500-88a2-1b156cec18dc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_e3c4e3ec-90fe-4d9b-afcc-b14913bb90b2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b02ac710-3608-45ba-b737-737317ca1ba0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_336a33ad-f230-4204-b6b0-3df53d251e70_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_99e78d4a-ed9b-44a4-bdb3-448bf5872f69_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:to="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_7c4c2cb7-2d78-4f39-975e-17c4c4a12f45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate_1a0b930b-5ef5-4584-90a9-45bc256e9260_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, plan assets, accounting policy election, measurement date</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" xlink:to="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_26075ba0-9740-4682-9c97-aa7574762afb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_a558c8e5-bf2e-4673-aee0-8f8fb703536e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ownership before transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b03f7cab-9b05-45b3-b29c-fd0647cdc6ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_45bbd02c-c471-48ec-af59-0a5c1e858da9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_c2e0f8f7-be30-4547-89c6-726e9c3146cc_terseLabel_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land And Leasehold Improvements</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:href="jnj-20210103.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:to="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_b745e889-4e54-45dd-8e9f-11278300799a_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Two</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_3ca3202d-21dd-4ca2-aad1-68e3f9b85ade_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate maturities of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_356ecafc-0125-43d6-a74f-21be655ba0b0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4d3ea9eb-3721-4a30-925f-1a2b21c9c2ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled/forfeited, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_e93d29fa-fc60-41ab-84f5-fed137c72f4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0fa2b025-075d-4c35-8c0a-7cbc10188898_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_9ab49f85-38d8-4d11-b494-9747f48125e1_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service credit (cost), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_0877d7d6-e0e8-40c7-bd81-96b4d2c8e55b_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20210103.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eff27cca-184a-446e-adb0-f35c45e59379_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb9da2cc-1fc8-4c0e-9583-0b77df81e564_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a25cc3c3-ee31-4559-83ed-fb04086d424f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_fb77037f-34c5-43cb-83a3-22d82afd193b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total loss/(income) recognized in other comprehensive income, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_f881a521-1b4a-4d87-a39c-157373f10812_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20210103.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_33b5fd4f-932f-43eb-b3e4-111ff73a34bd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3efacd12-4a50-4950-bb54-4c6dd25fd846_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_dff62086-ca33-42dc-b97e-4c2d8d3e78e1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_14f5a677-66eb-4e0b-8f29-3d3885a4c918_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74253b6b-264c-4002-bfd4-73506de29099_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_0c5c04e7-3603-41a2-90bb-060f604e85b7_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, provisional liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_80840820-61d7-4fe5-aac9-6e1d0bf98b8c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d48cc4fb-afde-45e6-b218-1d17d6da6f7b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_25d27e89-21b7-4471-9d8e-119a11c1f534_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_d65c1b30-b20d-4ee6-ac39-fb9d16fbaff2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4ddfb1e6-27cf-43e0-82ff-5e41e8614cae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rates:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_56b4676e-b7ed-48b3-b897-800cada4ae69_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50%&#160;Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20210103.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aea71f6b-805a-43ee-8b1d-c6ece73db756_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_e86b6aac-3e72-4849-9040-3e5f90d8f758_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_760d72f9-c0c9-46af-93f1-38b26e00cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ea9c439b-9b39-4c55-8acc-4826df56c85f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler3Member_6f54dbe8-d132-4bb9-ad7a-4989b2aff04d_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_label_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member" xlink:href="jnj-20210103.xsd#jnj_Wholesaler3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler3Member" xlink:to="lab_jnj_Wholesaler3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_16fc7e30-0260-49c2-a2c8-a6abdd10788f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_c0165831-0c46-4ea3-9b55-7ce0e396df86_terseLabel_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and handling costs as a percent of sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_label_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_documentation_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:href="jnj-20210103.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:to="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_7ef4f91d-986b-40a3-8492-d47de755a95e_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20210103.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b2533e35-0a1d-4696-a3d6-d2d9e239f430_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_1dc5704c-cd31-4ae7-8a72-472b1b24b6d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3a8f3540-21c8-498f-b01b-4db6bb1b2b12_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions (Note 18)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_cb0b8ca0-0092-4b79-bf04-93fbca054538_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20210103.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e5bd1f1f-f385-4566-a2c7-38648a285ba8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost charged for Long term incentive plan</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_81cdc6c9-8146-47f8-a1d8-a86920c705fe_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherReverseRepurchaseAgreementsMember_8b3e69a8-1d2e-4c15-be50-5ca9899a5524_terseLabel_en-US" xlink:label="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reverse repurchase agreements</link:label>
    <link:label id="lab_jnj_OtherReverseRepurchaseAgreementsMember_label_en-US" xlink:label="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reverse Repurchase Agreements [Member]</link:label>
    <link:label id="lab_jnj_OtherReverseRepurchaseAgreementsMember_documentation_en-US" xlink:label="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reverse Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherReverseRepurchaseAgreementsMember" xlink:href="jnj-20210103.xsd#jnj_OtherReverseRepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherReverseRepurchaseAgreementsMember" xlink:to="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c6ead33c-8e21-4b5c-ae5b-5bf34ea7aa90_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value&#160;&#8212; beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9ad3db0f-a2d9-49f3-8ea5-7cbf3beb9f3e_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value&#160;- End of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_037c572f-fd25-4ac5-90bf-e84796df25ae_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_bd5750af-b0b4-4e0d-9b7b-a86cea46cfc0_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Three</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_60c71000-e260-4a8a-b0b3-eab0be7d1b69_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_0c5dd3d1-a268-4357-a2e6-59973677fd33_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_89ef25ca-a193-4903-9288-cda1d41505b0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_12c64a8a-ea74-43de-9f09-7c768159ad8c_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and building equipment</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_53b3a835-64ec-4326-b444-29c1d1099007_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e3ccf217-5991-4d97-af75-99c3e2db08e5_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_7cc0181a-5265-4260-9206-5f734ac3e28a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LifeScanMember_3986f288-778f-4dc0-b255-5d07c18342b9_terseLabel_en-US" xlink:label="lab_jnj_LifeScanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LifeScan</link:label>
    <link:label id="lab_jnj_LifeScanMember_label_en-US" xlink:label="lab_jnj_LifeScanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LifeScan [Member]</link:label>
    <link:label id="lab_jnj_LifeScanMember_documentation_en-US" xlink:label="lab_jnj_LifeScanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LifeScan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LifeScanMember" xlink:href="jnj-20210103.xsd#jnj_LifeScanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LifeScanMember" xlink:to="lab_jnj_LifeScanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b31541f6-6c79-4b8f-b27a-d69baee59a89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_2b69997f-201b-4e82-bb69-a87fcb1de048_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_931d0c79-fcf9-49b7-b3a5-103708419758_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_30b5e9e8-dc5f-499f-93ef-8dd6f061fbdb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c8d959d6-5f8c-4f23-bd76-4cb6c66c5fce_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_a2653145-b9bc-4c92-935a-2eb235e6c891_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9293eef1-6ebc-4016-be83-d45cc26433b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24a2d4db-5b9e-4064-8c2a-f1021f6f5140_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average fair value of option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9500bc2e-9431-4f2c-b32d-8f87db4cc914_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_f673f271-5c87-41f6-9ea9-2f1b152bc122_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a8866514-67ae-4c1b-ba04-f6f8db330b24_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_72cddded-d4e5-4f8e-9f8b-f394c6989c79_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_d16c43e0-0238-4549-a100-3b0d42ce8c62_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20210103.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d044658f-f1ab-4759-ba1d-2b4ac311b271_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_bb2d79cb-4b2f-4e05-9306-84eb92a109ef_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7783e8b2-4dd2-4ce5-9321-3b1d4299d529_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Non-deductible intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7baaa531-1ec8-466c-842e-c1622461ee62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_13720891-ec69-4959-9166-9ceeb5e2b238_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_47a3cdf0-111b-4153-b3d8-f9f8769beced_terseLabel_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_label_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_documentation_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non long lived assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets" xlink:href="jnj-20210103.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonLongLivedAssets" xlink:to="lab_jnj_OtherNonLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_710b2a37-2e41-4603-8178-b7e7c8dce6ff_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid employee related obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_e1057c4c-5fd2-486c-a7c2-187d3ddf266c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_647bd266-772c-4fe7-a82c-e0f9ddce07bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_be5e53d6-1a0f-4e0f-9216-1df92b76cf36_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_07f07509-ab4d-4fc0-9238-87eb561abf45_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense convertible debt</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ddf4c323-99ed-4f4b-b7bf-6b5d2078fc84_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note&#160;13)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d524964b-4456-4b89-82c9-ad457fa67c35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_803bcad1-f3ed-406f-a202-b9127b11a1cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VerbSurgicalIncMember_4733fc15-bd33-48c4-950a-d1fc5f5c6956_terseLabel_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:label id="lab_jnj_VerbSurgicalIncMember_label_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:label id="lab_jnj_VerbSurgicalIncMember_documentation_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember" xlink:href="jnj-20210103.xsd#jnj_VerbSurgicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VerbSurgicalIncMember" xlink:to="lab_jnj_VerbSurgicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_b3f1db0d-bde6-4270-afdf-77c5ee7c1471_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_35e1338d-ffcb-4fe8-bf99-68055e353515_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20210103.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b0d8c9a8-5624-4deb-af1c-292267cc2574_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_65a979f3-35bf-444f-af53-2e5dea285992_terseLabel_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement plan benefits Employee compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_label_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_documentation_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Compensation Period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod" xlink:href="jnj-20210103.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeCompensationPeriod" xlink:to="lab_jnj_EmployeeCompensationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_67d1f83b-2784-4f9c-bdd8-0c54d3195c8a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_5579ca02-5be0-4667-9757-aa879c548b93_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI, deferred tax cost</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Deferred Income Tax</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Deferred Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_577a753b-88a5-412e-a908-9100723b81ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of RSU or PSU units settled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9fc30973-c545-4831-a196-99f5eea21724_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_20cf3769-1653-4285-84e3-c7a4739d86d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8d46588e-4cda-48e7-880d-5ee4e53267d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_4b2c144a-b9df-4928-9193-ffea68c4e896_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_5ab5f128-05cb-4bde-bbce-1af1ef3ea48a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_0d0bb86a-d317-434d-a70b-ffed9c6a2110_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company' Retirement Plan Asset Allocation and Target Allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_9b719135-4311-4d23-8777-f1693b937e71_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d30b4aad-0348-4e7d-b6ac-235e82a6b33a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_eb8f0726-14c6-4087-bc55-8f0b89c33243_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_19229427-098c-44bb-ad2f-61139cf73c7f_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20210103.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_79882ee2-78c6-41ad-995b-1f4a8c85c4d3_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedTaxesOnIncomeMember_6e5c694b-db29-4ab5-b4c1-0af6fd08966f_terseLabel_en-US" xlink:label="lab_jnj_AccruedTaxesOnIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Taxes On Income</link:label>
    <link:label id="lab_jnj_AccruedTaxesOnIncomeMember_label_en-US" xlink:label="lab_jnj_AccruedTaxesOnIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Taxes On Income [Member]</link:label>
    <link:label id="lab_jnj_AccruedTaxesOnIncomeMember_documentation_en-US" xlink:label="lab_jnj_AccruedTaxesOnIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Taxes On Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedTaxesOnIncomeMember" xlink:href="jnj-20210103.xsd#jnj_AccruedTaxesOnIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedTaxesOnIncomeMember" xlink:to="lab_jnj_AccruedTaxesOnIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_ef5f8ade-a0e8-45cf-8092-b32a599bd7ed_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_84b9443c-9f2f-42e6-9e79-7db0f90c2b25_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Four</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_10497c55-f699-4b4e-b76d-20c6d9328559_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_a406f951-badf-4693-bbb6-601609c65d8a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1565c453-5aaf-4e4a-a113-65f44275b0d6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ff18e26f-eb14-4cdb-b040-67e0c454b315_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_964a3263-7435-4a70-90c0-58bedd1a5911_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_00bc607d-e79f-4ad2-a21f-8ce6751fe62a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and the current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_02763174-801f-4c2b-b7ea-bbaf8cf5e742_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_160f06ec-2554-4645-800c-cdf318ae16da_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20210103.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_20b7c7d9-ff4e-4294-b412-d23602ffa6fe_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_beb2b5b3-2842-4521-837b-c95493378a58_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_e42158fc-3776-4c2d-b442-d0f5ad615f0c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4e8ec487-b8ae-4225-b258-6295b69983f1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangibles, amortization expense, year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_12829d50-b29d-4751-979b-e699bd2e1b55_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital and Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c44047d9-8bd3-406c-994a-a15ee768b36d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2294e1e5-6e77-4479-b372-b6973443923e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_8c528100-261b-4511-951b-75c7db08e17e_terseLabel_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investment funds</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_label_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investment Funds [Member]</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_documentation_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember" xlink:href="jnj-20210103.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShortTermInvestmentFundsMember" xlink:to="lab_jnj_ShortTermInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e532a37b-dcdb-466b-ae30-c582c05c97b0_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_dd60ee87-7802-4560-92b1-cae0e867d10a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0c8a8671-2d0a-4c11-928a-346aa929c3fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_69ffd117-11af-436b-98d2-8b44d5dc6a48_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale or Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2da87104-ce63-407c-a0f5-11f16578be6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_79aef7f8-dc13-421e-8961-81bbd7fc5f6b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ae807bee-792b-446a-b4b5-732948bceecf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_a5864a86-5ef3-42b3-aadc-10a9fba4ec1f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4f40a274-f48c-46d3-9686-5d2d1997aafd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f8a3a595-7c22-408c-89dc-be2ec0e4a952_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_20e11450-28be-4c50-8101-0379d350821d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeObligations_96c223b3-6c26-47d0-8587-fffb3655e60d_totalLabel_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total employee obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_label_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_documentation_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total employee obligations current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations" xlink:href="jnj-20210103.xsd#jnj_EmployeeObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeObligations" xlink:to="lab_jnj_EmployeeObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeb8e93e-fa99-43a3-97e9-633e023c0d4c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_2e0d7354-1633-4b4f-b1d5-1f694cefc66e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2154cd46-0399-4228-a2eb-188032f7e4b6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_5a4906c3-e23c-4b22-a4fd-f5f6c4e9a72f_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate reconciliation, litigation settlement, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_d8709965-7443-4c36-a5ad-2d99ac93be55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_6e344482-1172-4f67-9c95-82f79f3ffa3e_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of deferred tax asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_08a8edd6-29d4-4a66-a0e9-e5b349d2114a_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Notes&#160;1 and 5)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5c1c5c46-1265-4aca-929b-f0f1c53d2117_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_e044aca7-e72f-4cce-8887-87a46ba2b65b_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8920b04e-c699-4a22-a784-9e2680e4b613_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gain (loss), before tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_5731eb6b-a092-48ca-8ed5-ee353e6f4e8a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_label_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingGuidanceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingGuidanceMember" xlink:to="lab_us-gaap_AccountingGuidanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_62f3bb70-2ecf-403a-933b-a435be54d0e7_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral paid</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_80f5bce8-ba26-4861-a7fd-1f75bc1438da_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in net periodic benefit cost and other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_87188696-89c9-4b8c-9f3c-fbe23c693664_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_d881c6f0-933e-4aa7-8661-cc547a310cb4_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PANCREASEMember_8880ecac-911c-4829-bb5d-0e5ccfce0a74_terseLabel_en-US" xlink:label="lab_jnj_PANCREASEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PANCREASE</link:label>
    <link:label id="lab_jnj_PANCREASEMember_label_en-US" xlink:label="lab_jnj_PANCREASEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PANCREASE [Member]</link:label>
    <link:label id="lab_jnj_PANCREASEMember_documentation_en-US" xlink:label="lab_jnj_PANCREASEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PANCREASE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PANCREASEMember" xlink:href="jnj-20210103.xsd#jnj_PANCREASEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PANCREASEMember" xlink:to="lab_jnj_PANCREASEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e20cfe23-ca4a-4042-8119-029559d9bfe3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5b97f6a5-4a7a-4849-aae8-a02993967687_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20210103.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cc0942ef-aba3-40c4-8924-ba90fb4364f6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f9ae730b-58b3-4272-9196-206e671c9914_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_b881f115-7b27-4475-88ea-5c179d2baf1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits on share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProfitLossPercentToSales_76d83511-18a3-4d8a-a3d6-032a0732ec68_terseLabel_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profit share payments (less than)</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_label_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Loss Percent To Sales</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_documentation_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit loss percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales" xlink:href="jnj-20210103.xsd#jnj_ProfitLossPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProfitLossPercentToSales" xlink:to="lab_jnj_ProfitLossPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_d58798af-edc1-4bae-b719-424f8d69fd9f_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total currently payable</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_4d079b3a-5f61-40ab-8db3-f1f228d185e7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowed under the commercial paper program</link:label>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Commercial Paper, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:to="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_98bbb24e-8086-4655-9765-d1eacfd2af9c_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$129.51-$131.94</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFourMember" xlink:to="lab_jnj_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dc27fdd7-c3d9-4882-b472-b9e8807e8b8c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3dafc622-0fe6-4972-af15-fde1115b645d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_8da8b6da-2c11-4b9a-a866-29c6bba9ca2c_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_a69495e4-d0a1-43e7-b8f5-62007a1dc775_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20210103.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_d66fca6b-c1dc-4254-89fb-653dff2464d6_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_dd135d5f-7e3b-4f7c-93f0-3e490d72259f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_2987f22d-8e08-4af0-8289-ee560c9fe0e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_ccd134a0-7151-4d22-821a-513d80da3dde_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20210103.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_4d7d70f0-3d4e-4739-9996-0ec7cfd3f72d_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_32e91c7b-45ed-473f-b236-24e3b6b8bc28_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_ed98ccff-64a2-4e2f-af54-d9adf9d5a021_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_98389b93-3073-4fa6-b64c-2c6702197098_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_4db5bb39-c04f-43da-96b4-af6ad590e484_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of success factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_label_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:href="jnj-20210103.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:to="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_a5df6c81-872a-468a-a9f2-6d32b95d38f0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, other reconciling items, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_1417463c-3e21-4f24-9fa1-57efea3a605d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_7f4a2c0c-d921-4d9a-b049-4d0494697c8f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3c9e2292-6d45-4085-82b2-d630d46d76bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions of fair value of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_946f27c5-3213-4cc3-96d3-776dfe7e3b7d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4efd67f9-a8a2-4603-a3c7-788e97faf3a7_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_f3f9388e-dabc-4289-941a-fa755a8dd9c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other(2)</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_180193ca-ee4d-42b9-9c8c-7919c352502a_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:href="jnj-20210103.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:to="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_e2282e33-8bf4-445a-a1af-81fe4d062731_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f59a2cad-e9a7-4fa3-aaa1-1d877483445e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_78ea9c89-5526-49aa-b47a-f6b3aa918ecc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2018AcquisitionsMember_60bb9916-8618-4388-834e-089394e8acf8_terseLabel_en-US" xlink:label="lab_jnj_A2018AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Acquisitions</link:label>
    <link:label id="lab_jnj_A2018AcquisitionsMember_label_en-US" xlink:label="lab_jnj_A2018AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Acquisitions [Member]</link:label>
    <link:label id="lab_jnj_A2018AcquisitionsMember_documentation_en-US" xlink:label="lab_jnj_A2018AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2018AcquisitionsMember" xlink:href="jnj-20210103.xsd#jnj_A2018AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2018AcquisitionsMember" xlink:to="lab_jnj_A2018AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fd0bdc77-3dc7-42ed-a2c1-bfe831c5262d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1510c295-323c-4fb2-ac68-a0768a8ad967_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow data</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_99a061c1-c192-48ce-bf3a-dd024eb6099a_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_321b80c5-76db-460f-84d0-0835dd2aa4fd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_80be5e20-dabf-4157-8e29-14c35d78bcc6_verboseLabel_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due January 2022</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_a75f51e1-5cd3-4e90-b94f-e8b99de93347_terseLabel_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes due 2022 (1B Euro 1.2281)(2)/(1B Euro 1.1096)(3)</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_label_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_documentation_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member" xlink:href="jnj-20210103.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.250NotesDue2022Member" xlink:to="lab_jnj_A0.250NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_1647fa31-9ee8-48f7-a1fd-dc799bc78bbe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_f1016180-3a41-4ea4-9853-d630f0b6fb02_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_966c4975-4a57-42ac-88c9-9488bf2ed7e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_8da38e66-7651-4bd6-b229-96f5a9e3ef0a_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20210103.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_3837d792-a50e-410b-89ae-8880e5c64013_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20210103.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_58c435ec-dc10-498c-bc40-df3354175b95_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_04ef7138-71d4-4191-988b-032d90cc0ae7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_04a3c2d0-071c-4f9d-b1d6-7690bc0534ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f27042e8-6b07-4374-a81b-59c4c53b213b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bb2dd4b3-78bd-4257-a0ea-b2276c796f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_669d0303-4ecd-4811-bdfc-be5d6240e5cc_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes on international income (2)</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation related to domestic tax on international income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_68ecb906-d8eb-4cbe-98cf-7521f7cdc6c2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_8a2574a2-5360-47ef-ba1e-b368dd797ad4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-01 - Financial Instruments</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4cda792e-0168-4131-ade0-ebc0e3e3c5a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2fba9d16-62eb-4740-88a7-1629e8439661_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e8f37458-6cba-4a82-b2ce-99328194440c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_91a82c79-7ec2-40cf-8f1d-e77258871f8d_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20210103.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_38576952-2d82-4f34-b049-3db1bb0177ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4cf776b2-5b75-4a30-92f2-ed7d10ea6168_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4fc96064-5a41-42a4-9915-c3507e1a89a2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3fa38bf2-2bfe-4902-849a-1a3de3fdf746_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_42452995-df9f-4576-a2c5-9d8c35696313_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95%&#160;Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20210103.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_4d960dab-223f-4b43-8fd7-1a8cbe32d5d7_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20210103.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_aa30f49d-9fcf-4978-911a-4a073556591c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_ba978a31-e4c2-414e-b637-2e66d0853818_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6749cbcb-6780-42dc-ab97-3e3bc7525e61_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3e53cb27-ed59-4bc6-8f41-9fce7d756bed_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_af95a1e4-24ad-4ef4-89f6-0906f046c9f8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_b60d7805-9c97-4348-9e9c-010ce0631a30_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1df01f81-51a1-49e0-a194-9a5e00002b53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_ad744f26-4567-4bcc-885c-13ee6db29902_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Over (Under) Funded Status ABO</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan over (under) funded status ABO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:to="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_10d027d8-d0df-45cd-995d-82e8cb2be488_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b82a757b-c96e-4bf8-a6cc-eecfd374d743_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5767ee52-38ec-4b64-afff-a690e04ea165_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_f16f3b3b-6a1e-4e17-a7e5-d09c5e1848e2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NIZORALMember_dcd67f43-1304-4906-94aa-2a36b2e342ad_terseLabel_en-US" xlink:label="lab_jnj_NIZORALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIZORAL</link:label>
    <link:label id="lab_jnj_NIZORALMember_label_en-US" xlink:label="lab_jnj_NIZORALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIZORAL [Member]</link:label>
    <link:label id="lab_jnj_NIZORALMember_documentation_en-US" xlink:label="lab_jnj_NIZORALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIZORAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NIZORALMember" xlink:href="jnj-20210103.xsd#jnj_NIZORALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NIZORALMember" xlink:to="lab_jnj_NIZORALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_dbd00ae3-7f90-4c93-bfa3-2e955ecafba7_terseLabel_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sovereign Securities</link:label>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_label_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sovereign Securities [Member]</link:label>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_documentation_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sovereign Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember" xlink:href="jnj-20210103.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherSovereignSecuritiesMember" xlink:to="lab_jnj_OtherSovereignSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_e1e99715-3a3f-40fa-b16e-57743c871b4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_981ec64f-f3ec-415c-9720-5e66a698ea0e_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20210103.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e8ad9bf4-07b9-4218-9cf7-2bafefde5892_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_404b64e6-3a97-4da8-ba2e-6108a7e9793a_terseLabel_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_documentation_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_9ef19454-ffa3-4b9b-bb61-da6dfd75bb53_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (Note 5)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_e8637da1-8d7a-4ca5-89e7-521d1a5be712_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_71b4fe23-7547-4617-b233-7738e2a8b2d4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8ee2d2c-5d40-4a31-b587-d3e0af822558_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_60613610-499a-4413-9192-853e01fa6a54_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfSubsidiaryGainLossMember_797f62e1-db09-43c3-9f08-432c184d65a6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfSubsidiaryGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Subsidiary Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_SaleOfSubsidiaryGainLossMember_label_en-US" xlink:label="lab_us-gaap_SaleOfSubsidiaryGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Subsidiary Gain (Loss) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfSubsidiaryGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfSubsidiaryGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfSubsidiaryGainLossMember" xlink:to="lab_us-gaap_SaleOfSubsidiaryGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_110fad30-b3c6-4b08-a1c1-248b46c0d5c0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_67e11f19-33e2-4a5c-9be6-124f3419221f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_22629f8b-22bd-40b6-a97a-4a05f741deaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_7bd8a217-307d-43e3-8786-df4b20aa500d_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20210103.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_3a9eca08-dbd4-4f71-8c47-cefcb5b8f169_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20210103.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b83c7-23fb-4ae0-82bc-7360fa52fca3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a0e88011-97ed-4011-b68c-d4186497bf59_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b7d2f57-d27b-4d22-ad6f-ede40e3ae389_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5102133-dca1-40b6-8e64-fb7aaf21b309_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_0d1b9d2d-740d-40ea-ba38-58408ca0080d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_528416d4-ea43-4be0-a08a-7f4e8c579f62_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_d2a227c2-e952-4cba-8509-3bd4190c3c73_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, increase (decrease) in deferred tax asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_93c3a852-a0a3-42de-b37f-ff77cd9ede5e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8859626e-e786-4309-ba60-e29bc46ccd38_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_be98ed34-fc0a-480b-98bc-300553d82b2e_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ca731794-2a4f-44cc-96f4-90da02452953_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6b25f670-2dd1-440d-b2b0-562480cf75f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_178163e0-f937-4842-9d5d-972f49f7e325_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangibles, amortization expense, year four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5e81ebee-f51a-4291-a86c-76dacdaa1270_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Company And Business Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdb9ec35-798f-4e2d-9097-165bed3378ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d794d684-ffe8-48ca-948c-fe48ab3bd0da_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_d3c8309a-e647-4742-a202-ff17865ee767_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_89e03dc4-75cf-4dfc-ba48-33a6b3de282e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value, amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_38e3b67f-ecf3-4d39-8b3f-41b809e4657b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_253e6ad4-892a-477e-a6d5-3e3ac271f145_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_61bf5c68-6ada-4975-afe8-2616a81d6de6_negatedTerseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TJCA foreign tax credits, net deferred tax expense (benefit)</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_b2350332-3969-451a-821f-8dcc5fc2aa4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c5def35c-4dff-407e-9ded-4e8a02ea3285_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_7c4536c6-961d-424d-bcdb-4c1e10680465_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aff5be52-5917-41e9-9863-7ddb36635213_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5db7b6a7-de11-452f-87ae-489ac41e0030_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2eb50b13-5d5e-4ca1-8361-eda3d7d05c91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_f6c50c6a-1d43-44bf-b5ba-5341cda540f6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_5d8f6fae-1075-41bc-9f22-7f6ce8a53e4b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_a36ae53d-f5ad-45e5-82da-ac07ef566e5b_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_cb26a27d-d3a5-43ae-b5e1-16ba28e4fa35_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50%&#160;Notes due 2024 (500MM 1.3654 GBP )(2)/(500MM GBP 1.2987)(3)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20210103.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_29b78459-6c2a-4a1e-b799-da8fe7b4f865_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_8a033123-54f2-4323-9f55-e82c5e96bda0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_04749ffe-003e-487c-9e3b-c1c1ae02d623_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringChargeNetofAccrualAdjustment_253645d0-8d7d-42bf-8e27-dddd2c31b8af_terseLabel_en-US" xlink:label="lab_jnj_RestructuringChargeNetofAccrualAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charge, Net of Accrual Adjustment</link:label>
    <link:label id="lab_jnj_RestructuringChargeNetofAccrualAdjustment_label_en-US" xlink:label="lab_jnj_RestructuringChargeNetofAccrualAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charge, Net of Accrual Adjustment</link:label>
    <link:label id="lab_jnj_RestructuringChargeNetofAccrualAdjustment_documentation_en-US" xlink:label="lab_jnj_RestructuringChargeNetofAccrualAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charge, Net of Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringChargeNetofAccrualAdjustment" xlink:href="jnj-20210103.xsd#jnj_RestructuringChargeNetofAccrualAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringChargeNetofAccrualAdjustment" xlink:to="lab_jnj_RestructuringChargeNetofAccrualAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_d2469461-a21d-48fa-95b9-15d2d32c1686_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plans</link:label>
    <link:label id="lab_country_US_28c45121-10d2-4fb4-aeb4-b322ca2d1423_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_741fa0e6-82d6-49fc-8058-e84075c3ddc3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_96c2bdde-d595-466d-918d-d4ee9d650d9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_772c24a5-74bd-4acf-9e9d-3920f964e9e4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_984aba82-d7e4-4c80-bcd9-7065e19bf3fa_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of reclassification of cash flow hedge gain (loss)</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_a8dd4b3d-2e5e-47ba-9e7d-22a25c68eca0_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20210103.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_3519a7fd-e4ee-4a6f-9fc3-0504db84f76e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)(1)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f4874959-4e35-4740-89ca-38f2be3b9dcb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_05d4ee82-7828-4f3b-90f6-759354671b9d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fce88675-c84f-4afc-b6b8-ee81d64768f8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_74a7d3b5-514c-4778-bd0b-cac0f386a40e_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_610e00a6-9099-4778-95ce-b98171aae1ba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e1ae6d2f-e10f-4004-a313-05956f579804_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_5cb2a46e-4f0e-4276-9931-2cc88dd5f614_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73%&#160;Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20210103.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_b931eed1-38e2-4c15-9d42-eae8c1025d26_terseLabel_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense, including the amortization of capitalized interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_label_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation Expense Including Amortization Of Capitalized Interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_documentation_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense including the amortization of capitalized interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:href="jnj-20210103.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:to="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ee2e07e2-bf04-4d53-8d60-4f37a81f8ce7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_c90ff197-0c7a-4ba0-a43f-acebc54fede3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently payable:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_e82207a5-edb6-4c6e-bf5d-df91f629721a_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_a0998100-36bb-4586-b35d-e6bd9009637e_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_ed3d8b62-afcd-472f-9c9a-15d2bc8d818f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12983d1a-7721-402f-8fde-861d1dddfeef_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_7566a3f0-05bf-4167-9888-d93e4037a6a5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_94a57275-5ada-4bd7-b6f2-557981e9fde5_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_646935a6-a794-43f7-b1b8-a15bbff52c28_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e2caaa6-0486-4204-b2c4-729ded40cca1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_745e0c66-fb52-480f-9be1-dd01fb041959_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:to="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_66f063e7-e426-469d-9a7b-c6c030d5fc9c_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20210103.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_dc491dd8-c195-463e-86c6-d8b8efc5c398_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20210103.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c638422c-bb1c-45c5-a301-c009a3947e06_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_b27f61d3-bf36-431f-88a3-77513fa5bd71_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8b2aa311-7619-417f-927d-6d22dbee90de_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_71b784ec-1c57-43d0-9854-4fff14ad2e1e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f6d64aa0-781f-4255-83cb-e8f040e6cd41_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5c968c3c-b4e5-4e00-ae20-103e6d59ce8e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ed975676-65cb-4e97-991f-a6ffab95777a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ba99d893-59bd-444a-a531-6e52e3c6e688_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3fee5899-b893-4719-a24e-0aa105bc4340_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_08c9203f-2f45-4662-9afc-b0b2b9cd39d3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_d81369d7-62ad-4283-b337-b97988998876_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward" xlink:href="jnj-20210103.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward" xlink:to="lab_jnj_ChangesInTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedLossOnSecurities_7f07eb74-5dee-4dfc-a319-22015f88dbd2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedLossOnSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedLossOnSecurities_label_en-US" xlink:label="lab_us-gaap_UnrealizedLossOnSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedLossOnSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedLossOnSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedLossOnSecurities" xlink:to="lab_us-gaap_UnrealizedLossOnSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4274a269-c221-4199-85eb-baafed217389_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e10fd3b0-9554-4b1d-a408-258a28dd1369_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Range, Maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_58e5d84e-7ab1-4a93-a632-fbd4af9011b3_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$90.44-$100.06</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeTwoMember" xlink:to="lab_jnj_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_9c9300e2-7d3d-4eb3-b3cb-fd0cd7ee12d8_terseLabel_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of the assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_301f9f15-11ff-447c-a38a-54349178fbe5_terseLabel_en-US" xlink:label="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in earnings before taxes, percent</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_label_en-US" xlink:label="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Before Taxes, Percent</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_documentation_en-US" xlink:label="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Before Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:href="jnj-20210103.xsd#jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:to="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_f0b6af3a-3100-43ab-886f-1402b313bbff_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and building equipment</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7ecb6822-fc1b-45f3-a8d2-fdb9a06bdfbb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d2a250e7-bb66-4823-bdf0-58c7563d6c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_63ef437f-1401-4e55-a2b3-c45378d894ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9bad9260-b596-4a70-a47d-0082d92e08d2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonQualifiedPlansMember_853a0796-3183-4110-9bcb-8bbee1fa4ffd_terseLabel_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Qualified Plans</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_label_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember" xlink:href="jnj-20210103.xsd#jnj_NonQualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonQualifiedPlansMember" xlink:to="lab_jnj_NonQualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a0ae1893-6423-4187-8dca-abef6d4f2ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_16c1aef8-dc6a-41fd-8cae-bce94477b1b2_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Five</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_18062f97-53cb-4f5f-9933-cecce64c15b7_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" xlink:to="lab_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4f25491f-5962-4456-868e-e9e61d63bb91_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_119ed433-bbde-4e7a-9b70-56106ae3023a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_a850ef7e-bd49-4532-8a76-f1b3bfbeb20d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GeneralCorporateMember_1e2f1053-2cc6-4370-9978-0473a24eba45_terseLabel_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Corporate</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_label_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Corporate [Member]</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_documentation_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember" xlink:href="jnj-20210103.xsd#jnj_GeneralCorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GeneralCorporateMember" xlink:to="lab_jnj_GeneralCorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_0bdec69f-cb3b-49ff-b2d8-aa228ec99db7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_065e6a18-50a7-4873-8f69-fd6304350a0a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.65Notesdue2021Member_008103f6-a9c1-446c-b5de-e0b6dc20c0b7_terseLabel_en-US" xlink:label="lab_jnj_A1.65Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Notes due 2021</link:label>
    <link:label id="lab_jnj_A1.65Notesdue2021Member_label_en-US" xlink:label="lab_jnj_A1.65Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Notes due 2021 [Member]</link:label>
    <link:label id="lab_jnj_A1.65Notesdue2021Member_documentation_en-US" xlink:label="lab_jnj_A1.65Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.65Notesdue2021Member" xlink:href="jnj-20210103.xsd#jnj_A1.65Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.65Notesdue2021Member" xlink:to="lab_jnj_A1.65Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0ba6d861-7f3f-4673-a019-a76737aaa243_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_1e6c44f7-a742-498d-93ee-ec6dd3808ed4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_b5e71d8c-dae8-4cd5-963f-95e59de85f13_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20210103.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_bea0f9cd-c5b6-4288-9556-716c371e00de_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities, equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_e9837896-5cdc-4c5f-af58-67978d4384ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation - beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_9156aa2a-d267-4758-ab12-cdfb74c4e20f_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_85fdefbc-8088-4209-8dd4-179ebbaf6ae2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e7885fe0-931e-499b-a6ac-005246bf2e06_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_b24d3d6c-1d62-40f1-802b-8a7ac99dddbf_negatedTerseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in tax rate</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_76ccc526-8264-4841-bcae-8066d0263d23_terseLabel_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans (in shares)</link:label>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_label_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Shares Exercisable Under Stock Option Plans</link:label>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_documentation_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Shares Exercisable Under Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:href="jnj-20210103.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:to="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_00f58dcd-b9f8-49ca-b8e1-acaf54bd780e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled non cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CustomersCollectionPatternsAxis_610ff24d-f3aa-4486-a7a6-204b9783df79_terseLabel_en-US" xlink:label="lab_jnj_CustomersCollectionPatternsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Collection Patterns [Axis]</link:label>
    <link:label id="lab_jnj_CustomersCollectionPatternsAxis_label_en-US" xlink:label="lab_jnj_CustomersCollectionPatternsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Collection Patterns [Axis]</link:label>
    <link:label id="lab_jnj_CustomersCollectionPatternsAxis_documentation_en-US" xlink:label="lab_jnj_CustomersCollectionPatternsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Collection Patterns [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsAxis" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CustomersCollectionPatternsAxis" xlink:to="lab_jnj_CustomersCollectionPatternsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ceefb0be-3829-48a8-a4c0-42c6404b40e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b878d2e3-88a5-4277-9fd0-3ec016e7f0be_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_1777272a-48ce-4e96-8755-a50a497611f5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_57ab1a88-6295-4cde-80f2-3fbd7c52fdc3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_ffbd9bdf-d1e7-4654-bbf0-912cd18c4012_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_9730ca28-510f-4a8e-9413-ebd24d63d5d7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:to="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_88336743-7696-4029-9267-0883f7413171_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_12d0bf83-bafc-4df0-9d28-016876216c54_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_9232bed3-3086-453e-b8da-0a9e44e55d1b_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20210103.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_25601bc0-06c8-4eb3-8b3e-0045900596f6_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses (gains)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_f0207df7-8958-49da-8fd1-c3deda82f170_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_d2e795c5-f82c-451e-82d2-e7875823cd30_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_7739a50b-15bc-403b-8808-20503c5896fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of brands</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_83951074-215c-4ade-b83b-a1e3fb6e1e2e_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (cost) credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9d67d1a0-7a88-4c25-8601-968772b3c971_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_8921b6d6-c3e5-4301-86b1-02b9a5d807c2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_47738d1c-afc1-456d-863f-ae3f8ad59483_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Notes&#160;1 and 2)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1a245d2-774c-4252-8d6c-0eb2e23abebb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FundedPlansMember_6c255177-1675-4354-bce9-5d4aa2d1937e_terseLabel_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Plans</link:label>
    <link:label id="lab_jnj_FundedPlansMember_label_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Plans [Member]</link:label>
    <link:label id="lab_jnj_FundedPlansMember_documentation_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember" xlink:href="jnj-20210103.xsd#jnj_FundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FundedPlansMember" xlink:to="lab_jnj_FundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5f8d397d-c902-47fb-9e88-7598d162c048_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_c98b8bf5-44c4-4ca8-ae69-94b01bb7e9ad_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20210103.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_d9859041-9a20-4343-b4da-410be2d7721a_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of deferred tax liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_736f43b8-171b-48b5-8d23-5d6a5323865d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_e9464a4b-ce99-4e13-8991-fa5a8c9e8e37_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_27eb5911-9b80-4de3-aa1f-b234d7e59d97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2ef3dafb-4d4d-4ebb-9df3-15825a38a010_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c557a8a-fa06-4799-b189-333cae44c467_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding&#160;&#8212; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_da1e94ba-ccab-4f54-a5db-ff28f6d04b67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_187f8e28-17c6-443d-b281-8730111f7435_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of option activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_256458ce-3647-4248-84ad-c15907b83dd0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Income reported for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f8c625bc-aa23-4875-a4a8-8354ffe88eb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_a89eabaa-4779-4413-8efa-545246dd00db_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9f8ae7ac-479f-4da7-9106-29895d3cb399_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f6d0b889-6de2-4487-a9f4-86b5e76889ad_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_be5b41a2-c1b3-4856-84c7-addbb6de4707_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_d5fb2336-eb41-40a4-8cf2-caf73ab7ddb4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_ce97ccff-a458-460c-bb3a-fcd99381fd7e_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_9b6c29f4-dc6c-4569-9f9a-9e706ac37f7b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5601b644-af04-4584-967f-bdf5a0446ff0_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ab3de6b1-4fae-46c3-bc37-653f3e314390_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_a40d6f40-a7e3-4fe6-846b-a9a7d221182b_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of corridor of greater of market value of assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_label_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Corridor Of Greater Of Market Value Of Assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_documentation_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of corridor of greater of market value of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:href="jnj-20210103.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:to="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_7fd06a4b-0b17-4a79-8cc8-04803037bb47_terseLabel_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on unrecognized tax benefit liability</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_label_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_documentation_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:href="jnj-20210103.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:to="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8626f4e0-c4f9-4945-b977-f78a81973262_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_32b1a9a4-c946-4f46-8d87-bebc531b5e3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalent Composition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_d98725df-f6b3-42f1-aa65-5205f22ed1f4_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset recorded related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b7829c24-9965-4055-9f31-85a5241b5e31_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, canceled/forfieted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_264b2e8f-5150-4c04-8345-f967a897fd4f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_2f5dc263-dab2-4827-a8fd-b5c19c7005cf_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_df0c63d4-2944-4421-8df8-a96ffb8a5e90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis_8550223d-fddd-4541-ae2a-94ef0e8b9214_terseLabel_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis_documentation_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_jnj_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6ef8c2c5-14f9-4ef1-854e-5feb56cdbe49_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_a2b3556d-20c7-4e9c-a0c4-0d5b9cf64f82_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_48d14a7c-5b31-4358-aaa9-156fb816ca0f_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20210103.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_97d1dd0d-b0df-42e2-8689-ca0aeabf5288_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20210103.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_adcce168-2bc3-462a-af85-22f458026491_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_40c2b603-9d8d-49a1-a250-c49613c9f52c_terseLabel_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, receivables retained</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_label_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Receivables Retained</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_documentation_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Receivables Retained</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:href="jnj-20210103.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:to="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b52e73e5-fc8a-4598-b431-b1062cf78306_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_888e5f01-9b9c-451c-8b13-3c7a513cb4ee_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_942f5d00-9cbd-4084-892e-a567e5d4a71b_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20210103.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Debenturesdue2020Member_fe997570-8215-44ee-9ace-1b9fbd36b279_terseLabel_en-US" xlink:label="lab_jnj_A2.95Debenturesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95%&#160;Debentures due 2020</link:label>
    <link:label id="lab_jnj_A2.95Debenturesdue2020Member_label_en-US" xlink:label="lab_jnj_A2.95Debenturesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Debentures due 2020 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Debenturesdue2020Member_documentation_en-US" xlink:label="lab_jnj_A2.95Debenturesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Debentures due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Debenturesdue2020Member" xlink:href="jnj-20210103.xsd#jnj_A2.95Debenturesdue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Debenturesdue2020Member" xlink:to="lab_jnj_A2.95Debenturesdue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_b59c324f-b909-4db2-853f-100c18cd329f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_ea67b281-adf5-4c55-9073-cbf4b932990b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e6c92efc-e393-4a30-a6ff-4483dcfe5861_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9f4195f7-ee58-42bf-a535-289033a4fca3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other benefit plans&#160;</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_82386ce3-52ae-42cd-a922-dfe27e8eddfa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_579a84ea-0e54-4d4c-8316-5eff350d26fc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, Amounts</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_6027c4dd-7877-4a43-bc54-9d6e4d9adcbe_negatedTerseLabel_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments, settlements&#160;&amp; restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_label_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments And Settlements And Restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_documentation_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase or decrease related to curtailments, settlements and restructuring.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:href="jnj-20210103.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:to="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_ed4e32e5-3b3d-4054-b141-78e327e1aa8e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_4c57f4dc-f9a4-4749-b536-cd1246ef2cbf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6761ac9c-caf4-43c8-8d0c-c48746a69833_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a2b9cc6e-297f-495c-9725-c52b08439846_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f5a3f-3f98-46ff-ad2a-4d60eca6f594_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_83db5747-41e5-49e5-8587-c4511489e82e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline (ultimate trend)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1d3137a1-b3f8-46ae-a2fb-9fcb9e96e888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_668bb5db-bbbb-444b-8113-d7aceaf9d5e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_c0300404-171c-4f70-80a4-a57d2c31acff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_f7e6732d-7e54-42a6-87b5-c1860602822a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c7edb609-0eeb-4672-90bc-f8aca8f87b8a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_92cc58ff-f861-46d0-bd0a-031b4da7e16e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1b188c71-bdde-4cd9-84fc-6e1cd0903d12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_054dac03-b503-4f03-9a9e-5eb4e0cead38_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_ab2b5013-ccc3-4041-964c-633d2c144ee0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9fa52c85-1a6d-46e6-804c-93a1edd1f8fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_32919ab3-0e31-4320-a17c-122a3889a4e1_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20210103.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther_79579ff7-b8a3-47f9-96ae-0f077be9c58a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale (Note 18)</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_f8de2f6c-04f3-4680-b685-dd3634f1aa4d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_765891ff-2390-4b9f-bd58-ad9e6e7030aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c97c333e-e7a3-4384-9446-6650f54ab75a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_96d18469-6559-4cc2-8307-c36993a3e429_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CizHoldingsCo.Ltd.Member_b07fd016-e2ed-4c13-8895-f6458effa0ec_terseLabel_en-US" xlink:label="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ci:z Holdings Co. Ltd.</link:label>
    <link:label id="lab_jnj_CizHoldingsCo.Ltd.Member_label_en-US" xlink:label="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ci:z Holdings Co. Ltd. [Member]</link:label>
    <link:label id="lab_jnj_CizHoldingsCo.Ltd.Member_documentation_en-US" xlink:label="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ci:z Holdings Co. Ltd. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member" xlink:href="jnj-20210103.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CizHoldingsCo.Ltd.Member" xlink:to="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_d112f846-57df-46ae-8673-10fc7f891371_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b5365349-8ac6-4539-b018-d075a3d6b65f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_808c5b2a-9fae-47ad-ae83-23f26c485e46_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_4f2cfda4-3c78-42b3-a9d2-8f9b77878939_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Employee related obligations</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SegmentsTotalMember_c3fc3669-4226-431d-92a9-3cc175c750aa_terseLabel_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_label_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total [Member]</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_documentation_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember" xlink:href="jnj-20210103.xsd#jnj_SegmentsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SegmentsTotalMember" xlink:to="lab_jnj_SegmentsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_cbb16032-5f56-45fe-87ea-a5d4fe498efc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e9f54a43-b634-4f5c-8773-3388669b1a59_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_a43aa66f-2593-455b-92a0-e29ebe3b6828_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_31cd8469-f254-431a-b5ce-57c947ab23a3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_c8dda84c-5ffd-4a79-9c0d-caad48ae556e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_8cbf54d4-2920-4ae5-b802-6433a8dc7912_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_962c71e8-32ac-4c8b-94d7-f3951a36734b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans related to treasury stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_4ccc262b-a3f8-4091-8422-011f0599d40a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_38e557bd-90c1-4d04-806a-fb53d28c246b_terseLabel_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlements</link:label>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_label_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of an Asset (Payment) for Restructuring</link:label>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_documentation_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of an Asset (Payment) for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:href="jnj-20210103.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:to="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_4a4e1c18-b288-48cd-9c17-abd87ac23317_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_01e56bf7-9cdd-4746-a424-db2f31fc5a1b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_d4d05554-4523-49bc-8a3c-014a96de5bfd_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (7)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20210103.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b5a213e-3779-4b43-9fad-5db8a85cb013_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_0a79c08a-4d03-4069-8932-41b4cdc49ff2_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, duration of restructuring plan</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:href="jnj-20210103.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:to="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_1af4ca50-1968-4fc4-b5c1-a25beeb16af6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_b00f0459-4f86-403b-a3a8-cb4d1d06c507_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20210103.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_14f67cd1-f13c-43ac-a4f0-ae86872f635b_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_b9fac7ad-a56c-4758-812a-e4dc1c51c931_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestPercentage_6256d064-cdc9-48d7-9654-37fa68841a1a_terseLabel_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, equity interest, percentage</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestPercentage_label_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, Percentage</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestPercentage_documentation_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestPercentage" xlink:href="jnj-20210103.xsd#jnj_ConvertibleNoteEquityInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConvertibleNoteEquityInterestPercentage" xlink:to="lab_jnj_ConvertibleNoteEquityInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_731b5268-ba1f-4a6a-add9-152c173a9a1f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7d582956-8c8a-49dd-b4c3-cec184b3cf07_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_87bae953-cbf7-402e-88a5-a1b9c3155af9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2947e0e5-4e98-4e06-ac95-634f90228d03_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4652701b-7d21-4436-9f65-9d601c59bf0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c9e90701-86e0-4788-b976-64d701168dcb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4c5cf9f6-ab14-4beb-b2f1-8317517b4911_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2c2db23c-9b5e-4def-8f0b-d04542ef128d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_ac62e59b-76b5-4251-9c00-97df42a0df9e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f847dc20-1292-4cca-b74d-812272131743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_355d8363-0884-4ffd-8883-bbd89466f8db_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2014-09 - Revenue from Contracts with Customers</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9be7dc2e-3494-4db5-936d-6c4955db6c44_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b03c1bf2-a138-4520-b9d2-be299e83ed33_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_346b98de-dc64-4303-a7d4-e963c360138d_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6a8e4195-0046-41a9-a6f7-1ff15981b464_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_584826ef-e5f8-4f8e-84b5-306f300d4cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Range, Minimum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_70cec497-0e9d-4e08-8126-d254670ed0f1_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_27b67153-100f-48d9-8b55-a06aef38a570_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20210103.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_2445fbae-cc4a-453d-91c3-c80e8a868ac2_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1a78a821-fefb-4ed0-8631-b6ac103e9842_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1ae95270-6041-443b-9abd-a53c0e2c5747_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_0791083e-b9f0-459a-a294-c50f827bee45_terseLabel_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the benefit obligation and the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_d71cd7d0-8427-48ae-baba-bf4e971e2ceb_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities (Notes&#160;1 and 2)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_be6e51e7-a901-4e84-a5d8-8ece4db4db07_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_c4d5047d-ac56-4d22-9f69-23a910c237bc_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares repurchased under treasury stock method (in shares)</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20210103.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2859c85d-027c-4128-9cde-885593203862_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_430a9658-5324-4280-9453-32589e000869_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_1e70c12a-58d8-4215-94dd-f197a7ab5290_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_e008e625-b0a1-4b29-9803-0aac00b98cc1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts:</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e49d3ef-a408-457b-a331-e7547c19e573_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b990276a-82a4-476f-b654-6caf7e77417f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_21e8b108-797a-4603-b98e-7faa48895d13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_5f904570-a1df-4d93-bcfe-b8e636ebe56a_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b4e8bb13-e699-4a7a-8623-dcb6d04c7d86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_e14b718d-40bb-4176-8c25-4d64f2e09671_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bfb7c4da-537a-451c-874d-9be8d786c0d8_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LumpSumDistributionMember_2415b0c3-4af5-4559-9843-2ed2390cb6ac_terseLabel_en-US" xlink:label="lab_jnj_LumpSumDistributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum distribution</link:label>
    <link:label id="lab_jnj_LumpSumDistributionMember_label_en-US" xlink:label="lab_jnj_LumpSumDistributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum distribution [Member]</link:label>
    <link:label id="lab_jnj_LumpSumDistributionMember_documentation_en-US" xlink:label="lab_jnj_LumpSumDistributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LumpSumDistributionMember" xlink:href="jnj-20210103.xsd#jnj_LumpSumDistributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LumpSumDistributionMember" xlink:to="lab_jnj_LumpSumDistributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_3a23e6b9-161b-495a-9cdd-98c3e1afe879_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_2f04e366-d290-4849-9fa5-21c13f388a86_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Reserves&#160;&amp; liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_47c0b245-1a8e-4664-a2d3-c4fa4965a275_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 8)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_43cff310-1de9-4e91-9ace-74dc3ec0e8af_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_d6edf934-c509-476e-bc52-3a1f9283e12d_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_18ba5d2d-ec11-4e45-bf35-69ac7b861050_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a3ea3a0f-54ae-4d48-865f-230707ae2f63_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(Increase) in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_05ba9990-8d1f-4db0-aa18-063c58c00f76_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 1)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A130NotesDue2030Member_dc3e95d7-56cb-4be4-9be6-20a7e4c9e5ab_terseLabel_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member" xlink:href="jnj-20210103.xsd#jnj_A130NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A130NotesDue2030Member" xlink:to="lab_jnj_A130NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_e071269c-bf84-44b0-aed2-a6bcdaef41bb_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_4d43b4d9-534e-4a6f-b7bc-4b6f6f1af17d_terseLabel_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:href="jnj-20210103.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:to="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_fe5e111e-5ba8-4e44-8215-8a07ec624866_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_23108336-c197-43e5-817d-78b12f7870be_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_987f0702-f6cb-49d5-a486-196605de65e7_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20210103.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4e9e61a3-0808-4c9d-b965-41db8e4466fe_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_ebaa4ed3-46d1-4867-ac3a-c724935946e8_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate reconciliation, unrecognized tax benefits, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_15abfaf9-2cd7-415d-9c1e-bc502770f452_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_be774fa4-2124-4fbd-9b64-6ac3a5befea1_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Treasury Stock [Table Text Block]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:to="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_eb38b787-724b-454d-b555-867c8570f726_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a28cf73e-4e2b-4ef2-953d-43911752afb7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0684e530-441c-4646-8c5a-d2432b297303_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_6ec0de78-71c0-4aac-b543-1c1f56228d9b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_06ea073a-ad30-4996-b641-175a2c40bd72_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a65b39d3-dcfa-473f-9993-af241dab26d8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_54ae559e-da21-460d-89f0-fc54701c48a8_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20210103.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e4ac1267-beeb-4076-93ff-70de2ee42320_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_efdc39f2-e483-4db4-b3fd-37a1ecd3c505_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_286592a0-c398-4b2d-88bf-6ee18ae7a803_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_b3693178-6bce-4d77-9234-36f063bc1084_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectOfExchangeRates_ed1b0e76-ea17-45d4-8cda-5398ccfd1b29_terseLabel_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_label_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Exchange Rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_documentation_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Exchange Rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates" xlink:href="jnj-20210103.xsd#jnj_EffectOfExchangeRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectOfExchangeRates" xlink:to="lab_jnj_EffectOfExchangeRates" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2021Member_61cd24cb-0920-4e3b-af41-d6114e266471_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2021</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2021Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2021 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2021Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2021Member" xlink:href="jnj-20210103.xsd#jnj_A2.45Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2021Member" xlink:to="lab_jnj_A2.45Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_4744e57c-462c-4999-bfdb-25e84e80d726_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity during the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fc453879-6f26-47de-a40d-78bb665712fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_b3b662c7-257e-471a-92df-c10a79270db4_terseLabel_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Expense not allocated to segments</link:label>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_label_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Not Allocated To Segments</link:label>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_documentation_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments" xlink:href="jnj-20210103.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExpenseNotAllocatedToSegments" xlink:to="lab_jnj_ExpenseNotAllocatedToSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_c0861024-e92b-431b-9ea8-b5f7b4bfee6b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1ba591f4-13e0-4ab1-802e-e16d89f13488_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_06fea837-52b0-4308-81f9-e9048498a5e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_fb44273f-099e-4d20-8c5e-dc196ad9188e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_2720d4ca-b146-4565-9f79-c601e6fb69ed_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_edcf5e9e-3e67-46cb-9a46-8f5cd148f9f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3de6692a-abc8-4610-9676-e283108084ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6dd65f10-a25b-4034-bdbd-748704d31686_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled/forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_512b6bd0-c990-4db6-b6f3-6f3f672cec4e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_952653d4-501a-46af-9682-7092037e641e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c76c85e6-0ad0-429b-9786-5181352e22cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Differences and Carryforwards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_d03660a1-d3b8-4a9c-b4b6-5fcfc0a6080c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_79b0c22f-ce7f-4574-af04-a1495c7fdc6d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1be918ee-ac20-4a27-8f25-39c0a772541e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_04bd1fb0-1a76-4042-aa00-857f625b6c01_terseLabel_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022</link:label>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_label_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_documentation_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member" xlink:href="jnj-20210103.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.25Notesdue2022Member" xlink:to="lab_jnj_A2.25Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_bf58430b-4400-497c-b6c6-73dda3328f3b_terseLabel_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_label_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_documentation_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:href="jnj-20210103.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:to="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_072b9de8-8ae8-4f12-939a-28e47d0e23f5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_b49112d4-b549-4db9-87f1-ec974c157d38_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20210103.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_52b6ecfc-a077-43f7-a268-cbbf2c68fed4_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Notes&#160;1 and 5)</link:label>
    <link:label id="lab_us-gaap_Goodwill_e0f32a3d-4a5e-4bc2-b0d4-7634a46ec354_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_4de5bed0-4a86-4e63-a8c2-59bda78b818e_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_961681c4-58ab-401e-8f6d-fe6b2c8c4676_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_0fa59652-e655-45d6-9e11-7a0be746055e_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20210103.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_544c9354-c971-4687-8fc4-f9d64df1d0b9_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_da31cdd7-5f5a-4dde-a03c-1ed6ae25a28e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_572045d1-85d4-480a-84a6-b23d9dab210e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0df74dbf-91a3-4040-857b-34507ba3bd8d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f159c82-0200-45a5-bd6e-8087fff86702_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be3bbf71-1dae-4878-8718-0b4fedab2a77_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_b1e2b77b-025c-4427-bc5d-8946d7f62db1_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c94064c-f7ac-48aa-8b9a-c37ef2ca0dbe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6c662980-122c-4cc4-a6ce-4ea078aa5dec_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8be85313-c6df-46dd-a277-cb57ce877929_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_56f419d2-0402-4d86-ae91-b44885a48d65_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_cd2f0f7b-76ce-432d-8175-fabef15af7ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_76bc0f47-e93d-46c9-a4a9-6592a3b299ec_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, incomplete accounting, net adjustments for provisional income tax expense (benefit)</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Incomplete Accounting, Net Adjustments for Provisional Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Incomplete Accounting, Net Adjustments for Provisional Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" xlink:to="lab_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f4701200-1abe-448d-9ca3-31c83d86e8d2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_87a73354-48e1-4be3-9462-bbcdf1a6963f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8734ad86-d6e8-4040-b5df-0778b8f098e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f55dee25-c8e7-4dad-9077-efc7e40b7e3d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_9842e459-e959-4a55-bb73-b251f66333ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_f4788c13-aa98-49b0-9c09-c8c63d9d2651_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_d6aaa9b8-9eaa-47c2-9862-fa364651a5ba_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler1Member_9190827b-1bff-4cc6-b369-e1f5e7bcc10f_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_label_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member" xlink:href="jnj-20210103.xsd#jnj_Wholesaler1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler1Member" xlink:to="lab_jnj_Wholesaler1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_39a049ec-952c-4ea6-93bd-c21a93782372_terseLabel_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock-based compensation plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_label_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Based Compensation Plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_documentation_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock-based compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:href="jnj-20210103.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:to="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_913dbec1-fb3a-4add-90a0-5cdc1615e0c0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding (Notes 1 and 15)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b64eb782-9605-4bc5-9379-444dfcc52d08_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_289c1c45-9a98-4bba-8fad-29bd03eb9b26_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_935c6b48-ee9e-4990-8f11-ae52970325cb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net transition obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_d07c7848-244a-4653-b4c4-d778eb3253d0_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies by Nature of Contingency [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_8fb16c67-2bdf-4307-be03-e5f6334f2dc7_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_9a9e7c01-36f3-48dc-b9a7-87a9f48a6dd6_terseLabel_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_label_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_documentation_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate" xlink:href="jnj-20210103.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessAcquisitionDiscountRate" xlink:to="lab_jnj_BusinessAcquisitionDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_326f81e3-c5e5-4b41-911a-91662d067074_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation of foreign earnings amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_23c3232b-29de-46cf-af04-82871a13b243_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_e6c22dfc-416b-4f35-90ee-e8f500b37cb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_c9b61d49-4c8f-4e15-8743-480e13c5a504_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a63189f3-5fe1-4955-b83b-febb87e51648_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c4ddce1b-ea4e-41a2-bdcd-8f7bf1695850_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment at Cost and Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_acdb083c-de16-4e73-aced-0d6048f1baf0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable trade, less allowances for doubtful accounts $293 (2019, $226)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_55f3ad91-51d8-4aba-afef-414631a8bde3_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20210103.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1a4f6e41-3444-4aa4-93f8-ea4a1787c58e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ade9cb2f-ac5d-4501-ac93-127e6a40b320_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpiodsMember_b343fb5e-769a-4a8d-9d93-de1a76758c7e_terseLabel_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods</link:label>
    <link:label id="lab_jnj_OpiodsMember_label_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods [Member]</link:label>
    <link:label id="lab_jnj_OpiodsMember_documentation_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember" xlink:href="jnj-20210103.xsd#jnj_OpiodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpiodsMember" xlink:to="lab_jnj_OpiodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f648d81f-496a-4291-a041-9627cb51c190_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_dcdac6c9-38f7-4f09-bde8-df18acba33c3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_e37b2d57-54ab-4779-9d26-7e886f6109ad_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfEquityInvestments_4fee055d-cb2e-4082-bee2-d45bcebbbfaf_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Equity Investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfEquityInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_3421147a-61b7-43a9-b8df-03d04b17cd01_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_5d2a32a8-6683-4621-8bd2-206a72de11c8_terseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20210103.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_98d5e10d-b62b-4041-b22c-b35dbd9fc9e4_verboseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20210103.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_318b2894-5339-4f01-88ce-4a645b4ad88a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_b0b47357-de7f-49d1-9dbc-53dc4e2abd84_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20210103.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f55d1db9-1d7f-44d3-a51d-ad09357cbb06_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_f16cc346-5179-4e3a-af75-18fa3019b8b9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_b6fb682f-6c44-46cb-8daf-132aa92966ad_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20210103.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c4153421-8250-4e4b-8916-e4ebe3322aba_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_2a38f8ed-68b9-4d29-a897-a8f980bcd60e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_4e3d28ab-b2b9-4b5e-9aaf-807755b36c92_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year One</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_77d60a0b-3b38-46cf-bf7e-6c0da8f00969_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangibles, amortization expense, year five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_fbcc3c0c-36bc-4f24-8455-ee54c2d186d4_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20210103.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_f9a014e7-7730-46d2-b576-ecf8fa054abf_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option average life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_f295325e-4cc0-48aa-acf1-91320ce6f416_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Average Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ec9d9092-6315-47d3-906e-474224653d89_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0f8edd3-bc91-40bd-915b-620d99e14528_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_3bfcc8f2-aa02-4c40-b11b-e01876adf972_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost discount rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:to="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_337c06f5-c7a9-43bb-980d-d2f3fdbb6b09_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_07e6f0e5-1c7a-43b0-ae1e-8718a05fc6fd_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnSecurities_dc421d3e-10c0-4ad0-8385-5cdb5d676ffc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnSecurities_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnSecurities" xlink:to="lab_us-gaap_UnrealizedGainLossOnSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_9e8f929e-4bde-43d5-afa9-ffa5a4fa768d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_8f8968cf-25dd-406a-917b-1387ccbdea98_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_d3bf6d78-92c2-48b0-9b32-2851ae5640d5_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85%&#160;Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20210103.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_c4166705-5942-4a90-9d14-49bdd8dffdf8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_754c431d-471c-4fe1-80e4-af9a3d7e2b79_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5bc77525-e528-4148-918a-c84f1aa8c100_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_802858d4-7df1-4aca-9754-97419a651993_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20210103.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_461bf19e-03cc-4acd-a9a1-89dba89bd1b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain_938ceda2-7352-4684-a461-3a30caa12c6e_terseLabel_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain_documentation_en-US" xlink:label="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_jnj_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_21d9c1ec-f121-463a-8219-a017f2d47be6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_4c9f92a6-3eea-49de-8854-1270e02dca49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_e33bf7c1-0737-473d-88ab-e9040414b914_terseLabel_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note, equity Interest (in shares)</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_label_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, number of shares</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_documentation_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, number of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:href="jnj-20210103.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:to="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_25ed4420-d768-4e86-8acd-7cd46368c5e8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_dfedc0f7-ce5b-439e-9a02-a1c659ea10e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_2873894d-c6a5-4326-8110-928c131a6643_terseLabel_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_label_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations [Table Text Block]</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:to="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_b6493bc9-71d8-471c-88cf-3408ebcdf1e8_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20210103.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_26ad8e5c-384d-466e-8bb6-404b9b76aac9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_369b3c63-a20d-4fbc-b15f-fd6a2929cdef_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_e33a01d0-b1cf-49b2-bceb-6cca0ba1293f_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20210103.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1f3e3472-335f-48ff-8eee-d08f8cad6444_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bca9e340-7672-4768-a2bd-68cdec5a12c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_165e477e-6bb0-4537-93c3-54a4aa0f3af0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9115159a-7e8d-4767-86b9-21cd45e7eb61_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_95103909-1dec-4d6f-9155-18ff6bfdaf89_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b5d8d0c9-f307-41b1-8dfe-516b4706c121_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(1)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7a00c6b7-e33d-43e4-8896-fd75675f653a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_efdb840e-c019-4bc3-a26d-57cb7065ff09_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_8e6ac4ee-d815-4905-b979-c4968cd3f7c6_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, increase (decrease) from acquisition (sale) during period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RegulationCharge_7afd6f5b-ed9a-4864-b253-69067f48a608_terseLabel_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_label_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_documentation_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge" xlink:href="jnj-20210103.xsd#jnj_RegulationCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RegulationCharge" xlink:to="lab_jnj_RegulationCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_90e06c71-a48b-471c-b4b0-4c380273fbd6_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_8a5c234e-76f7-48db-ad9c-a2c79b1b4c15_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, inventory, current</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f8b78f15-ced4-4af4-9b5a-a1748990a24c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_f41a4a96-ca13-4ebe-bed3-5aaaec60d3ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CustomersCollectionPatternsDomain_71837904-91fb-4eea-94d9-c9f79fdfbeea_terseLabel_en-US" xlink:label="lab_jnj_CustomersCollectionPatternsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Collection Patterns [Domain]</link:label>
    <link:label id="lab_jnj_CustomersCollectionPatternsDomain_label_en-US" xlink:label="lab_jnj_CustomersCollectionPatternsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Collection Patterns [Domain]</link:label>
    <link:label id="lab_jnj_CustomersCollectionPatternsDomain_documentation_en-US" xlink:label="lab_jnj_CustomersCollectionPatternsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Collection Patterns [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsDomain" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CustomersCollectionPatternsDomain" xlink:to="lab_jnj_CustomersCollectionPatternsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_bca98a01-59d1-46ee-a0f9-85346916aba2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_a6462bcc-c946-4a24-9e2b-00a884bde6bc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_6c86ea51-8322-4286-a13d-04a5fcb9707c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_b20a7a70-c0a3-45fa-85e2-7cc329fd4330_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_03016dd8-f6a4-4f16-9bb5-c17b4d095cb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_aa658b30-5a87-4f72-ad84-2dd0c157846c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_3e9f62f9-2a6f-4b70-8c00-9d99586c3953_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_d31a7da3-0b27-4418-b05c-bd0de5c56621_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_df221969-b48c-4dea-af89-43f60524c353_verboseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_065f52d6-7874-49c8-b712-0a9ddf84c995_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_ecad5389-7b78-4726-beb2-c352429f0c99_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_10e09741-93d4-4fa3-afd4-8600db7e2953_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_09a07bac-8703-40cf-83ca-c67adeb79ef3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_599ef1ba-8b58-45ae-a216-1ca5cff78146_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanTextBlock_cdaabd8e-8a69-4a3a-9f7a-7b92bb9f7692_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_label_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Text Block]</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_documentation_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock" xlink:href="jnj-20210103.xsd#jnj_SavingsPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanTextBlock" xlink:to="lab_jnj_SavingsPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4bbb9bde-20d3-4836-8b2d-cb0c1357fad1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5f2ba7f-078a-4282-924a-611fd3ae97f9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_76ff1e28-777a-43b7-ad66-5d2cf3eb6049_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20210103.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b2da319a-0ccc-4e7d-bec0-a2682ea7bc99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ActelionMember_a11df987-3c44-4199-9b7a-074837a9edc0_terseLabel_en-US" xlink:label="lab_jnj_ActelionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actelion</link:label>
    <link:label id="lab_jnj_ActelionMember_label_en-US" xlink:label="lab_jnj_ActelionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actelion [Member]</link:label>
    <link:label id="lab_jnj_ActelionMember_documentation_en-US" xlink:label="lab_jnj_ActelionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actelion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ActelionMember" xlink:href="jnj-20210103.xsd#jnj_ActelionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ActelionMember" xlink:to="lab_jnj_ActelionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_fee576da-fa2a-4992-a904-6065b1c1aa50_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_65f4f6ab-5345-4c7b-8c7e-1d2e750ccdd2_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20210103.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_4c2e241d-3124-4fbb-b612-507749d58de3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_88e3f70a-0a1d-4789-82a0-d27dcd20a0e8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026-2030</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_5545c348-4f3c-467c-85e7-d31b6406f3b4_terseLabel_en-US" xlink:label="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3% Zero Coupon Convertible Subordinated Debentures due 2020</link:label>
    <link:label id="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_label_en-US" xlink:label="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3% Zero Coupon Convertible Subordinated Debentures due in 2020 [Member]</link:label>
    <link:label id="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_documentation_en-US" xlink:label="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3% Zero Coupon Convertible Subordinated Debentures due in 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" xlink:href="jnj-20210103.xsd#jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" xlink:to="lab_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c48b5809-cff6-4d69-8d5d-ea3f94fe296a_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_bf69804d-0cc1-4e05-a2df-336f06179a5f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of the assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_c13c3798-9496-4ff9-b059-caeaa7b28aab_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20210103.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_da296145-f5cc-41e0-bbaf-37ed2499eb01_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_7b05b46b-d6ff-4992-a186-e5dd77eeee22_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$100.48-$115.67</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeThreeMember" xlink:to="lab_jnj_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b59b0a80-fff9-43d2-aef1-41fd664b9551_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_3e368426-4c49-4231-8184-616ba5c197e5_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense related to change in tax rate from TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_d904b2e7-085a-4b1d-9e93-8749c1457284_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_81c63615-6bd4-4830-b157-837e2fb33a25_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_9cecb1a5-71fa-4799-9ec3-c645d619282b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_692a6075-e130-4d1b-ba57-1e0f352b427f_terseLabel_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum reverse repurchase agreement collateral (as a percent)</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_label_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_documentation_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:href="jnj-20210103.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:to="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5dda692b-644c-4d1a-adef-e71511769ca1_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e06daf86-4618-4c2f-8ccc-c466568c1883_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f16290d3-5c40-4eed-b6ba-6bfb8b3884e4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9b2c07a7-2e75-4526-9642-209adedbd540_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_458bbcfd-22d0-4c33-ac76-cb66e958821a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_95e1706b-4a47-4efe-92e7-b03278258f3a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0951b943-efac-4a4e-a759-ae0bae8ab5a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_efafe86c-ba3a-4d3e-8e7d-7501dbb9252a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_f4be1706-d3ed-4145-a74d-39fad755d540_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_b96b3eae-6700-4695-b1e1-210efa2aa32d_terseLabel_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_92154a19-9270-4678-a4f4-7197875bfc40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_d534615b-0dd2-47e3-80ff-b1cfd430ea25_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20210103.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_4c1e121c-4825-4872-8de1-be8d3f608d2e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_48536f20-5ac0-4bbb-9467-35ef2b837f97_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20210103.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_96301b9c-2fbc-46f4-88ec-7ee3ab987905_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IdorsiaMember_e1480964-1d4d-4faf-b86c-8fe2a87cb5d7_terseLabel_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_jnj_IdorsiaMember_label_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia [Member]</link:label>
    <link:label id="lab_jnj_IdorsiaMember_documentation_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember" xlink:href="jnj-20210103.xsd#jnj_IdorsiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IdorsiaMember" xlink:to="lab_jnj_IdorsiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4f35c7cf-c50e-42ca-90ac-fa77e0ce7b28_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f1dab75e-2164-4c7c-9b0f-46c68859c363_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2019AcquisitionsMember_7d37073a-300f-417e-a5e4-5a50d8a76394_terseLabel_en-US" xlink:label="lab_jnj_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions</link:label>
    <link:label id="lab_jnj_A2019AcquisitionsMember_label_en-US" xlink:label="lab_jnj_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions [Member]</link:label>
    <link:label id="lab_jnj_A2019AcquisitionsMember_documentation_en-US" xlink:label="lab_jnj_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2019AcquisitionsMember" xlink:href="jnj-20210103.xsd#jnj_A2019AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2019AcquisitionsMember" xlink:to="lab_jnj_A2019AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cb2b1eee-46b1-42ab-abd4-ebd32674a20d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_502f731a-85c2-4548-a4e1-2d6c197eefbe_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026-2030</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_448c4d22-1cfe-4869-b26f-199b99689bd0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options, tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3609e265-ef24-4f33-a8a3-b5c6fc55f511_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Stock Option Plans and Stock Compensation Agreements</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_64e7c32a-59bd-4288-8285-ff89c32ed26d_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20210103.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_431d0c3a-043f-4a3e-86c4-73457331f6b4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_e744365b-c3f7-4468-8863-5b99b135b3bf_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AdvancedSterilizationProductsMember_a26f8b98-b230-4026-b5a9-749e7f065c25_terseLabel_en-US" xlink:label="lab_jnj_AdvancedSterilizationProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdvancedSterilizationProducts</link:label>
    <link:label id="lab_jnj_AdvancedSterilizationProductsMember_label_en-US" xlink:label="lab_jnj_AdvancedSterilizationProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdvancedSterilizationProducts [Member]</link:label>
    <link:label id="lab_jnj_AdvancedSterilizationProductsMember_documentation_en-US" xlink:label="lab_jnj_AdvancedSterilizationProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdvancedSterilizationProducts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember" xlink:href="jnj-20210103.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AdvancedSterilizationProductsMember" xlink:to="lab_jnj_AdvancedSterilizationProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_c1541234-5c71-4e50-845c-7906a5ba1aef_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAF effect on tax rate</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_39e97056-140d-44bc-b8c9-7c6658fbd5f7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bcbbd103-6026-49a8-a66d-876aaeb8560d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options average price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f428a215-d1ba-4c37-8088-72b9cc09925a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0c96b810-30c2-45b1-bb6f-521f5d2adb79_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings per share (Notes 1 and 15)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f20e730a-3f8d-49c8-871f-4f53eb86c9ff_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6cd0376-7af7-4bf7-82a5-245fa9e826b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7c768a87-d403-40d3-ba2d-d0f319dd3061_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_13c525d8-ac96-4548-b5da-03a4e3a76b59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.950Notesdue2020Member_d189bb3f-bff5-4614-aa68-1f945230bad8_terseLabel_en-US" xlink:label="lab_jnj_A1.950Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.950% Notes due 2020</link:label>
    <link:label id="lab_jnj_A1.950Notesdue2020Member_label_en-US" xlink:label="lab_jnj_A1.950Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.950% Notes due 2020 [Member]</link:label>
    <link:label id="lab_jnj_A1.950Notesdue2020Member_documentation_en-US" xlink:label="lab_jnj_A1.950Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.950% Notes due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.950Notesdue2020Member" xlink:href="jnj-20210103.xsd#jnj_A1.950Notesdue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.950Notesdue2020Member" xlink:to="lab_jnj_A1.950Notesdue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_ae205bac-e8a5-47f2-b836-15bb96126277_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_59649c6f-8997-471b-97a2-70fd42fec603_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment and Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_837135b9-975c-43ef-b645-d14e00562103_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) On Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_9fde22e6-95a8-4181-9942-0680d403d8b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_05c71678-81f7-43fe-941a-35133fb59ff5_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20210103.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f2fec494-590c-4c98-a01d-97a565677ccf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average fair value of RSU's and PSU's granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_560fd8d3-1700-49de-a95c-bd45b380dcc2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_892f306b-be75-4c27-8c86-4d62c0b5b02f_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_b7268e05-9d59-41a1-8c75-d472e3e93082_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20210103.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b1cc41a-6cce-4c1b-b36a-f82b56d553d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_c0ce5f3f-10f6-4f37-9505-4ca4ea368405_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_0fbecafc-7520-4320-bdf1-41067d87bf0e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_0b757676-8130-4ece-8c99-e2b908bd64c4_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20210103.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_3a3038f1-279e-42cf-afab-34beaad9be03_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate, translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fa21eca6-4bd5-4e63-a4d7-151dd7571099_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangibles, amortization expense, year three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_6711262c-f99c-43cf-ae7a-2016ab51ac6b_terseLabel_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, expected period of cash outlays for severance paid</link:label>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_label_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</link:label>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_documentation_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:href="jnj-20210103.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:to="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_4404566e-64be-42f0-86f9-774c5da4b8bb_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20210103.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_8d57c335-8022-4d4c-a89f-d809376ece79_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current benefits payable</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_71b31099-033e-4882-91f2-7eed73068a2a_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5aa39a2c-323b-4111-8a4e-32c48d275c73_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ecebf38c-e4c8-4aeb-aa50-e1a9aa2a30fe_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected long-term rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_3d76d6ed-6b85-4e2c-b9d1-2545c5bc880c_negatedTerseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, increase (decrease), percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_066536be-10c9-4c85-9a72-30fd4a59ff69_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_37dc9b08-b740-4d33-a2ef-68e19ee1b99a_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_label_en-US" xlink:label="lab_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis" xlink:to="lab_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bc62dc0c-bca7-44c4-a7e5-364d3940a909_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_c8ffb35b-6ab4-4499-8e99-7d3dc5363dd3_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20210103.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_436b8202-e0ac-4177-8de8-050961940873_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_7ba3d1c9-88f0-4136-a727-53afcb9012a2_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20210103.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_715e6e23-743d-4f43-95a5-28c9c337e87e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55046b97-77a4-4ed6-b7e8-bd0219212a0d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_24601eb9-7a41-414c-8d78-1bbbb7d561ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f455405e-f4b0-4051-9c91-c875abfe55c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b7f8913c-1adb-4769-b6e6-55355395b9eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Maturities of Long Term Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c72dce49-7338-4ca1-a214-ef9e7efc64dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_93ec14ea-4d8b-4f28-a6d8-2d39a8f12e0b_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20210103.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_18d71ec8-6984-4516-8652-93066e0c46b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_82e5772e-b723-4812-a0cb-149088648857_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_914f6422-078a-4053-be0f-56abf8bbfc04_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_628233c4-46f5-4736-9474-7f736825d7d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_2c47fed5-a462-4c37-a532-70330c3d2da8_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_beb14523-a1b9-4207-80bc-d0d2711a9561_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_467d5dc1-f8e7-4613-af77-98845c27124a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_49cc42fe-db52-4f56-b703-9d0f2d9495f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_196ed033-a910-4a90-a753-9069342a51be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c5716df3-f298-46c6-83c0-92158e8fc13b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d67c29f9-d509-4570-8613-dca24bb3a343_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9aaef4b6-f54c-4eb0-88c9-ad157dc58f15_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_c3ed41ec-3820-46b2-963e-51f4336a246d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_49daec20-21cf-433d-92a6-1eb4eff94392_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_eee50d87-dbc5-42ff-87c4-e1966daba6c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_c205deaa-8ce1-4e01-baa3-5e0df7795eca_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-offs/Sales</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20210103.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39fd9af3-f4db-49f4-89ee-5d314b301bf4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, excluding goodwill</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_797b21a0-322b-4af8-9ab8-f34ebe592bb3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs incurred since announced</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_39a30636-d551-4ad4-8c4b-6182bf1f7f79_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(1)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler2Member_761797c4-4994-4a6b-b93f-4c66b47d6102_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_label_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member" xlink:href="jnj-20210103.xsd#jnj_Wholesaler2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler2Member" xlink:to="lab_jnj_Wholesaler2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_2274479d-949c-46ff-93c2-a2420bc1e82f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c01f2e51-6154-4313-9c0d-5ea858482a33_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d564bb0c-befc-4341-b860-3a9d6c8559d8_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_e3bfaaa6-1657-43c0-b2d3-7629729c10ed_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_edf620a5-a60f-4bf0-b4df-f6b41f0d1bc5_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20210103.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ae6a0b0f-3bae-49e4-8169-e5c88a765af8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4db7e4dd-c194-4373-b95a-1ea4c770b284_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost not yet recognized for option</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_af0a6b02-c4b6-4c9e-b6ba-d317e94bd5a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_1a1e162b-7ff0-4678-8de6-f60965e2cb90_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AMOMember_bc729230-f367-4614-97fe-3b4ae32907b2_terseLabel_en-US" xlink:label="lab_jnj_AMOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMO</link:label>
    <link:label id="lab_jnj_AMOMember_label_en-US" xlink:label="lab_jnj_AMOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMO [Member]</link:label>
    <link:label id="lab_jnj_AMOMember_documentation_en-US" xlink:label="lab_jnj_AMOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AMOMember" xlink:href="jnj-20210103.xsd#jnj_AMOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AMOMember" xlink:to="lab_jnj_AMOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_60ad0beb-9465-4976-8530-8f8105635a5c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_8f29c3aa-950f-4f47-9b52-84201004d4c6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_eddcb54f-7d84-4d9d-b52e-94c3e973c283_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_c9c1e513-0a98-4989-bef5-94b7b6cf1575_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), pension and other, effects of exchange rate net of tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">other comprehensive income loss, pension and other , effects of exchange rate net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_088ee95a-24dd-4863-8e16-91347a6ed2f1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be41052f-ab93-4e96-b681-746bfcd68080_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_d1bde067-f739-4cb8-aced-7a7eb62ed5b7_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures&#160;&amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_666b25a4-c258-4ceb-97a9-811278bd904a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bd1ff90e-41de-4ffd-b9c1-95efd8b4a1e4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_826c1e46-f175-4c03-8888-d1c1c0214559_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, measurement with unobservable inputs reconciliation, recurring basis, liability value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_61d9253c-d6ec-473d-a71d-b70b3ddfa76b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bbc5793e-9609-4cce-b65c-f38c3fd5211e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fe574e8f-be92-4610-9449-2d0e40833b2f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_b9d38f8e-edda-459f-82ee-696ac84ed219_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_6ab44795-462c-4b5a-a62d-af7ff801817a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_dad8ab8e-f17f-41fd-a25b-3e8c53b42089_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a8ec2abd-80bd-4d14-85e4-ccafe2d7baae_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1bce4006-7466-4fc1-9de2-f46895053deb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_377a4e7a-02a0-433b-b302-a1154016e190_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_aa4eb2ae-ad61-42ea-bd69-bf7ce2e2ced1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_c516a201-6826-4d15-99a1-2be2e757c802_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_15741813-29da-40c9-b79e-c7d995da3881_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8adbb6d-159e-4527-82f3-fa716fd5a52a_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_3b1370ba-6592-4ef5-9b5f-becfed322537_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_96696f57-ff48-4f6f-b3c1-cdafc6eeb8bf_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_250fb6fd-bc87-42b7-99c1-aee03a0410af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net operating loss carryforward international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f5421b0-cd15-4a49-b946-9bf74757068d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_62ca3e3e-7c5d-43f4-9700-a04947731910_terseLabel_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member" xlink:href="jnj-20210103.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.05Notesdue2023Member" xlink:to="lab_jnj_A2.05Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VELCADEMember_462e610d-ab8a-42f0-a38c-511ac580f5e8_terseLabel_en-US" xlink:label="lab_jnj_VELCADEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VELCADE</link:label>
    <link:label id="lab_jnj_VELCADEMember_label_en-US" xlink:label="lab_jnj_VELCADEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VELCADE [Member]</link:label>
    <link:label id="lab_jnj_VELCADEMember_documentation_en-US" xlink:label="lab_jnj_VELCADEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VELCADE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VELCADEMember" xlink:href="jnj-20210103.xsd#jnj_VELCADEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VELCADEMember" xlink:to="lab_jnj_VELCADEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_018ae556-45d6-4445-bb83-824628866d85_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:href="jnj-20210103.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:to="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_cec425e8-f77f-4c12-ae97-7521bbbbb961_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1779cda4-49e4-433e-a717-b5bfb5b1589d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6400d75a-0e6c-47e2-92a5-b5ddb0f7f8ce_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b8a63d9b-b6cd-4d20-90d0-8ae9e563372d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_794d6dd7-78a1-4111-b27b-378ba1ce9ef9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_fcab4101-1f81-4a44-a940-3f653d1be872_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sales by Segment of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20210103.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd5147c0-9b84-436c-a6f1-c9492fb952e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_59942aae-bea5-4817-921d-877ace037991_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_1c294259-4517-4bd7-ae3d-ab8cd8d3fac1_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_label_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Policy Text Block]</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:href="jnj-20210103.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:to="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_c7717992-fbad-4235-83fe-fc485086cd07_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20210103.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0823715a-a402-4c60-b3ae-35beb04ab2ba_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 8)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_d09bfb8e-c1ab-4297-ac3c-d6a98b387a2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_f7731d19-46d7-4da4-83cf-22ed93758b84_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, change in observable prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:href="jnj-20210103.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:to="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_76677153-a529-4533-bee3-a8bab208b4c6_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets other domestic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:to="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7dfa2c96-7a74-4ad5-8a31-feb90d51e8e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Disclosure Item Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8e54ccf4-7693-446f-9635-6b1aa59b4ebb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note&#160;18)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6fe9cfba-6335-46af-8114-7cf95cab9024_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition payments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_6d39fa5d-95fc-424e-aca3-0723053fc753_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_4778adf8-eccc-4789-a0b6-f620c38e1e22_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_10eb12b4-8866-4b11-9bae-fe6191354db9_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax effects</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_0a1a2fde-0930-46d6-9855-fed936fe3bef_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28cec22e-f071-4b8c-a53d-a77d496304e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_b165fd6a-e1e6-4bd2-9076-e9a44e400f77_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a0219492-6b33-4687-8b8e-d333f98965dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ef86310f-c779-49aa-8eed-519fa76553d2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_a1f0c16e-f886-4464-b251-546a28c39bde_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_f4857dd7-c114-405d-9c03-cd4548745b86_terseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b87c0fc6-1df2-4ad1-b51e-20e40f8d0ff2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1b5ac784-2529-4a44-a45e-9a3a1aa741c1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_70dc77ec-a1aa-4140-ac4b-b978441d1ba3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_a6ab81bc-0969-4a19-8dde-b4fab5104db8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_128c5fb3-ba46-488c-8f0f-4496d13dfc03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4bdcd30e-4f78-4341-b322-e81044ed923d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_93c8cb88-88ec-4325-a356-da87c75732c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_e7050b28-a0d9-4803-9743-68bb0e3e3b96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_3abd7d6a-30c5-4c84-ad57-d016b1545857_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability foreign taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_98948841-328c-4012-a00e-dd1e3ff1a9f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_a3618fde-36ed-4e58-80d4-a7fe20f7fe4a_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20210103.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_0aa2a5d2-3c47-42a4-af63-462394c0285a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 20)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_369e9982-9254-4d9a-b9d0-1b63f3365b41_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2012LongTermIncentivePlanMember_3c6206c8-7877-4b58-97cd-2ce7f75d8835_terseLabel_en-US" xlink:label="lab_jnj_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long-Term Incentive Plan</link:label>
    <link:label id="lab_jnj_A2012LongTermIncentivePlanMember_label_en-US" xlink:label="lab_jnj_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long-Term Incentive Plan [Member]</link:label>
    <link:label id="lab_jnj_A2012LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_jnj_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long-Term Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2012LongTermIncentivePlanMember" xlink:href="jnj-20210103.xsd#jnj_A2012LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2012LongTermIncentivePlanMember" xlink:to="lab_jnj_A2012LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_118bec3d-15ee-4cc6-95ba-991117390772_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20210103.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_d919720c-bbdf-45fe-bb5a-edcc617480a9_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of company's common stock to plan asset</link:label>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_label_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Company's Common Stock To Plan Asset</link:label>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_documentation_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the company's common stock to the total plan asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:href="jnj-20210103.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:to="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_74a87bf3-3e46-4868-8a86-c73c873e1717_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_55219acd-0f52-4539-a781-35021a512bb0_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20210103.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_388b8b90-828c-430a-8e3c-b89d0ce40869_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_3cad398d-4d78-49d6-b4ee-f65ea420500f_terseLabel_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Closing Date</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_label_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period [Policy Text Block]</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal period policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:href="jnj-20210103.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:to="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CommingledFundsMember_e9dd79cd-a18b-47fe-b429-f8d6ea2d5be0_terseLabel_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled funds</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_label_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled Funds [Member]</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_documentation_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember" xlink:href="jnj-20210103.xsd#jnj_CommingledFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CommingledFundsMember" xlink:to="lab_jnj_CommingledFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_e29ad970-0e37-4e5d-9b5d-9a241125bf1e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4eaff744-efac-4836-b51c-ca482a537a26_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_a33ffd6c-5e83-4368-bf09-2489392b3a4a_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Notes&#160;9 and 10)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1c679ea0-b725-429f-b65c-a220e797dc67_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations&#160;&#8212; non-current</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_64bed5be-6430-4575-a12d-e8c309e05b2a_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_5681dd99-68c4-4b5b-bf82-55ac08201f98_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_60c51d1a-6e82-463e-a31a-ba841e792e8a_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20210103.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_1c1925d8-8150-465b-aba8-f142d3eaec8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_40022fa6-d55a-43c0-a503-a9256029e7b0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_dd96d41d-ede2-47ba-b62b-89da9b3703cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_48289053-876a-45bb-8486-8b0119a73d59_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_0bf219f1-7bbd-474a-8a5a-f554ec302282_terseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20210103.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_eec48b65-9cb5-462a-b505-ceae9daf7fbd_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Notes&#160;1 and 3)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5b549b59-f240-4daa-be5d-36add74c5e85_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories (1)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_082707fd-bf92-4e73-a794-69ac437e6a86_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XO1Member_dde6f4f6-ba5b-4579-aacf-65a8c9326201_terseLabel_en-US" xlink:label="lab_jnj_XO1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XO1</link:label>
    <link:label id="lab_jnj_XO1Member_label_en-US" xlink:label="lab_jnj_XO1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XO1 [Member]</link:label>
    <link:label id="lab_jnj_XO1Member_documentation_en-US" xlink:label="lab_jnj_XO1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XO1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XO1Member" xlink:href="jnj-20210103.xsd#jnj_XO1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XO1Member" xlink:to="lab_jnj_XO1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5fb0b0be-e0d3-4d4e-bf35-7aa49931d65f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_120b9a7e-c928-422b-bf4e-284fd2b0504e_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_948019f1-897d-4501-860d-09ca0d2e56a1_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_003956bd-595c-4e06-a5b3-32cc51c6e8d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Severance Charges and Associated Spending</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_9aa9c94a-21ce-4413-a838-1134c4ff0902_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_843b35ef-074e-42bf-9422-47064ed0864f_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20210103.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e7ec5adf-985e-4c45-96ea-2baeb957db0c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_49dfff7a-3670-4ff2-8cbe-1e271c046fa1_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TJCA , provisional liability, non-current</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7107414-948b-466d-a1cb-5681fd022c1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_516ff5b9-d3f6-43b8-9736-00ae0098f3e9_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20210103.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7113004-8321-4348-8152-12d1e0f41a18_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_174c38ae-f262-4a41-a173-efee64861133_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_3aa86416-4385-44af-8069-df493b097f61_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_616f7211-e950-4164-b257-ffb91e45ba72_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_b10eb7f1-006d-4ad0-9a91-89f77996a47c_terseLabel_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_label_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees Engaged In Company Activities Worldwide</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_documentation_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees engaged in company activities worldwide.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:href="jnj-20210103.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:to="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_518a34eb-d245-4e82-8b14-be046c12e66d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_dc693329-c4bc-4dc0-bcab-0dd81d690913_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20210103.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e3ed99c1-7116-418c-8c5d-c0efd5692eb9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_efcbe1b6-d397-4aa5-a805-397ab19c9329_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65e1b88c-d003-4920-9af4-5dd75d8c1fec_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2093a655-2395-4032-9bf3-c4cd8dc9ca36_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5f55fdfe-270e-4a55-b05f-e698cbc6bae6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d580c265-614b-49c1-86d9-8e537592e3a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f0587eea-934d-4604-82a5-5770e02fc757_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_29d4eb34-ff62-4e65-8824-fd47b9f08e32_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20210103.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_fee5b2fe-643f-4191-8ab6-f66d4b726dab_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_1b52a4b6-2a4e-4c1e-8510-6aac12d6ea79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_1694050c-0f26-42d2-ae47-39fd5618e625_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1ac38d5c-0731-4875-af99-e59c98dfc7b0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations (1)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_4141a6f9-3c3c-453e-9664-479aab8b3370_terseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (Income) Expense</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20210103.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_8600f7b6-f167-4343-9622-f41636833a49_terseLabel_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for:</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract" xlink:href="jnj-20210103.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract" xlink:to="lab_jnj_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_6677fc7a-54ae-460b-9edc-fb44de26aabe_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Net Asset Value</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:to="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_5ae498fd-34b9-4662-a423-3ee3a1239af4_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, canceled/forfeited/adjusted</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:href="jnj-20210103.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AliosBiopharmaIncandXO1LimitedMember_600f3040-ee2c-4019-967e-837f96af4c28_terseLabel_en-US" xlink:label="lab_jnj_AliosBiopharmaIncandXO1LimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alios Biopharma Inc and XO1 Limited</link:label>
    <link:label id="lab_jnj_AliosBiopharmaIncandXO1LimitedMember_label_en-US" xlink:label="lab_jnj_AliosBiopharmaIncandXO1LimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alios Biopharma Inc and XO1 Limited [Member]</link:label>
    <link:label id="lab_jnj_AliosBiopharmaIncandXO1LimitedMember_documentation_en-US" xlink:label="lab_jnj_AliosBiopharmaIncandXO1LimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alios Biopharma Inc and XO1 Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AliosBiopharmaIncandXO1LimitedMember" xlink:href="jnj-20210103.xsd#jnj_AliosBiopharmaIncandXO1LimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AliosBiopharmaIncandXO1LimitedMember" xlink:to="lab_jnj_AliosBiopharmaIncandXO1LimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_141d5f42-6d9c-4f2f-8f9d-ecc7a926893f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0b23dc47-297c-4e5a-a67e-1ef243405b9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_402d2825-67fb-41a4-9079-6de513cf7a64_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_f5c4d425-0f5d-4e28-987e-69021fd78254_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20210103.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_0bc65cca-cd1d-4cbe-9266-343c6edd6244_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8c19870c-b8fd-4166-8046-67c2d9b17dde_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_QualifiedPlansMember_7737b96d-e4e6-441f-bc67-5e2038763186_terseLabel_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plans</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_label_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember" xlink:href="jnj-20210103.xsd#jnj_QualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_QualifiedPlansMember" xlink:to="lab_jnj_QualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_49c71f4f-fbad-4841-83e3-55d7c9645342_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_dc91ac7a-a087-4207-ae05-5dab9bdb4b8b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_00f62bf4-3146-47ac-879e-9491de080621_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccountingStandardUpdate201616Member_61e62547-47de-4590-bbf1-dbb315ac5c4a_terseLabel_en-US" xlink:label="lab_jnj_AccountingStandardUpdate201616Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-16 - Income Taxes: Intra-Entity Transfers</link:label>
    <link:label id="lab_jnj_AccountingStandardUpdate201616Member_label_en-US" xlink:label="lab_jnj_AccountingStandardUpdate201616Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standard Update 2016-16 [Member]</link:label>
    <link:label id="lab_jnj_AccountingStandardUpdate201616Member_documentation_en-US" xlink:label="lab_jnj_AccountingStandardUpdate201616Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standard Update 2016-16</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccountingStandardUpdate201616Member" xlink:href="jnj-20210103.xsd#jnj_AccountingStandardUpdate201616Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccountingStandardUpdate201616Member" xlink:to="lab_jnj_AccountingStandardUpdate201616Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0e5c883a-d52f-482e-9829-321ba388ff09_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6084c028-e865-4bbf-9a6c-a1f669b074c5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_776c3727-2008-40ad-90b6-d76331d1eddc_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanAbstract_2da8640d-39bd-4245-9715-7937241c0367_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_label_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_documentation_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract" xlink:href="jnj-20210103.xsd#jnj_SavingsPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanAbstract" xlink:to="lab_jnj_SavingsPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_5e631330-2049-4218-9fb2-0a7554f0e963_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95%&#160;Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20210103.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_dfc138d9-eeb3-41bc-9d9a-0bfe4ea20ec7_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_ebbfff36-ba5f-46f7-8322-d6686c374d18_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8eda01fa-b291-4546-b0fd-f8aaa8b370a2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(Decrease) in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_de0102fd-14bd-4fa0-805b-166f64b202d1_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ccd799ca-1950-42d9-9853-f118fd7ae570_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_32f59d8a-f729-446f-85cf-d4bab3b55dbc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ee506e90-df67-4911-a6fc-9a3acbe47f3b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_ce27af41-5d75-4a36-ba82-62136ace90db_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2021Member_0fe23599-28aa-41ad-bef7-6511c4728ae9_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2021</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2021Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2021 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2021Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2021Member" xlink:href="jnj-20210103.xsd#jnj_A3.55Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2021Member" xlink:to="lab_jnj_A3.55Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_5f5882d3-c028-4c06-9d60-f6f3de7d6881_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PROCRITEPREXMember_ddb9893a-7984-41ad-b7d9-823fd26177f2_terseLabel_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_label_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_documentation_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember" xlink:href="jnj-20210103.xsd#jnj_PROCRITEPREXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PROCRITEPREXMember" xlink:to="lab_jnj_PROCRITEPREXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3079b51b-692b-4c0f-87f4-fc093e1d4932_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_efbcc885-9aba-49a6-a06d-e42a240af6a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_f89a972e-f248-41b5-8813-e4eebe789b73_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedging transaction exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_4da7b89b-6753-4915-b41f-b1e96f61dda2_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20210103.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_f14fbead-1c93-4326-bce8-4a95efd0b101_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_7c948a9d-230c-4988-8f6c-ea75fa900558_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_71672839-a2f8-4b00-9d1b-785436169c92_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_615486b2-2293-41a4-a795-b07349741721_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20210103.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_d494bc4e-07dd-4c9f-9d5b-101db816f831_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TJCA, foreign tax credit percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_844edb5f-ec0e-4c97-aea2-f716c91587d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/ (Loss) On Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d35a9773-c22b-4e87-9509-64fdd5e7d21c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0f8e1974-f769-4018-b8c9-90454144c7b9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d1f48a63-cd93-40ee-815d-928fe9544146_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest, net of amount capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_4da2cceb-e345-4e00-9b9e-aaa5dbad852e_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20210103.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_77d8e993-6839-44ad-bd4d-640fab0de7a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_e9bb9f92-c463-48bf-b9de-b368626edf5e_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20210103.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ecaa369f-98dc-4560-81a5-76cb03a47daa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_0c2b169b-e11a-4d05-a118-7b519b332ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_52a4e548-4800-4080-9e91-4113ce8b56f6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6952f227-86db-4d3c-831d-eb96e8273bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_9f6680d2-efa2-41b1-8a8f-ca9783cc0ea2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ed888bca-838a-4967-8d74-e38ce2a84163_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f88e48c8-d8f2-4ffa-9a51-a18a3ae8a7d6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61641c1f-4325-410a-a30c-785f5e982364_terseLabel_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_label_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:href="jnj-20210103.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:to="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MomentaMember_663d314d-f4b5-43a7-a5f8-f53edde48fcb_terseLabel_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta</link:label>
    <link:label id="lab_jnj_MomentaMember_label_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta [Member]</link:label>
    <link:label id="lab_jnj_MomentaMember_documentation_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember" xlink:href="jnj-20210103.xsd#jnj_MomentaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MomentaMember" xlink:to="lab_jnj_MomentaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7185dd5c-459e-4de2-a946-33e36b152d49_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d86a2042-86ff-43be-abce-ca11dbbe609d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_47e49a9f-e9a2-4eae-96cd-64ae0c7b89f6_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_fd531300-cbb2-46a0-a0ea-698fe64dedef_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_a26bc67c-3874-425b-a83a-86cdddf4b7e3_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20210103.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_03b3db1b-979d-42a5-8363-94d204ce5f26_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20210103.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_5f3284ac-3d54-4f63-806e-75647383d751_terseLabel_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_label_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_documentation_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison of income tax expense at the Statutory rate and Company's tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:href="jnj-20210103.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:to="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_4a400d48-85f0-4349-b7d5-8d27111d2230_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't Securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_bb86f1c5-24c4-405c-acd3-7b8ae45421f3_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20210103.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_ae143673-f422-41f8-876c-03c687ce7647_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20210103.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_5241ca28-3e55-4efb-bb11-b04ab7d19ffd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains) losses(2)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a8793793-8ef6-4802-bcf3-0ae1e06b9828_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life of acquired intangibles</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_018edad1-9a0b-4dfa-a385-f3f0ac942be9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_7279433d-d3dc-4066-b838-c3b2fd18ac99_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20210103.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_0104059b-b3a9-4168-b54a-7afd220d5a3a_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, expected future savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20210103.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8095f30c-462e-4730-be20-10915e0920b0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6a55cd10-1188-4abf-83a4-e702f4354e91_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ef948b2b-de9e-4eaa-bde3-7680c55d6d69_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>jnj-20210103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:339fd7d9-9316-40d7-9d71-ee9342a8b33f,g:975259c4-ea12-43d4-8326-a0d386e906b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20210103.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1778bb9d-d7bd-46af-93c0-b7a83388c915" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1778bb9d-d7bd-46af-93c0-b7a83388c915" xlink:to="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ac46d9e9-0b70-4e0a-aba1-748ac1a5205d" xlink:to="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d28fa499-5555-4abe-bdf6-03dbdec81a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_us-gaap_CommonStockMember_d28fa499-5555-4abe-bdf6-03dbdec81a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_ed28b77a-0de7-44f1-b19a-7ffcc9658ef4" xlink:href="jnj-20210103.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A0.250NotesDue2022Member_ed28b77a-0de7-44f1-b19a-7ffcc9658ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_49f738d8-d00d-46f5-98ab-10e6c0d2df10" xlink:href="jnj-20210103.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A0.650NotesDue2024Member_49f738d8-d00d-46f5-98ab-10e6c0d2df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_6a795717-7aea-499f-b0d4-895c660106dc" xlink:href="jnj-20210103.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A5.50NotesDue2024Member_6a795717-7aea-499f-b0d4-895c660106dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_daca5bf2-0840-47ba-9056-2020707290bf" xlink:href="jnj-20210103.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A1.150NotesDue2028Member_daca5bf2-0840-47ba-9056-2020707290bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_51d885c2-af86-4b10-885d-fae3ae63c8ae" xlink:href="jnj-20210103.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73642712-5a2b-42b9-bb52-7951d037f332" xlink:to="loc_jnj_A1.650NotesDue2035Member_51d885c2-af86-4b10-885d-fae3ae63c8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_27af6ec2-7fa2-43e5-a907-7d3377c36114" xlink:to="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_48a50673-90aa-4b2c-83cf-ba4c52f1b3c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentType_48a50673-90aa-4b2c-83cf-ba4c52f1b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4efe58b3-1b25-4276-9d4b-b4c47457a84d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentAnnualReport_4efe58b3-1b25-4276-9d4b-b4c47457a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_81de251a-cc7d-44d2-95bd-7e4cef2a4120" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentPeriodEndDate_81de251a-cc7d-44d2-95bd-7e4cef2a4120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4aa54829-7a16-46c9-9b83-15001c9bef19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentTransitionReport_4aa54829-7a16-46c9-9b83-15001c9bef19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9675963d-ebe7-4ce8-926e-f83f54b76249" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityFileNumber_9675963d-ebe7-4ce8-926e-f83f54b76249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b2da2dbb-4e2d-4459-ba77-71b0a1fcff3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityRegistrantName_b2da2dbb-4e2d-4459-ba77-71b0a1fcff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9e02f1a4-627a-40b6-aaf5-10ab2824c1d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9e02f1a4-627a-40b6-aaf5-10ab2824c1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_963f1259-7707-427c-b673-dbc4c98f503d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityTaxIdentificationNumber_963f1259-7707-427c-b673-dbc4c98f503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6594c5d5-0e3a-46b5-be9b-c4a41995962d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressAddressLine1_6594c5d5-0e3a-46b5-be9b-c4a41995962d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_54dbb984-abbc-4b70-8683-dabd6224f574" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressCityOrTown_54dbb984-abbc-4b70-8683-dabd6224f574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c3170f3b-e177-4dc7-a3f1-f8be57728a39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressStateOrProvince_c3170f3b-e177-4dc7-a3f1-f8be57728a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e5278907-c416-481d-bc25-690f9f5abe95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityAddressPostalZipCode_e5278907-c416-481d-bc25-690f9f5abe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b22548d6-9797-4969-ac21-4277ab2d5641" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_CityAreaCode_b22548d6-9797-4969-ac21-4277ab2d5641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3395d4a6-2f95-480b-9cf8-7da04f4507e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_LocalPhoneNumber_3395d4a6-2f95-480b-9cf8-7da04f4507e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_495b5ab7-17bb-4237-aa14-99e114d5e472" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_Security12bTitle_495b5ab7-17bb-4237-aa14-99e114d5e472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_55890e16-2b69-4ad6-9365-a6afa9a98e13" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_TradingSymbol_55890e16-2b69-4ad6-9365-a6afa9a98e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ef8d70ec-73a1-4b36-abe2-d37541b8d990" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_SecurityExchangeName_ef8d70ec-73a1-4b36-abe2-d37541b8d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e89fcb90-a6ea-42ae-917b-05fab217d1a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e89fcb90-a6ea-42ae-917b-05fab217d1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7d8b1671-31ee-4d63-98dc-9648c71eaf21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityVoluntaryFilers_7d8b1671-31ee-4d63-98dc-9648c71eaf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b5020f97-7504-4f59-ad4a-e1c0c3c0134d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityCurrentReportingStatus_b5020f97-7504-4f59-ad4a-e1c0c3c0134d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_00a84bc2-1dde-43d2-ad69-5a3896e6e4cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityInteractiveDataCurrent_00a84bc2-1dde-43d2-ad69-5a3896e6e4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_88465712-b107-43e7-8faa-b86a7e9fb32c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityFilerCategory_88465712-b107-43e7-8faa-b86a7e9fb32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0b803d9e-3eeb-4e2d-b714-2f5e6fa476e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityEmergingGrowthCompany_0b803d9e-3eeb-4e2d-b714-2f5e6fa476e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a7ed84d2-4548-45f2-a0a4-86d3a79266e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntitySmallBusiness_a7ed84d2-4548-45f2-a0a4-86d3a79266e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8d16b2da-b9ac-496d-b0c3-b74bc9df4d78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8d16b2da-b9ac-496d-b0c3-b74bc9df4d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_874f0b5b-93ec-4e0b-9d8b-a6138dc0ea7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityShellCompany_874f0b5b-93ec-4e0b-9d8b-a6138dc0ea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_af0f727e-8783-4917-bbe0-4618bfd0f663" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityPublicFloat_af0f727e-8783-4917-bbe0-4618bfd0f663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fb561139-dcf3-43f1-a4c9-8dc54eaf7cc9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fb561139-dcf3-43f1-a4c9-8dc54eaf7cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_00702457-b9ad-4a50-b464-ea44f36e6016" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_EntityCentralIndexKey_00702457-b9ad-4a50-b464-ea44f36e6016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_feff0579-c353-49c8-8b96-789d76d1333f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_CurrentFiscalYearEndDate_feff0579-c353-49c8-8b96-789d76d1333f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_de3380dd-de2a-45fc-8f83-9e023a750e73" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentFiscalYearFocus_de3380dd-de2a-45fc-8f83-9e023a750e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8a9c7b9a-a357-480c-89c0-e61a55f3175b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8a9c7b9a-a357-480c-89c0-e61a55f3175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e61db2f9-086c-4796-924c-068c1008042f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_00b4b3c8-ca93-4093-937a-ad0fd12df91c" xlink:to="loc_dei_AmendmentFlag_e61db2f9-086c-4796-924c-068c1008042f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:to="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_366148ca-dc8e-41f4-b415-fb095360e5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_366148ca-dc8e-41f4-b415-fb095360e5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_23821d8d-7353-40c9-9056-1195f2e73c47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_23821d8d-7353-40c9-9056-1195f2e73c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3b49ca42-50a0-4b34-83ce-fd9b6c8ef53f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3b49ca42-50a0-4b34-83ce-fd9b6c8ef53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_235e4b92-ed03-4edd-b8d3-e65be23ad4f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_InventoryNet_235e4b92-ed03-4edd-b8d3-e65be23ad4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5f3f2aaa-0a1c-4262-8cec-cd3731ef71ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5f3f2aaa-0a1c-4262-8cec-cd3731ef71ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther_628f1ca4-54db-44b3-844d-4580362c0195" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther_628f1ca4-54db-44b3-844d-4580362c0195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_70278eae-6606-476e-b2af-7e8a020a5978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e637379e-2e79-42fc-a47b-b40157122ab9" xlink:to="loc_us-gaap_AssetsCurrent_70278eae-6606-476e-b2af-7e8a020a5978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_00c577e9-b8c2-486b-abea-dbc6f8657e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_00c577e9-b8c2-486b-abea-dbc6f8657e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7546cd09-3e16-46c3-abab-68590b8f09cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7546cd09-3e16-46c3-abab-68590b8f09cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_03318a22-dba8-4912-9f00-e0dadda2aa21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_Goodwill_03318a22-dba8-4912-9f00-e0dadda2aa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae24b079-a89c-40f4-a3f1-d8ff7abcb91c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae24b079-a89c-40f4-a3f1-d8ff7abcb91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b4baf7c2-5a6d-46a7-982a-173903d8468d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b4baf7c2-5a6d-46a7-982a-173903d8468d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a4cad551-3644-4f3c-91dd-d22d1ad48a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50b59700-79cd-44a6-a41d-48006e01b004" xlink:to="loc_us-gaap_Assets_a4cad551-3644-4f3c-91dd-d22d1ad48a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_02eb9756-5996-4734-a663-eaf2d3ec0833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_us-gaap_ShortTermBorrowings_02eb9756-5996-4734-a663-eaf2d3ec0833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_77a1a222-8dfa-4224-aabd-c38b6594793b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_us-gaap_AccountsPayableCurrent_77a1a222-8dfa-4224-aabd-c38b6594793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_894f5185-506e-416a-8d8d-4b625185b8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_894f5185-506e-416a-8d8d-4b625185b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_1f969dcd-ca21-444e-b14e-ba4d157dc5b6" xlink:href="jnj-20210103.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_1f969dcd-ca21-444e-b14e-ba4d157dc5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4a8a965f-f4ba-49a4-872c-9351a08fd03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4a8a965f-f4ba-49a4-872c-9351a08fd03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_23c85c9c-9c2b-4a50-8743-a8e3c2c15a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_23c85c9c-9c2b-4a50-8743-a8e3c2c15a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1bfa958c-04cb-409b-b120-f5bc99b8d693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_efbd4e7c-4388-499c-a58b-e5b9dc71ddd4" xlink:to="loc_us-gaap_LiabilitiesCurrent_1bfa958c-04cb-409b-b120-f5bc99b8d693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4fe8c91c-5fe0-4c4f-8c48-61a24f7af226" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4fe8c91c-5fe0-4c4f-8c48-61a24f7af226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a72e64e-eb39-4ab4-b96a-81d0786643db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a72e64e-eb39-4ab4-b96a-81d0786643db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_caad4ca7-e1ce-43d5-ab4d-2d720c432cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_caad4ca7-e1ce-43d5-ab4d-2d720c432cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fc42c86a-902f-4445-84b0-9f05c7bf2292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fc42c86a-902f-4445-84b0-9f05c7bf2292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2ef934fd-8dd3-43cd-8f15-12ac520c98b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2ef934fd-8dd3-43cd-8f15-12ac520c98b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_21020136-c020-413a-bf62-f224d0ddba57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_Liabilities_21020136-c020-413a-bf62-f224d0ddba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_80da2036-a7f3-4768-bcfb-4d5d32a3c3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_PreferredStockValue_80da2036-a7f3-4768-bcfb-4d5d32a3c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_da500a61-2e9b-481b-ab4d-0ecf093c051f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_CommonStockValue_da500a61-2e9b-481b-ab4d-0ecf093c051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68327b46-c1ea-4e9c-bd50-1312c3a0253d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68327b46-c1ea-4e9c-bd50-1312c3a0253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1f5051c-645e-409d-83a9-278b468e4c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1f5051c-645e-409d-83a9-278b468e4c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ba2b8a7f-30a7-4ed6-ac24-5b2c8d2ce115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ba2b8a7f-30a7-4ed6-ac24-5b2c8d2ce115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_cf51f865-5d25-4ecd-b962-efdbbbc283dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_TreasuryStockValue_cf51f865-5d25-4ecd-b962-efdbbbc283dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a2f6626-22be-4297-b186-802706a58fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_02ead6d7-b5de-412a-8049-256a5f1f535c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a2f6626-22be-4297-b186-802706a58fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28fcb42d-c49d-4e24-b889-4e8e8c62201e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf9ee89f-95d1-4632-a7ca-a887ac1b014a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_28fcb42d-c49d-4e24-b889-4e8e8c62201e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0b451344-9eaa-450c-af91-cbfa5ee829ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0b451344-9eaa-450c-af91-cbfa5ee829ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b2a4afa0-dade-42f8-ac7c-048ddb1488c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b2a4afa0-dade-42f8-ac7c-048ddb1488c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_af7f83a0-08d9-4616-a52a-e664ef8e5a18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_af7f83a0-08d9-4616-a52a-e664ef8e5a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_39559b4c-1659-4389-a02c-6045703ee705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd547871-28c8-4641-b9fe-69e62c77f1ae" xlink:to="loc_us-gaap_CommonStockSharesIssued_39559b4c-1659-4389-a02c-6045703ee705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8bb26fdc-7e70-44ca-b812-95a4a9b90f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0b973a40-5a7a-4f09-af38-f2b74a9d9b18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8bb26fdc-7e70-44ca-b812-95a4a9b90f9f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0b973a40-5a7a-4f09-af38-f2b74a9d9b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_41b51d6c-c60a-48e0-8a0c-9e60e6e4a527" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b973a40-5a7a-4f09-af38-f2b74a9d9b18" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_41b51d6c-c60a-48e0-8a0c-9e60e6e4a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8bb26fdc-7e70-44ca-b812-95a4a9b90f9f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0151e37f-0880-458b-8a5b-3023182426d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0151e37f-0880-458b-8a5b-3023182426d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b39cc04b-2e40-4db0-983d-ecec800dcbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b39cc04b-2e40-4db0-983d-ecec800dcbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_326ad922-3f3a-46bf-9574-9ac922135713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_326ad922-3f3a-46bf-9574-9ac922135713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1c8328ff-e16d-43cb-83e4-9f2e3831fd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:to="loc_us-gaap_CommonStockSharesIssued_1c8328ff-e16d-43cb-83e4-9f2e3831fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_3c934702-e06f-4eb2-a7e0-9b2fd12395fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3bb87ee0-1587-42d8-921c-e8e3056c9a81" xlink:to="loc_us-gaap_TreasuryStockShares_3c934702-e06f-4eb2-a7e0-9b2fd12395fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ffe426b9-ed70-4161-be1a-2a0dfd10b6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ffe426b9-ed70-4161-be1a-2a0dfd10b6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5b4f6cf1-6b68-4803-93f5-645f9fae04fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5b4f6cf1-6b68-4803-93f5-645f9fae04fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_399ee13d-a210-4315-8e7b-352fd14fa75a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_GrossProfit_399ee13d-a210-4315-8e7b-352fd14fa75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b13524c2-741f-4bc9-9450-ae3f954e8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b13524c2-741f-4bc9-9450-ae3f954e8acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a391ef2f-c32c-4748-9193-5a9a3475fc67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a391ef2f-c32c-4748-9193-5a9a3475fc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6ca29c76-e4e9-40be-85e0-fa004811a4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6ca29c76-e4e9-40be-85e0-fa004811a4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_20fd3020-9967-409e-b29a-4ccd3de59c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_20fd3020-9967-409e-b29a-4ccd3de59c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9649ca1-032f-4c8f-a126-b5a0210df49a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_InterestExpense_b9649ca1-032f-4c8f-a126-b5a0210df49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7814b6eb-c4b8-466c-926c-bf7d9095d451" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7814b6eb-c4b8-466c-926c-bf7d9095d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_66f9fc99-d32a-422e-989f-f8838034d5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_RestructuringCharges_66f9fc99-d32a-422e-989f-f8838034d5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_30a2a007-7d09-4a4f-b56f-cc330c259076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_30a2a007-7d09-4a4f-b56f-cc330c259076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0dce0c61-e2e9-4c58-a481-ef515dfe011b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0dce0c61-e2e9-4c58-a481-ef515dfe011b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_09bf9771-1ff4-497e-8ff1-730de35bd0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_NetIncomeLoss_09bf9771-1ff4-497e-8ff1-730de35bd0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_14ba39a3-0afa-4aa4-bb80-5336c3c1a529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_14ba39a3-0afa-4aa4-bb80-5336c3c1a529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_df5467a7-6a7e-42b7-8b0e-3b67dc8ead81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14ba39a3-0afa-4aa4-bb80-5336c3c1a529" xlink:to="loc_us-gaap_EarningsPerShareBasic_df5467a7-6a7e-42b7-8b0e-3b67dc8ead81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_da0b34c2-4e89-413e-9bfc-ad366e62b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14ba39a3-0afa-4aa4-bb80-5336c3c1a529" xlink:to="loc_us-gaap_EarningsPerShareDiluted_da0b34c2-4e89-413e-9bfc-ad366e62b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_01a97069-c940-4a34-b7d7-6cfe135e1e43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4b950f0-5260-44ec-a06e-74a39fe0a67c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_01a97069-c940-4a34-b7d7-6cfe135e1e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f5d4365-e857-423d-b711-0f43e17f89b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_01a97069-c940-4a34-b7d7-6cfe135e1e43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f5d4365-e857-423d-b711-0f43e17f89b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0c860d8a-064c-4f59-92ad-52f8c270c421" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_01a97069-c940-4a34-b7d7-6cfe135e1e43" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0c860d8a-064c-4f59-92ad-52f8c270c421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d84bd19-a321-4916-b9ad-405e64f849ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14ce088e-f80c-45da-a03d-8bdc133ba7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d84bd19-a321-4916-b9ad-405e64f849ff" xlink:to="loc_us-gaap_NetIncomeLoss_14ce088e-f80c-45da-a03d-8bdc133ba7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_57d9e98a-6a8a-47b3-88d2-8112fbcf5498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d84bd19-a321-4916-b9ad-405e64f849ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_57d9e98a-6a8a-47b3-88d2-8112fbcf5498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_f8e676f1-af94-4722-a8dd-64d5f2427e33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_57d9e98a-6a8a-47b3-88d2-8112fbcf5498" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_f8e676f1-af94-4722-a8dd-64d5f2427e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_abe85211-da4d-4efb-8c50-915fcbc7c046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_57d9e98a-6a8a-47b3-88d2-8112fbcf5498" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_abe85211-da4d-4efb-8c50-915fcbc7c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_818b8683-4787-43b8-a3a0-1f3c9e9d784d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_abe85211-da4d-4efb-8c50-915fcbc7c046" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_818b8683-4787-43b8-a3a0-1f3c9e9d784d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c1cd3ef9-54df-4782-b47b-c37bf0c08b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_abe85211-da4d-4efb-8c50-915fcbc7c046" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c1cd3ef9-54df-4782-b47b-c37bf0c08b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_11fdc14b-33e7-4c45-b9f8-3a88cba11888" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_abe85211-da4d-4efb-8c50-915fcbc7c046" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_11fdc14b-33e7-4c45-b9f8-3a88cba11888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_20eae43f-8205-4f58-b4a3-6cf01ff09498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_57d9e98a-6a8a-47b3-88d2-8112fbcf5498" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_20eae43f-8205-4f58-b4a3-6cf01ff09498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_1ac17dca-0ae6-488b-ba54-739d077ad568" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_20eae43f-8205-4f58-b4a3-6cf01ff09498" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_1ac17dca-0ae6-488b-ba54-739d077ad568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_247a7789-02e6-4b9a-9154-fdc598204405" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_20eae43f-8205-4f58-b4a3-6cf01ff09498" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_247a7789-02e6-4b9a-9154-fdc598204405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_2b0fd017-2488-47d9-b5dd-5e40e967c6fa" xlink:href="jnj-20210103.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_20eae43f-8205-4f58-b4a3-6cf01ff09498" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_2b0fd017-2488-47d9-b5dd-5e40e967c6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ab529f11-4679-40ac-aec4-1c5d56b22462" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_20eae43f-8205-4f58-b4a3-6cf01ff09498" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ab529f11-4679-40ac-aec4-1c5d56b22462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_642d4caa-c55c-43d2-a7f8-0ab5bba0b388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_57d9e98a-6a8a-47b3-88d2-8112fbcf5498" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_642d4caa-c55c-43d2-a7f8-0ab5bba0b388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_533ed44c-500f-4fc9-96e5-bcc0ebace3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_642d4caa-c55c-43d2-a7f8-0ab5bba0b388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_533ed44c-500f-4fc9-96e5-bcc0ebace3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_402dc3f3-6428-4364-ac12-df2d7a0417ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_642d4caa-c55c-43d2-a7f8-0ab5bba0b388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_402dc3f3-6428-4364-ac12-df2d7a0417ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f2dbd4e4-78e9-4407-b320-b0ba7e58b419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_642d4caa-c55c-43d2-a7f8-0ab5bba0b388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f2dbd4e4-78e9-4407-b320-b0ba7e58b419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c8731f9d-31cc-4f61-93ab-9d34ac7191f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d84bd19-a321-4916-b9ad-405e64f849ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c8731f9d-31cc-4f61-93ab-9d34ac7191f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9898341a-a5f6-48f0-a4bd-1a139744e349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d84bd19-a321-4916-b9ad-405e64f849ff" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9898341a-a5f6-48f0-a4bd-1a139744e349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9012ef49-477e-4d43-8290-545f79fdc2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e6a02994-098f-4a91-a9d0-d50490009708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9012ef49-477e-4d43-8290-545f79fdc2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e6a02994-098f-4a91-a9d0-d50490009708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_079e4545-e54f-4f9c-afa0-1d67628c7c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9012ef49-477e-4d43-8290-545f79fdc2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_079e4545-e54f-4f9c-afa0-1d67628c7c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_e41f203d-9503-4366-bbdb-fb7fe969486f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9012ef49-477e-4d43-8290-545f79fdc2e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_e41f203d-9503-4366-bbdb-fb7fe969486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8c476bd9-6497-4544-bc87-d4fc01095c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8c476bd9-6497-4544-bc87-d4fc01095c6e" xlink:to="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd825379-6028-4c5b-aa6d-9ac16fe44048" xlink:to="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fc99bbb4-3d3a-4ea8-b2e5-e2d1178f8b59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_RetainedEarningsMember_fc99bbb4-3d3a-4ea8-b2e5-e2d1178f8b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_92058b92-9148-42ca-9902-ebd44da907a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_92058b92-9148-42ca-9902-ebd44da907a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a336558b-36c3-4be8-8efd-722616182c81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_CommonStockMember_a336558b-36c3-4be8-8efd-722616182c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b026590-f959-49a4-b79f-6fbb2599853c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09bf5810-c3b4-427d-a3b0-7e809cd8e52a" xlink:to="loc_us-gaap_TreasuryStockMember_2b026590-f959-49a4-b79f-6fbb2599853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_6e85c3fb-04d7-4381-8cc0-c6ae95ada5f0" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_427ed249-44c7-4912-a2ae-38fc2b61a5cf" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_6e85c3fb-04d7-4381-8cc0-c6ae95ada5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_64b4d11b-cd57-460b-a780-d389b1ff38f3" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_6e85c3fb-04d7-4381-8cc0-c6ae95ada5f0" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_64b4d11b-cd57-460b-a780-d389b1ff38f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_859a6922-0927-4a48-b6b4-79c5d6f45d55" xlink:to="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ef885f4-6eae-4183-aa48-cb54c84965e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8ef885f4-6eae-4183-aa48-cb54c84965e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d47eab1f-f79e-4dc9-9dda-197d9180d392" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_NetIncomeLoss_d47eab1f-f79e-4dc9-9dda-197d9180d392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_88665fe3-5144-43d7-9bca-f7deb574501a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_DividendsCommonStockCash_88665fe3-5144-43d7-9bca-f7deb574501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_769299f3-1292-4bda-8bd9-41d5a6d4eaba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_769299f3-1292-4bda-8bd9-41d5a6d4eaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5fb7fa2b-cee1-4865-aba4-6b3b59be3999" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5fb7fa2b-cee1-4865-aba4-6b3b59be3999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_adbf1edf-4ce6-437e-b35d-55c2aef00b08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_StockholdersEquityOther_adbf1edf-4ce6-437e-b35d-55c2aef00b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5701fbf7-0473-4a14-8755-527105093abe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5701fbf7-0473-4a14-8755-527105093abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8e73c6c-6697-4bc2-85c2-42d6307ba2df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a441f0dc-3f1d-4238-8ae9-212ce22c6aae" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8e73c6c-6697-4bc2-85c2-42d6307ba2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d95e844b-bbf1-4902-a489-5ad718fc1c20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1b58769e-f518-49a0-8295-f6ee1362ec65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d95e844b-bbf1-4902-a489-5ad718fc1c20" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1b58769e-f518-49a0-8295-f6ee1362ec65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20210103.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d29135f1-f4e7-4fe6-919c-1725fa88e6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d29135f1-f4e7-4fe6-919c-1725fa88e6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_013ccf36-e25e-45dc-a342-d6856c356354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d29135f1-f4e7-4fe6-919c-1725fa88e6ee" xlink:to="loc_us-gaap_NetIncomeLoss_013ccf36-e25e-45dc-a342-d6856c356354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d29135f1-f4e7-4fe6-919c-1725fa88e6ee" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_64f2ceba-0c0c-4789-b75d-b7e66aae9580" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_64f2ceba-0c0c-4789-b75d-b7e66aae9580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d16d01f0-5bcd-4724-97a6-80be1fc4e830" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_ShareBasedCompensation_d16d01f0-5bcd-4724-97a6-80be1fc4e830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_589af4c5-7b34-4d66-a43a-0e63f574d43b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_AssetImpairmentCharges_589af4c5-7b34-4d66-a43a-0e63f574d43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f0410ef0-ff24-43ca-8aa7-da9b031885be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f0410ef0-ff24-43ca-8aa7-da9b031885be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_18486dfc-850d-4fb6-bc09-721755dc3dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_18486dfc-850d-4fb6-bc09-721755dc3dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d2011dfb-6616-4cc7-ba95-27a9dc60fe8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d2011dfb-6616-4cc7-ba95-27a9dc60fe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_324647ca-3f15-49c1-9f5d-4694b9b61fed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6ad289d-e928-4615-aa4c-22ccfdc6634a" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_324647ca-3f15-49c1-9f5d-4694b9b61fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d29135f1-f4e7-4fe6-919c-1725fa88e6ee" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6efa575a-7006-4455-8083-1463f46a221f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6efa575a-7006-4455-8083-1463f46a221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a34682ab-6e82-4663-9ecd-4f7b18b0b772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a34682ab-6e82-4663-9ecd-4f7b18b0b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fc80474c-8ca4-4d3a-977a-dc0eabf4bcc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fc80474c-8ca4-4d3a-977a-dc0eabf4bcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aa081dba-e1a6-4503-8149-9c62ac77558c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aa081dba-e1a6-4503-8149-9c62ac77558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_df017199-30fa-4be0-bb71-7f6ca1451810" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_df017199-30fa-4be0-bb71-7f6ca1451810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59e69ece-0456-4396-82d1-e2695f6cc8e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5d53ae4-1bcd-4bad-aaf9-8738b2760a64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59e69ece-0456-4396-82d1-e2695f6cc8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a17b4afc-d3af-408d-8ec6-f8a3e90154e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a17b4afc-d3af-408d-8ec6-f8a3e90154e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_36cc55e8-524c-4d94-a38e-9f8374b8f336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_36cc55e8-524c-4d94-a38e-9f8374b8f336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6102d98f-8089-4896-8784-01000df9f6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6102d98f-8089-4896-8784-01000df9f6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4f367c5c-0973-4483-b998-6ce2bc72591c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4f367c5c-0973-4483-b998-6ce2bc72591c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c1649ab5-8a14-4522-9e68-cde1bc45cdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c1649ab5-8a14-4522-9e68-cde1bc45cdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_75764b3d-9b30-47a6-aa8e-b1492c87b77f" xlink:href="jnj-20210103.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_75764b3d-9b30-47a6-aa8e-b1492c87b77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_736aac31-74ae-41a3-b0cc-18dd96c84d00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_736aac31-74ae-41a3-b0cc-18dd96c84d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79746c0a-6cf6-469a-866c-bcd25ed12fff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6b66f1bc-7f5c-494a-a52b-f5ccf1a805d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79746c0a-6cf6-469a-866c-bcd25ed12fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_7d17cd00-81a1-4feb-ab14-c8076de8330b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_7d17cd00-81a1-4feb-ab14-c8076de8330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b1a48bac-ccc7-4fda-ae1e-e57e2bbcbdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b1a48bac-ccc7-4fda-ae1e-e57e2bbcbdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_bbabccc4-7299-4635-bb28-84e0610795c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_bbabccc4-7299-4635-bb28-84e0610795c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5dbeb5ca-feea-40c5-a3d0-e33f4d60d457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_5dbeb5ca-feea-40c5-a3d0-e33f4d60d457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_24c84920-427c-4518-9e6f-b955ae4be8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_24c84920-427c-4518-9e6f-b955ae4be8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cde3ff99-9663-429e-a708-6b50f5d679c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cde3ff99-9663-429e-a708-6b50f5d679c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_fe11db03-5e40-4a1e-a5f6-5f058e542cd4" xlink:href="jnj-20210103.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_fe11db03-5e40-4a1e-a5f6-5f058e542cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3b97563c-4d7f-4fd4-99a4-d5e8fe4ac6f5" xlink:href="jnj-20210103.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3b97563c-4d7f-4fd4-99a4-d5e8fe4ac6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cb8360c1-8f91-4b1a-983c-e213e20b5786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cb8360c1-8f91-4b1a-983c-e213e20b5786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6c13be5-abe6-4740-83ee-05ad2bbf57c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9c67feb-a732-4f7a-bc7e-f03ca9863a58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6c13be5-abe6-4740-83ee-05ad2bbf57c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_409f4e16-7bab-4336-a41c-01a0eebb06a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_409f4e16-7bab-4336-a41c-01a0eebb06a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_01a92af7-aad1-4f60-b4cc-45a1e0e662f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_01a92af7-aad1-4f60-b4cc-45a1e0e662f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b004323-84b6-4479-9084-bc31cb2f4032" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b004323-84b6-4479-9084-bc31cb2f4032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3085c461-1845-4e5d-9600-7a84ca14a661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3085c461-1845-4e5d-9600-7a84ca14a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4b38086a-4323-4e30-8ff2-05f12c1c7979" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4b38086a-4323-4e30-8ff2-05f12c1c7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract_1de18162-ba0f-421e-95fd-e4ec860c2b72" xlink:href="jnj-20210103.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4b38086a-4323-4e30-8ff2-05f12c1c7979" xlink:to="loc_jnj_CashPaidDuringTheYearAbstract_1de18162-ba0f-421e-95fd-e4ec860c2b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_5eb0c994-cbe1-41c6-9ccd-ac5ff22ca532" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_1de18162-ba0f-421e-95fd-e4ec860c2b72" xlink:to="loc_us-gaap_InterestPaid_5eb0c994-cbe1-41c6-9ccd-ac5ff22ca532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ee215d84-7068-430b-92b7-db599e63ed32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_1de18162-ba0f-421e-95fd-e4ec860c2b72" xlink:to="loc_us-gaap_InterestPaidNet_ee215d84-7068-430b-92b7-db599e63ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_488b6c1f-8961-4d8a-9ac4-258a1652b268" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_1de18162-ba0f-421e-95fd-e4ec860c2b72" xlink:to="loc_us-gaap_IncomeTaxesPaid_488b6c1f-8961-4d8a-9ac4-258a1652b268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7c09fa44-9c3d-4bd7-b826-2c7bb813c252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7c09fa44-9c3d-4bd7-b826-2c7bb813c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_01e7df90-1756-4d6d-8af6-b7594115aa4e" xlink:href="jnj-20210103.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7c09fa44-9c3d-4bd7-b826-2c7bb813c252" xlink:to="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_01e7df90-1756-4d6d-8af6-b7594115aa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_8ba2e7ce-e98f-4ba6-a4c1-c79eeb2fe20e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7c09fa44-9c3d-4bd7-b826-2c7bb813c252" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_8ba2e7ce-e98f-4ba6-a4c1-c79eeb2fe20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0b19e1b0-ed3b-41c0-86a0-c4f6cdd3704b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e1d0b5b-fdd1-4d00-89f9-288e93ae0fe4" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0b19e1b0-ed3b-41c0-86a0-c4f6cdd3704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_1e229032-90eb-4af6-b47b-fe03bfe1e6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0b19e1b0-ed3b-41c0-86a0-c4f6cdd3704b" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_1e229032-90eb-4af6-b47b-fe03bfe1e6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ad4323fd-28b5-4675-8343-7653c34ca40d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0b19e1b0-ed3b-41c0-86a0-c4f6cdd3704b" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ad4323fd-28b5-4675-8343-7653c34ca40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_9bf6338d-972c-4709-b0e2-2beb892bde55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0b19e1b0-ed3b-41c0-86a0-c4f6cdd3704b" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_9bf6338d-972c-4709-b0e2-2beb892bde55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5403554d-84ae-4cde-8938-69b41c8b634d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cbe1d0aa-c6a3-4a0c-ae42-86ae5040a984" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5403554d-84ae-4cde-8938-69b41c8b634d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cbe1d0aa-c6a3-4a0c-ae42-86ae5040a984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_77eaebae-a8b8-4f81-ad7f-a185df6d3c92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_77eaebae-a8b8-4f81-ad7f-a185df6d3c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_24376ac1-3661-4e6a-9916-c7fc38e366cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_24376ac1-3661-4e6a-9916-c7fc38e366cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7742687-5676-40e4-96eb-6feab014150f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7742687-5676-40e4-96eb-6feab014150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_77395b46-1d36-4a6d-b3e3-1f1d397b1302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_77395b46-1d36-4a6d-b3e3-1f1d397b1302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_0d77cecb-0c9e-40d4-8495-43c0b6354381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_0d77cecb-0c9e-40d4-8495-43c0b6354381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ee3dc76b-7a28-4bed-b766-5f111d637010" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ee3dc76b-7a28-4bed-b766-5f111d637010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b590557a-e002-4f12-9ac5-d14024d20ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b590557a-e002-4f12-9ac5-d14024d20ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_3f904985-3e94-4768-ac5e-f2c74829220c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_3f904985-3e94-4768-ac5e-f2c74829220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_cd3aac46-fc97-4813-b62e-e553b5925178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_cd3aac46-fc97-4813-b62e-e553b5925178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7f61804e-fce0-4dc6-9f72-4da33b2640a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7f61804e-fce0-4dc6-9f72-4da33b2640a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_dac84195-9e95-49cd-800c-e6590fecd8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_dac84195-9e95-49cd-800c-e6590fecd8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_db5d7da3-568d-4804-9563-49a69551386f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_db5d7da3-568d-4804-9563-49a69551386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock_d7529a82-391d-47c0-941b-426cc50a8e1c" xlink:href="jnj-20210103.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_jnj_ProductLiabilityPolicyTextBlock_d7529a82-391d-47c0-941b-426cc50a8e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d76b765a-d01e-4385-948d-eaac268b31a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d76b765a-d01e-4385-948d-eaac268b31a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_0c440cfc-632c-423d-a6dd-5711bbec213c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_0c440cfc-632c-423d-a6dd-5711bbec213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_64d1ddf7-ef93-4715-b4a5-e4af7fef0323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_64d1ddf7-ef93-4715-b4a5-e4af7fef0323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f7db07a3-075d-48cd-a343-19e88f45b825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f7db07a3-075d-48cd-a343-19e88f45b825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_539d9b1b-95cb-47c0-a140-876525009a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_UseOfEstimates_539d9b1b-95cb-47c0-a140-876525009a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock_0ee45b02-0356-4d68-bf04-c4ec0513eeb7" xlink:href="jnj-20210103.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_jnj_FiscalPeriodPolicyTextBlock_0ee45b02-0356-4d68-bf04-c4ec0513eeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f5a15d3d-da40-449d-881d-a0bef05c27bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7a9834a-365b-4abb-a5f8-e4f139508223" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f5a15d3d-da40-449d-881d-a0bef05c27bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_810e246d-5c10-440f-bd4e-ffb3df7129da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_23f61af7-8dcf-4d32-a049-ea687a47eb78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_810e246d-5c10-440f-bd4e-ffb3df7129da" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_23f61af7-8dcf-4d32-a049-ea687a47eb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_3449258b-5cba-4891-aa47-26232fb7913e" xlink:href="jnj-20210103.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_810e246d-5c10-440f-bd4e-ffb3df7129da" xlink:to="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_3449258b-5cba-4891-aa47-26232fb7913e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30e93029-775c-4696-b170-1c4b83a979e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:href="jnj-20210103.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30e93029-775c-4696-b170-1c4b83a979e4" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c8bc152f-cfb5-4976-b581-f228fcec63e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1a1ac7f9-535e-4b4c-9ce3-4e10c06480cc" xlink:to="loc_us-gaap_SegmentDomain_c8bc152f-cfb5-4976-b581-f228fcec63e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_81ecd1f2-eecb-4b23-be00-0d25cfb383b2" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c8bc152f-cfb5-4976-b581-f228fcec63e8" xlink:to="loc_jnj_PharmaceuticalMember_81ecd1f2-eecb-4b23-be00-0d25cfb383b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79b2f86f-8d17-4abb-9be8-985cd5790fe2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6baad30b-96ec-43b7-a129-7c974fef32a3" xlink:to="loc_srt_ProductsAndServicesDomain_79b2f86f-8d17-4abb-9be8-985cd5790fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_bf8890ba-f9d7-454b-8d5f-911a5f8fd470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_79b2f86f-8d17-4abb-9be8-985cd5790fe2" xlink:to="loc_us-gaap_ShippingAndHandlingMember_bf8890ba-f9d7-454b-8d5f-911a5f8fd470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fff01edf-2f82-45e8-9d98-27b9c8ea7ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2166810f-0fdd-48f3-94cc-eb71b0177c01" xlink:to="loc_us-gaap_EquityComponentDomain_fff01edf-2f82-45e8-9d98-27b9c8ea7ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ce9677a-ddd8-4bfe-91a5-347c9dd84336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fff01edf-2f82-45e8-9d98-27b9c8ea7ddb" xlink:to="loc_us-gaap_RetainedEarningsMember_1ce9677a-ddd8-4bfe-91a5-347c9dd84336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_fef584b2-8244-4860-b97a-0caadc69521a" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_33ccc400-1f8b-4333-9a46-e7806dfae8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_33ccc400-1f8b-4333-9a46-e7806dfae8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_b7075e72-c15d-4f09-99d7-5254ff8d4816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_0ddfb4bd-bebb-468e-8079-a939d48dfa38" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_b7075e72-c15d-4f09-99d7-5254ff8d4816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingGuidanceMember_96ac0575-3370-4df8-be45-fed7622df282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_f0d89b53-2acf-43b1-8d40-6da9ddb686df" xlink:to="loc_us-gaap_AccountingGuidanceMember_96ac0575-3370-4df8-be45-fed7622df282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcae9355-5cf6-4b91-9813-7e876120a8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c7015d3-3055-4451-a533-6cf374bb1777" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcae9355-5cf6-4b91-9813-7e876120a8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_986604f5-ca9e-46ba-a0cf-2a7f3d9ef728" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcae9355-5cf6-4b91-9813-7e876120a8d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_986604f5-ca9e-46ba-a0cf-2a7f3d9ef728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0d95bf05-9e61-4108-95f8-0026370256c0" xlink:to="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60ac2c07-e106-465c-b843-760b7b1f4e80" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:to="loc_srt_MinimumMember_60ac2c07-e106-465c-b843-760b7b1f4e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f7b200f-e06c-4064-82e9-34aa1c41fac3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df86b18e-adf4-460b-b5ac-0578bed7585f" xlink:to="loc_srt_MaximumMember_5f7b200f-e06c-4064-82e9-34aa1c41fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CustomersCollectionPatternsDomain_94e92d30-870d-4860-a35e-2f9fbc4d4ec5" xlink:href="jnj-20210103.xsd#jnj_CustomersCollectionPatternsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CustomersCollectionPatternsAxis_67bdb2cd-03d9-4b2c-bb36-014d2559bff7" xlink:to="loc_jnj_CustomersCollectionPatternsDomain_94e92d30-870d-4860-a35e-2f9fbc4d4ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_16427e5e-b0c3-459f-af63-d464d17f41b1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_90f1d6f3-b381-42c0-bc31-1a8b5b117a10" xlink:to="loc_srt_SegmentGeographicalDomain_16427e5e-b0c3-459f-af63-d464d17f41b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4518926f-8ab0-4021-932c-3346ac36be80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9f0b5a41-79cb-4f44-9d61-af71c6845292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4518926f-8ab0-4021-932c-3346ac36be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_2b7e0710-6c94-4c23-9611-1ef40d384c47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4518926f-8ab0-4021-932c-3346ac36be80" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_2b7e0710-6c94-4c23-9611-1ef40d384c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:href="jnj-20210103.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_768ecb10-2067-4a26-b297-3004f37e678d" xlink:to="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_8e177e7a-67b8-40e9-81be-0b1aeb9b7455" xlink:href="jnj-20210103.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_8e177e7a-67b8-40e9-81be-0b1aeb9b7455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7f698f31-7126-408f-9f92-fbccf5dc46d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_NumberOfReportableSegments_7f698f31-7126-408f-9f92-fbccf5dc46d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_5be72d28-cc2d-4cef-aa0b-5d5b69d47478" xlink:href="jnj-20210103.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_5be72d28-cc2d-4cef-aa0b-5d5b69d47478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_a0f1c017-4570-4f62-bd9e-5cdbad8ff3c4" xlink:href="jnj-20210103.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_a0f1c017-4570-4f62-bd9e-5cdbad8ff3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6f8b29ad-6027-4c38-ab5a-b4312e07d1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6f8b29ad-6027-4c38-ab5a-b4312e07d1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_46b73a72-d612-4904-bad6-6af8ccf6aefc" xlink:href="jnj-20210103.xsd#jnj_SalesReturnReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_SalesReturnReserve_46b73a72-d612-4904-bad6-6af8ccf6aefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_49e13684-4160-406b-88cb-2de00b25dc4b" xlink:href="jnj-20210103.xsd#jnj_ProfitLossPercentToSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_ProfitLossPercentToSales_49e13684-4160-406b-88cb-2de00b25dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2da806dc-ad99-4616-a620-7fefe0c8be7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2da806dc-ad99-4616-a620-7fefe0c8be7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_c3325c63-1783-4a3d-8d63-953ff8a0aeed" xlink:href="jnj-20210103.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_c3325c63-1783-4a3d-8d63-953ff8a0aeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ca8c838e-c47c-442e-86de-5274fc62b612" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ca8c838e-c47c-442e-86de-5274fc62b612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_44d3ca4e-1110-4697-8463-ab48e6ac2300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_AdvertisingExpense_44d3ca4e-1110-4697-8463-ab48e6ac2300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0802097-3931-4d1a-b550-dd391dc75cef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0802097-3931-4d1a-b550-dd391dc75cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_53ae1912-202e-4113-a343-6b2bfef7ec8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseLiability_53ae1912-202e-4113-a343-6b2bfef7ec8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b4c50da9-17e4-4387-bebb-ddf4a6c8b384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseCost_b4c50da9-17e4-4387-bebb-ddf4a6c8b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a4de8369-805f-406e-b7dc-c5bc0632a93f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeasePayments_a4de8369-805f-406e-b7dc-c5bc0632a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_152f5e23-2e2e-4049-977a-9ee677c968ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_152f5e23-2e2e-4049-977a-9ee677c968ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_e7769b7d-a80a-4cd8-9fb2-ce39be121ac2" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_e7769b7d-a80a-4cd8-9fb2-ce39be121ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_f78c3246-8a1d-4c32-beb6-836572a0dead" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_f78c3246-8a1d-4c32-beb6-836572a0dead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_93567f80-55cb-4350-9b8d-58505042e176" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_93567f80-55cb-4350-9b8d-58505042e176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_9bc42ca2-f10e-4b6e-9d8e-e925cb2d36a9" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_9bc42ca2-f10e-4b6e-9d8e-e925cb2d36a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_4aa04384-c556-4409-94a9-b3a3fbcfe917" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_4aa04384-c556-4409-94a9-b3a3fbcfe917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_38ee4beb-76e0-4c99-88ea-c4fb67d8bcd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_38ee4beb-76e0-4c99-88ea-c4fb67d8bcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_77d42660-6822-4bff-b565-4baea2b39a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_77d42660-6822-4bff-b565-4baea2b39a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_58c6af8a-df2a-4a2c-9f0a-450e8c321845" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_48fff5bc-8416-4e86-b838-222d737b3b79" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_58c6af8a-df2a-4a2c-9f0a-450e8c321845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2e8bcc08-5d28-4fb3-a14a-0924129c9bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e8bcc08-5d28-4fb3-a14a-0924129c9bf3" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2f667e78-6cd3-46b2-87c0-6a514d4e93d7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_33748fcb-e524-4605-9964-8434b636cc21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_33748fcb-e524-4605-9964-8434b636cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_c638efa5-d7cd-4c75-b63b-64bc0827da45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_c638efa5-d7cd-4c75-b63b-64bc0827da45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccountingStandardUpdate201616Member_2af78c85-59e6-4ef0-a089-4ee777c0012b" xlink:href="jnj-20210103.xsd#jnj_AccountingStandardUpdate201616Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_215a33df-cb7f-42ab-97d7-b883bae7c599" xlink:to="loc_jnj_AccountingStandardUpdate201616Member_2af78c85-59e6-4ef0-a089-4ee777c0012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6e2af6a-1d2d-4618-87a8-cd02d5832c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6bf17f90-7e45-4400-a46c-961e8564b269" xlink:to="loc_us-gaap_EquityComponentDomain_f6e2af6a-1d2d-4618-87a8-cd02d5832c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_678eef79-75de-4910-aeb8-cba37792d952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f6e2af6a-1d2d-4618-87a8-cd02d5832c90" xlink:to="loc_us-gaap_RetainedEarningsMember_678eef79-75de-4910-aeb8-cba37792d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_5af9ac1e-c02f-4e3d-aca5-7077d8955029" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_66f4437d-3189-47ec-9b2b-d546d4f4cb6f" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_5af9ac1e-c02f-4e3d-aca5-7077d8955029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_288868c2-75d1-45dd-8431-ba16b89d789d" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_5af9ac1e-c02f-4e3d-aca5-7077d8955029" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_288868c2-75d1-45dd-8431-ba16b89d789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f9fa50a5-4b7a-4c23-96c2-b3ed79b6eca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_18897a45-5e2c-40e1-8719-16099828be2b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f9fa50a5-4b7a-4c23-96c2-b3ed79b6eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dec3269b-c4ae-4341-abe9-fd3d96f265d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f9fa50a5-4b7a-4c23-96c2-b3ed79b6eca7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dec3269b-c4ae-4341-abe9-fd3d96f265d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fbc8f40d-d590-4acd-abad-c690de54beae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fbc8f40d-d590-4acd-abad-c690de54beae" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:to="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a3a1597c-faa3-48ae-8d44-ace377bcb327" xlink:to="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ad42facd-83fa-4597-95a8-8f2eca32d3a2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:to="loc_srt_MinimumMember_ad42facd-83fa-4597-95a8-8f2eca32d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40158eb5-8bb8-49d5-9ad4-294eddca9d2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c00383d-86bf-4a81-9605-c85c8a85a083" xlink:to="loc_srt_MaximumMember_40158eb5-8bb8-49d5-9ad4-294eddca9d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d681d962-2034-406f-9c1a-62b1435d30c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_f5679c9c-e9b8-4437-a53e-4af598266f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_f5679c9c-e9b8-4437-a53e-4af598266f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_83e0d2ff-38b0-4a8a-8e4b-63a913d9d7b5" xlink:href="jnj-20210103.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_83e0d2ff-38b0-4a8a-8e4b-63a913d9d7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ba9d0ccf-fe16-4806-b98b-9c21952c503b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02ef56e1-59b9-4a57-8208-222ef1b127aa" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ba9d0ccf-fe16-4806-b98b-9c21952c503b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77070b47-d7af-4bdd-9035-4eb2fef1fde6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4182813-ea26-4968-a63b-ebd065cf5ea3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77070b47-d7af-4bdd-9035-4eb2fef1fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bc08e48-bbdf-46ca-9f42-e64e4e7d944d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77070b47-d7af-4bdd-9035-4eb2fef1fde6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bc08e48-bbdf-46ca-9f42-e64e4e7d944d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_20ae762b-be7c-4768-8667-764bdc4ec807" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_334f3c51-8aba-4683-bbd3-c88eb9290ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_20ae762b-be7c-4768-8667-764bdc4ec807" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_334f3c51-8aba-4683-bbd3-c88eb9290ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f0c40ae7-4b97-4682-8ba8-d8eb04364f52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a9e280e4-14ee-4a30-89c1-52eae83d7aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f0c40ae7-4b97-4682-8ba8-d8eb04364f52" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a9e280e4-14ee-4a30-89c1-52eae83d7aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_34970720-6139-4c8c-b311-a066c0f0b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f0c40ae7-4b97-4682-8ba8-d8eb04364f52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_34970720-6139-4c8c-b311-a066c0f0b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_972edae5-da6f-40a8-adf1-e07151aada80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_972edae5-da6f-40a8-adf1-e07151aada80" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_ecc0bbac-05ed-4279-861e-ef5f5a077ab6" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_dca83cc5-fbbf-423e-8099-c09d29fd1985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_dca83cc5-fbbf-423e-8099-c09d29fd1985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_092a18a1-32d1-48e0-b472-c5fbafc7be02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b8a2beb3-42b4-4bc3-b11d-8954b7c22f5f" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_092a18a1-32d1-48e0-b472-c5fbafc7be02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:to="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_7c22e6f5-fe7e-4c2f-85b8-ee1f4f180267" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ecf80d43-57c4-4e35-bff8-b10eae48a270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_CashMember_ecf80d43-57c4-4e35-bff8-b10eae48a270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_71e2009e-ee81-4a77-ab93-670f460f105a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_71e2009e-ee81-4a77-ab93-670f460f105a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_68a6c8db-4e7c-48eb-87a8-7230a9c1e4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_68a6c8db-4e7c-48eb-87a8-7230a9c1e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_54f3c2bd-6385-4961-926e-631e8a1ab1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_54f3c2bd-6385-4961-926e-631e8a1ab1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherReverseRepurchaseAgreementsMember_bb8221ba-e5fa-4ed5-a3aa-424485ee098d" xlink:href="jnj-20210103.xsd#jnj_OtherReverseRepurchaseAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_jnj_OtherReverseRepurchaseAgreementsMember_bb8221ba-e5fa-4ed5-a3aa-424485ee098d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6aed7453-dd4f-496c-9482-f9f49924ffdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6aed7453-dd4f-496c-9482-f9f49924ffdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8d7149fa-2719-4dd4-8f3f-d713b682901d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8d7149fa-2719-4dd4-8f3f-d713b682901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_f5f7ba8a-94ff-4f61-9c0d-09b46751600b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_us-gaap_BankTimeDepositsMember_f5f7ba8a-94ff-4f61-9c0d-09b46751600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember_5c66a98a-f429-4330-bef2-091edd1887aa" xlink:href="jnj-20210103.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_62d845a4-4f1d-4cf6-a0b1-56e5de387e55" xlink:to="loc_jnj_OtherSovereignSecuritiesMember_5c66a98a-f429-4330-bef2-091edd1887aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_bf7371b0-f35f-48ea-b959-012f1141d94e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9fd6971d-469b-4ef7-9661-e69eb0ee04a0" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_bf7371b0-f35f-48ea-b959-012f1141d94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_bf7371b0-f35f-48ea-b959-012f1141d94e" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_7665a399-c593-454d-958e-75b8b57ffcdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_HeldToMaturitySecurities_7665a399-c593-454d-958e-75b8b57ffcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b55a5cdb-b594-49f2-97e7-f309dc2d9ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b55a5cdb-b594-49f2-97e7-f309dc2d9ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c0ff6f0-dc23-45e0-8306-8aa6ecc33320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c0ff6f0-dc23-45e0-8306-8aa6ecc33320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a75999f8-66e9-4087-a70f-71625bf9ec3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a75999f8-66e9-4087-a70f-71625bf9ec3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4e7ad854-d0a4-4212-94a0-b28b9ebdb6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4e7ad854-d0a4-4212-94a0-b28b9ebdb6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_181d2f22-f3ac-476f-82ee-6b51d8c32a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_55f2a7c6-eae1-46f0-8778-ecfb9a476e0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_181d2f22-f3ac-476f-82ee-6b51d8c32a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_9fd8a321-e91d-4e20-a3ef-c4eb1fafcc47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_7ae5851c-b770-498d-9ea2-5f2fd6062056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_9fd8a321-e91d-4e20-a3ef-c4eb1fafcc47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_7ae5851c-b770-498d-9ea2-5f2fd6062056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5bf2df86-c513-403a-a7fa-11c3cd384aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_7ae5851c-b770-498d-9ea2-5f2fd6062056" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5bf2df86-c513-403a-a7fa-11c3cd384aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_9dca344e-c6b5-4123-8434-e27284aa5bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_7ae5851c-b770-498d-9ea2-5f2fd6062056" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_9dca344e-c6b5-4123-8434-e27284aa5bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_be479e10-0f17-456d-9080-6a04988b5608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_7ae5851c-b770-498d-9ea2-5f2fd6062056" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_be479e10-0f17-456d-9080-6a04988b5608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ac128ed2-716e-42a7-a5db-34ec394e8bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_7ae5851c-b770-498d-9ea2-5f2fd6062056" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ac128ed2-716e-42a7-a5db-34ec394e8bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aac3880a-a30c-40a5-90a2-dc17fd109aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_9fd8a321-e91d-4e20-a3ef-c4eb1fafcc47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aac3880a-a30c-40a5-90a2-dc17fd109aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d4a17963-a7e5-4195-b01e-c00b358a99b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aac3880a-a30c-40a5-90a2-dc17fd109aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d4a17963-a7e5-4195-b01e-c00b358a99b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6f391651-a7c2-48ca-8f78-f38f7b044d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aac3880a-a30c-40a5-90a2-dc17fd109aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6f391651-a7c2-48ca-8f78-f38f7b044d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a57b502e-8cf7-433f-82d1-6ae19e3b4f24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aac3880a-a30c-40a5-90a2-dc17fd109aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a57b502e-8cf7-433f-82d1-6ae19e3b4f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_74bf4ba0-c544-46f4-ae7a-7e83e1499548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aac3880a-a30c-40a5-90a2-dc17fd109aed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_74bf4ba0-c544-46f4-ae7a-7e83e1499548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20210103.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4d5213ad-7f6b-476b-a31f-ba4ef78eb471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a0feddee-045d-4141-a20d-3148bf8776f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4d5213ad-7f6b-476b-a31f-ba4ef78eb471" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a0feddee-045d-4141-a20d-3148bf8776f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c8ee2ac0-8fc7-4f98-a88e-b8792ced3457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_979a7a3e-8635-428e-9209-e85b34c0e3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c8ee2ac0-8fc7-4f98-a88e-b8792ced3457" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_979a7a3e-8635-428e-9209-e85b34c0e3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_18631f32-a644-48f7-857c-a469047068f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_9b84b6cc-f14b-4dc1-8323-5e8523ec919c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_18631f32-a644-48f7-857c-a469047068f9" xlink:to="loc_us-gaap_InventoryNetAbstract_9b84b6cc-f14b-4dc1-8323-5e8523ec919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_005338a2-efc0-4cd5-bc7e-78abb6be14e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9b84b6cc-f14b-4dc1-8323-5e8523ec919c" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_005338a2-efc0-4cd5-bc7e-78abb6be14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_18b1f8f6-f606-40e8-93b4-3940287de4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9b84b6cc-f14b-4dc1-8323-5e8523ec919c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_18b1f8f6-f606-40e8-93b4-3940287de4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b8a72297-cc55-457c-b150-c6b511ee55d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9b84b6cc-f14b-4dc1-8323-5e8523ec919c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b8a72297-cc55-457c-b150-c6b511ee55d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f9be3f01-ff33-4666-9d01-957726f1756f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_9b84b6cc-f14b-4dc1-8323-5e8523ec919c" xlink:to="loc_us-gaap_InventoryNet_f9be3f01-ff33-4666-9d01-957726f1756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4a9a814a-6add-4cc2-ab95-8ae39fa5cc56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_22828c6a-b60a-4182-bc17-eb07e581ca28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4a9a814a-6add-4cc2-ab95-8ae39fa5cc56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_22828c6a-b60a-4182-bc17-eb07e581ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_684fb7da-ebe7-452e-9f8e-6f31a16931e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_25115ec6-7fd5-443e-86a5-508be6262e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_684fb7da-ebe7-452e-9f8e-6f31a16931e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_25115ec6-7fd5-443e-86a5-508be6262e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_48a7cf24-1603-4361-88d5-8713246bc86e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_48a7cf24-1603-4361-88d5-8713246bc86e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_983c02cc-fb85-4b85-9e59-96826ca4987c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_Land_983c02cc-fb85-4b85-9e59-96826ca4987c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_3b1f87c0-98f9-4858-8b6d-a8d9beb652a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_3b1f87c0-98f9-4858-8b6d-a8d9beb652a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_34894e8f-2b97-4699-872a-19a4054e9ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_34894e8f-2b97-4699-872a-19a4054e9ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_f483be8e-ad6f-47e9-8662-e55956d2db89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_ConstructionInProgressGross_f483be8e-ad6f-47e9-8662-e55956d2db89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7f5095bd-dd27-444c-8e4c-6ece0b042413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7f5095bd-dd27-444c-8e4c-6ece0b042413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c24e8280-c34c-49d5-8046-df473d07ddd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c24e8280-c34c-49d5-8046-df473d07ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e2328b43-b7c8-48ab-bce8-1e63500748f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_d8b466fc-39c1-4507-92c1-f4e484b3542d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e2328b43-b7c8-48ab-bce8-1e63500748f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a328cd28-9e7b-4a65-afe7-d53b4d24226e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_77ea0646-19e1-48dc-afe7-4b3641748b20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a328cd28-9e7b-4a65-afe7-d53b4d24226e" xlink:to="loc_us-gaap_InterestCostsCapitalized_77ea0646-19e1-48dc-afe7-4b3641748b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_990fd826-98ca-4a03-bd6d-a86b66177fb1" xlink:href="jnj-20210103.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a328cd28-9e7b-4a65-afe7-d53b4d24226e" xlink:to="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_990fd826-98ca-4a03-bd6d-a86b66177fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f5a462be-73dd-4d51-a55d-6fc88a674915" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b0ef37b9-6080-4de1-9403-6bb62e7e3e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f5a462be-73dd-4d51-a55d-6fc88a674915" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b0ef37b9-6080-4de1-9403-6bb62e7e3e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1b99824b-00bd-45e4-9445-cdaf3619ea46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_8e55db19-5d2c-4bf0-833a-a85088e2a0c5" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1b99824b-00bd-45e4-9445-cdaf3619ea46" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_8e55db19-5d2c-4bf0-833a-a85088e2a0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_389b5148-4346-4f36-84c5-d537cc987bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1b99824b-00bd-45e4-9445-cdaf3619ea46" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_389b5148-4346-4f36-84c5-d537cc987bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_434101ca-9d09-41c2-aba5-ce67fa11a123" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1b99824b-00bd-45e4-9445-cdaf3619ea46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_434101ca-9d09-41c2-aba5-ce67fa11a123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_643cd584-710f-4d20-b638-6f8032d09e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_643cd584-710f-4d20-b638-6f8032d09e9d" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11b2e691-f114-4ac9-aa4b-63edba5f43a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_07c23f8c-49ac-49f8-b80b-1a9f7cb2e0fd" xlink:href="jnj-20210103.xsd#jnj_MomentaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:to="loc_jnj_MomentaMember_07c23f8c-49ac-49f8-b80b-1a9f7cb2e0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_4839b5d6-4b8a-4e4b-b50c-2db1cfacd119" xlink:href="jnj-20210103.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:to="loc_jnj_BermekimabMember_4839b5d6-4b8a-4e4b-b50c-2db1cfacd119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_fde261d8-f07d-49e9-aee7-fb2fc4b953ba" xlink:href="jnj-20210103.xsd#jnj_VerbSurgicalIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4756b92-bc77-43c1-9dcf-83bbaa7842b7" xlink:to="loc_jnj_VerbSurgicalIncMember_fde261d8-f07d-49e9-aee7-fb2fc4b953ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2b904ac-da22-421c-b9fb-7a32a55f7078" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_4402f605-4221-40e9-b0f8-baee14bd2917" xlink:href="jnj-20210103.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:to="loc_jnj_PatentsAndTrademarksMember_4402f605-4221-40e9-b0f8-baee14bd2917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_10af1b59-252f-4e10-89f8-0e8a4f97f1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_10af1b59-252f-4e10-89f8-0e8a4f97f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e2e036ed-d096-4e76-905b-16b2b00b8028" xlink:href="jnj-20210103.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_531c1014-f4f8-4e5c-af9c-d452fe4b0a3b" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e2e036ed-d096-4e76-905b-16b2b00b8028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a90df669-94c0-4916-81ac-3451ea6af585" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_4fe6389d-fd26-4779-94f3-aff5a3e169a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:to="loc_us-gaap_TrademarksMember_4fe6389d-fd26-4779-94f3-aff5a3e169a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1314f0dd-29f5-4e9e-8599-0b768a8d4cd6" xlink:href="jnj-20210103.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1314f0dd-29f5-4e9e-8599-0b768a8d4cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_65e5b724-81eb-4b6b-bece-f62c4454c18d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d56c437-226a-4c3f-9516-c2cf1155d22d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_65e5b724-81eb-4b6b-bece-f62c4454c18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:href="jnj-20210103.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_8c6a90e3-a6c4-4066-988c-aaf936234874" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f59fd69f-c3a4-4818-8f92-323c8ec772ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f59fd69f-c3a4-4818-8f92-323c8ec772ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bede8d92-cd2d-4057-9871-f701c179d0ca" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4ffff9e6-3968-4772-ae99-9832e372268c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4ffff9e6-3968-4772-ae99-9832e372268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2dc5e65-5136-419a-a483-b566c13d71bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2dc5e65-5136-419a-a483-b566c13d71bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd8815cc-c12b-41e2-91ad-ffdd5dcf1629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7931bf53-d39f-494b-8b0a-4dde793436d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fd8815cc-c12b-41e2-91ad-ffdd5dcf1629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d7ad55b6-c5b5-4a65-8a1f-07ff783a3a15" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f9363f80-ca81-4aa0-8d40-b6b000bc1559" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f9363f80-ca81-4aa0-8d40-b6b000bc1559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14339e9b-e824-4e2b-870c-8734333cceb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b4bf9890-2b6c-4943-8c8c-1ee0cf94120f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14339e9b-e824-4e2b-870c-8734333cceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9efdfeca-755e-4605-8fd7-9a7b3702a738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9efdfeca-755e-4605-8fd7-9a7b3702a738" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6d81c71d-2e4a-4bf4-9701-cdfc8b01d0bc" xlink:to="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_c2fdd1ca-f2a0-4ee9-9aa7-d4aefce2d091" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:to="loc_jnj_ConsumerMember_c2fdd1ca-f2a0-4ee9-9aa7-d4aefce2d091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_d8d88b68-499d-4867-9ba5-e0df1df7c869" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:to="loc_jnj_PharmaceuticalMember_d8d88b68-499d-4867-9ba5-e0df1df7c869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_9a3a34ee-6c6a-4e2d-8e08-fa435f7e5227" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f19a3840-c04b-494a-a91c-91e6b5a1a702" xlink:to="loc_jnj_MedicalDevicesMember_9a3a34ee-6c6a-4e2d-8e08-fa435f7e5227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_aad3e810-0d02-4b22-87a9-cd79e41482f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ecfbf399-1ed7-49cf-996d-4562a7447045" xlink:to="loc_us-gaap_GoodwillLineItems_aad3e810-0d02-4b22-87a9-cd79e41482f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_aad3e810-0d02-4b22-87a9-cd79e41482f2" xlink:to="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_879fa7bf-56c8-47db-a4bd-704bab2ade6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_Goodwill_879fa7bf-56c8-47db-a4bd-704bab2ade6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_421b363b-a102-4bb1-9b5b-b4171be1725b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_421b363b-a102-4bb1-9b5b-b4171be1725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_b451eb1b-3c5b-4b81-980b-e14bbcde812b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_b451eb1b-3c5b-4b81-980b-e14bbcde812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b4d2a0e5-306c-40a1-bf61-e01de77d5c60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_dc7873e3-0cc3-454d-b81a-6524bf3546f5" xlink:to="loc_us-gaap_Goodwill_b4d2a0e5-306c-40a1-bf61-e01de77d5c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_29c7a650-e13f-441d-85f1-6e43de243fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_29c7a650-e13f-441d-85f1-6e43de243fb3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3add845-13bc-4b5a-96b2-579a09d319e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_097deadd-5531-48c4-a52b-ce930f31327c" xlink:href="jnj-20210103.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:to="loc_jnj_PatentsAndTrademarksMember_097deadd-5531-48c4-a52b-ce930f31327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_f34f4536-46c8-45e5-aa68-14ae99495a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25f54d0-e656-4e3f-8ebb-8cec6befb4bb" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_f34f4536-46c8-45e5-aa68-14ae99495a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_69ba2902-4c83-4743-9f19-1d112cc7f0f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8e38a153-9177-4a70-b217-da2d28b311ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8e38a153-9177-4a70-b217-da2d28b311ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e70f6bfb-df48-470a-9922-08bd60839889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_096a3af0-6d9d-4782-9dfd-941003c46a96" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e70f6bfb-df48-470a-9922-08bd60839889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0f9c7cb9-5570-41a3-959c-174604995043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3f973666-13b4-48b7-8689-1167d6ff6ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0f9c7cb9-5570-41a3-959c-174604995043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3f973666-13b4-48b7-8689-1167d6ff6ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_20d6f775-153f-4f9d-a9d5-edb020ebd963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0f9c7cb9-5570-41a3-959c-174604995043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_20d6f775-153f-4f9d-a9d5-edb020ebd963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_14a1a606-541e-4c84-afcb-baeca947dae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0f9c7cb9-5570-41a3-959c-174604995043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_14a1a606-541e-4c84-afcb-baeca947dae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16cf1744-fc7a-4705-8422-58a1d6aba70b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0f9c7cb9-5570-41a3-959c-174604995043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16cf1744-fc7a-4705-8422-58a1d6aba70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fbb9b6d4-203e-4c3a-b00d-d3095b34477b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0f9c7cb9-5570-41a3-959c-174604995043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fbb9b6d4-203e-4c3a-b00d-d3095b34477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_62e24c9d-93b9-4f39-9be9-09512bd938db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a08c2607-885a-47e9-834a-53cbfef9ec5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_62e24c9d-93b9-4f39-9be9-09512bd938db" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a08c2607-885a-47e9-834a-53cbfef9ec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_283718c4-09bd-42db-b486-28aaf4b3f86f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_02d3d2c2-b056-4a1a-b520-9d244685682d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283718c4-09bd-42db-b486-28aaf4b3f86f" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_02d3d2c2-b056-4a1a-b520-9d244685682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_6396d4f7-c895-459a-8c5e-c19c2fc8ddff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283718c4-09bd-42db-b486-28aaf4b3f86f" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_6396d4f7-c895-459a-8c5e-c19c2fc8ddff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_4860b544-96ba-41eb-a16b-886010e065c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283718c4-09bd-42db-b486-28aaf4b3f86f" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_4860b544-96ba-41eb-a16b-886010e065c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2ccbc1ae-9ea2-4b7e-9767-8747c85fe83c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283718c4-09bd-42db-b486-28aaf4b3f86f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2ccbc1ae-9ea2-4b7e-9767-8747c85fe83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_682675c3-58ee-448c-99ad-eb9c26ad03ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283718c4-09bd-42db-b486-28aaf4b3f86f" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_682675c3-58ee-448c-99ad-eb9c26ad03ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dd346802-c09c-4b2e-82b1-6d964fafc1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd346802-c09c-4b2e-82b1-6d964fafc1e0" xlink:to="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d24311ca-dbcb-46bb-9713-88ba367c4889" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_24848588-3dfd-409a-b2bb-71d0147bc60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_24848588-3dfd-409a-b2bb-71d0147bc60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06709909-1903-459e-b949-2dd1b03c6da6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9109a383-6648-476c-b902-ac940b441bb2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06709909-1903-459e-b949-2dd1b03c6da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf5d5a0-8dcd-4293-93b4-33c4ba211574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c778856f-2bf6-4a08-b6b4-a567b415a583" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf5d5a0-8dcd-4293-93b4-33c4ba211574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_db186373-2c16-49c7-bbfc-fa06d54726b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf5d5a0-8dcd-4293-93b4-33c4ba211574" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_db186373-2c16-49c7-bbfc-fa06d54726b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_67cd2643-40eb-4c04-bda9-ad29c14072b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e202eadf-666a-4c1f-aa14-196c94f91a57" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_67cd2643-40eb-4c04-bda9-ad29c14072b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_72e9ae0a-cc94-4551-8215-b8499a5ddf16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_67cd2643-40eb-4c04-bda9-ad29c14072b1" xlink:to="loc_us-gaap_EquitySecuritiesMember_72e9ae0a-cc94-4551-8215-b8499a5ddf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a68ec473-863e-4299-9431-76a87c5d550b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_6b1c82ac-10cf-41b4-896c-f6454b7542b3" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_6b1c82ac-10cf-41b4-896c-f6454b7542b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_38548527-d4dc-4f20-8ece-8c7d6f5fb15c" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f7650d23-4e85-48ff-9c92-19caad708e32" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_38548527-d4dc-4f20-8ece-8c7d6f5fb15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aa576ff5-66a5-4094-af96-97d91ffcfc1c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_707aab59-0e51-468a-ad55-992a0300cc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:to="loc_us-gaap_ForeignExchangeContractMember_707aab59-0e51-468a-ad55-992a0300cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_03f10222-d46f-4091-b600-6eda6f288b53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_03f10222-d46f-4091-b600-6eda6f288b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_07922de2-9d54-490c-acbd-9dcc02a431cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc1ca395-41f4-4da5-b566-96c1d787a876" xlink:to="loc_us-gaap_InterestRateContractMember_07922de2-9d54-490c-acbd-9dcc02a431cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_90f22dc5-3214-4b80-bd43-e977f05d2671" xlink:to="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_e37f5eca-4a5b-4325-9bd2-948874cb8a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_e37f5eca-4a5b-4325-9bd2-948874cb8a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_5a83518a-e15d-4d46-abb6-270510d6f7ef" xlink:href="jnj-20210103.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_5a83518a-e15d-4d46-abb6-270510d6f7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ede1a7d-99b6-436e-a7fd-8b9d7c34d084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ede1a7d-99b6-436e-a7fd-8b9d7c34d084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6da11fe1-020a-4a5c-93e4-c996cb6258e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6da11fe1-020a-4a5c-93e4-c996cb6258e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1703da60-c008-4c61-81ba-a4637c780dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1703da60-c008-4c61-81ba-a4637c780dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_168cbecc-fc0d-430c-93a5-8f063060dca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_168cbecc-fc0d-430c-93a5-8f063060dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_cfcde34f-ed9b-4921-9681-7eed98209634" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_EquityFairValueAdjustment_cfcde34f-ed9b-4921-9681-7eed98209634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_6cf64ad1-409d-41c5-83d2-71e5477622b3" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_6cf64ad1-409d-41c5-83d2-71e5477622b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_11568976-bbaa-43be-95e3-7136ec3432ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_DerivativeNotionalAmount_11568976-bbaa-43be-95e3-7136ec3432ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_736ab5cf-1c97-4ab7-beea-03108f86b9db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_736ab5cf-1c97-4ab7-beea-03108f86b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e2bbe7d-3191-4654-8a80-8948ad9690d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e2bbe7d-3191-4654-8a80-8948ad9690d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79b9f507-de43-4ff1-aafb-4e052fb32af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79b9f507-de43-4ff1-aafb-4e052fb32af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_6b79e4ac-1f6d-4704-b1de-914382f39a73" xlink:href="jnj-20210103.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_6b79e4ac-1f6d-4704-b1de-914382f39a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_744a03bd-0e0a-45bf-897b-188e22e7b166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_744a03bd-0e0a-45bf-897b-188e22e7b166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6b29cd5b-e6d4-476a-8e22-fbcbea83f5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6b29cd5b-e6d4-476a-8e22-fbcbea83f5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c32ff995-d907-4bff-917d-88c11567c249" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c32ff995-d907-4bff-917d-88c11567c249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_03bead18-0c14-41bb-94a6-0d3bac927b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_698c7d04-577e-4e60-8969-23975cb492ed" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_03bead18-0c14-41bb-94a6-0d3bac927b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dcc13d7e-2367-4778-8ec9-e1e7f42ac734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dcc13d7e-2367-4778-8ec9-e1e7f42ac734" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0a5d9809-3996-4eac-9468-22768a4c13f7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_175e445d-972f-464b-ae24-9556683ac36b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_us-gaap_SalesMember_175e445d-972f-464b-ae24-9556683ac36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1d3c3c2f-b26c-44b2-8f32-874c05910fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_us-gaap_CostOfSalesMember_1d3c3c2f-b26c-44b2-8f32-874c05910fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53d3f338-dcfe-444c-949c-cbb0335e4116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53d3f338-dcfe-444c-949c-cbb0335e4116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_5b5e5d5d-61bb-4172-b56f-8a7f137e750d" xlink:href="jnj-20210103.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_5b5e5d5d-61bb-4172-b56f-8a7f137e750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_091d57b4-2000-4ade-bfa2-cf7b1dd6bde4" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566e2653-3b83-4928-8ffe-8e0582552f4c" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_091d57b4-2000-4ade-bfa2-cf7b1dd6bde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0aaf3d91-b231-4103-8026-5f35a984926f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a3830520-1097-4173-a559-89c5ea66dfd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:to="loc_us-gaap_InterestRateContractMember_a3830520-1097-4173-a559-89c5ea66dfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_a434081b-2909-47a6-8f6f-756d0c44e29f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_a434081b-2909-47a6-8f6f-756d0c44e29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_47a12e8c-7241-43db-932b-664e4382a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_061da8f9-0f44-44e5-b701-3d2ee3adeced" xlink:to="loc_us-gaap_ForeignExchangeContractMember_47a12e8c-7241-43db-932b-664e4382a9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6edc405e-1e10-4069-82e4-95621bc88bf9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_32d38d99-0fd9-4880-a291-6c1102868daa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:to="loc_us-gaap_FairValueHedgingMember_32d38d99-0fd9-4880-a291-6c1102868daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_427a2e99-1f85-478d-a237-13f7a81fee05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d25a6ef8-ade4-4100-8649-0bc3f086f5bf" xlink:to="loc_us-gaap_CashFlowHedgingMember_427a2e99-1f85-478d-a237-13f7a81fee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eb2768bf-dcef-4ede-b118-2b28fe961e9b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_44d301d4-0880-4a53-9176-235cefba2349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_44d301d4-0880-4a53-9176-235cefba2349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_45252a05-2313-46b4-91a1-14d88c3bae84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_45252a05-2313-46b4-91a1-14d88c3bae84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_37e69da2-a0ba-4859-a566-fd67c382d70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_37e69da2-a0ba-4859-a566-fd67c382d70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3ee0eea1-1bee-4a05-aa8c-d112094ffbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_97d81623-4bc3-42b2-b82e-92c916244f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3ee0eea1-1bee-4a05-aa8c-d112094ffbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_490ad245-dc29-4d0e-9575-1f410bed76d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_490ad245-dc29-4d0e-9575-1f410bed76d2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ad741b87-7fd5-4f46-b323-097c597fceb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_256dba64-532d-4645-ba24-a4faaf4ff924" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ad741b87-7fd5-4f46-b323-097c597fceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_44d37ad6-41ca-4463-bb96-c5edf084ea97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ad741b87-7fd5-4f46-b323-097c597fceb2" xlink:to="loc_us-gaap_FairValueHedgingMember_44d37ad6-41ca-4463-bb96-c5edf084ea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_90cfb055-852c-4766-8a77-52b58f176a9a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_8144ba9e-aaa1-4319-a573-a493a0c8f40f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:to="loc_us-gaap_InterestRateContractMember_8144ba9e-aaa1-4319-a573-a493a0c8f40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f592edd2-7470-474a-828a-465cd7facabd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3ae2356-6930-4338-b7df-2dffab62aeab" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f592edd2-7470-474a-828a-465cd7facabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ed87555a-354c-4dda-b167-6867c6c83bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_14af473f-c03e-4b2d-8c3b-9cba9d50a68a" xlink:to="loc_us-gaap_HedgingDesignationDomain_ed87555a-354c-4dda-b167-6867c6c83bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_07af93b0-c7c9-4cb9-9b57-c7e4858476c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ed87555a-354c-4dda-b167-6867c6c83bd4" xlink:to="loc_us-gaap_NondesignatedMember_07af93b0-c7c9-4cb9-9b57-c7e4858476c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba78c7ad-aef9-48e5-8a5e-36164dadfbc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5d659753-5f65-48f5-a15e-b8871bd90b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:to="loc_us-gaap_SalesMember_5d659753-5f65-48f5-a15e-b8871bd90b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_55e589e5-8f9c-4fbb-975e-b1d33f742cdf" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f3fb825d-fd4e-43a2-b81f-4aee096e7dcc" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_55e589e5-8f9c-4fbb-975e-b1d33f742cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_049af84a-ed50-48e2-8cdc-c421c8968791" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d067dc8a-d292-40b3-bf17-b5449e6834f1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_049af84a-ed50-48e2-8cdc-c421c8968791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e496a82f-ca4e-47ad-a7d3-93fd05850a15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_049af84a-ed50-48e2-8cdc-c421c8968791" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e496a82f-ca4e-47ad-a7d3-93fd05850a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d23933ad-b692-4f8b-98ad-243dd30df127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d23933ad-b692-4f8b-98ad-243dd30df127" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dde3c90-68ce-46b1-90f9-90e69a638090" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfSubsidiaryGainLossMember_2690d1c1-6cfc-4e5c-8362-e289f0d5ad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfSubsidiaryGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:to="loc_us-gaap_SaleOfSubsidiaryGainLossMember_2690d1c1-6cfc-4e5c-8362-e289f0d5ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_e3f073e1-d8f5-4b35-b9f8-a4cf4152f1b0" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7169aa69-e49e-414c-bb31-5fc1ea78f2d3" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_e3f073e1-d8f5-4b35-b9f8-a4cf4152f1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5e1a5cc9-dd44-4133-a8f6-31fc90e74e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4b0c9bbf-382a-4090-a873-7dcdbfaa9786" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5e1a5cc9-dd44-4133-a8f6-31fc90e74e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_0aaaf0be-f712-4359-9b34-c6d5d82e96a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5e1a5cc9-dd44-4133-a8f6-31fc90e74e86" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_0aaaf0be-f712-4359-9b34-c6d5d82e96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_41d2b7ec-1141-4a5c-98a6-5850c81190ce" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_937499e8-9742-431d-b26e-a55a7cb06661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_937499e8-9742-431d-b26e-a55a7cb06661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_08f0117e-09f2-4174-a610-a898299b7c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a048dd92-5754-4314-8dc8-588dc3b1a7b6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_08f0117e-09f2-4174-a610-a898299b7c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fd4c9708-8aa1-447f-95dc-c9d613e26638" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fd4c9708-8aa1-447f-95dc-c9d613e26638" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0d543771-f7d4-49d1-97a3-461b2ff9b6ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d106aba4-dd0e-4291-8354-e18a994e7913" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0d543771-f7d4-49d1-97a3-461b2ff9b6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f871137b-11f6-4807-b5cc-15d93aa6be0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0d543771-f7d4-49d1-97a3-461b2ff9b6ea" xlink:to="loc_us-gaap_EquitySecuritiesMember_f871137b-11f6-4807-b5cc-15d93aa6be0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a5bf0980-ee7e-4786-855f-b9023f765973" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_65f247b5-6016-4aac-bb02-1a1fc889ffdc" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_65f247b5-6016-4aac-bb02-1a1fc889ffdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_7ff8c326-c1f1-44e1-ab5c-8eb26b755666" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_56d7acc5-e137-4412-be30-bca9f6bbaa46" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_7ff8c326-c1f1-44e1-ab5c-8eb26b755666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_ba614703-57e7-43ad-aaef-43b50097a2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_8c059265-2f5f-4e8a-9541-13e25a62822d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_ba614703-57e7-43ad-aaef-43b50097a2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_ba614703-57e7-43ad-aaef-43b50097a2cc" xlink:to="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f6475413-98ba-4f36-b40b-d67b976c1de7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f6475413-98ba-4f36-b40b-d67b976c1de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_310f138f-9055-4653-afd1-6963cfa9f9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_EquityFairValueAdjustment_310f138f-9055-4653-afd1-6963cfa9f9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_40a06d91-665d-4efe-931f-f733249e0aeb" xlink:href="jnj-20210103.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_40a06d91-665d-4efe-931f-f733249e0aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ff614135-5c45-40d8-97cf-0813e3bccd80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ff614135-5c45-40d8-97cf-0813e3bccd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f4990a2-c7d5-4e81-824c-916c71cfbdca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_8b6f5444-1e02-41a4-b24b-e3e1f713affd" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f4990a2-c7d5-4e81-824c-916c71cfbdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_edd4642d-047b-4553-b636-d3f55d4f6ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_edd4642d-047b-4553-b636-d3f55d4f6ddf" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_638e62ca-7e3a-4e75-ae1e-5f4d954fbce2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7d424ef9-5eae-4473-b846-cde95ad3d1f5" xlink:to="loc_us-gaap_HedgingDesignationDomain_638e62ca-7e3a-4e75-ae1e-5f4d954fbce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9bc11d32-8d91-4249-92dd-2899493f8109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_638e62ca-7e3a-4e75-ae1e-5f4d954fbce2" xlink:to="loc_us-gaap_NondesignatedMember_9bc11d32-8d91-4249-92dd-2899493f8109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_deb59534-03da-4cf3-ac03-5ed67a60bf2a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9211402f-beb2-4eec-8ed9-5e8dea2ecbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:to="loc_us-gaap_InterestRateContractMember_9211402f-beb2-4eec-8ed9-5e8dea2ecbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_bb494e54-dd7d-4510-8362-c10658cd9698" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7671d92c-26eb-4810-983e-01776d07a687" xlink:to="loc_us-gaap_ForeignExchangeContractMember_bb494e54-dd7d-4510-8362-c10658cd9698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_201cc5a6-d8c6-48bb-9065-98e9299c9c50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ddc55022-5ebd-4721-bba3-b0505d0ab1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ddc55022-5ebd-4721-bba3-b0505d0ab1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0513710b-fe44-4f4c-a5a6-b71c0b13c582" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0513710b-fe44-4f4c-a5a6-b71c0b13c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5f49f004-b174-48dc-b4e4-0e02cd16eaef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515c7f01-d9e1-468b-b605-8ca765669c70" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5f49f004-b174-48dc-b4e4-0e02cd16eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46f69d3f-90f5-45b9-a1b5-251f62263606" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_2674c9ed-d6ba-4b1d-8cb2-4026535e2abd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46f69d3f-90f5-45b9-a1b5-251f62263606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f22443b4-04d0-4711-8a14-2fc950b36c62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_46f69d3f-90f5-45b9-a1b5-251f62263606" xlink:to="loc_us-gaap_EquitySecuritiesMember_f22443b4-04d0-4711-8a14-2fc950b36c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_222facd6-55f7-4550-8723-11a7c4639652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5d145fc-a1df-4beb-a890-cdf2ebaeb79e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_222facd6-55f7-4550-8723-11a7c4639652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_17d8bff4-321a-45dc-a0fa-721cfed8eaed" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_222facd6-55f7-4550-8723-11a7c4639652" xlink:to="loc_jnj_AurisHealthMember_17d8bff4-321a-45dc-a0fa-721cfed8eaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0c68e225-5fd9-4532-842b-f06ff8d0a2d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_31b5c0de-93c4-4200-b88b-c585d153e4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_31b5c0de-93c4-4200-b88b-c585d153e4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7ef7123f-1ae6-4877-a456-cbf039e66947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7084fb07-5a90-4218-b8d5-a86a3e667465" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7ef7123f-1ae6-4877-a456-cbf039e66947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4ffc396-d4ae-4b17-992b-1a3f8eb06fca" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b97f3194-1505-4e78-8413-545876dbb34c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b97f3194-1505-4e78-8413-545876dbb34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_c3829a61-675b-46dc-8a82-6281c9f3ffe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_c3829a61-675b-46dc-8a82-6281c9f3ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8c27a4ec-45f9-4019-b784-c9fa2c8608b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8c27a4ec-45f9-4019-b784-c9fa2c8608b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7eef99ab-6604-4946-bbe2-69699f89473a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_7eef99ab-6604-4946-bbe2-69699f89473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_57d4614c-ed67-447b-8d91-981626100021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_57d4614c-ed67-447b-8d91-981626100021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a7e52ae-211c-450c-81c4-b2fa4e0c09e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2a7e52ae-211c-450c-81c4-b2fa4e0c09e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_69b7b132-858b-4369-a924-f75dbc2f84db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_4aaf6ae6-e922-49d6-a866-26926395a1e4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_69b7b132-858b-4369-a924-f75dbc2f84db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_64fa852f-9b55-40ac-b2f9-b4da2c3012cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_64fa852f-9b55-40ac-b2f9-b4da2c3012cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_fc363727-1d0e-477b-a252-b5e5331be384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_fc363727-1d0e-477b-a252-b5e5331be384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7f2cbbcc-7cb6-4c53-8e1e-56e459021953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeAssets_7f2cbbcc-7cb6-4c53-8e1e-56e459021953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c897ced-1b4b-44b9-b689-af9a1d9938a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c897ced-1b4b-44b9-b689-af9a1d9938a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0e163f2f-0b0a-4d1f-aaab-99d5f55def1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0e163f2f-0b0a-4d1f-aaab-99d5f55def1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_51b7a6b3-c1c5-4514-b5e6-d1ae985cd6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeLiabilities_51b7a6b3-c1c5-4514-b5e6-d1ae985cd6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b7425309-36c3-4d1d-84cc-c4911f467ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b7425309-36c3-4d1d-84cc-c4911f467ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_93b4e2b8-8977-486d-9561-247b05fc8212" xlink:href="jnj-20210103.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_93b4e2b8-8977-486d-9561-247b05fc8212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d626002b-a80d-43c8-8ad1-88f3659e020e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d626002b-a80d-43c8-8ad1-88f3659e020e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7c95cc5d-35ca-41cc-a89b-5d231f1064ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7c95cc5d-35ca-41cc-a89b-5d231f1064ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_79217428-6cb9-4ff0-bbf4-054f13d39d47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_79217428-6cb9-4ff0-bbf4-054f13d39d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8582a220-dd86-477d-89f5-12cdb6fbd08f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8582a220-dd86-477d-89f5-12cdb6fbd08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc0e1261-838e-4bf1-b44a-4dad8e22439d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_19b58afa-1a45-4896-b974-bc0ccc77981d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc0e1261-838e-4bf1-b44a-4dad8e22439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Borrowings" xlink:type="simple" xlink:href="jnj-20210103.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5980c888-c4f9-4ecb-9062-69a4dc80dfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_348eb42d-9d6f-44ca-8a49-2c9fc2607a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5980c888-c4f9-4ecb-9062-69a4dc80dfd9" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_348eb42d-9d6f-44ca-8a49-2c9fc2607a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f429c8f7-27b9-4a3b-bc0b-7c17efa5430f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_bac41d9e-7666-4626-bac8-a7c0502a6d82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f429c8f7-27b9-4a3b-bc0b-7c17efa5430f" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_bac41d9e-7666-4626-bac8-a7c0502a6d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_656734e4-4afe-4547-85ea-2da10a5c182d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f429c8f7-27b9-4a3b-bc0b-7c17efa5430f" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_656734e4-4afe-4547-85ea-2da10a5c182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cbb9b7c2-cab4-4e81-92a1-4bf38e8d7125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cbb9b7c2-cab4-4e81-92a1-4bf38e8d7125" xlink:to="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_48ddb7fb-badf-43f8-95f2-5a7e6acc4eaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_5ecbdd6c-8122-447b-878a-15891d334191" xlink:href="jnj-20210103.xsd#jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member_5ecbdd6c-8122-447b-878a-15891d334191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Debenturesdue2020Member_07f14121-3778-449e-8b77-47aadd8979ba" xlink:href="jnj-20210103.xsd#jnj_A2.95Debenturesdue2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.95Debenturesdue2020Member_07f14121-3778-449e-8b77-47aadd8979ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.950Notesdue2020Member_0a8d4d60-28c7-4367-8f6a-c9721e8399b3" xlink:href="jnj-20210103.xsd#jnj_A1.950Notesdue2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.950Notesdue2020Member_0a8d4d60-28c7-4367-8f6a-c9721e8399b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2021Member_3dbdfdfb-b9b4-4626-acac-eaf73999b7e0" xlink:href="jnj-20210103.xsd#jnj_A3.55Notesdue2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.55Notesdue2021Member_3dbdfdfb-b9b4-4626-acac-eaf73999b7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2021Member_e414572b-fe91-408c-be1d-4093183e12e2" xlink:href="jnj-20210103.xsd#jnj_A2.45Notesdue2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.45Notesdue2021Member_e414572b-fe91-408c-be1d-4093183e12e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.65Notesdue2021Member_6d77948f-75ef-4b34-a264-58436851e2c1" xlink:href="jnj-20210103.xsd#jnj_A1.65Notesdue2021Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.65Notesdue2021Member_6d77948f-75ef-4b34-a264-58436851e2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_cb607ac3-99ec-4860-9161-fbf3eec4d801" xlink:href="jnj-20210103.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A0.250NotesDue2022Member_cb607ac3-99ec-4860-9161-fbf3eec4d801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member_8439d51a-bdad-4ae9-9326-0f00b430ae01" xlink:href="jnj-20210103.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.25Notesdue2022Member_8439d51a-bdad-4ae9-9326-0f00b430ae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_e1c237ba-25d7-427a-9f86-22bc98a70f2d" xlink:href="jnj-20210103.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_e1c237ba-25d7-427a-9f86-22bc98a70f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_5f0540fc-ef42-4156-b1ba-7d82f9c9d583" xlink:href="jnj-20210103.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.375Notesdue2023Member_5f0540fc-ef42-4156-b1ba-7d82f9c9d583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_fcc6ae55-28e1-45d3-b95f-e5e1baa83e7b" xlink:href="jnj-20210103.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.05Notesdue2023Member_fcc6ae55-28e1-45d3-b95f-e5e1baa83e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_e0a16005-0049-475a-822e-e42381c8e97b" xlink:href="jnj-20210103.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A0.650NotesDue2024Member_e0a16005-0049-475a-822e-e42381c8e97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_996e6ad0-16d2-42f6-a354-e6a42710cfbf" xlink:href="jnj-20210103.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A5.50NotesDue2024Member_996e6ad0-16d2-42f6-a354-e6a42710cfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_c8ca855e-533d-4817-a70a-3807c10e5917" xlink:href="jnj-20210103.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.625Notesdue2025Member_c8ca855e-533d-4817-a70a-3807c10e5917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_1944b01c-a8d3-4783-8b19-b2b53b93a0f7" xlink:href="jnj-20210103.xsd#jnj_A055NotesDue2025Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A055NotesDue2025Member_1944b01c-a8d3-4783-8b19-b2b53b93a0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_3a492ede-4390-4936-81eb-6b7ca0411702" xlink:href="jnj-20210103.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.45Notesdue2026Member_3a492ede-4390-4936-81eb-6b7ca0411702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_8e59275e-53da-40ca-8732-746679798fef" xlink:href="jnj-20210103.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.95Notesdue2027Member_8e59275e-53da-40ca-8732-746679798fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_e7e925c4-2f42-4dda-8023-7b0e9fc69b38" xlink:href="jnj-20210103.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A095NotesDue2027Member_e7e925c4-2f42-4dda-8023-7b0e9fc69b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_350b2fd1-05d6-403c-8b8d-4bcd3e142664" xlink:href="jnj-20210103.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.150NotesDue2028Member_350b2fd1-05d6-403c-8b8d-4bcd3e142664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_e33ce12f-f1ec-4730-a0a8-b2b6952e0536" xlink:href="jnj-20210103.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2.900Notesdue2028Member_e33ce12f-f1ec-4730-a0a8-b2b6952e0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_40da9fe9-dd42-4131-badd-2fc69270d577" xlink:href="jnj-20210103.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A6.95Notesdue2029Member_40da9fe9-dd42-4131-badd-2fc69270d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_92447877-e282-4705-b68d-9471e0c60ae1" xlink:href="jnj-20210103.xsd#jnj_A130NotesDue2030Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A130NotesDue2030Member_92447877-e282-4705-b68d-9471e0c60ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_57337bba-6538-4687-84d1-2f03f55d136d" xlink:href="jnj-20210103.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_57337bba-6538-4687-84d1-2f03f55d136d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_998dd85d-eee8-4730-bd80-8ee0f82372e0" xlink:href="jnj-20210103.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.375Notesdue2033Member_998dd85d-eee8-4730-bd80-8ee0f82372e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_968aa62d-f038-4635-a6f7-15c6d2de37a0" xlink:href="jnj-20210103.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A1.650NotesDue2035Member_968aa62d-f038-4635-a6f7-15c6d2de37a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_eeeac2ba-9025-41dd-af75-9ffca6cbc8ac" xlink:href="jnj-20210103.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.55Notesdue2036Member_eeeac2ba-9025-41dd-af75-9ffca6cbc8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_50ca7ed2-23dd-4828-8d8d-98008166ed01" xlink:href="jnj-20210103.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A5.95Notesdue2037Member_50ca7ed2-23dd-4828-8d8d-98008166ed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_52627f28-1bb1-4dd2-9333-037ba4639593" xlink:href="jnj-20210103.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.625Notesdue2037Member_52627f28-1bb1-4dd2-9333-037ba4639593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_c4722459-d43f-4b37-b7df-3d1ef49e44b4" xlink:href="jnj-20210103.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_c4722459-d43f-4b37-b7df-3d1ef49e44b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_2969233e-e6db-47b2-9608-19670b6993e7" xlink:href="jnj-20210103.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.400Notesdue2038Member_2969233e-e6db-47b2-9608-19670b6993e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_95e10374-094e-4b0d-a0b8-aa8a51877d53" xlink:href="jnj-20210103.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_95e10374-094e-4b0d-a0b8-aa8a51877d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_e9e628ba-29ce-4bf0-a159-17979c23583f" xlink:href="jnj-20210103.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A210NotesDue2040Member_e9e628ba-29ce-4bf0-a159-17979c23583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_b176ea70-7f32-4791-b0a1-c6eedfb199ca" xlink:href="jnj-20210103.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.85Notesdue2041Member_b176ea70-7f32-4791-b0a1-c6eedfb199ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_9510ba7a-1a29-4008-935c-b2814b32085b" xlink:href="jnj-20210103.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A4.50Notesdue2043Member_9510ba7a-1a29-4008-935c-b2814b32085b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_734f3482-30d1-476c-8fcb-e12cee90761b" xlink:href="jnj-20210103.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.70Notesdue2046Member_734f3482-30d1-476c-8fcb-e12cee90761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_9179d733-c74f-484e-9078-4154d39d7340" xlink:href="jnj-20210103.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.75Notesdue2047Member_9179d733-c74f-484e-9078-4154d39d7340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_c40c2b41-a656-4fe6-beea-785abcac84e4" xlink:href="jnj-20210103.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A3.500Notesdue2048Member_c40c2b41-a656-4fe6-beea-785abcac84e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_d5082afc-8c5d-456c-8bf0-b7a1cdbcaeaa" xlink:href="jnj-20210103.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2250NotesDue2050Member_d5082afc-8c5d-456c-8bf0-b7a1cdbcaeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_0880106a-f1dc-42e6-81c2-8d4adfd4529a" xlink:href="jnj-20210103.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_jnj_A2450NotesDue2060Member_0880106a-f1dc-42e6-81c2-8d4adfd4529a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_7a650ab3-14bc-493f-a072-b17ae2dc8134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0cfd8a5-b35a-4490-9394-d35a959353f2" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_7a650ab3-14bc-493f-a072-b17ae2dc8134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3abdc53-f1da-483c-b337-65e842066fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1295d018-dfae-4e6c-b772-260579158adb" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3abdc53-f1da-483c-b337-65e842066fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f379591c-4361-41de-9a16-8b5a8b7de5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c3abdc53-f1da-483c-b337-65e842066fb6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f379591c-4361-41de-9a16-8b5a8b7de5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_29b1e866-6018-45ac-b91f-bf94ae45fd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f379591c-4361-41de-9a16-8b5a8b7de5bd" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_29b1e866-6018-45ac-b91f-bf94ae45fd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9621b25e-2fe2-49fc-a7a5-2e17778242cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8e4cde8b-d8d3-4ed0-bb96-220f7091becd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9621b25e-2fe2-49fc-a7a5-2e17778242cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_18766fc1-5968-4403-a9dd-d28cc8a484d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9621b25e-2fe2-49fc-a7a5-2e17778242cb" xlink:to="loc_us-gaap_SeniorNotesMember_18766fc1-5968-4403-a9dd-d28cc8a484d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3e4731c-53ed-4d01-834b-380729b05a74" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a86991f8-e4f7-4cc5-aa0f-dfb1a9040876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a86991f8-e4f7-4cc5-aa0f-dfb1a9040876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_919d5b81-0100-4287-b20a-549703219045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_919d5b81-0100-4287-b20a-549703219045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4e07376e-1c1e-43d1-88e0-9c1b00383006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermDebt_4e07376e-1c1e-43d1-88e0-9c1b00383006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_49c09794-9fb9-4756-a077-fe0fde62b62a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermDebtCurrent_49c09794-9fb9-4756-a077-fe0fde62b62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_eeef1885-8961-47c5-9e1c-5f24da61ad3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_eeef1885-8961-47c5-9e1c-5f24da61ad3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35bd34b6-a0bb-467d-815c-5846d1602704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35bd34b6-a0bb-467d-815c-5846d1602704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f62f339e-d8ec-4175-8e0b-19a4bcf987a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f62f339e-d8ec-4175-8e0b-19a4bcf987a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_376c3b37-ffb6-4803-b8f7-c79d1fce3182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1b72508-75a7-44d0-8f8d-9ed0650ed002" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_376c3b37-ffb6-4803-b8f7-c79d1fce3182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9de915f8-4740-4ada-b701-74b956de7014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_43ec96ce-ae5d-4856-ba83-b2abc014cc09" xlink:href="jnj-20210103.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9de915f8-4740-4ada-b701-74b956de7014" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_43ec96ce-ae5d-4856-ba83-b2abc014cc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_30a0e0b3-9225-44e6-8252-2b4041cef8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9de915f8-4740-4ada-b701-74b956de7014" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_30a0e0b3-9225-44e6-8252-2b4041cef8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_9c959112-2b95-45ee-904d-0895517854e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9de915f8-4740-4ada-b701-74b956de7014" xlink:to="loc_us-gaap_DebtCurrent_9c959112-2b95-45ee-904d-0895517854e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_cf3d1b80-fcb3-4dfa-b07f-b3141cecfaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9de915f8-4740-4ada-b701-74b956de7014" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_cf3d1b80-fcb3-4dfa-b07f-b3141cecfaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f49dfe44-9457-4bce-b229-b6f3618e1a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9de915f8-4740-4ada-b701-74b956de7014" xlink:to="loc_us-gaap_LongTermDebtCurrent_f49dfe44-9457-4bce-b229-b6f3618e1a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3c6bb9ac-9a1f-4f76-897c-3a6d395715da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3c6bb9ac-9a1f-4f76-897c-3a6d395715da" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b979ee99-c869-4292-9e40-fe64be886867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b979ee99-c869-4292-9e40-fe64be886867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_736f4e71-7da2-4460-a20a-4b1eef7c1c15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_736f4e71-7da2-4460-a20a-4b1eef7c1c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_330e08ae-8a18-4bc2-90ba-c4c1d8ce1954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_330e08ae-8a18-4bc2-90ba-c4c1d8ce1954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cbf816c9-88b0-4dc8-8a14-0b69bf32397a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cbf816c9-88b0-4dc8-8a14-0b69bf32397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a4e29386-a499-4d7d-8428-977f14ada1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a4e29386-a499-4d7d-8428-977f14ada1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_0f938207-8c18-471a-b4d9-cabeb854e368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_6e60d6df-ed06-4d7d-83eb-cd9582bb8aac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_0f938207-8c18-471a-b4d9-cabeb854e368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c83bf1c-9d72-4dbd-ac30-0c2541939de8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3aa6cf04-6261-472c-b61c-88bd089ca1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c83bf1c-9d72-4dbd-ac30-0c2541939de8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3aa6cf04-6261-472c-b61c-88bd089ca1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2eb649dc-7950-42b1-a27b-21b33b8545bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ce9d623e-5ee0-4031-a49d-f8860defa795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2eb649dc-7950-42b1-a27b-21b33b8545bb" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ce9d623e-5ee0-4031-a49d-f8860defa795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_99d4d6d7-958b-47dc-b738-c6d1ae489f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2eb649dc-7950-42b1-a27b-21b33b8545bb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_99d4d6d7-958b-47dc-b738-c6d1ae489f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d0a31fed-4ad5-496c-9fa6-b936a708733d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2eb649dc-7950-42b1-a27b-21b33b8545bb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d0a31fed-4ad5-496c-9fa6-b936a708733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_99615cae-ded4-4099-95e3-c5b36809313a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2eb649dc-7950-42b1-a27b-21b33b8545bb" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_99615cae-ded4-4099-95e3-c5b36809313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c54d5193-f7f6-4852-bac5-8e5d651a04c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c034eeb-7885-412a-b3ec-c283afa573c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c54d5193-f7f6-4852-bac5-8e5d651a04c2" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c034eeb-7885-412a-b3ec-c283afa573c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a7ccfa86-41be-4663-bbaf-c1736315bc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c034eeb-7885-412a-b3ec-c283afa573c7" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a7ccfa86-41be-4663-bbaf-c1736315bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ff89aed6-3374-49d6-869d-167b6d52b9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c034eeb-7885-412a-b3ec-c283afa573c7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ff89aed6-3374-49d6-869d-167b6d52b9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_124fb8fc-26d5-4cf2-8467-d024e1dcd306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c034eeb-7885-412a-b3ec-c283afa573c7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_124fb8fc-26d5-4cf2-8467-d024e1dcd306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_89662813-2e2c-4dcf-b43e-2ae3f1244664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c54d5193-f7f6-4852-bac5-8e5d651a04c2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_89662813-2e2c-4dcf-b43e-2ae3f1244664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_915a7307-3348-4b40-be14-44fcbfbc5d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_89662813-2e2c-4dcf-b43e-2ae3f1244664" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_915a7307-3348-4b40-be14-44fcbfbc5d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6907bc81-fb0c-410f-8409-4ba986f305fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_89662813-2e2c-4dcf-b43e-2ae3f1244664" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6907bc81-fb0c-410f-8409-4ba986f305fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c182840a-750c-4ab1-9c1f-965697c77bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_89662813-2e2c-4dcf-b43e-2ae3f1244664" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c182840a-750c-4ab1-9c1f-965697c77bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1bd69613-9b18-4181-bdd7-d679547a94cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c54d5193-f7f6-4852-bac5-8e5d651a04c2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1bd69613-9b18-4181-bdd7-d679547a94cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_ae7f50d6-b6e4-4f65-93fe-90c897f8f255" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c54d5193-f7f6-4852-bac5-8e5d651a04c2" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_ae7f50d6-b6e4-4f65-93fe-90c897f8f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_6c57ddda-bd44-4b85-8c36-f9129e9b6cdd" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c54d5193-f7f6-4852-bac5-8e5d651a04c2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_6c57ddda-bd44-4b85-8c36-f9129e9b6cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c5c71d0a-50fe-4afe-803c-263af56d987e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_1168c636-e9c8-4285-9af7-1665bae5d28c" xlink:href="jnj-20210103.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5c71d0a-50fe-4afe-803c-263af56d987e" xlink:to="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_1168c636-e9c8-4285-9af7-1665bae5d28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fc0f4bc4-dd36-434d-8fd7-3ac3f891cc56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_1168c636-e9c8-4285-9af7-1665bae5d28c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fc0f4bc4-dd36-434d-8fd7-3ac3f891cc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b8e1a7b8-6e68-487e-8f14-887234b21eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_1168c636-e9c8-4285-9af7-1665bae5d28c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b8e1a7b8-6e68-487e-8f14-887234b21eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7f20d8e2-414c-45d3-85e0-657c2dbbcc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_1168c636-e9c8-4285-9af7-1665bae5d28c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7f20d8e2-414c-45d3-85e0-657c2dbbcc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_1168c636-e9c8-4285-9af7-1665bae5d28c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ee79edb8-9e71-49ef-9907-3d0d70778ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ee79edb8-9e71-49ef-9907-3d0d70778ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c2812056-58bc-4bc9-ac79-b17a8e3ff645" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c2812056-58bc-4bc9-ac79-b17a8e3ff645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_1dfc7584-0502-4604-9a37-0814e70409e7" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_1dfc7584-0502-4604-9a37-0814e70409e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_693c996b-469d-4ba6-a7b1-2fcddbe87fe0" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_693c996b-469d-4ba6-a7b1-2fcddbe87fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_014e199f-9e45-4858-9b01-f22bb8e080bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_014e199f-9e45-4858-9b01-f22bb8e080bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_acd98790-3044-40f5-8afc-435752bb5bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_acd98790-3044-40f5-8afc-435752bb5bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8c5d54d0-d93c-4416-ab92-a3f70e59e76e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8c5d54d0-d93c-4416-ab92-a3f70e59e76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_75ef3398-6148-4583-93e7-e9e8ef426aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0f77799b-7306-4f1b-ac04-575b1f7891fd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_75ef3398-6148-4583-93e7-e9e8ef426aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d89abbe8-cecd-419e-b14a-81368dfc7c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d89abbe8-cecd-419e-b14a-81368dfc7c7c" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_9c436930-0d4e-4c2b-9417-be75be999f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_9c436930-0d4e-4c2b-9417-be75be999f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2a9660b5-2540-4912-ba19-da472c374153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2a9660b5-2540-4912-ba19-da472c374153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_3495ef06-efa5-4bed-b15c-ff0313ac740f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_3495ef06-efa5-4bed-b15c-ff0313ac740f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_dc5f288d-3f05-4174-aa90-414e417bccd8" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_dc5f288d-3f05-4174-aa90-414e417bccd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_f570d26f-f20d-4647-a174-9b7ce5b73f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_f570d26f-f20d-4647-a174-9b7ce5b73f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_bfb5017c-62b2-43a5-b5de-5d34cb978d16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_bfb5017c-62b2-43a5-b5de-5d34cb978d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_a4c96bf0-cbb7-4107-9a7c-d30060cfabbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_a4c96bf0-cbb7-4107-9a7c-d30060cfabbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_aab514ba-3182-40b5-80b3-9ccb4b286977" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_aab514ba-3182-40b5-80b3-9ccb4b286977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_fc4929fe-5258-4205-9f7e-c0039f501512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_fc4929fe-5258-4205-9f7e-c0039f501512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_a76cbf2b-2a80-41ad-b736-afeffae60a97" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_a76cbf2b-2a80-41ad-b736-afeffae60a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a50ef8f4-819c-4a90-b618-07a87c984e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a50ef8f4-819c-4a90-b618-07a87c984e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_28b1e2ca-d235-4f15-b636-7e63f2851638" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign_28b1e2ca-d235-4f15-b636-7e63f2851638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_d4d8b3a4-0d24-4605-ab9b-cb4c9458f031" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_d4d8b3a4-0d24-4605-ab9b-cb4c9458f031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_9d7f18de-2312-4b1d-9f6d-b234783a4d70" xlink:href="jnj-20210103.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_9d7f18de-2312-4b1d-9f6d-b234783a4d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ff68536c-bdc0-4f6e-8345-2ec1d02af094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ff68536c-bdc0-4f6e-8345-2ec1d02af094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_43e9b5b5-fcb1-4de9-87cd-5f6360303549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_43e9b5b5-fcb1-4de9-87cd-5f6360303549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_98390c87-f520-41bb-8fa2-4a39c380bb6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2a88bc95-56bc-4b1e-8147-5e7b5c999a66" xlink:to="loc_us-gaap_DeferredTaxLiabilities_98390c87-f520-41bb-8fa2-4a39c380bb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddff9a9e-28f4-4c9f-b95d-5a1cbafad10d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddff9a9e-28f4-4c9f-b95d-5a1cbafad10d" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_65075fa3-37e1-4a3f-b482-0258ecc47ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_65075fa3-37e1-4a3f-b482-0258ecc47ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6a21ce7d-bc40-4549-bf30-75443a58cb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6a21ce7d-bc40-4549-bf30-75443a58cb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d4cea454-5fc7-4c28-a119-a23d5b8214d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d4cea454-5fc7-4c28-a119-a23d5b8214d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_af990224-9486-4771-929e-6ee83e7bfbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_af990224-9486-4771-929e-6ee83e7bfbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_48a00b4c-fd6f-493b-b6c3-7923617508b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_48a00b4c-fd6f-493b-b6c3-7923617508b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e86c2e85-96ed-4fb0-bf57-7d4c7f9582ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e86c2e85-96ed-4fb0-bf57-7d4c7f9582ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b07b5251-fac0-41c8-9f55-01103833d996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e2fb39c2-739a-44d5-a3d4-ff9c8b2d533a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b07b5251-fac0-41c8-9f55-01103833d996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6a65be56-dd63-4c6f-b726-844ad4ddd59b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a65be56-dd63-4c6f-b726-844ad4ddd59b" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3f029743-e99e-42a1-bc27-b7f1cccba7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_bbfcb560-d56c-4527-b8aa-3eaa0b4e8cb4" xlink:to="loc_us-gaap_LitigationStatusDomain_3f029743-e99e-42a1-bc27-b7f1cccba7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_9af184a5-ae05-4550-8d8d-0325a60515a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3f029743-e99e-42a1-bc27-b7f1cccba7ba" xlink:to="loc_us-gaap_PendingLitigationMember_9af184a5-ae05-4550-8d8d-0325a60515a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94d51f8b-7615-4135-951b-317c1e46baf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e467ae2f-570a-4597-9d27-79c1f79991b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94d51f8b-7615-4135-951b-317c1e46baf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedTaxesOnIncomeMember_2f2739df-6ee7-4b43-9af4-e1ba0c9bd7fc" xlink:href="jnj-20210103.xsd#jnj_AccruedTaxesOnIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94d51f8b-7615-4135-951b-317c1e46baf0" xlink:to="loc_jnj_AccruedTaxesOnIncomeMember_2f2739df-6ee7-4b43-9af4-e1ba0c9bd7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_9be12c7f-bf88-4f13-a27c-fa83621fb2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_78888534-e0f8-4d5b-b5af-dc3c82648876" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_9be12c7f-bf88-4f13-a27c-fa83621fb2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7c0147fa-60ec-4b53-98bc-ec118b876965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9be12c7f-bf88-4f13-a27c-fa83621fb2fa" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_7c0147fa-60ec-4b53-98bc-ec118b876965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67531cc0-f808-40f1-857e-d80d41673001" xlink:to="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_2640b1c6-6ebd-47df-a000-f7cd12f61322" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:to="loc_jnj_ConsumerMember_2640b1c6-6ebd-47df-a000-f7cd12f61322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_219c82e7-f485-43ff-a5a2-11357e308da8" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9ab563e6-c159-441f-aae1-099d201a3cf5" xlink:to="loc_jnj_PharmaceuticalMember_219c82e7-f485-43ff-a5a2-11357e308da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9e9abff6-c65e-4773-a5d5-bc6f7500488d" xlink:to="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_8a0fa0e0-0efd-41cf-bb9c-c91beff3c72e" xlink:href="jnj-20210103.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:to="loc_jnj_TalcMember_8a0fa0e0-0efd-41cf-bb9c-c91beff3c72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_43bfba13-2a29-4927-b08b-ad06d2548177" xlink:href="jnj-20210103.xsd#jnj_OpiodsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6baf6682-47ad-4aaa-8b8d-5f757a7839c4" xlink:to="loc_jnj_OpiodsMember_43bfba13-2a29-4927-b08b-ad06d2548177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_eadc0596-9472-485c-ab36-ba5e989518cb" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d927b98a-1a6f-432e-94e9-226ef58b9d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d927b98a-1a6f-432e-94e9-226ef58b9d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_f62c1f8b-b20a-4454-8663-aad09ef1d328" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_f62c1f8b-b20a-4454-8663-aad09ef1d328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_27da41c0-bf30-48ad-b052-aa2fa7f87fe4" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_27da41c0-bf30-48ad-b052-aa2fa7f87fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0942196f-3065-4cf9-9ceb-28832c2e7a04" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0942196f-3065-4cf9-9ceb-28832c2e7a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_870673e0-86c4-4b3b-90bd-27a803896458" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_870673e0-86c4-4b3b-90bd-27a803896458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_c116e6a0-57f1-47e8-8345-eee98de5c810" xlink:href="jnj-20210103.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_c116e6a0-57f1-47e8-8345-eee98de5c810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_bfa6b914-aa44-4afc-a76c-3db0311013fc" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_bfa6b914-aa44-4afc-a76c-3db0311013fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_9fd15674-2fc2-4657-9794-0d683318d5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_9fd15674-2fc2-4657-9794-0d683318d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_25e02910-26f3-4484-a60a-e4da69106d8e" xlink:href="jnj-20210103.xsd#jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_25e02910-26f3-4484-a60a-e4da69106d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_476acfd6-4ad6-4f15-96be-65acc7898f8d" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_476acfd6-4ad6-4f15-96be-65acc7898f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_38039199-7d6c-4a16-a81c-cf1623425cf8" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_38039199-7d6c-4a16-a81c-cf1623425cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5c37f9c0-1f30-4fd3-b505-332ad290cd30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5c37f9c0-1f30-4fd3-b505-332ad290cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d43c126d-b6e7-4719-90dd-83b9df87ca33" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d43c126d-b6e7-4719-90dd-83b9df87ca33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_6f8452af-c087-48bf-b457-15c907604842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_6f8452af-c087-48bf-b457-15c907604842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_b5294fb2-b7e6-4f93-ade1-72ccde5925a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_LitigationSettlementExpense_b5294fb2-b7e6-4f93-ade1-72ccde5925a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_5fb0960e-df22-499a-a3eb-7001b755beba" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_5fb0960e-df22-499a-a3eb-7001b755beba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_5979735a-a059-4a89-868d-e7a653c82467" xlink:href="jnj-20210103.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_5979735a-a059-4a89-868d-e7a653c82467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_1bfdc0cc-4a6b-4905-94a1-d3f4ce94420a" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_1bfdc0cc-4a6b-4905-94a1-d3f4ce94420a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_36746ab4-94dc-4de7-ad5f-99ea74ca7f3c" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_36746ab4-94dc-4de7-ad5f-99ea74ca7f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_04d67e96-3e88-434d-b572-a98e39793919" xlink:href="jnj-20210103.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_04d67e96-3e88-434d-b572-a98e39793919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_4ec30fa2-d8a7-4098-ba88-bbb995479c1b" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit_4ec30fa2-d8a7-4098-ba88-bbb995479c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a29df547-55fa-4f11-af9a-e8e1696d9dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a29df547-55fa-4f11-af9a-e8e1696d9dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_33399c19-573c-4a97-9f86-b1822ad12122" xlink:href="jnj-20210103.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax_33399c19-573c-4a97-9f86-b1822ad12122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_7b5a6479-3c8b-441d-9427-2b2f009d815b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_7b5a6479-3c8b-441d-9427-2b2f009d815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fe7e9ccb-0112-4cec-8eb5-0496ed361d32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fe7e9ccb-0112-4cec-8eb5-0496ed361d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_eb1859ec-ac1f-49f8-8693-000c7bf7d5e8" xlink:href="jnj-20210103.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_eb1859ec-ac1f-49f8-8693-000c7bf7d5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_52a71e36-2387-4b16-b339-7b7e469b3089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_52a71e36-2387-4b16-b339-7b7e469b3089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f9a2e9e8-0e3c-4b48-981a-ae4f4722ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00d5b69b-d6f4-4ffd-b2a9-74d8b6404498" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f9a2e9e8-0e3c-4b48-981a-ae4f4722ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligations"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_a7ee0490-9650-4fc6-81ae-cb05dce21d94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_307b4e8f-94bf-40b0-80fb-5622d062aa03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_a7ee0490-9650-4fc6-81ae-cb05dce21d94" xlink:to="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_307b4e8f-94bf-40b0-80fb-5622d062aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_2c621052-b63b-48b7-b468-9e515ca14891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock_ec47576d-c8a5-4869-9f3d-9c3724450057" xlink:href="jnj-20210103.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_2c621052-b63b-48b7-b468-9e515ca14891" xlink:to="loc_jnj_EmployeeRelatedObligationsTableTextBlock_ec47576d-c8a5-4869-9f3d-9c3724450057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_e72023ef-83b7-4a99-b0ca-53d22ae97fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_e72023ef-83b7-4a99-b0ca-53d22ae97fa5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_e16ab068-f7c8-4728-a676-cca64e9ae35a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_e16ab068-f7c8-4728-a676-cca64e9ae35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_4d662f71-0551-44e3-8d1d-e558b8fdcfed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_4d662f71-0551-44e3-8d1d-e558b8fdcfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_a084313d-1cff-4242-aaf7-596aa6ad7772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_a084313d-1cff-4242-aaf7-596aa6ad7772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_a65556dc-6a33-49bd-a0e2-84f1d0ea246b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_a65556dc-6a33-49bd-a0e2-84f1d0ea246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_7a671736-d209-4176-90fd-9bb0a190f234" xlink:href="jnj-20210103.xsd#jnj_EmployeeObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_jnj_EmployeeObligations_7a671736-d209-4176-90fd-9bb0a190f234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_87ea18bc-035a-44bc-85ab-6209ffa8bf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_87ea18bc-035a-44bc-85ab-6209ffa8bf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_971ede72-44c7-4e1a-a2d5-68d3c74c74dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_01153225-6269-4b37-97e9-c954fd985cca" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_971ede72-44c7-4e1a-a2d5-68d3c74c74dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EmployeeRelatedObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_da74ae97-6a10-4b8a-b5c2-2c20039bae5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a597091e-cc7f-4476-afcb-d1d88fe73343" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_da74ae97-6a10-4b8a-b5c2-2c20039bae5b" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a597091e-cc7f-4476-afcb-d1d88fe73343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1224f17b-e012-402c-9276-c561542b9d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_bd358161-896f-410f-a233-167010d7b6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1224f17b-e012-402c-9276-c561542b9d1c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_bd358161-896f-410f-a233-167010d7b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_87896505-5253-467f-89ab-0b54df4b227d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_87896505-5253-467f-89ab-0b54df4b227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_084ed550-305f-4a2f-800a-883636f66d96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_084ed550-305f-4a2f-800a-883636f66d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_a10ccd7e-013d-4dd4-b0f6-c3bcb5f786bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_a10ccd7e-013d-4dd4-b0f6-c3bcb5f786bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_316a7722-ec18-4c4b-9086-817faf4c26ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_316a7722-ec18-4c4b-9086-817faf4c26ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_228d131c-9bb7-4efb-9cc6-df1eb3723f76" xlink:href="jnj-20210103.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_228d131c-9bb7-4efb-9cc6-df1eb3723f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_c6b53816-846f-4082-a79e-30dcded411ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_c6b53816-846f-4082-a79e-30dcded411ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_9d73742a-8aec-4f15-9a03-a5cc57b462d7" xlink:href="jnj-20210103.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_9d73742a-8aec-4f15-9a03-a5cc57b462d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_40dc2534-a8f1-4d3c-a90c-8de61a17edaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_40dc2534-a8f1-4d3c-a90c-8de61a17edaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_b64cc75a-4875-4742-b112-e66120f628d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a79c72b-239d-49ca-b60b-d0a5012b4016" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_b64cc75a-4875-4742-b112-e66120f628d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_954a313d-ec25-4337-8576-96e63cbf0ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_954a313d-ec25-4337-8576-96e63cbf0ec2" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c148cbb7-af92-462c-93cc-ca0ec49d906e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_28223696-95ef-47bd-9f2d-8eef515a29b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_28223696-95ef-47bd-9f2d-8eef515a29b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_82c107ab-fd9f-4291-9fff-51f40a0c771e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ebdd8dca-7dcd-45af-8286-c2a290fe70a7" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_82c107ab-fd9f-4291-9fff-51f40a0c771e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41d25ffa-cbe3-402d-be62-6c865c5271e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_31159f4f-0bd1-4df1-99a1-62a88e6da565" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41d25ffa-cbe3-402d-be62-6c865c5271e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41d25ffa-cbe3-402d-be62-6c865c5271e0" xlink:to="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_cb67503f-4151-4fdb-8085-0827ea80d194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_cb67503f-4151-4fdb-8085-0827ea80d194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_06ce24b4-9793-43fb-a59a-7253fe9592d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_06ce24b4-9793-43fb-a59a-7253fe9592d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bb388392-c68f-41c2-8302-f1f0b36b120b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bb388392-c68f-41c2-8302-f1f0b36b120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9e33deb8-2d43-48d8-b219-4d83ae747128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_9e33deb8-2d43-48d8-b219-4d83ae747128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_d482fd55-c877-4c5b-933c-6a0f945e9894" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_d482fd55-c877-4c5b-933c-6a0f945e9894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_5d817dd7-1c69-48f9-9df9-4d4bfb6ca441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_5d817dd7-1c69-48f9-9df9-4d4bfb6ca441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_51aec211-f14c-4f4b-bea9-e48c8f9a9749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_5035882f-9ed1-47fd-b980-578177ffd5a2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_51aec211-f14c-4f4b-bea9-e48c8f9a9749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_f9969319-d0a9-4ab9-91c1-c6d580cfa01b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_954a313d-ec25-4337-8576-96e63cbf0ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_f9969319-d0a9-4ab9-91c1-c6d580cfa01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_85259490-2bca-41c0-9f7b-50a760a16473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_85259490-2bca-41c0-9f7b-50a760a16473" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_314d338d-ad6c-4dd8-a3a4-689153098ec3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ace26299-6770-4617-ba83-6de1645ffb90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ace26299-6770-4617-ba83-6de1645ffb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a5c84bfe-9374-4a2e-a5c6-dd0d4c625ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_261d4ec5-76d0-4b7c-bccb-f3a9c5b35ac1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a5c84bfe-9374-4a2e-a5c6-dd0d4c625ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_248b809f-42d0-4ef7-a738-1daf1baf6865" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_7460ca4f-00d2-443b-b153-79e418d20bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_7460ca4f-00d2-443b-b153-79e418d20bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_3085c2f1-c923-4912-8cf8-ea88390fe098" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_3085c2f1-c923-4912-8cf8-ea88390fe098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d9c77a66-9580-47fc-97b2-309e7dd7334e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_d9c77a66-9580-47fc-97b2-309e7dd7334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d8eb0694-d597-4236-8281-5767062597d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_c5512cbb-5fb2-4d31-b5b9-7831b82f8618" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d8eb0694-d597-4236-8281-5767062597d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56425cdf-b67e-4fd3-9e71-733960149028" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_d5671dc4-adae-4f91-84a8-c3c3544bd34d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_d5671dc4-adae-4f91-84a8-c3c3544bd34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_e51f9387-ada9-47ca-abcf-e5027197472b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a6893a1c-06a1-4006-8d8d-a000db62f229" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_e51f9387-ada9-47ca-abcf-e5027197472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dc436754-7e0b-44fb-822a-fd047bd7ed87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_c098c4ea-a65d-4617-b4ff-21cce65bec97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dc436754-7e0b-44fb-822a-fd047bd7ed87" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_c098c4ea-a65d-4617-b4ff-21cce65bec97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_0bd6af18-e72a-475e-b84a-6a724d245430" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_c098c4ea-a65d-4617-b4ff-21cce65bec97" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_0bd6af18-e72a-475e-b84a-6a724d245430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_1b4315ef-6c64-4653-9c0f-d32fc10bcc11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_c098c4ea-a65d-4617-b4ff-21cce65bec97" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_1b4315ef-6c64-4653-9c0f-d32fc10bcc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_c26683c6-ddb0-467e-92a6-4d48ce32780a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_c098c4ea-a65d-4617-b4ff-21cce65bec97" xlink:to="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_c26683c6-ddb0-467e-92a6-4d48ce32780a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4c9ff2f5-368d-40d8-a32f-2d5261d0e883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4c9ff2f5-368d-40d8-a32f-2d5261d0e883" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b194095a-1655-4c34-a32a-021e3ed5d3d1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_add33d88-c2ac-492e-ad7f-abf38835894b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_add33d88-c2ac-492e-ad7f-abf38835894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c1eff408-1778-4510-aea0-e50007c5c114" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf3c387d-fb8e-4de7-9ca5-e124f0bb7a72" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c1eff408-1778-4510-aea0-e50007c5c114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:to="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionTypeDomain_2be699e3-bf3b-41a2-a200-fe52587469e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis_036f273f-471a-4435-9514-5ad962342838" xlink:to="loc_us-gaap_DistributionTypeDomain_2be699e3-bf3b-41a2-a200-fe52587469e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LumpSumDistributionMember_07772139-754f-494a-a3ac-3c5709900f38" xlink:href="jnj-20210103.xsd#jnj_LumpSumDistributionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DistributionTypeDomain_2be699e3-bf3b-41a2-a200-fe52587469e2" xlink:to="loc_jnj_LumpSumDistributionMember_07772139-754f-494a-a3ac-3c5709900f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_be3a2a04-3eb3-4e4d-9689-e615fafdb6b2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4a281a3d-37a5-4aa3-b797-88c676c279be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4a281a3d-37a5-4aa3-b797-88c676c279be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fe466b46-d554-44fc-a01d-bbb6099877c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fe466b46-d554-44fc-a01d-bbb6099877c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_276ecbc8-d21a-4cdc-be4b-54955e8ec252" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_276ecbc8-d21a-4cdc-be4b-54955e8ec252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_87b441ec-07e6-4a89-ad93-85b84a521d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_87b441ec-07e6-4a89-ad93-85b84a521d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d315f1f6-f247-41d4-bc62-dc5799f5bdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d315f1f6-f247-41d4-bc62-dc5799f5bdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1daa0316-5e12-4ee9-85c2-7829dcdb168c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_1daa0316-5e12-4ee9-85c2-7829dcdb168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_5930fab7-08a1-43a1-90c3-b8bb827ccf2d" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_5930fab7-08a1-43a1-90c3-b8bb827ccf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_d6ea1a7d-1473-41a8-8b61-b7528d3b40a3" xlink:href="jnj-20210103.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_d6ea1a7d-1473-41a8-8b61-b7528d3b40a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f4b898b-4943-4a14-bafb-cbdc3d5f57fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f4b898b-4943-4a14-bafb-cbdc3d5f57fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_bf21bee1-2493-4945-b03b-93fc285c9b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_bf21bee1-2493-4945-b03b-93fc285c9b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_848eee64-6e77-4bca-8ce4-b8ab176fc9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_38009828-9018-419b-ba58-d58b7a2165c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_848eee64-6e77-4bca-8ce4-b8ab176fc9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1eb7e8c2-1c40-464c-881f-6ecb6dfd38ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1eb7e8c2-1c40-464c-881f-6ecb6dfd38ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_54cf68bf-f5a6-4d5b-83dc-e4e8b5b4da60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_54cf68bf-f5a6-4d5b-83dc-e4e8b5b4da60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ed107dc2-6214-4f6f-9aba-0b807a575b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ed107dc2-6214-4f6f-9aba-0b807a575b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dc700372-81a2-43cd-a8ba-609919df3e51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dc700372-81a2-43cd-a8ba-609919df3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_ea6db724-1da9-4383-94c7-b0612fb4f94d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_ea6db724-1da9-4383-94c7-b0612fb4f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_29ee6774-94cf-47b9-9b5b-f2c337d07654" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_29ee6774-94cf-47b9-9b5b-f2c337d07654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_dd4f00b3-7216-4e30-8c30-0ec7edb7839a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_dd4f00b3-7216-4e30-8c30-0ec7edb7839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6103ec5e-6d93-4ffb-b4ac-fdc4401fed98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6103ec5e-6d93-4ffb-b4ac-fdc4401fed98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5cb008d2-fa18-4925-8387-c9865aa2c1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5cb008d2-fa18-4925-8387-c9865aa2c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0bea0a5e-8c5a-477d-99e1-5d69dba55862" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_bb18c38a-b850-4608-b147-51ef2e01a1e3" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0bea0a5e-8c5a-477d-99e1-5d69dba55862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_fa7b1424-88de-4852-82ba-f4de495645a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_fa7b1424-88de-4852-82ba-f4de495645a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4910d089-77fa-49e3-af5f-ae0f95a4386c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4910d089-77fa-49e3-af5f-ae0f95a4386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_83148de3-72d3-43ae-b57b-1a0914f2185b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_83148de3-72d3-43ae-b57b-1a0914f2185b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_72f15d64-a0a7-42cb-a2d0-cc63952ab8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_c30607c8-5265-43ec-acf6-fbffd246418b" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_72f15d64-a0a7-42cb-a2d0-cc63952ab8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_b83db1ea-560e-4166-9810-277dd718caf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_b83db1ea-560e-4166-9810-277dd718caf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_249c0d12-0034-4c19-8e53-9fb74bcdfc36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_249c0d12-0034-4c19-8e53-9fb74bcdfc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_55f8f92a-5097-4262-8bd7-922eb4dbd8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_55f8f92a-5097-4262-8bd7-922eb4dbd8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5b91e41e-a5b6-4eeb-adda-fe56a6d62964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5b91e41e-a5b6-4eeb-adda-fe56a6d62964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9dd6c968-f6a5-4e85-85ba-b80b84a38290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9dd6c968-f6a5-4e85-85ba-b80b84a38290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_93829750-79c6-4a10-9200-1a803d5bb866" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_3bfe1a0b-8f6d-472c-bd81-e540506016bf" xlink:to="loc_us-gaap_PensionContributions_93829750-79c6-4a10-9200-1a803d5bb866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6237ede4-0595-4608-8f92-4a80081a8c64" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_981dba48-ae59-4d77-839a-7a0182f8b75c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_981dba48-ae59-4d77-839a-7a0182f8b75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_ed17ad1a-b464-444e-9e9c-658d5c87f660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_ed17ad1a-b464-444e-9e9c-658d5c87f660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_c18ef90b-b46b-48dd-a53a-ab4acf58c6df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_c18ef90b-b46b-48dd-a53a-ab4acf58c6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_161b3390-e816-47fd-be57-8bdc10ee2ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_161b3390-e816-47fd-be57-8bdc10ee2ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_53fb1ee5-8f49-455c-baae-0aa192a2aff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_53fb1ee5-8f49-455c-baae-0aa192a2aff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_6497b3a1-6871-46b0-a3d8-c7ef5a680a78" xlink:href="jnj-20210103.xsd#jnj_EffectOfExchangeRates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_jnj_EffectOfExchangeRates_6497b3a1-6871-46b0-a3d8-c7ef5a680a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_67d5a7f4-70ea-4fb7-bdda-02374019b0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_67d5a7f4-70ea-4fb7-bdda-02374019b0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_5cdfd95b-e78a-495a-a41f-1f51546e4d12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_4ec92eea-65a5-4bdc-aabc-f7b8d2fb531e" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_5cdfd95b-e78a-495a-a41f-1f51546e4d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28ff56df-8dd1-4668-9672-dddb1383f7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28ff56df-8dd1-4668-9672-dddb1383f7f7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30a804cf-a87e-44ae-8efd-80ca6e571716" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6bc85dfd-85a3-4516-8b0d-4ab2afdae935" xlink:to="loc_srt_RangeMember_30a804cf-a87e-44ae-8efd-80ca6e571716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_beea9e48-a353-43e6-9e81-459d34d3a79c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30a804cf-a87e-44ae-8efd-80ca6e571716" xlink:to="loc_srt_MaximumMember_beea9e48-a353-43e6-9e81-459d34d3a79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6f15b78b-9212-4fc2-8dba-e003928cdd47" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_4d8bfa05-c82a-4900-8300-cdfbc64bce92" xlink:href="jnj-20210103.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:to="loc_jnj_CommingledFundsMember_4d8bfa05-c82a-4900-8300-cdfbc64bce92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_e046f72d-8b7f-46e0-b11e-550959f9d0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1a505673-3ae7-4b1d-b810-86f38edc0fc8" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_e046f72d-8b7f-46e0-b11e-550959f9d0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2983653b-750c-455f-aa87-d8b2a7bd34d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d89ffb3-a2b3-4aaf-b496-e02c74c84fa3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2983653b-750c-455f-aa87-d8b2a7bd34d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd436c4a-e0c3-4213-bd63-de52e8354270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2983653b-750c-455f-aa87-d8b2a7bd34d4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd436c4a-e0c3-4213-bd63-de52e8354270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ce8e7099-59be-4bb3-983d-cf97f16b3611" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_9e01eeef-18da-4345-83a9-5d21fe36e5cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:to="loc_us-gaap_DomesticPlanMember_9e01eeef-18da-4345-83a9-5d21fe36e5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_56605e11-0b00-4639-a2a7-df83b754b947" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_9e01eeef-18da-4345-83a9-5d21fe36e5cc" xlink:to="loc_country_US_56605e11-0b00-4639-a2a7-df83b754b947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e6f70cf0-0db4-4fd8-b789-e05d45b28ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c32a2907-3cae-430e-9e0c-2a332bb49080" xlink:to="loc_us-gaap_ForeignPlanMember_e6f70cf0-0db4-4fd8-b789-e05d45b28ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_fc59ed20-1411-48d2-9339-f302edc538b2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_dba83aee-d0f8-419c-9eb4-76abe98924f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_dba83aee-d0f8-419c-9eb4-76abe98924f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a864f346-6019-4deb-90cc-5fce0a0d4dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f35d72ac-c42c-489c-84d8-f65e0ea0791c" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a864f346-6019-4deb-90cc-5fce0a0d4dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9273ff54-5a77-40b2-a32a-88669733e28c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_320a76e8-368a-439a-98d2-b9635fcb0598" xlink:href="jnj-20210103.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_EmployeeCompensationPeriod_320a76e8-368a-439a-98d2-b9635fcb0598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_6c640fce-2d57-411a-a28a-5114391e519b" xlink:href="jnj-20210103.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_6c640fce-2d57-411a-a28a-5114391e519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_7b63351e-92e6-4f01-92bd-ff7d7b728abc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_PensionContributions_7b63351e-92e6-4f01-92bd-ff7d7b728abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_a94ded6d-cb13-48c7-8555-8a60f24ff6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_a94ded6d-cb13-48c7-8555-8a60f24ff6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_86d340f4-40a2-4e3f-b6ef-28af2adaf81c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_86d340f4-40a2-4e3f-b6ef-28af2adaf81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_29d900bb-dce9-49c2-ba78-55a5c6813545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_29d900bb-dce9-49c2-ba78-55a5c6813545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b5039ff6-fd1d-4854-a452-9ed4b25f9870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b5039ff6-fd1d-4854-a452-9ed4b25f9870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_ab217f28-5f29-440c-8ea3-bd3ce8b7f19f" xlink:href="jnj-20210103.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_ab217f28-5f29-440c-8ea3-bd3ce8b7f19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_1c61c29f-5a1d-4ffe-992b-9745025e74ca" xlink:href="jnj-20210103.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a63dc2df-f47c-42a9-b9e8-fd5eb206e6e4" xlink:to="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_1c61c29f-5a1d-4ffe-992b-9745025e74ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate_68274c88-aa11-4f38-bded-90cf5f9bd13b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28ff56df-8dd1-4668-9672-dddb1383f7f7" xlink:to="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate_68274c88-aa11-4f38-bded-90cf5f9bd13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96e6160e-39c4-4936-9b56-2849712d4d21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_96e6160e-39c4-4936-9b56-2849712d4d21" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:to="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_17b91bb6-21f4-4a3f-8f21-0b153fb4fa9d" xlink:to="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_4120ee29-a4a5-40f7-9881-3413a38ef8f9" xlink:href="jnj-20210103.xsd#jnj_QualifiedPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_QualifiedPlansMember_4120ee29-a4a5-40f7-9881-3413a38ef8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_b4e8d085-6e8e-43a4-a429-7815c0ce67d6" xlink:href="jnj-20210103.xsd#jnj_NonQualifiedPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_NonQualifiedPlansMember_b4e8d085-6e8e-43a4-a429-7815c0ce67d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_0015942f-45d3-4b7e-8df7-38ce013310b0" xlink:href="jnj-20210103.xsd#jnj_FundedPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_FundedPlansMember_0015942f-45d3-4b7e-8df7-38ce013310b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_68bb025b-4b28-4e40-8d85-0e070876db1c" xlink:href="jnj-20210103.xsd#jnj_UnfundedPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a832206-4740-421c-8842-f1ea759d6f55" xlink:to="loc_jnj_UnfundedPlansMember_68bb025b-4b28-4e40-8d85-0e070876db1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d56f5821-3a0e-4933-9b4d-449eb988c9ff" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_b63fa35c-72b8-437d-b7dc-f27592ed6ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:to="loc_us-gaap_DomesticPlanMember_b63fa35c-72b8-437d-b7dc-f27592ed6ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5c676270-c060-438c-bd7d-c7f27c6dd983" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_b63fa35c-72b8-437d-b7dc-f27592ed6ff0" xlink:to="loc_country_US_5c676270-c060-438c-bd7d-c7f27c6dd983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_90f25287-ce56-457f-9e06-a28ca151ec08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_70171981-b7c1-40cf-a06a-991c666b90d0" xlink:to="loc_us-gaap_ForeignPlanMember_90f25287-ce56-457f-9e06-a28ca151ec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_eb459bb9-dd1d-40d7-862f-eb3d496b0bfe" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_34a6044b-eab1-4c02-bbda-4ce56847cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_34a6044b-eab1-4c02-bbda-4ce56847cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_fe381f84-9220-4d38-b3a9-4ab59978dee8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_fe381f84-9220-4d38-b3a9-4ab59978dee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e3bf2389-ab1a-4e42-9508-066cb85ed634" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e3bf2389-ab1a-4e42-9508-066cb85ed634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_aca986f4-0222-472f-b5ef-3c595613e8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_aca986f4-0222-472f-b5ef-3c595613e8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_87d0b292-8ee3-4f8b-abf1-85bbf1b6ba35" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff773906-4c4b-4252-b594-099e96782309" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_87d0b292-8ee3-4f8b-abf1-85bbf1b6ba35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c7ff0d56-dfbb-4753-ad88-b74d84d13014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c7ff0d56-dfbb-4753-ad88-b74d84d13014" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_783dfebe-8b6e-40d2-a912-c3db23609ec5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2e9e3c82-7491-45a9-a8af-0575e0eec998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2e9e3c82-7491-45a9-a8af-0575e0eec998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d1e0e40b-2f9c-40fa-9deb-7d3a12be4c59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_68a789fc-3a87-482d-80f0-ac678980c884" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d1e0e40b-2f9c-40fa-9deb-7d3a12be4c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_51104d5e-3c8f-44c4-a9f4-d3953ef6145a" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_13a4a723-31de-449f-848a-cea175240b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_13a4a723-31de-449f-848a-cea175240b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_420f754f-85a8-43af-b568-48afcb5f1772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_420f754f-85a8-43af-b568-48afcb5f1772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a0e6dc-eb85-42ec-841c-20b07cafcb58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_30a0e6dc-eb85-42ec-841c-20b07cafcb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_8181e8c2-b938-4c00-9122-5048d7ecb3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_8181e8c2-b938-4c00-9122-5048d7ecb3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_06233c84-aed0-4e73-9327-22a1223b6496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_06233c84-aed0-4e73-9327-22a1223b6496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b5528ca0-0fc3-4bd8-bf09-36597c3f458a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80012002-e48a-43d6-89a2-54471537d68b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b5528ca0-0fc3-4bd8-bf09-36597c3f458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_c6ae3c94-03aa-4377-97eb-8b44843e20df" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_c6ae3c94-03aa-4377-97eb-8b44843e20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_bd133e15-03a3-409e-b2cb-888ba4e71e94" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_bd133e15-03a3-409e-b2cb-888ba4e71e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_66d47050-5733-4cf3-9284-089432f4a310" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_66d47050-5733-4cf3-9284-089432f4a310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_fdc97761-d3c3-48ca-a896-29bb45e8407e" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_fdc97761-d3c3-48ca-a896-29bb45e8407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_4a6be7dd-e340-4648-bab7-37624907d641" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_4a6be7dd-e340-4648-bab7-37624907d641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_aba21810-d528-4fa9-8c26-4d2f3176ba20" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e7cac464-dd96-4b40-b69f-52552332308e" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_aba21810-d528-4fa9-8c26-4d2f3176ba20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bdf1d605-69fc-4090-ba1f-6945853732a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bdf1d605-69fc-4090-ba1f-6945853732a8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4007c8e6-b53b-4869-bb4c-9a50eac2166a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e75bf1c4-1a64-4d02-844c-4104502dd8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:to="loc_us-gaap_EquitySecuritiesMember_e75bf1c4-1a64-4d02-844c-4104502dd8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_4e6d77bc-a3a3-44e4-b789-5bf5c1385760" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_29062b1f-1657-4aea-bf18-86deeea0f87b" xlink:to="loc_us-gaap_DebtSecuritiesMember_4e6d77bc-a3a3-44e4-b789-5bf5c1385760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0b7e2ff7-8fd9-4a76-bb08-5cc9e4a199af" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_5e326bd6-fadb-4e28-adb6-db05d514ee3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_5e326bd6-fadb-4e28-adb6-db05d514ee3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b03f3b12-9481-4bcb-9cbf-aee88a29dc15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_afcecbed-ef74-479d-b168-fc0ef304a7b1" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b03f3b12-9481-4bcb-9cbf-aee88a29dc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0000d6fc-1d11-4d37-9cc2-b2ed5201d8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0000d6fc-1d11-4d37-9cc2-b2ed5201d8c7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7782b4d0-1550-4a4d-ab9b-e528f17944ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c31a8e45-bd73-4fc9-8a60-0d5c0eae70d7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7782b4d0-1550-4a4d-ab9b-e528f17944ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7f9f07b8-6c32-4fb1-a252-a8a36efd3b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7782b4d0-1550-4a4d-ab9b-e528f17944ca" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7f9f07b8-6c32-4fb1-a252-a8a36efd3b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_48d5926b-0a1c-44bc-8b82-2196167bcec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0d1eab04-51d8-4e8e-96c9-2f0995a7f9f8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_48d5926b-0a1c-44bc-8b82-2196167bcec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d8b7b5fa-3f18-459d-9ea7-fe08634bbb01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_48d5926b-0a1c-44bc-8b82-2196167bcec5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d8b7b5fa-3f18-459d-9ea7-fe08634bbb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6b3bf0ba-aa40-4732-b175-5013ef2a59cb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_0fc98718-6d7d-4e96-9954-2bfcd493a230" xlink:href="jnj-20210103.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_0fc98718-6d7d-4e96-9954-2bfcd493a230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_423a058c-2385-47bb-9eef-d87242bd687f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_423a058c-2385-47bb-9eef-d87242bd687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_18213af9-e005-45d8-bf80-0df885229bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_DebtSecuritiesMember_18213af9-e005-45d8-bf80-0df885229bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_de052f76-4f74-49a4-8a32-07ca5c8d7edd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_EquitySecuritiesMember_de052f76-4f74-49a4-8a32-07ca5c8d7edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_cddc04f5-9689-4f5b-890b-bfeba01c075a" xlink:href="jnj-20210103.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_jnj_CommingledFundsMember_cddc04f5-9689-4f5b-890b-bfeba01c075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_9dbf1edf-ed8d-4985-9b6c-d9e1550d035e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c78be24d-265f-4fdd-b7ea-a05feb7b5f42" xlink:to="loc_us-gaap_OtherAssetsMember_9dbf1edf-ed8d-4985-9b6c-d9e1550d035e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53242305-2db1-4532-84d1-4ac39d9f6fa3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_14516552-0645-4934-9eee-209931573f27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_14516552-0645-4934-9eee-209931573f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e5ee803d-6732-4ccf-8cca-4014ba90dda2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e5ee803d-6732-4ccf-8cca-4014ba90dda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_22c2c714-3869-4492-ae22-e8cd40468e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_441b3302-7413-4954-9548-5b59ff2fe056" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_22c2c714-3869-4492-ae22-e8cd40468e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b276645d-f6c3-4c5b-a7b0-db0e197ec6da" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fb21166f-deaf-4aed-9aba-631dcf04001b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fb21166f-deaf-4aed-9aba-631dcf04001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_0babb4a1-422f-408c-92a1-effdd18122f6" xlink:href="jnj-20210103.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3ae1ee6e-a5c5-4839-ab67-28899577b2e4" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_0babb4a1-422f-408c-92a1-effdd18122f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlan" xlink:type="simple" xlink:href="jnj-20210103.xsd#SavingsPlan"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_24420265-a6cc-4e88-b091-4ee3ebe3113a" xlink:href="jnj-20210103.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock_21ddf3e5-afea-4134-be23-6ed53f9d9661" xlink:href="jnj-20210103.xsd#jnj_SavingsPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_24420265-a6cc-4e88-b091-4ee3ebe3113a" xlink:to="loc_jnj_SavingsPlanTextBlock_21ddf3e5-afea-4134-be23-6ed53f9d9661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SavingsPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_4349f0b0-5c1f-4f27-a207-d3b9d67d7e6a" xlink:href="jnj-20210103.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_753421bc-c379-4c7f-a187-6fcd7e377338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_4349f0b0-5c1f-4f27-a207-d3b9d67d7e6a" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_753421bc-c379-4c7f-a187-6fcd7e377338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStock"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_af009014-9056-4bb1-adc8-6e47908b8fda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_ec291679-2c9b-4932-b50a-aeb1751d6a12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_af009014-9056-4bb1-adc8-6e47908b8fda" xlink:to="loc_us-gaap_TreasuryStockTextBlock_ec291679-2c9b-4932-b50a-aeb1751d6a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4c31499b-9021-4fe0-835c-3c64a1ef45c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock_2918d4f2-b563-4ee7-9c99-bc38dbada0fc" xlink:href="jnj-20210103.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4c31499b-9021-4fe0-835c-3c64a1ef45c8" xlink:to="loc_jnj_ChangesInTreasuryStockTableTextBlock_2918d4f2-b563-4ee7-9c99-bc38dbada0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_df320f6a-98a3-45d1-a130-5e66114e07ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_df320f6a-98a3-45d1-a130-5e66114e07ef" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eddcc37a-f873-4798-b4c9-db0c9765aa48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02c3ab2f-cf64-4e19-ac14-040a7d60cc1f" xlink:to="loc_us-gaap_EquityComponentDomain_eddcc37a-f873-4798-b4c9-db0c9765aa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_b01650da-e876-4169-b7fc-4200a9437f25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eddcc37a-f873-4798-b4c9-db0c9765aa48" xlink:to="loc_us-gaap_TreasuryStockMember_b01650da-e876-4169-b7fc-4200a9437f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a9847a48-d593-471a-8a95-8018f710c96a" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:href="jnj-20210103.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_3200e8e1-4f44-4af1-9f19-537b1aef45f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_TreasuryStockShares_3200e8e1-4f44-4af1-9f19-537b1aef45f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_e605915e-fe94-40df-ace0-c82fd4563dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_e605915e-fe94-40df-ace0-c82fd4563dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_75ba5c24-1e47-4233-b7c8-0cde939e4f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_75ba5c24-1e47-4233-b7c8-0cde939e4f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_77d4d065-31ff-4bc1-8e2f-5b39c245286b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e8498cfc-5b1d-4366-b6bb-8b375dc5ac1a" xlink:to="loc_us-gaap_TreasuryStockShares_77d4d065-31ff-4bc1-8e2f-5b39c245286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:href="jnj-20210103.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5576bf91-6410-410b-9756-e4927d1bf424" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_05f5442c-c036-4ce9-a2d6-7bf0ce3dcda5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_TreasuryStockValue_05f5442c-c036-4ce9-a2d6-7bf0ce3dcda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_9ec3c900-c9d3-49f4-9a89-bbb54e92f217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_9ec3c900-c9d3-49f4-9a89-bbb54e92f217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f292a11c-9767-4ae3-9baf-a7efeaa1f3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f292a11c-9767-4ae3-9baf-a7efeaa1f3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_66cac848-9060-4d72-8f91-c566c6d73139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_333aaa61-5435-4245-8356-6ff099fb62d7" xlink:to="loc_us-gaap_TreasuryStockValue_66cac848-9060-4d72-8f91-c566c6d73139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_327545ca-a20b-4ce3-aeb6-823312bfe83a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_327545ca-a20b-4ce3-aeb6-823312bfe83a" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_6f895a7f-d2cc-49b0-a860-10063d3090e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ae814850-11ff-4905-854b-62f88cd0a551" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_6f895a7f-d2cc-49b0-a860-10063d3090e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_53f466d7-758e-4b24-91d2-5ffd2d13f7e0" xlink:href="jnj-20210103.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_6f895a7f-d2cc-49b0-a860-10063d3090e2" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_53f466d7-758e-4b24-91d2-5ffd2d13f7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_817e77d4-7ee0-4834-ae2b-829a858e4ff5" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dd73b5cd-26d8-47d6-9dfd-d39765089acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_CommonStockSharesIssued_dd73b5cd-26d8-47d6-9dfd-d39765089acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b05d7a70-338c-4c8e-8ab8-f0603151f17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_b05d7a70-338c-4c8e-8ab8-f0603151f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_26c96af0-b3a3-45ff-815c-2203c9e6cf49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_82f26153-9110-4718-8f13-54d5ac811ba2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_26c96af0-b3a3-45ff-815c-2203c9e6cf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_41b8e32e-c4eb-4130-98cb-7d8f4fde0376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_327545ca-a20b-4ce3-aeb6-823312bfe83a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_41b8e32e-c4eb-4130-98cb-7d8f4fde0376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ee692b79-01a2-4df7-ac27-dc1c0d89a0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5f442b82-fc44-41f4-8483-bff14bafb4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ee692b79-01a2-4df7-ac27-dc1c0d89a0e6" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5f442b82-fc44-41f4-8483-bff14bafb4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4d629522-031d-4072-a7b7-167c333962a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5331229e-5e56-4cb9-87af-384d5f55e3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4d629522-031d-4072-a7b7-167c333962a0" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5331229e-5e56-4cb9-87af-384d5f55e3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0ba50d0f-abfb-4cad-9383-68549fee56ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0ba50d0f-abfb-4cad-9383-68549fee56ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dfd2581-25ae-41f1-9bc0-8b0e5b0814a8" xlink:to="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_71d9a21d-8e1a-4ad4-a173-543f3fafcfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_71d9a21d-8e1a-4ad4-a173-543f3fafcfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fdce4592-f989-4006-ae93-b47bbe98e5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fdce4592-f989-4006-ae93-b47bbe98e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_267aabfd-19d9-4401-8957-5d3a8b08f2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_267aabfd-19d9-4401-8957-5d3a8b08f2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_46cc2015-0a2f-4bc7-be98-6211684f9774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_46cc2015-0a2f-4bc7-be98-6211684f9774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfe54b6e-f5a9-4957-84dc-3ebb68b7853b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b5cfd6b-b665-4e73-aa0a-0f5e77f0646a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfe54b6e-f5a9-4957-84dc-3ebb68b7853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_eb1179ab-fdc3-4e56-8ded-c058c694f5b8" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionAxis_f9276bcb-a5e5-4f8e-b18d-ce99c2c7db09" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_eb1179ab-fdc3-4e56-8ded-c058c694f5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7cec4552-3dad-48a4-a60b-577d047a570b" xlink:href="jnj-20210103.xsd#jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CumulativeEffectPeriodOfAdoptionDomain_eb1179ab-fdc3-4e56-8ded-c058c694f5b8" xlink:to="loc_jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7cec4552-3dad-48a4-a60b-577d047a570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_520bf267-a3f9-4e42-8260-0fc86b3b4ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edeba8e1-5c29-419e-bf4d-ff24d855b2da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_520bf267-a3f9-4e42-8260-0fc86b3b4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_520bf267-a3f9-4e42-8260-0fc86b3b4ce4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ae3e919-8553-46e3-a1e4-ec16d1da628c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ae3e919-8553-46e3-a1e4-ec16d1da628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85f5305b-c726-4b77-99a7-63ceb6cda76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85f5305b-c726-4b77-99a7-63ceb6cda76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1ad4bcc-aa77-4558-bf3a-13ab71daa7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4ae78a45-5762-4bd7-af93-d6a4f3ec92cb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1ad4bcc-aa77-4558-bf3a-13ab71daa7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="simple" xlink:href="jnj-20210103.xsd#InternationalCurrencyTranslation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_d3f6f973-06db-4486-a96e-01b734bcdcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_6237ed06-38cc-49ec-8c84-8b9e85743dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_d3f6f973-06db-4486-a96e-01b734bcdcc7" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_6237ed06-38cc-49ec-8c84-8b9e85743dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#InternationalCurrencyTranslationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_9d264142-920f-418c-81f1-fdefb91dabd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777e9a4d-3fd0-4ba7-bad7-1ca70c33ad2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_9d264142-920f-418c-81f1-fdefb91dabd1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777e9a4d-3fd0-4ba7-bad7-1ca70c33ad2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4e7f0967-d141-4e80-ae6b-2c5810a8d994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_dd7cdfbd-dd3a-4740-bdf3-8216d5827cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e7f0967-d141-4e80-ae6b-2c5810a8d994" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_dd7cdfbd-dd3a-4740-bdf3-8216d5827cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ddecbba7-f349-46cb-8276-221c6970f883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_eaa215c0-c80b-4d8e-b211-3c098e6952fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ddecbba7-f349-46cb-8276-221c6970f883" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_eaa215c0-c80b-4d8e-b211-3c098e6952fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a61ff2ec-89a3-41bb-af6f-a36ab49c1e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a61ff2ec-89a3-41bb-af6f-a36ab49c1e1e" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_eb8ab2e8-d3ad-4d60-ad43-b9f8a3661508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_eb8ab2e8-d3ad-4d60-ad43-b9f8a3661508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91cd34a7-f2ab-4e8a-be36-98e16ae5b1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91cd34a7-f2ab-4e8a-be36-98e16ae5b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_4f1945f2-2e09-4da9-90b0-84cd248a61b9" xlink:href="jnj-20210103.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_4f1945f2-2e09-4da9-90b0-84cd248a61b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_ea0c333b-bd9e-4abe-b31c-86e2a0ed4d37" xlink:href="jnj-20210103.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_ea0c333b-bd9e-4abe-b31c-86e2a0ed4d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_cefe93a4-fc84-42cb-8192-4fba5d683e54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_cefe93a4-fc84-42cb-8192-4fba5d683e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86b94c39-b1d2-41c8-8f7b-b1fe9b7b7d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86b94c39-b1d2-41c8-8f7b-b1fe9b7b7d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_085b865e-c372-4e8f-9294-bc366ea8bdc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_ec7c3ac5-5dd0-43bf-9d26-6207bd7468a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_085b865e-c372-4e8f-9294-bc366ea8bdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6921e062-db52-4734-b333-bf39874a7692" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79d2ab15-0a4f-49a6-8788-4aadcb813072" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6921e062-db52-4734-b333-bf39874a7692" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79d2ab15-0a4f-49a6-8788-4aadcb813072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_266d3fa3-a50b-4443-8a21-55cb6bdbf127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6921e062-db52-4734-b333-bf39874a7692" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_266d3fa3-a50b-4443-8a21-55cb6bdbf127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d97abff5-f663-491b-897b-8f1c30d096e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a9286e38-af4e-48d7-bd55-5110f8eb882b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d97abff5-f663-491b-897b-8f1c30d096e7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a9286e38-af4e-48d7-bd55-5110f8eb882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5571cd3c-2420-4fa7-8f47-49a13b8efc53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1d5b7888-2ccc-461f-94da-0f0dc877b4fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5571cd3c-2420-4fa7-8f47-49a13b8efc53" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1d5b7888-2ccc-461f-94da-0f0dc877b4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_96067068-fa67-4cd0-9130-d3defef6fa63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5571cd3c-2420-4fa7-8f47-49a13b8efc53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_96067068-fa67-4cd0-9130-d3defef6fa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_cd6163d6-208b-48d4-9f35-447c78f0410d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5571cd3c-2420-4fa7-8f47-49a13b8efc53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_cd6163d6-208b-48d4-9f35-447c78f0410d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_107418fe-13fc-492e-8c54-a0ec0913c183" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5571cd3c-2420-4fa7-8f47-49a13b8efc53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_107418fe-13fc-492e-8c54-a0ec0913c183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1a3b928-e8ea-4178-921d-dc55052741e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1a3b928-e8ea-4178-921d-dc55052741e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_194544f5-0a77-4f71-9669-b4beb62ba3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_21dc0b56-04e1-4dc5-ad49-c731d01defa6" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_194544f5-0a77-4f71-9669-b4beb62ba3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2012LongTermIncentivePlanMember_5b46ce16-b3fa-4775-9044-bcba112d1516" xlink:href="jnj-20210103.xsd#jnj_A2012LongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_194544f5-0a77-4f71-9669-b4beb62ba3f8" xlink:to="loc_jnj_A2012LongTermIncentivePlanMember_5b46ce16-b3fa-4775-9044-bcba112d1516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_acf09802-75c1-4df1-ba26-d560d143c50a" xlink:to="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e44b3d49-c2ea-4d97-8a4d-781c8b364205" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:to="loc_srt_MinimumMember_e44b3d49-c2ea-4d97-8a4d-781c8b364205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfee6773-f54d-48f2-9b90-8e5cea7285bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b15e4e40-4d73-4f9f-8958-33c7cb4146a0" xlink:to="loc_srt_MaximumMember_bfee6773-f54d-48f2-9b90-8e5cea7285bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f6e37a93-1332-416c-8f40-a46c30be9fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3b40a786-24cc-47f4-ac85-74b3788ec0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3b40a786-24cc-47f4-ac85-74b3788ec0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c3b11745-962e-43f9-9003-859402554519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c3b11745-962e-43f9-9003-859402554519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7ae04c4f-ef89-4d5a-ac2a-b73514e59459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20ffd2b4-63b4-4e2f-9910-bad1c9d95726" xlink:to="loc_us-gaap_PerformanceSharesMember_7ae04c4f-ef89-4d5a-ac2a-b73514e59459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6cf3e91e-63c3-4f91-ad98-35609cc1a98c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_b2cf49ab-e0ec-4a4d-95de-ed12186b02ba" xlink:href="jnj-20210103.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_b2cf49ab-e0ec-4a4d-95de-ed12186b02ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3386fdf1-f1f2-4b22-87d5-e785c292a0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3386fdf1-f1f2-4b22-87d5-e785c292a0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4361fb36-555a-49ef-98fd-8241d4df7857" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4361fb36-555a-49ef-98fd-8241d4df7857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d47dac4d-2609-46d1-9361-b94c7f779e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d47dac4d-2609-46d1-9361-b94c7f779e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3307db39-72e0-4e30-8112-df9e032c782a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3307db39-72e0-4e30-8112-df9e032c782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_a118ace0-2889-43f7-8559-1658c1ed6ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_a118ace0-2889-43f7-8559-1658c1ed6ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13888827-6f2f-41a1-b9e6-10fbd91af442" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13888827-6f2f-41a1-b9e6-10fbd91af442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2a60d1c-e393-474e-8d6c-765509b1b29a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2a60d1c-e393-474e-8d6c-765509b1b29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_33b9a6e5-0f77-4f73-a063-2660d6ad8370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_33b9a6e5-0f77-4f73-a063-2660d6ad8370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d28fba8-5633-4e3d-b6e8-db4df9786280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d28fba8-5633-4e3d-b6e8-db4df9786280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_506f5f35-25d3-4489-95a1-2e6b718f5d86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_506f5f35-25d3-4489-95a1-2e6b718f5d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d85d8f64-9d20-4645-9f04-bc4e643a14e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d85d8f64-9d20-4645-9f04-bc4e643a14e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_558f9ed8-8ca9-4474-8681-222110b10d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_558f9ed8-8ca9-4474-8681-222110b10d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ffa129d1-a24d-4cdd-89f2-dd59493df8e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ffa129d1-a24d-4cdd-89f2-dd59493df8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d1c64626-74d5-46e4-8f06-c1a74256979c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d1c64626-74d5-46e4-8f06-c1a74256979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6d4c00cf-eee6-4de5-bb13-20c55195e3db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6d4c00cf-eee6-4de5-bb13-20c55195e3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3add0f4f-6eed-4be4-89f4-efa0329b3ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3add0f4f-6eed-4be4-89f4-efa0329b3ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9581138a-2a03-4e42-b945-7439b5f5abeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9581138a-2a03-4e42-b945-7439b5f5abeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c317e4f7-71f1-48bd-bac0-206c8c804d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_245dfa0f-a227-4dec-9f07-e3d4fd11763f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c317e4f7-71f1-48bd-bac0-206c8c804d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5bc7130-8135-4e18-8ee5-515d961116be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b8d0d31f-8e11-42d1-89f5-404901b471c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5bc7130-8135-4e18-8ee5-515d961116be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b8d0d31f-8e11-42d1-89f5-404901b471c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e1f4b01-2173-4b5d-84b1-b5c45320bdd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b8d0d31f-8e11-42d1-89f5-404901b471c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e1f4b01-2173-4b5d-84b1-b5c45320bdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bead7d31-7d7a-4bc5-bd23-04bf600dad85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b8d0d31f-8e11-42d1-89f5-404901b471c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bead7d31-7d7a-4bc5-bd23-04bf600dad85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cf24593e-31b0-4b4d-a0a6-7a98d8f3e127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b8d0d31f-8e11-42d1-89f5-404901b471c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cf24593e-31b0-4b4d-a0a6-7a98d8f3e127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_34abe576-0d9c-45a8-9a6d-81338e850bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b8d0d31f-8e11-42d1-89f5-404901b471c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_34abe576-0d9c-45a8-9a6d-81338e850bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3647aad4-d117-4508-ba7c-3a987861b0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90351cc3-50d6-4fe3-a0ae-a75fa5ea763e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3647aad4-d117-4508-ba7c-3a987861b0b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90351cc3-50d6-4fe3-a0ae-a75fa5ea763e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90351cc3-50d6-4fe3-a0ae-a75fa5ea763e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3af2e717-70f3-4705-921c-899a9a95a324" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3af2e717-70f3-4705-921c-899a9a95a324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_bbbe228a-36d0-4b39-a4da-22f63f745502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_bbbe228a-36d0-4b39-a4da-22f63f745502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74e96ee0-2a77-4fa1-96a9-b858e1609fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74e96ee0-2a77-4fa1-96a9-b858e1609fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e0027b61-99f8-4867-88dc-9b2dd97400e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e0027b61-99f8-4867-88dc-9b2dd97400e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_48cf5749-9f67-4108-a905-4ff1d8c3d948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b944264f-3ccc-439c-bf1c-34b811f07a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_48cf5749-9f67-4108-a905-4ff1d8c3d948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90351cc3-50d6-4fe3-a0ae-a75fa5ea763e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aced92ea-558e-434f-8026-39f3396c6bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aced92ea-558e-434f-8026-39f3396c6bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_526013c0-c70a-4b65-84ad-97cc89c4f424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_526013c0-c70a-4b65-84ad-97cc89c4f424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c839397c-8a80-481a-a9cd-3da051d8bf93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c839397c-8a80-481a-a9cd-3da051d8bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b6349ca4-f400-4e3f-8748-75d785831bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b6349ca4-f400-4e3f-8748-75d785831bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7a1f9921-e498-4885-a891-70fb2dd990b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7a1f9921-e498-4885-a891-70fb2dd990b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8f886a1b-ea57-4952-ae67-3823653a26d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b9c26ed-b803-49e4-874e-db9d7b167ca6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8f886a1b-ea57-4952-ae67-3823653a26d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dfd3529-caf6-4fa7-8ca3-79e1622e7a70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dfd3529-caf6-4fa7-8ca3-79e1622e7a70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_561e9f41-978f-41e6-a777-0a637c34f4d4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_3c46a372-476a-4524-b5ca-4ecb354d2520" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeOneMember_3c46a372-476a-4524-b5ca-4ecb354d2520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_a4120369-5efa-45eb-a7f2-b637b7b2584b" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_a4120369-5efa-45eb-a7f2-b637b7b2584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_d9f8d637-92bd-4edf-ade1-868565c75fd5" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_d9f8d637-92bd-4edf-ade1-868565c75fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_83e04ea9-5614-42e4-9647-db6877cc9edd" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeFourMember_83e04ea9-5614-42e4-9647-db6877cc9edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_9ea9d6b4-6bf5-4b71-a648-6e4af32656bc" xlink:href="jnj-20210103.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_89a974eb-bcac-4f5d-b3a5-1da6293c1d84" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_9ea9d6b4-6bf5-4b71-a648-6e4af32656bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f3581515-6188-4cb1-b22a-e30cf1b8a5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258e3195-aaae-48a7-a3c4-2137669d0181" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f3581515-6188-4cb1-b22a-e30cf1b8a5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:href="jnj-20210103.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f3581515-6188-4cb1-b22a-e30cf1b8a5d5" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_16ad97cc-ea82-4a96-9ef8-3e97968273a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_16ad97cc-ea82-4a96-9ef8-3e97968273a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e4d3b0b8-3bf5-469b-bc94-233f6c0cdab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e4d3b0b8-3bf5-469b-bc94-233f6c0cdab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c9ae90aa-1352-4b0b-99d1-8613cbdfb06a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c9ae90aa-1352-4b0b-99d1-8613cbdfb06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_564f6f2d-1a22-4ef8-9840-0b0027045573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_564f6f2d-1a22-4ef8-9840-0b0027045573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_cfca0d31-7834-40b7-ae17-747ad6517df0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_cfca0d31-7834-40b7-ae17-747ad6517df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d3b52e71-a34a-4514-b92f-960dfb651cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d3b52e71-a34a-4514-b92f-960dfb651cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9986919f-9193-4e30-9ed3-cd13d16b4284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_ef95ba9c-07fe-4ae4-8888-5eea077ecfa0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9986919f-9193-4e30-9ed3-cd13d16b4284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b250165b-4561-441e-ae86-ab7b764d5608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b250165b-4561-441e-ae86-ab7b764d5608" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:to="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4334f1de-521b-46ed-8e30-9083a28f30bc" xlink:to="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_97a37a48-8b6f-475e-9293-8697e3083efb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:to="loc_srt_MinimumMember_97a37a48-8b6f-475e-9293-8697e3083efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c18564e-b83b-4e70-bf7b-e205ce9ad383" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98d4ef8f-9cc1-451d-a86c-231155bc27e8" xlink:to="loc_srt_MaximumMember_1c18564e-b83b-4e70-bf7b-e205ce9ad383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:to="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0a42decc-774c-49e1-a5b3-727dc01a1e1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bf12f2d9-416b-4989-9da4-257ffee45b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:to="loc_us-gaap_PerformanceSharesMember_bf12f2d9-416b-4989-9da4-257ffee45b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8eae5bb6-ae49-450b-97e0-d295b24a002b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f08c5508-8a31-498a-b18e-be309d29fb7b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8eae5bb6-ae49-450b-97e0-d295b24a002b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fcdf764-9aee-4fb6-9801-a838d139bafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a339816-9923-42bc-b588-5b8c2a92ab90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fcdf764-9aee-4fb6-9801-a838d139bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cb0d72b6-2612-4f5e-8717-2cc82ee9c2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fcdf764-9aee-4fb6-9801-a838d139bafd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cb0d72b6-2612-4f5e-8717-2cc82ee9c2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cb0d72b6-2612-4f5e-8717-2cc82ee9c2aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d63b282b-5273-477f-a9f9-2b1dee9d2fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d63b282b-5273-477f-a9f9-2b1dee9d2fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fbc1bd0-5708-4724-8b1f-a5fb53e6e272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fbc1bd0-5708-4724-8b1f-a5fb53e6e272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_744d0b49-189d-48ce-a2ff-f1e46d12fe58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_744d0b49-189d-48ce-a2ff-f1e46d12fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2bb64ab9-92f8-4e3e-9a84-b38d5348c84b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2bb64ab9-92f8-4e3e-9a84-b38d5348c84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_ec9a5149-0809-4a18-be38-a12227264e34" xlink:href="jnj-20210103.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_ec9a5149-0809-4a18-be38-a12227264e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a42c98b4-949b-4ddb-b29e-c8cae126deab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0fcd307-76aa-4381-9bde-1fc5fc80a758" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a42c98b4-949b-4ddb-b29e-c8cae126deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4ca588a5-8d5c-4241-b843-04b6d09b1cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5635a92e-104f-4f02-a9cf-6ac6abfbe8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4ca588a5-8d5c-4241-b843-04b6d09b1cf5" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5635a92e-104f-4f02-a9cf-6ac6abfbe8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7c69edd9-8e17-468b-bef1-ae4f1757cd70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_b20912f9-9950-4010-874a-3414b6ea8d7b" xlink:href="jnj-20210103.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7c69edd9-8e17-468b-bef1-ae4f1757cd70" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_b20912f9-9950-4010-874a-3414b6ea8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b9a8dd13-77d8-4d5f-a433-7fea26c0d8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7c69edd9-8e17-468b-bef1-ae4f1757cd70" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b9a8dd13-77d8-4d5f-a433-7fea26c0d8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_87483b79-eefd-42ce-a2ee-a69e3ca38963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7c69edd9-8e17-468b-bef1-ae4f1757cd70" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_87483b79-eefd-42ce-a2ee-a69e3ca38963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ffe755e3-1b70-4e10-8927-f380cf91ea07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ffe755e3-1b70-4e10-8927-f380cf91ea07" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9c1078c1-7189-4d2c-a0a0-7276cb3177e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4de5dd56-b5fd-42cd-a451-11f5bc9cfb60" xlink:to="loc_us-gaap_LitigationStatusDomain_9c1078c1-7189-4d2c-a0a0-7276cb3177e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f453eb5b-14cd-4738-b678-aa04e804add1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_9c1078c1-7189-4d2c-a0a0-7276cb3177e6" xlink:to="loc_us-gaap_PendingLitigationMember_f453eb5b-14cd-4738-b678-aa04e804add1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_973559a1-0b02-4867-9a6c-4c3de90de1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7eb291da-fb23-434a-ba8e-9e25b942dfe0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_973559a1-0b02-4867-9a6c-4c3de90de1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_49af6e2d-8355-41ae-a7d7-51fb582ec187" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_973559a1-0b02-4867-9a6c-4c3de90de1b4" xlink:to="loc_jnj_AurisHealthMember_49af6e2d-8355-41ae-a7d7-51fb582ec187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_022c0fa9-4192-48c2-8bda-a963902e015f" xlink:to="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_97b11410-515c-42d3-8e4e-b15dc69c1706" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:to="loc_country_US_97b11410-515c-42d3-8e4e-b15dc69c1706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_25278d08-7206-4ad9-b5e1-5ca8b38584d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:to="loc_us-gaap_NonUsMember_25278d08-7206-4ad9-b5e1-5ca8b38584d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_4f067fb5-34ab-4ce7-802e-3b6a3812e0ba" xlink:href="jnj-20210103.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e72c6e46-fd12-42d1-8d9d-06b86c676b29" xlink:to="loc_jnj_UNITEDSTATESExportsMember_4f067fb5-34ab-4ce7-802e-3b6a3812e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a24bc8c1-1165-434c-941f-71ea65bc4119" xlink:to="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_69ec9ec9-b18f-4bf0-a688-6b95f261646e" xlink:href="jnj-20210103.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_BabyCareMember_69ec9ec9-b18f-4bf0-a688-6b95f261646e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_a72b3e04-a2d1-4fb8-96bd-81cbf55386d4" xlink:href="jnj-20210103.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OralCareMember_a72b3e04-a2d1-4fb8-96bd-81cbf55386d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_539aebc1-01cd-4812-b9e8-9b59ff8d1882" xlink:href="jnj-20210103.xsd#jnj_OTCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OTCMember_539aebc1-01cd-4812-b9e8-9b59ff8d1882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_83536384-3e2f-4887-85c6-7b6f22754db3" xlink:href="jnj-20210103.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_WomensHealthMember_83536384-3e2f-4887-85c6-7b6f22754db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_caf775a8-e900-46a2-add2-f481436580e2" xlink:href="jnj-20210103.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_WoundCareandOtherMember_caf775a8-e900-46a2-add2-f481436580e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_636399db-7071-48fd-bf94-73bf57bda788" xlink:href="jnj-20210103.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_RemicadeMember_636399db-7071-48fd-bf94-73bf57bda788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_ac9d7e81-79ad-445b-993c-8b3aedab8735" xlink:href="jnj-20210103.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SimponiSimponiAriaMember_ac9d7e81-79ad-445b-993c-8b3aedab8735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_a2cff7e0-9b6e-4e2e-b69e-3cc0a4c6831d" xlink:href="jnj-20210103.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_StelaraMember_a2cff7e0-9b6e-4e2e-b69e-3cc0a4c6831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_028c5d82-4135-4dad-a7d0-4751d5ff5aca" xlink:href="jnj-20210103.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_TremfyaMember_028c5d82-4135-4dad-a7d0-4751d5ff5aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_fd0be277-5863-4f43-9492-5be4a7374b15" xlink:href="jnj-20210103.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherImmunologyMember_fd0be277-5863-4f43-9492-5be4a7374b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_cf0e11a9-c0c7-46aa-91e4-071a4ccf041c" xlink:href="jnj-20210103.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_EDURANTrilpivirineMember_cf0e11a9-c0c7-46aa-91e4-071a4ccf041c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_30295b6c-a61e-46ab-9aec-425cad90d496" xlink:href="jnj-20210103.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_30295b6c-a61e-46ab-9aec-425cad90d496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_0fd90881-7b07-469b-9150-5ff9e2f2c0ff" xlink:href="jnj-20210103.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_0fd90881-7b07-469b-9150-5ff9e2f2c0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_9c360dca-4b4e-4006-bf25-c5407d352814" xlink:href="jnj-20210103.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_9c360dca-4b4e-4006-bf25-c5407d352814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c1bb69ab-f364-4fc6-bc92-0efbdc2a8681" xlink:href="jnj-20210103.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c1bb69ab-f364-4fc6-bc92-0efbdc2a8681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_a2df4a65-bb65-4706-920b-30f6699ac190" xlink:href="jnj-20210103.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_RISPERDALCONSTAMember_a2df4a65-bb65-4706-920b-30f6699ac190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_611adafc-da1f-4e4e-b0cc-3045ac2ae879" xlink:href="jnj-20210103.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_611adafc-da1f-4e4e-b0cc-3045ac2ae879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_1c8b3138-87bc-472b-85f0-cc5eed8a300f" xlink:href="jnj-20210103.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_DARZALEXMember_1c8b3138-87bc-472b-85f0-cc5eed8a300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_d505524d-598c-4bbd-8a1f-4138566ab5b5" xlink:href="jnj-20210103.xsd#jnj_ErleadaMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_ErleadaMember_d505524d-598c-4bbd-8a1f-4138566ab5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_1eedebc1-24f0-4560-a299-e02b4a3e330c" xlink:href="jnj-20210103.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_IMBRUVICAMember_1eedebc1-24f0-4560-a299-e02b4a3e330c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VELCADEMember_058209a2-2c5c-4cf5-91dc-4dca386639a5" xlink:href="jnj-20210103.xsd#jnj_VELCADEMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_VELCADEMember_058209a2-2c5c-4cf5-91dc-4dca386639a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_167aafd5-d270-4bc3-ad8b-ba735feec534" xlink:href="jnj-20210103.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_ZYTIGAMember_167aafd5-d270-4bc3-ad8b-ba735feec534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_7e9464b7-933c-4e57-9409-0d6d08d1b507" xlink:href="jnj-20210103.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherOncologyMember_7e9464b7-933c-4e57-9409-0d6d08d1b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_244bc6bf-6df6-4e84-b385-1d934d217158" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OPSUMITMember_244bc6bf-6df6-4e84-b385-1d934d217158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_e45a2826-dec5-4b0d-92c0-4ac608db4309" xlink:href="jnj-20210103.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_UPTRAVIMember_e45a2826-dec5-4b0d-92c0-4ac608db4309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_6048bc68-7e5c-4316-9346-1230940c3dcc" xlink:href="jnj-20210103.xsd#jnj_OtherMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_OtherMember_6048bc68-7e5c-4316-9346-1230940c3dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_c2f4d825-2726-4dcf-885d-c8e5be2c40ea" xlink:href="jnj-20210103.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_XareltoMember_c2f4d825-2726-4dcf-885d-c8e5be2c40ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_3688f9a7-6f99-4210-b103-7efb919044f1" xlink:href="jnj-20210103.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_3688f9a7-6f99-4210-b103-7efb919044f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_9ebc2fbd-dbad-49c9-994c-dca264e4f6b9" xlink:href="jnj-20210103.xsd#jnj_PROCRITEPREXMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_PROCRITEPREXMember_9ebc2fbd-dbad-49c9-994c-dca264e4f6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_aa42b899-0444-4dce-a747-8d5e46954a87" xlink:href="jnj-20210103.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_HIPSMember_aa42b899-0444-4dce-a747-8d5e46954a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_b51c6170-5320-4f85-9ba8-cd0ce26d16a2" xlink:href="jnj-20210103.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_KNEESMember_b51c6170-5320-4f85-9ba8-cd0ce26d16a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_b8351f55-3fb0-450e-92fd-2c2394f84d39" xlink:href="jnj-20210103.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_TRAUMAMember_b8351f55-3fb0-450e-92fd-2c2394f84d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_194eb03a-e7ba-4db1-8eab-d4f33c4bc39c" xlink:href="jnj-20210103.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SPINEOTHERMember_194eb03a-e7ba-4db1-8eab-d4f33c4bc39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_a6c24abb-9d19-48d0-8649-6553dbf7d96e" xlink:href="jnj-20210103.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_ADVANCEDMember_a6c24abb-9d19-48d0-8649-6553dbf7d96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_aa7d50cf-7f46-4096-881e-11127e9200b6" xlink:href="jnj-20210103.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_GENERALMember_aa7d50cf-7f46-4096-881e-11127e9200b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_6427c46f-8de3-4c8e-9e4a-a84cf667179a" xlink:href="jnj-20210103.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_6427c46f-8de3-4c8e-9e4a-a84cf667179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_15e997d1-3943-485f-91b8-4d11450ce55d" xlink:href="jnj-20210103.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SURGICALMember_15e997d1-3943-485f-91b8-4d11450ce55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_158044e1-1c3f-43b6-a6fb-4a547f900969" xlink:href="jnj-20210103.xsd#jnj_SkinHealthBeautyMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6a42eb0-c4a4-4014-90c7-13de7da3e528" xlink:to="loc_jnj_SkinHealthBeautyMember_158044e1-1c3f-43b6-a6fb-4a547f900969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7773a161-0680-4e02-acee-ecdca3f5bb1a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9eb03470-1d98-4d99-b3fe-5be57b486c14" xlink:to="loc_srt_ConsolidationItemsDomain_7773a161-0680-4e02-acee-ecdca3f5bb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8e396228-27fa-472a-b71f-ae80ef5b1aee" xlink:to="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_420d2400-0bb6-4f00-969f-d4c3ee13dd18" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:to="loc_jnj_ConsumerMember_420d2400-0bb6-4f00-969f-d4c3ee13dd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_da356966-904c-4c0d-a8aa-32916a19055e" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:to="loc_jnj_PharmaceuticalMember_da356966-904c-4c0d-a8aa-32916a19055e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a2e6030e-f4e1-45a6-97e0-db3090369b91" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_12cee77f-610b-4c91-b8e2-0f0790935d9d" xlink:to="loc_jnj_MedicalDevicesMember_a2e6030e-f4e1-45a6-97e0-db3090369b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_4f9d6440-a52e-4d33-91cc-3896ecac1025" xlink:to="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_3dde9e04-a141-494c-a070-4094815ccddc" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_ImmunologyMember_3dde9e04-a141-494c-a070-4094815ccddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_f1aeab1e-6249-4231-b14e-c50bbe4af3cb" xlink:href="jnj-20210103.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_InfectiousDiseasesMember_f1aeab1e-6249-4231-b14e-c50bbe4af3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_b4b90532-c290-49e4-b377-4f05838cf022" xlink:href="jnj-20210103.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_NeuroscienceMember_b4b90532-c290-49e4-b377-4f05838cf022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_6599171c-74ef-440b-8222-60ea166d6335" xlink:href="jnj-20210103.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_OncologyMember_6599171c-74ef-440b-8222-60ea166d6335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_0c2315ec-1032-4612-98e6-989c0aefd4ee" xlink:href="jnj-20210103.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_PulmonaryHypertensionMember_0c2315ec-1032-4612-98e6-989c0aefd4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_70d9e12b-642b-43c5-8c48-4a227ea41619" xlink:href="jnj-20210103.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_70d9e12b-642b-43c5-8c48-4a227ea41619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiabetesCareMember_37fc497c-b96a-4127-aae0-2d1b946eff3d" xlink:href="jnj-20210103.xsd#jnj_DiabetesCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_DiabetesCareMember_37fc497c-b96a-4127-aae0-2d1b946eff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_5f130678-0fe5-4e10-99a5-15bf2650f107" xlink:href="jnj-20210103.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_InterventionalSolutionsMember_5f130678-0fe5-4e10-99a5-15bf2650f107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_b038efc0-9a5a-477f-ae19-210289b40989" xlink:href="jnj-20210103.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_OrthopaedicsMember_b038efc0-9a5a-477f-ae19-210289b40989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_9059235d-14a0-4db9-b6f5-846a03b41928" xlink:href="jnj-20210103.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_SurgeryMember_9059235d-14a0-4db9-b6f5-846a03b41928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_f8d127a9-5aa1-4487-91a0-77bf790401ef" xlink:href="jnj-20210103.xsd#jnj_VisionMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_VisionMember_f8d127a9-5aa1-4487-91a0-77bf790401ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_9b9994f7-375c-46cf-8fe3-33cae8bc9bf6" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_71dba20d-271a-425e-96b7-0d715a715dad" xlink:to="loc_jnj_OPSUMITMember_9b9994f7-375c-46cf-8fe3-33cae8bc9bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_68ccef9f-df4f-4b4e-afdd-8cc543b0b6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_a27a1317-20b0-493a-b689-77ffb509a32b" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_68ccef9f-df4f-4b4e-afdd-8cc543b0b6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4dc5f5a7-d287-4397-966e-0ba1f9d38724" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a8f22638-55f8-4b19-a5d9-4f68a15fba58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a8f22638-55f8-4b19-a5d9-4f68a15fba58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b60a2d92-7055-4259-9b6e-65c497450cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b60a2d92-7055-4259-9b6e-65c497450cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3235b7ec-6ea5-450f-ab7f-22b2ac56b2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3235b7ec-6ea5-450f-ab7f-22b2ac56b2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_57050a8c-95ef-4d6f-b56a-f1d9265aa308" xlink:href="jnj-20210103.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a807ae22-6d4c-4aa1-8ca4-2ab817a2bb8d" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_57050a8c-95ef-4d6f-b56a-f1d9265aa308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_46e78da5-9c5f-44ce-8704-502558de5a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_46e78da5-9c5f-44ce-8704-502558de5a5c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c5a7bdb1-0b11-4e47-bf74-5d947c4b0272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_b1c3d34e-f8ec-4682-8013-4e1a9f4904e8" xlink:to="loc_us-gaap_SubsegmentsDomain_c5a7bdb1-0b11-4e47-bf74-5d947c4b0272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_2cc68c42-fee9-436a-846c-dd611450716e" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c5a7bdb1-0b11-4e47-bf74-5d947c4b0272" xlink:to="loc_jnj_ImmunologyMember_2cc68c42-fee9-436a-846c-dd611450716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79144071-e8ef-45d6-a45c-15ebd2ad2286" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_41155e2b-d995-4ce9-91f0-c8ef2a195729" xlink:to="loc_srt_ProductsAndServicesDomain_79144071-e8ef-45d6-a45c-15ebd2ad2286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ba71c0b4-4b14-4ea5-96de-ea88ccbb753e" xlink:to="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e8893190-44a5-41a4-9d6f-89332cd658ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e8893190-44a5-41a4-9d6f-89332cd658ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9059f39b-3e35-4166-b3cb-0196d6327146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8bc657b5-d17a-4df6-9383-493d7f4b05b3" xlink:to="loc_us-gaap_OperatingSegmentsMember_9059f39b-3e35-4166-b3cb-0196d6327146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_21d23a49-f306-43dd-ac4f-ff13472e07b5" xlink:to="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_a3e43b70-6fba-4e98-a46a-dba9cef130ac" xlink:href="jnj-20210103.xsd#jnj_GeneralCorporateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_GeneralCorporateMember_a3e43b70-6fba-4e98-a46a-dba9cef130ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_f0af4b7a-bf7d-4661-b8cd-8155b54e191a" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_ConsumerMember_f0af4b7a-bf7d-4661-b8cd-8155b54e191a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_63ffe20d-1694-4c6a-abac-945117c57ed4" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_PharmaceuticalMember_63ffe20d-1694-4c6a-abac-945117c57ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_f4b9cab2-b26d-49b0-a5ae-487a8ffb7c81" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_MedicalDevicesMember_f4b9cab2-b26d-49b0-a5ae-487a8ffb7c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_0ae83e14-d06f-4b55-8d09-66254b4d8687" xlink:href="jnj-20210103.xsd#jnj_SegmentsTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d40be6b-bc39-4bf7-bd93-026cc3501a1a" xlink:to="loc_jnj_SegmentsTotalMember_0ae83e14-d06f-4b55-8d09-66254b4d8687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_23cf3762-1aaf-470f-aa6c-5d6fd2c2e334" xlink:to="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f4e59b97-4990-4b5b-a479-7aa990878322" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:to="loc_country_US_f4e59b97-4990-4b5b-a479-7aa990878322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e0ad4e0c-cd91-481c-88e5-af2a36c8df20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_13431291-5735-4fa2-8c4f-fbf868d3939b" xlink:to="loc_us-gaap_NonUsMember_e0ad4e0c-cd91-481c-88e5-af2a36c8df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1c0fb63c-9311-4b15-aa8f-5cdb3c1d4918" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_88955a4c-89a0-4c9b-87bb-4e957788fe87" xlink:to="loc_srt_NameOfMajorCustomerDomain_1c0fb63c-9311-4b15-aa8f-5cdb3c1d4918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_ce4162d0-a2e4-4eb8-ba40-f4e8ccf18a15" xlink:href="jnj-20210103.xsd#jnj_Wholesaler2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1c0fb63c-9311-4b15-aa8f-5cdb3c1d4918" xlink:to="loc_jnj_Wholesaler2Member_ce4162d0-a2e4-4eb8-ba40-f4e8ccf18a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_401ab2d6-edf5-49b6-95da-311727a0c003" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_035ce90d-8864-4402-824a-e8637ea1e850" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_401ab2d6-edf5-49b6-95da-311727a0c003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c9256985-05d6-4740-a578-044f587218ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_401ab2d6-edf5-49b6-95da-311727a0c003" xlink:to="loc_us-gaap_SalesRevenueNetMember_c9256985-05d6-4740-a578-044f587218ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b0799f8-57e4-4a62-ab5a-a476b4987edc" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5133a368-d0f2-42e8-8196-57c35de46a27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5133a368-d0f2-42e8-8196-57c35de46a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments_07007725-83b3-40e6-b448-34f87b24ecf4" xlink:href="jnj-20210103.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_jnj_ExpenseNotAllocatedToSegments_07007725-83b3-40e6-b448-34f87b24ecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0c2d9b72-f1db-4367-bafb-b83c67f07b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_Assets_0c2d9b72-f1db-4367-bafb-b83c67f07b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04860b6a-e6b9-4a90-97c0-ea5a654da562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04860b6a-e6b9-4a90-97c0-ea5a654da562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4621a153-7047-461d-879d-6247099ad9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4621a153-7047-461d-879d-6247099ad9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b39d238-a087-4728-bd39-88787dca2a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b39d238-a087-4728-bd39-88787dca2a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ffa3534c-e5d1-430a-a6fb-fd6e9e18db30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ee41a505-db21-4393-96c9-342a49f5669f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ffa3534c-e5d1-430a-a6fb-fd6e9e18db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e697dca4-d066-4359-86ad-d9cff0c5d2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e697dca4-d066-4359-86ad-d9cff0c5d2c1" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c10b15f1-bbe9-44c6-9afb-5ff9ce249521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42789a5b-e666-4095-89bc-ee7c046442da" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c10b15f1-bbe9-44c6-9afb-5ff9ce249521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_be9f80f7-882c-47f9-8a45-6876d35a3eb0" xlink:href="jnj-20210103.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c10b15f1-bbe9-44c6-9afb-5ff9ce249521" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_be9f80f7-882c-47f9-8a45-6876d35a3eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_99157b58-f783-4263-902e-96ad22e17acf" xlink:to="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_bcc66f61-4cb7-4506-bd6c-d7eabcd9966f" xlink:href="jnj-20210103.xsd#jnj_Wholesaler1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:to="loc_jnj_Wholesaler1Member_bcc66f61-4cb7-4506-bd6c-d7eabcd9966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_bf2f8660-c924-47c9-8a00-6af934526323" xlink:href="jnj-20210103.xsd#jnj_Wholesaler2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:to="loc_jnj_Wholesaler2Member_bf2f8660-c924-47c9-8a00-6af934526323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_b195295b-b667-4b00-9646-c5c978fc6516" xlink:href="jnj-20210103.xsd#jnj_Wholesaler3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d0386415-d900-4125-8561-7cd494729568" xlink:to="loc_jnj_Wholesaler3Member_b195295b-b667-4b00-9646-c5c978fc6516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_80402bf7-4f2e-451e-a03e-190fd8e3a7c4" xlink:to="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0d941a16-12a9-46d5-b8da-675aa561b9a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0d941a16-12a9-46d5-b8da-675aa561b9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7cdef197-5e4e-48c5-9849-333a3d7a4e60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a3e2baad-f809-403c-9e0d-bba689331cd3" xlink:to="loc_us-gaap_OperatingSegmentsMember_7cdef197-5e4e-48c5-9849-333a3d7a4e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fa4b6ea5-31c6-4f6d-8a65-6a683235d623" xlink:to="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_cc51a593-4a21-4ff0-9cc7-c2c6a77ffbf5" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_country_US_cc51a593-4a21-4ff0-9cc7-c2c6a77ffbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_cdfeb495-a9bd-4b6a-b4f1-68b19a50014f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_srt_EuropeMember_cdfeb495-a9bd-4b6a-b4f1-68b19a50014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_2283e8f2-428a-4a43-b1a5-d1536e364f07" xlink:href="jnj-20210103.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_2283e8f2-428a-4a43-b1a5-d1536e364f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_ef5a1c78-18b9-4a34-afe8-583d45a62a39" xlink:href="jnj-20210103.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_jnj_AsiaPacificAfricaMember_ef5a1c78-18b9-4a34-afe8-583d45a62a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_09acdaf5-6388-4044-80ea-6c0d8498dc63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_us-gaap_OperatingSegmentsMember_09acdaf5-6388-4044-80ea-6c0d8498dc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1a29bf5e-3944-4bbb-bf49-3e1754219659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5b1865c-a6be-4a66-bfcf-372a59efa39e" xlink:to="loc_us-gaap_NonUsMember_1a29bf5e-3944-4bbb-bf49-3e1754219659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_775c5727-a425-4388-b8ba-9b19d87bcb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5b3a2090-9568-4ec5-b580-24e73ff8b697" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_775c5727-a425-4388-b8ba-9b19d87bcb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_9fb5b395-26dd-4498-b677-5f08aba27f04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_775c5727-a425-4388-b8ba-9b19d87bcb6b" xlink:to="loc_us-gaap_SalesRevenueNetMember_9fb5b395-26dd-4498-b677-5f08aba27f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_80d0661b-6d2b-43ad-891f-79883b468da4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NIZORALMember_a0dc0a5e-d10e-48a3-a0a7-f901137d5cc0" xlink:href="jnj-20210103.xsd#jnj_NIZORALMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:to="loc_jnj_NIZORALMember_a0dc0a5e-d10e-48a3-a0a7-f901137d5cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PANCREASEMember_eb47ed5f-f925-4982-9c45-ec88dc0e7154" xlink:href="jnj-20210103.xsd#jnj_PANCREASEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:to="loc_jnj_PANCREASEMember_eb47ed5f-f925-4982-9c45-ec88dc0e7154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LifeScanMember_d18f3522-5a6f-4fe1-bbe7-d7f1c13fe194" xlink:href="jnj-20210103.xsd#jnj_LifeScanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c66c23fe-7d10-42a9-879f-b31ceb641997" xlink:to="loc_jnj_LifeScanMember_d18f3522-5a6f-4fe1-bbe7-d7f1c13fe194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a91e03ae-f1c1-4ea2-a483-8b852f0f0419" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_c2172a9f-bf6a-45cf-aa78-e4b6ad7181c7" xlink:href="jnj-20210103.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_c2172a9f-bf6a-45cf-aa78-e4b6ad7181c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AliosBiopharmaIncandXO1LimitedMember_2503dadb-d78a-4c98-b38a-00c3316dfea2" xlink:href="jnj-20210103.xsd#jnj_AliosBiopharmaIncandXO1LimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_AliosBiopharmaIncandXO1LimitedMember_2503dadb-d78a-4c98-b38a-00c3316dfea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XO1Member_080dc333-84e4-49ce-9ff1-13e57eb7d76f" xlink:href="jnj-20210103.xsd#jnj_XO1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_XO1Member_080dc333-84e4-49ce-9ff1-13e57eb7d76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ActelionMember_d9df1c82-11d1-485b-8188-58d0f0beb542" xlink:href="jnj-20210103.xsd#jnj_ActelionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_ActelionMember_d9df1c82-11d1-485b-8188-58d0f0beb542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AMOMember_6ec9bbb8-147d-484e-bfdc-0231b5911a37" xlink:href="jnj-20210103.xsd#jnj_AMOMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_AMOMember_6ec9bbb8-147d-484e-bfdc-0231b5911a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_48c7c582-1340-4a5f-8116-e3b100e87bf8" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_357c2609-4dba-49eb-b4b4-49e7e9fdfa7f" xlink:to="loc_jnj_AurisHealthMember_48c7c582-1340-4a5f-8116-e3b100e87bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d8cc8b9e-b6c5-4216-82d7-4cc0120526fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_dd24bdcd-1764-43d3-8f83-78ee02416468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_dd24bdcd-1764-43d3-8f83-78ee02416468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_783e7411-800b-40e1-9044-325ace6970e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_647fc058-d647-4c36-ae73-f1ae2e6b6b4b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_783e7411-800b-40e1-9044-325ace6970e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46900bba-62c3-4d21-ac3a-c6cc59d69643" xlink:to="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_038f3f5b-5e75-4245-89e7-fa2c02ea9ef1" xlink:href="jnj-20210103.xsd#jnj_GeneralCorporateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_GeneralCorporateMember_038f3f5b-5e75-4245-89e7-fa2c02ea9ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_db9ab57e-ca91-4b16-8f58-cb18944ab00f" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_MedicalDevicesMember_db9ab57e-ca91-4b16-8f58-cb18944ab00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_af5223f1-846d-421e-a0df-377b7c06b507" xlink:href="jnj-20210103.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_ConsumerMember_af5223f1-846d-421e-a0df-377b7c06b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_7075a753-72c5-4429-9fcc-e46a30c1a9ea" xlink:href="jnj-20210103.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93056e9d-8d7a-42fd-bc12-1650c5eea561" xlink:to="loc_jnj_PharmaceuticalMember_7075a753-72c5-4429-9fcc-e46a30c1a9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1660768-3f2b-4279-b276-aa7c13a24066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9af24c94-a3b6-47f6-9f28-bcacbca7906e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1660768-3f2b-4279-b276-aa7c13a24066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_81a380a8-13c3-48ad-b743-62b0ab44488d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1660768-3f2b-4279-b276-aa7c13a24066" xlink:to="loc_us-gaap_OtherIncomeMember_81a380a8-13c3-48ad-b743-62b0ab44488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60445ded-2cc7-411a-b6da-93320cc4ed0a" xlink:to="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_ce1b438c-6b14-40b0-b7aa-1179065e0bd7" xlink:href="jnj-20210103.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_BabyCareMember_ce1b438c-6b14-40b0-b7aa-1179065e0bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_2e0f91bb-e6d3-4ecf-b3e9-7cd8100a2b9e" xlink:href="jnj-20210103.xsd#jnj_OTCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_OTCMember_2e0f91bb-e6d3-4ecf-b3e9-7cd8100a2b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_4babdd13-6a63-4b48-ba3a-123380acc31d" xlink:href="jnj-20210103.xsd#jnj_SkinHealthBeautyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_SkinHealthBeautyMember_4babdd13-6a63-4b48-ba3a-123380acc31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_cf07500e-b44e-4027-b7a7-40db71943fc1" xlink:href="jnj-20210103.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_OralCareMember_cf07500e-b44e-4027-b7a7-40db71943fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_ae0adb2d-24b9-4e56-8cab-8d940a951227" xlink:href="jnj-20210103.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_StelaraMember_ae0adb2d-24b9-4e56-8cab-8d940a951227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_19ef5b94-8c4e-4b86-86cf-6b05e8472c1b" xlink:href="jnj-20210103.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_TremfyaMember_19ef5b94-8c4e-4b86-86cf-6b05e8472c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_dda8e56f-0386-4274-8929-ee7a5e77cb57" xlink:href="jnj-20210103.xsd#jnj_ErleadaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_ErleadaMember_dda8e56f-0386-4274-8929-ee7a5e77cb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_c009448d-98d6-4e5f-a4d8-4d23d0614ab8" xlink:href="jnj-20210103.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_IMBRUVICAMember_c009448d-98d6-4e5f-a4d8-4d23d0614ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_3d8e043a-698e-4f0a-8a39-f4fe8ad3299d" xlink:href="jnj-20210103.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_DARZALEXMember_3d8e043a-698e-4f0a-8a39-f4fe8ad3299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_9a160066-9ccd-4692-a06f-fa9f3bb10fe4" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35fe9cc5-11f7-487f-9402-6bc6abb84dc5" xlink:to="loc_jnj_OPSUMITMember_9a160066-9ccd-4692-a06f-fa9f3bb10fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_dcaacec2-737d-4cfa-b323-9ccc31969a57" xlink:to="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_24c1fc15-5775-44be-9b89-b364a33c00b9" xlink:href="jnj-20210103.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_ImmunologyMember_24c1fc15-5775-44be-9b89-b364a33c00b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_da55ac60-3df3-49a6-a1c9-51f5e1501929" xlink:href="jnj-20210103.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_OncologyMember_da55ac60-3df3-49a6-a1c9-51f5e1501929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_89823dbb-013c-4819-8e6f-cedf692128d3" xlink:href="jnj-20210103.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_PulmonaryHypertensionMember_89823dbb-013c-4819-8e6f-cedf692128d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_1a3283cc-5170-4c23-895b-55d8e537b4b9" xlink:href="jnj-20210103.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_OPSUMITMember_1a3283cc-5170-4c23-895b-55d8e537b4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_9931651b-81f5-449f-a11b-89a11a7a139d" xlink:href="jnj-20210103.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_UPTRAVIMember_9931651b-81f5-449f-a11b-89a11a7a139d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_e48960c5-cf75-47fa-a67b-720f9a736707" xlink:href="jnj-20210103.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_InterventionalSolutionsMember_e48960c5-cf75-47fa-a67b-720f9a736707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiabetesCareMember_2995eb7c-cc7b-42c9-a228-74584013efa9" xlink:href="jnj-20210103.xsd#jnj_DiabetesCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_771e6c0a-f808-417a-9dbd-2f763091f8cc" xlink:to="loc_jnj_DiabetesCareMember_2995eb7c-cc7b-42c9-a228-74584013efa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_38f80e6d-a58c-44ae-9abd-02f12fafffcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_37d302a5-d1a6-486d-8279-e78ccfa69a79" xlink:to="loc_us-gaap_LitigationStatusDomain_38f80e6d-a58c-44ae-9abd-02f12fafffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_5f3b5f38-dbd8-467b-af37-3ae0521cf827" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_38f80e6d-a58c-44ae-9abd-02f12fafffcd" xlink:to="loc_us-gaap_PendingLitigationMember_5f3b5f38-dbd8-467b-af37-3ae0521cf827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_86842301-9759-48b9-8282-7abadf6c6b0d" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_95077fc5-f070-4305-bb5a-77c261956ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_95077fc5-f070-4305-bb5a-77c261956ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_93400399-800a-4cc2-92c2-e98f9883664e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_93400399-800a-4cc2-92c2-e98f9883664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62c681d1-c109-4473-9ec4-0e727b7f9b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62c681d1-c109-4473-9ec4-0e727b7f9b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_a541acdb-1500-497f-ab60-94c1dc7d3ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_NoncurrentAssets_a541acdb-1500-497f-ab60-94c1dc7d3ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_cb2c5f23-75dc-4873-9c96-3607062f5ec3" xlink:href="jnj-20210103.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_OtherNonLongLivedAssets_cb2c5f23-75dc-4873-9c96-3607062f5ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_87e831dd-ab26-4dc8-92a9-54255d3ccfff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_Assets_87e831dd-ab26-4dc8-92a9-54255d3ccfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7ac040a8-c6ba-444d-88b9-a48ed51a87bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7ac040a8-c6ba-444d-88b9-a48ed51a87bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c1938d8c-1e49-4470-9e79-7e93e96aa4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c1938d8c-1e49-4470-9e79-7e93e96aa4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ef8e2610-a180-4464-aad3-162c61b96ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ef8e2610-a180-4464-aad3-162c61b96ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c7098845-ffe2-4f1b-afa9-97a45c6fb17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c7098845-ffe2-4f1b-afa9-97a45c6fb17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedLossOnSecurities_42a7efe2-623d-4041-b775-c74e8dbf9f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedLossOnSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_UnrealizedLossOnSecurities_42a7efe2-623d-4041-b775-c74e8dbf9f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e7775e85-6298-42c5-afed-754a96c63b95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_RestructuringCharges_e7775e85-6298-42c5-afed-754a96c63b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_d0c95208-b08a-458c-98d5-1f7d42717119" xlink:href="jnj-20210103.xsd#jnj_RegulationCharge"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_RegulationCharge_d0c95208-b08a-458c-98d5-1f7d42717119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_d5895184-533d-4cc1-b578-226e21510abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_d5895184-533d-4cc1-b578-226e21510abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2a985dbd-cab9-4180-812d-41b1d9a338f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2a985dbd-cab9-4180-812d-41b1d9a338f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_58f56f43-3bee-4659-9962-1ba2a2a018de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_LitigationSettlementExpense_58f56f43-3bee-4659-9962-1ba2a2a018de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringChargeNetofAccrualAdjustment_a010c92c-ff22-4872-b7ea-8ec6d6a7cfaa" xlink:href="jnj-20210103.xsd#jnj_RestructuringChargeNetofAccrualAdjustment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_RestructuringChargeNetofAccrualAdjustment_a010c92c-ff22-4872-b7ea-8ec6d6a7cfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d03e6ae8-69f1-4057-a6c9-318c7c027266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d03e6ae8-69f1-4057-a6c9-318c7c027266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnSecurities_a3ddfffe-7581-4698-accc-f564cecee7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnSecurities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_UnrealizedGainLossOnSecurities_a3ddfffe-7581-4698-accc-f564cecee7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_271a7934-cd4a-4396-a697-450a1ad1f075" xlink:href="jnj-20210103.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_271a7934-cd4a-4396-a697-450a1ad1f075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4503722-464b-4ccd-bf50-82ba2c5407f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1108daa2-267c-4f17-bf48-ebcc172a2f58" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_a4503722-464b-4ccd-bf50-82ba2c5407f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20210103.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_18075023-9bca-43f3-add8-2dd1c4cfe914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ee450c85-afcb-406d-9f9b-47730390c304" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_18075023-9bca-43f3-add8-2dd1c4cfe914" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ee450c85-afcb-406d-9f9b-47730390c304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_72f7a562-6473-4101-b852-b9be18fe536a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_72f7a562-6473-4101-b852-b9be18fe536a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2c383fbc-29e8-4a66-8495-b7246a87f37e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0affd07d-3631-4e30-9240-8e5fe461354b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2c383fbc-29e8-4a66-8495-b7246a87f37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_3957c30e-d283-4a77-8c68-1cb84ec36f97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2c383fbc-29e8-4a66-8495-b7246a87f37e" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_3957c30e-d283-4a77-8c68-1cb84ec36f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_01f91d77-c7fd-4c26-8ddc-031e1b5e214a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LifeScanMember_f21a8119-cd38-4ca4-9ccb-e539c0cae4b4" xlink:href="jnj-20210103.xsd#jnj_LifeScanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_LifeScanMember_f21a8119-cd38-4ca4-9ccb-e539c0cae4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_17dd3ce6-e841-49ac-acdd-f1c9b5135046" xlink:href="jnj-20210103.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_17dd3ce6-e841-49ac-acdd-f1c9b5135046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_4f03a68e-8e61-4d09-958d-89073552c5f9" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_SupplyChainMember_4f03a68e-8e61-4d09-958d-89073552c5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_53107080-3135-481b-bae7-0fe222bc619e" xlink:href="jnj-20210103.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e4f3f5c-fbd0-4427-9308-b8980a5e6426" xlink:to="loc_jnj_EvraAndDoxilMember_53107080-3135-481b-bae7-0fe222bc619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9877b92d-cbec-499b-8023-4e16f0cc24a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4743059e-2d9c-47f0-bf4f-7d80f7f494e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9877b92d-cbec-499b-8023-4e16f0cc24a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_4f14d707-98fe-47fb-a666-85f304c792c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9877b92d-cbec-499b-8023-4e16f0cc24a0" xlink:to="loc_us-gaap_ConvertibleDebtMember_4f14d707-98fe-47fb-a666-85f304c792c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_42e380ce-1ae8-450d-b712-20dee99c525f" xlink:to="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce1db0d0-862a-4ab0-9a7c-08a80ead45e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:to="loc_srt_MaximumMember_ce1db0d0-862a-4ab0-9a7c-08a80ead45e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_643150b5-9280-47a6-9dfc-98f94e68d2c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cd1ae86a-576b-41cb-86c9-6bf072eab64c" xlink:to="loc_srt_MinimumMember_643150b5-9280-47a6-9dfc-98f94e68d2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4195524e-4fd1-4a2f-b91c-2b1d8163987c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2019AcquisitionsMember_00973847-c353-4ba1-9721-c5faf636117b" xlink:href="jnj-20210103.xsd#jnj_A2019AcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_A2019AcquisitionsMember_00973847-c353-4ba1-9721-c5faf636117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_330a679c-ed55-4014-91dc-a97281f4da08" xlink:href="jnj-20210103.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_AurisHealthMember_330a679c-ed55-4014-91dc-a97281f4da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2018AcquisitionsMember_ced18779-f249-414b-a0ba-5d3b8c98f4a6" xlink:href="jnj-20210103.xsd#jnj_A2018AcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_A2018AcquisitionsMember_ced18779-f249-414b-a0ba-5d3b8c98f4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_bfccf72f-23f4-4da3-8d27-f083a29e07b1" xlink:href="jnj-20210103.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_bfccf72f-23f4-4da3-8d27-f083a29e07b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember_ec910e8f-effe-469d-a5b1-2b8d015d97d1" xlink:href="jnj-20210103.xsd#jnj_IdorsiaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_IdorsiaMember_ec910e8f-effe-469d-a5b1-2b8d015d97d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_78fd30d6-7cb8-477a-a2bd-72836a808c69" xlink:href="jnj-20210103.xsd#jnj_MomentaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_MomentaMember_78fd30d6-7cb8-477a-a2bd-72836a808c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember_d72a1b5b-056e-457d-a855-7661709ea239" xlink:href="jnj-20210103.xsd#jnj_A2020AcquisitionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_A2020AcquisitionsMember_d72a1b5b-056e-457d-a855-7661709ea239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_a22520c2-9f05-4557-bc95-4c45e73f95f2" xlink:href="jnj-20210103.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_BermekimabMember_a22520c2-9f05-4557-bc95-4c45e73f95f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_f6310591-a055-4c5b-9d2b-da47f6774e2b" xlink:href="jnj-20210103.xsd#jnj_VerbSurgicalIncMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7af435f6-cd97-4642-b300-b518dbeb28f0" xlink:to="loc_jnj_VerbSurgicalIncMember_f6310591-a055-4c5b-9d2b-da47f6774e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32e33805-01e4-4e8d-9c37-b817f4c3fcc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_092fd5e3-bbaa-45a1-990c-fc2b27467110" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32e33805-01e4-4e8d-9c37-b817f4c3fcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_108a799e-2bc5-4a0e-9b73-46d4cd0bfde1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32e33805-01e4-4e8d-9c37-b817f4c3fcc1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_108a799e-2bc5-4a0e-9b73-46d4cd0bfde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48214fcb-3bef-4ba8-a7f7-c829d0f9401c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0dd37b42-d342-4993-b660-3abbbb4cbafa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48214fcb-3bef-4ba8-a7f7-c829d0f9401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dba6dd6c-bd64-4888-8d14-414182dd8140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_48214fcb-3bef-4ba8-a7f7-c829d0f9401c" xlink:to="loc_us-gaap_SubsequentEventMember_dba6dd6c-bd64-4888-8d14-414182dd8140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9137de69-e602-4fa2-a067-80718c25fc80" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0e67697-c7f6-45d8-9754-74735b08715e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0e67697-c7f6-45d8-9754-74735b08715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0d6d37d9-11b3-4051-b8a4-2f8927bf823c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0d6d37d9-11b3-4051-b8a4-2f8927bf823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1e1a1704-90a2-4536-82a1-1af1d320f119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1e1a1704-90a2-4536-82a1-1af1d320f119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f3a1e113-27c2-458f-a145-2a9146535dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_f3a1e113-27c2-458f-a145-2a9146535dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7ec9eb43-43f6-4687-83cb-4d7528bb19dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7ec9eb43-43f6-4687-83cb-4d7528bb19dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_7a4ad990-7b06-4001-96ff-67b3a6f69f16" xlink:href="jnj-20210103.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_7a4ad990-7b06-4001-96ff-67b3a6f69f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_21903879-0980-4afc-bb48-312a4b0ec605" xlink:href="jnj-20210103.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_21903879-0980-4afc-bb48-312a4b0ec605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f459b75d-28a9-4482-8715-8a59b0e7e212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f459b75d-28a9-4482-8715-8a59b0e7e212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05c124cb-2b64-45c2-bf09-3d6e2b7f08f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_Goodwill_05c124cb-2b64-45c2-bf09-3d6e2b7f08f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c3010ccf-85ae-4c87-b99c-4be03a5df11d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c3010ccf-85ae-4c87-b99c-4be03a5df11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_cef7aec9-1280-411b-b27e-e08851648963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_cef7aec9-1280-411b-b27e-e08851648963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_91c59503-1c48-4f3e-8480-fdf630f6e7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_91c59503-1c48-4f3e-8480-fdf630f6e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_44385de3-6665-4ddd-a03c-cca744d14955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_44385de3-6665-4ddd-a03c-cca744d14955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c640342a-3aa9-462b-a948-24b79a4f764e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c640342a-3aa9-462b-a948-24b79a4f764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_f29e1498-adc0-47ea-9f6a-97d6bbdcf6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_f29e1498-adc0-47ea-9f6a-97d6bbdcf6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d0ca28dc-ca3c-4234-807d-5af426d3d0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d0ca28dc-ca3c-4234-807d-5af426d3d0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_11070a11-985c-4f4c-b3e7-72dddc6daa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_11070a11-985c-4f4c-b3e7-72dddc6daa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_3ba37e06-f79a-463e-8f32-8972c2d8f1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_3ba37e06-f79a-463e-8f32-8972c2d8f1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1bd299b8-9529-40a9-9b44-cc473026e7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1bd299b8-9529-40a9-9b44-cc473026e7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_9d22f8f3-5475-467e-a315-0025df0a3fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_9d22f8f3-5475-467e-a315-0025df0a3fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6649ca45-09d2-4402-af3b-8685de19bfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6649ca45-09d2-4402-af3b-8685de19bfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_c66d2ba2-fdf3-46d5-a174-d22cffdd49ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_c66d2ba2-fdf3-46d5-a174-d22cffdd49ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_a8ed152f-f6e9-4740-9db9-c5f77c8c57e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_a8ed152f-f6e9-4740-9db9-c5f77c8c57e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_d8f64a40-e3c9-4e68-b912-8259b4451735" xlink:href="jnj-20210103.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_d8f64a40-e3c9-4e68-b912-8259b4451735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestPercentage_a31f2a4c-2c6d-43df-825b-2bd966f862d2" xlink:href="jnj-20210103.xsd#jnj_ConvertibleNoteEquityInterestPercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_ConvertibleNoteEquityInterestPercentage_a31f2a4c-2c6d-43df-825b-2bd966f862d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c319b37-2346-4ac3-a041-936d2a3e140f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_LongTermDebt_5c319b37-2346-4ac3-a041-936d2a3e140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7a272b30-2024-493e-9aae-e5ed46f14d08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7a272b30-2024-493e-9aae-e5ed46f14d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_01f254dc-6d5a-4771-8e83-b6664995ef0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_01f254dc-6d5a-4771-8e83-b6664995ef0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_3092090c-f472-4b11-8e13-67123df4e02e" xlink:href="jnj-20210103.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_3092090c-f472-4b11-8e13-67123df4e02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_865bcb64-0166-4ecf-9665-7ca82a18cf9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_865bcb64-0166-4ecf-9665-7ca82a18cf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_92c8eb9f-5033-4d1b-87ca-3cdba8dcaa96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_92c8eb9f-5033-4d1b-87ca-3cdba8dcaa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_71c811bb-1397-4bf4-8737-37df9de0f45b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5ecd0dc8-ec1e-488a-ae67-06b654e3b93c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_71c811bb-1397-4bf4-8737-37df9de0f45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20210103.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f928506-ad49-4c8e-8ebf-8c5380bdffc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3c7d2cc1-be6b-4b39-aa58-1b1b55f871c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f928506-ad49-4c8e-8ebf-8c5380bdffc1" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3c7d2cc1-be6b-4b39-aa58-1b1b55f871c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e52e829-c006-4a5e-8f2a-1538877272f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e52e829-c006-4a5e-8f2a-1538877272f4" xlink:to="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b0aaf2a3-b15c-46e3-b869-8468397a83e5" xlink:to="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8b989d5f-39ca-4450-a22a-aba7e912c958" xlink:href="jnj-20210103.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8b989d5f-39ca-4450-a22a-aba7e912c958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_94a2dc46-a2aa-4017-bd8d-db9a573152ee" xlink:href="jnj-20210103.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_DePuyASRU.S.Member_94a2dc46-a2aa-4017-bd8d-db9a573152ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_b11f1e59-3f19-443c-a4cb-100cf2e619e3" xlink:href="jnj-20210103.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_BabyPowderMember_b11f1e59-3f19-443c-a4cb-100cf2e619e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_05ca78c7-5795-43b6-8c8a-545166f70e62" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a89fb946-5635-4391-8a17-102db7017b9a" xlink:to="loc_jnj_RisperdalMember_05ca78c7-5795-43b6-8c8a-545166f70e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_43525f21-ab7a-402b-ae85-bcbb6ac5c369" xlink:to="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_754ba286-b754-420e-b986-3cee75a763d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:to="loc_us-gaap_PendingLitigationMember_754ba286-b754-420e-b986-3cee75a763d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_86c5207b-d47b-4c63-bd48-1374d00c6988" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:to="loc_us-gaap_SettledLitigationMember_86c5207b-d47b-4c63-bd48-1374d00c6988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_b1647549-ca14-461c-a729-f33eb2ac182b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_c0bb8d74-0369-4dcf-8c58-970c6eed73d5" xlink:to="loc_us-gaap_JudicialRulingMember_b1647549-ca14-461c-a729-f33eb2ac182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c7111c59-4562-4ff3-86fa-0573b19ad7da" xlink:to="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_05f2387b-da0b-4e2e-8f0c-3190f8f12739" xlink:href="jnj-20210103.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_XareltoMember_05f2387b-da0b-4e2e-8f0c-3190f8f12739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_fddd6d0e-2366-4f6d-8749-844a9e914ba7" xlink:href="jnj-20210103.xsd#jnj_AsrMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_AsrMember_fddd6d0e-2366-4f6d-8749-844a9e914ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_51ff02c0-fad6-449b-93ac-1dc4d8afb936" xlink:href="jnj-20210103.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_51ff02c0-fad6-449b-93ac-1dc4d8afb936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_5b66ee46-bddd-4bd5-b5fe-41be5ca0fdda" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_RisperdalMember_5b66ee46-bddd-4bd5-b5fe-41be5ca0fdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_f0fff40e-fdb7-47c9-bf5a-44140d4650e2" xlink:href="jnj-20210103.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_PelvicMeshesMember_f0fff40e-fdb7-47c9-bf5a-44140d4650e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_2f3e3651-b5f3-427a-b680-aea4eb1fa34f" xlink:href="jnj-20210103.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_BabyPowderMember_2f3e3651-b5f3-427a-b680-aea4eb1fa34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_d98b8162-c5f5-494a-a9ac-bdea934ac382" xlink:href="jnj-20210103.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_InvokanaMember_d98b8162-c5f5-494a-a9ac-bdea934ac382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_f6c86b72-1d77-4ea2-b93b-81da446e3c23" xlink:href="jnj-20210103.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_PhysiomeshMember_f6c86b72-1d77-4ea2-b93b-81da446e3c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_9347acd1-879b-47ad-af16-804ffd8c0823" xlink:href="jnj-20210103.xsd#jnj_TalcMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_TalcMember_9347acd1-879b-47ad-af16-804ffd8c0823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_60723383-7471-46d2-9253-fd9790f69371" xlink:href="jnj-20210103.xsd#jnj_OpiodsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be1edb-bb1b-43db-bb23-9c82d34bb6e1" xlink:to="loc_jnj_OpiodsMember_60723383-7471-46d2-9253-fd9790f69371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_8953469e-7a5f-48ce-9c72-54fea0d26186" xlink:href="jnj-20210103.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_c83b7fc4-effe-4804-aa9d-960efc3cf709" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_8953469e-7a5f-48ce-9c72-54fea0d26186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_f4dbf3e3-45ab-4dbb-ace2-3591f8bed06c" xlink:href="jnj-20210103.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_8953469e-7a5f-48ce-9c72-54fea0d26186" xlink:to="loc_jnj_RisperdalMember_f4dbf3e3-45ab-4dbb-ace2-3591f8bed06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_73d90223-9ced-4b1e-a01d-84948155cf94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ad2dccb7-3434-4e68-8d2a-691b602cf347" xlink:to="loc_us-gaap_LossContingencyNatureDomain_73d90223-9ced-4b1e-a01d-84948155cf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_28cd96b3-ea1b-4be5-9416-98ebf8a57257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_73d90223-9ced-4b1e-a01d-84948155cf94" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_28cd96b3-ea1b-4be5-9416-98ebf8a57257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aa5ae862-ee2e-4532-857b-c2b09262c146" xlink:to="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_702b7907-2f19-4d6b-966f-e23830b306f4" xlink:href="jnj-20210103.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_702b7907-2f19-4d6b-966f-e23830b306f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_632cd1ae-491d-42e1-bca5-b2b5a874e342" xlink:href="jnj-20210103.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_jnj_Numberofpatientsinsettlement_632cd1ae-491d-42e1-bca5-b2b5a874e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_8aa69806-bf08-450f-879a-7ac6072b5085" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_8aa69806-bf08-450f-879a-7ac6072b5085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_9bc39c45-a40b-4f8a-9996-4a4727f57dc2" xlink:href="jnj-20210103.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_9bc39c45-a40b-4f8a-9996-4a4727f57dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_69857cb8-2ceb-4fcd-8ad0-242b483b48e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_69857cb8-2ceb-4fcd-8ad0-242b483b48e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_a16ab2d6-2316-4f8c-990b-f8830e085695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_cd1d3e1a-3617-4886-8e5b-dceffa6b5ea4" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_a16ab2d6-2316-4f8c-990b-f8830e085695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20210103.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3acf33a2-528b-4d03-aea7-c04b13a2330e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0ff15e71-8f7f-4ecf-a892-6653b0286dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3acf33a2-528b-4d03-aea7-c04b13a2330e" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0ff15e71-8f7f-4ecf-a892-6653b0286dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5e2c2f35-971c-42c6-af23-ea93544c055a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_d0f9d75a-ca72-4b44-9a8b-0990efd2ef54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5e2c2f35-971c-42c6-af23-ea93544c055a" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_d0f9d75a-ca72-4b44-9a8b-0990efd2ef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee60928a-b6ac-43ab-afa2-650c876c3349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee60928a-b6ac-43ab-afa2-650c876c3349" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_03f1c8e7-070b-4171-891b-b2f5a51b0caf" xlink:to="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_1608d7f9-124d-43d5-a2d5-defdfbbbc622" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:to="loc_jnj_SupplyChainMember_1608d7f9-124d-43d5-a2d5-defdfbbbc622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_aa4ad053-cff7-4b78-9925-be4f61d0da18" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_48d7abe7-52f9-499d-b232-df7fecc939f3" xlink:to="loc_jnj_MedicalDevicesMember_aa4ad053-cff7-4b78-9925-be4f61d0da18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04446f6b-fe86-4289-933e-b381183a5ac1" xlink:to="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d83256c1-4db2-4921-86f1-ad6969a6e3f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:to="loc_srt_MinimumMember_d83256c1-4db2-4921-86f1-ad6969a6e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7537af75-7086-4053-b1c2-c5e1e2dc0248" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_275181b3-bb6d-4b9a-af1c-94b80736fe51" xlink:to="loc_srt_MaximumMember_7537af75-7086-4053-b1c2-c5e1e2dc0248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d040a62b-a693-4590-bd1d-c90976a2e49c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_189b1cfd-8ac3-4731-b470-b6ebfe19369c" xlink:to="loc_us-gaap_SegmentDomain_d040a62b-a693-4590-bd1d-c90976a2e49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_5f596702-806f-4c65-9e21-e61af50105be" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d040a62b-a693-4590-bd1d-c90976a2e49c" xlink:to="loc_jnj_MedicalDevicesMember_5f596702-806f-4c65-9e21-e61af50105be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_db60695a-70aa-414a-acb9-4d9202b57738" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_742ea33c-f0f5-4b46-a8fa-3fe32eb6e6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:to="loc_us-gaap_EmployeeSeveranceMember_742ea33c-f0f5-4b46-a8fa-3fe32eb6e6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_34db056b-b59e-4677-acbc-9e067b3fd6e8" xlink:href="jnj-20210103.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:to="loc_jnj_AssetWriteoffMember_34db056b-b59e-4677-acbc-9e067b3fd6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_978ae5e8-3747-483e-a49e-7a373d652d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_615a0ef2-0f24-4c6f-80c0-6b38411663ce" xlink:to="loc_us-gaap_OtherRestructuringMember_978ae5e8-3747-483e-a49e-7a373d652d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3932eccd-1a16-49d7-8982-a7d2bb3d6d80" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_433ff526-5249-452f-98df-b677d4464f65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:to="loc_us-gaap_RestructuringChargesMember_433ff526-5249-452f-98df-b677d4464f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b02b169c-3512-4894-9731-2e52b9ce7670" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:to="loc_us-gaap_CostOfSalesMember_b02b169c-3512-4894-9731-2e52b9ce7670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_ac16e21f-6d96-4989-85e9-d388456e148c" xlink:href="jnj-20210103.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fb0ff9b-b522-462b-bf5d-32632a1fb774" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_ac16e21f-6d96-4989-85e9-d388456e148c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84114c6a-983e-481c-98d5-ab3e2adcc423" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_23b0338b-1d89-4dd7-bbd3-852bcbfdf97d" xlink:href="jnj-20210103.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_23b0338b-1d89-4dd7-bbd3-852bcbfdf97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b775a7f7-eeb9-4934-9c6f-1532a539f86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b775a7f7-eeb9-4934-9c6f-1532a539f86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e7f87b95-98df-4d41-82e7-72fa75f7e76f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringCharges_e7f87b95-98df-4d41-82e7-72fa75f7e76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_cb9c20ef-bb61-4658-b415-2965f765df78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringReserve_cb9c20ef-bb61-4658-b415-2965f765df78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d5f40757-de7d-42e1-aba0-7b146e14707c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d5f40757-de7d-42e1-aba0-7b146e14707c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_f044a250-d595-4945-8f52-bae1e74752c5" xlink:href="jnj-20210103.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_f044a250-d595-4945-8f52-bae1e74752c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_9d0a4617-9ec8-4d27-93c1-3ff63b58275e" xlink:href="jnj-20210103.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94a07540-ef66-4c69-b4f0-999309658882" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_9d0a4617-9ec8-4d27-93c1-3ff63b58275e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20210103.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dd835bbc-a8c8-4b7c-9fa0-3be49c860abc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dd835bbc-a8c8-4b7c-9fa0-3be49c860abc" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_835e55c7-c17f-4245-b532-797ac35d1b31" xlink:to="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_e421c380-f77a-457b-b86c-b944a12cadd1" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:to="loc_jnj_SupplyChainMember_e421c380-f77a-457b-b86c-b944a12cadd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_d10cc7c4-7054-4736-aac8-301b77afc3ef" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2ffa532e-cde2-4008-91aa-9a603bfcb694" xlink:to="loc_jnj_MedicalDevicesMember_d10cc7c4-7054-4736-aac8-301b77afc3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_73b8f807-0c15-4aa5-9d8c-2d3a4d0240f4" xlink:to="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_9c1d2eec-dab5-4d95-beba-7a5c531cdbcc" xlink:href="jnj-20210103.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:to="loc_jnj_SupplyChainMember_9c1d2eec-dab5-4d95-beba-7a5c531cdbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a5f37b3c-271a-481b-8c41-e5a3b1a72669" xlink:href="jnj-20210103.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c547ce1b-1762-475e-ada0-cc1b42f78b2e" xlink:to="loc_jnj_MedicalDevicesMember_a5f37b3c-271a-481b-8c41-e5a3b1a72669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_00605307-0941-4e36-933a-3c763f9e370c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0c93ea7c-78ac-4186-b932-4bfdcd87498d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0c93ea7c-78ac-4186-b932-4bfdcd87498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_8b8cbce4-7e6b-484f-8754-68a080e55044" xlink:href="jnj-20210103.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:to="loc_jnj_AssetWriteoffMember_8b8cbce4-7e6b-484f-8754-68a080e55044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_d27035f6-87a6-4256-a661-904ecfa9b9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3205ce06-a20d-4825-9c9d-842afdac6c43" xlink:to="loc_us-gaap_OtherRestructuringMember_d27035f6-87a6-4256-a661-904ecfa9b9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_445b0699-1d99-4455-98a7-cf1ffe93b765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97b43722-cf12-48fb-aec1-e4ea707eccf3" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_445b0699-1d99-4455-98a7-cf1ffe93b765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_445b0699-1d99-4455-98a7-cf1ffe93b765" xlink:to="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0c8f95a6-941b-44d6-ac74-b61cbc410145" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReserve_0c8f95a6-941b-44d6-ac74-b61cbc410145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_17271cfc-3deb-483c-8fd4-a6d0e08ac8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_17271cfc-3deb-483c-8fd4-a6d0e08ac8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_eaf61c4b-463a-4ba1-9fc6-26285f916ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringCharges_eaf61c4b-463a-4ba1-9fc6-26285f916ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_c11eb6b3-09b8-421e-8229-a9d1b747e9dc" xlink:href="jnj-20210103.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_c11eb6b3-09b8-421e-8229-a9d1b747e9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_ae2ec483-a7f0-4386-9f37-aab50234a38e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_ae2ec483-a7f0-4386-9f37-aab50234a38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fb5b7829-068a-44a9-8f2f-641085c58044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_910d4a2e-fd23-4b11-ba9d-fed25f1053b6" xlink:to="loc_us-gaap_RestructuringReserve_fb5b7829-068a-44a9-8f2f-641085c58044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20210103_g1.jpg
<TEXT>
begin 644 jnj-20210103_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCXQ\5ZBT&E6-P&9# H1D9V#JZ9#;BT;[4*H7H ^Q**^4/V:_V^?C)>_M,?\
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M?#6IP<2V5Q8MYLDB'J#Y'G?CM/:@#Z6HKSK]DCXXP_M*?LT^"OCDD21R^(M
MAN+Z*+[D5V!Y=PB_[*S)(H]@*]%H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K\Y_VTOA;\/?C3_P72^#7PS^*GA2UUS0=2^%D_V_2[U28IO+
M37I4W $'B1$8>ZBOT8KY,_;-_P"":?C_ /:;_:A\/?M4?"_]K&]^&VN^'/"J
MZ-8OIWAC[7,O[V\9Y5F^UQ;=R7CQE=IX!Y^;  .W_P"'6_\ P3Y_Z-3\*_\
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M?X?1X],V6ZPRPW >8K>12JJDJ43:0.& (.G\,/\ @FW\3?$_Q[T3]H_]N?\
M::G^*6L^$W\SPCHEOH<6GZ9ITP(83F*/Y7<,JL,*OS(A8OM  !C?\%GOA=XI
M'P#\*?M9>!8U/B[X,>)[36X+B-<EK9I8EG&!@E1*EO(>P2-^.:X_QIX_T/\
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M)]S7SA_P02:*'X0?%?3=>(_X2B#XM7AUY7/[T V\ 3=W_P!:MSU[AO>OL/\
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MO[,GP5T[]G/]GWP?\#]-F25?#6@V]G/<1C"SSA<S2@=M\I=_^!5W5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=_P##
M+GPA_P"&E?\ AK/^R;O_ (33^P/[&^V?;G\G[)G.WRL[<Y_BZUZ)10 4444
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MX:L;BX4V-@\Y'FW21;<^>R@)O+$!0, $ UW]% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS^TKH.IZIX(M]6TZ_P!"U)M/\1>'?$6FM9ZCI-T &\J>%L[25(8,"5(Z'((
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MM26Z:LUZH^SIU*=:"G!II[-:I_,****@L**** "BBB@ HHHH **** "BBB@
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M (".OXYK*HHKW:=.G2CRP22\CP:E2I5ES3;;\PHHHJR HHHH **** "OPO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>Z:T:?HS^PJ-6EB*4:M-WC))IK9IZIKU"BBBLS0**** "BBB@ HHHH ****
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M>$6\&?';X;:?KMLJL+2YFCV75FQ'WX)UQ)$?]T@''((XK\</^"A__!';XO\
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MK^&WPU\2Q>(I;;7-9M[O4]=U&'!AC6.#(AB4@ABQ&Y78@DX"^L>(_P#@E_\
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M#"T<,G\3;?\ V[M^+_ _2?#G!QJ8NMBFOA2BO^WM7^"_$EHHHK\H/UL****
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M^V[="?3<X7^M?=U?DWB)?Z_1[<K_ #/U[PXY?[/K]^9?D%%%%?GA^C!1110
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MT)O[<YR_'E_]M"BBBORT_2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._B-^S
MQ\)?%OQA\-_M,>,=$O;[Q!X"T^\70%2=Y(H1*C"1EM^5:4CHP&[(7G@5\@6?
MQYT;]KO_ (*J_"K4KGP/KOPM;X>Z%JL]E:_$72GTK6/%+7<#1""W@8'=%& S
M\ODJTN%KW?\ :Y_;"^('[(GQO\$ZSX]\)VI^"FMVTUIXI\66NF7%Q=Z'J66\
MEY3&Y5;=P8Q_JRV1(0W 4^'?M+?&?X;?\%"OVHO@?\._V0+Y_%-SX#\>V_B;
MQ7XVTVQD6TT.PB9&:$SN@!>78,(#@M&BG))V@'<?L9K%\1_^"FW[3?Q0\1()
M[_PR^A>'-":09-G9^3*943/W0\D".0.I)/>EUA8?AE_P6WT=?#42V\/Q&^#,
MO_"0PQ+A;FYM;F4QW#CNXC@CC#=0 1WK#3XF^#_^">O_  48^)_B3X\W$NA^
M ?C78Z7J?A_Q9+:2/90:G9Q/%/:2NBGRW<R229/&W9GKFKW[.OB6Q_;6_P""
MD^J_MA?#BVNI_AOX!\ ?\(KX>\0S6CPPZQJ4MPTL\D D +(B22(QP.0A_BH
M^QO$&CQ^(=!OM EOKFU6^LY;=KFSDV31!T*[T;!VN,Y!P<$"O(/#7A[]FK_@
MF1^R4=(N]??3/!GA6&>66\U:2.2[OII9'D*G8B">=V;8JA<D!1T%7M!_;=^
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M7PSA,,U9J$6_67O2_%L****^:/H@HHHH **** "BBB@ HHHH **** "BBB@
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MNVW=M^K/[#P^'HX6A&C1CRPBDDELDM$@HHHK$V"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '"?''X$^&_C-HFRX"VNK6R'[!J2KRO?8_P#>0GMU'4=P
M?CCQKX(\2_#[Q!-X9\5Z:]M=0GH>5D7LZ'^)3V(_G7Z!5SWQ&^%_@WXIZ(=$
M\7:6)0,FWN8_EFMV/\2-V^G(/<&OL>&^*ZV3M4*]Y4?QCZ>7E\UY_&<3<(T,
MY3KT+1K?A+U\^S^3\O@BBO0OC5^SIXR^$%RU\R-J&C,^(=3ACX3/195_@/OT
M/8YX'GM?L6$QF%Q]!5L/-2B^J_K1^3U/QC&8+%9?B'1Q$'&2Z/\ K5>:T"@
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MQ>SBTU]Z/PO%83%8*LZ6(IN$ENI)I_<PHHHK<YPHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_8D^(OBGX7Z8\QN?'5N]M;FX@A)$MS;6<K"6>)=K_-E<;3NVD,  ?5^H^(-
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MJQL?V:O#U](EIX8\&ZK\0_&!A/*0VT;6M@A]0]S*X(/901TXYS]O.RT74O\
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M-&' ;'1AG!'8@CM0!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9*(K%2XVG!#!N]=]5?2=)TO0=+MM#T/38+.RLX$@L[.UA6.*")%"JB*H 50
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MC>+4V;?9R_V;[3Y/G?=\SR3OV^GOQ7K]?E6WP-^*-U_P3\D_X*91V3+\4/\
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MFYO,/H+N,5^HU% 'R+\9O^4(\G_9 M._]-T%'QF_Y0CR?]D"T[_TW05]=44
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M:;+I(I8EDWVTL;G"32#:25^;.,@$>+_\.4_^"97_ $;3_P"7EK7_ ,F5^Y\
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MVM6SOEQ!%J,8MF_W0JO"OK]F)K]<:* /CK_@M;_RC'\0_P#7WHO_ *604?\
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M/#]J;'0='M;&$N6,-G;K$I8]3A0!GWJU0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20210103_g10.jpg
<TEXT>
begin 644 jnj-20210103_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JIJ.NV>D7FGV]S<1PS:I.;6T1NL\HBDE*CW\N*1OHAJW7"?%W_DH
M'PM_[&>?_P!,NJ4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU+ 5]$?LS>/_ !O\4?@=H.O?$;X?_P#"K/&FH)*VI>%O[=@US^R66:1$7[9
M!%+OC5),J!M\S:>5- '>5PGQ=_Y*!\+?^QGG_P#3+JE=W7"?%W_DH'PM_P"Q
MGG_],NJ4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@_Q!_P""9GP1^*?C
M;5/$6O>"?MVLZS<-=7EQ_;%_%YTC<EMJ3JJY]% %>\45M1Q%6D[TI.+\FU^1
MS8K!X?$Q4<13C-+I))_F?-__  Z._9Z_Z)__ .5W4O\ Y(H_X='?L]?]$_\
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MO;*X3XN_\E ^%O\ V,\__IEU2@!/^$>^)_\ T.'@/_PD+O\ ^6='_"/?$_\
MZ'#P'_X2%W_\LZ[RB@#@_P#A'OB?_P!#AX#_ /"0N_\ Y9T?\(]\3_\ H</
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M -#AX#_\)"[_ /EG1_PCWQ/_ .AP\!_^$A=__+.N\HH X/\ X1[XG_\ 0X>
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M+O\ ^6='_"/?$_\ Z'#P'_X2%W_\LZ[RB@#@_P#A'OB?_P!#AX#_ /"0N_\
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M_P#+.N\HH X/_A'OB?\ ]#AX#_\ "0N__EG1_P (]\3_ /H</ ?_ (2%W_\
M+.N\HH X/_A'OB?_ -#AX#_\)"[_ /EG1_PCWQ/_ .AP\!_^$A=__+.N\HH
MX/\ X1[XG_\ 0X> _P#PD+O_ .6='_"/?$__ *'#P'_X2%W_ /+.N\HH X/_
M (1[XG_]#AX#_P#"0N__ )9T?\(]\3_^AP\!_P#A(7?_ ,LZ[RB@#@_^$>^)
M_P#T.'@/_P )"[_^6='_  CWQ/\ ^AP\!_\ A(7?_P LZ[RB@#@_^$>^)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@$VF"-@-^Z1O>O"OA/2_ OAVST?0],T_1M)T^,16ME8VZ6]O;(.BI&@"JOL
M!6A0!D^ _ NC_"_P/H_AKP]IUKH^@^'[*'3=-L;9-D-G;0H(XHD'9515 'H*
MUJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_#OQ7_P %
M:/VH_'_[</Q>T?P;\7? /A_QU\-?B6/#'A[]G/Q'HFF:.?'>CK<16\=S!KM]
M)$S7-P)#*L,,I9MH>,%'1& /W$HK\U?^#@/]OOXH?L9:]\!;#PW\3[/]GWX<
M>.M6U&#Q=\1W\)1>+;S198;3S+2T73VW[XYF,F]HT9P8T(=%5UFX?]J?_@HE
M^U!\$?\ @VRL?C9XDG;X>_'ZW>PMY[Z30;:.:X@?5EMH[J6PN8Y(H9KFT*2/
M'Y8"O*Q5(AMC0 _6*BOQQ^%O_!03XQ? G_@HO^SSX%L_VV/AA^VIX;^,.K7V
MB:]H7ASPMHMC=>&8HXHI%U 2Z7)+C8#(Q$TB I')MCDPSP?5G_!P3^W=X@_8
M#_8-M?$7A'QM#\._%'BCQ=I/ARR\0OI46JG28I93-=3BUECD6;;:P3Y783S\
MN&VT ?<5%?D&/^"J_C+X%?\ !(_XG?&+P?\ M4>'_P!KKQ3?:]I_AGPOJ$_@
M"W\'KX5O+F86Y%S9)MD;AFF0SHH;RUQN1B:V_#7_  4Q^/'_  3I\<?M1?##
MXZ>--#^/'B3X3_#&'XJ>$_$D?AZ'P^UTKA+:33[FWM<1^2MV\6UU_>;3*S,0
MZ1P@'ZPT5^5__!/+]M7]I;X<?MM? WP'\>OB1H/Q5T']JCX;R>-=$2T\,VVB
MS^!M0@@-[)8H]OC[5;FV?:9)LNSK'MV!'\[WC]N+]KGXA_!__@KK^QK\+_#G
MB#^SO OQ6_X2K_A*=,^P6TW]J?8M/CFMOWLD;2Q;)&+?NG3=G#;AQ0!]L45^
M<7C?_@YV^!_@2;QI+-\.?VA+_1OAOXLN?"7B[7=/\'1W6C^&98KB*VCNKJ[6
MY\I()Y9&6)03.QA<&%2T0D]C_:X_X+1?"_\ 9/\ C)X3\ 0^%_BM\5O%GBO0
MAXJ.G?#OPPVNS:/H[.$34+I0Z,L#$L?W8D<!"65=T>\ ^NJ*_(W_ ()O_P#!
MP/<+^PYX=\2?%6/XE?'7XG>/O&NOZ?X:\/?#[P?!>Z]>:58^6YN/LD MXUAA
M21 SMB1C)T8(Y3ZH\3?\%R_@[X8_9%\(_&^32?B%-X!U_P 3Q>$->N!I,,-U
M\/=1:012QZU!+.CVRPR'9(T8F .W;O$D9< ^RJ*\'_8=_P""AG@G_@H3#X[U
M'X=Z?XEN/"?@?7I/#L7B>[MX$TCQ-<19\V339$F=YH$^3,KI&K>8NS?\VWWB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X3XN_P#)0/A;_P!C//\
M^F75*[NN$^+O_)0/A;_V,\__ *9=4H [NBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M//\ ^F75* .[HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>:UXL\!7GC3PWJOPSN=2,%F;4W&^*]AOG,VV00-M=5C3*[5:1BXBB_X)@_\
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MVJ4_>;QM=CC=M9?:ZX3XN_\ )0/A;_V,\_\ Z9=4H 3_ (5#XB_Z*IXZ_P#
M/1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y
M H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%
M0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"B
MJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\
MP#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"
MN\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB
M@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#
MXB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\
MHJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P#
M/1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y
M H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%
M0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"B
MJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\
MP#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"
MN\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB
M@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#
MXB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\
MHJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P#
M/1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y
M H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%
M0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"B
MJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\
MP#T7_P"0*[RB@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"
MN\HH X/_ (5#XB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB
M@#@_^%0^(O\ HJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#
MXB_Z*IXZ_P# /1?_ ) H_P"%0^(O^BJ>.O\ P#T7_P"0*[RB@#@_^%0^(O\
MHJGCK_P#T7_Y H_X5#XB_P"BJ>.O_ /1?_D"N\HH X/_ (5#XB_Z*IXZ_P#
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M6D(]BV*[K_A4/B+_ **IXZ_\ ]%_^0*[RB@#@_\ A4/B+_HJGCK_ , ]%_\
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MOE>4\NY5.]E+94'/ H ],HJ.UM8K&UC@@CCAAA4)'&BA510,  #@ #C J2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M$^+O_)0/A;_V,\__ *9=4KNZX3XN_P#)0/A;_P!C//\ ^F75* .[HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\#^-W[;]NOPT^+T/P/L]
M$^-?Q<^$J0Q7_@?3M:AM[J*ZE;Y8IG;(C(19GV]6,#H/GX ![Q=W<=A:R3S.
ML<,*&21V. B@9)/T%?)D_P"WWXL_;!^$/PQ^('[']EX)^*O@W6_&B:1XOO\
M7I+K2FTO2XV*7<L$4HAD\Y#M()5^,%8I ^5['PA^S9XM^*G[2?PR^/GB+QC\
M0/ NH6/@=-,UGX56VLI<^'8K^X4RRF?8H6>:!Y6C\T##FWA9=H4JWN/@OP+H
MGPW\.PZ/X=T?2M!TFW9WBLM.M([6WB9W+N5CC 4%G9F) Y+$GDT >8? 7]A_
MPK^SQ^T)\7?B1H^K^+]0UKXT7MG?:U9ZKJGVK3[-[:)HHUM(MH\I2KMD,S'H
M 0JJH]DHHH **** "BBB@ HHHH **** "BBB@ HHJKK.M6?AW3)K[4+NUL;.
MW7?+<7$JQ11#U9F( 'UH M45\Q_%W_@JI\/?!>I?V3X3AU+XB:_(WEPVND1G
MR'?^[YQ!W?6-9*XPZ'^U%^UR&^W7EE\&?"MQ_P LH01J,B'Z'SMW)R"T(/IT
MH ^C_C1^U+X!_9]M6;Q9XFT[3;C;N6S#^=>2<<;84R^#QR0!SU%?.M]_P4,^
M(O[1-U)I_P #_AIJ%Y;[S&=>UE EO'SC.-PC4CDC=(Q_V.U=Y\%_^"7?PR^%
MUVNI:Q:77CC7"WF27>MMYT3/G)(A^X<_[>\^]?1-C8PZ99QV]M#%;V\*A(XH
MD")&HZ  < >PH ^/M*_X)O>,OCMJ46J_'+XE:IKIW"0:-I,GEVL)ZX#%0B^A
M"1 \<-T-?1_P>_9N\#? /3Q;^$_#6F:0VW:]PD>^ZF'^W,V9&^A;%=O10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
MY&ZQ_P %S_VC_'7[0'Q@O_A9\+?AGX\^&WP.\?2>#=>^'U@VI7OQ8U&U@N([
M6?5;6TA)B%N9G)!:([-CHV=C2  _7*BO@O\ X+*_\%._B1^PYXY^"/@_X;6G
MPF\/W7Q:O]1CN_&_Q7N[NQ\(^'X[2V$JV]Q) 4>.><O\C.X"^45\M_,+P^<_
M%K_@MO\ %#PM_P &^>E_M96/@7PKH_Q$G>TM9=*U2&ZN-%NV.J"PDNX%66*?
M[/.@,\0,A*"15+S!?,< _3JBOS3A_P""AW[7G['G[;WP)^'?[2V@?LUZQX7^
M/6J7?A_3+CX97.KQZGI=Y$L!6>6/4&_>09F56\N,A=VYI$.Q)?>O^"H?[=_B
M[]B?QC^S9I_A73?#>H0_&+XO:)X UIM6MYI6M;"]<K+);^7+&%G 'RLX=!W1
MJ /K*BOD3]NK]OKQC^S%_P %"?V2_A/H.F^&;SP[\>=2U^SU^YU"WGDO;-+"
MWM)83:LDR(A9IW#>8D@("X"\D[6L?\%H_P!EW0/VO?\ A1%Y\8/#MO\ % :B
M-';3&M[K[-'?%<_96OO*^QK-N_=^69@PE_=8\SY* /J&BOEG]J[_ (+7_LN_
ML0_'./X:_%#XM:7X9\:M;V]S)IPTR_OOL:3D^5]HEMH)(K=F #[971A&Z.0$
M=6/AW[9__!<.Z_8H_;=^*WAG7-.\+:G\+?A]\"!\3]/G@6Y&I:SK$VK6VG65
MC]IC,L26]Q+<PQB06[>6THD9]BL* /T7HK\@_@M_P<\Z1X_U_P#9>U+6]:^'
M&B^!?'FE>)O^%M:G-INHVK>%M6TG2([\6EBTL@WY:>W3 2X,IE6.(F0XK[^^
M#/\ P5)_9_\ V@/V7->^-/A7XH>'[WX9>%7ECUC6[E9K!=+>/;E)H;A(YHW;
M>FQ60-)YB; V]<@'OU%?.?[(_P#P5M_9S_;H\,>+-8^&/Q4T'7-.\"VYO?$$
MEY!<Z.VDVP0NUS*E['"P@558F;'EKM(+ @UB_LA_\%K/V8?V[_&NK>'/A7\5
M+/Q-KFBZ;)J]U92:-J.FS?98R!))&+JWB\W;D9$>Y@""1B@#ZFHKX]^%G_!?
M;]D3XT:3XBO_  [\9M+O+'PGX<F\5ZS<3Z/J5G%IVGQ7*VI>1IK9 LK3R1I'
M;_ZZ4RQ^7&X="?3/V(O^"F/P,_X*.:+K=]\%_B%IOC2/PY.D&IP+:7-A>69=
M=R.UO=113>6W(60)L9D=0Q9&  /=J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "N$^+O_ "4#X6_]C//_ .F75*[NN$^+O_)0/A;_ -C//_Z9=4H [NBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#:@_:Y.=8U2S^#?A6YZVUH#_:$B'CD*WFYQG(:2('^[TKT3X)_\$POA?\
M"6X2_P!0T^;QGKF[S'O=;83H7)R2(?\ 5\GG+AF]Z //KK_@H!\3OVD;F2Q^
M"/PUO7L68Q_V_K0"PIS@D#(B4C&<&1R?[F>#+HW_  34\5?&S5(=7^./Q(U;
MQ+,I\Q=(TR3RK2 ^@8@*!S@B.)/]ZOL*UM8[&VCAACCAAA4(D:*%5%'   X
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M9+5'EC#23(I5"6AE.TD'$9[E0WC_ ()_8:\5?MP_ 3X4WG[8&E^'V^*GPO\
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MK-K7@J2PU?4+:\T6[G</._VI)Q/,)65?,29Y$D"(&5@J@?2- !1110 4444
M%%%% !1110 4444 %%%% !7"?%W_ )*!\+?^QGG_ /3+JE=W7"?%W_DH'PM_
M[&>?_P!,NJ4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"?7_ (H>'OB1XGATS4+34+F/1;[0=+$\\%S?NCEE81O#P Q#!U;.#D>@:?\
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M/'EJ2'<O(P!Z)\7_ -L;X8_ 3QS\.O#?B[QAI>BZU\6M0.E^$;>4._\ ;ER
MAV1NBL@SYL0!<JI:1%!)8 \'I_[9GB[XJ^,_VA/ _@GX5^*]/\9?".Q5/#FH
M>*;4V7A[QG?SV<DMNL%PIYB$RHKD$$)(K9!)"]U\)/V./AM\%_A3\._!NE>%
M-+O-(^%-O'!X5?581J-WHQ1-@EAGF#2)(5R"ZD'!P,# KTZ@#Y7M_AA^TO\
MM#?#+]GCQ'KWCO2?@AXS\-ZI!J_Q/\+Z'IT6JV'B*$8\W3XYGE<PJ5##*O(%
M,Q.YS$A/;?#_ /X)X?#?X>_M&?&+XF1VNJZOJ_QTM+6P\5:=J]Y]NTFY@MX#
M (DMI 5".C,'1BRD,5 53MKW*B@# ^%WPL\-_!'X?Z7X4\'Z%I7AGPSH</V?
M3],TVV6WM;./).U(U "C))XZDD]36_110 4444 %%%% !1110 4444 %%%%
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M2\Y>XO\ R;WONBSU#XM?M>?#'X%^8OBKQOX?TJXASNM3<B:[&/\ IA'ND_\
M':\O_P"'@NK?$L^7\*_A#X^\;+)Q%J5]"NB:5)GH5GG^]CJ1M!Z>M>C_  D_
M8O\ A7\#1&WAGP+X?L;F'&V[DM_M5V,?]-I=TG_CU>GT>TPL/ABY>KLON6O_
M ),/V.85?XE2--=HKF?_ (%+3_R0^:?^$"_::^,?_(:\9^"?A3ILO_+MX?T]
MM5U +_=>6<A%;MNCZ>E6M'_X)C^ =2U&+4?'FI>,/BEJL9WB?Q-K,L\4;?[$
M*%4"]@K!@!7T912_M"LM*=H_X5;\=_O8+)<,W>O>H_[[<E_X"_=7R2,/P+\,
M_#GPOTH6/AO0='T"SP!Y.GV<=LAQZA ,GW-;E%%<<I-N[/4A",%RQ5EY!111
M2*"BBB@ HHHH **** "BBB@ HHHH **** "BBF7%S':0M)-(D<:#+.[;54>Y
MH ?16;IWC31]8>=;/5=.O&M4\R98+E)&B7U(4D@5@^&?CMX8\9>((M,TN_DO
M;J;./+M9?+7 )Y8J .E:*C4:;47IOIL<\L51BTG->]MJM?3N=A17%ZE\5[Z#
MQ%)I]GX0\27BPS^2UR85A@89P75F/S+WSQFK'C76/&-MK"V^@:/I-Q:M&";N
M\NRH5B3D%%&[CCIUS5?5Y72=E?NT0\;3LW&[L[:1;_0ZRBJ^EFZ;3+?[:L"W
MGEKYXA),8?'S;2>=N<XSSBK%8G4G=7"BBB@84444 %%%% %'Q-(T7AO4&5F5
MEMI""#@@[37\_%I^T+\0C:1?\5_XZ^X/^9@O/3_KI7] WBK_ )%C4O\ KUE_
M] -?SE6?_'G#_N#^5?9<*0C)5>9=OU/RCQ,K3A/#<C:TGL_\)V?_  T)\0?^
MA^\<_P#A07?_ ,<H_P"&A/B#_P!#]XY_\*"[_P#CE<A17UWL:?\ *ON/R[ZU
M6_G?WLZ__AH3X@_]#]XY_P#"@N__ (Y1_P -"?$'_H?O'/\ X4%W_P#'*Y"B
MCV-/^5?<'UJM_._O9Z1\/OB%\7/BMXQL?#_AWQ=X_P!6UK4G\NUM8O$5RK3-
M@G +2A1P">2!77_&3P-^T9^SWH%OJGC34/B1X?T^[F^SPSS^)Y)%>3&=N([A
MCT'<8JA^P=X^\,_"SXZR>(/%5]J&G:;IVCWZI/9V,EW*DLL#1(0J X(WY#,0
MH(&2*Z/QI^SSX)^+WPJM?$GP@UKQM>-:ZY:^'[[2?%\MLDXGN0?)F26,B((Q
M4@ACD=2:X<1+DK1@HKETN^6^K;5KW5NG?='L8.DZN$E5YY.I>5HJ:3M&*E?E
M:;DM7LX_"[79P/A#QM\8/'VD:Y?Z+XL\?:A:^&[0W^IM%XCN-UI;@X,I0S!F
M4'&2H.,C.*3PIXY^+_CC1-;U/2?%GC^\T[PW;K=:G<CQ'<QQ6<;-M4LS3 9+
M<!1ECV%=1I7AWQY_P3E^-GAS7/$6GZ>HO$D%Q8P:E;WL6I61PEQ#)Y3. &5L
M8;O@CID=5^VO?Z#\#O#UG\)_ *W4&B^()8O%FJ7$\8CDNA=+OL[4XSF."-L=
M>2>AQFE*I&4XQHQC)3^%K573]Z_HMN[T\QQP\X4ISQ,YPE3^*+;3U7N<M^[^
M*^T?>5]CQ#_AH3X@_P#0_>.?_"@O/_CE'_#0GQ!_Z'[QS_X4%W_\<K[I_P"'
M:_A+0I+/P?<?#FXU%);6)+WQZ?'5O;7%K</&&:2/36<*T*.<;7 <KG@G!/E?
M[*?[+/@V/P)JVI>-/!=KXC:SURZTN75M?\8#PUHL,<#;"]NT1:>=R>6RFU<@
M DYK*.8X22DXQVM_+K=V[Z?]O69U2R#,X2A"<[<U_P"?2ROK[NOK'F6FY\U?
M\-"?$'_H?O'/_A07?_QR@_M"_$$#_D?_ !S_ .%!=_\ QROJ/QA^S1\)_P!G
M[QK\<KK7O#>H>+M%^'\^CRZ18)K$UJT@O &,+3IR8\N!O*EMJ\8))KQ/]BW2
M=#\>?MO>"X;K3;>WT6\UMIX=.DD,T2;5DD@@+/RXWK&N6Z]^N*VH8JA5@ZD8
M>ZDG>RZQ4K;WO9_><6*R_%X>K&C4JKFE)Q2YI=).-[V2M==[VZ;VZ33_ ((_
MM3:KX'_X22WM_B])HYA-P)?[;N5D:,<[A"9A*?P3)KS'0_C%\4/$OB*TTBQ\
M:?$"YU2^N4L[>V77KL223,P18\&088L0.<<U:\3_ +0?Q N_V@;CQ=<:YK$?
MC"'5#(&\YU>"57P(0F>%7[@0# '&*]X_8V^#_CCQ[^T[\0/'6JZ!%9>+O!]I
M/J,.G72QZ9%_:]TC);@B3:B!=SRX)'W5[FI<W3INM64;<K=EY6TN][WM?36V
MFIM&BL17CAL+*IS<RBV]5;6\K*SC:S?+[SM?737P7QQ\3?BQ\-?%NH:#KWC#
MX@:7K&ES&"[M9?$%UO@<=0=LI!^H)!S7<?"CX;_M+?'+P[_;'A.7XJZQI>2%
MNTUZXAADQUV-+,H?_@.:[[]O?]GS7[73?A5XW\76MO::IKD-OX<\4O;WL5XO
MVJW(CCG:2)F4M+;@$^AC]ZY_]L&_USXB_MI77@&Z\4:?X-\.>'Y$TS1'U*]>
MSTK3;2. -'*2H(7S H.X+\S,*SIXB-6$534>;WKNUTN2R=DM7>Z:UVU-J^!E
MAZM1UY5.1<G*KVD^=-I-M-*R34G9^\K6[>?VFH_'*\^*L7@==<^)D7BZ:?[,
MFE7&N7=O<-)C('[R51@CD'.".0<5Z!X@_9H_:T\+:+<ZA?6?Q7CM+.,RRO'X
MD>=E4<D[([AF/X FO3O!GA#Q5I?[6W[/NH^*/''@WQ[9W$=SIVFZYH%S)>-+
M!;EPPFE9%\QD,A48R0%P>>LG[/OPF^&WPR\7:S\5_#?QH\6>.#\.9Y-2U#P_
MI7A^>POITW-\K>;*2;?/RR/LV[<@E:YZV,Y8W2CL]>635U)QZ6Y;VZ]7;H=F
M'RKFFXSE/XDDO:0BTG",F];\]KOX;72O97/D+_AH3X@_]#]XY_\ "@N__CE'
M_#0GQ!_Z'[QS_P"%!=__ !RN>\2ZS_PD7B/4-0$*6XOKF2X$2?=BWL6VCV&<
M51KVHTH.*;BD_D?)U,154FHU&U?1W:OYG7_\-"?$'_H?O'/_ (4%W_\ '*/^
M&A/B#_T/WCG_ ,*"[_\ CE<A15>QI_RK[B?K5;^=_>SK_P#AH3X@_P#0_>.?
M_"@N_P#XY7U]_P $3_BKXJ\;?M<ZM9ZUXH\2:U9IX5NI5@U#5)[J)7%U: ,%
MD<C< 2,XS@GUKX2K[/\ ^"%'_)Y6L?\ 8I7?_I795YN<4X+!5&DMNQ[W"^(J
MRS:@G)VYEU9^N-%%%?F)_104444 5]56Z?2[D6+6\=Z8F%NTZ%XEDP=I< @E
M<XR 02.XK^>3X'_!#XR?$O\ X+/>%[S3_P!G?7/@/\>M"USPWJOQ$UCP9%+I
M/@F?1DU/6AJ]ZNZ>2.:'4K1--C2,;OM%Q8WK;E<2B3^B.B@#X)_X*?\ P>\7
M>/\ _@J7^P=XAT'PKXCUO0/!_B3Q)/KVIV&FS7-GHD<MC;+$]U*BE(%=E95,
MA4,5(&2*^%_^"YW_  3/_;"\8VG[3/Q$L=%^%OQ0\,_$R?1]'TVRT2TUO5O'
MNE:#9ZE!-:6%A;10"WCC\X+<70'F;B)'W95<?N]10!^/O[:7PX\;> _VB_A?
M\1_VD?V,_#O[45G??"J3PGJ-S\,_#NJ>(KO0=92[FG2%;&[N##'9F&0$736R
MW*22R 2[46-_L#_@@Q^R[\0?V./^"7/PY\!_$R!M.\4:>;Z[.E-<BY;1+>YO
M)KB&T:0$AF1)!N )"DE02%K["HH *\3^+OP.T;_A8/P\/V[QA_Q,O$LZ2_\
M%6:I\@_LG4I/W?\ I'[H[D S'M.TLOW68'VRN$^+O_)0/A;_ -C//_Z9=4H
M;_PSCX?_ .@EX]_\+?6?_DJC_AG'P_\ ]!+Q[_X6^L__ "57>T4 <%_PSCX?
M_P"@EX]_\+?6?_DJC_AG'P__ -!+Q[_X6^L__)5=[10!P7_#./A__H)>/?\
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M_P"@EX]_\+?6?_DJC_AG'P__ -!+Q[_X6^L__)5=[10!P7_#./A__H)>/?\
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MPV?I*+_)A_;>$7Q.4?\ %"<?SBCU3_AG'P__ -!+Q[_X6^L__)5'_#./A_\
MZ"7CW_PM]9_^2J\K_P"'JWPGTW_D.-XQ\,8^]_:GAJ\CV?78C5NZ!_P4N^!/
MB3;]G^)&AQ[NGVI)K7_T:BXI2R_%+5TY?<RHYWE\G95X7[<RO]USM_\ AG'P
M_P#]!+Q[_P"%OK/_ ,E4?\,X^'_^@EX]_P#"WUG_ .2J30?VK/AAXIV_V;\1
MO UZS?P0Z[:L_P"*[\C\179:1XAT_P 01>987UG?1]=UO,L@_-2:YY4YQ^)-
M'=3Q%*I_#DGZ-,X[_AG'P_\ ]!+Q[_X6^L__ "51_P ,X^'_ /H)>/?_  M]
M9_\ DJN]HK,V."_X9Q\/_P#02\>_^%OK/_R51_PSCX?_ .@EX]_\+?6?_DJN
M]KE?B7\<_!OP:LOM'BOQ1H/A^/;N47U['#)(/]E"=S'V4$U48RD^6*NR*E2%
M.//-I+N]$9G_  SCX?\ ^@EX]_\ "WUG_P"2J/\ AG'P_P#]!+Q[_P"%OK/_
M ,E5Y5<_\%+_  [XRN)+7X9>#O'GQ2N58H)])TF2#3T8<'?<3!0HSQG:17E/
M[1'[;/QB\#V3?V_??#OX/-*F^+2HI/\ A)?$F",KB-<6RC'>4H">AKL_L^JO
MXMH?XG9_=O\ @>9_;6'EIATZG^!-K_P+2/\ Y,?54G[.OAV&-F;5/'BJHRS'
MQQK( 'J?]*KQ'XY?M ? OX%6DRW7C;QEKFJ1@[=.T;QUJ]Y,6'&UF6[\N,^S
MLIQV-?+G@K]EKXY?MYZBM]KGB#Q9'X3G(87WB2[:.WF&3\\%E'M0[N. I4$8
M\PU]I?LT_P#!.+X<_LX"WO(]/_X2/Q##@_VGJ:+(8F]8HON1^Q&6_P!HUSU8
MTXZ0ES?*R_'5_<CLP]2O/WJL.1=KW?SMHODV?(VL-^T%^U5J"R_#OP[\0/"/
MA>X4B.6^\7:ELN8F_B>6[N,2*1VA0_CUKK?@Q_P1K\8:=JUEJ_B+XC1^%]0M
M7,N[PNLS7NXG.?M4C+L8=,I'S[U^A-%53Q#IKW$K]VKO\=/PN9XC JN_WLY6
M[)N*_"S?S=O(^;[/_@E)\';R3[3XDT_Q%XWU5OOZEK^OW=Q=2?[Q1T4_]\UZ
M-H'[)W@_PII<=CI<GC#3;*'B.WM?&&KPQ)]%6Y 'Y5Z514UL15J_Q)-^K-,+
M@</A_P"!!1]$E?U?7YG!?\,X^'_^@EX]_P#"WUG_ .2J/^&<?#__ $$O'O\
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M$?"_@'PK;W1OIM-T8.RWUQ@@22O(2S;02 .@R:_8S^S[?_GA#_W[%']GV_\
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MPG^QY\%OV3_#NK>,K[2=,4Z':3:KJOB;Q)/]NN+:*%#)+<R33$B,*BEF9 H
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MX8?!RWT71_AKI46D>&O$WC?;?:M86Z6ZVWFQW%PJ$.\2JKF-'W#CD"O1+?\
M8@_: \0C^T]8_:"U.QUB7E[73UG-FO\ NA7B7\HA7V)10!\?_P##*_[4&@?\
M@OXY:;>;>GVZW)S]=T,E'_"#_ME>'O\ F<? &N;?6&)-W_DM'7V!10!\?_\
M">_MD^'NO@KP#K@7J1/$N?\ R:CH_P"&K?VG- _Y"GP,L;O;U^PW#'/TVRR5
M]@44 ?'_ /P\7^*FA\:Q^SAXT51]Z6W:Y*C_ ,E2/_'J/^'MUOI'_(<^$_Q
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MJW?VIX=T+4MW7[58139_[Z4U\N?\.J]6T?\ Y ?QN^(&E8^[\[MC_OB9*/\
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MYM6MQ>>8?X/)W[]Q_NXS13]SV:_EYUZ\_/\ ES_.W2^ERES<[_FY?ERJ*O\
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M7VE10,YSX=_"'PM\)-.^R^&?#VCZ%#C:PLK5(FD_WF RQ]V)-='110 4444
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M9M0O)9B>OVNX/!8\GRB1[4_98>'\2?-Y1_S?Z)B^LXZMI1I*"[S=W\HQ;O\
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M^"/A#XZ_&'X-?!OP#;ZU\=/A%X:36A#KMC*MG>7-Q;^99Q"_FW!0[O$K%-H
M9MN=C;>HT?X%?'3]KGX9?L]^,?B'XPUKX _$#P-KBZ_XU\(>#[];S2?$D:2D
M?V=<2+*0T+QHA(WRJOG2+\[!9%XZE24WS3=WYGJ4:-.E%0I144NB5E]R/"/B
M]HWB[QG\./BEKWQ"^-5UX[O/A+8M>^)_A]\-9H=0UBU/E&5+>2U1HTCE9 Q7
MS$;(5CDX-;7P:_8WU+Q;XB_9U^(7PH\!^&;/X8^)+.35O']C\4;.=O%-K!+
MC6L<-N,P1S*Q?. H#!#ET/'VA\-OV7OA[\'?BIXU\<>%_"&B:'XL^(TT%QXE
MU2T@\NXUB2%66-I3ZC<QXQDL2<DDUWE2:'S[\$O^";W@3X11?&"QU2\\0?$?
MPS\9M??7]5\.>,YHM8T73RW)M;6U>/RTMPV"$8-PD2Y(C6O>=&T:S\.Z1:Z?
MI]K;6.GV,*6]M;6\2Q0V\2*%1$10 JJH       JS10 4444 %%%% !1110
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M^,UN;&.4L;.+2HHUE3GY2^21_/WIWB?X.+XKUV:\F\2>*[:.8@BTM=0\F"/
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ME;T+K++<IZ_P?A5>QPT?BJ-_X5^K:_(CZUCY_P .BH_XYJ_W14OS1]D^,_\
M@IA\$?!=S]G;QYI^L7C';';Z-#+J33-Z*859/S8"L"Y_X*#ZUXH@9_!/P0^*
M.O1*,K=ZK:QZ'8R>XFF8C'N0*\,M?V5?%'P\^'4GB3Q%^T?X!^&WA%9A9SZE
MH+V^EZ:DAD\KR?.C:UB#>9\FW.=WRXSQ6W>?L ?"-_CGI'P\\=_&W7->^(VM
M:=)K-CX?FU:"'4+VTC8J\ZPR>9(8P0XR#SL?!.QL/VN&C\--OU?Z)+\P^KYA
M/^)64?\ ##7[Y.2_\E1T'BK]L?XP7NY;K5OV?_A;$?OQZMXE_M?48Q_LI;G8
MQ'N,5YIXJ_:,TW5-W_"8?M7^,-2W?>LO _AK^R?*'HMQL^;ZDYK1T(?L,^#_
M ($?$GXF1ZQ:^)O"?P=U&32/%FHFXU"[.EW<<B1M$88P/-)=T *(RMG@D9KT
MQ/VB_P!F7X2>/_@'H.B^#;&ZF_:/MGO?!.IZ=X2,L-Q;K;172RW$KH)(5:*:
M,@.-RY)<( Q!]>DOX<8Q]$G^+N_Q#^QZ<OXU2<_632^Z/*OP/G.R\<?L_P"O
M:KYUC\,OB[\8-7B.%N?$&IS7#.W^['(P.?>/\*]6\ ?%/XDZ0(_^%9?LGZ%X
M/8?ZJ:]L1;N?1F=DMR?J6_&O9O!__!0G2?%7B?\ :$\-Z'\,?BC+JG[.\"O/
M:KH0CC\7,]K-<)#I)#GSY&\DH%(0DRPE=P?C#U;]O_XD7_P ^!?CKPS^S?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 -F_U3?0U\U_'C]H72?V?]&T=KS3];U_6O$M\-+T+0M&@2;4-9
MNBI<Q1>8\<*;8U9VDFECC4+RX) /TI-_JF^AKX9_X*(ZIX!T_2_AXOQ&7Q-X
M=T>37U-CX^T:_%B_@*_"?N;B6<JXCCG),):1&A.[$@P01TX>32]7%?)O6U]+
MM:*^E['FXZ-Y1])/[E?6VMN]M;7MJ=W\%_VL-/\ BMX\UWPCJWA7QA\._&'A
M^SCU2?1?$T5IYUQ82':MY!-9W%S;2Q;PT;;)BZ.N'1=R%L3X%?MZ>%OC[\1[
M/P]I^@^+M(CUZQN]3\-ZMJ=M;II_BFUM9_(N)K4Q3R2J$?M<QPLRD,H92#7@
M<7[7WCOX0ZO\2-%\#^.+#]J#PYX;\!ZEXJLM1CM[>XN])U&.=1;Z9=W=C_HU
MX9HI78+'''*J6IRAWAC\T?LW?&#PS_P3I_:4\#SZ+XJ\%_&C0_BS#:0R>);?
M4YTLOA.MY<&6\M?L\;3Q6-I//*GDQN4?S<JY"].NE4YZD(]):?-N<8^FL=7?
MEW:^**7GU*/+3G);IW^2492?W2T5N;6V\6W^@,7[>]QXB\9^.-)\*_!?XN^-
M;?X?ZW/X?U74M*?0(K4W<,<<LBQ)=:I!.X"2H<^4,YP,GBN]\%_M1^$_B)^S
M,_Q8T6:_OO"L>D76L,OV5H;Q%MED,\#0R;2DZ-%(A1B,.N,XYKY@_9&^'GQ,
M\:?%K]IB7P;\5-'\&Z0WQ9U.&2TF\&QZQ,9/L=ENE6=KN+;E2N%V$ KG)SBO
M;?%'P%T7]F'_ ()W>-_!>@R7EQI^C^#M;=[J]D$ES>SRVUQ-/<2L !ODD=V.
M  ,X P*YJE:<,"Z_VO9QDK]W#F>VEKO3KMYVUITH3Q2H]/:..G92:ZZW]--_
M(W/&W[9GA7P'^R7IOQEO+/7I/"VJ6&GZC%;PP1-?K'>M$L09#($W RKN <@8
M.">,ZOQ+_:H\'?![7?$UIXDO+C3;7PAI5MJNIWY@,MO&+B8PP6Z+'NEDN)&
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M4C]GOQ!<>+-$T?5KRQDTR[U32(;R>SDSNM))$C=HCG!RI8KR >*TJ/FIR?\
M2NW9=^CNGJG?HXME&/+6AV=[?*U_+JK-:-6MK=+TZBBBO+/H HHHH **** "
MBOPZ\#_\%&OVH/VFO^"U6J>%?#?QM^'/P_OO".O>(M"@^$/BNUET_3-1TJRO
MM)BC5[@Q-+<ZC?027-U!)"CM$EE+L*PW$T8[O]L3_@HS^TYXE^-_[7/C#X9_
M%[P7\+_!7[&TFF > M6\+VNI/X_7:T]P]Y=2$7%K'/M,4)MBOF*RJIBD!F8
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M7D.N_P#!Q-X@\7_L[>$OB3X!^ 'CK5/#OC36+?1M.NC97%\RRS2R1(9(XTC
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M,JTY.\FQT\+1II1A%)+;0****S-PHHHH **** "BBB@ HHHH **** "BBB@
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M]O<I86T-U+?P!'=S:M#.CH9%24C(,2G (!ZW_P ,Z>'_ /H(>.__  M]:_\
MDJC_ (9T\/\ _00\=_\ A;ZU_P#)5?/'[#W_  6P^%O[=GQX;X=:/X5^+'@7
MQ!J&@+XL\.-XV\-?V/;^,M'9RBZAIK^8YF@8;75G"%U;*AMDFS["H X3_AG3
MP_\ ]!#QW_X6^M?_ "51_P ,Z>'_ /H(>.__  M]:_\ DJN[HH X3_AG3P__
M -!#QW_X6^M?_)5'_#.GA_\ Z"'CO_PM]:_^2J[NB@#A/^&=/#__ $$/'?\
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M-X?N(Y!%+:7:,Q"7"2D1[%9@[,GEF0.A8 ]#_P"&=/#_ /T$/'?_ (6^M?\
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M -!#QW_X6^M?_)5'_#.GA_\ Z"'CO_PM]:_^2J[NB@#A/^&=/#__ $$/'?\
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M *"'CO\ \+?6O_DJC_AG3P__ -!#QW_X6^M?_)5=W10!PG_#.GA__H(>._\
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M\N_8R_;#\"_MZ_LW>&?BI\.=0FU#POXH@:2(7$7DW5G*C%)K:>/)V2Q2*R,
M64E=RLZ,K-ZC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%?_
M  6I_;V^%/\ P3F^$OA+XA^+O!OA#QM\5$U":P^&5GJ\5K'<6U_*J)/<)>3#
M-E;HAC,\RL@P8U+#<I'VI7GOQR_9(^%/[3\VFR?$KX8_#WXAR:*)%T]O$WAR
MSU9K 2;?,$1N(W\O?L3=MQG8N<X% 'X?_M#?";0/A7_P2NL?B==?%WX>_&?Q
MAJ'[1OAWXH_&G7/!.KVVK:3H'GR21?9@+9F"P1M)$%W@%WE;'R[%'U3^R!X;
M^'/_  4:_P""PO[<5Y8R:3\1O@KXI\'>&/"NJ:CI5^9-*UN?[(/,ABNK=P)"
MJHRLT;Y7&,X(S^B'P[_8T^#_ ,(? GB+PMX3^%/PV\+^&?%\+VVO:1I'AFRL
MK#6XGC:)H[J"*-8YU:-W0K(&!5F'0D5T'P?^!O@G]GGP<OAWP!X/\+>!_#ZS
M/<C3/#^DP:99B5\;Y/*A14W-@9;&3@9H _-#_@F%X?L_@G^TK_P4NT_P3H[:
M!9^&=9LDT73/#&E0[[(1:3=&&*RM T,1=2%$<6^-2VU=R Y'R/\ \$K_ (@:
M!^RK\6OV)]'_ &:?VG/B=\7M/^*U[JND^.OA?KEW ]GX>T[=]HGNQI$4DZZ-
M)#+YLQ)ED>?YVCE,1F$G[V^#O@_X1^'?B?Q#KGA_PMX<T/6O%UPEWKM_I^FP
MVMUK4R*526YD10TSJI(#2%B 2 :Q/AQ^RK\+_@[\0M<\7>$?AOX!\*^*_$S2
M-K&M:/X?M+'4-6,DGFR&XGBC624O)\[;V.6^8Y/- '?4444 %%%% !1110 4
M444 %%%% !1110 4444 ?G[_ ,%M_P#@HSX!_P"">6J>![K2?#?PXU7]I;QY
M%/H'@75_$9L[*/PO:R$)-?7FH38-M8H\@)0R()F# '"2,GQ)XP^%?PY_8F^"
M_P"PIXFLOBYX+^*'A'PS\=I]3^)?C_1-6MK[0X-?U&))9)))86,4,4>  S["
ML:J[!=V*_8_XV?L4?!K]I;Q):ZS\1OA)\,?B!K%E;"RM[[Q)X6L=5N8( S.(
MDDGB=E0,[MM!QEV.,DU+X?\ V-/@_P"$_@[JGP[TKX4_#;3/A_KDQN=2\,VG
MAFRAT?4)3Y>9)K18Q#(Q\J+YF4G]VG]T8 /SN_X)7?!7X<_\%"OCE^W?J>M:
M3I/Q%^"OC3XN:8^FOYC2Z/KUUI06=W1HV"7$'G"W<\M%.A 8/&Y#>!_LZ_#/
M4/$__!"3_@I-X;\(Z4SSP?&;QH+/3]/@V[8+>/2Y&CBC0=!#&P"*.@P!7[<?
M#+X6^&?@KX&L/#'@WPYH/A+PUI8=;+2=%T^*PL;,.[2,(X8E5$W.[,=H&68G
MJ34/PV^#GA'X-6NK0>#_  KX;\*0Z]J<VM:G'H^F0V*ZC?S!1-=S")5$D\@1
M TC9=MJY)P* /QW_ ."//[06I>$/^"B/P3\#_#O]I+QA^T+X'^*?PA/B/Q[I
M&KZS'JMIX#U2! R"TAC4#28A+(L LB%,:NBOOQ#L_:RN#^#_ .RW\,?V>M7U
MK4/ 'PY\!^![_P 2.LFKW/A_0+33)M592[*UP\,:F4AI)""Y."['N<]Y0 44
M44 %%%% !1110 4444 %%%% !1110 5^8/\ P6^_X*'^$/V5?C+I7PO^&%O\
M(?#O[47QLT-]#N/B%XKN+'1[/P'H!)9KG4=0F7<RGRY3!;%F!DCW^7(PB@N/
MT^KR;XN?L$? O]H#QI+XD\>?!;X3>-O$5Q&D,NJ:_P"$-/U*]D1!A%,TT3.5
M4< $X Z4 ?E'9^#_ (.?\$Y_VPO^":^H:+\3/">O? ?P;H'C7PZ/B,-6MGT&
M35I[69KB62Z21X+?SKN>4!3(=IW)N/ELP]=_X(-_LO> ?VQ/V0?BIKOCKPGI
MGC3P'K7[1_B7XA>"8]3A:2PNHPD5I!=B$XCE0-]J4)(K(&!;;N4$?H?<?L:?
M!^[^"=O\-9OA3\-I?AS:S&YA\*OX9LFT2&4R-*9%L_+\D-YC,^X)G<Q/4DUV
M_@[P;H_P[\)Z;H/A_2=-T+0]&MH[+3].T^U2UM+&"-0L<442 )'&J@ *H
M % 'YE_\&V?Q8T[X"_\ !N]HOCK6,_V3X+@\4:[>X8*?(M;R\GDY/ ^5#R>!
M7J7_  ;Q?"&^MOV&6^-WC 17GQ4_:6U>Z\?^*M0"D>8L\\OV&WCW?,MO%;;#
M''RL9FD"DK@G[ \*?LX?#OP'\'[KX>:'X#\%Z+X OK>XM+CPS8Z);6^CW$-Q
MN%Q$]HB"%DEWOO4KA][;@<FN@\%>"=%^&OA'3?#_ (=TC2] T'1[=+2PTW3;
M5+6SL84&$BBBC 2-%  "J  .@H U**** "BBB@ HHHH **** "BBB@ HHHH
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M&D\J!$3>P506QDA1Z"NLH **** "BBB@ HHHH **** "BBB@ HHHH *_%?\
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M1==U30;6\U+2#'(98S;W$D;20E9"7&QAACD<\T ?E'^W?^VGX=_9/\ ?"_\
M9Q\&Q_"3P#^U!\5/AEI'A_QO\0_%UQ8Z1;^"-(2Q2*0W]], \TY$<PAMF8E3
ML?8=T:R4]'L?@W_P3Q_X*)?L&ZA8_$CPI>? C1OA?XC\)Z1\0)]8MCH5[J49
ME>XE:\5S;1-+*[C_ %F [>7G(Q7ZA_%7_@GY\!?CMXYO/$_CCX(_"'QEXEU
M1K=:MKG@[3M1OKD1HL:!YIH6=MJ*JC).%4 < 5JZO^QI\'_$'P8T_P"&]_\
M"GX;7WP[TB;[38^%[CPS92:+92[G?S(K-HS"C;I9&W*@.9'/5CD ^-/^#8RW
MFU#_ ()Y>)O$L4-Q'X?\<?$WQ+KWAZ26)HA<:?)<K&DBHP!52\4HQCJ#7Z*5
M1\,^&=-\%>&]/T;1M/L=)T?2;:.RL;&R@6WMK*"-0D<44: *B(JA550
M!5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20210103_g11.jpg
<TEXT>
begin 644 jnj-20210103_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMA:U+6K!QOW37YG5A<PPN);6'JQG;?EDG;ULRY17Y >"?VO](_8&_P""EO\
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M^""T_P#C==W10!PG_#+GPR_Z)SX$_P#!!:?_ !NC_AESX9?]$Y\"?^""T_\
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M?]$Y\"?^""T_^-UW=% '"?\ #+GPR_Z)SX$_\$%I_P#&Z/\ AESX9?\ 1.?
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MESX9?]$Y\"?^""T_^-UW=% '"?\ #+GPR_Z)SX$_\$%I_P#&Z/\ AESX9?\
M1.? G_@@M/\ XW7=T4 <)_PRY\,O^B<^!/\ P06G_P ;H_X9<^&7_1.? G_@
M@M/_ (W7=T4 <)_PRY\,O^B<^!/_  06G_QNC_AESX9?]$Y\"?\ @@M/_C==
MW10!PG_#+GPR_P"B<^!/_!!:?_&Z/^&7/AE_T3GP)_X(+3_XW7=T4 <)_P ,
MN?#+_HG/@3_P06G_ ,;H_P"&7/AE_P!$Y\"?^""T_P#C==W10!PG_#+GPR_Z
M)SX$_P#!!:?_ !NC_AESX9?]$Y\"?^""T_\ C==W10!PG_#+GPR_Z)SX$_\
M!!:?_&Z/^&7/AE_T3GP)_P"""T_^-UW=% '"?\,N?#+_ *)SX$_\$%I_\;H_
MX9<^&7_1.? G_@@M/_C==W10!PG_  RY\,O^B<^!/_!!:?\ QNC_ (9<^&7_
M $3GP)_X(+3_ .-UW=% '"?\,N?#+_HG/@3_ ,$%I_\ &Z/^&7/AE_T3GP)_
MX(+3_P"-UW=% '"?\,N?#+_HG/@3_P $%I_\;H_X9<^&7_1.? G_ ((+3_XW
M7=T4 <)_PRY\,O\ HG/@3_P06G_QNC_AESX9?]$Y\"?^""T_^-UW=% '"?\
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M$89U1?E0%B2S*  "22* -VBOG_\ X>D? G_H>O\ RBZA_P#&*/\ AZ1\"?\
MH>O_ "BZA_\ &* /H"BOG_\ X>D? G_H>O\ RBZA_P#&*/\ AZ1\"?\ H>O_
M "BZA_\ &* /H"BOG_\ X>D? G_H>O\ RBZA_P#&*M?M3ZAXD_:O_P"">WQ"
M;X"^)_L?BSQ=X7U"U\*:S!-)8R17922)2DI"O;R;PR+)\K1/AL@KF@#W:BOP
M8_X(9>$/!/[*W_!13X:>#;GPG\6OV3?BM=^$;S0?%O@7Q)97>H>'OC+=VJR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKQ7]LC
M]KO4OV44^'KZ9\,?'?Q,3QQXLM/#-T?#%I]I_P"$?CG)#7MR!G;"F#DG:N>"
MZY&0#<_:^_;#^'W["7P*U+XD?$_6I/#_ (/TF>WM[F\CLI[QD>>58HP(X4=V
MRS#HIP,FO/=1^%7Q)_:3^._Q%T;Q]+\-?%7[)?CSP7!8Z/H\$5PNMW-S.J"X
M:XD^51"Z--@HVX P%=C*Y;>^!W[(.M> /B+\8]2\<?$G7OBOX9^)VNQ:MI/A
MGQ%:I-I_@Z"-?^/.V5F<-&7VM]U /*0[2^^1_<401H%4!548  X H YSX/?"
M+PW\ ?A9X?\ !/@_2;?0O"WA6PBTS2]/@+,EI;Q*%1 S$LV .68EF.2222:Z
M2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I>(O#>G>+]%N--U;3
M[+5-.NUV3VMW L\,RYSAD8%6&0#@CM5VB@#S_P#X9.^%?_1,_A__ .$[:?\
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M=T2W&H:CJ,97[5=:=JID$VFO<!%+;%D^8MO,L96)?TBHH ^!?VZ_^"#WA_\
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M?^$K=_\ RPH [NBN$_L+XF_]#5X$_P#"5N__ )84?V%\3?\ H:O G_A*W?\
M\L* .[HKA/["^)O_ $-7@3_PE;O_ .6%']A?$W_H:O G_A*W?_RPH [NBN(M
M-$^)"7<1N/$_@B2 .#(L?ABZ1V7/(!-^0#CN0<>AKMZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH S?"G@_2/ FC?V=H>EZ;HVGB>:Y%K8
MVR6\/FS2O--)L0 ;I)9))&;&6=V8Y))K2HHH **** "BBB@#A/A%_P E ^*7
M_8SP?^F72Z[NN$^$7_)0/BE_V,\'_IETNN[H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDE$E+;"BK( ?I=17Y^:U_P %UO['_P""=O[./Q\_X5;YG_#0/CO3_!7]A?\
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MN1"QBFM)WB\M;NW++N7>@#*P)13E1^NU !1110 4444 %%%% !1110 4444
M<)\(O^2@?%+_ +&>#_TRZ77=UPGPB_Y*!\4O^QG@_P#3+I==W0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6/\0O'VC_"GP#KGBCQ!?1Z9H'AO3[C5=3O)%9EM+:"-I99
M"%!8A45FP 3QP#5'XT?%W0O@!\(?%'CKQ1=26/AOP;I5SK6JW$<+S-!:V\32
MRN$0%FPB,< 9.*\#^#'B3Q5^VW\6?AG\>/A_\5"W[-WB;P9/%=^!;_PVB3:S
M=RR2!;III%$D>WY%*<K^Y.W<LK&@"/X=_$CQQ^W!\6/A-\6OA-\1O!>L?LG^
M)_#.H1^(=!U#0I/[3URZ8RQ121-+&&C5)%V.CE !'("DGF*8_H;X7?"CPO\
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M\++H_A/1;/1[/@R>4N9;E@,;Y9#EI&]V)_*NLH **** "BBB@ HHHH ****
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MC;Q%\+]6U[3OLNF>)O#L\MM?:#.K*\4T1ADB<JK(H9%D3>A=-RALUZ97R?\
M\%I?V[/%W_!.7]A/5/B?X(T[PYJFOV.M:7IT=OKEO-/9F.YNDAD)6&6)]P5B
M5(< '&01Q2<F]RHTXQ^%'SW^SS_P3#_:F^+7[;?P)^*W[4?C#X%WG_#/6CW5
MIH]WX!MK]];\5W,]NMN7U.>ZBC4+]^8B$*A=Y (D$A*^$_$__@W0_:&\:?!K
MQ-^SC;>./V?[C]GO6O'L_C;3_%NK:)J%Q\0-#><H\@CB39:.X(:$L90TD;N=
M\898H_NOX^_\%[?V2?V7O'_B;PKXZ^,-AH/B3P?JBZ/JVF'0]4N+JVN6C,H
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MA)I\5WIEO!##J6G36T9D9ML941S(J#:6993(%AR_VQ_^"+_[0?[07QV^ _Q
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M<V)=-RO3=^^B2^21Z.7K$*%JT5%=%S.3\[MI?<KI=PHHHKF.\**** "BBB@
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M(O\ DH'Q2_[&>#_TRZ77=T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 45'/=Q6K1K))'&TS^7&&8+O;!.!ZG
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MWA4)'%$@1(P.P X ^E3445QGJ[:(**** "BBB@ HHHH **** "BBB@ HHHH
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M&C/#O_/IXT_\([5__D:N[HH X3_AHSP[_P ^GC3_ ,([5_\ Y&H_X:,\._\
M/IXT_P#".U?_ .1J[NB@#A/^&C/#O_/IXT_\([5__D:C_AHSP[_SZ>-/_".U
M?_Y&KNZ* .$_X:,\._\ /IXT_P#".U?_ .1J/^&C/#O_ #Z>-/\ PCM7_P#D
M:N[HH X3_AHSP[_SZ>-/_".U?_Y&H_X:,\._\^GC3_PCM7_^1J[NB@#A/^&C
M/#O_ #Z>-/\ PCM7_P#D:C_AHSP[_P ^GC3_ ,([5_\ Y&KNZ* .$_X:,\._
M\^GC3_PCM7_^1J/^&C/#O_/IXT_\([5__D:N[HH X3_AHSP[_P ^GC3_ ,([
M5_\ Y&H_X:,\._\ /IXT_P#".U?_ .1J[NB@#A/^&C/#O_/IXT_\([5__D:C
M_AHSP[_SZ>-/_".U?_Y&KNZ* .$_X:,\._\ /IXT_P#".U?_ .1J/^&C/#O_
M #Z>-/\ PCM7_P#D:N[HH X3_AHSP[_SZ>-/_".U?_Y&H_X:,\._\^GC3_PC
MM7_^1J[NB@#A/^&C/#O_ #Z>-/\ PCM7_P#D:C_AHSP[_P ^GC3_ ,([5_\
MY&KNZ* .$_X:,\._\^GC3_PCM7_^1J/^&C/#O_/IXT_\([5__D:N[HH X3_A
MHSP[_P ^GC3_ ,([5_\ Y&H_X:,\._\ /IXT_P#".U?_ .1J[NB@#A/^&C/#
MO_/IXT_\([5__D:C_AHSP[_SZ>-/_".U?_Y&KNZ* .$_X:,\._\ /IXT_P#"
M.U?_ .1J/^&C/#O_ #Z>-/\ PCM7_P#D:N[HH X3_AHSP[_SZ>-/_".U?_Y&
MH_X:,\._\^GC3_PCM7_^1J[NB@#A/^&C/#O_ #Z>-/\ PCM7_P#D:C_AHSP[
M_P ^GC3_ ,([5_\ Y&KNZ* .$_X:,\._\^GC3_PCM7_^1J/^&C/#O_/IXT_\
M([5__D:N[HH X3_AHSP[_P ^GC3_ ,([5_\ Y&H_X:,\._\ /IXT_P#".U?_
M .1J[NB@#A/^&C/#O_/IXT_\([5__D:C_AHSP[_SZ>-/_".U?_Y&KNZ* .$_
MX:,\._\ /IXT_P#".U?_ .1J/^&C/#O_ #Z>-/\ PCM7_P#D:JW[5_[4W@S]
MBG]GWQ'\3_B%J%QI?@_PK'#)J-S!:274D8EGC@CQ'&"S9DE0<#C.3@ FN'M_
MVB?B=X[_ &H/A='X'\!Z-XB_9W\<>%)->U'QX^J_9KRPN)(VEM(DLG E99$,
M!R5'^N;)0Q;7 -;XR?\ !0'X4?L[^#?^$B\?>(=2\%Z +B.U.HZWX>U*QM1+
M(<)'YDMNJ[FP<#.3@UQ.I?\ !1";6_VGM<^%NF?#7XL:;8Q>$VUK3_']SX+U
M&;0GO6=8TM1&(1*S+O#G.T$(PXX8M^#W_!,W2[?]GCQ/\-_CAXPUK]I31_$'
MC"?Q5;R>.8A<OI:$Q&WLXP6;$<)C8C;M4F60!%1ME?3D,2V\2QQJL<<8"JJC
M 4#H * /@OPY^SG'^U-^S!\*M$_:XU;Q'\1OB5\-?%*^+8]7\+>$-<TBRFNX
M)I3:[HX[.(.%B= W[M,E>.[-]:Q?'OPK!>S7,>F^+DN+@*LLJ^"M6#RA<[0Q
M^RY.,G&>F37H-% '"?\ #1GAW_GT\:?^$=J__P C4?\ #1GAW_GT\:?^$=J_
M_P C5W=% '"?\-&>'?\ GT\:?^$=J_\ \C4?\-&>'?\ GT\:?^$=J_\ \C5W
M3N(T+,0JJ,DGH!6)+X_L;S2M3FT=X]>N=+&)+6RE5Y"YZ+UQSS^1ZD8JHQ<M
MC.=2,/B?]+LNI@?\-&>'?^?3QI_X1VK_ /R-5<_M1^$1J0LMOBS[84\P0?\
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MO%=ZKX?M]4@EU33(90K1R3VRL98D<.A5G4!@RD9R* .GHHHH **** "BBB@
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17SQ\8/\
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M &,\'_IETNN[KA/A%_R4#XI?]C/!_P"F72Z[N@ HHHH **** "BBB@ HHHH
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M$7QJ^">JW.MZ3>^&;J[@TS3+IKK?"Z)N02D1Q6K-YB%?,BR!C.?I[P%X#MO
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MV#;=A>"W5&8>A8#)Z#K6HJA>@QSGBBBLY2<G=G1"G&"Y8*R\@HHHJ2@HHHH
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M+]JOQIXMTK6O"-MI^MW4,L$5W<W"S(%MH8SN"P,N<H>C'C%>6_\ #F7XF?\
M0P>!/_ N[_\ D>OU \8_\C/>?[P_]!%?']U^T/XPT'XS?M=0KXAT];/X<Z)H
MUYX;AUFYBM=-TJ:72III"\K;0B/*JLQ=L#'85]-'/L10H+M&-]NB2_$_.:_!
MN Q.*E)I\TI-[Z7;_P V?/\ _P .9?B9_P!#!X$_\"[O_P"1Z/\ AS+\3/\
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MTA=>)M>U7PS>V,VA7-@(]/GGDF#O-;N#AXD&W$9[YY'%??\ 7"_#H;?$3?\
M7%OYK7=5X&98J=>M[2IO8^TX?R^C@\)[&A\-V]7?<****\\]P*\+_P""C?A'
MXW>,/V3O$$?[/'B32/#OQ4L9(;[3%U6TM[BRUF.-P9["7SXW1!/%O57PI#[
M7C4LZ^Z44 ?BK_P2@_8E_:0_9BM?C9\>?#W[.N@_#+QA=>$=4\)^%/AJFKVM
MM_PDFJOX@N[V+4;D9AMXK>UCFCM8LNAFM[3='M26-FZS_@CQ^RG^TC\*/B+X
MLLOCQ^R[JH\8?'2+4;?XC_''5?BGHVK7ZPFVG-M;6^F6X9X;<,L$ BADP"4<
M_NX8XX_U^HH _&?]D'_@EY^U%_PF7[+?P3^)7@3POX=^$/[(_B^_\81?$2T\
M2V]VWCIH[AY=.@M]/3_2+9MTYWF<!3&CG*NJ1S9'CK_@D9^TUJ%AXQ_93LO
M_ANY_9_^('QJ/Q*N/BH_B6W232M'>1+J73CIG_'U)=AH419%'EEV )6-C+'^
MU]% !577-&B\0Z1<64\EU'#<H49[:YDMIE'^S)&RNI]U(-6J* /$?A=\"-'O
M?''Q(C?4O&BK9^(H84,?BS5(V8'2=.?+E;@%VRY&YLG:%7.U5 [/_AG?0_\
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ML]7_ /DFN[HH X3_ (9WT/\ Z"GCO_PL]7_^2:/^&=]#_P"@IX[_ /"SU?\
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MLGZ!>^%;>X^)'Q*\SQS)Y?A_9K/B%UUAL*1Y+"7:X.],$'!WJ!DD9]X\(?\
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M_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\
M)-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!P
MG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]
M!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%
MGJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT
M?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T
M%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9Z
MO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W
M10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.
M^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW
M_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__
M ,DT?\,[Z'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[
MZ'_T%/'?_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?
M_A9ZO_\ )-=W10!PG_#.^A_]!3QW_P"%GJ__ ,DT?\,[Z'_T%/'?_A9ZO_\
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M_M#?!WX@>!K7Q]:Z/X?T":+QI\,[+3HKO3M8U*YML<7T8>7;;S,-K>6-PA!
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M\=K<,?X6_B91@8Y'-;'B+Q/HOPW\-/?:MJ&F:%H]B@#3W<Z6UO H' +,0J@
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M Q4 +@5Z910 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2I-YFU1F/SF5!C"J%&/E&/HJBL3K"BBB@ HHHH **** "BBB@ HHHH ****
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M]$7OQ7_:=UBV::'X=_"[P;".3)KWB.2\6+_>-N /RKS_ ,7?&[XI:=N'B/\
M:,^!7@V0??BT+3_[4FC^D<SEOS%>#_$G_@DU^TIXS^&.AW,.H_"VZ^(*ZM#)
MJ_\ ;?C?5=0TA[ %_-6$KI4<_G./+ +$*N7^]@$]YX*_X)+^.O!O[9TGBXZ;
M\,M5^$+>'%L$\$ZAKEY/<+J@E#?;OMGV$'&P%?+V[3N/&0#4?7;?!3BOE?\
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M)_PD/Q-_Z%'P)_X5UW_\K:/^$A^)O_0H^!/_  KKO_Y6T =W17"?\)#\3?\
MH4? G_A77?\ \K:/^$A^)O\ T*/@3_PKKO\ ^5M '=T5PG_"0_$W_H4? G_A
M77?_ ,K:/^$A^)O_ $*/@3_PKKO_ .5M '=T5PG_  D/Q-_Z%'P)_P"%==__
M "MK)O?BE\1+#QQIOA]_!O@LWFJ65U?Q./%MSY2I;O;HX8_V=G<3<IC (P&R
M1@9 /4:*X3_A(?B;_P!"CX$_\*Z[_P#E;1_PD/Q-_P"A1\"?^%==_P#RMH [
MNBN$_P"$A^)O_0H^!/\ PKKO_P"5M'_"0_$W_H4? G_A77?_ ,K: .[HKA/^
M$A^)O_0H^!/_  KKO_Y6T?\ "0_$W_H4? G_ (5UW_\ *V@#NZ*X3_A(?B;_
M -"CX$_\*Z[_ /E;1_PD/Q-_Z%'P)_X5UW_\K: .[HKA/^$A^)O_ $*/@3_P
MKKO_ .5M9/@+XI?$3XB>!]'\06/@WP7%9ZW90W\"3^+;E9425 ZA@-.(# ,,
MX)&>YH ]1HKA/^$A^)O_ $*/@3_PKKO_ .5M'_"0_$W_ *%'P)_X5UW_ /*V
M@#NZ*X3_ (2'XF_]"CX$_P#"NN__ )6T?\)#\3?^A1\"?^%==_\ RMH [NBN
M$_X2'XF_]"CX$_\ "NN__E;1_P )#\3?^A1\"?\ A77?_P K: .[HKA/^$A^
M)O\ T*/@3_PKKO\ ^5M'_"0_$W_H4? G_A77?_RMH [NBO+;[XI_$2P\<:;X
M??P;X+-YJEE=7\3KXMN?*5+=[='#'^SL[B;E,8!& V2,#.O_ ,)#\3?^A1\"
M?^%==_\ RMH [NBN$_X2'XF_]"CX$_\ "NN__E;1_P )#\3?^A1\"?\ A77?
M_P K: .[HKA/^$A^)O\ T*/@3_PKKO\ ^5M'_"0_$W_H4? G_A77?_RMH [N
MBN$_X2'XF_\ 0H^!/_"NN_\ Y6T?\)#\3?\ H4? G_A77?\ \K: .[HKA/\
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M0D<^+;GRFCGDN(T /]G9W V[Y! &"N"<G !ZC17"?\)#\3?^A1\"?^%==_\
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MV.'_ )XQ_P#?(H^QP_\ /&/_ +Y%2447#E1&MK&O2.,9&#A1S1]CA_YXQ_\
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MB\._LU^"?AZ="TJ^74[F\TR_\9+Y:3:EILUQ)(TAAA+9E5MK%X6&8S$:]/\
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M'9+"ZJ ?T5:CH=GJ]W8SW-O'--IDYN;5V',$IC>(L/?RY9%^C&K5?D?^Q?\
ML^_\.PO^"SWQ"_9S^ +_ -F^#?%7P'3QQ9:+K^I7EYI2>)X;T645[)N=Y$24
M+^^$1!(8!<".-1H?\$<?A]\0OA9_P6V_:[T/XI_$*3XG^.K7PMX4FU/7?L*V
M-N[SVYG$%O;J2L4$(E\M ,;@F\@%B  ?K!17XG?%S]A_1?\ @EY_P63_ &:/
M$FG-\3M)T?XA>*KBP\5?&K7_ !;_ &O?_$#5M0$[0>'KVQA,4<$)>*$"<0!&
MWH2/W#/7[8T %%%% !1110 45^#O[>_[ FB_ /\ ;!\"67A3XE>+OBO_ ,%
M/BI\58O%EAXHL;BYLY_"?AO($L%S:"ZE@@TZ&W5T3>N7C#HH$$9C&+^W;\)8
M?VM_&?\ P4-^.WB?7/%47Q(_9?UC2M/^%>I6&LW-I_PA2V6V=FM4C=4W3NI+
MEU8JSLZ;7.Z@#]\M&T.S\/6DD%C;QVT,D\URR(.&EED:61OJTCLQ]V-6J_$7
M_@XS;XY?M _\$>=%^)U]\0M'T#X2W'A#PGJVH^%=,L#]O\5ZW?7$#3->SG"Q
MV=L&@DABBSYDK.T@'E0FOL7_ (+G?M->+(/A-#^SW\(K_P"R_%CXN:1J%W>W
MT>[/A+PO:PN^I:F[+S&S*!;0Y*EY9B$8,@- 'WK17Q'_ ,&XO_*$[X!_]@>[
M_P#3C=U]N4 %%%% !117QO\ \%B/V,/!_P"UAX \'ZM\8OBH_@?]GOX:W5SK
MWQ!\.R&6UM/&<06(6D4]W%<120K#,I9419&E>5 H5U1J /LBJLVAV=QK=OJ4
MEO&U]9P2VT,Y'S1QRM&TBCV8Q1D_[@K^>/0[CQEX9_X(ZZ;X1T&\\=>#_P!G
M[]I']I^T\'>!-+U"]FCU2S\ Z@UQ(88W9FDCAN# 04+L'#3,2ZS,TGV!_P $
M^OAGXM_9$_;A_;?_ &8_V=]2T[0/#?A32?#FO?#S3?%-W=ZEI?A2_O[$/=,"
MS/,\;O)YFTELM&@.<N6 /UFHK\G_ /@AG:>+?V>OB;^WZOB3Q%KWQ?\ &GA'
MQFD]]JAL-E]XGO(=/F<^5:Q%O+\QALBMXR0B[(UR%%?+?_!$WX,^%_V-?VHO
MV>9?VB_V1_&7PY^,_P 3)]9E\+?%K4O&%S(VLZM()W:"]T19$CTYFM;DP(LL
M9=G"-Y?S/+& ?T"4444 %%%% !15;6K:ZO-'NX;*Z6RO)872"X:(2B"0J0KE
M"0&VG!VDC.,5^%FF_L*^'?V5?^"KG[-_P]^$OQ$\7?%3]KJT\5R>,?CEX_BO
M+I8Y?"K3>9<6^J0-<SP6S30O#$D>2[;H68J9[?< ?NY570M#L_#&B6>FZ?;Q
MVMCI\"6UO!&,+#&BA54>P  K^<OX^VEUK'[+7[1G[>-QK7B3_AH;X3_M%3:)
MX6UF/5[F.'2M$MKJTMH])6 /Y1MC%=RHP*$NGRDD-('^Q/\ @X5^'_QAC_:!
M_9[\7:Y\0M,A^$/_  O?P9H7AOP1I=BRR7$KI-<7&I:C<,<O.LT,D4429B6(
MJ_$A?(!^O5%?A_\ \%S+O7OVL?\ @JIJGPAU+X,^,/VA_!OP]^% \4V7@C1O
M&G_"*6VG74MQ*MQKTMP=PEN8(S'##!Y<F_SF^4_,DGZ8?\$@_BCX2^,O_!-7
MX0^(/ NO>./$OA6XT3[-8WWC"XBN=<_T>:2WDANI8D1))(9(GAWJH#"(')SN
M(!](4444 %%%% !17Y__ /!:_P#8Z^$OQ>G\._%C]ISXE7EM^SG\)],N[F^^
M'0>XLK?Q'K$J2);W7VBWNHI9+E$8QPPHA<EG <+)*K?G[\/_ (;_ !"\;?L&
M?L$_LZ_%B\\:6?PU^-WQ+U">\\/ZAJ,L&I7/A2SV7&F:3=2QE9! R,KA P*)
MY&S88H]@!^_$VAV=QK=OJ4EO&U]9P2VT,Y'S1QRM&TBCV8Q1D_[@JU7Y-?\
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MR;Q=X>^)7QBOO!OPRTK4/ 4W@J:\GM/@K?L@=[C5A$\:6JR&(W6YO,!CEC)
M)5HP#^B.BO,_V++Z]U']COX4S:EXPL?B%J<G@_23>^*+*<SVWB.?['$);Z-R
M 629]T@) )#\@'BO3* "BBB@ HHK\K_^"_'['OP8N[GQ%\>/VG_B%K'B'X>Z
M'X/D\-^ /AE:R7%BR>(IF+)>6K0W2FZNY/NE&B"+&FZ4M'"-H!^J%58M#LX-
M<N-22WC6_NH([:6<#YWBC:1D0GT5I9"/]\U^'^G?L_\ CO\ :;\:?\$]?V5_
MVH[SQ1K6A:IX'U_Q5XU\/W6J7-I<ZQ<P1RMIL%])$Z3>9:P^2I^<.'$@8DDF
MO5?^"7%I\>OCC_P28\6?"?X9_%:/P7+\*_BQKGP\'C#5[=]4UK2O"=A&94AL
M WR&[#R06T;2D)!;%_+VO% % /UUHK^?_P"$MUX[D_X,Y_"\WA7_ (2FXT9M
M>OW^('_"/LQU:3PO_;]Z=3\H@YVF/'G$G9Y'G^9^Z\RO</\ @@Q\;OA#HO\
MP54^+WPO_9;U#Q$?V9=<\ 6GC/2M/U#^TOL46KPW4%C=7%B-1'VD1R;V21F^
M]+;E<E8HPH!^R%%%% !1110 45Y3^W%\ O%7[4G[*7C/X?>"_B)J'PH\1>*K
M1+*W\56-D;RYTJ,S1M-Y<:S0MNDA62(,LJLGF[P<J ?QO_9>\->%?V*_VG_V
MJ/%'[&5YK4?P3^"?P"U.'Q=K!U*>_P!!\3>.+."XN;>6!II)5EECC +-$0B?
MOE4*DH,H!^[>OZ%9^*-"O=,U"WCNK#48'M;F!Q\LT3J5=3[%21^-6Z_!G]@+
MX.6?[$/[1/\ P3H^)7@K5O$P\4?M9:/KDGQ8GU#6;J]7QE/+8Q7L5Q.LLC*)
M8I[EV#* 6*J6R2Y=WQK_ &!-(_9D_P""@_P!\+^ ?B7XK^+G[=VO?$V'QAX\
M\>6L]S:?V9X3P_VJ._M/M,\%M;FW>"-(CEI8E9.$DBB< _>2BOYVOVQO!TGQ
ML^''[>W[7.H:]XGM?CG^SG\94\(_#G7+75[B-?"VFZ=JEK:+;PP!Q"4ECN92
MZLA&]F;J\F_^@OX<>)I?&GP\T'6)XXX9M6TZWO9(TSM1I(E<@9YP">] &U11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YO_M6?\$2O
MC-\=O^"DEU^TEX1_:NA\!^(+&P&D>%["Z^%UCXB3PG9&())';-=W1C$DC&9V
MF6))/W\BYVD@]9^T[_P1Z^(WQWUOX;?$30/VE-6\"_M">#_"4W@CQ!\0;7P7
M97$/B[3)B[RH^F^:D5N_G.TB-'(?++-@%MCI]Z44 ?._P5_X)Q^%?V<?^";$
MG[-?@S4;RQT'_A%M1\.IJUW$+BX::^2?S[R1%*!V::XDDV J.=H*@#'E7C'_
M ((M:3XY_P""5OPW_9QO/'^HVFO?"5K#4_"WCFQTM89],UBR:1K:^%HTKJ5'
MFNK1&7)5V =3AA]NT4 ?+?\ P3?_ .";=U^Q#K?Q*\:>,OB/J/Q@^+_Q@U&W
MOO%?B^[T>#1UO$M8VBM((;.%FC@CBC9AA6.XG^$!57ZDHHH **** "OGW_@I
M_P#L9>)O^"@?['/B3X2^&?B9<?"G_A+FCMM5UB#2/[3DN; $F:S$8G@*K-A5
M=@_*;T(*N:^@J* /@7]D#_@CK\1_@Y\!->^"WQ6_:*M_BQ\!]6\#W7@NT\&:
M=\--,\)G2O.,8%XEY;222O,L8G_UFXO).979G7)L?\$^_P#@BMK'[)G[1'A_
MXB?$CXY:]\;;WX:>$1X%^&]E=^'[?1H/"&E%B'#F*1S=W!B"1"9]A">8&#YB
M\G[RHH ^;_\ AWS_ ,;8/^&H/^$N_P"::_\ "O/^$:_LK_J(?;/MGVOSO^ >
M5Y/OO[4?M+_\$^?^&B?V^?V>?CA_PEW]C_\ "A?[<_XDO]E?:/[<_M*T6V_X
M^/.7R/*V[O\ 5R;\X^7K7TA10 4444 %%%% !7YD>+O^"&?Q^_X;[^(?[0W@
MW]LB'PCXP\=/):6YN/A%I^N2:%I6_,&G6\EY=N(XXXPB,T21F4J68$L:_3>B
M@#\^OVT/^"(7BG]ICXKW7C?P?^T-KWPO\2>/_ D?P_\ BK+:>%;34(/']BBH
MIF2-Y$%A<.GFH9(R^$,:H$"R>=[O\<O^"</A_P"(7_!,35/V8?">K3>#_#<W
MA*+PCINI36W]HRV,,:(BRO'OB\YR$RWSIN9B>*^CJ* /S_\ ^"B__!%7Q;^W
M7^R5\$_@]I/QV_X0+PS\)[.SCU.)_!J:Q;^+;FSMX(;66>![N-%CC\J5O(?S
M48S#=G8IKZ(_80_9V^,7[.?@[6-,^+WQVA^.$T\L/]CSQ>!;#PG'HENB%3 L
M5FS+(&.T@MC:%P.*]XHH **** "BBB@#Y-_X+$_\$W/$_P#P50_9?M_A7HOQ
M<N/A/HEUJ<=[KKPZ#_:W]N0Q M%:NOVF#;&LVR4\MEHDXXKSWPI_P1V\>_$3
M]C3X@? ?X^_M!K\7/AWXFT/3]&\.6.C_  YTKP</!?V)P\$EL+1F60(T=MMC
M8!%6#:!AB*^]** /C;_@G?\ \$J->_9+^/7B;XN_%3XS:M\>/BQKV@6O@^UU
MZZ\/V^A0Z5HENR2+:);PR2!G>5%=Y6?+E5)&[>[]K\)_^"=EO\./^"A'QV^.
MEYXGCUJT^-^BZ1HT_AQ]*\I=,2QM1;L3<><WG"4 G;Y2;<XRW6OI2B@#\U_V
M?_\ @W>'P:^)OP[TW5OCMXJ\7?L_?!GQ5+XU\ _#&ZT&UA_L35#,T\4D^IJQ
MENHXY99W$;1H"9.H&\2?I1110 4444 %%%% 'Y:_"'_@@]^T?\ _VD/B+\4_
M"/[;D.E>+OBKJ?\ :'B2_F^#.F:C=7:"0LMM'-=WDKPVZ A%BB*HJI& N$0#
MMOVR/^"!,W[3/Q[^)6M>&/CKXJ^&?PW^/4NE2_%3P78:';7O_"4-82*5:UO9
M'#V#2(H#E$D#,6WAT/E#]%** /F'_@IK_P $UK#_ (*$?\$_=3^ 6E>)(_AU
MI=U_9L=G?QZ6=36PALIXI4B$!FB+ K$$R9!C.><8.7^WQ_P1,_9U_P""C_C&
MX\7?$SP+_;'CI-#_ +"T[6_[:U.W^P1*9GA/V>WNHHI/+DG=\,N6S@G&,?65
M% 'S#_P27_X)>^$_^"3G[*=K\.?#M[_;FJ7=T^I>(->\F:U_MV\;Y!/]GDGF
M6#$*11[(WVGR]V,L:^GJ** "BBB@ KXG_P""RW_!)[Q=_P %7_#'@/P_I?QI
M7X8>&?!^I2:Q?Z3+X0C\06OB&[!C^S/<1R7,4;1P!9<1.KH_GMN!VJ!]L44
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MXNT/X_0_#71_A6!?:5X?NO <'B6SDU;S68ZA*EQ=1PRL(Q"B)+"XCV.0?WK
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M-<ES 99=F!*$QYC9V9XS@?0-%% !1110 5R'Q_\  WB+XG_!#Q9X<\)>+)/
M?B;7=*N+#3?$<=D+V31)Y(RBW20ET#O&3N4%U&0.:Z^B@#\X_P#@E]_P16^-
MG_!,K6]%TK2?VL+77OA?;ZM/K&N^%$^$VFV5QXDFF0AWGU,W$MWYF[RSO9F8
M+$J#"@ 5_@U_P;OVGPI^.O@_[1\:/$6M?L^_#'QI+\0?!7PIET&VAAT+6&;S
M(V?45<RSP12/*R0F-0 P!8GS&D_22B@#YT_;#_8#_P"&L?VG?V>_B/\ \)9_
M8'_"A_$%YKO]G?V7]J_MS[1 D7E>;YR>1MV9W;),YQ@=:^?_ -M?_@AGXD_:
M!_: ^*WC;X7_ +0>O?!FQ_: T2#0/B=HH\+6NOP^)K:&W-JHAEFDC>S)MV=&
M,>XDN2" 2I_0NB@#C/V=?@1H/[+WP&\'?#GPNMXOAWP/H]MHFG?:YO.N&@@C
M6-6D? W.0N20 ,DX & .SHHH **** "OST_X*%?\$8/BI^VC^WQX1^.WAG]I
M>'X=77PYLEMO"&C77PXM/$EMH$S*?/ND%U="%YY'(;S#!O3RX<-F)&'Z%T4
M?"GQR_X)(?$[XY^"_@OXHO/VEM2T_P#::^"\^J"Q^*UKX&L%BU.UOWD66VGT
M82"V*K;M%"IWXS&SD$R$#VO_ ()Z_P#!/W0_^"?'[']E\+=)US4O$U_.]UJ6
MO^(]0C"W6O:K=DO=7CQ@D(&8A4CW,5C1%9Y&#2-] 44 ?#WP(_X(Y:M\ O\
M@D78_LP^'_CGXU\-^(-%DN[O3/B%X6BET.^M+F6_FO8R;>.Y8O"#+Y<D1F'F
MINPT;%67M/V O^";&N?LM?&#QU\5_BE\6M4^.GQF\?6EII%WXGNM!M=!M['2
M[4?N;.VLK<M'""YWR,&Q(RHVU6WL_P!6T4 %%%% !1110!X[^WY^S;XH_; _
M9%\:?#/PA\0[CX5ZOXRM%T]_$EOIG]HSV5LTB&XC2+SH>9H1)"6#@J)6(^8
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20210103_g2.jpg
<TEXT>
begin 644 jnj-20210103_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M,:C/&\;I)=SV]W'/=D/%$P$TCJ##%@ 1H%[K]CG]AG]F3]@3X:2?!O\ 9/\
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MX_\ BUX[T*1HK&*5)GM+2VT.]U"1R[HNZ1RF45DVCS"R 'YJ?\&KG[3'C?\
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M6<.F:=;OJ1NH[N>V\PW<A6*1U:V2-7:554.L;&=?VQH **** "BBB@ HHHH
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M11EF9CPH !))X % 'Y!_\%'_ -A_XH_\$E+/X=_M\?L.?MD?&O6_%R_%+0M
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M0BB@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
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MVT-@]S'&D@:&)U25<0Q$*P(!0=B0<7_AY_\ L _]'3^%_P#O_)_\11_P\_\
MV ?^CI_"_P#W_D_^(H \W^/7_!!;_@E;^T_\8=>^/WQY_9UUGQ'XO\2W?VC6
M=9NOBKXGC:9@,*BI%J2QQ1HN%2*-5CC4!455 %>J?L5?\$Y_V-/^"=^@:_X:
M_8]^#2^$K7Q1?PWFOM)K^H:E->311F.(M-?W$T@55+!4#!1N8@98DT_^'G_[
M /\ T=/X7_[_ ,G_ ,11_P //_V ?^CI_"__ '_D_P#B* />:*\&_P"'G_[
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M_$T?\(#X$_Z$K2/_  6Q?_$UK44>PH_RK[D'MZ_\S^]F3_P@/@3_ *$K2/\
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M%?SV?T6%%%% !1110!\F_P#!9W_DSVT_[*!H?_I17C->S?\ !9W_ ),]M/\
MLH&A_P#I17C-?J?AU_ Q'K'\F?E'B3_'PWI+\XA1117Z2?F04444 %%%% !1
M110!D?$#_D0];_[!%S_Z*:OK?_@F#_R8#\*_^Q6C_P#1CU\D?$#_ )$/6_\
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M_135];_\$P?^3 ?A7_V*T?\ Z,>ODCX@?\B'K?\ V"+G_P!%-7UO_P $P?\
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M?R9[Q1117YJ?IH4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^!_\
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M6?#'_90-%_\ 2M:])KS;]IW_ )%GPQ_V4#1?_2M:\?B'_D1XG_!+\CV>'?\
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M^CUK[XKX'_X*2?\ )_/PO_[)_JO_ */6O9X>_P"1YAO\<?S/%XC_ .1#B?\
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M^:GZ:%%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-1_\
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M[#SO_H%J?^ 2_P CSFBO1O\ ADS]H'_H0/\ RJVG_P =H_X9,_:!_P"A _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO/[+/_1CWQ _\**Q_P * /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/\
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MO/[+/_1CWQ _\**Q_P * /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/\
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+41#(((SDT4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20210103_g3.jpg
<TEXT>
begin 644 jnj-20210103_g3.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M:7%G>VSV]W;R?=EB=2K*?8@D?C7X#_L8_L _\%D_^#?S_@H!XU;]DW]C^?\
M:!^#7CXK9QQZ;XHM=/-Y;1RO)92S2RDFRN[<2R([21M"XEE"L<JZ 'U['^Q!
M_P %MO@O_P $%;C]C[P-^TEI6K_'VTU!K>T\26?BN5)K7PZUSDV=OJ=TD;+.
ML.565]OEQDHCJ4C8?EA_P5^\:_"?]G+X!_LP_'+]D&?1/#'Q]\&-/I/Q9^*?
MP;CN1IFH:Y#:VCR0G6 /)U:[C=6:;9)/M,S+(VUU!_7+_@L%\ /^"MO[:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^(/_  >\_P#)K/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4
M#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\
MT^3U^_U !1110 4444 %%%% !1110 4444 %%%% !169XU3Q?)X-U>/X?2V$
M>OMIEP-#?5=_V5;SRV\DS; 6\OS-N[:"=N<<U^6O[8__  2-\.?L>_L9>/\
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M2LTRB-7DVJ?CO]AO]KSXJ?MG_P#!0CX9?LW_ /!9+PE+\+?C7\&=(;Q!\-?
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MGA+P-I.AZCI&B:W!;";6KG4)-22XN#+;2RI.46PMU+N[2Y8AS@)0!]FT444
M%%%% !7\\/\ P59_Y2!_%#_L9Y/_ $!*_H>K^>'_ (*L_P#*0/XH?]C/)_Z
ME?H?A;_R6='_  S_ /2&?G/BK_R15?\ Q0_]+1\\T445_5)_)H4444 %%%%
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MX,_Y\/\ \#G_ )GP7_$5N-?^?\?_  "'^1]M_P##_?\ ;Y_Z#?AG_P )N/\
M^*H_X?[_ +?/_0;\,_\ A-Q__%5\244?\0NX,_Y\/_P.?^8?\16XU_Y_Q_\
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M5M%M:I7W/W(HHHK\%/Z "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
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M\0_^QGM/_28U^C]?G!_P;??\D(^(?_8SVG_I,:_1^OXIS_\ Y'N*_P"OD_\
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M_P"QGM/_ $F-?H_7YP?\&WW_ "0CXA_]C/:?^DQK]'Z_BG/_ /D>XK_KY/\
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M'I.E0ZK-KL.F6Z7US;Q07%XL*B66*-I&CC9\995:64JI. 9'(QN.0"Q1110
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MH_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\
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MCYXHKZ'_ .'4G_!0/_HU_P 3?^ Z?_%T?\.I/^"@?_1K_B;_ ,!T_P#BZ/\
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M /Q$/@S_ *"U_P" S_\ D3\\_P"(<\:_] <O_ H?_)'SQ17T/_PZD_X*!_\
M1K_B;_P'3_XNC_AU)_P4#_Z-?\3?^ Z?_%T?\1#X,_Z"U_X#/_Y$/^(<\:_]
M <O_  *'_P D?/%%?0__  ZD_P""@?\ T:_XF_\  =/_ (NC_AU)_P % _\
MHU_Q-_X#I_\ %T?\1#X,_P"@M?\ @,__ )$/^(<\:_\ 0'+_ ,"A_P#)'SQ1
M7T/_ ,.I/^"@?_1K_B;_ ,!T_P#BZ/\ AU)_P4#_ .C7_$W_ (#I_P#%T?\
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M "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D(HH
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MIOB&UL+YK+4Q8S?O;"Z558V]Q$P$EO*%9&\N15;:ZMC# GX1_:Q^(.J_&_\
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MOB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\
MA16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A
M0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^
MWU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@
M_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1
MO/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\
MT8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]
M\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PH
MK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\
M"C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(
MWG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6
M?^C'OB!_X45C_A0 ?\'O/_)K/P/_ .R@:C_Z0BBO@/\ X+Z?\%]/A%_P6$^$
H7@#X;_#?X ^)/!T_@[Q)=:E<W.N:G;SI<)+;B((HB&001G)HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20210103_g4.jpg
<TEXT>
begin 644 jnj-20210103_g4.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /YK?VW?\ @W=_X*6_L1_LG^.OVL/%/_!4R\US
M3_ NAMJ5WI.GZOK,<UTBNJ[$9YMH/S=3Z5^2G_#6'[4W_1ROQ _\+*^_^.U_
M7]_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^
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M1\*CP[\4Y89=%O8A9F_T^=X8(?-B82VH.&>.3RR0!L!/V9_P5)_X*X?LX_\
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M^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH ****
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MY/7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M('_!?C_E#9^T)_V3^;_T=%7\85?V>_\ !?C_ )0V?M"?]D_F_P#1T5?QA4 ?
MO]_P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P7X_Y0V?
MM"?]D_F_]'15_&%7]GO_  7X_P"4-G[0G_9/YO\ T=%7\85 '[_?\&FW_*4S
M]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\@?\%^/^4-G[0G_9/YO_1T
M5?QA5_9[_P %^/\ E#9^T)_V3^;_ -'15_&%0!^_W_!IM_RE,_:[_P"WC_T^
M3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?('_!?C_E#9^T)_V3^;_T=%7\85?V>_\
M!?C_ )0V?M"?]D_F_P#1T5?QA4 ?O]_P:;?\I3/VN_\ MX_]/D]?O]7X _\
M!IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_F_]'15_&%7]GO_  7X_P"4-G[0
MG_9/YO\ T=%7\85 '[_?\&FW_*4S]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_
M^WC_ -/D]?O]0 4444 <A=_M"? /3_$FO^#;[XW^$(=8\*:8^I>*=*E\2VJW
M.CV:(LC7-U$9-]O$$96,D@50K YP163^S;^US^S'^V%X2O/'7[+GQU\,^/-)
MTZ_:RU"]\-:K'<K;7 &?+D"G*$@AAD#<I!&0<U\.?M<_ #XJ_M]_&[XS_P#!
M/GX _%CX=6G@K7?B%X<U;]I;Q#::O>Q>*]-TE],LQ'H*VZV?D2M<QZ>"ER+K
M"0R/$\(*EIOJG]F'X%^.?AG^T'XSUUO@;X/\ > ++P7X?\+_  \TWPMJ*RS7
MEM8S:C(\MW&D$:P!%N84@B#2;!YQ+YDVJ >_T444 %%%% !1110 4444 %%?
M%?\ P46_X)N>"_VD?A_\0/CI^T#^U]\3O#%]H6AWM]X-O_"'CB[T72O!D%M
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MU[[7E7[67[%'[,W[<?A+0? 7[4OPLT_Q=HGAWQ)'KEAI6IQAH6NT@G@4NO\
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M"%_X"_\ Y(/^(DT/^@9_^!+_ .1/K7_AY_\ L _]'3^%_P#O_)_\11_P\_\
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M10 4444 %%%% !1110 5^3W[,/\ R+'B7_L?]:_]*WK]8:_)[]F'_D6/$O\
MV/\ K7_I6]?;< _\CQ_X)?G$^&\0?^1"O\<?RD>DT445^S'XH%%%% !1110
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M_P!"!_Y5;3_X[1_PR9^T#_T('_E5M/\ X[1_;>2_]!-/_P #C_F']AYW_P!
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MU*.2X>%2+4E"*::LT[=4%%%%>4>L%%%% 'P/_P %)/\ D_GX7_\ 9/\ 5?\
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M/_*K:?\ QVC^V\E_Z":?_@<?\P_L/._^@6I_X!+_ "/.:*]&_P"&3/V@?^A
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M_P#1T5?QA4 ?O]_P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\
MT^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'R!_P7X_Y0V?M"?]D_F_]'15_&%7]GO_  7X_P"4-G[0G_9/YO\ T=%7\85
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M_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110
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M_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\
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B/&FAZAXZ\-OIMIJVH:Y:20VKLZ-O=4&XCY>@]:_"V@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20210103_g5.jpg
<TEXT>
begin 644 jnj-20210103_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XR?&WX/\ [/'P\O\
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M> =VTL #]#=8UC2_#VDW.NZW?QVMG9P--=7,S82*-1EF8]@ ":\)C_X*L_\
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M:^./B]XUT>XUN\M=5\0-IFD^'-(ACE<W5[<QV]S)YDGDLL4$<+%CM+M&K(S
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MC//%-+ ES:Z@EN&FM'EA93*;<.F5+18="WR5\(O^#GOXF?M(?LI_%O\ :7^
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M?VGJK>?$S,!(F)HCN7(_>+_>%1_\$&_B-\/?#G_!M+^W!H'B'QUH]A?FP\9
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MVJ:C ;'6?M&H0 1V\Q;:[M&DK(\;;OEW(> :_I.HH _G/_9-^*7Q._X-:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YY^T?^U9\
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M:_.#]+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM-/W::^%>O\ ,_-_*RT"BBBOJCY,**** "BBB@ HHHH **** "BBB@ HHHH
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MYJ,MW=WDO]O:B-\LTK,\C8 &6). *^V* "BBB@ HHHH **** "BBB@ HHHH
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M8.'+"/WM]6WU;ZO]#^2,WSC,,]Q\\9C)\TY?<ET271+HOU"BBBO2/,"BBB@
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M(7A'2-!^#NES-KVN_%C6_$$%I;:=J<45I&+&82LHCC-LTDYF8A5\O!/->_\
M_!S;_P $P_V<OVJOV*->_P""HOPD^(MV/&W@71;76=,UVP\737ND:WI/F1*4
MA0RO#"=C"6*6V"!V4!M^\,OW7\%_^"/7_!./]GO]FSQU^R%\)/V;8--^'7Q*
M8MXT\-W/B75+U=18QK'N\VZNI)H6"HF#$Z%64,,,,UA_LZ_\$4OV$_V9O"=O
M\-?!.A^-M5\&66JIJ5A\/_%GQ'U74O#UO=I*)DF_LR:<VLC"4+(/-C<"1%D
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M&^!GQC\9?L^?%_P[\:? %Z8-6\-ZI%>6OS$+*%/SQ/CJDB%HV'=78=Z_I/\
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MLK*TA6.*")%"I&B* %4   #@ 59HHK^?&W)W9_1:2BK(****0PHHHH ****
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M7[GP?B-P_#/N&:O*OWE).<'UT7O+_MZ-U;O;L?@-1117]9G\AA1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?@5IJ2;?$&MQ0WTL7WH;-?WES*/]R%)&_P" UCB<12PF'G7JNT8)MOLDKO\
M VPV'JXO$0H4E>4VHI=VW9+[S]K/^"*GP&F^!G[ OABYU2P,&I^,YYO$E\K+
MR4N-JVWO@VT<#8[%S7UE5?2=*TW0M*MM$T>RCMK2SMT@M;>)<)%&BA511V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUQ7U22^MPCV\4A=WM[B8,J@[986B/S;0?H/_ (-<OV$_VZO^";WPC^(WP/\
MVR?V5M5\)OXE\60:QI.NQ>*M"U"S,8M/*>-Q9W\LR.&C7'[L@^8.1@X^I_\
M@H5/^W5^U+\,_$7['_[%7PJF\(Q>+K2;1?$WQL\=7<5I8Z-I\H,5T=.LHY&O
MKRZ:,NL;M%!"I8.LQ(& #\XO^#(JQ\6#X>_M(ZRBSKX1N/%/A^+05;=Y8NTB
MU!KK;G^+RI+'=WQMSVKI?^#V_P <^)-+_8X^#?P[L99%TK6?B1=7VH!"0KRV
MM@Z0JV.#Q=2G![KGM7VSI7[#7Q/_ ."5?_!(;Q%^S?\ \$F/#-KK?Q.T31GO
M="N_$"0"77M9EEB%W?2B1EB,YA5_)C<[!Y,$1W*O/SS^V#_P3<_X*%?\%?\
M_@A=X2^'W[9NCZ)H/[3?AS57\1Z?:,UO;PW<T4EU!';7!MRT-O)<64H+!#Y:
MS"/<(P&" 'S/_P '$GC'6OAK_P %(?\ @GQX_P#!3E-9TH:5/;"%OF?9JNGE
M(R!U5LNN.A#,.:_?6OR>\;_\$[_VB?\ @I9_P4A_9?\ VE?C=^SWKOPT\#_L
M\^#+"Z\5Q>+[FR-QK/B."=;A+"SBM9YO-MXYXH6>X;;&Z;E3<:_6&@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI2FTE?;7ON<N-Q=/ X2>(J)N,$V[;V7;8]"HKXM_X:S_ &@?^A__ /*5:?\
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MJ21-@\HZJP/! - %NBBHH[VSENY+"*[B:>%%>:%9 716SM)'4 [6P3UVGTH
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M1X)'CR0KF.0!U# !AN .UAD#I0!I4444 %%>>?M/_M5_ K]C3X37OQT_:/\
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M(/$EMK-O97,NGR:A8^8;>4J^Z.<.R!G5/+)RMCX2_&C_ (* _M;>'-)_:O\
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M'?R^+-?C\#78N_!6D>+/&^HZM9:+="%X5N8HKJ9_,F2.21(Y9C(\0=A&4R:
M.X^.W@'P[\5O@CXQ^&'B^R2YTKQ%X6U#3-2@D0,)()[>2*12#URK&O%/^".'
MQN\?_M&?\$M_@9\8_BE>7%UXAU?X?62ZM?7;$RWLL -N;ER?O/*(A*3W,A/>
MNM\9?LT3^#OA3\1_ '[-\^HZ;K7Q;U[4+_6/$.M:]<7\6BWE_ D%Q?Q1W$S%
M%CCC#16D 6(RA%(B1GD7T'X)_![P'^SW\'?"WP)^%VD_8?#G@[P_::-H=H6W
M-':VT*PQAFP-S;4!9NK$DGDT =11110 4444 %%%% !1110 4444 %%%% '
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MB70@9]-F\<)K:3^>=0$"?Z(#E&D#AQMV]Z]]_:$_9]^.GQB_X*,_#KXKZ/\
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MX+Y_\H]-2_[&K2__ $8U?:=?%G_!?/\ Y1Z:E_V-6E_^C&KZ7@[_ )*K!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1E5U*.H((P01P15;0]"T3PSI,&@^&]&M=/L;5-E
MM96-NL44*_W510 H]@*M44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20210103_g6.jpg
<TEXT>
begin 644 jnj-20210103_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'W_ %F>,_&G@[X<^%-0\=_$'Q7INA:'I-H]UJNL:Q?1VUK9P(,M+++(0D:
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MO-8UF.*+5I)%5E,+$X9-KQDR?<42)EAN&?PA_P""PJJ?^#3/]CARHR/%_AH
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M#_$_PE8^/OAOXPTS7]#U.'SM.UC1KZ.YMKF/)&Z.6,E6&01P>H([5\M_L?\
M_!1?XW_M'ZU\)[[Q5^S=X4M?!GQ?\*7>MZ!X]\!_$Y]?L;&:&WCF.E78?3K5
MHKT!I05&Y ;:4;MRL@^<[7]HC4?^">/_  <=_P##'&GW31?"[]JKP9'XK@T9
M>+;1O%Z_;(I;F%>D9N_[//G!1^\FNHW)RIR ?J-1110 4444 %%%% !1110
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M,PE:,0 _=W2J&(S7]+EOING6EU/?6EA!%-=,IN9HX@K2D# +$#+8' ST%34
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M>L4JKN"J&8?T3UF^(_!OA#QC%!!XN\*Z;JJ6TOFVR:E8QSB*3^^H<':WN.:
M/QH_X+ >#?V"/@1_P;B_%3PY^PW\-8O 7@'QSX^T6^\(6]Y-=0GQ7/\ VCI1
MEU"TBOI#<&)H;1@N54/':F9%,<BR/\1?\%C?B+X \2?\&^'[!GASP_XVTJ^U
M&WL)Q<6%KJ$<DT7D6@AFW(IW+LE^1LCAN#S7]0P  P!10!^$O_!WA;2>*_@W
M^R'^T+X4(U7P1I'B&_\ [1\4:7_I-E"+J/2Y+=C-'N7$B6LY4Y^;RSC-?MC\
M&OC1\.OV@? %I\5/A+KAU;PWJ3/_ &1K*6[QP:C$IV^? 7 ,D+$'9*!MD W(
M60JQZ/4-.T_5K-]/U2QAN;>48E@N(@Z.,YY4\'FI5544(B@ #  ' % 'XU_&
MWP1K/PB_X/(OA)\0O%=NT6D?$OX67:Z!?L,1//!HNHV\D.[H7#6R_+U_?Q_W
MAGS+_@[J\<>"[3]M[]C/3KKQ;ID=QH?B+4+W6H)+Z,/86SZAHQ2:8$YB1A#*
M0S8!$;X/RG'ZQ_M[_L%^%_VT=&\&^+M(\3_\(I\3?A7XHA\2_"OQW%9BX;2-
M1C92T,\6Y3<65PJ+'/!N7>H!!#*I'M'@*Z\=7O@[3KGXF:+I>G>(&MA_:UGH
MFHR7=I',.&\F:2*)W0]06C5L'!&10!^&O_!>GXO_  I_XB'/V'=:'Q)T(V6B
M:IX9N]9O5U6(PV%O-X@66*:9PVV)&B(D#,0-A#YVD&HOA?\ $/P#+_P>U^.]
M5B\;Z0UK=:,FE6UR-1B\N:_3PAI\#VJMNPTRS1R1&,?,'C9<9!%?O-10 5_/
M/_P;1?M!_"3]D?\ 8N_:XUG]HGQEIOA%KVP'B+0K+Q1,MF^N:>EKJ,'FV23%
M3>*9XS#^YW?O"J?>8 _T,5DZEX!\"ZTFGQ:QX+TF[722/[+6YTV*06>  /*W
M*?+P%7[N.@]* /Y\?V)_V5?B#^QI_P &K/[2OQ$_:,MV\)WGQA5[[PKHNO/]
MEFELQ';06K>7+M82W#+,Z)C<\0C<9##'-:Q\2OATW_!E;I/@=?'FC'6AX\>T
M.D?VG%]J$_\ PELMUY7E;M^_[.1-MQGRR'^[S7])-% '\VW_  5N^)?PYU__
M (-4OV.O".A>/=&O=53Q?HF_3;74XI+A?LNBZS%<YC5BP\J2:)'X^1I4!P6&
M>E_X.7_C1\(_%_[*?[ \_A3XF:%J2II8U*3[!JD4ICM!::3&9V"L2J;XY$R<
M?-&Z]48#^B2B@#\3_P!OCX=WGP-_X.=/V:?^"C?CG7;-_@OXYT>/2M/\?-=H
MVDV.H'2]0M([:2YSY48D:>WFC9F"OYKE2?+?$G_!.?X9^)/VAO\ @YX_:6_X
M*$?#^^@N?A%X/TR?1;CQQ;RJ=,O]0&GZ?:&UAG!\N8Q_9YY9&4E4$2EL>8F?
MVBUK0]$\2Z7-HGB+1[6_LKA=L]G>VZRQ2#.<,C @\@'D4NC:+HWAW3(=$\/Z
M3;6%E;KMM[2S@6**)<YPJ* %&3V% '\Y'_!$;XO?"K0/'_\ P4WU[7/B3H5I
M9:GX1UN]TVZN-6A2.[MOM&LCSHB6Q(F9X!N7()FC'\:Y[_\ X('>-OV2H_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **P/B3\5OAG\'/#,GC/XK^/\
M1_#FE1'#W^M:A';1;NRAG(W,>RC)/85\3?M%?\'!G[)WPR\_1_@=X;UCXA:D
MF0ES$AT_3@W3F:93*W/]V(J1T:O8RKA_.L[GRX&A*?FE[J]9.T5\V>+FW$61
MY%#FQV(C3\F_>?I%7D_DC[XJOJ>JZ7HEC)JFLZE;VEM"N9;BZF6.-!ZEF( K
M\,_C9_P7B_;R^*AFLO!OB'1? MA(2JP^&]*5YRGHT]R9&#?[4?E_A7RE\1_C
M#\6?C#JIUSXL?$W7_$MX6)%QKNKS73+]#(QVCV& *_2<M\',XKI2QM>-)=DG
M-_/X5]S9^9YGXT9-AVXX&A.J^\FH+Y?$_O2/Z$/B9_P4K_8,^$;/%XU_:G\)
M>;&<2V^D7YU*9#Z-'9B5E/L17C'C+_@OW_P3Z\,;O[$U7Q?XBV]/[&\,F/=]
M/M;P_KBOPSHK[+"^#W#E))UZM2;]8Q7W*+?XGQ>+\9N)*K:H4J<%Z2D_O<DO
MP/V%UC_@Y)_9Z@9AX?\ V>/&=T ?D-Y>6D&?KM>3'ZUSEY_P<N>%DG*Z?^R!
MJ$L?9YO&R1MU]!:-VQWK\G:*]BGX7\&06M!OUG/])(\6IXJ<;3>F(2](0_6+
M/UCMO^#EOPDT>;O]D/44;/ C\:1N,?4V@_E72>'_ /@Y(_9UN0O_  E7[/?C
M6R/\7]GW5I=8^F]XLU^/%%%3PNX,FK*@UZ3G^LF%/Q5XV@[O$)^L(?I%'[E^
M"?\ @O[_ ,$^_%4RQZ[J?C#PTIQF36_#)D ^OV.2<_I7M7P]_P""D_[!OQ1E
MBM_"/[57@_S9\"&#5-3&GR.3T 2Z$;$^V,U_.517CXOP>X=JZT*M2#]8R7W.
M-_Q/:PGC-Q)1=J]*G->DHO[U)K\#^IW3=3TW6+&+4](U""ZMIEW0W%M*'21?
M564D$?2IZ_F"^&_QL^,?P=OO[2^$WQ6\1^&9RVYI-!UJ>T+'_:\IEW?0U]6_
M G_@O)^W3\)C#I_CG6='\?:='A6B\1Z>([D)Z+<6_EL6_P!J02=?ICXW,O!W
M.:"<L%7C579IP?\ [<OO:/M,L\9\EQ#4<;0G2?=-37_MK^Y,_="BO@G]G3_@
MX*_9.^*,\&B?&SPUJ_P[U"7 -U<9U#3MQXQYT*"1>>[1!1W:OMOX?_$KX>?%
M?PW#XQ^&'CG2?$.E3_ZK4=%U".YA8^F^,D9'<=1WK\VS7A_.LDGRXZA*'FU[
MK])*\7\F?IN4\0Y)GL.; 5XU/)/WEZQ=I+YHVZ***\<]D**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH *ZKX1_''XP? 3Q3'XT^#/Q)UCPUJ<9&;G2;UHO-
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M^79+LDM$NP4445Z!YP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>UNH'BEB<I)'(I5D8'!!!Y!![4ROVU--'X:TT[,**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^:_\
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M%%?R:?UV%%%% !1110 4444 %%%% !1110 4444 %%%% 'P;_P %:?"2Z?\
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M#XJ:;Y^F:O!A)XP/.LIUYBN86/W9$;!!Z$94@JQ!_GJ_;#_9%^*?[%GQJO\
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M5\2_M-17_;JN_P#TK\ HHHK\Y/TD**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>W3BOS"_:Z_X-XOB%X<N;KQ9^QWXVB\0:?RZ^%/$=PD%]'_L17&!%-[>9Y1
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M_43_ (.N9X;G_@B)\0[FWD5XY->\.,CJ<A@=6MB"* /JS_@F1^T-\0OVL_\
M@G_\)?VE?BO]A_X23QMX+M=5UD:9;&&W$\H)81H68JHZ $D^YKY?_P"#A?\
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M&R__ "@Y^!'_ &#];_\ 3_J-?=] !1110 4444 %%%% !1110 4444 %%%%
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M3HG[1FD?#SPYJVH6-WJ]Y+X!DUB[E-K-YR)&PU&V2-2ZQDY1SA2,_-Q]744
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P #^$_VD;OP5X,^)7C+6]*\<VK:?I#0RP6FC7%]"RSWMK(\#&:%8R0X!5R
M V#0!]@T5\5^._VI_B1KO_!8?X5?LW_";]J0W7P\\3?"_7O$'B+PYHD&C7<7
MVRPGM(H4^T&UDN(T=9Y&=?-!) VE0,5[G<_MX_LR67Q*\.?##4?&U[;7'C#Q
M#=:!X4UNY\/WL>D:MJ]OYOFZ?!J#1?9GN!Y,P5/,_>-#(D9=D90 >PT5XOX
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M)))QR37,?\/#?VPO^BO_ /EOZ?\ _(]?O&$X$XDK82G4BZ-G%-7G/JO^O1^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20210103_g7.jpg
<TEXT>
begin 644 jnj-20210103_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+;_\$U_$O[.O@OX=?\%-+GXI>'?#<WBI;WPGXV^'&G0SF#4D@F5[1_,$@!>
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M*10RNIC8$$'@@CM0!X&/^"P__!*$G'_#R/X'_P#ASM,_^/U[)\(OCO\  _\
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M7AS2V?5[:>)5>6U>RD*2"X5&#"/JZD&/>'3< >]45\;_ /!/_P#X+H?L.?\
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M_@F;\//%VOZ]XWNKZ[T[^W]+TA)-"CU&VBDEELC<F4.T@$4B[DB:+<NWS,T
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MNUCCTN9)8(;B7^VHVG+%,2.HBSN.U4XP ?7O[1OP%^"?P ^%WQ;_ &O?@3\
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MXM9;_2]2M@%5;I9+2&42;!_J) 5C<N9OVOKX?_8__P""2.O_  Y_X*->/O\
M@JU^U1X_\+:[\4_&.C1:1I>B^!/#TVGZ/HELD$%N\X-Q-+-<W,D=NBF1BH4/
M( #N79]P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <K\;O@G\+/VC_A
M)X@^!7QN\&VOB'PGXITV2PUW1KPL$N8'ZC<A#(P(#*ZD,K*&4@@&OG[X4_\
M!+-O@#X)TWX3_ 3_ (*#?M#>$_!6BVXM='\(0:_H6HVUC:@;4MH9]2TBYNXX
MD7"HJSC8  , #'U710!Y9^S'^QQ\#?V2X/$5W\+=(U&YU[QEJBZEXU\8>(]7
MFU+6/$%VJ;$EN[N=F=PB?+'$NV*)21&B D5ZG110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7U?5]*\/Z3=:]KN
MHPV=E8V[W%Y=W,@2.")%+.[L>%4*"23P *^+M _X*\^*_B/XDTWQM\$/V)O'
M_C'X6ZIX U/Q3I.NZ;-IT.L:UI]I>V]N;^QT^>[C>2W83,R12>7<RC:4B.5#
M?8/Q$\"Z!\4/A_KOPT\5Q2/I?B+1[K3-22&38[6]Q$T4@5OX3M<X/:OQ5^#G
MQJ_:'_X-WOVMO!_P#_X*!O=^/OV?=)\#ZEH7PS^,'A;2VEN?#NC7.JV4BC6+
M= 66.&98H@1D@3@1M. L: '[(Z!\<O!7BCX%:1^T/X=L]9U#0-=\.V>M:7#I
MNAW%U?3VUU%'+"%MH$>0N5D3*@';R6("DCS?_@G=_P % OAE_P %)?@AJGQ]
M^$?@GQ%H.C:?XRU#P]':>*K6."]DDM#&'D>)'?RLL^ A8L-OS8/ ]:^%5]\.
M=3^&'AS4/@]J&FW?A*;0K1_#%SH\ZRVDNGF%?L[0NI(:,Q;"I!(*XKX0_P"#
M:;_DR7XC_P#9R'C7_P!*XZ .Z_: _P""S^E?!WX]^*O@1\,_^"=O[2_Q@_X0
MZ\BL=:\6_"?X;KJ>C)>M!'-):+<F= \T0D59% ^1P5/(->C_ /!/'_@HUX=_
MX*&Z7XZOM!_9L^)WPVN/A]XECT'7-,^)^BV]A=_;S;I</"(HIY65HXY8&8.%
M(\], Y./7OBK\0?AU^S1\%/%OQD\2V]MI?ASPCHFI^(]<-K"D:B.));RZEP,
M N[>8['JSN2<DDUXO_P2.^$7C'X8?L.>&O%?Q6LO)\=_$Z]OOB%X_P!V=XU;
M6[A[^2%O>".:&U [+;*.U 'K7[1GQ_T+]G/X?#QEJ'@WQ#XHU*]O4L/#GA'P
MEIXNM4UR_=7=;:VC9D3=LCDD>21TCCCBDDD=41F'@'[&G_!6WPY^TM^U/K_[
M#OQI_9>\?_!7XM:+X='B"T\*^.DMI8]7THR",W-I<VTCQR[78!@..&VLQCD"
M?6U]B*!KY-.:ZEMT9X88PGF,VT_*A<A03TY('/) K\S?A3^U>E]_P<#KX:_;
M>_8T\2_"_P <^(_A=/X8_9XUZ_URSU#3M6TJWFEU#4"\EKN1+R4@' D<11PK
M$0CREI@#].**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J/B;Q/X:
M\%>';WQ?XR\0V.D:3IEJ]SJ6J:G=I;V]I"@+/+)(Y"QHH!)9B  ,FKU?'/\
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MO_M%?.=%'^IO#?\ SX_\FG_\D'^NO$W_ #__ /)8?_(GT9_PW]_U2;_RO?\
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MS_\ _)8?_(GT9_PW]_U2;_RO?_:*/^&_O^J3?^5[_P"T5\YT4?ZF\-_\^/\
MR:?_ ,D'^NO$W_/_ /\ )8?_ ")]&?\ #?W_ %2;_P KW_VBC_AO[_JDW_E>
M_P#M%?.=%'^IO#?_ #X_\FG_ /)!_KKQ-_S_ /\ R6'_ ,B?1G_#?W_5)O\
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M\6T4?\0^R7_GY4^^/_R ?\1%SO\ Y]T_NE_\F?:7_#6?[/W_ $/_ /Y2KO\
M^-4?\-9_L_?]#_\ ^4J[_P#C5?%M%'_$/LE_Y^5/OC_\@'_$1<[_ .?=/[I?
M_)GVE_PUG^S]_P!#_P#^4J[_ /C5'_#6?[/W_0__ /E*N_\ XU7Q;11_Q#[)
M?^?E3[X__(!_Q$7._P#GW3^Z7_R9]I?\-9_L_?\ 0_\ _E*N_P#XU1_PUG^S
M]_T/_P#Y2KO_ .-5\6T4?\0^R7_GY4^^/_R ?\1%SO\ Y]T_NE_\F?:7_#6?
M[/W_ $/_ /Y2KO\ ^-4?\-9_L_?]#_\ ^4J[_P#C5?%M%'_$/LE_Y^5/OC_\
M@'_$1<[_ .?=/[I?_)GVE_PUG^S]_P!#_P#^4J[_ /C5'_#6?[/W_0__ /E*
MN_\ XU7Q;11_Q#[)?^?E3[X__(!_Q$7._P#GW3^Z7_R9]I?\-9_L_?\ 0_\
M_E*N_P#XU1_PUG^S]_T/_P#Y2KO_ .-5\6T4?\0^R7_GY4^^/_R ?\1%SO\
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M3O\ K[N?_1K5\1Q__P B2/\ C7Y2/NO#W_D>2_Z]R_.)ZA1117XT?M04444
M%%%% !1110 4444 %%%% 'Q'^TW_ ,EV\1?]?:?^BDK@Z[S]IO\ Y+MXB_Z^
MT_\ 125P=?T9E'_(IP_^"'_I*/YLSC_D;XC_ *^3_P#2F%%%%>@><%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?H=H7_(#L_^O2/_ -!%6JJZ%_R [/\ Z](__015JOYFJ?Q'
MZG]0T_X:] HHHJ"PHHHH *^:?V^/^0YX;_Z]+G_T*.OI:OFG]OC_ )#GAO\
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M/^-?E(^Z\/?^1Y+_ *]R_.)ZA1117XT?M04444 %%%% !1110 4444 %%%%
M'Q'^TW_R7;Q%_P!?:?\ HI*X.N\_:;_Y+MXB_P"OM/\ T4E<'7]&91_R*</_
M ((?^DH_FS./^1OB/^OD_P#TIA1117H'G!1110 4444 %%%% !1110 4444
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MO2/_ -!%6J_F:I_$?J?U#3_AKT"BBBH+"BBB@ KYI_;X_P"0YX;_ .O2Y_\
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M:U?$<?\ _(DC_C7Y2/NO#W_D>2_Z]R_.)ZA1117XT?M04444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ\/?^1Y+_KW+\XGJ%%%%?C1^U!1110 4444 %%%% !1110 4444 ?$?[3?\
MR7;Q%_U]I_Z*2N#KO/VF_P#DNWB+_K[3_P!%)7!U_1F4?\BG#_X(?^DH_FS.
M/^1OB/\ KY/_ -*84445Z!YP4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^AVA?\@.S_Z](_\
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M(_VF_P#DNWB+_K[3_P!%)7!UWG[3?_)=O$7_ %]I_P"BDK@Z_HS*/^13A_\
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MS_Z%'7TM7S3^WQ_R'/#?_7I<_P#H4=?5<%_\E%2])?\ I+/D^-_^2;K>L?\
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M9K17LI/HME\O3HYGA:;@I.4E3J>T3:2<KJ/,GJ[7<5K=[OKOL_LQ>#I?@O\
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M.+PE; J"C^\]W6W;GYFWN^9N+^5NBOTE%%%>J>2%%%% !1110 4444 %%%%
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MH_FS./\ D;XC_KY/_P!*84445Z!YP4444 %%%% !1110 4444 %%%% !117
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MCR<%CS5OX4?!30/A#JOBS5]$\3^(=1D\8>)I]<OX]=U=[J.TFE55,-LK ""
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MTY9>,@'_  3;_P"";?VC[!^T-^T-H'[OY;CPSX9O(OO]TNKA#VZ%(SUX9N,
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MM7Q''_\ R)(_XU^4C[KP]_Y'DO\ KW+\XGJ%%%%?C1^U!1110 4444 %%%%
M!1110 4444 ?$?[3?_)=O$7_ %]I_P"BDK@Z[S]IO_DNWB+_ *^T_P#125P=
M?T9E'_(IP_\ @A_Z2C^;,X_Y&^(_Z^3_ /2F%%%%>@><%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?H=H7_(#L_\ KTC_ /015JJNA?\ (#L_^O2/_P!!%6J_F:I_$?J?U#3_
M (:] HHHJ"PHHHH *^:?V^/^0YX;_P"O2Y_]"CKZ6KYI_;X_Y#GAO_KTN?\
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MAO\ Z]+G_P!"CKZ6KYI_;X_Y#GAO_KTN?_0HZ^JX+_Y**EZ2_P#26?)\;_\
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MD)T[_K[N?_1K5\1Q_P#\B2/^-?E(^Z\/?^1Y+_KW+\XGJ%%%%?C1^U!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3#_B'62?\_*GWQ_^0/S:_P"&E?V>O^BV^%?_  >P?_%4?\-*_L]?]%M\*_\
M@]@_^*K])?\ A1GP2_Z([X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV_P#B*/\
MB(.=?\^Z?W2_^3#_ (AUDG_/RI]\?_D#\VO^&E?V>O\ HMOA7_P>P?\ Q5'_
M  TK^SU_T6WPK_X/8/\ XJOTE_X49\$O^B.^%?\ PGK;_P"(H_X49\$O^B.^
M%?\ PGK;_P"(H_XB#G7_ #[I_=+_ .3#_B'62?\ /RI]\?\ Y _-K_AI7]GK
M_HMOA7_P>P?_ !5'_#2O[/7_ $6WPK_X/8/_ (JOTE_X49\$O^B.^%?_  GK
M;_XBC_A1GP2_Z([X5_\ ">MO_B*/^(@YU_S[I_=+_P"3#_B'62?\_*GWQ_\
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M%'_"C/@E_P!$=\*_^$];?_$4 >6?\/2/^"?/_1UGA7_P(D_^(KP[]KK]N?\
M8_\ BAJNB7/@;]HOPK?)9V\ZW#?VFL6PLR$?ZS;GH>E?8G_"C/@E_P!$=\*_
M^$];?_$4?\*,^"7_ $1WPK_X3UM_\17H97F5?*<;'%44G*-][VU5NC7?N>=F
MN6T,WP,L+6;496VM?1I]4^W8_-K_ (:5_9Z_Z+;X5_\ ![!_\51_PTK^SU_T
M6WPK_P"#V#_XJOTE_P"%&?!+_HCOA7_PGK;_ .(H_P"%&?!+_HCOA7_PGK;_
M .(KZO\ XB#G7_/NG]TO_DSY+_B'62?\_*GWQ_\ D#\VO^&E?V>O^BV^%?\
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M  >P?_%4?\-*_L]?]%M\*_\ @]@_^*K])?\ A1GP2_Z([X5_\)ZV_P#B*/\
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M[X5_\)ZV_P#B*/\ B(.=?\^Z?W2_^3#_ (AUDG_/RI]\?_D#\VO^&E?V>O\
MHMOA7_P>P?\ Q5'_  TK^SU_T6WPK_X/8/\ XJOTE_X49\$O^B.^%?\ PGK;
M_P"(H_X49\$O^B.^%?\ PGK;_P"(H_XB#G7_ #[I_=+_ .3#_B'62?\ /RI]
M\?\ Y _-K_AI7]GK_HMOA7_P>P?_ !5'_#2O[/7_ $6WPK_X/8/_ (JOTE_X
M49\$O^B.^%?_  GK;_XBC_A1GP2_Z([X5_\ ">MO_B*/^(@YU_S[I_=+_P"3
M#_B'62?\_*GWQ_\ D#\VO^&E?V>O^BV^%?\ P>P?_%4?\-*_L]?]%M\*_P#@
M]@_^*K])?^%&?!+_ *([X5_\)ZV_^(H_X49\$O\ HCOA7_PGK;_XBC_B(.=?
M\^Z?W2_^3#_B'62?\_*GWQ_^0/S:_P"&E?V>O^BV^%?_  >P?_%4?\-*_L]?
M]%M\*_\ @]@_^*K])?\ A1GP2_Z([X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV
M_P#B*/\ B(.=?\^Z?W2_^3#_ (AUDG_/RI]\?_D#\VO^&E?V>O\ HMOA7_P>
MP?\ Q5'_  TK^SU_T6WPK_X/8/\ XJOTE_X49\$O^B.^%?\ PGK;_P"(H_X4
M9\$O^B.^%?\ PGK;_P"(H_XB#G7_ #[I_=+_ .3#_B'62?\ /RI]\?\ Y _-
MK_AI7]GK_HMOA7_P>P?_ !5?2O[-G_!13]A[P!\)K+PSXM_::\*VE]%<3M)!
M]N,F TA(Y0$=#ZU](?\ "C/@E_T1WPK_ .$];?\ Q%'_  HSX)?]$=\*_P#A
M/6W_ ,17E9QQ5F&=858>O&"2:?NIIW2:ZR?<];)N$\NR/%O$4)S<FFO>::LV
MGTBNQY9_P](_X)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\ X$2?_$5ZG_PH
MSX)?]$=\*_\ A/6W_P 11_PHSX)?]$=\*_\ A/6W_P 17S)]0>6?\/2/^"?/
M_1UGA7_P(D_^(KW32=5T_7=+MM;TB[2>TO+=)[6>/[LD;J&5A[$$'\:Y[_A1
MGP2_Z([X5_\ ">MO_B*Z:"""U@2UM84CBC0+''&H"JH&  !T ':@!]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45X1\7O^
M"GW_  3P^ 7QBB_9^^-'[9WP[\,^,I'C230-7\300S6S. 46?+;;8L&4@2E"
M0P(X(KW%]1T^/3SJTE]"MJL/G-<F4",1XW;]W3;CG/3% $U%>9?![]L[]E3]
MH'Q3)X*^"_Q[\->(]46R>]@L],U%7:\M$<1O=6QX%W;JY53-"7C#,H+ L,U_
MVH?VY/V0/V*M+T[6/VK?VC/"?@.+5Y&328_$.K)#->E<;S#%S)(%W+N95(7<
M,D9% 'JM%<W\)/C%\*/CW\/].^*_P2^(^B>+?#.K1F33=>\/:G'=VMP 2K;9
M(R5)# J1G*D$$ @BN2\0_ML?LE>$_BM_PI'Q'^T)X7L_%"ZA;Z?/I<VJ(#;7
MLX!M[.:3_5P7,H9?+@D99)-Z[5;<,@'J-%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 445Y5^U#^W)^R!^Q5I>G:Q^U;^T9X3\!Q:O(R:3'XAU9(9KTKC>88N9)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20210103_g8.jpg
<TEXT>
begin 644 jnj-20210103_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *FOZ_H7A30[SQ-XHUJTTW3=/MGN;_4
M+^Y6&"VA12SR22.0J(J@DL2  "37R9H?_!=/_@G#X\\9ZCX)^"OQ(\8?$N31
M9=FN:E\+?A/XA\26&GGKE[G3K&:-E(R0T9<$#K7Y4_\ !X-_P4 ^+GC'X_\
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M;/CIH7C&\T/3K:\UVUT>YWRZ6L\MQ%'%=1D![:??:S@P2JDJ[/F49&?Y\/\
M@AE_P7<M/^"-^M>.OV!_^"B7P7\0V-I/\1+S4M:\3V=L9M6T;5Y%BM[I;Z!F
M#741,".)4)D7YL+,'79^Y'[%7A#]C_XP?'GQK_P4K_8L^)WAKQ!H7QA\*:/I
MOB6?PR%V7FI:;+>,MU..'BN?)O$ADCD59!Y*;ESF@#Z>K)\=>-=!^''@_4?'
M7BC[;_9VE6S7%Z=.TJXOIEC7[Q6"VCDEDP.2$1C@$XP#7Q3H/_!9WQ#^TO\
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MR?LQ:A^Q]\ _@]9>%_ >KZ==VFJZ;IT\IFO1=0F&>6:Y=FFFF:,[?-=RP"J
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M_LB_%3]D23]A+QW\'[?4/A:=-BL8/#-QJ%R_V6*)P\)AG:0S1-&RJ497!3:
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MVH_"F^NCYMI<S6T5F=2TRY"99=\<EI*0H,J"#S KJCHWT?\ MV?\$L?V&O\
M@I)#X?;]KKX+)X@O?"TSOH&L66K76G7UF'*EXQ/:R1NT;%0=C$J"-P ;FF_$
MG_@EG^Q/\4?!7@#P#K/PSU+3;#X6SW=UX F\-^+M2TR\T:^N2K2WZ7=K<)</
M=,RES-)([.\DC.79R: /R^_X-P_VHO\ @HC\ ?V^_%O_  1D_;\TBZUBX\ >
M"KJ^\-:CJTRWM[X>MTDLF$$-X"3+IUQ%+ Z L0C1P*H491?V?^-WC75?AK\%
M_%_Q&T*WMY;[0/"^H:E9Q7:,T3RP6TDJ*X5E)4LH! (.,X(ZUYS^S#_P3Z_9
MP_90^(OBSXU^ ]-UW6O'_CI8(_%GQ \:^([G6-9U""%56&W-Q<,QCA140"*,
M(OR)D'8N/6O&_A#1OB#X+U?P%XC21M/US2[C3[]89-CF&:-HW"MV.UC@]J /
M@WXD_L!_\$O/^#B;]D'P7^UEXO\  MK'K?BOPO;RV?C_ ,'7"6VM:3<A-LUC
M-*%9;@V\PDB,-PLBJ4;;MSNK\^?^"!_[*?[47_!.'_@NQ\>O^"=/@SXH2>(?
M">B?#N>?7]7MXV2Q=Y([.XTF]EAW,L5VHNQ&4R2 ]P 64;J_67X>?\$=?V-?
M@/IJZ7^RFOCKX/0O;1PZE#\,OB#J.G0:GL0(LMS;F5X)KC:.;@Q^<>[FO4OV
M6OV*_P!G+]C;2-;L/@1X$>SO_%.IG4O%WB75M4N-2UCQ!>G.;B]OKN22>Y?+
M.0'<JF]MH4$B@#\7_P#@RO\ #'B+X>_&G]K+X=?$RQO+#Q;I%QX;L]7TZ^/[
MZ&X@N-9CNEDR=V]9=JGW)SVK-_X,S/#'CC4OVI?VFOBOI9F_X0M[:RLIKK!$
M%S?/?7,T&TGAF2$3$XY43KG&\9_7#XM_\$F?V0/BE\<=?_:3T?3O%?@/QSXP
MT=M*\:^(OAIXSO=#E\16;!08KQ+9Q'*V%'[W:)>!\_ QW/P,_80_95_9F_9K
M?]DC]G_X7?\ "'>!9HI5N+#PWK-Y97<[R "2=[Z&9;MIV"J#-YOF;5"[L
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MKGQUX'\4:I\4/B%%\:O,NWCETR>)GAM19?ZJTLU2&WMO,XCMT!=G9Y&^F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVR:X^R6D*!(X_-G=Y),* -SLS'N37444 %%%% !1110 4444 %%%% !1110
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MEO:S:WYEV['P.=<<?V/F=3"?5^;EMKSVO>*>W*^]MS]&**_.>BO3_P"(<?\
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M **** "BBB@ HHHH **** "BBB@#Z,_8!_YFW_MP_P#;BOHROG/]@'_F;?\
MMP_]N*^C*_"N,O\ DI*__;O_ *1$_>^"O^29H?\ ;W_I<@HHHKY@^I"BBB@
MHHHH **** "BBB@ HHHH ^<_V_O^92_[?_\ VWKYSKZ,_;^_YE+_ +?_ /VW
MKYSK]UX-_P"2;H?]O?\ I<C\$XU_Y*:O_P!N_P#I$0HHHKZ<^6"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *^C/V ?^9M_[</_ &XKYSKZ,_8!
M_P"9M_[</_;BOF.,O^2;K_\ ;O\ Z7$^IX*_Y*:A_P!O?^D2/HRBBBOPH_>P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG/\ ;^_YE+_M_P#_
M &WKZ,KYS_;^_P"92_[?_P#VWKZ?@W_DI*'_ &]_Z1(^6XU_Y)FO_P!N_P#I
M<3YSHHHK]U/P0**** "BBB@ HHHH *X']H[]H[X<?LP_#BX^(OQ%U':JYCT[
M3H6'GZA/C*Q1J>I[ENBC)-;WQ5\?1_"WX<:U\19?#NH:LNC:?)=-IVE0>9//
MM&=JK^I/8 GM7XP_M+?M+?$?]J3XCS_$'X@WVU1F/2M*A<^1I\&<B.,'OT+,
M>6/)[  '[ ?LX_M'?#C]I[X<6_Q%^'6H[E;$>HZ=,P\_3Y\9:*11T/<-T88(
MKOJ_$']FG]I;XC_LM_$>#X@_#Z^W*<1ZKI4SGR-0@SDQR =^I5ARIY'<']C?
M@1\6+GXV_#2P^(]S\/M9\,_;P3'IFO0".?9VD [HW53QD8..: .QHKG_ (:^
M.Y_B)X=?Q!<>"-<T K?3VZV/B"R$%PXC<J)0F3\CXRI/)'.*/AKX_P#^%D>'
M7\1#P5X@T$)?3VPLO$NF_9;AO+<KYHCW-^[;&58XR,' H Z"BN?^&OQ!@^)?
MAU_$=MX4US1T2^GMA:>(-.-K.WEN5\P(23L;&58]1SBCX:_$.P^)WAQ_$NF^
M'M8TR);V>V%OKFGFVF8Q.4+A"2=C$94]QS0!T%%<_P##7XCZ+\4O#C^)]!T[
M4K6!+V>U,6JV+6\I>)RC'8W.TD<'N.:/AK\2_#7Q7\.-XJ\*+>"T6]FM?].L
MG@<O$Y1B%< [<@X/<<T =!17/_#7XF^$_BUX;;Q7X+N+B6R6]FM2]S9R0,9(
MG*/\L@!QN!P<8/:CX:_$_P %_%SPVWBWP'J4EW8+>S6IFEM)(3YL3E'&V15.
M P(SC![9H ^K/V ?^9M_[</_ &XKZ,KY3_X);_%+P)\7_#?B[Q=\.M=_M'3E
MO;>T-Q]EEA_?0O<I(NV55;A@1G&#V)KW[X)_'?X3_M%^"W^(?P9\7)K>C)J5
MSI[7T=I-"/M-O(8IDVS(C':ZD9Q@XX)%?AG&,)OB'$22T7)=]-81M]]F?O/!
M<X+AS#P;U?/9=7:<K_==?>==17*?!KXX?"K]H+P<WQ ^#GC"'7-'74;FQ:^@
MADC7[1!(8YH\2*IRKJ1G&#C@FI/A)\9?A?\ '?PB?'GPB\96FNZ0+ZXLS?6>
M[8)X)#'+'\P!RKJ5/':OFI4:L+\T6K:/39]GVV/IXUJ,^7EDGS*ZUW7==UJC
MIZ*YWX7_ !;^&GQJ\+GQK\*/&MAK^DB]GM#?Z;-YD8GA<QRQY_O*X*D=B*?\
M-_BG\./C#X;/C#X6>-]-\0:4+R:U.H:3=K-$)X7*2Q[E)&Y6!4CL12E2J1O>
M+5M'IL_,<:M.5N62=]5KNNZ-^BL/X??$SX=_%GP^?%GPP\<:3XATL7<UJ=0T
M:_CN81-$Y26/?&2-R,"K#.01@T_P+\1?A]\4-"/BCX:>.M&\1:8+F6V.HZ%J
M<5W )HF*21^9$S+O1@59<Y4@@X-#ISC>Z>F_D"J4Y6LUKMY^ALT5D^#?'G@?
MXC:,?$?P]\9Z3KVGBXD@-_HVHQ74/FQL5DCWQ,R[E8%67.01@U)X4\9^#_'F
ME'7O _BO3=9L1/)";W2;^.XB\U&*NF^,D;E8$$9R",&DX3C>ZV&IPE:SWV-*
MBJ/A[Q/X:\7::-8\)^(;'5+,R/&+K3KM)X]ZG:R[D)&0001V(J72=:T;7[3^
MT-"U:UO8-[)Y]I.LB;E.&7*DC(/!':DXR6Z&I1>S+-%0V&HZ?JD'VK3+^&YB
MW%?,@E#KN!P1D'J#3X+FWNH_-M9TD7)&Z-@1D=1Q19H=TSYV_;^_YE+_ +?_
M /VWKYSKZ,_;^_YE+_M__P#;>OG.OW3@W_DFZ'_;W_I<C\$XU_Y*:O\ ]N_^
MD1"BBBOISY8**** "BBB@ HHHH **^ _^"DG_!23[-]O_9Y_9YU_][\UOXF\
M36<OW.SVMNX[]0\@Z<JO.2#_ ()M_P#!23[3]@_9Y_:&U_\ >_+;^&?$UY+]
M_LEK<.>_0)(>O"MS@D ^_**** "BBB@ HHHH **** "OHS]@'_F;?^W#_P!N
M*^<Z^C/V ?\ F;?^W#_VXKYCC+_DFZ__ &[_ .EQ/J>"O^2FH?\ ;W_I$CZ,
MHHHK\*/WL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYS_ &_O
M^92_[?\ _P!MZ^C*^<_V_O\ F4O^W_\ ]MZ^GX-_Y*2A_P!O?^D2/EN-?^29
MK_\ ;O\ Z7$^<Z***_=3\$"BBB@ HHHH **** "OS[_X*2?\$V_L_P!O_:&_
M9YT#]W\UQXF\,V<7W.[W5N@[=2\8Z<LO&0/T$HH _/O_ ()M_P#!-O[1]@_:
M&_:&T#]W\MQX9\,WD7W^Z75PA[="D9Z\,W& ?T$HHH **** "BBB@ HHHH *
M*** /HS]@'_F;?\ MP_]N*^B8+:WM8_*M8$C7).V-0!D]3Q7SM^P#_S-O_;A
M_P"W%?1E?A7&7_)25_\ MW_TB)^]\%_\DS0_[?\ _2Y$-AIVGZ7!]ETRPAMH
MMQ;RX(@B[B<DX ZDU%HV@Z'X<M#I_A[1K2P@:5I6@L[98D+L<LV% &2>2>I-
M6Z*^9NSZBR*'AOPIX7\&Z:=&\(>&[#2K,S/*;73;-((_,<[G?:@ W,223U).
M33/"G@SP?X#THZ#X'\*:;HUB9Y)C9:381V\7FNQ9WV1@#<S$DG&23DUI44W*
M3O=[B4(JUEL9/@WP'X'^'.C'PY\/?!FDZ#IYN))S8:-IT5K#YLC%I)-D2JNY
MF)9FQDDY-,\"_#KX??"_0CX7^&G@71O#NF&YEN3IVA:9%:0&:5B\DGEQ*J[W
M8EF;&6)).36S10YS=[O??S!0@K66VWD8?P^^&?P[^$WA\^$_AAX'TGP]I9NY
MKHZ?HUA';0F:5R\LFR, ;G8EF.,DG)IGPW^%GPX^#WAL^#_A9X(TWP_I1O)K
MHZ?I-HL,1GF<O+)M4 ;F8EB>Y-;]%-U*DKW;UU?GZB5.G&UDM-%Y+R.<^%GP
MA^&?P2\+MX*^$W@NQT#27OI[UK#3X]D?GS.9)9,>K.2Q]S47PA^"WPN^ OA$
M^ _A!X-MM"TAK^XO38VC.4-Q/(9)9/G8G+.2QYQS7444Y5:LKWDW?5Z[ON^^
MXHTJ4;<L4K:+39=EVV1RGP:^!_PJ_9\\&GX??!SP?#H>CMJ%S?&Q@FDD4W$\
MAEFDS(S-EG8G&<#/ %,^"?P(^$_[.G@D_#KX,>$4T31FU&YOS91W<TP-Q<2F
M6:3=,[M\SL3C.!G@ <5UU%$JU:?-S2;YG=Z[ON^[U?WBC1HPY>6*7*K+1:+L
MNRT7W'R%^T5\ /A)^S7X&\*?#;X*>$O[%T5M3UG4#9?;[BY_TFXE@EF??/([
M_,[$XS@9P !Q7@GPT^&'@OX1>&CX1\!Z9):6!O)KHQ2W<DQ\V5R[G=(S-RQ)
MQG [8KZL_;^_YE+_ +?_ /VWKYSK]SX0G.KP]1G-W;Y[MZM^_(_!N,:<*7$=
M:$$DER62T2]R)S_PT^&7A/X2^&CX3\%V]Q%9&\FNBMS>23MYDKEW.Z0DXW$X
M&<#H*/AI\-?#OPI\-'PIX7GOI+4WDUR#J%Z]Q('E<NP#.<[<DX'8<5T%%?2G
MS)S_ ,-/ASI'PM\-'PMHNK:I>P&\FN?.U>_:XFW2N7*[VYV@G '8<4?#3X>6
M'PP\-'PQIWB'6-3C-Y-<_:=<U W,^9'+E=Y ^0$X5>PP*Z"B@#G_ (:?#Z#X
M9^&CX9MO%>N:RIO)KC[9XAU$W5QF1RY3>0/D7.%7'  %'PU\ ?\ "MO#1\-_
M\)KX@U_-Y-<?;_$NI?:KD>8Y?R]^U?D7.U5QPH YKH** .?^&G@2?X=>&CX=
MN?&^N>(&-Y-/_:'B&]$]P!(Y81[@!\BYVJ,<  5S]W\#=3O?@GK?P>O/C#XH
MGFUB.Z5?$L]XK7UL)F+!48 ?(@.T#@[>,CK7H%% 'X>_M'?LX_$?]F'XCW'P
MZ^(NG889DT[485/D:A!G"RQL>W8KU4\&C]G']G'XC_M/?$>W^'7PZT[+'$FH
MZC,I\C3X,X:61AV[!>K'@5^P'[2O[-7PX_:D^'$_P^^(-CAAF32M5A0>?I\^
M,"6,GMV93PPX/8@_9J_9J^''[+?PX@^'WP^L<L<2:KJLR#S]0GQ@RR$=NRJ.
M%' [D@'1?"KP))\,?AQHOP^E\4:AK3:1I\=LVJZK)OGN=HQN8_H!S@ #)QD]
M!110 4444 %%%% !1110 5]&?L _\S;_ -N'_MQ7SG7T9^P#_P S;_VX?^W%
M?,<9?\DW7_[=_P#2XGU/!7_)34/^WO\ TB1]&4445^%'[V%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5\Y_M_?\RE_V_\ _MO7T97SG^W]_P R
ME_V__P#MO7T_!O\ R4E#_M[_ -(D?+<:_P#),U_^W?\ TN)\YT445^ZGX(%%
M%% !114&IWDFGZ;<7\-A/=/! \BVML%,DQ4$A$W$#<<8&2!D\D4; E=D]%?$
MG[6/[0O_  4M_9#TO2_VH/%S?#G7? \GB2QL?$7PVT72KG[?IUM=3K#&(;YI
M/]*G#.B%O+1"[ B,KG'VS--#;PO<7$JQQQJ6=W; 4#DDD]!7'A\;#$5)T^5Q
ME&S::MH[V:\G9^:MJD=F)P53#4H5.92C*Z3B[ZJUT_-77D[Z-CJ*^3?V:_V[
MOB'^T/\ \%!_%GP4LM M['X<:?\ #6'7?"-S+!_I6L![U85U'=G*02@N8DQ\
MT7ER'&_ ^LJO"XNCC:;G2V3:^[].Q.+P=;!5%"KNTG]ZO]_<**^6_P#@JG^W
M'XT_8Y_9[UG6/@EHMOJGC6'38[\FZC$EOHNGFZBMC?7"Y&[=+*D,4><N[,P!
M6&7'1_M+?M/>-_AW)\&?A?X%-I!XE^+WB>WTS^U[NU\V+3;1+8W-Y<)'D!Y=
M@"1JQVAI-S!@FQL:F986G5G3;=X*+?\ V\VHI>;:-J>68JI2IU$E:;DE_P!N
MI.3?DD[]_(^@:*\+_8W_ &B_&?Q9\7?%7X+_ !+DM;K7_A7XX;1WU>RM?)34
MK&:%9[2=XP2$FV,R2!<*63<H4-M7K?A%\3?%/QB\?>(/%>A301^ -*=](T*8
M0@R:W?Q2E;N]1^UM&Z_9X\?ZQTG?E/*)UI8NE6A&4?M-JW72Z=_1JS\_5&-7
M!UJ,Y1G]E)WZ.Z35O5.Z6]K]F>CT445U'*%%%% !1110!]&?L _\S;_VX?\
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M;;5DXIJ*U6NKT=GY(_-W]MO]L_X$>._^"=/Q5T34'\6W7Q0^(PTV\\07EYX
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MIK3=IVNKZVN?4WQ \"_#7Q7]@\3_ !+TJPO+7PW))?VAU8JUK:R^65-RR/\
M)O1"X61AE [X(W&OD#]AK5_V2_B[_P %,OC+\<_V9_B+H<(@\*66@:CX5TNV
M>V?4[J.99+G5_*9$#1JPAMA(@;<XE9L!T:3W_4?C]\"_V*/AU\-/A5^TO\;M
M+T/4;_1K?1].U76'DCM[^YM+:%)G:=E\N$$LK;I60'?U)S7D]G\.?AU\<_\
M@J)X/_:H_9XN=.OM,\*^!-5LOB!XNT*1)+'5;B<I'8V(GB.RYGC!GEDP6,:I
M"KE28Q6>-E&IB*+ARN49Q<H_:5U:]T].5.[NM4B\#&=/#5U/F490DHR^P[.]
MK-:\S5E9Z-[7/KB\O+73K.74+Z=8H((VDFE<X5$49))] !FOS=_9=_;(T/XL
MZYXU_P""G_Q[^$7Q"\3:+I6K7FG?#F#1/"SW=AX-\/0?++?*)&16N)B'-Q-"
M)'C6$J2B':/M2U_:"^"/QP^*?Q#_ &.] \5W+>*_#&B1+XGM!I\R+;0WL&49
M)64)(0DB$A6X+#T./G'_ ()A>/OAW^RO^Q-J7[)G[4&MZ5X<\1_"74M8L?%6
MD:Q.J-?V=Q>7%U!=P1OAKF">.XV1E WF%2HRW%1CZGUC&T5"HE!*;ONO:1LD
MGTNO>=O)]5=:9?2^KX*LYTVZC=-6U3]G*[;6E[/W5==&NCL^@_:U\9Z-\<+G
M]F;]K/X6^(5U[X6:3\2HM6U[5+)6,%M!-:S6]O?SJ0#$D$S,DC. 82YWA=K8
MK?LE^-9OA!JG[27[2VLZ??/X)\4_%<3> +*VA(?Q#=>1#:%[)#@2_:[KRXHI
M =LC+NSM^:NM_P""/?P&^('[.?[ 7@WP!\3=+N--U:XDO=4?1[L$2Z=#=7,D
MT4#@\JXC96=3@J[LIY!KM/AY_P 9,?%M?CG>?O?!'@^ZN+3X=P-]S5+\!X+K
M6O1HU!DMK8]"AN)1N6:)EFA1K5G2Q4O=J32ERVVDX*+?^%+I_-;74JO7HT?;
M86/O4X-QYK[QY^9+_$VM_P"6[MH;7P"\'_\ "OFNM2^*GB32Y?B5XYD_M7Q'
M#%>J64(NV*RME8AFM;6,^4A  8B25@'F?/IU?EC\;[GQ-#^S+^UAXL\0>8OQ
MIL/VFK.+P+<J@;5HHQ=Z9_84=E_RT\MK8S>6%^\C3\$;J_4FQ:\:RA;441;@
MQ*9UC.5#X^8#VSFNS+,8J[E24;<J3WOO*:U_O7BV_4XLTP4L.HU7*_,VMK;1
M@]/[MI)+T):***]8\@**** "OHS]@'_F;?\ MP_]N*^<Z^C/V ?^9M_[</\
MVXKYCC+_ ))NO_V[_P"EQ/J>"O\ DIJ'_;W_ *1(^C****_"C]["BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *^<_V_O^92_P"W_P#]MZ^C*^<_
MV_O^92_[?_\ VWKZ?@W_ )*2A_V]_P"D2/EN-?\ DF:__;O_ *7$^<Z***_=
M3\$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /HS]@'_F;
M?^W#_P!N*^C*^<_V ?\ F;?^W#_VXKZ,K\*XR_Y*2O\ ]N_^D1/WO@K_ ))F
MA_V]_P"ER"BBBOF#ZD**** "BBB@ HHHH **** "BBB@#YS_ &_O^92_[?\
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MI\1BL-;N-+A>\MD.<K',5+H.3P"!R?6MFBBDHQC>RW&Y2E:[V"BBBF(****
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MW_DFZ'_;W_I<C\$XU_Y*:O\ ]N_^D1"BBBOISY8**** "BBB@ HHHH ****
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M2_[?_P#VWKZ,KYS_ &_O^92_[?\ _P!MZ^GX-_Y*2A_V]_Z1(^6XU_Y)FO\
M]N_^EQ/G.BBBOW4_! HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$^IX*_Y*:A_V]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^<_V_O\ F4O^W_\ ]MZ^C*^<_P!O[_F4O^W_ /\ ;>OI^#?^
M2DH?]O?^D2/EN-?^29K_ /;O_I<3YSHHHK]U/P0**** "BBB@ HHHH ****
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M_P!N*^8XR_Y)NO\ ]N_^EQ/J>"O^2FH?]O?^D2/HRBBBOPH_>PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OG/]O[_ )E+_M__ /;>OHROG/\
M;^_YE+_M_P#_ &WKZ?@W_DI*'_;W_I$CY;C7_DF:_P#V[_Z7$^<Z***_=3\$
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /HS]@'_F;?\
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M_P#;O_I$3][X*_Y)FA_V]_Z7(****^8/J0HHHH **** "BBB@ HHHH ****
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MW_MP_P#;BOHROPKC+_DI*_\ V[_Z1$_>^"O^29H?]O?^ER"BBBOF#ZD****
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MHHHKZ<^6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^C/V ?\
MF;?^W#_VXKYSKZ,_8!_YFW_MP_\ ;BOF.,O^2;K_ /;O_I<3ZG@K_DIJ'_;W
M_I$CZ,HHHK\*/WL**** "BBB@ HHHH **** "BBB@#C/C-\#/"'QSTRRTGQ?
MJFM6L=C.TT+:+JTEHS,5VD,4^\,=C7GW_#O?X)_]#;X[_P#"RN?\:]THH \+
M_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\:]THH \+_X=[_!/
M_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&O=** /"_^'>_P3_Z&WQW_P"%
ME<_XT?\ #O?X)_\ 0V^._P#PLKG_ !KW2B@#PO\ X=[_  3_ .AM\=_^%E<_
MXT?\.]_@G_T-OCO_ ,+*Y_QKW2B@#PO_ (=[_!/_ *&WQW_X65S_ (T?\.]_
M@G_T-OCO_P +*Y_QKW2B@#PO_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^._
M_"RN?\:]THH \+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\
M&O=** /"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&O=** /
M"_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&O=** /"_^'>_P
M3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\+*Y_QKW2B@#PO_AWO\$_^AM\=_\
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M>_9__8H^#WP&\5+C5/!/PM\/Z!J0W XN+/3;>WDY'!^:,]*Y/P5_P3,_9#\
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MV^%;'P-^U'X-UGQ#HVFZC#?VFF67C?6-*@6ZA+&*=DT^[@#NA8E6;)!P1T&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>jnj-20210103_g9.jpg
<TEXT>
begin 644 jnj-20210103_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/MEM=7LR+?5;'!).]HXXY=HP%^R3GDM7[E?M5?M/?!_]C']GGQ7^T_\ 'KQ
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M)?!%M)\5^'-4ETG6?A]KWB-?)^UB))HU2^6W.Z&2.0!9&@4[U=64 ;C\I?\
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M==\=D9-D:*Z(5,[X*1,2BF5C&) #ZYHKXT\$?\%8==\'_MX^$_\ @GA^V_\
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M\0Z]IL]AK6I6/Q1\22M?02G+B59M0=7;=\ZR$;T?#JRL :;^SC_P17_X)O\
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MH_X*.?M56Z2GRWLMS(#P2-8G /X!C^9K]8OV</\ @BI_P3?_ &1?BIK7QO\
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M\MQ"S.5" /\ ;7[$G_!+']AG_@G-<:S-^QG\(M2\&1>(?+.LV*^.];O[2Z=
M0DC6][>31"0 D"0*'P<9QQ3/V[_^"5/["/\ P4J/AN;]L;X'Q^*+CPG+*VB7
ML&L7EA<11RE3+ TMI+&[Q,44E&) (RNTDD@'X=?MBZ=K>B_\'17[,&F^-?VH
M4^+7B2/4/!A\3^*(19101WSZC<.UK!;V8"6D"(T9CA8O($=6=Y&<NWIG_!VA
M/#:?\%1/V1KVYD"0QK SR,> HUN DY]A7Z>_$/\ X(%_\$D?B9XH\!^+-<_8
MWT*SG^&]C#9^&;?0;Z[TZW$$4SSQI<16TJ+=$32/(6E#.[.V]F#$'T']M_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QM\+/AC\2XH8?B/\
M#G0?$"6Y)MTUO2(;L1$]=HE5MOX5O44 4/#/A3POX+T>/P]X.\-V&DV$/^IL
M=,LT@A3Z(@"C\!5^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .?\;_"7X5?$QH7^(_PS\/>(#;C%N=;T6"[,0Y^[YJ-MZGIZUJ:!X=\/^$]
M)AT#PMH5GIEA;KBWLM/M4AAB&<X5$ 5>?05<HH **** "BBB@ HHHH ****
M"BBB@ HHHH ***;//!:P/<W,R1QQH6DDD8!54#)))Z "@!U%0Z=J.GZQI\&K
M:3?PW5I=0K-:W5M*'CFC8!E=67(92"""."#4U !1110 4444 %%%% !1110
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M57DJZ3H=_BX^UW%_/"OF-9VWV2Z8%%5YRL4:[&F!7M?V]?'OC;5OAI=?LG?
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MW !Y]_P08_:8^/W[77_!*OX7?'']IF_.H>+KZ#4+*\UQHPK:O#::A<6D-XP
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M:YO5A47=Q9VK01228^9DC9Y"BD]%+L1ZGK5FB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\4_:0_8)^!7
M[2GCBW^,6NOXB\/^/=/\-7&@Z9XT\)>*[_3+N/3YF9VM9DMIDBNX/,;?Y4ZN
MNX9&#S7M=% 'A'[)/_!/;X&?LF>&XY=%_M37_&=UX-T_PWK_ ,0=;UB\GU.\
MLK2$1QV]O)+.[:?:A@72VMF2-&.[E_G/AVJ?\&V'_!&/7-6O-?UK]D[5KN^U
M"[ENK^]N?B]XLDEN9Y'+R2R.VJ$N[,Q9F))))).37W110!\S>(?^"/?_  3O
M\3_LBZ%^P?J7P(O8_A-X<U.34=-\'Z?X\URTC>Y>>2X:2XF@O4GO#YTC2 3R
M2!6VE0-BXX+X;_\ !NY_P1X^$WQ&\/\ Q7\#_LC2PZ[X6UNUU?0[F^^(WB.]
MBM[RVE66&4P7.H212[716VR(RG'((XK[6HH \DU3]A[]G'6?VT=,_P""@.H^
M#KE_B?I'@I_"MAK(U:X$*::TTDI0VX?RF;=++\Y7.'/HI'SWXN_X-RO^"/'C
M[Q;JGCWQM^R[K>K:WKFH2WVL:K?_ !@\62W%[<R-NDFE=M4)=V)R6/)K[?HH
M \P_9&_8S_9J_81^$*_ C]E+X91^%/"RZG<:BVG+J=W>O+=3D&6:2>[EEFD9
MMJC+.<!5 P  /3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O%OVOOBU\0?A=_P (]_P@GB#[#]N^U_:O]$BE
MW[/)V_ZQ&QC>W3'6O::^<_V_O^92_P"W_P#]MZ^BX3H4<3Q!1IU8J47S732:
M?N2>S/F^+J]?#</5JE&3C)<MFFTU[\5NM=CSG_AK/]H'_H?_ /RE6G_QJC_A
MK/\ :!_Z'_\ \I5I_P#&J\YHK]G_ +$R7_H&I_\ @$?\C\3_ +<SO_H*J?\
M@<O\ST;_ (:S_:!_Z'__ ,I5I_\ &J/^&L_V@?\ H?\ _P I5I_\:KSFBC^Q
M,E_Z!J?_ (!'_(/[<SO_ *"JG_@<O\ST;_AK/]H'_H?_ /RE6G_QJC_AK/\
M:!_Z'_\ \I5I_P#&J\YHH_L3)?\ H&I_^ 1_R#^W,[_Z"JG_ ('+_,]&_P"&
ML_V@?^A__P#*5:?_ !JC_AK/]H'_ *'_ /\ *5:?_&J\YHH_L3)?^@:G_P"
M1_R#^W,[_P"@JI_X'+_,]&_X:S_:!_Z'_P#\I5I_\:H_X:S_ &@?^A__ /*5
M:?\ QJO.:*/[$R7_ *!J?_@$?\@_MS._^@JI_P"!R_S/1O\ AK/]H'_H?_\
MRE6G_P :H_X:S_:!_P"A_P#_ "E6G_QJO.:*/[$R7_H&I_\ @$?\@_MS._\
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MI^#?^2DH?]O?^D2/EN-?^29K_P#;O_I<3YSHHHK]U/P0**** "BBB@ HHHH
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M_P#;O_I$0HHHKZ<^6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6;?4=,U&W6>RO;60/'-&PR&!'^15^@ HHHH **** "BBB@ HHHH ^C/V ?\
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MXB>"_B=H;>)? 7B"'4K%+N6V:X@# ":)BDB?, <A@0:;\/OB1X(^*F@-XG\
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MG2WD5O+$%NK>0QS1E945LJX(SC![$BNFL=.T_2X3;Z980V\;.79((@@+'DG
M'4^M+:65G80_9[&TBACW$[(HPHR>2<"OFY.C[W*GOIJM%YZ:O;73T/IXJNN7
MF:VUT>K\M=%OH[^O?EO@I\=_A/\ M%>#9/B!\&O%R:UI$6IW.G2W:6DT.VZM
MY#'-&4F1&!5P1G&#U!(YH^"GQW^$_P"T5X-D^('P:\7)K6D1:G<Z=+=I:30[
M;JWD,<T929$8%7!&<8/4$CFNK@MK>U0QVT"1J6)*HH R>IXH@MK>U0QVT"1J
M6)*HH R>IXHDZ#YN5/?35:+ST5WMKIZ=B*KKEYFMM=&KORU=EOIKZ]^4^"GQ
MW^$_[1/@Z3Q_\&O%R:UI$.J76G2W:6DT.RZMY#'-$4F1&!5P1G&#U!(YH^"G
MQW^$_P"T3X.D\?\ P:\7)K6D0ZI=:=+=I:30[+JWD,<T129$8%7!&<8/4$CF
MNK@MK>U0QVT"1J6)*HH R>IXH@MK>U0QVT"1J6)*HH R>IXHDZ#YN5/?35:+
MST5WMKIZ=B*KKEYFMM=&KORU=EOIKZ]^1^!OQ^^$G[27@J7XA_!;Q9_;.CPZ
MK=:;+=&PN+8I=6TABFC*7$:."K@C.W!Z@D<T? WX_?"3]I+P5+\0_@MXL_MG
M1X=5NM-ENC87%L4NK:0Q31E+B-'!5P1G;@]02.:[&BB3HOFY8M:Z:IV7GHKO
M;73TUT(*NN7FDGIK9-7?EJ[+?1W]=->.^!OQ^^$G[27@J7XA_!;Q9_;.CPZK
M=:;+=&PN+8I=6TABFC*7$:."K@C.W!Z@D<T? WX_?"3]I+P5+\0_@MXL_MG1
MX=5NM-ENC87%L4NK:0Q31E+B-'!5P1G;@]02.:[&BB3HOFY8M:Z:IV7GHKO;
M73TUT(*NN7FDGIK9-7?EJ[+?1W]=->-^!GQ[^%_[1W@J3XA?"/79M0TJ'5;K
M3I9KC3Y[5UN;>0QRH8YT1QA@1G&#U!(.:7X&_'OX7_M'>"I?B#\)-<FU#2X=
M5NM-EFN-/GM72YMY#%,ACG1'&&!&<8/4$@YKL:*)2HOFY8M:Z:WLO/17>VNG
MIV(1K+EYI)Z:Z6N^ZU=EOIKZZ:_(7[1GQ[^%_P"T=X*\+_$'X2:Y-J&EPZKK
M.FRS7&GSVKI<V\D$4R&.=$<88$9Q@]02#FO!/AK\3_!?Q<\.OXJ\":G)=64=
M]/:/)+:20LLT3E)%*R*K<,.N,'J*^K/V_O\ F4O^W_\ ]MZ^<Z_<^$'!\/47
M!67OVN[_ &Y=;+\D?@W&*FN(ZZF[OW+V5E\$>EW;[V<_\-?B?X+^+GAU_%7@
M34Y+JRCOI[1Y);22%EFB<I(I615;AAUQ@]11\-?B;X3^+/AQ_%/@RXN)+2.]
MGM'-U9R0.)8G*.-D@!QD<'&#U%=!17TA\R<_\-?B;X2^+/AU_%/@RYN);2.]
MGM'-U9R0.)8G*.-D@!ZC@XP1R*/AK\3?"?Q9\.OXI\&7%Q):1WT]HYNK.2!U
MEB<HX*2 'J.#C!'(KH** .?^&OQ-\)_%GPZ_BGP9<7$EI'?3VCFZLY('66)R
MC@I( >HX.,$<BCX:_$KPW\5O#K^*/"JWBVR7L]HZW]D]O()(G*/\C@'&1P>X
MYKH** .?^&OQ*\-_%;PZ_BCPJMXMLE[/:.M_9/;R"2)RC_(X!QD<'N.:Y^\_
M:(\+O\%==^-GAOPWKFJ6FAI="33(=,>.[FD@8JZK&X!QD9W=-N6Z"O0** /Q
M!_:6_:6^(_[4GQ'G^(/Q!OMJC,>E:5"Y\C3X,Y$<8/?H68\L>3V /V:?VEOB
M/^RW\1X/B#\/K[<IQ'JNE3.?(U"#.3'(!WZE6'*GD=P?KK_@I)_P3;^S_;_V
MAOV>= _=_-<>)O#-G%]SN]U;H.W4O&.G++QD _X)M_\ !-O[1]@_:&_:&T#]
MW\MQX9\,WD7W^Z75PA[="D9Z\,W& 0#[D^%7CZ/XI?#C1?B+%X=U#25UG3X[
MI=.U6#RYX-PSM9?U![@@]ZZ"BB@ HHHH **** "BBB@ KZ,_8!_YFW_MP_\
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M_P#VWKYSKZ,_;^_YE+_M_P#_ &WKYSK]UX-_Y)NA_P!O?^ER/P3C7_DIJ_\
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M0F\2_9XKN]U..,+:6<,4,TAVI(3)+*V$(1%C,FYBGJ7@/XE_'C7_ -HKQO\
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M%% !1110 4444 %%%% !1110 4444 %?.?[?W_,I?]O_ /[;U]&5\Y_M_?\
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M%% !7SG^W]_S*7_;_P#^V]?1E?.?[?W_ #*7_;__ .V]?3\&_P#)24/^WO\
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M 4444 %%%% !1110 4444 ?.?[?W_,I?]O\ _P"V]?.=?1G[?W_,I?\ ;_\
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M!]&?L _\S;_VX?\ MQ7T97SG^P#_ ,S;_P!N'_MQ7T97X5QE_P E)7_[=_\
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MBN)_X:5_9Z_Z+;X5_P#![!_\51_PTK^SU_T6WPK_ .#V#_XJC^V\E_Z":?\
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M^@FG_P"!Q_S#^P\[_P"@6I_X!+_([:BN)_X:5_9Z_P"BV^%?_![!_P#%4?\
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M**\#_P"'I'_!/G_HZSPK_P"!$G_Q%'_#TC_@GS_T=9X5_P# B3_XB@#WRBO
M_P#AZ1_P3Y_Z.L\*_P#@1)_\11_P](_X)\_]'6>%?_ B3_XB@#WRBO _^'I'
M_!/G_HZSPK_X$2?_ !%'_#TC_@GS_P!'6>%?_ B3_P"(H ]\HKP/_AZ1_P $
M^?\ HZSPK_X$2?\ Q%'_  ](_P""?/\ T=9X5_\  B3_ .(H ]\HKP/_ (>D
M?\$^?^CK/"O_ ($2?_$4?\/2/^"?/_1UGA7_ ,")/_B* ,_]O[_F4O\ M_\
M_;>OG.NS_:^_;N_8Z^*/_"/?\()^T;X5OOL/VO[5_P 3)8MF_P G;_K-N<[&
MZ9Z5XM_PTK^SU_T6WPK_ .#V#_XJOV;A/-,LPW#]&G5KPC)<UTY137OR>S9^
M)\795FF)XAK5*-"<HOELU&33]R*W2MN=M17$_P##2O[/7_1;?"O_ (/8/_BJ
M/^&E?V>O^BV^%?\ P>P?_%5]'_;>2_\ 033_ / X_P"9\W_8>=_] M3_ , E
M_D=M17$_\-*_L]?]%M\*_P#@]@_^*H_X:5_9Z_Z+;X5_\'L'_P 51_;>2_\
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M<UVXR27N26[5MS[EHKP/_AZ1_P $^?\ HZSPK_X$2?\ Q%'_  ](_P""?/\
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MBNIHH Y;_A1GP2_Z([X5_P#">MO_ (BC_A1GP2_Z([X5_P#">MO_ (BNIHH
MY;_A1GP2_P"B.^%?_">MO_B*/^%&?!+_ *([X5_\)ZV_^(KJ:* .6_X49\$O
M^B.^%?\ PGK;_P"(H_X49\$O^B.^%?\ PGK;_P"(KJ:* .6_X49\$O\ HCOA
M7_PGK;_XBC_A1GP2_P"B.^%?_">MO_B*ZFB@#EO^%&?!+_HCOA7_ ,)ZV_\
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M9\$O^B.^%?\ PGK;_P"(H_X49\$O^B.^%?\ PGK;_P"(KJ:* .6_X49\$O\
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M*V1L=LK$#BNEMO#GAZSUJX\26>@V46HWD:QW=_':HL\Z+]U7<#<P'8$\5=H
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MH5$4#H H  ]!5BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>jnj-20210103_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20210103"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20210103.xsd" xlink:type="simple"/>
    <context id="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8686edd54dc143a7a78f18f215ac305a_I20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="i2614e18acbee45a8bd82ab8bb34954d5_I20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="i2c4f2d96d955450db33852d746bfba34_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia22df427a71c4e69b4499cded92f3f76_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8e12ae720d2c4dc085eddd1250b291b7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7ba23fda59684540bdcab8d2c6182237_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iced5cdc4242a49e886f089e2363899f7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie7c2da1e43f14fe88eac34709ef35e41_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i375dae870e264e26b914483f200eb437_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2a614105f7d44e2eabdb115a8fef94dc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iaf4bf571e18643da8a5b4eb3bfc07a7d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3d809f74ca674af2a83700b574ef976a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i6a37f3f6ee9a4fd68dc6ebb535681918_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="if2de20cab02a4cf8a8defc94d4572ad4_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i876cc85cac534bcda664e8b8d9cf58fb_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i402d9278fd56456f8c7a670066d1ed23_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i36166563680d47089c116cbce4109090_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i411749566b1e45288b6797e92e4b8e37_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icbe1daa397894e5683897624a288d022_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="icafa9de0a8f744f78e2171c3ec5ff108_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i88f92b62ca0e43c1a522880b7018fd18_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ib841bff089b9422dba63507cc4961d15_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic15b04be239b4bcf895c4ac519a52aa5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i89ea54c1fcae41cc82257b51ac217450_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6b56c73c08ba4d7bb733cf5b7825663e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ifc6c299668f24a8ea824ffb03291a552_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0948aa56b8544fa694f8b50333d4293d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id5e8e0ca2b9b40cea02f25844dc6143f_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ia9621bec2f144b689a1fbfe1403aab26_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i18c818b3558a442cb0ffe1bce102d1a8_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">jnj:AccountingStandardUpdate201616Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i56111d6a08484b6890ddf01b41cb16b0_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i172e28d99e7b4636b5bf1e3bb60c3e46_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4144a962aa79467395df471e209ede69_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5f65202ffa114849be9dfc3aac018eaf_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i935569cc407846b1bd173f1920d291d7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1869c744df4f4e608a0eb1004c3f4aad_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i76d4081a3bd840dda4560e78dc05b7a5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie02722380d4b485fa4f666f9da3c34e9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0f18dc2fc4564ff9a05dbd7fba040656_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ide0733c2434242ba85b6c5b1c835e725_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i63df1bc915934ad68c8902ac19c99bea_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ied72d4ba20b14d21b01fa2d79d0cd268_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i12a63cb5e2c94bd8bd2df799531d614b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id01c9ba6bc554fc8a64421dc3895f2a7_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i75354123f4c84b55824bc84448f6036b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2017-01-02</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idf686c178a5b43e69308e5ab8e5a2e50_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie7b1533a3fb1425ea88cc6db6686d845_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia654d3afeed34b34bd201de560aa0413_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8e549fb8c84644b1b63e3d2064d641fa_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id2a7dcc9839c446fbccecdf7ba191688_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibc9b5802937d4976b598a9ea0fe267bf_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie8df9244611f44ff9e862d2f22238879_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4ff8fd01ac0a487098147e064c5c7c90_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i72a342c6145547bd8226fe95c213f2a9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i1c02f63bfeba457680dc2981ea77c247_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i9fcb9b3192c346bab96adcaf99402100_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i999eaa5539f8442a9db3d7527b669ae0_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ib68ca550e07c4272974f847b220b5bdf_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iecdc5e97696145adacdd25f020821810_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i45864798375349aa82cdbc0fe5b12467_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i525d9deca0aa4aa69bea7606b12ab349_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ib7656b3ff8f34856acd3408e287ef6db_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3a1e598b00f94535a80aa29acebd3c1b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iebd47e6dfd734f18ab3b1175104da7ee_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="idc844a985e9b4ab8acde3269099a7e3a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7cf08feba35c44f18b96be74a96747f7_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i0246814551b44afa8fc330cee4302c9e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icd28da37730341bf89cc859b43e1ce8b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i323d72d0abae4c60a66b9d7b0a4c7632_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i83996bd19a7d44aa89d8fa3abc440044_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i610e8d971e0146b5b0f50d10214d75f7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie2f9006a108d4ae79eef7c6e80d975ed_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6680195d23ef48f48b25fd080e30e045_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic991d846f0554fb3854353012c741e47_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i9af09372a20b4cf5bc9ca89867f6e9b5_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i7611c63653fb4652b6fe6457c1f44f7d_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ic8619876835d463982674bc871e45ae9_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5ecd7168647c48c487c55761ba2ced54_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i99e711fea4f3418abfe78e49bdbf2256_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i55c1789785ab45d596ef77f977c4b121_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia0ae3e960cac4c83aaf46f48e727ffc7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia50a679a6f554f4782e402d666b79722_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iccf138ab7f374295818f1906976dd6e3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9875f4baef3f4a1b948b6ce968e1cdc7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i27f4f225aff44f999a6680657f1c61d3_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i7ca6c05369c945429bb481abe32f8614_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i504dd38a7aa842119593f0983c422c2d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8640053c6b9d41e7b51cfc21fdc35a76_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i052b28db3f2e41379f8949dc73a4456c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1b584b81e4314c05bff5a3a53f02afbf_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie92ffcb6fd0b4017b7ebc21794532df0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4a30ff6ddef34c879c3a48899c85fd4c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iadc985f689ed44a3b6b5c0680b59cb08_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i50be13ffcdce471782b928e02e0ecb36_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2ca59ee60bd4461ea3d47a202e3a0c92_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia2d21b453745418380adcf639d9dcc50_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7c6f97ba35ec4096bcc04f4b4f8691c3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic742e9fd9fc14884addc84d349e1c28e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9bbdc1a64aa24c13b6889b62805de83b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1283aa8aad894085a364e383b421263f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibcdafeb6de434a389a8ae98d6c27bc71_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i49eaaa02ae0e4bdd942caea69069c9bb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i63d2fc906c86432098158cb4b10ed6af_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8768d9bd65b14a88998cc98eb8b56b71_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i15d6224b1442428383799310a443ccd9_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id484553bc7f246b2956d7fe4162e2291_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iff4cffd97e4a4b9db233400cb5173ef1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i685f5c13f8df4ef59a10c882dc33db9a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i168477b06e674a54857ad32c9063d70d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7df8b1f03a5d46d788ea587e459c0d92_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie2c58bd90b6d4d01aab3aef88e24fda1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i35f6e10d334f47eb89761629c9a42e6b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i91c7fd78bae849e18766ff5f722b4347_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1dc23bedbeef4fe2934d4b69926edf66_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if44491fa9fda4fc9977393ab1922d90e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i23c9442c717040c2b8f471f3da9878f2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7f5f27a8783b49c09ce94e0b992e4d45_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8b0ca0336ef04af5b1a42a37200ec54d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0f4c7294e0d1495194057b40b978d165_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SaleOfSubsidiaryGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i57b73114f3ec4b0082e498dd41bb847e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SaleOfSubsidiaryGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2916bc780e044ef49bef1e4b70c3cc9d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i244284a65da64e8d883b976f20dd4439_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i015f5e90b1d24aed9b099ce1619e99d5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia2f6938e747b4a25bcc25eac3741af90_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icc7bfc44c870488c80c19b43b875f537_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i2ece5d5ae1a84367837c469a116bdbd3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2c25167a6e4f4d47bddc86f00585a224_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i62e6ac332e264884b231e1297e1c4568_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if28e5b7c3ed4439f84c2bbe32744fe70_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ifdf0149aed5548e0a41ef000a1870d66_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i02cda706e4b2470e94e004280758bd89_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icce25e79e7eb4e0eb4f1dd38ac472371_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if0a5708acf3147969658a14d0f39da97_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7f676139595e41d48aef38e5bcbdc8dc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9326c68bd8144507a8d7e36dc93e9005_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i780693331f074588830546d5a4ad2799_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4c325d4d8dab4b0685cdeb50ada0d1a9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8aeb7bb33ec641c98e0fbde2d3d5c165_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i90af2ee9b9b540bb99b3f8e6d629a8f5_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5608ee32b2f64df4a13f8ff444c9fbdf_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ife02cb05cc8448539a1c0bccd6199532_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iaa1c9065eff4473ca7a6e26469472db4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if79c9faf646345eb9c242f049ae1e0cc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if7a9d7cee0f342329e91428213de8f04_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i063b1e7203cc48a383a856f56f95ece2_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iba78ecb5491f4fa1805dedb0bb402778_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4833811f03a34cdfbb1b8144a5e115c9_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i204902ff089e4411bef7c51531f107d1_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i150752b44d724b06a4b96ffabd4ea8b6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i522cea24f1ca42868d485da848eb40cd_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i795080089d5f41458b16a91c2923e0c6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0afabd84326c4799b8b58c05bbc630b4_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5d258167afb64a19982ff42e1d05bda3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id7d8d4d3851f43118320077adb8a55de_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icc6149e03b1a45c9a528cbe475bb4465_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i239971f81b48484183a8b472b82f6ded_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Debenturesdue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i643d86e5fb4949bc9b0b38833626e8a6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Debenturesdue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.950Notesdue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2855ce1111214d85ade50a6ccac8a618_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.950Notesdue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i926e8b4151584d75bb453778eff5a51c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic351de96f94f4e9b8747f6446b843a4d_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i9c3d81e50f874f138a3912b40b201c41_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib933e5916e15417a8a48a5669ccf5321_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i8a873dff1d3141a19512b0affe1fe2d8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic8212ea597cf4a84b23cd83df34ea924_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="icd2f7d24c9474d8c9cc4823797b8c083_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if6ee752114044428a8c20fe4f7ecb273_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i2dbe0979c7a14dc9b9f12e17af387027_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i96bfafa6c5fb4ce3ae20923ddd529bae_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie3f807d1cada4781ae10198fe16e1c99_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if95c57f111c64126bccc2fc3a980ce5a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib2a1b55a0d51409e9832bdbc47868c84_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i8a181a42de50462faa774006c9104b58_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2acd1bef02c94effbce52af8c909bec3_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id431690b092746cda0e3885506938117_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icb932f4d85de447b95ac9a2f2540bd06_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="icd739e0b217d43fca3ef7ba9585172e8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0369e6fc3c194082a81d79013d49d056_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iaa8bc6079d92403ca3c4b99e75498b57_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4c8d7bc47a734d679cb8e0230bf39855_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i1c683153e4274793b8e2b845aee7dc3b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id9fde6f193e0450fb608feb62094bab4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i38c696c925d1472b90cf70120a0702ca_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7c169ee681eb41d4b70cf224042a918b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i468ec06486014ee2bd6f5c7a72949cf0_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib92f79edb6394aabb7c66d1f0ceb9c1f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3c9f0124227242a3b37ef08fc5f78862_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id6e4daae8acd4186854161164075f779_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0b5d476254ef41008aa89433dcace0d4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i035991005b3545fdb445908803f01423_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i541337b24d2444a8bf14a78c6ec932fd_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i45d84507c060443eb3ceeb3ff733f151_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idbbe327f106f448cbd073f1bca885cb8_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3a322bcc2a514a30b7e05707bfb38724_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic8a4cd9bc3a54ec4a968860df1b0f6ba_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if7ba9d57b541417083a57e7550184805_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5584716e0e79483b8e1d3828aaab1e0f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i1965776d766f4468bd93699590f0d845_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iff628b0cf02144cd91a4abcc5053f028_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id83a16eac5254d0f8a32fb0408fb7209_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib3f4662ff9134017a1f5f7444f314e31_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i63438abe9f0244469fd820794902d862_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic49d24552bc346e1b4e0dab3a0e924b4_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i0a1673c8394c4e3f872d187343339109_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6bf9a86caabd4562bffba6ff39983416_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3df454f0c44e460bab62d61a065354d2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9ac8457d7f3f412bbba5cd8890c8ad72_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i51f46beeeb544a6f91f38d5f362744ee_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iebf5cf036d354852b5eaf7f1a747632f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i96f58bd4d50d4e84946db893d8650ed6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i782bc6f740614734a43da12dce22161b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i9b804bc029e642feb0493dd3906a185b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i05b581805ecd4967a8646eaf60bca900_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i70d754e14799477284511704f83b8d17_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7255430870174b0fa0d8627f1ec59a3d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id568183bd7d541139e4919632134334d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9f619870e5ab42bb830254e1a5d06b99_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0fff5e1fbc7546c895f24337e28ccd11_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ief45c201a3b243caa69c0e0f161b2ae4_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id8b7693bcded4747a5ab760537912c2a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iafd125a14e0d4e7a876c8945f58e61f6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i60f33f574f1a41b9bf5677aefeaf760f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i39181f4c3aa24aaa9646a538d7f62e4d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2a8df475fa9c4c4aa829c65373e7b7fa_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i24f8e23ceca94494b1b3b111eed8dbd5_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i72aeae00e1604bf385505263726995cb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i76fe11f963ad43deb7bbe15f647ec9ff_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i53872a4a35184b378900cbaf5b99200c_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ib4bb2eed805a40d391fb647db58d1d62_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7b6108907f204089b3f9838308be8b28_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia4a277a5e8eb4225adece7896cfdfc52_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="iac4d55843ee04cc9ba52c8e2dc31eb16_D20181001-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ifa0d22acfd9043efb1e18804222572bf_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ide9258c8a9684b738ee2e0f0983bd1f5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i500668a00ec14570b9277e4c2dbae643_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3f5f3419f6044ef6a113250635e22bb7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5b62f1bb84444e928443e80402f47547_D20200928-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2020-09-28</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8db67b67955942f7a04d431f570d4565_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i172efe01b0cb4ab689fa0a795f2f907b_D20191001-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id74cbe1f433b42e09645c83a947740b1_D20191201-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i94b21ae117b34c4292baffe418a58981_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">jnj:AccruedTaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i59f96e940f074bfc8bca8dd0210f851c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia08825d6475b4031a35401d638705874_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie8d76953cd864599b2189d147891aa04_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c88bca24e1a49eab2160ca290e744e6_D20191231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if190893c65874208b238876e963fff03_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i665364f0420d4c8a8fa01d3fb66d199d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2330bd0434aa4310950363941b7c32db_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if1e21ca84a744ed29c5bf847342b7b89_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="iac551cea27e04d75bcc80f2411447fe0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">jnj:LumpSumDistributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8258eb0443384fc2aa7fb34a0f018511_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i35d1b0ae517840b7b04db12cfe06d2d6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1b800eebfb2649a48e2c884cbf2aef11_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4266eb19a3a8489d8e8e570a500b29bc_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ida0e471c9e784988af7c2e3bdc2668b0_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i3606c1fcfe894326ac67e462f7a3db34_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i440d37782d3643f88c50da17d6fc2677_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia14aa1f13b66432c8bc417c76885faf9_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ica8f24a050764bfba17b5c0beb8b5068_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if68a6a311dd74eff8cdd501535848300_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i66bdef9c25ea4e9abf91f84961d6aaf4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i23f4166c654a437a80123fea9e702f7e_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i39331ef41a6c42108162921682abc122_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i10391e82429e4bf5a59079e301f6c6f6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ief3d442963634e13878545dad90c5606_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i75eebb92b9ee407fa174719e6be87d9d_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3c809f170b8d4ab7b2aa8e2af5723d0b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6e0df4d18d894d27a4ace305330ff2c6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i14ec1578bd1a4fb1a4e201e6ba58cf2a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib0ee1b6e5291404bbc84039bc844c771_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if4507a38bcbb4237894ed814ce9f93c2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibd2d58bc21d745699a63ffa711ad4c20_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i71c4e1c7cb22424181b106e85e819494_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib90ab3ae11824ef9a9e63764ee396732_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i9fcce09e193042308b79539a19454bc8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6a9090828474432593946d7091132f13_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4299477497a4436cad8f8ed08555cd49_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib4bfd5fd8a4849b08c174538fbba64c1_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ic8c53d1325b34f4cabf72ed3d2c9c03d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i792325894abd4ffe872badf07315f357_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i129ebaefb7b84569bc06b0cae2c77b85_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6cd3c76e5ce3480aaebe23360e85c8ac_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4d096bcce1824a9594a39c9fdd09e08f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4aa0b93fc2a44d95a845a5651a1abf3b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i31684a1d9e3b497ea871cfece2687bfc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9a9148ad612a4a91a72c08004fdadc69_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if88fb975b18b476f96a36b211ef744e7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iefa06dbe41e44403b1a57fde488fefa8_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i36ddca0f50e34485b4dbb719c9499ef6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8a3cb8cc1c9747babbcb69806e0246a4_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id51e2ec82259464f841cca599e785a2e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i89bcea9069d449e6ade65209250939b1_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i23da6adc713141f9a30805360f7fddc7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6d030f2dc9714f1788798bfe39569d3f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie44bbde50ab9441daec4c3cb7a16c7af_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5322cca6ec4b4e3fb447427aa4149354_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i37baf89ebe664ce9a576dfea58d33bad_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4e4a4cd8db9740f0a035240c81e02b17_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5156dbac2b5f45c38108ef2f637be5bf_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i577b94e8b1be4e33aaccad68c1cf0d03_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id3e156cdf11044ea928c031c1ffa9fea_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9a3e8fa9abf349568477263c121e67cf_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4e3d41233d3a49058c7ac617acee9369_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7a8d5729f306476ab77201ea6d9d8c04_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i02729f04daa74ab2afec896f6fe109e9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id4375b4a40664031a6ba86d8ee14c478_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i0cb5c8f0e0ef4681aa83c7d913234f1d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0a5af3e730484e88ae6a67a735660d62_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i861c44bcd9c04b65b80d256358edd695_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i81f1ea39b2a44d56b0c8c041d1b61bb8_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="icc243eb836834e7d8a931154b37942d5_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8d30b90acd1242b6b7de07bbdc790c8a_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4fd6e5e08fde46adb34424998ed53252_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibedb3aa745dd4b3ab1c320496d1ab20d_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia667826001184093afc78dfa8bbb419e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib5c067a1e923463bb25fd0faec7b3968_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i9677b9c0aeab4d24bd7207a87355007d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iad01912a4ccb42d5a3b1813a29d85078_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i032051d81b034bd089a0507d7eab7351_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9998429b4b654051adfe886dcefa9de9_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ifa343551b56f48118e1cb1327fb01697_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia709adb3e87945729cd80574e236e7fe_D20210104-20210104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="ie4380bdb86b74638b9120d6db37d52c0_I20181217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-17</instant>
        </period>
    </context>
    <context id="id395e3d2f83144c69ca528af2dc9b6b9_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6b3c455ecfae4ed6aaebdcec05ae3f52_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i25282ad7400d4720a2625e8c3bac6273_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia8e1cb44199148b9aa8fa2e71f1bd6fb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i170982da0e98496f80e2110280b52dd7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:CumulativeEffectPeriodOfAdoptionAxis">jnj:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic77626f7a811485e9b149e03c04b3bd1_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib6a59d85f18543f8b4ace4dea662cfa2_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i7956e74acd5f4f6eb52053c38a41f6d9_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib1cd916919904201816ef7744955d602_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib9a838ddab52405f87db30392fc1ced1_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i4b3e6d6e46264f57aae311381d35d955_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="id3159628ceb74cfd97a53e02385491b7_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i1231b2bbed144c9cba72d9e67e5e0304_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i79859b6ecac341359999ab29de172592_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia018521bd0ef4419b522652ba45df3d9_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iaa6936a6df91437db1d3e64cf273812d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i918db4b812b9414ba016263b04a7d008_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ief95ad78a93d49fca32ddc64ec71496f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie58dcb82268e44ae810d6cde038d160c_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i636f1ba05c0d4343b8591ecc77c0e529_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5fa8c9dffee24a899b4b02e4b15e6f89_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i28de37f2cd304efdb2a7bf164f22a948_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i192924f6280a4a68a046814fc0e0b7bb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7657b728884a46e2884084e7b77c4751_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3d6214de92714d768bcf627b37e0f72a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5f9f99d7635c4de3afb7d08a8b3b2d0b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia4ee948f3520495892dc498991ccc81e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie8cf02c8e230424b92126e9143e4345f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i82c7380a52f94930a5e9728def85437b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if4d4da45e8664cf1b3b70e33caab8fd4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2012LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4d20904ce51e457ba8a1053c58ed10cc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if3a57f6eb476464d869fe8e58ec3baa5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia9c4d02cb4644dbca38c88e2ebb556f8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i884a27a100b944dcb86bd6ea0016fcba_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id34d6ae79d964454a653e9d51a996c98_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i035510af86094fac8176e7f17a5a8164_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0b2305bec7da4f2a82adbb34c65352b3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i447115cb0801497ab64877cc7d65202a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7c11a139c5264dc098f209197b9366c2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if0884d95fb894f82b5b100cc5798017f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i78cd4383ab4a489fbbc505c984d58d74_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib5338fd4c73a4d98b5d7d7df1d88f226_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie1dee2245d414b138d2f2fa014b0a178_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia7b2cf13619f4c189b475866e1db542f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ied04bdd122824628b347ab436e1bf569_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1f365b4e320847d7ad7af8be0962aad8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4d56204d812a44748666c659338087eb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0c52ecff45c14b9dbccf4b05efc03a3b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i912305c8e84a4cd9a5729ccf10a90c3c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib67cc38656e54ec4aadccc96b338ed7a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iff3ec8dc893a4eb08f4f039c8952b873_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i8aa9e713b2ec41e4a8d7f2f7015848f6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2fc37409a7004e809321a0b83f5b2e71_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ifde892975c2e4c43ae1fcd0e5d45005b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie098a08a654f4b7abe7993bfd4dd32c9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1ce7db841b704ce795266988602b87c6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i56177ea4bd8e4146934538847bd76f90_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ieebab203f30b40578e7a8a359fececa9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i95fe395206684a69945b7b9c3f58e7e1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id7cfb00a6c644b59badb04917cfe1258_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i23ae8ca1fdaf4dcc9a7ead012204e832_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5b7516b2a14b4fda940e11d40fdca6e7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i21511c0be4db4f3891671c0f6c6ffd18_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i335dae4d42e84c4581347d01955f1f64_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie0d65234cd7741f08e1b93c317fe4a5b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3fe8305d0fc64ff09895323053e4ffbe_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i7bb778fa0cfd41c8a12511fe0a1f1029_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i012e56c28db14f779936dee4f0663505_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iec92ca19a30a48309e6628e2a8f20244_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iabe650b19559486c93d86c150a95b5ca_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia4646db66c32408f83925e7b65de220c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9072109358d34bb0a33a9db443472e65_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i29b6c87bbb9946978d28461a1b99eaa0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4a6e6a50ba9c4b93a9bd88ec99d6a9bc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i57621c82e86e424b9525ef5322132b41_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic5e07924ec664fd1b4eb1488d27b17d4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic7eb56f6db9146e38c34652e1c29f3dc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic23b6b4d466040ba9303881a85c0d1d2_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i662e2ae6c2c34af690533b7c98d16d8e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i488340eb739640078006e1dee0f62873_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibcea6cb52caa4862915d6b02fc027560_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ied78bd048a694419a8427933eb72392d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia923300cfa5443f39393219ed3df8cdd_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4b3ec188dee44471a3d0ba8180228043_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="id9e9fbcfc879430f9d122a98d64707af_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i51dc84cfa7aa490eb43a1cfcc7ac6f30_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4d533f088e0440e2bc56ad8a637e2e38_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3ffd4f096a224e07ae928cca78b4e4de_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i197bed260bce4946b5a7231cfb1df3e1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4dcce34e3ebf45f9b3244f8aaa0a8d20_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ifdebc3f23b09469baf4a9f0122afae32_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic95fcb4fef954b5e9b3114fc3c6f5020_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia93c39893598471497b999c626c42a07_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib56eebb67df6466bba36905010e95c70_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if32de10a72684de19ff4530b736045dc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic6b58fa445b5470b9212749daa49e050_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i0989699ff14a4823884100556badfa4b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7d0b10d0987c4ff38ea6459bb35a337e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i320d43febbce4eddbc6e86db0f7fce60_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie3fb35c032c54830a66c354d7509fe47_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i876f6ed6ca05447f944d86570700a552_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i12ef4da3b3054496b33a2ca8733dfd24_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic988bc0a70d740549dadd5223afb168b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i64253834ef464806b4d069ddf4d2ae7a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ifead9540ae7f43f58eb9a61955b1d421_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5b2664b750a04838a23a12a422f46697_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib4510201ad6a4fa8ba547b237e08d2f8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3809d28608ca4587b38a7d272fdddddc_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i4e2c0df1a61b4fe2bb9af795b4098c17_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i42535da45d984ed0b3ea9894283dbfa7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib2b952caaff249198b1de2498f27980a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3c315b2e311c4bdc9634124f9332a881_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia48a1be8bc394fc2b9d27103df366fbc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9db261aaf98a40ec9d2a8dbdfabd4470_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5fe1aec193de4494a45e355fad84fd94_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iced43ae2faee49b38a0995fdb81c4dae_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i07758926e90e4b6ebb241ff19ec7dcca_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8b14c2f869194b079873a9e2c3b0cc33_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i6d10d30f5cfa4f7689179597fd83e3ac_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i127b9a85fc754e41875443a867bbe47e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3b648e70887e488790cb76dab030b994_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i51bac2c9dccf4fe79c0fd65dddb23723_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6e66708363b54eb9a30dfcadae1d4bd6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idcfd365c13594c388391dd8f606395b5_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic6da3163227146f5a9725847bbe4a1d1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifcb09a7505de4bd1a2c402a208aac239_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3f44c413e1f9461792dfc16bf4623c21_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i4c3251c22f0d45b1b9ae5fc83e739d53_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2ed07a99d5b24e6d8dcde45e5daee9e3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i40f408e57c734f30b9827c8e291b4e68_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="if4f89457e4444472bd89ce7240eec506_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5d7c7407d5d84d95a2baef6467281a84_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic9049be4d27b48c5aff8d7cd9e980032_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ifc10c7bf0c354fa5b52dd6cef5049396_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i81fe65e2feac4ae6b2120d1875a0c1e5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia09afe5f0a47482c83a41681a20ed1b9_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i345326e0d32b44a6962d5d2da892271d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9ab9d0b991fd48e991a9b96176c324f5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i66d52b0dee934b1dad3311f32a844f83_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9b5fff7db08d4f9abfb174cf4e10a6cb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i95e5ec630f144fc3acae22bf27085f20_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ifa6da60607b34facb3254a559f43916c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9cd5a91ab72b4e1d9097ac42c6567a0f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic445948a0ea54f98984b624b677ef57e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icf7ef583b64341d883f7c307897087cb_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i936effeb3bdc459188220839b3a07583_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib164d78d863f45e2ae7113fb61a9029e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i747d55ed9e11415197a12256dc54b0fb_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="if6062ff1a7594fa99d8bd54ce25f0d81_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3aba33fa79c1416ea6970ea33209f4f8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4c1621cb45fd410eb6148886adccb29b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="icc79dde7b9524c7f9528487acaeaba31_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5504fd9e30f44cb48669bb12f3abdcad_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib28cf791d4a541b0a7be48bee043f2c4_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3139e2031ad04133bd86df70cf5dc7b7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i470e0543cb694cf698d82d768b3a393e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i502d99b70ee24908ab08e5b1a1fdc9bd_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i29c30844e0e04bf3aa64c9175c1c7fd1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i79af5256cde94f5aae78e06c7053dbeb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id9482dc808d3497f92fd904dae9e95e3_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i54eccf3ae4f74a0f8fc42744cab78245_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i50d2b9d9ef2047b0803fd7f801a13e03_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia3a43e0744bb4641978b43faa639422b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1493568c9a874d0bbfd3ede747e68727_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9bd29791072a4593acd00300786ece30_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6670255be7144d1f852e46cf45edb2ba_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i619ec00350b745b6b707b0e00977199e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib47f23d17ed74b6f9a95492b23352e5a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i05672cc4fbf64dc388663c69c856b524_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia91f997ab1f24f23bfd12aaf2ab15614_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i81f840440eb34b388c74e913d8269476_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i92a18540e4d94bd3921e7a8dd91fca8b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iac494f4524344162be998345479e44c2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib2133c409ef74fbcaaabe46d16259131_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i86abae86ef304b71abd0e05f56a5cb4f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i43234804dddb4e39b7ddee85e821a967_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i792f702c2cc44d72a6685098df435cdf_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ief8e69a00b4a46d4b0026d4c0d0d12de_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0ea4daf92846476fa2993fbc2006ccc7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie61c6e895ab34051980667f5cc645e57_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i00c7d4e5567e41369256434e8aab708e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8d2acee81d0547e1ab6097e1c5779efd_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i89005b4edd5a4426abae3cd99c1ad3a9_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i053973bac1e74eac9056a73ee8e0369c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9a61d75aede14dbca7feee7ab7b14409_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6f6b727d130644bdaf9d3ee590ee2f85_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i34651815cdaa41f5b30e1ebcb72f67bb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1714fea951a94bd59565d02ea54e3b38_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i06a27ed8f9954257a933b0c854a14620_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iac15d6fdeece4cdfbacf8aacc9f73307_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4cdb3211b66440c2ba0dbb80ae7f58f1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i23709666fd9b4b9ea264d620b5bd8e15_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i32432ddae9e74ae1b271e486737b86ad_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i29524c4a77594647acc6c76fcbbccde1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i54edbd81015f4d71a9b2afba7cffb29d_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i26701d71b41f4a00aa3ced442e39d1c3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i303f017761124c748caf83e92d8e5137_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4839bf6f46b740e2a03b47f4d2738e9c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1d32e636144642afa7ef1549b0cf2c03_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i238de9e4da3a4b15afbad05973803e62_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia8cfd3aae4874e2e8686d594c717025a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iddad0db124bf452ea8a03f1654bb68d0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i52a3c9526e9e4662b7dccc6799311ad5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibfb90c3f230e4c8cb8dfa5a94e4ea0bb_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5e9403e2d2a34f59a27b604645f5a91d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0f3be6ab9e8a4959a3c7edc4d122dd2a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie8d9238b55644986a871929c8502d84b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia08fa1ac964d47feb93b93f96ba831b1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i29d5fd3838e84f57b29637bc91f05499_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2a23ffdae8ac4614968f16731be20d0f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic2d55cd1871b4849bb0d4d5789fc18e6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie88eb0578dc746d18d2bb2f4b766788b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id0226112bc194a59900da0f717036e7a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="id16e7d880f794b4aa0ad45508b813488_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id9ba901333db44aaa2a276635feab345_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5ee2c3fb12d0480198cb47af51655b5b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i4abe4268a675407693e053bf7336a72b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifb60330c47204e6486cc5262ed47484a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9d84ff4a4b754e97a7cb601b7d5a4e6f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ifcd8d74955bb460f8122175f5d6f0469_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib3213efec3984b9a8c8df8f59eb63243_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i92945871d6174c00bc9287c3ee66e791_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i11cb446a20b54dcfba5a0fc4233773e0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i40dfc72b0ea04eeb97d07f73f58eecfd_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7377bec258e8441f845958db2721e43c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="icd129f2ac9974218ab05c39a71c03771_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if0e6af2ed39540228df21c0af815adb7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idfa6602c894b48bd8d6bcf1d385cdcc3_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3a95f7ec983548d2a4b1be09dfe6dd14_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1505070ebd0a4498bb3eeb1d51183e8e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib0f887aa0bba464abdb150467246ac4f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3a84d7d93ab64403bd293f1a7184f6bc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i90a0ba12fbda4d738d5db9238ec568dc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic414aca1c42548929deb4e53de7bf3fa_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i7f98810d8ec641999cf2687e6554daf7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iafc700d3856a47738103c578a87aca74_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i72eb6604597248ad85fbd375da229add_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="icf8cbbdb69ff4501b7d58fe605645a1e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i133aa20f96a643e3b9e5df71d2e8af4a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if209e8c87c5644aa8818bd0b6c6673ef_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i4e40cab631864801a237de46454322e6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8464c5bb4509404b8a2d4bbd9ed47d3f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i06797700580c400c90f77631adc320b5_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i32a9d490e235496da2b346ee89bee21c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0abddda703554fc8b7f0eeca2b43a200_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icbc276f6c9ac42e59b93c2d91c1fcde5_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i0eba5e2c532643d08b0d85206ddd448e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i61f37e7a407b4bb69c2edc826b1ad2a2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8f07175381b54765913104497ed4a90c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ifcc4b8397c4a4a5cbfc5afa71d671450_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i60171dccd6404eaea5b723a79f5333f9_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i20b03ca0cca94b2cb6387dde26985c9b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i620149fef35a4c07ac902b4826767002_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5f669e13dedf4bf9a965e8c1a83400fe_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0849b4ea29674dd19f07a50c794a4b02_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ibb490cfe0bd149a286b03d9b16aaaced_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id0514ef242a54da29c4d98a28258a7cb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1ed2d208b49b42d38d66bbe62caee7f9_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie5b7b2600f594a5aa2fadc8cc7f71802_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2576e6aa19bd4f7589777471e9b72143_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i78fdf8bb361f4fd9b717cad18dd32d62_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i0ca3908b695440b9ab57b7d0a7c3e94f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icfeb443990294b3cb5921c60bcfb0110_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib6107835bbd64528a0c3d22e0a42de81_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iee8abdb9b05d4466a2318541bcbf74e9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8f9fc36595b449aba78e7d403ab30aec_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3c3d8d5864694a0abc113e067abc2c41_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iac9dc42aaeba4a198434d55e6de7ff96_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2fc5bbc6288e430fa5c2521af7bb0b05_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3b895b26e49b4635b42b1536f531c608_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3d2ebeab6f904ed1960851a888d27083_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibc9626d02b2b410c86ebc7380f6c4249_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i383e3f60f86e4defb334fbc762820aa0_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i6453b112716e4400bade7786533a87c5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id571d247cd4b4ca39d865b8901589cdc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i69e3e0394dd94e10b095ea1364ee1671_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i10bb37e48c164c179f00b0da6b6266a0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic913c3a623e0461ba7fbea0de051f46d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idd9a2cb546bc494abb88fa69230744b1_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="idbb7775a898b4aad918975b899e54d3c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic31ddfb9acb84d7bbecc428a4394ceac_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie383e52a0d0e485d99e09377f32f2729_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia43b359b238e4d539c59daf943bf60eb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i80d21d69338a48978058495fdba87e9e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id13a02795b0645bda0393c88f521bbdc_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ice7c35cec2bc467f8499200ba6d32b5e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id16e7c1fa21d4e23b5881fbdc5d62704_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9f31422d2f4045b2b2c516a07d33107a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia0dd0eac24f4401fb171f8f4befd046e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i75c99618e8464f48b02c5800078fec9a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic411305d926f4262891fb8f8d32340ac_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="icf10274f9c344290a2ab99e9e34ae3e4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3de8d88c34794c23bebd5f7b5eeb5a8b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if49c3568a0f94b3889385d83ac006905_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:VELCADEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ibcf70cb300d841aebfe5a712007444ac_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3ab5a5f92fd941b288007441e9cc4cce_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i70838a32f63643e4a2f7ed13d212a9f0_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9e56b017393d48d9951e1963e9232f4e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5ec0b61f3e194449b1fc8232df6eb583_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i485ad9e4c9034407b529d2ddbbea2b28_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i068cc5432b3443beb8e11bb255e1e28a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ief79aa5fc89943f1856174ad8ab48c03_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4f6b259e70b34438a3f81e5332f8a6c9_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9cc3d26ae55e4532b24a34603fb51a5b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9c1612d385f0492da9095801326473f3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2a5d890f9dec439ba519c396e28a1b15_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic3432837e0994dea9738f6a9041dfb78_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iaf5720d7e06a47ec9ae85f4a20867f7d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7fce5a20ed35426db5a791a058567b31_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1fc0f82712f04ab1abd4713c5eb8122f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia4837e00061842c3848e83dc581c7c9a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ide8fc9994e3f4e679de95304641d1e6d_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="iee955b2a5ebc4440b0275a07f42d7859_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i72e5bca473514621971e568c7c81f9d7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7b32854703604f20a5087fc9da993d60_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie0bb8ef73842461881c87d256616bb58_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7f138d8eba8c4b139d79c8bdf04273e7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i513474c437a54da8bdb8d39a5690e05c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib8d33d060c4c47bd8ac7257d692df0ce_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9b7524e3946646b9b75238c6c4fda704_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if800a3c44fd14c1c8c9443c13229ce64_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1dc918ea034249e7a645f7ddf9922377_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0f9ad324b0e34c5b871ca5b7f591fc74_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id7d4dc4f88674bb784396e7150b232c5_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="id6b475ddaf2045f5b7e3e9c0ab7ddbc3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i78a58229b38848a6acee4aa1ee9a792a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ide3b9a020380440b8fe140b751c16e56_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i33f49a3f10784cb980bc81b0bf707db4_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="if409308149024b7ebf44549391b1ef28_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i48809d31e15f48cab0409d4e65adf936_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6e587520c5424f6895bb82d180fcead7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i15a298df88a04792b4eb06c9649f9c9a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1e5ccb426ed040e884937136da490957_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idbd627d84f8348118b3790e6522ee21e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2c1196be4a434582a11b0f92c5c054ae_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1c65c2e67bfc45cab7bd25c746b42db7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iee23e589317a442cbea6d9b4f7f79caf_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5255e36acbac418e85f849dfbdf10496_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i01c2543a19ee466493df5660744c8c1a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1bc4a076e7284a2eaa4ae25d6f7d0578_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i24218d83d9274436ab41302d751e3b17_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic3a92101e57d4ab0a5d2910e3c72d8ae_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i89b895fbb6804c319ca67eaf7a7749c6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id5474c52ea0d4a31a03b189d9522cbc0_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i6eeed4adf30e4bca9bfe818ab7159933_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6b55966cf5b64f81b16f40f0103bd79b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia72ebb598f0348479991c9709cd38a02_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5f3afdb891c54b018f5398d3af12ce2f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2964812dbd3b44c7a03684da9a06461c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i486c300ff24f47f0986efe5804106361_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i73e672c1ca294c19899b6194a13b72cb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5af8e2c89c584232828bbabcac9bc95e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if5402a284a5544b0ae6e3a3a7f7b8b18_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1d83c054ebbe4b55956a90c090dbf071_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i09262051be5d4a8fb49e116b991a4eed_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i59c5ed77ca06492184b99ba7d305dde6_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ied6485f71b8341e9811ab2c75108f37f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i14a2e2d4cb5a408b9c5fd9d323011fd3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic35c63055c2f4e329572b6eda58a7637_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i879becad18bd4e95871ce662ed38c9d1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id562b8bf54bb4dafba5e39bc08e96ecc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i83b7a0d4e280466f99120313fab3572a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="if63d4391de1046ffba12c5e6301213cb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i07304354d8544a92ba72a5cd3e890ebd_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibc8ba09528eb4bb28bf8fb46d9ca244b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i480f6951d5234710acb15ef442ff46aa_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7aeca666b4bc4fc8b825d67bbe516983_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3d23b54b71714d9ca21c6e5e0c22bd74_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i165535e13a5d4c17953e1ceaeaf9a636_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i91cabadcdb3c4f10bc97956908c95e3f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7e918889cc434945be946be6a986c17b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9783c1f9b69e46c8847fdb36caed3e61_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4abe8487be1443f188c6f578a79c2d92_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i341822625ecb4b4789deb017f8eacc8a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ibe8b3fbd369743afa2505d9b81d9cd9e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia244f37fb23c45d2a6cd8570deccad0c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i72ed9b3951644e8abc03bd12c9e6b297_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5adfcd1c9908434da345ec1cdc576590_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib343bfa6ba954633998789b6a1a44c3c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i05ec7eee76274b6493178830f9f7d290_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i90b1e5791e5f4ac6950916274d1a1a6f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib6c7c3bbbd614afca59c1426a0da0a51_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id53466858e60466d81703523ed53029d_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib84e7f7d93694ba9afaee8823f713cb8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8899b6c537174b6bbb5cde0f33fd376b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iaf39fa1409e84c67a5e97a853263bb6c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i98aeab42d1474d458315de624b42191b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie3f4bd5c13cb4fba9645bb22fcc6521b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7d3c1d6bec994f689672b19d7ecd0241_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i17584700f12d46519383938af1d81aaa_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i118e59fd747d42de9edbb08a4f24b0ba_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6189787c7fe14e36bbdd2e76d9f9f4c3_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i94060b92688f449b9834a0a900890956_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7be240152e5849b4b1feb9af434e0747_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0b7c8be14d314237b657ffc8dd65696f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic73286ade02445b5a9462beaac74a9d3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0f577a1a44334d43acea15693cd75f1f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idab38ca802ca4be19e8b830de0bd397f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="icf88388476f7405085cc966583cf4258_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6c66119908c84aaba2703e6fe5ffeedc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i59ccda52b00f47bcb73709353baeb316_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9f8d35a5e5ef4407bffb29a594a0b67a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i8ef4d0b58d4549e9bdb73412623a21cc_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i602f30549c0b40dca5fd1936741a49ad_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i82c25e6b99024ef091459862efb9cccb_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i86e4feada2044b02b8313b9e00c0baf3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i84231515127f477eb578427ea2f07294_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if83acb0fa39e4ec5b03d0835e324823a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie60adb8fb0924a0ea419ad5f553698f5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia8d5ffdf03b74d129cfd23b12757518e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idf12e303cd9b4f9fb10ed1589f36e8b6_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="if24fa043dc87454ea84b0044287fcaeb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4adf09a8d993410584b7b18acfb4bcbb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i126f946d4eff41e79ab7d3a7a64eecee_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3840b8b2b071410383b4675e805cf313_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i438f65df2ab74a928e7eeb7a53d02ffc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibfd684566d004f179917d4aa4d8f8074_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia90b9c38b8ba47e296c57ea9b6458d43_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i87926cc32eaa46ecad04830aafda7bb2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if03ba8d91f4e4f95a4fdce30f489c09f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i144f5567202f48639bb4c9aa1ae3ae2a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4d98497323f94faeae1879738e0122bf_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6d2a5de64df24728adc2bf05ed12b93b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="id4513084142340079843a021ce48dc83_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if15cbbc611c14b21845dc1db3b286330_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2a7fdaef25374c44aa45e900e5e25eaa_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i2ff8717040d04c1fa009b692e8390c77_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic78e09ea97bc419d9c3c1d2ecfb21982_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib09b4f177eec41fc949ba626af3d336b_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i984713bea368485d96053638749455fe_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id0e007c86e9f4211a41a7172c74f9c4f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4b60c868bb3c4036ae62855e7e30207f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i70fc17a765d04f8ca815d5ff108cec48_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iabedf0861be54d2fbcb151e97d5f1c7d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie905100914424975b112e4f3270118ce_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5092dd6970434ce3ac47038270cde937_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6813483c57994daeb367d9fe1563ce78_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i22ef9ca58c57427da68fbca6011ad745_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1fc9621c078648dcbf56a98adff1c4c4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i24f6dafdf0c741be8ac3cdeab113c489_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if93a7c1c81884a3db1790c74e2bef12c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i04eb94163afc4fbe93b4ab697abbfae9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i902ee0627dea4cd5bb60dc3491346db1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iad2fbad72def446b993089efac46d5a8_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9cf163dd98ff4ed8968cab176f2563bb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6c4892515aa44a64a0209fc1e0bb2fad_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i37215466423046af9249e8abed9ad02e_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3906b91aa1a748e0a8a00991d75431d0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idc4d058982654390a2a9623f748a295e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i026871ca845542edba6aa179e4c87502_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i95433015053341168b9d624012babd6b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifdf587116ba149d5bcba993340189069_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6fd6b74d14444536bdddf7ba271c1cc6_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i99d6c4422d1d40f684a09913056b9472_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5a281af66cf04b96ba6e7ac36ebeaebf_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0196237488ef4eceb6b0ea1bd91e0dbb_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i10b655adc4f8423ebd42175f161edd73_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i78c26b4e162a49b9b197f1640463053d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1769fb5f785f43cf8b7d381fe86af413_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic9d9753225f044ebbfafcd3370a90ed3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if13294f9754845688655bd40b3653471_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie09529f945de41caaf3bef2e44de7877_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i03f5c7f59b794e47882cf0b139603a2a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iee94c42379ca4ae7b59723ae48eb43f7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibdcdb5946b6e40db92ff0a19f1cde8c0_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3fe224c1cfa742a4b21d4f7862c83e03_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if064eea59802474d80fe24566892332e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie0883d7bb7144c62b0468b8a4d80e4e8_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i1981696707f74ea485655942372b2873_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i937763a9251e44e7955bb4a051ffa322_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9c754ff60a3c4d0f8af0b237cc3e417e_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ibec42c4dc9ed465e911fa5c37e44ccf7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i392c683c8aa34ea48aad01f0ea87e36d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2c0ee73c79784b42b048a39b82f15449_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i999165b6e8ed4882bd941a2d188bcf37_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8caff817f2b44b13b3564e9cfa3e7994_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic7f935698e0f466fafbc30ad31035145_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i6e4986f2ad3a4f63a2c9caa1b763924f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibec43032d4244efb878a5a63619550e6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i69ce0e7d756944dab4eba19c5dd8a08c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i4f63065772bc45baa7b3cae1ddb30035_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie86b777937ae417b9621ef2d6deff23b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i62a6a11dfe68475a8e53247f2ea77b46_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i94beb64c27374b788645e22ad29711ab_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibb9802f870444ad395ac0a641a75f539_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7dfc9343e80548ada1bc35627fe66ec6_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i18b4a8e9fa4442188bdbda3ba66062e6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic17b6a75086b4b339878cc6f6e4ee32e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i729754834d2e497cb672920410a2293f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic99d3a2205024fd7aa3983a217efd24d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia3a672c335384c4b8c7925ba2498c104_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i593bcd3da2134b72a6c456811d3bc68f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i06378183c0c04df6aee2790130a1c904_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9550ff545c364be7bf6bf5426c596967_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6c31bf3540b249a5abfdb33d6014307e_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i751b8108d9d349959d4405809c8ab185_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ieb989f6f7b574d94a635536180d59536_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i581f35bde0a74622a88029dde8d73d94_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ic132a1e2f99f416cb0d2e0b8c3db41d2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i01c7263d4b1b4d6baaf5dc29b81024f1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9fd3d0d30a41486ca32673d4a704becf_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="id3f31428fd964ba5aa8c86b194d7c991_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic706f0504b304e95a8c897adb4eb5bdb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i90e188e5ac28451ea93d0fd0cf9f30b6_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="if72196f5c2fe4ccbb68e25e0300f191a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i05c0225e9d5c41288c143c63de199e35_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i079eba6ad58c4cdaa2289aea2957a33a_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ib235d8407dc543329206c5389bc899ed_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0fe938c1143d420c9f0d0cd44b50a6f9_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i58266c3fbe6e420ba392695ba369fbac_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie3362deef6ba432593d2905bb07487d3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i34d31af3f79b48dcbc05247b533fb5c8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9b492b8ad5b746c4af5adfc5a3bbe67e_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5079c809180e4e87babea3c6989b7547_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i17e3d6f06df7480d93661480c79c1945_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i58588fe179f34bbabe168069b7a7b71c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie24857abc09b4ecfa16764d38c143530_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2e939c765bc94e7bb66e7118c3f4a40a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i37350417ebd24c1ab07e70ff74cec182_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3121943b0bc44e4988cad36f10e55132_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i93a0dbe0f615447893dc66aacf30202d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2433804bf27d4a1ba35c905c2d32c4a2_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3f554723bee640bab353dcfcaa1353a1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9f7ebf2e8efe428dba5d7904ddaedacb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibf8d7c0a664e4c77a5fbeba28997ebfa_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i642be708def7413dabc7b84d041f991f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i47de1912a2bc4859b0defe8556c3f667_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2df63a4309a0439b9c69ba7538fca3be_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i077c5383de0a4ef5b6e04faef9537701_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ieae4a2195e634b988c290e9a18191ee3_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if841232101534f53b580eec2b5065a8b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i2edbe06fd12f48158aa18ec4e99452f4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2244f03ed8794c27a6ca06574aa2e8bd_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i2bef2be8cac3404983af1188af384ef4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i05c2d444872e4307aeeecc3b63c90b14_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iadcb5421eef24006804c7c3cea1e9fcb_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ia95e9493ef57449b82086c14a005a57e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i95d8373ae98f4edd99b0fbc74c83f2b7_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5f8bf98199ca4359a65148eaa4b30c82_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3a0c83283a7a4e978c00244503b2a25f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idf6cefb7c53d43baacb94f6acb2d8f23_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i0f65207fc7f44ad2ae85cee82bd938ca_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i742ec0e39c9e4a5aa684735e52151b2d_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3b28a8f605f94f75b14c686dc2522e6a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8d1c8604abf643c9a12b71cd7d31eb00_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8e5dcf1d4a1e417bb4b42eab3fa4b8ac_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ie728c62d2459463bb8fc5167f5c487da_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icaf1dfe1a8b944b8bc2c86ec9a44bdcf_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i67c617cfb7894c9d832fc9595def2dd1_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="idad324e736f04bc29364176151a23e2a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6887fdffd35c41348f9aeb0c27b07ba2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iaea71296fec64699bfe2bf754f22f26c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i0a788b9d1d084972933b07d5c268c034_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i875011bdf5ae45a088eff8aa4e901299_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie8e58bfcff40486e8072fafaac9bd118_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i31e3eb051f454593ad2310cf80ffb554_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i079da15a84a34e4198ff651865a8038c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i12c62fc9b4be4d35bc62769025bc8c59_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i1befbfcdf8fc41b68d2d73068d97c2a6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5579c03fb48a43a7a109405d767a3964_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0d3881ea9c694735ae5a5c61f3442642_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3d15cee058f64c2c9ad5c5d19645970c_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3fc3b1a2bc054935a96c8c42b944c4ca_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia9a7c95098b948b58ef457213dbf6381_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i221d578ffbb64653ba21c30b54079cc0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia3b64bc0f1de4cf19d38861ea0a431a2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i748076e324e04eb6876fea17432e0764_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="id4009a5bef5c4d3e93a8d64a351d480c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ied02b691df1a4793820eca15169c551b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ic94bee8dba224f25ab579c909f351412_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i035675e545034a8daa97c38652231215_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id9e242133e6a48148ee336086579aa09_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i94f6eed880b84772b8aefd785e874762_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie2df61011b564018ad5b03df881363ff_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1f14ae1615dc4d17b4edf556db9b6006_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i62050a01eb854e2383bc3ec498ccf086_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i808364999df6460a849022d9b066670a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2e2e498bbaa444e9ac4c96b0df2ceafe_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie6728846518144a681a82a2d46f3f018_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i61dcd5aafdb0485db71a09a4bad0bcb2_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i085fffe12cf44fa092d9246b89d54cba_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="icb9530f3d6cd435ba9e67542e9eca210_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i911bd91ee4bc41389629447824db808e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i619793eecabc489ba4c2968bb061e22f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ActelionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6f0cb54bb4974193979769bf8aec917e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia0899ff9af5041b68f780bfabfc0a5f0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibd9e566fe73f466bbb7ee14bb2b8034f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:NIZORALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i3d1841e88ae54dceb0af523351880c07_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AliosBiopharmaIncandXO1LimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i902af15964e14194a303f3a664cb5d2f_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:XO1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i750e6f140fa94894b04bd3d8acbe99bd_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ActelionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i58e829bbfb07485da5515f522d722695_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:PANCREASEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="idcc4dd426fcc453da67295531f6d0a7e_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i527f590d7fbc4382b88ea8ad34d70258_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:LifeScanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="i9cf7c5be7f3c4332b89431499d7c18c8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8b3c10dbd47946ebbad7615c4da0af0e_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i8d63527739004691b878d7ebe2f0a1b6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id21a208c5c3e4881b44ca05ec83a15c8_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i64316c7eddcf4074a9e3ee4d29f82ef0_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2020AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8731480903f6482bafd102f3dcab3c69_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i87db8efd958244a086dfb46539fdfb06_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="ibb66e5604cfd4dbfbc2df6782a9418d5_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i9bf0b675d1ee4f0cad2d1afbe56a8367_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i4ce3e1e959704f30a9e61a34717734cd_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i89223357c4f64e06b825e78a40cb5914_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i293ef2d918614098b4af9e84d27cc0ff_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="icdbc095e470a470e9234a55fe342dda1_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="iad9394419046465abc7a8a563ce9e079_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i60b1b3c5341149fca7bbc49f7508a82f_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i9554efac170a48719f2fd4fef3bcbdbc_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2019AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i7466a929aa8c4da48b0b5cb2da5733b3_D20190117-20190117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-17</startDate>
            <endDate>2019-01-17</endDate>
        </period>
    </context>
    <context id="i663d1a94c8284c94915423956a325ff7_I20190116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-16</instant>
        </period>
    </context>
    <context id="i7648739eff244460aefb5458b95e548d_D20181231-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7ac7036ab4264656876135eb9e269635_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1106f749feaf4b4cb34daeb9bbc0f5ac_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="ieeb51f3819d4439da404f8ebcd058d23_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i1b2666b42496425cb2f87473681fa480_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0d2155f5644e4dce929f352545f25b9f_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i64e9ef76a8044ece8caf57dbe8808101_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="ibbc2347889084c24a2bdc712e0cc9afe_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="if510052c46844b89bee55dd2cfd123f1_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2018AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i247bfdef30e445f58022d1b433046fee_D20210131-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-31</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i9f90809fb51f474687fab70275e523bb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i59587efcd1fc4831b82133e2feac03fa_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ifb3df5df054d4ba598290335491d4bf2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i9660ad42e8a84744909a1e88ade1ded0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib62a0d3a2f984c819f0cd7b260d86045_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:LifeScanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i6010a5c09da44a07ab46d7f9c737f126_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i41be97a9ae2043408fba6895a0bca20a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iff7c87d97d384ee8b13f6b2bb84ea65c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if9ba6a98f87b46e1aafbd453b6cbee6c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id60518cf26184f7a82d1ae1e544e152f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i29ae50e5d88b4f2faf456858615a5efb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i819517bf3729470f83f19c033eb4aeff_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib8a1e028ec54452c8c607218170270d2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i967a3fc676f546c3a8ec55596e5787c8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4c869ba4eacc4ad3a8ea220ccc8ce54d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i164e958688a24886ab9f0f49cc22f175_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i23d356a726004e2aaf26a0f9b26a887a_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i5afa073421a4484a853139dff12ed57e_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i6c1602e34a30408c9b6b1eb1cf04b157_D20200601-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="ib585935f9ab54509bc2c182dc59b672f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic3622ddfe4f643408286c1811a8e2b4d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpiodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib66ffb4e00ec4bfd99ace0da88568cd0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9e799e62cf254001826c3bf820d212b7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9d76339e798d40b08ed4feec1c3cae2d_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i58f5234f04df45daa5a30c1a7134b2bc_D20200120-20200120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-20</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i24d9eecdd6ae4f3982b1ec0858319020_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i85fbe5d13d1a4ca09991c8182c6da15a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9e552d1e71b44a168a599c7ac19462c1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic6a8b086cd8c45da82107e88550189d0_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if57129aa1e5d4dd0b0777a7d8ed0c1ee_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8f3db082046d4ae0b5256a896c8b18a9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i66486cf0443e494881f3ec5e470b3cf6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iec0388b7a5cc4f76940dc1229b081637_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8dfa403febc6441b9219104ff7cd304a_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ia0f8b2a1ad4d49c49598e20c0474fab0_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ia94268397a144c34b6f7724fc2cdb014_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ifa2c59fc0efa48c49cd68b3b84b0c5f0_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i459a0dc9569c4a9aab6a75035673c567_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i29c7279bfa824e409e9b9a1bca808c58_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iac916c18208c47b09c67460db8030f1d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2ca0b385d9944272b5ded6645bb7a626_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i510e7e5ac227414a98e421f182a041c0_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id5dcc642308e468f9618c6b56e3244fa_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i7e8af39bf4fc4285b5f5f5676ae6623a_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i1e8b0d8063934ca2b90208c4804102c2_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9c7895941dcd4d76b03e835972649586_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic98eded4ee3746d6af8c7edc2e830f5b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic7b6a6cceab84226b776a371d5bbe868_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i98674305aeea4bbab7dbaabd6920816d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i57c8bafe3cd14d5c9e1491d8bbf1f32f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>jnj:Employee</measure>
    </unit>
    <unit id="segment">
        <measure>jnj:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="stockbasedcompensationplans">
        <measure>jnj:StockBasedCompensationPlans</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="patient">
        <measure>jnj:patient</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl8yLTEtMS0xLTA_4374aeea-554a-4170-ba3e-5092aea088c9">0000200406</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl80LTEtMS0xLTA_cf3d262b-1485-4d27-99e6-1bfb44e43a69">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl81LTEtMS0xLTA_ba56b40b-b8b5-4790-b6a0-13976d6dc99b">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N180L2ZyYWc6Y2IwN2ZlY2I0MjQ4NDM5ZDlmZDZlNDRkM2QzYWVhNTUvdGFibGU6ZmYwMWM1M2U0ZTMxNGM1MGJkNDE0NTc2Nzc4M2RmNzYvdGFibGVyYW5nZTpmZjAxYzUzZTRlMzE0YzUwYmQ0MTQ1NzY3NzgzZGY3Nl82LTEtMS0xLTA_3df08fe7-1a66-4a8e-85f2-1e1d1b2ebdd9">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92">us-gaap:OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0">us-gaap:OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAw_50c9d071-d9ef-47d6-9139-e15972b2b906">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6MGE4MTE0ODhiZTEwNGU3NWJmODJhYmY1NmM3NGRlYWMvdGFibGVyYW5nZTowYTgxMTQ4OGJlMTA0ZTc1YmY4MmFiZjU2Yzc0ZGVhY18wLTAtMS0xLTA_dd13ce5d-7e4c-4e88-8fec-56b710de6ab6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8xMTY_e7de1bba-dd0e-4015-81f2-d590dbaab9c9">2021-01-03</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8xMTY_bdae9209-6a1d-4a8c-b1fa-e40ff2a813c5">--01-03</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6M2EyYzBjN2M1MjM3NGFhMDhkOTc2NDQ2NjMyNGZhNDAvdGFibGVyYW5nZTozYTJjMGM3YzUyMzc0YWEwOGQ5NzY0NDY2MzI0ZmE0MF8wLTAtMS0xLTA_fe93f907-28b7-4a1b-adbe-585a06401eea">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk1_ecf1ca67-3dde-4c38-9fa2-d07668969ecd">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDkx_8715e1d1-54de-4654-b3cc-d89c3d88bba0">JOHNSON &amp; JOHNSON</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6MjMyYmZlZjZmNWRlNDk5MTk5ZTQ4ODA1NDY1MmNkYWYvdGFibGVyYW5nZToyMzJiZmVmNmY1ZGU0OTkxOTllNDg4MDU0NjUyY2RhZl8wLTAtMS0xLTA_d1fca63b-2b48-4aca-ae4f-db23812d1a69">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6MjMyYmZlZjZmNWRlNDk5MTk5ZTQ4ODA1NDY1MmNkYWYvdGFibGVyYW5nZToyMzJiZmVmNmY1ZGU0OTkxOTllNDg4MDU0NjUyY2RhZl8wLTItMS0xLTA_38956f93-45e3-4552-b8f6-202791d76439">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDky_abcbfb20-dd30-44d9-a738-bc5a114ef3c6">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk4_af8aa92e-87f0-46c9-9e08-c8fb488d9727">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk2_3a77efd8-5c5a-484b-9218-247407b10365">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk3_30284606-6309-4d7b-aef8-ca1b736f3134">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk5_67438a82-c537-4420-8704-378a19d8dac6">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAx_05d906a1-2820-47d0-a34c-f9eca361a5ff">524-0400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8xLTAtMS0xLTA_c28bb7e2-d58d-4d4b-9328-0fd7f12d068c">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8xLTEtMS0xLTA_2b906bab-feca-4316-89ae-7b2e1cc240e8">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4af19fc7a2e34566906ea7469a0cfed8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8xLTItMS0xLTA_85e76268-0b92-4c1b-849f-2ef752b1f206">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8yLTAtMS0xLTA_233b261e-2950-4288-a536-c0223c7817f2">0.250% Notes Due January 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8yLTEtMS0xLTA_b0e5f166-246a-4806-8a93-f059e22381b6">JNJ22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6b299c1322604a48909da3fe0459b71b_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8yLTItMS0xLTA_75408e62-aff2-4b01-aaaa-a503c6a56d59">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8zLTAtMS0xLTA_be3dc72c-1a22-48a0-b48e-bb56854c9795">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8zLTEtMS0xLTA_e87db860-870e-457c-8a5c-db13d9c61e5b">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic87f1e525a88407ba11e82f2736308e2_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl8zLTItMS0xLTA_70814b9e-4208-46dc-b989-47194b8d37d5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl80LTAtMS0xLTA_28a0bff7-6e36-40f7-8390-80ccaf2cde6d">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl80LTEtMS0xLTA_adca03a0-57ee-420c-aca5-102d34f3ca80">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i42152ba5be3143c19862cf46dc4acf49_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl80LTItMS0xLTA_04dc415d-035e-4a54-8c4b-51ae1da48cfc">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl81LTAtMS0xLTA_fe49863f-9646-4def-b17b-3673873e514a">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl81LTEtMS0xLTA_40f0525c-33eb-4ca4-9ef3-fc6f6d62fc01">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib032cebb39c64cd999f418df58f0813c_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl81LTItMS0xLTA_d4a642d4-ee88-4813-b0d1-fd8dcc006639">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl82LTAtMS0xLTA_91b959ac-6c03-4d42-a531-db6e6aac2535">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl82LTEtMS0xLTA_344ed559-c844-4970-9e21-18b447ccae9f">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id34c83e711854c8bbef8835b2a99e901_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6NzgzZjk3ZTE2YmRhNDRjZmIzMzYzMDkzNTMyMmUzNDYvdGFibGVyYW5nZTo3ODNmOTdlMTZiZGE0NGNmYjMzNjMwOTM1MzIyZTM0Nl82LTItMS0xLTA_2d86e60c-8a4c-49ab-95a3-0453e9a89527">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAy_1dee311a-ae7a-4bdd-8134-25befe444b8a">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTAz_17c501ae-18e7-4b6b-936a-2629be583ca1">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDkz_217c7b6f-d7ec-4400-b39d-f1b747863db6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDk0_9265d5bc-bbfc-466c-af52-791de18f550a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6ZDNkMGIwNjUyNDg1NGJhNzhjYTJiNjU4ZGZiNmEyOWUvdGFibGVyYW5nZTpkM2QwYjA2NTI0ODU0YmE3OGNhMmI2NThkZmI2YTI5ZV8wLTEtMS0xLTA_4d87a64c-5306-4259-8e69-33b98ac20efc">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6ZDNkMGIwNjUyNDg1NGJhNzhjYTJiNjU4ZGZiNmEyOWUvdGFibGVyYW5nZTpkM2QwYjA2NTI0ODU0YmE3OGNhMmI2NThkZmI2YTI5ZV8xLTQtMS0xLTA_d471b9c3-77d1-4c20-8797-148822e62d2c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGFibGU6ZDNkMGIwNjUyNDg1NGJhNzhjYTJiNjU4ZGZiNmEyOWUvdGFibGVyYW5nZTpkM2QwYjA2NTI0ODU0YmE3OGNhMmI2NThkZmI2YTI5ZV8yLTItMS0xLTA_e4744fa6-14d5-4d28-9551-406bcc6a5748">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8xMDQ0NTM2MDQ2NjgxMw_f709ae2b-80f3-400b-a1a1-f3fcb01a18d3">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNTA0_68b47266-6b17-468f-aac0-95c78bf69ab4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i8686edd54dc143a7a78f18f215ac305a_I20200628"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yMzc4_b65f28aa-bfb3-4d15-ad75-a8e771ba6c3a"
      unitRef="usd">363000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2614e18acbee45a8bd82ab8bb34954d5_I20210216"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xL2ZyYWc6YzI2ZjMyM2IxYzg5NGFmZmE0Njc1NTQ4OGE0MmIyMGQvdGV4dHJlZ2lvbjpjMjZmMzIzYjFjODk0YWZmYTQ2NzU1NDg4YTQyYjIwZF8yNDE1_b29eaf02-2efa-465b-be65-465849ad3d1e"
      unitRef="shares">2628679824</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMtMS0xLTEtMA_7cff0b4e-e9ef-4e0a-9363-bbbd845a3369"
      unitRef="usd">13985000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMtMy0xLTEtMA_beb83466-7f44-40cd-866a-c18321af9cdb"
      unitRef="usd">17305000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQtMS0xLTEtMA_99aabf6a-92a6-446c-b663-554f93707e63"
      unitRef="usd">11200000000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQtMy0xLTEtMA_b07bff83-8d5f-4eeb-832a-f27f482612bb"
      unitRef="usd">1982000000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMC0xLTEtMC90ZXh0cmVnaW9uOmI3Zjk2MjMzMjBiYjQwZDA5YzUwMTYwM2NjY2U2ODdkXzEwNDQ1MzYwNDY0MDAy_1f806fa0-beb5-4608-865c-f066168089e0"
      unitRef="usd">293000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMC0xLTEtMC90ZXh0cmVnaW9uOmI3Zjk2MjMzMjBiYjQwZDA5YzUwMTYwM2NjY2U2ODdkXzEwNDQ1MzYwNDY0MDA4_a0448510-1ede-416b-9acb-0566759d31b3"
      unitRef="usd">226000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMS0xLTEtMA_50c101a7-ab9b-4a29-b9cf-0a83dad44695"
      unitRef="usd">13576000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzUtMy0xLTEtMA_0f3d91cf-d266-4c0f-bfdd-255c54971641"
      unitRef="usd">14481000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzYtMS0xLTEtMA_6043f179-e24d-40cf-ab57-97fb375bbfc9"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzYtMy0xLTEtMA_6e7101e5-fc96-460f-8400-d81c927ad16b"
      unitRef="usd">9020000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzgtMS0xLTEtMA_03f75bbb-1710-44e7-b48d-61369263f242"
      unitRef="usd">3132000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzgtMy0xLTEtMA_96111967-86ee-4363-917b-c6296d69b436"
      unitRef="usd">2392000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzktMS0xLTEtMA_b7011065-47fb-479d-a158-6297e101a7bb"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzktMy0xLTEtMA_98bb605a-043e-4f2b-ba9d-8ef90066a28c"
      unitRef="usd">94000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther>
    <us-gaap:AssetsCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEwLTEtMS0xLTA_fe7f1501-3e28-48f9-8c76-22f941e13a5a"
      unitRef="usd">51237000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEwLTMtMS0xLTA_aa31dc7a-932d-4db2-9a20-072f2d4576f5"
      unitRef="usd">45274000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzExLTEtMS0xLTA_559a4e40-0352-4aab-93f8-ff3f0e4396b9"
      unitRef="usd">18766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzExLTMtMS0xLTA_0e0e90cb-bafa-4ceb-9894-8cbc583b81b3"
      unitRef="usd">17658000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEyLTEtMS0xLTA_b279dd9b-ab45-497d-8de6-276a8b1a96bb"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEyLTMtMS0xLTA_8e1802c9-f9d7-4424-b6aa-c85732be4828"
      unitRef="usd">47643000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEzLTEtMS0xLTA_b004e358-f0db-4b27-b61f-ac5f9fa43940"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzEzLTMtMS0xLTA_37910069-73db-4909-9e42-3c70f630a648"
      unitRef="usd">33639000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE0LTEtMS0xLTA_5bc882e6-b59b-413d-8d1a-7d9e663a6371"
      unitRef="usd">8534000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE0LTMtMS0xLTA_1897e2a8-0ead-445f-a59b-1f71037aa592"
      unitRef="usd">7819000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE1LTEtMS0xLTA_de3bf9b1-972e-4b85-89a0-27675e62be19"
      unitRef="usd">6562000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE1LTMtMS0xLTA_3fd94708-cb3d-45c9-aa0a-faabfc5f7e3e"
      unitRef="usd">5695000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE2LTEtMS0xLTA_e158f724-df9e-48ca-91c2-42106bd693ce"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE2LTMtMS0xLTA_02f576f4-c284-4216-a6a6-3c3e44491f9c"
      unitRef="usd">157728000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE5LTEtMS0xLTA_160eda75-7ae4-4714-88b8-b87310da6c34"
      unitRef="usd">2631000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzE5LTMtMS0xLTA_130f2f71-a788-42a4-b9e9-b23c84458de4"
      unitRef="usd">1202000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIwLTEtMS0xLTA_2e714b38-9a20-4459-b75d-cf6965b70705"
      unitRef="usd">9505000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIwLTMtMS0xLTA_11248ea8-2b85-4910-8de8-512b78d565f9"
      unitRef="usd">8544000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIxLTEtMS0xLTA_9b4965e1-1d35-4831-adbc-e812ea89799d"
      unitRef="usd">13968000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIxLTMtMS0xLTA_76c16027-0257-4ac0-b411-1fd71191b882"
      unitRef="usd">9715000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIyLTEtMS0xLTA_6c44d427-b1b7-4f62-bef3-6735926d808b"
      unitRef="usd">11513000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIyLTMtMS0xLTA_12109b4b-7287-4049-a898-686ab31aa66f"
      unitRef="usd">10883000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIzLTEtMS0xLTA_35a5c9a6-e04f-41fe-92e3-122861a221c1"
      unitRef="usd">3484000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzIzLTMtMS0xLTA_14d1971b-ccda-44bd-bace-f9ce1bd875c1"
      unitRef="usd">3354000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI0LTEtMS0xLTA_9a5e937a-d82c-4607-b85f-6225e189209d"
      unitRef="usd">1392000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI0LTMtMS0xLTA_385353c7-8a1e-4140-92d2-aac550f35aca"
      unitRef="usd">2266000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI1LTEtMS0xLTA_f4cdd2eb-948b-4f25-b67a-b130d1cd07ee"
      unitRef="usd">42493000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI1LTMtMS0xLTA_3bd205da-94b4-41c6-b33e-582cbdc3a0b6"
      unitRef="usd">35964000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI2LTEtMS0xLTA_74f8154b-3269-49f9-a1c4-1d85fffc2744"
      unitRef="usd">32635000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI2LTMtMS0xLTA_9c16aeac-74e7-4b5c-93e3-5f543f6e934f"
      unitRef="usd">26494000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI3LTEtMS0xLTA_f9476d30-b455-4e03-8b30-b6c373caf5db"
      unitRef="usd">7214000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI3LTMtMS0xLTA_c7f26d3b-6b31-4a8e-92e7-2b0fdef76e95"
      unitRef="usd">5958000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI4LTEtMS0xLTA_2661efa9-441f-4e0b-ad47-3d216c39a6bc"
      unitRef="usd">10771000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI4LTMtMS0xLTA_1cbe8b4c-af5b-4bea-accc-26d7f5beec0d"
      unitRef="usd">10663000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI5LTEtMS0xLTA_caceb2b8-1d0f-4696-b916-26f0579a77d7"
      unitRef="usd">6559000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzI5LTMtMS0xLTA_d5970415-3aae-49ff-b1fc-4b1fd96e1c15"
      unitRef="usd">7444000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMwLTEtMS0xLTA_02c0334e-542d-4f08-9498-16070e408d10"
      unitRef="usd">11944000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMwLTMtMS0xLTA_836c039a-cd9b-4c7a-b0ff-df011ce0574f"
      unitRef="usd">11734000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMxLTEtMS0xLTA_65743cfd-0eea-43af-86fc-5c0616c9b3a7"
      unitRef="usd">111616000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzMxLTMtMS0xLTA_84a97ac8-c6fc-492f-abc4-6bacd6e45950"
      unitRef="usd">98257000000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo3OTQxNmU4ZjBkMmE0YzUyYmIxODUyNGFlMjhjMjA1NV8xMDQ0NTM2MDQ2Mzk2Mw_b1ef37b6-e83b-41a2-8837-007f725314b1"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo3OTQxNmU4ZjBkMmE0YzUyYmIxODUyNGFlMjhjMjA1NV8xMDQ0NTM2MDQ2Mzk2Mw_cc3a80e3-a4d9-4a6c-bc1c-662a61688386"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTEtMS0xLTA_f05e5434-ea08-47ac-9c47-e5d4f1e480be"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM0LTMtMS0xLTA_bb37c7e2-e72a-4572-b457-a43c9fb045d6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA1OQ_031391fa-00b3-4ce8-ba1d-6bad8c733b55"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA1OQ_afe9a256-55e8-4ce6-ad14-7350d3f5429c"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA3NQ_2b2af63a-ea60-4154-99a2-698d31429b0b"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA3NQ_f6e7c478-6c39-457f-8e64-a4370fb84ca8"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA5MQ_45d0753a-3891-4b28-b493-4599f18d5b88"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNjgwOGZhNDljNTQ0NTY4ODNhMDk0ZTViYmYyNmI5Zl8xMDQ0NTM2MDQ2NDA5MQ_bd49c32a-3bca-44d6-9bcf-f61cebf294b2"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTEtMS0xLTA_e0e94667-f9b1-4683-bf05-d03fd0af88cb"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM1LTMtMS0xLTA_4b2e98b6-5125-49d2-990e-5b75bdbfb86b"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM2LTEtMS0xLTA_077cbf96-ae6c-41f6-aa40-73a16e74f9ed"
      unitRef="usd">-15242000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM2LTMtMS0xLTA_0ead9899-c757-476d-b2b4-cdc22d910f67"
      unitRef="usd">-15891000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM3LTEtMS0xLTA_60343a8c-6a84-45c6-82d9-46a76c3ef669"
      unitRef="usd">113890000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM3LTMtMS0xLTA_a4f4f3d4-7f02-446e-ad78-e3907870cbef"
      unitRef="usd">110659000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM4LTEtMS0xLTA_dc714698-4a8a-447a-bf68-5d034db2623d"
      unitRef="usd">101768000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM4LTMtMS0xLTA_93217892-2a33-4dc1-9f3c-cb64b5a6e120"
      unitRef="usd">97888000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockShares
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjpjYzZiNjNkZTc3MTY0MjQyYmExN2VjMzE2MTZkMzg1YV8xMDQ0NTM2MDQ2NDAzNw_784a1d16-07a0-4e3f-8f51-baa0d2a65958"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjpjYzZiNjNkZTc3MTY0MjQyYmExN2VjMzE2MTZkMzg1YV8xMDQ0NTM2MDQ2NDA1MQ_c3d3682e-6d78-462e-ac3e-4e268e645ff0"
      unitRef="shares">487336000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTEtMS0xLTA_99791e43-4434-46f4-ba05-ec68ac6334e1"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzM5LTMtMS0xLTA_20402a1e-5201-4309-b641-0ddc5d5b50df"
      unitRef="usd">38417000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQwLTEtMS0xLTA_1f157a0b-3a8c-44d3-94ba-1eeafc33a8b3"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQwLTMtMS0xLTA_f1dd902e-05b6-4612-b885-622c529fa35e"
      unitRef="usd">59471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQxLTEtMS0xLTA_2ed61015-504d-481d-bf27-6f3786dc8349"
      unitRef="usd">174894000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMDYvZnJhZzo1MDk4ZDQxMWVkNTQ0NmVmOWQ2YzE1MTVhYjY3MGEzOC90YWJsZToxYzcyNjZjYjZlOTY0YzNkODQ5ZGE2YjlhNTAyOWRiZi90YWJsZXJhbmdlOjFjNzI2NmNiNmU5NjRjM2Q4NDlkYTZiOWE1MDI5ZGJmXzQxLTMtMS0xLTA_828c6bd6-7195-4be5-b0f1-eb476365e0a6"
      unitRef="usd">157728000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEtMS0xLTEtMA_edc41550-da2b-403f-84f6-ebbcfa34566e"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEtMy0xLTEtMA_8802b06b-1d17-4524-88d6-e60bcb7631ad"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEtNS0xLTEtMA_73ea1650-c9b2-4b35-956e-38a1331505da"
      unitRef="usd">81581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzItMS0xLTEtMA_00f4788f-cd20-421a-95dd-d133268b49d5"
      unitRef="usd">28427000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzItMy0xLTEtMA_5e63f181-f836-44cc-94f4-88fb34d47269"
      unitRef="usd">27556000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzItNS0xLTEtMA_796d2d7a-a8a9-4898-9e31-5a26469fb9e6"
      unitRef="usd">27091000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzMtMS0xLTEtMA_b5adc7cd-3424-4b37-ab2f-580cd4b8c385"
      unitRef="usd">54157000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzMtMy0xLTEtMA_2228ead5-22ca-4c37-a62e-0661973ca535"
      unitRef="usd">54503000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzMtNS0xLTEtMA_ec9ac78b-c354-4d81-9729-d6a748b1cf73"
      unitRef="usd">54490000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzQtMS0xLTEtMA_ff2beccb-266a-4bf9-89b5-c64201900fe1"
      unitRef="usd">22084000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzQtMy0xLTEtMA_b629c0cc-6a46-46d1-b6a2-d98b65c6d06a"
      unitRef="usd">22178000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzQtNS0xLTEtMA_3c774077-7c9d-4e8f-ab72-e93b5b1f1092"
      unitRef="usd">22540000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzUtMS0xLTEtMA_c8e63725-9845-49cc-8cd5-5b7431e903f4"
      unitRef="usd">12159000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzUtMy0xLTEtMA_9fcd7b69-bbcf-4604-86e9-528f9dfb7029"
      unitRef="usd">11355000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzUtNS0xLTEtMA_ab9d1e55-ae5d-4792-8a52-2e01d0f1abc9"
      unitRef="usd">10775000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzYtMS0xLTEtMA_4d947838-0c86-4437-8d32-5ab029d4de6d"
      unitRef="usd">181000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzYtMy0xLTEtMA_c5e81c42-743e-4d5d-9c11-8fdfeb8a0c04"
      unitRef="usd">890000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzYtNS0xLTEtMA_f0ae13a5-6f0a-46fe-b04b-30260a7d475a"
      unitRef="usd">1126000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzctMS0xLTEtMA_7d54126e-7c23-4a72-a509-67fecd10a2d0"
      unitRef="usd">111000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzctMy0xLTEtMA_eba2bd1a-6a79-47c9-aba6-1293ab8c273e"
      unitRef="usd">357000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzctNS0xLTEtMA_4fa41b31-3e20-49b2-9d9a-2a14631d4f2c"
      unitRef="usd">611000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzgtMS0xLTEtMA_5cb1ad7a-b3ca-4c7f-a905-3187bf654afa"
      unitRef="usd">201000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzgtMy0xLTEtMA_df4e8561-600b-4fe0-bee7-a81b42253844"
      unitRef="usd">318000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzgtNS0xLTEtMA_59926d7e-41fb-4d66-a541-8c68f37dfede"
      unitRef="usd">1005000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzktMS0xLTEtMA_c4926f28-ece7-470a-8c52-3454c08fa7bd"
      unitRef="usd">-2899000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzktMy0xLTEtMA_a79d9d12-9c4e-49ba-aa09-86b4a315d01e"
      unitRef="usd">-2525000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzktNS0xLTEtMA_40371961-129b-4aa6-8774-09fe97def73d"
      unitRef="usd">-1405000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEwLTEtMS0xLTA_6df869b9-5364-436d-9a38-5b95084f44a4"
      unitRef="usd">247000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEwLTMtMS0xLTA_392776c9-f63e-442c-8b33-c0f1399acedd"
      unitRef="usd">266000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEwLTUtMS0xLTA_fee72094-16f8-4a16-916d-6c3d7b2b159d"
      unitRef="usd">251000000</us-gaap:RestructuringCharges>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzExLTEtMS0xLTA_5a276888-60c2-46ad-895c-ad1b1ee5e7fc"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzExLTMtMS0xLTA_93ea693f-d481-41ff-8257-ae7a24534659"
      unitRef="usd">17328000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzExLTUtMS0xLTA_61a5e430-24ca-4aad-a847-638dbd974e9a"
      unitRef="usd">17999000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEyLTEtMS0xLTA_779a7339-7d43-4e2d-8acf-d9d0d6865049"
      unitRef="usd">1783000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEyLTMtMS0xLTA_09601d10-634e-4819-a51f-f5ba246a980b"
      unitRef="usd">2209000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEyLTUtMS0xLTA_748603d3-f884-45b0-8fe7-644e17191e14"
      unitRef="usd">2702000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEzLTEtMS0xLTA_97c84e33-d77a-47f1-a1bb-f5a0073f02b3"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEzLTMtMS0xLTA_091fd51e-026f-48d8-9e65-b9e11e4506b7"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzEzLTUtMS0xLTA_580d4857-1c9c-48e8-a0ef-d67f260cb531"
      unitRef="usd">15297000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE2LTEtMS0xLTA_3876ec82-d604-47f6-94a5-cf2cc277c2ff"
      unitRef="usdPerShare">5.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE2LTMtMS0xLTA_f52a37cb-af96-4170-8d9c-edfba893ef9c"
      unitRef="usdPerShare">5.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE2LTUtMS0xLTA_07cb47e4-b717-436b-a6f6-ef0f5d2fbbec"
      unitRef="usdPerShare">5.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE3LTEtMS0xLTA_407ccd2c-f7ea-4511-8702-89a935b5babf"
      unitRef="usdPerShare">5.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE3LTMtMS0xLTA_7cc44f1b-cad3-42d6-8c7e-9a60173c50dd"
      unitRef="usdPerShare">5.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE3LTUtMS0xLTA_982e060c-91dc-4533-b3cb-4dd46aecf133"
      unitRef="usdPerShare">5.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE5LTEtMS0xLTA_8b1695b2-dc6f-4557-a72f-b0cf1203b4ec"
      unitRef="shares">2632800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE5LTMtMS0xLTA_bad6c05f-ceb5-4af0-b441-037a7ea6e8b8"
      unitRef="shares">2645100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzE5LTUtMS0xLTA_6593f624-2158-48ba-88f8-c910345ef50e"
      unitRef="shares">2681500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzIwLTEtMS0xLTA_1ac71163-3ee4-410f-bc64-5158ee09f2d7"
      unitRef="shares">2670700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzIwLTMtMS0xLTA_7858be5d-2a6a-4f11-9c76-3799bbf64723"
      unitRef="shares">2684300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTIvZnJhZzphZGI3OGE1OTczNjM0NTA4YjRjZDg0MWVkYTViMWYyYi90YWJsZTpmZTM3YzgzNDBjMGI0NmM4YWZhODc3YTZhOWE5YmFmMi90YWJsZXJhbmdlOmZlMzdjODM0MGMwYjQ2YzhhZmE4NzdhNmE5YTliYWYyXzIwLTUtMS0xLTA_1ac6d818-37d2-49eb-a240-c671d86daf29"
      unitRef="shares">2728700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEtMS0xLTEtMA_3458aaf0-6f93-4029-9e2d-92452661513e"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEtMy0xLTEtMA_44f51d6b-1012-4b02-b9f4-ca41514c3863"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEtNS0xLTEtMA_24632c52-8718-445f-bf82-c460a30c345b"
      unitRef="usd">15297000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzQtMS0xLTEtMA_d29d0e00-5105-4d3a-a6eb-3eda62c1788b"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzQtMy0xLTEtMA_8119455b-82b0-4577-8f34-485125cdf2f2"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzQtNS0xLTEtMA_456a9824-90b6-4b35-a1a4-8116ce6b1f38"
      unitRef="usd">-1518000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzctMS0xLTEtMA_549b41ff-a802-4cdf-a469-4b984a206a4b"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzctMy0xLTEtMA_232a2f3c-ef7c-4532-98b5-e07d78e73d0d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzctNS0xLTEtMA_e38ea875-22a0-4f46-b9ec-8db9c0352f2e"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzgtMS0xLTEtMA_4a5b2b1c-556a-4baf-a7aa-e5cb817fe155"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzgtMy0xLTEtMA_5c34317c-26e0-454e-aa2b-c09efcb24d7f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzgtNS0xLTEtMA_3f7a6c2c-a0b2-4062-8b9c-cfa77f91474a"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzktMS0xLTEtMA_2e970330-d148-4888-a7db-c3e68174b331"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzktMy0xLTEtMA_9af1abc7-eb6a-4d13-aebe-b00671108e8f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzktNS0xLTEtMA_bb1d329f-d4c9-490b-a01c-994fd570d3c0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEyLTEtMS0xLTA_4ebfb591-2e46-44c1-97c0-e6a456182301"
      unitRef="usd">-1298000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEyLTMtMS0xLTA_9fc8deca-34be-4844-ab3e-a85621ae93f1"
      unitRef="usd">18000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEyLTUtMS0xLTA_e71e60b1-6e9f-4fe8-9a58-3024f3929fb2"
      unitRef="usd">44000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEzLTEtMS0xLTA_348951c8-5ca1-447b-85d0-63bedfee1cef"
      unitRef="usd">1135000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEzLTMtMS0xLTA_269c4a4d-9f11-4438-afac-1b58ab83b657"
      unitRef="usd">714000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzEzLTUtMS0xLTA_258b4ab6-834c-47df-84bc-fe6a9f0c6641"
      unitRef="usd">56000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE0LTEtMS0xLTA_67e81eeb-17ac-45d7-9f03-072eefc7ffcb"
      unitRef="usd">229000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE0LTMtMS0xLTA_26e3c267-c1e3-43d3-bce4-a7614537902c"
      unitRef="usd">1000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE0LTUtMS0xLTA_44240578-7fd3-4d0b-a13e-df0cfb63f0b0"
      unitRef="usd">-92000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE1LTEtMS0xLTA_db7d0e36-b92d-45e7-9f98-d99e50fc9cb1"
      unitRef="usd">66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE1LTMtMS0xLTA_a63f67b3-6c90-4902-9ea7-4d167f7d8024"
      unitRef="usd">733000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE1LTUtMS0xLTA_41b05e8b-d31a-4a1a-8c86-d21dc1121176"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE4LTEtMS0xLTA_02ae4109-625e-4045-a5c3-44f327fd18a5"
      unitRef="usd">1000000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE4LTMtMS0xLTA_4e6f60b6-8ca7-4b3c-98d6-ee8202a1a1a6"
      unitRef="usd">-107000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE4LTUtMS0xLTA_f0f7341e-a6f8-4440-91d0-07ac25e5d394"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE5LTEtMS0xLTA_4d54ee1e-bf4d-4b9f-8167-9b34ee97a453"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE5LTMtMS0xLTA_ae863451-eb37-4c40-a128-d7b78ef042d0"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzE5LTUtMS0xLTA_5af04fbf-2192-4e14-917d-e85b9977ca01"
      unitRef="usd">192000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIwLTEtMS0xLTA_15950ad7-868e-463c-b7fb-d3509820c585"
      unitRef="usd">947000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIwLTMtMS0xLTA_3fa3a6e0-943f-4ee2-863f-cf80d743ade9"
      unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIwLTUtMS0xLTA_5461f173-9daa-415c-bb59-8a028791aabf"
      unitRef="usd">-265000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIyLTEtMS0xLTA_a1fca621-13bd-4c85-90eb-7edb77ddcc2b"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIyLTMtMS0xLTA_99765979-92cc-4cc3-bb9f-2231e7babaf9"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzIyLTUtMS0xLTA_c039f320-28d6-4e09-a38e-8a7f50e1d314"
      unitRef="usd">-1791000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzI0LTEtMS0xLTA_a9d640f3-f071-48d9-aea9-2171574e143b"
      unitRef="usd">15363000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzI0LTMtMS0xLTA_7f6d6149-c138-4747-b2f0-191115b61aab"
      unitRef="usd">14450000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTo2MGEzYzVkYzQ4YzE0Y2NkODUyM2U1YmFiM2E2YmJiYi90YWJsZXJhbmdlOjYwYTNjNWRjNDhjMTRjY2Q4NTIzZTViYWIzYTZiYmJiXzI0LTUtMS0xLTA_8afe244d-716f-42e0-88ef-014da225b12b"
      unitRef="usd">13506000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDE5MA_6cb84a6f-b51e-4a42-a751-ad3326a1d5f3"
      unitRef="usd">536000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDE5NQ_6ef63fbb-7489-41fb-893f-00b57fd99363"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIwMQ_fd91fb58-279a-4610-bb91-6ef3e07edbfa"
      unitRef="usd">236000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIwNg_70380704-abe8-44ee-af09-bd17459078e5"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIxMg_5448318a-f02d-48fb-b7ff-3650057303a9"
      unitRef="usd">-222000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIxNg_ce7161e5-3a55-4309-89be-0f47903e758b"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIyMg_b370047d-bd52-477c-b713-d6bfd32d6384"
      unitRef="usd">252000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIyNw_4fef733a-f8d4-494e-b2b1-008c650b442d"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMTUvZnJhZzplZjFjZGJkMzdjMWI0N2I3YWU5ZWVlNWFjNzc2NDY4MS90YWJsZTplZWNhZjJlZGQ1ZDA0ODM2YjA2YTY1ZDY5Njc4MWQzYy90YWJsZXJhbmdlOmVlY2FmMmVkZDVkMDQ4MzZiMDZhNjVkNjk2NzgxZDNjXzItMC0xLTEtMTM2MDAvdGV4dHJlZ2lvbjo5ZmJhMzc1NjdiNGE0NjliYjE4YjY4MzgwZTRiMmNjZV8xMDQ0NTM2MDQ2NDIzMg_ab9c7bd5-0a64-47e8-a8c5-fa4657344dd2"
      unitRef="usd">-70000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtMS0xLTEtMA_a4c90053-a641-4497-817c-84815cfe23b7"
      unitRef="usd">60160000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e12ae720d2c4dc085eddd1250b291b7_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtMy0xLTEtMA_68e8a395-c668-4583-b422-31c7a7f082db"
      unitRef="usd">101793000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ba23fda59684540bdcab8d2c6182237_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtNS0xLTEtMA_16a1eec9-f26c-4083-9dd1-c4f23a6a0210"
      unitRef="usd">-13199000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iced5cdc4242a49e886f089e2363899f7_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtNy0xLTEtMA_be739aa1-01e6-42ed-83c9-abdb3d511286"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7c2da1e43f14fe88eac34709ef35e41_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEtOS0xLTEtMA_2c779a1e-c7d1-42e9-b0a9-1d99623af90b"
      unitRef="usd">-31554000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i375dae870e264e26b914483f200eb437_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMS0xLTEtMjcwOQ_2aad1243-5b8a-495d-bf19-e338990f7ee2"
      unitRef="usd">-486000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a614105f7d44e2eabdb115a8fef94dc_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMy0xLTEtMjcwNQ_bfdc14ad-8411-428a-b75c-3c6f02da8145"
      unitRef="usd">-254000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf4bf571e18643da8a5b4eb3bfc07a7d_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItNS0xLTEtMjcxMw_e4e50327-e932-4783-be08-f9a3c8a4f208"
      unitRef="usd">-232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMS0xLTEtMA_10db52a9-9ecd-40a7-8b8f-33cd83aff686"
      unitRef="usd">15297000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzItMy0xLTEtMA_f5e186ce-55d9-4860-9378-08f6605ad480"
      unitRef="usd">15297000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtMC0xLTEtMzcxNi90ZXh0cmVnaW9uOjQyMjVlMTY1ODc3ZTRmOTk4NGY1NDRjY2Q1Zjk3NmQ3XzEwNDQ1MzYwNDYzOTE3_9e72277f-440d-4ec2-bb95-6123784ebfe1"
      unitRef="usdPerShare">3.54</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzMtMS0xLTEtMA_73014713-a5e8-49c7-befe-57f9ff7e51d4"
      unitRef="usd">9494000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzMtMy0xLTEtMA_e82130be-e249-41bb-92da-d98e36a68364"
      unitRef="usd">9494000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtMS0xLTEtMA_063eb03e-cbbf-4549-8135-0f5c6a114b77"
      unitRef="usd">1949000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtMy0xLTEtMA_e8c65a4a-5c06-440a-8413-c70e7ffb0bdf"
      unitRef="usd">-1111000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzQtOS0xLTEtMA_90baee95-c500-4cc5-b204-3875a4a63676"
      unitRef="usd">3060000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzUtMS0xLTEtMA_f09d11ea-771f-42c7-91b2-54205e5463f9"
      unitRef="usd">5868000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzUtOS0xLTEtMA_b689166d-1475-40fc-b4c6-6d232f8a8eab"
      unitRef="usd">5868000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzYtMS0xLTEtMA_a74e7c4b-faa3-4899-a6d3-94f8d52b7cd5"
      unitRef="usd">15000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id873bbc4dead4e40a2ca55489bb3e6b2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzYtMy0xLTEtMA_c14e45df-dea1-44df-96a0-f8956c031ee2"
      unitRef="usd">15000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzctMS0xLTEtMA_2e1682db-ff80-4b60-a0f0-a1eb114027ff"
      unitRef="usd">-1791000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3d809f74ca674af2a83700b574ef976a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzctNS0xLTEtMA_a6815558-ffee-4c75-80de-a8d84897d3ff"
      unitRef="usd">-1791000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtMS0xLTEtMA_2fe98a11-9ab6-4171-a75b-8675d7c5063b"
      unitRef="usd">59752000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a37f3f6ee9a4fd68dc6ebb535681918_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtMy0xLTEtMA_c4b875f8-df30-4d0d-844b-19065e18b924"
      unitRef="usd">106216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2de20cab02a4cf8a8defc94d4572ad4_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtNS0xLTEtMA_b48bb73e-a6c0-469b-ba9d-0c68be6ee425"
      unitRef="usd">-15222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i876cc85cac534bcda664e8b8d9cf58fb_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtNy0xLTEtMA_1a77c3cf-4d46-4698-bb55-a0038e56ee1e"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i402d9278fd56456f8c7a670066d1ed23_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzgtOS0xLTEtMA_96a0a5ce-fb94-498e-aee8-703f866571eb"
      unitRef="usd">-34362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEwLTEtMS0xLTA_df3ccc3e-21fd-4620-97ea-5ff0658cf2ee"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEwLTMtMS0xLTA_41e50b52-17e5-405e-b0d0-714ad0978ec5"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTAtMS0xLTM3MjAvdGV4dHJlZ2lvbjo1YzNjYjk2Mzg1YzY0YmRkYTg0MTA3NWZmYmVjZjAxYl8xMDQ0NTM2MDQ2MzkxNw_7afccbaf-7095-471d-a0ba-2c2e047c4064"
      unitRef="usdPerShare">3.75</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzExLTEtMS0xLTA_b4ae2974-46e1-43b4-8a5b-c31f378a9237"
      unitRef="usd">9917000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzExLTMtMS0xLTA_e843c558-24d1-4b77-9e1f-a18cdf463a8f"
      unitRef="usd">9917000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTEtMS0xLTA_3fdeeae5-2448-4116-be2b-b8013bd933c2"
      unitRef="usd">1933000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTMtMS0xLTA_18aa44a0-daaa-4dab-bd6b-5673ad64b3ba"
      unitRef="usd">-758000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEyLTktMS0xLTA_d03ba3f2-0707-4410-9d0a-d0dc819b881f"
      unitRef="usd">2691000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEzLTEtMS0xLTA_0c103caf-1b2d-47d7-9f21-3d547aab1998"
      unitRef="usd">6746000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzEzLTktMS0xLTA_0be3ea46-f17b-46e9-ba8e-e6520b840c73"
      unitRef="usd">6746000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE0LTEtMS0xLTA_5308a118-e7e9-496b-8a7e-ce9c47d1034c"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ifd1a4849d2bb44fd80cab6e56c982221_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE0LTMtMS0xLTA_c90cc2d4-3978-4a0e-99a6-3c652613bd08"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE1LTEtMS0xLTA_166e51ec-85a6-4e26-9d78-9aa6bbbc853b"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i411749566b1e45288b6797e92e4b8e37_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE1LTUtMS0xLTA_2ea406bb-4402-4703-8c41-3d8e716ea850"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTEtMS0xLTA_663443b9-e849-4c55-9c50-41c3f2a02fea"
      unitRef="usd">59471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icbe1daa397894e5683897624a288d022_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTMtMS0xLTA_7661bb87-da40-408e-b8d2-9be2ceaa5214"
      unitRef="usd">110659000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icafa9de0a8f744f78e2171c3ec5ff108_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTUtMS0xLTA_981735e4-970a-48de-b435-85f2b6702a7d"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88f92b62ca0e43c1a522880b7018fd18_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTctMS0xLTA_9b1770d3-f11a-4d9c-8d1e-d86b0178c6bf"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib841bff089b9422dba63507cc4961d15_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE2LTktMS0xLTA_35f5dfa5-7e3b-48f3-b728-8bb796e81213"
      unitRef="usd">-38417000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE4LTEtMS0xLTA_6329325e-b3dc-4049-b2cb-5d799213f07f"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE4LTMtMS0xLTA_82495ba6-9d68-4996-803d-4807cd447954"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTAtMS0xLTM3MjQvdGV4dHJlZ2lvbjo3ZGExNmZjYWFhZWE0ZjYxODE4ODE2OWJkODdhMzFjOF8xMDQ0NTM2MDQ2MzkxNw_81446582-ae1c-4740-8465-2bb67665d18b"
      unitRef="usdPerShare">3.98</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE5LTEtMS0xLTA_761cf8ca-9c40-432d-b69e-7cd19f0f54a1"
      unitRef="usd">10481000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzE5LTMtMS0xLTA_58fbde5a-9966-485a-b74d-2d71826f1b57"
      unitRef="usd">10481000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTEtMS0xLTA_34c7d7bd-0a6b-4871-9c23-bbe202fbf856"
      unitRef="usd">2217000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTMtMS0xLTA_4c34e924-38b7-4d05-86a9-7605288df61b"
      unitRef="usd">-931000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIwLTktMS0xLTA_aebd1231-df46-4ddc-a835-9f456d9a4378"
      unitRef="usd">3148000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIxLTEtMS0xLTA_34cdf215-0880-407c-82b2-0999f4cef182"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIxLTktMS0xLTA_e9fa4284-9ef1-4e4d-bb8a-0b0806ecf651"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIyLTEtMS0xLTA_95017a09-020c-4107-a67a-568b0a0fca38"
      unitRef="usd">71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iaa89ae1f4c1347539f9fef7ddcd04794_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIyLTMtMS0xLTA_7399954d-f7b6-426c-8d76-b6c0a201ac5a"
      unitRef="usd">71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIzLTEtMS0xLTA_8a0b6e42-55c2-496f-9b1a-4c80757b85af"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic15b04be239b4bcf895c4ac519a52aa5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzIzLTUtMS0xLTA_bf221e66-33ae-4e84-a89e-b93014db20e1"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTEtMS0xLTA_9efa2316-8f52-45ee-8c17-d642fb5299c3"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89ea54c1fcae41cc82257b51ac217450_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTMtMS0xLTA_0a2818b1-d785-45ef-a273-02305307f214"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b56c73c08ba4d7bb733cf5b7825663e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTUtMS0xLTA_c68b75b4-32b3-4d67-80c8-c4a00fb7c28f"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc6c299668f24a8ea824ffb03291a552_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTctMS0xLTA_3a3f4e91-a658-465e-98ec-d2a2bc038279"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0948aa56b8544fa694f8b50333d4293d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjEvZnJhZzo3ZjViNThkYTlhZjY0Y2M4OWFkMmYyNDliN2I0YTQxYi90YWJsZTo5ODZkYmYxNGFiMjE0YWE3OWIzZDQ4ZGNiMDAyOWY2Zi90YWJsZXJhbmdlOjk4NmRiZjE0YWIyMTRhYTc5YjNkNDhkY2IwMDI5ZjZmXzI0LTktMS0xLTA_1f24bdfb-7718-4745-97a7-b8462ba42001"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzItMS0xLTEtMA_e51b0c4c-ab56-4968-a26a-9b3a406e5e06"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzItMy0xLTEtMA_e9c5ccc2-5995-4ad0-9950-04289a9f4fc6"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzItNS0xLTEtMA_bb6ccaae-ed84-4a09-ab8f-f3540a856f23"
      unitRef="usd">15297000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQtMS0xLTEtMA_d4dd214b-39d1-4e53-b926-ceb198e08e7b"
      unitRef="usd">7231000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQtMy0xLTEtMA_e6c4f4a5-d102-4a58-870e-d1fa3f39f861"
      unitRef="usd">7009000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQtNS0xLTEtMA_2300734a-96f7-4593-a166-47a01d691cf0"
      unitRef="usd">6929000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUtMS0xLTEtMA_b140c185-8b4d-4b11-b0eb-ee375dcee52a"
      unitRef="usd">1005000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUtMy0xLTEtMA_6763c02b-dc4c-495f-804f-1c4b57109376"
      unitRef="usd">977000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUtNS0xLTEtMA_00d96d4c-2b19-4ef2-8f44-2922c2b1e961"
      unitRef="usd">978000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzctMS0xLTEtMA_13971f57-1805-4516-b241-a2ce928503f0"
      unitRef="usd">233000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzctMy0xLTEtMA_70969919-411b-46f8-917f-a62f98e212cd"
      unitRef="usd">1096000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzctNS0xLTEtMA_21b80199-8bd3-4f5b-b1a1-a27fbaf2c7b4"
      unitRef="usd">1258000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMS0xLTEtODM1Nw_2193cf8f-82cd-44ad-8b77-bf1f3e03bfe0"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMy0xLTEtODM3MQ_701e01c0-dbc3-4ac4-a3f3-c2cdcd77e712"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtNS0xLTEtODM3MQ_c596238a-7cce-4f45-ae29-b7bf79020765"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMS0xLTEtMA_34ee67cf-9854-4820-9302-2ac3e6efcee9"
      unitRef="usd">111000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtMy0xLTEtMA_8008fd62-7b75-4de3-8e50-98146b9e579d"
      unitRef="usd">2154000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzgtNS0xLTEtMA_395908b9-3fee-4cf6-b9d0-2e6846ca63fa"
      unitRef="usd">1217000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEwLTEtMS0xLTA_8d8db244-9298-4df0-8a51-4dca5eda5675"
      unitRef="usd">-1141000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEwLTMtMS0xLTA_395db5fa-c791-467b-b185-48af1d98ab30"
      unitRef="usd">-2476000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEwLTUtMS0xLTA_a279da40-79bb-4e88-b9b2-175f32dd6bd8"
      unitRef="usd">-1016000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzExLTEtMS0xLTA_372ff8c0-4faa-477b-b97e-1eeb56e69d92"
      unitRef="usd">63000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzExLTMtMS0xLTA_1593d461-b298-4a2c-a1db-a2baec0e7eb2"
      unitRef="usd">-20000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzExLTUtMS0xLTA_14baf188-1c2d-4b95-8afc-cee992140ce8"
      unitRef="usd">-31000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEzLTEtMS0xLTA_1f0c860c-6ef8-4a2f-a7e3-0917ea7e54b2"
      unitRef="usd">-774000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEzLTMtMS0xLTA_e70e57f3-f0ca-4cca-a974-cadb56e76cb7"
      unitRef="usd">289000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzEzLTUtMS0xLTA_57259cac-b18b-4411-80eb-46ac4a193ad6"
      unitRef="usd">1185000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE0LTEtMS0xLTA_56fb5888-50a9-45a0-b844-7c03e69d7707"
      unitRef="usd">265000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE0LTMtMS0xLTA_46e3c0ab-062f-4ce1-a8e9-5fb2d4ea61f0"
      unitRef="usd">277000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE0LTUtMS0xLTA_ead7a225-c9df-4cd2-8c31-3bf04e16baa6"
      unitRef="usd">644000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE1LTEtMS0xLTA_bf21ba84-9d45-4489-a447-d0a31780fea1"
      unitRef="usd">5141000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE1LTMtMS0xLTA_044c1653-b004-4d29-a2e2-1f7580c9ff1f"
      unitRef="usd">4060000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE1LTUtMS0xLTA_822e4a39-346b-414c-ab83-05b84171403c"
      unitRef="usd">3951000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE2LTEtMS0xLTA_bb26da87-4d68-43c9-9bec-089c798d2c88"
      unitRef="usd">3704000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE2LTMtMS0xLTA_4e0a3dfc-622b-42b9-bcaa-13fa6a7c754d"
      unitRef="usd">1054000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE2LTUtMS0xLTA_be77397d-6feb-4b08-b871-d9ab911258e7"
      unitRef="usd">275000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE3LTEtMS0xLTA_4d07c094-8ff5-49c5-9097-dcf0216a2200"
      unitRef="usd">744000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE3LTMtMS0xLTA_d43e33ff-931f-4bea-a4d1-f84e52b3309e"
      unitRef="usd">1425000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE3LTUtMS0xLTA_3a23c185-a61a-4487-8afc-8c50a2d07c11"
      unitRef="usd">-1844000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE4LTEtMS0xLTA_65a1cedb-f2b8-48cc-9ea4-7a20c1fb7882"
      unitRef="usd">23536000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE4LTMtMS0xLTA_931930af-e5ce-4a8b-af79-65f7b71f11cc"
      unitRef="usd">23416000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzE4LTUtMS0xLTA_9484345a-3f6c-4dc4-9983-eb63838cbbae"
      unitRef="usd">22201000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIwLTEtMS0xLTA_41808216-a9d1-4ece-8d39-74eb87d75408"
      unitRef="usd">3347000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIwLTMtMS0xLTA_986038e6-a823-4a9f-82db-7b28f92bce9b"
      unitRef="usd">3498000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIwLTUtMS0xLTA_83cb139a-f7cd-44fe-a946-fb3867c6da28"
      unitRef="usd">3670000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIxLTEtMS0xLTA_137e9d2c-99c0-449a-8acf-92000be8cc5e"
      unitRef="usd">305000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIxLTMtMS0xLTA_98dfd558-ea6a-48f9-b129-37f700577e8b"
      unitRef="usd">3265000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIxLTUtMS0xLTA_ccea054e-511e-4c58-abd6-790ded022f8e"
      unitRef="usd">3203000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIyLTEtMS0xLTA_99eb4b76-3573-41f6-9346-3c2bdfe7b473"
      unitRef="usd">7323000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIyLTMtMS0xLTA_188017a6-0987-4b0a-aaec-71d411e50070"
      unitRef="usd">5810000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIyLTUtMS0xLTA_614caa7b-1db3-4f08-8bee-82f782f9d480"
      unitRef="usd">899000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIzLTEtMS0xLTA_238c7a69-d910-4dde-a00e-4db94c7df572"
      unitRef="usd">21089000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIzLTMtMS0xLTA_edc29292-a6b7-4b02-bcea-9f68a83851b9"
      unitRef="usd">3920000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzIzLTUtMS0xLTA_6adef89c-f770-465c-9282-da9071ec4ce8"
      unitRef="usd">5626000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI0LTEtMS0xLTA_67a07686-b5f7-4d49-80a2-58dab8a95ae7"
      unitRef="usd">12137000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI0LTMtMS0xLTA_c0229a3d-a2d4-4a68-8a27-c1b946e36eb0"
      unitRef="usd">3387000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI0LTUtMS0xLTA_eac22850-e4da-4066-86c9-7112f501e1be"
      unitRef="usd">4289000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI1LTEtMS0xLTA_4bea3a1d-4599-4ca5-b60d-d47ec872f2a5"
      unitRef="usd">-987000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI1LTMtMS0xLTA_d2310ce8-c27d-404f-992e-814d11a0ce32"
      unitRef="usd">338000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI1LTUtMS0xLTA_94526cbb-3f4a-4006-8d8c-44601c00cbfc"
      unitRef="usd">0</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI2LTEtMS0xLTA_880b1a8d-0323-457b-8800-422d6c85ff5e"
      unitRef="usd">521000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI2LTMtMS0xLTA_8a2901e6-71aa-44f3-ad8e-ddc88c1165ff"
      unitRef="usd">-44000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI2LTUtMS0xLTA_2a93d1af-fe6d-472b-9819-21cfa01c7a3a"
      unitRef="usd">464000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI3LTEtMS0xLTA_e1c76edc-94b2-4a79-bbb7-ebe22980fc9b"
      unitRef="usd">-20825000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI3LTMtMS0xLTA_de862f1b-e029-4270-8de0-643befcaf722"
      unitRef="usd">-6194000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI3LTUtMS0xLTA_5c429feb-f5b9-41c2-a42d-346a3ee4582a"
      unitRef="usd">-3167000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI5LTEtMS0xLTA_0846a599-31a2-4b9c-bd45-455f5f42c927"
      unitRef="usd">10481000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI5LTMtMS0xLTA_91ebbbbb-3b98-4bb6-8292-cc925eed6ec9"
      unitRef="usd">9917000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzI5LTUtMS0xLTA_c4179f6f-b66c-47ac-a25d-0adc555f011e"
      unitRef="usd">9494000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMwLTEtMS0xLTA_f3dd6c86-5ced-4056-822a-a6321793ba9c"
      unitRef="usd">3221000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMwLTMtMS0xLTA_789b1db2-6e51-4d1d-84d1-5ca4e8928894"
      unitRef="usd">6746000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMwLTUtMS0xLTA_bd8aa92a-2ce5-49b0-8bda-987ae9a25aca"
      unitRef="usd">5868000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMxLTEtMS0xLTA_38c2b6bf-efb6-44ad-80a7-92c4d4e388c8"
      unitRef="usd">3391000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMxLTMtMS0xLTA_4e464885-b708-49e0-8856-4213dd23850b"
      unitRef="usd">39000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMxLTUtMS0xLTA_5cbb10e7-57a8-4eec-b0c4-e7a8c5a0f037"
      unitRef="usd">80000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMyLTEtMS0xLTA_eff9db91-d600-4923-b25c-903c17cc392d"
      unitRef="usd">2663000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMyLTMtMS0xLTA_159d6398-cdfe-4fea-9a5c-eb368e3f031a"
      unitRef="usd">100000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMyLTUtMS0xLTA_a84fccce-d423-4211-acc8-6e403bd3e742"
      unitRef="usd">2479000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMzLTEtMS0xLTA_a042a409-097d-4ce8-bd97-1bbba45d2deb"
      unitRef="usd">7431000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMzLTMtMS0xLTA_020e0183-fa41-4110-be32-86cb1642a189"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzMzLTUtMS0xLTA_95920d68-dcd2-4195-b5f8-77398bae2536"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM0LTEtMS0xLTA_1f4e25c1-ea40-4798-88df-bdac3ee08401"
      unitRef="usd">1064000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM0LTMtMS0xLTA_f31bdcf0-389c-4bd8-8f32-cc72043e096a"
      unitRef="usd">2823000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM0LTUtMS0xLTA_0c578ac4-9efd-4900-9fa2-fd35fc95ffe4"
      unitRef="usd">1555000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM1LTEtMS0xLTA_adcdedce-ad2d-4ecb-9cb7-e98cd2a654d9"
      unitRef="usd">1114000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM1LTMtMS0xLTA_b86b7091-c2b2-436d-9a48-5ae0e8892805"
      unitRef="usd">954000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM1LTUtMS0xLTA_a7ad85c2-289f-40ec-829a-28ab0c97e5aa"
      unitRef="usd">949000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTEtMS0xLTExNDMx_6b0d46fb-8887-4175-b8e7-96d9a11ba52c"
      unitRef="usd">-333000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTMtMS0xLTExNDMx_dad45658-dd5d-4275-a073-01f065cf79d8"
      unitRef="usd">100000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTUtMS0xLTExNDMx_dcdc5b69-1d9c-4153-8b84-83b17078b0f0"
      unitRef="usd">25000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTEtMS0xLTA_ef797b74-374c-45c4-b59b-26ed74a3d4d0"
      unitRef="usd">-294000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTMtMS0xLTA_0cab03b3-d958-45b5-aa23-88f5e36ee030"
      unitRef="usd">475000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM3LTUtMS0xLTA_71d03770-19fe-4118-a58a-9621297c1c46"
      unitRef="usd">-173000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM4LTEtMS0xLTA_23e38814-de7b-477a-8296-50dc8fe2cf7b"
      unitRef="usd">-6120000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM4LTMtMS0xLTA_364c46af-3d3d-4a4c-bcf9-586cc3bde5a8"
      unitRef="usd">-18015000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM4LTUtMS0xLTA_59cf4c13-f380-4f4a-aa82-be2b97d146d0"
      unitRef="usd">-18510000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM5LTEtMS0xLTA_f434cb05-599b-44ca-8cd4-e8660051c39e"
      unitRef="usd">89000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM5LTMtMS0xLTA_a3f57379-0607-469f-83e9-db70d77108ea"
      unitRef="usd">-9000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzM5LTUtMS0xLTA_f9fbe7ab-2fcd-4e9f-9b25-41fa818a7a64"
      unitRef="usd">-241000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQwLTEtMS0xLTA_fa60565d-00d4-4c11-bbdc-b731e8093cea"
      unitRef="usd">-3320000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQwLTMtMS0xLTA_b1d3d87d-3752-40c0-ab35-768007fdba44"
      unitRef="usd">-802000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQwLTUtMS0xLTA_11254487-4eff-49b0-9709-c5ea4361f58e"
      unitRef="usd">283000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQxLTEtMS0xLTA_1bdc8e5f-4488-4fe4-ba37-63f045eb49fe"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQxLTMtMS0xLTA_6312db3d-28cf-48a5-a022-c31eb9d2e7da"
      unitRef="usd">18107000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQxLTUtMS0xLTA_d6236470-4854-4207-b873-f143b8cb567d"
      unitRef="usd">17824000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQyLTEtMS0xLTA_68553d61-4c6d-4042-8757-f5f3e6e78200"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQyLTMtMS0xLTA_69909bf4-e718-4295-ac1f-cc40e5af4628"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQyLTUtMS0xLTA_d2b69e9d-d557-41d9-b6e0-19dbf08568f7"
      unitRef="usd">18107000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaid
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ2LTEtMS0xLTA_37dbc1c6-eb4c-43c9-8d69-051981199f3a"
      unitRef="usd">904000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ2LTMtMS0xLTA_7ab57371-a924-442b-9d0d-ee8867721627"
      unitRef="usd">995000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ2LTUtMS0xLTA_658d4b13-ba7e-458c-a29a-d29391255485"
      unitRef="usd">1049000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaidNet
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ3LTEtMS0xLTA_7174a3ba-3661-4f31-8325-32e2b5a99b91"
      unitRef="usd">841000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ3LTMtMS0xLTA_3c1a786e-178b-4391-90d0-60fba7f2c989"
      unitRef="usd">925000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ3LTUtMS0xLTA_8679782e-a14b-4585-a751-d1ee22852910"
      unitRef="usd">963000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ4LTEtMS0xLTA_8048083e-81ed-496b-b8c8-ac5b91522dab"
      unitRef="usd">4619000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ4LTMtMS0xLTA_947c2003-9473-4fd1-95f9-9c48a62ef4e4"
      unitRef="usd">4191000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzQ4LTUtMS0xLTA_0debb9ff-3de9-425d-bcfc-d946e3969f61"
      unitRef="usd">4570000000</us-gaap:IncomeTaxesPaid>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUxLTEtMS0xLTA_eaefdb5b-6b7a-4bf8-a6aa-bc748defb18c"
      unitRef="usd">1937000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUxLTMtMS0xLTA_5682e907-d318-4b9d-9138-ed6f05f99101"
      unitRef="usd">1736000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUxLTUtMS0xLTA_27b57bff-d6bb-4c28-99e7-5e277e16e901"
      unitRef="usd">2095000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUyLTEtMS0xLTA_4d546fdf-5132-4fd6-8e6f-aae19dc04b1d"
      unitRef="usd">27000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUyLTMtMS0xLTA_03817a52-c056-4e99-835f-07460b6c64a9"
      unitRef="usd">1000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzUyLTUtMS0xLTA_18114bab-df98-4ebe-a2e6-624664e66e1b"
      unitRef="usd">6000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU1LTEtMS0xLTA_d967714b-a39e-4221-8131-adb633ab67e6"
      unitRef="usd">7755000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU1LTMtMS0xLTA_2d7151cf-a685-4a97-ac28-d9abbc677fa9"
      unitRef="usd">7228000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU1LTUtMS0xLTA_a520fb2b-bcc4-4268-8928-da772000caa7"
      unitRef="usd">1047000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU2LTEtMS0xLTA_1ddbc613-0705-4d56-a35f-03fba8f733db"
      unitRef="usd">432000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU2LTMtMS0xLTA_05b12915-498e-4274-82a0-1c4b509a5935"
      unitRef="usd">1418000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU2LTUtMS0xLTA_be64d80b-13cc-4b2c-8ec6-2c90fcc9ab90"
      unitRef="usd">148000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU3LTEtMS0xLTA_80aadc6f-2cd7-4808-9075-9d6895565322"
      unitRef="usd">7323000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU3LTMtMS0xLTA_69a74aa0-e95f-4ad2-8a16-168da1561037"
      unitRef="usd">5810000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMjcvZnJhZzowMDNiODU0MDI3Y2E0MWJhOGZmN2ExYTU0MWZkZjYwNS90YWJsZTowNWY0MWM5Y2U0YjE0NGFhOGRkMTQ2Yzg2ZTc0ZTMwMi90YWJsZXJhbmdlOjA1ZjQxYzljZTRiMTQ0YWE4ZGQxNDZjODZlNzRlMzAyXzU3LTUtMS0xLTA_5f211490-0a0b-460d-9b47-71e9d3e6935e"
      unitRef="usd">899000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDY4_4f80d403-f879-4444-8081-8685f0fc1648">Summary of Significant Accounting Policies&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of the Company and Business Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized into three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women&#x2019;s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2018-18: Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13: Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity&#x2019;s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2018-14: Compensation - Defined Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2014-09 - Revenue from Contracts with Customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2016-01 - Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2016-16 - Income Taxes: Intra-Entity Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Adopted as of January 3, 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;- 30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion and $7.0 billion as of January&#160;3, 2021 and December&#160;29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2020,&#160;2019&#160;and&#160;2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred were $1.0 billion, $1.0 billion and $1.1 billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.0&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The lease liability was $1.1&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion and $0.3&#160;billion in 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments to collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, co-developed with Bayer HealthCare AG and IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.2 billion and $2.6 billion in fiscal years 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $7.7&#160;billion, of which $6.9&#160;billion is classified as noncurrent and reflected as &#x201c;Long-term taxes payable&#x201d; on the Company&#x2019;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 8 to the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further information regarding income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Annual Closing Date&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDc4_4d39df96-28e6-40b3-8087-469a3410b561">Principles of ConsolidationThe consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTE4_b5d1a860-ce08-4954-8c87-b7e4ae3945cd">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of the Company and Business Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;The Company is organized into three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women&#x2019;s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzQ1NQ_3426247d-00e0-456f-99d2-9f797d2e9571"
      unitRef="employee">134500</jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide>
    <us-gaap:NumberOfReportableSegments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzc3Mg_f4f47ca1-8846-44ec-8b72-b0acbd679b24"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTE5_7c46c958-6b02-4f1b-8cbd-1f10b6cd13c8">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2018-18: Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13: Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity&#x2019;s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2018-14: Compensation - Defined Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2014-09 - Revenue from Contracts with Customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2016-01 - Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2016-16 - Income Taxes: Intra-Entity Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Adopted as of January 3, 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4NjU3_799a8f2c-b13f-4dfc-9e31-32a5e35c590b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2014-09 - Revenue from Contracts with Customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2016-01 - Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2016-16 - Income Taxes: Intra-Entity Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5e8e0ca2b9b40cea02f25844dc6143f_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzEtMi0xLTEtMTMyNjc_cbf53adf-eded-432a-ae05-a04ce4cfd27c"
      unitRef="usd">-47000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9621bec2f144b689a1fbfe1403aab26_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzItMi0xLTEtMTMyNzQ_3f5e8039-8da6-480f-9149-bab7dc989382"
      unitRef="usd">232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18c818b3558a442cb0ffe1bce102d1a8_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzMtMi0xLTEtMTMyNzQ_5ffc3783-7910-4136-bc96-70d27dd57d35"
      unitRef="usd">-439000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56111d6a08484b6890ddf01b41cb16b0_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTozNTQ2NzYxMWUzMDI0MDNhODU2MmJhMjM1MzQxYTNhOC90YWJsZXJhbmdlOjM1NDY3NjExZTMwMjQwM2E4NTYyYmEyMzUzNDFhM2E4XzQtMi0xLTEtMTMyNzQ_d48b74f0-0c33-459c-a106-6e93d0d5b710"
      unitRef="usd">-254000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDcw_0ea9c43a-6ad2-4f5d-b448-4d056c741807">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgzMzI_56d46f0e-cf79-4899-84ce-c639236746a6"
      unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzg3MDU_c8c4d1da-c3e0-403e-99b9-557acb3d2506"
      unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDY5_a6e312fc-2d2c-40a9-8c3d-659622f6554d">InvestmentsInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDYz_77754dfa-e387-41c5-93c9-5febba2a62ac">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;- 30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between &lt;/span&gt;&lt;/div&gt;the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <jnj:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDcy_4f89f05b-df8f-4642-bc68-87f537b96fcb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;- 30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i172e28d99e7b4636b5bf1e3bb60c3e46_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzAtMS0xLTEtMzcyOS90ZXh0cmVnaW9uOjdhMzczNTNkYjhkMTQwNTFiZWQ3M2FlNjdlYzQ0YTJlXzEwNDQ1MzYwNDYzODkx_472aa700-42c4-4ca3-ab2a-8e5c39dfcbd0">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4144a962aa79467395df471e209ede69_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzAtMS0xLTEtMzcyOS90ZXh0cmVnaW9uOjdhMzczNTNkYjhkMTQwNTFiZWQ3M2FlNjdlYzQ0YTJlXzEwNDQ1MzYwNDYzODk2_e0c13779-fef1-490d-b251-02e7edd735c7">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5f65202ffa114849be9dfc3aac018eaf_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzEtMS0xLTEtMzczNy90ZXh0cmVnaW9uOmQzNWRhNTFjNzI3MjRlNjJiZTYwOTYyMDU0Nzg3NDYwXzEwNDQ1MzYwNDYzODkx_a80a40c4-9eef-415e-92cb-b8a4e27e6232">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i935569cc407846b1bd173f1920d291d7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzEtMS0xLTEtMzczNy90ZXh0cmVnaW9uOmQzNWRhNTFjNzI3MjRlNjJiZTYwOTYyMDU0Nzg3NDYwXzEwNDQ1MzYwNDYzODk2_46f05adf-eee3-473c-9613-3fa568665abf">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1869c744df4f4e608a0eb1004c3f4aad_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzItMS0xLTEtMzc0NS90ZXh0cmVnaW9uOjQ4YWRiMWM4YzAxMTQyNTU4Y2QxMDIyYjQ1NGM4YzVhXzEwNDQ1MzYwNDYzODg5_71e78d10-ad1f-4802-938f-24239e5985fb">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i76d4081a3bd840dda4560e78dc05b7a5_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90YWJsZTo1OTkwZjU3NjcwYjk0OWJkOGI4MTI3NWFkZmEzNWRmNi90YWJsZXJhbmdlOjU5OTBmNTc2NzBiOTQ5YmQ4YjgxMjc1YWRmYTM1ZGY2XzItMS0xLTEtMzc0NS90ZXh0cmVnaW9uOjQ4YWRiMWM4YzAxMTQyNTU4Y2QxMDIyYjQ1NGM4YzVhXzEwNDQ1MzYwNDYzODk0_d38e3f13-fdc9-4e24-9b49-42e97f74c5d4">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie02722380d4b485fa4f666f9da3c34e9_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwMjE0_7693e68a-28bd-43d5-b82c-24848560ee27">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0f18dc2fc4564ff9a05dbd7fba040656_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwMjIw_18dee211-497c-498e-b76f-a457546d93a0">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTI1_70975e9a-7090-4709-9d37-c69c3436d0cf">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion and $7.0 billion as of January&#160;3, 2021 and December&#160;29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2020,&#160;2019&#160;and&#160;2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ide0733c2434242ba85b6c5b1c835e725_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzExOTcy_900a41bd-70d3-434c-b9b8-6227fec66dba"
      unitRef="usd">7200000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i63df1bc915934ad68c8902ac19c99bea_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzExOTc5_0640411e-393d-4e7d-bf2b-0a1babde3ab1"
      unitRef="usd">7000000000.0</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:SalesReturnReserve
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEzNTM4_53c53451-7411-49bd-9d69-0486738ac39c"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEzNTM4_973c8185-2b95-49db-ba3a-997fc4c12b2c"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEzNTM4_b55c6d98-1972-4669-942a-0c2856140829"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:ProfitLossPercentToSales
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NDM0_4b2e1356-6e80-4b59-9875-b5878317211d"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NDM0_6ce549f2-e012-4264-a2a3-3f4d025c9433"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NDM0_dd1b4c99-d817-488d-98d1-2b45f2ea3701"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTM5_7799f714-02dc-4b7c-b7ee-11d7409543a3">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred were $1.0 billion, $1.0 billion and $1.1 billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ied72d4ba20b14d21b01fa2d79d0cd268_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NjU1_af4e236f-076d-4f22-8739-309d4b8911cd"
      unitRef="usd">1000000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i12a63cb5e2c94bd8bd2df799531d614b_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NjU5_b4457de3-5179-4007-98dc-6fab85886013"
      unitRef="usd">1000000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id01c9ba6bc554fc8a64421dc3895f2a7_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0NjY2_3ad0ab79-617e-42cf-8f3d-1dc167c600af"
      unitRef="usd">1100000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0ODM4_362c3593-62be-453c-b9e3-fc73167505c7"
      unitRef="number">0.005</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0ODM4_4f5d176b-d05d-4bcc-9f87-ea73cea2bd1c"
      unitRef="number">0.005</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzE0ODM4_fe9c54e7-1094-4f10-bcd1-4cbeee903c91"
      unitRef="number">0.005</jnj:ShippingandHandlingCostsasaPercentofSales>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTUy_1654fd35-3683-48df-81f3-97dd302c572d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTMz_24cc667a-5a4b-4543-ad12-9393634e1877">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDg0_67a5f5f3-f5f5-4f33-914a-244ac57ba8d3">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzg3OTYwOTMwNzY5OTE_27642f34-2546-447c-992c-9fd23dfdde85">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.0&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The lease liability was $1.1&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion and $0.3&#160;billion in 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyNDQ_c067e68d-fc46-4f1d-880d-33b57b9ddec4"
      unitRef="usd">1000000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyNTg_c3009482-335f-4347-9d3b-c9d2be7862aa"
      unitRef="usd">1000000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyNzI_3aa1fec4-f651-46cd-9849-3cbb1b4e2a19"
      unitRef="usd">1100000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIyODg_f88e65c4-7eac-48ed-8000-9fc4e48a436b"
      unitRef="usd">1000000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzMDI_d0cc1250-fc7b-4f2b-9003-02904be922cc"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzMTY_27bacbb6-0a77-4eae-9517-fbeb8483a692"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzMzA_ce03c0a6-95ce-416f-8c68-263e23fc12a5"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzNDQ_9e1defd4-deae-4543-b1a3-448874e01a23"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNjIzNTg_9de80419-e871-4cba-ab87-8b1344e0dc94"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <jnj:ProductLiabilityPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTcz_b1aa5e1d-237d-4792-9806-af12c3d4ec84">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt; The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</jnj:ProductLiabilityPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTM0_d345fc29-01c9-4d88-b04d-b1788b12d701">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments to collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, co-developed with Bayer HealthCare AG and IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i75354123f4c84b55824bc84448f6036b_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwMDky_e30869a4-2c9d-4b5a-950f-f168cdc4eb0b"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDg1_d618d761-df4d-45d7-8820-20fe3fc73314">AdvertisingCosts associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwODIx_e7056814-53ae-44fa-97aa-70d1fffd9147"
      unitRef="usd">2100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwODI1_c0629b92-7a14-40f2-89f7-a447adee84b3"
      unitRef="usd">2200000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIwODMy_c1d53de5-5f79-4aa4-9a1f-652e82ba97ac"
      unitRef="usd">2600000000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTQw_c34c2946-6f21-47f7-9177-01fcf79b094b">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $7.7&#160;billion, of which $6.9&#160;billion is classified as noncurrent and reflected as &#x201c;Long-term taxes payable&#x201d; on the Company&#x2019;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company &lt;/span&gt;&lt;/div&gt;intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MDk_695b7df2-5b7f-453a-915a-7fcf1372306a"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MTQ_09a1ccd5-419b-4f29-aa3b-120616a31ff1"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent
      contextRef="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MjU_07537ff8-f6f7-4209-8cec-11165b1a17d6"
      unitRef="number">0.155</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent
      contextRef="if149e2b4509a47bbabc4e3611c35cb53_D20170102-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MTk_21ab7541-3909-4661-9c30-1c84c09f3331"
      unitRef="number">0.080</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4MzI_d1a9c38a-35ee-4e21-b9cf-87615f667cfd"
      unitRef="usd">7700000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzgyNDYzMzcyNTg4NDY_f97b1448-5fde-47ea-b179-1bedc21389cc"
      unitRef="usd">6900000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzIzMTYw_a96d1fcb-a20e-4068-a4bc-dbd98da1a2b2"
      unitRef="usd">700000000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDY3_84e89e59-df62-448d-9a03-a07a4080afb9">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTAx_072edb3f-ddce-49cf-9f47-a0de37d5fa3e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <jnj:FiscalPeriodPolicyTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MDc2_5363c3e8-1e72-4e72-94e1-2cd27a9f622e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Annual Closing Date&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;</jnj:FiscalPeriodPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzI1MTg2_de0f880e-4f2c-4a96-a190-3712be31a6de">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90ZXh0cmVnaW9uOjA4YWE4NDFiNTQyYTQyNmJhNGRlOTM0NzliYzU5ZDU2XzEwODI_4440b13a-36ed-4950-82e9-ad92699ee20b">Cash, Cash Equivalents and Current Marketable Securities&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal year 2019, the carrying amount was the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale debt securities at January&#160;3, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90ZXh0cmVnaW9uOjA4YWE4NDFiNTQyYTQyNmJhNGRlOTM0NzliYzU5ZDU2XzEwOTQ_64f9032f-92f5-4cdc-a8be-529f4f5ea518">&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="idf686c178a5b43e69308e5ab8e5a2e50_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItMi0xLTEtMA_cfeb513e-35c8-4cb0-86f9-13f2d17690dd"
      unitRef="usd">2863000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItOC0xLTEtMA_4ebe03ca-c996-4ecd-bb6c-41688836dcbf"
      unitRef="usd">2863000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idf686c178a5b43e69308e5ab8e5a2e50_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItMTAtMS0xLTA_9bdcb583-b726-4593-92fa-0f1d9ad825a6"
      unitRef="usd">2863000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idf686c178a5b43e69308e5ab8e5a2e50_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzItMTItMS0xLTA_2ebbc79e-0e16-46d6-9ba9-26987cfa9c64"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtMi0xLTEtMA_9088c4c3-be84-4d08-83c5-379d5412393f"
      unitRef="usd">690000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtOC0xLTEtMA_825956d8-2ffd-410e-9ec5-9d195e0b5749"
      unitRef="usd">690000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtMTAtMS0xLTA_f15bef06-146d-4a34-85ff-d73dcc6d9bc3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie7b1533a3fb1425ea88cc6db6686d845_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzQtMTItMS0xLTA_11109065-3e4b-47c8-91e0-fcb7f6b59826"
      unitRef="usd">690000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtMi0xLTEtMA_662ce96c-8ff2-4871-bfac-d58416cec07e"
      unitRef="usd">1937000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtOC0xLTEtMA_03d35ca2-f6d4-4a75-92e1-e276436e14f9"
      unitRef="usd">1937000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtMTAtMS0xLTA_eed58a1a-48b7-4b8e-93d9-eab1424c6349"
      unitRef="usd">1937000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3f3494e19d3645a4882b0218f6e9fa0e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzUtMTItMS0xLTA_7615d94e-2ea2-4aa7-8561-c6714391d147"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctMi0xLTEtMA_86681fd8-8266-443a-b169-041cddf9a7b9"
      unitRef="usd">2674000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctOC0xLTEtMA_aebfb4ef-8711-4e97-ad0e-614a26b5bcb6"
      unitRef="usd">2674000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctMTAtMS0xLTA_a0b896e7-0231-488b-b16e-7e112069e55c"
      unitRef="usd">1451000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia654d3afeed34b34bd201de560aa0413_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzctMTItMS0xLTA_4dd931fe-18d3-4033-87cd-8d2f80a31845"
      unitRef="usd">1223000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtMi0xLTEtMA_dcdf1988-088b-4935-87cb-0794271382d6"
      unitRef="usd">2102000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtOC0xLTEtMA_c4655fbc-0ef8-4088-aab6-e56ad02fb8b5"
      unitRef="usd">2102000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtMTAtMS0xLTA_822caaf9-7a24-44cd-b4aa-4ea3a4a7eab6"
      unitRef="usd">2102000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8e549fb8c84644b1b63e3d2064d641fa_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzgtMTItMS0xLTA_d4b3f96d-aa8a-4ab6-8658-c51e5f270269"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktMi0xLTEtMA_2a08cb1c-4080-4f70-a762-34f1eba6110c"
      unitRef="usd">877000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktOC0xLTEtMA_a33af9b6-58ac-41c8-a525-332509d20b00"
      unitRef="usd">877000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktMTAtMS0xLTA_63f856b3-4e95-4cd2-99ed-1455d24fb11e"
      unitRef="usd">877000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id2a7dcc9839c446fbccecdf7ba191688_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzktMTItMS0xLTA_08c58885-9eec-454f-9a29-e3d495e996bd"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTItMS0xLTA_a96956b9-6e6b-4f4b-9fa5-76cb82fe09ac"
      unitRef="usd">11143000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTgtMS0xLTA_4312f75f-a534-42de-84aa-533ef7310184"
      unitRef="usd">11143000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTEwLTEtMS0w_d0143461-5931-468d-9fbb-5fe9358f05ab"
      unitRef="usd">9230000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idb50baf3796c455ea7b7d2f4fbb565c9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEwLTEyLTEtMS0w_76f2b74b-0e14-46a9-9e8f-7e0d1ccd2605"
      unitRef="usd">1913000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTItMS0xLTA_c350c91a-da67-4efb-a899-75c09d191d25"
      unitRef="usd">13777000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTQtMS0xLTA_fc7267be-9efc-4eda-9012-b6cab08e910b"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTgtMS0xLTA_01afc756-c0b7-4cd7-b957-f29f3ee8661f"
      unitRef="usd">13778000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTEwLTEtMS0w_9851b111-a4e2-49b5-8bcd-13f51514e4d3"
      unitRef="usd">4731000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibc9b5802937d4976b598a9ea0fe267bf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEyLTEyLTEtMS0w_6e471151-a98d-407a-84ea-ce5989ede9b1"
      unitRef="usd">9047000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTItMS0xLTA_7e32389e-4aac-4339-ae6d-982bd0d2de6e"
      unitRef="usd">14000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTgtMS0xLTA_1eb5c21d-a2e1-4e0d-9d6e-1a6608564f4a"
      unitRef="usd">14000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTEwLTEtMS0w_225a9ee8-3d74-4878-9324-28d39646c223"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie8df9244611f44ff9e862d2f22238879_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzEzLTEyLTEtMS0w_259c4162-9e53-42e5-a7ab-0b64f6585599"
      unitRef="usd">14000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTItMS0xLTA_d9602e23-a25b-4de6-9b5e-c34045fb2576"
      unitRef="usd">250000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTgtMS0xLTA_d377a9b8-9ab1-444e-b4e9-703613eb1540"
      unitRef="usd">250000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTEwLTEtMS0w_73870f8f-8484-4aaf-9c19-0fd0178c97a1"
      unitRef="usd">24000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i4ff8fd01ac0a487098147e064c5c7c90_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE0LTEyLTEtMS0w_dacf650d-a427-4f5c-a127-638919a83626"
      unitRef="usd">226000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTItMS0xLTA_23ecae3a-5ffa-41d2-a14c-483c7f8472d7"
      unitRef="usd">14041000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTQtMS0xLTA_3fdf96f6-2d3b-44c9-98f2-f056ab1e3aeb"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTgtMS0xLTA_d9af2110-db30-42a4-a95b-f9b502d238e1"
      unitRef="usd">14042000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTEwLTEtMS0w_bd73f6ab-0e4e-498a-b74c-d7b8b0bd2c6a"
      unitRef="usd">4755000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i72a342c6145547bd8226fe95c213f2a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE2LTEyLTEtMS0w_5a6e4ccc-58c2-41f5-bb4f-17f43d12c17d"
      unitRef="usd">9287000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE4LTEwLTEtMS0w_12647176-819e-4b02-944c-67d8bd5832da"
      unitRef="usd">13985000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTo4MjAxZmM0NTdkYWU0M2U2OGQyZDkxMzdlNjgzZDhmMS90YWJsZXJhbmdlOjgyMDFmYzQ1N2RhZTQzZTY4ZDJkOTEzN2U2ODNkOGYxXzE4LTEyLTEtMS0w_2bf7391e-283e-4809-8685-748434c97f9a"
      unitRef="usd">11200000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i1c02f63bfeba457680dc2981ea77c247_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzItMi0xLTEtMA_c41d594c-0003-4241-a94e-539a0a578b5a"
      unitRef="usd">2637000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1c02f63bfeba457680dc2981ea77c247_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzItMTAtMS0xLTA_b0b10982-9d40-4201-ad67-9911ef732eae"
      unitRef="usd">2637000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1c02f63bfeba457680dc2981ea77c247_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzItMTItMS0xLTA_322c81a2-8f83-47b1-b69a-b469cbaf5cd3"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i9fcb9b3192c346bab96adcaf99402100_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzQtMi0xLTEtMA_c18ac24c-5473-4f16-bf55-39390ee2223d"
      unitRef="usd">439000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9fcb9b3192c346bab96adcaf99402100_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzQtMTAtMS0xLTA_ab4e2b37-68e5-4b43-aaec-3455406e2c7f"
      unitRef="usd">149000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9fcb9b3192c346bab96adcaf99402100_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzQtMTItMS0xLTA_1f163f05-d475-4b03-9443-001db6601543"
      unitRef="usd">290000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i999eaa5539f8442a9db3d7527b669ae0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzUtMi0xLTEtMA_01c2a60e-7a64-43bd-a9ab-f3ff9e0ea20c"
      unitRef="usd">6375000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i999eaa5539f8442a9db3d7527b669ae0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzUtMTAtMS0xLTA_d2c69f6d-bbba-4f91-8f74-8d5eac08a476"
      unitRef="usd">6375000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i999eaa5539f8442a9db3d7527b669ae0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzUtMTItMS0xLTA_87bf7b2c-511e-4cf1-9447-690245008e06"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ib68ca550e07c4272974f847b220b5bdf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzYtMi0xLTEtMA_c102ead2-678e-4917-b219-d13da470a193"
      unitRef="usd">375000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib68ca550e07c4272974f847b220b5bdf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzYtMTAtMS0xLTA_a4f04c4a-df21-437f-8b08-3f87b4e23f87"
      unitRef="usd">375000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib68ca550e07c4272974f847b220b5bdf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzYtMTItMS0xLTA_19423db8-4295-4502-bb1c-7a4cb1e937ac"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iecdc5e97696145adacdd25f020821810_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzctMi0xLTEtMA_37ed2e58-a6df-4334-978b-3d9ae5d58414"
      unitRef="usd">1323000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecdc5e97696145adacdd25f020821810_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzctMTAtMS0xLTA_bb2280b0-b5da-4388-bf1a-2342a175ac09"
      unitRef="usd">889000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iecdc5e97696145adacdd25f020821810_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzctMTItMS0xLTA_82ce7e89-41df-45d1-af07-ca56bfc74938"
      unitRef="usd">434000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzgtMi0xLTEtMA_8db0ddea-e03d-4ae3-b5e6-fc1aa74c3c7d"
      unitRef="usd">2864000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzgtMTAtMS0xLTA_c984ed47-239c-48eb-84c3-a5635dd5f1ff"
      unitRef="usd">2864000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id04e9fa417b84b5590a2e4b5ed1e336b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzgtMTItMS0xLTA_fe825aba-f0df-45b8-a30c-527d999c2b18"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i45864798375349aa82cdbc0fe5b12467_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzktMi0xLTEtMA_ece6665c-950b-4737-9146-98b7ae0ccc82"
      unitRef="usd">906000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i45864798375349aa82cdbc0fe5b12467_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzktMTAtMS0xLTA_07c3a0b1-a095-465a-9629-0ab710f9457f"
      unitRef="usd">906000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i45864798375349aa82cdbc0fe5b12467_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzktMTItMS0xLTA_430008b9-b8f9-43d2-ae64-9e635f4f8031"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i525d9deca0aa4aa69bea7606b12ab349_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEwLTItMS0xLTA_b1431f37-457d-43dc-a8d6-028dae8ddcc6"
      unitRef="usd">14919000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i525d9deca0aa4aa69bea7606b12ab349_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEwLTEwLTEtMS0w_53df9c52-3960-4f31-baa3-5edab101802e"
      unitRef="usd">14195000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i525d9deca0aa4aa69bea7606b12ab349_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEwLTEyLTEtMS0w_e7246594-b5b5-4ffa-ba34-e1ba0bdf8ac5"
      unitRef="usd">724000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib7656b3ff8f34856acd3408e287ef6db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEyLTItMS0xLTA_7efd7688-0a15-41ee-a633-cb52ea1920ef"
      unitRef="usd">4102000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7656b3ff8f34856acd3408e287ef6db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEyLTEwLTEtMS0w_466b6e6d-2e89-4890-b48e-085347794cee"
      unitRef="usd">3095000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib7656b3ff8f34856acd3408e287ef6db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzEyLTEyLTEtMS0w_4bf8759c-5c9f-491b-9fc2-489503dd6461"
      unitRef="usd">1007000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3a1e598b00f94535a80aa29acebd3c1b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE0LTItMS0xLTA_8c0b2c7f-d4dd-4447-ae7b-f605b63dd1da"
      unitRef="usd">266000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a1e598b00f94535a80aa29acebd3c1b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE0LTEwLTEtMS0w_7391a2d3-cb78-4e87-8b45-e4225514948c"
      unitRef="usd">15000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3a1e598b00f94535a80aa29acebd3c1b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE0LTEyLTEtMS0w_2dfa660c-a82e-414e-8e01-1bcf21f3eb76"
      unitRef="usd">251000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iebd47e6dfd734f18ab3b1175104da7ee_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE2LTItMS0xLTA_0dcc8c45-ad7c-4bd4-b623-678d9850a861"
      unitRef="usd">4368000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iebd47e6dfd734f18ab3b1175104da7ee_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE2LTEwLTEtMS0w_c0235084-489d-476f-bd1a-14e210d19fd4"
      unitRef="usd">3110000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iebd47e6dfd734f18ab3b1175104da7ee_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE2LTEyLTEtMS0w_feb8bb77-28d1-4b43-9716-d61eecf96af5"
      unitRef="usd">1258000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE4LTEwLTEtMS0w_ec7aa162-74a5-493f-833d-c4963e82c835"
      unitRef="usd">17305000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZToyZDk2ZjM0YWJiZGE0ZTViOTllZDFkZGI0YTc3MWZiZS90YWJsZXJhbmdlOjJkOTZmMzRhYmJkYTRlNWI5OWVkMWRkYjRhNzcxZmJlXzE4LTEyLTEtMS0w_35d348c4-4128-4195-ae5c-0ef889f99853"
      unitRef="usd">1982000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90ZXh0cmVnaW9uOjA4YWE4NDFiNTQyYTQyNmJhNGRlOTM0NzliYzU5ZDU2XzEwODM_ca7a05bf-7610-41d9-9dee-16445251be19">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale debt securities at January&#160;3, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzEtMi0xLTEtMA_e2aaf139-510d-4154-a8d9-b42a1e04eb2e"
      unitRef="usd">14026000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzEtNC0xLTEtMA_bbac13ec-942b-4ebf-9eac-728866aebc0c"
      unitRef="usd">14027000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzItMi0xLTEtMA_e5fa8a63-ad1b-4c16-a153-dedcd3df1350"
      unitRef="usd">15000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzItNC0xLTEtMA_b94cee72-8f25-4369-acc2-484e65ac1253"
      unitRef="usd">15000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzMtMi0xLTEtMA_394a9a42-d632-416b-935c-dc4acfca4b6b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzMtNC0xLTEtMA_387912e6-03ff-4ecd-a3a5-b0f27308b0ca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzQtMi0xLTEtMA_f109375a-c290-488f-b5f3-80544d469479"
      unitRef="usd">14041000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzkvZnJhZzowOGFhODQxYjU0MmE0MjZiYTRkZTkzNDc5YmM1OWQ1Ni90YWJsZTozOWJiNWYxNWE2ZTE0ODU2YjA4OTY4ZGU5ZDZkNDBjMS90YWJsZXJhbmdlOjM5YmI1ZjE1YTZlMTQ4NTZiMDg5NjhkZTlkNmQ0MGMxXzQtNC0xLTEtMA_fae3eec9-af74-4dc2-b866-243caf8abee4"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90ZXh0cmVnaW9uOjIyMjMzZmZjOTA0NzRmMzk5NGRhMDNlNDBkZDk2ZDBiXzIwOQ_b7b5f4f9-d76c-479e-b5d8-d2768ac4ec1c">Inventories&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2020 and 2019, inventories were comprised of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90ZXh0cmVnaW9uOjIyMjMzZmZjOTA0NzRmMzk5NGRhMDNlNDBkZDk2ZDBiXzIwNQ_28f29a68-79a6-4ccb-b8f3-2c31df7cf708">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2020 and 2019, inventories were comprised of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021.</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzEtMi0xLTEtMA_7ea3296a-b081-495c-9052-6ebe0ddb0c58"
      unitRef="usd">1410000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzEtNC0xLTEtMA_046b3d78-dc28-4bf8-9f87-c523317dd7d0"
      unitRef="usd">1117000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzItMi0xLTEtMA_e8b21608-876d-437e-a038-4eb59f94696f"
      unitRef="usd">2040000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzItNC0xLTEtMA_348e69a0-9b75-4453-92cc-360b78acf482"
      unitRef="usd">1832000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzMtMi0xLTEtMA_81a8cd83-339f-432d-b71f-01ffe41a4d46"
      unitRef="usd">5894000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzMtNC0xLTEtMA_f2d0872d-2cf3-41a9-9a98-f59293e6e55d"
      unitRef="usd">6071000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzQtMi0xLTEtMA_a92e778f-019b-4b1e-b6bc-60e4ae27562e"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDIvZnJhZzoyMjIzM2ZmYzkwNDc0ZjM5OTRkYTAzZTQwZGQ5NmQwYi90YWJsZTo5NDJiYjI3ZWY5YmY0NmFiYmJmZDY5Zjk5MDkzN2JhOS90YWJsZXJhbmdlOjk0MmJiMjdlZjliZjQ2YWJiYmZkNjlmOTkwOTM3YmE5XzQtNC0xLTEtMA_480191a5-5c8d-4f4e-a281-10f0934beb28"
      unitRef="usd">9020000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzg5NA_9a504198-7f57-4c7e-9605-28ac61263b34">Property, Plant and Equipment&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December&#160;29, 2019. There were no assets held for sale at January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2020, 2019 and 2018 was $63 million, $70 million and $86 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including the amortization of capitalized interest in fiscal years 2020, 2019 and 2018 was $2.6 billion, $2.5 billion and $2.6 billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzg5MA_59f3b0ad-0552-4957-95f2-39fac1119f2e">&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December&#160;29, 2019. There were no assets held for sale at January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzEtMi0xLTEtMA_53e78836-9882-4c1f-bf7c-ba28278269bb"
      unitRef="usd">882000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzEtNC0xLTEtMA_3c539468-af68-475a-a6fd-67b89a4d0691"
      unitRef="usd">854000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzItMi0xLTEtMA_4ed5aa27-8f77-4091-8ffa-2524beb19075"
      unitRef="usd">12502000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzItNC0xLTEtMA_5d400718-2fb5-4757-b0f7-226d6cf4ec43"
      unitRef="usd">11877000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzMtMi0xLTEtMA_578a27c7-d389-4630-b847-f461b7b46900"
      unitRef="usd">29104000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzMtNC0xLTEtMA_6b61c6ec-24f8-46cc-b198-f89cc1b845cd"
      unitRef="usd">26964000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzQtMi0xLTEtMA_fae2b2a4-6bce-40cd-9c65-c9cc34f071e4"
      unitRef="usd">4316000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzQtNC0xLTEtMA_31defd98-12e1-4d69-b54c-0a3c58dccaf9"
      unitRef="usd">3637000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzUtMi0xLTEtMA_d742d112-0a0b-4ea2-998a-1fad8f18c8d2"
      unitRef="usd">46804000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzUtNC0xLTEtMA_14e7fdb1-2fc9-4e58-9301-f692b1f93529"
      unitRef="usd">43332000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzYtMi0xLTEtMA_41ac11d6-eeb4-42f6-80ac-068dd5866a69"
      unitRef="usd">28038000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzYtNC0xLTEtMA_22ad274f-979c-47b6-93bf-05e7d6180ac6"
      unitRef="usd">25674000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzctMi0xLTEtMA_f29cc53d-b4e4-440e-b572-3998388c4cc3"
      unitRef="usd">18766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90YWJsZTo5MjY3YWM0OGFjZDk0MGVkYTQyMDU1MmI4MDRiNDg2My90YWJsZXJhbmdlOjkyNjdhYzQ4YWNkOTQwZWRhNDIwNTUyYjgwNGI0ODYzXzctNC0xLTEtMA_e85d9d71-e745-4eda-8817-eaee22bb2c30"
      unitRef="usd">17658000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InterestCostsCapitalized
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzQxNw_7c0119a7-19c6-4edc-a2f5-ae9aea96363e"
      unitRef="usd">63000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzQyMQ_f4c05eaf-ce0d-4651-97ea-0361c3abbfc4"
      unitRef="usd">70000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzQyOA_731a2046-84a2-4d64-822f-9ed53273b4f8"
      unitRef="usd">86000000</us-gaap:InterestCostsCapitalized>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzU0MA_9274a83a-cabe-47c0-87b3-f866f37599b0"
      unitRef="usd">2600000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzgyNDYzMzcyMDkyNzU_c7f32de5-4c68-4e81-b718-e1abaf092c76"
      unitRef="usd">2500000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDUvZnJhZzpiYTY0ZTUzNTJlYzU0Nzg0Yjk1NGI2NDY1ZGQ0NTEwMC90ZXh0cmVnaW9uOmJhNjRlNTM1MmVjNTQ3ODRiOTU0YjY0NjVkZDQ1MTAwXzgyNDYzMzcyMDkyODU_be6bf712-11ae-42d4-baab-b13369b8576e"
      unitRef="usd">2600000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwNzg_b85f0402-01b5-4e8e-baf8-c2f7e4074a6a">Intangible Assets and Goodwill&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0&#160;billion from Momenta Pharmaceuticals, Inc., $0.8&#160;billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4&#160;billion from the acquisition of all outstanding shares in Verb Surgical, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of January&#160;3, 2021 and December&#160;29, 2019, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,048&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36,393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in cost of products sold was $4.7 billion, $4.5 billion and $4.4 billion before tax, for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Intangible asset write-downs are included in Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwODY_3027afc1-0ffc-4af9-9e67-a8700ff970d4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0&#160;billion from Momenta Pharmaceuticals, Inc., $0.8&#160;billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4&#160;billion from the acquisition of all outstanding shares in Verb Surgical, Inc.&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzItMi0xLTEtMA_75469ebc-ffd4-42f1-bd8d-64d6ce8f9024"
      unitRef="usd">39990000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzItNC0xLTEtMA_90778bdc-c0de-4e58-bb5f-496119047796"
      unitRef="usd">36634000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzMtMi0xLTEtMA_fa95262b-8ae3-43d5-9e2d-a24c0d32bfc5"
      unitRef="usd">17618000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzMtNC0xLTEtMA_0fa2b454-b16c-4992-9fc9-e72bbe23473a"
      unitRef="usd">13154000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4ea5a3d24e8649c98787b3705f87b7ba_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzQtMi0xLTEtMA_31118b6d-b3c9-4aa8-8499-34f4c816a3da"
      unitRef="usd">22372000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8fa09f09f4e24a50ac00fea8dc11aa38_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzQtNC0xLTEtMA_98ec88b4-2310-46a0-991d-af1c8e1bcac7"
      unitRef="usd">23480000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idc844a985e9b4ab8acde3269099a7e3a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzUtMi0xLTEtMA_36b53122-0977-4803-902f-cede4d2e18b1"
      unitRef="usd">22898000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7cf08feba35c44f18b96be74a96747f7_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzUtNC0xLTEtMA_d136aee9-c4d3-4c4e-923d-2c78d626d434"
      unitRef="usd">22056000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idc844a985e9b4ab8acde3269099a7e3a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzYtMi0xLTEtMA_67ce7b3b-03c0-4a4c-9f95-953729536487"
      unitRef="usd">10912000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7cf08feba35c44f18b96be74a96747f7_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzYtNC0xLTEtMA_47132065-3289-47fb-b659-b5f5a8a9eaa8"
      unitRef="usd">9462000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idc844a985e9b4ab8acde3269099a7e3a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzctMi0xLTEtMA_328f3205-5f5a-4a88-90fa-68913a231283"
      unitRef="usd">11986000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7cf08feba35c44f18b96be74a96747f7_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzctNC0xLTEtMA_f5d1c841-4b55-4450-a40d-fe82575ee639"
      unitRef="usd">12594000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0246814551b44afa8fc330cee4302c9e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzktMi0xLTEtMA_bfd1a410-4d99-4c8b-a86e-d7e062634a42"
      unitRef="usd">7195000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icd28da37730341bf89cc859b43e1ce8b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzktNC0xLTEtMA_0da9cc76-16b5-4d42-bb1a-bbe59e7869d2"
      unitRef="usd">6922000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i323d72d0abae4c60a66b9d7b0a4c7632_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEwLTItMS0xLTA_124507fd-ba1b-47d3-b629-06b3c36b5b0d"
      unitRef="usd">11849000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i83996bd19a7d44aa89d8fa3abc440044_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEwLTQtMS0xLTA_2a0d618b-a8e8-49eb-93c9-938fe29479d7"
      unitRef="usd">4647000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzExLTItMS0xLTA_3d97e671-b334-4ba6-86c7-e46ca22effe5"
      unitRef="usd">19044000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzExLTQtMS0xLTA_9107c077-092a-4c86-a7a7-d74728d265b7"
      unitRef="usd">11569000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEyLTItMS0xLTA_60b0fa22-f351-40a3-ac36-51ef83ad5e40"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTo5MTEwYmE2MDEzMTY0NTk5ODE5ODMyMTA3NDRkNDcwYS90YWJsZXJhbmdlOjkxMTBiYTYwMTMxNjQ1OTk4MTk4MzIxMDc0NGQ0NzBhXzEyLTQtMS0xLTA_620ce587-bd69-4494-bb07-8a5f93c38026"
      unitRef="usd">47643000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i610e8d971e0146b5b0f50d10214d75f7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzgyNDYzMzcyMTkxNjg_07cd5ed7-60be-4821-a6e1-0ad0bf825b2c"
      unitRef="usd">6000000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie2f9006a108d4ae79eef7c6e80d975ed_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzg3OTYwOTMwMzA2MjM_2e8c2935-e1bf-4332-8121-9c8e9f51e62a"
      unitRef="usd">800000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6680195d23ef48f48b25fd080e30e045_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzg3OTYwOTMwMzA2Mzc_f141f6b7-f2f1-443c-a912-91c1dd3311ca"
      unitRef="usd">400000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwODk_896ecd89-c3a4-47d5-b553-e7ae34f33fb9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of January&#160;3, 2021 and December&#160;29, 2019, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,048&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36,393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ic991d846f0554fb3854353012c741e47_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtMi0xLTEtMA_4af8dd2b-163e-4128-bcde-8294b0331142"
      unitRef="usd">8670000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9af09372a20b4cf5bc9ca89867f6e9b5_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtNC0xLTEtMA_6c1a13bf-616b-423c-b265-3690b8ef8491"
      unitRef="usd">9063000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7611c63653fb4652b6fe6457c1f44f7d_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtNi0xLTEtMA_6ff73dab-0057-44ee-9b56-91f5ba48a1f8"
      unitRef="usd">12720000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzEtOC0xLTEtMA_7be0f463-a1f3-4b2c-9bdb-7ca79c17919f"
      unitRef="usd">30453000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItMi0xLTEtMA_c06ba65f-6d1b-4607-a45d-536e2fc30b09"
      unitRef="usd">1188000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItNC0xLTEtMA_61943342-2eab-4cb3-bef7-d3fa2df74543"
      unitRef="usd">75000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItNi0xLTEtMA_00437407-594b-430d-9762-96a14c47e83d"
      unitRef="usd">2018000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzItOC0xLTEtMA_9cb8dfab-01f9-4a65-a79b-9af00fd57bc8"
      unitRef="usd">3281000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtMi0xLTEtMA_89e6a684-98da-46d1-ac83-8ce55c9f15cf"
      unitRef="usd">-122000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtNC0xLTEtMA_5fcc3555-7a62-42d5-94f0-890c2c08ec93"
      unitRef="usd">31000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtNi0xLTEtMA_06ae00b2-c28b-4e55-b47c-335d7c62a1ed"
      unitRef="usd">-4000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzQtOC0xLTEtMA_4747ae5e-8781-4576-8995-86b7efce7112"
      unitRef="usd">-95000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i5ecd7168647c48c487c55761ba2ced54_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtMi0xLTEtMA_0841d868-4f45-496c-b058-af8256cc4966"
      unitRef="usd">9736000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i63df1bc915934ad68c8902ac19c99bea_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtNC0xLTEtMA_1b40424d-b1b1-40bb-910d-9dcd64ea7d18"
      unitRef="usd">9169000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i99e711fea4f3418abfe78e49bdbf2256_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtNi0xLTEtMA_071c5976-68f4-4afc-8939-41e69a30e6f9"
      unitRef="usd">14734000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzUtOC0xLTEtMA_c5db150b-fb94-4b48-b61e-10f3b2face75"
      unitRef="usd">33639000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtMi0xLTEtMA_b11dfadd-a3dd-442d-9cd8-a51caf174852"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtNC0xLTEtMA_bc97924f-4d6b-4cd9-8e13-f354dd9eceba"
      unitRef="usd">1222000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtNi0xLTEtMA_64203f9c-83a4-473f-af31-150bea2e61cc"
      unitRef="usd">238000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzYtOC0xLTEtMA_1c89a30f-2b6a-4117-ad3f-735edf3ef3cf"
      unitRef="usd">1460000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtMi0xLTEtMA_f5f22745-998e-4e6b-8ac3-fd1caa356a7a"
      unitRef="usd">600000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtNC0xLTEtMA_080fd1ef-1018-423c-8b75-761a55ed76d3"
      unitRef="usd">618000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtNi0xLTEtMA_ba6c02d6-0bac-4070-b771-6da9d9348da5"
      unitRef="usd">76000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzgtOC0xLTEtMA_826c86bd-729c-4584-bfd2-47dbc7be1e0b"
      unitRef="usd">1294000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i55c1789785ab45d596ef77f977c4b121_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktMi0xLTEtMA_a6db9b63-3e30-4fd6-a12e-097318c10901"
      unitRef="usd">10336000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ide0733c2434242ba85b6c5b1c835e725_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktNC0xLTEtMA_0c97a855-899b-46e4-af8c-0019b600b539"
      unitRef="usd">11009000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia0ae3e960cac4c83aaf46f48e727ffc7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktNi0xLTEtMA_7d69fc0b-f9aa-4773-b8d6-e72617087e3a"
      unitRef="usd">15048000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTphZDAxOGMzZDAwZjk0OGJkYWVmYzljOGQ4YjViZmNlMS90YWJsZXJhbmdlOmFkMDE4YzNkMDBmOTQ4YmRhZWZjOWM4ZDhiNWJmY2UxXzktOC0xLTEtMA_cbd3a500-4a15-4e72-b5b0-0200f8fe1369"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia50a679a6f554f4782e402d666b79722_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE0ODY_216d1793-c4de-41a2-9eb0-fed73850881b">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iccf138ab7f374295818f1906976dd6e3_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE1ODk_49e4b85b-2650-438e-bd7c-6b22df0bdd22">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE2Nzg_14b2b0db-827f-4789-aa0e-f97252304930"
      unitRef="usd">4700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE2ODI_0d5dd2cb-b039-4f24-9447-a1417ab39a35"
      unitRef="usd">4500000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzE2ODk_c6692315-572f-40e3-930b-150a3b63639f"
      unitRef="usd">4400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90ZXh0cmVnaW9uOjI2ZjZlMDM0MzYyMzQ2Nzc5YTZjZWFjZjNiYjhkYWIyXzIwODQ_af989fb6-f599-4198-bef2-281fa421ff74">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItMC0xLTEtMA_df120c32-3509-4f85-9c7f-03e643ea30bf"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItMi0xLTEtMA_bbd6358b-109d-45f4-8571-de575cd784e8"
      unitRef="usd">4200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItNC0xLTEtMA_2fd75c88-eef2-4b46-a49e-7ebc25f7f811"
      unitRef="usd">4100000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItNi0xLTEtMA_65829162-d0dd-4674-b7d4-9ba96d408992"
      unitRef="usd">3900000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNDgvZnJhZzoyNmY2ZTAzNDM2MjM0Njc3OWE2Y2VhY2YzYmI4ZGFiMi90YWJsZTpmNmQ0MmU0NWQyNTM0MTExYTRmODhmNWFhMTY0MWRhZi90YWJsZXJhbmdlOmY2ZDQyZTQ1ZDI1MzQxMTFhNGY4OGY1YWExNjQxZGFmXzItOC0xLTEtMA_e9cf403b-b642-4c62-aed0-4f79c65e6e16"
      unitRef="usd">3200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1NzM_cb7fe061-344c-4a87-a367-7d55626148b9">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges.  The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.  As of January&#160;3, 2021, the total amount of cash collateral paid by the Company under the CSA amounted to $1.1 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings.  The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions.      As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively. As of December&#160;29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $45.3 billion and  $20.1 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. The effect of which are immaterial for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of January&#160;3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $652 million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts, net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of net investment hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)           Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019 for equity investments without readily determinable market values, $76 million and $57 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were $21 million and $19 million, respectively, of changes in fair value reflected in net income due to changes in observable prices.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#160;&#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#160;&#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#160;&#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;3, 2021 and December&#160;29, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)(3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2019 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,148 million, which are classified as Level&#160;1 and contingent consideration of $1,715 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $1 million of non-current assets as of December&#160;29, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as non-current other assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $594 million, $1,631 million (primarily related to Auris Health) and $397 million, classified as non-current other liabilities as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Includes $39 million and $84&#160;million classified as current liabilities as of January&#160;3, 2021 and December&#160;29, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzE2NjU_3e569a18-870b-40ba-a53a-d679ecc4084a"
      unitRef="usd">1100000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzIzMDc_c53177a0-0a9e-4c4c-aeb1-b419617578cf"
      unitRef="usd">37800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9875f4baef3f4a1b948b6ce968e1cdc7_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzIzMTU_64dc6d72-99e9-4f8e-9a0a-b30c9476f735"
      unitRef="usd">30600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i27f4f225aff44f999a6680657f1c61d3_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzI0ODk_788fed35-998b-41bc-a71f-f37a540d01f7"
      unitRef="usd">45300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7ca6c05369c945429bb481abe32f8614_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzI0OTM_c6b5e04a-6976-4783-97ca-115935e93768"
      unitRef="usd">20100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzQ2OTY_06321e26-5f37-449f-ba54-0a91f4623b19"
      unitRef="usd">-652000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzQ5NTU_3a3b62c8-a7a1-4467-9330-ebfd200b8163">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzUxMTY_a8bd0458-9848-4078-9cbd-6592624ec74e">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1ODQ_e2e25262-eacb-4b45-bad0-5d8c0ec47761">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i504dd38a7aa842119593f0983c422c2d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTEtMS0xLTA_40e5e685-31fd-41e0-89c0-75b789a1832b"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i8640053c6b9d41e7b51cfc21fdc35a76_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTItMS0xLTA_9f467888-e075-4972-a592-2ea6f41e1730"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i052b28db3f2e41379f8949dc73a4456c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTMtMS0xLTA_b51140f4-4a8c-4f6f-ac10-cf751e32c087"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1b584b81e4314c05bff5a3a53f02afbf_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTQtMS0xLTA_0179bccb-8587-4bb8-949f-9fc7b09f9316"
      unitRef="usd">153000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie92ffcb6fd0b4017b7ebc21794532df0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTUtMS0xLTA_adb6fd41-2d93-4c12-98a5-3196c92dce00"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4a30ff6ddef34c879c3a48899c85fd4c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTYtMS0xLTA_c4427248-1471-405f-8ac3-9585b481f3d2"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iadc985f689ed44a3b6b5c0680b59cb08_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTctMS0xLTA_6e337c1c-b9cc-401e-9fe1-7fbe1adc67db"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i50be13ffcdce471782b928e02e0ecb36_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTgtMS0xLTA_bd752854-0a28-4776-89d6-91c962b166df"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i2ca59ee60bd4461ea3d47a202e3a0c92_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTktMS0xLTA_69df6724-cdaa-4954-8d9b-4a0ecf2363fd"
      unitRef="usd">159000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia2d21b453745418380adcf639d9dcc50_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzEzLTEwLTEtMS0w_5adc64f9-e076-492a-8b49-805ee37e920a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i504dd38a7aa842119593f0983c422c2d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTEtMS0xLTA_1502778c-762a-4352-aa79-c8a43b497ce3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8640053c6b9d41e7b51cfc21fdc35a76_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTItMS0xLTA_106d6f30-d168-49dc-81b4-466fdb4400b4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i052b28db3f2e41379f8949dc73a4456c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTMtMS0xLTA_4aafccf6-f205-436e-882c-2df8eb76e2a4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1b584b81e4314c05bff5a3a53f02afbf_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTQtMS0xLTA_ae42cfab-23e8-43ae-ba31-419d3b2e184d"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie92ffcb6fd0b4017b7ebc21794532df0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTUtMS0xLTA_01598e92-5bbf-4415-9372-34d5177ad518"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4a30ff6ddef34c879c3a48899c85fd4c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTYtMS0xLTA_3e165e44-e50d-4891-bb4d-d0f7b519aaef"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iadc985f689ed44a3b6b5c0680b59cb08_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTctMS0xLTA_705ec87a-e346-468a-9f0c-75f2e3a4b18b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i50be13ffcdce471782b928e02e0ecb36_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTgtMS0xLTA_d65e71fc-e64a-4e81-9649-6daa68f6019f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2ca59ee60bd4461ea3d47a202e3a0c92_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTktMS0xLTA_33507419-4bd2-4659-9180-8c9933832487"
      unitRef="usd">159000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia2d21b453745418380adcf639d9dcc50_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE0LTEwLTEtMS0w_be348e68-487a-4e7f-89d1-654b7f77faf6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i7c6f97ba35ec4096bcc04f4b4f8691c3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTEtMS0xLTA_3055f910-3678-4746-a89a-a5ddf5b16517"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic742e9fd9fc14884addc84d349e1c28e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTItMS0xLTA_09ac02a0-51c3-42ab-8ac1-c644c1f88dde"
      unitRef="usd">-329000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i9bbdc1a64aa24c13b6889b62805de83b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTMtMS0xLTA_c5378416-ec67-419c-a446-5bf7419a1863"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1283aa8aad894085a364e383b421263f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTQtMS0xLTA_f68e261a-fd10-403c-8add-f3b9cbf5a9cd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ibcdafeb6de434a389a8ae98d6c27bc71_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTUtMS0xLTA_da645ae2-43ba-46aa-b624-b987c20344e8"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i49eaaa02ae0e4bdd942caea69069c9bb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTYtMS0xLTA_d2a69661-8e3b-46d0-900c-ed79fe914b19"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i63d2fc906c86432098158cb4b10ed6af_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTctMS0xLTA_9308164d-e77e-42a9-b531-af1e833e6185"
      unitRef="usd">-321000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i8768d9bd65b14a88998cc98eb8b56b71_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTgtMS0xLTA_91a0664e-448a-443b-a195-327e9684287d"
      unitRef="usd">-105000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i15d6224b1442428383799310a443ccd9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTktMS0xLTA_c4b424a3-4278-4513-b80a-14f45856e175"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id484553bc7f246b2956d7fe4162e2291_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzE4LTEwLTEtMS0w_5c743009-1bcf-4eab-ba7e-2908fec55c7e"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i7c6f97ba35ec4096bcc04f4b4f8691c3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTEtMS0xLTA_b8211bae-52bb-4276-81d1-506dbf53a9a3"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic742e9fd9fc14884addc84d349e1c28e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTItMS0xLTA_61e1d0ba-9d9f-4a1a-aebf-5b6ec3f9415f"
      unitRef="usd">298000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9bbdc1a64aa24c13b6889b62805de83b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTMtMS0xLTA_ccefa7f9-c56f-4980-8f89-3c0d79493c15"
      unitRef="usd">-191000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1283aa8aad894085a364e383b421263f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTQtMS0xLTA_837b5504-2eb5-4e7e-9648-4a5416b8256e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ibcdafeb6de434a389a8ae98d6c27bc71_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTUtMS0xLTA_ca7fbf91-dc3b-4383-9df3-3fc41aaccf44"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i49eaaa02ae0e4bdd942caea69069c9bb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTYtMS0xLTA_6974a136-1e9f-43dd-8464-261aef6443a4"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i63d2fc906c86432098158cb4b10ed6af_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTctMS0xLTA_4521c149-2d55-4ebd-a297-6cf0cca88315"
      unitRef="usd">-606000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i8768d9bd65b14a88998cc98eb8b56b71_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTgtMS0xLTA_be515fa4-96a5-4ef5-afdd-212488e699b3"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i15d6224b1442428383799310a443ccd9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTktMS0xLTA_bc1663f8-1e29-4676-baf4-c9641ec3d2e6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id484553bc7f246b2956d7fe4162e2291_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzIyLTEwLTEtMS0w_d59e4c43-17ab-4d12-b509-a4c09a73d5c1"
      unitRef="usd">39000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="iff4cffd97e4a4b9db233400cb5173ef1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTEtMS0xLTA_ab95d0e9-96fc-45bc-9827-ca5b06a4ea90"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i685f5c13f8df4ef59a10c882dc33db9a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTItMS0xLTA_71eb4336-a2d1-4f30-8fff-39e0a163f4fe"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i168477b06e674a54857ad32c9063d70d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTMtMS0xLTA_4da5f8f2-7226-4e21-ad42-046a2e642936"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i7df8b1f03a5d46d788ea587e459c0d92_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTQtMS0xLTA_c3877b73-b5e5-4e57-bcf5-94ead10c0400"
      unitRef="usd">370000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie2c58bd90b6d4d01aab3aef88e24fda1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTUtMS0xLTA_9f4d241d-f966-4b38-961d-f1d646baa34b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i35f6e10d334f47eb89761629c9a42e6b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTYtMS0xLTA_7c9792ce-c1dc-4722-8db9-0ff4ce06c36a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i91c7fd78bae849e18766ff5f722b4347_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTctMS0xLTA_4f548181-29fd-40d1-97c3-34abc6f045f0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1dc23bedbeef4fe2934d4b69926edf66_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTgtMS0xLTA_c72e30d8-f797-4b32-9350-1301b62d8fc3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="if44491fa9fda4fc9977393ab1922d90e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTktMS0xLTA_c9a31c7b-ea7e-4a54-b374-5f6333db52a2"
      unitRef="usd">292000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i23c9442c717040c2b8f471f3da9878f2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI1LTEwLTEtMS0w_a7eb333d-96a8-48f5-939d-4dd579e0f95b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="iff4cffd97e4a4b9db233400cb5173ef1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTEtMS0xLTA_0cb35282-5611-4d3b-82b6-c2bee4911c82"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i685f5c13f8df4ef59a10c882dc33db9a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTItMS0xLTA_287c92eb-fc91-474c-a0bb-8049a34bef2e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i168477b06e674a54857ad32c9063d70d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTMtMS0xLTA_74035c3f-b0c9-4717-b37b-86699bcec8a2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i7df8b1f03a5d46d788ea587e459c0d92_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTQtMS0xLTA_4b15388a-b685-4d35-ae59-c760a0f8a8b1"
      unitRef="usd">748000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ie2c58bd90b6d4d01aab3aef88e24fda1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTUtMS0xLTA_d5cc1bfe-ccf2-4c40-84fd-dee4c15eebeb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i35f6e10d334f47eb89761629c9a42e6b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTYtMS0xLTA_8fc47b53-9302-485a-9cea-c4d66aba4a8d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i91c7fd78bae849e18766ff5f722b4347_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTctMS0xLTA_6332f1d5-d095-4dec-bed6-aebf6d717f39"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1dc23bedbeef4fe2934d4b69926edf66_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTgtMS0xLTA_1a9ed8f1-52ec-4d7e-a27c-6243b65bc97a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if44491fa9fda4fc9977393ab1922d90e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTktMS0xLTA_6ff94946-1f7b-43d2-84a7-d3e28ebcbb07"
      unitRef="usd">417000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i23c9442c717040c2b8f471f3da9878f2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NzRkNzc1MzkwOGY0MDAzOThiZmU4ZjFkOTg1MjRkMi90YWJsZXJhbmdlOjk3NGQ3NzUzOTA4ZjQwMDM5OGJmZThmMWQ5ODUyNGQyXzI3LTEwLTEtMS0w_2a229481-5142-4dd0-8e0c-df2410de14ec"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1Nzk_4f970217-b9c3-4536-8e99-84a5d3ce1a95">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7f5f27a8783b49c09ce94e0b992e4d45_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3NmJlYWY3MWFiYWE0Yjg5OWI4NDBjNjg1NWRmZDBhMS90YWJsZXJhbmdlOjc2YmVhZjcxYWJhYTRiODk5Yjg0MGM2ODU1ZGZkMGExXzQtNy0xLTEtMA_52189669-d4a2-40f5-960c-460069226625"
      unitRef="usd">24000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8b0ca0336ef04af5b1a42a37200ec54d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3NmJlYWY3MWFiYWE0Yjg5OWI4NDBjNjg1NWRmZDBhMS90YWJsZXJhbmdlOjc2YmVhZjcxYWJhYTRiODk5Yjg0MGM2ODU1ZGZkMGExXzQtOS0xLTEtMA_e8464ab2-7461-4d62-91d5-e21becefb6b7"
      unitRef="usd">-144000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1NzQ_33f237d2-d732-4c6b-9431-c8ed161ded81">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of net investment hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)           Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtMi0xLTEtMA_6e1e848c-334c-44e9-bef3-1880315ab095"
      unitRef="usd">-473000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtNC0xLTEtMA_f52a35dd-8f30-4050-9333-2104afe6bc92"
      unitRef="usd">121000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i0f4c7294e0d1495194057b40b978d165_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtOC0xLTEtMA_5590753c-13fd-4e55-9425-69228756f6e4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i57b73114f3ec4b0082e498dd41bb847e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzMtMTAtMS0xLTA_864383c5-6149-48b3-bf09-a7e0d4eca105"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2916bc780e044ef49bef1e4b70c3cc9d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtMi0xLTEtMA_4dffc57d-062e-44fb-a40d-47a0b4160d0e"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i244284a65da64e8d883b976f20dd4439_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtNC0xLTEtMA_dc8ed36a-7f4d-425f-8c82-a1f65d835b07"
      unitRef="usd">488000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i015f5e90b1d24aed9b099ce1619e99d5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtOC0xLTEtMA_3e6fbfcc-fd88-4bce-be49-e4a694042bb5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ia2f6938e747b4a25bcc25eac3741af90_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo3ZWZjMWUzMzI4MWY0ZjkwOGNlODJiNzJjZWIwZGY0Zi90YWJsZXJhbmdlOjdlZmMxZTMzMjgxZjRmOTA4Y2U4MmI3MmNlYjBkZjRmXzQtMTAtMS0xLTA_5c39a5e1-7b05-4963-a46d-7bc406cf6121"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1NzU_bbfdc5ad-84ab-4f38-b0ca-3dc902ad56d8">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="icc7bfc44c870488c80c19b43b875f537_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItMi0xLTEtMA_ebdefe89-fc3b-485e-a330-bb8d2503add5"
      unitRef="usd">1148000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i2ece5d5ae1a84367837c469a116bdbd3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItNC0xLTEtMA_6168e05a-c9e8-4b21-b2a8-add4445fc23a"
      unitRef="usd">527000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i2ece5d5ae1a84367837c469a116bdbd3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItNi0xLTEtMA_5d45ae00-13d3-4f53-a71e-2e58b9fa44ec"
      unitRef="usd">-194000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2c25167a6e4f4d47bddc86f00585a224_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItOC0xLTEtMA_3ea3cdf7-a068-4c2c-b8ef-4438b6989336"
      unitRef="usd">1481000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2c25167a6e4f4d47bddc86f00585a224_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzItMTAtMS0xLTA_92e46787-6a4e-4457-9f6d-c2b9098d56ac"
      unitRef="usd">1481000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i62e6ac332e264884b231e1297e1c4568_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtMi0xLTEtMA_75bb0dec-0273-4e41-9489-bbc38a7f196b"
      unitRef="usd">712000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtNC0xLTEtMA_62b755df-d88b-41bd-83db-54f0384386cf"
      unitRef="usd">-55000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtNi0xLTEtMA_12a9fcb0-e0eb-4b5f-9199-c3b5d38b6aa7"
      unitRef="usd">81000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="if28e5b7c3ed4439f84c2bbe32744fe70_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtOC0xLTEtMA_fd60333f-8fb1-4a7c-8791-28691c507243"
      unitRef="usd">738000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if28e5b7c3ed4439f84c2bbe32744fe70_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpkOGJhMTI5N2RjYmY0YjNiOGMyODJiYjEzNzEyMmVlNy90YWJsZXJhbmdlOmQ4YmExMjk3ZGNiZjRiM2I4YzI4MmJiMTM3MTIyZWU3XzQtMTAtMS0xLTA_65b5fb08-23d2-4d07-aa90-43396e704036"
      unitRef="usd">738000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ifdf0149aed5548e0a41ef000a1870d66_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItMi0xLTEtMA_8fbaef0e-997c-4937-a106-f2483d10c309"
      unitRef="usd">511000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i02cda706e4b2470e94e004280758bd89_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItNC0xLTEtMA_b0ac480e-ad4c-4d61-8d27-4c4518e23026"
      unitRef="usd">533000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i02cda706e4b2470e94e004280758bd89_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItNi0xLTEtMA_d1363239-008f-4799-8bee-970354dc0f7f"
      unitRef="usd">104000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="icc7bfc44c870488c80c19b43b875f537_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItOC0xLTEtMA_ca7d3a4a-491d-4092-aeeb-f447c980218d"
      unitRef="usd">1148000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icc7bfc44c870488c80c19b43b875f537_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzItMTAtMS0xLTA_00a88c95-a623-4b9d-890b-e360cd37fa53"
      unitRef="usd">1148000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="icce25e79e7eb4e0eb4f1dd38ac472371_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtMi0xLTEtMA_b177f098-0b23-42fa-bdb5-ee5fd1cc1def"
      unitRef="usd">681000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtNC0xLTEtMA_92123d0c-06ee-4496-b91f-f230a300ed19"
      unitRef="usd">-38000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtNi0xLTEtMA_b29cbcca-61dc-4849-b1e3-b24ee5c27279"
      unitRef="usd">69000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i62e6ac332e264884b231e1297e1c4568_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtOC0xLTEtMA_d95c7533-e58f-4392-99ec-c35a27372c79"
      unitRef="usd">712000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i62e6ac332e264884b231e1297e1c4568_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo5NjUzNDMwYWM4ZmI0MDBlOTE0MGFjNDY4MDRhYmI2ZS90YWJsZXJhbmdlOjk2NTM0MzBhYzhmYjQwMGU5MTQwYWM0NjgwNGFiYjZlXzQtMTAtMS0xLTA_6270ecd9-7887-483d-b6ea-11585cf9beec"
      unitRef="usd">712000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzYzNTI_1be0facd-0487-4413-b957-78508fb8e1d4"
      unitRef="usd">-76000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzYzNTk_0264d558-cc85-4329-8bb8-fc2370e175d9"
      unitRef="usd">-57000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices
      contextRef="ia16784f2d4bf41bb98e8254123d4f086_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzY0NzI_299c42f6-a7c6-452c-ab13-d084b3a1e122"
      unitRef="usd">21000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices
      contextRef="iff0a2ad67037465fadfe170af569e8d4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzY0Nzk_40c0af31-7319-4e0b-9126-79e3d365cdd1"
      unitRef="usd">19000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzk1OTc_e6d4478d-f309-44ec-af19-e4a717280606">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;3, 2021 and December&#160;29, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)(3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;902&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2019 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,148 million, which are classified as Level&#160;1 and contingent consideration of $1,715 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $1 million of non-current assets as of December&#160;29, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as non-current other assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $594 million, $1,631 million (primarily related to Auris Health) and $397 million, classified as non-current other liabilities as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Includes $39 million and $84&#160;million classified as current liabilities as of January&#160;3, 2021 and December&#160;29, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if0a5708acf3147969658a14d0f39da97_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtMi0xLTEtMA_9faad6a0-7a63-48b5-abb5-7af2bed95fc9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtNC0xLTEtMA_a3f70050-700e-49fa-8fc8-33110ba8fc93"
      unitRef="usd">849000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtNi0xLTEtMA_77b6f8f5-8486-4ef5-98a7-2668f47bb579"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtOC0xLTEtMA_cad7e554-e9cc-4254-9271-7cd96d630e6c"
      unitRef="usd">849000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzQtMTAtMS0xLTA_be6eac3e-44d8-47c4-9242-d0d2adf4c981"
      unitRef="usd">209000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i780693331f074588830546d5a4ad2799_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtMi0xLTEtMA_b097cfa3-d2d5-43ae-8bdf-331201c52334"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i4c325d4d8dab4b0685cdeb50ada0d1a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtNC0xLTEtMA_62d7ab91-77cd-4034-b909-6359f4281bec"
      unitRef="usd">240000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i8aeb7bb33ec641c98e0fbde2d3d5c165_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtNi0xLTEtMA_82bca205-a6e2-43b6-a30e-f06eb62b6bee"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i90af2ee9b9b540bb99b3f8e6d629a8f5_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtOC0xLTEtMA_56f81e8d-cec6-4f40-9031-bfd084bd3514"
      unitRef="usd">240000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i5608ee32b2f64df4a13f8ff444c9fbdf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzUtMTAtMS0xLTA_d86cebe4-38b9-42ac-a599-442bbd89fbfa"
      unitRef="usd">693000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctMi0xLTEtMA_58de8483-7a4e-432a-9896-a785ca75431e"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctNC0xLTEtMA_3201d865-df68-40c8-9481-459489fb5e68"
      unitRef="usd">1089000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctNi0xLTEtMA_576fae5c-3f32-49f3-adec-e0a9760803bd"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctOC0xLTEtMA_d2060f50-040a-4334-ab68-9b319b74ffa2"
      unitRef="usd">1089000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if7a9d7cee0f342329e91428213de8f04_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzctMTAtMS0xLTA_ec943320-ee52-406f-b1d9-2943b2aff3f3"
      unitRef="usd">902000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if0a5708acf3147969658a14d0f39da97_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktMi0xLTEtMA_d72be5e7-464c-4887-a043-b5a35b2decba"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktNC0xLTEtMA_22efaf12-5c1f-48a4-838c-8e332a16b9a0"
      unitRef="usd">702000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktNi0xLTEtMA_2c092e6e-30dc-43d9-8e51-3a28d9f31cbc"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktOC0xLTEtMA_4351197c-2a3a-4133-84a7-bbc3e29c8453"
      unitRef="usd">702000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzktMTAtMS0xLTA_de9f7c57-0749-47a1-948f-59c13d2b6620"
      unitRef="usd">426000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i780693331f074588830546d5a4ad2799_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTItMS0xLTA_71a91fe1-c050-4dd5-9d15-3042f5760d74"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i4c325d4d8dab4b0685cdeb50ada0d1a9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTQtMS0xLTA_61a7a557-d3ea-44f4-b5bd-21308e9add5f"
      unitRef="usd">1569000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i8aeb7bb33ec641c98e0fbde2d3d5c165_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTYtMS0xLTA_98dbd32e-9ce3-4378-b22a-c63874570768"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i90af2ee9b9b540bb99b3f8e6d629a8f5_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTgtMS0xLTA_ac2b4079-607c-42a4-a268-68b2646dc156"
      unitRef="usd">1569000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i5608ee32b2f64df4a13f8ff444c9fbdf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEwLTEwLTEtMS0w_ee7817fc-5af2-4358-ad9b-a9be51b64072"
      unitRef="usd">193000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTItMS0xLTA_7c392b5f-e703-48a5-b1fd-c311fa362d15"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTQtMS0xLTA_9fe84179-ec64-4e61-b23b-4c2eec1dad78"
      unitRef="usd">2271000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTYtMS0xLTA_cc0a50b5-058a-49e0-b888-2f343b429a04"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTgtMS0xLTA_7f035e70-7452-4720-a817-f088fe251f4c"
      unitRef="usd">2271000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if7a9d7cee0f342329e91428213de8f04_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzEzLTEwLTEtMS0w_479a920c-5b1b-4ed7-84d9-ea5adfb8f780"
      unitRef="usd">619000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="if0a5708acf3147969658a14d0f39da97_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTItMS0xLTA_9d6f7d23-4246-460e-9ff8-dd13eef0a2ae"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTQtMS0xLTA_26ebcf55-b0fa-472a-9bf4-21c6ecbda5aa"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTYtMS0xLTA_cfb16353-a21b-41db-8e82-b84a4acc94d6"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTgtMS0xLTA_f2fd7c43-de7d-4067-81e4-22ecec1ec7fa"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE2LTEwLTEtMS0w_4ab720bd-78c6-4406-8514-fa69751073f2"
      unitRef="usd">23000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="if0a5708acf3147969658a14d0f39da97_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTItMS0xLTA_62b35006-5d90-48e2-9634-f0c1c09d3e60"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i7f676139595e41d48aef38e5bcbdc8dc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTQtMS0xLTA_61d70446-7b60-4658-ba0e-37edb18de921"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i9326c68bd8144507a8d7e36dc93e9005_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTYtMS0xLTA_a5ed293c-8bfa-4b29-acac-8fd631777937"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie9de1edf016c4eb3bb4e8ca74aee0ca2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTgtMS0xLTA_d1b7e98c-eef8-4738-9e52-5c816277e313"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i49a2cf6d895a4ed7b429d608a0a6d389_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzE4LTEwLTEtMS0w_a47afc7e-78a8-4c53-8fec-a37a7c69a738"
      unitRef="usd">33000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTItMS0xLTA_2590b73a-ca51-4329-8301-b57afeae53d9"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTQtMS0xLTA_0e80b5c3-8e61-46be-9534-ca4db18e2382"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTYtMS0xLTA_5bc049bb-c711-4637-8594-064cbd557ab1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTgtMS0xLTA_abe3d4ca-7b9f-4df1-9f13-917de91c24e2"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIwLTEwLTEtMS0w_efe061eb-09ee-4ceb-8976-0d266f071d55"
      unitRef="usd">1148000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife02cb05cc8448539a1c0bccd6199532_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTItMS0xLTA_d874306a-a232-4323-b866-cb812aabdca4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa1c9065eff4473ca7a6e26469472db4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTQtMS0xLTA_97847380-2d44-462d-b7f7-3bda9ac92b50"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTYtMS0xLTA_9a56e681-c0fb-4ae3-a732-976c299408cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTgtMS0xLTA_1df5892a-9562-43cd-82a8-2b9597ee6d7f"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIxLTEwLTEtMS0w_3dfdc9fe-1eb4-4945-a286-6e2bd451447e"
      unitRef="usd">4368000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if79c9faf646345eb9c242f049ae1e0cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIzLTYtMS0xLTA_fc0703f6-d2f7-4546-9fb4-053cca4386b5"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIzLTgtMS0xLTA_9d70c763-edc9-4fde-96f1-5ad0853cfce2"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTpjNWEzN2I1NDYzYzk0MmIxOTEyMzU0Y2E5YTZiOWE3YS90YWJsZXJhbmdlOmM1YTM3YjU0NjNjOTQyYjE5MTIzNTRjYTlhNmI5YTdhXzIzLTEwLTEtMS0w_31bdb023-5ade-4d54-94cf-dd1be3282cc2"
      unitRef="usd">1715000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzItMi0xLTEtMA_6eeab449-2ca9-457c-b236-8006413ded94"
      unitRef="usd">1138000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzItNC0xLTEtMA_7ca13335-1867-44fd-b3f6-0104821366c9"
      unitRef="usd">925000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzMtMi0xLTEtMA_10da1e72-4d56-4edb-a891-fcdae92372e8"
      unitRef="usd">1107000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzMtNC0xLTEtMA_48adf7be-6524-4bba-9ef4-974671404dbd"
      unitRef="usd">841000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzQtMi0xLTEtMA_a663cdcf-1051-4246-a9b6-c4e4e3a4cac1"
      unitRef="usd">31000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzQtNC0xLTEtMA_9169b0ff-b87a-42f0-b8e7-1d9114b4cbba"
      unitRef="usd">84000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzYtMi0xLTEtMA_be8652cf-3410-4fab-93a3-91f8c4fe5294"
      unitRef="usd">2309000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzYtNC0xLTEtMA_883904d4-0c54-4bfe-8b94-6b3a584d6946"
      unitRef="usd">652000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzctMi0xLTEtMA_f5b699e5-9b68-44b0-9c9b-d25260c77a5f"
      unitRef="usd">2172000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzctNC0xLTEtMA_646344e7-e672-49d3-abd7-48922616dc98"
      unitRef="usd">586000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzgtMi0xLTEtMA_33dc7bfc-2493-44ec-905b-2194e9709bc6"
      unitRef="usd">137000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTozYzhiNTE4MWJlYjg0MDdmOGJjMzEwNGI4ZjY3NWRlNC90YWJsZXJhbmdlOjNjOGI1MTgxYmViODQwN2Y4YmMzMTA0YjhmNjc1ZGU0XzgtNC0xLTEtMA_632cf8f3-e263-47d2-bf46-6fa8c995136c"
      unitRef="usd">66000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzItMy0xLTEtMA_88d98fa8-a647-44bb-99a5-f71515ecca16"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzItNC0xLTEtMA_4d5a3282-1158-4403-8890-b1a773b4736d"
      unitRef="usd">397000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzItNS0xLTEtMA_e6fbc487-0641-42d8-b587-230f065337ad"
      unitRef="usd">600000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzMtMy0xLTEtMA_0c165173-4509-41be-b618-75cc443c2e38"
      unitRef="usd">-1089000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzMtNC0xLTEtMA_ee158545-0e80-4e21-b42d-c8112a523ad1"
      unitRef="usd">151000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzMtNS0xLTEtMA_91c212d8-bfb8-4f35-b6a9-0a7b13288dbc"
      unitRef="usd">-156000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzQtMy0xLTEtMA_10155666-7b83-43bc-8f91-debe9902c706"
      unitRef="usd">106000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzQtNC0xLTEtMA_d9cfbbb9-0a16-4992-8733-01b65d5aad12"
      unitRef="usd">1246000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzQtNS0xLTEtMA_9354191d-61f4-461f-9f3c-07e3e3d8dca9"
      unitRef="usd">125000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzUtMy0xLTEtMA_a9c7c6e6-ff26-47c0-bf79-8ceeda5ecae0"
      unitRef="usd">-99000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzUtNC0xLTEtMA_f2768cd8-9e70-40af-ad88-c347cf809136"
      unitRef="usd">-79000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzUtNS0xLTEtMA_38005592-7ed6-42ac-bb5c-be021fd4c1a6"
      unitRef="usd">-172000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzYtMy0xLTEtMA_b16734bd-f2a1-4ff6-b762-a64f0c9773c1"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzYtNC0xLTEtMA_eaeea04a-9258-42ce-a424-2f92c19e8166"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90YWJsZTo4Mjg4ZDk2MmRjY2M0YTRmYjgzNjJmOGU3YjEwMjA2MS90YWJsZXJhbmdlOjgyODhkOTYyZGNjYzRhNGZiODM2MmY4ZTdiMTAyMDYxXzYtNS0xLTEtMA_c589e082-60a1-4bd3-91a6-1e0fdece4ff6"
      unitRef="usd">397000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i063b1e7203cc48a383a856f56f95ece2_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzg3Mzk_bf5070bc-31e5-4e94-ac5a-475eeaf60f5e"
      unitRef="usd">1148000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iba78ecb5491f4fa1805dedb0bb402778_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzg4MDc_7f09de28-233f-49b0-b43b-e32d40c03a06"
      unitRef="usd">1715000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i4833811f03a34cdfbb1b8144a5e115c9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0Xzg4NDM_349bdb53-06f1-429c-a28f-c881ed841fd4"
      unitRef="usd">1000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i204902ff089e4411bef7c51531f107d1_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkxODU_f4f78a53-7a97-4be9-a979-c438223c4f7a"
      unitRef="usd">594000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i150752b44d724b06a4b96ffabd4ea8b6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkyMjU_912b196e-b0d9-4f4b-9d3d-1655c5793160"
      unitRef="usd">1631000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i522cea24f1ca42868d485da848eb40cd_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkyMzI_83403921-5805-4638-b578-6f814501a1ff"
      unitRef="usd">397000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i795080089d5f41458b16a91c2923e0c6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzkzMjM_ec24a50d-974b-4457-9eea-40d64b2b22b1"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0afabd84326c4799b8b58c05bbc630b4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzE0MjkzNjUxMTcxNzI0_195e9501-e1ee-4136-aa8c-251fd015349f"
      unitRef="usd">84000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5d258167afb64a19982ff42e1d05bda3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTEvZnJhZzoyMzEyZDlkM2JkY2Q0MjFlYWMwOTQwZmNiMDE4ZjVmNC90ZXh0cmVnaW9uOjIzMTJkOWQzYmRjZDQyMWVhYzA5NDBmY2IwMThmNWY0XzgyNDYzMzcyMjAxMzM_cf2b1cf1-d83f-4c51-ae3d-676dd6541008"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE3NTc_95007396-297e-49bb-b480-727da97f884d">Borrowings&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3% Zero Coupon Convertible Subordinated Debentures due 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&#160;Debentures due 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.950% Notes due 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250% Notes due 2022                                                        (1B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1B Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73%&#160;Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500MM 1.3654 GBP )&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(500MM GBP 1.2987)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028                                                (750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035                                                     (1.5B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1.5B Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.400%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at December&#160;29, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The excess of the fair value over the carrying value of debt was $5.4 billion at the end of fiscal year 2020 and $3.0 billion at the end of fiscal year 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has access to substantial sources of funds at numerous banks worldwide. In September 2020, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September&#160;9, 2021.  Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, London Interbank Offered Rates (LIBOR), Secured Overnight Financing Rate (SOFR) Swap Curve or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreements are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Throughout fiscal year 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $2.6 billion at the end of fiscal year 2020, of which $1.8 billion is the current portion of the long-term debt, and the remainder is commercial paper and local borrowings by international subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout fiscal year 2019, the Company continued to have access to liquidity through the commercial paper market.  Short-term borrowings and the current portion of long-term debt amounted to approximately $1.2 billion at the end of fiscal year 2019, of which $1.1 billion is the current portion of the long term debt, and the remainder principally represents local borrowing by international subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate maturities of long-term debt obligations commencing in 2021 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;After 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,515&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE3NjU_18bad44a-a9a6-4d6b-ac7f-65bb89cc2faa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3% Zero Coupon Convertible Subordinated Debentures due 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&#160;Debentures due 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.950% Notes due 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250% Notes due 2022                                                        (1B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1B Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73%&#160;Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500MM 1.3654 GBP )&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(500MM GBP 1.2987)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028                                                (750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035                                                     (1.5B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1.5B Euro 1.1096)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.400%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at December&#160;29, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The excess of the fair value over the carrying value of debt was $5.4 billion at the end of fiscal year 2020 and $3.0 billion at the end of fiscal year 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5&#160;billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7d8d4d3851f43118320077adb8a55de_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtMC0xLTEtMzE5Mi90ZXh0cmVnaW9uOjk2Mjk5MjE0ZGY3NTRmOWJiMmMxZWQ1ZmRiNzMxZGZlXzEwNDQ1MzYwNDYzOTM3_35b67673-b18b-4d95-8f55-ccae2fcd1b05"
      unitRef="number">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id7d8d4d3851f43118320077adb8a55de_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtMi0xLTEtMjk4NA_68f0f5a9-4beb-405d-a6a5-934ab1e087ac"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id7d8d4d3851f43118320077adb8a55de_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtNC0xLTEtMjk4Nw_3667dd5c-91e9-4fc7-8849-64aa73cf565e"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="icc6149e03b1a45c9a528cbe475bb4465_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtNi0xLTEtMjk5MA_2d8ec99a-106d-4d01-aa3f-586f41606da1"
      unitRef="usd">51000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icc6149e03b1a45c9a528cbe475bb4465_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEtOC0xLTEtMjk5NA_35773f81-58f9-452b-9a1e-25c3e4b1c626"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i239971f81b48484183a8b472b82f6ded_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItMC0xLTEtMzc1OC90ZXh0cmVnaW9uOmU2ZGJhYjljNjhiMDQwNmU5NWUzMzhhZDYyYzE4MTE1XzEwNDQ1MzYwNDYzOTA2_a49cf508-387f-42b7-9441-fea8b108c296"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i239971f81b48484183a8b472b82f6ded_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItMi0xLTEtMjk4NA_a2a442f3-b7bb-4a33-86d3-1c1c1a57381b"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i239971f81b48484183a8b472b82f6ded_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItNC0xLTEtMjk4Nw_bf167bc3-44f9-4827-aef5-aa4149098220"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i643d86e5fb4949bc9b0b38833626e8a6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItNi0xLTEtMjk5MA_1ad90e08-18b2-47d2-90da-fa2a73073cf8"
      unitRef="usd">549000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i643d86e5fb4949bc9b0b38833626e8a6_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzItOC0xLTEtMjk5NA_53df8585-d0f3-4e2f-8311-8da0e5053ade"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtMC0xLTEtMzc2My90ZXh0cmVnaW9uOmZhZDk0ODAyYzQxMzRiODM4M2E1NzNmZDZlNGNhMDM2XzEwNDQ1MzYwNDYzOTAz_df480566-099a-4bf7-bc2e-1d20bc7a967b"
      unitRef="number">0.01950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtMi0xLTEtMjk4NA_c937d57a-6a16-46ff-89e8-dd48955ec561"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i77e3f976804e4c5ab180e0ac49b5b15a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtNC0xLTEtMjk4Nw_2dfff19b-5da5-49bf-ab42-98cfa37ad925"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2855ce1111214d85ade50a6ccac8a618_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtNi0xLTEtMjk5MA_d4c688c3-8d71-49e8-a645-0cb928600024"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2855ce1111214d85ade50a6ccac8a618_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMtOC0xLTEtMjk5NA_a928f2ab-b186-4335-965e-abb9d95a59a8"
      unitRef="number">0.0199</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i926e8b4151584d75bb453778eff5a51c_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtMC0xLTEtMzc2Ny90ZXh0cmVnaW9uOjNmZGY5ODY1Mzk0MjRmMDBhNWVmYmNhZmZhNDcxMTNmXzEwNDQ1MzYwNDYzOTAx_3e5298d3-74b7-4ee5-8957-4cb059df6101"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i926e8b4151584d75bb453778eff5a51c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtMi0xLTEtMjk4NA_02bfa69b-1275-488d-a494-36bd6a467a2e"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i926e8b4151584d75bb453778eff5a51c_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtNC0xLTEtMjk4Nw_8646950d-0a05-479e-b96b-5a9ffeb8a095"
      unitRef="number">0.0367</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ic351de96f94f4e9b8747f6446b843a4d_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtNi0xLTEtMjk5MA_68fea48b-4e9a-44d2-be2f-cafdee3d5e29"
      unitRef="usd">449000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic351de96f94f4e9b8747f6446b843a4d_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQtOC0xLTEtMjk5NA_d8b5c9ee-5985-4b7d-84b6-f1ad752da9ee"
      unitRef="number">0.0367</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9c3d81e50f874f138a3912b40b201c41_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjoyZTk3ZDViNDhiZmY0OTJkOGZlNjFmZGJmMGE0OGEzMl8xMDQ0NTM2MDQ2MzkwMQ_b8db402e-3c4b-4a73-b27d-e7e1d495a133"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9c3d81e50f874f138a3912b40b201c41_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTItMS0xLTA_4efd6461-e1e1-45ac-92bd-6136763f6590"
      unitRef="usd">350000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9c3d81e50f874f138a3912b40b201c41_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTQtMS0xLTA_bf938f32-1f49-4cdf-9bdf-49202fd37076"
      unitRef="number">0.0248</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib933e5916e15417a8a48a5669ccf5321_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTYtMS0xLTA_3b13c8e3-3365-4e25-b57c-202b8b5ef4d8"
      unitRef="usd">349000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib933e5916e15417a8a48a5669ccf5321_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTgtMS0xLTA_6047d8ba-b4a2-4a5e-9f01-a1ae6dbcb53a"
      unitRef="number">0.0248</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a873dff1d3141a19512b0affe1fe2d8_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtMC0xLTEtMzc3NS90ZXh0cmVnaW9uOjU0NTZmMDgxZWQ3YTQ3M2U4MWEzM2EyYjhhN2Y3MDE5XzEwNDQ1MzYwNDYzOTAx_3eaecd5a-cc6f-49bb-b353-54c353834f08"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8a873dff1d3141a19512b0affe1fe2d8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtMi0xLTEtMzAxNw_8fba8eab-0a0e-4259-8133-4f8259d80d58"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8a873dff1d3141a19512b0affe1fe2d8_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtNC0xLTEtMzAyMg_f765b6cd-d2c0-4a10-8e0d-9427654ab224"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ic8212ea597cf4a84b23cd83df34ea924_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtNi0xLTEtMzAyOQ_293f3537-e8f1-4b79-8a63-286ff79b6de5"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic8212ea597cf4a84b23cd83df34ea924_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzYtOC0xLTEtMzAzNw_84a26807-44c6-47e7-8e32-99cdf4878916"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl8xMDQ0NTM2MDQ2Mzk5OA_9fcdbc9a-6194-4558-9c23-8fb610473271"
      unitRef="number">0.00250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl8xMDQ0NTM2MDQ2NDAwMw_24cedde1-8205-4ec7-8b0a-04ebdae5128a"
      unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl8xMDQ0NTM2MDQ2NDAxMg_e9f91741-8068-4803-b81e-7b0762d554e6"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl84MjQ2MzM3MjA4NDg3_85d708a8-b5fa-424d-8b2f-6b25ef0adc1a"
      unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjo3ODgwZWYyMWU3YWI0ZjE2YWI2Zjk0MzgyNTk2NTQzYl84MjQ2MzM3MjA4NDc3_89283b0a-44c8-4bff-b993-bb740cb5c43e"
      unitRef="number">1.1096</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTItMS0xLTA_01bda025-5b26-4526-8830-1af1eba2d5cb"
      unitRef="usd">1227000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icd2f7d24c9474d8c9cc4823797b8c083_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTQtMS0xLTA_2c5c6c69-1a29-404b-a6f7-7ffe1f965a36"
      unitRef="number">0.0026</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTYtMS0xLTA_2c2f0b35-1b28-439b-a852-01dc1bf19ecc"
      unitRef="usd">1108000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if6ee752114044428a8c20fe4f7ecb273_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzExLTgtMS0xLTA_7403fbac-b43e-4cdc-bbde-c84aa1089e3a"
      unitRef="number">0.0026</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2dbe0979c7a14dc9b9f12e17af387027_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NWY2NmIxZjVjNzU0MjZjYWRlMDU1MzVkNmMyY2JmZl8xMDQ0NTM2MDQ2MzkwMQ_38bd89ab-14c7-4a6e-9df9-5a9d6f505586"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2dbe0979c7a14dc9b9f12e17af387027_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTItMS0xLTA_40b044d3-25c5-44b3-a6bb-44cbfa76d54d"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2dbe0979c7a14dc9b9f12e17af387027_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTQtMS0xLTA_055a33a9-2d21-464e-9cdd-5eb38e7ca97a"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i96bfafa6c5fb4ce3ae20923ddd529bae_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTYtMS0xLTA_caa09c8a-1065-42fd-a03b-196fe7bf265e"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i96bfafa6c5fb4ce3ae20923ddd529bae_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEyLTgtMS0xLTA_98f76704-02fb-4b47-9962-9481e88ada14"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4NjQ5YWQwNzNkZDc0MmY1OGU3NzZhMjBkN2U5YmNlZF8xMDQ0NTM2MDQ2MzkwNg_1985ea59-a144-44b3-b149-b989416fc494"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTItMS0xLTA_cce64f6b-b1e2-41aa-b00c-2f9b62dc2b2d"
      unitRef="usd">250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if25356b66c4c44d6839cd4e0d5d66bfc_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTQtMS0xLTA_67dfcb05-8e38-4f05-b56d-7fb9ede7886b"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ie3f807d1cada4781ae10198fe16e1c99_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTYtMS0xLTA_d8a0b926-77a8-4fb2-94fb-80a5bad638ce"
      unitRef="usd">250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie3f807d1cada4781ae10198fe16e1c99_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTgtMS0xLTA_ccddaac7-b006-446e-95a9-57ecf9f24970"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if95c57f111c64126bccc2fc3a980ce5a_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyMDk2MDViNTg1ZjY0ODkwYWIwOGQ3MGI3MWM0MzRjYl8xMDQ0NTM2MDQ2MzkwMw_33b63260-72ab-487f-8355-a852ec73bba5"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if95c57f111c64126bccc2fc3a980ce5a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTItMS0xLTA_b3ee1202-36f0-4525-bf37-1c3c899f144e"
      unitRef="usd">803000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if95c57f111c64126bccc2fc3a980ce5a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTQtMS0xLTA_bdb438ee-d7e1-4884-9af4-c4430bf3c5da"
      unitRef="number">0.0317</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib2a1b55a0d51409e9832bdbc47868c84_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTYtMS0xLTA_14b0e016-d371-4b50-8aed-d0e9f4bd670c"
      unitRef="usd">804000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib2a1b55a0d51409e9832bdbc47868c84_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE0LTgtMS0xLTA_f888dfad-895e-43d0-ae9e-8e0da2b76bb0"
      unitRef="number">0.0317</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a181a42de50462faa774006c9104b58_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjo2MmNjMmI4ODJiNzE0NWI2OTMyNDMzNGU1MDMwOGM4Yl8xMDQ0NTM2MDQ2MzkwMQ_04f0ef85-9d96-46d0-b329-88128a808a1f"
      unitRef="number">0.0205</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8a181a42de50462faa774006c9104b58_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTItMS0xLTA_bea7719b-e59a-4818-888f-cb9315fae62d"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8a181a42de50462faa774006c9104b58_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTQtMS0xLTA_4ae25c4e-8b9e-44d8-96b8-c065f5ef4074"
      unitRef="number">0.0209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2acd1bef02c94effbce52af8c909bec3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTYtMS0xLTA_d3d42281-cd51-4860-b56c-8a2062cea230"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2acd1bef02c94effbce52af8c909bec3_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTgtMS0xLTA_1e47308f-afcd-4ad7-bde9-104113e904cd"
      unitRef="number">0.0209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id431690b092746cda0e3885506938117_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl8xMDQ0NTM2MDQ2Mzk5Ng_ff9137c9-b24f-413a-8019-95717997c2e0"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id431690b092746cda0e3885506938117_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl8xMDQ0NTM2MDQ2NDAwMw_f251909d-421c-437f-ab16-3c05445feffb"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="id431690b092746cda0e3885506938117_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl84MjQ2MzM3MjA4NTM5_576af96b-e93f-4088-a256-438d24384f9b"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl84MjQ2MzM3MjA4NTYw_f7f69eb5-457a-42c5-b8ac-43f19f4fb9b5"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDFjODc4YjU4ZDU0ZDc1YTJkN2ZlZGU0MjI1NGY5Nl84MjQ2MzM3MjA4NTQz_ffac935d-a593-4b3c-ab22-94440d6daeea"
      unitRef="number">1.1096</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="id431690b092746cda0e3885506938117_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTItMS0xLTA_b47fb4c9-cc9a-4517-8e70-6717942f2a01"
      unitRef="usd">919000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id431690b092746cda0e3885506938117_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTQtMS0xLTA_4027426b-e60f-40e5-b4ee-e04893618b75"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTYtMS0xLTA_abc83084-82e3-4959-9b7a-748b0f80f69e"
      unitRef="usd">829000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icb932f4d85de447b95ac9a2f2540bd06_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE2LTgtMS0xLTA_9b2bf076-1937-43e9-a120-4c5fb2a9527e"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV8xMDQ0NTM2MDQ2Mzk3NQ_8196318a-95f9-41d5-95f8-300aeb3d79c6"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV8xMDQ0NTM2MDQ2Mzk4Mg_edc6b1d5-7a52-47e6-92a2-8cb4af7a911c"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV84MjQ2MzM3MjA4NDUy_f369ed62-10f9-4135-b506-419dd7ae8eaa"
      unitRef="number">1.3654</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV84MjQ2MzM3MjA4NTIz_b08197d9-de32-4ebc-8e77-f32b2340a842"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjplMzMyMzlmNTUxNzA0YTQyYmM4OWQwYTg2OTMwZGJlNV84MjQ2MzM3MjA4NTE3_0aa188b7-78e0-4292-b998-fed1f4ab7e39"
      unitRef="number">1.2987</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTItMS0xLTA_61ed2e79-e6da-48b6-9247-77729b88b739"
      unitRef="usd">679000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icd739e0b217d43fca3ef7ba9585172e8_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTQtMS0xLTA_1ef32773-11c7-499c-a0de-62d4800bc202"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTYtMS0xLTA_92c86e94-3f12-4e13-9d8a-7a63f2c78cc4"
      unitRef="usd">645000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0369e6fc3c194082a81d79013d49d056_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTgtMS0xLTA_555aa74a-19a3-4f79-af78-4790eafe550f"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa8bc6079d92403ca3c4b99e75498b57_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjpjNGQwYmNlZThlMDA0OTg3YmZmYjRiYmRmMjI4YzVjNV8xMDQ0NTM2MDQ2MzkwMw_8d9d9a4e-2a4c-460b-9669-25fe2b3bb412"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iaa8bc6079d92403ca3c4b99e75498b57_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTItMS0xLTA_6b169eb9-2102-4e4f-9e76-34ccad636e7b"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iaa8bc6079d92403ca3c4b99e75498b57_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTQtMS0xLTA_ec7b61f0-3d8a-4f82-9afb-00f6d935ac4c"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i4c8d7bc47a734d679cb8e0230bf39855_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTYtMS0xLTA_872d61d9-3e0a-483b-bdf2-9c8b34ede78b"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i4c8d7bc47a734d679cb8e0230bf39855_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTgtMS0xLTA_369238c5-3eee-4122-9b04-251a68ca8d68"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1c683153e4274793b8e2b845aee7dc3b_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEwLTAtMS0xLTI5MTAvdGV4dHJlZ2lvbjoyYzM3ZWI4ZjRlZjc0ODc3ODI1ODU4YjFmMzk5OGRiZl84Nzk2MDkzMDIyMjQ4_396203f1-0632-4a42-83cf-015b4ccb158a"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id9fde6f193e0450fb608feb62094bab4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTItMS0xLTMwNTY_6fc5f256-b382-4182-9e78-2275f8d022d1"
      unitRef="usd">996000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id9fde6f193e0450fb608feb62094bab4_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE1LTQtMS0xLTMwNjg_69438567-80d2-44f5-b49e-09fc11222890"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38c696c925d1472b90cf70120a0702ca_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMzI2OGMxZjhhY2U0ODM5OGVkMTNiNGEwM2NjN2FjOF8xMDQ0NTM2MDQ2MzkwMQ_b79baa30-ae6a-4e11-bfbd-f105e5d97f36"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i38c696c925d1472b90cf70120a0702ca_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTItMS0xLTA_6684106b-d10f-4bf4-8ebf-6d837f3c28ba"
      unitRef="usd">1994000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i38c696c925d1472b90cf70120a0702ca_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTQtMS0xLTA_03f79c33-a177-452e-8b86-bdb138166749"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i7c169ee681eb41d4b70cf224042a918b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTYtMS0xLTA_b9df3702-71b2-4362-beb2-82f4b5f4d58b"
      unitRef="usd">1993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7c169ee681eb41d4b70cf224042a918b_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE5LTgtMS0xLTA_6720be95-3c89-4780-b7bf-a6675eb83f37"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i468ec06486014ee2bd6f5c7a72949cf0_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDE4ZDljOGFjYWY0NWUxYWI5ZmNmZGM3ZDU2NWE2ZF8xMDQ0NTM2MDQ2MzkwMQ_ab156fc1-fa6d-4b38-a082-79043a83f457"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i468ec06486014ee2bd6f5c7a72949cf0_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTItMS0xLTA_473b17bd-b3af-4bf7-98b7-e248dbaa95e7"
      unitRef="usd">997000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i468ec06486014ee2bd6f5c7a72949cf0_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTQtMS0xLTA_b9c096af-ce7c-42c4-9a8d-cfd52d9d91a2"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib92f79edb6394aabb7c66d1f0ceb9c1f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTYtMS0xLTA_804618ae-2f30-4878-af1d-abab5857182d"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib92f79edb6394aabb7c66d1f0ceb9c1f_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIwLTgtMS0xLTA_996b8c95-662d-4f97-ba34-499d7ad00ddc"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3c9f0124227242a3b37ef08fc5f78862_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzEzLTAtMS0xLTI5MTYvdGV4dHJlZ2lvbjo3MzU0YjQzZGY4NjQ0MjVkOWNjNTNkZTlkNDIxNjcxMV84Nzk2MDkzMDIyMjY1_b886cf6a-63dd-4fbb-baf8-b9bf64d1fd5c"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id6e4daae8acd4186854161164075f779_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTItMS0xLTMwODc_956ae90f-0551-4084-9778-8fb9ee6e2d84"
      unitRef="usd">1494000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id6e4daae8acd4186854161164075f779_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE4LTQtMS0xLTMwOTA_e56a880c-26d7-40c8-88e3-8acfc9b3930c"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY18xMDQ0NTM2MDQ2Mzk5NQ_2fc686fe-c88e-4350-b7e8-0569ae1e10f5"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY18xMDQ0NTM2MDQ2NDAwMQ_bed6314b-f1d2-457a-9423-ab43751c67e0"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY18xMDQ0NTM2MDQ2NDAxMA_4d94e6ec-7945-4ff1-af18-7fb097e80cce"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i035991005b3545fdb445908803f01423_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY184MjQ2MzM3MjA4NDcy_3de0d6f7-ebe6-438c-955e-8073d2a99304"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i035991005b3545fdb445908803f01423_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxOGNmNGQwZjI3NGQ0N2ViOWM3YTM2YzllZmU0ZDlhY184MjQ2MzM3MjA4NDY2_318da1e4-fe95-47de-8df1-523b0435c783"
      unitRef="number">1.1096</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTItMS0xLTA_e688173f-6521-469d-9c8b-b2e050d684a4"
      unitRef="usd">915000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0b5d476254ef41008aa89433dcace0d4_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTQtMS0xLTA_9ce1e977-5e81-41d9-8ff9-dd7e17aea127"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i035991005b3545fdb445908803f01423_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTYtMS0xLTA_e5f2a9df-3156-472c-8c73-92868582131f"
      unitRef="usd">825000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i035991005b3545fdb445908803f01423_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIxLTgtMS0xLTA_437ec22a-46d7-4b94-a3a6-5f36f0abc2d8"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTgyZDgzMGM0Y2Y0ODdiODM1M2Y3M2ViY2E0YTFlN18xMDQ0NTM2MDQ2MzkwMQ_f5f9f889-192e-4f04-b4e2-96d21cf222d7"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTItMS0xLTA_2d3c8682-e592-40c4-9238-4688413ef01d"
      unitRef="usd">1495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3c0ab3e8f6f7469aa9b45e701968bff7_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTQtMS0xLTA_2e6cd7e2-45bb-40e4-8e2f-563060e01cfb"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i541337b24d2444a8bf14a78c6ec932fd_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTYtMS0xLTA_21fb19c8-3930-45cb-9baa-855e2abad029"
      unitRef="usd">1494000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i541337b24d2444a8bf14a78c6ec932fd_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTgtMS0xLTA_7eb251f6-11ce-49fe-93e6-3d75f584bcbc"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i45d84507c060443eb3ceeb3ff733f151_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjkwOTU4MGUzZWI0MjIyOTU2NzE1ZGZjMzhlYmI0ZV8xMDQ0NTM2MDQ2MzkwMQ_e1e3aef0-b435-4590-a692-08dfaca9eaba"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i45d84507c060443eb3ceeb3ff733f151_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTItMS0xLTA_9f120c18-84ec-48b8-a19b-ce37dbc13874"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i45d84507c060443eb3ceeb3ff733f151_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTQtMS0xLTA_69394b88-8401-4f66-b691-f85b6d899979"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="idbbe327f106f448cbd073f1bca885cb8_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTYtMS0xLTA_7c9f251f-9e32-430f-b050-4084a525cf12"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idbbe327f106f448cbd073f1bca885cb8_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIzLTgtMS0xLTA_430d21c3-5058-40bb-bf2a-0014dc1c0292"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3a322bcc2a514a30b7e05707bfb38724_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzE3LTAtMS0xLTI5MjIvdGV4dHJlZ2lvbjo4MjUwYzNhMmQwMzc0MjFiYjMyMGU3ODYzYTc2Zjc2N184Nzk2MDkzMDIyMjU3_6fd531be-be55-4837-98eb-6c7a18954fe5"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic8a4cd9bc3a54ec4a968860df1b0f6ba_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTItMS0xLTMxMDU_b2f3ffc4-aecc-417b-865d-a214d47208a6"
      unitRef="usd">1743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic8a4cd9bc3a54ec4a968860df1b0f6ba_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzIyLTQtMS0xLTMxMDU_8a7607b1-8f17-4666-b5df-52dc2be10ad0"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if7ba9d57b541417083a57e7550184805_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjplM2QyMjM1ZTc0MWY0MTE5ODJhMDUwNmRkNjk3MTYwNl8xMDQ0NTM2MDQ2MzkwNg_c7d0157d-64db-4986-991a-be0e2ea1ef41"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if7ba9d57b541417083a57e7550184805_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTItMS0xLTA_1c97c6c6-9db1-4b7b-999b-b81ad9d3fa09"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if7ba9d57b541417083a57e7550184805_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTQtMS0xLTA_2c402405-197e-429d-bdd9-903d2c4aaf10"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i5584716e0e79483b8e1d3828aaab1e0f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTYtMS0xLTA_ed00be76-54d3-4f26-a5da-08c7064c3039"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5584716e0e79483b8e1d3828aaab1e0f_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI0LTgtMS0xLTA_370b3e8e-992e-46a6-8273-3b4552061872"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1965776d766f4468bd93699590f0d845_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjoyODUwM2U4Y2U5ZTc0ZmE5OTQ0ODdiY2U1YmY3ZTFkZl8xMDQ0NTM2MDQ2MzkwMw_2048c733-2662-4fbd-9e69-4b4b4ffe20e6"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1965776d766f4468bd93699590f0d845_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTItMS0xLTA_787b09b3-b8d8-4fc9-8aa0-9fafdf2ce3b9"
      unitRef="usd">855000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1965776d766f4468bd93699590f0d845_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTQtMS0xLTA_1f06544a-de3c-4bd2-b40f-ed33102054ab"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iff628b0cf02144cd91a4abcc5053f028_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTYtMS0xLTA_ffbf5131-1915-41ec-a24a-6530abd61945"
      unitRef="usd">855000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iff628b0cf02144cd91a4abcc5053f028_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI1LTgtMS0xLTA_9b4f726c-9a93-46f7-b2fc-38f5cf292afb"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N18xMDQ0NTM2MDQ2Mzk5OA_fda2d6b9-6d71-41aa-8698-00d9dcde4b2f"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N18xMDQ0NTM2MDQ2NDAwNA_a77c48fc-f012-420e-a18c-3566544214a5"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N18xMDQ0NTM2MDQ2NDAxMw_264147a7-f3d3-4bd1-aa05-05adee4b7d12"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N184MjQ2MzM3MjA4NDc1_2443512c-24dd-412f-a1b9-bb5b2157e0dd"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjowM2NkYmIwNzdmZTM0NmQ2YmU5ZjcxNTQzMDZiNjc1N184MjQ2MzM3MjA4NDY5_dbea0acb-e92a-4ebf-826e-e70e469f6b33"
      unitRef="number">1.1096</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTItMS0xLTA_71d7249b-ee4c-4a2e-b738-fbe289d45b76"
      unitRef="usd">1827000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id83a16eac5254d0f8a32fb0408fb7209_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTQtMS0xLTA_58816237-3adf-4820-862c-143e12e89407"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTYtMS0xLTA_47ffe6b1-0dbe-4334-bb8d-3a1a2627eefd"
      unitRef="usd">1649000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib3f4662ff9134017a1f5f7444f314e31_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI2LTgtMS0xLTA_4a6adf73-3870-4593-9b0e-95c824b171fb"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i63438abe9f0244469fd820794902d862_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjozMDBlMGVkOWUzOTg0Yzc3OTJkOTVjNjE1NDc3YTg4YV8xMDQ0NTM2MDQ2MzkwMA_7e65f168-9523-4f54-a32d-9106dcb899ea"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i63438abe9f0244469fd820794902d862_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTItMS0xLTA_445fc134-d24c-4322-b961-ab47fa8b5da2"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i63438abe9f0244469fd820794902d862_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTQtMS0xLTA_57e7107b-7160-4752-9c7a-c7f5de5b7195"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ic49d24552bc346e1b4e0dab3a0e924b4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTYtMS0xLTA_485c344b-aa21-4b8c-b06e-44143d1cd2fa"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic49d24552bc346e1b4e0dab3a0e924b4_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTgtMS0xLTA_e56c8ec4-9ab5-4f63-83e0-af0448b44857"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0a1673c8394c4e3f872d187343339109_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpjZmMyYTVjNmNiM2U0YjAyOGEzNGMwOGM4NWIyNTk1NF8xMDQ0NTM2MDQ2MzkwMQ_899d98a5-b0ac-4531-9fdc-4f13f0af967c"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0a1673c8394c4e3f872d187343339109_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTItMS0xLTA_03ca757c-b316-4336-82dd-606519c3a844"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0a1673c8394c4e3f872d187343339109_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTQtMS0xLTA_67e47937-40a9-4b53-8b9c-ee07a42769bf"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i6bf9a86caabd4562bffba6ff39983416_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTYtMS0xLTA_b57c95aa-c622-40c4-b1d7-895beede9df6"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6bf9a86caabd4562bffba6ff39983416_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI4LTgtMS0xLTA_2b2c5616-2893-4eb2-9945-70f6e4def437"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3df454f0c44e460bab62d61a065354d2_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZDIzMTU1YjlkNWE0MDlmYmFlNWJjMDZmNTcwYjg1Zl8xMDQ0NTM2MDQ2MzkwMw_75145913-5686-461f-b018-9fddfb404047"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3df454f0c44e460bab62d61a065354d2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTItMS0xLTA_9ac2d0d2-3501-4f3e-9774-eb45c6e50ca1"
      unitRef="usd">1488000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3df454f0c44e460bab62d61a065354d2_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTQtMS0xLTA_f2b8d688-8622-42bb-8c10-fb3710a3e521"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i9ac8457d7f3f412bbba5cd8890c8ad72_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTYtMS0xLTA_ef04c492-e66d-4df9-8f82-8d892158caf8"
      unitRef="usd">1487000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9ac8457d7f3f412bbba5cd8890c8ad72_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI5LTgtMS0xLTA_16275028-b0c7-4f31-ab28-c1078f1cb593"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51f46beeeb544a6f91f38d5f362744ee_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo2YzZjMjJmNGMyMDI0YjEwODhhMjFjNzFkMTdmMjVhMV8xMDQ0NTM2MDQ2MzkwNg_07d75cac-0e67-4ba9-a477-6c0610e03087"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i51f46beeeb544a6f91f38d5f362744ee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTItMS0xLTA_493fccdc-8722-4d0c-983e-3ecd4733f8f5"
      unitRef="usd">696000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i51f46beeeb544a6f91f38d5f362744ee_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTQtMS0xLTA_43e2e678-bfcc-441e-8508-38331cf8028f"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iebf5cf036d354852b5eaf7f1a747632f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTYtMS0xLTA_c56580dc-30ee-4f5e-a731-5003f7150e0b"
      unitRef="usd">696000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iebf5cf036d354852b5eaf7f1a747632f_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMwLTgtMS0xLTA_6a450b82-02e9-4750-8c3f-9db1123e49eb"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i96f58bd4d50d4e84946db893d8650ed6_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMDEzYTUyNGY4ZjQ0ODFjYWUzMTkwNjRiNjQ3MDg5YV8xMDQ0NTM2MDQ2MzkwMw_7f269941-9311-4f40-a0c9-8f79248fc7a4"
      unitRef="number">0.03400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i96f58bd4d50d4e84946db893d8650ed6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTItMS0xLTA_318475b9-c195-450f-b1ac-0df2080b5041"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i96f58bd4d50d4e84946db893d8650ed6_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTQtMS0xLTA_df387c8d-95e1-4c06-8d80-27232dd0a634"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i782bc6f740614734a43da12dce22161b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTYtMS0xLTA_7293908d-e158-4f69-a4d0-48f9be85695e"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i782bc6f740614734a43da12dce22161b_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMxLTgtMS0xLTA_e3b9c3dc-1b99-4ad9-91c5-28fb2939758e"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b804bc029e642feb0493dd3906a185b_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpkY2VjZWQ5ZDM3MzI0YjI2YWIxNGE2M2M2ZmQ0YzFkY18xMDQ0NTM2MDQ2MzkwNg_b9548cc9-a700-4ce3-9e36-edf4195bee00"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9b804bc029e642feb0493dd3906a185b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTItMS0xLTA_655f89a6-6cf3-48f0-b7af-665a079c286a"
      unitRef="usd">539000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9b804bc029e642feb0493dd3906a185b_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTQtMS0xLTA_1577af40-5e79-4aa5-aafe-fc157ae705ff"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i05b581805ecd4967a8646eaf60bca900_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTYtMS0xLTA_1ce800a5-6c8c-4d72-9513-60f4249efb06"
      unitRef="usd">539000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i05b581805ecd4967a8646eaf60bca900_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTgtMS0xLTA_cfabbce8-2ad4-44d7-a71c-6c06826944ae"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i70d754e14799477284511704f83b8d17_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzI3LTAtMS0xLTI5MjkvdGV4dHJlZ2lvbjozZjFkNmEyNWNhODQ0NmUwOTc4NjAyN2FkNzljMmEwZF84Nzk2MDkzMDIyMjUw_3c98d801-21f7-4049-b32c-7ef522582617"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7255430870174b0fa0d8627f1ec59a3d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTItMS0xLTMxMjI_b30e06a6-2f6e-4768-85f9-9d457a8aeb6c"
      unitRef="usd">986000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7255430870174b0fa0d8627f1ec59a3d_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMyLTQtMS0xLTMxMjI_4fdd668b-2830-4c96-bfc3-f35dd63c18c4"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id568183bd7d541139e4919632134334d_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiYWQ0NjU0MjE4NzU0NjkzYTgyYTdjZDI0NTM0ODUyN18xMDQ0NTM2MDQ2MzkwMQ_414ddd83-0ea4-45ad-a5f8-e82dfb14226e"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id568183bd7d541139e4919632134334d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTItMS0xLTA_28dd1f60-c299-4ef4-8f30-13a89df6744b"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id568183bd7d541139e4919632134334d_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTQtMS0xLTA_23a5662b-ba67-4a25-bc9c-57d1c562d1a2"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i9f619870e5ab42bb830254e1a5d06b99_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTYtMS0xLTA_943136a3-58a3-48d9-ada9-be75aa99368b"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9f619870e5ab42bb830254e1a5d06b99_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTgtMS0xLTA_f9d7adc1-f07a-4e0d-b31a-8c41fea0ad94"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjpiYjA0NmU2NGIxZjI0ODZkYmEwMGUxOTY1MWMwNzQxN18xMDQ0NTM2MDQ2MzkwMQ_f2602229-aa2c-4824-a340-b0c1bb80b9da"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTItMS0xLTA_15566a16-9b77-400e-bfb7-c40a78119ce4"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i138a7a09c0194ec1b4e274aa8a3e1eac_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTQtMS0xLTA_ea970ed2-edae-44a7-8df1-d09831d84eae"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i0fff5e1fbc7546c895f24337e28ccd11_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTYtMS0xLTA_18306f87-6430-49d2-bdcc-7d46b95472fa"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0fff5e1fbc7546c895f24337e28ccd11_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTgtMS0xLTA_4e2a9dd2-6ee7-4dda-899d-2d95613f0171"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjphYTQ4OTJlMDM0MTc0OGY5OTA0ZTE1NTZiYTJkYTk1ZF8xMDQ0NTM2MDQ2MzkwMQ_9fac370f-8641-4337-b166-371cd9cf9379"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTItMS0xLTA_06b43772-7f1a-43e0-bdde-1c73a22d5ac5"
      unitRef="usd">1974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic26fbe6910f2453cbc5cf6cb04bc4026_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTQtMS0xLTA_f250640f-16e6-452e-8fc4-450d1415aafb"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ief45c201a3b243caa69c0e0f161b2ae4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTYtMS0xLTA_d4d930ff-adfc-47da-9aa9-cba749b343cb"
      unitRef="usd">1973000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ief45c201a3b243caa69c0e0f161b2ae4_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM1LTgtMS0xLTA_f8795937-8f01-40e9-b691-020096f5bae3"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8b7693bcded4747a5ab760537912c2a_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyOGU1NzkxNDYzYzk0YzdlODJhYTk4MDZlNDAzNmE5NV8xMDQ0NTM2MDQ2MzkwMQ_6a81c9a9-2858-47aa-885e-b6d540323987"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id8b7693bcded4747a5ab760537912c2a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTItMS0xLTA_f9cf1fc1-3524-4f28-98fb-c46591f58ae0"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id8b7693bcded4747a5ab760537912c2a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTQtMS0xLTA_a3968cc2-9973-4832-a7d2-e7ae93daffa0"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iafd125a14e0d4e7a876c8945f58e61f6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTYtMS0xLTA_e32c0ba0-60f2-47c9-acb8-0ca0b61a244a"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iafd125a14e0d4e7a876c8945f58e61f6_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM2LTgtMS0xLTA_2efb0c29-57e2-4733-ab65-4303becc7b4e"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjowMzFjYWM1ZDQ4Y2I0MzQ5OTQzN2M4YTQ5ZDUxZjIzZF8xMDQ0NTM2MDQ2MzkwMw_1e5e61f1-3268-456c-9cb5-79c834b058ce"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTItMS0xLTA_591c19a4-9da1-4d97-b072-cfa4871a3b2f"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1c5d45f5591c49d9be0f0bf1cb9a53ec_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTQtMS0xLTA_efda1236-f4b8-4a2c-a737-de9975d1a9ef"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i60f33f574f1a41b9bf5677aefeaf760f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTYtMS0xLTA_0e9ecc99-9248-44f4-8ad9-67d0ad34aa35"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i60f33f574f1a41b9bf5677aefeaf760f_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM3LTgtMS0xLTA_8aa021a1-d3f4-4581-87dc-33310e888085"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i39181f4c3aa24aaa9646a538d7f62e4d_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzMzLTAtMS0xLTI5MzQvdGV4dHJlZ2lvbjoxMDU0ZmI2ZTgwNGU0MGIwYWNiNTg1N2UxMDllNTczZV84MjQ2MzM3MjA4MzY0_67822f10-613e-4047-921a-1562ae2525ae"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2a8df475fa9c4c4aa829c65373e7b7fa_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTItMS0xLTMxMzc_4f236253-e571-4eb3-9569-fcfa57b53c23"
      unitRef="usd">984000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2a8df475fa9c4c4aa829c65373e7b7fa_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTQtMS0xLTMxMzc_fa34116d-7f4b-4f48-a083-69a13521e049"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i24f8e23ceca94494b1b3b111eed8dbd5_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM0LTAtMS0xLTI5MzQvdGV4dHJlZ2lvbjo1OTYzMzJhMjRhOWQ0ZjU3YjAyYjgyMzZjMmJjMTEzNV84MjQ2MzM3MjA4MzU5_ea921cde-3b60-4122-87ea-b141451084e2"
      unitRef="number">0.02450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i72aeae00e1604bf385505263726995cb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTItMS0xLTMxMzc_ac2c6480-88f4-45d3-ac7d-34d2d967e9c6"
      unitRef="usd">1228000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i72aeae00e1604bf385505263726995cb_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTQtMS0xLTMxMzc_0597c1db-e01b-41e3-8f83-a1a316d061bd"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i76fe11f963ad43deb7bbe15f647ec9ff_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTItMS0xLTA_782ae723-5372-4e5d-820a-5be68ec04863"
      unitRef="usd">7000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i76fe11f963ad43deb7bbe15f647ec9ff_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTQtMS0xLTA_6c223a4a-e2ee-4f15-944e-a1897713a8a2"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i53872a4a35184b378900cbaf5b99200c_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTYtMS0xLTA_cf434d33-a898-4e5b-9e4b-4ee89cb0323c"
      unitRef="usd">18000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i53872a4a35184b378900cbaf5b99200c_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM4LTgtMS0xLTA_f5df61a3-3829-4197-ada4-dbe690d6a78b"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib4bb2eed805a40d391fb647db58d1d62_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTItMS0xLTA_2ae468ae-11c5-480e-a09a-aafae88330d9"
      unitRef="usd">34434000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTQtMS0xLTA_3bfd9722-1cf6-4565-bc13-1319bc026e58"
      unitRef="number">0.0285</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i7b6108907f204089b3f9838308be8b28_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTYtMS0xLTA_3d91f0ea-ae67-47e9-9670-ed10e7ef1e32"
      unitRef="usd">27594000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzM5LTgtMS0xLTA_986efdfb-896b-4b27-9aa5-3c73b27f49eb"
      unitRef="number">0.0319</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib4bb2eed805a40d391fb647db58d1d62_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQwLTItMS0xLTA_ad2bd6e4-e3d0-41dc-af0c-50b54469c65d"
      unitRef="usd">1799000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7b6108907f204089b3f9838308be8b28_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQwLTYtMS0xLTA_7fe04676-0779-42e0-86ad-63d05720a113"
      unitRef="usd">1100000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib4bb2eed805a40d391fb647db58d1d62_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQxLTItMS0xLTA_92698fd2-5c38-4c79-a239-548e5e960ef2"
      unitRef="usd">32635000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7b6108907f204089b3f9838308be8b28_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZTpjNWRlMGZjMzAwMGM0M2IxOGZjMmM2MTNlN2I4YjBiZS90YWJsZXJhbmdlOmM1ZGUwZmMzMDAwYzQzYjE4ZmMyYzYxM2U3YjhiMGJlXzQxLTYtMS0xLTA_7355e50a-ed6b-4cc9-aeb8-3dea2f5dc70d"
      unitRef="usd">26494000000</us-gaap:LongTermDebtNoncurrent>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzIxNg_a5eb56c7-3062-4ce0-ac06-df25393d79c4"
      unitRef="usd">5400000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzIyOQ_fb868794-961f-4cc0-8210-44958aa8a5f7"
      unitRef="usd">3000000000.0</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia4a277a5e8eb4225adece7896cfdfc52_I20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzkzNDU4NDg4MzgwNzM_25891e93-d716-49ba-8df3-35b21a1c31cc"
      unitRef="usd">7500000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzU5MA_403eba5f-2b52-412d-a1a6-8eb2a8bd69f7"
      unitRef="usd">10000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzExNDc_e672cc13-7cec-4dd0-a207-e6f2d861715c"
      unitRef="usd">2600000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermCommercialPaperCurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzExNzc_a34c501e-0828-4adc-a3dd-12f69746d5c8"
      unitRef="usd">1800000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:DebtCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE1MTA_b1697896-b44f-48e6-b845-14e61a9f7aea"
      unitRef="usd">1200000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermCommercialPaperCurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE1NDQ_699a5c37-5f5c-40ac-832a-cc9ec2da02c1"
      unitRef="usd">1100000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90ZXh0cmVnaW9uOjMxOGViZGM1MDAzMDQ4ZDY5MGFmYTdjMGZjNGE4YzMxXzE3NzM_898ebecd-72e0-4034-a21c-87719fbb2551">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate maturities of long-term debt obligations commencing in 2021 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;After 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,515&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItMC0xLTEtMA_c56b4d62-6c55-4c56-838a-0a593d85e7ac"
      unitRef="usd">1799000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItMi0xLTEtMA_82a87a22-7ef3-4ec9-a529-76baa00aa759"
      unitRef="usd">2226000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItNC0xLTEtMA_41cdf4e0-9ab1-45b6-a46b-222cc657501d"
      unitRef="usd">1552000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItNi0xLTEtMA_f1d8179a-7468-4b71-b88d-c76b9d5c78b0"
      unitRef="usd">1598000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItOC0xLTEtMA_2b6b3de9-d6dc-4eeb-8001-94595813c81f"
      unitRef="usd">1744000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNTcvZnJhZzozMThlYmRjNTAwMzA0OGQ2OTBhZmE3YzBmYzRhOGMzMS90YWJsZToyM2Q2NDBjOWY2OTM0ZmZiYjAzZDc2ZWFmMDQyYWVmOS90YWJsZXJhbmdlOjIzZDY0MGM5ZjY5MzRmZmJiMDNkNzZlYWYwNDJhZWY5XzItMTAtMS0xLTA_f6e5ec96-061d-4706-b906-825fb2fd58ab"
      unitRef="usd">25515000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEwNDQ1MzYwNTA5ODM5_e6ff8502-2e0f-4c28-98db-fe7f39b7659a">Income Taxes&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for taxes on income consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,702&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes $1.4 billion of deferred tax expense for the adoption of the deferred method to account for GILTI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2020, 2019 and 2018, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes on international income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on Capital Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TCJA and related impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The fiscal year 2020 tax rate decreased by 1.9% compared to the fiscal year 2019 tax rate, which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#x201c;step-up&#x201d;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#x201c;step-up&#x201d;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4&#160;billion or 2.6% benefit to the Company&#x2019;s annual effective tax rate, comprised of the following items: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#x2019;s Swiss subsidiaries&#x2019; assets as described above; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Also, in the fiscal fourth quarter of 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;reflected as a &#x201c;Tax Benefits on Capital Loss&#x201d; on the effective tax rate reconciliation. In addition in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the impact of the accrual of litigation costs related to Talc for $4.0&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the accrual of additional legal costs, including an additional $1.0&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested; reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18); and reversal of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2019 tax rate decreased by 2.3% compared to the fiscal year 2018 tax rate. In addition to the impact of TRAF discussed in more detail below, the primary drivers of the net decrease were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2%. This benefit has been reflected as &#x201c;TCJA and related impacts&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company&#x2019;s annual effective tax rate by approximately 2.1%. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate.  This benefit has been reflected as &#x201c;TCJA and related impacts&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. Subsequent to December 29, 2019, the Company received and agreed to Notices of Proposed Adjustments (NOPAs) from the IRS. The Company believes it is adequately reserved for potential exposures.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;There were several one-time tax impacts that resulted in a cumulative net tax benefit to the 2018 annual effective tax rate of 1.2%. These items included the LifeScan divestiture, the adjustment to the 2017 provisional TCJA tax charge and the acceleration of certain tax deductions as part of the 2017 tax return. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;More income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $0.1&#160;billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.6&#160;billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a $0.9&#160;billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#x2019;s Swiss subsidiaries&#x2019; assets; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $450&#160;million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal year 2018, the Company completed its full assessment and finalized the accounting for the impact of the TCJA. The Company recorded net adjustments to the above components of the provisional charge of approximately $0.2 billion. These revisions were based on updated estimates and additional analysis by management as well as applying interpretative guidance issued by the U.S. Department of Treasury to the &lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;facts and circumstances that existed as of the TCJA enactment date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This charge was primarily related to additional deferred tax liabilities for foreign local and withholding taxes for the remaining balance of undistributed foreign earnings as of December 31, 2017 that were not provided for in the 2017 provisional charge.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described in Note 1, in the fiscal year 2018, the Company elected to treat GILTI as a period expense under the deferred method and recorded a deferred tax cost of approximately $1.4 billion in the fiscal year 2018 related to facts and circumstances that existed on the date of TCJA enactment. During 2018, the Company reorganized the ownership structure of certain foreign subsidiaries which resulted in a reduction of certain foreign withholding taxes that it had recognized as part of the provisional TCJA tax charge in the fourth quarter of 2017. Following the completion of this restructuring and as a result of clarification by Swiss tax authorities regarding the applicability of withholding tax to repatriation of certain earnings, the Company reversed a deferred tax liability of $2.8 billion and a related deferred tax asset of $0.9 billion for U.S. foreign tax credits, for a net deferred tax benefit of $1.9 billion. This benefit has been reflected as &#x201c;TCJA and related impacts&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 Deferred Tax*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income reported for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has wholly-owned international subsidiaries that have cumulative net losses.  The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The unrecognized tax benefits of $3.4 billion at January&#160;3, 2021, if recognized, would affect the Company&#x2019;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2012. As of December 29, 2019, the Company classified unrecognized tax benefits and related interest &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;of  approximately $0.9 billion as a current liability on the &#x201c;Accrued taxes on Income&#x201d; line of the Consolidated Balance Sheet. In the fiscal year 2020, the Company made its final payments for approximately $0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $32 million, $50 million and $53 million in fiscal years 2020, 2019 and 2018, respectively. The total amount of accrued interest was $468&#160;million and $559 million in fiscal years 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NTEw_e3421767-b39d-4ad7-b456-01dac2b9baaa">&lt;div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for taxes on income consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,702&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;Includes $1.4 billion of deferred tax expense for the adoption of the deferred method to account for GILTI.</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzItMi0xLTEtMA_d159dde7-690a-430f-ba77-abb3533a8666"
      unitRef="usd">1026000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzItNC0xLTEtMA_786fe131-baf3-4bde-a63c-e5f919a1bf52"
      unitRef="usd">1941000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzItNi0xLTEtMA_aa15ca17-db2c-4034-9ebe-c86bbc8ccabf"
      unitRef="usd">1284000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzQtMi0xLTEtMA_d19e1589-5de3-4387-a9b7-2a41152f8b57"
      unitRef="usd">1898000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzQtNC0xLTEtMA_efb9ba91-e948-4f04-beac-84d7bbe8e20f"
      unitRef="usd">2744000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzQtNi0xLTEtMA_e5049f00-7489-4a37-9b80-cfba2a80221d"
      unitRef="usd">2434000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzUtMi0xLTEtMA_69b987ab-1197-47ca-896c-2c2a8dfb2cbf"
      unitRef="usd">2924000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzUtNC0xLTEtMA_1cd35b90-9311-45eb-bc1f-aa12529f6b45"
      unitRef="usd">4685000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzUtNi0xLTEtMA_2aafcd27-d46e-43fd-9ce9-efed766d78f2"
      unitRef="usd">3718000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzctMi0xLTEtMA_af15d670-7a39-4808-9422-0236e47c1ddc"
      unitRef="usd">-76000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzctNC0xLTEtMA_46d2b036-2641-4266-9f17-d555b1a37d70"
      unitRef="usd">-814000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzctNi0xLTEtMA_9d0c6d4a-4a15-45a9-8b0f-a57ef55063b4"
      unitRef="usd">1210000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzktMi0xLTEtMA_372f36e1-4168-4006-9cf0-8bebbeea821b"
      unitRef="usd">-1065000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzktNC0xLTEtMA_0bd1f948-0528-4f79-99f0-5f17a71cb325"
      unitRef="usd">-1662000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzktNi0xLTEtMA_9146ee6c-09d2-41bc-a899-2e1c6d09f028"
      unitRef="usd">-2226000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzEwLTItMS0xLTA_139543c0-d37c-4c68-b5b8-5aae465a66e1"
      unitRef="usd">-1141000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzEwLTQtMS0xLTA_2c8944e3-2342-4f6a-9210-26a19cb65f05"
      unitRef="usd">-2476000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzEwLTYtMS0xLTA_710e3662-ff5f-4378-9ea9-8d00ba53265b"
      unitRef="usd">-1016000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzExLTItMS0xLTA_8674dd8b-2eb9-4c66-9fc7-3821163739b1"
      unitRef="usd">1783000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzExLTQtMS0xLTA_b7e6c4d9-7160-4e66-a238-0bc104c9cf66"
      unitRef="usd">2209000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowZmRhMzhiY2Q5MGU0MzZmYTA4YzIyZmMzNDA0ODIwZC90YWJsZXJhbmdlOjBmZGEzOGJjZDkwZTQzNmZhMDhjMjJmYzM0MDQ4MjBkXzExLTYtMS0xLTA_717addcb-eec5-4397-8d84-03a2cf893392"
      unitRef="usd">2702000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax
      contextRef="iac4d55843ee04cc9ba52c8e2dc31eb16_D20181001-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgx_363c9bc7-1301-4f18-af21-37475b1c94c2"
      unitRef="usd">1400000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NTA2_af204344-7e56-4171-acbe-299456000986">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2020, 2019 and 2018, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes on international income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on Capital Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TCJA and related impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI0NA_0c6ceb1f-a09f-499a-9ac2-6cb6bb04cf8b"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI0NA_60d6c920-c4d1-49b9-a567-439fdcbca114"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEtMi0xLTEtMA_775fc39b-aaae-459f-8a59-ea0dc31bbe76"
      unitRef="usd">4312000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEtNC0xLTEtMA_fba2d9ff-04f6-4b3a-9b20-02310f24dc0e"
      unitRef="usd">3543000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEtNi0xLTEtMA_218970cd-f46f-4083-a26a-c85e1ab17bd9"
      unitRef="usd">5575000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzItMi0xLTEtMA_a880fcf2-82d3-4dd5-895f-007e6fb74d70"
      unitRef="usd">12185000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzItNC0xLTEtMA_032a34cc-b09d-48f1-8796-14ffc0aefd7d"
      unitRef="usd">13785000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzItNi0xLTEtMA_a81026bd-34b0-408b-8fd2-0f367a7e4bf6"
      unitRef="usd">12424000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzMtMi0xLTEtMA_7059a354-725e-487a-acf1-efcfb2be85b3"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzMtNC0xLTEtMA_7585fd0e-8a90-4e4d-85c6-deab7c27fcfe"
      unitRef="usd">17328000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzMtNi0xLTEtMA_b5d22cd1-8266-4114-87d0-f56c9f917390"
      unitRef="usd">17999000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzUtMi0xLTEtMA_8c9df112-0b18-4aee-94a2-8c1213bcbd20"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzUtNC0xLTEtMA_7bf6c339-c51c-4667-8066-3e29cf09b2e3"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzUtNi0xLTEtMA_fe283c7c-38b4-4ecc-8708-e90b354aa10b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzYtMi0xLTEtMA_035891d4-b5b4-48ec-bc4e-614029fbe2ae"
      unitRef="number">-0.099</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzYtNC0xLTEtMA_6e9b5b28-cf6f-428a-bdd2-94e00755c622"
      unitRef="number">-0.059</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzYtNi0xLTEtMA_a99e4e31-8bcd-4fa6-b342-520c809e0c69"
      unitRef="number">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEwLTItMS0xLTA_be0710c2-3d8f-4f59-83c7-8dc94b92c6b7"
      unitRef="number">0.027</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEwLTQtMS0xLTA_577db522-08e3-4172-8082-307dea5019a8"
      unitRef="number">0.018</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEwLTYtMS0xLTA_afe1bf81-3595-406a-bc39-53acd881bd4c"
      unitRef="number">0.014</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTItMS0xLTEwMTUx_c47ca902-4c48-4783-a9f5-3516f1c18074"
      unitRef="number">-0.012</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTQtMS0xLTEwMTU1_0b4940c0-7d5c-4dfc-80f6-8417a31cc84b"
      unitRef="number">-0.003</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTItMS0xLTA_ed40a5b4-2a95-4239-bd82-58e8e6dafb61"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTQtMS0xLTA_4ec6a4a0-2324-49fc-acc8-d4ae4fc0769b"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzExLTYtMS0xLTA_93404753-850a-4206-9eb0-2a90a2037bf5"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE0LTItMS0xLTEwMjkw_600b41c1-73b1-4707-9ee0-36d3b7d6f36a"
      unitRef="rate">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE0LTQtMS0xLTEwMjkw_fed54e77-d0a5-4613-9f79-19b5db7d4a07"
      unitRef="rate">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE0LTYtMS0xLTEwMjkw_357b79d3-883b-4f1d-9fe7-d6cebafde749"
      unitRef="rate">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEzLTItMS0xLTA_dc539143-fddf-487d-8be7-2ff91b1a13a0"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEzLTQtMS0xLTA_bc8d6314-fe6d-4e25-ad66-7dc2ee5eb1a0"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzEzLTYtMS0xLTA_3d80b8b5-21c1-493d-9885-853e9c8edf6e"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE1LTItMS0xLTA_53105f39-9837-4b59-83c9-b785f6525650"
      unitRef="number">0.108</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE1LTQtMS0xLTA_718a3f55-d6d8-4b03-80f2-130817798bbf"
      unitRef="number">0.127</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTowMmQxYjdhNjM5MGU0NTBjYmMxYTU1Yjk2MGY1ZDFiOC90YWJsZXJhbmdlOjAyZDFiN2E2MzkwZTQ1MGNiYzFhNTViOTYwZjVkMWI4XzE1LTYtMS0xLTA_3ba95f28-9d3e-4e58-a256-2fa74e18d4d8"
      unitRef="number">0.150</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE0MTM_b00c0aa9-3dac-42b6-b850-7aa28be79e26"
      unitRef="number">-0.019</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzIxMjg_a17f5e48-13ed-4e45-bef1-420c61954624"
      unitRef="usd">400000000</jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzIxNDI_79868f99-b2f6-4b93-8530-370698c60396"
      unitRef="number">0.026</jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzQ0OTY_d68632f2-cd81-43c5-8fcc-fa61dc3d172d"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzQ4MDU_3a16443c-e111-4a7e-9177-2fc41dab3b37"
      unitRef="usd">450000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzUwNjM_ffce115a-533c-48c0-b891-7f9b3c85df9d"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzg2ODU_bb6d1a3e-c5a1-42a3-89c2-414514c2dc87"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:LitigationSettlementExpense
      contextRef="ifa0d22acfd9043efb1e18804222572bf_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk2NjU_103f72dd-be3d-4f68-b1e6-ba9770da49a8"
      unitRef="usd">4000000000.0</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent
      contextRef="ide9258c8a9684b738ee2e0f0983bd1f5_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk2ODk_c06c1711-e3c1-4a33-abcd-ea6e645434f6"
      unitRef="number">0.235</jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i500668a00ec14570b9277e4c2dbae643_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk2OTY_23238309-c554-429a-8c5c-1e2ab199243e"
      unitRef="usd">1000000000.0</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent
      contextRef="i3f5f3419f6044ef6a113250635e22bb7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyMzk3MTA_15bc6ce5-969a-4c76-95af-bb8c91379e56"
      unitRef="number">0.214</jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDA5MzI_d9694401-ecd0-45ad-ad5a-07ce2ad1f918"
      unitRef="number">0.023</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability
      contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIxMTM_26e89adb-cbab-475d-9a92-695d802f68b1"
      unitRef="usd">600000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset
      contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIxNTI_b1f0aff9-1525-49cc-a82b-5e6701ab76e6"
      unitRef="usd">200000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit
      contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIyMTk_10f11dfa-147e-43ff-95e7-314ba3195891"
      unitRef="usd">400000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent
      contextRef="i5b62f1bb84444e928443e80402f47547_D20200928-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzIyNjY_a8838d33-b39b-45a4-8d30-55192c5dd8b7"
      unitRef="number">-0.022</jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i8db67b67955942f7a04d431f570d4565_I20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI0NTc_c8cd69e3-993d-4970-9500-a17309214add"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:IncreaseDecreaseInEarningsBeforeTaxesPercent
      contextRef="i172efe01b0cb4ab689fa0a795f2f907b_D20191001-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI1ODg_d549e8e1-8cb8-48df-b28f-6837a7eb1a9f"
      unitRef="number">-0.235</jnj:IncreaseDecreaseInEarningsBeforeTaxesPercent>
    <jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent
      contextRef="i172efe01b0cb4ab689fa0a795f2f907b_D20191001-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzI2NjI_f8da9457-c2cf-4a11-8f5e-efa8cca26e11"
      unitRef="number">-0.021</jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset
      contextRef="id74cbe1f433b42e09645c83a947740b1_D20191201-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzMwNTM_b2187702-9200-407f-a4d1-081391d891e9"
      unitRef="usd">300000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset>
    <jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent
      contextRef="id74cbe1f433b42e09645c83a947740b1_D20191201-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzMwNTk_efe0211f-686d-4cd4-8adb-b5cb0c0113e7"
      unitRef="number">0.017</jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzMzNDE_951882fb-ec5f-47a2-a565-10dfda1d64fc"
      unitRef="usd">300000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <jnj:EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzM0MTc_a5cd2f68-10e8-4158-98b9-070ac0be98e9"
      unitRef="number">0.015</jnj:EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzQwMTk_0f0872c0-99ea-4ba2-9d92-52a0585814c7"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMyNjQ_36970def-a72e-478d-a5e5-c65d58fb3446"
      unitRef="usd">100000000</jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMyODM_8258f8e0-3e9c-4f8a-b089-358b7f9247d5"
      unitRef="number">0.006</jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMzMDI_f480fdc0-0d4c-44bf-b9cb-74f4de5189a2"
      unitRef="usd">600000000</jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMzMjk_fd505fdd-a883-44c4-94b7-212072079117"
      unitRef="usd">900000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNDMzNTY_ea3b46b4-0983-4ab0-bdc3-f952ba1367c7"
      unitRef="usd">450000000</jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit>
    <jnj:TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEwNTQw_0257a329-e137-4ff6-be25-f4ed54fe0b7d"
      unitRef="usd">200000000</jnj:TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax
      contextRef="iac4d55843ee04cc9ba52c8e2dc31eb16_D20181001-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzExNDA2_363c9bc7-1301-4f18-af21-37475b1c94c2"
      unitRef="usd">1400000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEyMDg3_6ee1f7d5-d3d3-4124-8ff3-26d1659c37d6"
      unitRef="usd">2800000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEyMTI2_0ba90ddf-d338-4eab-bfdf-77204e36beda"
      unitRef="usd">900000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzEyMTkz_a0d275c6-7089-42a3-bcf1-8f33e3eca47d"
      unitRef="usd">-1900000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NDkz_b26911d1-8e8d-4827-8c11-10ed28f49c0d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 Deferred Tax*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income reported for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzItMi0xLTEtMA_d38bc30d-1a3f-4931-889d-355c931b9ca8"
      unitRef="usd">2434000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzItNi0xLTEtMA_53af5eb3-a59b-49a2-b390-ade23b95e26c"
      unitRef="usd">2473000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzMtMi0xLTEtMA_5cc084ae-fa80-4bdc-9b39-fac8dceaf6d2"
      unitRef="usd">627000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzMtNi0xLTEtMA_097cf931-e6ab-4c2a-a68a-5ea3373da807"
      unitRef="usd">595000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzQtMi0xLTEtMA_47607607-a791-4d1f-b541-477a01771674"
      unitRef="usd">721000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzQtNi0xLTEtMA_b9126dc8-64a2-4b27-8818-7ddff963465e"
      unitRef="usd">1122000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzUtNC0xLTEtMA_0b270919-3082-456c-831f-440901196851"
      unitRef="usd">6567000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzUtOC0xLTEtMA_7b90aa63-c0fb-4f19-9b95-f0357d17d494"
      unitRef="usd">5835000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzYtMi0xLTEtMA_3ca4f50b-c5f7-41fa-9610-51105790a3d8"
      unitRef="usd">1517000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzYtNi0xLTEtMA_9d6aeef6-0c80-4848-ab7c-93765c3c4375"
      unitRef="usd">1189000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzctMi0xLTEtMA_a6df92f8-4db7-4967-a2ab-a6a763020729"
      unitRef="usd">3466000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzctNi0xLTEtMA_e4e07f0b-5444-4101-9238-6666de811805"
      unitRef="usd">2337000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzgtMi0xLTEtMA_babfa070-4fb1-4042-af20-35f65a0fba18"
      unitRef="usd">1705000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzgtNi0xLTEtMA_010993ad-505a-4f3a-bb93-61073e487102"
      unitRef="usd">1605000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktMi0xLTEtMA_79ca4b8b-db1d-4160-9d1d-eb6404fa7210"
      unitRef="usd">990000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <jnj:DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktNC0xLTEtMA_952c8e8d-29b5-49a3-b024-19a19f6a2926"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktNi0xLTEtMA_b06c8238-f413-44c1-8753-5067de3cdae1"
      unitRef="usd">838000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <jnj:DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzktOC0xLTEtMA_a7268f3e-5e13-4b87-b57e-d72ed7ad8861"
      unitRef="usd"
      xsi:nil="true"/>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTItMS0xLTA_2e4a479f-7235-4bf6-8c85-8f49ebf11817"
      unitRef="usd">812000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTQtMS0xLTA_663a5980-5d7f-448b-8cfc-15c57c98d3a8"
      unitRef="usd">1435000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTYtMS0xLTA_1f9803fa-32c5-4912-8e83-c8ea26694628"
      unitRef="usd">765000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEwLTgtMS0xLTA_f670a64b-b9e4-410d-ada9-f605adf7e859"
      unitRef="usd">1289000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzExLTQtMS0xLTA_61379ff1-9528-4475-bd8e-e4b3f28db542"
      unitRef="usd">3606000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzExLTgtMS0xLTA_ad44ee63-bbcc-4528-beee-191b7d1db298"
      unitRef="usd">2965000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTItMS0xLTA_cdf68925-53d1-4065-9e43-8b2084fb7390"
      unitRef="usd">854000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTQtMS0xLTA_33adc81c-79bb-4cec-b384-6746fdaa7f78"
      unitRef="usd">211000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTYtMS0xLTA_c336bd5e-fe2a-4f6f-b1f3-b6fc82f72836"
      unitRef="usd">696000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEyLTgtMS0xLTA_22cd2806-d3b9-49ef-87d6-d312a4bdb109"
      unitRef="usd">81000000</us-gaap:DeferredTaxLiabilitiesOther>
    <jnj:DeferredTaxAssetsOtherDomestic
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEzLTItMS0xLTA_561d9e4e-cc53-435a-9058-d39f0bf5e078"
      unitRef="usd">12000000</jnj:DeferredTaxAssetsOtherDomestic>
    <jnj:DeferredTaxAssetsOtherDomestic
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzEzLTYtMS0xLTA_e0ac5497-7c7c-40e5-999e-eeb8352e1e76"
      unitRef="usd">411000000</jnj:DeferredTaxAssetsOtherDomestic>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTItMS0xLTA_6f496211-eb9a-4632-9453-020b856f74f0"
      unitRef="usd">13138000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTQtMS0xLTA_3f0edf4b-b590-4cc0-bf2a-a36973359113"
      unitRef="usd">11819000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTYtMS0xLTA_f0f0c71b-fc98-4f0c-8b2c-e705a9a74700"
      unitRef="usd">12031000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTo0OWVlODc0MTFhNTA0NTg3YWJiNGVjNDcwNGZhZTc3OC90YWJsZXJhbmdlOjQ5ZWU4NzQxMWE1MDQ1ODdhYmI0ZWM0NzA0ZmFlNzc4XzE0LTgtMS0xLTA_e9d55ab6-472d-498e-8a00-0145864aa1ca"
      unitRef="usd">10170000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NDk3_2846d4ef-1b6c-43ff-a63b-6f117901d600">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzEtMi0xLTEtMA_c9aa41ae-1f3b-45d3-b99e-cf1b5b502680"
      unitRef="usd">3853000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzEtNC0xLTEtMA_face7413-04d3-4eb9-8ca8-2fa1fe5ffb50"
      unitRef="usd">3326000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzEtNi0xLTEtMA_0f898b6a-7972-4932-8fdd-b00d65402082"
      unitRef="usd">3151000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzItMi0xLTEtMA_62dbea65-7b48-4496-99b9-7e665194e14e"
      unitRef="usd">265000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzItNC0xLTEtMA_19c1d999-d29f-4f8a-a72e-25590c47f5f9"
      unitRef="usd">249000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzItNi0xLTEtMA_70f058c1-9e89-4384-b184-c7926401abc2"
      unitRef="usd">242000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzMtMi0xLTEtMA_648f1a0c-5092-4df4-8207-f41dfaa517be"
      unitRef="usd">668000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzMtNC0xLTEtMA_7723f5e2-147a-4328-a93b-ea639ad11401"
      unitRef="usd">408000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzMtNi0xLTEtMA_e4a6b563-3d7d-4e5e-b456-6270675eb7c5"
      unitRef="usd">145000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzQtMi0xLTEtMA_56cff4ac-08f4-499f-a9f5-0d86e07f8f23"
      unitRef="usd">551000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzQtNC0xLTEtMA_793d36a4-21c8-4ddf-8c5e-246257e575f7"
      unitRef="usd">105000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzQtNi0xLTEtMA_54ab1b13-47e2-449c-9ea9-cc77907d5fe1"
      unitRef="usd">137000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzUtMi0xLTEtMA_11db080b-20aa-488b-bf1b-e901f4aec5f6"
      unitRef="usd">839000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzUtNC0xLTEtMA_a3027080-f179-4524-ab04-7bb4dc6ac66f"
      unitRef="usd">9000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzUtNi0xLTEtMA_618dd568-b6b6-4f00-b274-bb43e4db228b"
      unitRef="usd">40000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzYtMi0xLTEtMA_90aef1ba-9e9a-42a8-8663-b3ba3032f79c"
      unitRef="usd">23000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzYtNC0xLTEtMA_6b82c7b4-eded-4b4d-9cba-40638ead5f12"
      unitRef="usd">16000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzYtNi0xLTEtMA_99abb9b6-b62e-48ba-b2ac-a22062b19c4f"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzctMi0xLTEtMA_d1d31d0c-dda0-4125-ac7a-164e38ac5d9f"
      unitRef="usd">3373000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzctNC0xLTEtMA_4e5440de-3e59-4c5f-80b3-98fc13f491e5"
      unitRef="usd">3853000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90YWJsZTpiNzQzNmMxNjQ3MjU0MmE4YjU1NmFiMWQ4M2RkNjM3Yi90YWJsZXJhbmdlOmI3NDM2YzE2NDcyNTQyYThiNTU2YWIxZDgzZGQ2MzdiXzctNi0xLTEtMA_20b53b63-7aec-4bdf-89b9-f38d9601141f"
      unitRef="usd">3326000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE0MzMy_439573aa-017d-4d4b-ab65-0be297bb9853"
      unitRef="usd">3400000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i94b21ae117b34c4292baffe418a58981_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE0OTgy_f7fc4e85-0faf-4d5e-bf72-a33d0b639b65"
      unitRef="usd">900000000</us-gaap:UnrecognizedTaxBenefits>
    <jnj:UnrecognizedTaxBenefitLiabilityPayment
      contextRef="i59f96e940f074bfc8bca8dd0210f851c_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE1MjU0_3283d000-d69e-41a1-afaf-60669b495855"
      unitRef="usd">700000000</jnj:UnrecognizedTaxBenefitLiabilityPayment>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2MzYx_87ea08de-67cd-4ef8-923f-9f415ada082f"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2MzY1_e9318006-de4b-4c26-b789-a0d2a99af320"
      unitRef="usd">50000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2Mzcy_516a8e84-c99e-4e36-912a-23424cf1f045"
      unitRef="usd">53000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzgyNDYzMzcyNTE2NDU_47c8b6f2-9a46-46fa-b3e2-683f1a7cf9f0"
      unitRef="usd">468000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjMvZnJhZzpmZmIyODMwNGYxMWE0NGVhOTk1YmRhNTUzZGMzOWNmZC90ZXh0cmVnaW9uOmZmYjI4MzA0ZjExYTQ0ZWE5OTViZGE1NTNkYzM5Y2ZkXzE2NDQ4_00d73aa1-f865-4980-bb6b-d28dd24ba674"
      unitRef="usd">559000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzI4NA_d397e3ad-5ed6-43c7-a67a-1ece4dfc4608">Employee Related Obligations&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal 2020 and fiscal  2019, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,663&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid employee related obligations of $656 million and $551 million for 2020 and 2019, respectively, are included in Other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <jnj:EmployeeRelatedObligationsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzI4Nw_f284052c-5968-4c14-95fa-ac74b1ce9147">&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal 2020 and fiscal  2019, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,663&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:EmployeeRelatedObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzEtMi0xLTEtMA_3af12ed6-a703-4b0a-a08f-e7a64d8d5222"
      unitRef="usd">5761000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzEtNC0xLTEtMA_97462502-1901-4a4d-8975-546271c99204"
      unitRef="usd">5538000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzItMi0xLTEtMA_3b49062d-fad0-4c5a-a8e8-f4e15ba9e332"
      unitRef="usd">2229000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzItNC0xLTEtMA_beb9556b-fb4d-4885-85cd-9107fd01286f"
      unitRef="usd">2297000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzMtMi0xLTEtMA_cd1b6b55-6f7d-460b-bdb0-80179459a6bf"
      unitRef="usd">3078000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzMtNC0xLTEtMA_67fdfc86-ed18-49e4-aa43-2574e7361424"
      unitRef="usd">3004000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzQtMi0xLTEtMA_d209485f-982a-4b20-8188-d0620b498506"
      unitRef="usd">250000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzQtNC0xLTEtMA_9522a59a-9f32-441f-9953-37f01192a70e"
      unitRef="usd">338000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <jnj:EmployeeObligations
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzUtMi0xLTEtMA_eed601d6-9ed7-4ee3-9fa0-5635bc4db39f"
      unitRef="usd">11318000000</jnj:EmployeeObligations>
    <jnj:EmployeeObligations
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzUtNC0xLTEtMA_9f156a38-3086-49b4-9cb4-130842ccd5d5"
      unitRef="usd">11177000000</jnj:EmployeeObligations>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzYtMi0xLTEtMA_f86da943-64e8-4fe9-99a4-20e33da394e9"
      unitRef="usd">547000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzYtNC0xLTEtMA_ed03a4a8-355d-404c-8f78-c8e7ade86e39"
      unitRef="usd">514000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzctMi0xLTEtMA_26ff1f0c-2666-4fd1-a4e8-d3f9889a2cab"
      unitRef="usd">10771000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90YWJsZToxYWQxZDYwMDkwYzk0MzE2OTNiNDY0MGFjOWI4ZmIzOC90YWJsZXJhbmdlOjFhZDFkNjAwOTBjOTQzMTY5M2I0NjQwYWM5YjhmYjM4XzctNC0xLTEtMA_31429931-ef28-4412-a603-f57c6896fbdc"
      unitRef="usd">10663000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzE4MQ_ed9946c9-6aed-46fc-9c42-397f5279c5fd"
      unitRef="usd">656000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNjkvZnJhZzoyOTkyMmQzNGVjZjM0Njk1YWNkY2QyY2JhNGRlNDEzZC90ZXh0cmVnaW9uOjI5OTIyZDM0ZWNmMzQ2OTVhY2RjZDJjYmE0ZGU0MTNkXzE4OA_d5e2043c-1cf3-4c2f-8ef5-6c4767b7c6d6"
      unitRef="usd">551000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjE0_9d1512c1-3ac6-47e9-af7d-586b34a74e2e">Pensions and Other Benefit Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S.&#160;retired employees and their dependents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#x2019;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PBO as of January 3, 2021 by approximately $1.8&#160;billion and is included in the &#x201c;Amendments&#x201d; line in the Change in Benefit Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 and 2019 the Company used December 31, 2020 and December 31, 2019, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;923&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the assumed health care cost trend rates, for all individuals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Health Care Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33,416&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,095&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,004&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company contributed $441 million and $429 million to its U.S.&#160;and international pension plans, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2020 and December&#160;31, 2019, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $8.8 billion, $9.8 billion and $4.4 billion, respectively, at the end of 2020, and $4.3 billion, $5.2 billion and $0.9 billion, respectively, at the end of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026-2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026-2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#x2019;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Determination of Fair Value of Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a description of the valuation methodologies used for the investments measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Short-term investment funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Debt instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commingled funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,602&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,053&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $90 million and $84 million at December&#160;31, 2020 and December&#160;31, 2019, respectively and U.S. short-term investment funds (Level 2) of $31 million at December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;The fair value of Johnson&#160;&amp;amp; Johnson Common Stock directly held in plan assets was $946 million (2.5% of total plan assets) at December&#160;31, 2020 and $984 million (3.1% of total plan assets) at December&#160;31, 2019.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <jnj:EmployeeCompensationPeriod
      contextRef="ia08825d6475b4031a35401d638705874_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzYxNg_701280b2-8f2e-4378-8b6e-a9b6bbdcbdf7">P5Y</jnj:EmployeeCompensationPeriod>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzgyNDYzMzcyMjE5Nzc_d69c1850-f6a7-42f2-a3ab-5d9e517a1545"
      unitRef="usd">-1800000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDate
      contextRef="ie8d76953cd864599b2189d147891aa04_D20201231-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEzMjE_e8f8409a-926b-450d-90a5-96fe5326a6c9">2020-12-31</us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDate>
    <us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDate
      contextRef="i5c88bca24e1a49eab2160ca290e744e6_D20191231-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEzMjg_8f6b9133-c048-43a1-a9c0-ab9a6e40c2fd">2019-12-31</us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDate>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjI3_bbbf9917-71bd-4760-bff0-8183b585ef3a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;923&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItMi0xLTEtMA_37e493a6-61b2-4c13-a5b4-545b048b218a"
      unitRef="usd">1380000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItNC0xLTEtMA_9a19afc5-56c6-4d2e-9783-e9cce6b4a122"
      unitRef="usd">1163000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItNi0xLTEtMA_ab4ea4b3-290b-4daa-a086-90cfe69f19fe"
      unitRef="usd">1283000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItOC0xLTEtMA_90d9e1ce-8eb3-4cae-a938-4640f6bae57a"
      unitRef="usd">287000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItMTAtMS0xLTA_15746500-eae1-4d73-b6e0-d13e6d943cfe"
      unitRef="usd">274000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzItMTItMS0xLTA_a13f498c-87e9-4d81-91ef-73a76393cba7"
      unitRef="usd">269000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtMi0xLTEtMA_bd5d7b90-f571-44bd-a9c6-2a5d37cf16c2"
      unitRef="usd">955000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtNC0xLTEtMA_de06469a-3a76-4f6b-8937-7b3e7eef2814"
      unitRef="usd">1096000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtNi0xLTEtMA_3096faaf-b2fa-4508-b87e-ceafc4ea02b7"
      unitRef="usd">996000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtOC0xLTEtMA_264fcc23-d67a-489e-a4a7-09d94db945f5"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtMTAtMS0xLTA_9df28468-1cd5-4b3c-a5da-57135a0a18a2"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzMtMTItMS0xLTA_1a5c686f-af08-4c77-9a24-757b53a3ac10"
      unitRef="usd">148000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtMi0xLTEtMA_cfdc8198-71da-4551-84ad-fea89ac8a601"
      unitRef="usd">2461000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtNC0xLTEtMA_d8f811ee-0f04-4eb1-9b40-d0d2940c47f0"
      unitRef="usd">2322000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtNi0xLTEtMA_ee68a987-fb2b-4e6b-8ccd-a1d8e465d498"
      unitRef="usd">2212000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtOC0xLTEtMA_a757f169-a12d-4cb4-83d4-f58baafe064f"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtMTAtMS0xLTA_b1f47f38-373e-4971-a0c8-c6530abe8ab6"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzQtMTItMS0xLTA_03607a8b-e81c-44f7-80a6-358821717c51"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtMi0xLTEtMA_4a6b8a10-a09d-4cb5-b176-24e12205dfc7"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtNC0xLTEtMA_f4e9b295-0da4-4bc2-b698-9b89742c3b18"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtNi0xLTEtMA_2f8565ab-8023-427c-baf5-b565a36c5ace"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtOC0xLTEtMA_fc6398c4-b2d9-47f8-81b7-80e057c27a08"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtMTAtMS0xLTA_929c85b6-491a-4ba2-849b-aa8d84f5633d"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzUtMTItMS0xLTA_9067fcc8-e1b5-43fe-8d24-b250002d5b2b"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctMi0xLTEtMA_9ada4b5f-21f6-4138-880f-b9be1c2e4ec3"
      unitRef="usd">-891000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctNC0xLTEtMA_2d41e524-34a2-47c0-93bc-65ff3d591dfd"
      unitRef="usd">-579000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctNi0xLTEtMA_40132a72-95aa-402f-ae0a-20b2232f7937"
      unitRef="usd">-852000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctOC0xLTEtMA_b0f4d3f5-9ee4-406f-9464-3ba78ea6ea5e"
      unitRef="usd">-142000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctMTAtMS0xLTA_7f045fb2-85b3-4598-a5fd-2094703225f0"
      unitRef="usd">-129000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzctMTItMS0xLTA_0eb7d43f-1b06-48dc-8ad9-d546df8220e1"
      unitRef="usd">-123000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtMi0xLTEtMA_e2de089d-893a-4c54-85fa-4d0255764ed1"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtNC0xLTEtMA_2c6e75c3-7a97-4128-95a0-51e85a33cb60"
      unitRef="usd">-73000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtNi0xLTEtMA_0a3ca520-6b0c-4d08-ad00-8be817ef2150"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtOC0xLTEtMA_c9ed7207-6a5d-435e-9289-96eaa08cbbfc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtMTAtMS0xLTA_7a97cd46-478c-427e-9943-e145ce4c957e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzgtMTItMS0xLTA_4077f504-12c0-44c3-8f72-7de19856c8ab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktMi0xLTEtMA_b3688221-7160-4e1f-8386-299e282506ef"
      unitRef="usd">790000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktNC0xLTEtMA_9f1812c0-125c-483a-8e6f-ec7e7325d258"
      unitRef="usd">593000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktNi0xLTEtMA_62025aed-d772-4682-baac-d2e523c8b52d"
      unitRef="usd">923000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktOC0xLTEtMA_38a89891-b1e3-4646-b2f7-e74aad7f6c5c"
      unitRef="usd">524000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktMTAtMS0xLTA_f5534a80-5fa4-4cac-9d89-9d637ee389e8"
      unitRef="usd">551000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkNmI2NTcwZDAyMmM0NjY4YWI4NWIwMGU4NWY2YmE1YS90YWJsZXJhbmdlOmQ2YjY1NzBkMDIyYzQ2NjhhYjg1YjAwZTg1ZjZiYTVhXzktMTItMS0xLTA_0a979dba-a871-4369-8c5e-3f639fbf8b7d"
      unitRef="usd">502000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzIwNzg_e370dbb6-27d8-4601-b3ce-18e89c5bd964"
      unitRef="number">0.10</jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjE4_efaac352-936e-47be-af68-94859abfd7a6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtMi0xLTEtMA_feca6a4c-93a0-4480-ae9b-e9771925c7e4"
      unitRef="number">0.0282</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtNC0xLTEtMA_e1b3ca5c-370b-4597-9a52-c91719b5dca2"
      unitRef="number">0.0363</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtNi0xLTEtMA_9a39deb9-9a52-4b89-9701-2931302b007f"
      unitRef="number">0.0320</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtOC0xLTEtMA_5cb97988-6583-44c8-99e8-d3beb842ee98"
      unitRef="number">0.0304</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtMTAtMS0xLTA_84818e01-b11e-41de-8909-b3e4939b39e7"
      unitRef="number">0.0445</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzMtMTItMS0xLTA_55104e04-4ac6-4712-9a6d-c2361da1c688"
      unitRef="number">0.0385</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtMi0xLTEtMA_db832dd8-3c9c-4aab-a387-4ecf3aadb91f"
      unitRef="number">0.0313</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtNC0xLTEtMA_173a8598-c370-47b6-9c2f-17bfa74d49b6"
      unitRef="number">0.0413</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtNi0xLTEtMA_68000cf9-0a11-46d2-b6e9-58bbf67f797f"
      unitRef="number">0.0360</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtOC0xLTEtMA_9f9ef37d-80e1-494c-9e9a-bd50066a22aa"
      unitRef="number">0.0308</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtMTAtMS0xLTA_66ccc2aa-d2f4-4616-9e16-ee7c9db2037d"
      unitRef="number">0.0425</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzQtMTItMS0xLTA_8192e9f7-25c6-4847-a099-c0e12a7f37d7"
      unitRef="number">0.0362</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtMi0xLTEtMA_980cb75c-8a28-4d35-a8b0-6c7a7663ec2d"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtNC0xLTEtMA_b9f67966-28e8-4e55-8ecd-3ff2149de6ac"
      unitRef="number">0.0399</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtNi0xLTEtMA_71724544-a9a9-4321-8118-c2807008ffb8"
      unitRef="number">0.0398</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtOC0xLTEtMA_bb866e5c-d607-49c5-acb5-f4ce240b81f0"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtMTAtMS0xLTA_71773110-1ce0-4403-86d8-706d57b0568c"
      unitRef="number">0.0429</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i42e8056fa5844bb5a4d135dcd7874e1f_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzUtMTItMS0xLTA_0c173782-244f-4e55-a9b4-40c126de83c1"
      unitRef="number">0.0429</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzYtMi0xLTEtMA_f74a0026-30e3-4b38-bf26-5c4d2572b135"
      unitRef="number">0.0812</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzYtNC0xLTEtMA_c300768d-4de9-4382-ab5c-04d902d31be1"
      unitRef="number">0.0831</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i89412899f05f4deaa64839d768b1ff06_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzYtNi0xLTEtMA_01d8c70c-283f-49b5-93e6-eaad97755b22"
      unitRef="number">0.0846</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktMi0xLTEtMA_6ee852fb-d33b-4d35-8238-0d685ddfafec"
      unitRef="number">0.0214</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktNC0xLTEtMA_a22f7b0e-d421-475d-9895-7d563d29f1c7"
      unitRef="number">0.0291</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktNi0xLTEtMA_fbec6a62-4681-4d3d-9c7d-33768cf6c876"
      unitRef="number">0.0376</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktOC0xLTEtMA_9ae7d33a-78b2-4ad0-8bb1-d9418ef41eb3"
      unitRef="number">0.0223</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktMTAtMS0xLTA_0b88c74c-596a-415b-9a81-75709392c10c"
      unitRef="number">0.0339</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzktMTItMS0xLTA_76299cb0-dc73-4bc9-b98f-1e215f231ea3"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTItMS0xLTA_60672739-6672-401a-bc61-0c695535559f"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTQtMS0xLTA_edf47813-eed7-44e9-bd35-80d0140921ac"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTYtMS0xLTA_3e13e659-edf5-4654-b869-af743dfe8fa7"
      unitRef="number">0.0397</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTgtMS0xLTA_c4194cee-09a8-4c88-b803-3d1c227cbbac"
      unitRef="number">0.0427</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTEwLTEtMS0w_32be733f-c0a3-4779-9cac-edfec668beeb"
      unitRef="number">0.0429</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpmOTM5MGZmNmQ1MjQ0OWI4ODU4M2Q4YjRlMTkzNWM4YS90YWJsZXJhbmdlOmY5MzkwZmY2ZDUyNDQ5Yjg4NTgzZDhiNGUxOTM1YzhhXzEwLTEyLTEtMS0w_9ab65133-8614-4c66-a60c-ab014b8720f6"
      unitRef="number">0.0429</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjEw_ab10c965-731c-4f01-a958-2056c1e2342a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the assumed health care cost trend rates, for all individuals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Health Care Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzEtMi0xLTEtMA_fd63eb70-292a-47e3-8517-ff173db06448"
      unitRef="number">0.0568</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzEtNC0xLTEtMA_11217c83-0e90-42f3-a841-e1f3a375cb09"
      unitRef="number">0.0587</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzItMi0xLTEtMA_c7dc0690-6249-4f18-baca-5ae59f7cfe77"
      unitRef="number">0.0449</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzItNC0xLTEtMA_baff71cd-13fe-4f8f-b3d8-0dace22e260c"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzMtMi0xLTEtMA_dc58b314-eef6-4a61-8c95-f36784f95cf3">2040</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpkZjI1MmZjODA2NDU0ZTUxOTdlYjUxNDBkZjNkMjkzNi90YWJsZXJhbmdlOmRmMjUyZmM4MDY0NTRlNTE5N2ViNTE0MGRmM2QyOTM2XzMtNC0xLTEtMA_14727632-12b9-4627-abbf-3dcb5d658905">2040</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjI5_ac796105-4381-4689-b727-58b698365611">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33,416&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,095&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,004&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtMi0xLTEtMA_b89e5de4-67c7-47a2-a45a-b1aaf08fca08"
      unitRef="usd">37188000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtNC0xLTEtMA_c3610ecb-e9e6-4938-a062-1c574fe10e36"
      unitRef="usd">31670000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtNi0xLTEtMA_8f844032-f3a6-4e9b-8221-93b32a7620c4"
      unitRef="usd">5076000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMtOC0xLTEtMA_58f9fc54-8c4e-49e5-bd6b-d256396f4138"
      unitRef="usd">4480000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtMi0xLTEtMA_004bbf8e-799e-422f-8956-f5771b5d52d2"
      unitRef="usd">1380000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtNC0xLTEtMA_f775187e-e729-4220-a526-46a05be77886"
      unitRef="usd">1163000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtNi0xLTEtMA_a9353d74-f198-4b73-a51b-dcbe1e338c2f"
      unitRef="usd">287000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQtOC0xLTEtMA_0f0f9ae5-143c-449b-a0ff-b02ed01645b0"
      unitRef="usd">274000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtMi0xLTEtMA_2bb30ef5-e70d-4302-abb2-43b38e63eb3b"
      unitRef="usd">955000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtNC0xLTEtMA_b830b0a3-1716-4bad-94af-5e0dadc7a6d5"
      unitRef="usd">1096000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtNi0xLTEtMA_74996417-3ca3-4e19-94cf-80a4fb8ec1a0"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzUtOC0xLTEtMA_7b8a6bee-120c-46a2-9c90-e6ff81939473"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtMi0xLTEtMA_5fb31629-ff24-48c0-b3e0-964e9e921d1f"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtNC0xLTEtMA_d5a335b3-54eb-490d-bfc1-1fd4bde0d062"
      unitRef="usd">63000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtNi0xLTEtMA_2273bf2d-cd86-4455-9c3b-b06a69dccd8c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzYtOC0xLTEtMA_d75f9271-6e6f-4a71-a18c-709d3e57ebee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctMi0xLTEtMA_dd5f7e3d-a0f7-45ef-9e8f-f23098361e3a"
      unitRef="usd">-1780000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctNC0xLTEtMA_73a4af8e-542d-4afb-986e-80fa9ecfe3eb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctNi0xLTEtMA_fff42b97-c1a9-46f4-8e9b-d7b8e09045e7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzctOC0xLTEtMA_fe31b6c5-fa1a-4128-999c-e3b04f285fad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtMi0xLTEtMA_fccaa1f9-4ada-4e27-945c-42f3156e5ebf"
      unitRef="usd">-5716000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtNC0xLTEtMA_43dd1da0-279d-4a0f-bff9-0979360a5ac6"
      unitRef="usd">-5178000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtNi0xLTEtMA_cf987dc8-978e-40f7-bb12-dbf5a6c32138"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzgtOC0xLTEtMA_cb8733bf-4a33-4a78-9f62-97fc552c2636"
      unitRef="usd">-562000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktMi0xLTEtMA_3a31f354-7fca-4ced-8d25-36bc3cb3db5d"
      unitRef="usd">-88000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktNC0xLTEtMA_176d9471-3448-4f20-aab9-c6b55467f870"
      unitRef="usd">-278000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktNi0xLTEtMA_5f196ab9-d0d4-4f7a-9719-0768446a0242"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzktOC0xLTEtMA_5303fd12-b9ba-4e4a-8795-e6bbf5ff3d3b"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTItMS0xLTA_5568841f-96c5-450a-aa25-fd67aea81075"
      unitRef="usd">24000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTQtMS0xLTA_70250369-0d10-4a37-821a-b8c89a4b91bb"
      unitRef="usd">172000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTYtMS0xLTA_a441b0ab-1fb5-4a75-903b-fe47c10a7a19"
      unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEwLTgtMS0xLTA_79a55ed8-8aed-418a-8d24-e403b19ea54d"
      unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTItMS0xLTA_83514a4e-a8f9-44ce-8c23-4819a7286fb2"
      unitRef="usd">1111000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTQtMS0xLTA_c4c1430d-d023-4be9-96a1-84ad1a308993"
      unitRef="usd">1555000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTYtMS0xLTA_cd13238c-f4aa-47fa-9df0-a7a6c396b44a"
      unitRef="usd">396000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzExLTgtMS0xLTA_09c2409c-5395-4021-b27b-8f25027d2b06"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTItMS0xLTA_e2a40344-7ab8-4f32-a5a0-9614345c4d96"
      unitRef="usd">-1003000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTQtMS0xLTA_d7da1a15-95c3-46cd-8c70-3a05a39af5d3"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTYtMS0xLTA_5856a27f-9a86-49f5-9447-1395c79563b8"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEyLTgtMS0xLTA_c15338f0-8bb5-42be-8121-14533b781f06"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTItMS0xLTA_22b40239-b5ca-44ac-96ed-93302ebd53a0"
      unitRef="usd">43300000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTQtMS0xLTA_33dc2d51-81cd-4928-af9d-c8260a4a60bb"
      unitRef="usd">37188000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTYtMS0xLTA_562a4012-a368-4d66-960e-49ba665a1089"
      unitRef="usd">5028000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzEzLTgtMS0xLTA_0c5089f9-e4aa-4e70-bb8d-1f5478134ee9"
      unitRef="usd">5076000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTItMS0xLTA_9768f94e-7f49-4c89-a9e7-66351cb453a8"
      unitRef="usd">32201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39f53cbefe4c4fcdb267d23a0bc7f29d_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTQtMS0xLTA_50c46eee-4c17-415e-8d46-4c797b1cc7fe"
      unitRef="usd">26818000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTYtMS0xLTA_46633776-b1d7-4412-828f-f49a4118fa30"
      unitRef="usd">115000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1e21ca84a744ed29c5bf847342b7b89_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE1LTgtMS0xLTA_ce86bbe5-cacd-4c89-9565-dd1aecfc7f18"
      unitRef="usd">180000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTItMS0xLTA_4dc7ea0f-f36a-4a83-b5f4-ea5fb99ab729"
      unitRef="usd">5524000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTQtMS0xLTA_dcbb56de-d45d-4d50-a92c-1bb49ba9d820"
      unitRef="usd">6185000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTYtMS0xLTA_9fc70c44-35ec-4732-b377-f955ed1a2947"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE2LTgtMS0xLTA_d698477e-e3ef-4e2a-bff7-9182b15a6b9e"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTItMS0xLTA_4131ef88-d6ec-4498-9921-7422d5e2eb6f"
      unitRef="usd">870000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTQtMS0xLTA_73ae5951-c2f0-4cf2-9651-dac39d26e366"
      unitRef="usd">908000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTYtMS0xLTA_470a91d8-27f8-4639-b4c7-3141b4d04600"
      unitRef="usd">357000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE3LTgtMS0xLTA_b13a7678-8bb3-4e36-8352-6062fbe783fa"
      unitRef="usd">347000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTItMS0xLTA_e71a1094-6ddf-4e04-ac6b-024199eedfd3"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTQtMS0xLTA_1370b3f8-9adf-4713-a2f5-3b4b45f623f1"
      unitRef="usd">63000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTYtMS0xLTA_aef3f9d7-0fe4-424e-a2b0-857f65b41db6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE4LTgtMS0xLTA_ebec5439-71e7-41ea-a27a-4652cc56652a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTItMS0xLTA_8024339f-2b66-4454-842e-c246cc608ed3"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTQtMS0xLTA_da25d100-7db3-4084-a806-713023f4f47b"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTYtMS0xLTA_1b1511bc-1993-45e7-b371-2e0e33e058d6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzE5LTgtMS0xLTA_71f8eede-561e-43a7-b8e3-70737930efa7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTItMS0xLTA_01d3d7af-d402-4d9d-8650-391b5c904940"
      unitRef="usd">-84000000</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTQtMS0xLTA_7229a223-bba1-4fad-94e4-91104da1224b"
      unitRef="usd">-274000000</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTYtMS0xLTA_6410f946-637f-421e-b2ea-2a7f8947a52d"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIwLTgtMS0xLTA_1c8dcde6-073f-4d56-99aa-cbecc59d474c"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTItMS0xLTA_6b57db76-b8cf-45af-8f25-a163475a598d"
      unitRef="usd">1111000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTQtMS0xLTA_59c0440d-b99d-4c88-a4b2-4ad8ea4d65d5"
      unitRef="usd">1555000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTYtMS0xLTA_64452031-d3a1-4f60-a198-0bd6902d7bbb"
      unitRef="usd">396000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIxLTgtMS0xLTA_561c7470-8b4a-46ca-9954-4bc0ffdd0688"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTItMS0xLTA_5cc3c79b-b6dc-455d-9ada-d0e794da38c8"
      unitRef="usd">747000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTQtMS0xLTA_68ba041c-d257-492a-957e-ec0273cd88cd"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTYtMS0xLTA_4223f5d8-63b5-46c3-869e-319e0703a370"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIyLTgtMS0xLTA_55de62b2-e18e-4de4-aee0-ca1e56c2f010"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTItMS0xLTA_05b763d6-bcba-49c1-b9f2-a63498585b80"
      unitRef="usd">38195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTQtMS0xLTA_6fb09835-8020-4fc0-84bb-1a3ee623dc3e"
      unitRef="usd">32201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTYtMS0xLTA_3cd1336b-5cea-4058-9919-0e61de2a4119"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzIzLTgtMS0xLTA_520edc9e-bcfc-40ea-8b61-595291c90357"
      unitRef="usd">115000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTItMS0xLTA_9dbad1ae-4d03-4ff1-ac21-eb47c471b405"
      unitRef="usd">-5105000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTQtMS0xLTA_ff11234e-a5c9-41c1-b8d2-761a7264fc18"
      unitRef="usd">-4987000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTYtMS0xLTA_f4390dde-360d-4be3-8830-92ae02576b8b"
      unitRef="usd">-4938000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI0LTgtMS0xLTA_f168c5d6-672a-43bb-9083-08cf7d0648d9"
      unitRef="usd">-4961000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTItMS0xLTA_98fdd7c3-a7ae-46f6-96c6-b70980465961"
      unitRef="usd">656000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTQtMS0xLTA_332e1076-5f7a-4351-9b26-7dd88018b586"
      unitRef="usd">551000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTYtMS0xLTA_cd9983c5-5097-4d13-8bc2-e78dea279fe8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI2LTgtMS0xLTA_0daf97e4-3cf1-436b-b565-f394b1417fb6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTItMS0xLTA_5d80a100-2c32-4045-9594-ce7d1619cc06"
      unitRef="usd">125000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTQtMS0xLTA_ed3adf8d-631b-47ea-b8ed-dbe89b5a983a"
      unitRef="usd">113000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTYtMS0xLTA_772ada8d-853a-4533-b499-4e354da3e64b"
      unitRef="usd">418000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI3LTgtMS0xLTA_30095cce-2d60-4ae2-b0e2-8e2e979b5bb8"
      unitRef="usd">397000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTItMS0xLTA_23e16a20-7cf3-4b7f-8372-d958856c885a"
      unitRef="usd">5636000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTQtMS0xLTA_fce27a8f-7588-4448-9df3-c512d845a1c4"
      unitRef="usd">5425000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTYtMS0xLTA_92238092-038b-4c00-90f2-2c4e86901eef"
      unitRef="usd">4520000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI4LTgtMS0xLTA_d9be94c4-8fe5-4223-9454-46f64266dce8"
      unitRef="usd">4564000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTItMS0xLTA_df6c7def-4ac4-4271-88eb-c8e5837c9840"
      unitRef="usd">-5105000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTQtMS0xLTA_6e3bdadd-2b83-49c8-aa7f-2950d0c5769d"
      unitRef="usd">-4987000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTYtMS0xLTA_a4ea3739-2403-45bf-bc79-4583563bc2d6"
      unitRef="usd">-4938000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzI5LTgtMS0xLTA_b76662e0-4aaa-4414-ab63-19f443dfa6fa"
      unitRef="usd">-4961000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTItMS0xLTA_63f9e03a-439a-4c65-96a6-9883c8b8e5c7"
      unitRef="usd">-10860000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTQtMS0xLTA_c09644c9-0a02-4e22-b5d0-0889d4f056a8"
      unitRef="usd">-8835000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTYtMS0xLTA_500f5a13-2d36-4d5a-95d9-eeb666056f9e"
      unitRef="usd">-1463000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMxLTgtMS0xLTA_ebc49c39-d81e-4a90-8f2e-446e094f0243"
      unitRef="usd">-1685000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTItMS0xLTA_3b3af827-0cce-42f4-9fe8-f0825a46b747"
      unitRef="usd">-1797000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTQtMS0xLTA_575b0eb6-6e8a-4a10-ad8e-7d9a31c7f035"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTYtMS0xLTA_bc313aa4-91f7-4f40-a565-9db47091db4e"
      unitRef="usd">-44000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMyLTgtMS0xLTA_4312e47d-927b-4a48-b6dc-dc7a3cad4450"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTItMS0xLTA_6e4ecff0-2545-4ff2-a81c-ac03b6f46f7a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTQtMS0xLTA_9df913d3-e2d4-45c4-9b75-128895185128"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTYtMS0xLTA_8a1176c5-4019-48d9-a24d-64ea4677e25f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzMzLTgtMS0xLTA_d700fd62-9571-429d-92a5-18576f5082f0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTItMS0xLTA_943bb0d7-39ab-4588-9838-7aa71958bbb9"
      unitRef="usd">9063000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTQtMS0xLTA_62799f7c-06bb-4082-8012-3d2ea6fdd1bc"
      unitRef="usd">8827000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTYtMS0xLTA_77cb8469-6d35-4fa8-b8ab-314e83e0522a"
      unitRef="usd">1419000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i7570501d894e4ab2a8eac2f9f3a9fcf3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM0LTgtMS0xLTA_c11e6633-2451-4f2c-9fe2-412e4c65c354"
      unitRef="usd">1610000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM2LTItMS0xLTA_79befde2-1951-48c4-b804-93cfb493ac2a"
      unitRef="usd">40356000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i2330bd0434aa4310950363941b7c32db_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM2LTQtMS0xLTA_fc819827-b108-49e4-8b7c-aa126bad8be9"
      unitRef="usd">33416000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:PensionContributions
      contextRef="iac551cea27e04d75bcc80f2411447fe0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzM4LTAtMS0xLTc1NjUvdGV4dHJlZ2lvbjoxZGZiNWU4YTI0OWY0NzdmYmJjOTkzNjI1YzI4OWM5Zl84MjQ2MzM3MjEwMTY1_c1636054-f752-4875-8bf4-46b1a4397221"
      unitRef="usd">514000000</us-gaap:PensionContributions>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTItMS0xLTA_8e88e9cf-d00c-451b-ba49-1cf5bf6acbe6"
      unitRef="usd">790000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTQtMS0xLTA_18882c82-d048-4e49-b98b-a8da437e018b"
      unitRef="usd">593000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTYtMS0xLTA_7d938d95-93d5-485d-a92e-676d9debe5e2"
      unitRef="usd">524000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQyLTgtMS0xLTA_00c97422-e06b-4139-9ecc-5ee9f101d17f"
      unitRef="usd">551000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTItMS0xLTA_65c685f8-9d9b-4846-ab3e-b88abe48edb8"
      unitRef="usd">-2616000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTQtMS0xLTA_8822a0c6-7396-4dfc-a54a-bc4c31e76d34"
      unitRef="usd">-1084000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTYtMS0xLTA_0b54a042-a27d-4470-a588-5784680ef764"
      unitRef="usd">81000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQzLTgtMS0xLTA_0ad11bed-21b1-4625-911c-72627e74d0cf"
      unitRef="usd">-550000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTItMS0xLTA_39497eec-31d4-441a-abde-eef2a4937fc4"
      unitRef="usd">-891000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTQtMS0xLTA_fb7649bb-1cb9-4b8c-86b3-5bf5dd3b0757"
      unitRef="usd">-579000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTYtMS0xLTA_59b3b3b3-40d4-486f-b845-7829c578ddff"
      unitRef="usd">-142000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ0LTgtMS0xLTA_e49337af-e16f-4e17-86c6-dd362beb136f"
      unitRef="usd">-129000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTItMS0xLTA_50f0d910-7b2a-4454-aa1a-9fee2d9697a1"
      unitRef="usd">-1780000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTQtMS0xLTA_a04c6513-3dee-485d-a838-f0df88a31892"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTYtMS0xLTA_2b38bc38-2034-42d7-bd9f-d0c32774b5ab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ1LTgtMS0xLTA_d2be7d99-714e-4c49-8847-0903d008a153"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTItMS0xLTA_33587b31-540a-4ed8-a4bd-ee74e34d8755"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTQtMS0xLTA_e4bee3c7-8fa1-45c7-a533-ae81b714843a"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTYtMS0xLTA_dd863ba9-a371-4ed4-ab3c-8c96fe2dc2f4"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ2LTgtMS0xLTA_7f845fa2-0746-4264-8310-80a66d6a3211"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <jnj:EffectOfExchangeRates
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTItMS0xLTA_7c1ffa23-107d-4da9-b8a5-d02b291fe489"
      unitRef="usd">293000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTQtMS0xLTA_38fbd627-c6ec-4fe8-b3ef-e9091917f63f"
      unitRef="usd">1000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTYtMS0xLTA_f1e15dbc-bfca-4904-b36f-cb21f456ae79"
      unitRef="usd">1000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ3LTgtMS0xLTA_514350b6-89f6-4e37-be91-f68a5e231cb2"
      unitRef="usd">1000000</jnj:EffectOfExchangeRates>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTItMS0xLTA_a31d4f23-c537-4a8f-b105-64e7be0ed8bf"
      unitRef="usd">236000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTQtMS0xLTA_7bf25673-4bcc-42b0-9dec-96b8f5ce7018"
      unitRef="usd">502000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTYtMS0xLTA_6a928d43-934f-4e8b-9734-4883abac49f4"
      unitRef="usd">-191000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ4LTgtMS0xLTA_2f66a643-9977-4e68-be6d-707ac06070ac"
      unitRef="usd">453000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTItMS0xLTA_2b08dfc4-9df2-4f8c-bc48-a0e0341497a7"
      unitRef="usd">1026000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="if190893c65874208b238876e963fff03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTQtMS0xLTA_1cf4b2ad-48ab-40b2-b37a-19ae3251487f"
      unitRef="usd">1095000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="iedc0eec9d52f4afbb25e5fffe23456fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTYtMS0xLTA_d34795d2-699a-4782-9394-6236b50e6144"
      unitRef="usd">333000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i94706bf44d7c416aa26ce36f6068db10_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZjE3NTUzNWQ2MjQ0MzIxOTdkYTViMGVmNDI1MDk4Yy90YWJsZXJhbmdlOmNmMTc1NTM1ZDYyNDQzMjE5N2RhNWIwZWY0MjUwOThjXzQ5LTgtMS0xLTA_d5e6952f-75d1-42fd-a07a-e03c1b74dc50"
      unitRef="usd">1004000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:PensionContributions
      contextRef="i8258eb0443384fc2aa7fb34a0f018511_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ0MDY_f52167dc-2aca-45f3-b144-dc222b761225"
      unitRef="usd">441000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="i35d1b0ae517840b7b04db12cfe06d2d6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ0MTM_ba83258e-0634-4cf3-ad5f-6a6b3bf219fb"
      unitRef="usd">429000000</us-gaap:PensionContributions>
    <jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMTY2_98bb5db3-64e5-40d7-846a-7c7965eac9d4">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2020 and December&#160;31, 2019, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtMS0xLTEtMA_3287d6ae-f846-42df-85a3-8f484e88797e"
      unitRef="usd">25554000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtMi0xLTEtMA_70fc7bef-cb78-4ed1-ad06-3dfc81a80be0"
      unitRef="usd">21398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtMy0xLTEtMA_cdf973a4-cd35-42c8-8a30-6afad3f70d67"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNC0xLTEtMA_759fb7e3-9942-4beb-9ca5-c9269cee2d57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNS0xLTEtMA_9c2cd99a-a0a9-41ce-8f37-0a75b3661ca7"
      unitRef="usd">12641000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNi0xLTEtMA_6ebfb786-900a-4161-8f09-8960454fabac"
      unitRef="usd">10803000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtNy0xLTEtMA_49fa89e2-15f0-4a9b-89bb-2f7590400b07"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzMtOC0xLTEtMA_797406e0-d31e-4eca-9a28-19e7d295f29f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtMS0xLTEtMA_8b0b7d45-fa55-45ef-a767-8cac8d426384"
      unitRef="usd">25466000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtMi0xLTEtMA_0174bb87-971e-41bd-9e42-f1f0021d4c79"
      unitRef="usd">22034000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtMy0xLTEtMA_98f984ba-1f0f-4875-8512-53cb6948eda0"
      unitRef="usd">2748000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNC0xLTEtMA_1f512452-b598-403e-afdc-7a2ea0ef4657"
      unitRef="usd">2544000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNS0xLTEtMA_44ab8170-913e-4efe-8080-8e154e853494"
      unitRef="usd">14541000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNi0xLTEtMA_2c743a7d-be18-419d-a7d1-ffcc6728f346"
      unitRef="usd">12132000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtNy0xLTEtMA_05c69364-7b60-46e1-9583-2ca341490336"
      unitRef="usd">545000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzQtOC0xLTEtMA_c4250f78-5efe-4ec5-87f3-bc9e2fc6abb3"
      unitRef="usd">478000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtMS0xLTEtMA_98f52cd5-6607-494b-a226-0e846313387f"
      unitRef="usd">24158000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtMi0xLTEtMA_9cd83b26-12a3-4ae7-adeb-b3655c7230fe"
      unitRef="usd">19831000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtMy0xLTEtMA_f5ac8c60-cce0-4158-a64b-ca3725670592"
      unitRef="usd">2495000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNC0xLTEtMA_62753646-1f5e-46aa-859e-f13636a32b7e"
      unitRef="usd">2115000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNS0xLTEtMA_7c6b0100-2a59-4c77-ba2b-4230ed8f4649"
      unitRef="usd">13210000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNi0xLTEtMA_33ec37cd-7022-4a28-bd70-fe925bc884be"
      unitRef="usd">11040000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtNy0xLTEtMA_a387d933-982e-434e-a0a2-92e95de83f89"
      unitRef="usd">493000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzUtOC0xLTEtMA_fc2e0e03-f6f1-4d78-958f-31936df27c33"
      unitRef="usd">430000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctMS0xLTEtMA_2f6c721c-b95e-4a07-a195-ad829e32dd70"
      unitRef="usd">88000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctMi0xLTEtMA_86cc3357-1eb9-42b1-ae92-83ad027c30ab"
      unitRef="usd">-636000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctMy0xLTEtMA_bb84cc1a-729d-42e3-b01d-30ef1499042c"
      unitRef="usd">-2748000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNC0xLTEtMA_8e6ac36c-d386-416c-a4d4-8f036c7f549f"
      unitRef="usd">-2544000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNS0xLTEtMA_f8f8a059-f2a0-487d-9612-2be597518cf0"
      unitRef="usd">-1900000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNi0xLTEtMA_66d71701-9922-4489-8731-45a9d5e1684a"
      unitRef="usd">-1329000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctNy0xLTEtMA_6651ea0a-ff0b-43a6-9f92-8bd85a001f4d"
      unitRef="usd">-545000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzctOC0xLTEtMA_ffa9e6ab-d240-4a0b-8a72-87f52af1887a"
      unitRef="usd">-478000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i1b800eebfb2649a48e2c884cbf2aef11_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtMS0xLTEtMA_1e694e9c-21c5-4fe0-8378-1e83b9616546"
      unitRef="usd">1396000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i4266eb19a3a8489d8e8e570a500b29bc_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtMi0xLTEtMA_5e16232c-ae81-4810-98d3-6555f94d0725"
      unitRef="usd">1567000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i17f235da37c9414c9287bbbd5ce9a9cc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtMy0xLTEtMA_ce71ae3b-c788-44bc-8a89-6a083c55ca36"
      unitRef="usd">-2495000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ida0e471c9e784988af7c2e3bdc2668b0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNC0xLTEtMA_24d5dc77-f018-43e7-8436-34513830e819"
      unitRef="usd">-2115000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="idb7a80e98b1d47c4b8ac8d048c0ea822_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNS0xLTEtMA_15e1a955-60fb-4463-b5a0-adcd195eefe8"
      unitRef="usd">-569000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i3606c1fcfe894326ac67e462f7a3db34_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNi0xLTEtMA_d6c4ea3f-8f00-404c-ad16-4b012648cbfb"
      unitRef="usd">-237000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i440d37782d3643f88c50da17d6fc2677_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtNy0xLTEtMA_fa2d8dd7-edcc-4345-b0ba-85f9ac49d659"
      unitRef="usd">-493000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ia14aa1f13b66432c8bc417c76885faf9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjNjcyMzdiYTJhNjg0NWExODgwYmY1NTVmZTNkZTEyZS90YWJsZXJhbmdlOmM2NzIzN2JhMmE2ODQ1YTE4ODBiZjU1NWZlM2RlMTJlXzgtOC0xLTEtMA_421b591c-ac45-4880-b3b0-6ecffc53e469"
      unitRef="usd">-430000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ4NTM_9928c1f6-e478-4bff-909b-e2f839188a5c"
      unitRef="usd">8800000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ4NTc_5298fba9-d735-4022-86df-aeabf4f18e11"
      unitRef="usd">9800000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ4NjQ_eea9f515-4ab0-4a4f-88e5-207edcdf1147"
      unitRef="usd">4400000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ5MDQ_5fe91adf-3253-4ec7-928b-32b4002776d7"
      unitRef="usd">4300000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ5MDg_1b45b155-9fa4-46d9-a79f-ae4d8348fb53"
      unitRef="usd">5200000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzQ5MTU_9302de9b-d7a3-4f3c-8399-91adb90506b8"
      unitRef="usd">900000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjIy_1ade95e9-467a-45fa-b64c-da30b136d583">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026-2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItMi0xLTEtMA_e0667b53-1137-401a-bbcb-91c3c2f3d3a7"
      unitRef="usd">1257000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItNC0xLTEtMA_018285ff-d385-4a6d-a531-f5657676bdf6"
      unitRef="usd">1292000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItNi0xLTEtMA_1adc1d10-b2cd-4889-b271-8a56d1c7ee14"
      unitRef="usd">1388000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItOC0xLTEtMA_f2ac0e3a-e32c-4233-8c1d-ca7a10f11109"
      unitRef="usd">1424000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItMTAtMS0xLTA_fb95f154-c27a-46e7-a1cb-ff01e6e949b6"
      unitRef="usd">1494000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i665364f0420d4c8a8fa01d3fb66d199d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzItMTItMS0xLTA_fd1f4c45-505f-43ed-8604-ab83e20b5e32"
      unitRef="usd">8795000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtMi0xLTEtMA_e8f7a74d-45bd-4b0a-9f4b-a696532c0532"
      unitRef="usd">427000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtNC0xLTEtMA_7b791ae9-ee03-4e0f-a183-40208f4ee6a4"
      unitRef="usd">440000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtNi0xLTEtMA_140fe6e8-5bfd-4d3f-b3d8-0ea0dd9cd774"
      unitRef="usd">453000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtOC0xLTEtMA_61bbacbe-d406-41a3-8bef-6c29124c6693"
      unitRef="usd">465000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtMTAtMS0xLTA_3efac331-a19e-4c74-b78f-bef4d27da572"
      unitRef="usd">417000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i97f4ee9cb63e41e9b25de4656f998a6e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo0MzI5ZWVlOTYwN2Y0NjM4OWU4NTM2YTY4YzUwNzU1ZS90YWJsZXJhbmdlOjQzMjllZWU5NjA3ZjQ2Mzg5ZTg1MzZhNjhjNTA3NTVlXzUtMTItMS0xLTA_50d97c46-58fe-43d4-9742-ed789d797b74"
      unitRef="usd">2273000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMTc0_52ed39c6-2c46-4432-8ef5-24ff46b7e0fa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026-2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtMi0xLTEtMA_dab3358d-351a-4569-a2ec-894fd2ec533a"
      unitRef="usd">110000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtNC0xLTEtMA_fef55db7-0d02-4c20-b3f5-3fd4d1cd5228"
      unitRef="usd">116000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtNi0xLTEtMA_6bfe9912-927a-4891-9bc0-763edd67727d"
      unitRef="usd">121000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtOC0xLTEtMA_a62f208f-1b56-48c6-93f9-061d14a89492"
      unitRef="usd">130000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtMTAtMS0xLTA_cdab16ea-3810-4d80-b888-2d9b30ac0b53"
      unitRef="usd">136000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTo2ZGJkODY2ZDFlMTk0OTEwYmEzMzkyY2JlMWNhMDFkMi90YWJsZXJhbmdlOjZkYmQ4NjZkMWUxOTQ5MTBiYTMzOTJjYmUxY2EwMWQyXzEtMTItMS0xLTA_96c9d4e0-765a-41c1-bb85-d2508a183973"
      unitRef="usd">787000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjIz_8159a7ca-0164-4901-b025-ee6d32372892">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ica8f24a050764bfba17b5c0beb8b5068_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzMtMi0xLTEtMA_962206d3-6476-4f63-8370-8b8ea7791328"
      unitRef="number">0.66</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="if68a6a311dd74eff8cdd501535848300_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzMtNC0xLTEtMA_23f3a155-4ac5-45df-bfbb-3f8b16c0ccdf"
      unitRef="number">0.74</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ica8f24a050764bfba17b5c0beb8b5068_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzMtNi0xLTEtMA_ed5420b1-1503-40a1-a687-e73723d91c8f"
      unitRef="number">0.67</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i66bdef9c25ea4e9abf91f84961d6aaf4_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzQtMi0xLTEtMA_84dd4879-3641-41d5-8eb4-c4c5d1096396"
      unitRef="number">0.34</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i23f4166c654a437a80123fea9e702f7e_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzQtNC0xLTEtMA_7da2982b-1a89-4119-a287-cf35a51d06ef"
      unitRef="number">0.26</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i66bdef9c25ea4e9abf91f84961d6aaf4_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzQtNi0xLTEtMA_75b8cd9f-761c-436b-85a2-c6c4f3813ada"
      unitRef="number">0.33</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzUtMi0xLTEtMA_526e43b9-5f56-49d9-92be-7f81718652a4"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzUtNC0xLTEtMA_1390c756-b56b-4ae5-a412-37edc37ed89a"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTozNmNkNWYwOGEzNmQ0ZGZlODI1N2NmZDg3NWRlMjA5NC90YWJsZXJhbmdlOjM2Y2Q1ZjA4YTM2ZDRkZmU4MjU3Y2ZkODc1ZGUyMDk0XzUtNi0xLTEtMA_1fe53008-70a7-4bbd-84a3-687d0acb23a6"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMjA1_b92d88ee-6a35-45fe-bc07-69b3dde4de20">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,602&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,053&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39331ef41a6c42108162921682abc122_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMi0xLTEtMA_b00f1943-e642-44cb-ab0d-ec14edac291d"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i10391e82429e4bf5a59079e301f6c6f6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtNC0xLTEtMA_8ad6014d-3f17-4c4f-84f4-7cd4e6beb17d"
      unitRef="usd">119000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ief3d442963634e13878545dad90c5606_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtNi0xLTEtMA_6d6c8a10-db29-4994-a9e3-f71868ae148d"
      unitRef="usd">763000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75eebb92b9ee407fa174719e6be87d9d_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtOC0xLTEtMA_c0353c7c-c950-4f99-8ea9-7b5b6f940d74"
      unitRef="usd">405000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c809f170b8d4ab7b2aa8e2af5723d0b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMTAtMS0xLTA_f1e8850f-c2e5-4848-9d38-ca94668865c1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e0df4d18d894d27a4ace305330ff2c6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMTItMS0xLTA_c5584a00-0636-474b-b586-d15a52a2eecf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14ec1578bd1a4fb1a4e201e6ba58cf2a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMTgtMS0xLTA_219b4c4a-61fe-4602-9647-19a031992001"
      unitRef="usd">890000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib0ee1b6e5291404bbc84039bc844c771_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzMtMjAtMS0xLTA_66608935-5a36-46cd-8431-407a6ef60049"
      unitRef="usd">524000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if4507a38bcbb4237894ed814ce9f93c2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMi0xLTEtMA_18505ff4-dd77-4aa0-9836-b6e51503195f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd2d58bc21d745699a63ffa711ad4c20_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtNC0xLTEtMA_178de497-cb66-4c85-9e90-74ec97c2b1b2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i71c4e1c7cb22424181b106e85e819494_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtNi0xLTEtMA_41d776fa-2c33-472a-a9f1-642a94a913d1"
      unitRef="usd">5023000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib90ab3ae11824ef9a9e63764ee396732_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtOC0xLTEtMA_913c4934-6d21-410f-a765-8d80613d8e8f"
      unitRef="usd">4140000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9fcce09e193042308b79539a19454bc8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMTAtMS0xLTA_4c692410-2aa9-48fc-9c97-e538abd7cbbb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a9090828474432593946d7091132f13_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMTItMS0xLTA_05da9bba-073b-4013-ae39-081d53ce2539"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4299477497a4436cad8f8ed08555cd49_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMTgtMS0xLTA_e04066dc-5603-4aa4-8aab-68ead62bb9ff"
      unitRef="usd">5023000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib4bfd5fd8a4849b08c174538fbba64c1_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzQtMjAtMS0xLTA_d44e37ab-bf62-455e-9745-c066e0c1b2ab"
      unitRef="usd">4140000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8c53d1325b34f4cabf72ed3d2c9c03d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMi0xLTEtMA_213b289e-3029-4ab5-b606-94888c3b1bf0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i792325894abd4ffe872badf07315f357_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtNC0xLTEtMA_3b83cf77-98f8-4b2c-8b36-b6d3ae1aa684"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i129ebaefb7b84569bc06b0cae2c77b85_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtNi0xLTEtMA_a64d5efa-b692-46a9-b28a-641b40c94ceb"
      unitRef="usd">3931000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6cd3c76e5ce3480aaebe23360e85c8ac_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtOC0xLTEtMA_7c2da6be-cf46-4c36-a06f-24a516ceeb4a"
      unitRef="usd">3452000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d096bcce1824a9594a39c9fdd09e08f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMTAtMS0xLTA_4f1da97b-6be1-4708-b495-39b5f21bc282"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4aa0b93fc2a44d95a845a5651a1abf3b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMTItMS0xLTA_53a77ee3-4d3c-442d-b004-7065b13ea2e4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i31684a1d9e3b497ea871cfece2687bfc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMTgtMS0xLTA_b0731a96-37d3-4568-9940-bc830e92d4a6"
      unitRef="usd">3931000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a9148ad612a4a91a72c08004fdadc69_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzUtMjAtMS0xLTA_52cf91e6-3bde-4dfd-9aa5-ffea1cdda7b1"
      unitRef="usd">3452000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if88fb975b18b476f96a36b211ef744e7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMi0xLTEtMA_9b74e819-1264-4dc5-bd82-dcb58acc9752"
      unitRef="usd">14375000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iefa06dbe41e44403b1a57fde488fefa8_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtNC0xLTEtMA_128b5e6f-4d14-4d5b-a6e8-e250f1cfe649"
      unitRef="usd">12483000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i36ddca0f50e34485b4dbb719c9499ef6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtNi0xLTEtMA_d03e004a-20d1-47fb-b152-8b5e4f711682"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a3cb8cc1c9747babbcb69806e0246a4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtOC0xLTEtMA_7b8d5694-d193-41a4-a315-5c48ca279880"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id51e2ec82259464f841cca599e785a2e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMTAtMS0xLTA_8bd74906-cb19-4b93-acf9-6c10da774a3c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89bcea9069d449e6ade65209250939b1_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMTItMS0xLTA_a258d893-1f91-4c74-b558-62f82075f21d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i23da6adc713141f9a30805360f7fddc7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMTgtMS0xLTA_c5268e6a-f63f-4c43-a340-e40fa65ea53b"
      unitRef="usd">14377000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d030f2dc9714f1788798bfe39569d3f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzYtMjAtMS0xLTA_3ccb7134-1a29-4c70-969d-e0b7f0999426"
      unitRef="usd">12485000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie44bbde50ab9441daec4c3cb7a16c7af_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMi0xLTEtMA_5bf972a1-de85-4967-9929-dc25bdb35bfc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5322cca6ec4b4e3fb447427aa4149354_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctNC0xLTEtMA_9af506e5-05ce-471e-8394-5c0ee8fe54b5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37baf89ebe664ce9a576dfea58d33bad_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctNi0xLTEtMA_b861b91a-3b7c-43f0-b53e-b3bebd8207fd"
      unitRef="usd">4690000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e4a4cd8db9740f0a035240c81e02b17_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctOC0xLTEtMA_f25585c4-ea0c-4103-a747-523de80f92ea"
      unitRef="usd">3338000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5156dbac2b5f45c38108ef2f637be5bf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTAtMS0xLTA_7e1b6089-a30d-48f6-8bc9-0ce2f69840c6"
      unitRef="usd">160000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i577b94e8b1be4e33aaccad68c1cf0d03_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTItMS0xLTA_5dcb8164-9c90-46e7-96b3-ba5a1abcf0df"
      unitRef="usd">181000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="id3e156cdf11044ea928c031c1ffa9fea_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTQtMS0xLTA_7fd807e5-b51e-44d3-ba08-f19c500fef31"
      unitRef="usd">8236000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i9a3e8fa9abf349568477263c121e67cf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTYtMS0xLTA_f821436b-976e-4325-b984-eba7097e2920"
      unitRef="usd">7580000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id3e156cdf11044ea928c031c1ffa9fea_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMTgtMS0xLTA_65ca5197-27c8-48f1-a40b-bb08a281b84a"
      unitRef="usd">13086000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a3e8fa9abf349568477263c121e67cf_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzctMjAtMS0xLTA_00aab275-a5fe-43c3-8c20-7a9dea3c8134"
      unitRef="usd">11099000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e3d41233d3a49058c7ac617acee9369_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMi0xLTEtMA_bb5b91c1-fbf4-4179-9b21-85b89b0876e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a8d5729f306476ab77201ea6d9d8c04_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktNC0xLTEtMA_dfa67acb-ef1a-4c63-b970-fc8db7124960"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02729f04daa74ab2afec896f6fe109e9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktNi0xLTEtMA_d15c8784-1942-4d5a-a606-893284152b49"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id4375b4a40664031a6ba86d8ee14c478_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktOC0xLTEtMA_28c2e5b7-1589-4f1a-9489-17030c2e306a"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0cb5c8f0e0ef4681aa83c7d913234f1d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTAtMS0xLTA_61723a3c-7bb5-4885-9958-9084581f71c3"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a5af3e730484e88ae6a67a735660d62_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTItMS0xLTA_c0cc7f83-a8ca-4956-9668-72004e236731"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i861c44bcd9c04b65b80d256358edd695_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTQtMS0xLTA_30e991d1-ae3b-4b6a-8113-d1160e471603"
      unitRef="usd">856000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i81f1ea39b2a44d56b0c8c041d1b61bb8_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTYtMS0xLTA_654693a1-be68-4f3c-af4c-3bd7e0f46d10"
      unitRef="usd">473000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i861c44bcd9c04b65b80d256358edd695_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMTgtMS0xLTA_d90ebe5d-0434-4ba3-90d8-0b5571689bb6"
      unitRef="usd">888000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i81f1ea39b2a44d56b0c8c041d1b61bb8_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzktMjAtMS0xLTA_709fb103-dd4f-4c02-9465-afc952cf7cfa"
      unitRef="usd">501000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc243eb836834e7d8a931154b37942d5_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTItMS0xLTA_29b0bf28-c3d2-439a-8864-e2961e7c994c"
      unitRef="usd">14502000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d30b90acd1242b6b7de07bbdc790c8a_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTQtMS0xLTA_85135ac1-0fcf-4ee1-bd86-98c7ae43eee0"
      unitRef="usd">12602000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4fd6e5e08fde46adb34424998ed53252_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTYtMS0xLTA_dd51e78d-52c2-4f13-8468-0b6c5502e45d"
      unitRef="usd">14420000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibedb3aa745dd4b3ab1c320496d1ab20d_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTgtMS0xLTA_a3377b12-6e60-42a8-9620-b81a0c9ab2d5"
      unitRef="usd">11346000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia667826001184093afc78dfa8bbb419e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTEwLTEtMS0w_4c3383d6-4e04-4dec-affb-4c26780f88f4"
      unitRef="usd">181000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5c067a1e923463bb25fd0faec7b3968_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTEyLTEtMS0w_ab35db0a-fd1d-42c8-98f8-a34160551aea"
      unitRef="usd">200000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i9677b9c0aeab4d24bd7207a87355007d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTE0LTEtMS0w_7aa83e6b-940a-49d9-9223-596411cae48a"
      unitRef="usd">9092000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="iad01912a4ccb42d5a3b1813a29d85078_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTE2LTEtMS0w_262ff880-4506-4150-bd82-98bbab2f9db3"
      unitRef="usd">8053000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9677b9c0aeab4d24bd7207a87355007d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTE4LTEtMS0w_42a17313-06fc-43c5-8be1-46292656cf69"
      unitRef="usd">38195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad01912a4ccb42d5a3b1813a29d85078_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90YWJsZTpjZDMzZWU0MDVkZDk0YzMyYmNjYjhiNjY3NTZkMzFiYy90YWJsZXJhbmdlOmNkMzNlZTQwNWRkOTRjMzJiY2NiOGI2Njc1NmQzMWJjXzEwLTIwLTEtMS0w_3e882534-1ec2-4bbf-b239-0d0263e63f23"
      unitRef="usd">32201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i032051d81b034bd089a0507d7eab7351_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEwODIz_62f4bfde-e8f3-473b-a844-723a16876f76"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9998429b4b654051adfe886dcefa9de9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEwODMw_bdb8a3b5-e2c8-4d69-8afe-d7385e3e6a93"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifa343551b56f48118e1cb1327fb01697_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzEwODkw_9d527ff3-3cf3-43a2-87e8-21314c9e7852"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMDM0_b9dd03ea-f10d-4a4c-a2c4-749873e603d2"
      unitRef="usd">946000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:PercentageOfCompanysCommonStockToPlanAsset
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMDM4_a66df840-9cea-4964-836a-74bf927fa01c"
      unitRef="number">0.025</jnj:PercentageOfCompanysCommonStockToPlanAsset>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMDk4_3902e8d9-c911-4730-b439-3201b4b0dd37"
      unitRef="usd">984000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:PercentageOfCompanysCommonStockToPlanAsset
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzIvZnJhZzoxZjgzMWU1NGFiZmM0NmQwOGMzOTQ5ZWYxYzc1MDc3Yy90ZXh0cmVnaW9uOjFmODMxZTU0YWJmYzQ2ZDA4YzM5NDllZjFjNzUwNzdjXzExMTAy_6c146efe-ec33-4ef5-984e-dbe47df362c0"
      unitRef="number">0.031</jnj:PercentageOfCompanysCommonStockToPlanAsset>
    <jnj:SavingsPlanTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM5Mg_776f41a4-6c57-46c3-b022-f16ed78ab4c6">Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $243 million, $235 million and $242 million in fiscal years 2020, 2019 and 2018, respectively.</jnj:SavingsPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM0Mg_4d269f39-f879-448b-980a-169c56109e5f"
      unitRef="usd">243000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM0Ng_601698e8-78c2-4383-8ef7-5955b2992fbf"
      unitRef="usd">235000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xNzgvZnJhZzpiYmUwYThkNTFiYzg0ZjcxOGEwZGYzZDM4OTlhNzU1Ni90ZXh0cmVnaW9uOmJiZTBhOGQ1MWJjODRmNzE4YTBkZjNkMzg5OWE3NTU2XzM1Mw_b36d4b93-111a-4691-80c0-fc94aaf48ee5"
      unitRef="usd">242000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzgxMw_ee1e3395-7070-44ce-9e6f-510051cba8b0">Capital and Treasury Stock&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash dividends paid were $3.98 per share in fiscal year 2020, compared with dividends of $3.75 per share in fiscal year 2019, and $3.54 per share in fiscal year 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 4, 2021, the Board of Directors declared a regular cash dividend of $1.01 per share, payable on March 9, 2021 to shareholders of record as of February 23, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <jnj:ChangesInTreasuryStockTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzgxNQ_1a9f4536-f3fb-4ad1-80eb-e124dd134c0a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:ChangesInTreasuryStockTableTextBlock>
    <us-gaap:TreasuryStockShares
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzItMi0xLTEtMA_8c79330e-3635-406d-b813-a2580d0bf9ab"
      unitRef="shares">437318000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzItNC0xLTEtMA_1c782670-263f-4b16-9396-95dc59e5433d"
      unitRef="usd">31554000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzMtMi0xLTEtMA_da6943ef-67e6-4c15-a3e9-4083f6d3aa8b"
      unitRef="shares">22082000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzMtNC0xLTEtMA_7cb10cb7-9399-4ed6-b547-07d3c88598c5"
      unitRef="usd">3060000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzQtMi0xLTEtMA_85e88286-ac98-41d4-a13e-f82e4c9046a6"
      unitRef="shares">42283000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7188c7127a744039ae13cbc733a4d543_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzQtNC0xLTEtMA_73cf1126-aee8-4620-bd9b-e8ed9e98c09d"
      unitRef="usd">5868000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzUtMi0xLTEtMA_ec00e630-c64f-498e-94a1-f13fd7043e43"
      unitRef="shares">457519000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzUtNC0xLTEtMA_ca36cd8d-824d-4ba4-b577-88f3076a84e3"
      unitRef="usd">34362000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzYtMi0xLTEtMA_a6f20212-8545-4d2b-9256-c14785ca1bf9"
      unitRef="shares">20053000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzYtNC0xLTEtMA_7b744ec4-52b7-4853-abbc-922a2e58cb6c"
      unitRef="usd">2691000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzctMi0xLTEtMA_b4d21d70-ab1d-4dbe-b954-de23cb56fda5"
      unitRef="shares">49870000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i36166563680d47089c116cbce4109090_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzctNC0xLTEtMA_5b6c9b88-f37b-4157-a0aa-020d5d323603"
      unitRef="usd">6746000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzgtMi0xLTEtMA_aea76904-b83a-40dc-92f0-ffe9e79be08f"
      unitRef="shares">487336000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzgtNC0xLTEtMA_025868a2-6107-48da-9e68-9cc437ff90ae"
      unitRef="usd">38417000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzktMi0xLTEtMA_456108c4-32a3-48d2-b167-309f8ffe1b9e"
      unitRef="shares">21765000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzktNC0xLTEtMA_9cba2bb4-0e25-48a2-8979-79c4a95d30e4"
      unitRef="usd">3148000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzEwLTItMS0xLTA_629eb967-8426-4263-a933-4839685add89"
      unitRef="shares">21760000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i65f9879a1bd543afa592dd9216077c10_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzEwLTQtMS0xLTA_3aa98b91-aca6-4339-9a32-8cd3180fe01c"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzExLTItMS0xLTA_a62bf26a-7df9-412d-817d-d66dcc48be6c"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90YWJsZTpmMTQ5ZWVkZWYzZmQ0ZDlhODg4MTc3ODAzYjA0ZWZlYS90YWJsZXJhbmdlOmYxNDllZWRlZjNmZDRkOWE4ODgxNzc4MDNiMDRlZmVhXzExLTQtMS0xLTA_915ffc4f-ec28-421b-9efd-570ebb0d4630"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzEyNw_2b384f37-8a03-4e71-99b9-9c45c16f936c"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzEyNw_ece16346-8132-4da4-b727-ce134b9ee125"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzEyNw_edc5bf93-1ed8-423d-ba83-daf5e20068e7"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzE5Mg_59acfa83-68be-4a6a-8d35-0cfadd319ac9"
      unitRef="usdPerShare">3.98</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzIzOQ_9f306429-9ab8-4685-b661-638b4611b7dc"
      unitRef="usdPerShare">3.75</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzI2Mw_6b3b009d-63e8-4712-a3da-ee0d8d8fe49d"
      unitRef="usdPerShare">3.54</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ia709adb3e87945729cd80574e236e7fe_D20210104-20210104"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzgyNDYzMzcyMDk2MjQ_f2ae5954-bd32-4031-bbf7-2eefbc9fa2ca"
      unitRef="usdPerShare">1.01</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie4380bdb86b74638b9120d6db37d52c0_I20181217"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODEvZnJhZzphNGZkZWE0ZmZkYTI0N2U0YWQ4NjU1MDU5ZWQxZmRmNy90ZXh0cmVnaW9uOmE0ZmRlYTRmZmRhMjQ3ZTRhZDg2NTUwNTllZDFmZGY3XzQzNA_795a5906-140e-494a-83fc-315e5a52d87f"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90ZXh0cmVnaW9uOmZiYzI1MGMyYWEwYzRkYTdhMjU0MmQ0NmMwMTVhNTE0Xzk3Ng_d578a098-3951-4c47-96e5-77f1226d0215">Accumulated Other Comprehensive Income (Loss)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss) On Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives &amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative adjustment to retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2018 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2019 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2020 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Per the adoption of ASU 2016-01- Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90ZXh0cmVnaW9uOmZiYzI1MGMyYWEwYzRkYTdhMjU0MmQ0NmMwMTVhNTE0Xzk4NA_453693a4-7c1b-4f22-b929-d14d10fcf5a2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss) On Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives &amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative adjustment to retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2018 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2019 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2020 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Per the adoption of ASU 2016-01- Financial Instruments&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id395e3d2f83144c69ca528af2dc9b6b9_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtMi0xLTEtMA_0304e6be-0002-40a6-b5e9-16a2ae351a1a"
      unitRef="usd">-7351000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b3c455ecfae4ed6aaebdcec05ae3f52_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtNC0xLTEtMA_2327e5a0-c83b-4017-baa6-1072fa4ab523"
      unitRef="usd">232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25282ad7400d4720a2625e8c3bac6273_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtNi0xLTEtMA_91e5307f-e4c5-45e4-b2ae-be340256c46b"
      unitRef="usd">-6150000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8e1cb44199148b9aa8fa2e71f1bd6fb_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtOC0xLTEtMA_ca2127df-f079-46d6-9c8c-182343784e3a"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ba23fda59684540bdcab8d2c6182237_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzEtMTAtMS0xLTA_d12e99ac-d2a8-41a4-b4ae-47cfe4b73ca0"
      unitRef="usd">-13199000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i170982da0e98496f80e2110280b52dd7_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItNC0xLTEtNDE1OA_02c5f599-8532-4dbe-ba11-cc6a84f7a730"
      unitRef="usd">-232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf4bf571e18643da8a5b4eb3bfc07a7d_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItMTAtMS0xLTcyOTg_2169e67b-4d1d-41e1-93c1-4febd62ab7f3"
      unitRef="usd">-232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic77626f7a811485e9b149e03c04b3bd1_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItMi0xLTEtMA_7a356bf8-fe4e-4157-a724-c019bd2cdd66"
      unitRef="usd">-1518000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib6a59d85f18543f8b4ace4dea662cfa2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItNC0xLTEtMA_1b514e62-ddac-4238-af23-be244eb8a321"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7956e74acd5f4f6eb52053c38a41f6d9_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItNi0xLTEtMA_021b8ee0-c6ef-4e9d-aff9-7684c03a4283"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib1cd916919904201816ef7744955d602_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItOC0xLTEtMA_101e8d76-1623-4907-8a0d-4b7767481d2a"
      unitRef="usd">-265000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3d809f74ca674af2a83700b574ef976a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzItMTAtMS0xLTA_fe281d84-b287-4fdf-93f6-c75bd4d52f70"
      unitRef="usd">-1791000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9a838ddab52405f87db30392fc1ced1_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtMi0xLTEtMA_165ca984-485a-45f3-84f0-98027c7f36d8"
      unitRef="usd">-8869000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b3e6d6e46264f57aae311381d35d955_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtNC0xLTEtMA_f96c2901-ea5e-4915-bab7-229b4bdd745c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3159628ceb74cfd97a53e02385491b7_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtNi0xLTEtMA_5e5c63c9-d6a8-4a31-8a0e-d81c862a284c"
      unitRef="usd">-6158000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1231b2bbed144c9cba72d9e67e5e0304_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtOC0xLTEtMA_b9d9a66c-fbbb-4b19-8e67-b36cbf9c4229"
      unitRef="usd">-195000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2de20cab02a4cf8a8defc94d4572ad4_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzMtMTAtMS0xLTA_b402f250-6df9-4e88-b9c3-ec99c766a513"
      unitRef="usd">-15222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i79859b6ecac341359999ab29de172592_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtMi0xLTEtMA_1d4182ff-8616-4bd6-b90e-3157989c74a9"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia018521bd0ef4419b522652ba45df3d9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtNC0xLTEtMA_c6ff9193-cf88-49c1-84f5-a876e59fa275"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa6936a6df91437db1d3e64cf273812d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtNi0xLTEtMA_e55f1b86-5632-41f9-a746-7e49ca2c17f6"
      unitRef="usd">-733000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i918db4b812b9414ba016263b04a7d008_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtOC0xLTEtMA_7612163b-2189-42c9-946a-47d723b12cfd"
      unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i411749566b1e45288b6797e92e4b8e37_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzUtMTAtMS0xLTA_cf4756f4-76e7-41c6-bd62-31b31dba32ef"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief95ad78a93d49fca32ddc64ec71496f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtMi0xLTEtMA_07df2bda-18c3-49f2-b4e7-755b3c0e8722"
      unitRef="usd">-8705000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie58dcb82268e44ae810d6cde038d160c_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtNC0xLTEtMA_5569c1b5-c99f-4dd6-82da-8ee95a842a76"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i636f1ba05c0d4343b8591ecc77c0e529_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtNi0xLTEtMA_6c8d6e07-0048-4ae9-8c0c-ff6f2d19df9a"
      unitRef="usd">-6891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fa8c9dffee24a899b4b02e4b15e6f89_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtOC0xLTEtMA_3cf4701e-aeb6-4162-98b8-4f3a2eed93db"
      unitRef="usd">-295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icafa9de0a8f744f78e2171c3ec5ff108_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzYtMTAtMS0xLTA_a568793a-87d7-4899-9e4b-076085bc38ec"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i28de37f2cd304efdb2a7bf164f22a948_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtMi0xLTEtMA_e36f0d8f-087e-4f4d-85b7-8adcf01a79f9"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i192924f6280a4a68a046814fc0e0b7bb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtNC0xLTEtMA_c89e5c31-3036-45b8-bcd2-bb9fb1175f28"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7657b728884a46e2884084e7b77c4751_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtNi0xLTEtMA_90dd8313-e36f-4819-b6e0-bb732a91ae42"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3d6214de92714d768bcf627b37e0f72a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtOC0xLTEtMA_dc097ba6-3d58-4344-90d3-d01e0fd7499d"
      unitRef="usd">947000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic15b04be239b4bcf895c4ac519a52aa5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzgtMTAtMS0xLTA_6f88f55b-010b-4352-97b6-442dca67ccf4"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f9f99d7635c4de3afb7d08a8b3b2d0b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktMi0xLTEtMA_d29876be-3bab-420a-8870-d467acba6a42"
      unitRef="usd">-8938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4ee948f3520495892dc498991ccc81e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktNC0xLTEtMA_19c60a82-98cb-45d9-8b30-96a405aa107a"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8cf02c8e230424b92126e9143e4345f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktNi0xLTEtMA_53ab217a-0945-4d10-8a3c-3c8721697728"
      unitRef="usd">-6957000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82c7380a52f94930a5e9728def85437b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktOC0xLTEtMA_f1ee79bd-e8ee-4c0f-8483-9517ce99ec51"
      unitRef="usd">652000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b56c73c08ba4d7bb733cf5b7825663e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xODcvZnJhZzpmYmMyNTBjMmFhMGM0ZGE3YTI1NDJkNDZjMDE1YTUxNC90YWJsZTo5NWYxOGE1NGVkZDk0NDAxODY1YTY2YmViMjI0ZjZjYS90YWJsZXJhbmdlOjk1ZjE4YTU0ZWRkOTQ0MDE4NjVhNjZiZWIyMjRmNmNhXzktMTAtMS0xLTA_bfe362da-8f1c-4fe1-8739-9a62f17f05d1"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ForeignCurrencyDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzNjA_07f2e3d9-d45f-47f7-a113-95a9b0112c6f">International Currency Translation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes during fiscal years 2020, 2019 and 2018 for foreign currency translation adjustments is included in Note&#160;13. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net currency transaction gains and losses included in Other (income) expense were losses of $209 million, $267 million and $265 million in fiscal years 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzMTA_bb89a863-3b9a-42b3-ab37-3c7564d4ffbc"
      unitRef="usd">-209000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzMTQ_dfaad384-df89-42bb-a05b-518437a265ef"
      unitRef="usd">-267000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTAvZnJhZzphN2QxMTRjMWRmZGM0MGVhOTc1M2U4NzdjODc3NzVlNS90ZXh0cmVnaW9uOmE3ZDExNGMxZGZkYzQwZWE5NzUzZTg3N2M4Nzc3NWU1XzEzMjE_32df9436-eef9-4d9d-91e2-959a5e770b28"
      unitRef="usd">-265000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgxMg_b5bd4fa6-f067-4b1a-8da4-d1b32722ba51">Earnings Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,728.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than their average market value. As of January 3, 2021, the Company did not have convertible debt. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#x2019;s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation for fiscal year 2018 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock. The diluted net earnings per share calculation for fiscal year 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgxMA_547f5d03-06ca-4be3-a868-56dd1c5a9220">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,728.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzEtMi0xLTEtMA_2a9dc668-fe42-495d-8eed-81bf966ff10c"
      unitRef="usdPerShare">5.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzEtNC0xLTEtMA_9da60255-b930-44af-a0bc-1ee6c9e8d306"
      unitRef="usdPerShare">5.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzEtNi0xLTEtMA_4c63bff8-4c36-4bdf-bb38-d45ea406e404"
      unitRef="usdPerShare">5.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzItMi0xLTEtMA_1b858ad0-b311-4111-be5e-f341dd490319"
      unitRef="shares">2632800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzItNC0xLTEtMA_bf2f4229-694f-4c66-a0a2-a65cff554a58"
      unitRef="shares">2645100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzItNi0xLTEtMA_9fad4178-56ef-4f21-b607-59e1cf184932"
      unitRef="shares">2681500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzMtMi0xLTEtMA_bc92d271-3f97-4136-983d-81e8e4d1ff3e"
      unitRef="shares">118300000</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzMtNC0xLTEtMA_b252ef46-85d1-4ff3-a9e9-e8888d64bab7"
      unitRef="shares">136300000</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzMtNi0xLTEtMA_3d8194b0-062d-405e-b2d8-1a4eb129309d"
      unitRef="shares">139000000.0</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzQtMi0xLTEtMA_853d5bf7-aa5d-4bd9-9387-c6538cdae4af"
      unitRef="shares">80400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzQtNC0xLTEtMA_d2e38248-5ef4-408e-a20a-44da2a63334f"
      unitRef="shares">97800000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzQtNi0xLTEtMA_b4114399-61d6-41d5-be90-3be0e4c413b2"
      unitRef="shares">92500000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzUtMi0xLTEtMA_d821f94e-7669-4016-a87a-605cfcb0657f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzUtNC0xLTEtMA_448e6d1e-0ee7-4548-ad74-4a13e7c84ed7"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzUtNi0xLTEtMA_611562fe-8f75-46bf-b0ad-14c06e58bea8"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzYtMi0xLTEtMA_c89c6398-55f1-46da-ada9-70af2ce71e29"
      unitRef="shares">2670700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzYtNC0xLTEtMA_c71c7f56-3f2c-4374-bc71-e823da68ceb0"
      unitRef="shares">2684300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzYtNi0xLTEtMA_4f7dddb8-a35b-4ba9-aee5-71e7a4b2a602"
      unitRef="shares">2728700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzctMi0xLTEtMA_331bb6bf-c744-43bf-b799-c353f4fb4d82"
      unitRef="usdPerShare">5.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzctNC0xLTEtMA_e5680d76-0b1e-43a9-b399-8e9c47f3b57e"
      unitRef="usdPerShare">5.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90YWJsZTo5Y2E5ZDFmNjhhNjU0YjcxOTRhYWNlYmIwMmIyZTk4ZS90YWJsZXJhbmdlOjljYTlkMWY2OGE2NTRiNzE5NGFhY2ViYjAyYjJlOThlXzctNi0xLTEtMA_4de04e45-c39a-44d8-a8f1-521abb67c717"
      unitRef="usdPerShare">5.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgyNDYzMzcyMDk4NTg_297186d5-bc64-4fa1-808f-99e00b630a75"
      unitRef="shares">18000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzMyOQ_5566fe5e-770f-4f29-9e3c-27db5097ea83"
      unitRef="usd">1000000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzMyOQ_fcff3773-0e8a-4f3b-8a91-f5726a6b71da"
      unitRef="usd">1000000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgyNDYzMzcyMTE2MDI_5566fe5e-770f-4f29-9e3c-27db5097ea83"
      unitRef="usd">1000000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xOTMvZnJhZzphYWMxZDY4NzNmMzM0NmZmOGVhZGMxNGE0NDY4ZDhiZi90ZXh0cmVnaW9uOmFhYzFkNjg3M2YzMzQ2ZmY4ZWFkYzE0YTQ0NjhkOGJmXzgyNDYzMzcyMTE2MDI_fcff3773-0e8a-4f3b-8a91-f5726a6b71da"
      unitRef="usd">1000000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4NjQ_4cbf7adc-0e48-4cc0-8c36-7d51b0f2206e">Common Stock, Stock Option Plans and Stock Compensation Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January&#160;3, 2021, the Company had 2 stock-based compensation plans.  The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012.  Shares available for future grants under the 2012 Long-Term Incentive Plan were 277 million at the end of fiscal year 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The compensation cost that has been charged against income for these plans was $1,005 million, $977 million and $978 million for fiscal years 2020, 2019 and 2018, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $210 million, $227 million and $192 million for fiscal years 2020, 2019 and 2018, respectively. The Company also recognized additional income tax benefits of $248&#160;million, $209&#160;million and $264&#160;million for fiscal years 2020, 2019 and 2018, respectively, for which options were exercised or restricted shares were vested. The total &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;unrecognized compensation cost was $804 million, $823 million and $827 million for fiscal years 2020, 2019 and 2018, respectively.  The weighted average period for this cost to be recognized was 1.76&#160;years, 1.71&#160;years and 1.73&#160;years for fiscal years 2020, 2019, and 2018, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options expire 10&#160;years from the date of grant and vest over service periods that range from 6 months to 4 years.  All options are granted at the average of the high and low prices of the Company&#x2019;s Common Stock on the New York Stock Exchange on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2020, 2019 and 2018 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp;amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of options granted was $16.42, $17.80 and $17.98, in fiscal years 2020, 2019 and 2018, respectively.  The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plan as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, and changes during the years ending on those dates is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;116.22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $1,021 million, $807 million and $1,028 million in fiscal years 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock options outstanding and exercisable at January&#160;3, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$62.20-$72.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$90.44-$100.06&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.48-$115.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$129.51-$131.94&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$141.06-$151.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$116.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$96.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding at December&#160;29, 2019 and December&#160;30, 2018 were 111,637 and an average life of 6.0 years and 109,652 and an average life of 6.2&#160;years, respectively. Stock options exercisable at December&#160;29, 2019 and December&#160;30, 2018 were 60,761 at an average price of $88.88 and 54,862 at an average price of $82.03, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Share Units and Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp;amp; Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of January&#160;3, 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of the restricted share units granted was $139.58, $121.31 and $119.67 in fiscal years 2020, 2019 and 2018, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $650 million, $586 million and $614 million in 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of the performance share units granted was $160.54, $124.67 and $120.64 in fiscal years 2020, 2019 and 2018, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; &lt;/span&gt;&lt;/div&gt;The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $91 million, $119 million and $129 million in fiscal years 2020, 2019 and 2018, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <jnj:NumberOfStockBasedCompensationPlans
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzk2_c86451aa-cfe9-4cff-a47a-ade9f725a92c"
      unitRef="stockbasedcompensationplans">2</jnj:NumberOfStockBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if4d4da45e8664cf1b3b70e33caab8fd4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwMw_0e6553c2-cd28-4f27-bdc5-24f94515e04a"
      unitRef="shares">650000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if4d4da45e8664cf1b3b70e33caab8fd4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzc0MA_eb39f90b-7191-4e8c-b2d4-67a8ce696987"
      unitRef="shares">277000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzg0MA_209b45bf-eb42-402f-abc6-0c358f2c98ae"
      unitRef="usd">1005000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzg0NA_720ff8f8-a7a6-4268-972e-f5938e867b48"
      unitRef="usd">977000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzg1MQ_f0e09dda-05a6-498c-92f1-7124ac4a1fe7"
      unitRef="usd">978000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzk5MA_650786bf-c22c-427a-b452-697357da31cf"
      unitRef="usd">210000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzk5NA_494c2194-fa7c-4507-8d84-cd05a2bca8cb"
      unitRef="usd">227000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwMDE_e63d9894-baf2-4324-9bce-844cc21c6a26"
      unitRef="usd">192000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzgyNDYzMzcyMTY5NDE_72615c5a-eefe-4081-8924-ca5545a5bf83"
      unitRef="usd">248000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzgyNDYzMzcyMTY5NTU_03e1da2d-3f48-486c-aed7-c753adf7bddc"
      unitRef="usd">209000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzgyNDYzMzcyMTY5Njk_9bf2363b-2751-411b-9586-c935922a204b"
      unitRef="usd">264000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwODI_9b002f73-e723-4477-83b1-742ef82fd47f"
      unitRef="usd">804000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwODY_049478a4-71da-4fc2-8bce-21a0e1af1a34"
      unitRef="usd">823000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwOTM_0f52a228-58aa-46ce-b31e-045f537da29d"
      unitRef="usd">827000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzExOTM_00fd5659-b190-4d56-8f81-b996db861be2">P1Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEyMDM_fb7352d0-54bc-473a-a1e4-dff1f93bc470">P1Y8M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEyMTY_0bd3dfe4-8a5d-460b-949b-72aeaa9a7066">P1Y8M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i4d20904ce51e457ba8a1053c58ed10cc_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzE2MDA_7337f28a-6cb0-4bbe-9ada-ddb649f45877">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if3a57f6eb476464d869fe8e58ec3baa5_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzE2Nzg_dca5a00b-1b8e-486c-9b6d-d02315ad9c9c">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia9c4d02cb4644dbca38c88e2ebb556f8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzE2ODQ_6c85fb58-b3a0-4fc5-83b8-3129fb0dea53">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4OTI_e38accea-1ef5-4f69-91f7-382749110fd0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of options granted was $16.42, $17.80 and $17.98, in fiscal years 2020, 2019 and 2018, respectively.  The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI0OTY_62867fcf-32a7-4c03-803b-7ae3be2f9161"
      unitRef="usdPerShare">16.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI1MDA_82ca979e-8a08-40a1-9e6a-1066ee55f630"
      unitRef="usdPerShare">17.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI1MDc_691735c4-dfa9-4021-92fd-2cdae6b5777d"
      unitRef="usdPerShare">17.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzEtMS0xLTEtMA_e1c38546-2dbc-4915-9d2a-8a239c11b4ec"
      unitRef="number">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzEtMy0xLTEtMA_6620cb13-e7af-4c5a-b2e9-b4ab3d412422"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzEtNS0xLTEtMA_8ec6b9a1-f5d4-4460-a5ef-580b7d776254"
      unitRef="number">0.0277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzItMS0xLTEtMA_774048c7-59b8-4fa1-aee4-9c23cd41c35c"
      unitRef="number">0.1533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzItMy0xLTEtMA_380fd282-29e8-4291-baad-e82b7f0e7f21"
      unitRef="number">0.1627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzItNS0xLTEtMA_03caf195-6404-4620-baee-05c22cc66a45"
      unitRef="number">0.1577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzMtMS0xLTEtMA_c9a189ac-b4fe-4f0e-83bf-8e2538e9bcd5">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzMtMy0xLTEtMA_0fc7f68d-a546-494b-b4c5-754ee55335da">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzMtNS0xLTEtMA_df1b9a53-fcfb-4278-bbf1-7b42c5c7db76">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzQtMS0xLTEtMA_7bf8e32d-2954-4bb4-8d1f-1e044248af62"
      unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzQtMy0xLTEtMA_be8c6025-8a2f-40d3-b319-60d6f518e45b"
      unitRef="number">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZToxNjg2ODFlMDAwODQ0MjIzYmYyMDI4ZjM3NGVhM2NmOS90YWJsZXJhbmdlOjE2ODY4MWUwMDA4NDQyMjNiZjIwMjhmMzc0ZWEzY2Y5XzQtNS0xLTEtMA_6bcee124-d786-4f4d-b5de-0a0017f01bc9"
      unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4NzI_d9654fc4-a47a-43c4-b227-14cae72f0443">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plan as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, and changes during the years ending on those dates is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;116.22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEtMi0xLTEtMA_eae877f5-cda7-427b-9051-c6aea6e39d7e"
      unitRef="shares">111306000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEtNC0xLTEtMA_86e090b3-7186-411b-bb09-d24eca2e5721"
      unitRef="usdPerShare">90.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia22df427a71c4e69b4499cded92f3f76_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEtNi0xLTEtMA_f9f335f5-cfec-42e6-869e-f798a25838e0"
      unitRef="usd">5480000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzItMi0xLTEtMA_6286e6bd-40d0-4466-b8e9-8c8a50141134"
      unitRef="shares">17115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzItNC0xLTEtMA_47779f7a-283c-4b66-be32-c62bde02d8a4"
      unitRef="usdPerShare">129.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzMtMi0xLTEtMA_f8c2db68-5c14-4040-9e22-fabca6f66aa3"
      unitRef="shares">16228000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzMtNC0xLTEtMA_96196fdd-b5b3-4e90-b7cb-96ab5348de7d"
      unitRef="usdPerShare">75.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzQtMi0xLTEtMA_8250c65b-5267-48e8-a5fe-2b305203507b"
      unitRef="shares">2541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzQtNC0xLTEtMA_4193c81a-3c4d-4a7c-b3ad-b4591211a078"
      unitRef="usdPerShare">112.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzUtMi0xLTEtMA_59dd1f3f-2e23-4245-8ec3-002c73cf6b8c"
      unitRef="shares">109652000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzUtNC0xLTEtMA_7b5010be-2524-46b7-a6f3-11ebd8752849"
      unitRef="usdPerShare">98.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzUtNi0xLTEtMA_afbf18af-cf82-4cdb-ae4a-352f3a939517"
      unitRef="usd">3214000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzYtMi0xLTEtMA_ddc440d7-dc47-4893-82e6-7fe13a3d6cf7"
      unitRef="shares">19745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzYtNC0xLTEtMA_6c7b5f14-890d-4dfd-a94c-c8699bba0d10"
      unitRef="usdPerShare">131.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzctMi0xLTEtMA_3b111668-981e-47a9-8f09-0c81644944bf"
      unitRef="shares">14785000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzctNC0xLTEtMA_2d8f991c-7502-41d2-b416-d9ff5c941836"
      unitRef="usdPerShare">82.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzgtMi0xLTEtMA_0eb9fbbf-b875-4d60-9a46-45da6d109ea5"
      unitRef="shares">2975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzgtNC0xLTEtMA_ce9b2343-2191-4534-853b-f7aeb3ae9f43"
      unitRef="usdPerShare">125.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzktMi0xLTEtMA_e89ddf11-36b1-41fc-8068-cc34644bfc8c"
      unitRef="shares">111637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzktNC0xLTEtMA_5d65419f-775d-4dce-aae7-d6aa1d62bdff"
      unitRef="usdPerShare">105.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzktNi0xLTEtMA_78c5b048-dbc3-4c50-a070-bda39bf5b8d5"
      unitRef="usd">4478000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEwLTItMS0xLTA_b7266cb6-7fa7-424d-b20b-2a5e4d589356"
      unitRef="shares">20723000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEwLTQtMS0xLTA_dc2d3599-6104-4abe-b6d0-a03d5c345440"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzExLTItMS0xLTA_6392160d-3ee5-4db1-8a00-03f8881fb9f0"
      unitRef="shares">16275000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzExLTQtMS0xLTA_a956d082-e29e-4821-9da0-15a8c0670851"
      unitRef="usdPerShare">86.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEyLTItMS0xLTA_06c6e39f-9c2a-4619-a009-6f8c8b65ecf9"
      unitRef="shares">1835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEyLTQtMS0xLTA_bd04521e-3210-4d3a-984e-0b7c648fc458"
      unitRef="usdPerShare">137.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEzLTItMS0xLTA_b098df92-564f-40bb-98d0-cd2a0945d216"
      unitRef="shares">114250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEzLTQtMS0xLTA_e5db5199-5da8-4b03-8150-5dfed7ad5890"
      unitRef="usdPerShare">116.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTowN2UyYTE2OGQxMzE0NDY1OWU0Y2IyNjRlMzZhMTFhMy90YWJsZXJhbmdlOjA3ZTJhMTY4ZDEzMTQ0NjU5ZTRjYjI2NGUzNmExMWEzXzEzLTYtMS0xLTA_0feb15da-f39b-4f6d-92e2-063edbb76c97"
      unitRef="usd">4703000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI4MTI_7f89d5ac-5991-4d3b-a260-b1a728fcb591"
      unitRef="usd">1021000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI4MTY_251a2648-7cf0-4b10-8776-5fba37318139"
      unitRef="usd">807000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzI4MjM_2bfe90a5-5272-42a3-ac68-b63fed7fa86a"
      unitRef="usd">1028000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4ODk_9b2ffb24-8d9b-4686-93a6-a19ce5ff139c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock options outstanding and exercisable at January&#160;3, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$62.20-$72.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$90.44-$100.06&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.48-$115.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$129.51-$131.94&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$141.06-$151.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$116.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$96.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTU0NjA3MGM3MTQ2YTY4Nzk3NTk1M2YxY2Q2NzUxXzEwNDQ1MzYwNDYzODk0_e8f0c273-fed5-4a41-9286-25566c7ed1a2"
      unitRef="usdPerShare">62.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTU0NjA3MGM3MTQ2YTY4Nzk3NTk1M2YxY2Q2NzUxXzEwNDQ1MzYwNDYzOTAy_c0755768-9a99-49b4-bd7a-77c9ae1e4c80"
      unitRef="usdPerShare">72.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMi0xLTEtMA_11d624e1-868a-42f5-a6c8-09323b34a6db"
      unitRef="shares">11111000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i5e90832f0d9544d5be21fae2ab17a039_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItNC0xLTEtMA_1e966050-88d1-4db6-a9dc-c63b796a444b">P1Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItNi0xLTEtMA_cdc6a3de-803e-4b59-a35d-ddac9ce75ee7"
      unitRef="usdPerShare">70.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItOC0xLTEtMA_0c0e805b-b0c8-4398-8264-77356b952100"
      unitRef="shares">11111000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i884a27a100b944dcb86bd6ea0016fcba_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzItMTAtMS0xLTA_d7ca3c1d-91bc-473e-9f69-a6b1c9a49ac3"
      unitRef="usdPerShare">70.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE2YTdjZDAzNWZiNjQ1NzViZWVjY2EzZmYyODJlZDEyXzEwNDQ1MzYwNDYzODk0_256e0305-4956-4acf-9611-fec114e1ab91"
      unitRef="usdPerShare">90.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmE2YTdjZDAzNWZiNjQ1NzViZWVjY2EzZmYyODJlZDEyXzEwNDQ1MzYwNDYzOTAy_33d34acf-3afd-4631-bd62-8a62695ea699"
      unitRef="usdPerShare">100.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMi0xLTEtMA_d363e90b-6db3-4c72-88e0-fb1742cfc110"
      unitRef="shares">22304000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i670f88ab965a4e55ab365ab56709c990_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtNC0xLTEtMA_705bdd91-9808-4dc3-a803-592a33b59def">P3Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtNi0xLTEtMA_5fb3b9c2-f0a0-41bd-a6c5-edd90195670f"
      unitRef="usdPerShare">95.36</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtOC0xLTEtMA_995c8fa3-8534-4e12-bb42-d4024d136a14"
      unitRef="shares">22304000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="id34d6ae79d964454a653e9d51a996c98_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzMtMTAtMS0xLTA_752c54df-751c-4a08-b0b9-565552bbebb3"
      unitRef="usdPerShare">95.36</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i035510af86094fac8176e7f17a5a8164_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQxMWQyY2ZjNTBiMTQxNjNhNjhhYTkxMWI2NWZlNzdkXzEwNDQ1MzYwNDYzODk3_a493f184-3734-45c5-8545-76e8c680b397"
      unitRef="usdPerShare">100.48</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i035510af86094fac8176e7f17a5a8164_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQxMWQyY2ZjNTBiMTQxNjNhNjhhYTkxMWI2NWZlNzdkXzEwNDQ1MzYwNDYzOTA2_a0229fa0-6a26-473d-9f66-937a4b052852"
      unitRef="usdPerShare">115.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMi0xLTEtMA_f08205b6-bc5b-4db3-9c0d-74affb03bb7e"
      unitRef="shares">28180000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i035510af86094fac8176e7f17a5a8164_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtNC0xLTEtMA_3abc832c-c97f-4eb9-a43a-0f8dc121a7a1">P5Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtNi0xLTEtMA_2fd18e8d-0390-4fd3-b50c-bb5f9f16aa01"
      unitRef="usdPerShare">108.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtOC0xLTEtMA_367f3136-d12a-4c95-b5e5-e7f4b121852b"
      unitRef="shares">27695000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i9bac2a7cd33b47bc9b8a13af6879af14_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzQtMTAtMS0xLTA_3cd5d5d5-5e38-46aa-b106-d0541945ccc4"
      unitRef="usdPerShare">108.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgwNWY1OGMyOTZmMDQ0MzlhMmRhNDU0YTNlMTVmYjBkXzEwNDQ1MzYwNDYzODk3_86b2c67b-2a5e-4006-bc1b-12fc7c8616dc"
      unitRef="usdPerShare">129.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgwNWY1OGMyOTZmMDQ0MzlhMmRhNDU0YTNlMTVmYjBkXzEwNDQ1MzYwNDYzOTA2_f6d09b0f-c730-4863-aac9-8f964750ac40"
      unitRef="usdPerShare">131.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMi0xLTEtMA_16f9617d-8e53-4c4d-b38d-eff73146d298"
      unitRef="shares">32553000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i88a9bdf7d4bf4da4854cd527083de6fe_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtNC0xLTEtMA_0f30615f-cf59-4b39-97ae-022f801cfc97">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtNi0xLTEtMA_2b47d10b-17bc-4e2c-88d4-c62c065f50ea"
      unitRef="usdPerShare">130.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtOC0xLTEtMA_215312a4-5a3f-4d5a-8fd9-6335deabcfda"
      unitRef="shares">145000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i0b2305bec7da4f2a82adbb34c65352b3_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzUtMTAtMS0xLTA_80ce2068-32c1-40f9-9524-75d0ebc94a2e"
      unitRef="usdPerShare">130.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjExODVjN2NhZWJmOTQwYzdiNGViYzYxZDMzN2IxMzhmXzEwNDQ1MzYwNDYzODk3_89753e95-945d-417b-8a2a-c0fc4fc9a306"
      unitRef="usdPerShare">141.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjExODVjN2NhZWJmOTQwYzdiNGViYzYxZDMzN2IxMzhmXzEwNDQ1MzYwNDYzOTA2_b593c40b-bb8c-46c2-a6ef-812ea03a2e7b"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i447115cb0801497ab64877cc7d65202a_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMi0xLTEtMA_1c555588-ebc1-406f-b40c-fef97d70aebc"
      unitRef="shares">20102000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ie2dc66e1a7fb4c1896b7fa216a7a05e4_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtNC0xLTEtMA_86467689-601c-4dd7-a451-e667e3a821da">P9Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i447115cb0801497ab64877cc7d65202a_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtNi0xLTEtMA_f993953d-dbf9-4554-b65e-63a57b18da18"
      unitRef="usdPerShare">151.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i447115cb0801497ab64877cc7d65202a_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtOC0xLTEtMA_89d5d727-d395-41f0-a221-2d02f1c91708"
      unitRef="shares">34000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i447115cb0801497ab64877cc7d65202a_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzYtMTAtMS0xLTA_cfb67abf-f9e0-45e1-a8b4-e90995be7e3b"
      unitRef="usdPerShare">151.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctMi0xLTEtMA_9dcc41ce-a83e-4728-a694-9c0bad0463d8"
      unitRef="shares">114250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctNC0xLTEtMA_68d60a4e-d5e6-4842-9b50-02cc1741267e">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctNi0xLTEtMA_5bc8b885-7515-4ac2-815f-895ef3e263ab"
      unitRef="usdPerShare">116.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctOC0xLTEtMA_c7184832-f5be-423c-b973-92dac394a49d"
      unitRef="shares">61289000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTo5YTQ2MTdiZmU3YTE0YmJhOGUwYTRkYjQ2MTBjOTc1NC90YWJsZXJhbmdlOjlhNDYxN2JmZTdhMTRiYmE4ZTBhNGRiNDYxMGM5NzU0XzctMTAtMS0xLTA_b88b2ba2-8c49-4cdf-b9ef-023ef285c2cb"
      unitRef="usdPerShare">96.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMwMzU_d0ce3a0d-3ee9-476c-b101-b098b11e90b7"
      unitRef="shares">111637000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMwNjE_4423bb70-037a-448b-9af5-1c64429ef6a1">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMwNzQ_4a67bc84-7b7d-476f-ae95-e8366681e9a1"
      unitRef="shares">109652000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMxMDA_6df23f19-fd7b-4823-8df4-ee0f566a168c">P6Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMxNjg_42a40499-e2d7-43ac-aeb5-e27b7e89e49c"
      unitRef="shares">60761000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMxOTQ_b3493145-1774-40bd-9ed6-9c490eef4d01"
      unitRef="usdPerShare">88.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMyMDE_8e204701-99d3-4f7d-b4b9-3e859e975634"
      unitRef="shares">54862000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7d47ca3aeb654a86ad3c3ad675822c76_I20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMyMjc_eb749b9f-95fc-4920-9451-63c8221d7fb7"
      unitRef="usdPerShare">82.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7c11a139c5264dc098f209197b9366c2_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMzODc_78fbbe8e-0aad-4734-8c64-4302e9132e51">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if0884d95fb894f82b5b100cc5798017f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzMzOTM_dc1e261a-00e3-4a5e-8b8d-f9175a9ae7f2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwNDQ1MzYwNDY5ODUw_700d0fdf-be62-43dc-a54c-858f94e396ef">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i78cd4383ab4a489fbbc505c984d58d74_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzM2ODY_1d7b860a-695e-4cd0-be46-f66d4b69b7c7">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib5338fd4c73a4d98b5d7d7df1d88f226_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzM2OTI_fe5f2c32-0e47-4079-ba7a-07bfba1ea1e4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwNDQ1MzYwNDY5ODUx_53f87213-d3b4-4ca2-bf59-c0af9345a393">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzEwNDQ1MzYwNDY5ODUy_eabc73f9-3ba2-40dc-855e-9d4de9428cc9">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i78cd4383ab4a489fbbc505c984d58d74_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQwNjU_5850a394-8231-4a22-a2e3-207b07c0d996"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib5338fd4c73a4d98b5d7d7df1d88f226_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQwNzE_dcef6a2a-1eaa-4076-87cb-7293dcd03ff2"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4NjM_f22b3b00-09cf-4ee2-8ef0-de86689ea24b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of January&#160;3, 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie1dee2245d414b138d2f2fa014b0a178_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzktMi0xLTEtMA_e5bc6756-7fb0-4c55-b93e-56ae6522b364"
      unitRef="shares">16769000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia7b2cf13619f4c189b475866e1db542f_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzktNC0xLTEtMA_8ab65ba8-96e0-4e9f-9337-def2af715c22"
      unitRef="shares">2174000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEwLTItMS0xLTA_c9d6124e-4b7d-4675-8f78-80a991025b75"
      unitRef="shares">5051000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEwLTQtMS0xLTA_f091031b-305e-421c-a0c5-6960d5f1a8c0"
      unitRef="shares">816000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzExLTItMS0xLTA_3e60d686-e957-47f9-b633-f20aea80ca3d"
      unitRef="shares">6042000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzExLTQtMS0xLTA_154a4f1f-8f64-4176-849e-804ec455400c"
      unitRef="shares">702000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEyLTItMS0xLTA_bde3967e-473c-494b-86cf-147de1202713"
      unitRef="shares">780000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEyLTQtMS0xLTA_d26a8056-2c22-4fbb-86cb-36f3659c7905"
      unitRef="shares">-52000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1f365b4e320847d7ad7af8be0962aad8_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEzLTItMS0xLTA_72bd3294-8f21-4e2b-bbdc-cd88994d294d"
      unitRef="shares">14998000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4d56204d812a44748666c659338087eb_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90YWJsZTpjODgzNmQ5YjVlOTU0Yjc1YmU0NTQ4NGQ2N2RlYmNlNy90YWJsZXJhbmdlOmM4ODM2ZDliNWU5NTRiNzViZTQ1NDg0ZDY3ZGViY2U3XzEzLTQtMS0xLTA_75c2c55a-45d7-4d1a-b502-6adbb9070691"
      unitRef="shares">2236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQ3MzQ_93872ca1-0515-42f7-8a45-5da6c725a3b0"
      unitRef="usdPerShare">139.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0c52ecff45c14b9dbccf4b05efc03a3b_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQ3Mzg_c4ffa498-cbdc-4390-aa50-55061e8d0c63"
      unitRef="usdPerShare">121.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i912305c8e84a4cd9a5729ccf10a90c3c_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzQ3NDU_d3b30946-c320-425f-ab5c-cab1e59a6143"
      unitRef="usdPerShare">119.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ied04bdd122824628b347ab436e1bf569_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwMjk_b36e126f-a3d2-4ea7-afe6-a3b7372adcd0"
      unitRef="usd">650000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0c52ecff45c14b9dbccf4b05efc03a3b_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwMzM_5a2bffc7-d76e-45ac-b86c-657546817ef2"
      unitRef="usd">586000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i912305c8e84a4cd9a5729ccf10a90c3c_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUwNDA_8026d46c-6df7-42ff-a32c-16e2c088093a"
      unitRef="usd">614000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUxNTA_30cd9ca6-14f8-45fd-9c6b-aab25f25773b"
      unitRef="usdPerShare">160.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib67cc38656e54ec4aadccc96b338ed7a_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUxNTQ_1770638a-eb3b-49b9-accd-79cf7c5950e6"
      unitRef="usdPerShare">124.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iff3ec8dc893a4eb08f4f039c8952b873_D20180101-20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzUxNjE_956c2e98-6227-43eb-995d-357c956ff9bc"
      unitRef="usdPerShare">120.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ifa820bc2bcab44e5b622f4294d4b0308_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4MTY_3384b6e6-3fdb-4fad-9a9d-d36dda855c43"
      unitRef="usd">91000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib67cc38656e54ec4aadccc96b338ed7a_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4MjA_cc6939aa-6887-4e09-b19d-6660ff0be003"
      unitRef="usd">119000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iff3ec8dc893a4eb08f4f039c8952b873_D20180101-20181230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDIvZnJhZzpkNzMwYjBjYmRjYjE0OTI0OTJkYjU1OTc5MzQwYzZmYS90ZXh0cmVnaW9uOmQ3MzBiMGNiZGNiMTQ5MjQ5MmRiNTU5NzkzNDBjNmZhXzU4Mjc_7cec6fb1-1b05-4cbf-8425-6f0f0f69690e"
      unitRef="usd">129000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDQ1MzYwNDgwMzI3_8a494b52-2ac5-485a-9775-a2fa181224a5">Segments of Business* and Geographic Areas&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;20 vs. &#x2019;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;19 vs. &#x2019;18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Previously referred to as Consumer&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Previously referred to as Beauty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; /                                              &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;  REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:48pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;VELCADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diabetes Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Previously referred to as Spine &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (Loss) Before Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,929&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81,581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;General corporate includes cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.5&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.2&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9 billion related to the Alios asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A research and development expense of $0.3 billion for an upfront payment related to argenx &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.6 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Actelion acquisition and integration related costs of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring charge of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $2.0 billion from the divestiture of the ASP business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Auris Health acquisition and integration related costs of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.3 billion from the divestiture of NIZORAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Actelion acquisition and integration related costs of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized loss on securities of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $1.7 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.6 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;AMO acquisition and integration related costs of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.5 billion from the divestiture of the LifeScan business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyNjc_b03c7c3e-2fd2-4535-8156-a35e496c56a1">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;20 vs. &#x2019;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;19 vs. &#x2019;18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Previously referred to as Consumer&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Previously referred to as Beauty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; /                                              &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;  REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:48pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;VELCADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diabetes Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Previously referred to as Spine &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aa9e713b2ec41e4a8d7f2f7015848f6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtMi0xLTEtMA_e13ef4ae-6ee1-4412-ac59-8db641885df8"
      unitRef="usd">2460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fc37409a7004e809321a0b83f5b2e71_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtNC0xLTEtMA_1d50afc3-c2d3-422c-93be-d0bf48c8b285"
      unitRef="usd">2010000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifde892975c2e4c43ae1fcd0e5d45005b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtNi0xLTEtMA_3d034ef1-7bde-4448-96fa-418d106b83ce"
      unitRef="usd">1850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8aa9e713b2ec41e4a8d7f2f7015848f6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtOC0xLTEtMA_13ec5c77-b94c-45f8-80ec-ed5c562045a8"
      unitRef="number">0.224</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2fc37409a7004e809321a0b83f5b2e71_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUtMTAtMS0xLTA_66c0a739-b73f-438b-b0c3-d3a0985741ce"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie098a08a654f4b7abe7993bfd4dd32c9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtMi0xLTEtMA_56e1a33d-7505-4bd0-be3e-7832f3655aa9"
      unitRef="usd">2364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ce7db841b704ce795266988602b87c6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtNC0xLTEtMA_7adf752d-bec7-4438-8e86-eab4ea7cfdd3"
      unitRef="usd">2434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56177ea4bd8e4146934538847bd76f90_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtNi0xLTEtMA_34173ba2-fe39-4ea9-b5fa-9c55d44feee1"
      unitRef="usd">2484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie098a08a654f4b7abe7993bfd4dd32c9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtOC0xLTEtMA_d5da5da6-2756-48f8-ab0a-8920c087944e"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1ce7db841b704ce795266988602b87c6_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYtMTAtMS0xLTA_140790cd-5a18-49d0-98ec-2ded07e2afe6"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieebab203f30b40578e7a8a359fececa9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctMi0xLTEtMA_5c168917-8460-4e62-aa9c-4f284164413e"
      unitRef="usd">4824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95fe395206684a69945b7b9c3f58e7e1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctNC0xLTEtMA_69fd171e-5c4c-4cb6-b9d9-fe5259550186"
      unitRef="usd">4444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7cfb00a6c644b59badb04917cfe1258_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctNi0xLTEtMA_6a67f5a6-6a65-464d-8b6e-37ea3d59ac78"
      unitRef="usd">4334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieebab203f30b40578e7a8a359fececa9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctOC0xLTEtMA_2165e28b-e6d4-449c-8907-5ae0ff0b18ea"
      unitRef="number">0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i95fe395206684a69945b7b9c3f58e7e1_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzctMTAtMS0xLTA_08963788-2d62-4148-9ca6-422835bd2144"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23ae8ca1fdaf4dcc9a7ead012204e832_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktMi0xLTEtMA_c6f80e8d-1d4b-488f-b9d5-7ac32e50438d"
      unitRef="usd">2350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b7516b2a14b4fda940e11d40fdca6e7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktNC0xLTEtMA_6ca6018d-7729-42eb-9628-3ce43188927b"
      unitRef="usd">2392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21511c0be4db4f3891671c0f6c6ffd18_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktNi0xLTEtMA_2f205fb2-74fc-4295-b8f3-8b7d5a67d89e"
      unitRef="usd">2403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i23ae8ca1fdaf4dcc9a7ead012204e832_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktOC0xLTEtMA_d5bad91f-e343-4e1d-b492-d7253fc39d2f"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b7516b2a14b4fda940e11d40fdca6e7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzktMTAtMS0xLTA_e50937b5-1541-4817-81f7-35a0a6e60051"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i335dae4d42e84c4581347d01955f1f64_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTItMS0xLTA_0b889551-b129-43f4-ab57-8d4c8f0a35b2"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0d65234cd7741f08e1b93c317fe4a5b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTQtMS0xLTA_d0eb7c89-6d07-4ebe-a10a-f845cede64a8"
      unitRef="usd">2201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fe8305d0fc64ff09895323053e4ffbe_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTYtMS0xLTA_5984945d-749e-4bf3-9a66-9999f1d6c241"
      unitRef="usd">1979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i335dae4d42e84c4581347d01955f1f64_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTgtMS0xLTA_e8ca6085-31a9-47fb-89d8-d85b74b2a3c1"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie0d65234cd7741f08e1b93c317fe4a5b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwLTEwLTEtMS0w_1a0168f4-d1ff-408f-aee9-a8ba068fd216"
      unitRef="number">0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bb778fa0cfd41c8a12511fe0a1f1029_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTItMS0xLTA_cbd6422a-71e8-48a3-afbb-8ffed5ddae3a"
      unitRef="usd">4450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i012e56c28db14f779936dee4f0663505_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTQtMS0xLTA_7f0eb054-f030-4257-9caf-30c6f7e39603"
      unitRef="usd">4593000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec92ca19a30a48309e6628e2a8f20244_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTYtMS0xLTA_0e277a42-4eb1-4666-aa37-1d56f6a5bfa3"
      unitRef="usd">4382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7bb778fa0cfd41c8a12511fe0a1f1029_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTgtMS0xLTA_b4cc1912-8ee3-4b5c-ae2c-b6d10f702074"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i012e56c28db14f779936dee4f0663505_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExLTEwLTEtMS0w_84e4d9fe-2abe-478a-8b1f-04593aa21f39"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabe650b19559486c93d86c150a95b5ca_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTItMS0xLTA_4153e877-3b98-47db-8eb3-cdfd04ce8434"
      unitRef="usd">683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4646db66c32408f83925e7b65de220c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTQtMS0xLTA_6abe70f8-9cf2-4185-bd08-02173f7675cf"
      unitRef="usd">621000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9072109358d34bb0a33a9db443472e65_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTYtMS0xLTA_93bdac44-037e-4977-afb7-ba192de1c46f"
      unitRef="usd">637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iabe650b19559486c93d86c150a95b5ca_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTgtMS0xLTA_ffa382f5-eaa9-44c3-a1f5-10b84413a568"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia4646db66c32408f83925e7b65de220c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzLTEwLTEtMS0w_92dce8c6-fff8-4281-a24e-6c582088f6ab"
      unitRef="number">-0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29b6c87bbb9946978d28461a1b99eaa0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTItMS0xLTA_f85fd2d7-3e59-49f7-8361-fe835a33569b"
      unitRef="usd">958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a6e6a50ba9c4b93a9bd88ec99d6a9bc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTQtMS0xLTA_ac570288-73e9-43a7-bbe4-d856c801a9cb"
      unitRef="usd">906000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57621c82e86e424b9525ef5322132b41_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTYtMS0xLTA_9c58ce06-f407-431e-a13c-e51689e06efa"
      unitRef="usd">918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29b6c87bbb9946978d28461a1b99eaa0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTgtMS0xLTA_c7f84d1d-aced-4c51-b708-78f25a6ecf21"
      unitRef="number">0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4a6e6a50ba9c4b93a9bd88ec99d6a9bc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0LTEwLTEtMS0w_6df77c02-3223-4657-bd74-63630f0d8150"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5e07924ec664fd1b4eb1488d27b17d4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTItMS0xLTA_34bb837b-9fc8-42f5-808f-8bb2c368dea7"
      unitRef="usd">1641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7eb56f6db9146e38c34652e1c29f3dc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTQtMS0xLTA_1120d27a-5270-44a2-b866-60f79d7d73e2"
      unitRef="usd">1528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic23b6b4d466040ba9303881a85c0d1d2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTYtMS0xLTA_f888d5a7-7027-4fe7-bf74-424f6040e4dc"
      unitRef="usd">1555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic5e07924ec664fd1b4eb1488d27b17d4_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTgtMS0xLTA_a90f4f1d-0080-47c6-8d15-667105e0d956"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic7eb56f6db9146e38c34652e1c29f3dc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1LTEwLTEtMS0w_078b73b4-08d8-48cf-876c-553adaa339ef"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i662e2ae6c2c34af690533b7c98d16d8e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTItMS0xLTA_f0dc65cd-cb07-48c9-b773-fc1932239ff5"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i488340eb739640078006e1dee0f62873_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTQtMS0xLTA_f792a45c-adeb-4426-8576-5352e4553d13"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcea6cb52caa4862915d6b02fc027560_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTYtMS0xLTA_eb322583-4229-4150-9c53-8af2437614da"
      unitRef="usd">422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i662e2ae6c2c34af690533b7c98d16d8e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTgtMS0xLTA_f2b840bb-5e5e-48c6-8a5d-ba2de6f0f479"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i488340eb739640078006e1dee0f62873_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3LTEwLTEtMS0w_2eb40ee7-7bac-404a-967c-45fc459a46eb"
      unitRef="number">-0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied78bd048a694419a8427933eb72392d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTItMS0xLTA_0437c5a1-edde-44c5-9242-41790893854d"
      unitRef="usd">1141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia923300cfa5443f39393219ed3df8cdd_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTQtMS0xLTA_54c80ff7-dc59-4288-9b8b-bb0a83c1d105"
      unitRef="usd">1313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b3ec188dee44471a3d0ba8180228043_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTYtMS0xLTA_49bd1a18-c517-48c2-a50c-f9e590025976"
      unitRef="usd">1436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied78bd048a694419a8427933eb72392d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTgtMS0xLTA_10e3d5fb-13eb-4929-ab63-6d09cba5641b"
      unitRef="number">-0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia923300cfa5443f39393219ed3df8cdd_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4LTEwLTEtMS0w_72cd3f26-8d83-47bc-aacb-2a485c08b442"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9e9fbcfc879430f9d122a98d64707af_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTItMS0xLTA_254582d0-a6de-44f0-a51a-d72b45c9e00f"
      unitRef="usd">1517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51dc84cfa7aa490eb43a1cfcc7ac6f30_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTQtMS0xLTA_079366c4-b918-443d-bd7f-8b1c48e83241"
      unitRef="usd">1675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d533f088e0440e2bc56ad8a637e2e38_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTYtMS0xLTA_bd14f38d-3dd4-4669-9cab-c07bf0aa74ac"
      unitRef="usd">1858000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9e9fbcfc879430f9d122a98d64707af_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTgtMS0xLTA_70377ef5-c88e-49a5-9e1d-053773de5e3c"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51dc84cfa7aa490eb43a1cfcc7ac6f30_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5LTEwLTEtMS0w_8464920e-2e7b-4222-8d39-19d962010243"
      unitRef="number">-0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ffd4f096a224e07ae928cca78b4e4de_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTItMS0xLTA_db9aff3e-2c9c-402c-af82-c3256dd25778"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i197bed260bce4946b5a7231cfb1df3e1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTQtMS0xLTA_5bc649f6-10d8-402f-a814-db66ec8801db"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dcce34e3ebf45f9b3244f8aaa0a8d20_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTYtMS0xLTA_2235ea3b-f54e-45ba-b4c8-cf7a89745c2e"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3ffd4f096a224e07ae928cca78b4e4de_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTgtMS0xLTA_547cbe19-9137-48a3-8f96-c23931446220"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i197bed260bce4946b5a7231cfb1df3e1_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxLTEwLTEtMS0w_7b4c7d9d-b303-4b9e-9aed-3ec9c6c8d79a"
      unitRef="number">-0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdebc3f23b09469baf4a9f0122afae32_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTItMS0xLTA_9bf4f30e-8476-4881-955e-4e28d4db0850"
      unitRef="usd">888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic95fcb4fef954b5e9b3114fc3c6f5020_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTQtMS0xLTA_5e2af42e-1861-486a-9546-7a97569f3b46"
      unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia93c39893598471497b999c626c42a07_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTYtMS0xLTA_07302306-97fe-4ae1-bfbb-62861d2f3332"
      unitRef="usd">1036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifdebc3f23b09469baf4a9f0122afae32_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTgtMS0xLTA_fa243ee1-d919-4b2e-83f4-3a932fa9ad74"
      unitRef="number">-0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic95fcb4fef954b5e9b3114fc3c6f5020_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyLTEwLTEtMS0w_eb5ea235-5182-4090-b72d-a929c03e1604"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib56eebb67df6466bba36905010e95c70_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTItMS0xLTA_0d40f1db-c03b-4258-afe1-14f23fd94ea8"
      unitRef="usd">901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if32de10a72684de19ff4530b736045dc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTQtMS0xLTA_5bfd0332-0f72-4b15-bce6-f117a54311c4"
      unitRef="usd">986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6b58fa445b5470b9212749daa49e050_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTYtMS0xLTA_58dbbf63-b09b-4557-a8c1-73ae60b463f1"
      unitRef="usd">1049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib56eebb67df6466bba36905010e95c70_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTgtMS0xLTA_018b14f5-5658-49dd-a29e-a1e9758b08ae"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if32de10a72684de19ff4530b736045dc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzLTEwLTEtMS0w_0cbcdafc-4608-4b57-8b0d-b8a027adb6e7"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0989699ff14a4823884100556badfa4b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTItMS0xLTA_6f74315a-f241-4032-8369-d095bf020bde"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d0b10d0987c4ff38ea6459bb35a337e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTQtMS0xLTA_33513c4f-e313-4ff6-bb6b-62c00a35b3f3"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i320d43febbce4eddbc6e86db0f7fce60_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTYtMS0xLTA_757f7f9c-b6a4-47d5-8234-caf244722b00"
      unitRef="usd">436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0989699ff14a4823884100556badfa4b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTgtMS0xLTA_7eb49f92-c586-41f5-a230-5ef52ddf1288"
      unitRef="number">0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d0b10d0987c4ff38ea6459bb35a337e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI1LTEwLTEtMS0w_cf177bba-56ec-4ed4-8fca-2afceb68ef0a"
      unitRef="number">0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3fb35c032c54830a66c354d7509fe47_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTItMS0xLTA_647f0b8a-e3a0-4aa2-b65e-020fa6288e8f"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i876f6ed6ca05447f944d86570700a552_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTQtMS0xLTA_b2204319-f118-43bd-9858-06d2c98c0547"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ef4da3b3054496b33a2ca8733dfd24_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTYtMS0xLTA_e789a9e8-77b3-45e5-8d6a-69aa9774ca49"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3fb35c032c54830a66c354d7509fe47_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTgtMS0xLTA_503752e6-d695-4e7a-b4f8-2881cef207e5"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i876f6ed6ca05447f944d86570700a552_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI2LTEwLTEtMS0w_51153a3e-0e47-4cf9-a221-326a7ed60f27"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic988bc0a70d740549dadd5223afb168b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTItMS0xLTA_ed79536f-87c6-4625-accb-b3c54265aaab"
      unitRef="usd">720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64253834ef464806b4d069ddf4d2ae7a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTQtMS0xLTA_bb11ce6e-6df7-4f0b-9f1d-96434a49418d"
      unitRef="usd">671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifead9540ae7f43f58eb9a61955b1d421_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTYtMS0xLTA_4b789d3f-5647-4f27-bd12-c5a5bc37dec4"
      unitRef="usd">675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic988bc0a70d740549dadd5223afb168b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTgtMS0xLTA_b59f2cdd-2a1a-4598-b903-63261fb55168"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64253834ef464806b4d069ddf4d2ae7a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI3LTEwLTEtMS0w_57d320f9-7065-46b7-b26c-86f2328ec8ec"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b2664b750a04838a23a12a422f46697_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTItMS0xLTA_c9d9a4f5-b7a9-4827-ba96-29598405f2d9"
      unitRef="usd">6362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4510201ad6a4fa8ba547b237e08d2f8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTQtMS0xLTA_67b081c9-6f7b-4763-b64f-788750ddbe52"
      unitRef="usd">5839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3809d28608ca4587b38a7d272fdddddc_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTYtMS0xLTA_cca69a4f-09d5-4cbd-a072-11cdd744d9e4"
      unitRef="usd">5761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b2664b750a04838a23a12a422f46697_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTgtMS0xLTA_a7560c94-4d3c-4ca9-824b-7f592b693424"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4510201ad6a4fa8ba547b237e08d2f8_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzI5LTEwLTEtMS0w_f651a41a-d8d4-46cb-9254-de2c34c17405"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e2c0df1a61b4fe2bb9af795b4098c17_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTItMS0xLTA_6a344bf3-1566-4051-98cd-368353835759"
      unitRef="usd">7691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42535da45d984ed0b3ea9894283dbfa7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTQtMS0xLTA_fe91952b-414a-45ee-a651-b25041c42700"
      unitRef="usd">8059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2b952caaff249198b1de2498f27980a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTYtMS0xLTA_7baeab39-bca3-4a6c-ae7b-341bafd66707"
      unitRef="usd">8092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e2c0df1a61b4fe2bb9af795b4098c17_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTgtMS0xLTA_b67f06a3-f218-44c7-a4bc-e3c4d704d5d8"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42535da45d984ed0b3ea9894283dbfa7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMwLTEwLTEtMS0w_758e3322-6132-49bc-aca1-e56cfb47ee1e"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTItMS0xLTA_969c3fd7-c4e1-482b-b35e-6743759d6561"
      unitRef="usd">14053000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTQtMS0xLTA_6f0d4d99-ebf6-4204-aa7b-d7160bede68d"
      unitRef="usd">13898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c315b2e311c4bdc9634124f9332a881_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTYtMS0xLTA_58d36caf-2688-4ba7-82f6-ff028243baba"
      unitRef="usd">13853000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTgtMS0xLTA_3177ad54-5734-4a2f-b4e2-d6dff32f56ec"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzMxLTEwLTEtMS0w_5545f9b3-5dbf-41dc-bdd0-477aee841cec"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia48a1be8bc394fc2b9d27103df366fbc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTItMS0xLTA_ac999e71-9688-4f76-83cd-9f939524c00b"
      unitRef="usd">10175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9db261aaf98a40ec9d2a8dbdfabd4470_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTQtMS0xLTA_3ea0e0f7-c681-4b53-b723-c7113b212f00"
      unitRef="usd">9641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fe1aec193de4494a45e355fad84fd94_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTYtMS0xLTA_41758ed0-5353-497e-8798-e60604871f6b"
      unitRef="usd">9073000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia48a1be8bc394fc2b9d27103df366fbc_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTgtMS0xLTA_d32e0709-3ddb-4440-99cc-0ad88e2e0b60"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9db261aaf98a40ec9d2a8dbdfabd4470_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM1LTEwLTEtMS0w_7112a900-4dbc-4733-a189-65c89d303e01"
      unitRef="number">0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iced43ae2faee49b38a0995fdb81c4dae_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTItMS0xLTA_c50ebcab-66b4-462b-9392-86522f64c718"
      unitRef="usd">4880000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07758926e90e4b6ebb241ff19ec7dcca_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTQtMS0xLTA_f3f2ca48-419a-43c7-af79-231bd83d971a"
      unitRef="usd">4309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b14c2f869194b079873a9e2c3b0cc33_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTYtMS0xLTA_04d5f002-5f1d-488b-8f29-ef5d5642cd32"
      unitRef="usd">4047000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iced43ae2faee49b38a0995fdb81c4dae_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTgtMS0xLTA_7e374f50-9bfd-4e69-b125-bfb6fc524c2b"
      unitRef="number">0.132</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07758926e90e4b6ebb241ff19ec7dcca_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM2LTEwLTEtMS0w_122f3c80-517a-45b2-b5e1-b0f60e0a0edb"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d10d30f5cfa4f7689179597fd83e3ac_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTItMS0xLTA_3f951166-54bf-490a-8106-51694383ddc0"
      unitRef="usd">15055000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i127b9a85fc754e41875443a867bbe47e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTQtMS0xLTA_f85a382b-4ae6-4064-bfa1-887e614f6ae0"
      unitRef="usd">13950000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b648e70887e488790cb76dab030b994_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTYtMS0xLTA_b9ef580a-bd6b-4534-8dda-6df363ee6477"
      unitRef="usd">13120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d10d30f5cfa4f7689179597fd83e3ac_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTgtMS0xLTA_fa4e182d-3619-4c55-8054-5a3742a4e65d"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i127b9a85fc754e41875443a867bbe47e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM3LTEwLTEtMS0w_1978f585-5979-4859-8254-7241b7af4caa"
      unitRef="number">0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51bac2c9dccf4fe79c0fd65dddb23723_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTItMS0xLTA_8d863de5-8489-4d4c-8f1a-84dbb7c83242"
      unitRef="usd">2508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e66708363b54eb9a30dfcadae1d4bd6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTQtMS0xLTA_8ea596fa-a683-4165-b8e0-8ae39accc2ed"
      unitRef="usd">3079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcfd365c13594c388391dd8f606395b5_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTYtMS0xLTA_b4e7b50e-a137-4bcb-a14a-00313ac22c7b"
      unitRef="usd">3664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51bac2c9dccf4fe79c0fd65dddb23723_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTgtMS0xLTA_ed343a62-9823-4f2b-9bcb-ded6d892220f"
      unitRef="number">-0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6e66708363b54eb9a30dfcadae1d4bd6_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzM5LTEwLTEtMS0w_42bf8069-94ef-49a8-acf4-af102f654b95"
      unitRef="number">-0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6da3163227146f5a9725847bbe4a1d1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTItMS0xLTA_71296374-64d5-4179-b7c0-9d477a5a41ee"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcb09a7505de4bd1a2c402a208aac239_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTQtMS0xLTA_3ace73b6-94b4-4b5a-851c-53bf43cdad79"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f44c413e1f9461792dfc16bf4623c21_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTYtMS0xLTA_ffe05e3d-1600-4c76-bf70-0bc11da20789"
      unitRef="usd">436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6da3163227146f5a9725847bbe4a1d1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTgtMS0xLTA_49676890-1bd7-4fde-8449-04a34131c9c2"
      unitRef="number">0.180</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcb09a7505de4bd1a2c402a208aac239_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQwLTEwLTEtMS0w_abcfac3f-0b79-4e6f-ba71-ada6717e6caa"
      unitRef="number">-0.327</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c3251c22f0d45b1b9ae5fc83e739d53_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTItMS0xLTA_8025ff36-ca58-473f-89e5-d856395eba14"
      unitRef="usd">893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ed07a99d5b24e6d8dcde45e5daee9e3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTQtMS0xLTA_158f8dc1-c911-4bc1-9695-511e33fc27e2"
      unitRef="usd">1007000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40f408e57c734f30b9827c8e291b4e68_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTYtMS0xLTA_8c92a626-0bf2-42cc-937a-7cab5535c54c"
      unitRef="usd">1226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4c3251c22f0d45b1b9ae5fc83e739d53_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTgtMS0xLTA_59b8b051-3d32-4703-ab70-a0712a2f9683"
      unitRef="number">-0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ed07a99d5b24e6d8dcde45e5daee9e3_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQxLTEwLTEtMS0w_8cd74cd1-3199-4aac-b8ef-1b158e3883eb"
      unitRef="number">-0.178</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4f89457e4444472bd89ce7240eec506_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTItMS0xLTA_d55b79be-6b49-464c-9e74-177c8a5ab15c"
      unitRef="usd">3747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d7c7407d5d84d95a2baef6467281a84_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTQtMS0xLTA_bede36ba-ea8f-4a07-a3dd-c284e587f3d0"
      unitRef="usd">4380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9049be4d27b48c5aff8d7cd9e980032_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTYtMS0xLTA_d4619584-2baf-4c72-88d0-fc3af9c38593"
      unitRef="usd">5326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if4f89457e4444472bd89ce7240eec506_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTgtMS0xLTA_6e0819d6-b559-4ed6-af81-0caec35ea4a6"
      unitRef="number">-0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5d7c7407d5d84d95a2baef6467281a84_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQyLTEwLTEtMS0w_d74f12aa-ea43-4163-9496-21625e4033f1"
      unitRef="number">-0.178</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc10c7bf0c354fa5b52dd6cef5049396_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTItMS0xLTA_58c6c3bb-595f-4f39-9716-6d50e1e80f29"
      unitRef="usd">1155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81fe65e2feac4ae6b2120d1875a0c1e5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTQtMS0xLTA_a44a92ae-0c26-49fc-b6fa-e1ef40dce49f"
      unitRef="usd">1159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia09afe5f0a47482c83a41681a20ed1b9_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTYtMS0xLTA_3b3b9104-8c38-4693-8a3c-944d55667df0"
      unitRef="usd">1051000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifc10c7bf0c354fa5b52dd6cef5049396_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTgtMS0xLTA_64a917e8-65b1-4d86-9b23-b94ee4e64e93"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i81fe65e2feac4ae6b2120d1875a0c1e5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ0LTEwLTEtMS0w_4a75db21-7000-4709-9ff7-f07ce5b4a305"
      unitRef="number">0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i345326e0d32b44a6962d5d2da892271d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTItMS0xLTA_a54a8084-b9e7-4052-a684-c5358f05b351"
      unitRef="usd">1088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ab9d0b991fd48e991a9b96176c324f5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTQtMS0xLTA_a3ab95fb-32f1-40f2-b9b7-cf856d3b0ad4"
      unitRef="usd">1029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66d52b0dee934b1dad3311f32a844f83_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTYtMS0xLTA_8c332715-5bc7-4dbd-ae1f-03b1bd2ba470"
      unitRef="usd">1033000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i345326e0d32b44a6962d5d2da892271d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTgtMS0xLTA_9c71cac0-cbec-4ec3-9e6b-584621403615"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9ab9d0b991fd48e991a9b96176c324f5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ1LTEwLTEtMS0w_53b8718e-9ab3-49fa-8409-e2d55ada17ab"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b5fff7db08d4f9abfb174cf4e10a6cb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTItMS0xLTA_af7b885e-3ca4-4cae-a6c3-f4b56e781cac"
      unitRef="usd">2243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95e5ec630f144fc3acae22bf27085f20_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTQtMS0xLTA_01a03879-15e7-4901-8e6c-cdce45016ccb"
      unitRef="usd">2188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa6da60607b34facb3254a559f43916c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTYtMS0xLTA_e5739885-0951-4f7e-b3ca-75e274ffc66b"
      unitRef="usd">2084000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9b5fff7db08d4f9abfb174cf4e10a6cb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTgtMS0xLTA_582a7e38-2139-4a04-bc29-cd031b026c2e"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i95e5ec630f144fc3acae22bf27085f20_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ2LTEwLTEtMS0w_3c4ae076-a0c7-43ad-a28a-9a6cac0b26d6"
      unitRef="number">0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cd5a91ab72b4e1d9097ac42c6567a0f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTItMS0xLTA_4a6c3c4b-b9c0-41a5-aff5-a37b394e893c"
      unitRef="usd">5240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic445948a0ea54f98984b624b677ef57e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTQtMS0xLTA_0e8bc49d-f09d-4c2e-ad55-5890a33ca457"
      unitRef="usd">4346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf7ef583b64341d883f7c307897087cb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTYtMS0xLTA_398bbf82-ecb1-44de-b314-1a4296dd51bf"
      unitRef="usd">3469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cd5a91ab72b4e1d9097ac42c6567a0f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTgtMS0xLTA_84717541-5a95-40ad-87f9-cd2935024ca0"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic445948a0ea54f98984b624b677ef57e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ4LTEwLTEtMS0w_4e5bd9ab-8698-4b01-b906-8931566cf25d"
      unitRef="number">0.253</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i936effeb3bdc459188220839b3a07583_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTItMS0xLTA_8b17b4a9-d232-4c6e-8be7-6c5773bd7879"
      unitRef="usd">2467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib164d78d863f45e2ae7113fb61a9029e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTQtMS0xLTA_d83636fe-d225-4ca7-906c-cf5edc9a29d1"
      unitRef="usd">2015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i747d55ed9e11415197a12256dc54b0fb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTYtMS0xLTA_dd1e4a2d-ac4c-4d55-b4e7-3b8db2a15695"
      unitRef="usd">1687000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i936effeb3bdc459188220839b3a07583_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTgtMS0xLTA_fd6d7b98-0edd-4087-9624-ebea351ccae0"
      unitRef="number">0.224</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib164d78d863f45e2ae7113fb61a9029e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzQ5LTEwLTEtMS0w_5b0a4586-0525-4eb8-ad5c-6b8d170310b7"
      unitRef="number">0.194</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6062ff1a7594fa99d8bd54ce25f0d81_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTItMS0xLTA_91b055db-7672-481c-8ec7-5dd794af57cf"
      unitRef="usd">7707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aba33fa79c1416ea6970ea33209f4f8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTQtMS0xLTA_5b5a5535-0d44-4df6-a9c9-6f09ab752441"
      unitRef="usd">6361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c1621cb45fd410eb6148886adccb29b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTYtMS0xLTA_fbfa7bfe-9598-484c-9204-988f4fd44931"
      unitRef="usd">5156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if6062ff1a7594fa99d8bd54ce25f0d81_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTgtMS0xLTA_2de46c85-8115-49ce-bb69-8518d53e9944"
      unitRef="number">0.211</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3aba33fa79c1416ea6970ea33209f4f8_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUwLTEwLTEtMS0w_90ff9d13-06e2-4ffe-a975-b9727649e36d"
      unitRef="number">0.234</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc79dde7b9524c7f9528487acaeaba31_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTItMS0xLTA_2c47deb7-9acb-47b7-888e-feac5fd8b0cf"
      unitRef="usd">926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5504fd9e30f44cb48669bb12f3abdcad_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTQtMS0xLTA_de09878c-53bd-4765-a57f-34e779765e49"
      unitRef="usd">764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib28cf791d4a541b0a7be48bee043f2c4_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTYtMS0xLTA_34601347-64da-4c23-bac9-873ed3b2788a"
      unitRef="usd">453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icc79dde7b9524c7f9528487acaeaba31_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTgtMS0xLTA_1c5ddf3b-0ff8-427c-a474-f10a0b1484a7"
      unitRef="number">0.213</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5504fd9e30f44cb48669bb12f3abdcad_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUyLTEwLTEtMS0w_bc9774d5-304b-451f-8b15-cafae3dd3353"
      unitRef="number">0.685</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3139e2031ad04133bd86df70cf5dc7b7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTItMS0xLTA_be30fa27-adc6-45d6-9b2f-9e1f7a979f5f"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i470e0543cb694cf698d82d768b3a393e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTQtMS0xLTA_5c0e40e9-d501-4314-8107-10e820ce59f3"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i502d99b70ee24908ab08e5b1a1fdc9bd_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTYtMS0xLTA_78f088fb-dcbe-4b6d-b3ee-aa557b94c1c9"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3139e2031ad04133bd86df70cf5dc7b7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzUzLTgtMS0xLTA_e2db7c43-c2ac-4656-9fa2-464b9939325d"
      unitRef="number">0.699</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29c30844e0e04bf3aa64c9175c1c7fd1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTItMS0xLTA_8630aeed-e26e-4d9b-839e-8983dc0bfbb7"
      unitRef="usd">1347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79af5256cde94f5aae78e06c7053dbeb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTQtMS0xLTA_aaee8f38-7cb9-47ad-a654-afde9a4f49cf"
      unitRef="usd">1012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9482dc808d3497f92fd904dae9e95e3_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTYtMS0xLTA_cd2e0392-3676-497b-a093-573e838e024a"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29c30844e0e04bf3aa64c9175c1c7fd1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTgtMS0xLTA_084ff3b7-51ac-4f7b-b2f7-84c1d0672c7f"
      unitRef="number">0.332</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i79af5256cde94f5aae78e06c7053dbeb_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU0LTEwLTEtMS0w_0481fb56-3b78-4533-9527-136e8fc9f1a3"
      unitRef="number">0.859</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54eccf3ae4f74a0f8fc42744cab78245_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTItMS0xLTA_a5d7e526-cbca-4999-afc4-ce87127230db"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50d2b9d9ef2047b0803fd7f801a13e03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTQtMS0xLTA_b48e1337-9b77-4f75-9515-ca5070ffb1b5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3a43e0744bb4641978b43faa639422b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTYtMS0xLTA_7ef25ea7-223d-42c6-b292-440d2fc6c2e3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i54eccf3ae4f74a0f8fc42744cab78245_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTgtMS0xLTA_f57de296-70ba-4838-a169-5274d8e924f4"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i50d2b9d9ef2047b0803fd7f801a13e03_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU2LTEwLTEtMS0w_bb38fa37-5551-4f2e-b398-eb4502f62e31"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1493568c9a874d0bbfd3ede747e68727_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTItMS0xLTA_a0dfb201-bc33-4840-b8ab-95a3fd31acc4"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bd29791072a4593acd00300786ece30_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTQtMS0xLTA_71a916fa-f003-4c84-979e-3a0cddacbf9f"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6670255be7144d1f852e46cf45edb2ba_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTYtMS0xLTA_ca1933c3-66d9-4d29-aaf3-cccbb936170b"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1493568c9a874d0bbfd3ede747e68727_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTgtMS0xLTA_1c89dbdf-1726-4d76-bfdf-53e95e5c6982"
      unitRef="number">0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9bd29791072a4593acd00300786ece30_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU3LTEwLTEtMS0w_59299446-03ad-4fea-8102-c98fe1452bf2"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i619ec00350b745b6b707b0e00977199e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTItMS0xLTA_2d0bdc58-5d13-4289-bca7-9ca9ee51346f"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib47f23d17ed74b6f9a95492b23352e5a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTQtMS0xLTA_8ec2223d-56d3-4874-952a-21f133b456ef"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05672cc4fbf64dc388663c69c856b524_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTYtMS0xLTA_6cc6460b-fa88-407c-a190-3fcf5f2e096d"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i619ec00350b745b6b707b0e00977199e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTgtMS0xLTA_6d377103-a906-4ad0-bed3-452c5b4a9c89"
      unitRef="number">0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib47f23d17ed74b6f9a95492b23352e5a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzU4LTEwLTEtMS0w_61600f60-e041-4cd5-a612-0c31cd59168d"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia91f997ab1f24f23bfd12aaf2ab15614_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTItMS0xLTA_9b518ee3-a241-4f51-952a-b76c14166ed8"
      unitRef="usd">1735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81f840440eb34b388c74e913d8269476_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTQtMS0xLTA_f8c5a9e1-fc46-4ea0-9753-2aec046757a4"
      unitRef="usd">1597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92a18540e4d94bd3921e7a8dd91fca8b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTYtMS0xLTA_71c6b0a4-ff17-4938-8fef-3b2008c1821c"
      unitRef="usd">1378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia91f997ab1f24f23bfd12aaf2ab15614_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTgtMS0xLTA_f8ac8346-9497-4f4f-8bda-7f55de1d4433"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i81f840440eb34b388c74e913d8269476_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYxLTEwLTEtMS0w_ece30e48-2ee9-46ab-8687-6bd36bafca28"
      unitRef="number">0.159</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac494f4524344162be998345479e44c2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTItMS0xLTA_4df8251f-b4fc-4f2f-88b5-280d123b9b6a"
      unitRef="usd">1839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2133c409ef74fbcaaabe46d16259131_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTQtMS0xLTA_76e3f174-446b-40b8-8fb1-9b0a97364fff"
      unitRef="usd">1815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86abae86ef304b71abd0e05f56a5cb4f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTYtMS0xLTA_608b4b43-616a-4ae4-907a-aa574f21a018"
      unitRef="usd">1926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iac494f4524344162be998345479e44c2_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTgtMS0xLTA_691e2713-d433-468c-bded-2acc54c0b4af"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib2133c409ef74fbcaaabe46d16259131_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYyLTEwLTEtMS0w_19a01691-1b8c-45ea-9b24-c350a3fcf1bd"
      unitRef="number">-0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTItMS0xLTA_be04b9d7-2ce9-4963-bcbe-3478837c80bb"
      unitRef="usd">3574000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43234804dddb4e39b7ddee85e821a967_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTQtMS0xLTA_909da36a-57e1-4459-85f8-f5d58b3ac757"
      unitRef="usd">3413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i792f702c2cc44d72a6685098df435cdf_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTYtMS0xLTA_9323bc66-b81e-4068-b7d2-4f9395d150b0"
      unitRef="usd">3304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTgtMS0xLTA_40c9086c-9e8f-49df-96b7-be0043501727"
      unitRef="number">0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i43234804dddb4e39b7ddee85e821a967_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzYzLTEwLTEtMS0w_1dfbd4b8-c041-4139-8cad-203b5798c6b2"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief8e69a00b4a46d4b0026d4c0d0d12de_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTItMS0xLTA_361d9162-bbda-41cb-a9e6-908f9e5ec01d"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ea4daf92846476fa2993fbc2006ccc7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTQtMS0xLTA_4d4b0dfd-66ea-49a3-aae3-0e458c9234c4"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie61c6e895ab34051980667f5cc645e57_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTYtMS0xLTA_35de307c-d4ba-413a-ba40-90d4aabcaf0c"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ief8e69a00b4a46d4b0026d4c0d0d12de_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTgtMS0xLTA_e45b573e-8cd8-470a-a9ff-b7f5d655c017"
      unitRef="number">-0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ea4daf92846476fa2993fbc2006ccc7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY1LTEwLTEtMS0w_7696c53c-bd6d-4392-838a-1239441a4924"
      unitRef="number">-0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00c7d4e5567e41369256434e8aab708e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTItMS0xLTA_6ed53a71-6af5-4655-a3fa-e9e7152dd806"
      unitRef="usd">920000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d2acee81d0547e1ab6097e1c5779efd_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTQtMS0xLTA_ff39955a-7e85-44d9-8cb2-426fb852e6ba"
      unitRef="usd">812000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89005b4edd5a4426abae3cd99c1ad3a9_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTYtMS0xLTA_1c94002d-5469-41c7-aac3-75d1d251a783"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00c7d4e5567e41369256434e8aab708e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTgtMS0xLTA_e3c5c0bd-1b70-4f89-bbba-6f74fe672ed0"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8d2acee81d0547e1ab6097e1c5779efd_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY2LTEwLTEtMS0w_26ca5658-da27-4ce4-903f-78c34aaf7293"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i053973bac1e74eac9056a73ee8e0369c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTItMS0xLTA_0c34de84-9274-4694-9d61-d09b916f4abf"
      unitRef="usd">964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a61d75aede14dbca7feee7ab7b14409_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTQtMS0xLTA_76acd952-2a54-4246-81d0-8d04bc396e96"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f6b727d130644bdaf9d3ee590ee2f85_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTYtMS0xLTA_7a0e25bf-fc7d-4c0c-a608-d433ac4e137c"
      unitRef="usd">816000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i053973bac1e74eac9056a73ee8e0369c_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTgtMS0xLTA_12f0fa5d-90a0-491d-8c7e-6b97a008f8dd"
      unitRef="number">0.119</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a61d75aede14dbca7feee7ab7b14409_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY3LTEwLTEtMS0w_67a40c57-b987-4293-937b-653b8373fc67"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34651815cdaa41f5b30e1ebcb72f67bb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTItMS0xLTA_4f5ce016-e911-43f9-be03-5211c521afb4"
      unitRef="usd">1587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1714fea951a94bd59565d02ea54e3b38_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTQtMS0xLTA_ce7ba341-2f04-4d4c-84c1-e204951e5dfb"
      unitRef="usd">1422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06a27ed8f9954257a933b0c854a14620_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTYtMS0xLTA_98de5d8d-34bd-48af-ba7c-adaf9ce1fc01"
      unitRef="usd">1169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i34651815cdaa41f5b30e1ebcb72f67bb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTgtMS0xLTA_0a9cf678-0395-437a-8dcb-8a43107bcb80"
      unitRef="number">0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1714fea951a94bd59565d02ea54e3b38_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzY5LTEwLTEtMS0w_87a3e6dc-097b-4179-92af-8081569a00ad"
      unitRef="number">0.216</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac15d6fdeece4cdfbacf8aacc9f73307_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTItMS0xLTA_633b9381-2de1-4d3a-8dae-cba2befe93ca"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cdb3211b66440c2ba0dbb80ae7f58f1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTQtMS0xLTA_87220a1a-ef92-4f5e-b4d3-ccf1f53ab9cb"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23709666fd9b4b9ea264d620b5bd8e15_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTYtMS0xLTA_7202eda8-ca9d-425c-851e-0df7d31611e2"
      unitRef="usd">786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iac15d6fdeece4cdfbacf8aacc9f73307_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTgtMS0xLTA_a6a275cc-87a0-4aca-8a6d-5da4d4d7162e"
      unitRef="number">-0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4cdb3211b66440c2ba0dbb80ae7f58f1_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcwLTEwLTEtMS0w_0e61cdac-e079-4a1c-b9f7-b0375b62d42e"
      unitRef="number">-0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32432ddae9e74ae1b271e486737b86ad_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTItMS0xLTA_3eb1ed1b-8172-44f6-b383-1f98eef44d9c"
      unitRef="usd">2184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29524c4a77594647acc6c76fcbbccde1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTQtMS0xLTA_c053aca9-ef80-459c-b2a6-0eb98d106400"
      unitRef="usd">2110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54edbd81015f4d71a9b2afba7cffb29d_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTYtMS0xLTA_451a9684-596e-4fa4-8281-f9882c9ee099"
      unitRef="usd">1955000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i32432ddae9e74ae1b271e486737b86ad_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTgtMS0xLTA_ddd61dbf-c911-472c-b3a8-092827176024"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29524c4a77594647acc6c76fcbbccde1_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzcxLTEwLTEtMS0w_8e8b0d24-d11b-407a-a4f9-8aa7efe0903e"
      unitRef="number">0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26701d71b41f4a00aa3ced442e39d1c3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTItMS0xLTA_84dfcb46-93bc-44b5-b606-a29595528402"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i303f017761124c748caf83e92d8e5137_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTQtMS0xLTA_fd7a7fa5-bbb0-4dc4-96f7-ce66c2ddccb2"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4839bf6f46b740e2a03b47f4d2738e9c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTYtMS0xLTA_0da44197-21ef-4e97-bb7b-ba38477cf286"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26701d71b41f4a00aa3ced442e39d1c3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTgtMS0xLTA_1345a792-007f-49a4-bbd6-5197192f43b7"
      unitRef="number">-0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i303f017761124c748caf83e92d8e5137_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzczLTEwLTEtMS0w_f4c6c115-ab14-43d7-945d-3a2c2c1d988a"
      unitRef="number">-0.165</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d32e636144642afa7ef1549b0cf2c03_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTItMS0xLTA_b9a8e6e8-80d3-4a17-9df5-5a41e0f2aaf2"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i238de9e4da3a4b15afbad05973803e62_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTQtMS0xLTA_8797a470-887e-4f70-ae97-8b6418bfdad6"
      unitRef="usd">315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8cfd3aae4874e2e8686d594c717025a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTYtMS0xLTA_a05be174-cf81-4118-97c4-216f7b913f2f"
      unitRef="usd">382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1d32e636144642afa7ef1549b0cf2c03_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTgtMS0xLTA_b72b22a0-4942-4f11-9956-20765cc61ef0"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i238de9e4da3a4b15afbad05973803e62_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc0LTEwLTEtMS0w_834ce300-9a02-4079-a755-e29026a5384e"
      unitRef="number">-0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddad0db124bf452ea8a03f1654bb68d0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTItMS0xLTA_33004a31-1800-4518-87a6-dcba5bf26656"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52a3c9526e9e4662b7dccc6799311ad5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTQtMS0xLTA_3b3cddef-6417-4889-aa02-6743423a9732"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfb90c3f230e4c8cb8dfa5a94e4ea0bb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTYtMS0xLTA_6e41fc5e-4236-4948-abcb-4e18bca1c469"
      unitRef="usd">533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iddad0db124bf452ea8a03f1654bb68d0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTgtMS0xLTA_e915695a-a295-475a-8d71-2109aa3c5bd3"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i52a3c9526e9e4662b7dccc6799311ad5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc1LTEwLTEtMS0w_790b0baf-f47f-4376-9857-a5daf7ed6af8"
      unitRef="number">-0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9403e2d2a34f59a27b604645f5a91d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTItMS0xLTA_2d6be3f2-5f06-4001-9a3e-c7c987544ca2"
      unitRef="usd">3091000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f3be6ab9e8a4959a3c7edc4d122dd2a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTQtMS0xLTA_24a6f9c5-2db9-4814-aa91-a7d3e43a60cd"
      unitRef="usd">2919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8d9238b55644986a871929c8502d84b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTYtMS0xLTA_8bfaa4ab-ed12-4fbb-bd2f-8fc4514d03f1"
      unitRef="usd">2574000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5e9403e2d2a34f59a27b604645f5a91d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTgtMS0xLTA_8dfa9ab5-3c69-4e18-abd7-a95129219b1e"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f3be6ab9e8a4959a3c7edc4d122dd2a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc4LTEwLTEtMS0w_730fe598-3cc5-438a-9fdc-175e9fa55736"
      unitRef="number">0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia08fa1ac964d47feb93b93f96ba831b1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTItMS0xLTA_c6c09175-654e-48ed-a5de-3e2ff21a1f93"
      unitRef="usd">3457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29d5fd3838e84f57b29637bc91f05499_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTQtMS0xLTA_d5f057d0-2a8c-4fdd-a8cf-e7484aca50d1"
      unitRef="usd">3409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a23ffdae8ac4614968f16731be20d0f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTYtMS0xLTA_55cb11fc-16cf-4f3c-8fc0-de8fb9bc7d2c"
      unitRef="usd">3503000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia08fa1ac964d47feb93b93f96ba831b1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTgtMS0xLTA_72a47080-1aab-4167-b5aa-8b4a278076c2"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29d5fd3838e84f57b29637bc91f05499_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzc5LTEwLTEtMS0w_387a0b08-bda0-4933-90a5-fefd73175c03"
      unitRef="number">-0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2d55cd1871b4849bb0d4d5789fc18e6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTItMS0xLTA_16176590-e4f0-41a4-9dbd-2f622702d32b"
      unitRef="usd">6548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie88eb0578dc746d18d2bb2f4b766788b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTQtMS0xLTA_8752f83a-4953-4165-b174-aa99d3f73708"
      unitRef="usd">6328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0226112bc194a59900da0f717036e7a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTYtMS0xLTA_9e6a067e-83dc-4d3f-aea0-6bb803b19d7e"
      unitRef="usd">6077000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic2d55cd1871b4849bb0d4d5789fc18e6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTgtMS0xLTA_4fd807d7-c7a5-438f-b47a-d037cb984724"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie88eb0578dc746d18d2bb2f4b766788b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgwLTEwLTEtMS0w_7fef854d-6e8a-45ab-9b72-cf4c46a085a1"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id16e7d880f794b4aa0ad45508b813488_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTItMS0xLTA_8e39f8cf-311a-42d8-a872-81d3bf2e4e0c"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9ba901333db44aaa2a276635feab345_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTQtMS0xLTA_aa105f4c-6fa9-4e56-8764-206b5f5b085c"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ee2c3fb12d0480198cb47af51655b5b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTYtMS0xLTA_92961d0b-981a-4b7e-977e-800c6e107839"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id16e7d880f794b4aa0ad45508b813488_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTgtMS0xLTA_5083650f-a68b-47bc-8d9f-d1f8654f036e"
      unitRef="number">-0.214</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9ba901333db44aaa2a276635feab345_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgyLTEwLTEtMS0w_e8d614e3-2a25-4cb7-a320-f6806c755793"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4abe4268a675407693e053bf7336a72b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTItMS0xLTA_8cad7345-62dc-46f5-bb20-f9a7b9dc7e18"
      unitRef="usd">439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb60330c47204e6486cc5262ed47484a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTQtMS0xLTA_d410dd3d-46ad-4782-8c58-c39c45f4e1af"
      unitRef="usd">463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d84ff4a4b754e97a7cb601b7d5a4e6f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTYtMS0xLTA_fde6d499-7844-44a2-92a4-dd243c8f336a"
      unitRef="usd">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4abe4268a675407693e053bf7336a72b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTgtMS0xLTA_87954841-622d-4429-acaf-c5425f7cf419"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifb60330c47204e6486cc5262ed47484a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzgzLTEwLTEtMS0w_fd146b31-a539-43a6-9133-3c787b8d432c"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd8d74955bb460f8122175f5d6f0469_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTItMS0xLTA_751aa6f1-64db-4b63-ac5e-22bb4d96c67a"
      unitRef="usd">622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3213efec3984b9a8c8df8f59eb63243_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTQtMS0xLTA_0a8c8f23-ec5f-4c11-8916-91f7eb512193"
      unitRef="usd">696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92945871d6174c00bc9287c3ee66e791_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTYtMS0xLTA_6f4b4eea-6d72-46b0-8ed8-1c9e9a037e07"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcd8d74955bb460f8122175f5d6f0469_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTgtMS0xLTA_e9508685-b703-45cf-8927-4e369acb8f91"
      unitRef="number">-0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib3213efec3984b9a8c8df8f59eb63243_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg0LTEwLTEtMS0w_8901b157-3bbd-466a-9b06-cae3a5382ad3"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11cb446a20b54dcfba5a0fc4233773e0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTItMS0xLTA_67c4d70f-6fe4-4fb6-bf74-54ffbd3ec176"
      unitRef="usd">2314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40dfc72b0ea04eeb97d07f73f58eecfd_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTQtMS0xLTA_f557fc43-55cd-42e5-94a6-02d64f131798"
      unitRef="usd">2107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7377bec258e8441f845958db2721e43c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTYtMS0xLTA_e701dc98-4378-4f98-925a-6d1336a199d9"
      unitRef="usd">1791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11cb446a20b54dcfba5a0fc4233773e0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTgtMS0xLTA_2e0414bd-8afa-44c9-9eb6-d4f4ce912fce"
      unitRef="number">0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i40dfc72b0ea04eeb97d07f73f58eecfd_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg2LTEwLTEtMS0w_29e6dbc2-473d-4a79-b11d-b1163193f8e0"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd129f2ac9974218ab05c39a71c03771_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTItMS0xLTA_2b70c1dd-e337-4562-80df-278ca50adf59"
      unitRef="usd">1339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0e6af2ed39540228df21c0af815adb7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTQtMS0xLTA_c035ff0c-3bbc-4126-8908-ecea657078b3"
      unitRef="usd">1224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfa6602c894b48bd8d6bcf1d385cdcc3_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTYtMS0xLTA_a289e1a5-31d9-44e8-8616-25bc10e11072"
      unitRef="usd">1137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd129f2ac9974218ab05c39a71c03771_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTgtMS0xLTA_1c37f4ec-cbcc-4864-a05b-202563cc5db4"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if0e6af2ed39540228df21c0af815adb7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg3LTEwLTEtMS0w_388d1962-0030-48bc-8c39-073c0ae65798"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a95f7ec983548d2a4b1be09dfe6dd14_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTItMS0xLTA_af0bcfa5-eaf5-4884-9cbc-c6e4d5c804b5"
      unitRef="usd">3653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1505070ebd0a4498bb3eeb1d51183e8e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTQtMS0xLTA_c19d8362-4f1a-4306-b1a0-de6a3eddbfeb"
      unitRef="usd">3330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0f887aa0bba464abdb150467246ac4f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTYtMS0xLTA_9a529b3f-0701-4eb1-b821-70de936fa4d1"
      unitRef="usd">2928000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3a95f7ec983548d2a4b1be09dfe6dd14_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTgtMS0xLTA_06cb2a43-4368-4ec9-83a9-48ef8160fa53"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1505070ebd0a4498bb3eeb1d51183e8e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzg4LTEwLTEtMS0w_288cf262-51c0-40fe-bd86-695d108403b6"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a84d7d93ab64403bd293f1a7184f6bc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTItMS0xLTA_5ad89f69-74ee-4567-93e2-21c36930be78"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90a0ba12fbda4d738d5db9238ec568dc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTQtMS0xLTA_4e116fd5-49d4-4bf3-8477-02947283eb87"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic414aca1c42548929deb4e53de7bf3fa_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTYtMS0xLTA_f4bdd573-7395-4184-9bf0-c976fa749951"
      unitRef="usd">315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3a84d7d93ab64403bd293f1a7184f6bc_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTgtMS0xLTA_41770572-f6d0-401c-bbba-1132f18ef449"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i90a0ba12fbda4d738d5db9238ec568dc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkwLTEwLTEtMS0w_526291b3-3c1e-477c-a853-92d9028cc589"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f98810d8ec641999cf2687e6554daf7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTItMS0xLTA_25a8d947-9daf-45a9-b632-4e061af1989a"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafc700d3856a47738103c578a87aca74_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTQtMS0xLTA_a7e7b31b-aada-4677-94cb-35aa10846039"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72eb6604597248ad85fbd375da229add_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTYtMS0xLTA_510a6b9e-38aa-4116-af3b-d287faa2edb0"
      unitRef="usd">422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7f98810d8ec641999cf2687e6554daf7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTgtMS0xLTA_b64a9da9-7ca8-4ce0-8521-4c934273aa1f"
      unitRef="number">-0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iafc700d3856a47738103c578a87aca74_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkxLTEwLTEtMS0w_a840d233-67e2-4c87-818c-1ce1a000e376"
      unitRef="number">-0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf8cbbdb69ff4501b7d58fe605645a1e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTItMS0xLTA_a7486b04-1deb-4e98-be8e-39b5d61185f4"
      unitRef="usd">642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i133aa20f96a643e3b9e5df71d2e8af4a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTQtMS0xLTA_c8fbdabf-ac1c-40f4-90ac-689f9da356f4"
      unitRef="usd">688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if209e8c87c5644aa8818bd0b6c6673ef_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTYtMS0xLTA_1e1e4e0e-547d-4427-9898-b0e1f7153ea6"
      unitRef="usd">737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf8cbbdb69ff4501b7d58fe605645a1e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTgtMS0xLTA_69aac6f3-6bf6-486b-a39c-9b6ada77954a"
      unitRef="number">-0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i133aa20f96a643e3b9e5df71d2e8af4a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzkyLTEwLTEtMS0w_7ced2229-6cad-4fa9-b9e8-8e0a6712be9d"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e40cab631864801a237de46454322e6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTItMS0xLTA_ab777257-d3a0-42bc-a71b-1494f0c5ab41"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8464c5bb4509404b8a2d4bbd9ed47d3f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTQtMS0xLTA_1da39e26-2afb-4325-b322-3a1b8421c666"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06797700580c400c90f77631adc320b5_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTYtMS0xLTA_d61be547-f116-4dc5-a7b5-19984218f6f6"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e40cab631864801a237de46454322e6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTgtMS0xLTA_695e2961-d59d-426c-907e-06baeea11155"
      unitRef="number">0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8464c5bb4509404b8a2d4bbd9ed47d3f_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk0LTEwLTEtMS0w_e6740329-69d7-4048-9ed7-ce6086121416"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32a9d490e235496da2b346ee89bee21c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTItMS0xLTA_299ba37e-d7ca-46e4-8e82-d58bb8fbb270"
      unitRef="usd">1334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0abddda703554fc8b7f0eeca2b43a200_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTQtMS0xLTA_59d6f612-73c1-4f03-a1d9-e160758b3d63"
      unitRef="usd">1349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbc276f6c9ac42e59b93c2d91c1fcde5_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTYtMS0xLTA_5c7dec90-9b4b-459a-b6e2-3d6ae5fbae19"
      unitRef="usd">1510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i32a9d490e235496da2b346ee89bee21c_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTgtMS0xLTA_ac7c459d-0e05-4a6d-bfba-b25367d50a9d"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0abddda703554fc8b7f0eeca2b43a200_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk1LTEwLTEtMS0w_ee1dfdf0-34fe-49f9-a372-3c5bdcd2c2c4"
      unitRef="number">-0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eba5e2c532643d08b0d85206ddd448e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTItMS0xLTA_c74aef5c-f93b-4824-8f6c-1306ce5f66d8"
      unitRef="usd">1632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61f37e7a407b4bb69c2edc826b1ad2a2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTQtMS0xLTA_d59fe180-23af-4caa-8d10-51d60c91e07c"
      unitRef="usd">1614000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f07175381b54765913104497ed4a90c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTYtMS0xLTA_f7a34b8f-562d-4bc8-b8c0-69b60f89ba5d"
      unitRef="usd">1749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0eba5e2c532643d08b0d85206ddd448e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTgtMS0xLTA_0bbf3883-964b-40bd-bfcb-5a3944f2b755"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i61f37e7a407b4bb69c2edc826b1ad2a2_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk2LTEwLTEtMS0w_a45c3f3f-5d2e-4d57-9b59-c31fe8bf57eb"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc4b8397c4a4a5cbfc5afa71d671450_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTItMS0xLTA_f772c969-1319-4e12-969f-b8cdc9898b92"
      unitRef="usd">5092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60171dccd6404eaea5b723a79f5333f9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTQtMS0xLTA_8d86a8cb-2cca-4469-8ef5-e41440fa13ae"
      unitRef="usd">4299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20b03ca0cca94b2cb6387dde26985c9b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTYtMS0xLTA_52f681c5-bd69-4df3-ae7a-71a50c892caa"
      unitRef="usd">4331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcc4b8397c4a4a5cbfc5afa71d671450_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTgtMS0xLTA_37e500c1-3018-4c17-be95-61810e8732d0"
      unitRef="number">0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i60171dccd6404eaea5b723a79f5333f9_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzk5LTEwLTEtMS0w_dcd7b79c-ce24-474d-8b04-430cf82c67a7"
      unitRef="number">-0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i620149fef35a4c07ac902b4826767002_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC0yLTEtMS0w_3a136d90-582b-41b3-88f0-e86ce379223e"
      unitRef="usd">7275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f669e13dedf4bf9a965e8c1a83400fe_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC00LTEtMS0w_364482bc-3f49-4d6e-b3d0-2905315e2ac9"
      unitRef="usd">6393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0849b4ea29674dd19f07a50c794a4b02_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC02LTEtMS0w_ca8b9d22-ca67-4fda-8d6b-a2db34b14786"
      unitRef="usd">5513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i620149fef35a4c07ac902b4826767002_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC04LTEtMS0w_6b548ff6-8011-4fa5-9f64-500727bfba99"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5f669e13dedf4bf9a965e8c1a83400fe_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMC0xMC0xLTEtMA_bfa5c4b6-61a6-430c-9d47-7b51dc59ee53"
      unitRef="number">0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb490cfe0bd149a286b03d9b16aaaced_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS0yLTEtMS0w_01903c32-acd6-44bc-97d3-cadfff851fc1"
      unitRef="usd">12367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0514ef242a54da29c4d98a28258a7cb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS00LTEtMS0w_f6ec5deb-6126-464b-9dd8-fbeeb9b7b459"
      unitRef="usd">10692000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ed2d208b49b42d38d66bbe62caee7f9_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS02LTEtMS0w_464f2b7c-4ab8-4769-8498-50a1677165ae"
      unitRef="usd">9844000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibb490cfe0bd149a286b03d9b16aaaced_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS04LTEtMS0w_9d260e4a-1f30-419e-952c-5597edd0be1a"
      unitRef="number">0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id0514ef242a54da29c4d98a28258a7cb_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMS0xMC0xLTEtMA_1026024f-070e-4052-b1ed-a768038770dd"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5b7b2600f594a5aa2fadc8cc7f71802_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy0yLTEtMS0w_fac61369-03b1-47b5-a614-66fe00166a01"
      unitRef="usd">2232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2576e6aa19bd4f7589777471e9b72143_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy00LTEtMS0w_07f8eb49-2d6f-4535-b03f-4e78ff830ba2"
      unitRef="usd">1567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78fdf8bb361f4fd9b717cad18dd32d62_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy02LTEtMS0w_db604ff4-f8cd-46b0-ba17-0f72dd7788ce"
      unitRef="usd">1203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie5b7b2600f594a5aa2fadc8cc7f71802_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy04LTEtMS0w_6bb1902c-4fd3-438c-bb5f-aac2113bfaac"
      unitRef="number">0.424</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2576e6aa19bd4f7589777471e9b72143_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwMy0xMC0xLTEtMA_c80ee0e8-11d1-4fc2-9e67-78a2ebbe7020"
      unitRef="number">0.303</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ca3908b695440b9ab57b7d0a7c3e94f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC0yLTEtMS0w_c46f7edc-8e3a-4c31-9343-f7645c598414"
      unitRef="usd">1958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfeb443990294b3cb5921c60bcfb0110_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC00LTEtMS0w_027cf084-7cea-4a07-b949-aacf0e5a1d17"
      unitRef="usd">1430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6107835bbd64528a0c3d22e0a42de81_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC02LTEtMS0w_47b9031f-1be0-472a-9631-59a9a66ecb3b"
      unitRef="usd">822000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ca3908b695440b9ab57b7d0a7c3e94f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC04LTEtMS0w_e64b9b12-ee54-426c-8b1c-76eb34be6644"
      unitRef="number">0.369</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icfeb443990294b3cb5921c60bcfb0110_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNC0xMC0xLTEtMA_76b35e42-2481-45f3-8962-e79f9202c8ef"
      unitRef="number">0.739</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee8abdb9b05d4466a2318541bcbf74e9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS0yLTEtMS0w_ae9b37a0-61a6-4ff4-adba-0068a783a566"
      unitRef="usd">4190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f9fc36595b449aba78e7d403ab30aec_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS00LTEtMS0w_4cfdc62d-d114-4c96-9ad4-e92c56927347"
      unitRef="usd">2998000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c3d8d5864694a0abc113e067abc2c41_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS02LTEtMS0w_c6400139-7d2e-4504-8da7-f663ad407836"
      unitRef="usd">2025000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee8abdb9b05d4466a2318541bcbf74e9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS04LTEtMS0w_6cd2c7a2-835e-4ab5-97fb-7c8cef5e9313"
      unitRef="number">0.398</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f9fc36595b449aba78e7d403ab30aec_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNS0xMC0xLTEtMA_aa1a16b8-fa1a-4435-ab7f-ef60fbaba4f5"
      unitRef="number">0.480</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac9dc42aaeba4a198434d55e6de7ff96_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy0yLTEtMS00MjE0_6eaa2734-0007-423d-a94e-360452392964"
      unitRef="usd">583000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fc5bbc6288e430fa5c2521af7bb0b05_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy00LTEtMS00MjIz_ac94b6ea-db5b-464e-9a72-aead6c2223bd"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b895b26e49b4635b42b1536f531c608_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy02LTEtMS03MDU4_3c0ff1e4-ec2f-4949-8a86-91941287a8b5"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iac9dc42aaeba4a198434d55e6de7ff96_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy04LTEtMS00MjM4_cb67df1e-07c9-417d-9ccf-b981c83bd033"
      unitRef="number">0.961</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d2ebeab6f904ed1960851a888d27083_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC0yLTEtMS00MjE0_81572f2b-9ec4-431d-8729-92bf2f9b8e42"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc9626d02b2b410c86ebc7380f6c4249_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC00LTEtMS00MjIz_2a52dec1-d5d9-47c5-9acf-6079a1ef1f0b"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i383e3f60f86e4defb334fbc762820aa0_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC02LTEtMS03MDU4_2508313b-6daa-471c-b0cb-ee127a0f59b2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6453b112716e4400bade7786533a87c5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS0yLTEtMS00MjE0_f5610c33-b4f2-4c97-8f43-cfb5e1fc3246"
      unitRef="usd">760000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id571d247cd4b4ca39d865b8901589cdc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS00LTEtMS00MjIz_adc5457c-79a8-4c03-95c2-e4309dde9850"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69e3e0394dd94e10b095ea1364ee1671_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS02LTEtMS03MDU4_9f5f7fe9-489d-4075-8f9a-31652abaeba4"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10bb37e48c164c179f00b0da6b6266a0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy0yLTEtMS0w_76dbb248-9ec7-4849-85de-e6852ba6c9d0"
      unitRef="usd">1821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic913c3a623e0461ba7fbea0de051f46d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy00LTEtMS0w_acb2b1ed-cf05-4e0e-b007-ca34d978fff3"
      unitRef="usd">1555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd9a2cb546bc494abb88fa69230744b1_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy02LTEtMS0w_f995a0b5-ad55-4140-93fe-ea3d2026019e"
      unitRef="usd">1129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i10bb37e48c164c179f00b0da6b6266a0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy04LTEtMS0w_d9592491-eae0-4493-87d7-0424e8455dc4"
      unitRef="number">0.171</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic913c3a623e0461ba7fbea0de051f46d_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwNy0xMC0xLTEtMA_96f1e9f8-5728-407e-b345-500fc11ff703"
      unitRef="number">0.377</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbb7775a898b4aad918975b899e54d3c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC0yLTEtMS0w_a37be0e5-1f85-4892-a677-e05c54495b10"
      unitRef="usd">2307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic31ddfb9acb84d7bbecc428a4394ceac_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC00LTEtMS0w_54a62964-5c8e-424d-ae9f-667e8cecc051"
      unitRef="usd">1856000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie383e52a0d0e485d99e09377f32f2729_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC02LTEtMS0w_901713fa-e742-47cc-bf00-230c657cdf2d"
      unitRef="usd">1486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idbb7775a898b4aad918975b899e54d3c_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC04LTEtMS0w_346444f5-2478-4d8b-8f0b-2444f82cc89c"
      unitRef="number">0.243</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic31ddfb9acb84d7bbecc428a4394ceac_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOC0xMC0xLTEtMA_4d7d3daf-9845-423a-bb1d-471787c03780"
      unitRef="number">0.249</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia43b359b238e4d539c59daf943bf60eb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS0yLTEtMS0w_0821d29b-676e-4326-a649-95e8e2fc68d8"
      unitRef="usd">4128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80d21d69338a48978058495fdba87e9e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS00LTEtMS0w_6dbae0da-f1a7-4d04-bf85-31d3f216bee3"
      unitRef="usd">3411000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id13a02795b0645bda0393c88f521bbdc_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS02LTEtMS0w_49107ddd-42fd-4358-8e0b-5b89987d5849"
      unitRef="usd">2615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia43b359b238e4d539c59daf943bf60eb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS04LTEtMS0w_54aa0936-d435-47f7-ae68-6d6e8d33c4b7"
      unitRef="number">0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i80d21d69338a48978058495fdba87e9e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEwOS0xMC0xLTEtMA_307b961a-7a02-464f-8bb3-4225b098342f"
      unitRef="number">0.304</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice7c35cec2bc467f8499200ba6d32b5e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS0yLTEtMS0w_319dd030-1443-4dea-8e95-83847a84f9aa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id16e7c1fa21d4e23b5881fbdc5d62704_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS00LTEtMS0w_7db0876e-1038-4dea-996d-6f389295ef1a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f31422d2f4045b2b2c516a07d33107a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS02LTEtMS0w_47390f72-7b54-4d75-91cc-08acc72a8d00"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice7c35cec2bc467f8499200ba6d32b5e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS04LTEtMS0w_d093f50d-c819-45e5-953d-d2a6996bb17c"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id16e7c1fa21d4e23b5881fbdc5d62704_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMS0xMC0xLTEtMA_5fe88c42-eaa0-4122-b225-1e93dc7f4478"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0dd0eac24f4401fb171f8f4befd046e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi0yLTEtMS0w_c41058fa-47fb-47e2-ba16-54a64ca461bf"
      unitRef="usd">408000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75c99618e8464f48b02c5800078fec9a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi00LTEtMS0w_c7752937-2d43-41bf-a94a-6106e82fc800"
      unitRef="usd">751000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic411305d926f4262891fb8f8d32340ac_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi02LTEtMS0w_7fa6ba4b-9e3a-42c1-bb51-a40f4fbd94de"
      unitRef="usd">1116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia0dd0eac24f4401fb171f8f4befd046e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi04LTEtMS0w_1c5bf1c7-3b7f-411e-b511-87173fddc5ea"
      unitRef="number">-0.457</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75c99618e8464f48b02c5800078fec9a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMi0xMC0xLTEtMA_c439c395-f35d-4211-a50d-6f955b0475b8"
      unitRef="number">-0.327</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf10274f9c344290a2ab99e9e34ae3e4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy0yLTEtMS0w_f26589d0-a751-4cfd-ba9c-89a217da68c4"
      unitRef="usd">408000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3de8d88c34794c23bebd5f7b5eeb5a8b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy00LTEtMS0w_9dda05cf-a971-4c42-a73e-811a27f549a0"
      unitRef="usd">751000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if49c3568a0f94b3889385d83ac006905_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy02LTEtMS0w_9a9e6685-6c02-445b-bdeb-3c581001369e"
      unitRef="usd">1116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf10274f9c344290a2ab99e9e34ae3e4_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy04LTEtMS0w_c6ccf8b2-b06d-487f-86ac-80af0f5c9f9d"
      unitRef="number">-0.457</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3de8d88c34794c23bebd5f7b5eeb5a8b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExMy0xMC0xLTEtMA_e4653057-7b2d-4ebc-9085-61c32dd06919"
      unitRef="number">-0.327</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcf70cb300d841aebfe5a712007444ac_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS0yLTEtMS0w_c2b1bd54-4226-4408-a6bc-6b6c773ce9ad"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ab5a5f92fd941b288007441e9cc4cce_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS00LTEtMS0w_716fcefc-73d4-4570-bb11-35d232a8f657"
      unitRef="usd">810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70838a32f63643e4a2f7ed13d212a9f0_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS02LTEtMS0w_50cbaddd-d1f1-4fea-85d1-35f87da05f21"
      unitRef="usd">1771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibcf70cb300d841aebfe5a712007444ac_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS04LTEtMS0w_f08fd492-e194-4821-839d-4c386e0a0721"
      unitRef="number">-0.540</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3ab5a5f92fd941b288007441e9cc4cce_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNS0xMC0xLTEtMA_9e99310e-975a-4e77-a6f5-64aa62996c09"
      unitRef="number">-0.543</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e56b017393d48d9951e1963e9232f4e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi0yLTEtMS0w_c9056184-ba11-4ff3-86d1-2b8966ddab9f"
      unitRef="usd">2097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ec0b61f3e194449b1fc8232df6eb583_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi00LTEtMS0w_b07227ff-feea-43d8-9130-c319ee863b36"
      unitRef="usd">1985000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i485ad9e4c9034407b529d2ddbbea2b28_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi02LTEtMS0w_31b8380e-d42d-4dff-9ad8-a0af84536ff4"
      unitRef="usd">1727000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e56b017393d48d9951e1963e9232f4e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi04LTEtMS0w_58cfbbbc-57dd-48ee-b74b-023e2d79838b"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5ec0b61f3e194449b1fc8232df6eb583_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNi0xMC0xLTEtMA_72f6b57f-a474-4d42-b88f-bb36dba38630"
      unitRef="number">0.150</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i068cc5432b3443beb8e11bb255e1e28a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy0yLTEtMS0w_9fde6fe6-ea51-4c71-90ef-fe225a7a83e7"
      unitRef="usd">2470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief79aa5fc89943f1856174ad8ab48c03_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy00LTEtMS0w_fa7ccbbe-a06a-412e-807d-1219e7968dac"
      unitRef="usd">2795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f6b259e70b34438a3f81e5332f8a6c9_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy02LTEtMS0w_eebe039c-4240-4c51-98b2-9b69e302c4a1"
      unitRef="usd">3498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i068cc5432b3443beb8e11bb255e1e28a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy04LTEtMS0w_2d58cef7-e164-49a9-b834-cef1fee305e7"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ief79aa5fc89943f1856174ad8ab48c03_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExNy0xMC0xLTEtMA_d4cb4b1c-f062-4bcc-b9ec-9b9d10d79a72"
      unitRef="number">-0.201</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cc3d26ae55e4532b24a34603fb51a5b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS0yLTEtMS0w_f9751454-5b73-4edb-8b91-70ae878b4903"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c1612d385f0492da9095801326473f3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS00LTEtMS0w_4b71ca29-0408-461f-88f3-b38aa668ecc1"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a5d890f9dec439ba519c396e28a1b15_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS02LTEtMS0w_6e883133-0571-48a7-9a30-344662b7ef5f"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cc3d26ae55e4532b24a34603fb51a5b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS04LTEtMS0w_b2b4ea34-5cbc-453f-b4ad-9d0fedff3dce"
      unitRef="number">0.192</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c1612d385f0492da9095801326473f3_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzExOS0xMC0xLTEtMA_ca22d2c1-b9b5-468f-84c1-baf38fa523a8"
      unitRef="number">-0.327</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3432837e0994dea9738f6a9041dfb78_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC0yLTEtMS0w_b2bfa9bc-26d8-4fd3-bec5-5b5607987c2c"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf5720d7e06a47ec9ae85f4a20867f7d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC00LTEtMS0w_45e740d9-27c7-48e3-9a9e-68fdaeceede5"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fce5a20ed35426db5a791a058567b31_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC02LTEtMS0w_716bb07a-4c16-4562-929a-fd5c8eeeda81"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic3432837e0994dea9738f6a9041dfb78_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC04LTEtMS0w_985a737b-3f51-44c7-b1e2-50d63c2b8127"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaf5720d7e06a47ec9ae85f4a20867f7d_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMC0xMC0xLTEtMA_f01c1606-4336-434a-bdcf-5e0594854228"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fc0f82712f04ab1abd4713c5eb8122f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS0yLTEtMS0w_a323c46a-c385-4e78-903a-0dddd188689b"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4837e00061842c3848e83dc581c7c9a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS00LTEtMS0w_ea8ccbd1-f567-40c4-a7ba-c77ded8376de"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide8fc9994e3f4e679de95304641d1e6d_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS02LTEtMS0w_a3ec411b-84a7-458f-9b64-08ee81acbde4"
      unitRef="usd">466000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1fc0f82712f04ab1abd4713c5eb8122f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS04LTEtMS0w_d00d7cc6-f4c6-48fd-a83f-26eea7c1bf29"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia4837e00061842c3848e83dc581c7c9a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyMS0xMC0xLTEtMA_d4b1c14a-aee6-49b5-b756-73d057b6028e"
      unitRef="number">-0.127</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee955b2a5ebc4440b0275a07f42d7859_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC0yLTEtMS0w_fa11f3bd-01be-4e37-b3d9-a9d7dda2593a"
      unitRef="usd">2133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72e5bca473514621971e568c7c81f9d7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC00LTEtMS0w_bcf7fd13-de45-4b37-8a9e-6537b5bfa9f1"
      unitRef="usd">1684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b32854703604f20a5087fc9da993d60_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC02LTEtMS0w_9e4454ab-f144-40f8-a73e-0165d01a783b"
      unitRef="usd">1651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee955b2a5ebc4440b0275a07f42d7859_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC04LTEtMS0w_92730184-7ac0-4e4a-acc7-f639dbaa687f"
      unitRef="number">0.266</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i72e5bca473514621971e568c7c81f9d7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNC0xMC0xLTEtMA_a9ab1019-bfa4-4035-a723-49b83133cd04"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0bb8ef73842461881c87d256616bb58_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS0yLTEtMS0w_f654f881-1116-4a35-a160-41b7b790c940"
      unitRef="usd">1015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f138d8eba8c4b139d79c8bdf04273e7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS00LTEtMS0w_629a6bc7-9693-4381-ae7d-8a890bc2258a"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i513474c437a54da8bdb8d39a5690e05c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS02LTEtMS0w_c481125a-9958-43e6-92d3-c6837a224f9a"
      unitRef="usd">922000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie0bb8ef73842461881c87d256616bb58_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS04LTEtMS0w_b55d020b-078a-47a3-b2f9-c3635bcef38e"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7f138d8eba8c4b139d79c8bdf04273e7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNS0xMC0xLTEtMA_4e038348-54a7-452e-92b9-943061f07c1e"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8d33d060c4c47bd8ac7257d692df0ce_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi0yLTEtMS0w_864a3268-6eb4-4993-86ef-3ee4771f661f"
      unitRef="usd">3148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b7524e3946646b9b75238c6c4fda704_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi00LTEtMS0w_b523229a-1fc3-43b4-9eb8-d03bc58f3d90"
      unitRef="usd">2623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if800a3c44fd14c1c8c9443c13229ce64_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi02LTEtMS0w_c1ca1cb0-19ec-4ebe-9ec1-bd3b1dd9fc64"
      unitRef="usd">2573000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib8d33d060c4c47bd8ac7257d692df0ce_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi04LTEtMS0w_1250a645-5498-42fb-988d-e046320c8a9b"
      unitRef="number">0.200</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9b7524e3946646b9b75238c6c4fda704_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyNi0xMC0xLTEtMA_2a9a56b2-e0f9-4513-bc70-365e89d0c062"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc918ea034249e7a645f7ddf9922377_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC0yLTEtMS0w_ff76f332-d2cb-4d71-b5e1-e4189cec6629"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f9ad324b0e34c5b871ca5b7f591fc74_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC00LTEtMS0w_e715387a-ec90-4f84-8ab0-31f7e6b3d4b5"
      unitRef="usd">766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7d4dc4f88674bb784396e7150b232c5_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC02LTEtMS0w_aea0e82b-da0f-4398-b32b-2bfcf36c060b"
      unitRef="usd">700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1dc918ea034249e7a645f7ddf9922377_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC04LTEtMS0w_e932cd6f-4f5c-4f2f-bf5c-cfb4181fc4cc"
      unitRef="number">0.317</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6b475ddaf2045f5b7e3e9c0ab7ddbc3_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOC0xMC0xLTEtMA_7ee744c8-b183-4657-8e59-8b1c0906bf2d"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78a58229b38848a6acee4aa1ee9a792a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS0yLTEtMS0w_c39aad6f-e524-4dde-9ccf-07f89e96dabf"
      unitRef="usd">631000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide3b9a020380440b8fe140b751c16e56_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS00LTEtMS0w_de0914a3-51e2-444f-9f3e-6ea6af236d12"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33f49a3f10784cb980bc81b0bf707db4_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS02LTEtMS0w_185bb2eb-3d11-449f-9e53-2d4fe71800ae"
      unitRef="usd">515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78a58229b38848a6acee4aa1ee9a792a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS04LTEtMS0w_5f527fc8-9677-448d-a2fd-68fd715d002f"
      unitRef="number">0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if409308149024b7ebf44549391b1ef28_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEyOS0xMC0xLTEtMA_00dbc5c8-3025-4236-9e28-71cdc574856a"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48809d31e15f48cab0409d4e65adf936_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC0yLTEtMS0w_3705b8a7-d1c2-4c53-8b5b-76ba6a3a6df1"
      unitRef="usd">1639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e587520c5424f6895bb82d180fcead7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC00LTEtMS0w_2bccf492-fcf0-4dc1-8f78-ae7d8c0c268d"
      unitRef="usd">1327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15a298df88a04792b4eb06c9649f9c9a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC02LTEtMS0w_45e5d4ee-ee2e-4871-8005-1954ff3e5c73"
      unitRef="usd">1215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i48809d31e15f48cab0409d4e65adf936_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC04LTEtMS0w_c44a6193-816e-4086-8827-b6f4fb94b553"
      unitRef="number">0.235</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6e587520c5424f6895bb82d180fcead7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzMC0xMC0xLTEtMA_415d29c0-196c-4880-a0a2-d2c9e4f0b78f"
      unitRef="number">0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5ccb426ed040e884937136da490957_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi0yLTEtMS0w_181a773a-1979-4e4c-9e5c-b0e1181352d3"
      unitRef="usd">955000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbd627d84f8348118b3790e6522ee21e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi00LTEtMS0w_968e9ad6-87cb-41b9-8be1-c8b1aadc3b54"
      unitRef="usd">714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c1196be4a434582a11b0f92c5c054ae_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi02LTEtMS0w_7d1907ef-d39b-4f7d-bd90-74774aebaba6"
      unitRef="usd">598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1e5ccb426ed040e884937136da490957_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi04LTEtMS0w_57527d4d-9710-406a-b456-ff111d0027b7"
      unitRef="number">0.338</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idbd627d84f8348118b3790e6522ee21e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNi0xMC0xLTEtMA_7233f52d-9ac4-4007-a227-5b232ab922e5"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c65c2e67bfc45cab7bd25c746b42db7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy0yLTEtMS0w_d09e147b-8e1d-4e50-b421-a5cc1463e2e0"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee23e589317a442cbea6d9b4f7f79caf_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy00LTEtMS0w_01dcd1cf-9d97-4f69-97bd-8391e5275135"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5255e36acbac418e85f849dfbdf10496_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy02LTEtMS0w_73a8ee35-b4cd-4aa1-896f-55e8bd67581e"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1c65c2e67bfc45cab7bd25c746b42db7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy04LTEtMS0w_091d0215-d239-4d39-92b6-8e47c6ad3916"
      unitRef="number">0.309</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee23e589317a442cbea6d9b4f7f79caf_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzNy0xMC0xLTEtMA_c19bfcfd-f0a7-4585-8ab6-421ca9d337ba"
      unitRef="number">0.624</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01c2543a19ee466493df5660744c8c1a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC0yLTEtMS0w_0b2f270b-01a6-4ab6-95d6-630714a9fbbd"
      unitRef="usd">1093000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bc4a076e7284a2eaa4ae25d6f7d0578_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC00LTEtMS0w_ebf8b324-72e7-4f21-89da-13ee6a0d2d34"
      unitRef="usd">819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24218d83d9274436ab41302d751e3b17_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC02LTEtMS0w_52690cfa-c255-4bc0-8002-0be24765efd4"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01c2543a19ee466493df5660744c8c1a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC04LTEtMS0w_029190d2-7288-4b8e-a610-095132c38fde"
      unitRef="number">0.335</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1bc4a076e7284a2eaa4ae25d6f7d0578_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzEzOC0xMC0xLTEtMA_db4292b4-3221-4c81-9181-3f294444fabe"
      unitRef="number">0.235</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3a92101e57d4ab0a5d2910e3c72d8ae_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC0yLTEtMS0w_8e541c89-e3e2-4bfb-8c1b-8debc11aad92"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89b895fbb6804c319ca67eaf7a7749c6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC00LTEtMS0w_21c95b7b-ebae-456a-821d-7cbd9d050c21"
      unitRef="usd">205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5474c52ea0d4a31a03b189d9522cbc0_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC02LTEtMS0w_29170da8-4971-424b-8c9a-123d333232ad"
      unitRef="usd">353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic3a92101e57d4ab0a5d2910e3c72d8ae_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC04LTEtMS0w_51e093fb-1b3b-4779-a127-78694f40f382"
      unitRef="number">-0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i89b895fbb6804c319ca67eaf7a7749c6_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MC0xMC0xLTEtMA_f940f063-8b40-4c5c-8a54-e2ab4f34ba1b"
      unitRef="number">-0.419</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eeed4adf30e4bca9bfe818ab7159933_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS0yLTEtMS0w_707615e5-bd98-4fac-b66c-7453ab93d628"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b55966cf5b64f81b16f40f0103bd79b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS00LTEtMS0w_187d4cc7-4001-400f-bf7f-44e7cb17daa0"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia72ebb598f0348479991c9709cd38a02_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS02LTEtMS0w_6562d2dd-68d1-40d8-a2c8-675443ba30c4"
      unitRef="usd">342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6eeed4adf30e4bca9bfe818ab7159933_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS04LTEtMS0w_94213a17-2f82-4d48-8c51-bb47de486626"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6b55966cf5b64f81b16f40f0103bd79b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0MS0xMC0xLTEtMA_9763daf1-0eb9-4573-81f8-86ef5c5ff8e1"
      unitRef="number">-0.205</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f3afdb891c54b018f5398d3af12ce2f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi0yLTEtMS0w_b93e38a1-76a5-4fe0-9a4a-a2fb709a84d5"
      unitRef="usd">416000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2964812dbd3b44c7a03684da9a06461c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi00LTEtMS0w_e65494ca-a951-4747-92a3-ee963c84fe0a"
      unitRef="usd">476000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i486c300ff24f47f0986efe5804106361_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi02LTEtMS0w_ddec0f8e-2955-4a00-ba5f-a4ad4fda8270"
      unitRef="usd">695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5f3afdb891c54b018f5398d3af12ce2f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi04LTEtMS0w_c0c71283-f0dc-486f-a05e-47d88a8521cb"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2964812dbd3b44c7a03684da9a06461c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Mi0xMC0xLTEtMA_67c617d0-5d26-4e54-905d-0f4ba0bb6993"
      unitRef="number">-0.315</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73e672c1ca294c19899b6194a13b72cb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC0yLTEtMS0w_aebccf70-e304-48a8-99cf-b2664a27f85e"
      unitRef="usd">3509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5af8e2c89c584232828bbabcac9bc95e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC00LTEtMS0w_1238952c-96a3-4ee8-945d-73981bdbdd90"
      unitRef="usd">3734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5402a284a5544b0ae6e3a3a7f7b8b18_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC02LTEtMS0w_aefc7bce-83d0-4700-9f4e-c8bdb56aa8d5"
      unitRef="usd">4279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i73e672c1ca294c19899b6194a13b72cb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC04LTEtMS0w_d86970b3-6074-44bc-9bce-22e5bb2547a1"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5af8e2c89c584232828bbabcac9bc95e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NC0xMC0xLTEtMA_fb10cbbf-4d91-4701-9adc-b1a1b7e973a4"
      unitRef="number">-0.127</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d83c054ebbe4b55956a90c090dbf071_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS0yLTEtMS0w_7a46f0f7-b13f-4a5a-9e19-8dbb4c93c898"
      unitRef="usd">1369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09262051be5d4a8fb49e116b991a4eed_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS00LTEtMS0w_19b7f22c-e414-4dc0-a5c8-aab7fb9736c0"
      unitRef="usd">1458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59c5ed77ca06492184b99ba7d305dde6_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS02LTEtMS0w_eb12c6c1-f95d-48c5-ba80-6b8e57498afe"
      unitRef="usd">1537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1d83c054ebbe4b55956a90c090dbf071_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS04LTEtMS0w_6c7c9e18-5340-4abe-8033-eadd51ec4c09"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i09262051be5d4a8fb49e116b991a4eed_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0NS0xMC0xLTEtMA_82f8fbb8-2f43-42f5-864e-5d408f302e23"
      unitRef="number">-0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied6485f71b8341e9811ab2c75108f37f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni0yLTEtMS0w_a145b2f1-85e2-4271-96da-6d22f1d3a86f"
      unitRef="usd">4878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14a2e2d4cb5a408b9c5fd9d323011fd3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni00LTEtMS0w_fdfab8e3-5323-4032-8cc6-84562e615fce"
      unitRef="usd">5192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic35c63055c2f4e329572b6eda58a7637_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni02LTEtMS0w_7295006c-7465-410e-9b9d-82408a110da3"
      unitRef="usd">5816000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied6485f71b8341e9811ab2c75108f37f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni04LTEtMS0w_c4481510-9de6-4fad-aea6-83ede5fc7b88"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i14a2e2d4cb5a408b9c5fd9d323011fd3_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0Ni0xMC0xLTEtMA_50134c34-5933-4de3-b3bc-81aa0d8d94b6"
      unitRef="number">-0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i879becad18bd4e95871ce662ed38c9d1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC0yLTEtMS0w_03610f50-cd24-483b-9bb9-a77d21602eb6"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id562b8bf54bb4dafba5e39bc08e96ecc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC00LTEtMS0w_dec4e2c6-efdc-4ba8-8bc3-80162435c83c"
      unitRef="usd">2313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83b7a0d4e280466f99120313fab3572a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC02LTEtMS0w_41babf23-2ba0-48cf-b537-8f8626789977"
      unitRef="usd">2477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i879becad18bd4e95871ce662ed38c9d1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC04LTEtMS0w_6db401c3-a42e-4bed-aaca-5b77bf4df7b2"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id562b8bf54bb4dafba5e39bc08e96ecc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OC0xMC0xLTEtMA_85076ade-d6a6-4988-a46f-cbe92fa1edcf"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if63d4391de1046ffba12c5e6301213cb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS0yLTEtMS0w_bf41f91d-5974-46f4-868e-50bfdc5d7069"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07304354d8544a92ba72a5cd3e890ebd_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS00LTEtMS0w_4a636063-b15f-4454-bd31-d09a3260080e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc8ba09528eb4bb28bf8fb46d9ca244b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS02LTEtMS0w_53def9e0-b510-41b5-8a69-67801ca09a3d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if63d4391de1046ffba12c5e6301213cb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS04LTEtMS0w_158b86c7-fc4c-4899-95d0-fa8c647b0598"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07304354d8544a92ba72a5cd3e890ebd_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE0OS0xMC0xLTEtMA_f9701eb0-178b-4197-b586-07b2b4311f8a"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i480f6951d5234710acb15ef442ff46aa_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC0yLTEtMS0w_8fd04328-79c4-4d83-b1be-2fd29e021604"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aeca666b4bc4fc8b825d67bbe516983_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC00LTEtMS0w_f336789a-b0b8-47eb-ad95-f19222948032"
      unitRef="usd">2313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d23b54b71714d9ca21c6e5e0c22bd74_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC02LTEtMS0w_1f7b17ac-575c-4ab5-9ff6-a4aedf87bc40"
      unitRef="usd">2477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i480f6951d5234710acb15ef442ff46aa_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC04LTEtMS0w_9c3ebad2-9beb-43b7-b6fb-4a35f3165fcc"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7aeca666b4bc4fc8b825d67bbe516983_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1MC0xMC0xLTEtMA_13082043-bc7d-4f74-ab69-821c5b0b72c6"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165535e13a5d4c17953e1ceaeaf9a636_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi0yLTEtMS0w_45645ffa-17d8-449d-9267-a03f3bad774f"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91cabadcdb3c4f10bc97956908c95e3f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi00LTEtMS0w_681709a7-b100-4048-93ab-8b540b196cd4"
      unitRef="usd">536000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e918889cc434945be946be6a986c17b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi02LTEtMS0w_d40a5a01-4cf6-4f93-a42e-ba5c01528a53"
      unitRef="usd">711000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i165535e13a5d4c17953e1ceaeaf9a636_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi04LTEtMS0w_1621d6e3-fac0-4214-90df-194c27c78c93"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i91cabadcdb3c4f10bc97956908c95e3f_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Mi0xMC0xLTEtMA_b5716a92-ed24-4f7d-a062-117de2e55d51"
      unitRef="number">-0.246</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9783c1f9b69e46c8847fdb36caed3e61_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My0yLTEtMS0w_acc9e4f4-df13-45a6-bbf1-957fcbdea1b0"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4abe8487be1443f188c6f578a79c2d92_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My00LTEtMS0w_242a3c49-d4d1-41c7-921a-7b8a166fcec6"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i341822625ecb4b4789deb017f8eacc8a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My02LTEtMS0w_da1fc6d8-6433-405a-8c84-5fb0948119d9"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9783c1f9b69e46c8847fdb36caed3e61_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My04LTEtMS0w_e73fe208-4946-4572-82d4-b66e29dc605c"
      unitRef="number">0.163</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4abe8487be1443f188c6f578a79c2d92_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1My0xMC0xLTEtMA_346d1096-ed80-488c-b245-20c613ae530e"
      unitRef="number">0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe8b3fbd369743afa2505d9b81d9cd9e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC0yLTEtMS0w_2a5ab7cd-3381-4b82-97ba-fd034e4a93b4"
      unitRef="usd">795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia244f37fb23c45d2a6cd8570deccad0c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC00LTEtMS0w_eb7517c8-5b89-4a44-b9a3-19d3b86a7f99"
      unitRef="usd">735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72ed9b3951644e8abc03bd12c9e6b297_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC02LTEtMS0w_7ab5c343-0f8b-4cfb-887f-571ca217c4e5"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibe8b3fbd369743afa2505d9b81d9cd9e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC04LTEtMS0w_24f3d564-a569-4e31-be2a-a6357feb1ed0"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia244f37fb23c45d2a6cd8570deccad0c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1NC0xMC0xLTEtMA_86c6c6f7-399f-459f-b665-776ceadd20fd"
      unitRef="number">-0.165</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5adfcd1c9908434da345ec1cdc576590_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni0yLTEtMS0w_2e98474d-84d4-41c7-8e58-4875779f0331"
      unitRef="usd">277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib343bfa6ba954633998789b6a1a44c3c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni00LTEtMS0w_484c4a21-70cc-412f-90f0-7bf070626a9a"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05ec7eee76274b6493178830f9f7d290_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni02LTEtMS0w_d3641605-2439-4f8f-8a82-3ce016cc3b5a"
      unitRef="usd">674000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5adfcd1c9908434da345ec1cdc576590_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni04LTEtMS0w_1b3c0150-5c53-4695-bf21-3ccde9c110e4"
      unitRef="number">-0.451</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib343bfa6ba954633998789b6a1a44c3c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ni0xMC0xLTEtMA_9bfbe50a-4d74-4662-a7d0-72dcb6c64c8d"
      unitRef="number">-0.251</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90b1e5791e5f4ac6950916274d1a1a6f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny0yLTEtMS0w_afcc8e39-3903-41a4-86d5-e3eb30322fe2"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6c7c3bbbd614afca59c1426a0da0a51_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny00LTEtMS0w_d520bb69-8f74-4d83-9cf2-3a6dd4d48483"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id53466858e60466d81703523ed53029d_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny02LTEtMS0w_067e6ffc-0d87-4948-9e2e-c4a7ea0ec39c"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i90b1e5791e5f4ac6950916274d1a1a6f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny04LTEtMS0w_49ec1f81-34e8-46eb-ae5b-07ee1734f55e"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib6c7c3bbbd614afca59c1426a0da0a51_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1Ny0xMC0xLTEtMA_f0ea6c8a-b157-491c-9f91-3ff94098d60f"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib84e7f7d93694ba9afaee8823f713cb8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC0yLTEtMS0w_cba55735-b6bb-44be-bf8b-8d725bb5a1fa"
      unitRef="usd">552000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8899b6c537174b6bbb5cde0f33fd376b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC00LTEtMS0w_6f0ac88e-7a59-4908-b31e-af9da2ac77f9"
      unitRef="usd">790000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf39fa1409e84c67a5e97a853263bb6c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC02LTEtMS0w_56f5fa05-5b4a-4fba-8e5f-4805dc4f15be"
      unitRef="usd">988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib84e7f7d93694ba9afaee8823f713cb8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC04LTEtMS0w_6d9dba0c-0182-416e-b1c3-fe81fe9c46ea"
      unitRef="number">-0.302</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8899b6c537174b6bbb5cde0f33fd376b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE1OC0xMC0xLTEtMA_08445fc8-aa21-445c-8818-147943e97c89"
      unitRef="number">-0.200</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98aeab42d1474d458315de624b42191b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC0yLTEtMS0w_ba7089e9-6d4f-4610-bdde-17367dcc5c89"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3f4bd5c13cb4fba9645bb22fcc6521b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC00LTEtMS0w_1f95413e-0d1b-4ecc-bf80-8acf71310a39"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d3c1d6bec994f689672b19d7ecd0241_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC02LTEtMS0w_3460c1b5-86f2-4770-afc0-b1c70b5ace5c"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i98aeab42d1474d458315de624b42191b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC04LTEtMS0w_ab9216b5-9376-4fd2-afd3-a1fa52ec1f6c"
      unitRef="number">-0.151</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3f4bd5c13cb4fba9645bb22fcc6521b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MC0xMC0xLTEtMA_fcb763bd-d9b3-434c-b204-c8fecf4503ff"
      unitRef="number">-0.091</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17584700f12d46519383938af1d81aaa_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS0yLTEtMS0w_fca06611-9cbf-45bf-a07c-08b1481f3696"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i118e59fd747d42de9edbb08a4f24b0ba_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS00LTEtMS0w_27b1133c-2541-43cb-a984-c549307ae756"
      unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6189787c7fe14e36bbdd2e76d9f9f4c3_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS02LTEtMS0w_860b4549-e10d-4b2a-b633-f0fc6eaf25da"
      unitRef="usd">1053000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i17584700f12d46519383938af1d81aaa_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS04LTEtMS0w_58a33756-ea16-4e57-ab8c-94bceb17e99f"
      unitRef="number">-0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i118e59fd747d42de9edbb08a4f24b0ba_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2MS0xMC0xLTEtMA_00d33fb2-0a8f-478d-99a6-7d5c8202ae61"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94060b92688f449b9834a0a900890956_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi0yLTEtMS0w_ed2d9dbb-4be1-4295-8424-a5ef04ddb08f"
      unitRef="usd">1186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7be240152e5849b4b1feb9af434e0747_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi00LTEtMS0w_0e4ea413-4c54-4552-8809-8fb32858e85e"
      unitRef="usd">1353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7c8be14d314237b657ffc8dd65696f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi02LTEtMS0w_3bdf71ca-f077-4db6-a780-d6867f09ecbe"
      unitRef="usd">1470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94060b92688f449b9834a0a900890956_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi04LTEtMS0w_30a56a4e-a7ad-4c59-9be9-ca023e29db28"
      unitRef="number">-0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7be240152e5849b4b1feb9af434e0747_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Mi0xMC0xLTEtMA_04eb6f2c-08f5-43dc-a8cc-f583e196238e"
      unitRef="number">-0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic73286ade02445b5a9462beaac74a9d3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS0yLTEtMS0w_f9b58407-4746-4399-ab4b-94437b5d6432"
      unitRef="usd">25735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f577a1a44334d43acea15693cd75f1f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS00LTEtMS0w_4d575139-91a0-4c4b-89ec-709b5957bbda"
      unitRef="usd">23874000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idab38ca802ca4be19e8b830de0bd397f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS02LTEtMS0w_4eaebf3b-14df-4bf4-8d68-82cfdbdbf208"
      unitRef="usd">23286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic73286ade02445b5a9462beaac74a9d3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS04LTEtMS0w_089a962e-9319-4b47-b234-14bf9bab2d9f"
      unitRef="number">0.078</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f577a1a44334d43acea15693cd75f1f_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2NS0xMC0xLTEtMA_d3d4ad35-f5d3-47f8-80cd-e395190177cc"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf88388476f7405085cc966583cf4258_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni0yLTEtMS0w_59727efe-f480-4be6-b067-221e3414663a"
      unitRef="usd">19837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c66119908c84aaba2703e6fe5ffeedc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni00LTEtMS0w_7f6e996a-5e92-43d0-8597-f57f39efe16b"
      unitRef="usd">18324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59ccda52b00f47bcb73709353baeb316_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni02LTEtMS0w_733c7074-23a8-469f-98c9-8878d0c9136b"
      unitRef="usd">17448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf88388476f7405085cc966583cf4258_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni04LTEtMS0w_2e3340ac-a575-40a8-a493-3ca07fbaa59e"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6c66119908c84aaba2703e6fe5ffeedc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ni0xMC0xLTEtMA_96ed5c2a-0d8a-4ea6-89ea-6214ffc11f0d"
      unitRef="number">0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny0yLTEtMS0w_b74eaf06-520a-47ca-af82-87f777659fae"
      unitRef="usd">45572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny00LTEtMS0w_df3b90f6-a54c-4dce-9766-fbd2fb0c67ae"
      unitRef="usd">42198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f8d35a5e5ef4407bffb29a594a0b67a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny02LTEtMS0w_b7c6e32e-734f-4bd7-bf90-be28cfb6c63a"
      unitRef="usd">40734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny04LTEtMS0w_0b129a44-4996-471a-a4fe-20b0b9dfa65b"
      unitRef="number">0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE2Ny0xMC0xLTEtMA_8fc2cad0-5c67-4702-88e3-79d8cb5e62cd"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ef4d0b58d4549e9bdb73412623a21cc_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3MS02LTEtMS0w_f9768785-24d2-432e-85cd-0455cb05f790"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i602f30549c0b40dca5fd1936741a49ad_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3Mi02LTEtMS0w_0654338e-0949-4cd9-a51d-4f51db486b52"
      unitRef="usd">638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82c25e6b99024ef091459862efb9cccb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3My02LTEtMS0w_170a4325-8519-4041-a9e0-5618d108141a"
      unitRef="usd">1009000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86e4feada2044b02b8313b9e00c0baf3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS0yLTEtMS0w_b19ea7dc-a5d7-49bb-9109-046988f67d43"
      unitRef="usd">1452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84231515127f477eb578427ea2f07294_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS00LTEtMS0w_4f3a0b43-e625-4aeb-9c3c-74775742cb39"
      unitRef="usd">1443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if83acb0fa39e4ec5b03d0835e324823a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS02LTEtMS0w_e3bebb81-2289-4677-900f-8c7b36cbb06b"
      unitRef="usd">1283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i86e4feada2044b02b8313b9e00c0baf3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS04LTEtMS0w_cb42f880-48b1-4124-a7f3-586514a366f2"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i84231515127f477eb578427ea2f07294_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE3OS0xMC0xLTEtMA_676fc122-3957-4215-b8d1-3215c5184bbf"
      unitRef="number">0.125</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie60adb8fb0924a0ea419ad5f553698f5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC0yLTEtMS0w_1aec4fa4-5161-4e1c-8abf-35e536242c53"
      unitRef="usd">1594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8d5ffdf03b74d129cfd23b12757518e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC00LTEtMS0w_b893d68e-d154-45d4-bde9-f632d4f5e762"
      unitRef="usd">1554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf12e303cd9b4f9fb10ed1589f36e8b6_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC02LTEtMS0w_4475dd90-3e38-4c06-8f4a-63d75c014499"
      unitRef="usd">1363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie60adb8fb0924a0ea419ad5f553698f5_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC04LTEtMS0w_77dcd044-64f5-4d17-ac13-cab3dc8eee28"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia8d5ffdf03b74d129cfd23b12757518e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MC0xMC0xLTEtMA_0034323c-09a2-4484-a988-4c37a27235bb"
      unitRef="number">0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if24fa043dc87454ea84b0044287fcaeb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS0yLTEtMS0w_2fda79f5-1c37-485b-9f91-88b7df2c086b"
      unitRef="usd">3046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4adf09a8d993410584b7b18acfb4bcbb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS00LTEtMS0w_9033105f-1086-4313-80db-cc202093db89"
      unitRef="usd">2997000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i126f946d4eff41e79ab7d3a7a64eecee_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS02LTEtMS0w_aa284c0b-d04d-4c79-8b8b-d68f2cae4692"
      unitRef="usd">2646000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if24fa043dc87454ea84b0044287fcaeb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS04LTEtMS0w_152a32a7-6cc3-49a7-ad6d-f6771aa4e92e"
      unitRef="number">0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4adf09a8d993410584b7b18acfb4bcbb_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4MS0xMC0xLTEtMA_093f15f9-f7e3-4662-90b8-523080bc724a"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3840b8b2b071410383b4675e805cf313_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My0yLTEtMS0w_296555ac-3623-45b9-b0a5-5be5c04fcd4a"
      unitRef="usd">4779000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i438f65df2ab74a928e7eeb7a53d02ffc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My00LTEtMS0w_77245270-1085-44ce-8584-82081bb5ef66"
      unitRef="usd">5319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfd684566d004f179917d4aa4d8f8074_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My02LTEtMS0w_f906a562-db54-4dd0-b889-2f1367f25b10"
      unitRef="usd">5281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3840b8b2b071410383b4675e805cf313_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My04LTEtMS0w_f2f1d314-3f4b-4458-b9c7-150a468dac6d"
      unitRef="number">-0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i438f65df2ab74a928e7eeb7a53d02ffc_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4My0xMC0xLTEtMA_43253449-86aa-4fe3-b7ee-c7167df089a6"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia90b9c38b8ba47e296c57ea9b6458d43_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC0yLTEtMS0w_68dff2a2-9a6a-4913-8337-e726c19a4279"
      unitRef="usd">2984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87926cc32eaa46ecad04830aafda7bb2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC00LTEtMS0w_95940f86-f0b4-4af9-b2b5-015100dc37a8"
      unitRef="usd">3520000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if03ba8d91f4e4f95a4fdce30f489c09f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC02LTEtMS0w_61ac46ee-c8ba-41f3-9cef-30a58c60e353"
      unitRef="usd">3604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia90b9c38b8ba47e296c57ea9b6458d43_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC04LTEtMS0w_38294dc5-07d9-412f-a078-dfdccb38dc67"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i87926cc32eaa46ecad04830aafda7bb2_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NC0xMC0xLTEtMA_4385bdac-d912-4ed2-952f-8c8e6009129b"
      unitRef="number">-0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i144f5567202f48639bb4c9aa1ae3ae2a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS0yLTEtMS0w_17ef1056-7d21-448c-8777-69c6735bd10b"
      unitRef="usd">7763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d98497323f94faeae1879738e0122bf_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS00LTEtMS0w_77f3f39b-f7c1-4c9f-a9e7-dc1ba21f2a5d"
      unitRef="usd">8839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d2a5de64df24728adc2bf05ed12b93b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS02LTEtMS0w_ae81877f-052f-4dc8-9568-f539193bb18f"
      unitRef="usd">8885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i144f5567202f48639bb4c9aa1ae3ae2a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS04LTEtMS0w_2bad8455-68ff-4182-bff0-a5a3550c3f4d"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d98497323f94faeae1879738e0122bf_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4NS0xMC0xLTEtMA_c67ea865-75a9-4b20-aa06-0fb44cb32aae"
      unitRef="number">-0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4513084142340079843a021ce48dc83_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny0yLTEtMS0w_8ee6f304-9527-4de9-8e1a-b461476113ba"
      unitRef="usd">793000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if15cbbc611c14b21845dc1db3b286330_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny00LTEtMS0w_2725044f-e612-4422-95b6-fb4e2cbda144"
      unitRef="usd">863000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a7fdaef25374c44aa45e900e5e25eaa_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny02LTEtMS0w_c8b79c3d-6340-403d-8931-25cd1b6ac7d4"
      unitRef="usd">841000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id4513084142340079843a021ce48dc83_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny04LTEtMS0w_41264ef8-3b88-4e1f-88dd-adc2d69e13a2"
      unitRef="number">-0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if15cbbc611c14b21845dc1db3b286330_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4Ny0xMC0xLTEtMA_6df6ddf1-febb-48dd-9233-2e40e36f73c5"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ff8717040d04c1fa009b692e8390c77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC0yLTEtMS0w_6ad9a411-edc5-4fcf-be3a-ba136182d3d8"
      unitRef="usd">487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic78e09ea97bc419d9c3c1d2ecfb21982_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC00LTEtMS0w_dff5bf42-9cd3-43dd-87fd-4de5d6951f90"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib09b4f177eec41fc949ba626af3d336b_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC02LTEtMS0w_1005cc7c-262d-4595-8093-aa69ef8f8e3c"
      unitRef="usd">577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ff8717040d04c1fa009b692e8390c77_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC04LTEtMS0w_ce89a146-97e2-4c74-a5da-d6d7b3854809"
      unitRef="number">-0.153</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic78e09ea97bc419d9c3c1d2ecfb21982_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OC0xMC0xLTEtMA_033ac04d-e270-4520-b5de-b323341269b5"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i984713bea368485d96053638749455fe_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS0yLTEtMS0w_4217466b-1da2-465b-ad79-20154954517f"
      unitRef="usd">1280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0e007c86e9f4211a41a7172c74f9c4f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS00LTEtMS0w_b0746479-8740-4561-822b-22562f10064f"
      unitRef="usd">1438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b60c868bb3c4036ae62855e7e30207f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS02LTEtMS0w_98db88cf-6d10-456c-bbe4-c990d0eee459"
      unitRef="usd">1418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i984713bea368485d96053638749455fe_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS04LTEtMS0w_9c0b59d5-9adf-4e75-b202-fc26a58693e2"
      unitRef="number">-0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id0e007c86e9f4211a41a7172c74f9c4f_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE4OS0xMC0xLTEtMA_a5f793d5-9558-471a-8088-db00f2daa3d1"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70fc17a765d04f8ca815d5ff108cec48_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS0yLTEtMS0w_d23caf0b-7165-4f13-9d42-8617757a107b"
      unitRef="usd">743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabedf0861be54d2fbcb151e97d5f1c7d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS00LTEtMS0w_ad1f5ab0-cf6a-47ce-98a1-2c070fd6ee10"
      unitRef="usd">889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie905100914424975b112e4f3270118ce_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS02LTEtMS0w_a37f4964-1a98-486d-909d-7b710ac72b8f"
      unitRef="usd">911000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i70fc17a765d04f8ca815d5ff108cec48_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS04LTEtMS0w_b36086a1-3be5-49ec-bc99-2c679008b3f8"
      unitRef="number">-0.164</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iabedf0861be54d2fbcb151e97d5f1c7d_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5MS0xMC0xLTEtMA_cfb7f26e-c646-489d-969a-e225c24857b4"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5092dd6970434ce3ac47038270cde937_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi0yLTEtMS0w_fed5df4e-69d9-4fe3-a6d7-2f135256702d"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6813483c57994daeb367d9fe1563ce78_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi00LTEtMS0w_57db4161-4c57-4ba2-9f57-17f69e49b4b0"
      unitRef="usd">591000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22ef9ca58c57427da68fbca6011ad745_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi02LTEtMS0w_c58886fe-d6d2-4746-a153-e70d5ab54147"
      unitRef="usd">591000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5092dd6970434ce3ac47038270cde937_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi04LTEtMS0w_5ded04aa-b307-48c6-8ecf-99c3c85e2b16"
      unitRef="number">-0.278</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6813483c57994daeb367d9fe1563ce78_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Mi0xMC0xLTEtMA_33c5ed2d-b2e7-4704-8814-f0bd790127e9"
      unitRef="number">0.000</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fc9621c078648dcbf56a98adff1c4c4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My0yLTEtMS0w_58a73669-be29-42ea-9b1e-98bc313d097a"
      unitRef="usd">1170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24f6dafdf0c741be8ac3cdeab113c489_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My00LTEtMS0w_d271bdec-503b-41c9-ba4b-e6f7ddeef1c8"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if93a7c1c81884a3db1790c74e2bef12c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My02LTEtMS0w_fe003340-9d38-469f-ba43-cebbe71c2ccc"
      unitRef="usd">1502000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1fc9621c078648dcbf56a98adff1c4c4_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My04LTEtMS0w_84a75fa3-a9b7-4f36-9d7a-e3e23f7791e6"
      unitRef="number">-0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i24f6dafdf0c741be8ac3cdeab113c489_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5My0xMC0xLTEtMA_ecfe545a-4212-44fe-b0b5-86ac3e1628fd"
      unitRef="number">-0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04eb94163afc4fbe93b4ab697abbfae9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS0yLTEtMS0w_cb7848c9-91bb-4259-8776-3ffa9826cc0e"
      unitRef="usd">1648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i902ee0627dea4cd5bb60dc3491346db1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS00LTEtMS0w_1cc7d879-01d0-4134-8856-696c92fa55fd"
      unitRef="usd">1652000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad2fbad72def446b993089efac46d5a8_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS02LTEtMS0w_84cb1677-2c03-49fc-a116-1c03c3e345bd"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04eb94163afc4fbe93b4ab697abbfae9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS04LTEtMS0w_b7949641-87b6-438e-923a-bb1819ba3377"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i902ee0627dea4cd5bb60dc3491346db1_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5NS0xMC0xLTEtMA_c3252b91-b6c1-4f44-9386-c41876a23ff2"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cf163dd98ff4ed8968cab176f2563bb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni0yLTEtMS0w_5d2ea023-c4f5-448c-b6c7-fac4f5ad3c9b"
      unitRef="usd">966000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c4892515aa44a64a0209fc1e0bb2fad_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni00LTEtMS0w_0c392ea8-e9f9-4aca-a464-222031a6f9e3"
      unitRef="usd">1068000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37215466423046af9249e8abed9ad02e_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni02LTEtMS0w_3de37d46-ac27-42ca-bf81-cd07804c63a2"
      unitRef="usd">1100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cf163dd98ff4ed8968cab176f2563bb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni04LTEtMS0w_f7ecb684-32ac-45bf-82e0-1ecf8a2d02c8"
      unitRef="number">-0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6c4892515aa44a64a0209fc1e0bb2fad_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ni0xMC0xLTEtMA_476f5e71-8cde-433f-9bc0-1f1e385d94d0"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3906b91aa1a748e0a8a00991d75431d0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny0yLTEtMS0w_baba4c4e-e842-42e2-bb4e-a37657f1d977"
      unitRef="usd">2614000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc4d058982654390a2a9623f748a295e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny00LTEtMS0w_4e5bea63-6491-4d25-bbe4-3ae6daf1d777"
      unitRef="usd">2720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i026871ca845542edba6aa179e4c87502_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny02LTEtMS0w_2f8fba0e-53a0-4c34-b508-d15521cd0f6c"
      unitRef="usd">2699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3906b91aa1a748e0a8a00991d75431d0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny04LTEtMS0w_4cfd03de-9246-4a72-a857-1deb27fcb360"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idc4d058982654390a2a9623f748a295e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5Ny0xMC0xLTEtMA_6bc304a8-c89f-4f97-9f9f-fa90cafc3a5e"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95433015053341168b9d624012babd6b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS0yLTEtMS0w_64475553-9673-46a5-9a1f-c98115551048"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdf587116ba149d5bcba993340189069_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS00LTEtMS0w_4defec9d-cdd3-4cf0-82db-293725810101"
      unitRef="usd">1915000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fd6b74d14444536bdddf7ba271c1cc6_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS02LTEtMS0w_89f622f6-bf14-406b-8981-f2d2ef014289"
      unitRef="usd">1930000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i95433015053341168b9d624012babd6b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS04LTEtMS0w_65d77d32-7330-4bc2-81ab-5697475af632"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifdf587116ba149d5bcba993340189069_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzE5OS0xMC0xLTEtMA_c223059a-97f0-4ce6-9ef1-310cc6b7f4cd"
      unitRef="number">-0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d6c4422d1d40f684a09913056b9472_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC0yLTEtMS0w_d2ba7a57-3fa9-419d-88d7-dc579c51d52e"
      unitRef="usd">1104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a281af66cf04b96ba6e7ac36ebeaebf_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC00LTEtMS0w_8c724e2d-57ab-45d8-9ead-fa66166b46cb"
      unitRef="usd">1286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0196237488ef4eceb6b0ea1bd91e0dbb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC02LTEtMS0w_96ade25b-0cad-4347-a486-9fcb7bf4ae62"
      unitRef="usd">1336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i99d6c4422d1d40f684a09913056b9472_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC04LTEtMS0w_627e2583-5444-4fbc-bf33-32cf165e950e"
      unitRef="number">-0.141</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5a281af66cf04b96ba6e7ac36ebeaebf_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMC0xMC0xLTEtMA_5dcf5087-9971-4d5e-b355-f3c0e884c759"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10b655adc4f8423ebd42175f161edd73_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS0yLTEtMS0w_ca75d146-d5e5-4cc4-92bd-81a2d71245cf"
      unitRef="usd">2699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78c26b4e162a49b9b197f1640463053d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS00LTEtMS0w_3eec300e-eab9-495d-88ca-3ae7eb5af5a0"
      unitRef="usd">3201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1769fb5f785f43cf8b7d381fe86af413_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS02LTEtMS0w_80202a84-dd5b-450e-814d-82df0bff63c3"
      unitRef="usd">3266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i10b655adc4f8423ebd42175f161edd73_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS04LTEtMS0w_81f429dd-4239-4104-be2e-25eab7f456d8"
      unitRef="number">-0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78c26b4e162a49b9b197f1640463053d_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMS0xMC0xLTEtMA_f3b9ab3b-47ed-4b45-811b-9727c56d2d0c"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9d9753225f044ebbfafcd3370a90ed3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy0yLTEtMS0w_b5d1ec1a-d778-4c36-ab68-7409dd28dec8"
      unitRef="usd">3249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if13294f9754845688655bd40b3653471_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy00LTEtMS0w_525f167e-7451-4c91-bbb6-2f642a318362"
      unitRef="usd">3828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie09529f945de41caaf3bef2e44de7877_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy02LTEtMS0w_c8005983-eb65-4073-ae3b-3850d58f2ce9"
      unitRef="usd">4125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic9d9753225f044ebbfafcd3370a90ed3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy04LTEtMS0w_363fbf6a-0a3f-4f6a-a860-f611499417c8"
      unitRef="number">-0.151</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if13294f9754845688655bd40b3653471_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwMy0xMC0xLTEtMA_a50d2ffa-dae0-4093-b07c-bb081094c7fd"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03f5c7f59b794e47882cf0b139603a2a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC0yLTEtMS0w_5f10a165-7e66-4696-87c8-301075cbb314"
      unitRef="usd">4983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee94c42379ca4ae7b59723ae48eb43f7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC00LTEtMS0w_e7b9f247-a7a2-4c39-8367-740de372c66d"
      unitRef="usd">5673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdcdb5946b6e40db92ff0a19f1cde8c0_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC02LTEtMS0w_d63d6c8d-e95d-436a-aa9c-551479db398b"
      unitRef="usd">5776000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03f5c7f59b794e47882cf0b139603a2a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC04LTEtMS0w_329b51fb-788e-4b84-9d93-bd2233173fcb"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee94c42379ca4ae7b59723ae48eb43f7_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNC0xMC0xLTEtMA_769ae329-2f7c-4c3b-9645-28b9f8e550a0"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fe224c1cfa742a4b21d4f7862c83e03_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS0yLTEtMS0w_9888964b-6569-44a8-a297-46dd2b69ce4c"
      unitRef="usd">8232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if064eea59802474d80fe24566892332e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS00LTEtMS0w_ad46b95d-cf0f-41ed-adb8-73bb5e7f0999"
      unitRef="usd">9501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0883d7bb7144c62b0468b8a4d80e4e8_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS02LTEtMS0w_8ef8bfc3-5914-4667-9fcd-00167d3b0bce"
      unitRef="usd">9901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3fe224c1cfa742a4b21d4f7862c83e03_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS04LTEtMS0w_5fefbfe8-4b26-4d4d-91be-99fd9f1c468f"
      unitRef="number">-0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if064eea59802474d80fe24566892332e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNS0xMC0xLTEtMA_ac9398cf-32d7-4fcb-9c26-15b7f99591c9"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1981696707f74ea485655942372b2873_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy0yLTEtMS0w_2ea97710-ea01-4057-9271-75f1268d2094"
      unitRef="usd">1535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i937763a9251e44e7955bb4a051ffa322_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy00LTEtMS0w_7d7f9575-526a-4335-bc8c-2e2cbc528e36"
      unitRef="usd">1637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c754ff60a3c4d0f8af0b237cc3e417e_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy02LTEtMS0w_c92ac87e-487d-451e-8fb7-9d422c98b9a7"
      unitRef="usd">1657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1981696707f74ea485655942372b2873_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy04LTEtMS0w_e4135529-487b-4078-9cc0-0bc0bf2e4415"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i937763a9251e44e7955bb4a051ffa322_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwNy0xMC0xLTEtMA_2a0857a8-af73-4902-bf42-f7cc8f923f2c"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibec42c4dc9ed465e911fa5c37e44ccf7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC0yLTEtMS0w_d740e695-2adc-4cf9-8b79-42ec1317159d"
      unitRef="usd">2304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i392c683c8aa34ea48aad01f0ea87e36d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC00LTEtMS0w_0d0634b1-21c0-4b3d-98ae-d528d7163a3c"
      unitRef="usd">2458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c0ee73c79784b42b048a39b82f15449_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC02LTEtMS0w_795845ed-f0b8-4c7b-bc96-dd2128b06a89"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibec42c4dc9ed465e911fa5c37e44ccf7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC04LTEtMS0w_a3d9a31d-b3fa-4f58-9c0f-15918e79cc74"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i392c683c8aa34ea48aad01f0ea87e36d_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOC0xMC0xLTEtMA_6acd051d-efbc-4f47-92fa-839d952f05fe"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i999165b6e8ed4882bd941a2d188bcf37_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS0yLTEtMS0w_1595b95f-4a20-484a-b50b-9417c7b70260"
      unitRef="usd">3839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8caff817f2b44b13b3564e9cfa3e7994_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS00LTEtMS0w_f399d742-985e-48f1-b30f-e666608bd3c4"
      unitRef="usd">4095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7f935698e0f466fafbc30ad31035145_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS02LTEtMS0w_27ca9e7b-c271-487b-9c23-4d0cc586a4e5"
      unitRef="usd">4002000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i999165b6e8ed4882bd941a2d188bcf37_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS04LTEtMS0w_b3588b5e-fe08-4260-aabf-5ca66b0542df"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8caff817f2b44b13b3564e9cfa3e7994_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIwOS0xMC0xLTEtMA_eb033a2a-0053-4262-9231-5d14dff6fad6"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e4986f2ad3a4f63a2c9caa1b763924f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS0yLTEtMS0w_05eb101e-e298-45c7-ad61-b09328deda30"
      unitRef="usd">1714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibec43032d4244efb878a5a63619550e6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS00LTEtMS0w_6a5a3027-affc-472c-8cdd-2842a611676b"
      unitRef="usd">2192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69ce0e7d756944dab4eba19c5dd8a08c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS02LTEtMS0w_cbc44de2-7554-4a4c-83fe-18d09733167f"
      unitRef="usd">2468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6e4986f2ad3a4f63a2c9caa1b763924f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS04LTEtMS0w_72a1c516-dda5-4d3d-ad87-3df4100d5090"
      unitRef="number">-0.218</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibec43032d4244efb878a5a63619550e6_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMS0xMC0xLTEtMA_deb377d2-c3e6-4814-bb44-f42b3533cfdb"
      unitRef="number">-0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f63065772bc45baa7b3cae1ddb30035_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi0yLTEtMS0w_731c6b33-7616-4e80-9f89-34cc74de3e9b"
      unitRef="usd">2679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie86b777937ae417b9621ef2d6deff23b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi00LTEtMS0w_bc00978f-fcfb-4be5-9c56-220f3722a5bc"
      unitRef="usd">3215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62a6a11dfe68475a8e53247f2ea77b46_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi02LTEtMS0w_040f215a-497d-47b9-9522-ae4918afd3b9"
      unitRef="usd">3431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4f63065772bc45baa7b3cae1ddb30035_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi04LTEtMS0w_afdcd920-0288-4b85-bfad-de1b3333e0bd"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie86b777937ae417b9621ef2d6deff23b_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMi0xMC0xLTEtMA_af1c3342-589f-4cab-bf84-0af84f243aec"
      unitRef="number">-0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94beb64c27374b788645e22ad29711ab_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy0yLTEtMS0w_ed4dcbd3-e4b9-404e-97a2-9c24656b3166"
      unitRef="usd">4392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb9802f870444ad395ac0a641a75f539_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy00LTEtMS0w_4ac6db61-0aa7-451c-99ce-68af61446a6e"
      unitRef="usd">5406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dfc9343e80548ada1bc35627fe66ec6_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy02LTEtMS0w_68e7b251-40cc-4eeb-9a35-f0ac471603d4"
      unitRef="usd">5899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94beb64c27374b788645e22ad29711ab_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy04LTEtMS0w_d1ff5d57-ad17-4d49-9815-23762386a855"
      unitRef="number">-0.188</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibb9802f870444ad395ac0a641a75f539_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxMy0xMC0xLTEtMA_437553d1-9e1d-438f-b01a-8cd66718e531"
      unitRef="number">-0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18b4a8e9fa4442188bdbda3ba66062e6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS0yLTEtMS0w_c6c5dfaf-6c46-42ae-84e8-a205053a212e"
      unitRef="usd">1557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic17b6a75086b4b339878cc6f6e4ee32e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS00LTEtMS0w_c8ca70a8-8be5-4d05-8cba-6be6b040f92f"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i729754834d2e497cb672920410a2293f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS02LTEtMS0w_81db3d57-e026-4b83-b9b2-bf2b33fcf407"
      unitRef="usd">1777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i18b4a8e9fa4442188bdbda3ba66062e6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS04LTEtMS0w_96f4f8bd-38c4-4f16-801b-630e104afe22"
      unitRef="number">-0.132</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic17b6a75086b4b339878cc6f6e4ee32e_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIxOS0xMC0xLTEtMA_bcd11b49-d6f0-433f-8757-cf56bd91ba52"
      unitRef="number">0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic99d3a2205024fd7aa3983a217efd24d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC0yLTEtMS0w_222602e2-054b-4b07-a052-0dc3d11d6491"
      unitRef="usd">2362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3a672c335384c4b8c7925ba2498c104_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC00LTEtMS0w_8337c2ab-73b9-44e6-9832-04ec463c773c"
      unitRef="usd">2830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i593bcd3da2134b72a6c456811d3bc68f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC02LTEtMS0w_98c62d75-7148-455f-a24c-c17129ec2ecd"
      unitRef="usd">2776000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic99d3a2205024fd7aa3983a217efd24d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC04LTEtMS0w_8a6161c2-a320-4f35-a140-41588ef02b05"
      unitRef="number">-0.165</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia3a672c335384c4b8c7925ba2498c104_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMC0xMC0xLTEtMA_9197a58f-3235-4812-b20d-4544315e6797"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06378183c0c04df6aee2790130a1c904_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS0yLTEtMS0w_9e7eff31-c681-403b-b659-b24418dfef8f"
      unitRef="usd">3919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9550ff545c364be7bf6bf5426c596967_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS00LTEtMS0w_1bd7ebbf-9d94-4f78-b647-027b9bbcf9db"
      unitRef="usd">4624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c31bf3540b249a5abfdb33d6014307e_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS02LTEtMS0w_6c9f96d7-a25d-4d4f-b482-f7ab29f22cce"
      unitRef="usd">4553000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i06378183c0c04df6aee2790130a1c904_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS04LTEtMS0w_09b88cf7-afb1-4073-8cfd-e998b939ef5e"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9550ff545c364be7bf6bf5426c596967_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMS0xMC0xLTEtMA_63182ecf-5c8c-4e4f-bc26-fcd983132ff9"
      unitRef="number">0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i751b8108d9d349959d4405809c8ab185_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy0yLTEtMS0w_748625c6-6a8f-4cf8-b9c1-69b70620f7db"
      unitRef="usd">1213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb989f6f7b574d94a635536180d59536_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy00LTEtMS0w_4a2820fc-eead-421b-92ac-f92ea322344b"
      unitRef="usd">1304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i581f35bde0a74622a88029dde8d73d94_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy02LTEtMS0w_3745b0c5-02d9-4f93-af54-f7b63534e17c"
      unitRef="usd">1237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i751b8108d9d349959d4405809c8ab185_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy04LTEtMS0w_7b00efd2-1f91-40b0-91f4-4f4d1695a6db"
      unitRef="number">-0.070</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieb989f6f7b574d94a635536180d59536_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyMy0xMC0xLTEtMA_00c74062-3284-48c9-9746-8db5ef071fe5"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic132a1e2f99f416cb0d2e0b8c3db41d2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC0yLTEtMS0w_b3aa0c90-a6b9-4a1c-b32c-dd7abbeade65"
      unitRef="usd">1781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01c7263d4b1b4d6baaf5dc29b81024f1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC00LTEtMS0w_ccb51067-3e4d-431c-90b7-13471e2ad332"
      unitRef="usd">2088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fd3d0d30a41486ca32673d4a704becf_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC02LTEtMS0w_630f11c1-b3dd-46e2-9f91-130220c8c9f8"
      unitRef="usd">2065000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic132a1e2f99f416cb0d2e0b8c3db41d2_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC04LTEtMS0w_0883ca1a-e674-4fa2-9a11-24bed508c4af"
      unitRef="number">-0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01c7263d4b1b4d6baaf5dc29b81024f1_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNC0xMC0xLTEtMA_a830a82c-64be-44d1-b654-2c067c859606"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3f31428fd964ba5aa8c86b194d7c991_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS0yLTEtMS0w_14817fad-8f91-4b81-ac77-15844ad45e4b"
      unitRef="usd">2994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic706f0504b304e95a8c897adb4eb5bdb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS00LTEtMS0w_47ec2308-c0cb-4437-a4cd-e1939d1d3204"
      unitRef="usd">3392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90e188e5ac28451ea93d0fd0cf9f30b6_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS02LTEtMS0w_9263848a-80db-41e3-a6eb-45d2ef09c098"
      unitRef="usd">3302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3f31428fd964ba5aa8c86b194d7c991_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS04LTEtMS0w_1c9f6d86-b72f-453a-8695-5bc87fb6d93e"
      unitRef="number">-0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic706f0504b304e95a8c897adb4eb5bdb_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNS0xMC0xLTEtMA_4feab345-54a2-4dff-adff-1c9a91a99d6d"
      unitRef="number">0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72196f5c2fe4ccbb68e25e0300f191a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy0yLTEtMS0w_ac79a15e-73fa-402f-81bf-efa3ee19db8b"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05c0225e9d5c41288c143c63de199e35_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy00LTEtMS0w_6f0da8cb-1e59-4a33-9fa5-bd0163922816"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i079eba6ad58c4cdaa2289aea2957a33a_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy02LTEtMS0w_a892919e-3b1e-4965-9723-efef555d8947"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if72196f5c2fe4ccbb68e25e0300f191a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy04LTEtMS0w_66f8eae5-dada-4d8b-91b7-4d6f98bb5a24"
      unitRef="number">-0.297</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i05c0225e9d5c41288c143c63de199e35_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyNy0xMC0xLTEtMA_a5aad8ec-1b48-45c7-b9ec-915892ff4f95"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib235d8407dc543329206c5389bc899ed_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC0yLTEtMS0w_ea849efd-2351-4891-972a-38b0d6757735"
      unitRef="usd">581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fe938c1143d420c9f0d0cd44b50a6f9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC00LTEtMS0w_07004a89-fb0c-473e-afe2-8a273195a360"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58266c3fbe6e420ba392695ba369fbac_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC02LTEtMS0w_fec5c52b-4921-4cde-9e2b-bd9a1abaf2e9"
      unitRef="usd">711000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib235d8407dc543329206c5389bc899ed_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC04LTEtMS0w_f1027ae6-f5c9-4914-b7b5-770459bd1658"
      unitRef="number">-0.217</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0fe938c1143d420c9f0d0cd44b50a6f9_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOC0xMC0xLTEtMA_3c190d97-02a7-4fcf-8f80-f55db7c42962"
      unitRef="number">0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3362deef6ba432593d2905bb07487d3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS0yLTEtMS0w_7458c978-ba97-416f-9e72-3090a0ca1ed1"
      unitRef="usd">925000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34d31af3f79b48dcbc05247b533fb5c8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS00LTEtMS0w_954108b4-cda4-40e3-9c04-7345d95920ab"
      unitRef="usd">1232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b492b8ad5b746c4af5adfc5a3bbe67e_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS02LTEtMS0w_e16d345f-d36b-43b4-a233-b272b05f1da2"
      unitRef="usd">1251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3362deef6ba432593d2905bb07487d3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS04LTEtMS0w_8fdb1b48-9831-44bb-8b1c-ba6809efaf6d"
      unitRef="number">-0.249</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i34d31af3f79b48dcbc05247b533fb5c8_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIyOS0xMC0xLTEtMA_ac6b04ff-cdd9-438a-8c19-6d64f551ef45"
      unitRef="number">-0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5079c809180e4e87babea3c6989b7547_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi0yLTEtMS0w_e6e4caf4-8dd6-4834-910c-cf13e20dcae6"
      unitRef="usd">11036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17e3d6f06df7480d93661480c79c1945_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi00LTEtMS0w_d61f5270-e9ba-4c29-a07e-3e06de0a4069"
      unitRef="usd">12384000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58588fe179f34bbabe168069b7a7b71c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi02LTEtMS0w_b537d9cb-ea90-4da9-a62d-ec97511f96a5"
      unitRef="usd">12837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5079c809180e4e87babea3c6989b7547_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi04LTEtMS0w_831e1e85-1aea-4b86-8959-a9ee483574d3"
      unitRef="number">-0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i17e3d6f06df7480d93661480c79c1945_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMi0xMC0xLTEtMA_42fa83b4-cb29-4400-bc1c-7d80ccb3f6d2"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie24857abc09b4ecfa16764d38c143530_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy0yLTEtMS0w_b5aef4c9-57b1-43c9-8d5c-46ab3a36089f"
      unitRef="usd">11923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e939c765bc94e7bb66e7118c3f4a40a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy00LTEtMS0w_8cc68c33-88ab-47dc-9a53-d2579ac4493c"
      unitRef="usd">13579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37350417ebd24c1ab07e70ff74cec182_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy02LTEtMS0w_f05c23a4-450d-49c8-82aa-b92afbc84232"
      unitRef="usd">14157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie24857abc09b4ecfa16764d38c143530_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy04LTEtMS0w_0545d544-62bf-4a56-9bf2-21fe70fe7c9e"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2e939c765bc94e7bb66e7118c3f4a40a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzMy0xMC0xLTEtMA_56141862-55ed-4665-9c74-8138761f8663"
      unitRef="number">-0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC0yLTEtMS0w_99c4e58b-d0a3-4b88-a37a-a05b9243c1a3"
      unitRef="usd">22959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC00LTEtMS0w_84f0cb2c-3b65-4586-817d-4d0a3488463c"
      unitRef="usd">25963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC02LTEtMS0w_cf9e26fd-640d-4587-b120-91d2706b3b85"
      unitRef="usd">26994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC04LTEtMS0w_cdec7539-784b-4554-aa04-2a2fcc0db172"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNC0xMC0xLTEtMA_76f15165-f754-4194-8db5-2644395e1a0f"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3121943b0bc44e4988cad36f10e55132_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy0yLTEtMS0w_e648ecf7-976f-4a8b-ad5f-ae0bc4b1604b"
      unitRef="usd">43133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a0dbe0f615447893dc66aacf30202d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy00LTEtMS0w_df462f45-fc12-4a37-8483-686960292af6"
      unitRef="usd">42097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2433804bf27d4a1ba35c905c2d32c4a2_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy02LTEtMS0w_66238e22-7236-406c-9bb9-3ecd7c968257"
      unitRef="usd">41884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3121943b0bc44e4988cad36f10e55132_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy04LTEtMS0w_f6c65c6c-d7ab-45d7-8115-efe7fbea96ca"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i93a0dbe0f615447893dc66aacf30202d_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzNy0xMC0xLTEtMA_8dfb549d-90a5-4305-9371-f2df23c42fe4"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f554723bee640bab353dcfcaa1353a1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC0yLTEtMS0w_a6b36ff6-948c-4372-84f6-385a2171036d"
      unitRef="usd">39451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f7ebf2e8efe428dba5d7904ddaedacb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC00LTEtMS0w_805f4460-ff38-429e-b64b-2202497ce5ca"
      unitRef="usd">39962000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf8d7c0a664e4c77a5fbeba28997ebfa_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC02LTEtMS0w_09e33f7f-9fa0-4070-8424-074e3b40298c"
      unitRef="usd">39697000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f554723bee640bab353dcfcaa1353a1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC04LTEtMS0w_445fc533-8f75-4510-8bb1-8262da18619a"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9f7ebf2e8efe428dba5d7904ddaedacb_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOC0xMC0xLTEtMA_2db208d1-f889-46a0-82ae-4b89fbf44224"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS0yLTEtMS0w_6aeaa8ed-d593-417b-acf4-4696120df9ba"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS00LTEtMS0w_440f0141-5e7e-4a94-a19c-12ece8600b2a"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS02LTEtMS0w_f7be9921-2416-449b-8c3d-c76c6d0d511b"
      unitRef="usd">81581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS04LTEtMS0w_918ba0a0-8d91-43de-88f8-a286ad6be309"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo0OGMxODBmZjQ0YWI0NDNhYWQyMGEwZGUwNzI2OWIyYi90YWJsZXJhbmdlOjQ4YzE4MGZmNDRhYjQ0M2FhZDIwYTBkZTA3MjY5YjJiXzIzOS0xMC0xLTEtMA_56dafd73-0b8e-45fb-a524-534f6460058b"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyNTk_19d2a6b9-c663-4ba3-9953-a1350885e281">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (Loss) Before Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,929&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i642be708def7413dabc7b84d041f991f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItMi0xLTEtMA_22b0f42b-ab5b-41dd-959a-bbdf2b11b52a"
      unitRef="usd">-1064000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItNC0xLTEtMA_87c4748b-49f1-4697-8d3a-b3298782b489"
      unitRef="usd">2061000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItNi0xLTEtMA_c3daabb9-3e44-4af7-b9a8-412f327034c2"
      unitRef="usd">2320000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:Assets
      contextRef="i47de1912a2bc4859b0defe8556c3f667_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItOC0xLTEtMA_f55584a4-6f0b-414f-bad7-e2c82735bb08"
      unitRef="usd">27355000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2df63a4309a0439b9c69ba7538fca3be_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzItMTAtMS0xLTA_aadd9080-cbaa-46fb-8f13-812a506f127c"
      unitRef="usd">26618000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtMi0xLTEtMA_a494a78b-d870-4f6e-b7a5-14289df6f21a"
      unitRef="usd">15462000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtNC0xLTEtMA_5db3d409-6ad4-4ad9-9f01-e69a73f0c225"
      unitRef="usd">8816000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtNi0xLTEtMA_f02f1a17-97af-4abd-b08f-0decd364e53e"
      unitRef="usd">12568000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:Assets
      contextRef="i077c5383de0a4ef5b6e04faef9537701_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtOC0xLTEtMA_095ff482-9270-4095-af75-306dfe62cabe"
      unitRef="usd">66158000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ieae4a2195e634b988c290e9a18191ee3_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzMtMTAtMS0xLTA_5499fa53-44d7-443e-8c65-4dd0efd4dff7"
      unitRef="usd">56292000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtMi0xLTEtMA_644ee50f-d7a9-4129-8666-fa45220fbec9"
      unitRef="usd">3044000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if841232101534f53b580eec2b5065a8b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtNC0xLTEtMA_ca14a88b-2153-4322-b08a-426681823271"
      unitRef="usd">7286000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtNi0xLTEtMA_716896de-bfcc-4ba7-a63a-cbd42f8d0168"
      unitRef="usd">4397000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:Assets
      contextRef="i2edbe06fd12f48158aa18ec4e99452f4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtOC0xLTEtMA_6f57c5ac-48e3-4c5d-a923-7b7286e70ee5"
      unitRef="usd">49578000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2244f03ed8794c27a6ca06574aa2e8bd_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzQtMTAtMS0xLTA_541e6f91-5791-4848-956a-9791521e77f2"
      unitRef="usd">49462000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2bef2be8cac3404983af1188af384ef4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtMi0xLTEtMA_23c1370d-c561-4ebb-b745-a55062885f72"
      unitRef="usd">17442000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i05c2d444872e4307aeeecc3b63c90b14_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtNC0xLTEtMA_de0c5c58-2d8b-421c-9d40-a5354cae2c16"
      unitRef="usd">18163000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iadcb5421eef24006804c7c3cea1e9fcb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtNi0xLTEtMA_2089d645-67bb-43ad-9d82-f02063632c8d"
      unitRef="usd">19285000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:Assets
      contextRef="ia95e9493ef57449b82086c14a005a57e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtOC0xLTEtMA_179329fc-1edf-4af1-b6c1-0b6adf96a24f"
      unitRef="usd">143091000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i95d8373ae98f4edd99b0fbc74c83f2b7_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzUtMTAtMS0xLTA_09576d62-4219-4619-8993-a83c018e918d"
      unitRef="usd">132372000000</us-gaap:Assets>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i5f8bf98199ca4359a65148eaa4b30c82_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzYtMi0xLTEtMA_9aba8fea-d544-4bd7-bae7-77e02c1b7f51"
      unitRef="usd">945000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i3a0c83283a7a4e978c00244503b2a25f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzYtNC0xLTEtMA_3b9aabd6-bad6-420d-a64e-3a24be53a750"
      unitRef="usd">835000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="idf6cefb7c53d43baacb94f6acb2d8f23_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzYtNi0xLTEtMA_3d1db67f-fec4-4c13-b805-aeada8965bfa"
      unitRef="usd">1286000000</jnj:ExpenseNotAllocatedToSegments>
    <us-gaap:Assets
      contextRef="i0f65207fc7f44ad2ae85cee82bd938ca_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzctOC0xLTEtMA_3922b38e-f369-49aa-94c6-82384c1cd30b"
      unitRef="usd">31803000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i742ec0e39c9e4a5aa684735e52151b2d_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzctMTAtMS0xLTA_6abad42a-5191-400c-8dd3-e62c240a2cf8"
      unitRef="usd">25356000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtMi0xLTEtMA_4a3b6c10-cfe1-415f-93ad-9d55a55107e7"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtNC0xLTEtMA_6a00b941-79ba-4bde-a064-00d99e7e0707"
      unitRef="usd">17328000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtNi0xLTEtMA_fc3ffe98-4db9-4b13-9477-bfb37b929513"
      unitRef="usd">17999000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:Assets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtOC0xLTEtMA_83020a88-9fa7-4ca6-aac3-f9e4a3df4614"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZToxMWZhNmY3MTVkZmM0ODlkYmU5MTUwZTVjNGIyZDIzOC90YWJsZXJhbmdlOjExZmE2ZjcxNWRmYzQ4OWRiZTkxNTBlNWM0YjJkMjM4XzgtMTAtMS0xLTA_86cfa0c9-52b4-4d09-b3dc-dd8e15728ffe"
      unitRef="usd">157728000000</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i642be708def7413dabc7b84d041f991f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItMi0xLTEtMA_9cfdc1d9-ae8a-4c8f-a7af-862b39b96057"
      unitRef="usd">248000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItNC0xLTEtMA_84d982ac-f20d-4847-8e5b-6b1603184361"
      unitRef="usd">328000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItNi0xLTEtMA_5bca527d-0106-497d-9314-249470d0c316"
      unitRef="usd">438000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i642be708def7413dabc7b84d041f991f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItOC0xLTEtMA_17e5cf28-c46c-4cc5-a9b4-6ffa4c975c7b"
      unitRef="usd">785000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i19025b3ff08c42a78c014b5536bb4744_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItMTAtMS0xLTA_6d39f5c5-c573-4cd4-a43b-1a0ec013183f"
      unitRef="usd">765000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i003ba041a1a34edf87fa4472605b9e40_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzItMTItMS0xLTA_48f67229-a7be-4606-b10f-632a05009981"
      unitRef="usd">688000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtMi0xLTEtMA_8c7916f2-2b15-48b9-8b4e-2e3b9662c9c9"
      unitRef="usd">863000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtNC0xLTEtMA_b2419235-e131-4437-a32e-c4f7526d4346"
      unitRef="usd">950000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtNi0xLTEtMA_a7fdcc34-3585-4b22-82fb-42c169bf4074"
      unitRef="usd">1012000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtOC0xLTEtMA_f526c18c-6343-4aca-8326-771bab75c62b"
      unitRef="usd">4006000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtMTAtMS0xLTA_4bb4d3fa-aea7-45d7-b7d0-5bb4b5a20f08"
      unitRef="usd">3910000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i915e779f6406409c8859f17cc594ac1f_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzMtMTItMS0xLTA_bb58b473-76e3-4339-9021-7155e6beb6ab"
      unitRef="usd">3802000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtMi0xLTEtMA_12209410-b325-45da-835b-d438387ef24e"
      unitRef="usd">1980000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="if841232101534f53b580eec2b5065a8b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtNC0xLTEtMA_80f6e633-af5e-4588-9e2f-bf182d5e430b"
      unitRef="usd">1912000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtNi0xLTEtMA_0f5d2e0c-619b-47c9-9393-75033685162b"
      unitRef="usd">1843000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iffa644441b6946dabb484229f4f1dd84_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtOC0xLTEtMA_71a8efce-0353-4d68-8f61-64f7a101bc18"
      unitRef="usd">2140000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if841232101534f53b580eec2b5065a8b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtMTAtMS0xLTA_dc5fd0b6-45c9-4c52-9dcc-b501180e4982"
      unitRef="usd">2014000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i12ccdcf4220a45dd83100ea59a033835_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzQtMTItMS0xLTA_2513da18-a36c-4baa-a45c-a7967d61e971"
      unitRef="usd">2103000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i3b28a8f605f94f75b14c686dc2522e6a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtMi0xLTEtMA_70d61819-ddea-4951-9c6d-f61565b3be49"
      unitRef="usd">3091000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i8d1c8604abf643c9a12b71cd7d31eb00_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtNC0xLTEtMA_de7ab41d-f8ac-4313-8263-9f7cff2d3e44"
      unitRef="usd">3190000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i8e5dcf1d4a1e417bb4b42eab3fa4b8ac_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtNi0xLTEtMA_ebec7deb-fe8d-4ff3-b536-8af7d9beae2d"
      unitRef="usd">3293000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b28a8f605f94f75b14c686dc2522e6a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtOC0xLTEtMA_42032500-70f9-4e57-b353-3ed9208115b9"
      unitRef="usd">6931000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8d1c8604abf643c9a12b71cd7d31eb00_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtMTAtMS0xLTA_ef812d02-ab83-49db-a08a-1e256d3a00a8"
      unitRef="usd">6689000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8e5dcf1d4a1e417bb4b42eab3fa4b8ac_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzUtMTItMS0xLTA_7a5232cb-912b-49fb-af5d-bd57b31b97d1"
      unitRef="usd">6593000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ie728c62d2459463bb8fc5167f5c487da_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtMi0xLTEtMA_c484f7ab-edc1-4d40-8207-d4e7acd2a1af"
      unitRef="usd">256000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="icaf1dfe1a8b944b8bc2c86ec9a44bdcf_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtNC0xLTEtMA_d58b9103-6257-4465-a9a8-ca8594287d9d"
      unitRef="usd">308000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i67c617cfb7894c9d832fc9595def2dd1_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtNi0xLTEtMA_3927b920-ff6b-4e19-92f3-e8012da29c95"
      unitRef="usd">377000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie728c62d2459463bb8fc5167f5c487da_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtOC0xLTEtMA_da9024e1-731c-41f9-9057-5c0a46696b9b"
      unitRef="usd">300000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icaf1dfe1a8b944b8bc2c86ec9a44bdcf_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtMTAtMS0xLTA_57b39ed1-7974-4277-9db0-8c6b5ec9c588"
      unitRef="usd">320000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i67c617cfb7894c9d832fc9595def2dd1_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzYtMTItMS0xLTA_51c000b4-d7de-41a2-9975-37f5e52b5649"
      unitRef="usd">336000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctMi0xLTEtMA_2e90b9a4-49b2-4513-b252-d13aa544e0e7"
      unitRef="usd">3347000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctNC0xLTEtMA_3c2ff393-6ec8-47d6-b1e2-b6bd1bad9041"
      unitRef="usd">3498000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctNi0xLTEtMA_1b35929c-46b4-422e-be33-dc4faed4d948"
      unitRef="usd">3670000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctOC0xLTEtMA_9fac8a9a-ffe7-45b4-9707-a8aa530bde3e"
      unitRef="usd">7231000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctMTAtMS0xLTA_f279f652-7d33-45b2-ad60-31e034cd0046"
      unitRef="usd">7009000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTpjNWU1ZGFkNGJkNjQ0MDc1OWI0MGNmNDk0MTliODg0MS90YWJsZXJhbmdlOmM1ZTVkYWQ0YmQ2NDQwNzU5YjQwY2Y0OTQxOWI4ODQxXzctMTItMS0xLTA_aa67f2d8-5421-47d0-954d-05e19ed1d81d"
      unitRef="usd">6929000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDQ1MzYwNDgwMzI4_d91855bd-55c6-451d-8ec0-53795aeb5ffe">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81,581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;157,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;General corporate includes cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.5&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.2&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9 billion related to the Alios asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A research and development expense of $0.3 billion for an upfront payment related to argenx &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.6 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Actelion acquisition and integration related costs of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring charge of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $2.0 billion from the divestiture of the ASP business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Auris Health acquisition and integration related costs of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.3 billion from the divestiture of NIZORAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Actelion acquisition and integration related costs of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized loss on securities of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $1.7 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.6 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;AMO acquisition and integration related costs of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.5 billion from the divestiture of the LifeScan business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idad324e736f04bc29364176151a23e2a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItMi0xLTEtMA_dd1812ff-46e2-4d6c-b23e-6acfd8158c7b"
      unitRef="usd">43133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6887fdffd35c41348f9aeb0c27b07ba2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItNC0xLTEtMA_53d4723d-3dcc-4f04-af0e-7b40e0a0d0b8"
      unitRef="usd">42097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaea71296fec64699bfe2bf754f22f26c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItNi0xLTEtMA_f13dd31c-df81-4932-adef-4cf6fd6029cd"
      unitRef="usd">41884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i0a788b9d1d084972933b07d5c268c034_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItOC0xLTEtMA_42e80199-68c6-4b5f-9e3a-33f806495302"
      unitRef="usd">49951000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i875011bdf5ae45a088eff8aa4e901299_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzItMTAtMS0xLTA_20af1b58-9a80-4d34-9bca-67e20e52104b"
      unitRef="usd">41528000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8e58bfcff40486e8072fafaac9bd118_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtMi0xLTEtMA_88781ea2-a313-42fb-91a8-9cc8508e50b3"
      unitRef="usd">18980000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31e3eb051f454593ad2310cf80ffb554_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtNC0xLTEtMA_4a193886-43b4-4462-b968-6d3b7656dbe9"
      unitRef="usd">18466000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i079da15a84a34e4198ff651865a8038c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtNi0xLTEtMA_678b3346-ea87-4375-a93e-cde00690aa82"
      unitRef="usd">18753000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i12c62fc9b4be4d35bc62769025bc8c59_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtOC0xLTEtMA_3d67be3e-15ae-4032-9b4f-449fe4a78f60"
      unitRef="usd">49363000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1befbfcdf8fc41b68d2d73068d97c2a6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzMtMTAtMS0xLTA_1e79ce11-7f87-467d-9a24-cad4e70ef901"
      unitRef="usd">48015000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5579c03fb48a43a7a109405d767a3964_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtMi0xLTEtMA_9d08988d-3fc1-4a04-a25c-dd1d9ce67a4f"
      unitRef="usd">5335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d3881ea9c694735ae5a5c61f3442642_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtNC0xLTEtMA_3cfcfd40-6afe-4ee2-915f-f249dcef5cbc"
      unitRef="usd">5941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d15cee058f64c2c9ad5c5d19645970c_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtNi0xLTEtMA_14f08fcf-b70f-457e-9236-83d9e495391d"
      unitRef="usd">6113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i3fc3b1a2bc054935a96c8c42b944c4ca_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtOC0xLTEtMA_0e4bea66-4d87-48b1-b019-9771cd221076"
      unitRef="usd">2734000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia9a7c95098b948b58ef457213dbf6381_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzQtMTAtMS0xLTA_90e1a0e9-ade8-43ac-9524-5a10988683ce"
      unitRef="usd">2862000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i221d578ffbb64653ba21c30b54079cc0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtMi0xLTEtMA_779cd14c-0fd7-4847-a936-de4950b624d0"
      unitRef="usd">15136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3b64bc0f1de4cf19d38861ea0a431a2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtNC0xLTEtMA_c3665870-e0e5-4e1d-997e-183ef5d3b5e4"
      unitRef="usd">15555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i748076e324e04eb6876fea17432e0764_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtNi0xLTEtMA_52823f5d-9a28-43a0-94f9-3ce9aa4dc698"
      unitRef="usd">14831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="id4009a5bef5c4d3e93a8d64a351d480c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtOC0xLTEtMA_57e5dcef-c188-4668-a429-73b6acdaa4fb"
      unitRef="usd">5484000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ied02b691df1a4793820eca15169c551b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzUtMTAtMS0xLTA_435f5a4f-8d16-436b-8474-a845929d2d18"
      unitRef="usd">5486000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bef2be8cac3404983af1188af384ef4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtMi0xLTEtMA_f21e1792-8690-4aba-859f-edda7544bf8f"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05c2d444872e4307aeeecc3b63c90b14_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtNC0xLTEtMA_e7652cce-e65b-48be-b8c4-3247c1807736"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadcb5421eef24006804c7c3cea1e9fcb_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtNi0xLTEtMA_3b06506d-8093-4c4a-8b1a-45a66911c2f7"
      unitRef="usd">81581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="ic94bee8dba224f25ab579c909f351412_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtOC0xLTEtMA_86bd7f96-4b58-4f5e-b3a2-32ba4047fa10"
      unitRef="usd">107532000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i035675e545034a8daa97c38652231215_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzYtMTAtMS0xLTA_34240742-7b12-43d5-9730-0a8a8d61254d"
      unitRef="usd">97891000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0f65207fc7f44ad2ae85cee82bd938ca_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzctOC0xLTEtMA_6e6ec473-bea4-4e1a-ae1c-17ed26f28c4e"
      unitRef="usd">1029000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i742ec0e39c9e4a5aa684735e52151b2d_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzctMTAtMS0xLTA_069390c0-c069-4a66-83b8-9cab29aad282"
      unitRef="usd">1049000000</us-gaap:NoncurrentAssets>
    <jnj:OtherNonLongLivedAssets
      contextRef="id9e242133e6a48148ee336086579aa09_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzgtOC0xLTEtMA_e036c826-9250-4625-a39b-55fb53646bf3"
      unitRef="usd">66333000000</jnj:OtherNonLongLivedAssets>
    <jnj:OtherNonLongLivedAssets
      contextRef="i94f6eed880b84772b8aefd785e874762_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzgtMTAtMS0xLTA_3a1519c6-c2a8-40a3-b7c8-47878dcf07c5"
      unitRef="usd">58788000000</jnj:OtherNonLongLivedAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktMi0xLTEtMA_9a3b03e5-747d-4e21-be61-02788fe6dd29"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktNC0xLTEtMA_830ca4ae-fa67-4f7c-a2a8-d8b0160e75aa"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktNi0xLTEtMA_f38bc595-bc00-4357-b5a9-d3a5379fb193"
      unitRef="usd">81581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Assets
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktOC0xLTEtMA_43bc1d53-7197-4ddb-87c2-9ff5c5097f7f"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90YWJsZTo5OTVmYWM1NTAwZDA0NmZkOTcxNjk1YWRjNWYxNzM0Mi90YWJsZXJhbmdlOjk5NWZhYzU1MDBkMDQ2ZmQ5NzE2OTVhZGM1ZjE3MzQyXzktMTAtMS0xLTA_dbeea2d1-3e93-4285-a7f9-d27125cf1dec"
      unitRef="usd">157728000000</us-gaap:Assets>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMwMQ_d0293478-623a-4de5-a6ce-e10195513301"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie2df61011b564018ad5b03df881363ff_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzM0NA_b1cdc816-1e38-4554-8fc4-3a74b1b58f5e"
      unitRef="number">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1f14ae1615dc4d17b4edf556db9b6006_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzM0OA_adaee313-8a5b-4f69-9133-0c9576573c07"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i62050a01eb854e2383bc3ec498ccf086_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzM1NQ_bdb9729e-1541-4426-b58f-4c967a903eb6"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzQ2Nw_d0293478-623a-4de5-a6ce-e10195513301"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i808364999df6460a849022d9b066670a_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzUxMA_3098d963-54f0-45e4-82a8-55e8c2839fa3"
      unitRef="number">0.150</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e2e498bbaa444e9ac4c96b0df2ceafe_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzUxNA_f06d1b91-9742-48c8-a4d1-52ac8aefbab8"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie6728846518144a681a82a2d46f3f018_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzUyMQ_e6a49907-f855-4e40-bdfe-c4df65b2985c"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzYzMQ_7b3becae-8ee4-4ae3-a599-e2c76c964dfa"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i61dcd5aafdb0485db71a09a4bad0bcb2_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzY3NA_36aa7c3d-db0d-4ab3-9a83-96e0cf72b5af"
      unitRef="number">0.140</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i085fffe12cf44fa092d9246b89d54cba_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEyMDk0NjI3OTA4OTIx_d00ab711-784b-4ba3-8b26-95df6c8f1979"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i085fffe12cf44fa092d9246b89d54cba_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzY4MQ_cd626769-c540-43ff-a4c1-41ecce3951b9"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4da2513a70a34537aa49f31fb399dd1b_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQwOTQ_5db3da26-f3fe-4c42-8831-923effbb5d39"
      unitRef="usd">3900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQzNTI_64031ae1-bf9c-45ea-87fa-cc6d80fe3175"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:UnrealizedGainLossOnSecurities
      contextRef="id8f845c3d6be4af6902ffdf4fa244e7e_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQ3MTM_7d6edc5f-966c-4ee4-9ef4-9aa92eef59c3"
      unitRef="usd">500000000</us-gaap:UnrealizedGainLossOnSecurities>
    <us-gaap:RestructuringCharges
      contextRef="iea3aeb0c10f4436dbef3484089b0465e_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTQ3NDI_3f8ce6ac-5efe-4e4a-90aa-af24267f1c7d"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="icb9530f3d6cd435ba9e67542e9eca210_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTU3MjQ_57c71b2d-4e3f-45a1-9fa6-067206a21dfb"
      unitRef="usd">-1100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTY0MjI_f2129c5f-0a7b-489f-968b-8954e0d47de3"
      unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTYxNjU_0d094764-a455-42c8-b360-cf1691f23530"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzgyNDYzMzcyMTY0MDg_e049c4c1-899a-49b2-8227-bc9673bd3176"
      unitRef="usd">200000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:RegulationCharge
      contextRef="i0bfd65760ca8422290aecd1fa882ab4f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDQ1MzYwNDgwMzQz_5634f2a7-a9df-491a-96c7-9f1587283981"
      unitRef="usd">100000000</jnj:RegulationCharge>
    <us-gaap:GainLossOnSaleOfEquityInvestments
      contextRef="i911bd91ee4bc41389629447824db808e_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3Xzk0OQ_29560f52-2d7c-4e94-9f48-df4b876049cb"
      unitRef="usd">300000000</us-gaap:GainLossOnSaleOfEquityInvestments>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwNDk_655169c8-6fa1-4919-baa5-543f963bddc2"
      unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="ic8619876835d463982674bc871e45ae9_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEwODI_7f899899-4bdb-4610-9f28-207e5b4e6b3e"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzExNDQ_b0830a81-ad85-410b-ac05-ad2a39d70334"
      unitRef="usd">4300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i8db67b67955942f7a04d431f570d4565_I20191031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzExNTc_cff145ad-e344-4661-9cfc-2aa50d51de8d"
      unitRef="usd">4000000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzEzOTE_56079dff-d1b0-46fc-b5f4-5381c9f116b4"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE0NjA_b8af435a-6a55-4c18-8e24-f6be201b4106"
      unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnrealizedGainLossOnSecurities
      contextRef="ib57e82ed175145df99c35c70fbe25bbe_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE1NDE_1aa1781c-7468-468f-b12e-ad06fce19cd6"
      unitRef="usd">600000000</us-gaap:UnrealizedGainLossOnSecurities>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i619793eecabc489ba4c2968bb061e22f_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE1ODM_4b0ebaca-494d-41e7-b12c-afe2bd1d8898"
      unitRef="usd">200000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RestructuringCharges
      contextRef="i0e5abd8b683b4c56bb4e30be868e4282_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE2MTY_19521b0f-be79-4b64-957c-b0bda682e69b"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i6f0cb54bb4974193979769bf8aec917e_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE2Njc_f9d4d271-6940-40d6-8d18-52b86fff2536"
      unitRef="usd">2000000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:RestructuringCharges
      contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE3NDY_36c315c3-6c07-483e-ae48-8905af42abcd"
      unitRef="usd">400000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4c139e784fdc451f8e42c027bd08f436_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE3NzI_bc596e80-3f96-45e9-8b5c-524574d3d4f7"
      unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ia0899ff9af5041b68f780bfabfc0a5f0_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE4MjE_e14f5c90-6bf1-42f2-9adc-ba37a4996719"
      unitRef="usd">100000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ibd9e566fe73f466bbb7ee14bb2b8034f_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE4NjY_0ef8dfea-7f77-49a8-97df-be7e5c1e17c2"
      unitRef="usd">300000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i3c315b2e311c4bdc9634124f9332a881_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzE5Mjg_c154699b-be53-4b5f-b297-035c89afa8e1"
      unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i3d1841e88ae54dceb0af523351880c07_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIwMTc_ca9bcab5-92d9-4996-aaa7-bfd5f843865a"
      unitRef="usd">1100000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i902af15964e14194a303f3a664cb5d2f_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIxMTU_31117ff7-3e32-4cda-8ea7-86884e947d4e"
      unitRef="usd">-200000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i750e6f140fa94894b04bd3d8acbe99bd_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIxNTc_3b2c639c-cde7-4e13-b0f1-28502b3ac37e"
      unitRef="usd">200000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:UnrealizedLossOnSecurities
      contextRef="i9f8d35a5e5ef4407bffb29a594a0b67a_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIxOTQ_a0959a46-b785-43c8-aef7-293de85a16ca"
      unitRef="usd">200000000</us-gaap:UnrealizedLossOnSecurities>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i58e829bbfb07485da5515f522d722695_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIyMTE_9439a4d1-193e-4871-b04d-05714c19166a"
      unitRef="usd">200000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIzNDg_8253662e-4e25-4d9e-8aa6-5d12c2bd2839"
      unitRef="usd">1700000000</us-gaap:LitigationSettlementExpense>
    <jnj:RestructuringChargeNetofAccrualAdjustment
      contextRef="i5e60ef03ef22459c9e66932e0d9b985e_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzIzODY_525aed56-4f92-4607-90a3-45054db78842"
      unitRef="usd">600000000</jnj:RestructuringChargeNetofAccrualAdjustment>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="idcc4dd426fcc453da67295531f6d0a7e_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzI0MjM_910bdb31-730c-490c-8710-f441f53e36c7"
      unitRef="usd">100000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i527f590d7fbc4382b88ea8ad34d70258_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzI0NDA_2052e822-c9e8-46b9-9aaa-8567f33d13b4"
      unitRef="usd">500000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:NoncurrentAssets
      contextRef="i9cf7c5be7f3c4332b89431499d7c18c8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMxMzg_04996377-dd52-4eff-95ed-118231b71b2c"
      unitRef="usd">18766000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i8b3c10dbd47946ebbad7615c4da0af0e_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMxNDU_ffc5087f-6ab8-4005-931c-fc808b425c26"
      unitRef="usd">17658000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i8d63527739004691b878d7ebe2f0a1b6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyMjA_6fab88e1-0baa-4cc6-8de2-eb2acf77fb14"
      unitRef="usd">89795000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id21a208c5c3e4881b44ca05ec83a15c8_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMDgvZnJhZzpjMjUwYzhjYTc3ZGM0ZjQ3YjFkMGU0YmU2MjM5M2NlNy90ZXh0cmVnaW9uOmMyNTBjOGNhNzdkYzRmNDdiMWQwZTRiZTYyMzkzY2U3XzMyMjc_36575cb3-7b3f-49e5-9d03-85b83ceb5bac"
      unitRef="usd">81282000000</us-gaap:NoncurrentAssets>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE3ODkw_03990f93-3402-4eb6-9eb9-301717ea6dfd">Acquisitions and Divestitures&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain businesses were acquired for $7.3&#160;billion in cash and $0.4&#160;billion of liabilities assumed during fiscal year 2020. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant  robotics and data science capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.8&#160;billion applying a probability of success factor that ranged from 20% to  60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%.  XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.4&#160;billion, goodwill for $0.2&#160;billion, other assets of $0.2&#160;billion and liabilities assumed of $0.3&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;amp;D) of $6.0&#160;billion, goodwill of $1.2&#160;billion, other assets of $0.5&#160;billion and liabilities of $1.6&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;amp;D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2019 certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately &#xa5;230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company treated this transaction as a business combination and included it in the Consumer Health segment.  During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities of $0.4 billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 1, 2019 the Company&#160;completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&amp;amp;D for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $1.1&#160;billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company&#x2019;s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&amp;amp;D impairment charge of $0.1&#160;billion related to timing and progression of the digital surgery platforms. A probability of success factor ranging from 55% to 95% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;amp;D. The discount rate applied was approximately 10%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2018 certain businesses were acquired for $0.9 billion in cash and $0.1 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $1.0 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2020, 2019 and 2018 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#x2019;s results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subsequent to fiscal 2020, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment and received combined proceeds of approximately $0.6&#160;billion. The Company will reflect these brand divestitures in its 2021 financial results.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2020, the Company sold 11.8&#160;million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company. The transaction resulted in gross proceeds of approximately CHF 337&#160;million ($357&#160;million) based on a sales price of CHF 28.55/share and an immaterial net loss. The Company currently has rights to at least an additional 38.7&#160;million shares (or approximately 20% of Idorsia equity) through a convertible loan with a principal amount of CHF 445&#160;million (due June 2027). Idorsia also has access to an approximate CHF 243&#160;million credit facility with the Company. As of January 3, 2021, Idorsia has not made any draw-downs under the credit facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $2.0 billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2018, the Company divested the LifeScan Inc business for approximately $2.1 billion and retained certain net liabilities. Other divestitures in fiscal year 2018 included: NIZORAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, RoC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and certain non-strategic Pharmaceutical products. In 2018, the pre-tax gains on the divestitures were approximately $1.2 billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal year 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world&#x2019;s leading manufacturing services providers for health care products and technology products.&#160;The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of employees and manufacturing sites. The transfers were completed in fiscal year 2020.&#160;As of January 3, 2021, there were no assets held for sale on the Consolidated Balance Sheet. As of December 29, 2019, the assets held for sale on the Consolidated Balance Sheet were $0.1 billion of inventory and property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 20 to the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTkzNjM_2c797caa-af66-4475-b0ff-d21d2a1512b4"
      unitRef="usd">7300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i2c4f2d96d955450db33852d746bfba34_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTkzODA_df8ca3ee-3e87-4b4b-af0e-a098e53b410f"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i64316c7eddcf4074a9e3ee4d29f82ef0_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzk4OTU2MDQ2NzkyMzM_c3f42a42-b0fd-4117-8391-f6cce635ecca"
      unitRef="usd">7500000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i8731480903f6482bafd102f3dcab3c69_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTkzOTQ_2b8af96b-fbcb-4fbc-89a7-00405171135e"
      unitRef="usd">800000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i87db8efd958244a086dfb46539fdfb06_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0MTM_a0827778-ed68-4692-9e51-e7cbcab4ae2f"
      unitRef="usd">800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="ibb66e5604cfd4dbfbc2df6782a9418d5_I20200329"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODc0NTQ_441d39be-0b46-4b7b-87f5-a21dfe9e4836"
      unitRef="number">0.20</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i9bf0b675d1ee4f0cad2d1afbe56a8367_I20200329"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0MDg_44f377de-9a97-4cb9-ab0c-8527ae2e58c2"
      unitRef="number">0.60</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="i87db8efd958244a086dfb46539fdfb06_I20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0Mjc_8ce40778-3294-4b19-94fa-66d8590a088e"
      unitRef="number">0.16</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0MzI_6f0ed15e-21a2-4e0d-b3ea-09ba62d19cfd"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0NDY_b3ec9682-6bfd-4e67-b68f-904f73f41d3e"
      unitRef="usd">200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0NjA_6833f2dd-18e7-40c0-83bc-70e9f2bbc33d"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0NzQ_5450be35-a360-4bc3-b729-5a31901eb64e"
      unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i4ce3e1e959704f30a9e61a34717734cd_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk0OTA_e0135013-04ed-472c-9bf8-80607c170f3d"
      unitRef="usd">400000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i89223357c4f64e06b825e78a40cb5914_D20201001-20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4NjA2OTY_950eb325-621a-4c66-a586-22bc157c8a2f"
      unitRef="usd">6100000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i293ef2d918614098b4af9e84d27cc0ff_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNjI1NTk_cf1f662f-7785-4f0c-a423-4fd8db4e0e38"
      unitRef="usd">6000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk1Njg_6ffb7dd2-1b69-4a2d-befa-22c84c6b2059"
      unitRef="usd">1200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODk5MTc_1c7f580e-2e9d-4a8b-9e92-78b0b1b31e3a"
      unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk1ODI_3d52fc4c-dd88-4070-b5d5-76621ef8ccf3"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="iad9394419046465abc7a8a563ce9e079_I20201001"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk1OTY_0e68daae-8ec1-4a63-90c2-f4d0f8f47daf"
      unitRef="number">0.20</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i60b1b3c5341149fca7bbc49f7508a82f_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk2MDE_5c2effc4-2d6d-4735-918f-246e0d4f6412"
      unitRef="number">0.77</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="icdbc095e470a470e9234a55fe342dda1_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzgyNDYzMzcyNTk2MDY_19e6578a-a6e1-4523-81ee-00b8adb796bb"
      unitRef="number">0.13</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzcz_e1a30799-610d-4239-9cc4-a5aaa71f241e"
      unitRef="usd">5800000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i6a63a2948df54bb087c11ba82ffaf3fb_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzg4_fe93dd36-5edb-433c-9828-ca3a399ec8e4"
      unitRef="usd">1400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i9554efac170a48719f2fd4fef3bcbdbc_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4NTQ4OTI_088278dc-0cfc-4150-9c14-3bc83669bb18"
      unitRef="usd">6800000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7466a929aa8c4da48b0b5cb2da5733b3_D20190117-20190117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE0ODE_ad6ac70d-4f9b-4c35-af4b-7574cabb797a"
      unitRef="jpy">230000000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7466a929aa8c4da48b0b5cb2da5733b3_D20190117-20190117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE1MTY_df80b8cf-aa27-4d68-9662-5b2f6c5db507"
      unitRef="usd">2100000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i663d1a94c8284c94915423956a325ff7_I20190116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE1NDc_59fb40e1-b57f-4fe6-a234-cfe9f1b60628"
      unitRef="number">109.06</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7648739eff244460aefb5458b95e548d_D20181231-20190331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzIxOTU_c4e46fd0-9122-4845-b4d8-f42bbb986a89"
      unitRef="usd">300000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzI2NjM_064d2695-2f01-4c8d-aa71-b3d44e43a57a"
      unitRef="usd">1500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzI2ODA_c7bcea9a-814a-4500-8752-a8e118df4cdc"
      unitRef="usd">1200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i7ddb4ec8a97640f9a9646164675f7b3b_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzI3MDI_311fa9e4-6d00-4b05-8089-e71179ddb3d6"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7ac7036ab4264656876135eb9e269635_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzMxMDI_041b0c4b-4170-49c2-ba99-4f6d0f177298">P15Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1106f749feaf4b4cb34daeb9bbc0f5ac_D20190401-20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzMzNTU_2135c9bc-46cf-4c1e-95a0-1962ce23a322"
      unitRef="usd">3400000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM0MjE_c9cf9b5e-3476-4d76-8f61-2bd760da35a0"
      unitRef="usd">2350000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM5NTI_6af175ae-7873-4322-abfa-e01ac56f5a07"
      unitRef="usd">3000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM5Njk_261d9c65-8926-4d24-a59c-588827cd0da2"
      unitRef="usd">2000000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzM5OTg_a9025c6a-a056-42ac-9788-bfd6efe93ab0"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQwMjg_ef3d175e-a643-47a9-bba9-0b6e954691b9"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1b2666b42496425cb2f87473681fa480_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODU2MzE_075bd650-c286-4156-b55f-749356fa9968"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0d2155f5644e4dce929f352545f25b9f_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4ODcxMTk_7bd062b6-420c-44a7-886c-6f85b3017875"
      unitRef="usd">100000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i64e9ef76a8044ece8caf57dbe8808101_I20190401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQzNDY_4a9357e8-2050-47f4-9d18-d360481bf64d"
      unitRef="number">0.55</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="ibbc2347889084c24a2bdc712e0cc9afe_I20190401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQzNTI_97e91199-a716-4da5-8624-49c733575626"
      unitRef="number">0.95</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="ieeb51f3819d4439da404f8ebcd058d23_I20190401"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzQ1Mjc_23c03cfb-2479-4950-be4d-8ba7e6b426fa"
      unitRef="number">0.10</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzU0Njk_249d69e6-0ac1-45db-a7e4-17d4593d910f"
      unitRef="usd">900000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzU0ODQ_1a194ef0-2a36-441a-9922-3b20adccd686"
      unitRef="usd">100000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="if510052c46844b89bee55dd2cfd123f1_I20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzY0MTg_f194e56a-b3ac-4ea4-b373-dd8fdf153f62"
      unitRef="usd">1000000000.0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i247bfdef30e445f58022d1b433046fee_D20210131-20210131"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTg1OTM_0dd565fb-9451-48d9-b209-297dcbe77e7e"
      unitRef="usd">600000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTI0Nzg_ffd74aae-6a4e-4fef-a5cd-236d68425149"
      unitRef="shares">11800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTI0OTI_b9cff3ba-c124-4043-bf7d-884eab55e493"
      unitRef="number">0.083</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzkzNDU4NDg4OTI0OTg_219b3390-d999-4815-b3f1-90ec10340513"
      unitRef="chf">337000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMjkw_5cb347c5-ce4c-4608-8f01-460f32c51738"
      unitRef="usd">357000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i59587efcd1fc4831b82133e2feac03fa_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzA0_b046c36d-17a1-42a2-ae0e-5fd366781899"
      unitRef="usdPerShare">28.55</us-gaap:SaleOfStockPricePerShare>
    <jnj:ConvertibleNoteEquityInterestNumberOfShares
      contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzEx_aef80863-e9db-4ea2-a1bc-5c3c65384b29"
      unitRef="shares">38700000</jnj:ConvertibleNoteEquityInterestNumberOfShares>
    <jnj:ConvertibleNoteEquityInterestPercentage
      contextRef="i9f90809fb51f474687fab70275e523bb_D20191230-20210103"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzI1_bd0df540-e831-43d7-be26-d0a2deb60fe4"
      unitRef="number">0.20</jnj:ConvertibleNoteEquityInterestPercentage>
    <us-gaap:LongTermDebt
      contextRef="ifb3df5df054d4ba598290335491d4bf2_I20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzMw_63748b55-92c4-433b-90b3-100c9944377a"
      unitRef="chf">445000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i59587efcd1fc4831b82133e2feac03fa_I20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzEwNDQ1MzYwNTIwMzQz_3b289394-a804-4c8b-9c75-47419d8604be"
      unitRef="chf">243000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2MDQ3_6d86dc40-c662-4e50-acb1-7339416a4cb7"
      unitRef="usd">2800000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash
      contextRef="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2MDY1_841599ce-a3f0-46ab-9068-13c110c66e72"
      unitRef="usd">2700000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <jnj:DisposalGroupIncludingDiscontinuedOperationReceivablesRetained
      contextRef="i84b1c22d3eae4e07a85f0198a5bf8b96_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2MDg5_8945022c-a733-40af-b294-d4730c849cec"
      unitRef="usd">100000000</jnj:DisposalGroupIncludingDiscontinuedOperationReceivablesRetained>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i9660ad42e8a84744909a1e88ade1ded0_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2Mzg0_4f65561b-de5f-442a-9288-6d07870a4c2a"
      unitRef="usd">2000000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ib62a0d3a2f984c819f0cd7b260d86045_I20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2NDY3_74311162-ff7e-4c40-8c6f-356499311cd3"
      unitRef="usd">2100000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="idafcd741dc1847b6b4b33246b0f87278_D20180101-20181230"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE2Njc3_e10b0bb0-a102-4296-ba37-0c1f7f30194f"
      unitRef="usd">1200000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="i6010a5c09da44a07ab46d7f9c737f126_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTQvZnJhZzpiZTA2NDQ5NjEyMzM0ZmE0YWQxZjFiODFmYmJmNTE4Yy90ZXh0cmVnaW9uOmJlMDY0NDk2MTIzMzRmYTRhZDFmMWI4MWZiYmY1MThjXzE3Mjk5_9abaf1b5-e111-4ed1-8ae5-477d3021d389"
      unitRef="usd">100000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzEwNDQ1MzYwODkxNjUy_2fbcc4b3-089f-4e6b-8fb5-135b0dd7836f">Legal Proceedings&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January&#160;3, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The most significant of these cases include: the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Acetabular Cup System; pelvic meshes; RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; body powders containing talc, primarily JOHNSONS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder; INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; and ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Flexible Composite Mesh. As of January&#160;3, 2021, in the United States there were approximately 560 plaintiffs with direct claims in pending lawsuits regarding &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;injuries allegedly due to the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; 7,800 with respect to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Acetabular Cup System; 14,900 with respect to pelvic meshes; 9,300 with respect to RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; 12,600 with respect to XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; 25,000 with respect to body powders containing talc; 300 with respect to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and 4,200 with respect to ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Flexible Composite Mesh.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; XL Acetabular System and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000  claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle &lt;/span&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the class actions filed in that country&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices.  In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. The Company is appealing the decision. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss.  The form of the individual case assessment process has not yet been determined by the Court. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh product&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;s. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160; Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Ventral Patch hernia mesh products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In September 2019, plaintiffs&#x2019; attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE&#x2122; Polypropylene Hernia System (&#x201c;PHS&#x201d;) cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. Discovery is underway in these cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Flexible Composite Mesh, PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Ventral Patch, and PROLENE&#x2122; Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8&#160;million by the trial judge. The Company and plaintiff are each appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson (J&amp;amp;J); and JPI&#x2019;s collaboration partner for XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&amp;amp;J announced an agreement in principle to the settle the XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Personal injury claims alleging that talc causes cancer have been made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied  plaintiffs&#x2019; attempt to limit the scope of testimony of certain of the Company&#x2019;s witnesses. With this ruling made, case-specific discovery has begun per the Court&#x2019;s directive. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In talc cases that have previously gone to trial, the Company has obtained defense verdicts in a number of them, but there have also been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018  verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion and, with additional interest as of January 3, 2021, as the Company pursues further appeal, is currently $2.5&#160;billion (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and the Company is currently seeking review by the United States Supreme Court. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; decision currently on appeal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in connection with product liability litigation associated with body powders containing talc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019; potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company&#x2019;s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company&#x2019;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants&#x2019; committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus) filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements.  The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus&#x2019;s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates allowing Debtors to proceed with soliciting votes on the Plan. The Company intends to continue to object to the Plan. A hearing to consider confirmation of the Plan has been scheduled for June 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S&#xae; Baby Powder, and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. Discovery is underway.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp;amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt; Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete&lt;/span&gt;&lt;span style="color:#d13438;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;A lawsuit pending in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act relating to JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Baby Powder has been resolved in the Company&#x2019;s favor. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing has been scheduled for April 2021. Limited informal discovery is continuing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission (SEC) and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries. In November 2020, the SEC terminated its investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, the federal cases, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy).  MedIdea alleged infringement of United States Patent Nos. 6,558,426 (&#x2019;426); 8,273,132 (&#x2019;132); 8,721,730 (&#x2019;730)  and 9,492,280 (&#x2019;280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contact feature of the ATTUNE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. In November 2019, judgment was entered in favor of DePuy. In January 2021, the U.S. Court of Appeals for the Federal Circuit affirmed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#x2019;s RELIEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Spin and RELIEVEA SpinPlus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#x2019;s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures, MONOCRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures, PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures, STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Antibacterial Sutures and STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; MONOCRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plus Antibacterial Sutures infringe plaintiffs&#x2019; United States Patent Nos. 6,596,296 (&#x2019;296) and 7,033,603 (&#x2019;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UT is seeking damages and an injunction.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the USPTO denied institution of the &#x2019;296 patent IPR and granted institution of the &#x2019;603 patent IPR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UT dismissed the &#x2019;603 patent from the suit and no longer accuses PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures or STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#x2019;200); 6,491,701 (&#x2019;701); 6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447); 8,620,473 (&#x2019;473); 8,801,601 (&#x2019;601); and 9,452,276 (&#x2019;276) based on Auris&#x2019; Monarch&#x2122; Platform.  Auris filed IPR Petitions with the USPTO regarding the &#x2019;200, &#x2019;056, &#x2019;601 &#x2019;701, &#x2019;447, &#x2019;276 and &#x2019;906 patents. Intuitive subsequently dropped the &#x2019;200, &#x2019;473 and &#x2019;701 patents from the suit.  In December 2019, the USPTO instituted review of the &#x2019;601 patent and denied review of the &#x2019;056 patent.  In February and March 2020, the USPTO instituted review of the &#x2019;200, &#x2019;447, &#x2019;701 and &#x2019;906 patents and denied review of the &#x2019;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#x2019;601 patent to be invalid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intuitive has appealed that decision.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The district court trial is scheduled to begin in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#x2122; Spacer, ZERO-P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Spacer, ZERO-P NATURAL&#x2122; Plate, SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; LR Spacer and SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Evolution System.  RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2020, the case was stayed pending IPR proceedings filed by the Consolidated Defendants involving the asserted patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Virtual Surgical Planning Services and the TruMatch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trial is scheduled for October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits pending against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen)  initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex&#x2019;s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of Canadian Patent No. 2,661,422 (&#x2019;422). The final hearing concluded in May 2019.  In October 2019, the Court issued an order prohibiting the Canadian Minister of Health from approving Apotex&#x2019;s ANDS until the expiration of the &#x2019;422 patent. In November 2019, Apotex filed an appeal.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in January 2019, Janssen initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex, Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;422 patent. The final hearing in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In August 2020, Janssen initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (Jamp) in Canada in response to Jamp&#x2019;s filing of an ANDS seeking approval to market a generic version of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; before the expiration of the &#x2019;422 patent. The final hearing is scheduled to begin in May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;422 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Intellectual Property GmbH and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd. (collectively, DRL) which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of U.S. Patent No.  9,539,218 (&#x2019;218). In this lawsuit, JPI and Bayer were seeking an order enjoining DRL from marketing their generic versions of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents. In November 2020, JPI and Bayer entered into a confidential settlement agreement with DRL, and the case was voluntarily dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp;amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; XR before expiration of MTPC&#x2019;s United States Patent Nos. 7,943,582 (&#x2019;582) and/or 8,513,202 (&#x2019;202) relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include  MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus); Sandoz, Inc. (Sandoz); and Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin). These cases were consolidated into one action (Polymorph Main Action), which has been scheduled for trial starting in April 2021. In December 2020, Janssen and MTPC entered into a confidential settlement with Sandoz and in January 2021, Janssen and MTPC entered into a confidential settlement with Lupin. The cases against Sandoz and Lupin were voluntarily dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;and IVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;before expiration of MTPC&#x2019;s United States Patent No. 7,943,788 (&#x2019;788), 8,222,219 (&#x2019;219) and/or 8,785,403 (&#x2019;403) relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt; XR (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;582 patent and &#x2019;202 patent relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.  In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;788 patent.  In &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;582 patent and &#x2019;202 patent relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of United States Patent No. 10,617,668 relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. These lawsuits have not been consolidated with the Main Actions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt; and/or, INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the Canadian Patent Nos. 2,534,024 and 2,671,357. The final hearing is scheduled to begin in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n October 2020, Actelion Pharmaceuticals Ltd (Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Laurus Labs Limited and PharmaQ, Inc. (collectively, Laurus), which filed an ANDA seeking approval to market generic versions of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of U.S. Patent No. 7,094,781 (&#x2019;781). Actelion was seeking an order enjoining Laurus from marketing generic versions of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;781 patent. In January 2021, Actelion entered into a settlement agreement with Laurus. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Trial is scheduled to begin in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Trial is scheduled to begin in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 10 mg before the expiration of the &#x2019;770 patent and Canadian Patent No. 2,621,273 (&#x2019;273). Trial is scheduled to begin in April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of United States Patent No. 9,439,906 (&#x2019;906).  Trial concluded in October 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the &#x2019;906 patent. The USPTO denied the Petition in September 2020, and Mylan appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada)  in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent.  In  May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, would infringe claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid for obviousness. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Final Hearing is scheduled to begin in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. The Final Hearing is scheduled to begin in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; 140 mg capsules before expiration of Pharmacyclics&#x2019;  United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Cipla Limited and Cipla USA Inc. (collectively, Cipla); Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2019, Pharmacyclics and JBI amended their complaint against Sandoz to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, Pharmacyclics and JBI amended their complaint against Cipla to allege infringement of United States Patent Nos. 10,106,548, and 10,125,140.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, Pharmacyclics and JBI amended their complaint against Cipla to further allege infringement of United States Patent No. 10,016,435. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, Pharmacyclics and JBI amended their complaints against Cipla and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232. In August 2019, the Court granted a joint stipulation to stay the litigation against Cipla.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trial in the actions against Sandoz and Alvogen took place in October 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2019, Sandoz filed an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;IPR Petition with&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the USPTO, seeking to invalidate United States Patent No. 9,795,604.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2020, the USPTO issued a final decision in the IPR invalidating certain claims of the &#x2019;604 patent and upholding the validity of certain claims in the &#x2019;604 patent. The final decision was not appealed by the parties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen and Sandoz asserting infringement of United States Patent No. 10,478,439.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent No. 10,463,668. In October 2020, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent Nos. 10,752,634 and 10,695,350 and amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,653,696. In December 2020 the Court entered a joint stipulation dismissing the complaint against Sandoz. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus Worldwide DMCC and Cadila Healthcare Limited (collectively, Zydus), which filed an ANDA seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,008,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,386 and 10,478,439.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trials in the actions against Alvogen and Zydus are scheduled to begin in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before expiration of Nippon Shinyaku&#x2019;s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Actelion is the exclusive licensee of the asserted patents. The defendants include Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic); MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (collectively, MSN); ); VGYAAN Pharmaceuticals LLC (VGYAAN); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus). In January 2021, the Court entered joint stipulations dismissing VGYAAN and MSN from suit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before expiration of United States Patent No. 10,143,693 relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial.  In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than 3,100 lawsuits related to the marketing of opioids, including DURAGESIC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical companies, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina; Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 370 cases pending in various state&#160;courts. There are over 2,800 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804).&#160;In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $572&#160;million, subject to a final order to be issued by the Court.&#160;The Court issued a final judgment reducing the amount to $465&#160;million. Johnson &amp;amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed and future claims by states, cities and counties. The Company cannot predict if or when the agreement will be finalized and individual cases are ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp;amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#x2019;s rejection of his demand. In August 2020, Johnson &amp;amp; Johnson moved to dismiss the amended complaint, and as of December 2020, that motion was fully briefed. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#x2019; request to reassign the second-filed case to the division where the first-filed case is pending. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; In re Johnson &amp;amp; Johnson Opioid Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp;amp; Johnson&#x2019;s motion. Johnson &amp;amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the shareholders in the consolidated action filed a motion for voluntary dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#x2122; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; case filed pursuant to the False Claims Act against the companies. In February 2016, the district court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the district court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. The relators&#x2019; remaining claims are now pending before the district court. In July 2020, the Court ordered the relators to complete discovery by August 2020; the Relators have requested an extension of the August 2020 deadline that DePuy opposed and additional discovery-related motions have been filed by both parties. Additionally, DePuy has requested a schedule for the filing of a motion to strike and to dismiss the relators&#x2019; second amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company is appealing the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;penalty judgment. In April 2020, the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Company settled the West Virginia. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2012, Therakos, Inc. (Therakos), formerly a subsidiary of Johnson &amp;amp; Johnson and part of the Ortho-Clinical Diagnostics, Inc. (OCD) franchise, received a letter from the civil division of the United States Attorney's Office for the Eastern District of Pennsylvania informing Therakos that the United States Attorney's Office was investigating the sales and marketing of Uvadex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (methoxsalen) and the Uvar Xts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and Cellex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Systems during the period 2000 to the present. The United States Attorney's Office requested that OCD and Johnson &amp;amp; Johnson preserve documents that could relate to the investigation. Therakos was subsequently acquired by an affiliate of Gores Capital Partners III, L.P. in January 2013, and OCD was divested in June 2014. Following the divestiture of OCD, Johnson &amp;amp; Johnson retained OCD&#x2019;s portion of any liability resulting from the investigation for activity that occurred prior to the sale of Therakos. Following production of documents to and settlement discussions with the U.S. Attorney&#x2019;s Office, J&amp;amp;J affiliate Medical Device Business Services, Inc. agreed to resolve claims under the federal False Claims Act and analogous state laws in a settlement announced in November  2020. In the settlement agreement, Medical Device Business Services expressly denied any wrongful conduct. As a result of the settlement, a qui tam complaint filed by two relators pending in the U.S. District Court for the Eastern District of Pennsylvania will be dismissed. Separate settlement agreements with the states participating in the settlement are in the process of being finalized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder and JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson &amp;amp; Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted J&amp;amp;J and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing is complete and oral argument was held in February 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-one states have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Several states have issued Civil Investigative Demands seeking documents and other information. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#x2019;s Office for the Southern District of New York related to JPI&#x2019;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and INTELENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160; In February 2021, the Court stayed the case and ordered mediation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2019, the Unites States Department of Justice notified Janssen Biotech, Inc. that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, OLYSIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp;amp; Johnson and DePuy Synthes, Inc. have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. We continue to actively respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp;amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Baby Powder.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The complaint seeks damages but does not allege personal injury.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, JJCI moved to dismiss the complaint.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;) in connection with its importation into the United States. In August 2020, US CBP formally rejected Janssen&#x2019;s Supplemental Petition challenging the penalties assessment and demanded payment of the mitigated penalty.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, US CBP agreed to not refer the matter to the Office of Chief Counsel at this time, pending resolution of the related Classification Litigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2013, Janssen Ortho sued the United States in the United States Court of International Trade (the Classification Litigation) seeking a determination that darunavir ethanolate is exempt from duties upon importation into the United States. In February 2020, the Court ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States appealed to the United States Court of Appeals for the Federal Circuit.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2020, Genmab A/S brought an arbitration against Janssen Biotech, Inc. pursuant to a 2012 License Agreement between the parties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The arbitration relates to royalties for certain Janssen daratumumab products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice is complete. No trial date has been set.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research &amp;amp; Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages. In November 2020, Defendants moved to dismiss the complaint. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania.  Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The complaint seeks damages and injunctive relief. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE&#xae; against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co, filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson in connection with its investigation of whether Janssen&#x2019;s REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracting practices violate federal antitrust laws. The Company produced documents and information responsive to the Civil Investigative Demand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#x2019;s decision to the United States Court of Appeals for the District of Columbia Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals US, Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160; The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160; TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. Plaintiffs have appealed the decision to the United States Court of Appeals for the Fourth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Blue Cross &amp;amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Several additional complaints were filed thereafter in Virginia and New Jersey.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case for pretrial purposes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp;amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in order to delay generic entry, and seek damages and injunctive relief. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California.  The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;development and marketing of combination antiretroviral therapies (cART) to treat HIV.  The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California.  The complaint alleges that certain of BWI&#x2019;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;amp;J, Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter Zantac (ranitidine) products. Plaintiffs in the underlying actions allege that Zantac and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i41be97a9ae2043408fba6895a0bca20a_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQyNjI_724f8f3b-d357-44e3-97e6-e8389667e51c"
      unitRef="claimant">560</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="iff7c87d97d384ee8b13f6b2bb84ea65c_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ0MjY_aaa7d932-92f0-4eca-a191-dc0a4d9eb73c"
      unitRef="claimant">7800</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="if9ba6a98f87b46e1aafbd453b6cbee6c_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ0ODI_a5ed6dee-ecc5-4242-bf93-138c01271663"
      unitRef="claimant">14900</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="id60518cf26184f7a82d1ae1e544e152f_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ1MTY_c3ee7f57-5faa-4394-ab8a-d76886bd9bf4"
      unitRef="claimant">9300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i29ae50e5d88b4f2faf456858615a5efb_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ1NDc_8724b2cf-65c7-4f23-bed4-e73eb6abda1a"
      unitRef="claimant">12600</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i819517bf3729470f83f19c033eb4aeff_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ1NzY_f2d1f411-24c3-46f2-b38a-05cee71b7ba0"
      unitRef="claimant">25000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ib8a1e028ec54452c8c607218170270d2_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ2MjU_7ee88a68-2416-463a-8157-6d3b3f891016"
      unitRef="claimant">300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i967a3fc676f546c3a8ec55596e5787c8_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzQ2NjA_5111146b-bb8a-49eb-b179-f5c8561360ce"
      unitRef="claimant">4200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="i4c869ba4eacc4ad3a8ea220ccc8ce54d_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkwMjY2NTY_aed7ae5a-ecc5-46ec-bb94-3ce1e5be4b16"
      unitRef="patient">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i164e958688a24886ab9f0f49cc22f175_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkwMjY2ODA_6d22fc9c-e8a7-46fe-b9cc-5e02390222f1"
      unitRef="usd">8000000000.0</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i23d356a726004e2aaf26a0f9b26a887a_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkwMjY3MDc_bdf81112-17fe-4aca-84b6-d5a4b286f6f9"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i5afa073421a4484a853139dff12ed57e_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MjYyODk_d5214248-1df1-4526-a010-38aecc2edb1b"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i6c1602e34a30408c9b6b1eb1cf04b157_D20200601-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MjYzMDM_f1176bee-615b-4a4a-bc69-a53379b2817a"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ib585935f9ab54509bc2c182dc59b672f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzkzNDU4NDkxOTMwMDE_4d3e416a-6aea-4519-9c1a-32d514d1ffb9"
      unitRef="usd">2500000000</us-gaap:LossContingencyDamagesSoughtValue>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ic3622ddfe4f643408286c1811a8e2b4d_I20210103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2Mjg3NzI_40ec8a90-23c5-4f9f-b96b-8342e714d502"
      unitRef="claimant">3100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib66ffb4e00ec4bfd99ace0da88568cd0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2Mjg3OTI_c51be88e-8e1f-4c21-a5d0-2c7239767b14"
      unitRef="usd">572000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i9e799e62cf254001826c3bf820d212b7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2Mjg4MTk_bb4b4c8b-6b89-43a6-89fb-7a5601b6d08c"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i8db67b67955942f7a04d431f570d4565_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI3NDQ_a9653318-af31-4fd5-90aa-4e73749c915f"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="i9d76339e798d40b08ed4feec1c3cae2d_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI3Njc_7d0c26a6-a335-4451-bc28-32db3cda4cb7"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i9d76339e798d40b08ed4feec1c3cae2d_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI3OTA_d179de57-ce0d-45fa-944e-1432c3ed29e5"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i58f5234f04df45daa5a30c1a7134b2bc_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI4Mjc_7cb8b06a-6c32-4bc8-b017-4fbfcbf4369d"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i58f5234f04df45daa5a30c1a7134b2bc_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMTcvZnJhZzowMTVlNGY2NDQ1YmQ0ODQ5YmQ0Mjc5N2E1N2FhMTAwZC90ZXh0cmVnaW9uOjAxNWU0ZjY0NDViZDQ4NDliZDQyNzk3YTU3YWExMDBkXzgyNDYzMzc2MzI4NTQ_2074600f-c53c-4213-affe-25b4ee99eda8"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzI1NjM_9fb689da-0c6e-4c6e-83cb-185cd2236436">Restructuring&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the Global Supply Chain restructuring strategic collaborations see Note 18 to the Consolidated Financial Statements. In fiscal year 2020, the Company recorded a pre-tax charge of $0.4 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.2 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.3 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, December&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, December&#160;29, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;3, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Represents gain on sale of an asset&lt;/span&gt;&lt;/div&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzc1MA_d0714023-ec4c-42f5-9b82-7480dac65cf7"
      unitRef="usd">400000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i24d9eecdd6ae4f3982b1ec0858319020_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzgzOA_80dde6e6-f57b-4e1a-a8b8-e1576bb69d82"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i85fbe5d13d1a4ca09991c8182c6da15a_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzg1OQ_fa591160-8c45-4e42-a037-6c7cd7600712"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9e552d1e71b44a168a599c7ac19462c1_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzg5Mg_d67bf5cf-4008-4ac3-8d75-2c14e60b2775"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ic6a8b086cd8c45da82107e88550189d0_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzk1OA_14b756f4-0755-43be-811c-19a9bea0c7bc"
      unitRef="usd">1300000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="if57129aa1e5d4dd0b0777a7d8ed0c1ee_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzExODU_1d23994c-78de-4936-ab85-6b8512cb6e11"
      unitRef="usd">600000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i8f3db082046d4ae0b5256a896c8b18a9_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzExOTE_723c3919-eebf-4257-8eba-33ce528d0e4a"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="if57129aa1e5d4dd0b0777a7d8ed0c1ee_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNDg_db435a2a-7acd-4c45-a041-2f54651b2e67"
      unitRef="usd">1900000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i8f3db082046d4ae0b5256a896c8b18a9_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNTQ_a131aa2d-133f-454e-92ea-f143377a5d8d"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="i66486cf0443e494881f3ec5e470b3cf6_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNjc_47109fa4-d82e-43ef-8c70-5d8c28b22032">P4Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="iec0388b7a5cc4f76940dc1229b081637_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzEzNzM_51f85a80-6dd0-463c-a931-81b2d77300b2">P5Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzI1NjY_4b1901fb-facc-4523-8e1e-4ace996992ae">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, December&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, December&#160;29, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;3, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Represents gain on sale of an asset&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i8dfa403febc6441b9219104ff7cd304a_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTEtMS0xLTA_9b6cb737-8957-43ac-9dcf-434ccc092475"
      unitRef="usd">194000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia0f8b2a1ad4d49c49598e20c0474fab0_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTItMS0xLTA_ed65c75e-772f-4e92-81d9-0d84ed660d30"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia94268397a144c34b6f7724fc2cdb014_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTMtMS0xLTA_d44bb0aa-c1a8-4930-9fe9-04fa1d589709"
      unitRef="usd">48000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ifa2c59fc0efa48c49cd68b3b84b0c5f0_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzE4LTUtMS0xLTA_8aefa40f-6570-4e9a-96c1-12000080214c"
      unitRef="usd">242000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i459a0dc9569c4a9aab6a75035673c567_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTEtMS0xLTA_af8fc59b-9f43-423c-9571-07bf3f61cb6b"
      unitRef="usd">30000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i29c7279bfa824e409e9b9a1bca808c58_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTItMS0xLTA_28c951aa-94c1-4626-95a8-acbde0a3dfe5"
      unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="iac916c18208c47b09c67460db8030f1d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTMtMS0xLTA_63135601-b827-4efc-bec1-30d8f91c866e"
      unitRef="usd">32000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i2ca0b385d9944272b5ded6645bb7a626_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIwLTUtMS0xLTA_48933db3-9b86-4def-936f-12ceb43c73b4"
      unitRef="usd">62000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReserve
      contextRef="i510e7e5ac227414a98e421f182a041c0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTEtMS0xLTA_4a2174e6-35db-41bf-ad05-17b67b519e00"
      unitRef="usd">164000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id5dcc642308e468f9618c6b56e3244fa_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTItMS0xLTA_397b18b6-3e8c-4ff3-af7d-c7b213ab8f64"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7e8af39bf4fc4285b5f5f5676ae6623a_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTMtMS0xLTA_e31a73b4-cead-4939-bff2-4d9ceb19c2ce"
      unitRef="usd">16000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1e8b0d8063934ca2b90208c4804102c2_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzIyLTUtMS0xLTA_c9e04316-4b8a-4876-a3fe-ccf90e24432d"
      unitRef="usd">180000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTEtMS0xLTA_90d4882b-0d88-4c9f-8c2f-2ae8a781080b"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTItMS0xLTA_d8f7cb71-d6c2-428b-876d-2e713930096e"
      unitRef="usd">43000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9c7895941dcd4d76b03e835972649586_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTMtMS0xLTA_b54e0a17-fb77-4485-a952-5d940423b4bc"
      unitRef="usd">405000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI1LTUtMS0xLTA_48758ce2-a94c-49ee-a477-b359f28b4adf"
      unitRef="usd">448000000</us-gaap:RestructuringCharges>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTEtMS0xLTA_93ea67f1-d003-42f2-aadd-9d418d87ece4"
      unitRef="usd">-29000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTItMS0xLTA_72217ea7-8aa6-4bdc-b2d9-4982cc11d72b"
      unitRef="usd">24000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i9c7895941dcd4d76b03e835972649586_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTMtMS0xLTA_63af8494-36f7-4085-afee-7f64eaa35545"
      unitRef="usd">-399000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI2LTUtMS0xLTA_9639f7b5-251a-4f27-82d4-11817ee86141"
      unitRef="usd">-404000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i62578e92999c4758bc6c34ef641655f6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTEtMS0xLTA_bd7005e9-4354-4d5e-b389-4a4b66d6aa79"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ibd5eca407ce34c73981b0accca40675c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTItMS0xLTA_68942c13-c30b-478c-af19-2f7ce554a0cd"
      unitRef="usd">67000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i9c7895941dcd4d76b03e835972649586_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTMtMS0xLTA_f08796fc-f32f-436a-8a9b-3767e8d9c862"
      unitRef="usd">13000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i0f07c77aa8e94b1d81cc5aae0d1665d1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI3LTUtMS0xLTA_86d0a11c-ab5b-49c9-aa56-806b12d880f3"
      unitRef="usd">80000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="ic98eded4ee3746d6af8c7edc2e830f5b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTEtMS0xLTA_79f72ca9-3798-46c1-8fae-85aa5f4aab78"
      unitRef="usd">135000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic7b6a6cceab84226b776a371d5bbe868_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTItMS0xLTA_7cb12550-d654-46f8-8164-9cb2d04dbece"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i98674305aeea4bbab7dbaabd6920816d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTMtMS0xLTA_a5a60d3a-c223-470d-8410-81d141e76a70"
      unitRef="usd">9000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i57c8bafe3cd14d5c9e1491d8bbf1f32f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90YWJsZTo1MDViOTA0NjU1ODU0MTRjYmUwMDE2OWJhNzkzZWQ5MS90YWJsZXJhbmdlOjUwNWI5MDQ2NTU4NTQxNGNiZTAwMTY5YmE3OTNlZDkxXzI4LTUtMS0xLTA_63cf717c-3b47-4453-b224-3a5e553494a1"
      unitRef="usd">144000000</us-gaap:RestructuringReserve>
    <jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid
      contextRef="i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18yMjAvZnJhZzoxOTczMTE5OTA1Y2I0OTM0YjFkMTBiNTY2ZGQ3YjhmMS90ZXh0cmVnaW9uOjE5NzMxMTk5MDVjYjQ5MzRiMWQxMGI1NjZkZDdiOGYxXzE3NTQ_a07d548d-3a9a-49ce-9e53-e487162fd5ad">P2Y</jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841087028920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">JOHNSON & JOHNSON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,628,679,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member', window );">0.250% Notes Due January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes Due January 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090936552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Notes&#160;1 and 2)</a></td>
<td class="nump">$ 13,985<span></span>
</td>
<td class="nump">$ 17,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities (Notes&#160;1 and 2)</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable trade, less allowances for doubtful accounts $293 (2019, $226)</a></td>
<td class="nump">13,576<span></span>
</td>
<td class="nump">14,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Notes&#160;1 and 3)</a></td>
<td class="nump">9,344<span></span>
</td>
<td class="nump">9,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">3,132<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther', window );">Assets held for sale (Note 18)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">51,237<span></span>
</td>
<td class="nump">45,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net (Notes&#160;1 and 4)</a></td>
<td class="nump">18,766<span></span>
</td>
<td class="nump">17,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Notes&#160;1 and 5)</a></td>
<td class="nump">53,402<span></span>
</td>
<td class="nump">47,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="nump">36,393<span></span>
</td>
<td class="nump">33,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note&#160;8)</a></td>
<td class="nump">8,534<span></span>
</td>
<td class="nump">7,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,562<span></span>
</td>
<td class="nump">5,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">174,894<span></span>
</td>
<td class="nump">157,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable (Note&#160;7)</a></td>
<td class="nump">2,631<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,505<span></span>
</td>
<td class="nump">8,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,968<span></span>
</td>
<td class="nump">9,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">11,513<span></span>
</td>
<td class="nump">10,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 8)</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,493<span></span>
</td>
<td class="nump">35,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note&#160;7)</a></td>
<td class="nump">32,635<span></span>
</td>
<td class="nump">26,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 8)</a></td>
<td class="nump">7,214<span></span>
</td>
<td class="nump">5,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations (Notes&#160;9 and 10)</a></td>
<td class="nump">10,771<span></span>
</td>
<td class="nump">10,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 1)</a></td>
<td class="nump">6,559<span></span>
</td>
<td class="nump">7,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">11,944<span></span>
</td>
<td class="nump">11,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">111,616<span></span>
</td>
<td class="nump">98,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note&#160;13)</a></td>
<td class="num">(15,242)<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">113,890<span></span>
</td>
<td class="nump">110,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' Equity before Treasury Stock</a></td>
<td class="nump">101,768<span></span>
</td>
<td class="nump">97,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (Note&#160;12) (487,331,000&#160;shares and 487,336,000&#160;shares)</a></td>
<td class="nump">38,490<span></span>
</td>
<td class="nump">38,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">59,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 174,894<span></span>
</td>
<td class="nump">$ 157,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841086507128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">487,331,000<span></span>
</td>
<td class="nump">487,336,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091656664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
<td class="nump">$ 81,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">28,427<span></span>
</td>
<td class="nump">27,556<span></span>
</td>
<td class="nump">27,091<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">54,157<span></span>
</td>
<td class="nump">54,503<span></span>
</td>
<td class="nump">54,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">22,084<span></span>
</td>
<td class="nump">22,178<span></span>
</td>
<td class="nump">22,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">12,159<span></span>
</td>
<td class="nump">11,355<span></span>
</td>
<td class="nump">10,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized (Note&#160;4)</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">2,899<span></span>
</td>
<td class="nump">2,525<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 20)</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">16,497<span></span>
</td>
<td class="nump">17,328<span></span>
</td>
<td class="nump">17,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note&#160;8)</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">2,702<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,714<span></span>
</td>
<td class="nump">$ 15,119<span></span>
</td>
<td class="nump">$ 15,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings per share (Notes 1 and 15)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Average shares outstanding (Notes 1 and 15)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">2,632.8<span></span>
</td>
<td class="nump">2,645.1<span></span>
</td>
<td class="nump">2,681.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">2,670.7<span></span>
</td>
<td class="nump">2,684.3<span></span>
</td>
<td class="nump">2,728.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841086213496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,714<span></span>
</td>
<td class="nump">$ 15,119<span></span>
</td>
<td class="nump">$ 15,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Income (Loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(1,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service credit (cost), net of amortization</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss), net of amortization</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax', window );">Effect of exchange rates</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Net change</a></td>
<td class="nump">947<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">649<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 15,363<span></span>
</td>
<td class="nump">$ 14,450<span></span>
</td>
<td class="nump">$ 13,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>other comprehensive income loss, pension and other , effects of exchange rate net of tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109978405&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841186111208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee benefits</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax', window );">Derivatives &amp; hedges</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091116376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Income (Loss) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 60,160<span></span>
</td>
<td class="num">$ (486)<span></span>
</td>
<td class="nump">$ 101,793<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
<td class="num">$ (13,199)<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (31,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">15,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(9,494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(5,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 30, 2018</a></td>
<td class="nump">59,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(34,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">15,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(9,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 29, 2019</a></td>
<td class="nump">59,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">14,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(10,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(3,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 03, 2021</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,490)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091129944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 3.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091270120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,714<span></span>
</td>
<td class="nump">$ 15,119<span></span>
</td>
<td class="nump">$ 15,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">7,009<span></span>
</td>
<td class="nump">6,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(1,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="nump">63<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease/(Increase) in accounts receivable</a></td>
<td class="nump">774<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="nump">5,141<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">3,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Increase in other current and non-current assets</a></td>
<td class="num">(3,704)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Increase/(Decrease) in other current and non-current liabilities</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
<td class="num">(1,844)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">23,536<span></span>
</td>
<td class="nump">23,416<span></span>
</td>
<td class="nump">22,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(3,347)<span></span>
</td>
<td class="num">(3,498)<span></span>
</td>
<td class="num">(3,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
<td class="nump">3,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note&#160;18)</a></td>
<td class="num">(7,323)<span></span>
</td>
<td class="num">(5,810)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(21,089)<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
<td class="num">(5,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">12,137<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="nump">4,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(987)<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(521)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(20,825)<span></span>
</td>
<td class="num">(6,194)<span></span>
</td>
<td class="num">(3,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(10,481)<span></span>
</td>
<td class="num">(9,917)<span></span>
</td>
<td class="num">(9,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
<td class="num">(5,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">3,391<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(2,663)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">7,431<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(2,823)<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(333)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(294)<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used by financing activities</a></td>
<td class="num">(6,120)<span></span>
</td>
<td class="num">(18,015)<span></span>
</td>
<td class="num">(18,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">89<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease)/Increase in cash and cash equivalents</a></td>
<td class="num">(3,320)<span></span>
</td>
<td class="num">(802)<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year (Note&#160;1)</a></td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">18,107<span></span>
</td>
<td class="nump">17,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year (Note&#160;1)</a></td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">18,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">995<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net of amount capitalized</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">4,619<span></span>
</td>
<td class="nump">4,191<span></span>
</td>
<td class="nump">4,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds', window );">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">2,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">7,755<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="num">(432)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions (Note 18)</a></td>
<td class="nump">$ 7,323<span></span>
</td>
<td class="nump">$ 5,810<span></span>
</td>
<td class="nump">$ 899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During The Year [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071138920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women&#8217;s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2018-18: Collaborative Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13: Financial Instruments - Credit Losses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity&#8217;s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2018-14: Compensation - Defined Benefit Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  </span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"/><td style="width:61.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2014-09 - Revenue from Contracts with Customers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-01 - Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-16 - Income Taxes: Intra-Entity Transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 3, 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;- 30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion and $7.0 billion as of January&#160;3, 2021 and December&#160;29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2020,&#160;2019&#160;and&#160;2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $1.0 billion, $1.0 billion and $1.1 billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.0&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The lease liability was $1.1&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion and $0.3&#160;billion in 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, co-developed with Bayer HealthCare AG and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, licensed from Genmab A/S.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.2 billion and $2.6 billion in fiscal years 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $7.7&#160;billion, of which $6.9&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information regarding income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072925704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents and Current Marketable Securities</a></td>
<td class="text">Cash, Cash Equivalents and Current Marketable Securities<div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%"><tr><td style="width:1.0%"/><td style="width:59.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.086%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gov't Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal year 2019, the carrying amount was the same as the estimated fair value.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;3, 2021 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.157%"><tr><td style="width:1.0%"/><td style="width:43.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072256248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, inventories were comprised of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"/><td style="width:66.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span>See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071132152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"/><td style="width:67.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,766</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December&#160;29, 2019. There were no assets held for sale at January&#160;3, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2020, 2019 and 2018 was $63 million, $70 million and $86 million, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2020, 2019 and 2018 was $2.6 billion, $2.5 billion and $2.6 billion, respectively. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072233736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,056&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,569</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,643</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0&#160;billion from Momenta Pharmaceuticals, Inc., $0.8&#160;billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4&#160;billion from the acquisition of all outstanding shares in Verb Surgical, Inc.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;3, 2021 and December&#160;29, 2019, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:33.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in cost of products sold was $4.7 billion, $4.5 billion and $4.4 billion before tax, for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071132152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges.  The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.  As of January&#160;3, 2021, the total amount of cash collateral paid by the Company under the CSA amounted to $1.1 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings.  The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions.      As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively. As of December&#160;29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $45.3 billion and  $20.1 billion, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. The effect of which are immaterial for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of January&#160;3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $652 million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts, net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019, net of tax:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019 for equity investments without readily determinable market values, $76 million and $57 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were $21 million and $19 million, respectively, of changes in fair value reflected in net income due to changes in observable prices.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div><div style="margin-top:7pt"><span><br/></span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;3, 2021 and December&#160;29, 2019 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.409%"><tr><td style="width:1.0%"/><td style="width:53.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.695%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2019 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,148 million, which are classified as Level&#160;1 and contingent consideration of $1,715 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $1 million of non-current assets as of December&#160;29, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $594 million, $1,631 million (primarily related to Auris Health) and $397 million, classified as non-current other liabilities as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Includes $39 million and $84&#160;million classified as current liabilities as of January&#160;3, 2021 and December&#160;29, 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071085880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3% Zero Coupon Convertible Subordinated Debentures due 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%&#160;Debentures due 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.950% Notes due 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250% Notes due 2022                                                        (1B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1B Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500MM 1.3654 GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(500MM GBP 1.2987)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028                                                (750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035                                                     (1.5B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1.5B Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.400%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Notes due 2050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.450% Notes due 2060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;3, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at December&#160;29, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the fair value over the carrying value of debt was $5.4 billion at the end of fiscal year 2020 and $3.0 billion at the end of fiscal year 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2020, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September&#160;9, 2021.  Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, London Interbank Offered Rates (LIBOR), Secured Overnight Financing Rate (SOFR) Swap Curve or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Throughout fiscal year 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $2.6 billion at the end of fiscal year 2020, of which $1.8 billion is the current portion of the long-term debt, and the remainder is commercial paper and local borrowings by international subsidiaries. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout fiscal year 2019, the Company continued to have access to liquidity through the commercial paper market.  Short-term borrowings and the current portion of long-term debt amounted to approximately $1.2 billion at the end of fiscal year 2019, of which $1.1 billion is the current portion of the long term debt, and the remainder principally represents local borrowing by international subsidiaries. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2021 are:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.087%"><tr><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,799</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,515</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071094248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $1.4 billion of deferred tax expense for the adoption of the deferred method to account for GILTI. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2020, 2019 and 2018, to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on Capital Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA and related impacts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fiscal year 2020 tax rate decreased by 1.9% compared to the fiscal year 2019 tax rate, which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#8220;step-up&#8221;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#8220;step-up&#8221;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4&#160;billion or 2.6% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets as described above; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, in the fiscal fourth quarter of 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">reflected as a &#8220;Tax Benefits on Capital Loss&#8221; on the effective tax rate reconciliation. In addition in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accrual of litigation costs related to Talc for $4.0&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accrual of additional legal costs, including an additional $1.0&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested; reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18); and reversal of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. </span></div><div><span><br/></span></div><div style="margin-bottom:9.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2019 tax rate decreased by 2.3% compared to the fiscal year 2018 tax rate. In addition to the impact of TRAF discussed in more detail below, the primary drivers of the net decrease were as follows: </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2%. This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company&#8217;s annual effective tax rate by approximately 2.1%. </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate.  This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. Subsequent to December 29, 2019, the Company received and agreed to Notices of Proposed Adjustments (NOPAs) from the IRS. The Company believes it is adequately reserved for potential exposures.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There were several one-time tax impacts that resulted in a cumulative net tax benefit to the 2018 annual effective tax rate of 1.2%. These items included the LifeScan divestiture, the adjustment to the 2017 provisional TCJA tax charge and the acceleration of certain tax deductions as part of the 2017 tax return. </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2018. </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $0.1&#160;billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.6&#160;billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $0.9&#160;billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $450&#160;million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="margin-bottom:9.9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year 2018, the Company completed its full assessment and finalized the accounting for the impact of the TCJA. The Company recorded net adjustments to the above components of the provisional charge of approximately $0.2 billion. These revisions were based on updated estimates and additional analysis by management as well as applying interpretative guidance issued by the U.S. Department of Treasury to the </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facts and circumstances that existed as of the TCJA enactment date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This charge was primarily related to additional deferred tax liabilities for foreign local and withholding taxes for the remaining balance of undistributed foreign earnings as of December 31, 2017 that were not provided for in the 2017 provisional charge.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described in Note 1, in the fiscal year 2018, the Company elected to treat GILTI as a period expense under the deferred method and recorded a deferred tax cost of approximately $1.4 billion in the fiscal year 2018 related to facts and circumstances that existed on the date of TCJA enactment. During 2018, the Company reorganized the ownership structure of certain foreign subsidiaries which resulted in a reduction of certain foreign withholding taxes that it had recognized as part of the provisional TCJA tax charge in the fourth quarter of 2017. Following the completion of this restructuring and as a result of clarification by Swiss tax authorities regarding the applicability of withholding tax to repatriation of certain earnings, the Company reversed a deferred tax liability of $2.8 billion and a related deferred tax asset of $0.9 billion for U.S. foreign tax credits, for a net deferred tax benefit of $1.9 billion. This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:40.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Deferred Tax*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation &amp; amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward international</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,170)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has wholly-owned international subsidiaries that have cumulative net losses.  The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"><tr><td style="width:1.0%"/><td style="width:50.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The unrecognized tax benefits of $3.4 billion at January&#160;3, 2021, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2012. As of December 29, 2019, the Company classified unrecognized tax benefits and related interest </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">of  approximately $0.9 billion as a current liability on the &#8220;Accrued taxes on Income&#8221; line of the Consolidated Balance Sheet. In the fiscal year 2020, the Company made its final payments for approximately $0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $32 million, $50 million and $53 million in fiscal years 2020, 2019 and 2018, respectively. The total amount of accrued interest was $468&#160;million and $559 million in fiscal years 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072278552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Related Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Employee Related Obligations</a></td>
<td class="text">Employee Related Obligations<div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2020 and fiscal  2019, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid employee related obligations of $656 million and $551 million for 2020 and 2019, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072261512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">Pensions and Other Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PBO as of January 3, 2021 by approximately $1.8&#160;billion and is included in the &#8220;Amendments&#8221; line in the Change in Benefit Obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019 the Company used December 31, 2020 and December 31, 2019, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:39.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed health care cost trend rates, for all individuals:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"/><td style="width:71.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health Care Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,987)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,961)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,961)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. </span></div></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(191)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,004</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company contributed $441 million and $429 million to its U.S.&#160;and international pension plans, respectively.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2020 and December&#160;31, 2019, respectively:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $8.8 billion, $9.8 billion and $4.4 billion, respectively, at the end of 2020, and $4.3 billion, $5.2 billion and $0.9 billion, respectively, at the end of 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Fair Value of Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Hierarchy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Short-term investment funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government and agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commingled funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"/><td style="width:18.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,602</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $90 million and $84 million at December&#160;31, 2020 and December&#160;31, 2019, respectively and U.S. short-term investment funds (Level 2) of $31 million at December&#160;31, 2019. </span></div>The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $946 million (2.5% of total plan assets) at December&#160;31, 2020 and $984 million (3.1% of total plan assets) at December&#160;31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841070892312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SavingsPlanTextBlock', window );">Savings Plan</a></td>
<td class="text">Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $243 million, $235 million and $242 million in fiscal years 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841081403848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Capital and Treasury Stock</a></td>
<td class="text">Capital and Treasury Stock<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,490&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2020, 2019 and 2018.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends paid were $3.98 per share in fiscal year 2020, compared with dividends of $3.75 per share in fiscal year 2019, and $3.54 per share in fiscal year 2018. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Board of Directors declared a regular cash dividend of $1.01 per share, payable on March 9, 2021 to shareholders of record as of February 23, 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072428232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">Accumulated Other Comprehensive Income (Loss)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,351)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative adjustment to retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2018 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,869)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2019 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,891)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Per the adoption of ASU 2016-01- Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072223800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International Currency Translation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">International Currency Transalation</a></td>
<td class="text">International Currency Translation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes during fiscal years 2020, 2019 and 2018 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net currency transaction gains and losses included in Other (income) expense were losses of $209 million, $267 million and $265 million in fiscal years 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071093128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than their average market value. As of January 3, 2021, the Company did not have convertible debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2018 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock. The diluted net earnings per share calculation for fiscal year 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072352328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Common Stock, Stock Option Plans and Stock Compensation Agreements</a></td>
<td class="text">Common Stock, Stock Option Plans and Stock Compensation Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January&#160;3, 2021, the Company had 2 stock-based compensation plans.  The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012.  Shares available for future grants under the 2012 Long-Term Incentive Plan were 277 million at the end of fiscal year 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The compensation cost that has been charged against income for these plans was $1,005 million, $977 million and $978 million for fiscal years 2020, 2019 and 2018, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $210 million, $227 million and $192 million for fiscal years 2020, 2019 and 2018, respectively. The Company also recognized additional income tax benefits of $248&#160;million, $209&#160;million and $264&#160;million for fiscal years 2020, 2019 and 2018, respectively, for which options were exercised or restricted shares were vested. The total </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">unrecognized compensation cost was $804 million, $823 million and $827 million for fiscal years 2020, 2019 and 2018, respectively.  The weighted average period for this cost to be recognized was 1.76&#160;years, 1.71&#160;years and 1.73&#160;years for fiscal years 2020, 2019, and 2018, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options expire 10&#160;years from the date of grant and vest over service periods that range from 6 months to 4 years.  All options are granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2020, 2019 and 2018 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $16.42, $17.80 and $17.98, in fiscal years 2020, 2019 and 2018, respectively.  The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, and changes during the years ending on those dates is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"><tr><td style="width:1.0%"/><td style="width:47.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116.22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $1,021 million, $807 million and $1,028 million in fiscal years 2020, 2019 and 2018, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;3, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"><tr><td style="width:1.0%"/><td style="width:29.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$62.20-$72.54</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.79</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.44-$100.06</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.36</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.48-$115.67</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$129.51-$131.94</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.53</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$141.06-$151.41</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$116.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$96.97</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding at December&#160;29, 2019 and December&#160;30, 2018 were 111,637 and an average life of 6.0 years and 109,652 and an average life of 6.2&#160;years, respectively. Stock options exercisable at December&#160;29, 2019 and December&#160;30, 2018 were 60,761 at an average price of $88.88 and 54,862 at an average price of $82.03, respectively. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units and Performance Share Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;3, 2021 is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"/><td style="width:55.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of the restricted share units granted was $139.58, $121.31 and $119.67 in fiscal years 2020, 2019 and 2018, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $650 million, $586 million and $614 million in 2020, 2019 and 2018, respectively.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the performance share units granted was $160.54, $124.67 and $120.64 in fiscal years 2020, 2019 and 2018, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; </span></div>The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $91 million, $119 million and $129 million in fiscal years 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072381224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">Segments of Business* and Geographic Areas<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;19 vs. &#8217;18</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously referred to as Consumer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously referred to as Beauty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">  REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:48pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Previously referred to as Spine &amp; Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,999</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,929</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,581</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.5&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.2&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1 billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9 billion related to the Alios asset</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A research and development expense of $0.3 billion for an upfront payment related to argenx </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.6 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring charge of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $2.0 billion from the divestiture of the ASP business</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Auris Health acquisition and integration related costs of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.3 billion from the divestiture of NIZORAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3 billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized loss on securities of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $1.7 billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.6 billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">AMO acquisition and integration related costs of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.5 billion from the divestiture of the LifeScan business</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072261512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and Divestitures<div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain businesses were acquired for $7.3&#160;billion in cash and $0.4&#160;billion of liabilities assumed during fiscal year 2020. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant  robotics and data science capabilities.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.8&#160;billion applying a probability of success factor that ranged from 20% to  60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%.  XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.4&#160;billion, goodwill for $0.2&#160;billion, other assets of $0.2&#160;billion and liabilities assumed of $0.3&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;D) of $6.0&#160;billion, goodwill of $1.2&#160;billion, other assets of $0.5&#160;billion and liabilities of $1.6&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019 certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately &#165;230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treated this transaction as a business combination and included it in the Consumer Health segment.  During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities of $0.4 billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 1, 2019 the Company&#160;completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&amp;D for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $1.1&#160;billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company&#8217;s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&amp;D impairment charge of $0.1&#160;billion related to timing and progression of the digital surgery platforms. A probability of success factor ranging from 55% to 95% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied was approximately 10%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2018 certain businesses were acquired for $0.9 billion in cash and $0.1 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $1.0 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2020, 2019 and 2018 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to fiscal 2020, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment and received combined proceeds of approximately $0.6&#160;billion. The Company will reflect these brand divestitures in its 2021 financial results.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, the Company sold 11.8&#160;million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company. The transaction resulted in gross proceeds of approximately CHF 337&#160;million ($357&#160;million) based on a sales price of CHF 28.55/share and an immaterial net loss. The Company currently has rights to at least an additional 38.7&#160;million shares (or approximately 20% of Idorsia equity) through a convertible loan with a principal amount of CHF 445&#160;million (due June 2027). Idorsia also has access to an approximate CHF 243&#160;million credit facility with the Company. As of January 3, 2021, Idorsia has not made any draw-downs under the credit facility. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $2.0 billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2018, the Company divested the LifeScan Inc business for approximately $2.1 billion and retained certain net liabilities. Other divestitures in fiscal year 2018 included: NIZORAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RoC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain non-strategic Pharmaceutical products. In 2018, the pre-tax gains on the divestitures were approximately $1.2 billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world&#8217;s leading manufacturing services providers for health care products and technology products.&#160;The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of employees and manufacturing sites. The transfers were completed in fiscal year 2020.&#160;As of January 3, 2021, there were no assets held for sale on the Consolidated Balance Sheet. As of December 29, 2019, the assets held for sale on the Consolidated Balance Sheet were $0.1 billion of inventory and property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 20 to the Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072311400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal Proceedings<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January&#160;3, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh. As of January&#160;3, 2021, in the United States there were approximately 560 plaintiffs with direct claims in pending lawsuits regarding </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; 7,800 with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Acetabular Cup System; 14,900 with respect to pelvic meshes; 9,300 with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; 12,600 with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; 25,000 with respect to body powders containing talc; 300 with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and 4,200 with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Flexible Composite Mesh.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000  claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices.  In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. The Company is appealing the decision. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss.  The form of the individual case assessment process has not yet been determined by the Court. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160; Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Ventral Patch hernia mesh products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In September 2019, plaintiffs&#8217; attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE&#8482; Polypropylene Hernia System (&#8220;PHS&#8221;) cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. Discovery is underway in these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8&#160;million by the trial judge. The Company and plaintiff are each appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson (J&amp;J); and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&amp;J announced an agreement in principle to the settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Personal injury claims alleging that talc causes cancer have been made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied  plaintiffs&#8217; attempt to limit the scope of testimony of certain of the Company&#8217;s witnesses. With this ruling made, case-specific discovery has begun per the Court&#8217;s directive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In talc cases that have previously gone to trial, the Company has obtained defense verdicts in a number of them, but there have also been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018  verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion and, with additional interest as of January 3, 2021, as the Company pursues further appeal, is currently $2.5&#160;billion (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and the Company is currently seeking review by the United States Supreme Court. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision currently on appeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in connection with product liability litigation associated with body powders containing talc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217; potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company&#8217;s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company&#8217;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants&#8217; committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus) filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements.  The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus&#8217;s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates allowing Debtors to proceed with soliciting votes on the Plan. The Company intends to continue to object to the Plan. A hearing to consider confirmation of the Plan has been scheduled for June 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S&#174; Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. Discovery is underway.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete</span><span style="color:#d13438;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">A lawsuit pending in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Baby Powder has been resolved in the Company&#8217;s favor. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing has been scheduled for April 2021. Limited informal discovery is continuing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission (SEC) and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries. In November 2020, the SEC terminated its investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, the federal cases, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy).  MedIdea alleged infringement of United States Patent Nos. 6,558,426 (&#8217;426); 8,273,132 (&#8217;132); 8,721,730 (&#8217;730)  and 9,492,280 (&#8217;280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contact feature of the ATTUNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. In November 2019, judgment was entered in favor of DePuy. In January 2021, the U.S. Court of Appeals for the Federal Circuit affirmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antibacterial Sutures and STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plus Antibacterial Sutures infringe plaintiffs&#8217; United States Patent Nos. 6,596,296 (&#8217;296) and 7,033,603 (&#8217;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT is seeking damages and an injunction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the USPTO denied institution of the &#8217;296 patent IPR and granted institution of the &#8217;603 patent IPR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT dismissed the &#8217;603 patent from the suit and no longer accuses PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures or STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform.  Auris filed IPR Petitions with the USPTO regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit.  In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent.  In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intuitive has appealed that decision.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The district court trial is scheduled to begin in June 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Evolution System.  RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2020, the case was stayed pending IPR proceedings filed by the Consolidated Defendants involving the asserted patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial is scheduled for October 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits pending against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen)  initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex&#8217;s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of Canadian Patent No. 2,661,422 (&#8217;422). The final hearing concluded in May 2019.  In October 2019, the Court issued an order prohibiting the Canadian Minister of Health from approving Apotex&#8217;s ANDS until the expiration of the &#8217;422 patent. In November 2019, Apotex filed an appeal.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2019, Janssen initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex, Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent. The final hearing in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, Janssen initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (Jamp) in Canada in response to Jamp&#8217;s filing of an ANDS seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> before the expiration of the &#8217;422 patent. The final hearing is scheduled to begin in May 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Intellectual Property GmbH and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd. (collectively, DRL) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of U.S. Patent No.  9,539,218 (&#8217;218). In this lawsuit, JPI and Bayer were seeking an order enjoining DRL from marketing their generic versions of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. In November 2020, JPI and Bayer entered into a confidential settlement agreement with DRL, and the case was voluntarily dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include  MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus); Sandoz, Inc. (Sandoz); and Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin). These cases were consolidated into one action (Polymorph Main Action), which has been scheduled for trial starting in April 2021. In December 2020, Janssen and MTPC entered into a confidential settlement with Sandoz and in January 2021, Janssen and MTPC entered into a confidential settlement with Lupin. The cases against Sandoz and Lupin were voluntarily dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and IVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788), 8,222,219 (&#8217;219) and/or 8,785,403 (&#8217;403) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> XR (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent.  In </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of United States Patent No. 10,617,668 relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These lawsuits have not been consolidated with the Main Actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,534,024 and 2,671,357. The final hearing is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n October 2020, Actelion Pharmaceuticals Ltd (Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Laurus Labs Limited and PharmaQ, Inc. (collectively, Laurus), which filed an ANDA seeking approval to market generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of U.S. Patent No. 7,094,781 (&#8217;781). Actelion was seeking an order enjoining Laurus from marketing generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;781 patent. In January 2021, Actelion entered into a settlement agreement with Laurus. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is scheduled to begin in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906).  Trial concluded in October 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the &#8217;906 patent. The USPTO denied the Petition in September 2020, and Mylan appealed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada)  in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent.  In  May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Final Hearing is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. The Final Hearing is scheduled to begin in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> 140 mg capsules before expiration of Pharmacyclics&#8217;  United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Cipla Limited and Cipla USA Inc. (collectively, Cipla); Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2019, Pharmacyclics and JBI amended their complaint against Sandoz to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, Pharmacyclics and JBI amended their complaint against Cipla to allege infringement of United States Patent Nos. 10,106,548, and 10,125,140.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, Pharmacyclics and JBI amended their complaint against Cipla to further allege infringement of United States Patent No. 10,016,435. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Pharmacyclics and JBI amended their complaints against Cipla and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232. In August 2019, the Court granted a joint stipulation to stay the litigation against Cipla.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial in the actions against Sandoz and Alvogen took place in October 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2019, Sandoz filed an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IPR Petition with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the USPTO, seeking to invalidate United States Patent No. 9,795,604.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the USPTO issued a final decision in the IPR invalidating certain claims of the &#8217;604 patent and upholding the validity of certain claims in the &#8217;604 patent. The final decision was not appealed by the parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen and Sandoz asserting infringement of United States Patent No. 10,478,439.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent No. 10,463,668. In October 2020, Pharmacyclics and JBI amended their complaint against Sandoz to further allege infringement of U.S. Patent Nos. 10,752,634 and 10,695,350 and amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,653,696. In December 2020 the Court entered a joint stipulation dismissing the complaint against Sandoz. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus Worldwide DMCC and Cadila Healthcare Limited (collectively, Zydus), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,008,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,386 and 10,478,439.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trials in the actions against Alvogen and Zydus are scheduled to begin in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion is the exclusive licensee of the asserted patents. The defendants include Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic); MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (collectively, MSN); ); VGYAAN Pharmaceuticals LLC (VGYAAN); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus). In January 2021, the Court entered joint stipulations dismissing VGYAAN and MSN from suit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of United States Patent No. 10,143,693 relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patent.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial.  In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than 3,100 lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical companies, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina; Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 370 cases pending in various state&#160;courts. There are over 2,800 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804).&#160;In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $572&#160;million, subject to a final order to be issued by the Court.&#160;The Court issued a final judgment reducing the amount to $465&#160;million. Johnson &amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed and future claims by states, cities and counties. The Company cannot predict if or when the agreement will be finalized and individual cases are ongoing. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint, and as of December 2020, that motion was fully briefed. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the shareholders in the consolidated action filed a motion for voluntary dismissal.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> case filed pursuant to the False Claims Act against the companies. In February 2016, the district court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the district court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. The relators&#8217; remaining claims are now pending before the district court. In July 2020, the Court ordered the relators to complete discovery by August 2020; the Relators have requested an extension of the August 2020 deadline that DePuy opposed and additional discovery-related motions have been filed by both parties. Additionally, DePuy has requested a schedule for the filing of a motion to strike and to dismiss the relators&#8217; second amended complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">penalty judgment. In April 2020, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company settled the West Virginia. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2012, Therakos, Inc. (Therakos), formerly a subsidiary of Johnson &amp; Johnson and part of the Ortho-Clinical Diagnostics, Inc. (OCD) franchise, received a letter from the civil division of the United States Attorney's Office for the Eastern District of Pennsylvania informing Therakos that the United States Attorney's Office was investigating the sales and marketing of Uvadex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (methoxsalen) and the Uvar Xts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Cellex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Systems during the period 2000 to the present. The United States Attorney's Office requested that OCD and Johnson &amp; Johnson preserve documents that could relate to the investigation. Therakos was subsequently acquired by an affiliate of Gores Capital Partners III, L.P. in January 2013, and OCD was divested in June 2014. Following the divestiture of OCD, Johnson &amp; Johnson retained OCD&#8217;s portion of any liability resulting from the investigation for activity that occurred prior to the sale of Therakos. Following production of documents to and settlement discussions with the U.S. Attorney&#8217;s Office, J&amp;J affiliate Medical Device Business Services, Inc. agreed to resolve claims under the federal False Claims Act and analogous state laws in a settlement announced in November  2020. In the settlement agreement, Medical Device Business Services expressly denied any wrongful conduct. As a result of the settlement, a qui tam complaint filed by two relators pending in the U.S. District Court for the Eastern District of Pennsylvania will be dismissed. Separate settlement agreements with the states participating in the settlement are in the process of being finalized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder and JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson &amp; Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted J&amp;J and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing is complete and oral argument was held in February 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-one states have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Several states have issued Civil Investigative Demands seeking documents and other information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160; In February 2021, the Court stayed the case and ordered mediation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the Unites States Department of Justice notified Janssen Biotech, Inc. that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy Synthes, Inc. have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. We continue to actively respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baby Powder.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The complaint seeks damages but does not allege personal injury.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, JJCI moved to dismiss the complaint.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) in connection with its importation into the United States. In August 2020, US CBP formally rejected Janssen&#8217;s Supplemental Petition challenging the penalties assessment and demanded payment of the mitigated penalty.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, US CBP agreed to not refer the matter to the Office of Chief Counsel at this time, pending resolution of the related Classification Litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2013, Janssen Ortho sued the United States in the United States Court of International Trade (the Classification Litigation) seeking a determination that darunavir ethanolate is exempt from duties upon importation into the United States. In February 2020, the Court ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States appealed to the United States Court of Appeals for the Federal Circuit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, Genmab A/S brought an arbitration against Janssen Biotech, Inc. pursuant to a 2012 License Agreement between the parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The arbitration relates to royalties for certain Janssen daratumumab products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice is complete. No trial date has been set.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research &amp; Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages. In November 2020, Defendants moved to dismiss the complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania.  Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks damages and injunctive relief. Discovery is ongoing. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE&#174; against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co, filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#8217;s decision to the United States Court of Appeals for the District of Columbia Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals US, Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160; The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. Plaintiffs have appealed the decision to the United States Court of Appeals for the Fourth Circuit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Several additional complaints were filed thereafter in Virginia and New Jersey.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case for pretrial purposes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to delay generic entry, and seek damages and injunctive relief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California.  The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">development and marketing of combination antiretroviral therapies (cART) to treat HIV.  The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California.  The complaint alleges that certain of BWI&#8217;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;J, Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter Zantac (ranitidine) products. Plaintiffs in the underlying actions allege that Zantac and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091307992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the Global Supply Chain restructuring strategic collaborations see Note 18 to the Consolidated Financial Statements. In fiscal year 2020, the Company recorded a pre-tax charge of $0.4 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.2 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.3 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;30, 2018</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;29, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents gain on sale of an asset</span></div>The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072658056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Description of the Company And Business Segments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately 134,500&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div>The Company is organized into three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women&#8217;s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2018-18: Collaborative Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13: Financial Instruments - Credit Losses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity&#8217;s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2018-14: Compensation - Defined Benefit Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  </span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"/><td style="width:61.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2014-09 - Revenue from Contracts with Customers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-01 - Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-16 - Income Taxes: Intra-Entity Transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 3, 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">InvestmentsInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment and Depreciation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;- 30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between </span></div>the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion and $7.0 billion as of January&#160;3, 2021 and December&#160;29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2020,&#160;2019&#160;and&#160;2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $1.0 billion, $1.0 billion and $1.1 billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_14c84a58-97f7-4f9f-b828-aa6fba7abd92"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njcy_7bf9c3d2-d1c6-4053-8449-c581895063f0">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc2_adda8d47-e5bf-4045-8283-b34af2a589f9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc3_c96acc81-2417-40c1-959b-ff9504611f29">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_373f8cbd-3062-4a3c-ae80-3043f0ae9dc9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YjdiMzA2NmE0ODQ4ZjViZTc5MGE1NDc4YmRlMDY3L3NlYzoyNmI3YjMwNjZhNDg0OGY1YmU3OTBhNTQ3OGJkZTA2N18xMzMvZnJhZzo3NjgxNGQ5N2EzNDY0NGI2ODBmOThhMWUxNGZkMTU1Yy90ZXh0cmVnaW9uOjc2ODE0ZDk3YTM0NjQ0YjY4MGY5OGExZTE0ZmQxNTVjXzEwNDQ1MzYwNTE4Njc0_cf99bf77-67c2-4ff4-9d6b-e89130e20daa">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.0&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The lease liability was $1.1&#160;billion and $1.0&#160;billion in 2020 and 2019, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion and $0.3&#160;billion in 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityPolicyTextBlock', window );">Product Liability</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, co-developed with Bayer HealthCare AG and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, licensed from Genmab A/S.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text">AdvertisingCosts associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $7.7&#160;billion, of which $6.9&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company </span></div>intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FiscalPeriodPolicyTextBlock', window );">Annual Closing Date</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FiscalPeriodPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FiscalPeriodPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091733304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of New Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018:  </span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"/><td style="width:61.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2014-09 - Revenue from Contracts with Customers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-01 - Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2016-16 - Income Taxes: Intra-Entity Transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;- 30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072359336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Cash Equivalent Composition</a></td>
<td class="text"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.573%"><tr><td style="width:1.0%"/><td style="width:59.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.086%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gov't Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Contractual Maturities of Available for Sale Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;3, 2021 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.157%"><tr><td style="width:1.0%"/><td style="width:43.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841081386552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, inventories were comprised of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"/><td style="width:66.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span>See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841092055624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment at Cost and Accumulated Depreciation</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"/><td style="width:67.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,766</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December&#160;29, 2019. There were no assets held for sale at January&#160;3, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841087135208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,056&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,569</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,643</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0&#160;billion from Momenta Pharmaceuticals, Inc., $0.8&#160;billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4&#160;billion from the acquisition of all outstanding shares in Verb Surgical, Inc.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;3, 2021 and December&#160;29, 2019, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:33.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841081181656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019, net of tax:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Effect of Net Investment Hedges</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;3, 2021 and December&#160;29, 2019:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;3, 2021 and December&#160;29, 2019 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">902</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.409%"><tr><td style="width:1.0%"/><td style="width:53.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.695%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2019 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,148 million, which are classified as Level&#160;1 and contingent consideration of $1,715 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $1 million of non-current assets as of December&#160;29, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $594 million, $1,631 million (primarily related to Auris Health) and $397 million, classified as non-current other liabilities as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, respectively. Includes $39 million and $84&#160;million classified as current liabilities as of January&#160;3, 2021 and December&#160;29, 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072556248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3% Zero Coupon Convertible Subordinated Debentures due 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%&#160;Debentures due 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.950% Notes due 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250% Notes due 2022                                                        (1B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1B Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500MM 1.3654 GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(500MM GBP 1.2987)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028                                                (750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035                                                     (1.5B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1.5B Euro 1.1096)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.400%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Notes due 2050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.450% Notes due 2060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;3, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at December&#160;29, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the fair value over the carrying value of debt was $5.4 billion at the end of fiscal year 2020 and $3.0 billion at the end of fiscal year 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5&#160;billion.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Maturities of Long Term Obligations</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2021 are:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.087%"><tr><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,799</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,515</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841084357576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span>Includes $1.4 billion of deferred tax expense for the adoption of the deferred method to account for GILTI.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2020, 2019 and 2018, to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on Capital Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA and related impacts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Temporary Differences and Carryforwards</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:40.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Deferred Tax*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation &amp; amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward international</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,170)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"><tr><td style="width:1.0%"/><td style="width:50.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072317160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Related Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EmployeeRelatedObligationsTableTextBlock', window );">Employee Related Obligations</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2020 and fiscal  2019, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeRelatedObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee related obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeRelatedObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072202072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:39.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Assumed Health Care Cost Trend Rates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed health care cost trend rates, for all individuals:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"/><td style="width:71.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health Care Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,987)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,961)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,961)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,416</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. </span></div></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(191)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,004</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock', window );">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2020 and December&#160;31, 2019, respectively:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock', window );">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Company' Retirement Plan Asset Allocation and Target Allocations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans Disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"/><td style="width:18.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,602</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to the benefit obligation and the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated future employer contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071062920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockTableTextBlock', window );">Changes in Treasury Stock</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,490&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841073095160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,351)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative adjustment to retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2018 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,869)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2019 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,891)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Per the adoption of ASU 2016-01- Financial Instruments</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072314568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091928760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Valuation Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $16.42, $17.80 and $17.98, in fiscal years 2020, 2019 and 2018, respectively.  The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;3, 2021, December&#160;29, 2019 and December&#160;30, 2018, and changes during the years ending on those dates is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.690%"><tr><td style="width:1.0%"/><td style="width:47.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116.22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Options Outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;3, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"><tr><td style="width:1.0%"/><td style="width:29.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$62.20-$72.54</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.79</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.44-$100.06</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.36</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.48-$115.67</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$129.51-$131.94</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.53</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$141.06-$151.41</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$116.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$96.97</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Restricted Share Units</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;3, 2021 is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"/><td style="width:55.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841073616840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Schedule of Sales by Segment of Business</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;19 vs. &#8217;18</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously referred to as Consumer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously referred to as Beauty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">  REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:48pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Previously referred to as Spine &amp; Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,999</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,929</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81,581</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.5&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.2&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1 billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9 billion related to the Alios asset</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A research and development expense of $0.3 billion for an upfront payment related to argenx </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.6 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring charge of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $2.0 billion from the divestiture of the ASP business</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Auris Health acquisition and integration related costs of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.3 billion from the divestiture of NIZORAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3 billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized loss on securities of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $1.7 billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.6 billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">AMO acquisition and integration related costs of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.5 billion from the divestiture of the LifeScan business</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072416600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of Severance Charges and Associated Spending</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;30, 2018</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;29, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents gain on sale of an asset</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841085511512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>Employee </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide', window );">Number of employees | Employee</a></td>
<td class="nump">134,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of business segments | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued Rebates Returns And Promotions</a></td>
<td class="nump">$ 11,513<span></span>
</td>
<td class="nump">$ 10,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement', window );">Minimum reverse repurchase agreement collateral (as a percent)</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesReturnReserve', window );">Sales return reserve (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProfitLossPercentToSales', window );">Percentage of profit share payments (less than)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 28,427<span></span>
</td>
<td class="nump">$ 27,556<span></span>
</td>
<td class="nump">$ 27,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShippingandHandlingCostsasaPercentofSales', window );">Shipping and handling costs as a percent of sales</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present Value of lease liabilities</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability', window );">TCJA, provisional liability</a></td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent', window );">TJCA , provisional liability, non-current</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Repatriation of foreign earnings amount</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued Rebates Returns And Promotions</a></td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationOfCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationOfCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees engaged in company activities worldwide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProfitLossPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit loss percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProfitLossPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesReturnReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales return reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesReturnReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShippingandHandlingCostsasaPercentofSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shipping and Handling Costs as a Percent of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShippingandHandlingCostsasaPercentofSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090344648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 59,471<span></span>
</td>
<td class="nump">$ 59,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CumulativeEffectPeriodOfAdoptionAxis=jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="nump">$ 113,890<span></span>
</td>
<td class="nump">$ 110,659<span></span>
</td>
<td class="nump">$ 106,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 - Revenue from Contracts with Customers | Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">ASU 2016-01 - Financial Instruments | Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=jnj_AccountingStandardUpdate201616Member', window );">ASU 2016-16 - Income Taxes: Intra-Entity Transfers | Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative Effect of Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CumulativeEffectPeriodOfAdoptionAxis=jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CumulativeEffectPeriodOfAdoptionAxis=jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=jnj_AccountingStandardUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=jnj_AccountingStandardUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090944984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land And Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land And Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841080368008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">$ 13,985<span></span>
</td>
<td class="nump">$ 17,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">11,143<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">14,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">11,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. Sovereign Securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">6,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">6,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Other Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">2,674<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">4,755<span></span>
</td>
<td class="nump">3,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">14,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">9,287<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">13,777<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">4,731<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">13,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">9,047<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Other Sovereign Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt Securities, Held-to-maturity, Fair Value</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=jnj_OtherReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=jnj_OtherReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=jnj_OtherSovereignSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=jnj_OtherSovereignSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841172482680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 14,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">14,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 14,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841070916504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,410<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,894<span></span>
</td>
<td class="nump">6,071<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories (1)</a></td>
<td class="nump">$ 9,344<span></span>
</td>
<td class="nump">$ 9,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841092227080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land and land improvements</a></td>
<td class="nump">$ 882<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and building equipment</a></td>
<td class="nump">12,502<span></span>
</td>
<td class="nump">11,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">29,104<span></span>
</td>
<td class="nump">26,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">3,637<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">46,804<span></span>
</td>
<td class="nump">43,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="nump">28,038<span></span>
</td>
<td class="nump">25,674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net(1)</a></td>
<td class="nump">$ 18,766<span></span>
</td>
<td class="nump">$ 17,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091292232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest expense capitalized</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest', window );">Depreciation expense, including the amortization of capitalized interest</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation expense including the amortization of capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090813608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and Development in Process</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="nump">19,044<span></span>
</td>
<td class="nump">11,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="nump">53,402<span></span>
</td>
<td class="nump">47,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="nump">7,195<span></span>
</td>
<td class="nump">6,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="nump">11,849<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="nump">39,990<span></span>
</td>
<td class="nump">36,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="nump">17,618<span></span>
</td>
<td class="nump">13,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="nump">22,372<span></span>
</td>
<td class="nump">23,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="nump">22,898<span></span>
</td>
<td class="nump">22,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">9,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="nump">11,986<span></span>
</td>
<td class="nump">$ 12,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and Development in Process</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and Development in Process</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember', window );">Verb Surgical Inc. | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and Development in Process</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841080366296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">$ 33,639<span></span>
</td>
<td class="nump">$ 30,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">36,393<span></span>
</td>
<td class="nump">33,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">9,736<span></span>
</td>
<td class="nump">8,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="nump">600<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">10,336<span></span>
</td>
<td class="nump">9,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">9,169<span></span>
</td>
<td class="nump">9,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">11,009<span></span>
</td>
<td class="nump">9,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">14,734<span></span>
</td>
<td class="nump">12,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">$ 15,048<span></span>
</td>
<td class="nump">$ 14,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841081242712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841071008696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite lived intangibles, amortization expense next twelve months</a></td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite lived intangibles, amortization expense, year two</a></td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite lived intangibles, amortization expense, year three</a></td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite lived intangibles, amortization expense, year four</a></td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite lived intangibles, amortization expense, year five</a></td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841082931144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">6,562<span></span>
</td>
<td class="nump">5,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</a></td>
<td class="num">$ (652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Description of reclassification of cash flow hedge gain (loss)</a></td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedging transaction exposure</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">$ (1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral paid</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">37,800<span></span>
</td>
<td class="nump">45,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">30,600<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments with Readily Determinable Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="num">(194)<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without Readily Determinable Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices', window );">Equity, fair value adjustment, change in observable prices</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Change in Observable Prices</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentChangeinObservablePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841086184136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">44<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">298<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">$ (52)<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841080020584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts: | Not Designated as Hedging Instrument | Other (Income) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">$ (144)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091385816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="num">$ (473)<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SaleOfSubsidiaryGainLossMember', window );">Sale of Subsidiary Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Gain/(Loss) Reclassified From Accumulated OCI Into Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Gain/(Loss) Reclassified From Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SaleOfSubsidiaryGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SaleOfSubsidiaryGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841086836904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">$ 6,562<span></span>
</td>
<td class="nump">$ 5,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments with Readily Determinable Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="num">(194)<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without Readily Determinable Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841081620856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Apr. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">$ 1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">2,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">$ 1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">14,042<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative Asset, Fair Value, Gross Asset</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Derivative Asset, Fair Value, Gross Liability</a></td>
<td class="num">(1,107)<span></span>
</td>
<td class="num">(841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liability, Fair Value, Gross Liability</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Derivative Liability, Fair Value, Gross Asset</a></td>
<td class="num">(2,172)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (7)</a></td>
<td class="num">(1,089)<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">2,271<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">14,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative Asset, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivative Instruments in Hedges, Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivative Instruments in Hedges, Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841156565768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Schedule of Long-term Debt Instruments (Details)<br> &#8364; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Sep. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
<td class="nump">3.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermCommercialPaperCurrent', window );">Borrowed under the commercial paper program</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">32,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">34,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">1,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 32,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member', window );">3% Zero Coupon Convertible Subordinated Debentures due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Debenturesdue2020Member', window );">2.95%&#160;Debentures due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.950Notesdue2020Member', window );">1.950% Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2021Member', window );">3.55% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2021Member', window );">2.45% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.65Notesdue2021Member', window );">1.65% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member', window );">0.250% Notes due 2022 (1B Euro 1.2281)(2)/(1B Euro 1.1096)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member', window );">2.25% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73%&#160;Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50%&#160;Notes due 2024 (500MM 1.3654 GBP )(2)/(500MM GBP 1.2987)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.3654<span></span>
</td>
<td class="nump">1.3654<span></span>
</td>
<td class="nump">1.3654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2987<span></span>
</td>
<td class="nump">1.2987<span></span>
</td>
<td class="nump">1.2987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member', window );">0.55% Notes due 2025(5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member', window );">0.55% Notes due 2025(5) | Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95%&#160;Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95%&#160;Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.2281)(2)/(1.5B Euro 1.1096)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
<td class="nump">1.1096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95%&#160;Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85%&#160;Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.400%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50%&#160;Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.500% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.250% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.250% Notes due 2050 | Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.450% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.450% Notes due 2060 | Carrying (Reported) Amount, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommercialPaperCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommercialPaperCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Debenturesdue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Debenturesdue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.950Notesdue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.950Notesdue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.65Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.65Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841076671992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of fair value over carrying value of debt</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity under credit facility</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and the current portion of long-term debt</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermCommercialPaperCurrent', window );">Borrowed under the commercial paper program</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommercialPaperCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommercialPaperCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841085517496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Aggregate Maturities of Long Term Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Aggregate maturities of long-term obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">2,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">1,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">After 2025</a></td>
<td class="nump">$ 25,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091537944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Currently payable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total currently payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">4,685<span></span>
</td>
<td class="nump">3,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="num">(2,226)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,783<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 2,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax', window );">GILTI, deferred tax cost</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss', window );">Tax benefits on Capital Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Deferred Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841069774728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract', window );"><strong>Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.&#160;</a></td>
<td class="nump">$ 4,312<span></span>
</td>
<td class="nump">$ 3,543<span></span>
</td>
<td class="nump">$ 5,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">12,185<span></span>
</td>
<td class="nump">13,785<span></span>
</td>
<td class="nump">12,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 16,497<span></span>
</td>
<td class="nump">$ 17,328<span></span>
</td>
<td class="nump">$ 17,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">International operations (1)</a></td>
<td class="num">(9.90%)<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome', window );">U.S. taxes on international income (2)</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss', window );">Tax benefits on Capital Loss</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Tax benefits on share-based compensation</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">TCJA and related impacts</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">All other</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comparison of income tax expense at the Statutory rate and Company's tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation related to domestic tax on international income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091540936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Deferred Tax Assets, Employee related obligations</a></td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">$ 2,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Stock based compensation</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Deferred Tax Assets, Property, Plant and Equipment</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized', window );">Deferred Tax Assets, International R&amp;D capitalized for tax</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Deferred Tax Assets, Reserves&#160;&amp; liabilities</a></td>
<td class="nump">3,466<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Tax Assets, Income reported for tax purposes</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred Tax Assets, Net operating loss carryforward international</a></td>
<td class="nump">990<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings', window );">Deferred Tax Assets, Undistributed Foreign Earnings</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Miscellaneous international</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsOtherDomestic', window );">Deferred Tax Assets Other Domestic</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred Tax Liabilities, Non-deductible intangibles</a></td>
<td class="num">(6,567)<span></span>
</td>
<td class="num">(5,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign', window );">Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Deferred Tax Liabilities, Undistributed Foreign Earnings</a></td>
<td class="num">(1,435)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome', window );">Deferred Tax Liability, Global Intangible Low-Taxed Income</a></td>
<td class="num">(3,606)<span></span>
</td>
<td class="num">(2,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Miscellaneous international</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Total deferred income taxes</a></td>
<td class="nump">13,138<span></span>
</td>
<td class="nump">12,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Total deferred income taxes</a></td>
<td class="num">$ (11,819)<span></span>
</td>
<td class="num">$ (10,170)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets international research and development capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets other domestic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Undistributed Foreign Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Global Intangible Low-Taxed Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072289896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Summary of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year</a></td>
<td class="nump">$ 3,853<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
<td class="nump">$ 3,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior period tax positions</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior period tax positions</a></td>
<td class="num">(551)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(839)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year</a></td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841078521736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent', window );">Net decrease in tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability', window );">Reversal of deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset', window );">Reversal of deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit', window );">TJCA foreign tax credits, net deferred tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Effective income tax rate reconciliation, increase (decrease), percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent', window );">TJCA, foreign tax credit percent</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent', window );">Increase (decrease) in earnings before taxes, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent', window );">Effective tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset', window );">TCJA, increase (decrease) in deferred tax asset</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase (decrease) in unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent', window );">Effective tax rate reconciliation, unrecognized tax benefits, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Effective income tax rate reconciliation, other reconciling items, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit', window );">Income tax expense recorded related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent', window );">TRAF effect on tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit', window );">Income tax expense related to change in tax rate from TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset', window );">Deferred tax asset recorded related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit', window );">Deferred tax expense related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit', window );">Tax Cuts and Jobs Act, incomplete accounting, net adjustments for provisional income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Deferred tax liability foreign taxes</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax', window );">GILTI, deferred tax cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate reconciliation, deduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3,853<span></span>
</td>
<td class="nump">3,373<span></span>
</td>
<td class="nump">3,853<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">3,853<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
<td class="nump">$ 3,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent', window );">Effective tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OpiodsMember', window );">Opiods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent', window );">Effective tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Opiods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_UnrecognizedTaxBenefitLiabilityPayment', window );">Payment on unrecognized tax benefit liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=jnj_AccruedTaxesOnIncomeMember', window );">Accrued Taxes On Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Before Taxes, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act, Incomplete Accounting, Net Adjustments for Provisional Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Deferred Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_UnrecognizedTaxBenefitLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefit Liability, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_UnrecognizedTaxBenefitLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OpiodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OpiodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=jnj_AccruedTaxesOnIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=jnj_AccruedTaxesOnIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072202072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Related Obligations - Employee Related Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities', window );">Pension benefits</a></td>
<td class="nump">$ 5,761<span></span>
</td>
<td class="nump">$ 5,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent', window );">Postretirement benefits</a></td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent', window );">Postemployment benefits</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">3,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EmployeeObligations', window );">Total employee obligations</a></td>
<td class="nump">11,318<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Less current benefits payable</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations&#160;&#8212; non-current</a></td>
<td class="nump">$ 10,771<span></span>
</td>
<td class="nump">$ 10,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total employee obligations current and non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072529560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Related Obligations - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Prepaid employee related obligations</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090907064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2,461)<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
<td class="num">(2,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841068751896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">2.82%<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">3.13%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.99%<span></span>
</td>
<td class="nump">3.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">8.12%<span></span>
</td>
<td class="nump">8.31%<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">3.08%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.23%<span></span>
</td>
<td class="nump">3.39%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091948088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract', window );"><strong>Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Health care cost trend rate assumed for next year</a></td>
<td class="nump">5.68%<span></span>
</td>
<td class="nump">5.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline (ultimate trend)</a></td>
<td class="nump">4.49%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">2040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year ultimate health care cost trend rate is expected to be reached, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841068949368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(547)<span></span>
</td>
<td class="num">(514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(10,771)<span></span>
</td>
<td class="num">(10,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis=jnj_LumpSumDistributionMember', window );">Lump-sum distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">37,188<span></span>
</td>
<td class="nump">31,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses(2)</a></td>
<td class="nump">5,716<span></span>
</td>
<td class="nump">5,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(1,111)<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">43,300<span></span>
</td>
<td class="nump">37,188<span></span>
</td>
<td class="nump">31,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">32,201<span></span>
</td>
<td class="nump">26,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">5,524<span></span>
</td>
<td class="nump">6,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(1,111)<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">38,195<span></span>
</td>
<td class="nump">32,201<span></span>
</td>
<td class="nump">26,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="num">(5,105)<span></span>
</td>
<td class="num">(4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(5,636)<span></span>
</td>
<td class="num">(5,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="num">(5,105)<span></span>
</td>
<td class="num">(4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">10,860<span></span>
</td>
<td class="nump">8,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)(1)</a></td>
<td class="num">(1,797)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">9,063<span></span>
</td>
<td class="nump">8,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">40,356<span></span>
</td>
<td class="nump">33,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="nump">2,616<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(891)<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">5,076<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses(2)</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="num">(4,938)<span></span>
</td>
<td class="num">(4,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(4,520)<span></span>
</td>
<td class="num">(4,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="num">(4,938)<span></span>
</td>
<td class="num">(4,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)(1)</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="num">(191)<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CurtailmentsAndSettlementsAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease related to curtailments, settlements and restructuring.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CurtailmentsAndSettlementsAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectOfExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect Of Exchange Rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectOfExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis=jnj_LumpSumDistributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis=jnj_LumpSumDistributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841087112888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets', window );">Percentage of corridor of greater of market value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation unfunded plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation, unfunded plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets', window );">Fair value of company's common stock directly held in plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageOfCompanysCommonStockToPlanAsset', window );">Percentage of company's common stock to plan asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate', window );">Defined benefit plan, plan assets, accounting policy election, measurement date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,195<span></span>
</td>
<td class="nump">$ 32,201<span></span>
</td>
<td class="nump">$ 26,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember', window );">Commingled funds | Level 2 | Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments | Level 2 | Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EmployeeCompensationPeriod', window );">Retirement plan benefits Employee compensation Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeCompensationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Compensation Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeCompensationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of company's common stock directly held in plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCompanysCommonStockToPlanAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the company's common stock to the total plan asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCompanysCommonStockToPlanAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of corridor of greater of market value of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Month-end measurement date applicable when an accounting policy election is made to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (u)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841077927672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember', window );">Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 25,554<span></span>
</td>
<td class="nump">$ 21,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">25,466<span></span>
</td>
<td class="nump">22,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">24,158<span></span>
</td>
<td class="nump">19,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">88<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember', window );">Non-Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">2,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(2,748)<span></span>
</td>
<td class="num">(2,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">(2,495)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember', window );">Funded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">12,641<span></span>
</td>
<td class="nump">10,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">14,541<span></span>
</td>
<td class="nump">12,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">13,210<span></span>
</td>
<td class="nump">11,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(1,900)<span></span>
</td>
<td class="num">(1,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">(569)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember', window );">Unfunded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(545)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">$ (493)<span></span>
</td>
<td class="num">$ (430)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan over (under) funded status ABO</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanOverUnderFundedStatusABO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_QualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_FundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_UnfundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841087055432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026-2030</a></td>
<td class="nump">8,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other benefit plans&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026-2030</a></td>
<td class="nump">$ 2,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090895944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne', window );">2021</a></td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo', window );">2022</a></td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree', window );">2023</a></td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour', window );">2024</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive', window );">2025</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter', window );">2026-2030</a></td>
<td class="nump">$ 787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841077073624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)<br></strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841193856872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 38,195<span></span>
</td>
<td class="nump">$ 32,201<span></span>
</td>
<td class="nump">$ 26,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">38,195<span></span>
</td>
<td class="nump">32,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">9,092<span></span>
</td>
<td class="nump">8,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,502<span></span>
</td>
<td class="nump">12,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,420<span></span>
</td>
<td class="nump">11,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">5,023<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">5,023<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,377<span></span>
</td>
<td class="nump">12,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,375<span></span>
</td>
<td class="nump">12,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">13,086<span></span>
</td>
<td class="nump">11,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841201117384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings Plan - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090531592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Balance, Shares</a></td>
<td class="nump">487,336<span></span>
</td>
<td class="nump">457,519<span></span>
</td>
<td class="nump">437,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Employee compensation and stock option plans, Shares</a></td>
<td class="num">(21,765)<span></span>
</td>
<td class="num">(20,053)<span></span>
</td>
<td class="num">(22,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Ending Balance, Shares</a></td>
<td class="nump">487,331<span></span>
</td>
<td class="nump">487,336<span></span>
</td>
<td class="nump">457,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Balance</a></td>
<td class="nump">$ 38,417<span></span>
</td>
<td class="nump">$ 34,362<span></span>
</td>
<td class="nump">$ 31,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Employee compensation and stock option plans related to treasury stock</a></td>
<td class="num">(3,148)<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="num">(3,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, Amounts</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">5,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Ending Balance</a></td>
<td class="nump">$ 38,490<span></span>
</td>
<td class="nump">$ 38,417<span></span>
</td>
<td class="nump">$ 34,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, Shares</a></td>
<td class="nump">21,760<span></span>
</td>
<td class="nump">49,870<span></span>
</td>
<td class="nump">42,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, Amounts</a></td>
<td class="nump">$ 3,221<span></span>
</td>
<td class="nump">$ 6,746<span></span>
</td>
<td class="nump">$ 5,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in Treasury Stock Shares Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesinTreasuryStockSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091862856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common Stock, Dividends, Per Share, Declared</a></td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember', window );">December 17, 2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841090694392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 59,471<span></span>
</td>
<td class="nump">$ 59,752<span></span>
</td>
<td class="nump">$ 60,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">649<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">59,471<span></span>
</td>
<td class="nump">59,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CumulativeEffectPeriodOfAdoptionAxis=jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(8,705)<span></span>
</td>
<td class="num">(8,869)<span></span>
</td>
<td class="num">(7,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(1,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(8,938)<span></span>
</td>
<td class="num">(8,705)<span></span>
</td>
<td class="num">(8,869)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gain/(Loss) On Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gain/(Loss) On Securities | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(6,891)<span></span>
</td>
<td class="num">(6,158)<span></span>
</td>
<td class="num">(6,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(6,957)<span></span>
</td>
<td class="num">(6,891)<span></span>
</td>
<td class="num">(6,158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gain/ (Loss) On Derivatives &amp; Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">947<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">652<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(15,891)<span></span>
</td>
<td class="num">(15,222)<span></span>
</td>
<td class="num">(13,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">649<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (15,242)<span></span>
</td>
<td class="num">$ (15,891)<span></span>
</td>
<td class="num">(15,222)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CumulativeEffectPeriodOfAdoptionAxis=jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CumulativeEffectPeriodOfAdoptionAxis=jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841072297224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International Currency Translation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss), before tax</a></td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (267)<span></span>
</td>
<td class="num">$ (265)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841073493480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding&#160;&#8212; basic (in shares)</a></td>
<td class="nump">2,632.8<span></span>
</td>
<td class="nump">2,645.1<span></span>
</td>
<td class="nump">2,681.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PotentialSharesExercisableUnderStockOptionPlans', window );">Potential shares exercisable under stock option plans (in shares)</a></td>
<td class="nump">118.3<span></span>
</td>
<td class="nump">136.3<span></span>
</td>
<td class="nump">139.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares repurchased under treasury stock method (in shares)</a></td>
<td class="num">(80.4)<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
<td class="num">(92.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Convertible debt shares (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,670.7<span></span>
</td>
<td class="nump">2,684.3<span></span>
</td>
<td class="nump">2,728.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PotentialSharesExercisableUnderStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Shares Exercisable Under Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PotentialSharesExercisableUnderStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1930-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841092685192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Interest expense convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The after-tax amount of interest recognized in the period associated with any convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841085944776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>StockBasedCompensationPlans </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NumberOfStockBasedCompensationPlans', window );">Number of stock-based compensation plans | StockBasedCompensationPlans</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost charged for Long term incentive plan</a></td>
<td class="nump">$ 1,005.0<span></span>
</td>
<td class="nump">$ 977.0<span></span>
</td>
<td class="nump">$ 978.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Total income tax benefit recognized</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="nump">227.0<span></span>
</td>
<td class="nump">192.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Exercise of options, tax benefit</a></td>
<td class="nump">248.0<span></span>
</td>
<td class="nump">209.0<span></span>
</td>
<td class="nump">264.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized for option</a></td>
<td class="nump">$ 804.0<span></span>
</td>
<td class="nump">$ 823.0<span></span>
</td>
<td class="nump">$ 827.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for total compensation cost not yet recognized</a></td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">1 year 8 months 15 days<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of option granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="nump">$ 17.80<span></span>
</td>
<td class="nump">$ 17.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 1,021.0<span></span>
</td>
<td class="nump">$ 807.0<span></span>
</td>
<td class="nump">$ 1,028.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding (in shares) | shares</a></td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
<td class="nump">109,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Stock option average life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,761<span></span>
</td>
<td class="nump">54,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.88<span></span>
</td>
<td class="nump">$ 82.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted | $ / shares</a></td>
<td class="nump">$ 139.58<span></span>
</td>
<td class="nump">$ 121.31<span></span>
</td>
<td class="nump">$ 119.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="nump">$ 586.0<span></span>
</td>
<td class="nump">$ 614.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted | $ / shares</a></td>
<td class="nump">$ 160.54<span></span>
</td>
<td class="nump">$ 124.67<span></span>
</td>
<td class="nump">$ 120.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled</a></td>
<td class="nump">$ 91.0<span></span>
</td>
<td class="nump">$ 119.0<span></span>
</td>
<td class="nump">$ 129.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=jnj_A2012LongTermIncentivePlanMember', window );">2012 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under long-term incentive plan | shares</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under long-term incentive plan | shares</a></td>
<td class="nump">277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfStockBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock-based compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfStockBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=jnj_A2012LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=jnj_A2012LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841076667256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions of fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">2.56%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">15.33%<span></span>
</td>
<td class="nump">16.27%<span></span>
</td>
<td class="nump">15.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841169940136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Outstanding Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of period</a></td>
<td class="nump">111,637<span></span>
</td>
<td class="nump">109,652<span></span>
</td>
<td class="nump">111,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">20,723<span></span>
</td>
<td class="nump">19,745<span></span>
</td>
<td class="nump">17,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(16,275)<span></span>
</td>
<td class="num">(14,785)<span></span>
</td>
<td class="num">(16,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled/forfeited</a></td>
<td class="num">(1,835)<span></span>
</td>
<td class="num">(2,975)<span></span>
</td>
<td class="num">(2,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of period</a></td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
<td class="nump">109,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price beginning of period</a></td>
<td class="nump">$ 105.63<span></span>
</td>
<td class="nump">$ 98.29<span></span>
</td>
<td class="nump">$ 90.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, average exercise price (in dollars per share)</a></td>
<td class="nump">151.41<span></span>
</td>
<td class="nump">131.94<span></span>
</td>
<td class="nump">129.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, average exercise price (in dollars per share)</a></td>
<td class="nump">86.05<span></span>
</td>
<td class="nump">82.43<span></span>
</td>
<td class="nump">75.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled/forfeited, average exercise price (in dollars per share)</a></td>
<td class="nump">137.62<span></span>
</td>
<td class="nump">125.11<span></span>
</td>
<td class="nump">112.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price end of period</a></td>
<td class="nump">$ 116.22<span></span>
</td>
<td class="nump">$ 105.63<span></span>
</td>
<td class="nump">$ 98.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 4,703<span></span>
</td>
<td class="nump">$ 4,478<span></span>
</td>
<td class="nump">$ 3,214<span></span>
</td>
<td class="nump">$ 5,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841076533208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
<td class="nump">109,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 116.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">61,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 96.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember', window );">$62.20-$72.54</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">62.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 72.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 70.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 70.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember', window );">$90.44-$100.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">90.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 100.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">22,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 95.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">22,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 95.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember', window );">$100.48-$115.67</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">100.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 115.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">28,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 108.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">27,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 108.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember', window );">$129.51-$131.94</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">129.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 131.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">32,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 130.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 130.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember', window );">$141.06-$151.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">141.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">20,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841091862856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 03, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Beginning balance</a></td>
<td class="nump">2,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, granted</a></td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, issued</a></td>
<td class="num">(702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Shares, canceled/forfeited/adjusted</a></td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Ending balance</a></td>
<td class="nump">2,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Beginning balance</a></td>
<td class="nump">16,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, granted</a></td>
<td class="nump">5,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, issued</a></td>
<td class="num">(6,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, canceled/forfieted</a></td>
<td class="num">(780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Ending balance</a></td>
<td class="nump">14,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139840991577656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
<td class="nump">$ 81,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,053<span></span>
</td>
<td class="nump">$ 13,898<span></span>
</td>
<td class="nump">13,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 45,572<span></span>
</td>
<td class="nump">$ 42,198<span></span>
</td>
<td class="nump">40,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 15,055<span></span>
</td>
<td class="nump">$ 13,950<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 3,413<span></span>
</td>
<td class="nump">3,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,548<span></span>
</td>
<td class="nump">$ 6,328<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 12,367<span></span>
</td>
<td class="nump">$ 10,692<span></span>
</td>
<td class="nump">9,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,148<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,878<span></span>
</td>
<td class="nump">$ 5,192<span></span>
</td>
<td class="nump">5,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(10.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 22,959<span></span>
</td>
<td class="nump">$ 25,963<span></span>
</td>
<td class="nump">26,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Diabetes Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,046<span></span>
</td>
<td class="nump">$ 2,997<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,763<span></span>
</td>
<td class="nump">$ 8,839<span></span>
</td>
<td class="nump">8,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 8,232<span></span>
</td>
<td class="nump">$ 9,501<span></span>
</td>
<td class="nump">9,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.40%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,919<span></span>
</td>
<td class="nump">$ 4,624<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.20%)<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_BabyCareMember', window );">Baby Care | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OralCareMember', window );">Oral Care | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 1,528<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTCMember', window );">OTC | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,824<span></span>
</td>
<td class="nump">$ 4,444<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember', window );">Women's Health | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.60%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember', window );">Wound Care and Other | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RemicadeMember', window );">Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,747<span></span>
</td>
<td class="nump">$ 4,380<span></span>
</td>
<td class="nump">5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(14.40%)<span></span>
</td>
<td class="num">(17.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember', window );">Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,243<span></span>
</td>
<td class="nump">$ 2,188<span></span>
</td>
<td class="nump">2,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_StelaraMember', window );">Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">$ 6,361<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TremfyaMember', window );">Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">33.20%<span></span>
</td>
<td class="nump">85.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember', window );">Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember', window );">EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 964<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember', window );">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember', window );">Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.20%)<span></span>
</td>
<td class="num">(17.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember', window );">CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(10.60%)<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember', window );">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">$ 3,330<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember', window );">RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.80%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember', window );">OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember', window );">DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,190<span></span>
</td>
<td class="nump">$ 2,998<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">39.80%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ErleadaMember', window );">Erleada | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember', window );">IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,128<span></span>
</td>
<td class="nump">$ 3,411<span></span>
</td>
<td class="nump">2,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_VELCADEMember', window );">VELCADE | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(45.70%)<span></span>
</td>
<td class="num">(32.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember', window );">ZYTIGA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,470<span></span>
</td>
<td class="nump">$ 2,795<span></span>
</td>
<td class="nump">3,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="num">(20.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember', window );">Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="num">(12.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember', window );">OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember', window );">UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">33.50%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="num">(31.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.40%)<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,345<span></span>
</td>
<td class="nump">$ 2,313<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(6.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember', window );">INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 795<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="num">(16.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember', window );">PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(30.20%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_HIPSMember', window );">HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">$ 1,438<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_KNEESMember', window );">KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember', window );">TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,614<span></span>
</td>
<td class="nump">$ 2,720<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember', window );">SPINE &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,699<span></span>
</td>
<td class="nump">$ 3,201<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.70%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember', window );">ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,839<span></span>
</td>
<td class="nump">$ 4,095<span></span>
</td>
<td class="nump">4,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_GENERALMember', window );">GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,392<span></span>
</td>
<td class="nump">$ 5,406<span></span>
</td>
<td class="nump">5,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(18.80%)<span></span>
</td>
<td class="num">(8.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember', window );">CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">$ 3,392<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.70%)<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SURGICALMember', window );">SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 925<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(24.90%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember', window );">Skin health/Beauty | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,450<span></span>
</td>
<td class="nump">$ 4,593<span></span>
</td>
<td class="nump">4,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 43,133<span></span>
</td>
<td class="nump">$ 42,097<span></span>
</td>
<td class="nump">41,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,362<span></span>
</td>
<td class="nump">$ 5,839<span></span>
</td>
<td class="nump">5,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 25,735<span></span>
</td>
<td class="nump">$ 23,874<span></span>
</td>
<td class="nump">23,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 10,175<span></span>
</td>
<td class="nump">$ 9,641<span></span>
</td>
<td class="nump">9,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="nump">$ 1,597<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">15.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,091<span></span>
</td>
<td class="nump">$ 2,919<span></span>
</td>
<td class="nump">2,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,092<span></span>
</td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.50%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">26.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,509<span></span>
</td>
<td class="nump">$ 3,734<span></span>
</td>
<td class="nump">4,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(12.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,036<span></span>
</td>
<td class="nump">$ 12,384<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(10.90%)<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Diabetes Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,779<span></span>
</td>
<td class="nump">$ 5,319<span></span>
</td>
<td class="nump">5,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(10.20%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,249<span></span>
</td>
<td class="nump">$ 3,828<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.10%)<span></span>
</td>
<td class="num">(7.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,557<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.20%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Baby Care | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Oral Care | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTC | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">$ 2,010<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Women's Health | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="num">(5.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Wound Care and Other | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,508<span></span>
</td>
<td class="nump">$ 3,079<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(18.50%)<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="nump">$ 1,159<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,240<span></span>
</td>
<td class="nump">$ 4,346<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.60%<span></span>
</td>
<td class="nump">25.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.30%<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.20%)<span></span>
</td>
<td class="num">(13.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 1,422<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">11.60%<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(17.60%)<span></span>
</td>
<td class="num">(16.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(21.40%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,314<span></span>
</td>
<td class="nump">$ 2,107<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">42.40%<span></span>
</td>
<td class="nump">30.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Erleada | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">96.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,821<span></span>
</td>
<td class="nump">$ 1,555<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="nump">37.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | VELCADE | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ZYTIGA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(54.00%)<span></span>
</td>
<td class="num">(54.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.20%<span></span>
</td>
<td class="num">(32.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">31.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">33.80%<span></span>
</td>
<td class="nump">19.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(17.60%)<span></span>
</td>
<td class="num">(41.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.10%)<span></span>
</td>
<td class="num">(9.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,345<span></span>
</td>
<td class="nump">$ 2,313<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(6.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="num">(24.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(45.10%)<span></span>
</td>
<td class="num">(25.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 793<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.20%)<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">$ 889<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(16.40%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">$ 1,652<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SPINE &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">$ 1,915<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(16.70%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 1,637<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 2,192<span></span>
</td>
<td class="nump">2,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(21.80%)<span></span>
</td>
<td class="num">(11.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(29.70%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Skin health/Beauty | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 39,451<span></span>
</td>
<td class="nump">$ 39,962<span></span>
</td>
<td class="nump">39,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,691<span></span>
</td>
<td class="nump">$ 8,059<span></span>
</td>
<td class="nump">8,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 19,837<span></span>
</td>
<td class="nump">$ 18,324<span></span>
</td>
<td class="nump">17,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,880<span></span>
</td>
<td class="nump">$ 4,309<span></span>
</td>
<td class="nump">4,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,839<span></span>
</td>
<td class="nump">$ 1,815<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,457<span></span>
</td>
<td class="nump">$ 3,409<span></span>
</td>
<td class="nump">3,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,275<span></span>
</td>
<td class="nump">$ 6,393<span></span>
</td>
<td class="nump">5,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,369<span></span>
</td>
<td class="nump">$ 1,458<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.10%)<span></span>
</td>
<td class="num">(5.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,923<span></span>
</td>
<td class="nump">$ 13,579<span></span>
</td>
<td class="nump">14,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Diabetes Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,594<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,984<span></span>
</td>
<td class="nump">$ 3,520<span></span>
</td>
<td class="nump">3,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.20%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,983<span></span>
</td>
<td class="nump">$ 5,673<span></span>
</td>
<td class="nump">5,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,362<span></span>
</td>
<td class="nump">$ 2,830<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(16.50%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Baby Care | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.10%)<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Oral Care | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTC | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,364<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Women's Health | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 888<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.80%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Wound Care and Other | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.40%)<span></span>
</td>
<td class="num">(17.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,467<span></span>
</td>
<td class="nump">$ 2,015<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">69.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.40%)<span></span>
</td>
<td class="num">(12.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="num">(17.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">$ 1,224<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(11.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,334<span></span>
</td>
<td class="nump">$ 1,349<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(10.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">36.90%<span></span>
</td>
<td class="nump">73.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Erleada | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,307<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | VELCADE | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(45.70%)<span></span>
</td>
<td class="num">(32.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ZYTIGA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="nump">$ 1,985<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(7.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">30.90%<span></span>
</td>
<td class="nump">62.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(9.20%)<span></span>
</td>
<td class="num">(20.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.30%)<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.30%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(27.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(9.60%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SPINE &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(14.10%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,304<span></span>
</td>
<td class="nump">$ 2,458<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,679<span></span>
</td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">3,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(16.70%)<span></span>
</td>
<td class="num">(6.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(14.70%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(21.70%)<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Skin health/Beauty | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,201<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember', window );">UNITED STATES Exports | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="num">(32.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business Combination, Acquisition Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ErleadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ErleadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_VELCADEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_VELCADEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841156556200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 16,497<span></span>
</td>
<td class="nump">$ 17,328<span></span>
</td>
<td class="nump">$ 17,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">174,894<span></span>
</td>
<td class="nump">157,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">3,347<span></span>
</td>
<td class="nump">3,498<span></span>
</td>
<td class="nump">3,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">7,009<span></span>
</td>
<td class="nump">6,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
<td class="nump">$ 81,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member', window );">Wholesaler 2 | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 43,133<span></span>
</td>
<td class="nump">$ 42,097<span></span>
</td>
<td class="nump">$ 41,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">39,451<span></span>
</td>
<td class="nump">39,962<span></span>
</td>
<td class="nump">39,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">13,898<span></span>
</td>
<td class="nump">13,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">6,362<span></span>
</td>
<td class="nump">5,839<span></span>
</td>
<td class="nump">5,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">7,691<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
<td class="nump">8,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">45,572<span></span>
</td>
<td class="nump">42,198<span></span>
</td>
<td class="nump">40,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">25,735<span></span>
</td>
<td class="nump">23,874<span></span>
</td>
<td class="nump">23,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">19,837<span></span>
</td>
<td class="nump">18,324<span></span>
</td>
<td class="nump">17,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">22,959<span></span>
</td>
<td class="nump">25,963<span></span>
</td>
<td class="nump">26,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">11,036<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">11,923<span></span>
</td>
<td class="nump">13,579<span></span>
</td>
<td class="nump">14,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember', window );">Segments Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">143,091<span></span>
</td>
<td class="nump">132,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">3,190<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">6,931<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExpenseNotAllocatedToSegments', window );">Less: Expense not allocated to segments</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | General Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">31,803<span></span>
</td>
<td class="nump">25,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">18,163<span></span>
</td>
<td class="nump">19,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">82,584<span></span>
</td>
<td class="nump">82,059<span></span>
</td>
<td class="nump">81,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">43,133<span></span>
</td>
<td class="nump">42,097<span></span>
</td>
<td class="nump">41,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">27,355<span></span>
</td>
<td class="nump">26,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">15,462<span></span>
</td>
<td class="nump">8,816<span></span>
</td>
<td class="nump">12,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">66,158<span></span>
</td>
<td class="nump">56,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
<td class="nump">3,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">4,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">49,578<span></span>
</td>
<td class="nump">49,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">13,950<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">10,175<span></span>
</td>
<td class="nump">9,641<span></span>
</td>
<td class="nump">9,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,880<span></span>
</td>
<td class="nump">$ 4,309<span></span>
</td>
<td class="nump">$ 4,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExpenseNotAllocatedToSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExpenseNotAllocatedToSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841074485208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 30, 2018 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
<td class="nump">$ 81,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">174,894<span></span>
</td>
<td class="nump">157,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 22,959<span></span>
</td>
<td class="nump">$ 25,963<span></span>
</td>
<td class="nump">26,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RegulationCharge', window );">Regulation charge</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringChargeNetofAccrualAdjustment', window );">Restructuring Charge, Net of Accrual Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,046<span></span>
</td>
<td class="nump">$ 2,997<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Diabetes Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,053<span></span>
</td>
<td class="nump">$ 13,898<span></span>
</td>
<td class="nump">13,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,824<span></span>
</td>
<td class="nump">$ 4,444<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | Skin health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,450<span></span>
</td>
<td class="nump">$ 4,593<span></span>
</td>
<td class="nump">4,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 1,528<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 45,572<span></span>
</td>
<td class="nump">$ 42,198<span></span>
</td>
<td class="nump">40,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedLossOnSecurities', window );">Unrealized loss on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 15,055<span></span>
</td>
<td class="nump">$ 13,950<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 12,367<span></span>
</td>
<td class="nump">$ 10,692<span></span>
</td>
<td class="nump">9,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,148<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Stelara | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">$ 6,361<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Tremfya | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">33.20%<span></span>
</td>
<td class="nump">85.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Erleada | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | IMBRUVICA | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,128<span></span>
</td>
<td class="nump">$ 3,411<span></span>
</td>
<td class="nump">2,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | DARZALEX | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,190<span></span>
</td>
<td class="nump">$ 2,998<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">39.80%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | OPSUMIT | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">$ 18,766<span></span>
</td>
<td class="nump">$ 17,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">89,795<span></span>
</td>
<td class="nump">81,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member', window );">Ci:z Holdings Co. Ltd. | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Gain (Loss) on Sale of Equity Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaIncandXO1LimitedMember', window );">Alios Biopharma Inc and XO1 Limited | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_XO1Member', window );">XO1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember', window );">Actelion | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AMOMember', window );">AMO | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | Medical Devices | Other Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 43,133<span></span>
</td>
<td class="nump">$ 42,097<span></span>
</td>
<td class="nump">41,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,036<span></span>
</td>
<td class="nump">$ 12,384<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(10.90%)<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Diabetes Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,362<span></span>
</td>
<td class="nump">$ 5,839<span></span>
</td>
<td class="nump">5,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">$ 2,010<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer | Skin health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 25,735<span></span>
</td>
<td class="nump">$ 23,874<span></span>
</td>
<td class="nump">23,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 10,175<span></span>
</td>
<td class="nump">$ 9,641<span></span>
</td>
<td class="nump">9,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,092<span></span>
</td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.50%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">26.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Stelara | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,240<span></span>
</td>
<td class="nump">$ 4,346<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.60%<span></span>
</td>
<td class="nump">25.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Tremfya | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.30%<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Erleada | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">96.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | IMBRUVICA | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,821<span></span>
</td>
<td class="nump">$ 1,555<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="nump">37.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | DARZALEX | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">42.40%<span></span>
</td>
<td class="nump">30.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | OPSUMIT | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">31.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 39,451<span></span>
</td>
<td class="nump">$ 39,962<span></span>
</td>
<td class="nump">39,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,923<span></span>
</td>
<td class="nump">$ 13,579<span></span>
</td>
<td class="nump">14,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,594<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Diabetes Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,691<span></span>
</td>
<td class="nump">$ 8,059<span></span>
</td>
<td class="nump">8,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.10%)<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,364<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer | Skin health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,201<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 19,837<span></span>
</td>
<td class="nump">$ 18,324<span></span>
</td>
<td class="nump">17,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,880<span></span>
</td>
<td class="nump">$ 4,309<span></span>
</td>
<td class="nump">4,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,275<span></span>
</td>
<td class="nump">$ 6,393<span></span>
</td>
<td class="nump">5,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Stelara | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,467<span></span>
</td>
<td class="nump">$ 2,015<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Tremfya | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">69.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Erleada | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | IMBRUVICA | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,307<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | DARZALEX | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">36.90%<span></span>
</td>
<td class="nump">73.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | OPSUMIT | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherNonLongLivedAssets', window );">Other Non Long Lived Assets</a></td>
<td class="nump">$ 66,333<span></span>
</td>
<td class="nump">58,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | General Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">31,803<span></span>
</td>
<td class="nump">25,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">82,584<span></span>
</td>
<td class="nump">82,059<span></span>
</td>
<td class="nump">81,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">107,532<span></span>
</td>
<td class="nump">97,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">49,578<span></span>
</td>
<td class="nump">49,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">27,355<span></span>
</td>
<td class="nump">26,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">66,158<span></span>
</td>
<td class="nump">56,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnSecurities', window );">Unrealized Gain (Loss) on Securities</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | NIZORAL | Consumer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PANCREASE | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | LifeScan | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">43,133<span></span>
</td>
<td class="nump">42,097<span></span>
</td>
<td class="nump">41,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">49,951<span></span>
</td>
<td class="nump">41,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">18,980<span></span>
</td>
<td class="nump">18,466<span></span>
</td>
<td class="nump">18,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">49,363<span></span>
</td>
<td class="nump">48,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Western Hemisphere excluding U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="nump">5,941<span></span>
</td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">15,136<span></span>
</td>
<td class="nump">15,555<span></span>
</td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">$ 5,484<span></span>
</td>
<td class="nump">$ 5,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member', window );">Wholesaler 1 | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member', window );">Wholesaler 2 | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member', window );">Wholesaler 3 | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember', window );">AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember', window );">AdvancedSterilizationProducts | Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non long lived assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RegulationCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulation charge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RegulationCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringChargeNetofAccrualAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charge, Net of Accrual Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringChargeNetofAccrualAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in the income statement on unsold other securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedLossOnSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedLossOnSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ErleadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ErleadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaIncandXO1LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaIncandXO1LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_XO1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_XO1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AMOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AMOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_NIZORALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_NIZORALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_PANCREASEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_PANCREASEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_LifeScanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_LifeScanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841092595576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details)<br> $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 17, 2019 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th"><div>Jan. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,639<span></span>
</td>
<td class="nump">$ 30,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_A2019AcquisitionsMember', window );">2019 Acquisitions | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Purchase price over fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_A2018AcquisitionsMember', window );">2018 Acquisitions | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Purchase price over fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member', window );">Ci:z Holdings Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">&#165; 230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life of acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 3 months 18 days<span></span>
</td>
<td class="text">15 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember', window );">Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Sale of stock, percentage of ownership before transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sale of available-for-sale securities, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">SFr 337.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConvertibleNoteEquityInterestNumberOfShares', window );">Convertible note, equity Interest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConvertibleNoteEquityInterestPercentage', window );">Convertible Note, equity interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 243.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember', window );">2020 Acquisitions | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Purchase price over fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember', window );">Verb Surgical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 445.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember', window );">AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember', window );">Evra and Doxil | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of brands</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember', window );">Discontinued Operations, Held-for-sale or Disposed of by Sale | LifeScan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal group, including discontinued operation, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember', window );">Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal group, including discontinued operation, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash', window );">Disposal group, including discontinued operation, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained', window );">Disposal group, including discontinued operation, receivables retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember', window );">Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Disposal group, including discontinued operation, inventory, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessAcquisitionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessAcquisitionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationProbabilityOfSuccessFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Probability Of Success Factor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationProbabilityOfSuccessFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConvertibleNoteEquityInterestNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Note, Equity Interest, number of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConvertibleNoteEquityInterestNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConvertibleNoteEquityInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Note, Equity Interest, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConvertibleNoteEquityInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Receivables Retained</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand, demand deposits with banks or financial institutions, and  other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_A2019AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_A2019AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_A2018AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_A2018AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_LifeScanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_LifeScanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841080626952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>claimant </div>
<div>patient</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">Xarelto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpiodsMember', window );">Opiods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Number of plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss Contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value | $</a></td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member] | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member] | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpiodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpiodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841076540536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid', window );">Restructuring and related cost, expected period of cash outlays for severance paid</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring costs incurred since announced</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Pre-tax restructuring charges</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Restructuring and related cost, expected future savings</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Restructuring and related cost, duration of restructuring plan</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Pre-tax restructuring charges</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Restructuring and related cost, expected future savings</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Restructuring and related cost, duration of restructuring plan</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Other(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Duration of Restructuring Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostDurationofRestructuringPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139841076623512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember', window );">Supply Chain | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember', window );">Supply Chain | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember', window );">Supply Chain | Other(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">$ (13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Other(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on Sale of an Asset (Payment) for Restructuring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GainOnSaleOfAnAssetPaymentForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the accrual for restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>129
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"90?).?A!++UCW:\VMH,45"S7: 1SKW1S1T5TT1W+8K8K[(XJ"R"*G\3FE6
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M@L.IC;7)ZT#?$RR/PTFZ.8;0RWI65H"-^\HLG$_:SI>U_5\Z_!_5TV@@=8H
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M;Z2&^\K#EUX>S W>.]GWLC$?]R(OA=( ^/M.PHB-7_0#3K?&;_X'4$L#!!0
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M*L]9M&F>'9&W&ZC&&V^GR[:O(P P%2!!]0**+  UE7NH5FQ9I:*P63!RLOS
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MY& $:=<.C92R:>/.2;#FXA\]E!7.@;JJF!C=>;;TNQX&)N>-Y3K/S7' QCA
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M=%CFQ>)/N3"9YF_\,9%%+DV\**JXGK (%98AJ\"QVX9[V\(MH 31^LL&0_?
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MQ7Z<MWP-9K58B)RA2.\%-3-<KUP0A%PV>". +V0B'NWH@-2@]2TJ2%I[>G@
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MM+^_^8E52W=G0I?C#<P-2[SR<DT;\/M"8<*T$Q*PNT1?_ -02P,$%     @
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MNP :7RLZ2(:&(Q@??\L_ 5!+ P04    " "%A%92=I5 ?OL%  !Q#@  &0
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M1];ND5X<>'H9U5TFTE% +1ND,??;B/2.OB;#>&,I-DEW>K=60A%F&8R&0.)
M8+&(LI#ZWAALBB6K4V.[^AQT'7\<1M$)Q"$<)R=PG ]/]K-;)X_8Y6(4IS2&
MU$=A0@\)Q#%I9OX%[-;]%8HH8BTD"25A"IXCF 8!L-:.4K8BZ=GF]^F"'['>
MQ42/^CP(B-^0NCYC38_S&+B!%_X$Q=5ZCX8.A+MJ.4>C=.F+?;Y?U*GO24[]
M'M?_9X '%&*?^*Y;B9Q14%O.=K#Q@0[-%GW7K-YOVS9%U7:"00)C?763<)1M
M01^MKDI?X4=)?[3N2<%/PTV'^I9-MEIVC!0&@I,/P@?$W;NSYR,?QCY=$[&G
MB';Z<EWX7#5VCOX 72W[3[886)#PXLM2+U@2B<AVA#]UQ4RO*,4GZ]0(%O(N
M<V@="=>3[7&=0XY'SBD_]S1CG29Q(.1[I.M%42!ZA>IBIZ7R]@_>2[5\YO02
M\A#Q$/.0\#"D5 LN]41$?@QIC$7N1WYSAP@_DJ0"M0)U5;=]-+2.JO11O5:-
M; I%:W'GZ$7M:]='59:^^>A+B:37E3W8G7X;X?W2*4='4]O?=R(=;%T#J)JG
M_K+#FR&=YKH;P>;MYCYUT5TC'J=WE[$;26).?BN<D&G0'PU[8+H+3O?@]-Q?
M*L;:4>OXOS.Z$Z+A"?1]HBDCJP=VL+EEGO\-4$L#!!0    ( (6$5E(25>L)
M[A$  "P\   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;-4[VW+;.):_
M@O*Z9NTJ11:INSM)E>,D,][J=&?CGMF'K7V 24CB-$6H"3*V]NOW7  0I"C+
M27H>]L$6+\#!N=\ OG[4Y>]FHU0EGK9Y8=Z<;:IJ=WUU99*-VDHSU#M5P)N5
M+K>R@MMR?65VI9(I3=KF5_%H-+O:RJPX>_N:GGTNW[[6=95GA?I<"E-OM[+<
MOU.Y?GQS%IVY!U^R]:;"!U=O7^_D6MVKZN^[SR7<77DH:;95A<ET(4JU>G-V
M$UV_F^!X&O"/3#V:X%H@)0]:_XXW=^F;LQ$BI'*55 A!PL]7=:OR' $!&G]8
MF&=^29P87COH'XEVH.5!&G6K\__*TFKSYFQQ)E*UDG5>?=&/?U.6GBG"2W1N
MZ+]XY+'CR9E(:E/IK9T,&&RS@G_ED^5#,&$Q.C(AMA-BPIL7(BS?RTJ^?5WJ
M1U'B:("&%T0JS0;DL@*%<E^5\#:#>=7;CS(KQ3]D7BOQ24E3EPHX7IG75Q4
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MGHF2OTWEFTKOZ'O0!UU5>DN7&R6!<3@ WN/'!>X&%_ ?"+_]/U!+ P04
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M;CL0@\8B<,7RS8BFK87;A6=)6$+_U^%J0.L.,'!E=(SQ6D[D<@SGXVKHFIS
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ML,$=PUV'/Y:$=OJGZ(?UR[P$Y@!Y(B$5(P!<9*L+5KI"JZV"$W&FMJ^-;DE
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M.JB= =U72MF]X )TO[');U!+ P04    " "%A%92$XX\=%87  !#2   &0
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M;QH"OC>/$KS&$7)*1/ $-/#\,!!Q%(MHGCP1,8H@\OP8.>P"H3$R6B^"?0(
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M\YVAC(,4_WN<&XRK)?BI:Z"(G[X3<QHIF%%C\:U<-N[/%%=1M<SD@*Z/]GF
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M^'U=PCJ:+[1!]W>#7OTO4$L#!!0    ( (6$5E*X1@/IM (  .0%   9
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M!SYFMP;.R9$DML6QT B$#OU0]9R!=Z)L>Z /!'$PI=-W0T-! JUZ9H#M.X-
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MUI%'XN. T6QI&6JHY^#(+8!$CB$J82R@%,BH@9XNMCJ;CRZ&T\/EW3[]'#N
M7@S@E\B.X=H]LA[!V1=PIKA>X-?@;".ZVU'1]Z$UNKJ-N6T74]$EM<&H.<SW
MR^^'ZX?0F0^3.?!=C 3P$9\[?@,LU XP ,%&//S^^P.\,70DB(78 L@;NE3@
M8MAD_@81.+Z\O+F:7$Q>_UXO*-E(__3%UX[J@7T6__>P#^?08;L?C;,[(9;;
M4ITG)1(MDFQC:M]0=VY(@8T?2%ZS*6O7T,0(7$755!$U VCT#YW/!2C":(!.
M@Z#BZCX0W*C1^<UT>#7?*?I4%4FZ2=XG!=A  W^.0G01G&U)' 3SHR@($7D!
MU.J[A!?,Z\.2+<B%V0*8.; ])CN &G9S/1V]&\_FP\>U>>=L\FK\V^,MW)E<
M' R:_7XYOWG7C0PWH**8EQ ?<$VL(O[4)0-4J!>$R@_JM"0!J!E%[;"P&0I]
M6[A%B)@SL!41H/&3JU]&9_/QY&:FSL>ST7 VFNW@#4Y.$S T$=9>#2Q'6<IH
MF $&8VIGQ#5C6PQ ^Y)R7 0NDHFN40)"7L7;(B\729PM=BD9L ^?[X=D6F)F
M.@EWUET4K,+GU2+VN9:1?-+3AY[B]5V$#X)2\VKYONR=20V)ZFPT;5MB'5>K
MAW2SBK-D&56-/#88B8;86I.-"!:"273#E(G2 [L!R8*O(@%Y4$-+"MC1"SWE
M>4Q/DBT=NO[5V]'KH9K= )ZNKEJ2_#:ZOAA/KAYO-"/GT_'5N]8XP,K;\=E\
MV$D*QA9S"X;[(9,MO-@_\AT$HL2:UB08ME N!Y[N'T2:YTJ,D0X@'@%% TE>
MOIJ.9]>CZ7F3\[M"8+<4@VX!C80G#;9W;$CHA8GIYSV_3ESV(:9[#E0'//<A
M'EA-S7_\D\9UKT8WT\GL;#R"+7<+ _L]3[B++2A]3#-L8<.$SU!(FT5V2$('
MT_@=*FD8@9[-X3Z'DP[Y(D"V:#$!5]B*T]=A*&3;9HIUN>DC;/'[&IP!+HE,
MZV)U\A@:"!F[O31IOD^&X6'BL!\ MVS270+G^7#Z;G@Q^JUC=RW"NI[D;@2$
MP_T;ZRB?$00"X;) .5)?#\[H@^0=D'8[%).'DDLUHIMNY! V1M.+T?"\DTT9
M)T1W.%/H04M(59U52;;=?9;YGO^UTYF/ LAP!YBA^7!\^6IZ P_OHB-F:*@]
M_):4@/!L_*.XA XE" *7]-@!1FH'VM!.=ZLZD&Q"X/'@L8ASBXISU-O1Q1'K
M^G-YU %3\UW*;2-K]!Q):0T%:\GRF5'O?I^/7[>B/[I-"N!4D2.U18NXVF.6
M 0\-!.Q]L/2>ZY +\N4H &%9R<AA0%7Z@&FWSLO60?YP?+J"'[K44EBG3B8#
M$"9[%XJ TQ;7@#?X5IU 0E8(3U%-8HHQ=06& "1&^(>E'/.[ PLZGB>HR]2&
M::ZWZ1HS% _JS<,F+JJF'=9$@6V,L#2&K =5:F(Q:N-C2@E+AX")$"'  LP^
M\ K0;X>N[VDCB<B0'EHR:'*-$F<\[SBE1=-!4!\UL:&TX1'P>, %EY40V0VR
MM)1!AW!#1#):(IB.R&Q%!=Y<SZ?#M^-# LG2%LCDPB)&("0\#G6#VQ;@QJ4_
MHY30!YP54H?TE5!2D^%JLF1MTGIC0HSQN&OV), 1:W6+1M!B'V "P$;%JVOW
M< _-Z2D'*.#!D6A*@CDTA3&H49=)_CXJ%]LT*N#;EW#GVSQ-RC7>M(I79GKF
M>]^PJ:'9<I!*I_&,(YPG=0)1D$Y G4&(\V['S?H!&"DX>RA%*@.OF53@^[?A
M='0QGW23K.-*JC42'W[-/CRJYU"(KT6+=KQ]9NZKMY-_#MM<H;YS.3IT1Q<,
MU45L^< TEP&HG6/1---42/BTF'X,<=2T$1EV(F\/ KON4-3D[WHZ.9N.6QQ[
M!*+;R440VJ7;(;D3Q*AT+2\="?"Y!O:0*H 8!B>-ZSS*X+I@X<A$(3A #R[<
M^)5UTO91(: LL&UB1+U<>+Q: *4TW11Q9IN V/.[71Q;FBGT=UN0C[[E2+O'
MVG4Y.GV!>L^N%#G:P)L<OFC,@UI86FX=QT0^AS?: 4(=XOA]QV%%9-0A\#J@
M!SZ[4_!,I%Y+O)X)V #1+D?GLO8Y*2 8^WD2W<85"J[']E;7Q0RRP3[]=M-S
M=[!G@O;@1ZFZ XE\X=&\[^.LF7B6IUO^N2\%'9<TQ7&H7XU$P:K;?D))J!8=
M2?/"U8!/K"ULYT!%*!?8U@!-88'N.<P37EVR38IJE6^B>)DLFJ4=Y$,VH(S-
MJPYLB7!XE/4$<P@#5I@N"D%P8,L1OQ+G.RRN4/5#LD#*5ER#&MFT\%W$RIOQ
M=5-,^01:#D4=!%?""'W$R!U4?2[(H>O7?FQVM+GMGCJPA+L)@[/K9&R="$;\
M\VJTJ]U\J#= 81C:ML2M(Z(?M7!9F;DH$?BOIZ5S8W5RDJ!#WY%574M+%23@
MR-F0E6XNASO+>DX@25=H*("E)]HU1UDI]*1=Z7$T6\@(5J$3AVU&+;P;O(.=
M=]#@L&E$6HBIV?7X:M3'RV0ZGZF_1>O-3PT@],S)OH@.I8E0MQ*,)7JH6]G!
M$TU><A6)698'=3N+.&(.^UZU($9ZWKAZGAC*W[7?9]OB/BX>=LE*.QP;@%Z2
M9+I[</*/V\P./(X%@<<F(AS5VSN2?2A!(#P_A"W8<V3W=U?X"\\;GK\=HAHZ
MWRM!&B]LJ-,RD@+K28\DT-))T9(NZQQ4CV6?OAUQ='4'Q,'EE0[AU=YLU.O1
MU6BZPT/PR;H.K4\28&QZ3G"R:[QT%_>DB4G6 Y)I[+VUO,, <.1HPD7=[S%9
MTROLNB\>4 EODT<N2.RH:V IWR2H3!WOW;Z3E@ZUQMZ$Z8KV)=GI#MRP+^&
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M9.5W0-?X,?AAVP^K9+&2NV?Y>A-E#XHQ22ON#FM5*3[#0HXP4B;W&=489=4
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M:7,;-Q+]*RC%SEI5%,5#E\\J'?%&+B=664GVJOT SH DRC.#,8 1S?SZ?=W
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MPC\4'U29@!%X(!RW=DQR8D+!695!OW;)3@*KY,HRREGMWC%7)'RJI].PNV.
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MV@"%03;,P9B"Z%"X]'X_-2H2)='"]R"7*!JI8UR::(<<@$RJ+EW >4V,(YF
M[0LNKC#Y>$+832D1SG\?Q-Z9QK_VND:.I6GO;!/6_MSD''0F6PJ,VPN1 LRY
M-7RP(^%KRX]],S;@95JA=*)]*-,4.2!;1B+?S0,&4_*1&*/>>J36&ZE@"KUR
MNM&(/8VKK3]"/V#K=%I> ?FPUI'L5,*TZZ.I,U]MX 3%U%+CYDA1[9:>%5Y(
MQ-VS6M&_[12AJRN1@^)O- 26)&4XJ5L'*GR;G;QO[<I]VJ6!KL^INBM*4TI
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M(+8"B,A/1@2F6<B\XWWW6&TQ]D+AJ(W^A"21@E=7 #;!".( I$JP&FS;L=M
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MAMCXB.Q]&F3OTZ.2\TWD\B&Q^]F#DY<]T->F+/BD""V[3+!HLJ=1Q3'R@0_
MB?H7D1Q1##*H\-H*CHBE+SL[V5A@/F^V81#A$##Z&HX.T7@*C'=*$;N>H&#D
MZZ:Q#)%WML#>UIX+^;B[J@<:0BNP,4/*FB@TP9)$28#AP868JNB7P?$W]'5C
MUIAQN2:G#4PNL+;W04VA]-^R#RS2'JS:1L<H;[YW_Q [P;SV#7@^%&?9#0PH
M:S2V04Z,U3MB,Q)FA<&/,##)4@(#JR"J);Y$PQ?:&\PL%X,2@%,B=!-C@A
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M 4X*6+_T6&+WC')2DI-R>F.D*H)#(ZS)A6$Q<6FKCCAQ +Y0,"F&*,%R79=
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MV9U/Y]&P#XRZ Q+"A)[#Q@ 97[C:38.Y?5082YR%XDR,>HD$4[=(C[AB#8?
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M00M].WUQJ+2BUQKZ(<F!^<(.T4J<$$S:%,.EDM*GB&)<JI&LQ'=[4BM>2\/
M5.:V5=.97!F34#N5UX?2E3V^%8J7UN'$(P#A<\HTXYVWG]Z\_? &I ']+X4]
M)-<+?W.0N?71",VL0;XK2GC3!#2Q%8_^G^<168"(#HL=S<;XOCS"=>ZDC*2?
M 9R(6!6,6R6AZ-F><U3XU8_G5R_]966A*8H3):RO(O]B8KFD_ELG@?2L]6L7
MBYQJ'V\GOP1PR+*']B[XJ7QL \L=_&-9:W)L;+QOQV8\\N0G8]#W$I([D4@2
M[MG?P7BGQD\HC//+T6 *C8U6[L[QMJRG,'__8I8H\AOSV=\8G&)!08$LOB8+
M3CC?4P"8:[7]OKPB>YI[("')70>6P5TS +$%OS<I4WV.FF!U>H-OK[V&^UV\
MTC$;5#/-;A]9?13Y^\" 5@)'I-D$08V4Z>];7,/66WJ HHD.J!\J#41 0B_P
M&>NZ)])_UH8N6DF:I5?"[\-#=WUYMDIABBG] Y#D28.>XI48AYB/AP&2S" =
MB9^8[POA@J @^6)A-L4@N5G6]*Y&/_;S!?$BBMGQ*R1^ 1D5@W> X"L49T,.
MU%=-I%X"5RZ2 \5R"_I"BL<[*7:F@ E*(12:$3FA6(?B-!N0_*F\#1=8WM#/
M7B#I8X'CRB2.?3K*8=\^W>[HVXFC^!JK5[;L45\ -KN(>%MC:A--U0)'L)5/
MQ41H&5. FPH\XUU.9)SX<AJJZ*'"LR98L![(MEY\DO)?DJ8-6?L[^>+N%I!9
M;'::'6]2^LCE,J^]73]XXE\V!1$GF)1<^^(O8[C[)R#P(;0*J2J$ A")3HJ_
M,!&#\O"]2:_9)34<.D>2LE:Z:.U3ZKV0'N@75NN^(G#*7Z4V3K:'A$"5SI0A
M'^Q+#U=DC.*](KW.T?2"D7Y]A$_OA#@#%T\CL?-5O_11>O73*$O]C<)O. 37
M-LG"+&P H=<HD6K5G0K*@FXYI@2==^'0,<=\E.9F9=8?_MZ).O43A]UF+J<+
MYIGW+L21IJ( 5!A4SV-;N9 F*/EL)WA7QMXE**1K^'A"2< 7E"Z@-8L5Z6D-
MA4PDEV1HN8:)[5PLJGRAUO4-JDFZQK:JXV#_FQE^P-RT(>"+2"$/AFT"7PDI
M=DB<G8&28@H@9S;^+W[][<VKT^FS<-_OH*GN?S #]QU9SQ\EN2R<T4355V$/
M,"8@#>8CN81_ 5YI$N<<4=<XW<II-Y8MA.<,OL80!8:P*#;=1?[WD([2HI"P
M#RL].E+.'7]V9*,733UTE53TI+UWQB$C3_D<,PFL+K_F8;$RFVQBOE!JQ=?\
MX9T-)OA?NN)\,<?:Z4'IEHPY"LVM: &U0$>+4*])Q U?&X"Y5Y[C^]&\B9 (
M#W]#!C>\)8E'3K[N76^##L5"NUR>IJ5"+%!;])7"E0GI]PGM9^HUM4U] 557
M?:KJFV#G)==+!Q(\?']+>I.*O]63/$06KJ$JJH^)@"T?Q&#"DUN;4^H;#1)^
M_!$!\B+J;MYB B?[#:#LEP)&R3T&["Z7(>/2</.6%%#[RW9$C?BP>?*@(&[P
MDK*\GY$#&'L7M>&-:Y;*W&)"J1WX=8$#2>&[%:Z6X')QY.KLWG$.XUF((KG(
M3;;Y.>(@N0:'$2'B9B1F%(LI:BK*-^Z^?N?18>G_/L71',0L]A7/CG<&RS7E
M%T!6E!>"E0?MJB^>Y: RA4VC+<2**CE'?S$ W1TCGLT5YB1 <1M-<E/0F$2@
M**Z";[RW-5:_H-A >405@BFAD&!R+ P>S> PS2?'C(K*$*"D&"481O967.<^
MJ64SG/D9A(/ XJYC5BFKBPRMY7BO&U.2Q&86FAOA^K_),HI!NKF)3U+AX<#S
MCX]20^RRGAUOBKXT^16P@Z3P95.HBW !!#K&_C(,,5K3VLHD'L@M+11WI4J*
M)/N45H4,;OI!\IM^8""LZ)<+'?\4$/^\7_A4^5]'/.??!(R/\T\KOM/-"B\&
M+LT2AD[&3Q[=XYX;_Z:MM_0+@?.Z;>L-O03]#;H/'X#OES4X7O(&%PB_&?G#
M_P)02P,$%     @ A8164O83]=2G P  X0<  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL?57?;^(X$/Y71N@>0-HV(4"WBP )**O;U?94%7K[L+H'
MDTR(;QT[:SNEW%]_,PZDK-3R /&/F?F^\7QC3_;&_G0%HH>74FDW[13>5^,H
M<FF!I7#7ID)-.[FQI? TM;O(519%%IQ*%25Q?!.50NK.;!+6'NQL8FJOI,8'
M"ZXN2V$/"U1F/^WT.Z>%1[DK/"]$LTDE=KA&_U0]6)I%;91,EJB=-!HLYM/.
MO#]>C-@^&/PM<>_.QL"9;(WYR9,OV;03,R%4F'J.(.CSC$M4B@,1C5_'F)T6
MDAW/QZ?HGT/NE,M6.%P:]5UFOIAV;CN082YJY1_-_D\\YA,(ID:Y\ _[QG:4
M=""MG3?ET9D8E%(W7_%R/(<SA]OX'8?DZ) $W@U08'DGO)A-K-F#96N*QH.0
M:O F<E)S4=;>TJXD/S];-\4 D\-:[K3,92JTAWF:FEI[J7?P8)1,)3KH;L16
MH>M-(D_ [!ZE1Y!% Y*\ ])/X-YH7SA8Z0RSWP-$Q+BEG9QH+Y*+$;\*?0WQ
MX ,D<=*_$&_0'L,@Q!N\$^^M?'_,M\Y;DLT_%P"&+< P  S?.V?JIJQ6R ?]
M%VGU'- :3>,42>O>O76ZET-O"H3<*&HOCN:Y2,<>D_]1&IZVT[JLE6#] ^8Y
M-02([%\25T D.64(W@3+).[? K<\Q]H*)8@7<[;HJ<,Q Q26]QS4%3=59JK0
M761"[@ZIS=K$G!<Z$S9S('4(/(;N'1$5-JS<2Z7(U?5@^4IOU=";M_3@BT[I
MMJ'(W3ML1CTF^W@BM#H1FJ^?&&5X%7^"*]I_1EW3R5A3PI+4QY5TU%V^(#SN
M*R0:?T!W^+%W<KVYBOOD^EEJ2EL*1=BD@+HYI620O-KU;\B.F%$4V(@7=&.:
M$<35BE+W!]A8H5W."-WAX%,/-L93.$)+1L/>!3F-6CF-+M9\Y;RD*XG2?W*8
MUPJ^T>$YKL+<.7Q;19<CD@HKM/[P 2K%-P"5#O!7+:M0!&&1R\F PD-JG+\&
MUMW2E)70!ZB]5*W:N&OX,KQB#"C1%R9C:AG2NT'GV@CF&6VPQC:5NDE%G5+A
M71'2&<.BEBIC43&O[6GR2C")J2"#& [(ZOK&5OQ3K)?"J QD65G";&K99^OD
M9'TOTH*8TBWX>]()&?4'C=%;-8O.KEU2TRX\+@Z"_IL;N%UMWZ]Y<VV_FC>/
MW[VP.ZD=\<W)-;[^2,6RS8/23+RIPB6^-9ZD&X8%O<%HV8#V<V/\:<( [:L^
M^Q]02P,$%     @ A8164G/9.[XA!0  MPT  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&ULK5=M;]LV$/XK!Z_H&D"S14J6Y#0QD+AINP'9BCKM/@S[
M0,MG2Z@DNB1E-_OU.U*R_!+'Z(8"B4Q2]W[/\4Y7&ZF^Z S1P+>RJ/1U+S-F
M=3D8Z#3#4NB^7&%%;Q92E<+05BT'>J50S!U360RX[T>#4N15;WSESCZH\96L
M39%7^$&!KLM2J,=;+.3FNL=ZVX./^3(S]F POEJ))4[1?%I]4+0;=%+F>8F5
MSF4%"A?7O1MV>3NT]([@<XX;O;<&Z\E,RB]V\^O\NN=;@[# U%@)@G[6.,&B
ML(+(C*^MS%ZGTC+NK[?2WSK?R9>9T#B1Q9_YW&37O:0'<UR(NC ?Y>8]MOXX
M U-9:/>$34,;13U(:VUDV3*3!65>-;_B6QN'/8;$?X:!MPS<V=TH<E:^$4:,
MKY3<@++4),TNG*N.FXS+*YN4J5'T-B<^,YX(G7E@GW#WM<[7HL#*:!#5'":U
M4K2!>Z&^H!&S F&*::URDZ.&5P_V1%]<#0R9884-TE;E;:.2/Z.2<;B7E<DT
MW%5SG!\*&)#]G1-\Z\0M/ROQ-U'UP0\\X#YG9^0%75 ")R\X$Y0F!,=Q^>MF
MIHTB*/U]1DW8J0F=FO _JH&)+%=2YQ:VI\)[7NJ- 9,A(,F5"[=<Y#H5!3RB
M4#9"OM/)?3;R('7IMT_ H_2G;?K+7?KU+OT;5 @IV:ERC5;3);QZ(XM"* UY
M!?=Y49#U^J)1.!%*/>;5$FY*69/,3Y7"5"ZK_!_B?4=7!]QIDU.-T?:MR!5\
M%D6-35Q>BG+U^FDFSJ/3D;\ [B51 "]_2CCCK]O=X=GOLOKE4W_:AZE<DTOY
MLCH .;N :.1WU,=KQ_D1B5,C75&K6J4971$@E@JQ='8R;Q3$'5.S.SR;2+62
MBGRGVV1F]H-LU7,OBL,]%^R.>>&0T9/SP)82/K9)@D5=S341,9_OL=C=X=D#
MW:NDS8&L49/$.X/L>G\_K6=&&D+0"V#,8^$N>NUVY/' MUZQH G).[G^V>P'
MDC@#+R:9K%DD$'IQP(C3#V/X@U"J3F> [7P_7#X?-3[<)<FN>0B<1SLOQ%KD
MA0,,]330A"=XQ2^LB2%9PZR)=L&MB<.A=2Z)X<&Q_N]R<?Z/DJ&-&/7+9VN%
MC9[4R@\H@HC0UCR_'_9A,*(XC(!_'\PC+XB'[7.KI$GK>3Y+O\]SOAB8%Q#D
MDV1$YH6GH9]$8?M\'NPC/W+_IP >$HJMYQX;#2$F[)S <NB**?!\(F&>[\?G
MT!A%P(8$1/8=" R]($I(,&.VG/@P^0&XB[W MV:.$NZ<?X_%'(PD!F.I'@F"
M:]2F28=0+E%2V9M8&! E+=TMG4IMG$(:_0IWLJ1[6P,Y4$BM\8B7<$WMIB(<
MZ[YS[N:IS\>A.E:^L)U@[3K!)C<9U-61;FM.J[SCJP@+MN^);^BJ2SH0NDZ%
MF1TFUTC'M,?^F18^[%KX\'P+IT'&C@,U)>F^":CUA PX]'<J#DKS5%<_J\C.
MYI=Z)5*\[I$C&M4:>^.'S/;@G07E@06V]9] VI.H&Z#YJ::)'-H)RB5":&(I
M:&;7SW7VB47$K="YWN_9;]ILV=!7V P=S=5*=[#[B1V-6!C*2T=B,B7K94:S
MRKHYT;9JZ&]'N_=J2VVP:D^VI=P5O:N;8U]W=WQSPY]"P&!OF"Y1+=TG@Z8X
MTV7<S-7=:?=5<M,,XSORYI.&KN6EQ6F!"V+U^S'E6#6?"<W&R)4;S6?2T*#O
MEAE]6:&R!/1^(:79;JR"[EMM_"]02P,$%     @ A8164LF:;+:) @  4@4
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MGR )\R2F,4G.X8M2E6?IM"K1D(XPSIUQDJ5PS26GFJQ@[;U.P\E%#F=A?)[
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M7./98AZ 'IKV,+&J\XURKRRU73]LZ)U#[0QH_Z HZ^/$$4POY_H[4$L#!!0
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MGSM*!E1VQJIF90P&C6S[J[A?Y6'#( ]?,8A7!K'GW3OR+"^%%:?'6BU)N]E
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M7F#L7!V^9U&C%9ZO+5UQY:^7?"=10ZM&>&)MG^@EH:>7HQ'R(!N'T) P2YP
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M;UL!_(>>7=%">30EXMJ06!L<VMHZ?1<R;N0[)YDX?3O <P _'+69M(F!S&Y
M1B-BNK=RFV6^&NCC]R>L,U%31-OXB/U3U-@^VK ]]F5[$4Y7\_U&O6*0%#GF
MQ15- 9M-QX%><\<@I66URSD>6&4ZGUK8W VT<0$T( 1]*("V#[I/8[ 3LH#B
M.@**C@=7\-(]?2TC=HR'-($^J4&3W>3QIA1-_* D"+5:EP.%@R*\IREI;2C
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MATO8OS"!$^#]G'-5W2"#^@OWY9]02P,$%     @ A8164E_RAZXO!@  ^@\
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M<1OUR/J7IE^T9N%>=T/3XJWHR!D>Y]JR /@3@W)8+=C YKE_\1]02P,$%
M  @ A8164JMCIEL6"   @Q,  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&ULM5C;<MLX$OT5E#:9E:<8B7=*CNTJ7S*SGDJF7+:S^["U#Q )29A0A!:
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M+0V4J?DSL#!NV9WE=F.5?F2WW K&FXJY#<WCWU%B\[EPS<RAF1;LP]=A]>>
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M3KH''Y/;=4T/SEZ]V$2WZD;5GS?7)>[.>BK+)%-YE12Y*-7JY<F%=?[:DC2
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M\$B<0+3T7EZ7R:+A)"4\2X#8+AZX@+R6&CK,")Q8AA^8IT?APS9C=RBE RT
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M_'[.!_+)%4$EI,!$UZK[(>K868MZH9"Y 86BKT*Q7Q##H6&"1_ +. Q^$2[
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MG1_W((L.D@XV'1PZN(S@GDL39G7]*%\?=Z$<Q7'I$B27H>1>4D#P'+1Q#!T
M=A^V_.' UA] .'6VR:J17!P/CF+YL'KIVU-9P#*W6]+FGS.0]TF>9 V9Q+!A
MT*:&G?!+PAU'MSY,[2*F@UO:DZQ]*[/)V@7%AQ;4Q_U=^,V0L>I 8X5"@<N$
M;LN5 #0A;1J&A9>[_1BJ@$9H.T.MP)]'T,Q9]$5U!;+F<OX-[7',"6R/0R-B
M#TA9&& !M/B!/VD_@T\:K$=WW<DB=A6NTXNX@*;B+8;X%)6WHZ>'[6)ZRD_3
M'K_M*%&-V<]>#VN#<6'%Z$9SMAW1;[M;7--$56MV"!T Z3$71ZMN0:,D:PUV
M%O<*A[>_-TG] "@;-Z7NK"!#?B=\VA?S:%?E4BWJX<^4.:D&;Y'EL%]F\2[8
MX#BE4;G5J'SR)LA>?<9KH$T]P&=J !Y4WS3]1S9 =LIWGO$'. 45E3J\9JAU
M&ZY<1SV]J-(</PFNG0.!%>0SJ%)B2/DF 5Q?)3&U2H?7G_-B09&'N;S*-TW;
ME[\:\/-^P ^55]KR-4J>_8-V+ 452/I*]E=VUS1K@=C_!^FV5S=KR%'OWVZE
MQEB7@P%UAO"6[R&=F.ZCS:: ZD<$G;\70%-YGU*C6Y7'(S/>'4A-=$QA6,A=
MCTTR?)?M/\EI)Z'=6]AYV39"*O4,Q]WO^$Z]N^]Y0*&V[Q(*=>B+%?$X/1[A
MZQ$N!2$DE]N40R^)=_=UQ_ @/MNP;>1[#Y$WL)#KJ6CT#9?VDVQ4VQ[CUC!L
M\W_KVWLS6P)*MF@'(' ]P&4;*#5 \6F-;''L$L\8:)N203R='( .QLFVXS$W
M$F$CQ.P2?)E &.,6.%EZV[!*[DAXW69A:\$=LXGNH54#Q^EVHZF52&TK_HA#
M+>>'0M39X).Z3"&@TH>#U-A!YM5?U_5/^X\3+_0G>=O7]9>-[Q&/83PB52L,
M->>^>R)*_;&@OJF+#7^@MRCJNLCX<JTBE CT GY?%0@+[0U-T'^R^>I_4$L#
M!!0    ( (6$5E($/JE!]P(  ,4&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;)55WT_;,!#^5T[1'D"*2.+\:(K:2A28MDE("-CV,.W!3:]-A!,'
MVZ'TO]_92;N.025>$OORW>?O[GR7R4:J1UTB&GBI1:.G7FE,>QX$NBBQYOI,
MMMC0EY54-3>T5>M MPKYTCG5(F!AF 4UKQIO-G&V6S6;R,Z(JL%;!;JK:ZZV
M<Q1R,_4B;V>XJ]:EL89@-FGY&N_1?&]O%>V"/<NRJK'1E6Q X6KJ743G\\3B
M'>!'A1M]L 8;R4+*1[OYNIQZH16$ @MC&3B]GO$2A;!$).-IX/3V1UK'P_6.
M_;.+G6)9<(V74ORLEJ:<>KD'2USQ3I@[N?F"0SRIY2NDT.X)FQX;9QX4G3:R
M'IQ)05TU_9N_#'DX<,C#=QS8X,"<[OX@I_**&SZ;*+D!9='$9A<N5.=-XJK&
M%N7>*/I:D9^97?*V,EP ;Y;P0%75G=K"O9'%(YP\\(5 ?3H)#!UDX4$QD,Y[
M4O8.:<3@1C:FU'#=+''Y+T% "O<RV4[FG!UE_,:;,PAC'UC(HB-\\3[LV/'%
M[_!=/W65V<*OBX4VBF[&[R.<R9XS<9S)>ZDL>;-&#57S*I-O)? HE>W$<]WR
M J<>M9I&]8S>(;_9\6M7J0TJ//^O?!>U[!KC\#>5$-0#5(^7 EOS&GI?<C4(
M+V6GZ2[HTYVQ9X$Y%[PI$+B!*RRP7J"".++UB$:0Q",_CG+X9$UIFL!UW0JY
M181"UC0^-.\[D.Y8+UBVSM 2IX83QOPP9Z=P$OMA%I["';:=*DKJ-9 K2U$3
MMG=,F,_R&%(_S_*W-85.4PY).O+3: QQXL<9^ZBBT _3F!0Q/QM'QQ6-_7P4
M0N:/DNQ-16SL%(TAR2E+<09Q[B>4M \JBOQ1EKH<14E^5)&#AA#[C$6'BJB'
M.IJ[,'31H">R52-%XQ#>ZH'@8+34J-9N@&HZD"Y%/V7VUOV,ONA'TU]X/^!O
MN%I7%(O %;F&9Z/4 ]4/S7YC9.L&U4(:&GMN6=)_!I4%T/>5E&:WL0?L_URS
M/U!+ P04    " "%A%92H+-X;%P#  #V!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6R556UOVS80_BL';1AD0(TDRK*ES#:0E[;+T*Q&TVX?AGV@
M)=KB2I$N2=7-O^^1DF4':(+MBT12]SSWW/'NM#@H_=DTC%GXU@IIED%C[?XR
MCDW5L)::"[5G$K]LE6ZIQ:W>Q6:O&:T]J!4Q29)9W%(N@]7"GZWU:J$Z*[AD
M:PVF:UNJ'Z^94(=ED ;'@P]\UUAW$*\6>[IC#\Q^VJ\U[N*1I>8MDX8K"9IM
ME\%5>GD]=?;>X$_.#N9L#2Z2C5*?W>:N7@:)$\0$JZQCH/CZRFZ8$(X(97P9
M.(/1I0.>KX_L;WSL&,N&&G:CQ%^\MLTR* *HV99VPGY0A]_8$$_N^"HEC'_"
MH;?-\P"JSEC5#F!4T'+9O^FW(0]G@")Y!D & /&Z>T=>Y2VU=+70Z@#:62.;
M6_A0/1K%<>DNY<%J_,H19U=75=6UG:"6U?#>-DS#C6KQ>AN7]Z\,[F2E6@;A
M.V7,!,*/=".8F2QBB[X=0UP-?JY[/^09/RF!>R5M8^"UK%G]E"!&T:-R<E1^
M35YD_)W*"TBR"$A"TA?XLC$3F>?+GN%[_:7C]A'^OMH8J[%8_GF!<SIR3CWG
M]!E.ETLEF;0&U!;^6ZY_E-O_XT5YYNH),Q]N4?A;K!2>&NN,T1:V2F!K<KF[
MA/ 6UU0;!, ]%P+[!NVQ_+&X);S%'H^'2G@OX8%5G>:6,[S3=B_4(V-PS23;
M<@MK0:7I ?!162K@EE6LW:"R+'57EL[A9PCG49:G$R 9@7 6I7DR@7D"89I%
M:5E.X*9/EXN UO]B,^ TL& 53@.+U)A&1K5$Y09"Y,#Z1+)^]0?.,_120-50
MN4.)81KE:3&!7WXJ2$I^A;!PIK/<@:)YB<"3PB3JL6$1%;/R#.,T.EQ:>EP>
M$7+R58Z^TMGTA)EGF;--,+9PYMA&/Z2,>ASZF2?Y$S]%Z4,Y^O';W@])3C$1
MQYTZW@F4TSG,IB5@7W0X7F'H#)?F(BJSHC>,RGP^@5E.>OG3(6EKE.-J@=9J
M[Z>E*]>'3T[>[%62OH(W7%)9<;S(.XG]T;F;,#_JD/AL%K5,[_S$-5ASG;3]
M6!I/QZ%^U<^RDWG_1[BG>L>QC 3;(C2YF.,,U?V4[3=6[?UDVRB+<](O&_PQ
M,>T,\/M6*7O<. ?CKV[U'5!+ P04    " "%A%927M1B7T$#   S!P  &0
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M%(+@P)8C?B7.MU]<H>J'9(&4K;@&-;)IX;N(E7?CJZ:8\@FT'(HZ"*Z$$?J
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M[C U=X8-)%D?AF@S?ZD647G?EZN*_[5)/D)97)^SKZ+B#S9G4RH&/!.)6C8
MKM1-K=OI7DIW2'L_JW.,OJOS]U9B:.<%CYYN:FSMD_-BC00*A;X \'':Z$J@
MNQ9BT?!C $:5QJ*<03=;?_/J["<\L?IV81B YHM EF4E5?/R;)&LT[@V#X4
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M6S;7\:%ZM!7'I=N5"6D[RRV.!B-FLE-P7_CY6/ 5$RC) )-S&!5:6P.NF7Y
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MV)S4^8PH3)F\ './#S-T?G:!SA MT!UE# 3DR%80B>:QTX;ZIJ;V3E#?XF*
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M0XY20,JX/C:K]W<I.?IT3#X1)L@-X]RT4,<^FH(LK9^UR2=-\G!/\GY(;J3
M0I,KD4/^EL W2CHYX5K.)#S(^(V*'@FB$Q(&87]'0=/#\!2R'@G/+;Q_O@.>
M?@ >!0Y^=D!-U#4G<GS1?S7GU^5<HS(7Y_>!5(,NU<"E&NQ)=2T0%&@D\&P<
M10/):,60<O:ZW9>F#0W;T+%9:WE*1E'L/VT>]?N0T^!M2/H^Y&S4A;S1,>QT
M# _J2,&X7\:H,Y56RXGY2C->YTPL"19 :"D5LM<F1BXVI9K(YAQV:1Z^JS8<
M!5N2ICN"AMM!Z3^8&N7^QJTN02V=.VJ2R5I@<R.ZU<Z +YWO;*U/C#$W/OJ7
MIG'U&ZJ63&C"86$H@]ZI*4DU3ME,4%;..^82C1.Y86%^+J!L@-E?2(GKB4W0
M_:Z2/U!+ P04    " "%A%92(OESO\X$  !&%0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6S%6-MNXS80_17"V(==H(E%4I:EP#&0Q$WK(@&,I+M]
M*/I 2[0M1!)=D8ZW13^^HXM%61<F]=;8%UN7F>&9"\^,.-F+]$5N.%?H:QPE
M\GJP46I[-1Q*?\-C)B_%EB?P9B72F"FX3==#N4TY"W*E.!H2RW*&,0N3P722
M/UNDTXG8J2A,^")%<A?'+/WKED=B?SW @\.#IW"]4=F#X72R96O^S-7G[2*%
MNV%E)0ACGLA0)"CEJ^O!#;Z:49(IY!)?0KZ7M6N4N;(4XB6[F0?7 RM#Q"/N
MJ\P$@[]7?L>C*+,$./XLC0ZJ-3/%^O7!^GWN/#BS9)+?B>BW,%";ZX$[0 %?
ML5VDGL3^9UXZ-,KL^2*2^2_:E[+6 /D[J41<*@.".$R*?_:U#$1- 3L]"J14
M($T%NT>!E@KTO0IVJ6#GD2E<R>,P8XI-)ZG8HS23!FO911[,7!O<#Y,L[\\J
MA;<AZ*GI/%$L68?+B*,;*;F2B"4!^DF(8!]&$;I SU!IP0Y>BQ5Z0_CCC"L6
M1O(3J'U^GJ&/'SZA#RA,T".\A23+R5 !Y&SAH5_"NRW@D1YXF*!'D:B-1#\F
M 0^.#0S!U\IA<G#XEA@M_L*22V31'Q"Q".X =&=6GW'_$A$O4\=>A_KL'>K4
MRM5=@S>T2A_-[=$>>_=A$BI^\0![)T WD(PYA&E5?]C.V>\/8 3-%8_E'P8(
M=@7!SB'8/1">N.0L]3=Y+<SX*U#)%HA!98E?I,+GLC/OA=%1;C0CI]<I=B$?
MK_54M&5<SSJ6F778P<2IA(Y<&E4NC8Q1K<6,%3';AVH##AUBBR*(K;PR1,^I
MEG*,T9L?VPQ@D<;:7<$K;#IUISW+MAOAZY#"(\?KCLVX CPV OY5*!:U4<*6
M3[CJPCINH1A1VR(-K&TI>^S8M!NK6V%US5A3%D";A!9JR)17&?/.7138TJQL
MG:$L2J/U*(ZQ-VJ$ND/*\0CI#C6N-1)LA+S8 0E !\ZP7FR+C0^308T< DT.
MIB 1O2(Y>T8TT6)ZCHS0CCWHVEXS)6TQV[''/2G1S(S-U+Q@"F(M\\;PKKV
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MUL9W2.4+,S\8N7(K9"X--M==IOB1 <HZX/U$2K,]6('RLV7P%U!+ P04
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M@ Z@H8'G257/,1LHY\*)],1&^F,\#_O!.?@@" >",W1 _'3P@OU>5.J56][
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MH78&]+U0RCY/7(#V8CCY!5!+ P04    " "%A%924EF=4M #  "U#0  &0
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M(H\$]9'L?6J"BLC!P^ $;I:-](OT9H'^0F ^4%CR[;?*5#D1Q*WQX1\J4!"
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M"<582N\.RD5F]0_8!G?RW $#^H@,D1:<52[LKI(%"PVYI $%%9A3@0456!*
M2LX G4%$'*>4"\USB..U,L1*D=L'I"5P\A0"YC8V+JP0@8( 5(("N 4BK\@6
M@7)K&UAU^X'<(@O<T(H _H2"$STDS.T^*/J4TH"" %2" OHV(IVH2^FIU\J
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MB'2*G^#=*?MP0#B0A6X(")#X8XC&WYRZ@KABIF>GJ4!!!>948$$%E@2@DC-
M0!#%P EU)1I3"Y:.!$"U9K%)4IP!Z4$6N:$@B%NCA# 5* A )2B @B!J?D?L
MQ!T\#R4^1X^[%;B=,GC <1 !P6/WX@[N)^S%3;44DRUS@Z5N+VZJ93G%4HDV
M_#5*3!A(?2PBL)U19T!;D$5.GGUC0%N012=[^@USU05"+^E#!0HJ,*<""RJP
M) "5G '.@Z@)3FDJXR?<LG3T,[:(E3) 0(80D4)R2YGPHU#Z"48#"@)P&!2@
MC<@06<%(OPD76 ^B JU!%KLY@1@#JA"?[@0BXBHR_!K<%14HJ,"<"BRHP)(
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MBAN?.2$"!0&H! *TYLQ^BF'R(>)L?$@A2TWW<$")CR$B=F%_ZS.<>[8?^F9
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M[@KY5+=MO=G_>5\M;ZNF-^C^_7/=E>7#BXO._]>Z^6W_&6_^#U!+ P04
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M:*B= ZWG2MGMQ 5HG\C)/U!+ P04    " "%A%923Y:-%D\"   5!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6R%E5%OVC 4A?^*%?6AE5:<&$)"
M%2)!T;1-0T-EW9X-W 2K3LQL0[I_/]L)*1VAO!#;N>=\]X3822HA7]060*/7
M@I=J[&VUWCU@K-9;**CJB1V4YDXF9$&UF<H<JYT$NG&B@F/B^T-<4%9Z:>+6
M%C)-Q%YS5L)"(K4O"BK_3H&+:NP%WG'AB>5;;1=PFNQH#DO0S[N%-#/<NFQ8
M :5BHD02LK$W"1ZFL:UW!;\85.IDC&R2E1 O=O)U,_9\VQ!P6&OK0,WE (_
MN34R;?QI/+T6:86GXZ/[9Y?=9%E1!8^"_V8;O1U[L8<VD-$]UT^B^@)-GM#Z
MK057[A=53:WOH?5>:5$T8M-!P<KZ2E^;YW B(,$% 6D$Q/5=@UR7,ZIIFDA1
M(6FKC9L=N*A.;9ICI?U3EEJ:N\SH=#H5TBA8F2MTCR9Y+B&G&M"<ZKUDFH%"
M(D/?19FCGR +]&/%F2DPSU.AVQEHRKBZ0S>(E6C..+?K"=:F+^N.UTT/T[H'
M<J&';[3L(;__"1&?!,_+&;J]N7OO@DV/;3321B/.MG_!]BU-\2X--VGNM4TC
MWM)\P.NWO+[C#2[P;/==X6M5Z%1VCQS2(!J-$GSH8 U:UN :BW2Q:M7PA$4(
M&7:SPI857F/UNUCA&2L(0]+-&K:LX376H(LU[&"-XFY6U+*B:ZRPBQ6=LZ+!
MH)L5MZSX0]8D,R\<ND2,S]X0$H9!^!\2G^QR>V#.J<R9V8<<,J/S>Y$QD/4A
M5$^TV+F-OQ+:'"-NN#7G-DA;8.YG0NCCQ)XE[9<@_0=02P,$%     @ A816
M4BHRX?25 P  H P  !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULK5=A
M;^(X$/TK5K0GM=(NL9V0A J0MH2[X[25JFU[]]D0 ]$F-F>;TO[[LYTTA<3)
M5G?W!>+DO3?SQD,\3$]<_)![2A5X*0LF9]Y>J<.-[\O-GI9$COB!,OUDRT5)
ME%Z*G2\/@I+,DLK"QQ!&?DERYLVG]MZ]F$_Y414YH_<"R&-9$O%Z2PM^FGG(
M>[OQ/=_ME;GASZ<'LJ,/5#T=[H5>^8U*EI>4R9PS(.AVYGU%-TL4&()%_)G3
MDSR[!L;*FO,?9K'*9AXT&=&";I21(/KKF2YH41@EG<??M:C7Q#3$\^LW]5^M
M>6UF321=\.*O/%/[F9=X(*-;<BS4=W[ZG=:&QD9OPPMI/\&IPL:1!S9'J7A9
MDW4&9<ZJ;_)2%^*,H'7<!%P3<)O0%R&H"4&;$/80PIH0?I0PK@G6NE]YMX5+
MB2+SJ> G( Q:JYD+6WW+UO7*F6F4!R7TTUSSU'S%-KRDX)&\4 F^@'O!GW/;
M!+H'P<7#JY0JDA?R6L.>'E)P]>D:? (Y W=Y46B&G/I*)V1D_4T=_+8*CGN"
M!^".,[678,DRFCGXBV$^P@,"OJY$4P[\5HY;/*B8TLT(!/ SP! EKH2&Z7\0
M-@(P,'2,'/3T ]'QQ$:?..C+?YW\13&"IC<"JQ?TZ"V.0E"FBE=P(*]D7=";
M =&P$0VM:-@C^C1Z& %E.LI5WHH[MESSCGN>(XBCJ?]\7D0':!*B2]#2 <))
MV( N<A\WN8\'<U\Q104CY@U'BGX3E4AT'CJ9)"T371".P[!EP@$*@QX346,B
M&C3QR)5.?M/>6Y>1J!M^@ELYIEU0&"7CEI$N*(A1XC82-T;BP?9,Z99J$]E0
M5R:-5O(?NC+I9/\E;C>E Y.@]GYV00@CZ"[#I$E]\G\TY:2;'X)1:Y]2%RJ*
M<,N& X7QV<_TP@>"[T<1_$!G9O6V.H\#Z,@/M7_[J0N&P_:6+9UJ$/7Y.#M2
MT:"/RT/4[@C0B]R>IDY;J/NRBI.@[:J+PAA.VJ8<J!CB'D_XW1,>]/3;ZMOC
MZG.S.<85V'"IG(<^[MH)84^;H_?3" 7#[:%#KBFCVUS9>B[((3<-\XU+9\?_
M1.X*C3#\Y=IU2O^,"4=!AUF9\L\FL9**G1V!I:[4D:EJ"FGN-F/V5SM<MNXO
MS/AM)[QWF6IVOR-BES,)"KK5DG 4ZSJ+:ARN%HH?[+RWYDI/C_9RK_]"4&$
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MGGBKRM^[TM^@Q5\8@'M:B*V<KTAQ>D[@2?%U!(*W"-P%5L;OJ'"!'_X* C^
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M :E@PW8"EZK[!$,_J>,KE3#^2;H^]UT:D')G4,D!;"N0O.G?[&GPX0@079X
MQ ,@_E] ,@"\<[2OS+<U9\CR3*N.:)=MV=S">^/1MAO>N*^X0FU/N<5A_D&V
M0CT#D"4(AE"1KVO!M\Q9;,A;\H5IS9S1Y'P.R+@P%W;W834GYV<7Y(SPAMQS
M(5QV1M'6XUAI.6C?]MKQ">T[UDQ(F+PA<1A'+\"+U^%S*"<DOG+PZ.IO.+4N
MC%;$HQ6QYTM.\!5*VKMA?.^C'84R:,B/F[5!;4?NYRLZR:B3>)W+$SH+#2WC
M%8&#]7K04G^L?\G,GC7UK.YR[O-I.LWH_MBQ?W/2-!IS^G+IT;2XFWK/]);;
MKRU@8U'AQ,VV[J>_#U"U?H#6"NTX^F5M?QB@78(]WRB%A\#-Y/@+RG\#4$L#
M!!0    ( (6$5E+^=*0[=P0  %T3   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<U+GAM;+5876^C.!3]*U8T#ZVT+=A  E42J4EFM;-29Z-6L_OL!B=! S9K
M.TUW?OW:0"&Q#:W4]B4!<N['N??:AWAZ9/RGV!,BP7.14S$;[:4L;SQ/;/:D
MP.*:E82J7[:,%UBJ6[[S1,D)3BNC(O>0[X^] F=T-)]6S]9\/F4'F6>4K#D0
MAZ+ _+\%R=EQ-H*CEP?WV6XO]0-O/BWQCCP0^:-<<W7GM5[2K"!49(P"3K:S
MT2V\6:%0&U2(OS-R%"?70%-Y9.RGOOF6SD:^SHCD9".U"ZR^GLB2Y+GVI/+X
MMW$Z:F-JP]/K%^^_5^05F4<LR)+E_V2IW,]&\0BD9(L/N;QGQS](0RC2_C8L
M%]4G.#98?P0V!R%9T1BK#(J,UM_XN2G$B0$<]QB@Q@"9!F&/0= 8!&\U"!N#
MJM1>3:6JPPI+/)]R=@1<HY4W?5$5L[)6]#.J^_X@N?HU4W9ROJY;* "F*?A+
M[@D'"T+)-I-@G6/U_ HL65$R2J@4@&W!=S6+:\(SEF:;%KID0H*+%9$XR\6E
MLOGQL (77R[!%Y!1<)?EN8XQ]:3*6,?U-DUVBSH[U),=1.".4;D7X"M-27KN
MP%-46[[HA>\"#7K\$]-KX >_ >0CZ$AH.6R^(IMK@!)M#A.'^>H-YH%?F<<#
M;(*V>T'E+^CQ=]X:JEI3OK3FL6G-1K5F(%+81@JK2&%/I%NUUM-"1W)UL;:-
M*EN]TSS-KV#L^U/OR1$R:D-&@R'OB<PXT3'K41Q@,6Y=CC^Y7I,VTF0P^0?"
MG[(-<;BK*U9;CT\J!H.X*U@]BQ.KK!".@W/0R@%"<> N?=QF'P]F_XU*PHEP
M5:-./[;23Z+(R-[&0#\9&]D[')U@SI)/VN23P>2_/I=*5$BJ9$D>. 5*74HU
M/P +0=SCFUA)7*%P# T^+E2 D$'(A4(0N2E!O]NF_5?6'^,R^X4KL52S6ZJQ
M5?+]RI0U3D^S,?)=.B"A0<D!Z9DO>"([\)7%O6$[FOU2;5+2?\ \PSG(F6J1
M !<[];XB+IV$H)5*G)B-<H"B26*2<GB*^MJ$.EIHD-;RP+4&5AME):EJY&1.
M>C?.QMU9@P*3CHV9F)N  P-[N'3: H-!+M_?MCTV1 ([R<3<SQR@*+&HV* $
M]<U;)U_P/?K5&)^M6CBQ]F,'K$?C8"=R<%CE'.]< _(#.Z6#GRUUL-,Z^#ZQ
M@[;:H7AB%M<!FEA;D0,T3GIZT*D=?*?<08>6!=8Z=8#BR"3@ (5Q#X%.\>!'
M2QYTZ)35$0?&U.]A/^>OZ)W8H<\0.V3+U%5@:L-;0*M70.>L.LE#GR)YR!8J
M&)HJ[@(A4_*<H)Z=%762ASY6\I M5>8^^SID-0@Y9]()'OI P4,.+4.A2<0!
MBJQI"ZPW^,CO>1-!G>"A]P@>LO^Q64T8@M1)>2?G#@7AN^K\1JB2':BL_Y*W
M3]LSHMOJ9,1XOH WJ_JDIW-3'SS=8;Y3*P/D9*M<^M<3E0^OSW+J&\G*ZG3C
MD4G)BNIR3W!*N :HW[>,R9<;': ]49O_#U!+ P04    " "%A%928I@%CP($
M   Y$@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6RU6%V/XR84_2O(
MTDJMU+4-]N1CE42:)%MU*VTWFM%NGQG[)J%KFQ3(9/KO"]BQ,ZD-,^KL2P*8
M<[CW7. "LQ,7W^4>0*&GLJCD/-@K=?@013+;0TEER ]0Z2];+DJJ=%7L(GD0
M0',+*HN(Q/$H*BFK@L7,MFW$8L:/JF 5; 22Q[*DXI\E%/PT#W!P;KACN[TR
M#=%B=J [N ?U]; 1NA:U+#DKH9*,5TC =A[<X@]K/#4 V^,;@Y.\*"/CR@/G
MWTWE4SX/8F,1%) I0T'UWR.LH"@,D[;C[X8T:,<TP,ORF?U7Z[QVYH%*6/'B
M3Y:K_3R8!"B'+3T6ZHZ??H/&H1O#E_%"VE]T:OK& <J.4O&R 6L+2E;5__2I
M$>("@$<# -( R#4@'0 D#2!Y*2!M *E5IG;%ZK"FBBYF@I^0,+TUFRE8,2U:
MN\\J$_=[)?17IG%JL:E#*!&M<O1%[4&@)52P90IM"JK;WZ,[JD"BKQ)RI#A:
MPZ.>+ =TFZDC%8P6:"- 0J70-UH< ?&M;N!_Z;#J_F>J+P\%VU$;Z)_6H"@K
MY,^S2&G[C151UMBZK&TE [9B@C[S2NTE^ECED#\GB+3CK??D[/V2.!E_IU6(
MXN071&*">PQ:N>%KR$)$I@:.ISWP]0O@26SA$X<W21O+Q/*E WQWH)B TL3"
MQLY!F;:4J:5,!BC_T#O/!@3C.<O::*ZX5 [NFY;[QFGN/8A'E@'*-!W*F<SX
M45LN]&SKFQIN+A).R+N^ +IA23A*^F!K'XS$[QP*C%H%1DZ>3Y4"O7C4"R5P
MDR4A[O5EY8:E ["U;[214X)Q*\'8/6>UKV;/8%6FTY8$7=!JE#JMR7J_*,Q^
M(_OD<!.G87QM8"V'&Y:$TVFO'%[8Q"7'I)5CXN3Y^'2H=\Z"5[OW>G:4=C88
MA02HHZB0EN2@%S>B4H+JU<4]PB3$_2O%!TMPKRX^6#IRZ3)M=9DZ]Z'_)A('
M*8Z[Y!<[S5O[EIP'3T*<]HKIQ4W[U?3@DG#LE!-?I'W\H]:=AWEPX?EQ YJX
M<7KIC9V:D$X3XF3J.?ZX>+NTC),W3Z*XR] X?<,TZB%+PGA@0KMQ:9C>] ?/
M-][D&O=<ANXP@=TY^96YU,.F=;C>SQL=W+@T) ,Z> \BU[OR<QVZ(P5V)^;_
ML[!])X5^WU9^7']*?3WNN2;=&0./WS![=+D:NY.;/WNX\20D_2<V#RX)DP%!
MW3B]2)UG-MQE8SS]89/,S:R#?KV;-YIX<0.:O!I7:Q)=W*E+$#O[-B&1#7A]
MP6Q;V_>/6WOKOVI?FG<1>U?O:.I'E<]4[)B^8A>PU91Q.-9[A*C?*>J*X@=[
M<W_@2O'2%O= <Q"F@_Z^Y5R=*V: ]K5H\2]02P,$%     @ A8164J_I/J&P
M @  AP<  !D   !X;"]W;W)K<VAE971S+W-H965T-S<N>&ULE57;;MI $/V5
MD:5*J91B8PRY")" M$HK146D:555?5CL :]B>^GN4)*_[^S:."0U3ON"]W;.
MG#.[S QW2M^;%)'@(<\*,_)2HLVE[YLXQ5R8CMI@P3LKI7-!/-5KWVPTBL2!
M\LP/@V#@YT(6WGCHUN9Z/%1;RF2!<PUFF^="/TXQ4[N1U_7V"PNY3LDN^./A
M1JSQ%NEN,]<\\VN61.98&*D*T+@:>9/NY6Q@S[L#7R7NS,$8K).E4O=V\C$9
M>8$5A!G&9!D$?W[C#+/,$K&,7Q6G5X>TP,/QGOV#\\Y>EL+@3&7?9$+IR#OW
M(,&5V&:T4+MKK/ST+5^L,N-^85>=#3R(MX947H%902Z+\BL>JCP< +J#(X"P
M H0O =$10*\"])S14IFS=25(C(=:[4#;T\QF!RXW#LUN9&%O\98T[TK&T7A>
M7H@!423PF5+4,,4"5Y)@G@E>?P<3PU>,"5RCR"B%F= (,V4(OFADT$(0&CBY
M0A(R,V^'/K$L2^['E81I*2$\(J$;PHTJ*#7POD@P>4[@LY_:5+@W-0U;&3^)
MH@-![Q3"(.PV")JUPZ\P[D!X8>'=BQ8YO3K'/<?7.\JWXI7D66)/_RVM/R9+
M0YK?^L\6'5&M(W(ZHB,ZJDBQC13;2.0B:8X$HE+#=0$*?"!X1*&;[K(]1+\S
M.'_3E/'78.=G;UH<]FN'_58>FS0@!;M4QBGP:_[+IS2U53Z78&PIX(3_]#)W
M8'NT\1&W1XXZT46C\==@_:#-^* V/FCE:7YBW_D.V]X7+%!P6S!PM[?_M->4
M@G8-81 %31GX7U29 /^@IN6HUZ[4&[[/;4%E):A7ZVXR<47TQ?J4NTS9%)YH
MRA9U(_1:<HG+<,640>>,[TJ79;^<D-JXRKE4Q'78#5/NE*CM =Y?*47[B0U0
M]][Q'U!+ P04    " "%A%92S(U0.-(+  #>1   &0   'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6S-G%UOVS@6AO\*D1D4"=#4(BE14IL&2.,IMHOI3-!,
M9R\&>Z'8=*(=6?)(<M+.KU_J(Z9$'A[9:;O; FUCYR5U2)'O0_+(/GLHRC^K
M.REK\FF=Y=7KH[NZWKR<S:K%G5PGU8MB(W/UFU51KI-:O2QO9]6FE,FR+;3.
M9LSSQ&R=I/G1^5G[WE5Y?E9LZRS-Y55)JNUZG92?W\BL>'A]1(\>W_B0WM[5
MS1NS\[--<BNO9?UQ<U6J5[-=+<MT+?,J+7)2RM7KHPOZ<AY'38%6\7LJ'ZK!
MSZ1IRDU1_-F\>+=\?>0U$<E,+NJFBD3]=R\O998U-:DX_NHK/=I=LRDX_/FQ
M]K=MXU5C;I)*7A;9O])E???Z*#HB2[E*MEG]H7CXA^P;%#3U+8JL:O\E#[W6
M.R*+;547Z[ZPBF"=YMW_R:>^(P8%J' 48'T!9A;P'05X7X#O6\#O"_AMSW1-
M:?MAGM3)^5E9/)"R4:O:FA_:SFQ+J^:G>7/?K^M2_395Y>KSJ^X65B3)E^37
M^DZ6Y(W,Y2JMR566J/=/R;4::\MM)DFQ(K^HD?AVFR_EDES72;VMR/%<UDF:
M52=*^?%Z3HY_/"$_DC0G[],L:VH^F]4JSN9JLT4?TYLN)N:(B3+ROLCKNXK\
MU%QI7,%,-7#72O;8RC<,K?&?2?Z">/PY81ZC0$"7>/&Y7+P@+&Z*TQ@H/M^C
M./?:XA'2&KZ[9[RMCSOJN[Q+\EO9]/'CK?KU)DMODV8B(=7[N^K]MGK?4?V%
MFM9+];<&;UU7-FC+-J9R?WY*(\\[F]T#EPQVEPS0%EVLBZVZ'OD@%\5MGOZM
MAI=JG1J-Y+)8;Y+\\[,?(D;#5Q5YDZA1N9#DNC7%A1I?:54W([,1KXI,^5B:
MW[Y$ND'L8A)H-_Q2Y*>+;5FJCB!)54FX.[HZQ* [1"!VG=$-+F%U61!0N,/"
M77 A&MQE'UB6)C=IEM:I!*,+K>A. S\TPH-$U(?CBW;Q17MWWD2,D7UYZH4A
M-:($94)P.,YX%V>,QOGS=KTY5<PC2S6,RO1F.S&'J*=]U4.']%Q-S%R-XZ&;
M/B?P0.]\MQGJI;QK#/E>DG?YHEA+<OQS42EO_>/B1L6G(/EO++B!Z5-\^"A[
M?6PMJ0NRZ4&^:2P?\L>^OF'W.\<(93H,AH;Q0=9I*1NKZ6"#M4V;(_TF[DBU
M/5+<'Z_*XC]JU:)NW4U_@6)W 07!&WF;YKDRH<:5/LND! 'H6_W)0QI%QJ"'
M9%2$#K>EVFYI@#;A6I;WJ7+115'58'B!=5W*(\^,#E#1P8SLV-BKAO9'6>28
MMU2[,\7M^5U>RU)6M;L-MC7'06 VP191+Q9F$X"J!J)Q"[2%4]S#FR%/-DE9
MIXM4,:ZEV6Y6PLLFVZJ%Z9.0QM79VLTI;N?XDH!"WAS:P\66N0:RMF^*^_?%
MHMXF99IDY/A6;7*44V;*+V5US$[ 2&/;QD)J\AI2J?; L3)-!.:AL<Z5K5=U
M6F_5L'WV Q7>JV?)>O-*;7W^VJ95ZKSK?;6C[K6< A(Q9\P:%&P"%-NR6=VW
MM_XY48N@.FO]>M2 9AJ66W4G2N5Z8 ML>IPRWVP!(*(A<[1 ,X;AC.DA4*F9
MEB[)JBS6+>7 ,!D0@?IC!@K)@H&UC"/5X&(<C?2GU4IAI:&&_+3H(%8F-;QH
MZJL:^Y;'S4AM%7-X =/X8U^$/V44&/B8332?<\_T"D &\'$.R=Q\9)J/#-^/
MP(LWO;)XFZ0E^3W)MNVFN#7RBW:+0/[XH/8@Y&U1/B3E$ENL,4TZAI.NK;[;
M@9"D)JOFVO?-M?LYV&R-V*O]UAW,)AEG:EMJ=K\M8R*B+CO1R&,X\EJ[SI1A
M**_(2;_@1'97S(99$-C. 6$Q<LU'#3V&0Z_?>DYCF=E@BT)K1-NBV'-UJ.8?
MP_EW^!J"V7"SUA"0QN$;7../X_B[UO" XN( P*AI:*#(L1#C&G(<A]Q3P<P!
M8D7FX(1$+'1LG;C&&G\2UI"YQ/>C&RASTHT/SJR^'MVXS:W0.K: 1([5 M=P
MXQ-PP[WVM#F1Q/R5 T"*:&QN.R"9;<-S0(;8,-=XX_CVKS_!K;H3W$EF<WN?
M=QI0SVH4(//C*'1$J_G'Q7=S.,@URCB.LOV.!SF )NM\$! Y#PBYQA>?P-=^
MQV\<VKPQZ]Y"*NIB@L87Q_%UP#$AMYET&@AN]24D\YG#OGQ-+Q^GUV]%W2Y<
MS"'8#+(B2Y=)NR#NQU^;CAFOSB:FF ^ #9ABD,P]Q7Q-0)]^;X>5OD:=CZ.N
MR3DENWU^L[\'>]#F%O4B82[# %D4<=?PT'3S<;I=E6E1JOVQ/E8CQXM2+M/Z
MY)B"1Q&^C2^UW8U-RD$RA__[@P0/3KF/^6 @YZI[U=W*NX7.8#,'1FT3R>IA
M3#(.6 /+QX'5S;X;N2I*2>KD$Y'M:@(>"#:&8L\\E;P$5%'$7!-)L\K']VH7
MB\5VO<U:-Y@Z?N[#M;=:OL<M1@ RSGW7VM?7&//#)\]\8^(W\_!*JH&^3!<[
M_64[U"^[H3Y((H_]X;@SB!/2&,3SQQOYF[J1^WF%AIX_D7=2,6X>8WP\GW"=
M$/LVU,+8&LZV*(C-,VY %+M.6GQ-1W^"CB/C:P\X3]S^9X./">MH$U IEW3L
M1@)-QP"GHQHO:@OZ=W<&I#"7[V79 72P&9L;$D@5A+$C9(V\ -_T(8X-Q@J>
M3EIGW(#,E1K7_ MP_IF=NQE%?MR$?D*ZT,'(@0T=,\,&-*Y!H9D8?+T=7P"<
M5)JS[!(0.5;)@49A@*.P(TLS0F?':6]2XU5>T?K98N1GG?+Y@$A@HX#MF[5@
M!42!Y]C'!H/G*?8!YK@AN<L;6]MV-Q-L&I#Z\YC5-D@5.Q9;@89L@$,6>$P)
M@4>@61C@+'QBYCC0= IP.GV-S'$ \,@+K9ZW5;X?N:Q($RG B325-PX "$7F
MDA82A<:QV1P2"8?I"\TI@7-J,FDL;-A0;OH0)(J,K=H<$OF.E;O0U!(3U#KX
MO%=@1.K;LS>TA(:6F((6EC$6-F^LH##)."A-)($3Z<!LL0#V7J&Y)0=$@7#X
MM]!8$CB6GGHD+:;W9ZAD'*[&C<!Q\W72Q,+&A14\)AD'/WC.#\?) 1EB8>_"
M3KGYN,@EI/*Y8ZDB-)X$?N)XR'I*V$>*EHL!1Y..$#7@Q!<!;N(03$!H8^:3
M#J#*!. <4+D!*#0 1?S_3@R'FF8A3K.OF1@. 5Q1T^L@D:M/0\VT$&?:H4GA
MT,85-;-ND,:Q>@@UTT*<:7LGA$.;73RP'KL%1+[C "K4B LG#B(/7B"$-L!,
MUT4EXT UX4*<<!/IX' :9*AD')4&68B#[*G<#:?1A4K&X6ITA4]"%S9Y]B(8
MI'(2+!P\M/[U"!;:>+)Z%).,0]0$"R<(]H4)X!!ZS,.,V]987CN'1$ZOU?P*
M\0W<@9G?$,BF^3$WD0S+A&.\1!IP$?X,_?\R\QMI7D4XK_;+_$;3^RY4,@Y.
M,RJ:8-2>'[J #ORH>5\A%8\=C(HTHR*<48=\. 38@OD!LWH2E G7AU@TI*)]
M3@>_6=8WL@D&32]8YIQ>&G;14YYR_*99WTBC+<+1ME_6-[)!17TKV0>IA.L!
MP4CC+)IX@/_@I&\$?-;*-]>ND"AT!3OX0!8.MJ?G?"/LN?T^Y+T?[8\TJB(<
M58?D?",@K>4/%OQ]E(!*4$>@L:94_/1/>GTW*=18XRV>P-LA*=08^%R8]7PN
M) K,9]UZT>A3DJX\2*QQ&!_R[,A$"C4&<!>9Z4A % 2N,:21&$^<3#XI@1I#
MSY#X9G(/5#'';CC6;(RG/@=P4 (UGM[0H9)QE)IQ,;ZA^\+D:6QOVK@U(E#-
M.&Z-OQC'WR%;I1C FQDC)AF'J/$7X_C[EJG3&& @M1X- %1^X/I$L"9EC)/R
M6^=.^\L/G8Y;.29 1#W/7-#.!E_\L);E;?L%&I6*1*&G^W:$W;N[+^FX:+^:
MPGC_#7TY[[YJ0U?3??/'^Z2\3?.*9'*EJO1>-,<89?=E&MV+NMBT7R]Q4]1U
ML6Y_O)/)4I:-0/U^513UXXOF KNO-#G_+U!+ P04    " "%A%920_3M.-T$
M  #)%   &0   'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6R]6-]OZC84?K[[
M*RQTI]TK]4+L)!2N*%);6JW3[89:=7N8]F 2 UZ=F#D.%&E__&PG)($DANI.
MO("3G._\M+]SDM&&B]=D28@$;Q&+DZO.4LK5UUXO"98DPDF7KTBLGLRYB+!4
MEV+12U:"X-" (M9#CM/O19C&G?'(W)N*\8BGDM&83 5(TBC"8GM#&-]<=6!G
M=^.)+I92W^B-1RN\(,]$OJRF0EWU"BTAC4B<4!X#0>97G6OX]=YU-,!(_$[)
M)JFL@0YEQOFKOG@(KSJ.]H@P$DBM JN_-;DEC&E-RH]_<J6=PJ8&5M<[[?<F
M>!7,#"?DEK,_:"B75YU!!X1DCE,FG_CF9Y('Y&M] 6>)^06;7-;I@"!-)(]R
ML/(@HG'VC]_R1%0 L-\"0#D G0IP<X!["/!: %X.\$X%^#G /Q70SP%]D_LL
M62;3$RSQ>"3X!@@MK;3IA2F70:L$TUCOK&<IU%.J<'(\S39) G <@M_DD@AP
M0V(RIQ),&5;WOX!?L1!8UQ]\FA")*4L^J[LOSQ/PZ>-G\!'0&#Q2QK2644\J
MG[3F7I#;O\GLHQ;[$Q)T@0LO '*0TP"_/1D.APWPB1W^"XZ[P'&-==@ OSO!
M.AJV6K\_Q7G'P ?[\)XJ8U%+5-02&7UNJ[ZYNA/N%1!,:!(PGJ2"@#^_J<?@
M09(H^<MBSBW,N<:<U[IU1$!BJ?@'\#D(N! TY$*O%XKC)#%+15>OBA_7F*5&
M#"<)D4W[9&(W!IVNX_QH\=HKO/:LBJZ#((U2IOP+P2Q/%)\QNL"&Z=)XGL:A
M>K;2N[_)STR];]1KWEZ/!P-';=UU==_4A3RW(K3GN5]X[MOS+?C?BH\;_;XX
MP?%,>[_BT[#N>%W(1VV.]PO'^W;']3Z\;BU\OV;2\VI^U86&;6Y=%FY=6MVZ
MQU24&S/@T0K'VY\2O8K43E#4&[R"D J5<[8%2\)"374ZO99=?%DK_-#K'\32
M(#/PFF,9%+$,WG46&V.1O.)]D_-V&ZCK'Y[ +!X[S.U"Z\$=%B$.K7IV[+;;
M_#J4BVHY+M28$O TEC1>@!5G--B"W01S 2*"-0FJH4B"4)W^IE9US(&LU_SP
MX4-;LWJ'@L.&L9<3Z)3MV['J?"*2YE%-ZP=_7VEE)H#G:"2P;%P0?0]#Y.CJ
MB7$'<.@?G*LF,:0RO2]VWR"&^@/=@9M.("S;(;2WJ(;IR9:<LF%![RS5*/L,
M/-)HCE2CH9$<TG6##(3^82'\6B'@H(748=ELH+W;O'2?N\>S7S8)>'F6[)=,
M#NU\><MC*>@L->.(INS\-:ZUK^?Z]ALH;$ECR;;03E8/L9K@8C-<8'8TGZ@D
M+.2<(Y^H)#,$_]]\YOKV\HF&S?E$E=G<3G&WJA.KQL14Z'I02\"_X!M9$P:0
M6KV/.E!)2<@]2[)+KD+VZ?H(=:#Z7%RCCERFFOZVZ0B5E(;LE/:\Y$)^43LZ
M @_QFB12=\SOJD')1ZA_EAJ4C(7L<ZV]!G>H/GZZ+6R!2M)"=M)ZQ&\T2B.5
MQG<,)*@D(S0\RYMMR5+NR6.5F3#SH3,!=]&*\2TA9L963)*]-:KQF_*P\:W6
M;L<'6X)%8Y)ZE8\Z^B/?(Q8+&B> D;E2Y70O505%]MTLNY!\9;[SS+B4/#++
M)<$A$5I /9]S+G<7^M-1\?5R_!]02P,$%     @ A8164D&.U"5-!   4A0
M !D   !X;"]W;W)K<VAE971S+W-H965T.# N>&ULO5A=;]LV%/TKA-"'%I@M
MD?JP5=@&DAC!,JRKER#=P[ 'QJ)MKI3H453< ?OQ(R5%DB5*KMT@+[8HG7M]
M[B%U+LW9@8NOZ8X0";[%+$GGUD[*_4?;3M<[$N-TS/<D44\V7,18JJ'8VNE>
M$!SE03&SD>,$=HQI8BUF^;V56,QX)AE-R$J -(MC+/Z])HP?YA:T7F[<T^U.
MZAOV8K;'6_) Y.-^)=3(KK)$-"9)2GD"!-G,K2OX\0:%.B!'?*'DD#:N@2[E
MB?.O>G 7S2U',R*,K*5.@=77,[DAC.E,BL<_95*K^DT=V+Q^R7Z;%Z^*><(I
MN>'L#QK)W=R:6B B&YPQ><\//Y.R(%_G6W.6YI_@4&(="ZRS5/*X#%8,8IH4
MW_A;*40C 'H] :@,0-\;X)8!;EYHP2PO:XDE7LP$/P"AT2J;OLBUR:-5-331
MT_@@A7I*59Q<K(H920%.(O!9[H@ UR0A&RK!BF%U?P3NDF*U:-7O"<.21$!R
MH+ 5]/,3H]L"H?/H1[>8"O %LXP OLES@:LT)3(%[Y=$8LK2#RKWX\,2O'_W
M ;P#- &?*&.:R\R6JC+-SUZ755P75:">*G[!R1@X[D\ .0@:PF^&PY=D/08H
MU.$P/ ZWE9Z5J*@2%>7YO)Y\OV>8T0U5.A4:_@<>QP_C8C"0WJW2NWEZMY?N
M1MV)CB8*+&FZ9CS-! %__JH>@SM)XO2O@9_SJI_S!JMIS)UI9HI@/P_6IO&\
M0+[O>S/[N3D!!A1TPVF%.F+F5\S\86:"_ZWLH"%%O1!-5(MLP1%5+PA:5 TH
MY+B>F6I040T&J5ZMUUF<%2_/]Y$-NC0\Z$];9+LH&$Y=:"8[J<A.7E7728?$
MM,VS"QD%;F"F.:UH3E]9TVE7+3=LS[\!Y <3,]6PHAH.4OV-)Z,+70$ZM94[
M;^$+L-$[X(\X0QG=5-)I:3T(.695FR\<=M]S5V^9[NA-FWCM!6Q"^5Z/*\#:
MRJ'[RFNX3'AL#*'?IFM 0>CWT*U; 3S1"\[5UNN^]R9Q3;!^=>O^ (<;Q 7J
M=MU_9)+7!.O7M^X2<+A-W&9)U#"(NT02D>1D,3OM%+6_P\F;.$7MU'#8JD\Y
MA<%S4>#!MNH&F#-UW![5:W.&P^Y\]JH.NSP\OTO7 %.['F2FBVJ?1\XKK^HR
MX7'C0[#MQB88=+P>1T9UGT G^L29^J)N5QC!T.G0-<%<%/;0;>S>AQO(!?IV
MF\/(#\(V7P,*N3T["U2W$#3<0AZ3S8^X!JK-'WEOX1JHMF]T8G\_[!JH:\*=
M)3($.695>S0:]NBS5W-WC^Y[[89B 'F3GK]'J/9Y-+R1OV E=S?J7NBVR1I
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M]:*XCA0#Q;/\"C#C2E\H\M>UOL*!,!OT^I)S]3HPMXKJ4AC] 5!+ P04
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M\7T=9Y SW9,E%+B22I4S@U.U\G6I@"4.E L_I'3@YXP7WG3L; LU'<O*"%[
M0A%=Y3E3=V<@Y'KB!=Z]X8*O,F,-_G1<LA5<@OE1+A3._)8EX3D4FLN"*$@G
MWFEP,@M""W [?G)8ZXTQL:$LI;RRD_-DXE&K" 3$QE(P_-W #(2P3*CCNB'U
M6I\6N#F^9__H@L=@EDS#3(I?/#'9Q#OV2 (IJX2YD.M/T 1T9/EB*;3[DG6S
MEWHDKK21>0-&!3DOZC^[;1*Q 0CZ>P!A P@?"X@:0.0"K96YL.;,L.E8R351
M=C>RV8'+C4-C-+RP9;PT"E<YXLQT45=$$U8DY)O)0)$S*"#EABP$0_M[,I-Y
MR8J[U^0"#%> -:S7R*G6V&>G0LB8U35!CN],K;:LFKR9@V%<Z+=CWZ!DZ]B/
M&WEGM;QPC[S/K.@1&KTC(0V#'?!9-WP.<8^$(PL/1MMP'Q/59BMLLQ4ZOF@O
M7XJ69"M%9,YU+*2N%)#?7W"9G!O(]9\.=U'K+G+N^GN+HV*;;9EN)%SORF(W
M3T!IC])7N_+W'\"M4/IM*/U.IG_:8E<4W12'Q1RU8HXZF3Y<5]S<$0UQI;CA
MH#LX!RWGX"5:8]BZ&SY3:W3S# ;[.J,;-^P?J,5Q&\CQTQNCFV(P/*!EU&H9
M=1+-86D>UQ4!?3A?Z4OT1;!QH ?/U!D'B*(=)6X.W6Y@N*.GMH-Y.&^#\.G=
M<8 CBO;)\3?N3?MH^8K>.%Y8 E)DHKTA'B.J?@?4$R-+=Y4NI<&+V0TS?#N!
MLAMP/972W$_L[=R^QJ9_ 5!+ P04    " "%A%92PX5SV_4&  #O,@  &0
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MFK]6N#U!.P-\7RIE]X)ST.WC[!]02P,$%     @ A8164C2,B1S? P  BPX
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MD80#=A=@@X"G%MAIP$_8Q3V[^+7E(?=$30Q'DC_I=2<_D_PV5[6*PB-R?A+
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M..#SM1!ZMS'74?-!-/T-4$L#!!0    ( (6$5E(;V\_8EP4  /4<   9
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MO +(WU>,B<>;:H#VI'/^/U!+ P04    " "%A%92IV05RV\"  #B!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6R-5$UOVS ,_2N$T4,+M+%CI^D'
M$@--O&$=T*%HU^TP[*#83"Q4EC))B=M_/TIVO+1(LEYLB>)[)$7QC6JEGTV)
M:.&E$M*,@]+:Y748FKS$BIF>6J*DD[G2%;.TU8O0+#6RPH,J$<91- PKQF60
MCKSM7J<CM;*"2[S78%95Q?3K!(6JQT$_V!@>^**TSA"FHR5;X"/:I^6]IEW8
ML12\0FFXDJ!Q/@YN^M?9P/E[AQ\<:[.U!E?)3*EGM[DMQD'D$D*!N74,C'YK
MG*(0CHC2^--R!EU(!]Q>;]@_^]JIEADS.%7B)R]L.0XN RAPSE;"/JCZ"[;U
MG#N^7 GCOU"WOE$ ^<I85;5@RJ#BLOFSE_8>M@#]X1Y W +B]X#!'D#2 I*/
M @8MP%]UV)3B[R%CEJ4CK6K0SIO8W,)?ID=3^5RZMC]:3:><<#:]E1:U9*X'
M3,!TI37*_!6^:R:-\&8X@V],:^;Z \<96L:%.2'KTV,&QT<G< 1<PAT7@IS-
M*+24E>,.\S:#29-!O">#?@QW2MK2P"=98/&6(*1RNIKB34V3^"#C5R9[$"6G
M$$=Q?T="T\/P#/,>Q%<.WK_: <\^ $\B#[\\4$W2=2CQ?,D>/GK>]'CE[M[\
MNID9JVEX?A^(-.@B#7RDP7\BY9M(UD5BS8 N2$+@6"AC3DYAAB0X"):][.IW
M$^7<1W&RLT[/XHAN<KW=@UU.PXNW3ME.I_/.J:DRW'K]%>J%5Q$#N5I)VSR:
MSMH)U8V?SW?V"0E8HS?_:!KUNV-ZP:4!@7.BC'H7E))N%*796+7T,S93EB;6
M+TL28=3.@<[G2MG-Q@7H9#W]"U!+ P04    " "%A%92(?G_.J8#  #4"P
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M**3*A,#ZYP6V0*F)I//XIP[JM',:8_>ZB?[5PFN8/9:PY?1ODJE\Y<0.RN"
M3U0]\O,O4 /-3+R44VG_HW.M]1R4GJ3B16W6&12$5;_XM5Z(CL&/;AB"VA#T
M#=,;AK VA#]JF-:&J5V9"L6N0X(57B\%/R-AU#J:N;"+:=T:GS!3]R<E]%.B
M?6K]!0M&V%&B'0CTE&,!Z!-ZA)2SE%"";6WX 6VP)"GZ0^_#UE"V!L510NA)
M079+\2$!A0F5'W7PGY"+I!F5S0]AZ(%0JJ>22U=I*).:F]8 FPH@N '@!^B!
M,Y5+](5ED%T&</5JM$L2-$NR"48C_H;9!'GASRCP G\@H>VX/8%T@H*%L?N+
M 7OR _;0L_9XA"9L"QS:>.&->->UW-M:,ETIZ%9*-K7,ZEH.*T92FK8I36U*
MTQLI;<82^*!W0\8IQ:(S^G%H7U23S.TDYGA[6<\F,[WB+]U:#8GFP:4H&12U
MF@O&6<LX&V6\?P&AS\UFB^L35RK,,@W[_IT?>9_?OXL#/_A<%\- 5\I!TFJJ
MN)-?$(7!).ZQ#LFFLXG?HQV2Q?YD-@P<M<#1*/".*V"*8-H@PRN(E$B\IX!.
M^M74I50\?4:\M!NQI)C)M\"CJU1]/YZ$/>X!51CU54FEBBY4BV'F><L\'V7^
M':2\:W@%E">1YOH;E-6\2G^(Y4E\J\$+4#G/WD*>7\%\BKW)U.O\]0JZ'; L
MYOW=D0RI@EM5C]L5B$=78,N9WNB*F")GL%?-8KP!&5_5PNLQQ5?9>IU7LB(:
MUUSP+%J>Q?]\;?67JSD8WX!;#+Q?\ZOLMT.R>'JU;0=D\R"^Q>E[W[_[WBAI
M,GK*_X=CN)ZG=P[W]^B@*NK##JO\'JO;:7<*$$?;-DJ4\A-3U6>^'6U;TWO;
MD/7&-Z9EM6W4]S!5O_N Q9'H\XG"08?4Q=.'IJA:R.I&\=(V57NN=(MF+W/=
M=H,P OW\P/5Y6-^8"=I&?OTO4$L#!!0    ( (6$5E+J P<UG (  %<&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;(U5;6_:,!#^*Z=H'UJI(R]
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M\PVKEO"_J"L8E:J2]M@#J 5<>P%N&&V&\4T416FX.:*[W^KNG]7]("W28[2
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M00.C10;Y#8PVF;$=X[3".'5B_*X[ (D WQ$F.QJP(2RA!2"Q-WX;:/>\4&K
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M;Z,X%,>_BA7E84;J +YP&Z61VF96NZ,=337=RS--G 0-X"R07K[]&N-@*.#
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MF?@/GF59:P;6QRQGL33F$<1A4OX&+U*(F@$B/09(&J W!K#/ $L#_+8&N\>
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MQVU:?N=0GN3L(-[\/[(\9[$XW--@0].B +^_92P_G1055%^;+/\'4$L#!!0
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M1@5I#YC_.R'TT\(2U%/OXG]02P,$%     @ A8164DQSI/2P,0  ]J\! !D
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MYT-L\JKW^?;FL+MZ:%Q^!U?K[?V?J_\\?!*H@3">!O*A@;0;@*>!>FB@NC:
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M(!@<PJ_3LT4IS&<C2P6B)8@LAK%"S 21!3%6F6N9A+0!!2,R#)1SA"(CMIQ
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MT,5OL\GD12(%!+> &' +0' +" *W ():D=I0\Q$5E64VV@((M$7N>QD 1+:
M&&0+KI-CG8GOH#_;5A)-K>$:--RG^;'E?'C^;O@RH::H]PCF"Q#= H+0+8#
M5@@#]L8 '6;#_,= T"V$SCV'5@#1+2 &W8+KI.^GH'--%;-("XAN 4^D6RS.
MIK-)[R^KJ^M_/AR3?HEF$>H"8J N *$N( CJ @B(1:DR>\& #,N%_:X*!.Q"
MY,JSG06(=@$Q:!=<)\?YU=U'K3X!]LZ_C)E?$? "G@B\&([?#V>CR?B9'']
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M"O@ $2D@!I&"ZZ0O_ +EFB:\0%'^8Y 4L]WVO\\7K0]#Z2<&00(000*"$"2
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M?PP$ B+W7>$,B  !,0@07"?>JR"YAH*Y4QP0^P$8]H-?G<\_)P\(_0 QT ^
MT \0!/T !-5!**=,E P#G3DZI4[,>3<>$?\!8O ?N$[ZQGM2GFVJV;URQ'\
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M<M)[YI)U<&6O-124?A@,0R"!<EP=?XT/US1ER\T0ID$S%(1:H_=\K2 40XW
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M, P.(I V.?,C6K39WA:8<RD& 2,,@V2HM?G'>MN[O.-Q#]X4J]O#]V[P8X.
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M:\*:@AB@+!#6%,0QR@+A)_+0@1X$ P[T(%C_@9ZPCB/"C@,RM,?YDN@\&#)
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M[@$Q:V\C1IR8SN*V(0?;:6&<$8_?7$OM<<#O<CK;<V!<25N91HQ0Y-2EVN6
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MDZ[^/:E]43+DE7M2>XNDCROWQ+Y,3Y*P;489J5C%T-90.[;1H!U7[@E).3[
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MYD) 2#"%X9#7'1 21&#XIUZ,CW?]-S'-[M=#<("AW[B:U^!;(\5_PY#[;F@
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MC9=UJC MDW&(&$P"/,?."QNII0#& 0*5!@$K+5O=>WB.=SCBS@8%3 -!3(,
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M"=\""G0&75662>6VB]^Q8ABV4V>1*_>>)8[K%21T"BC0*?2DLOY!?#L H2F
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M!\$,<0)$+GX:),0)> CB!&D0C)RG;')+P?H0W@04>!/<BKL?#@0)6P(.RI:
MA"T!>V%+0(X&@;F_X,0BU29:1(8M(75&@H0L 0]!EB -HF(7!YC4,E&BVA(/
M)K EB+'@HPXS"'\"#LJ?@(0_ 7LI.8],-?E867LW1DK;:?I<S7E7)5,DS IX
MB*KSTB" $AR)\#&@4#]^5)1W13E9Y4^"2B6W4_1V3OS0H$7CD= CH, _<%]#
MR:QP,UP@U<-$IC9\'"N+7P:9\O Z35+711DA.4"!Y(!_,<8J_)PO\LUU_$[
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( (6$5E+?; T^^08  -A#   /
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MYV(E_9=RGW*ZV'W!WI&1<-FWRKUA3Q<#(R>/[DRC%N[3%]&1:(2N933$L2.
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M4[T=0&^G>CN WD[U=@"]G>KM 'H[U=L!]/:JMP?H[55O#]#;J]X>H+=7O3U
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MG>X[%1^GSWT_WHJ^UE7 =YH]73[;W[[_NORZ6-\P5Z;;^XSQZ2]02P,$%
M  @ A8164H1UFX=C @  83H  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=O?
M;ILP%,?Q5XFXK0+88 -3TYMVMULO]@(,G :%?[+=+GW[.:2MM*F+5F72OC=!
MB>WS._A(G[M<?WN>C5L=AGYTFVCG_?PI25RS,T/MXFDV8UC93G:H??AJ'Y*Y
M;O;U@TEDFNJDF49O1K_VQQK1S?6=V=:/O5]]/H2?73>-F\B:WD6KV]/&8]8F
MJN>Y[YK:A_7D:6Q_2UF_),3AY++'[;K9784-4?)NPG'ESP$OY[X^&6N[UJSN
M:^N_U$/8E1SZQ/GGWKCX?(EW>IRVVZXQ[=0\#N%([&9KZM;MC/%#'Y^*7IU/
M]N&&S>E37)R_E#D7&';>VVEV86+6?#SN=23'T^LY%#+6=^=?\2TQE+[X_<QQ
MVJUI_S([7.^/R>Z7>;AD>5Q^Q[_.^*W^!_N0D#XR2!\YI \%Z4-#^B@@?920
M/BI('R*E-$(155!(%113!05505%54%@5%%<%!59!D5529)44625%5DF155)D
ME119)45629%54F25%%DSBJP91=:,(FM&D36CR)I19,THLF8463.*K!E%UIPB
M:TZ1-:?(FE-DS2FRYA19<XJL.476G")K3I%54615%%D5159%D5519%44615%
M5D6155%D5119-45639%54V35%%DU159-D5539-44635%5DV1M:#(6E!D+2BR
M%A19"XJL!476@B)K09&UH,A:4&0M*;*6%%E+BJPE1=:2(FM)D;6DR%I29"TI
MLI8462N*K!5%UHHB:T61M:+(6E%DK2BR5A19*XJL%456D5)H%2G%5I%2<!7I
M_]3U^S3M_W'\\HR'NAM?\Y/EGZ4W/P%02P$"% ,4    " "%A%92!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( (6$5E();E<G[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (6$5E*97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MA8164G<J$E<-!P  R24  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (6$5E+\"\MWN <  #$@   8
M          " @5$/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " "%A%92=AOQZ=T"  !V"   &               @($_%P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ A8164G(85JTV!0  V!,
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M965T."YX;6Q02P$"% ,4    " "%A%92"\8-1E,*  !!+@  &
M    @('-+P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MA8164H)D02N#)0  K7$  !D              ("!5CH  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " "%A%92+ZO_W= %  !0#P  &0
M            @($08   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( (6$5E+E.(0)>P(  $H%   9              " @1=F  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ A8164C!/BS8Y!
M" H  !D              ("!R6@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " "%A%92=I5 ?OL%  !Q#@  &0              @($Y
M;0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (6$5E(2
M5>L)[A$  "P\   9              " @6MS  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ A8164C.KT*$B"   2A4  !D
M     ("!D(4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (6$5E(%*W^7#P0  *@)   9              "
M@4O   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ A816
M4D&!=)IP!   )@H  !D              ("!D<0  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " "%A%923\4Y7E4$  !["@  &0
M        @($XR0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( (6$5E)LJ:\.$@0  %P+   9              " @<3-  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ A8164GJ=L;.%"P  K"$
M !D              ("!#=(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " "%A%92R+G3 .(4  #6-0  &0              @(')W0
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (6$5E+^]!<J
MS0T  -@O   9              " @>+R  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ A8164F//:J22)P  E8<  !D
M ("!Y@ ! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "%
MA%92#VIALV\&  "E#@  &0              @(&O* $ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (6$5E)ZBT9'Y2,  #]R   9
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M970S-"YX;6Q02P$"% ,4    " "%A%92P0; HW8%   D#0  &0
M    @('A8@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M (6$5E+Y*<<S5 D  .T>   9              " @8YH 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ A8164E_RAZXO!@  ^@\  !D
M             ("!&7(! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " "%A%92JV.F6Q8(  "#$P  &0              @(%_> $ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( (6$5E( _-V_V (
M "P&   9              " @<R  0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ A8164O10'8?N#0  OBD  !D              ("!
MVX,! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "%A%92
M!#ZI0?<"  #%!@  &0              @($ D@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( (6$5E*@LWAL7 ,  /8&   9
M      " @2Z5 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ A8164E[48E]! P  ,P<  !D              ("!P9@! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "%A%92D%W<(-H%  "G#@
M&0              @($YG $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( (6$5E(39V6'414  %\W   9              " @4JB 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ A8164@TW/48+
M!   :P@  !D              ("!TK<! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " "%A%92IY/H@O8&  "*'P  &0
M@($4O $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (6$
M5E*%IUEXZ@,  #,1   9              " @4'# 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ A8164@\6L2 ) P  APP  !D
M         ("!8L<! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    " "%A%92#+9:I& '  !Y,   &0              @(&BR@$ >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( (6$5E*Q"3.5K0(   \(
M   9              " @3G2 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ A8164KV??]1D @  - 8  !D              ("!'=4!
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "%A%92/*@0
M$0(#  #?"   &0              @(&XUP$ >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( (6$5E(UJY:JH@(  +H&   9
M  " @?': 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MA8164B+Y<[_.!   1A4  !D              ("!RMT! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " "%A%92#5P<)Q0$   K$0  &0
M            @('/X@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( (6$5E++W+'#Z (  ,((   9              " @1KG 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ A8164LX*'PAI @
MP@8  !D              ("!.>H! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " "%A%92H4K8T-\&  "B'0  &0              @('9
M[ $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (6$5E+O
M66A0&P8  ",K   9              " @>_S 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ A8164N"/[\NX @  )P8  !D
M     ("!0?H! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (6$5E*WRD9ZW@(  "X'   9              "
M@1$A @!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ A816
M4D^6C19/ @  %08  !D              ("!)B0" 'AL+W=O<FMS:&5E=',O
M<VAE970V-RYX;6Q02P$"% ,4    " "%A%92*C+A])4#  "@#   &0
M        @(&L)@( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0
M   ( (6$5E(SV<X(5@0  - 0   9              " @7@J @!X;"]W;W)K
M<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ A8164N+>)N^V!   3!$
M !D              ("!!2\" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q0
M2P$"% ,4    " "%A%924'C,G5@#  "]"@  &0              @('R,P(
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( (6$5E)$O.%'
M] <  (LI   9              " @8$W @!X;"]W;W)K<VAE971S+W-H965T
M-S(N>&UL4$L! A0#%     @ A8164@A@_F3H @  C@@  !D
M ("!K#\" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " "%
MA%92=UIE51T"  ".!   &0              @('+0@( >&PO=V]R:W-H965T
M<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( (6$5E+^=*0[=P0  %T3   9
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M970W.2YX;6Q02P$"% ,4    " "%A%9208[4)4T$  !2%   &0
M    @($*8@( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    (
M (6$5E(EXP-Q$@,  " *   9              " @8YF @!X;"]W;W)K<VAE
M971S+W-H965T.#$N>&UL4$L! A0#%     @ A8164E89UC]W @  3P8  !D
M             ("!UVD" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"
M% ,4    " "%A%92\+JL!:8"  "9"0  &0              @(&%; ( >&PO
M=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( (6$5E+#A7/;]08
M .\R   9              " @6)O @!X;"]W;W)K<VAE971S+W-H965T.#0N
M>&UL4$L! A0#%     @ A8164N4V?YI, @  FP4  !D              ("!
MCG8" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " "%A%92
M-(R)'-\#  "+#@  &0              @($1>0( >&PO=V]R:W-H965T<R]S
M:&5E=#@V+GAM;%!+ 0(4 Q0    ( (6$5E+G*,XL$ ,  !P)   9
M      " @2=] @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%
M  @ A8164AO;S]B7!0  ]1P  !D              ("!;H " 'AL+W=O<FMS
M:&5E=',O<VAE970X."YX;6Q02P$"% ,4    " "%A%92IV05RV\"  #B!0
M&0              @($\A@( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+
M 0(4 Q0    ( (6$5E(A^?\ZI@,  -0+   9              " @>*( @!X
M;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ A8164NH#!S6<
M @  5P8  !D              ("!OXP" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,2YX;6Q02P$"% ,4    " "%A%921*K$C4@'   ')0  &0
M@(&2CP( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( (6$
M5E)9%5ADX@(  " )   9              " @1&7 @!X;"]W;W)K<VAE971S
M+W-H965T.3,N>&UL4$L! A0#%     @ A8164A6="]U:!   $1   !D
M         ("!*IH" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4
M    " "%A%92H7%0$/<%  !Y(@  &0              @(&[G@( >&PO=V]R
M:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( (6$5E*4CD3*9 ,   $+
M   9              " @>FD @!X;"]W;W)K<VAE971S+W-H965T.38N>&UL
M4$L! A0#%     @ A8164DQSI/2P,0  ]J\! !D              ("!A*@"
M 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " "%A%92OVV&
M/5\)  "&.0  &0              @(%KV@( >&PO=V]R:W-H965T<R]S:&5E
M=#DX+GAM;%!+ 0(4 Q0    ( (6$5E*JPOAY+!L   /:   9
M  " @0'D @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @
MA8164E537IVC"P  4$$  !H              ("!9/\" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,# N>&UL4$L! A0#%     @ A8164H?T;9A6!0  @QH  !H
M             ("!/PL# 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L!
M A0#%     @ A8164NL)[U2F!0  ^1\  !H              ("!S1 # 'AL
M+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ A8164KM]G$C*
M!0  7"(  !H              ("!JQ8# 'AL+W=O<FMS:&5E=',O<VAE970Q
M,#,N>&UL4$L! A0#%     @ A8164L>L /2C @  ,A    T
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;72YX;6Q02P4&     &\ ;P"$'@  02T#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1060</ContextCount>
  <ElementCount>654</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>251</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144109 - Disclosure - Employee Related Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligations</Role>
      <ShortName>Employee Related Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148110 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2160111 - Disclosure - Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsPlan</Role>
      <ShortName>Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2162112 - Disclosure - Capital and Treasury Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStock</Role>
      <ShortName>Capital and Treasury Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2166113 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2169114 - Disclosure - International Currency Translation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalCurrencyTranslation</Role>
      <ShortName>International Currency Translation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2171115 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2175116 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2182117 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2187118 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2189119 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2191120 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Borrowings</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Employee Related Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsTables</Role>
      <ShortName>Employee Related Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EmployeeRelatedObligations</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2349310 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2363311 - Disclosure - Capital and Treasury Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockTables</Role>
      <ShortName>Capital and Treasury Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CapitalandTreasuryStock</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2367312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2372313 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2376314 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2383315 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2392316 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails</Role>
      <ShortName>Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Intangible Assets and Goodwill - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails</Role>
      <ShortName>Borrowings - Schedule of Long-term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails</Role>
      <ShortName>Borrowings - Aggregate Maturities of Long Term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Temporary Differences and Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails</Role>
      <ShortName>Employee Related Obligations - Employee Related Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Employee Related Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails</Role>
      <ShortName>Employee Related Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2457436 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2458437 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2459438 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - Savings Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsPlanNarrativeDetails</Role>
      <ShortName>Savings Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2464440 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails</Role>
      <ShortName>Capital and Treasury Stock - Changes in Treasury Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2465441 - Disclosure - Capital and Treasury Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails</Role>
      <ShortName>Capital and Treasury Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2468442 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2470443 - Disclosure - International Currency Translation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails</Role>
      <ShortName>International Currency Translation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2473444 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails</Role>
      <ShortName>Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2474445 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2479448 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2480449 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2481450 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2484451 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2485452 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2486453 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2488454 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2490455 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2493456 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="jnj-20210103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2494457 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails</Role>
      <ShortName>Restructuring - Summary of Severance Charges and Associated Spending (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="jnj-20210103.htm">jnj-20210103.htm</File>
    <File>ex21-subsidiariesxform10xk.htm</File>
    <File>ex23-pwcconsentxform10xkx2.htm</File>
    <File>ex31-jjexcessplanx2020rest.htm</File>
    <File>ex311-302certofceoxform10x.htm</File>
    <File>ex312-302certofcfoxform10x.htm</File>
    <File>ex321-906certofceoxform10x.htm</File>
    <File>ex322-906certofcfoxform10x.htm</File>
    <File>jnj-20210103.xsd</File>
    <File>jnj-20210103_cal.xml</File>
    <File>jnj-20210103_def.xml</File>
    <File>jnj-20210103_lab.xml</File>
    <File>jnj-20210103_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20210103_g1.jpg</File>
    <File>jnj-20210103_g10.jpg</File>
    <File>jnj-20210103_g11.jpg</File>
    <File>jnj-20210103_g2.jpg</File>
    <File>jnj-20210103_g3.jpg</File>
    <File>jnj-20210103_g4.jpg</File>
    <File>jnj-20210103_g5.jpg</File>
    <File>jnj-20210103_g6.jpg</File>
    <File>jnj-20210103_g7.jpg</File>
    <File>jnj-20210103_g8.jpg</File>
    <File>jnj-20210103_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>134
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20210103.htm": {
   "axisCustom": 1,
   "axisStandard": 47,
   "contextCount": 1060,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20210103_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20210103_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20210103.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20210103_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20210103_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20210103.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 1064,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 6,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 10
   },
   "keyCustom": 97,
   "keyStandard": 557,
   "memberCustom": 156,
   "memberStandard": 77,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20210103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.jnj.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488454 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i29ae50e5d88b4f2faf456858615a5efb_I20210103",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2490455 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i29ae50e5d88b4f2faf456858615a5efb_I20210103",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2493456 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2494457 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)",
     "role": "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
     "shortName": "Restructuring - Summary of Severance Charges and Associated Spending (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i57c8bafe3cd14d5c9e1491d8bbf1f32f_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Borrowings",
     "role": "http://www.jnj.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144109 - Disclosure - Employee Related Obligations",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligations",
     "shortName": "Employee Related Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148110 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SavingsPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160111 - Disclosure - Savings Plan",
     "role": "http://www.jnj.com/role/SavingsPlan",
     "shortName": "Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SavingsPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162112 - Disclosure - Capital and Treasury Stock",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStock",
     "shortName": "Capital and Treasury Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166113 - Disclosure - Accumulated Other Comprehensive Income (Loss)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Accumulated Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169114 - Disclosure - International Currency Translation",
     "role": "http://www.jnj.com/role/InternationalCurrencyTranslation",
     "shortName": "International Currency Translation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171115 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175116 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2182117 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2187118 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2189119 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2191120 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Borrowings (Tables)",
     "role": "http://www.jnj.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.jnj.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Employee Related Obligations (Tables)",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsTables",
     "shortName": "Employee Related Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349310 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363311 - Disclosure - Capital and Treasury Stock (Tables)",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockTables",
     "shortName": "Capital and Treasury Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372313 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2376314 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2383315 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2392316 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i56111d6a08484b6890ddf01b41cb16b0_I20180101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i172e28d99e7b4636b5bf1e3bb60c3e46_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i172e28d99e7b4636b5bf1e3bb60c3e46_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
     "shortName": "Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i6a63a2948df54bb087c11ba82ffaf3fb_I20191229",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Intangible Assets and Goodwill - Amortization of Intangible Assets (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i504dd38a7aa842119593f0983c422c2d_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i504dd38a7aa842119593f0983c422c2d_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i7f5f27a8783b49c09ce94e0b992e4d45_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i7f5f27a8783b49c09ce94e0b992e4d45_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "role": "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
     "shortName": "Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ia4a277a5e8eb4225adece7896cfdfc52_I20200927",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ExcessOfFairValueOverCarryingValueOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.jnj.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ExcessOfFairValueOverCarryingValueOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "role": "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails",
     "shortName": "Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ia22df427a71c4e69b4499cded92f3f76_I20171231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "iced5cdc4242a49e886f089e2363899f7_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails",
     "shortName": "Income Taxes - Temporary Differences and Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i6a63a2948df54bb087c11ba82ffaf3fb_I20191229",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
     "shortName": "Employee Related Obligations - Employee Related Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Employee Related Obligations - Narrative (Details)",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails",
     "shortName": "Employee Related Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAmendments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
     "shortName": "Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "if991d6ef992c4c638b1341f3c39b23b2_D20191230-20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails",
     "shortName": "Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAmendments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails",
     "shortName": "Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "iac551cea27e04d75bcc80f2411447fe0_D20181231-20191229",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
     "shortName": "Pensions and Other Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i1b800eebfb2649a48e2c884cbf2aef11_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
     "shortName": "Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i1b800eebfb2649a48e2c884cbf2aef11_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i665364f0420d4c8a8fa01d3fb66d199d_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i665364f0420d4c8a8fa01d3fb66d199d_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457436 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails",
     "shortName": "Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458437 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
     "shortName": "Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i665364f0420d4c8a8fa01d3fb66d199d_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459438 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
     "shortName": "Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9677b9c0aeab4d24bd7207a87355007d_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - Savings Plan - Narrative (Details)",
     "role": "http://www.jnj.com/role/SavingsPlanNarrativeDetails",
     "shortName": "Savings Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i6a63a2948df54bb087c11ba82ffaf3fb_I20191229",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464440 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
     "shortName": "Capital and Treasury Stock - Changes in Treasury Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ia22df427a71c4e69b4499cded92f3f76_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465441 - Disclosure - Capital and Treasury Stock - Narrative (Details)",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
     "shortName": "Capital and Treasury Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i7d47ca3aeb654a86ad3c3ad675822c76_I20181230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i6a63a2948df54bb087c11ba82ffaf3fb_I20191229",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468442 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "id395e3d2f83144c69ca528af2dc9b6b9_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470443 - Disclosure - International Currency Translation - Narrative (Details)",
     "role": "http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails",
     "shortName": "International Currency Translation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473444 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails",
     "shortName": "Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-5",
      "lang": "en-US",
      "name": "jnj:PotentialSharesExercisableUnderStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474445 - Disclosure - Earnings Per Share - Narrative (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i6a63a2948df54bb087c11ba82ffaf3fb_I20191229",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479448 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ia22df427a71c4e69b4499cded92f3f76_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480449 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i2c4f2d96d955450db33852d746bfba34_I20210103",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ia7b2cf13619f4c189b475866e1db542f_I20191229",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481450 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ia7b2cf13619f4c189b475866e1db542f_I20191229",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484451 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i7c4454b8a7d54ee1860064a2fa909c21_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485452 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "i9154cf2376e64b2aad6121cd9ea9dbc7_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486453 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210103.htm",
      "contextRef": "ic237bdc13a0649a8be7c56b4adcf0e6c_D20181231-20191229",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 251,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S. Plans"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.250NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.250% Notes Due 2022 [Member]",
        "label": "0.250% Notes Due 2022 [Member]",
        "terseLabel": "0.250% Notes due 2022 (1B Euro 1.2281)(2)/(1B Euro 1.1096)(3)",
        "verboseLabel": "0.250% Notes Due January 2022"
       }
      }
     },
     "localname": "A0.250NotesDue2022Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A055NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.55% Notes due 2025",
        "label": "0.55% Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025(5)"
       }
      }
     },
     "localname": "A055NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.2281)(2)/(1.5B Euro 1.1096)(3)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.65Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Notes due 2021 [Member]",
        "label": "1.65% Notes due 2021 [Member]",
        "terseLabel": "1.65% Notes due 2021"
       }
      }
     },
     "localname": "A1.65Notesdue2021Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.950Notesdue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.950% Notes due 2020 [Member]",
        "label": "1.950% Notes due 2020 [Member]",
        "terseLabel": "1.950% Notes due 2020"
       }
      }
     },
     "localname": "A1.950Notesdue2020Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A130NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.30% Notes due 2030",
        "label": "1.30% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A130NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.05Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.05% Notes due 2023 [Member]",
        "label": "2.05% Notes due 2023 [Member]",
        "terseLabel": "2.05% Notes due 2023"
       }
      }
     },
     "localname": "A2.05Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.25Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Notes due 2022 [Member]",
        "label": "2.25% Notes due 2022 [Member]",
        "terseLabel": "2.25% Notes due 2022"
       }
      }
     },
     "localname": "A2.25Notesdue2022Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2021 [Member]",
        "label": "2.45% Notes due 2021 [Member]",
        "terseLabel": "2.45% Notes due 2021"
       }
      }
     },
     "localname": "A2.45Notesdue2021Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Debenturesdue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Debentures due 2020 [Member]",
        "label": "2.95% Debentures due 2020 [Member]",
        "terseLabel": "2.95%\u00a0Debentures due 2020"
       }
      }
     },
     "localname": "A2.95Debenturesdue2020Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2012LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2012 Long-Term Incentive Plan [Member]",
        "label": "2012 Long-Term Incentive Plan [Member]",
        "terseLabel": "2012 Long-Term Incentive Plan"
       }
      }
     },
     "localname": "A2012LongTermIncentivePlanMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2018AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Acquisitions",
        "label": "2018 Acquisitions [Member]",
        "terseLabel": "2018 Acquisitions"
       }
      }
     },
     "localname": "A2018AcquisitionsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2019AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Acquisitions [Member]",
        "label": "2019 Acquisitions [Member]",
        "terseLabel": "2019 Acquisitions"
       }
      }
     },
     "localname": "A2019AcquisitionsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2020AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Acquisitions",
        "label": "2020 Acquisitions [Member]",
        "terseLabel": "2020 Acquisitions"
       }
      }
     },
     "localname": "A2020AcquisitionsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.250% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.450% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.400%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.500% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2021 [Member]",
        "label": "3.55% Notes due 2021 [Member]",
        "terseLabel": "3.55% Notes due 2021"
       }
      }
     },
     "localname": "A3.55Notesdue2021Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3% Zero Coupon Convertible Subordinated Debentures due in 2020 [Member]",
        "label": "3% Zero Coupon Convertible Subordinated Debentures due in 2020 [Member]",
        "terseLabel": "3% Zero Coupon Convertible Subordinated Debentures due 2020"
       }
      }
     },
     "localname": "A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50%\u00a0Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95%\u00a0Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50%\u00a0Notes due 2024 (500MM 1.3654 GBP )(2)/(500MM GBP 1.2987)(3)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85%\u00a0Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95%\u00a0Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73%\u00a0Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95%\u00a0Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AMOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMO",
        "label": "AMO [Member]",
        "terseLabel": "AMO"
       }
      }
     },
     "localname": "AMOMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccountingStandardUpdate201616Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standard Update 2016-16",
        "label": "Accounting Standard Update 2016-16 [Member]",
        "terseLabel": "ASU 2016-16 - Income Taxes: Intra-Entity Transfers"
       }
      }
     },
     "localname": "AccountingStandardUpdate201616Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "terseLabel": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AccruedTaxesOnIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Taxes On Income [Member]",
        "label": "Accrued Taxes On Income [Member]",
        "terseLabel": "Accrued Taxes On Income"
       }
      }
     },
     "localname": "AccruedTaxesOnIncomeMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ActelionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actelion",
        "label": "Actelion [Member]",
        "terseLabel": "Actelion"
       }
      }
     },
     "localname": "ActelionMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AdvancedSterilizationProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AdvancedSterilizationProducts [Member]",
        "label": "AdvancedSterilizationProducts [Member]",
        "terseLabel": "AdvancedSterilizationProducts"
       }
      }
     },
     "localname": "AdvancedSterilizationProductsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AliosBiopharmaIncandXO1LimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alios Biopharma Inc and XO1 Limited [Member]",
        "label": "Alios Biopharma Inc and XO1 Limited [Member]",
        "terseLabel": "Alios Biopharma Inc and XO1 Limited"
       }
      }
     },
     "localname": "AliosBiopharmaIncandXO1LimitedMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-offs/Sales"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BusinessAcquisitionDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Discount Rate",
        "label": "Business Acquisition, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessAcquisitionDiscountRate",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_BusinessCombinationProbabilityOfSuccessFactor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Probability Of Success Factor",
        "label": "Business Combination, Probability Of Success Factor",
        "terseLabel": "Probability of success factor"
       }
      }
     },
     "localname": "BusinessCombinationProbabilityOfSuccessFactor",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA/Methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES/OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular/Metabolism/Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashPaidDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During The Year [Abstract]",
        "label": "Cash Paid During The Year [Abstract]",
        "terseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearAbstract",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ChangesInTreasuryStockRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in treasury stock.",
        "label": "Changes In Treasury Stock [Roll Forward]",
        "terseLabel": "Changes in treasury stock"
       }
      }
     },
     "localname": "ChangesInTreasuryStockRollForward",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ChangesInTreasuryStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in treasury stock.",
        "label": "Changes In Treasury Stock [Table Text Block]",
        "terseLabel": "Changes in Treasury Stock"
       }
      }
     },
     "localname": "ChangesInTreasuryStockTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ChangesinTreasuryStockSharesOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "label": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "terseLabel": "Changes in Treasury Stock Shares Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ChangesinTreasuryStockSharesOutstandingRollForward",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_CizHoldingsCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ci:z Holdings Co. Ltd. [Member]",
        "label": "Ci:z Holdings Co. Ltd. [Member]",
        "terseLabel": "Ci:z Holdings Co. Ltd."
       }
      }
     },
     "localname": "CizHoldingsCo.Ltd.Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commingled funds.",
        "label": "Commingled Funds [Member]",
        "terseLabel": "Commingled funds"
       }
      }
     },
     "localname": "CommingledFundsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comparison of income tax expense at the Statutory rate and Company's tax rate.",
        "label": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract",
        "terseLabel": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract"
       }
      }
     },
     "localname": "ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationOfCreditRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk.",
        "label": "Concentration of Credit Risk [Line Items]",
        "terseLabel": "Concentration of Credit Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskLineItems",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationOfCreditRiskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of Credit Risk [Table]",
        "label": "Concentration of Credit Risk [Table]",
        "terseLabel": "Concentration of Credit Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskTable",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "Consumer"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ConvertibleNoteEquityInterestNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Note, Equity Interest, number of shares",
        "label": "Convertible Note, Equity Interest, number of shares",
        "terseLabel": "Convertible note, equity Interest (in shares)"
       }
      }
     },
     "localname": "ConvertibleNoteEquityInterestNumberOfShares",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ConvertibleNoteEquityInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Note, Equity Interest, Percentage",
        "label": "Convertible Note, Equity Interest, Percentage",
        "terseLabel": "Convertible Note, equity interest, percentage"
       }
      }
     },
     "localname": "ConvertibleNoteEquityInterestPercentage",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Effect, Period of Adoption, Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Effect, Period of Adoption",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Effect, Period of Adoption",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CurtailmentsAndSettlementsAndRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase or decrease related to curtailments, settlements and restructuring.",
        "label": "Curtailments And Settlements And Restructuring",
        "negatedTerseLabel": "Curtailments, settlements\u00a0&amp; restructuring"
       }
      }
     },
     "localname": "CurtailmentsAndSettlementsAndRestructuring",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CustomersCollectionPatternsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers Collection Patterns [Axis]",
        "label": "Customers Collection Patterns [Axis]",
        "terseLabel": "Customers Collection Patterns [Axis]"
       }
      }
     },
     "localname": "CustomersCollectionPatternsAxis",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_CustomersCollectionPatternsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers Collection Patterns [Domain]",
        "label": "Customers Collection Patterns [Domain]",
        "terseLabel": "Customers Collection Patterns [Domain]"
       }
      }
     },
     "localname": "CustomersCollectionPatternsDomain",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_December172018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 17, 2018 Share Repurchase Program [Member]",
        "label": "December 17, 2018 Share Repurchase Program [Member]",
        "terseLabel": "December 17, 2018 Share Repurchase Program"
       }
      }
     },
     "localname": "December172018ShareRepurchaseProgramMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets international research and development capitalized.",
        "label": "Deferred Tax Assets International Research And Development Capitalized",
        "terseLabel": "Deferred Tax Assets, International R&amp;D capitalized for tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsOtherDomestic": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets other domestic.",
        "label": "Deferred Tax Assets Other Domestic",
        "terseLabel": "Deferred Tax Assets Other Domestic"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherDomestic",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsUndistributedForeignEarnings": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "label": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "terseLabel": "Deferred Tax Assets, Undistributed Foreign Earnings"
       }
      }
     },
     "localname": "DeferredTaxAssetsUndistributedForeignEarnings",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign",
        "label": "Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign",
        "negatedTerseLabel": "Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLossCarryforwardsForeign",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "label": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "negatedTerseLabel": "Deferred Tax Liability, Global Intangible Low-Taxed Income"
       }
      }
     },
     "localname": "DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "terseLabel": "Investments Measured at Net Asset Value"
       }
      }
     },
     "localname": "DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "terseLabel": "Interest cost discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "label": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "terseLabel": "Divestitures\u00a0&amp; acquisitions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in five fiscal years thereafter.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter",
        "terseLabel": "2026-2030"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year five.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year four.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year one.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year three.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year two.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanOverUnderFundedStatusABO": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan over (under) funded status ABO",
        "label": "Defined Benefit Plan Over (Under) Funded Status ABO",
        "terseLabel": "Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanOverUnderFundedStatusABO",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "label": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "terseLabel": "Divestitures\u00a0&amp; acquisitions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation expense including the amortization of capitalized interest.",
        "label": "Depreciation Expense Including Amortization Of Capitalized Interest",
        "terseLabel": "Depreciation expense, including the amortization of capitalized interest"
       }
      }
     },
     "localname": "DepreciationExpenseIncludingAmortizationOfCapitalizedInterest",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DiabetesCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes Care [Member]",
        "label": "Diabetes Care [Member]",
        "terseLabel": "Diabetes Care"
       }
      }
     },
     "localname": "DiabetesCareMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Receivables Retained",
        "label": "Disposal Group, Including Discontinued Operation, Receivables Retained",
        "terseLabel": "Disposal group, including discontinued operation, receivables retained"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationReceivablesRetained",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT/rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectOfExchangeRates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect Of Exchange Rates.",
        "label": "Effect Of Exchange Rates",
        "terseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "EffectOfExchangeRates",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Capital Loss",
        "label": "Effective Income Tax Rate Reconciliation, Capital Loss",
        "terseLabel": "Tax benefits on Capital Loss"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCapitalLoss",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "negatedTerseLabel": "Effective income tax rate reconciliation, increase (decrease), percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation related to domestic tax on international income.",
        "label": "Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income",
        "terseLabel": "U.S. taxes on international income (2)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent",
        "label": "Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent",
        "terseLabel": "TRAF effect on tax rate"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Litigation Settlement, Percent",
        "label": "Effective Tax Rate Reconciliation, Litigation Settlement, Percent",
        "terseLabel": "Effective tax rate reconciliation, litigation settlement, percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationLitigationSettlementPercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "label": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "negatedTerseLabel": "Net decrease in tax rate"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent",
        "label": "Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent",
        "terseLabel": "TJCA, foreign tax credit percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent",
        "label": "Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent",
        "terseLabel": "Effective tax rate reconciliation, unrecognized tax benefits, percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EmployeeCompensationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Compensation Period.",
        "label": "Employee Compensation Period",
        "terseLabel": "Retirement plan benefits Employee compensation Period"
       }
      }
     },
     "localname": "EmployeeCompensationPeriod",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_EmployeeObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total employee obligations current and non current.",
        "label": "Employee Obligations",
        "totalLabel": "Total employee obligations"
       }
      }
     },
     "localname": "EmployeeObligations",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EmployeeRelatedObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee related obligations.",
        "label": "Employee Related Obligations [Table Text Block]",
        "terseLabel": "Employee Related Obligations"
       }
      }
     },
     "localname": "EmployeeRelatedObligationsTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_EquityFairValueAdjustmentChangeinObservablePrices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "label": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "terseLabel": "Equity, fair value adjustment, change in observable prices"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentChangeinObservablePrices",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Equity investments, increase (decrease) from acquisition (sale) during period"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with Readily Determinable Value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without Readily Determinable Value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ErleadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erleada",
        "label": "Erleada [Member]",
        "terseLabel": "Erleada"
       }
      }
     },
     "localname": "ErleadaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated useful lives of the assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of fair value over carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$141.06-$151.41"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$129.51-$131.94"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range.",
        "label": "Exercise Price Range One Member",
        "terseLabel": "$62.20-$72.54"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$100.48-$115.67"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$90.44-$100.06"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExpenseNotAllocatedToSegments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense not allocated to segments.",
        "label": "Expense Not Allocated To Segments",
        "terseLabel": "Less: Expense not allocated to segments"
       }
      }
     },
     "localname": "ExpenseNotAllocatedToSegments",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (7)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of company's common stock directly held in plan assets.",
        "label": "Fair Value Of Company's Common Stock Directly Held In Plan Assets",
        "terseLabel": "Fair value of company's common stock directly held in plan assets"
       }
      }
     },
     "localname": "FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense related to change in tax rate from TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "terseLabel": "Deferred tax asset recorded related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense recorded related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_FiscalPeriodPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period policy.",
        "label": "Fiscal Period [Policy Text Block]",
        "terseLabel": "Annual Closing Date"
       }
      }
     },
     "localname": "FiscalPeriodPolicyTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_FundedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded plans.",
        "label": "Funded Plans [Member]",
        "terseLabel": "Funded Plans"
       }
      }
     },
     "localname": "FundedPlansMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GainOnSaleOfAnAssetPaymentForRestructuring": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on Sale of an Asset (Payment) for Restructuring",
        "label": "Gain on Sale of an Asset (Payment) for Restructuring",
        "terseLabel": "Cash settlements"
       }
      }
     },
     "localname": "GainOnSaleOfAnAssetPaymentForRestructuring",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_GeneralCorporateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General corporate member.",
        "label": "General Corporate [Member]",
        "terseLabel": "General Corporate"
       }
      }
     },
     "localname": "GeneralCorporateMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA/INVOKAMET"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IdorsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia [Member]",
        "label": "Idorsia [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Earnings Before Taxes, Percent",
        "label": "Increase (Decrease) In Earnings Before Taxes, Percent",
        "terseLabel": "Increase (decrease) in earnings before taxes, percent"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsBeforeTaxesPercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the benefit obligation and the fair value of plan assets.",
        "label": "Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]",
        "terseLabel": "Information Related to the Benefit Obligation and the Fair Value of Plan Assets"
       }
      }
     },
     "localname": "InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "terseLabel": "Interest (Income) Expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "terseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LandAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land and leasehold improvements.",
        "label": "Land And Leasehold Improvements [Member]",
        "terseLabel": "Land And Leasehold Improvements"
       }
      }
     },
     "localname": "LandAndLeaseholdImprovementsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LifeScanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LifeScan [Member]",
        "label": "LifeScan [Member]",
        "terseLabel": "LifeScan"
       }
      }
     },
     "localname": "LifeScanMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies [Axis]"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies [Domain]"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss Contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LumpSumDistributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lump-sum distribution",
        "label": "Lump-sum distribution [Member]",
        "terseLabel": "Lump-sum distribution"
       }
      }
     },
     "localname": "LumpSumDistributionMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "Medical Devices",
        "verboseLabel": "Medical Devices"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "label": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "terseLabel": "Minimum reverse repurchase agreement collateral (as a percent)"
       }
      }
     },
     "localname": "MinimumCollateralValueasaPercentReverseRepurchaseAgreement",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_MomentaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Momenta",
        "label": "Momenta [Member]",
        "terseLabel": "Momenta"
       }
      }
     },
     "localname": "MomentaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NIZORALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NIZORAL [Member]",
        "label": "NIZORAL [Member]",
        "terseLabel": "NIZORAL"
       }
      }
     },
     "localname": "NIZORALMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NonQualifiedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non qualified plans.",
        "label": "Non Qualified Plans [Member]",
        "terseLabel": "Non-Qualified Plans"
       }
      }
     },
     "localname": "NonQualifiedPlansMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employees engaged in company activities worldwide.",
        "label": "Number Of Employees Engaged In Company Activities Worldwide",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_NumberOfStockBasedCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock-based compensation plans.",
        "label": "Number Of Stock Based Compensation Plans",
        "terseLabel": "Number of stock-based compensation plans"
       }
      }
     },
     "localname": "NumberOfStockBasedCompensationPlans",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpiodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opiods [Member]",
        "label": "Opiods [Member]",
        "terseLabel": "Opiods"
       }
      }
     },
     "localname": "OpiodsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "other comprehensive income loss, pension and other , effects of exchange rate net of tax",
        "label": "Other comprehensive income (loss), pension and other, effects of exchange rate net of tax",
        "negatedTerseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service credit (cost), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (Income) Expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "Other Infectious Diseases"
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonLongLivedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non long lived assets.",
        "label": "Other Non Long Lived Assets",
        "terseLabel": "Other Non Long Lived Assets"
       }
      }
     },
     "localname": "OtherNonLongLivedAssets",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherReverseRepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Reverse Repurchase Agreements [Member]",
        "label": "Other Reverse Repurchase Agreements [Member]",
        "terseLabel": "Other Reverse repurchase agreements"
       }
      }
     },
     "localname": "OtherReverseRepurchaseAgreementsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherSovereignSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Sovereign Securities",
        "label": "Other Sovereign Securities [Member]",
        "terseLabel": "Other Sovereign Securities"
       }
      }
     },
     "localname": "OtherSovereignSecuritiesMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PANCREASEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PANCREASE [Member]",
        "label": "PANCREASE [Member]",
        "terseLabel": "PANCREASE"
       }
      }
     },
     "localname": "PANCREASEMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PROCRITEPREXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PROCRIT/EPREX [Member]",
        "label": "PROCRIT/EPREX [Member]",
        "terseLabel": "PROCRIT/EPREX"
       }
      }
     },
     "localname": "PROCRITEPREXMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percentage Change In Sales By Segment Of Business"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageOfCompanysCommonStockToPlanAsset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the company's common stock to the total plan asset.",
        "label": "Percentage Of Company's Common Stock To Plan Asset",
        "terseLabel": "Percentage of company's common stock to plan asset"
       }
      }
     },
     "localname": "PercentageOfCompanysCommonStockToPlanAsset",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of corridor of greater of market value of assets.",
        "label": "Percentage Of Corridor Of Greater Of Market Value Of Assets",
        "terseLabel": "Percentage of corridor of greater of market value of assets"
       }
      }
     },
     "localname": "PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "Pharmaceutical",
        "verboseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PotentialSharesExercisableUnderStockOptionPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Shares Exercisable Under Stock Option Plans",
        "label": "Potential Shares Exercisable Under Stock Option Plans",
        "terseLabel": "Potential shares exercisable under stock option plans (in shares)"
       }
      }
     },
     "localname": "PotentialSharesExercisableUnderStockOptionPlans",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_ProductLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability.",
        "label": "Product Liability [Policy Text Block]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityPolicyTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ProfitLossPercentToSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss percent to sales.",
        "label": "Profit Loss Percent To Sales",
        "terseLabel": "Percentage of profit share payments (less than)"
       }
      }
     },
     "localname": "ProfitLossPercentToSales",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "verboseLabel": "Purchased in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_QualifiedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified plans.",
        "label": "Qualified Plans [Member]",
        "terseLabel": "Qualified Plans"
       }
      }
     },
     "localname": "QualifiedPlansMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RegulationCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulation charge",
        "label": "Regulation charge",
        "terseLabel": "Regulation charge"
       }
      }
     },
     "localname": "RegulationCharge",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid",
        "label": "Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid",
        "terseLabel": "Restructuring and related cost, expected period of cash outlays for severance paid"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringChargeNetofAccrualAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charge, Net of Accrual Adjustment",
        "label": "Restructuring Charge, Net of Accrual Adjustment",
        "terseLabel": "Restructuring Charge, Net of Accrual Adjustment"
       }
      }
     },
     "localname": "RestructuringChargeNetofAccrualAdjustment",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RestructuringandRelatedCostDurationofRestructuringPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "label": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "terseLabel": "Restructuring and related cost, duration of restructuring plan"
       }
      }
     },
     "localname": "RestructuringandRelatedCostDurationofRestructuringPlan",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Restructuring and related cost, expected future savings"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Schedule of Sales by Segment of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesReturnReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales return reserve",
        "label": "Sales Return Reserve",
        "terseLabel": "Sales return reserve (as a percent)"
       }
      }
     },
     "localname": "SalesReturnReserve",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SavingsPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings Plan.",
        "label": "Savings Plan [Abstract]",
        "terseLabel": "Savings Plan [Abstract]"
       }
      }
     },
     "localname": "SavingsPlanAbstract",
     "nsuri": "http://www.jnj.com/20210103",
     "xbrltype": "stringItemType"
    },
    "jnj_SavingsPlanTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings Plan.",
        "label": "Savings Plan [Text Block]",
        "terseLabel": "Savings Plan"
       }
      }
     },
     "localname": "SavingsPlanTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated future employer contributions.",
        "label": "Schedule Of Estimated Future Employer Contributions [Table Text Block]",
        "terseLabel": "Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans"
       }
      }
     },
     "localname": "ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SegmentsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segments Total",
        "label": "Segments Total [Member]",
        "terseLabel": "Segments Total"
       }
      }
     },
     "localname": "SegmentsTotalMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "terseLabel": "Shares, canceled/forfeited/adjusted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]",
        "terseLabel": "Stock options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares repurchased under treasury stock method (in shares)"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShippingandHandlingCostsasaPercentofSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping and Handling Costs as a Percent of Sales",
        "label": "Shipping and Handling Costs as a Percent of Sales",
        "terseLabel": "Shipping and handling costs as a percent of sales"
       }
      }
     },
     "localname": "ShippingandHandlingCostsasaPercentofSales",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ShortTermInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment funds.",
        "label": "Short Term Investment Funds [Member]",
        "terseLabel": "Short-term investment funds"
       }
      }
     },
     "localname": "ShortTermInvestmentFundsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "Simponi/Simponi Aria"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SkinHealthBeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Skin health/Beauty",
        "label": "Skin health/Beauty [Member]",
        "terseLabel": "Skin health/Beauty"
       }
      }
     },
     "localname": "SkinHealthBeautyMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "Stelara"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act, Incomplete Accounting, Net Adjustments for Provisional Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Net Adjustments for Provisional Income Tax Expense (Benefit)",
        "terseLabel": "Tax Cuts and Jobs Act, incomplete accounting, net adjustments for provisional income tax expense (benefit)"
       }
      }
     },
     "localname": "TaxCutsAndJobsActIncompleteAccountingNetAdjustmentsForProvisionalIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset",
        "terseLabel": "TCJA, increase (decrease) in deferred tax asset"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)",
        "negatedTerseLabel": "TJCA foreign tax credits, net deferred tax expense (benefit)"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset",
        "terseLabel": "Reversal of deferred tax asset"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability",
        "terseLabel": "Reversal of deferred tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Deferred Income Tax",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Deferred Income Tax",
        "terseLabel": "GILTI, deferred tax cost"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeDeferredIncomeTax",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability",
        "terseLabel": "TCJA, provisional liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "terseLabel": "TJCA , provisional liability, non-current"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "terseLabel": "TCJA, undistributed foreign earnings percent related to cash and cash equivalents"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "terseLabel": "TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.",
        "label": "Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds",
        "terseLabel": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards"
       }
      }
     },
     "localname": "TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "Tremfya"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "UNITED STATES Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnfundedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfunded plans.",
        "label": "Unfunded Plans [Member]",
        "terseLabel": "Unfunded Plans"
       }
      }
     },
     "localname": "UnfundedPlansMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnrecognizedTaxBenefitLiabilityPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefit Liability, Payment",
        "label": "Unrecognized Tax Benefit Liability, Payment",
        "terseLabel": "Payment on unrecognized tax benefit liability"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitLiabilityPayment",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_VELCADEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VELCADE [Member]",
        "label": "VELCADE [Member]",
        "terseLabel": "VELCADE"
       }
      }
     },
     "localname": "VELCADEMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VerbSurgicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verb Surgical Inc.",
        "label": "Verb Surgical Inc. [Member]",
        "terseLabel": "Verb Surgical Inc."
       }
      }
     },
     "localname": "VerbSurgicalIncMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 1 [Member]",
        "label": "Wholesaler 1 [Member]",
        "terseLabel": "Wholesaler 1"
       }
      }
     },
     "localname": "Wholesaler1Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 2 [Member]",
        "label": "Wholesaler 2 [Member]",
        "terseLabel": "Wholesaler 2"
       }
      }
     },
     "localname": "Wholesaler2Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 3 [Member]",
        "label": "Wholesaler 3 [Member]",
        "terseLabel": "Wholesaler 3"
       }
      }
     },
     "localname": "Wholesaler3Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care and Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XO1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XO1",
        "label": "XO1 [Member]",
        "terseLabel": "XO1"
       }
      }
     },
     "localname": "XO1Member",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "Xarelto"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20210103",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r182",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r195",
      "r314",
      "r318",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r192",
      "r314",
      "r316",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r194",
      "r314",
      "r317",
      "r615",
      "r624",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingGuidanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previous accounting guidance and the new accounting guidance.",
        "label": "Accounting Guidance [Domain]",
        "terseLabel": "Accounting Guidance [Domain]"
       }
      }
     },
     "localname": "AccountingGuidanceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASU 2014-09 - Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "ASU 2016-01 - Financial Instruments"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r11",
      "r32",
      "r197",
      "r198",
      "r315"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable trade, less allowances for doubtful accounts $293 (2019, $226)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r26",
      "r582",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 8)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r28",
      "r582",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 1)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r80",
      "r88",
      "r91",
      "r357",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r257"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r88",
      "r98",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Gain/ (Loss) On Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r88",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Gain/(Loss) On Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r85",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note\u00a013)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r84",
      "r88",
      "r91",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r73",
      "r88",
      "r91",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life of acquired intangibles"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r383",
      "r385",
      "r421",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r385",
      "r415",
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation cost charged for Long term incentive plan"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r35",
      "r199",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r130",
      "r238",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive income"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]",
        "terseLabel": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "terseLabel": "Deferred net losses (gains) on derivatives included in accumulated other comprehensive income"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r130",
      "r254"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r187",
      "r580",
      "r602"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Identifiable Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r65"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current, Other",
        "terseLabel": "Assets held for sale (Note 18)"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r202",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Carrying Amount, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "verboseLabel": "Marketable securities (Notes\u00a01 and 2)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r204",
      "r207",
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r204",
      "r206",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r204",
      "r208",
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "terseLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r204",
      "r208",
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "terseLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r204",
      "r205",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r200",
      "r203",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available for Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r386",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r496",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(1)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and building equipment"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r16",
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and building equipment"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs",
        "verboseLabel": "Business Combination, Acquisition Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r468",
      "r469",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r466",
      "r468",
      "r469",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r129",
      "r474"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration reversal"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r467",
      "r470",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Other assets assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable securities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r45",
      "r132"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash &amp; Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents (Notes\u00a01 and 2)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r133",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r18",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Current Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r124",
      "r132",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year (Note\u00a01)",
        "periodStartLabel": "Cash and cash equivalents, beginning of year (Note\u00a01)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r124",
      "r552"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease)/Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral paid"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common Stock, Dividends, Per Share, Declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u00a0\u2014 par value $1.00 per share (Note\u00a012) (authorized 4,320,000,000\u00a0shares; issued 3,119,843,000\u00a0shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]",
        "terseLabel": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Compensation Related Costs, General [Text Block]",
        "terseLabel": "Employee Related Obligations"
       }
      }
     },
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r94",
      "r96",
      "r478",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r545",
      "r546",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r176",
      "r177",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r479",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r345",
      "r379",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(1)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Products Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r345",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross currency interest rate swaps contracts:",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r453",
      "r457"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "U.S. taxes"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r455"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "International taxes"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r453",
      "r457"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total currently payable"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Currently payable:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r135",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of debt"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and the current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r26",
      "r27",
      "r581",
      "r584",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r560",
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r58",
      "r299",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r59",
      "r144",
      "r302",
      "r303",
      "r304",
      "r305",
      "r559",
      "r560",
      "r562",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities",
        "verboseLabel": "Debt instruments"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 4.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r454",
      "r457"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S. taxes"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r454",
      "r457"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "International taxes"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note\u00a08)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r143",
      "r454",
      "r457"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r433",
      "r448"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 8)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r429",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred Tax Assets, Income reported for tax purposes"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r427",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred Tax Assets, Net operating loss carryforward international"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r429",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred Tax Assets, Miscellaneous international"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Deferred Tax Assets, Property, Plant and Equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r427",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Deferred Tax Assets, Employee related obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r427",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Deferred Tax Assets, Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r428",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Deferred Tax Assets, Reserves\u00a0&amp; liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r433",
      "r448"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred Tax Liabilities, Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r429",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Deferred Tax Liabilities, Non-deductible intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r429",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Deferred Tax Liabilities, Miscellaneous international"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedTerseLabel": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "terseLabel": "Deferred tax liability foreign taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "auth_ref": [
      "r325",
      "r342",
      "r583",
      "r604"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 1.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan",
        "terseLabel": "Pension benefits"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Month-end measurement date applicable when an accounting policy election is made to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end, in CCYY-MM-DD format.",
        "label": "Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date",
        "terseLabel": "Defined benefit plan, plan assets, accounting policy election, measurement date"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccountingPolicyElectionMeasurementDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r81",
      "r88"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "totalLabel": "Total before tax effects"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r88",
      "r357"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedLabel": "Net actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r88",
      "r357"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)(1)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax": {
     "auth_ref": [
      "r83",
      "r88",
      "r357"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax",
        "terseLabel": "Unrecognized net transition obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r336",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gains) losses(2)"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r353",
      "r375",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses (gains)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r354",
      "r376",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r325",
      "r342"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Total recognized in the consolidated balance sheet\u00a0\u2014 end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts Recognized in the Company\u2019s Balance Sheet consist of the following:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r22",
      "r325",
      "r326",
      "r342",
      "r579",
      "r601"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Non-current assets",
        "verboseLabel": "Prepaid employee related obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]",
        "terseLabel": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of increase in compensation levels"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Service cost discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected long-term rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of increase in compensation levels"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Projected benefit obligation - end of year",
        "periodStartLabel": "Projected benefit obligation - beginning of year",
        "terseLabel": "Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r333",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefits paid from plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r363",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "verboseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r338",
      "r345",
      "r346",
      "r378",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter",
        "terseLabel": "2026-2030"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r352",
      "r374",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r335",
      "r345",
      "r346",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Plan assets at fair value\u00a0- End of year",
        "periodStartLabel": "Plan assets at fair value\u00a0\u2014 beginning of year",
        "verboseLabel": "Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r325",
      "r342"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Projected Benefit Obligation",
        "totalLabel": "Funded status - end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Health care cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r329",
      "r351",
      "r373",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r349",
      "r371",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit cost",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r367",
      "r368",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation unfunded plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r367",
      "r368",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r367",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation, unfunded plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r340",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid from plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r344",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target Allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r355",
      "r377"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedTerseLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r328",
      "r350",
      "r372",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline (ultimate trend)"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "terseLabel": "Percent of Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year ultimate health care cost trend rate is expected to be reached, in CCYY format.",
        "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate",
        "terseLabel": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SavingsPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r130",
      "r185"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r67",
      "r71",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Derivative Asset, Fair Value, Gross Liability"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r68",
      "r69",
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Derivative Asset, Noncurrent"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r506",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r66",
      "r70",
      "r499",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative Asset, Fair Value, Gross Asset"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r66",
      "r70",
      "r499",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative Liability, Fair Value, Gross Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r497",
      "r500",
      "r508",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r493",
      "r497",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r493",
      "r497",
      "r508",
      "r516",
      "r517",
      "r523",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r68",
      "r69",
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r67",
      "r71",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "negatedTerseLabel": "Derivative Liability, Fair Value, Gross Asset"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r148",
      "r487",
      "r489",
      "r490",
      "r493",
      "r495",
      "r503",
      "r508",
      "r520",
      "r522",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r149",
      "r487",
      "r489",
      "r493",
      "r495",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "terseLabel": "Description of reclassification of cash flow hedge gain (loss)"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Common Stock, Stock Option Plans and Stock Compensation Agreements"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale or disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Held-for-sale or Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and  other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.",
        "label": "Disposal Group, Including Discontinued Operation, Cash",
        "terseLabel": "Disposal group, including discontinued operation, cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal group, including discontinued operation, consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r7",
      "r255",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Disposal group, including discontinued operation, inventory, current"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DistributionTypeDomain": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Types of distribution made by the entity.",
        "label": "Distribution Type [Domain]",
        "terseLabel": "Distribution Type [Domain]"
       }
      }
     },
     "localname": "DistributionTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis": {
     "auth_ref": [
      "r162",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of distribution.",
        "label": "Distribution Type [Axis]",
        "terseLabel": "Distribution Type [Axis]"
       }
      }
     },
     "localname": "DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net earnings per share (Notes 1 and 15)"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r103",
      "r154",
      "r158",
      "r160",
      "r161",
      "r162",
      "r166",
      "r591",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r103",
      "r154",
      "r158",
      "r160",
      "r161",
      "r162",
      "r166",
      "r591",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net earnings per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r163",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r146",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Tax rates:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r434",
      "r435",
      "r456"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r434",
      "r435",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "negatedTerseLabel": "Effective income tax rate reconciliation, deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "auth_ref": [
      "r434",
      "r435",
      "r456"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "negatedTerseLabel": "Tax benefits on share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r434",
      "r435",
      "r456"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "International operations (1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r434",
      "r435",
      "r456"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "All other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Effective income tax rate reconciliation, other reconciling items, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "TCJA and related impacts"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities [Abstract]",
        "terseLabel": "Employee-related Liabilities [Abstract]"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost not yet recognized for option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Total income tax benefit recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Exercise of options, tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Equity, fair value adjustment"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity method investments, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity Securities, FV-NI"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r19",
      "r25",
      "r216",
      "r587",
      "r600",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value, amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r530",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r379",
      "r531",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r530",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r533",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value, Disclosure Item Amounts [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r345",
      "r346",
      "r379",
      "r531",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r345",
      "r346",
      "r379",
      "r531",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r345",
      "r346",
      "r379",
      "r531",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Fair Value, measurement with unobservable inputs reconciliation, recurring basis, liability value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r536",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r496",
      "r503",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "verboseLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Finite lived intangibles, amortization expense next twelve months"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Finite lived intangibles, amortization expense, year five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Finite lived intangibles, amortization expense, year four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Finite lived intangibles, amortization expense, year three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Finite lived intangibles, amortization expense, year two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r239",
      "r242",
      "r246",
      "r250",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r246",
      "r577"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite lived intangible assets gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite lived intangible assets net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "terseLabel": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "terseLabel": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.",
        "label": "Foreign Currency Disclosure [Text Block]",
        "terseLabel": "International Currency Transalation"
       }
      }
     },
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InternationalCurrencyTranslation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign currency exchange rate, translation"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r549",
      "r550",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction gain (loss), before tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTranslationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation [Abstract]",
        "terseLabel": "Foreign Currency Translation [Abstract]"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r345",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts",
        "verboseLabel": "Forward foreign exchange contracts:"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (Loss) on Disposition of Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r130",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain (Loss) on Disposition of Business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.",
        "label": "Gain (Loss) on Sale of Equity Investments",
        "terseLabel": "Gain (Loss) on Sale of Equity Investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfEquityInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill end of period",
        "periodStartLabel": "Goodwill beginning of period",
        "terseLabel": "Goodwill (Notes\u00a01 and 5)",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r235",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r493",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r200",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "terseLabel": "Carrying Amount, held-to-maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Debt Securities, Held-to-maturity, Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r130",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, excluding goodwill"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Earnings before provision for taxes on income",
        "totalLabel": "Earnings before provision for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r186",
      "r458"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note\u00a08)",
        "totalLabel": "Provision for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r140",
      "r431",
      "r432",
      "r445",
      "r446",
      "r449",
      "r459",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r434",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "Repatriation of foreign earnings amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r126",
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease/(Increase) in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Increase in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Increase/(Decrease) in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r159",
      "r164"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "verboseLabel": "Convertible debt shares (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r241",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r241",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r237",
      "r244"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Notes\u00a01 and 5)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Purchase price over fair value of assets acquired"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest expense capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r100",
      "r184",
      "r557",
      "r561",
      "r592"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized (Note\u00a04)"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The after-tax amount of interest recognized in the period associated with any convertible debt.",
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Interest expense convertible debt"
       }
      }
     },
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r123",
      "r125",
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest, net of amount capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r345",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swaps contracts:"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r36",
      "r229"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r10",
      "r63",
      "r226"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories (1)",
        "verboseLabel": "Inventories (Notes\u00a01 and 3)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r64",
      "r140",
      "r170",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r38",
      "r39",
      "r229"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r37",
      "r229"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r109",
      "r183"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r15",
      "r48"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land and land improvements"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r585",
      "r608"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity under credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermCommercialPaperCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Long-term Commercial Paper, Current",
        "terseLabel": "Borrowed under the commercial paper program"
       }
      }
     },
     "localname": "LongTermCommercialPaperCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r27",
      "r298",
      "r584",
      "r606"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Aggregate maturities of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less current portion",
        "verboseLabel": "Current portion of long term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r151",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "After 2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r151",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r151",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r151",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r151",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r151",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note\u00a07)",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r59",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r290",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "verboseLabel": "Loss Contingencies by Nature of Contingency [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r290",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r280",
      "r283",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Loss contingency, damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r280",
      "r283",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought, value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r284",
      "r289",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r290",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r16",
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r12",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Current Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedging transaction exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r124",
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r92",
      "r95",
      "r102",
      "r131",
      "r164",
      "r590",
      "r611"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r153",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r135",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions (Note 18)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r135",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r135",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r568",
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present Value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r566",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r182",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r496",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r82",
      "r85",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r72",
      "r85",
      "r548",
      "r553",
      "r554"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r85",
      "r89",
      "r90",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "negatedLabel": "Amortization of prior service (cost) credit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r76",
      "r77",
      "r85"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r74",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r85",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r75",
      "r85",
      "r505",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r72",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain/(Loss) Reclassified From Accumulated OCI Into Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r93",
      "r96",
      "r98",
      "r301"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive Income (Loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r81",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "terseLabel": "Total loss/(income) recognized in other comprehensive income, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r81",
      "r85"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r79",
      "r85",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "negatedLabel": "Net actuarial (gain) loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r81",
      "r86",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r85",
      "r89",
      "r90",
      "r215"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": {
     "auth_ref": [
      "r85",
      "r89",
      "r90",
      "r494"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r85",
      "r89",
      "r90",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Amortization of net actuarial loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r74",
      "r85",
      "r527"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": {
     "auth_ref": [
      "r74",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax",
        "terseLabel": "Derivatives &amp; hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r76",
      "r85"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r212",
      "r224",
      "r345",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income [Member]"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r322",
      "r365",
      "r366",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other benefit plans",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r325",
      "r342",
      "r583",
      "r604"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 2.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan",
        "terseLabel": "Postretirement benefits"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other(2)"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r114",
      "r117",
      "r150"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note\u00a018)",
        "verboseLabel": "Acquisition payments"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "verboseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r26",
      "r325",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Current liabilities",
        "terseLabel": "Less current benefits payable"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r28",
      "r325",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Non-current liabilities",
        "terseLabel": "Employee related obligations\u00a0\u2014 non-current",
        "verboseLabel": "Employee related obligations (Notes\u00a09 and 10)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r321",
      "r365",
      "r366",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Retirement plans",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r386",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [
      "r323",
      "r324",
      "r588",
      "r610"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 3.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.",
        "label": "Postemployment Benefits Liability",
        "terseLabel": "Postemployment benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000\u00a0shares)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r13",
      "r43",
      "r44"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of brands"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "verboseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r119",
      "r122",
      "r150"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r112",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sale of available-for-sale securities, equity"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Additions to Property, Plant &amp; Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r49",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Total property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r258",
      "r609"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property, plant and equipment, net(1)",
        "verboseLabel": "Property, plant and equipment, net (Notes\u00a01 and 4)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r140",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment and Depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment at Cost and Accumulated Depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of the assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to prospectively adopted accounting guidance.",
        "label": "Prospective Adoption of New Accounting Pronouncements [Axis]",
        "terseLabel": "Prospective Adoption of New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r104",
      "r222"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Summary of unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "U.S. Reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r426",
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "R&amp;D Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r140",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Research and Development in Process",
        "verboseLabel": "In-process research and development (Note 5)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r264",
      "r267",
      "r274",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring costs incurred since announced"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r264",
      "r267",
      "r274",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Pre-tax restructuring charges"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r130",
      "r263",
      "r270",
      "r276"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 20)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r266",
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r265",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReservePeriodIncreaseDecrease": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the accrual for restructuring costs.",
        "label": "Restructuring Reserve, Period Increase (Decrease)",
        "negatedTerseLabel": "Activity during the period"
       }
      }
     },
     "localname": "RestructuringReservePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r263",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Settled non cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r306",
      "r607"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r366",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r366",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r321",
      "r322",
      "r365",
      "r366",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r321",
      "r322",
      "r365",
      "r366",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales to Customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Sale of stock, percentage of ownership before transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SaleOfSubsidiaryGainLossMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about gain (loss) from sale of equity interest in subsidiary have been included.",
        "label": "Sale of Subsidiary Gain (Loss) [Member]",
        "terseLabel": "Sale of Subsidiary Gain (Loss)"
       }
      }
     },
     "localname": "SaleOfSubsidiaryGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Company' Retirement Plan Asset Allocation and Target Allocations"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Cash Equivalent Composition"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r59",
      "r144",
      "r302",
      "r303",
      "r304",
      "r305",
      "r559",
      "r560",
      "r562",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Temporary Differences and Carryforwards"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r365",
      "r366",
      "r369",
      "r370",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "auth_ref": [
      "r365",
      "r366",
      "r369",
      "r370",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effect of Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r497",
      "r508",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Assumed Health Care Cost Trend Rates"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r17",
      "r40",
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Aggregate Maturities of Long Term Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "terseLabel": "Schedule of Net Funded Status"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r153",
      "r155",
      "r168",
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Schedule of New Accounting Pronouncements"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r49",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r268",
      "r269",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r265",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Summary of Severance Charges and Associated Spending"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r105",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r99",
      "r101",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r181",
      "r187",
      "r188",
      "r189",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r181",
      "r187",
      "r188",
      "r189",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of Segment Reporting Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r398",
      "r403",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Share Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r386",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r391",
      "r403",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Description of the Company And Business Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r108",
      "r225"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Shares, canceled/forfieted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average fair value of RSU's and PSU's granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Shares, Ending balance",
        "periodStartLabel": "Shares, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Shares, issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair Value of RSU or PSU units settled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions of fair value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under long-term incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants under long-term incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Summary of option activity under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options canceled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average fair value of option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r393",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding end of period",
        "periodStartLabel": "Options outstanding beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Outstanding Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options exercise price end of period",
        "periodStartLabel": "Options exercise price beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r384",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled/forfeited, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Price Range, Minimum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable number of Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Outstanding number of Options (in shares)",
        "verboseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Price Range, Maximum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Stock options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r410",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Average Life",
        "verboseLabel": "Stock option average life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r23",
      "r581",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Loans and notes payable (Note\u00a07)"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software Development"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. Sovereign Securities(1)"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r6",
      "r187",
      "r235",
      "r261",
      "r267",
      "r278",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r62",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "negatedLabel": "Employee compensation and stock option plans, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r301",
      "r306",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "negatedLabel": "Employee compensation and stock option plans related to treasury stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' Equity before Treasury Stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r476",
      "r477",
      "r483"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Cumulative Effect of Adjustment",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items [Axis]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items [Domain]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r437",
      "r444",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow data"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r61",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount",
        "verboseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r61",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "periodEndLabel": "Treasury Stock, Ending Balance, Shares",
        "periodStartLabel": "Treasury Stock, Balance, Shares",
        "verboseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r31",
      "r301",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "verboseLabel": "Repurchase of common stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "Capital and Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r61",
      "r308",
      "r311"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "periodEndLabel": "Treasury Stock, Ending Balance",
        "periodStartLabel": "Treasury Stock, Balance",
        "verboseLabel": "Less: common stock held in treasury, at cost (Note\u00a012) (487,331,000\u00a0shares and 487,336,000\u00a0shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r301",
      "r306",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock, Amounts"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesScheduleofCumulativeEffectAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r345",
      "r586",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't Securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnSecurities": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in the income statement on unsold other securities.",
        "label": "Unrealized Gain (Loss) on Securities",
        "terseLabel": "Unrealized Gain (Loss) on Securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedLossOnSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Loss on Securities",
        "terseLabel": "Unrealized loss on securities"
       }
      }
     },
     "localname": "UnrealizedLossOnSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r430",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest on income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r157",
      "r162"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Average shares outstanding (Notes 1 and 15)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r156",
      "r162"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Average shares outstanding\u00a0\u2014 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6284393-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e14981-108350"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187171-122770"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(u)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624186-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624258-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061172-113977"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r631": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r632": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r633": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r634": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r635": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-03(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>135
<FILENAME>0000200406-21-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-21-000008-xbrl.zip
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M<ZD!%.B%I-%+\]"_"-Z^4M ^3LR1#AKNJ/'3B[?O/_E 8-\F+,'B#C;N&Z=
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M.DXZ3CI.KEGDVK8O_Z 5R]?ZI=C52.9PQ,.I_B=22?S[_P-02P,$%     @
MA8164FL"S' / P  %@@  !X   !E>#(S+7!W8V-O;G-E;G1X9F]R;3$P>&MX
M,BYH=&W55=MNVS@0?>]73!TTV0*1)4KR378-M+;<NILZAJ,B[5-!2R.+B"0*
M)&W5^_5+79RF%P/[LMBN'@B.9N;,.;S-Y/G\=A9\7ON0J"R%]<<W-\L9= S3
MO'=FICD/YO N^' #;M<B$ B:2Z88SVEJFOZJ YU$J<(SS;(LNZ73Y6)G!ANS
M@G+-E'.)W4A%G>FD^J-'I-'TV>2Y8<"<A_L,<P6A0*HP@KUD^0[N(Y0/8!AM
MU(P71\%VB0+;L@G<<_' #K3Q*Z92G)YP)F9C3\RZR&3+H^-T$K$#L.A5AQ''
M(704]OM('-?NT1%U26_D#FE_2/K#N/^%:)*F#F]RI#JF^*J3L=Q(L*KON79W
MT"O4N&212CQB62\Z=>AT$O-<Z7I"YS?3!N8G,(5?E4%3MLN]6E*G23VY0YYR
MX5U8]3>N/$9,,Y8>O:N 92AAA25L>$;SJVNIM\&0*%C<!$KV%VI.FEYME@WE
M@<9)68XG"<2N2/N?WBW?+(/+"]*WQK;S/>FGVJG8:?F*%QX9:>0G]$.]WBC^
M(_ZSV]6=OPK@=@'+U=Q?^WK0YL9_N[P+_(T_/YWAU[/9[<=5L%R]A<5R\^&?
M"!T4IUWYQ88^;O:_I]C]I>)[A 0%;H\0\EQ6=T9Q4 D"RT,N"BYH=2-!^P7&
M.C /*U<=L<$=DZH-N%/ZHE5W18*V%EQD<&<,X8\5EUUP',>P";%[UG4])T-B
MC>QVWG>&O4$[MT<]5_^G>=3:[F#8>UG;+:130;:(3M\=C5X"C^$]3W*IZUY>
M.,/QHZ4=?"\T<2U#052_! O<BCT51[!UG?K>"TRU!/T\M,)CEM,\9#356_&H
MJ6)0.3&.,53L@#E*615@U6G5+U:U?$KP%/@!Q1.,IKB&OX8R86$"M"B0"MDL
M(I.-+F(9?W;/G(C?Z;1<7KB#L:Q'6 L68JE72"1\+W'&>8%:U\W-&@#^!UH6
MNDQ",UA3\7!=@[[7_/'XN]#[\:">?6-^:"(%;[JHUQSL _[45DZ)6ZX4SSSK
M6PK=2I[NU?F4<P_UV1[5CDW'K'OW]&]02P,$%     @ A8164K1-$H*W-0
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MIT<=6@U\$^; 'QQ/))D;1#R'XTW<Z!8'A$>\T(43"SP7>53:=6HG,8&EC82
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MWU+2]-J2)DN:+&E:>8?#WL\?4*^!75P.^Y?#QV[B^QA;F_:P2(Z[ LS?8+/
MV6'WY*S]ZT>;!;H'!ZN-^D_HL9KF?V\NW,/%P.T.NL[@<GC]Z>+S.=JZ&Z3\
MS=_M(J3XR74FB1C_Z\4/*_AB]E^LS\(/?GKI5GGL]D(I@.D%,./+ 0+IC872
M38'2P^< I8?=?>W87''^<UCX* G:YCU8:=X??S@XV7];__\#U_)-S^+''TX/
M#_??LJO""T"1HT\.WEJ<M3B[-O=&.'MH<;:$L^>Q+RRR6F1=MWLC9#VRR%I!
MUBA+0 47OO-+$N<SB[@6<=?MW@AQCRWBEA'W^LKBJL75=;LWPM57%E=+N-J?
MSL)X+A*+L!9AU^W>"&%/+,*6$?9Z<-.SV&JQ==WNC;#UM<76$K:^[UTYQ_MG
M/178;A'7(NZZW1LA[JE%W!KBOH^3:1ZZ%F<MSJ[;O1'.GEF<+>'L+XD;^6,7
M(VB%;SFNQ=YUO3?$WH-]B[TE[+UR\8("N%:+LQ9GU^[>"&=M#%059^>4VWV3
M ?(ZF#UJ4=>B[KK=&Z&N#86JH.["J@L6C3<,C8^>"1K;(*D*&H=N9)'5(NNZ
MW1LAJPV,JB.KT_.G012D&8!%;,,N+.JNW;T1ZMHXJ0KJ7CN6U5I\7<=[(WRU
M85)E?/WO'#8X#H1OT=:B[5K>&Z&MC9<JH^WU[S;LPN+LVMX;X:P-E2KC[(V8
MN0P-SOLDGCHW(KD+/&M"MOB[=O=&^&O#IBKXF[E9GL7)W/D03(.,"WA;[+78
MNV[W9A9+&G2=_H?!+X.?!Q\&P_^A$GU7O>OAX'QPU;-5OC8)<(^? ^ >V?I)
M>DU]N)!@%(1!-K=8:K%T;>Z-L-2&"<DU7<%KL8_=5W1@+L*$Q5B+L6MS;X9
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MR ^4L?49V\Z]"3:'5"RX>F74M X/<5F)NT,0"W<.=]FHBSHBX,HVG^GB0VU
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MV*CMK2Z!*A3#]6/$#%_-2."630!VE9S5$%?#&Y;!-52Q^=4N9O4$:0'X!FC
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MP>+A_N/DT9>CV)_#/Y-L&K[[_U!+ P04    " "%A%92))7"!S$(  "&)@
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M7\7<^4U4^>N_T'+?BAW_!5!+ P04    " "%A%92=.SA72\(  "*)@  '@
M &5X,S$R+3,P,F-E<G1O9F-F;WAF;W)M,3!X+FAT;>U:;6_;.!+^?K^"ZV"[
M">!7V6E<.S7@.@[J;B\I4A>]_72@)<HB(HE:DK+C_?7[D)3?XN3BH(?+R[5
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MG$INM.>N4EAN2\TTN3+L;7-"6:JWR8\V"=I@DV,'9111Y><Q-80%FZP&ZRJ
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MJ!QJT9=:*G,P>_KO$]U=Y7[BV$KJS>"$P91(S 8:$+0<B^61EIE=YH*)*S/
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M/%3?DZ&Y"M1ZV:EDR2Z QK@*S>21C@+<,VF<J-=<ED")O:S*)"T#.^KGXR:
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MVDJ$UNGHJ@NY;]UL% %M*5GU SBQ55&J.-)NX5O'B\E4%HN;_-_CR6)RL7G
MS>/Y9/$/P</ERUW<BE13U1!5?0Z:2GEKL]?Q30DK90R:56V_*[PCM'POR\\!
MYY_+?'9[=OQJ-E4Y_EKFRPD=RI-CFLWK9-4Q35^J+SE6T5Z/93+5;VH&\8_,
MT4(1XWM_/\VA,+C,))#40P*<3+5NMW\<![9UYEF^E&1;M@2J",'V,A-!<J3.
M,U:I UN;NU'"!6 &LJ8(ON8HH1$4*,2%#/F<O8\N2L8!,JOM@66=Z]62^%92
MS 8$."#9WD\.62$*9 ,.;"U683$/9\O1+,7E$%BL_N<LU!RP2C 8F9'53NP
ME=?M@&2-5M(/ZM @8H,-&>I*  2?4I;6 @8[P+3@;TN!&R&<0V24:77VP58I
ML15H()J[)D@MJBPC36@1ZL!&<I6(K--&6 .\55?5%(MF?4:OX]_[".O;, Q0
MW_Z=  \CV@@5[R44&\4&L DS@B:<,1;F%KRS ]O(52*R1AO)F).OK=GJ+5BT
M):B%&&Q-;!-7\\ V8F_$$6V$L[-.,)3$#7#5WHIK5HP\"!8W0!%T*Q!9HXUP
M=2U5!UP@J?SETE>+.)]*HLPF^X%MQ-QPI_+WS@J2+5X5=SR=G. AQ_-WXWPD
MN- 4]YO)8@;.IJ_O_O#X[.5G3YT][J__*+PMBJ3@K 4#O;4U9G:F";0D3"[Y
M@0WN2N%=9\6LDIB2"J>^ZYX+E:8^405#\SD9-\3^^]_4">Z\#]QB@[NHI2,U
M;)KS]W(9BT?]\,7Y6FMPA5 &-I*K1&2=B^Y=\"%2C P,4&/VA6L_,B74J&"-
M7 &(-Y+_L'PYR@I@\2WWQ5.,%2%EBZ(8E*QZ6I,>+D.L>]L66-9I+25P2,U:
MVW<INDC,[!I[+-FP#%U5]C=\.N_ 1K$4<F@I!%2/I=*K2,G>4256JXF9\\B)
MSI5"LM9J@,W]Z+A>WX?H&F)*8$SD8@U0&+D:X&Z8$8W$(=>^,-<XS3ZE-5)G
MY;!I$FH*"8^<G%PE(FNTD0K>QF)(Y6^"R!6-^)Q#Z%TVLK4CYR;F1KR0+L(@
M1L)4O&M]9K(*0*(2D LZ5<A@J)J19_*O%)*UULR2+V+(V:0&TQB]M$180@XV
M.1DYDH0;HQC)NY+9"WKUFR6S[VY]_Z=+9L;'(E'E,_>S.;/#;&LJQOH*I9HP
MLL%=);KK/-, ,W$TJ=3BP'BU-P8J15* DBF,')7<C7BA0!.VU^ ^:*24:^KI
M#"8/-:;"E$5UCJ'FBPJ&@8WD2B%9HY5H\I^]#5Y M5LJ7@%QE"&@2*KL:6 K
M,:=+-.X,92.UM*J!Q!8O!H)I%$UN0M&9 H0C]*)8$R"?_'[G]A _. G7_7UO
MX6+R09_FVSB?OYU,7SR65[/Y4NK-H]GQ=/GNY7<F"SZ<]=</0A6?.9;(Q85J
M^^+I8K@E8YU!DS0['KF"]\':D3@((HDU$1:)V0KUEL?]G.?F5'Z PV(S#1W@
MK@Z1=6ZZCUG81,C16!"-;36VP"I 7('";8 CAGYW2?LY1-(@-D+%M52D4O0%
M$(D2QUAM,]Q;^=@!6JEM!2)KM!'/I6G8 .>2_H6>?)*FJH-#2SG' 9J5_;;D
M*.<EQR@F4J- 192,7,'FF /8:&T$DQ22-$##V34!LM> ?T050Z%"TMP3I($U
M)B/F MY71A931TX7[ U[H?"41X'$AU(4BD ^0&B5 $(Q.1O?#ZMS(T]072DD
M:XUP!LE+;K&E?I0W%H(@FBN5F*FUL6N!Q9S?KC6*E6A(\SZ1@^H  !4&"Y@T
MHQ7N4U<C;PZZ4DC6F2N%FONI*YHO&0 OY%GT+[4/[YL-(^\.BA>5>1G$2.K)
M:;C-FM@ ,E,U2:$@QIP#T\C;3*\2D75&$O3.$;/#H/[*&TIB0C*)&OF<W-!Z
MRY\+[7Z4G=B<$;@68H^J@1E00WJ.IJJ5F!9I@"+HE><NUY4JJ^46-212[0$V
MF:R429)",#9#'N-TL=\ !'[=WL*/LJ OA S)1C&2"N0^ VFKSTXS620K9N2"
MX)7#LLZ9X1)#2K&FV+5'/Y2O^%B*IK+-=)TXM+5<6(P\C*6T%ETFPTUO"CWJ
M6014,1),\/J[D>7@E4*RSK6O&D34=R$'%_IIN%GU82,=MMPH.3-RJ=9>7&CI
M1UE!H1DKQ.A:*]:#L0EM"RT!0#^Z6/S(+16N%)(U6DGTX#.2%/52"D0LK69G
M--P7X^K8,TP7.\'X458J,)3J( 3-93U$L=3W22)Y-%(<C-!8=BL06>?1&QI'
MDN?L"S#T/9/)59N36H[WQ0X=2<*%6H\?91HV4BN8(V-O+1^BH]8(8VN^E.S!
MCKVF^^H066?UK38(T P#"$1#2-'5:-'$X%5^C1U'+BP@'L9("K(F@ZFFIK++
M.B+"P#7G8CAC30.<&+0=D*RS);E5 4PB0@% '5:QS><:FH].9;",W,LZW,B_
M*JB,,N,IU(*F[CY6]559E5<0;*E93)"B9HT#6\J5P[+.GHBQA:P!O@9303(4
MB)5RZ9V0@Y$ZP"$8O^/ X/Q$]#"6DK*F)7VIAHD65 $C^(K651;G;+0C+Z.^
M4DC6:264#1 ;5R2":T(&U$2J+R:BS6'D?4)P(Y@/G!>,,J5E H7<S_T3KE!B
MTG1%LWELJHT9BS$#6\J5P[+.CNVFI@!B^Y$]D))3A6QM,M#Z]%8=NB."?NSW
M!<AA["2Y$,";G(Q-0*:AZ65'%5_"H: ?X,") 5<)C$F5&J)Z5$\UU0#6^B)0
M;%&!;GLI#@:@RN^XU'PNGX51^O^6%FU1TY6 !(XH>]/7NUL,U40:NH'<52*R
MSK4!/F-"4UAO"L)]]L E0,SHQ0J.W&D1;IP__0)&61I@6FM!;"-6X1$YE]"<
MNJLD+C-7._*DYU4BLLY^/RXVDEBL422"9^+ +3+U- J,&[NND,XC,LJ<IS0(
MK!BC)[4-1HSJP,2T7E)P*&//>5X=(FM=/4,I%D]<I4*"A!KA4S3!)X6!W0"+
M=W\/D?.1?93I'&S5NH"V+P< 29A3#R806L@2;1MYSO,J$5EKAYY0^_B'8ONB
MC4+JL0PURU0P>!E9:WF-[.?=UBCUZ6B:]RWT(Y00+!5J(::$TOJ$3AQZQ?*5
M0K+.E0'%9MN /:+31 1+A*CFD6MJT<G06;N[<&)%&*6.XC#7!BDT++T?OR:'
MKG#4T.XE46HCQ_8_B<@GO^&U[6+@H&5QGH6Q !0@2YZLM2(U5ZHC[S70W.\<
M5^(HUILT(4(Q1FS4A+7YWLXYN.B3ZWM >.3YOC^)R-YZ_Y KL8FUK42/%7P5
M2D1B0XN0A$MK8W+E[+E'RY<R[Q<\$3Z>3Y8360R"2^@[DA'0!YN!?,K%&"9L
M@4K1,>0Q9>J&<%FC5B4@<CVTF8!@JDK71FHKE4*NMHZP&^+ZNCJ*UJ@=I=9G
M-',AWTKVV9M,DFF$'7AC0;?.?N" 3I/T(%D(5,%C%1;UB9%;;1Q.K,[T,RRV
M%;K[L^F+I<R/NM-[^O:57,3KB4PGL_E*V%RJ,9D#4PY<6@<B#+5O_O8B!I@+
M87"L>4!E;X5L_,\=)4"V1HUW]8/SYK*A^82AT*\[7][!I71ZY@.KXV'?#>F[
MY]Y]S'KN4G?@S?NW.'GFT\;MW;D%<WW-KPXN.%[.OWZL3YR]^-,/^D13G4.U
M@&(4AD96;,Y&S<.%Y*BM$"A]X ^V/20]6>H K%S9\6(RE<7BR<DM%N^5_^W9
M=*%"8OZY@G\Q7WY]7P7'"USJX]NXD/?O\10/>?WF=X%SY2*1?H=S'P:^/\>Y
MBS,U4ES(G'M[%:#DLXCKA>C25\K8%@9@RG6$+1@38T;-X]E"2(8TO"4!=I50
M(O@!8/L3!O[]2YP?(<OQ<L)X>)EF_NB5(G )<7;SC/$M- ^VM-X#3EI$:[T+
M)OH@SA&E 1AS/8$+%%VS1!GT/_76N;?PTUAN7*_"PPJXE;[-5P;<GQRW4VF9
MKW;<<J6H:5TJ(11P+:&!?J!=4V_9=_V>'4ICO-TVGK_+"]YQO?O(XP_RN.]U
M;#2->W_19>=KYL"_$\2?,^^=G#0QE@P3(,5<5*UBZ@O;FB;@=.J(3K.#*\FY
M_X(?^-3LX(,\]W.46@(FL0V\USQ73(D0.'OL&Q' D#USX-L];N[*QZT N7XV
MM4WD@<$51]B:@,T8<LD#K*"\A8<X97GR4F1Y?\8K8S\W[\$\/Y;Z%-_(XM'T
MWI1G1Z.4;D)I)4H!S3<24./<&Z#6VJ-8R\'R )KD#*.3<5<0;AXO7\[F^M$>
MXM$'E9Q[^M7G4SQ\+*]E>BQ/9/YZPG+O\9-=E"UH<G:A1M4H!!IDT0<PMD:?
MDPDYP4#8/I;EY*2<^KT:XJ\K=-^?O* _N;@C39.8>DNF^L-R':G*8YR^.'W#
M_O !OID<'1_M(F4DUQ1+\%RSQK92U&_GTH_ RL6BRK<3I:N4Z1'NY(<MBW"J
M=/NX?4J$^_#2S\D0.'?/Z?K6&2B".F[1Z.-BI/>%B.],[4P9;-VXG?+MTY7!
M6L:ME:(.2?0?Q\#JF<AJAMP\>Z6>)[=W48,ZDF:+R<5S[('&F:QHYIQ4:43?
M6C/^= +BO4%LK_;;6F#SG[38M6CY7,"Z7$HSH4$5Q C9%XT::KH*[.G,DAKJ
MU<TL[2"PW0PO?^KK8NBO;$2XU. :8"-R08+:JC@/(3;:(5>\6M_R_6RQG+^[
M\!38:^*="R03J0'4Q& CHHLL/K9H8JYDS0YYYVW">B,.&YQDHP:,(0,0!81J
M?:A<DT9FL6V''/9V8;T!'QYC\!&:4<55@3/FAIKP^T;]&-!2!MBJL4TQ^7+6
MXWMOJ!KP@ C>FA*,[\>U6DKL71V@ ==V0K36#4^M;RJ7)L#0N)*+J3J/AC@U
M=V)%8SO*#4'T@:/[G+XEJ8%(88I>P$I1L5H%HH:Y4C+& ?IP;GDLNYPEOB&9
MH %)<T@!)(=9D%TKS6-IW 8XOG,8U-;H#IL59QDS8"]E5E<X4,N]>:2C1+F,
M[PZW![7U>4CD$"P+NB1&T[Q S+FW2[$6(#49*<6[,U%D)G3<)UT7#[#*T]G)
MQ8_F]R='DZ74[U5<3V5^Z^WY2]_CW.=H[Q\?O7IR?'3^@EW,]K(+N7<0!>^S
M:A>'F!JIUC1-/U"P=M@JSI-7"OYL?G'RG?N^B?G;KW]XLEOU&<W/+1F48%,&
MHUY639BL8[7;6%V-NX7BN_TSL[E,7JQ4Z2X6W2QE8T2H:3X!!2&+XYR!J3F4
M9@<X [@C\WY-1?>J_SS&PW[3N@J4Z]KNNS'+OQ35"RY&(5O0JX;*I6;)HD(8
M@S'D"@VP5_0:X;[.[D*I.77DZ!,7L,#%Y41$-; 4+#Q =Z'UX/$9-'LXF_XI
MIFV+R5<T LER$8W?)6=LB9UXJJR^(-, O<.O%_3K[+M'";.1DLE62 R4D7,U
MD-D(9C? #O1+46R?P81OCZ=U+//WT42V3>5Z+N!=1(Y)(/8=$+YJ-K83YK^+
M'%BC'X#>?B*E[*J/X%O.'$Q%FVK4K#RF <XIV#8._#!MPWD"M(!HF_44E06N
M+Z\'FSC%G$/#-D!_]6O+@G7VJ\;<'* ))D70_%_=  4V))0IF)BWWQ=<+('W
ML;_UMO]]<[&0Y6U<RHO9?"(?;(^[^]]C_0[#]79J,6-$;VVM":2US+4&8X,/
MFK[[,0[^V7*TUGG^=:0JK; +@J")-?4S&37IBK9&Q 8[:EM#=DUS_1S3&#F&
M?NY<SY.L_DI0TV2CXEAVU+*&[*3FB_=6%"^,#&I V497G(W9(;$=(8_]>#NN
M;^?RWV.9\ML/M,O9Q><N73SNH,TGTQ>74^"\RFUL'QF4=S_^0X<9Y_SR[7UY
M+8>_,2[WIJ^.EXO5%7]TE,[E6%,7?T]>SN;+IS(_NC=]+8OE"D]5@Z/X/S66
M8B4[<$54!P8,Q:0BWMBF3G&$$P#V-K6WJ>V*4])\!36HZ*,'L3ZG'"!4K,5P
MB&: LX#V-G5)-N6NE4VM=9VF"%%Q5$3 I(8V0;)%(DE.]70!]#Y.[6UJUVUJ
MG?D49U.:389R!:1$#C&+PQ:2\]4,T/5_;U.79%-_=.SB;MG4.@^+$E,;5)O[
MCH+J$@*R9E/!>].:XWT^M;>IZV%3ZURUU@\=#BE3M0B-]"_1^ZOTPY"YC7!N
MY-ZF1J7Q&D,#&1%+48(K%@P0<0;C2_\'.*4!6@[N:3PJC=>Y]PZ"2>@S,1&X
M?LX02,T66$HKGO>S,&/2>-R*\=F+?GCRW>RUS*=]%&_/YJ]F\]6"H,7-:;WY
M0H'5%PPW/4W5U:"FYFQ-$&(IV)N58;(6*[ ;8.''WMCVQC9(9$N602PG)N?
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M;2@.R28TO@Q D0NA^U="9O7;Q<WCY<O9O"=1/TRKS,^!NA(ZM][>?2-SGO2
M/V$Y1[@>\W_]W*.I["(9>IG3)=4#AHJ2@7L/@QH%C;&Q,0UP*/SH'+@4R1>3
M:3DCE1@0) 0DKS]1T-\7+L7L;?QC^#[]>;:+-EX]U(B22BTJ"@)@#%Y*#19+
MB5SRWL8OFP.7<[A;;S]EL.5H"C3D;%/OTJ-!/&"V$?8V_E%\7\YE)R-Y(62'
MB:OWFA\2%](TWV.+.15L=I1"S- LN)R2;,9"M:4*U'JI+0?@&EQ2$5\EGG3E
MVMOYA\]].SN>[Z*9&U*@-6?CI%1H#GN''2(/K$$]./)[,[]T$ES.A)FK'*-8
M3(V ;2Z14D-G(VI2'F0?S3\.\.3U3@9S@&1M8#+96"@)*4).B=7H8] WVJ?E
MET^"2['RQ-:J*BL<7(3*IN3F3+$E4?$QLAO RC=6P7\LBZ5BOI2Z(LP/T\ER
M\?C)#[MH_LWD#+6$1EE3N^PHD#6&.:2B#B&U06ER)57\ZT0357^&V!$C 4B@
MZ%P#5T!3!>/-"),]?P#F]S)OL_D13EE.0L<NPI@R5_#9*XB:W95&Q,$$+NH"
M0JYI!.FWL:!P+0A"P?N^EH:31PT+F4)-^K]F:U;]X.*@!+F2<' M""*VBC@'
MH?8MU=;GZIIKJ+D#&;0C'"RTZ6!^2?WTR7&S/MK25CD]00JY9_F5 K@!-C]O
MSJ@N9W=S-4"UZHAG!]%E\J"Y-7A%A%J((RU]V+3!;-[IV>9C(!#O3 :-AZA_
M6B8Q)3K$.L"TYJ8QO*35IB$Z S7W@^X@@?J[R#$4E3 F)QE@!?DV.+UUSA-S
M<,*M06#5 Z42<U-=$*2Q\>AIH(XKFS:8S?=3606GP%GZ]E2N!5?']*C(,%@,
M>QZHF>N6@;F1OMN)V><8H@00!HU:S%PBJ:\4C6;C6^959U\;L<G6O'"NG(NF
MYT(F-VC&%WT<'.7DQ[?)JX=Q ]:8$8LDZTFC)5@!S#5I%IV,#1ER&Z'*\JL]
M<+>.%Y.I+!9/3FYQX2C(Z>+X2/YH>OP/W[)7<KZ?S^HQ+Q_-G\C\]83/3=8]
M>GI['6_P[OM\)WUSUJN7$\;3TPG_?_;>KMFNVTC3_$L ,@%DSAU+9MB,MBF%
M1+FKZZ8C/\N*ED0')56T__U@J:2*F>DIN4Q26GNM#<KD/F<?FE_K3;Q/)H!,
M>_O#M]^_^]O_]>47]\IN6AI,+"QSJ2.H,+0J10FRZS&+YT+>L-5X?8OS(&X\
MN[5 0Y"H:5ZB._92NE[(XK8:+^_449BDD(R.*Y.=HC&90=/1'9I=J8SW&ZOQ
M%\3R\Y_H]=MOO_S@L5D?JOQ+6G:UF*Z$5>=QVWHN_!^#B48YT@ ;V[*?79:G
M>'<?=<X05*? BH,!.Q#A5)\C?[H+MKW[J65YAHF'BK8""46Q]$DQA00Z9UB8
M;!-_2*F<<[6I9\!RTS(&H0QF[#J5;>7"2S6Q<^&'E,HI9N?34DN180-1.ZNX
M%N2ZWH[:.FVS>TRIG&! #23(I*9+HINQ+$KRLE:/H^ &5SB+_W!2^>)_??7M
M'T*^_OXO_Q3RP_=_NWZ!XYP6+3I['=JDHN+2)V.)6AU+NLF(N0UO2_,D@VVU
MUVI% WU)$XCKF.OS7(:;Z74;[);F688.T%V6+K$%H6&G"CB7H7/O6?-:#3&>
M5)K_2%GEDLX>Y;C!"V@^)]8L%%49#.K,0.E7.HRW-?KK:_04BX=<Z4_I7G(E
MT9F%B3L<QPXAUJ<:V^*W1L_V^JDZ)Z442\=J)+4M+LTH*Y^OI>WJ\:^OT4OZ
M;ZDM^K!&KA5S'N<&AL=:U\H8T$O?_OOPNCEGCJEQ,ZDL4 27.W*,T2B:' T\
M&N+VQ OHY@2?$HW1BQXY*",-8_#U8^U%N&NW2PZ8.ELWG[Z3KS^1=W^OY\^'
M,M1=B\N" X?K& 8-"R4!MQY31_=HK=BVP&>6Y#FWVLI<:Q]#)P=4+0(@[(H(
M.-M:0+>[/K<DS]@=9AU&*\U49AP\R1OAJ%+7YR%RJ0[J3R;)VQ>1448,65AY
M3'M1AJ,_,-%*4=C'^G@[^-;F>:>-YVC5J 6-^''P8U]PF1U:J] 4Z[;RK<VS
M/-UZE,D-P\; ]*H86I&6M4^MT_<&\:^GS4OZK,W0/G(ERUQQ!) !CMZB6N,$
MWS[[N'HYQ?NL@0Y%QS'6\UMT!@6(JE"WXM7;]KX'ULL)?C1&BR8QK*V%17)P
MZ0 ZC<GK<+K"9(]??GC_)/JWCP$NCW?_ZZ[%X45#@"5T @\L95(IX\?NHB5'
M^X]>-@]M>5N2]W)5M9!AVIN)((W&M?O0TM)*FWU<X?[JEN2]C#M\DGI!DL&(
ME86P3098ZV8#;KZ-^V$E>?OBL' #*,52.B(D,!RMHS@</,G<MX-O;9YEY:@0
M5HF.$W?'B"L!7VDR+?=NC0I>H5/BUN9-B\/.P:F61I,12O+1)EY6*CYPEBE7
MF;ET16U>TF=[=2-<-CM76L(K94:0NN1C4VPDE.VS#ZN7<[S/.\ QV"T*8HFF
MUH?XRB!@1@NXPL79Y]7+&;=9,QVS\)#6,)8#!3<RDY5Y8J!?H3C\<)L)__WM
M\1/__<SY]4L?YS0YY*GA;12U0,:A7>;R.$NMGK![,6U9GN2N9@$8$)K8DQ4:
M8I*(%"%O5R@2;UG>KU"<'FJ0#;0<IXA5$H7SZ#$E*;%[3#VX+&]?+#;N:8H9
MR1VUQUHW:\4T6"EL+^T*2>S6YXT+QG+T1F%BZ$PX*R[X9&8;;1@V*7/;^M;G
MF?ZN?42HCNDY< Q5@>,4UQ)D<+>Y;PG]NOJ\I.<F-(]:5MH\"-='?(QFA*(3
M1L&^3Q4_N&;..5D\M%,*8M>.LRBWVB:R'UL/L=:;[8,/KID3O.GHVS5XK2X5
M!:D=(Q]J*;T/%5]2TNU-[Z.9'[[U8Y-#OO5/O__+'0[0G>*!TXO6XDNBTS 3
M*&1@9U7H C!C>^#6YFGM#UMQA%Q8;X'AKC:"AFO)F1:7.&^\M7G3>G) KB72
M"C3K1QLR.;KX=/39"V?@W)[^^-J\?5&9YL@1/DQ*1YS)B$ZCSS)+D=[;-O<M
MTM-=OK9(= &%0Z0\%$":"4T 3V^[H>,6Z?EV;TRD5F06G[ATRB[NO360U#IH
MI_"_@4@O:<$#6P<"7&O<0"I'4X(RV'TM>4UBRK;@QQ?..8/>0YP[EB62Q!_G
M*RK+.-K7:G5LNWW3)81S@E5U;6.@KD14RLI,299)U2;8VEJ"!N_,]$'+&*?8
MDV*OZ\%5\2&80BH=IS:84<A;TK:GQQ3+.?58*NR-1B$3[#1U+2[3VVSIQS?;
MEO2H8CG!AC":%<^ZF.4XUMATX4M.[HJ%R>JVH4?/L\_I>K2RI>YK=7$F#"\*
M(4R,C< U9<];?735G-.8J!W=;4TDLR%7II4BQ?J(LDVF(MN8'EXU9]SK-*@K
M60JHU5#=> #6ALD 38B>,\.^Y),4)*D:I :,:6LU6%2Z@,(3QLB?VK#?AC4^
M^XN\^T8L?OC^"-;S\?2__G?[0;_[/_XVK[[YYH=OWW[]]E]O.>6.7=NHRYB8
M!$O8$J:0JZ>H(\Z;7>O9RKP.,_6,*F&5P0.1<3%W0.\I3IC.-]MVW<J\CIM;
M.()$2XE /HI,A;FG*RU.<[E9OXW?5)G_"--?1*+G#*^=LQ.W$5P"=81JPYI9
M.6RZV<UV=;=$+^COI!6M)0VNC%HFTP3A: 9:S. *'1ZW1.]M],-K<2C9+05S
M#N(ZN?-,)PB0G;8_O&S.:7S5IK)03YL= RO-H[^RT)BJ@7>[LG1'V9RS>ZT#
M*68AFH'K!RZF<[AH@7*,%MV&^/BR.>,X556Q9KRP/C%CLI7TT=W].";38)O4
M^Y[&^SR^6;^)/\!<Y(OH_YP#S#'&6C1A@"ZW7<8+Q7,]-HGJJ#ZVVV[]WQD;
MW-)A=*O0&0V(@*L[Y2@#N&O?V+#U?V?^L87(4 >T-BN.[,*S=<(?<RVI7C?_
MO+<RC]_PR]>OWKS\W1=O7KQY^<7+__W7M^^^_^"*TF\3=8\1$N?T#3,M++.7
M[K$0J$HS+$U:(5FI O!&HAT23T9)D(B&%:(FXZB3VTH2ZM#$T<#N=EMMA\35
M0N*,"Q &K5=K+8MCU[I2Y^AI!#&!O>_"T8-LP#U3()R"2RV\3.&E>6T8P\EM
M<5./[A+!<85)UCL0;A8(YXQ&*8F%HD^;@'GL.E&;1M&XZ@J,*PP>VX%PNT X
M8Q@+)C'V><R>19Q-G=AB-BP1ULO8:+3%>=XX45_K,Y;IW0F=NS25.(8*S$95
M"#>N;'&>UWZ>"[(&>IN*9%TR:>GU&)E,I?PTQFHCQ!;G*;9NM=C4+$<GW)2N
MO;D/B^Q+M,#;UM];G%]\]<U?WW[[U4\O+]Y])7O3])$9@FK&Z-$RQ%!B:*NM
M^'%258K5Z)LA=B0\![!(8<GH600G4C,"P3H62+<27I4WL.Q(> XZ NS01A2'
MIH@R>+258C87XN-LC6\ZNDPDW/ "V#G=,439C\L7-1TIUJNP\JAS&#3,C4D[
M))Z-E\;PWK1X! -J=7& 6O/H2(68M*_M[I!X-G!B[9DY70LYYO*,U#K1$H_9
MK<-N-GOAVB'Q&#(]!V9Z]+ !)>M:J0W$)%K3;+-0S[9;?6V9/@)@I R744:9
M"IAB"JVC],Z)P'7<K(GWENE53=^\R\H'=39=1N]<>(IAL]''E)+;]-];IM_'
MU_)N%PL?&B8,L3.2E)"^F)>84$=;W^>,[+O'R9;_K2'%\I Y'2U; *L304Z#
M,HD73,^?4KX-*5O^-X4?&)$9"NJV?* 2M58(6$'*[+2O#CVX_&]8^3MG.ED=
MZ).<!B3V. 9FU@JIHPJ7QIN"=AP\!0Y-G-Y[.$>M6'M=J?#2>A]N';7DQJ$=
M!T_!14?3I9999:[D.(\KI:3>T:+U+$Z[%\W9<? 8VCR%54!4 %(FVUJC1\A8
MN6JLMUKAX[[;9I6MS=,N'EL=K9IB3\=:8@$T$M$0-]/&FQ^V-L_K+V>3W6,>
M$QS19JX70IK'[OFQHFY/?V]MOGD7W^3?=JGOH;&A]W*,VPHH1P<M11J#56O+
MQ1-NXAL;MOQO3";:R')R=92.58M,#22-* C9;#?EW_*_,_Q !8Y6H(H7K #J
M-#QGL>QN4^>&G\>6_PT+>Z=0$,X2I2.8#D;+P>34? Y2$&#8&ST[#IX"AWII
MSJPK&J(A%Q(]^L5IE9INK+YQ:,?!,W!18X-"B+%L 77EPC+0N,YNU6;NH0.G
MQ\%C:/,45IDLV5L?YL&8720F11DV2P?7T,TJ6YNG#2MB7-QL5,@!>2:W="['
MT'0.[K%O#V]MGC=($<-L67E@3I22E(9M(IKHI(9]>_K[:O/3[_\2[_[+XOE0
MQKU/R>^<#9_B3=DYLA6<*[\KD#YS+<I2(<KNAK_#X!E(14!PR7VM_ZHXL/(D
M1<B5Z %C:_M(R@Z#9X"BB@Q]D+'01"^JZ1 >$V<,FFUO %TD#&Y8^#NGB8IZ
MX\FUS";8&<2\%"AET@@+V$U4=CP\%28=L]=;[QJS(GI-ZBUPV'$;SK6I;$S:
M\?!,O#0JARU'Z$4G=ATZR\JAHQ2>L_)/-T(W+YT?#X^AT7-N+>/,!EYG^$0=
MR<(=N6D#6*MWE\TP6Z-G<T7I8S8S3,V!;D T!MA@HSZTMWWN=FOT=*\7KLD\
M16LV7"NJIM<FDFV]TT?%[?4/7+7[-L.^_^KM#]_][JOO0KZ+OP>]EW1Z6@D9
M%L02"JAK$;6)P16<VF"<8SO]5NBY/L]-*O4E4'1&=>!68PJYK[75A/8VRU;H
MV2YOR)BXF!,0ZV@:S 38<7(@6MLN?X6BTU/8O;8*8%@X<J[,R41$ X<OU?;E
M^G7;_9;J@_@^#5$)&I%04&<5]>.&5?8AW11S^_Z6ZH, P#QZ7:.23.\846F4
M,E!:"A>VMN]Z7$8^YUP=A09(!=U=,8!UND=0#VI5>,QMRE>1SSFM-;GE+,V.
M8CCZ;#(&]<+DB=#-MU%>2#XGF%<DQ6 I15%6)H"Z'NQZL>+%:_.]'_W>^R@O
M?_?EYR]>OWGWU==__>K?OGJW_D2[GG,%/RXAZ)+<" ?.D=*8827+2[##S+8?
M[XAX,L2(46T$<1<%++TRE3%F=K.!/?K<B+$CXKFHJ12;CM'[F($5!K=^#/H)
M$M%9:%/3@U2G?NOH>ZS0..=(@;<EE:#JI>.,*CH*KU?K<W+D[@>Z0^,!0N.<
M/0TNI2N&>Q?$]N,.!Y@S6Q4'X<U1.S0>(33. *H./$'%:DP,,2Y]R(3E(U$6
M7MD&JBW7!X(<EE%]=@F/BJXF,R-B+OC7BEAX0\Z6ZP.!Q\BALTVO4 :B'M5-
M7VMKYZ--9U+?X+'E^D P #CZ4F$W%\&:7:%$#;6EX1Q3=</ ^\KUL\]?_LNK
M+]Z\.%X_^?2?7OWS>OWTC^N-+_['G]Y\^2\O=O7Q"O119\4,X5[E.!/?N8_N
MI85T#%#8D]IV?#Q*?)QS-W1(F^&4S!U;G\( 6HPZ2L71RL:='1\/$Q^GW%BI
MW4=ZA 6:IXHEB9AQ3H"R>W9=H@[Y:\?B8P7*.4=SS15:K3I6VERLJ117I2(Q
MLU/N^S([4!XN4$XAK@:S\!C+4UA1.:0-]$5:VM4IZBXP[4!YP$ YH[35$)K_
M.,Y@HD35-FL@C0E3CW'6&[VV>!\6A]J/$ZY1YNQ\G(U>&<.P.=)4S3PV#FWQ
M/BZB= Q?,+*6U)[HLPIKDY7Z3LO4QGLRW1;OXV)#&[/4)5K%FBBEB("%([8
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M KH +K2NYM;GZ%PV*EQ/N)]]_NDGG[]Z\_*SSU_^\_4+EJ> B *"I@P5[C@
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MC)IJDD.7'C_.7RE3,[6Q=$8I.N8S]W>[Y/.D]1B]:"?'CARLOE8#K&TT..9
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MJFX&S[!ZL_')@T'VMW$:E_)#?"'%(N7?3'066D*+!12TC]%*0%S%L2PDS?D
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M\$SBKKYUW$JO>1:^9<>-5;&U/<!&U.4FQJ (!?7)B"?\*.2^XT>6W:K/M6/
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M/7Y)70_?Q/54-U/#LXUZA,N(%J41FOH.@DZ*7POMJK%L>DX-VO8E+<>_G?0
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MY/';P=Y_S/[I@0W_VOTOY]\.+O^*?#.DTF:=P(P<4+ FZU"+6IW(B3@SX:=
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MCV4K63:&IA;9<,GBM))EM;G0L[9>?Y#G-#% OG I5:OQ5L!L"FFM3?<#DU;
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M\IS1F"4Q3R8&G4ZF%1D?Z\IE#@_ R/=6E.67-!>=),N^8LUR,6VQL&5<QN4
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MEHGP$Z[X AL'U;=,*KUPA3!-(0<?PJT537,\?PF*+A $J'MN4A^SS<+-1>F
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M'\3)%U8\#9//A<&+^!L2):<C=1UR!"U>&OO#X;@J@WPF=\YWMHU\(,=#6F;
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MD842NSJ64)2SN'FWSC/>R\?GZ [5CF@5NS]M3+#I_3V.+T#&H*.^!S^,JY#
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M$TUZ4X+";'X_*>)Q1AD3!@"86;08MOSI60/2T8, *_>DT B#A089C<-(6/U
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M"662<)^ETL=2E4725_/E3Y2@SX2;#L/&%$'C6!?UB(Z)KZY$R#_'G]99%-;
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MF]P)+L$&'D>Y)]*Q4+6'9?G)<$C@0(+[I6<\/]5>8F2KO*\3+%K2";&?CX5
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MP3W:M45\,I_HCH,)EC5SK@*QK["?B\&+)&WKW\0 <4 *7>SX3Q1U+EJ&AHG
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MB7@02C-TZF-WD:=<Q=HH/XLR5^F0)>C1'Z=@LJ^O_0-.3P^6__YWK75:IZE
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M,C2P"W/E_NK3Q>TI:MO3]CWZ:K\E(P,-1U)/;?<:UQ!71@:J.!FA'1G>972
M_;R_O?K\\5^GJ&Y/VWS6U7;I0+QT;BM'4DLOV]R\X5Z.1/Q&:;)VZ:;V#<?[
M*32;?5K3\BX@+ZR</&TK5&^<#2HQM(0AF3<^0:SW2D_.;3C:3ZB2WQU3,V0G
MFS_8 9[QWLM,EZ.QUXIAV5:[_<[AU6]*3ZXZ NGH<DB.]"(K);J.UI<D=Z@.
M;$/CQ5<?OMU>?+D_]'AQ+=5DONW,[0?;AV]DFGC;L<N]QKD:$D5Y% UDBO@4
MT:[KVO"X\'[X*>+A#C3^S>W5OZ_O[O>3(NYJ@Y?I?+TNI;\9:-\H"+[+K^^O
M_RGAMPW\ 'I?/TGJVQ)Z=__Z?/_MWT< /%G?L45=?%E+648%JT=2Z819P\,D
M$O$;U7=HW>-"NRSO$.4=.TJGG;8KV3'D28"FHZ@C@SPGB/:SMF;(!@&-5%I/
M57E\H9'O!::-$W!E>4=I(/;4;F<@4ZF20-832-N0!"*=R&IKBK0#[)W:5)*3
MY1WLY^77+Y=7MWL*MQ][?<>,AM.%,Y]2U[9(*&L\MBXG-\H>?I+N?]4H&I;M
MOM)P7U"B?;,&@2VM)_W_QNC\7=1W7'_Y?O7;A7+W[>[^ZLN7(\@5UY%H_^?5
MS:?KK_L9JG[TP!,4>'][_>48:A7J .'][=7WZ\MC*).1E1YE<\EJKRO;5#8>
M2>VVK/0X0<0/M<9UV9&!LAU8S;?7=S=7MQ\N/BF77[_LJSZUV0VT3ML5[G5D
MD*KI*"K=&;KA 0N)]HV"5#UM(&-4C:Q1V;ZP4E:PO+"38*_=N(YR$DDK2-(;
M=V9#.HD5(+YT<^6&H_VXC@,\55GYU<7WR6Z.VXSH-=1V[Y ZU$@'KFH*::F]
MH2$I1/J/E5)=]Z#Z9C6<Y@Z_R&(G7NR'B]M_7WRZVD\7B&;'B4_;MN^H^K!Q
MF3^)I.6#^,.AG")X@HAO#[4CP[O,S_(^E;>?KBX^'&Q:]DQ_+3.SVTX2[#5N
M"(%$T?)\F\8ESYOE69<5V$,!B\9C_J]_W2!2*CW.7=3U?WY_^^W[]>7!ZD#I
M<F[O<AJ-LVHEDE8G0AQ9UD\B?L-1NHV+!TF7<P<*]_O5I\N+#U<GJ&Y/VYGI
MM!I79BI1M!02Z,IN=2>(]K-.5^O+4N#C4K/__M?]]6\'[]36 5?E#1G9/@FI
M#U2E$).&+^M2<^)VO-KI-\Z0ETA:1E)_>&2MMB7B-^M4HY?I5--PG!]7/?7V
MIX!DM?7V7JI>MDF$]%(K#R0TKNV]]%*K./US9&@_KC.K3YW^N8F<F><2?Z'\
M?3&'U5$W +]0D0=42\.SK>JRQ;HDD/4$8J@]HRT)1'J1E1)=2VM)FCM4+[:A
M >RO-W??/E_?'WH$6^:)R]KY:J_=N G9$DG+2&HW;_B<],(KR!24G\G9<+S+
M?#'[^>WF_O;B^_4)JMM3L=W72?+64/9%;CB2!GI9BZCA/HY$^V;GO^0 [./T
M;5F:]IFP^.&HX#-#'L/=/N'<N!%1$D5+*.HW#D72U:VB-LJ0'9(/,-M\27S+
M]AY(8$8.\94WRF<:DI'GV,$,_F"J5V:>2\.VHP[Z,O,L"60M@715_:":4#;<
M4Y)$MPG1G?6TEBQ?/B[G^)\7MU>?[K\>GALL$[\O/(32[C0NMR21M(*DYE7(
M2V^XBO+KLC,W&HYVF?>-YUI__<?%G@9:'_E)X3<*A][GJU,L4SL5SV--KXSF
M'9B5*%I"4;MQ*)(Q@0J*);3&C7"3<8$=6"HWMU\O;P^_(+P60^7JYO8DAVJ<
MML_6[3:N?[1$T;(9V;@N[#*:4D%M0;NE&;*VH)&U!5L7],FJ@BVJS_5!V>(J
MZ4=7CJ1VMW%'!*0G74T%7$>FUQNII9[LMS(E_HR8-&+K4NZ(0X-]] )[[KZ1
MYUO4/^<0>=L&6K"\:.10!0'Q/$,T#KJORAIL)0#0%$FPIOJOJW;[AU3=51H!
M!^3FOI"M&DA=AJH/#ZFXM&;JDA[Z_FER<% M;783(*@#SK]6,^CL34B ,>,8
M<AT9#H/-=;L$T!/;5>:^[?G*@A)?(3/ 9!@H4_) E1&EKN)3TR%!8(]M:BFA
M!QMUQYX_8[]&OD_=D-\Y]VD ?Q ,K.>#Y/5M\*_*#?5-7-6$*A.?8A]U)9S"
M2A#?"FS:]4)E1HD+A#J.G'VO>X/\A+']P4?]]7Z.:VX([1N?/MA>%#@+Q79-
M)[* 7H"XUG0!/D@(&_5"^!K!&L!J%6^LW-]>7'ZZNKJM*Y&V/1AY(JU62#Y.
M;7.J/)( Q59,M2"O3<<+@&P#.B<X=,%91Z]_^Y^1_^9O*U_&VQ#OZAA:'R&Q
M"J9'VPJG0NED;Q366RN]A8P"SXG"];<L*]3JPS,,H@K[+X8(4W#IIIAE"BMQ
MR#R@;^-?WL4*TG;9\]A-[V;$G]AN;,<6$!+;,/]: &4XT(;]'L)%1%3$BP7(
M- :R);.%?]<VM$Y[_=<M35_[71V/U;5!9[/'%L:7>HEI\JP=W5ZY=(O"C>:0
M*"\7-PJ2]P4&6?;GU$_A,*'G([ A?IR3,=@1;XGS2!;!+V]R6YT!Z2YQ_S+C
MKI<@Y80,@ZKM6F#>O-4'\[H8_WHVBURFVT&6>E9D@O488)!/>:0^55[I74U7
M1K;C8#L)L >,EM%2P:H4]B*0ED+P"Q- &S#-UM>&ORH@FDUO!F*86YU@1&3-
M5,L'*>HJHP7LUO?@$=$\)#_8W7?W5Y\N;FLK(7ZI6JQ3*RIG41#2'[8;S<CH
M-2+KTO>F[E\"5(T,.\2UE&^.27VV+>72<V"C ?L8$$'=23C%V^YOKSY__-?!
MXJ!6T^1L$L%J?B0HN D\WR:!'6C*_11@S8P6 NLG#M@LWG@<T! 9X?+K]^L/
MY_I081L&KK'H#/&"_W<\X$7!E< B@)WK.L=>'C9^;'?LV#]MAA\KHBB=8NEE
M,1N2>=!O?#H"-'#>&-FP6U@+2"X4:C1D6]=2>ZFIPOT>Q2YL T,"X/5+RMD5
MY1P> &L%'<A!4P2K&'OY-CP;_KB*?&].%?IS;OL\W/"1COP(VU@9+; \E/<I
MY\'.L*7544C 6JV$-#9H R;0Y..@CS$$'MP/"@+#B\+ MBBSW;ZY-NJD.QQ?
M&*#Y%T0.L_W@>@)_HMTH#,2C45.U(@D &4X],-D$-D#97( CAWLASAJ%I#R"
MF:XX]@\*E@5'$<?/./)9%$_B:1]X>I9?-'$ZTBUB)9)%II!Q$BLOQ H:V7GA
M!NJDIS)CCJ1L%/..YZ.WBLXLMP?!7F*)AIC[-/"4^+?XK-@(6,>%ML"S=J>)
M^SEC/LN1[ [)ECL@ *WQEOFU.Z:(^"AUS@O#+VVM5R[ZTM'ZST5?X%>@2QM#
MYIS>11 F(;V[?WV^__9OZ?]O)7M0QAP>Y&J%V>_?/GV[/%ARJU70'1[0ZN7.
M)V-P2W&VF]NK?U_?W1\L8=8*:12#",#+K^^O:SLM>LBL_0: ]_73 9-?K7R^
M$MG-6N@\IAXP)J<_>5&&'2XDS^\CS)=SB]'#:;II_H5&OA>8-G7--48YX#$V
MRI\VQ@%ESQCCFG(#B)S#2BW/I4"5[N2<F"*T]@>X")C9#I2)[SV&TVS>-%92
MUU^^7_UVH=Q]N[N_^E)?ZZ5#%A9O_GEU\^GZZQ<)NVURSO,L_<(?,QLC6Z^9
MD!7$>7][_>5PW<E:2?/^]NK[]>7AZJ-::7/L>S/%A8?-8=E8Z1R$8/7SG.X<
M0ZU!B$(>,_,T%K'K?(.9/?%9<31_ZNWUW<W5[8>+3\KEUR_27M@RH^K;02PZ
MN,"PJ(F7L>0@ /;RZE:"=CO0SF@X73CS*75MB\EC81$G=O #Q3BW3]PPT)IN
MDL7EYZDY1LRI31^PUC<VA%[A >-RL5*]^VRPE(?^?7L4L2R!^#Z6%6@-+@=/
M/US<_OOB4WT=D@Y:8I]96+@=S7CY5&KNQ@)<U EB#H6E.ET.<\RED/F"B1#$
MCT,BUYSB-T0)HI$9A<2E&&O'HR^10U;R-'CCE?9->Z=<?WY_^PU4[L&*G7KQ
M9X_\"%C-3HNK1 I,L,S$\49,LR+$9^ IHK>(K!FST13X,,%CG)2SQ'TQ8@49
ML+I%=L,$GL(HX>KVT]7%!XF\K9!'P'P'5IF!N_Y:R]0;. LU)_9 8KITPO:&
MIX5 =IJ8T@8^Y?K;SLK#?__K_OJW@T5(O4J<C&P\Q^*C:T5,FCI6WZ\^'7)N
MN%ZHCCP_I']ZLXR0FE 7'F8NE7<JS:_P7#/W\2D[J9T6]#]M'ADMK?6L><0:
M@L22 6[Z>G/W[7-]G34/6P#/B&ECM2YQ.9O7/$C[L($):Z$_[3F9O.:&>N(
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MK8.UK4[O@&)QTO>LF$ P0-"7!"+]WBJ)3M>D3*K*GMD'/<LK]W_E<453BN7
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M00 P!3FE#G-\?O>F;@ DP>=:QW]="\<<?CU7?O_]PZ7*"?H,?W^M*I$+3.8
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MNPI-N82_5/X9]@A[($[2EAR@\(,*^SSM&Q9BG!'V\\KHQHG4I'E4R&!+X5X
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M6-:$M;;T[9JVU;'6MK[=4R4-'!$-&)NM9_MN@%5V-]ML+M;&(\N>#1X.FPZ
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MRH1=ZJ$$E&O7N7A#0('Y+.4_$4@[ZB._ & ':K88 52"ZT7@GX&/[,#KD<7
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MQ;$5%'-!O-1<S752:8W?QD?%U14S-@=/]G7.QO!"K-DKK/1=OI2A'MXE1$>
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M$ =N!W:PW*P6O!1 6L1JNW$>=#K?PXP[\/&'.LE(/G!YQK:@#\NCC&R0P6A
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M/:4[$\ERAXHZ=NRF.3K??-%QQY--P^P>0,UF\8':*IVGV3F,#L\AVQ?G-(]
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M\9-=XZ"G/7OJUGCJU.USAV[W<E;X><)A:\Y!LZ5UV@B^:]=T(@M>XF>C65$
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M;+ 035'6JL"L ;4/^VE#4LH">0J(B5S<X,2%1_"=C:A+QS;L#:DE KS[(1%
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MOV8<[D!4Q$=W#&W8Q#K>*'@QK   Q7[%)UBTPTCFCCICX" P7@A:V)=,B$]
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M7(\)6R8]?DD>C;K[V!*2BV)S1KV+:C!Z(!A--!]3FGE%A 9.8@LHAP(8R3+
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M!U:(+22$>L H=H!F4 )%52 4' KH*90.P=3J1"U5%\?:?[%Z%*+6X#EJ\)A
M2,*#"BL-K%,&4!NS\&%@$2Z#"%D?[("8Q1$T6)!ETN#GY92XJTZHK@]: 7I1
MP:4:C:9#HXFFK#S #;&9 ]![#2C1&9 \F#/,0HZX589H$=$(-<./=:;^4CI+
M7C#2++8RJ$::J9&FPGNH5D);"6S$%ZIP!K2Q%/ @UXY[RA0+EHN23<Q$#31U
M2= O]^5-[_2T/8S!U+S/[9OPCC!VW[7QFMXBD*1NCR1-MU9WI#_/<@_FG._2
MO.\H7P*;O^F29C_S)<VK?C?I$US#O.I+MFCGN6M_?YJYO^^7A0J#8<]^RY<B
MJ0Y^W?C1'A[WSH>-,]UO?->=<]_X39^'7_7#![@$P(&G#0:Q:=>M!&X057(P
M%PZWTWH[32Y..;/].+&$#(/-T>A'O [6O.X^O X&/E?RNN_NW6?J_OUGYPAW
MOIN37IC7AY_A&6%=_OBV&];H\/+3Q>'ISL^]K4\7K7=O.[LGQR>[)YNH]3G.
M-\SK8!>'?_'NY3>\^^.+03XCPG#@)3& (HV!E$0 "$4F,".(&G2'B7"CA#W,
M'U%+V/.4,&N)EM 3H*E3@&IN@;'( LZQYH@':9,\]FD*6!O_?X,M<J-3-I>\
M,=U,*%X'+A['-WCI^SVG!\=W:^'G>$S51OO4JE>IWX+,,THH\!I*0(/]#I2E
M GCF:(8\E=#XR)D215BB:$4=;US*>&.MMH^IMF-?FS%$6.$Q\ )K0)G L0!3
MA!./6)492)GCRZBVBW9+/)FE%7U7O>Y-9M;8O/K'7>KYWO<3QYR?+36ID?D
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M+2F@S'(@<<R@Y5IP2WS&N8JEPB1@T#)92K6#8_4<'+4J/X(JC]F$IAG-B*-
M9! #2KD'V@D)/%%02 &M\:D'"6SRI>I$^!*<'K^HV9ON9JL5ZP>P"BPC>5V+
MLM+M5$[ZAP]O]@=]KP?G_8OT>HU.TZ'31(]V9P6B7,EXTT2,/,8.21F7@+G
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M;NWYO:1J?TO?;395W^U5:.3[G)[Q$NSGO>&Q[X?9G9[U_;'O#MK?_>A>X4X
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MON_:B\9!/PRYDRK87C?^L:Q)/,6PRU%7!CTNNWL^<;WPGK];QT<G?W:.WGU
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MU7[U"F*I1;&VV,G(*1+"T]R/+2'C,H64UU@)Y;2P:>.YY!<Y,!^N=7H-D-4
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M_#%UZ7X=#%\.3MPXG?2V)VM3$>EFB/1YT6]@BJ:D/48\68NXRD:&41&1&)V
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M]FRT\=/2HQ[!UCTG_><%MWGXY__7#7]Z?FY YW%D619DHRF^7[3."]+@>"I
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MTR_*H5]!EI %]&38=,0L&17#&#M'\+.'F2R@T\NEX@4[PB05_OADZ _S<2O
M4&EN$^?3U:3J?^=/?QC&C!59^OO+XYAAUZ5CF*3K-U793:9%])/[+C-/%+Z4
MSG&1UWR;(_M/T^US/KQ!'X9=QNB;HNUIXGYW/"G=+>#4).:/87KL:)SK"^;W
M@.?(R2V3BH%<*)3IDI;&T7QY5+@LFOY A="BVY3B?LAE!/VF-&KV(&5F!PXV
M7$$Z '8_&![G.B28E>@6O[J9IRV>32:DD\#RFI8!PXU'.6%\/G\PZ1/M\L/K
MU]NC'R\6"ER]XY>((1^0&B,/O%1$EU2:7!O7*PP7H(%#+#G*,VJ23#^15_ZW
M^1R_69[C_?D<-QV;^AU[E!57*<@HXE VZ)6^4K_P5JR6.&-G[]=%.IW=;K][
M='+T8O:XI>.:'=D)*=?K9J%?S]9Y>[K,,_\(T2>GISY\V?VR\U[(P&7"$?F4
M62.U,4AS#W]*9BB3BDLK-YX3?#'R_W\F&6?3?L+GA#H,8E/BE^N.<F57OZF#
M*B@Z8<+/MN42T]2D*O X#H^ZXTE%T2C;>' 1B&DOA@\3^KC1: !85"J[9LO^
M%71K"@L/%V6B^<("9FUW?H"?F</WC^=!:_'N@'Z]DMQG<XD(/%]3UEBJ&4,W
M(_8@,P;9R7CC9W\X)4R8(U#LEXJ5IGYT/K"F+BS;@=FR[?8GB3OPI2IE:R=E
M;/?E7^^]]CR08)%GF;P*LXB,<08)H:QW+%"!OR%E\Y[=^8\"\3GY$TR K":=
M'75!N9>W5VQ1#./<C@J-KW6987%M_JA6V+5W[!CMS*R?Z@S!6,5[*R,C-'E$
M _6P_RUH&<\"DL)(2I,4@E]@5-18D&0!"CUAW+@$ZR"Y)-@XBHVW]+SS-)_T
M;Y /KP?IZC<??_&!SXGH8>R%1@$5\3];,NEMJ9',T8U&IX Y-QP7 ]$/BB+,
MEO'$9/P FJ?Q>YI*WZ5KP8:<IJ)GJH&K!F,_ 41EN$!@/Z+"FG?.0F] Q@Z'
MW69$TTKCT$EV:ETTL';2/S>T/-K)V!H[8_*;V5TY!K,?[-1,T><GZ?>Y*#DS
M096/A_$P\S5]*A7+@R,P8+8O#G5QE--/FP+PB9\U.)YP)(PNP<KIEYH*\.:W
M3[NC6-@8SBZYH#?(!01@_FQU=HOU4&SR$/-;F:>L,7XRQR7X2!,6BG*YM],B
M@,:\G[E?L$IENHN]40X2EIZIL8I@OL_!?MD%*.:Y+P&UT8D_G(VC^:UI#?JT
M1F%T&,&\RQIDV53*<;AX.CHWL,:=R%&M[K AC,B^<DEC'DT*&1:_#+MY83-,
M",%F^V^SH9MHBMTOX5<ZEZ5R#R5!?PSSQAB?Y<+L\78_Y"#*<=4($XWPY;U2
M"C _6119)N,F7B##/%A$*3IGJ974^@ML]8HX:GC0CEMN5.Y?QWSR5#C!63#M
MY]B=;HK-4J_?;/G9QBA_O8R9FZ4[H0Z_^^V:#?M74[C]:Q332>]W0,31?FIZ
MEQV4T\4GO5G]66ZM8!(6#H6D$^*24^2\U$BK))AR1B;?HFJT^2X[GNVR.-]E
MPSCU#HK7.1I?X=AFO3 :#VV^,RK,C4=Q?#@(64^$A6TZI_F8Z^V3LI/ S_\T
MYZQM=."S;]EBD_-/683T+BK%C-Z2FG]/I9B66YA\7S78UVY+R);29A4U78\B
MY_&7DVZOD.3D?>NF?\PV\"H2'->_+/YKZH H&JD.QD3EN&32"9=(9,Y)[%GD
M\E)U<)Z(.)P,\_GFM<V:J>Y(<4V5Q"33A.P?_'/Z[N-?<*T_??OQ'[S_][_^
MV?]MA^\>[+"]OW_]Y]T1W.OOUT=[%SI9_B5@/$=[!Y[N??FENW_PIWA[]"=_
M"V/8_>C)6[@&% YY]]M;^K]?MB==+%^-=[_XL_TWYY54.(3WO^P=[/WS]N-A
M[J)YNG?P:_?=WW^R7?IK;^]C@'D!Q77PK]Y2^3185OLO__G\GBNP L &09QZ
MCKBW#%DP#)".PN=V*-Z%G+:"SSO*C9V,.E_;7IQPGM/_X0<,EXH9$1)7)();
M&D.4IFZO1[Z]Z/N(/6%*&91B(H@;')"C@B!,HXHA*":\VGC.KMA>>>%'5[%Z
M//*DUM^+EYN#%KDP-^?W91=X"";4RHJ6'K=R$TD*@)64+"%<<^-BAC-FK<=$
M1YLJ^CP\^KQ:1)\O>^<]L*,_\V_ L_WZ<>_+#MO]^!H0YU\P1V]/]P_>GNV^
M_ OO??G X)E.+U5N5F/+,>@U T8=XD1$9*AWR&G+(U514D;S8<KW*#?#A)#&
M>XZ5YM(1%XABB1B* S4D7.Y*U^WU>+87?9^/PT6I]HV1(:Z81T82AEBR0FHI
MA77I:MMI9<IM#3VW7>L/X<WAV7+(H7ILW_38-&".XCSD5B918FUQ=' 9]RQQ
M:T-%G8='G9U%U,%[%TQJN.[OU]W=OW?YVR_;G\&D/ML[^(N_I7]^WGVY<_;V
MXY]D[[?\V;\/+Z+.!_$>'"BE \'(!I)R!2Y%ANF$**?,1&&T2 Y0YWMTFI*!
M8TTL<T%S'(+E0N+\:QX+IZRHN^MQ[ZY_\/O = 0SAJ$4O$%@)8'QY#B\HM&H
MI+@7@>?F:=^ATVY7,+($T@^?.KF4/6Q+2Y<2"Y^R?>=CXY.<0C,:I/&IG72"
M6V@35P+J,ZKOYI#\Z'*UN-EP^,_8LLOM^_W89':5X^[)C0L)^K S<'D,#3?_
M^6&4L]1<])5[U91F/B]FPP_SKY71E2. ^:G_-</WTWM,"=,G79YR3ZR2V%92
MB+X&0Q%312G+3:H=!SBS/$DID\F'>(S'&C=:.:OB[L=7^+V2AD6I+:+:9?*:
M(,!1HAX4BX95 $4 +M/&\PN2WYEWP[MT-7$BH$!H\J!,>$K&8A%<4,E9S+$4
M-<A\!ZNY<_H>)AT6C.2@F_+PCX[(*9D0Z'0EN R&6;SQ7'\%Q[^1T=XN#)ZF
MCN2T&-0K.;&35)K2?R_7=96\'X"P:49QTV<YMV4>3;NGE)J"U!N<CK8Z?V?,
MG<)YIH ;E_RF)CNWY,5/$GH:S(5[]P='S>9O&JG UST@=FFTL)B],BLR*WVB
M7<Q)S'F_QUDYV[F!3G UYSV=Y5];3/ <38]+MSH["Z>G.2%XE@LT:[=0!A%#
MT^&E-+C(><--YXJ04T/G0PC=E.(P=[&;M:;Y#MKXRIA>&=,K8WI; PU<KB]C
M^C<9T,]EA('"<YKH2(@G/"GGE'$8!Q*YMDG:>V(^OTE:[S=SV)[/T'Y6DKR0
M^#AM^;RL-8J6^,_)H$GY+V5NQ\/2OM.6RN/Q/'=U<ZG>YK3;Z\T;^RS\3J-%
M;6=!B\[TTT)Z[DGIAKV@7R]1&/>8=#GA='T];Y94LRUW#W;(>X6-$M%8!"\P
MXO O,H$IY*4!WXO)@'UJ??;DE+%W87E;R)8P:[,U[W\W::U7VN26MO&CQO5?
MJ%^==/<KN=A@WHV:QO*%T25W&BK1@(9&?M(MKZ3QP;6CG#G^\]P;WVPZ%A4;
M=32_;CSAARO-NQJ>F*D!^F$P",6>]LMM#N?L"Q]Z Y?[.=NS8M\V \P#&)\=
M9YV8"Y FUB0K78T,[@10&J6Y\:?N:%8\.K6[A]'EI/+-R61T^[E^+ <;-B>=
MT6"RC@:SPM[,<P\OIC,XC( Z_5F;Z()/RP_01#B6NB?:$0#8L%L,MN76ADVJ
M^V+M )C-)[,>AV6(S8S,RQ:[H_DZAS++\,UM[X>9O>'U].E>-P-MN@S_,7ND
MJ3&^U"UJ*8E^ZRLL_2WQTB9MJQ<6X -LL9)5.HS+3L=\0R]VWVP"7*6G=0Z7
M-:^:LNY2H3'58PN=,S>7*3_*YW._;+&_WO(*ESU_=!S'W7'I>PWWR^6<DW4J
M Y[KM-G0I\*7V4#*(VQV0++@#J4_=NYY-YST S^&GRFE("?C7$=2=G$L>1ZV
M=S;J-CL5=N_'IDO>A9%/J['S!LV$)9-FZYU1;I8=MCK;A22J%'G KQPW]$]3
M\9UORN)V37O]-8_672CM*^4LDXOFLKW<#'[>S'NRI_.7_]IZL[6Y4),_W9JK
MW7;T6MMN?#<_?KT]G]NCEZ*<T'E1(J%-L_1)%+CYHUM6&F3A:-Z<_&B"0[ P
M_W43.O&(%6.><L8II\YJX:07CGC-1%149$ZQBU6[2"_%V9[U3X["8#SY?#'M
M?P)7$RF88-5V/\R!:E:W:YZ<W?3J\_Z!/WMO,+:<N)!Y(!F"A?#(@<>!)*4J
M12]E<&"QJZV+=;L=US2J*%OC)JLN64C$>;"&#>-@ VNO#:;6$^.-<=$6)CDP
M@ZFIJWXGJR[>8\DQ)R0B9EA /*J 7*(.84N<=2$RZTA>=?R555_D]FJBKQ."
MKTF9SV5\49N VZ/<2A5,H=[9<EG&O!+OHOI(1:M-@!M>YTR*XS* V;MS])Z6
MSA4W<ZJ@X*NGAP,P=&#AAPM*N% ;H(;:(/,PH.G5^2N3@>26T7:8JP/MV"ZI
MZ.F!%/QJ8Y\V5:/-/LW=G=MNY+PIYNG,WERR$Y;,QIG1L& A-+9M\[7F!HN/
MWOECNC2%_2%^/NRZ[AB X61T,KNXL%[D:[.)D>=RU DGI5%4*!'JS9E=4PR"
MX9+IE.V@HW)9,_2\LXH-T>M-"X*S]S%YE+(5OC06<%[O6=7.G*8L;[/1PHSD
MSX8PV/8?*9Q;QVGOX_S6I.-YL?J+O;4L365Q)@']YGJ8HLD:@ G8;2S,34#B
MW'A@YC0T+'&Q%S8[Y6!V-OEY)>R2+Y/7HQ'UT=(HI\,!Z;QL=TV6H!B:A5QO
M>L=2-3-C.VHX4!J"CCQF@(;1:.K3[)0EA!U</(^9KWB>$6]A"Q0VE<*IM!A%
MFA\%%_ZZT90W9<DE2[/-G(NWL\^Y!'"S7[MT%B[SZ+J7CSY;JPVL_K:]_4?G
MPTFW^4+S^XU#OMA-NWCB)5X[:;*6IS5^AIG.W7JO'LS<9<R<4KVIR$[B<<L7
M=J=\AOU1CGQU_B?:WK@!T3^6[>]1_#"OTK>]HUR1'S^#6S,J.F%"J ,_E1W9
M\S^SU)<<7"T/^R7.?KVQ3WN@>SZ5T.#DI\XY\K.;=]S)>!8^G+(6;IWC[4JY
MYKKA?IPRW(SFPE-<CXPT?=BU9\L[8/JEKVW]*=_B.#-!+_'ZN!QK*&7PGPL<
M9Z_D1M0XGC+E@B?,@K(W5KNHO) .#"Z?<)2^!!LUH8R@R\RMI?K9L@B-)?6Z
M&?E3)KR!>Q_L\O>"><&X($CQ<EH--K0)TJ#_G[UW;6HCR=:%_XK"[]GG]+Q!
M,GF_=)]P!&UL;SH::-NX/?"%R"O("(DMB<;PZT]F5I54$L+<!!10$],V1E*I
M*G.ME>OZ/)!*+HC4EBC[$\:1A9OF=+ N7B_NFZ3"Q.TRA&#*#0Q28"&+34L@
MRZ#</=ANVFTV30F2Z T8P$:QN&G. *.)!DJ)8*E%V.!;;]H]0:C:3;MNTPQC
MECLE 5(" \JCDBF*-8 62\81A3+:KK=H0;1R_2\R^I0N$''[T9THLK.%M7:G
MPSR8FR! 2F>Q!HP[*D,;B.%*]2-2Q4_QW)O\2E[M/,Z6R+.KUQ!_<A(L%QFS
M,MN3(5+TY/SK]*(/D:MH4W\SG?AV4':8),A,E^O*1;&MEAU=F74QRA-\%!4A
M.7/=@2OP3HI\7^G-O2NJ;ME-6W!_54MBE4_/]_+/H!<=$E XF'/)^,DGBR,Z
MNG3^N(!^SCA!12&A\&>J2U[IJTX^.DV;SONLI>/T=_V.+M_+Y>SR-"(K';!\
M@='$>:A=HURYOIMSX&HN2PZ4!CV7GSG#G]52UCD +./PG,V;].)<@N4I<GZC
MLD7'^>!SCV?V@!:7&K+SF=W362<K6L%!QKG)=QFZ45(/TXV4U9C1)*#/_29F
M4$E6_<;KCF'UJ)/LY-#/=*L6JSA;#OJ0"BB]4K$[9<B4.HX6WU'&N[XK-.@R
M/;._\NW]&4.>$J-P9Y"/D%=]:L"M]4VX'X]BCPA+3 82 FI8/#6D8, P*21!
M B/DGM(_:[?NRJWCUC.J @8>HGC@8TZ!QCH-J%$',;.*$O*47EJ[=5=NG7/(
M4*L4<!()0*6,49%T41T,90%[301$;]Z2N_MJTW"Y/$Q&D_/N&B-_"S?LJ;)X
MWG>V!O%P12+=>I51F930I]027Z8D$>GH"Z?#G!=UW9$^.!CZ SU_XOZ\"?9A
MFY:^''9/THC'6M_]=]RK1-_S+CI8;>?2YLXFVQ="J2 2:3=V-IY3P@(CO ?Q
M>!(4*D:))HWO7*JV..MBM<D-Z5V:N;?#\M[*0:');%+VZ&Y3Q?1.8$>-QM @
MZC R$ 6-G5 .6H>YO.8\N5$Y<T)#$N]U.WQ,*>6H0U_\,.<WOT0O_C67,N/K
M7]&^#M1CP@. @CM  \9 "J( @2INCU0HVJK%R8&JE+ERJWU'6'-B#?,XNB'&
M2>.P"U&%&4'1,E)SC??>[OM2]IWM&TJ9<)X AA*L/X0B.1H6\*"-9%)RB,C/
M]_W6C0L.(JN,YL8R1H.5FE.*8RQ I(J^C1;7>/_MUB]CZW?Q/M$.:A-WG2/A
M$P!8 #(0!U)8QH7E$.J0MAY=O?53_JDBXL]9O-RBD*4B;=]LK\+*8B_39S+"
ME5I!N@#Y/>[VNPE:,F<J4DJH/RJS'B6WR-0UFY(AY/+SPL.J.[ISMF&I)87R
MYO2L(S>:4B0,0AL(Q6?8I/N$8TN8(H!C$X64D=18%<U5L()$*64P(X@]84VO
MW<L;[V7B-D."&^ @BSZ&L1:HJ#W :T&LU]@X]+15HW8O;[R7P2O+J!< 046C
MOX@@,-8A0*WQWBM(K$)OWL)5=M<$Q>7,0]&>W^N5^?E:?OE)P_*-JF^A#<3C
M-<[W$8]>G2,,$"X)H-)%MP(% I1PCD!L60SX&A^(5YO:]8]/"+LX_*[=T1PT
M=S'-?5;-[(PR<U8_-UPF6(_<HU/,Y-5&PDN6U= =CE*A=*7\:7 Z+M&[GU2G
MDL.>1@ZCS[[1'^O^03<^1 $TWVK9YL[FQ3ZFUG(N-&":FN@749( H1(6E"*<
M4(^D:#YKZ'1O.\7F9G>]VOR&*%Z.-DZC2@R[XR(0Z743K5F>:(W^R5P?84DN
M4G:$'I3/4LSC3A^W!*?(S8BI32'$0&?L2R =XRLJ95?V5/3.YTA09DN_J;FW
MYW/3=%[#W(91PYP8^V@4T@4R2_"D[30';F&0DMZ=_SG5P_A4JYT/Q:CNW*='
MQ03P#%K%Y-9^=L'<USH:#/K1/'5#YRR7F].1W?FKI)!)ZP).A@-;8'24/>+S
M<$G=T>4YO4P?.K-VE]>XDQI2>_G^\N1D[[SL>T@S5NFJD[5;2;:T*'6?#+K]
M<=D4,'>Y:ADNWTSGFCO)*Z%-?+"X&+?\MK-A8CE,E8B0KI)GW8JE+S$]&M]9
MO7%)]J=\L.6RS8!)5>/[96/$912J[G#F RNU=HT$!5/U_D[%./?O3N0O'8 +
M,%M6.YVJ>E3H-)LM#/FQ[O;R8.;/;=<UI^=/T5(6FN9K8-%:A)468:5%6&F0
MB!8(*^+Y(JQ<BY@RA["2J"*"8$$':JD+\?TL(,@DPR;^+>2#<VFNQZO^DXU=
M&R.@S7A/^S$\8('%T#O^P0 -) ;AB&J *=4Q##=:NN:7Q*?-&AO]-#HU2W_P
MM*'!VI1+,/D3LY' 2LY5N8E41N]N<O^S?:5E@^HL/6*:%M(URNP/4\R=[JBD
MBNZ6\#V%+W4V..VY8OZLK(14I-AU2NV3-'F>NF(JH \]1098G?L6719DRB[;
M$BINEFG251! H]%IT;L[&8:[A,M0WN)IIFRL\!46$WZ759ZKXJX8DD0#VHU+
M51!K#[T'O10N= Z[\3TQ@CA/#QF_(GT\;FGI7Y^<QKLX'95XJ_EY\L3BY+%7
MBICLSW2M8B]1<E+3F](5#N/NIV"JO'"!U%I[,ZF_.25E$FO:NREF8(Z3IFN<
M&=(F9FM6*G*_?-F*G"!?2X;0BLER.L6YB*(T#1J>^'[&N"AFU\HQ73\CD0DE
M,$%&%*FDZ4"G[AP6#.I)2(JL;.%@QQ!N-"B&^L;G)_D!+KVS\;'(+/N\K52R
MURLZY9,('W9/1A.LFOR$*;;VQR68S'3/"CG-<(WI\]W14<GFGK4DUR[]P7E5
M[4SV0H^J4>P<D([U4=JD2ZM8$;^G>;I4NNSG-O+Y[S7?B\IJB;X;-W3RE5&8
M?NW\@OY5"&:JI!XG/8A?'->BDB>;YO&BZQ]U:C)8F6*F&!L/JEG$V;'+,+''
M928@V:S?.K_@\HMB:#U.H?6BST[POXJ)OSS4,$K<XB6K3:XGE_=7C0EVTN.,
MXA>0\@NBG"<+,-=(WT_9@[@&T]NKF=O?\EK^0JNUR!M4V-"TOO$*\2[RWD5#
M-$ATA258S]SENN/3,DJ<#1)YD01P11"9WSP9X$[KN/ ,NYX)_6J_[6$]J3]3
MZLG_F8B'7KTK=1#O(_&!Q/N[B*_OO-_'@E,<" 6840XH%18HA5,ITV'B@G->
MLJ?@^%SL/A6[>!DEJ@&6=\I571U/R1.8CJ,4'DCFORH82$N,LS2H4PP)I1Q.
MY0AD(QDJO*SBG?&'?_QYX2T5D]NIGEBBFN64X"@?8=UT(A74VB>SG*@Y:3?E
M1,UJ7AW*R>(F.NQNS5CE 9HZIM1JYW,U,OXU?MDOG[>__JN>,,K[T_FS='NZ
MY3S2%%JX5^S??,?,S.XEB&S0_0$.NU'X^K^^(NVL,1CLO*=;W^WY/J)64LTD
M2'P%,>A1(<&82Z U#T8+;9S"<WY'NWZU]1,F*$L<!@[9:-X@(T!2JH!E$DG%
M("<!OGF[7>AKEN.);<E_K;2R><7:XOWH(<28FPK@F0EQ;2D#430),(3J@*/0
MJJ!:V;QJ_<B^55Q;*Q' -$W%0(N 8LJ $*)@4HY02!/,%;QB;VI4YT4T6=YV
MF1<O,]PG@@1IC0,$<@RH)A;H-/Q'((W*K[URMA73GZR?#4J9( 3@PL;U"X$F
M2 L#O%2(0(^AT[HRH5<*Z4W /Y,[%1V*RI^8@A3-.#S)R=']>OFS2+=4@\^%
MAY6<L2GA:/V^ZN!'=2S:=.UC?51=8#+5JX?%G/H$4#*_GN;.CX^[X^(]!8IM
M$5WYNI.30&1J():+^X5_2ER_TOESH,OP.5XMX<SH\P+1.CM<B2$B/ZSS9OPB
M(%;K,K#8IZP22R4.;=4TE-]GX[:D.?LBK9=FTF?&YJNMGR2L4IXC9Q-.C^=W
M?L(0-!6IV4:%TPPS5 P,%8G$&!.;P7 X.$L2,[ST[?5 >@)-7D0#\W<=Y:(*
M*:H$W*5[G[W?DE@I?\_Q20*L&A>W$ ./ C])NX2$5UVV@%+Z<_)LHPSX5<$E
M#*KD9P+\&B=8UZ1?Q0?'OJX(!6) ]?YYX9Y3R8+[:5P@":?<4;R+\\F0?LZT
M7@9J_^&'-N4T\LO%%ZUVMF>#BJJ??@ZC."UT3B(E 0-)V-*.=&^PN0EOR?<*
MZ-J<YQPD/(L)&MAY\6(%;*Q=<5^_5D%8@JN-'^D.BK1.1@OI5Z8AR5TAX(7E
M.-:C3&M5#'1T],'05X 8)0I6,;<Y.HQ7+1:RNM*"9/M*92SB!4_TS"(5+_3!
M1%=.!OV<O6F\5:AOS135,6W27'19#$R<Z(10_(\_[-I>:J>(WW\:$JIQ =XR
M"8%S_E./=:=LV9EY=7HD%4?,22&F61\'EZ/:LW@SMYD<PI8&[!1WBC'*H#.$
M2(:=H-S$V([0*X!N^2T&AB9*DM4\Q^[;(4;NV;R^XIFA@_/$$9A(XK>^;\2?
M/^U;R(7GTH%@4QXL( >DA-%I)(8)HZ(?:.GBR;$B:7IGW%O-B<8J-18S:@R4
MPB)DM$Q4WX$$<P7N;2L$2Q>"G8-]2R",6X'CKK.0<(]%XHLPP"J'C1>2X^3J
M7B\$\2C+O8GEU-A"A-M9Q_2\^=:C\L#.6Y&I1.9B8Y]HC4*T#2!PA@#E-D%;
M4 6(-089ZK%&:O'8X3.S&^WVSV__]OK!?I#2<Q:W7WAM 94^'AO1$0(J'B.I
MMX@2;I9E,>8=G0*LX-88!?><,;N'"*7QLU9Z"NFYV%S?V'?06H093/.?)L$4
M&* @) !B!:GQ"F-KT]@9^;GTW ZKX)[SHNW^+VG_=W;WL3 ZGA,<0"T$H%Y[
MH!@2(!AO))5$\U3=N7;_;X]9<+_Q[U8$EB0"%VO[UD-BH>9QXZT'%/$ I.42
M8$X\)B&:AT3G=[T(E ?(3^$*$COVZ+#HF<NUWQ*M<3Y?4^^,FZ29ZBG49W3F
M_%5FQUJA*X4N!;O*(^>#H\ EDY/'[0S2!% JI: >(HW)0]B=ISMZ6C&8%X,8
M[BKG):1( 2]%GG770!LI@#2(T"@&SBIZ"]MSE?/Z%*.W)2!C@GR=!"ZOO?DK
MS=K:B_VHZ9I% P#BPCI A<(Q8H4<Z("P)8YZ*^G\. 3!T'$BN0M04"'2$ 0+
MU#FF%$0^O;^Y??>(U7C[)L+0D!:RM9)+IDZ_4DL*V9[N'L]V4J_D<D-_ENH]
MUS16ZM65>"V3JTNY:%+KBI\224Q@[I+>CF=0B&89]FS\NMR(/RG8+. -S-PA
M16]OK<B5RIV)2W!8#'C6^NRK2^1^N6'N?HWJ612E=@H&GF)E,B6(^WXZ2E]7
M-*N5I!UI3G5QEZKQF9%P6F2; Y?./15YY';" EP]M3_0O8Q<W9^$V'WO785\
M'5(I+#>S%R1#5=%M,'EWQH2N5C\CGU^]?/&V!N7TPSB7(\H>XOAG?,AXL3Q1
MFG<K,=[XO%L'.G7OUNMDL[PT;N"KBE\2F=R'6"QF.3X<I2'1X>1^^<E^%).I
M-[[Q:]M]&U8_6CP6=JU=>WNI)CCRO9#:IT^'N>(V80;+3&*]<S X2ZL9C6$U
M)5.^T1;7*.B'2JE-BSZ1\PKM?O;Z)0+\2F4*2MHLZ\NR9/T+4MO^@:\X@W+7
M4);.M-M^@6!6_O_/]WE^N+?SF,W;G\L)^K6^6Y_.S[\O:KW%@?XJS_$$JDPH
M"Q8KD  ( 752 @.IBYZ\D-&#PRZ!*L^=XT[KN/2$QD#?4JSBVS14DI#H\!D*
MW<).[Z:<XR49=@U1H281#3G./U\%^%!V)Y1D"L4_7$$66![""WB]UKZ\ZP@"
M$Z-R<=D)CTC]T5<[G:\G83@HJ]GQJ:+V#OJU1I;CQ%Z2H:.[\3C((VS%_%84
MCG[1Q%!\X95X%362A:K)8^%#G)Y4$-4%#$0&-#PX[>G,A)4[(?Y)=%I__?S6
M1J=F5#!L%:R^EZZ0[R *:G><,($J+K]+J KQH\=EP7Z"KA F1WU%)%*Z77$=
MUR8&<7KEW$Z0*$YJ'6&S+2[%W-H4[2(Z8@FO*#5Y6'MZ?%I\2WEWSX,!<H:"
MLY^Y%//(UM5D&RLU,K4L2\6JS/$LQ[4TW311==B/3W)P7IZ*!;7>H!*YDB_F
M^#CU_>1MZ+CAZ4$ZIUQN:AL5]()CWTL].*<%W4ONH5M(8#*]LV[_GT$OWOGX
M;-#Y)5XC[HG_UT3LX@E>'IX%<4I]UK-;==;5%&'2S9>'SLH)U1IE=9K!JJ@P
MS_30C<HQQIQ7JZY7/642,EN.?14,E/$F<KJM>J8Y)<R,F;5GJFBTIQ],$R7)
M$)0/6CUGG3'\*HV?!R\M,4TK\OGQL&M.RSZL$#W7[(!>OL5RG#B:A6R?5FK&
M*:_*X%SW8GQ1A#XA!BZSC"HKY>EUD!8L4>WDA1G8<M@O*_*$^*\ ^DGHJ7&W
MXKT>%?N17:JYE<W-/+G!KF9$[P%QTL*5M' E+5Q)@T2T@"N1SQ>NY%KXD3F_
MWF!LH%4\!EDI<VM4L P[; T5V'H,KXI_KXT'GC(U5CICB78X-]_/.A_I,.LG
MQZ1RXZ;^0]'9.3T&TYDR)>L=^E"V]2ZB(ONY_YX22_IT5/0_UR;&2UJX8DZS
M_KFRI7=4-6$GV-UX&U,BE]F1\K+%(P]E;_2KFUZI&-T&QR529KYVV0]>;&<Y
M_G#Y#$YCIZ.R>WGTZQ5QTC5X7+-&FF<;<@^;/V_A!R>595>KDI&[6'8J5QDA
M=S+!/W^-$;QTPYYOEMW=L$^MM='V*-'>]QTHU3)Z.CZ$W^YJQA\YIL]6<BN#
MH/Q[IT3@>%>7WXE(7GUBW64-; YJ'F<5Y(U.JR*T?Z#';=R63YBJTH:_KS!@
M_JH9M)F5N+46A/R_WTJSE%)6<44Z>2:J4SW=+=<K7N2)')F=E!L!Z;P[SSCB
M>;RD+!7];WU\\MOBZ&D"G'0GH2I7\!:>XPO?A2^7$-SO)Z)WT]JG>_[/.5B/
M[M2_)T'\: *_M= UZ_P2P]HQ6)"^^]?_OPQ#=R>9?&[+_JXD'9Y0]2::WJ48
MQV>S!!/)JY'B7!D//+6Q>S:KNEUFK7-0\4L9W_PKIZY?EV&KBB?5N5EX8L7!
M>@M3-_0++5UKZ&ZJY=>$WJ_,YEVU&E/^\RM$L36 C1"X%Z-^E\*)GQR^J9)S
MD(JO_6(A^^-ZIUUK :_;@EHF\O;2.9O5;F!J3T!Q56KOYYDT ?G2<W"*KRI%
MEY&#>S;R=9.@Z]D\S.;4,[O4"S):P$TSVR"2#\\%@=6T<Z36+[)Z8UU[[!+)
MAY)"KJ KG1#(Y7I!7)0T4MX?)%:9[C]=5[9)?"_@;/5X"H04%^1@Z/4X/_JM
MN40%(XPB3$*"*C2,24Q-_(E2&3@DW%PSV[.Q]>$RS6V_J).D;__<'1V5?(7Z
MP*/73%:X<;:Y?G2^[PF47&D*L%6)>))IH!@,(" NK;/4&VC>O+U,5?A?50/$
M>)" BDIBI1FLJ.OJ7\^J<>DPU_<*F9W1]+*]Z"0Y"Z/J,8M>KMG^GMS(5$)0
M=^VTY#CMG_G/VN?W?^YL5\NRU$?FJ^P&S[R@W21E6@%97=!,D;KUTP5RO4'0
MWQ[DOF^X5:F[!TP7/Z_U[_H\[M5_>]T;'[Y+=GWM8]ZMC<W?/W_]>^/=6KO0
M=UGHGXAXH0N@Z/:JMN&OHFOOW/:Z=M3Y\\]W"5*JLV;,W]UI(WO33<&7 OPJ
MTW2/?V(6XC,FLH'4W%9O&JP-Y,Q;C*GZKZ]]WEO[\_U_6K&\BU@6*U]%E!]]
M_UB;SMJ_ORP8+KG4>_=$;6^/WF>^N W^@:<NUER6FU%%&=U.3FZN'Z#]N)#2
M"8Z "S0Z7LP)("5.RQ@\213N!%V:G,04DA 4M$XSJBU6D$$L#-?11?;Q _,3
M%[6EO]R$VH@9A\6=9-<^9ZYDC2Y14NCI\\Z.%90-URFTF9U4G&^_+UN3YSN6
MM4O0F=EY2QFJ:@!CT4!3;<VG@QIG@V'/G75=XM#)Q):9F*:;V[Q]S__3'67D
ME:%VW<%*@B3L)ZYAU]6%PY+Z2](40.WY5AX?-T'>8F"^M@KE?-4K'I;?.-M>
MW_BQ[P5D7"(*&$E "33$4$MH#01T*(3@%*+BS5N\ -VK\R38/.U^WV>_44*!
MQ,HH#(2.FTYAP$"J(("F5&CGO:2&I/W&5^[WHV/QM%M^CRW?/-^WR#'B/ ,L
M" 6HUA0HC0+@#'N)C8[Z;M.6\ZNW/(V?%&S112+N>B">QQRAW<@E_AW]H_7B
M-G<^G>U;0J-[0CG@ 2- $Z^*0D( B((-B19443/OQ0D2"*=:"D4%M1"9X*)K
M$PRQWKKHXS1^;K80@DZ4 M\4NLGREL;IEF:Y B>8$M6 ^M"'&'CGJE3F?,P
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M[*VSS"O!54*VUDY;YS +$,.HQ!*UU;+&F&);C_>(\ Y[)H'F+D0GBE"@A#2
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MWI(5V&9"6F6^ES*W29*EJO T24)-D((I"YA5(0$1&J""Q4F9&23.<<I1 J:
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MT_;,E<Y!$OZV;:9MFWD9+MJ5?>NMD;^]D?]:]]+21*1#"$>K#@V@7F.@E-0
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M9;0F(2@!W26:I*>K3]V<SB:]+0]%Y]]EKWH:!'2G:E&6]!I"7:-6);L3=8U
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MMC8HGK-GST]/3XG[E()1D5ON3'"4,1C4.T$4B^DF<=Y2J]MBO9W,IB-;9T3
MT2 CDT=<.(^,I@IY*QR6ED=K\,(LZ_DLYT$MZQ>!6*E% O.*)1U2=F4:2[#7
MF@;/6'#&%L0N/6*G.<J*1,<9D\C20!!/+.<^IH28B=@2R1)/BTNF*HA](!^V
MU%PIX+!1JIP%IX6R@=$<&69!X5 0N_2(G68K\V!%THDB1:E$/%*";. 482XM
MC9)3PQ;GO2Z(?:"BO)"T(PDS*P*706D=K="@(POC<1C?>ENN[5@.;$Y3DSW3
MP(<50T[$' <6"CF?!#*@^0;0HC 0SLHZ4U>SJ0HN6X'+2+W0+ACL9. !$VL=
MLS$!/"E/P19K=?G1.DU.-HD'RDE R4B0I(YIL%OS/TF07#IK&7=%DK8<L4PD
M&0D.C/'$573:*$DD-=Y8#NK03;*4"V+;C=AILK+R1AGJ(_(D>,1! T8Z.(-P
M]C)&+#V3MB"VY8@UQ*L$*J^S4><Z=ZVD3$DD.$W'&5<%L4N/V)GDY22XAM-$
MU*2 . X$&>498MPZ+Q/F(A6/<-L1"\R6,A>#@[7R%*EA/' GC:$RAB1E0>S2
M(W::R^P5C0P'C9(R*FO%%!DF,"(,$R=IT,FS@MB6(S9QS@U)%IBNY<D;HQ0S
MS#IB* 7K-I9^JTN$S9E>R,8RT)X<BKG):G;U(\<41V #L1R<$]32W%'FWOU6
M"RX?!I>4><,Y]8HHS+&G3H/12A(+UFBE$RV2=.G1.I/%#"!U&9>Y+$@CKK,G
MF!E0@T,0RD2<C&BE@ZGT$'V63SZKS-Q'Z"%Z[P*;Q]N=&TJJ_[K7$I^-%&YK
M3F*I*%JD+&:SF8EPN$Q039&0A(  9@YIZB0"%2Q&,)6(U[34_+4<MVW-3"RX
M73!NI_F)5"MO:'0H>0.X5=PCBQV %W.3X[,QT=+LK>VX;6M^8L'M@G$[S5)4
M'#/A64(.>P.X)2I[J@"W,C?#\-%K6^1MVW'[]%F*!:$+1N@T5Y$[(IC6^2YW
M+;)&+)"-PB"O)+8X:0M'O[*N>.E.WE)TMC57L6!VP9B=9BP&X3UQ*2+O$T7<
M<XPTG#4*8,-Z(F)T<7$.Y8+;EY6Q6'"[8-Q.\Q9U\EPYP9!A&'"KA47&1XL\
M#U):9[G5H>"VY;AM:]YBP>V"<3O-7I2,T42"0 &;K"-'CUP,LK[&!^PAHA(S
M!;<MQVU;LQ<+;A>,VVD.([$F!IT($A0@RX.*R%+ED:2<.2F<-VIQ=0(%M\\U
MA[$@=,$(G68R@N9DN.$2D:3RQ2"!@B5K%0HL4AV==PZKE75.5$%G.]'9UDS&
M@ME%YU!,\QFIA5/D&L0JX31G,6*D(_8H),H)#I'PZ-LH5DL^X[-\LC[67X;6
M'4;X.W2^KD]H;GMT! S0K_\W_'(RP@S)^)@[=HYY[/I_N_XOZ^=D60^S%%^[
ML-3+K@K!?:),R2BYH]8&22CQP41K@O-J;FC@(N/]V^_%,#J,[U+-@C?@)5^!
ME7Z-@^W><"/F2RGL,(97@\Q] :";W<&P#W/I#@=_#^&3^J=WZ6VG:[N^8P__
MC/V:WW=]?-4-TU_W!IW,'?[=:QCU3C[-'5C(;X<]?["D3/K3/WO8'_VG:S^:
M$<SQ;&OGCX-W']^?P5SV/VV\/]WZ^)^]W;-78GOCMZ-=NGFR!8QW^^,N_N?L
M@&R?'7SFR2@X%H6<\0QQP23P66.RAB0"\Q',&[%211!EQYEF^J,,B9HF'EEI
M4!R4AIV]"*+\$ 0QD$%5P['J#"J@FBJF%'V=?!NF]%-U>T/X]X2"*CNH]AH:
MJCKG1)25@WJ(U,D2NSJ-MC^H8C? %_ZPW9'MGS;RA*U6F80KVPW51O3QR,5^
M\PDU^2-B?KT6;4>V#Z]%C;#X53:MNNOY3Z12KP\3SQ+IT!X/XJ^3'_XU84>=
M;KT?]9<NRZ!A[_A?)YTPW/O5R#7&1=:OQD)H/'SS*5FK5:]+ K'YC*DU8?BU
M'^,U<L?/A-!W^N;W)DO)FB#7?WS78<4:IV+AHQ*VA@E=^,Z2-2[-XB?+UP2[
MV61_H.LL42[_3QL9;8#Z3K?:ZAP>@G087+DOYSM+O$%3Y._L1B-^V]1U?"(B
M,SO-UD[URT__KBL9_KI0R=#81Q4\-Y79B]@ULYR[EG=JO%&U#C6S69O=^C<_
MW+"[-L,>2P^0 []FRV70.^R$JM5%-?.W<$;WJT#YJS8NR.ZQ_E?-*(!W:GF_
M#'<;+*X;^E,"93Z['6M5U5BA:LL9+L7>313/:J)SWH]_C%G$<^$?;WM]^&>W
M>O/-[]GNEUB]GER.T9:[,9:A=J\VPZN?FOL&?J[BM^/8'=Q$LM]Z!TO=XS.M
M>U1))*JL5IHY;CPV/AH>L3.&1AZXN'4^]U0SF+C?WW6GO]N.P^?B;V?;1W_
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MA ]Z_?$333ND 0P\&!T.<TU>75[0<[#+7^O1CX'DXOES=5E"B'V8P[ /I]'
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M6]9N6;ME[98MU2UK>XT3S\MK:G]Y]N:^R:.+Y@=,[ ?@Z/Z<%D$J1N)?)<<
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M4TBOWEB\W?OB6:#Z<D(Y->(]6/1MI-5\!CY^R%3+DG,_*T[:'!407FL94RS
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MB?O'\>0H#^#V%6(W.BB.FU+V<$:](^OBF28#Y;S2/3G+G[YE%-2K-X/A/X5
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MGJ^" =;FW<([)4Q>2NG0ZD[N&#=LI,LL"&[(#RC1RUQ,H'5@R?,5N=6=S &
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MO58YMH(+0.XH29)UO-.CL.711,LHZK&S.)=HIJ"0YF8QWFF$O<5.$DLYM[5
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M_)GYH:8,H(S<%HMQ+S")"&NJ47:#(,M"0(0F:6 ?@O :Q-G6;.G7$66 E%D
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M:2QL:)_W!A?FOT<7G\7>:1ON:1>VVKSREM]V_SC<W9IEI>):8L;MFY,/V'#
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M0-H(4,JPBC(YQ<MJ\81NDOLWCENQ8EHUIS\?@ZOF]+MQ^F0I3$8MX]XCATU
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MCYDED@,ZH4@(P)15$1FB<N*3YR18QQQ3&V^XF#W5+LX&,#6+.:.B.0.P&AJ
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MU&JDI63(,0=*$J-)&;_QAL[6,GBVOI^:OY_"QJGY^Q'Y>\+2D4Y3KQQ',<2
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MSW<]UBM%HB772':-A1=I(Q,_3SOC=3B)R'6B_8)L DAX99L7]K*[\:_I=GM
MNM>X_SKC+E9>1NTE)X&E$L.66*%PX#A&S7-]?<FU\LQ+I9Q)8-(\H>H#H%O8
M<Q 3WT#1Z.4FG;?1=0QWE-A(B'*,>TX-=5DB<J*MT$:3!;ZF6M>YGZYS<'AR
M>9Q4\CQJ4&Z23:#KY.(=25%D&0L8C#(#BL_&&[PU&^\]UG5 6HY*?#<';:HO
M"_@F2]VLR5#\>MO[3K\2LD!V\%W5V[3\EKPN,DF5^D0IIUNE#5'*WE]LT[9
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MN8;#._TF/_WZI]I1V9@[>9;QH]2>Y" ;A9[U;OKV.5'-,2P/$D9J4&$(1T:
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M1<MVN[#0/@9XU0ZWQ[%XN7E";WH97 -7RNV6[71:\%!'[;SN'W?^W&G!(8I
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M1T44P$.1,BYD<D4V:@X;U>JQ!,-T, (9%@3B6@1D#8U(*AE,B"Z*2(&-Z.T
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M<^]R5LEMX>0V=8)0@+8R<J*L=02TX<0*"T1QH;RD23$H)PC%HXYY5&JKU/8
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M>)PG'B<>I [*XU)1PIVT!(+6Q#ON":"IFJ+)H,"BP2I6<44K()<3D O9!:V
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MFJP[08Q/F:C +>,0E+("\:ON'#:M^*WXK1N=<_)_IS8Z1<HN",'0;K:)0-!
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M(9UDD:J$YA"?UUFGBMWEQ.Z]Z=WJS]P+@"?*5TMO0K29:,4" :$\,=)Q$E2
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M674&"AH"M4'!DP)7%%LJJ8C:,U@M216K=8;E1XM+G<&0*!A6"47N!>(B<N1
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MK-:5:IQZ,5U)4Z^8QE;09+AA\$,T*J>QI-R;5MUATM40M  0-.&B3R1&95Q
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MI23>F$MI<Q0H^2/V_SJPB^1):EYPX\Y7X*:-'>"<UE'SO(E;1[M'6\"1P)G
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MY)Q()A%I+<Y-$+!NR#L.KM=*=:U4UZ&4N?+H1"B%294881(%DGO;>R. 1Z-
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MOPSSIHUS&N&O,0L<V3ZHD&6O>%9RZUSY0S2T^!GZ4?R/]\>]03N/_%T_=H!
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MSJ-PDM+$P6 )W&&&]7V)[[37#X/8K>EOCO1WI:J+V-KX<KH'XC;@E .A45+
MGP!VK> >::&3X9$9&=/*VO"@'R/*!#A%E9-D5XFJ1O'U( *]](M,HK>092GH
M5DL!GDG+'O5.NL-*QH5>'%]N ]:U04X"X.6[/&QY)Y;:+-#AHP2D]H$SS8!&
M+=<&T-@+++P!W!0ZJ'O72Z@%Y-PQDFYM[.R!\NJTQ!9)DUN(^("!0+E$24K
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M*-7VL0X6^T08SY\XN/Q$..6@=<-_#2'0T_Z>^T<O9H&O'WU]@S/ BY7BUYE
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M/_]X*L&_B9\_NE/"5W_YC2WR;^BR]C32Y2Y[X3$ ?\T6Z;][,&!5C^B&FN&
M]E)V^*I"MIW?Q[O8S,S.IY#0>*\4*39.-8A1IA!3J<:'+YR))R^^ZZLGV[OW
M987TI.J_8=/>]QU]^*/^_/3D3R_7Q_4'_C=SQF]Q?_6\<V[V>3YB,(9G,VF]
MNSN+P5YRW8N;R]MP>B.-=B[UX]]]Z;[P\QV'&VZH4[\<0<$G]=O'3T96^D%?
MJ1X^?OK]DQ5US_GRQ<K_]=VO/^TK^U=??W8_X^=_O6L^__KC?IV__/ON7S\U
M_?O=W:_O\EWWK'CVY97_[L_W[O_YZX_^>N^K>[^4?W_VRR??W/N@O^9_??SC
MY_<_Z:_ULY_O]M7_A1_/MJO<ES_>_>4.?A%U'+ED!TYS#P,B*T@(#.J:CL#.
MD?*SX+ OV;6\-R*ZX#J%7@N'/DPU!O6.N6H?&T&+N?VV]<[SH=BH'W\>^7A]
M^O2_-B'"7^OCGJ5_^U4?__<ZJ4_/5;)>OCW3:YK97"CUO/Z-O/S&,:'TA[&.
MU)TXU!1R,55#S^D;F;$7?$,/]>8XXU"7>BS\[&9^U%[<R95UA-KW,]W_;8]F
MD\$<,E9P;11_,#)$RZ/X@RN)SWV4[;G1M"YZ0AMBKE1<B17%8$E2O9$8SCW&
M-],0B4^]I3<*H.@4 ]U 0R3V;W;5W^TQ9$]=?+/616_AQ9H>U,I\L3?R8GW
M0WFQ_9F5!3'_ROMB71RI7WPJYG?>TROS&,L'VNMIL]".'J?O?_^TOXKZY.FM
MZ[@?<J"WXW_=>O^K(<5=I;_5 3WP__'!6+B?;#K!W7TF;%UW([@W;7ZRSX?A
MMPU3+WX6AL)WF9/^B\[''N>-NUQ_F'GCSM^X.&F\^-[\/_]7=#:\Z\RM'YZ>
MWGK^V7S.EMQ+*R_=RWC1HO>;K89G8M;BQ_*Z[_K\D4?Z(_=M,[2'OMD7(_E^
MC\2&CG;K;U4??O?5?]Z(?NV'&/W:%W/!/N(8,=@4SY^[<_JTC@OTV-+^YP7[
M'M?MCG1D%E.7SD#G'9MW["CNV"JO<5R.OZ_HZGW__1MU]IW7F->XB6O\$9PF
MGTW1K_K]T]-_GM[$]'V5.WBAM=KJ[N/_O<0N_@K>5*MRC3M?T1I5I0:+R=5,
MMI+&$IIKP5@>147^=97W_@H5K9_4'^JC[^M?GCS^IN<PWXU7]Z\'WWWU8COA
MPY_RP^_'+7[OZ=/:_ROW]:<5E:.^V0;^,Q>XQ_W:=W_ZZ(,_?]/_;?^[.^;>
M!_>^^NQ?'__<7]N/G__UTQ_O_7+'??2O.S]_]N W+G!??TR?_?(AW?WKY]_<
M^^"3KS[KWW_7_>6KSS^X\^-G]_\\7A_>_?HS_NSK_^_!__SRZ4L=?RW61EK!
MUVJ!R#K0S *Q)$\V1BXM#A,X\N>M'][,!&[V4EDAX:YE#&1$>ZQ'=9RB=U9-
MBMBX0Q_LZTY"3,+71?A.IUU;V&@?7LBN()!S&013A3+JKF*.R44>A/=9>Q)^
MO(2W4J,X&::?E3*A5MM& 1X78F,XO>Y4RB1\981OUW L!JDV"R&5VM=P&EVU
MFT)?OXLUOL_B>9Q&N1TOL&^:A!\HX8^>&R!?9Z#^4LGL/^J3L=.H7]9G)2QW
M'KVJB/97=L%->"\%[T<[RS/6S#D$2$)YN*V,GLXU0RV<-T;=K", =Z?G[0S>
M"KMO X+_];8;9!S]Q+$P_I\3Q[XR]_OO_>K?[GTV&E @!6Q &!,DT^/\@FHD
M<B [EOUX>EWN[;,5XG6(KW=&\<ZCS3D:?3A;(]YDRE,[!FJB>J9&*>@X^]A3
MWU:H%'3YM;ZU,^59T^3WV:YLR;Y:12P0>!S 3\5 JE@A1'2C6Q/W0'B(&GB!
M"]059[_9_W"]A/<5+I04R:9@J'\L[+R7&+T93AO93]GRL C?D2V#EA;8E<YU
M#D ]O(%81[MW3<.>.K<^AV\V)G 2?L2$L[<A5.TS?*QDR0L28XP44@F^B9FR
MY8$1OB-;D@V8U$&K/8GI4/=,AIN"9.9"U&JMF_Y3%"?AAT;XJWL87R@_+(S4
M+VYA/'6(F\-X1\ L7'0TCP(7V /%%D&348CB3#8Q"%'M&)^>]\*:/<B/A=^%
M<?CD=^^I](Z.:,D$,;D JXU TG-IB36#*[684-UH!#, /K]Y.#N%OQ4)\5^/
MGSPL/SXH]=9ESM;/C9$W%Q!KTN0,-C2)#(=8@T9%EE9SS3H%Q(.:]?)+ F*V
M/HH-$,F;GGQX!ZJ2@9KKRY@GLMBC%KH=W4KV72?A-T&X\$@^V1GO(ZD7(4XA
M2<;&'?8ZZQX/C/ = =%+*S;8"IQ'845.'I(4@5;9L3#W<?6#<*))^!$37D)N
MR1CUN4_JB25I28;ZS)];M8[C%! /C/#M&N[5A\;JH7_ 0)X*Q.0K8*B*A45S
MB(-P7+Y%, E?"^$7ZX?+ O59OK0G>'=D0V<]5Q<35%\(B'KL'<4$8*V;Q@PV
M5AW52SS1/6IT%T;@$]U]Y<X[BJ&)XC'$"*[TO)GL.' P&D:2<Q$Y%6>)AF*X
M)G;W77GXUIQ__OGO!X^>N_[\Z<]5O__NYP/T_G%+O'\.P85@7N-XKS%W*&[*
M8>*/&CE=<& ;M<:LMA5M5'(6[4EO,3T\&N<WT,VMB4,*K_Z]NS61?8NFQ@*V
M4 **L0WADB%H1E?9$,:RJ6V>QSF/F?">!K'UR:FE1!US(5-M?R1,*SW6KF%N
M31P6X;M;$WT ^]@5",%)SYI&$VOO(F"NA#9&<2%M"!<W"3]>PIUE:[-)E4HG
M'*-8'_KGS?<5H!4[MR8.C?#M&NZ:,]R2@T M=\*%(<6&$%,HK#Z4*'53VVQP
M$GY@A%^Q-G)AI#YK(_>-\4NUS4F+V 85"8&J+9!(')3@&%M&*:Z=G-G3L* T
M<O*[;GX7QN&3W[VGTCL[%3U=%@R)P3+9GDN/@C_; B"KZ8/GC6%[<F8N,%=Y
M*P!/>X1IC["W] .1B_;<H^>?D3)QM$BA!R;"W&SS-"7$0YKW/OSQ[_?O;'=H
M4XQ]'"TD.Q0&; 2:N$]^A7)L1I&3&_E'?VCFV<KC1;R:XMDAY1("V69BM4DP
MHPVMDKXP?9P:XN$@_O&OB!<S6FA' 5],Z+E)JJ#6*+1(G&NIGC;&<;?[P$[$
MCQ=Q;#6BX6):]M2:D3[O8U^S&6O_--4I(AX:XI_]BCA+)"$N$$@J4&H(HMZ#
M]%_-%I\=V6'L*N'\X>J)^+H1OZ(*L3!8GRK$_CG^<JM"Q+'A%QG0:H_&0TL0
MI40HD5.@Y!1SYY@N<&J<%@FK!?BJ#B>+(O%9YKPW;#?_'^C^^(558WWLN7.Q
MK0&9V$!K%="8U/0O%&=]7W_MZ>)M^NF/,/T15G)OKY![A)1"B$U-;H5LCFH=
M6]NJ4=NL<=,?X; FOY]V%<2<BB?G%(*M$2@J@K;4 Y?6:N'2@U'4S?'I685X
MS(@;ZRKW1#.69*F%8<OF2ZW4C/?(AJ>">&B(;Q7$T$Q-A@F:Z3,T.0[C&%<#
M--FW4%%\GZ\[XBRS2.F($:]97%8KBD8IHI'JO8O5:6Q]U2::"N*A(;Y5$$UU
M(2BYL3]@@;SWH(H!;&'??,\[FVX0QS@KC0\-\2LJB N#]:D@[I_CK8*8*.<Q
M.!!K1:#$&;2Z#,D7:UHPS@0Z.</3\UM]LQ!QM0!?C=^%D?A4$/>&[8Z"&*E2
MD5;!::I (2K$9!L8ZD&UJK,-92C_<46K[W$5(5YLDO#1$WUXZWU]4F^TQ'!>
M8UYC&@Q,@X'5W-0KJ )]O?)LTB@P$(H^"Y;^NV6CPCW\U$MH^S/UWW/L\<NN
M@$^6L<80 )/$'GJ4U).'A)!+*\.D/Q+VE,''J>T=,\7DR9?D?48W]J\CBN,:
MDN=2G3/Y$O+]I'C_%&\U>C]ZX9@V#-;:L%J+#*F8"'W*#=B"#YQ;I]@MKO&=
M%*^78C&AK[""' M22D8154JB/H,'UY?I2RCTD^+]4[R5X053T4P$!D,%DKXJ
M:TL!DEIQI=I,?E",Y\\13XH/E.(+-;R%0?74\/;&[E9Z;TTQNL90=13O4D90
MVS^U)L71)D39QY,SN:"_V61WW>Q><0-M82P]-]#V3_&.$M_7V9[S9@^M]6B:
M7+2@CBKXS-&9&%N/M"_V+)Y. -,)X !GMZL8D4GR.8:4D@AY";&X2-ZJ[9_W
M5<],K6]]LYO9U?I:Y%9<"8"5>XPB+4!$;V&<#>6>+;*7/KD)+]YFG*>,UDLQ
M#4,;[>F%2J8DJ))*C#6+%-\_GEK?.BG>:GV:.1@7(P2LP[1# Z14:1P3[-.S
ML7U<!\7F_#'!2?'14,S!.YNCJ]%7<IUC[DE&8W3.HDMDI]:W2HIWM+Z>4.1J
M>J)!PY<#[?#EP R51\?1_H7:M%-LYUI\-!1?[/NY+*B>6M_>V-UJ?3FT2,46
MT%P+4!X&6L'T!3DVQSV\RLW9DS.^P.]SLKMN=J^H]2V,I:?6MW^*=[0^7UH(
MV3CH41,">>Z!= D$'CV:9DJT;(9M[_DS+V_%;V.6\\T3^WO*+C)7$\11S=Y3
M*S:-<V$4>VP2D@UE>GX>UK1G=T7 41H2,220EL<.1V.(P[(DIN0R^EBJAN$6
MYFD6"QTSXJ&F<;BS)+'D*\:,?05TU68G#<ME9,")^*H0WRJ$UCK3IVH%=L$
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M"'T&=T!-4+A8-LD,Q-',5?QH$+]0@U@8JT\!<6_T;@5$,EE,]!FDQM9C\-)
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M52^E[_04'Y0^X^RI4':*/CG(M8^].*(#2X6E*G4.5S=SR/QJZSL?@A\&\,:
M>DE])^/V2.HC]D%#1I=49\V\B&/UQ56Q)#E1E):F\\*>NNJ7\\)NG1<^^?0/
M3__W1Q]\\?LOOGSZZ:?+@.&M&S#\GZ>_^\TGGWVZ;NS;OK$OW[E??O[)I_^Y
MWK=O_?9^^?G3/WSR\258LBRODW6-,[O&JHTNKY-W+<2&4!6@2/2:H=6NDL7W
M"C$EQ&1^^=N?5988C^NE!2LT]-V5;N"@:W':$5R&WK4EJP'+U4U\DL*>Y@,O
MQ-_V"2??>L6HWL2#F3(VCQU3SV16>UO^]N>&^*&8VG/&L5HG-XV/'43+CD&*
M\[$5Z"$%9)J(![^G YX+\;>,.([-6JW&/*=O0>@$F3,UC1B#0:K+W_[<$#]4
M6@U]:)7)0<+QH8_/..99> VSF3XP-[ZZ"4^0]V2SNQ!_^Y6:C;'ZJM2<C-Y#
MA36:AP#:'$D7!U#9S<*::]"AVGA8O=K5#5^O\3.7S>[&('RQ>S)VCZJLD:TT
MK=$!SI/)@NPTA#8_E!0X=3(_ME[<?J+BC,NL^U,-EWO*Z<9CMA"Y1ZG,"#&0
MJ,\UL6"H?@0E_VYF]TH\]K7\I6/Y,"KZ&EIS-N)+![E$1V,7<Q&I2O;2>KY-
M/-*R5KEDQ+NW(CU:2YS!QTBMQT&W= I9FN*2#\\-\8-\.!;IW+NOLXVL.@BQ
M.&)/SJI)R>B1=+K#/8EQ.39<,.*M2RD^5IK&K*2-6M':0TN4:ZLU+?GPW! _
MR(<2B2U(=BDT=@!&CDHH+F:MP5L('N-$/*3-%8*%^%X0OWL\YK98?4D0)Z/W
M(!^&FK"#55>UC@V:"CCQ6><#RB75FIO"E _7]GS9[&X,PA>[)V/W2#Y,1"WP
M2)N]'VOJ"*RJH['@.H]I/#H; ?8LSN-V[^7EQ[+\6'9R;Q^0=23AW-$J4\I
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MOV;BR#@[2@0H!)U%WIK-]TKE]@MX"V4@'KJ,; XL)LU$H6NKN96('AY84%F
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M41UD,?ZV1UXIY@B6&$J!HK?_FJB6"KT)>EC-A&?'^%$SX7B6<9IHAEZG1#A
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MW*G9<...ZC5(U]SK^Q@X;\8OB_%C<64^!^JI9NACN4FZ"8A7! DQ)T*N@O7
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M)IX%G2IG=^H8O$N63DG2%A&O#O*CB-@&NH:19WY"%:C5#EIRAN$MC;FRYW*
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MRB*21U]GEA-0F0F'14;H)30V9XI4-L;7B/$C18,S ^LM&CP#QD?=CUMO@<S
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M0P(.GN]_5B]*G8I(JB-X1,T!+=F6$Z]KZ?O\U(& 1PP69P92>LY 63/(#%@
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M[&ML_X3MG_"L[HHJ,6LNH8Q"W4@X,^LJQR9/LEV2KRZ>.O5/2-VTE!B@6XA
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MOF7$I^/V5$;L'G"Y7$,(C(O<&7"O9\0M4AMC!EPMWSVD^[-''5QQ/^(O;YG
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MJ#,):2$TPX*V1 S>I/!B55Y2PJ&!]RF!]XZ:> /OPX%W-K[I<HD:?&:>!\U
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M+L&LT!I)#XLFU$X)7<<72?5^#J77US'7H736\,]>PM%]'!.Y28SR:7-:*<$
M_2>B\6!R((GF@)01,CY$S@[F:7HT7\*<&>WMK#N?5$CN07 6E=152:F&AXXL
M@W+*62P2:IV=KG=W5E(6N"=< [0#0FM%JE90M"(QQQ&3C)H;'5R<I^'1 #UW
M0,^>C>#%H%&*A:*1 %TK_:$L+!;A9-8(DUY.!.B[.P<;H!<7T$*FE%,AH<P#
ML7IVBBZ!0?O %3&[;M[^Q0;TJ83F16>)/#$C?&1@$YD<RI,%HFDEC=-BXAH4
M70=W#KDW0"\NH!]2Y6YNA'N ](RWWXK@L"1D7&G%(!O'7#&"&2@VT-+%)&H'
MMZZ IG0_94@_H-+=('T?=O2,MS\G73*/AE1NDM"0M&0^I\1H,04I6@C>R8II
M+BY6U6Z8?C*8?DB]NV'Z7C!]ZNV7NIZA%(X%54_GQ1 8+6IBP7ICLQ'HK9C(
MZ;NW19XCII]#@OYO^''2N^<.?5;G&,!\Q@>25)0ND/+*=?$UFS0*2,:9G*26
M$DUHD8 %9KO?9R,!EA.C.>%9SA@8>"V83R8S,DRTT5%%4F%J:)-[,:?0YL*<
M36Q4, \J<%DD9SB$6 RHY(.0T8J4;58"(^<MAK#05# 30\AH0P1!V'>!]!XE
M%'/2*.:+3:7(K!"@4H'P\\I<:E3PM*@ -1E!(D,0",+6A#>0&*(J 2+MJ19]
M6&PJ.-4*,&*R&2,KZ#*#4A2+6AGF0K'91PPH<Z4"Z>=UX*]1P9.B@H<T$)I#
MY![(8"9N 9(KJ3EGEA?/ +5EL48P%&8ON1-"1S(13->K9B(T,GAD$Z&1P7WX
M"V8B'EAHI3*7+$2G&/@<6> N,(%2FZP"Y\%5-C#N8NOGQ@:-#1[42FAL<"]L
M<!HKL4%+)5-DQ-J1V*#$FH&86<S:1B6BM[G6.>KJY3$4GL.QB9]Q#X>A3_<W
MW!\,PQC;P8G[I#RTTB4CLP3MP:@874E:&%MT F?S=:RAYOVX5U;[,!L3H46I
M*5F184Z"00;.G.2694 ;4I9!A/)BE=2=!0K_-LS.&;,ID(Y24 07/9!B$I,D
M(P;)>J&_2(%IQ8X>'[.SP0M-ZT2\R8S4E@&86E(Y.):"(\Z5Q+*^>BSYO HN
M-LPN(&:-34;85*)U'I+/3LF2O/8Z8Y$YB];B80$P>RIGE9<V>LE9*8:,!Q2>
M>5D40UHBF8/TM':$66L;9I\N9N>N&S>;_QY0.Q,.R,%S26!E5HG$:HL)YCG)
M7)UX &.\B;X60^#M$,,31NW<M>.&VONP:6?\]M4?YS$3;+T%!M):YG,DRS:9
MJ&GADG:U+I%LL'W"L)V[@MQ@>R^P/76P:Y%H]T1@V68D:1LD\]YJIDA!0BVC
M-I/\7+5(OJCG<!3A_6#8SU]Z&>_O+,(U(R'3:7BI:+'RX"#V\20:LK2MX"YO
MDG[]5G#SGZ!%D0"7S\S-ZM)!*E)9@P:B#"$;(47*'@.I \FVDQL++!K2;)1"
MHN>1]&T&/DH&6B@6I98L"Q6"!D".MN9H*KCH/SE&TF,PYYW"OG/ \O)EB=P7
MPR\UD27B,+(T:;-S4H'(#D6;M(D0R/KD:%([=[+01#83NE%)EE)KVQA,CH'-
MM5<62A9-S"*&[#G4OMY=\!>#-XW(&I$M.9'E4%*V((C+'%C:]!"5DF B+\Y*
MZ]JIF<4FLIFJFE%I+WUBM'C5Q2:1152*Y00E8(;L85+ZV]B+3K9&9(]&9,W.
M;G;V4MO9S0E[#[P^$_'T)207?&"E8&WI0.3N+;<L.#*T%8\9%;Y8M5UYR0&H
MQNM-05UR*GM(2[M1V7TX#6?"P$76IB1:,IM),R4NDXQ$$V=*(%>0,N>U*:3M
M<G[Q^%;CLL9E2\YE#VEL-RZ[%RX[C8V'8&R1V3$-4E3'(6=>0V9<HZBI+MF)
M/#F8+AN7S2VN_X]QH"^EW[GWY^KQM&X<[-)4I.G?%7"]O8,PG>?)VZ9W&H?_
M.)GWZ<?/?'H.!M19 /Z6=C ?]'&SO,,_<>\ 1_\<#G9??QWC<"_T?SH8T;WA
M<$20_&6P]_&7WI^87XU&.![]^.UG''P<AOV=.A>OAAA&6_6NMVAT/_8'Z?.2
M@O6/?^_PM/NOO?#>'Q#POFUL_?AI\^>-G8W#_/G#X3L"*HWY_=LO?VR]H[%^
M^+9^^/GP@_Q=_?OP]1<"IE@__$"_/WY9/WP#V]D+IW7,3.M4Z]^*S!PFSK2R
M7@>,FJRE*?O29J"9K9090N(%T KM B01HE:8O.=D7 E?D+@6B0_W:0W'PP-\
M<7%_T:XY!LH1I$"N6$VPVQ^,)A[,ET/LT];[$W_XTLOCG6,1,?/!(P3QTX^$
M2& Y&%_]D?,X>?BD$UF'U)G\=PRA"1!/;VH"?AI)/^R/\.7Q@Q]R;[3?#]]>
M]O8FUYM\Z(?=,/S8VSOFDCI]YX _N>'IRT>3XMV*MZ;.RU%FS]$7'TW9RF3*
MSG'9]#4E5T!=_3)?$5>^]AB7%2L.KG?92_.<S(F"]EU=3EUXZTW=@PNU12>H
MJ0VC9AG^2L$Q\W-G>#H/'Y%%XMO/+!2BZ9>A_R5\&[WXQYE;W:6M>P[]YX%[
MM<@Y$3RS8FI*YP&5+4IJ(2.I$1@#>NVA9%=L\<G#>3;3()1W2')*%]#*!2^"
M3QB3XC(%;E]<]3W?9<&SWR,T7=DI-*(X");>6GPIM3^P$"*B/+L1SF+;3+;>
M':CB/#$,]H\)P:\XK6Y#"  KVMT.N7_]FE9R[GS@5BSW;:Q+,U8G8>YC]2L
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M)V!K!H)AN1H4/!H)F;]8%;HK[MZ9NH4R%Q?B01&TR:(H@E8^%>&KH] (##R
M$NTT^+)!?,8QF)0QVEG.D*-F@"+7SO/(:B7:HK.*&F$"<:T7*>K9(#YGB%MP
M9&IBK0C# :-QUA0,PH*22"] \PPN&<1/I;B63BK"<DUGF!@KG'DHGI&-XD.
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MK94H)O-@YRKFFK?H.B#D=)UM+WC,40EF%4\,//T@K9NS B"*5JA,LO>0O-5
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M><EF^_5TR)OEM^F _SD9[\EF8?+9[9;/AQMKOP.-"S;7$J?Q; .(K'Q$QHD
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MMOM8IFJ>%=(]\+:>Q2''3EZLNE2.@U_8(Y!\/><6<\#FC(:^98*2;#O1,$I
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MX@.5H A^9D'QSX$%[_K" M>Q+,/OL\0R^G82._U 9ZQO<\_R[" *#"<!0;%
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MH2Q5)IPE4<Y/Q/CTC<7\^W:BX!V<_B]''!#J.P(V>U7Y'0"@A?;?2;D%Z1U
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M!MJ?O.*-5)RA.JP*;)9>2ZR#$8,%%!.@<#4 %MO$[^9%,1VCSJL8 \6N5XG
M5#5LK6=/<6Y(/5YQ_WL$MWA.\)?C'=>=+D06%T$"5B3.4*54-77QBJ'7$\;Q
M2XQF9,I<O]E&?MDYUH*(UFX$D<D$>2'Z'05_FIU0SK_)7 ,Y/A(OOK%&=<T#
M[8"BDQ1.Q>&#-Y2Z4H,[P=!XQ<Y*WL"9\%KN1Z%-7=C53-]:H56STI#1SL36
M&8^N37DKMFY^OW^T?[+S0?MP@,;YV<'QT=-CHN+058#5QT(@:N%&V7O1$%0
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M9A[M4BX'6RS. 3K_R/"*4C3$=8@!:XVRS$:VS:V0K\BU,6_EH&!_I]IAFB&
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MUNX1TP?F:8#Q%=B@U=FNZ0(A@AG&(FPLS*PXX<[6/;*I9+V**&518(!F[YM
MQ;87ZD'D>K:KQZ&O6WIBQ%M1NDX47+M/7,L =4<W^J%O>F"A)5$_Y$#+EA[[
M"?8\=%T.HG3>0'MR4;JEVX>@6S-B>FCY3AP$MFUZ9NC$Z->VG3#T&/#S+=VN
M$]W6GA7;#RPK#BWLK>OV[9@G_<!RD[YA1CRTK<BS0OO%&W=-Z/91?2H_TZ/;
MO!2A-)H!Y:5T#>EX_OQ]!?;N&#KWN,,BT_1LPV:!SVW32$!/PVY7D?",WY&K
M;_GW:OS[NNG"L)EI>#9W^Y83AWW;"),^BW6G;WBAZX6.$7!=?_'&<+>)'&M*
M6;$31Y%KFY8.).6"KNP:?N2&CLLMT[83MIBRMHD</XS>:D^%%7BAX8= ;]R/
M^G:26'V6>("R7F@:%@O]Q+6WGHJ?@&X][K/$"L+$3B+;])W02>!_KN<R[KJF
M=0/=;BGT$2BT]D1PRV!HM?0CSF),Y CZ89*88-L$8-(80026#4K$+7$^7^(T
MN!_JL:^[5F#9$3-#'+;B1[8/RJIN1N:6.'\H<=;NA@CT4=LRW+X=^JQO^Y[;
M9U;"^U&4!#H'A<<R8R!.?S[DMDWDV*ZQ3>2X(^O<Q3D>V41T350)';\NT:+K
M[C)HN\;#K+$R>L[@^B:@I^#MS3_EQ")M<1NYFW2<#A \/QW'-1W/YX$9!$%D
M>XX?1FYDV1SL3\-UG 4MP>_I09@=)+55@992@8Q6Z94>V[YOAEC[X??M*, N
MXF;2-QE8E)YOZ+X>/I@'H9L9/*#7[GG36!@[/&*V[D4<[ C/"GPCU%D4X>]<
MSXF6H+$M-3T"-=7^N-A/O"CTC'[L1F#CFW[8!Z,B[IO<,\#XT_4 \P[L^0$,
M-Q+2XQGU*]CNSYNT@LCS R>PC3B*[=AS0]WBON4$GNG:@>,O([ZVI/4(I%4[
MTD+'YCHSO'X2>E[?MGVGSP+'[#MQ8.NV:84VSKNS=6==:.ONMN-/KTS>=]CU
MEAH?AQJ;B3J@XT?<!!K$<=@!YWUF UV&P#,3$'LVBQ.@QOL7*#Z@RO@SN%8Z
M;%>PHK223R9#,;1^6SCSF#9L"0>&OS4''[UG:7:<81OZXV0GH_[T']DUWL6[
MO&@QIBU'6HTCF2U#UN+,]1)0O74=JV<2X$V KOT@M@T_]CT><?O%&W-^\MV3
MI_P^3\)["KMV2VZ/3&ZUI>N9IN%QYO5]QC!^%D?]T(P#4 5\,XH,(_;,$&N@
MURARMK')I?.3-+I([JZ3-.S;)FD\3_ZTBF+P -Z!K6+P8SE5LQ:();X=V'W+
M3;R^K:/C( %[Q0.]CC-F.8[MO'AC!6NH&6RS;QZ">A_ F["EWA]+O;6C(7"M
M(/%"IV\Z!NO;B0D:AQG;?</P0?_@OFO8!KK]YA6-IRP)^LGBXZ?D7H@U +\6
MH;]A&R=?ISBY3!64M_1G.KG(IQ/T"YE;UK0::[*:'H<P]G3=X6#S6([=M\&(
M[8>6#S\R.W3=V&7,"S8G=/Z<Z'$5[>!Q@^I;TGM TJN]#ZX?V&9D6/W(TL.^
M[?D1Z/1&T#<3N$90Z)D>Q2_>N-X]E()'(KAM?'!-#/(MT?X8HJT-\43WO<!-
MHGYB8==ARV5]GP5AW_)<C_MQ$/FN^>*-,9\<LTE$^]R]A=9]O(4_!W-ZW.R%
M+7-Z0.;4Z.GJQCHS#- C0@<TBB *^HPY;M_7W= P8]_7$^O%FXY*H"=A3C]O
MPXS?639EQ;6<XX+M,DSC!XTO?T@V:BQ@H_=VU:Z=MV@[>X:$0A3X/.:QS;GE
MV>@<2/S(XW%D@MZJ)TZ(-:!WE05;QK\:XV_-GO&"Q#,C%H :&OA]&_MX^PGC
M?1]$MI/8C(6>CUKIBGFEV^R1'T997N@R%X[*0M\V33?T/)=9GA$[8<A]UU],
M6=N6)3^,WAJ)(Q'H4XZC]V,7O:9NXO=]P[7[012:L6['(<>&"-N6)<^>;@/?
M]6Q+=QCGS Y#X+-Q"-PV=@-3!XR(MQ+QAU)H[:=A#L,)4*P?F:;5MST][ONV
MH>.(*,,V.'!73W_Q9CY=8DN;SX8V'2_R0Y9P*X(KCYTHX(8=&+$?AHF!WKLM
M;?Y0VOS42&:*$L_PHKX5VE@%Y5C]T#3MOL4<[CB6'=C, &W57J>\R]4[EFQF
MZX[M&AV](GZ9L'#(E9OCX?U(SL"_U4]CWN2G,99UU#SHMH,E]OSBC4;%._ET
M,F37)9HK6LEAJ^@)TUC!-?Y]S*,)C[5)KH5<*Z=A.6'9)&7#X;4V9FF,W]5R
M^(HVN>!:!F2K22EP-!W!EJ(9E<QP["@Q+<_EKAV:C,6N81I1'' 6Q&'D=7JN
M&U84'#/Z-9X6V-BEF2O7$@,[67R"=\#CW;R<[,LCB&;:QPF>^%@<^%U>G*KC
M?H3#;*BX^.N_%WHT^B-C?P;3XZ_[SM$_A]\/SRZ!_?_Q]?-7$ __G*2'?_[G
M^^'[ P/V<?G77IS"/G#JF 5[^,)T+W9L/P8>'S#T3/-^P('O<]OW#-=,8H?%
M+]Y4+;'EQ;ZA[CJEEF8:BZ*\B EIKM+)!:'";CX"=+[^=ZF-AX"?&LMB;9@#
M!6A#=E4.M+9W<O/(UGQ2LCT&$!< ^F@XC6'5<9%_!20G<LU*I-/H0F.E5K(A
M*U(N*)N/QL/\FL-/Y70\SN%@V3E>%3R?@J*6TNG%10'-EM,A/2"7+ >;?F'6
M*^T);TPPI!+Y*,(3M>-"\"A@FA/L436%FT+JR,L2;Z$L\RBESRN2F@"C*A.X
M]SQI7":L^#L+TZ%VD$4#O/0Q*R;X"'X%N"*L<4YL>#AD80X_PKLW_C+M)Z6^
M$SXN@&RR2:F=,^!_<)E :1R!#IMAF*D]$WQI<T[Z&>5BFDWI/AI7\.;_#XM?
MWCSV_=QNT)G*H&ON4\A'DQEZ9'@\3+ACZXX>Q*X;&6[$_,2,;--Y\>:L%@":
M_'X^+4%E*#C_QH93(H44P%=K&X6PW<J*+ "OBZ94)\9$9)".\$< ]EBDPY=:
M/.7X/'Z*TB:#K\,R."R#[D31$BY^S@I4).6;D=ZR<U[T)[P8*38*TJEY@!"0
MCN/.)A=L0N_@W]-R4B_2VCYJ3>4T2=(HQ0YTL*NH4H_>#_,07GD*[!=@L7N!
MN".DXSF@?B;V3VJ*4*FN+M)(D+XPL4K@!<.A-F&7=,Z(MS=*'TIP$SP0$TO!
MT4?X'19_G983 3)@%!F/X&-67&LI  GT:WP'[(^-0 &'1T(>Y2..4 E1Q:9U
MX$; %H>?!O-(/"_39RPRVQQX2-?S5'^5QI,+Y45H?%'8>;_J]5=86.;#Z63Q
M5V9-QQ_O"Q%,@OY1$"$;I3Y4$0/*$4<>E_Q7]9?7<5K"M5[_FF:T'GWI]8@5
MYVG6EY#H8(MT8/&Q!$K@#P+/1;C("+Y\L039@$ V8Z"+SRQS8%N+/]8'QL+/
MGF)98^#;RRW;F<_@WF>^R!TR'-8'18EJX,^.'($.H[KY)QY#2 $W]$)+=UUF
M^[:?."'W ITYMN?C##O7^V*:U@OUK8NB!M\Y[X<%9Y=]E@#7_94-K\ 4>_%+
M"T+ X?LS3&.6WA>+RSGVTX!W!,R/%X\.<&\6X(9#2B"JW2B2#K*8@QX8HX@X
M ?VLA$V!T/HX#8>@J^V /37-2,*\2XO1 F5@730%.MJ9D+YO<Q"O>,"]M !)
MFA="^IQ>@%B\R(? ]DK\]/?\(BM!G?@?-AJ_5C^MR3%IQ5_3">!+M,2='H_!
M>$+1G OY_2[-0"% 3?YT BJ'%+8 @P-$/!2ON[!FD0^%B*\?%\@!=[XF<+CQ
MNO_DV@7[!BK!%+0&'DL=)1**".(M6I#Y,(U)E9.Y55IYP?ED,0(0F$@KG(9E
M&J?"='V):V.TUM1?2TV'?C)>OT(E!A<3&5N:3-:B9=38(TU-/.I5^J-2,%M;
M+.O+0NN*%1F<HNSA#W@JP%ZTVKZAJ8Q*$7W _YZFDVM:%Q]#3UHRS*^DM<U
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M2;A2)2[%_%R:4H@KP+!;%F'%U?*6RH$OQO/#9I$AK8@1VQ2@;0K0-@5H?5.
MC-53@)XFF6==;(I==!QB?&V'[-U#-H&#;TQX(%*[%];Z2.P>Q<%HFL$'E*[!
MA_D5227U,0-Y1%[C(A?^OD@.6)9AQ<KT7\ZC)%V)!6^_-R]F?<:MCZ5H%.^*
MJOAVI1&BWBUR),@G)?3'4NI*E7=&> /$V802)-==SD5/BG.:?<N'WZ27E=Q_
MHB *)/!PR+-S\D1(B0ZBC60P"5S^7?LZC<^E^G!VT3RA5!867%"<P]Y1*6'#
M"55^D)Z!,?N&F:X4N27<:YA#C*GJH U>7>1#+MVD(F  [^FAZZBQ.6GE+=@=
M84Q/JK\B,9K, #X7&%FP +H;ZOA-Y[WE=3KTM;SG=5%.5PSH4BCCXP4K1BSB
M4P&.$QXBN$Y4&CDI\<9K&<&*M5VXEYYVR&-XNA!(+WY(XS4!PHU'UG;(L0"W
M'PH7^E$.IS66IKUVQ@!:H><9O!ZC$Z!63[G@3(!_&/Z@8HP2/<A $2'(6&G3
MD5]1F,Y@K0IE7>C78.+6:G T+4%<PY.DE\-WRR3E\4!>4>WO%6@J33YB3^J;
M0J67F,Q%Y!-([1M6^* 2J-QWK/),->UJ=,?A,:C>0E262&91>UBH4A,=A$7G
MIBC>*V$D8GNPT$X4%1B=E^?HP5_ #,FD4?T1 )A/6J2Z,(4/?2E-IS,93K4=
M6F^S5<LA-HK.125%5-',N$T+YSE:17+7*O:'W"4%11APDWZW!&'@W9P7;$31
M!&0=PF,O]O,O;V!JL,TA74%7HLA >X=0;IQ3G&%N6>D<JL.4R^QM;JWNFU3^
M_+CMRA=>C2J/1>+P%*49HG9/NT@!%0L")SI'BI13<[LQH!R9M-,)6I)(5R#'
M,8S AM<4[) >K:^B[!< ?LDG#7M2:US)[+V)AQ>6=JX50SHC/R3YE81+H";(
MVOM-5B]HKX).27/HCCD)(Q9E9-X)&7G959%0?RD4(;=LI\"DZR<*:F"GTBQF
M,*51&]5\>L09"E9Z9 JX0?Y*S&M0N@U<= S,=8@27-6)UE5.TI5[ 2!M>!5H
MCP \M96&%J0R9<4Q>))@%@;6/W4"M",,@XZTT5A<4(.O; ;N__!H0!P7C3B8
MQ)KJ;I<"NKPI%?P4;J5,^BA)6JHU2 65 <1555&2;"7O#,JJH%QGCE#E&'L4
MXFLF7U=OJ@KYFKA(85B,4$M.79$*L?..X[4B?CT42@A"#/0!"J(1TR [EK7R
M9JIW2$FK9 90/!QVF/XCH)46,54!(S6+Y@GR1H#C15S6 ZZ,W+VVZD0,!4T?
M8"CSTJQF$!VT*#YM$1]Q#T'%<JUHR-)124TF9+Q"H</, R)NU4I]1BVQ>8,M
M5H(!'/G=A PSX/WE!/9UW= !&UQ%@"L3*-PZ_FR6E]P8*PKTQ!)Z-Z,#Y)\O
M%$)WW2N9.:/YI+7J\PVU>#X C@DMG&*M  ( =]HP<\[8,%J3H]W,5SO,F%(3
M2=U&< ]S!L.!#!5TX Z$EM@'0!;S*F#-]@08\G,B3C*A6]4B ,V>L']22OZL
M2GAE+D2MH5/-,&7GD4LGKE/I2%>N5'K:#< [; 2WKFOM%-B<.#K&;%$]C3%9
MD&OP)_!3T&,I\A1RCK'.3&0N,*R=+R=MFFTJ+LKE(>!#I?4"0AH&!H=X#MQ6
M6E:*6N4X:M4LW[CO=U4N; 7(=N+L5,3Q9C@\)OV+9%K: [JN*(,0X$6_"/EU
MWH(D\GTLL[@6A\!7[Z@/I&%&UTYWVK[W/)D0W+ P0!A/K'(G(1Z+F&?E6))I
M=C+(1"$L(=MK-2^M\Z0 &A><?4.S"JBS9D2DJS7$7 .[JOI[I8:I.GQAI2K4
M(E9V*9N1M!>N]RKOAI%T%SP<S>1\"E3 *-S:0.R6L$0Y1R5:5:88&S&,?Y7Y
M%)-45>$#B@>.WQ96^32KFQA)IR-R8J7H\]=:297[)-:H:0W="%ED@,T +2:P
M$IUC*,S$$M7OX%9PD=G7PFXXPP@^O!HV^;KR?*FB$_&:UA6]Q@,4PB775-T1
M,"2O,5@TK=X&V@6L0-IWD99(=J*<GY+RQ6(M35^@!+P?'VVD;N!SV93*4] V
MSY&@D7T)F?FZ>;\LNJ#,HG:)W A;Q_2% M*8"_]:(:U\3U6'5P#!]*5$%MUG
MT$HOJO=E\2^"2"4L,FRC@1B"KTA)811Z+>%?P1O,IN(_'<Q&IL&GI;R+)@=E
MZIL(YM^G<&^F;OBXZW_9 T_Y#90# #-$T1%5E$(J4 <6(J $\ZP;OY0JRB'<
M"2C-*6QE*@J"=\9CCJR?7I=Q=$#H/>$(FDW18U>8?8TN#'-@U"Z,#'1)D<E0
M=W*@F#=F,BZHA)&E@@H@XVF!J *LHR"*8K2I'F*W=/@#(."MCGHK\+!,)5V3
M=">0-MK4D#3$-AQ2,E8'/YV.T?B4 $  (EGROZ?B): 5I3RNU<@J.;RYDY+S
M2Z$/?DM!O$O8MBN16N\9M-V0,\F1S?>H+AJED">-_#D0J,@!2K (X-6":D7'
MNE+554BXB?/#CB4JM=(O!0NKT%.N*KZ(B R*!5YFE06YH*@@J8TSX5!+N" N
MRL8&-4#Y1(F-:I+XVSF"K8/3+DCA5;1+]S?3$@6?:M9,-41S0MD2";6ABO)R
MHG+PI?$E6LPIGD!VG-H3*U7W*2+\-K@RB4?U[>=9C9_SIJER!=>:SK#606<5
MJ3 'L3S.KV(1"JM*71" /[L[BVP^1*0&_![&,47Z:3M?=YA> JU=Y'DLG/-2
ME9(9>+6"2E_=IIIL4TVVJ28;E&IB_O2I)C?R<,6>J>9(VC2MU/Q9[U^WY5G5
MA),85086YK[6\2H- W_:4!:_W\&+OZ+_OL.E-5\%NH3'@]2I6A"MBS=LZXKO
M<,5WN3%;:;$=FL5BKWLW<2C_3\O=TZPOK+U8MWFP6NIF!W2:R2AW<>J?WU#?
MU*7<JW(,1K;%;!F8T*E5PK*R.V:@*=WFN/%IC8!XHBE=6U-'N\SRJTQK>+QK
MN[^A^,UV]VU44O0O<LQ#5OZK*>C_PW;!F:KFD!\*)2[F?-2L8GHM?>7-@K"Y
M4."0RZPAR:O@]9@V)OWW5:*WJ R0/[0V)LR0QO';0/OV:O:--1=6.'\S2ZMS
M_2MDQ7M/V+>\($2504B1J5%A8^54%!G8-4[/82SJ:B*T,+_9JOUD=+T(NQIW
MVN:X32Q?$^YZ]UB#BBX<C],\C3<B1W,S @RY .@VQK"-,6QC#'>),6R]_X_D
M_6^Y*(D7X) (8J75%[%ER!0=I&$AKA%3G:47DEAH8UC!.6J?F>H85F4=20:H
M[E&\>D+IY!(GI)Z?I,,Z,^'X<L@N0$9H.V"E%QF_UMZ+PD=)>+*[1.TPZXI:
MJ#XW%>_\E^.9VDB& >J 1,N?3H$$F?AHNXYZ?!YDR@--[ZCWD0G]>*'OO-TC
MN^TC5]YQ!!NZ*]#T)$-.+3_03F6ZN"C-/ ::I.9HU!BM>7:69?F48FY4KXQ%
MP<CC"RXY:5;7BLHB RI[;"9H5K$.1AV"_F4WDT#;GFD22A)7!MI!<V,8G&EM
M#/=0YZ.E(1"F-AT3E63-B,R_ZHB-_&PX["/>U6^6-]O8/V '8KC$NAI_!7)1
M>;!@Q)*,PFN!Q\"X(NIRTQ-4I2J6<8-MW!9MGACL:2("%_^J8CP2I2IZDI*D
MURQ95.RTD4Y$O#UK7(YPXZ*R,L2LY-MB,>AC[KY8&6LEN*IN/2@2Z_+S0KM"
MS.O'N3(@'@B.-8-*^>(9)FNE4#YN9$#QP74)#BA+^#8.6G'B*IJPLO=MWNLF
M58&;N5*NPFH=H-OZZI[:^MKZZA;[ZA37W'KK'L9;-\\ 'MYA)[H*GN>B)J]2
M,3)^GM/ )S%39.O4^WF<>D^LM)C+E0L^92_;7\I?M(^8*'^%%<)$ ;LY=OXJ
MM0\?/JZ)I'H'K[E@(^TC*RY[M.COZ R[7I<"E'<\+"C7S#1%LMF:[$L-+J!T
MI'@F :XF>JE5 0_&:@7TSS!0(HW U*FC&BV!1HBPB*3OKO(0MFLCL \W5E:'
MP#XR>G$J>E.KM[3)>5Y1VN:U;/-:MGDMZYO78CWN%"5W.T6IQ1,>IJGWFINC
M=-)/U+#@5-B.8KRZK=M5$VM6A PTU_[Q]R''3MUD.9FZ;LZ&EYI=51J]>N=L
MPVXC8+5I"[2PF(A#64B-810-.ZC7;(^*X<)*R^ZU+,*[[P:.79UOL4@EG$ZI
M".]7PQ\_E9BK47IVADA'Y_XJ\5H94LWN_%5CN*4A-=":08"[07KIGJ&LK#K<
MM?N%=EWV"CU$*XOPH3M.KCWJ',S<4WE#<^0L5RZMB_Q*V/#JYGI"I^UJG2@0
MI." >WR5-HIS ?.Z^3IZ=A2>4$/.3F29G1+0Y>=IXH&J6^CNW4A-V]O]&[5#
M.!+N?]O$<=W0NHLE-80:A2I53^U'DV5S#6$P"#ABE[+*OFR)K2;7GJIM=4X8
M>M@178@J<M;;K/+3[YP3)&;U#.3<-TUZ1ZN=RFI%<F$B63:<QB#8OZ5%GHD#
M$WHW(:">8B+Z0'''9@,"$3QK]#L3]5VC/$,S>+$H:KC@&OWZ)S+?(,ZC*7Y&
M'*[IA\_:GO EV[A/YM%D,4M=>S)ZVVQ"O\!I72?B5#?9"O73<+3>+/4!;%2X
M@;I8+Z@PO!\98A[#YFAQ9S^(#S5B\7)((W"4Q1[+WFP7D<;8G^[!0'2;)"C5
M6*6TJ!1WV4H+\T1@?50,TE6#>Y5]VG+*N'1Q]_#QS'IT\K'RY 0#W['NXLFQ
MO4%@^P_N<C$'COOPCAS;'1B!>7='SOV],S_>_R*V%F/V)HF47RE<AT\)1_X.
M)C"^SXOR\KI"P]N]4H_HP%H_$/V>EWQ\H?T^T/[,AY<M*#T;-'GQYFZ(L DG
M$XZA9W:HGP,I=R\8B%L&BO#\X/1G=J'/$DOWO_-H2AZ-/["QVD>PM#'M![2D
MW8N4)PV_\S%&[WGQ?!$9CUN#H^NXFW_*E7&XI4=TA(2VPS.VD=]MY'=S([_V
MHT9^+7,;^6WQA-,+5O"+?(A14=&\7/LH4G+)!_Z^8..+<@TRH,1F^03#==A>
MJ)JG@4]IYV*;[6Z@T70T%;Q<UF"4C;,6XJP+W'CH$8:/3B=Y=$D!0A62H %L
ML. U>6J$/S23/W&1SBH]2T*PU6W!&DGS<QM3FY%!:#DG6*SP/VPT?JU]S/.B
MVIVCZW)K!V!V?N\M]ZV9Z0CTU2KV=^NW?^-L"'#']K[:_M_3=$Q>2UI$5#S)
M*Z %D5!+488HBX;^!41"KL<T^\;+B7"@[O&(8U6<!)6!L#(<6J+S(UVT_,,9
MGMU.P.:U+0F5-8-E/7H%8VM :*C[8N=^3I,"%?06^VVE:)[DXU^#5;RV.UAH
MMVR&:3<K<;3/F)%P"T?YG0#RN_:-ZK]B4&GGB\@7'B8=G6ME$?WOBZ_9USX2
M%B"%]>7<T =?Q^<O<)#+HH_:6I]IV>/O=U%C7!^^B()A.<!OO+/6] >NN5@3
MNJN6!+?B&M9VV4U;UGX(3WC(HDM1P-J7#"F*.$^2URMHO+>NT:$*"SWKOM;O
M38S27TK'12&WA,&[X4=TG_\1O>=_1/_Y'S%X]D<T]55\I/-G3>B?UU(900T'
MCJI1,:6F-OW(/L?[@^'W_"(KL8$1Z>/RISM=_3W!L2YX@2;90-=_;A 8SL R
M?VX0V-; OILD>S8@L-R!\9,3@N,/[JBR/1L0>'.\X+Z&S-H*PU.2@A_)^T5^
MIV>N ]U'UFW2*0UC$#QWVY+8M?7<#1,XI3ZPGKMM DS7&-CV<S\EF&"#P'T0
M(VQC1$M7B.0^^L4FW//]+:I-.&7@WY5D-^B0AJ$/?./YGS(8>'<3I9MT2LL;
M^'=3BS;IE+8_,*V?RWX1D?2H(Y#^W%6*G\2@T=V!_1.H^L'/8-"XYD"_FZ]U
M@TYIZL' >?ZGM-U9IW%W*G9'=LQJU:0/D)=DZ(^9F"2/LR@SR5B<F61T9B:9
M_B-E)M591J\;V[<>+>E(2"C]3EE'UL VG0=/87$&GOOPN4S;5;>K;E?%59>C
MV&UVV&T9*<]=K8<CWLVSLE%'?.Y*(+:\>?Y'?.ZQB6TRZC,YXC89]3D<\;D'
M?+?)J-MDU&TRZB(0! /_;@S@V8# - ;>3PX"U[IK#M>S 4%@#JR?/"4YL ?.
MSTT(IFD/['ME8&P^"+Q@<$>M]]F P+4'_KVRC38>!);N#;R?FQU:MC$P.N*-
MSSFW99N;_\Q.:0Z>O=O[7X9QY^3033JEX]XU;7*33NGY _.Y1S'^9?CZP'WN
MSE.J0#"?_RDQ+>G9\UC3<NYJ&V[0*2T]&'C/7I)8+DB2A_&(;XQBNZT,>K:G
M-,!2O5<5^4:<TK('WO,O)_'-NVI_&W1*TS1G^>]S/.7=-8:-.J4Q")Y]R9[I
M&@/]V?-8$[C/'9,A-NB4EFG_!/+2LH.!:?Q<SMMM8>+S/F4 */WL#VD8[L!Z
M[CF^5#?M/'M'@^%[ ^?YNZP#_R=PS)N&\3.XK#UOH#_[4UI@@#[_4]H@29QG
M+R]M/Q@$]KRBNTQ5M+7LS(#MW*KMW*KMW*HU0E$YM\II4^PBZK_KW"KGQ9NU
MF%O5'G.BV'(?K^M7QU9W* >']_$WCWXCW5T?#B9\I 75H)P?OX4V;$Q[H)L(
MC-W?=H[>[Y]J!T?:SM&>MG=PNO/^9'__</_H[%3[\^#L-VUG=_?XT]'9#O[B
M^$C]>'#TGK[P[N!HYVCW8.<#?G7WP_'IIY/]9?I4N$\VPUW.09K[\RB?X,SS
M(5 X$$C'2*-E:<-_L?F(NK,VF JJ&K4TV3T^.CLY_G!*6/?QY'AW?P]0[?3)
M<8U6_#6= -./[H%]>VD9#?-R6N 8L6Q2@'2BX5L?BSSB,?RZ_$$W<ONV=\38
M.)[%:O"9&$<'(A4D)(^U\!I^FY;:"1_GQ:37G(VF\6]L.&4X<8W62!(>H9J8
M\;)4J\6\!/E)I\]A99IHCI^EDU*+:S!%33"-:S#1^+?946RW?X^F]XE7X^9R
M.!\]3M//THSZ\M!."O[W-"W$,R%7*ZMCUR=-Q2R_@H!0RG4F6I+B,+H<I.8T
M'.&1:%8[/;K_/;I@V3G7=B)XM(2O1JA/QCVQS;+$OY;3$: V7%U,!Q#+PP]7
M*<!<O'("-U^-""S'/$J3%)Z0GY[N[U9@*:8T&0_6P?,![/9NAU.:1<-IS'OT
MQGPZT88IG(-@TUOXI?4"+(ODS$,)Q"@?C:89,/Z)>'O7,#\@(=!O1C3Z68
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MK'5$$7X+R?/O8VH*MS,NTJ%FNCUB  --VQD.M;QQR8!5DR(EE)(XII+^L7"
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M8H&C$DE[C@CFW<!87)WPLW6XA)\-S33TK1;[EM:QME.2GR2[W#+?YX\:"\O
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M?^2%\/*?=#QYE?Z4441W$G"7F'7IBJZ3'0A"TY?YX=>$&=I #+TX"$3#Y\S
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MQ^ P5%&!*KV5WD#R+QWY+VT@&*4B^W6/_[W,#X]D?C6>N/Y,'@')#H/('>)
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MG=)RE>"Z^W&/!O'2&@U?+D87LBRN(J1N[EF6PHC0_0FL5B-$_3:6+*60VR#
MTMVKPII<YKE2N[V^WPZ)^AE7=C,L5-L)V%N#!^H8K(+;3ZSZ,OL1<I5??+)Z
M!:7G+^B8Y!?+(>@*!+CN[!"':>;FNFQL2K:Z:M.[-WR@([XNLOL SP8A_F2M
M[_;\Y"$A_F5]9,,/'.Z63_:?).A U2*V7E>F!>Z-_GZJ@LV6X-[$KRPBO5V(
MM$\GE<+UQ@THW<;KQ9_$=,Q5%L524-W\#V*/:C75Z2\@P8B7PY(<#XM0=/?G
M93 >6E][$DGD@73S;+5:V<2U2VF>6P6X[GX\0;:)[=TC>-A$,AG*877WX"L*
M7D=Q, 76Z"(ON6A2#JR[#UN7,(/B;OLOC,:I'FA@<7,9E:^@W9])F/ S(>X/
MVJO"DEJG O^[M'H &_O/W>?N4'9I=0-(][RQ&A<YN]IJR;;J5?#:>V)>W!;*
MH<D?]1#@Z.Z1PLM;5E+"DX?_POZ$SAFV;X#('GLY9L>GO10;.- -B=6^R+[9
M8LK?B2L'UZT)DJB?J$"R$NK!%$E>WYCL3]*L%K@?2KF'>QICLDI34[AT*2>Q
M[U/2NK?+LX\22BUO%;ANY?SC'^/>9\GK=WD8W1SST$K8\W,/<RGZ,6K(!^".
M<).=M]BR-Y,+T(=JV*D/[DGW[)M0NO5ND%R'IIXNNRD,M;I#NEMP9G29I9M"
MY)&%O")J72JZ>UW<1*USC=\SYVNG5@Y4[\>V)]F?9R%T2UZE!';=8XR=:!ZH
M5(LWUL<_)%?-A"BZY3Z:D2 :HV"^KA*C4 =$AJ6[5]\(Y0;NY:?O)DA>EJD"
MU]T/]I:HC5W^Q/)XAB!@)4U(%R-I3C0??<<^O_MTA^PXDIRF5$'K%DSO^6OW
MLS5Z&8V[S\_6[]W!8Z__/![VGO^PQL/NUUYG+/&R:Q#0W=>*E+07W\4ACZ6R
M-W+A[#Z]W\(FT9@ZIZ"+<.N!_@&)RF^V!X?5BHE2[]^PWCRJ%S] #IGZ4""%
M<I8L?:N\UZ0R3>7PJ*(?Z$KZ#9X45+HO60:I>U(\81_/XSD\9445BGHY[+A_
M71-T"&4:PTQ=I54QH4IY[D)2<_$]_I89N\_6][E+)]ON56/H%NU@V/VC-QI;
M\&>G?]?[G?[9?Z0?1O]X&K_\(3'LJMC:>XF\-TRW'^&L["1T(TQ7!-7-OFJ>
M-)\TMM>?E-U+WCD-6T;^0&WO]H>E6%".<4>J!WH$"Y6^6X^$>M)LOP,6D;(+
MO9-7"!?C:9]# 9I/EI+;61M NGE.KT^E%RK#KC^UIQ!@2PX0UA7ZOI' <W]@
MMUIAMR/V3ALHY0M;C_%\,8KG]ZD3+(VM"A!TBS-_ A0$V"54'I_I3CP"P3S9
MP7<4)64/>(!0\3!)C9360Z6MS>7X!]F_#69$#]0$)\7OV+49$H=4D2'RJY)5
M7HVD6_.M]L5EM@"U*7]2I@)>=T]DS[Z);\FH8NON97F=4RL((*#+3^K7(,G>
MV_IA!VYZ01OJ_;-4_56,@I<R##LP@SP6RI@@RJ$+%2Q99C]*8G@4@0^+X)&*
M@^!.=SW&YD4SE_$DFU.5\+JUC3W05Z..:Q6X]GZ8Z8N)W&C)D[S*P77WH[BL
M]NG&CU4E?6 Y\ZS.2VC=]6NLS-4D#O/B-I3%]I:=&1TQ2=2^"'@  LS5X@Q%
M4625VF8J5 Y3C) ZEYUD5_),NU)PW2*M+#PEO)@DPSJ8ZT8=NL22.0I"" @S
M)]8?V!'=R_B2>\<*B+I%M\7)SK_[).E_P@%2]R>D%/4GZ]J =$7IV$&PI#U(
MMKKWZ%50BD"9P*%65/K2&XS$]BL+H5OON;>]&NWU_=W>?$$_PM^$C_(IXQ]H
MW+D_&+T\]<:2C7L>2+?,Z'1P,7FS0P?>WGR"1SB)A\.Y0EZ)$JKN_EFM9F8+
M9$KO]I5#Z^Y%IJZQ],62,E#-63&6^P:SC^X!:(L>_HNUE%01D]4"5T'5+9YO
M* 0'Y N:XW !CS^N+HR]2,RW"J;NWG7P7U^(YS*W@5P\1JZD=$<UO.Z>I.FW
MF=KRK-Q8[$?@]U0N3%(\W=<W&MGPB"P*406N6SKIFU7P5E6:5=J?9)Y% 0^7
M^W3KA"#Y$UAUR1VH<U%X[7 S57Q"^YE14*A#Q2.8DN#J[H0/=,2L^Z_6<Z=[
M+YD.&U"Z9P'SGIZ)#V?KO*R(^&"P$OXPPS-T':?.HN14?@-(MTBLQL55+I!N
M2J\F5\#K[LF#:K&4$D#=O)<^]TKB:(^/QRI0TST*<%!:Y^BD"EQW/Y+ZB.&8
M1++W4$I!=?-?<I.+.ARO26H<]3-B!SR+!]H;4IU[6).*5C=S,.QWAKUQ=S#L
M_BY+$BU"ZI9720(C1F%28)BNG(0* 2*#$Q+ P7&8Q$OKO .C1N] DU"L$-L#
MV\$3[%B3 #N2%;H27+><>T]WPY>OO8[L@LHFF&Z^-PQU6WYL50ZNNQ^\-/^W
M&79F'1)[[ETFHY^_DYN[K?Z$Z*HK2?RH3TUWHD:K6,RE)8T\BG!T2W55U'EU
MH;58VGGUOM,]A: <.!0*+C] ?(O?=/8D;VOMN16]IU<[Y=COY\U.$>E#/?&B
MAJU]72>:50FO>\Z\/%,7Z'XTML;=4?<GO+@N*U!9C:"[+]OGW<X"] Y7*A*R
M!^I+R9(^1562U' /IDR295[<9 M5R;:C5>"Z%7SS29L!\;"SE-?@D>(=0/F=
MWO/7_G]9SQ;_\ZDK.:"N!-<MHUJEEJ4/^VU+3?MC?X+WL=:71+9[7RN+K]=[
MNK>&?UB/LD##)I1V#54H":/LY6U'[$#/8C[3\>NSHR.ZE/%B2$F>/O5:APCR
M\YV('2I5CD<=$H?JW;+#&L5*ZV6@NA7<"DMR@G)2RD#H9C:G$[;O)EO'#@FC
MO)N9I,Q4]JD^H0-U3#.O+)<4I+S' >V+M_R"/*CHMBI:)G]>HB:YPSR9O*<^
M'**>*51*DBP[)9"ZE?UK][%CW7<E)=/S0+IY?N[]T9>6J=X TLUS>='-(?&\
M!Q[IK]S8R1$UNY8EE=Q@FUV[_%L62;>XX($ %,C*<.6!=//<F\]C7\%#*,+I
MYEPE@+N9722[W+ 33<V%@UJ-YFTF<TJ6ZEH%KENLA7MAS#=- _#JU\DVT [3
M#>B^!3:4KR4_L20OH0Q2MZA&>+X@/D[^L (LR[2JA-?=$_$[HN75X4)E8[(5
M4;W69! 0*(#'7D1@*&/"WAH5Q28K$#2;Q<N+V^S9M>PMA"IPW1K*KG-O'-E*
M+Y@(<73WJ+^@#<D*C^1@='/\;4:H1E.M#B2/%I0 ZN:]/_[2'3YW7X;]4:?7
M?>Y(-F^5X+K[H1*H_-Q['/>&%&_U#N5[E-NNT<J!QDD[_>>QU1D_=I]'W1&3
MN.2N326\;JU(JX^Q;6ZA=@O++)96+A/B[CL9,OFB6J?,:O^! M*AQ(B?.509
MQ:\D<"&7$[DY.X]]A22@G6CJEKC*#$W?DDW\K_<P JI-'*@%$ 2;[Q-^R"0'
M!/-AF]BUD-P[Q:)2)(75\;MGSZCF65%$ A\M/U.Y0=7@T<5_DID?L@?!,G\;
M2-X<W9J<[EE%+7RG.X1ZZ=%LZ2UFR,<NE:!T61 AZ>Y3,6@(-5+K!AJS.+I[
M5(AUY#(2RY_%Z=@+'-D>[#;58RAUZ1YFD"69?1T2+$@@U>8J:-U"9_&LZKKE
M*A4<%;!U]W*(0]J8*[NE4P#3S7<QN9#.H'C.K_Z^@$]I>P[+M?.GSRA)M,/.
M*N<PC-*T&+98JMP3?\\F=8>R+ZYRC_Y=2M/9*^!UJT5%\C1S$Q<>BI#EL%&'
M[:1'7B&=/,T%>R0_H*2_RUW*U#2O',RZ^=I[:?) O=CDM!/G3SOY=8X^'0O:
M/R@0H7YN6HN2[G(GK5S$LB4+<%:!ZYXJ_7%'%I+J' ROX"!(,S<VH71SO9[X
M(]!CJKPO"W#4J7FX:LJN@"GAZNYA]_YE:#V/ ^PM\!NF\T?FYE?"Z^Y);I-,
MK5(PA6>GR80]]F)[ZVIE:GMQ,84#->LE#HZ7[$?@@'YUF7Z5&48F"GED.U(]
MS"U.$FZB=MWR/.+P2VOI579!R4(AUH&JQ; W&G2']]9CI_\\DKT-5P&L>WK_
MUW.W*RG6E0/1S:_E81+>8;*@=F1N4X^0K@&_]YN/>$Z)NI*E0PGWW]?#7S_0
M#H;.#,WMW_[VWU!+ P04    " "&A%92(S?0S"PT  "<. ( %    &IN:BTR
M,#(Q,#$P,U]C86PN>&UL[7U;=ULWDN[[_ J?S.M!!_=+K^D^R[&3=,Y*8A_;
MF9XW+EP*$CL4Z=DD':M__2EL4A(E41(O +7MZ4Q/8M$4\-4%0%6A4/4?_^?S
MQ>3%)^CFX]GT+]^P/]%O7L TSM)X>O:7;W[[\ .QW_R?O_[;O_W'_R+DO[Y[
M]_.+U[.XO(#IXL6K#OP"THL_QHOS%W]/,/_]1>YF%R_^/NM^'W_RA/RU_Z57
MLX^7W?CL?/&"4\[N_FWW9R%<3B8YX@331-)DB$N&$0 G)/<V")'_]]F?G5%<
MN2@)>,:)%$D2*[@FGB9A-3BJ@^X'G8RGO_^Y_"OX.;Q XJ;S_L>_?'.^6'S\
M\[??_O'''W_Z'+K)GV;=V;><4O'MU;>_67_]\[WO_R'Z;S/GW+?]WUY_=3[>
M]D4<EGW[7[_\_#Z>PX4GX^E\X:>Q3# ?_WG>?_CS+/I%S_,G<;UX\!OE)W+U
M-5(^(L@=P?[T>9Z^^>N_O7BQ8D<WF\ [R"_*?W][]].M*?\Q_<>?XNSBV_)W
MW[Z:H2:\]6<%:?^;B\N/\)=OYN.+CY/KS\X[R'_Y!G^/%(E21D69[M]O?O?;
MFYFCG\3EI"?T9_QY/4*9:V\0\'D!TP1I<_@]")O.9Y-Q*AK[G9\48;P_!UC,
M#R+TH;&.)GPGD->,*+-=S3>9Q5M?FA3UFG57OSGQ 2;]IZ/EG)QY_W'T?C&+
MOY_/)@G7_O?_O1PO+G^:QLFR+/RWLZX ?[E8=..P7/@P@0^S7V>X+4P7B!1'
M//MINH .YHN1UQX\UX)P"(G(R",)&13)64;& =<OY-L,79/?:W+V\]"K\QH5
MJC5SW\)D,;_ZA)1/"&5KK?[WNO!7(CN<B2\C[H9%SI#>+,ZA>S6[^-C!.4SG
MXT^ @&87\/-L/O\5%F_R!_]Y9*RS22I#M(P1N>4-\=()9%EBC#.I@N<MN+4G
MSMMLV=#EEUU\,>N0YWA4?//B#R@;^_K46('V7;RGY+?WK/4WOITO+R[Z,<EX
M 1=7OU^.D&?7T\7L=%)>:1HRY5A5? <+/YY"^MYW4R1\O@'Z->1Q'"]&D'UP
MV@N2F'9$0I;$&V.)5<!URHD;H5IHW]/0=E$X_C]'X2K+LIJ.H>)?S*8]@_[3
M3Y8PRME+*P7J-PN4R !HQU$A2?9),!5#UJ:)1MT%LHO^B/\Y^G.4G*IIRP?T
M$.;+[G(#A[ &F(Z!"(<VOF3:$N<"BM=ECWNF8A'MF@;Z<A_*+AHC;S2&?.TJ
M<Z2PJBG-?59\!WG6P2U\HV!4X+C)$:$R>HU!91*2I"3*D"D(+23HTUB=6] =
MRX*W"!BZ#M(M66@7; Z$68O^+V>XTQMT]QQ'"2G\OVQ8"X*W8!FV<7BLMMQ=
M%\<*XY3V7<A<@W2X]*U'.D50Q"F+X++T%#G@E3/_LN_:ZTQE4553H7W]F!29
M$A%%[J5'/T8:CSS(GG#M$D7CTT+T7XBW^GS&7VWE:BG$=HZ"2%Y(Y] 6$0I1
M9 X$;0A!<!%X$9,J9 _%49!?C:X<)89JRO#SV(?Q9+P8PWSD:/DG 1%69-1&
M&8EC@%"2"DX%&SQMX@!L8*A(SJLE6@;3Q2@9HQE'(]EYJ7!+-X($Y?L[#33'
MA3=2-0F"WH<R)./L4+G?U>(C&5Y/CV?3LP_07;R&L"@>V!H+!ZZ$T!)]K1!P
M38%$:U"APR0BU=DJP5B3K6T[G"%96M44X'C&5U."UVMW8'72X@&[022>N2/.
M@\A*9Q*U0-] XIX=C'!$Q11  CBFH84V/(%K2#92+;6H*8IJ^O&V&&+(UNG*
M.GL[FR\Z6(P[*)?FQ?I'O^ [F.(?%F\G?CK?Q'RCVM12]"ICN0LO"@W \9PN
MT#V3/IN4)6^B1570#\G&JJ5KIQ=K3:^O6VZLDEN(,FB?+8O$)HL'*8V1A%#2
M+Y1 U\"P%%23P^LQ4+OHC_K"]*>:$*JI1:_'V]54A8 N!FC"I;=('AZL+@J)
M,K1)BPR>Q29*\3"D751"?V$J44D ]?:)^1P6UQ8V@$6?,")E6J%Q)1,CWD=-
MHO..":YEEJ[)QK")XN@PA)^?XY9=_E,<[$]^@H/.7RY>^:Z['$_/5DZQR\+Y
MB+NR4C:7@!SZ$5PZ$F-$ZR$E%E63PW8G=$-RZ [7D'N!B>J"J;<,/OGQI%RS
M_3#KWB.N]X"K\I;SZ0-3U&M!;-: JS/AZM092(HB6A-UHKS-F?D4LB'Y?O5T
MI:Y :II5LR4J[3N(@ J,^-#GN$+D($6TYA1)'O=NB4"(C1(I9]%%H[QTME6>
MUX.@AN0"5M2.6F*HIA@_33_AW+/NLOB@5$H>#:JF<\D3*8PBSMI$^NMSB[^L
M6).+ZDT00_+'Z@G^8#;7<_4[^.C'Z?O/']$YA"O7\ Z%AM/D(!!&P2"%5!+/
MJ2;6N:B=YVCL-Y'_#MB&Y&;54XO:0JEL7O\-)FE]COTZ6[SUW>)-?CV>?YS-
M_>3';K;\N,;8HQX)I@SWZ%FD#(Q()37QF7(""93Q1E!PM)T1OA?6(7EH%4^7
MQD*KK%TC[J33AE'B!'7%$O+$\I10ON!$E, @M;$[^NGK>J ,SV<1<94ZGCF1
M%(!8(4MXWR2G<(VZ&$[L@0[!_=I+QMOU^1 .5SPU9Q^A6UR6,.D"]^?B_WTL
M4=1RCC.**]4)3:3FZ/$YZDE0P1#\ S-!,J>R;7-</@QJ>%[542I0C?\5#>:%
MGYZ-T71?D8= OO^\3G_]<39+?XPGDQ%D/)IY#B0Q6> 5K0V&$\X2>(<8A6T2
MC]H%W/ \JZ,TI+H\JFG*]>R>42>2E20)17'G"IYXX2B!D*/46H&53<ZY?21^
M6I?J*(D?Q-=V5^K7:C?BWCHKF2?*X^$D+3.(1V:BA>596>XE;Y(N]#"DX7E-
M1TF^$N_KWDJM,6S<APB1I.62<!_Q6$HTH$GM%=%9&,^$R#HVR:_:BF9XGLY1
M&G \QULD"EZ9J%$;A\X:(Z%WU;-/)&2G"3?:*AF55;G)L?]49MT!#UO.9]VB
M9#%]-^NZV1\E+WP$(G,K(1,1>4+JA",N&TN2%$$[Y5).35R<+5B&Y.@<J0=W
M-?Q8SE>_,GCK+TN@^HJVS&+,$E>O-1[=L!P<"?@1+F:+R]GPP'R30VX[G"&Y
M.Y45H0+_:V?E;*%0*>^9BXX8EP7",8C$24ZT39Y"SE**)D^]'D0T)/>FOD94
MD,+12O&/Z3^NH+R#X!<P?P>+93>=HW^._OK%K'!F/E):4^$"E%Q&1:20"7VN
M: E'TSS38(*B=]YWW2M>LMM,0W)O*DF\ 8NK[07?7WR<S"X!WD'_K&>;-D9(
MEEE-O%1HX&7JB3-:$>:I%HYQ34ULL2<\B6Q([E#EO:&N5!JF<UZ'<V7@0D(B
M*09&I/&&!._0IDG>* HRN=#DKO%!1$/RE-H<'$=*H87GA/O9_8=EH\!YC$P8
M0@/*4+IBWF3-2;9.08 <J6_]0FDKL)IORU(2,5/K":X[M.DE;MM>:TEBUB"M
M@*A<D^>J#[XM&XP7=;Q.//(F:R^^-ZP3<5#)#$%C5O@O1)SPO)=*$I<\8J?&
M PB5G#Q1(8GCRY<-QE>KKV[/(.T[FOH?W][E\<_X<\U2A&]].3_.83'&26ZC
M.*XNX>V!6Q4I? 1^M=*-[Q?X[W)7.9_EJ^(*1W)JZY 5>?0TY$KU''^%Q<WK
M?]1TD1FCAH")I;Z$+?52M2"1<8,>K4N"-PDBW$)Q_,7PU4@_X':#7%V,ITMD
MX)N/T/42F:\>S&]88;^,I[.NWQY62QZWHMNCK':/7V!Q/DLEA7"^Z(4S$MYG
M<#D04'B224I+"!WY%PUUP*P42C8)PIV0QB$9)X=KZ_W;ZF$J2<7TB#7P=4[C
M^IGA*'(+45N*YRF'\OPY$ZN-((QJ[K((++,FEP</X-G3%FE;4*VV>AW'_7KY
M#QV2\[:;%0"4&># $C%1( !J$_&44I(]DXYR+Z-H$A+:P'!\2:M/,%W"U;KM
M?%S\?;PX?[6<+Y#GW7722;F=Q/^E4LXF)*9!*X0592P9"I0XYBD1ADIK?9*-
M\H .P#JD_?90S;E?VJJMR"I6()HOWN22V-*[(]!]&D>8OT<78L0XR*PLX+8M
M&)'!E01=K4C4.D1!(1K5I$S:PY &M7?64I5*$JA\CI[&4-#"I<28)<GF/@C(
M2$CH^@KCHU<4O/&-GOT\DS5YW%DF37#"ESS"S- OSYJA7XXG*K<9$F>&XB<G
M/<N>=[,>JJ;>2QL\4(3U@H#0QW=^1)NL\Q.D^66Z&$_'\T5ATR=8FVPC:@WM
MKW$]+\E,00,IQ)&LI<V>YTQEFS2;G> -:O/_4E2O@>0K5FJ= PY3'KB_1G-I
M,NO3Z]>0;BRDB&SI,R]Q!>'!."_GY2BK9*CR$=V*4M@,_R%N]2[#>6F3YMHW
MN<,X O.>Z2'_TM]3ZDACI;X&-I)HN46K O'>E5=V> A8*32Q*09KM#8I-HF?
M/8%K4&7>OVSE/$S659_5KXA;,>#Z4B<+KF@$04Q.ADCPG'@=<JD%&(0%&VAJ
M4K[E(4!#2HGY4C2NBG!K/DCK9[^R(H12Z/7*1#@O26&XP1)+&:I_H#0FI4&T
M*5Y\!\>>Z33_VLN.E67=5RV_SJ:S%7/*C72A^PI32HH%A2I@9>1$VL")RTH1
M[G@4BAK0;8J$/ YK%W4S_]K'6@FZIN6VZ)9QL>P0SZMSWYW!?,2M &8S)4I0
MP&60. DB94)%M%9PZ[UJ<GNP#<PNBF;_M:]5ENHI\ELVDQ^V]"FHF+JQ;?1&
M61Q/$E(IH6/+/%=-'0Y*?DHL9%0H0RAH063,DH0 ^"_-L_:.F6@:77M4I:/*
M6?Q4TPRA6#(IR-*0..-""H[@@J2$2@<V)Y$E;5)XYTMKSOF<.KKU[*TIV&HG
M\-UL!/#2T4BLBA8A>$L\=8(PX43R-&MKF^C6(ZE9SYLY.B0E.EQ4=9V%!_3X
MX5J8+],_EBN[XEK7/7.I%#HD1K"(Z)DA+JKRM D"#\@CY]J]FJ] 0"M&_C;M
MP$_&_X3TM]FD+VKBQ],"[LUT TXWGN-?O>[MJ[?0C6?IFK$2=PI) Q#+2DL>
M7[KHB/)"7@HOJ0(G\TD9>RQ!0SI1GD7[=SU*3JHY)]E0WD&<^/E\G,=Q)?%K
M1A;'Y>6;5S^M>?TFWU!X38XJ;>RR+;JJ$Y%*QU*@F1(?L@L\9<54D]NJ9A0-
MZBYVT$OAM,ISDK7P&M?JI_[Z>/[_EKC,\V6?R/8W2&<;L,%:A(H^-D^QSUU2
MQ">I" ?F0/( R,]3Z_Q.R-L?IS>[X0:@Q[;#K$6)3#B213;(2_Q7<#835:H/
M9@\)3+O 9U52OI0CM+Z.[W]V-E63@9R:MVB[\3YQEX/$,LG>E3I-Y:6DB)FP
M#!)BD$;F)E'7!K1\,2?E\VG\J33E)"K_: .LS<Y76^P/:2 FYCQ1V<E2@;DT
M:HS(7&\5A&! MHEX-*+GF"HO.T#R3T)"(&]Q@^S6.=4E*>A5!VE<$,[RRXL2
M*_GG>C%NVU5G*ZM0>1TM\%(O#G=5KS,)-#@2*1>0.4V>W:FUN[6:S' H^E+.
MX%,MI<W2-\.1TEYZ5Z6RTF'[<U[OSSMS)\\ZI/'*N+G'DFOZ6<B:JV@(31*W
M=IN >.8= 1\<YRQY*Y^Z!1L>54.*)W]):V_@^M=\_=V1Q_<Y0US,W^3O/\=S
M/SV#=WYQ?1DPBB8QR:PIK=!+!0D'I?]S)C8"$S2!,"S7.;%VPC.DNGA?DLXW
MD_E)#.%K9"[2%',.1(C2?IH"*S=,0)(V!H\X"CZ=-'CQ\!WQ<X3)!$3K,V,$
M B]RRX($;QFQS E0#IANTQ6]<IALN%;D07JXC^M:7\Z#=U2%T=1"!I(%T[C;
MV8Q'H]0DI6"M4MPIVN2AV$D<U0'':)KK\JF48GA) -:Z0(V0Q,N^&U6PQ!HD
MQCC-,PV@Y=V:L4-. ABND=5<A9M)O;G.(F"4SG15(#->?NAPG?FX6*W'_J>5
M1*]<EU6"[3W/:+HJ)A$-.BI1$M N$LFX)BY[3J(%!SQZP=1)K:Z:Q VI[/*S
MZ?JS:<L $J)KE@#<:ZK3I4J?O$S@JLQL/5YNUJUM4")P"]R&?&FE<-M&;\JQ
M4ZM5Z5S_PV3V1\WRDS=CMEJ.VT'7*T!9)GC;S3Z-<;3O+G^;EY?KJP<O_6-V
M]"57%8.%<,*'$(FR!DUJ3B4)IN_:+C3G&C+:U(U2H'>$>'272W_9,_W#;/V&
M_\&VBZ.D8N9!. *N;T5C:&E;S8E34<D@\8^\2:1D=XA[AD2:E_9KH6;WVF2V
M$6#--JH1(/7ORU8I=OA)6A;BUVT;1\X;KK1&3]7%4%Z#,>(C@M,F9LC4V]#F
M$<O3T(9T6W0J?:HKKWIZ=%?/-Q\H2A-I%I*6+M:6R.0,<4$H8CP5(0DJ/30I
MMO@8J$&5FWFNS>A0(37;?G[QY27JXA(WQE>SR01ZAVW^)F\"M='K8!2ZA\QP
M(B5'_<[1$%!*@'%.9]8D%'4 UB%YXL^T0=66:/4=ZX=9MXFYCR=L8PK-8+G)
M%+F@/2X2"R1X*8B0T1AD%@5H4EQP3YQ[EHWYJO:U%J)L=T)^MYR/IZ6Z[2H0
M5AAU5:AK1(.UV<9$-!6V/#)-Q$H?"'B;0&IEO6GR-&P?D(.J(_-<)V@M(5;)
MD+E2_NOU@&SZ,%OEUKU??OPXZQ8OSSI8^?';6!-SS-H$1I0O+WQ2U 1I""13
M<-E(;A2_\Q!K:V;,L3B&5#*FL6*=7&SU*F,C5\K_%P?V$Q[TB*TO)C*."TC]
M.IBFVQ]L?'.5R_G3-';@Y_ :5O^]?J:]F<*SRNL9":_1!@6T$:1+I>V/(.@F
M.Y*$# I$:;;8Q L]+9D52@1LT]8W5W6$-K4U*64C>H@)"D/[^VCG& D09,A!
MX ]-;L!VASBD%)H!:_N6V@,M=*!F&8M==U29K:6E!$/@W)9"5Z7 .Z<D>A!&
M*R%3FZR#0P.\SUP XXO7T6-UH+6._C">^FF\C0^,+6^, PFKTI(,_X1>*S$6
M @T4(A--*M;N#G%(N2]?OHX>JP/UVCWW)-[.=WXS/8K!(T,I%QY*9D,IOY\4
M+C9:%EMF,I22@XKQ%LK<@)8AQ=Z^(*U_;JVJMX7/IA%QO.G>^FZQ_J%WS>?C
M]3L6_/!B-H6%[RY75R=7GOMF#](YRA@2&QGTJFAI,\.LEG@,.4 K*7'B!3I8
MDEG&4I.549>,QDS]3S]9PIM\&P;R+O?OC5/QB1V11J&%:54BBO*H=! QM"E,
M>Q#:(7D=SZC#]T[#YI(_U<I?0]W&(.&L4-12PFUI0:-0I9P7Z!XI:XT7(L<V
M_98.1CRHU/PO3EN/58'6[L8VESVQH $,)\'03"2C0"PZ003-3X;_P_,TVA.Z
M&T^&;?9GQGU+YV6,LV5O<D1 HR),8$2UUB$81C+WQ2N$PA 7B"O_6"F-IDU*
MANT"[DO(<SI6M;;T-ZTKM&IKZS5DZ/KF-W%K!U8F51 J,6(,KGJ9"_T4CR@O
M7(K9R(Q[30M->@+7D )+)]*AFI*JJ#X?.XCCGDWXYPFLGP5LOHD?.>^L9A*(
M]SZN2L5:/*8(,QZ""AE":K(I[P)N2-&?DRE299G5ZS1X[COX#O?'5-XTH'*O
ML%!FJ DL$.4B:C:D3)Q@@FB1/>00!(0FEUO;X0PI<G(BC:D@EWK=N6^*P?H)
MS*^=*M3?\H>?+C[Z<5?N@J_:-1A.0^ ^D"R5)])[A4Z6 ,(#4&VUUUDTT9Y]
M@7X)J4FU%:NI,&OV-'[ >GOK+XOI5O#&V"UO>6HC':-F3AH2^U+XZ*<1"TP3
M2K4RCL6 GY_6"'\,[I[Y2E^#]IU KM5T\"J3"C?@,)[V3%RUS3DKJV,VG2.C
MNK6\NA*9[M-A7O5!:J3KHI#U)C_P*U?47;*1R@ *O1""W@CNZ=PH4C+BB4K.
MQN+J>]?$WC\1?5] [E1M+1^BYM3,D/\T+D4G?IAUKV?+L,C+R=4B'L6 QX*D
MD: IJXFDP1*7F"<^ZR"HR\:')H5@'P.U9QNNKT$!J\FHX8%>4BNF^$N%UM(V
M3BC%B8K6H"--)7$!_6HMN(@A&Z/;%%)]%-4N>N.^,NNPGI@::DZ?1G]#^>J1
MF594:!\]VJ5(JTR)$NMB)MX8"YHE94RC7J:[P-LI DN_>F4Z6G(GTZI-Z],
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MQE5:2KSL([PK"@[@W)-#'EWM?1_(3;E3I2S^GE,TYE[+ OKK3D5OH>L[A1[
MK7M#'%N9Z5%(5:D]O##^]H$J4UZ_"/Z="4H*TS2.)^,>YRQ_Y^?C^"LLKK[W
M<?V]Q>SU>%+Z6VWYNR.*?35$4UD2S1A5Z4W0W_N+44@O/T'GS^#7Y46 [DU>
M@^FGG[]9+N8E:(V81I*#U(H%@L*01-)LB*6B%#J4QFM1>I,UR3S?$^>Q]_ /
M3'=OGEZ<(Z>,3L #29E[9(H2)!@(A+'2K<DF9:0_(5.VHQQ2OGE+K;M[,]Y.
ME%4ZK;V=X3I>C/UD!>C[S]#%\;SLW[_A\NYZE^_-Q\+3/B0Y"BF+D"2R@AM%
M9,Z)6.V!>*!>4]!!,?O$]GG M$/*-3J%\K263!756>'Z^_DXGK^:+2?I.SQM
M/BZ[>%Z:MO<8;P4.?H'%^2R-J%?&6@-$H4X0R1,G3F1%6 HN!IZ8V:F-RD&3
M#RI;YU1ZU%Y,U=+/T#E=7U%/T&F]F$U7V%\N5I>51?<_S%[-ILBQ<J."S(*P
M> ]QV:W;H5#I(LN>N)PC,H8+XI(#PCBN#1 ZZ3:/9X_$/:1B1J<\&D\I[F95
MA>\8W#5J"3\U9&4?H>6UTTJL95^Y>UZA_JSB\1O]&5Z>=; JV')(6/S@N8X-
ME-<A\GD8??CUUY$S/A?3ZU^A'8JDQE50M;F?2QQ#W'RNDC)*DJ1?YR8O+SX>
MF5#4%,YSB6]O5CV31*\:X&[\VE4OW.>0Z YPGDVB^[+JF26Z^HU-F_0Y!?HP
MFF>7YXZ,>F9QOH,Y6O_QRM?X;7I4&^ZV>)Y=I#LSZ[A4.CB[6/4J^&XY'T]A
M7N#]"+.SSG\\'\>7)7IP2$[=+L,>FURW-_3FG#K8X-YC\!-PK;H9O<ND[SW.
M&2[77[WYYA&)G15F/0&W]R*\O1BNDY;7WWX''TMYX.G9QD.DQC+9!\(I!'0P
M2TXHK7?P":9+*$&_[S_WF1N35\OY8G8!7?F]GV?3LY_1$TNK%V'A\F8@/^F'
M.I5,JP$]J>3;L/?(S+;_7HY7[VL+A-<X_7PQ+@^!#DMC>WBTHW/6=@3:BAT5
M@C'[C-Z.70T#*C_#6:F?/(L Q7TXA$?WACB2$8]#JDKMX8KQT$B5::\O\-Z_
M6$;4JY+3LC_AMW__2'(? 5./R(.M\VVCU"2XNKU]:_0*N]_CX]5D1<,=[M8\
M-Y$P*)>ATPBOSLNSR;+CXAD^B^.28OT>'?3CHDX5)JW)W@ID;\I@?=-:_A7\
M'/[Z;_\?4$L#!!0    ( (:$5E*N)WD#7OX  %KW"@ 4    :FYJ+3(P,C$P
M,3 S7V1E9BYX;6SLO5N76S>2+OA^?H7'YW5@XWZIU=5GZ6)7:XYL>4ERUYEY
MX0H @13+3%)-,F6K?_T$R&1>F&3F)KG!S*3=O<J6Y-3>'^*+#40$XO)O_^N/
M\]$W7W Z&T[&?_]6?,>__0;':9*'X[._?_OKQQ^9__9__?O_^!__]G\Q]G]>
MOG_[S>M)NCC'\?R;5U.$.>9O?A_./WWSSXRSW[XIT\GY-_^<3'\;?@'&_GWQ
MEUY-/G^=#L\^S;^17(KU_SK]FU*A9)<#"TI8IGEV+&0G&&)06H*/2I7_^^QO
MP1EI0M(,04BF5=;,*VD9\*R\Q<!MM(N'CH;CW_Y6_Q%AAM_0XL:SQ6___NVG
M^?SSW[[__O???__NCS@=?3>9GGTO.5??KW[ZV\L?_^/.S_^N%C\M0@C?+_[K
MU8_.AIM^D!XKOO\_/[W]D#[A.;#A>#:'<;I^ ;T^SZ_^XDTTYOOE?Z0?G0W_
M-EO\_;>3!/,%/0\NX9NM/U%_QU8_QNH?,1*D$M_],<O?_OO_^.:;I>1@FJ:3
M$;['\LWE+W]]_^8NTN%X_GT>GG]_^3/?PVA$B!=/F'_]C'__=C8\_SS"U9]]
MFF+9BGZUY K*5#C_LS[M^X,Q?2(@TW01D=&?XK@J>(\8-SW]<,Q7SV(9"UR,
MYCTBOOOL7O%.SF'8IX#O/+H'M(L'L7,\CSCM$^JMY][ N0*YCK ^\E_C?WV7
M)N??+Y"]FM 6_ N<X<.HZ.^QNI5RP=7B[==_]\:;B>+A>%AWC;?TV\L'U%?M
MC '_F.,X8_[VFV'^^[=#&W@&TA]O M?:RE!X#IY+2-XX\&)P_9B*9H5G-$FW
MGCJJ>]KDBH011!PM_G20<3A8'3)OQF4R/8?+9>";.9[/!IQ''57R+$%0=&+0
M/X)RP"#SDH7,)8ATE\C92C%FF+X[FWSYGMY#;$I>?U$%RAD7E_OA_WP(PU+2
MAZWM(_WL0'LPW#I: 0=@.LI$QUHJ+().1A9!Z[0]KJ6^\S;V:SUY,5VMXO)S
MV?-[JD9  R;GDQY$N.2'X'_[S62:<?KW;WD?5+X8CR]@]!X_3Z;S@<:"ALP6
M)J(T3$MGR:#1D46=M-/U&]&Y1TIOOON$J-U;I'<I%GU0_ M.AY/\PSB_)J-W
MX$5&:02PE%QF6F?)@HF9.=0)BP0M).^1XULO/R&2]Q?J799E+WOR%,CDJ(M<
M:1Z T5X&YJ!Z)S:1GQ(]*:(A"S^%B$6$/O?GM?>?$-<'B?8NW>H0NG\8SX?S
MKS\.1_CS117'(%AG@E69843'2-T\"](B*UX5HZ.S4O=!\_I[3X#>@T1YEU9]
M.*WO\6PXFY.VS7^&<QQ$F4'F&)E&67<5$\@R<(XY$3F(DDI1?5B+F]Y],O0>
M(-*[%)O#*7XS3I,I;2*+17Z8T^'Q:G(QGD^_OIID' 3D9/:!9E;2"C6/E@$4
MPP2'*+W4263?&^/W0CD9!>A/X'?UP1ZN#Q_ACS>95CXLPV6D[&HO4D5(4D_G
MN*MV8V*Q>@HY)IV"+X:K/DSQ>T&<C [T(>2[[+O#V7^1\Q1GL\M_U>6*@36!
MO+]L&$=%*FFC81%#9$F3&1D"G5"R/^8W #@9U@\5[EW&?6^,OZ)?OIM^G/P^
M'AA-YU'PFD&,B9&9P9FW9$QFB-E*J8MQNF^^KU]_:FSO*=B[7(?>N%X<.N^F
MOTPG7X;CA(.DA.-%18:"+ ^=DV- ^Q"9F1&-<]*#ZL]BWXSAU%@_1,0;HBX'
M1=9N ?ME,IO#Z/\;?EY8&VBD\X&.FJ2KW^A%9C%)PVS@)11#SPFF;^9O(3@U
MWO<7[P;6#PJVU7WGQ11A 21*:;3/E@472/V"#0R2%-7"<&179F.UZ('GF^\\
M 6;W%N$&+@\*J=5+Z]$OGR;C56! J6"R!LMD"884BT<64O',9>"Z:,,=]N&6
MK;_W!#@]2)0;>#TH=O8!T\64E$S(^'$X'^% !Q-I6W!,N!H2D(J."1":A8!"
MZ&Q0.]D#K^OO/0%>#Q+E!EX/"IY]G$+-^?GP]3Q.1@-CZ Q .@!DI$U#0]U#
ME#4,+!0($#R2%AU.ZJV7G@"C^PMQ YT'!<I6NO7#'^D3C,]P$;C#XK/CF)A3
M0*= 5);,>I0L*V>TB#Z'T,>UU:9WGP"Y!XMT \<]!+_^B:/1_QZ3K_8!849G
M1'XSFUW0(8$^E!0#)W5#\M(E( NTKS!N"IW]PF4!KC<[>0N($V"]/R%OH+^'
MZ-=_3D87XSE,%W<PT]G 91^%=94C1/+:+*W3Y\2"U3XY@5!D'V;SQI>?#-V'
M"'4#S3V$O%Y=3*>TUN7=:3UBR%F_F VB(6H*&??.<,UT,63ADV5(+GOB224N
M5"_))O=A.!G2>Q#Q!NY["(&]&<]Q"FD^_(*O80Z7.&FUX#7YYDSDC#4E6A(P
M,C0,*!\L6M2I]'C/M0G#R7#?@X@WI*3T$ );;$"O8(YGD^G7@??:&B<DBZ+>
MM2ATS!< %KT%AZ%$)?N[S+[UZI-A>G^!;B#XH&C7$L\/YS@]H]WF']/)[_-/
MKR;GGV'\=<"CYRH'9 KQ\IX].O($93%H"VAGL0__ZQX()T/XX0+>0/Q!H;$E
MK@_G,!J]O)C1,F>S 6E;]C7E31OMZ1^%=AH.FGF;%;@@K<7^HMJW7GTR1.\O
MT T$'Q0C>Y/*],5%'M)/O)C/<39?K//'$9P-?!:VYL^P&"#5D"SI'9D1I'QT
MSH1<='9]1$&W(S@!NGL2[P;6>T@_^_")7,75+N.=+CR:2.M"@H,U4$NN!'F+
M0I'_P!%<?^?US3>? ,L'BG,#NSUDGOUR$4?#].-H O,!%%Z<=,B\\[0P\OM9
MC,B9ML+'0JNSMK\S^L:+3X;;?86Y@=H>XFBD9.<UN6V2?OOP":8X>W<QKV6;
M-: [*-%8(51@.16"5Z_!0:? 2.N,)O??I=1?NL%]2$Z&_-[$O4$;>@BKO:)5
M3V'T9ISQC_^-9"]RQZ4VKAXLF6DPG$5M:SFRUD61*\A%'X5:&U]^.IP?(-0-
M-!\45KMT\7\<SA*,_E^$Z:H,I6 IW+C DC)U)Z+%^A@L<SYD9[-02O415MGV
M_A,@NQ?1;N#[H%#::J77J'ZD/YG1?U/*\YQ91@G53TC,%SJ":E(S.0J&H^OC
M%-_R^A-@NP_!;JCOZ:4P<XEI66:V1.4A)$?;#0-%^X[VG%"%Q!E: <84)9R)
MO=-] \#)$;ZO<#=0?E T[05!R@M8U0^D-^8H2V#<6_(4'&TR0>K$N/5)<.ZY
MEGULXK=>>@+4[B_$#73V4I%Y8WD?(8YP(!T4BTDR5Z V@D'#H*8KNJR4<TF1
MW=A'IO>V]_=(\HV>*4?\:@\2Z*;BZF^6W3#^ED:3&>:_?SN?7N#U'T[&<_QC
M_L,(Z[O__NT,S\[OW!MUUXR+&3L#^#Q8I"K7![T:P6SVKBS<B!=_#&<#2-KF
M@*2S-55=(R?)1!#,:0^)=B')S88+T15-!69QP=7EBTA%1/@>1_/9ZD]8_9,;
MNO(@HAX5YIZ&-@\JT!Y<3UK(O,?R_!6PFWA>+S;.3H@&:QUV^M2&NY#Z/!RV
M]0BZ5H*>.9LT$?AQ5,$IJV6]X3,@:TYE#"Q&0U] ,")SY8I2&])3GX\*W&J[
M](@:L(N<6S!_'4[Z:6$U#;+T!70(S-#_,4U_A<5<+.,JQXS)"\+9A/AU),>S
M"_NB9YWM@V3;8\^=?XW_-7C!OY.&_SR9X^SU!9+E)B\Q(8&*CBPAGFOC 5T$
MBX)\$5=*2L$:CV7-,+S32>N^YS];%GL36H]?[24F>PN3OL2D0W'*9\\RYYEI
M6PP+'B(3'&WBF4Q<P;L1N?'YSYW(PX768_.<!2;SW49(%F@U3I!U"34W-H3"
M(J]].X-)UA)7-J<N/&Y^_/.FL0>1]=@39P%)?"=N8?*KO1X2F%@DXUZ3G> B
ML,"-73C-CCL9>"Q=:-SR_.?-8Q]"Z[$+SB6F6UN$,I>8:"G>&W+^H'C+=!2<
MT>\S*X *T*KDX:%6D_<]_[D3>;C0MO:Z^;?OUV3REGZ[5Y?0\6PR&N;:=_DE
MC&I+X0^?$.>SVP@Z=@W=]JQ#NXAVPKC65=19F8//41F;M) :9 G*\13 @R)!
M#SK!/5R0OT"]N?J$\V&"#AV-NTOU]H,;B?@>]&OR1I#*Q)0D)-3)<X\&(WT@
MLD81L[Y'WEL7LI?PK]S3V:3\ -/Q<'QVJ#)O?&1_ G\8\9JH!5B?B_0RH-(J
M"B"]SJ@+'?0I>E2#7< ?+.2:2C7%3S5Z\ 5K6Z?S_5H.=W]Z&]$_N(YUA:]I
M1%&1@96\+G10VV ,ZIC)^RD@8"L+#RRI!2%];D([O>IH5'7?J)*/4) 'KR'4
M3G/>:,UMBE(()8,4N_#6<.OZKXOA_&N?&]?R@8VVK0UHU\3.M0@6DS8F*VVD
M\38FK4/BTM'_[/;/Y?+9/5WOO+VZ]@*M1>$Y,55$KJ7QGI'E%9@4,J&4R<*Z
M\=KSO<X5E,/OKLA<_309D8$X6TJ+M'-T4?/>?JF%9V0QS^?38;R8URN;CY.?
M)^-ZBT:,TA//%H5*.)L//!8R1(MF%@&9%EXQ .U9BH8.=!VLP0WEO7T(I _X
MQW<6#M2IN[=A1V>QQT#J:A4_XWRY-;Z=S&:#K!U"%(45%VJ5:^W(FS,P$5P.
MPO.L0I.KDELHGKUF["_3!M<BKX=?AIDV]MF-&/XKF'T:>&^M*:B8$5K7RD;'
M0DQ ,#-&X[3A EIPO0W0LZ>]%TGW&)E=X7J1_W4QFR].YX^3%SDOI JC7V"8
MWXQ?P>?A'$:+!.PZ%RA7JXE,)ECVZ:9];3:<XP><?ADF7&9ZO<<T.5MR\Y\P
MNL"!LT&&4.HXH2 96=3 ?,R!-K-LP)(O";&))K5>V+/7R"?%?(_1ZM7Z/DX1
M9A?3KXM/;8'H12+<T[J6V?PGG'^:Y($IL>:Z1)80!=.^MM^)M55Q5-&$B"J$
M#84;AVMG%W#/7L-Z9Z#'4/AV0^T=N8#3 >18!.926]1;VI8=LJA,9L8D"5@X
MCWQ#(68+^WF!Y]GK0A]R[K%9_ K6 L2&6$ USLA2>U<^PA\#X[@HL3C&M5-,
MUY9KWAG#C'2"&QX4/;>%+G0!]^P5HW<&>FPAW[,WESPZE6QBUM9^F[5QR.+N
M2,ML%7<19-Z0=?XT??(#HC;+7%-O I"!(!D/DH11O=IHHV8N))-MT2:;#1T-
M>HS8'"5?N]ENNK<LGUR.]E(CZPXP&5=C=)%]&+.71KG +)>>S@83&9#-R (D
M80MJS76CX_<>5,?.U>Z#[6V*<[#4&T0CUC!=WMEW =4R67LCJD?.USZ<O4DK
MT1]-+WB(Q7C!65*D_%JZS$!%SAQZ'E+V:&23P,(1]:%K\O:1U&$7B3=0@_<X
M)Q285Q??ERDX)840(P%2N8X;0:#M4*)A*+,0SA=/;F0+/=@,Y_CV> ]<37H7
M=(/+B!<I79Q?C.J-XC:?X1)HD-SX&"0+HO9VD@E8"%PRC%GK7"N:8$,-8 \A
MQZX(3T%)VM!QE-(/4,H:@L243>1-1B3+&TMF3DHKK/ R^0T]<$^B]*-_/3A,
MO UN-&Y%'2\AR<BE-8&S$DQ@.H!FT87";(E1FA"\V33EL><P[^EP?JB(>\Y-
M?[7<B&C?^:$43)=S@]^5%WGR>2'::@[1"C%+3=!TJL-.A&10^W$K7Y*,M0/!
M>CO<C>G-7=[UC/W$)N+LN:#D(7R7"MX%X6:_<2_B'\,O;,/6#JIP@*A[+A?K
MB-2B-TF5R+C.M:&O%\RG1)N@!0P&,IC2I7CL,95ABU/X5'1A%PD?60>N;[Q7
M]50Z:O)=(DNY-J2QG%QDYSG+RH<H2B&1J#[.A+7W'L\$:,7;+J?%(4+?ZD:V
M*)FYFZ?:*M-ZT]-;YO+N4/CA52#KKV11"[A!AER S'7TUD6CO7L@L;=="G7-
ME?IQ-/F]S_*/ZV<VRFS?C'E-Y#D55$H%:;32'"4X(^L%88E9VASR]A3V3? [
M"_K#Q?DY3+].RH?AV7@QM'D\)Y^^SNU>W N.AFF(^TB[XX,/$_D^Z-=576>N
M%1UVVJ,6(,"3EGOR>@H:77/8=U](S\)O3L)1R>A$2LK R0PQO!86I"PB9.\2
M87(ZQA"ZDG($<A8^5CMJ+A]_#&(VK62]_A(T_5^F(R"C5@+ 1MJ;?"&_/LNL
M>4=:[BZJ9U)^ANET88N\KB'L43MZ[KSH&$3=O[HURB1JIZ7D61>A0^81A9;<
MYJB"<0"I(V5WWGF >3X9IT6'WRJ:=^75%/-P_GXX^^WM54Z$]J44$Q/SB^G"
MM"&SZ)5G4LKLE(LJNM#%('_P38>X&<LIJ^_*#Z1-DZ^(LQ_&9W"&-6MVV8C^
M11T41 J LW].IJ/\^S#CP-<IV>B D2'E&9WS@7D1D?$H &.(3J^GNVQ<V3[O
M/K*[T2_+-UV-YH)O44)SB7DY-JSN?Q^6^3.S@2LVD*\CF!.2Q,!]8:$$R4I,
MJ9A<^V\UN8;8#NDD-*5GR??=UBBEZ07F]QC)D)^]Q_G%=#Q[,<Z_D&@F51"S
M@8GH9):>I21SS8LM#("\9)--M"'3MKX^ V9S(XX'WW02=#<0:L_QZI](K.<7
MYZ\FHWI;.H71(A4>9O +3JM$WN,7G,[(#/I\,4V?8(8OSJ:X</(&9 R+Q(5C
MVM0F?,5*%NM4*I-RM8Q+4:E+T[+]$9R,BAR)A 9U+*3$GW$Z__K+J!IHXUPC
M+9\KL%]G6"Y&;X<%![;X*.N0!,OK54\B@4 TP"(9ZQ)YG3/;Y'ZS [:3T*!6
M7/3<V^D#C%;;WWN<X?0+#K2-3H&3+%LAF0Y<LU@GC5LHG@X["UBZ=%F[^^23
MX+4'H?58E%+1D(:5X;P6/UQN3!\G"X #'5 HZS6CU=$NQ&UDWJ?(9$;.HZQ6
M2^Q Y+;GGPR=O0BP00U)+7E[5_XQF>1JF5Q63LX^3$9Y(#/XVKJ/00ZACK2R
M#*SDS!4LR),GTZ5)7<AV2">A#3U+_JY.[#U':K'M?!I^_CPD!W:<_X/^1S]R
M5H'.KDV225DJ;E)*FF05$XO99Z R\XL1XT:5XH$#8NZRA7=]X4F0WT[$=_5@
M[T%3UQIZ0P9U[9?PX S%((%/M%ID2;O$M)98AY1BK7W3)=EZ9=^F0_D]H$Y"
M17J7_EW-V'LDU761/KDE\^&,5/>'/VH!/ADG.JL$&ID0H@Y #(X63;H*47NT
MD*3BO(4^W(5R4EIPH*0WA(D.CAV^(U\#:C#^+3FJ^'YX]HG.,?(T7LQF.!\@
M]UQRPJ2"$DR36\&B,9SEK(+(R9F$3:R&>U&=E$KT)_\-VG%P7OMM=&^'$(>C
MX?SKP"A 4;.ZR *H/:,$*:S2BMDH(YDU#I-O4ZV^&<\):\1^,M^@"P?GO-_&
M58V<0=3)\ R!3!JL?86\8Q%C)/4L&BR9MLHW*8*Y"^6$-6!G26\@_^  X6U(
MO\#7Y24'Z(Q>V< \-Z7ZN\BB(U<GT<JY51+"ID&E?2O "LX)*\%>$M^@" ?W
MLEDF8%Z57WV$/][#'&M?IG&B?0J6G1Y^Q%SCWS63[(*>]_76#P^$D<6@5$QB
MW<FX#BS4 2 !T3J7@O78Y/3H ?M)J=BQN=R@CP?%,0G#JXMY#;C\/Y,X>Y'(
M<B+FW:_C/)PM>XU@_G$RQ>'9>%5F6O,9Z>?KOVI<_0MYYK4WV7(QES[9 )VS
M(=9B)<^!Z90]"R5*EE"%B$(*,LL[!$,:P3L)%7PJ]&U0R;VCL'NN:5'9^O$3
MC#LMKCB?E-26>:@=7>C7U1"@WRIKG 2>$;H$ZEKC_#,K:3M"-VCK0?'A+8M;
M[/"?1SC'&[EZT\F7X6S1O?':)0G*6%<\KYW4(EFEY)F&Z#,SWG##M43A[/[*
MV!7&J>M:$SHVJ-+>(>8>L-=V8!?36M@Q"#'5^GW)BN!D442R<$/VR#!(6I;,
MRD*7_,S> /VE7@=1M$'1#HY87YN@MVS5]_@9:$^^%-W:KCS0 )P<9TVNDB&Q
M:4Z6JB:/.BI0)::"033I5K\/V)/0N:.QM2&7KN>X^(:/X*I*BK /QT#K@M$O
MD]F"IA]JFOQL&$?T%V?S@2(?2-.ASIQ%3D=\(._=(["D2[0N^YARD]NU'M=P
M4@KY6-QNT-.>(_1K]P<[K,.YK*6UG%DO:R/M4E@TUM"O $%&%2 <(:*_-_X3
MUL_C<+I!-WN^,;CZSE[M_)$9GVI:'+!<)'GT(!-Y]-6W-QRK]R2\;M+'M:\%
MG+!V'HG5#>IY6#N?;3):MK5QUF.J@S8EM[6MC23YR'H-R[DNRJ%UODN4Y?ZW
MM.X+W-B=Z%&$3ZY?\,N+&<EG-EM5\RR:FM3Z[>1*8$:9ZO5HTM>$BD0F>.)6
M>YZ:),#?B^K8?:#Z9GY;[^"#&6C0Y>\2RV4SDRY@6O8,OH7FD7L%'\[6NAX<
M+.KF_">R[>OM%TLEDDT5'*FY\8(5*7U)F*S"-NW#V_/>M2=P8]IWD7#/)92_
M?(+I.22\6'29N>PJY 6F+(IDB#6^&J5B$3EG/$M#$)57L<N]X*9G/\*(C?U%
M/>E13CV60\^F\UJ9D2_2_-WT,@5_H9$V F3%(ZOS1)DF@X:!D(&Y%)PN6)0$
MU>%+I>??^$KI=^M?Z#8 )W)&]R+?'NM>;^"Y672QZC76 =0.Q_,NY-]%<]SC
MN1^B[K+>DY1[W*KO!^="E,7;PGRNE;40"6;M%!R\J7WA B_8)>[Z%*G?<D(?
MD?E=A-O"%KNLNWEQ77=S>?K$XGW@$5@)M<F@T9$@FL*"$&"*+UF[)K4+6Q$=
M[VSOD;%UPZP7<3?H?7+_? HIK/6"%\9+SDS[HEC0*3&,3D0NG$N\2?N3)S7B
MYU@N^\$,-&ALL+DO>1=0?XW[V96]3O-=]A']T<;]E%+X8E D[9.2]K*Z.>;@
MF70Q)(_@<H[/7!\.&O?3OSKL(O'CC?L1"8.M6<PY9U\OSI".,S!,:;*7Z(^T
M4K:%'CSM<3\[<=5MW,\N@FXQ[N=Z//6/D^G/^/NM#*@Q_3+A=6"+S&3C=93,
MRSI%W5O.8B#L/)%MG6PPLLV\^IU0GIAQT8ZA!G.>/]+/73<E7TVTZH"II:VQ
M"=3CF!H-N5R?'=,7$0V.G(W8>,XEZIB717V:/ACFN0L,@@I9^UQ -;E+.)YR
M/&!W/+)N["+_!CIQO5BRO\89IGGVZ^?:BYUHTSQ<@E0JI:0Y9Z+XFMZMR/H"
M;1FZVE^F /K2)$6K$[KC&RF'$WEWVES/++294+@5I.5B%91QW!ETDB5AR% O
M-7NVAF>,-+H43Y(030S83NA.7%7V8Z'!KD(;Y^SSLL!SM?1WY<&ME6<?HE%,
M0BHU4"P8 >7,9B"#/%IOV\R/WP?LB=FZS?GJL8W@W0_A'Q?## 1M96UUP-72
M[-T&['%,W_;4;MV@>N"EJ<6SAB]82-PXPY2JC7!S\;0_:\,*9F>ES$7Z)K42
MQ]67!ZSAIZ,NN]#19*[N6MNTEU]?XCA].H?I;\MDH^0X':Z*-EACF-9&,#!D
MDME$NZV.43C7I*CK(6 G=C3URD.3QJ?K^%;H5AF$'?"U/(X> O@XQU*_M#ZH
M,SUP<I0]9@UG3(!!$423BF4Z!L&"%ZI.,7962 Z^S0R-Q]&9!XZFQU697:AH
M<ETT0WI@;>KP&K_@:++HRW[9RG%U8GIK:4,U+$% <BLC,.!T($MP1>6 Q<DF
MH;P.V([O>/=+Z)T[I7[9Z#D5]3V,SY;)5SP'$PLW+* 53 ON63!D27$N+9E5
MTMC4)2.I4Q[:U5M/Q +97Y(]]M*^ G$5.GH81M^YI3?>?_QLTCT96.?P /'U
MG#1Z$PXY-38*CPQRT<MAP=% 8N3W^$A^CO&F2\CK:;!X3V)HOR3N(K6>R;N<
ML[.:]<PAR<0=0\'I"+$FL>@U'2$$R451-/K>=M=;;SYN7N?>LI_T(;B>S\:?
MX(\;0$QQ47)>&'*;:D]+S;S$P)0&$$F+ JFW^HQ;;WZ&#.XMN)X+I%Y=S.:3
M<YS.ZK2K&JJ:C'^!^1SK4+1%PKF+.<J4&2<SJ]8 D7)%98D-G:4Q(9:R%IC9
M,O;^WM><B)'3MT!['!_Q +15&4@'<)L-HEU9?XQP2>_T=*/] -D>[V._!!DT
M!ID59][QO,S(@%K^*4LH,>FL,749/?M(Q&\QFAZ7]UU$VK.!=94%_ ^<G$WA
M\Z=:W+E8;N!%9%L4B\J3Y4CF XM)"2; 1Q.%<"!Z,[:VHCB17;\_2?<X%&8!
M:ED:?!/22B<[@.K;\=V*YOAN<$]L35J)NN]M8"LX8;5T2)M1Y$DQ;4)A4*QB
M65N=A2M:Q"XA\:?(_ST.]#'IWT7";7*'-@\A??FU)E,M%UTX^2Q:,!=JF7_1
MFH5L!>%T(EFOC0Q-KNH[8#N1$Z(5&RT&26W%6!&N]K0.&%O>PG; ^&CY0?T2
MW%6!#B3GF#O/#:C:"!]DK62&6,>L2L&"(LM;*6TA*1N[A?R>C_X\G"_TZ.JS
M"R<M^@%,ROQWF.*-F\#+()F,#KFCC=>FH)E.4K%@!9W-6#3/RNNDFZ0(;45T
M_&O8WOE;+P'O1?A;8\S_]OV:I-[2;Q?_8?'G51+OL7Q3__WK^S=74OO]]]^_
MHX/YNS0Y_WXAK0\7Y^<P_3HI'X9GXV$A:XND<9U2-QD-TQ!G'](GS!<CG)17
M%^<7(ZA9>,M).3>*5%[7>L;1[#;TV;#V47\@S-$ Q/?7LK@MHTLDMW3IZ%+!
MVO4SU]FVP_SW;X?<&&4$.,]CTEJXF(M29"L;XV+)Q@X:X#EL:[DG\?+=]-6G
M&M5_,[[Y$\-Q&GZN34Y7+39+*& XU,Z[#E9?09+D+6!V(5I,T&0+.ACYX=TY
M)NFW3Y,1?<VS95'QFW$:7>0%D=/E?*GE%)5J(W^<U!;<$[*A)R-ZXMF;\1RG
M.)N3U9&4M"&RI &95G2*T;L"*UGE8(NT)G>Y(-JCC4<?\(^_WQ]78^\V!#DZ
MZ0T*K?:5X=+;$]X'!]HP@[+>S*%@WI&."<M#\-)'E$TZ21R$NG5#XJ>AGL<C
M]JFT-=ZMN%86:QTZ3R9;5C5E3M(*$UEP8$2]=0@J-SFLGG2;@T=0GH,Z(>Q"
MXK&*W+M@^JL3PH%<=JEVWX>(HRF),*!4+BQ%5YB6$%EPV;'HO8J +ID0GK=R
M]-H)H7_=V$'^C]@)P6E?4F1HY")[RK 0:O(368G1*IN2;%*1\9PZ(>Q$Y)Z=
M$+JS\&B=$))5GG8RP[)+=;RF,XRP169U3-Q+EZ'-Z)CGU FAE:KLQT+/N4MW
M 5[C$W8E :AC6#T99@'K#)3"&7 ?Z%?H:E<[+M;=M8WI2UW>]8PY;R+.'AN"
M7P<@[FMB:&,1K@3.7"UDUK65"VB;:EP:O2&-E+:)A?&D>L(^OC_3'TD--&AS
M \0NH/YJ&[LK>YWZA.XC^N.UC;5(.YX%)K*DT\T*3Y\!>)8RE]EX)5-H<AW]
M7-K&]J\.NTC\>&UCK?.(Q07F3$:F@Z!U8B14$91S0>9@FB1$/?&VL;MPU:UM
M["Z"[M'S6.9MW[YM_ 6GPTF^-J^6"F^+ULIE(JI:/0Y)UZ.,+!MMLRXZ15LZ
MF)-=WO7G,1R:2+_'EO-=\*U.LPX(=RJ7Z?+6QZB9Z9NM'53A %'W7CW3":F!
M$B )9(E+\LA090:)7&;'G<L^&,-E>.+*<&\=S>/KPBX2/K(.7$=]5RZT]][Z
M).L1)Y@V.=>XFF 1A(T^9$?_Z^,(67OOD2<5-^!ME]/B$*$_D6RU'V;SX3D9
MW_G7&9:+T5M:[&Q2%I/"FR>I=7GW,7+3=I;!6DI:+@Z,],YG4!J< B&\UIX,
M5QML=+QC2EH7&(URH]]>948X^BAXU(YE!_2M1%+AP!5Y71AEP2)*QB:=?Q^&
MUBPQ?"7N0G9E#2>C]BS&3*NW"5@H6C*T&C6Z'+3.1UW]-;8GE/6[G[9T3@K?
MDX\&5T2K)-%W97L&],(?25J0UR$4PUJ7HX/U#.K]!,;,K4G%8*<)H;O'A#L"
M/%9F5F.5:<+'8V=9W6ZM W1ZF. 2*P"*:0]8N[!J,EA0.1=35+)+]M33[O75
MEL^-G;]VD6O#7E%=8)QHYZ^=&-C2-&H?\35DDR?.E2=WPMM(>QEXP4)-8TC>
M) _> />]-1YZ&IV_^B!Q%ZDU[?P%6<L"B8"H K5&VK%@P#-?)"90,BOH;;[O
M$^G\M9/LMW;^VD5P33M_:2Z,QVB8C]'3N9 -"P2.R: QYP0AR]0;@T^C\]?>
M#.XMN$=J#Y"M%SE825PH79N3%1:2 &9E%%J9K'@ZKB?Z>.T!CF(OM>*F07I%
MEWK4+A#_ZA70![][%'OO0\XC]0K@$HNQ*)@),=!^:QSSDGLF)?T'$85TT&1J
MYW/N%=!:?7;AI(':O+P8CO)RF/WJEV_./T\G7Y;WUZM).<:ZD$)B&.H1JY6K
MC>R1X!83O*QW54TF875"]X2BB?OR.FE-2L^9'V]AG G<6X09UNK6#>B\0IYE
M*4SYVD,!/#"/.C*K( B50W:Q2Q?$A]]T.O0WD&R#'>,G2)^&8YQ^O;GRU90_
M,K9Y2H45%&2K>6Y9##[2CBE%,#(9KIJ4^MZ#Z734HV\"MAJS?=W:OH+9I_J_
M"O(+C*H*DW:_NIA.*V"8_H:+JO</F"ZF]![<YW9V]W<<=@M[X)K6;EL5+TY*
M2,:Y6ME?(D\E>L@A*N*OQ,%!RVM'U,(S.PI=EV\Z,FF;UK=^41Z*]A80M0S:
M^@3T"RM<4HK6Z[+8G;J[2VU'8/WA^A.W_LXB6W6V$.W^Z1+-H!Q9!?:2T/KG
MK;3V#I,2I"/<R2!+\%GEY&+BZ&%W'>F*ZL Q8/3X%^MOF5W?>\;BE!-D?!1E
M"ITR"'3*F'HPRR*$)G])-YF^_0"N@Z>?W66#WO;ATV0Z_XC3\S?C+WA9C?PB
MSN932/.!,46"2Y8AT&&N;:DMJIUG2/MX .TL\F:2V WJ(PR\ZE&+[DQ':TM5
M@_R+_\!1_CCY">;U2_YZ_44/G+4&5 @LF5"[V^K,@O'(G(D^&E=*RDWR=+8!
M>AQ%:4GFI $3+>K]O]#67;?['R?3#R2&UQCGU^A>G-=^4?^-^=5D-G\)LR%]
M0,: 2;F.2ZD-!4.1+#AT]#WQD)/, =H,8]P5Z,EK5%/F&MPY;-Z97\Q?P73Z
M=3@^^T\87># )UY*E4.N/:6T09*((H?2 UA,9.@JV:24KQ.ZD]>I_CGJL;[G
MH:WT1QA.EP#!F1!"\<Q:#$QS[Q@X7I@35II8 AG'32)"#R([>07JEYN[RJ,/
M#R1N\&^6KL] HX/LC6:9 VV04M &J8&S*'T,&'.TT"498H] XE9,)Z\P??%Q
M5U5,JWWF14K+NA;,OXZGF"9GXWK0_L=D<6?RC\7P""^R+%+2V0J)D01*G0N'
MS$8CLD]* F^2>K$_Y)-7M".Q>5</;7])])N/YV7&2BC9!B=J@7>(M>6+8\%:
MP=#2I\(1.7TY;3/H[T%WK/3YEMY__S0\=N+\:F5OQF4R/5^,37GY]15]"6>3
MZ==WY89#\761E4"V'8]Q,203:8'2!>:M0(;%% /<.8A-=K6.^!X_J:PWQ9BT
M)ZA!+.'=_!-./WZ"\4<\_SR9PO3KF_//9/A5'5U.XWD[F<UP]OYJEWTS7C66
MN%P5;<CORHVM__+FLLO"6N:B-5O9XV2P-=&GR5-6AF>E[=&#C!C)M9:1[-Z8
M%(N"=@X?C(XN25DZS4,_=2U_(,_N>2OY+CK00+FKM3PG).O6\FIZ=@*O4C*L
MQ)I#+Q4RSVL,FX<LZ:03P3=IZGD_K./[,$^$_PVN3D_DM6@;NXI;T^<Y@YM^
M_ZI (T@0'HA\69M >"2/7SO)DBD12G(1>9,N7@\!^TN]&A#88.^Z7NU5/G5=
M$=I"*H\.Z[@*\N!-] Q1%%V$Y](V&:EP%\HI.RD'B;W!C=-M1*L/XK_A1A?>
M+@A;.A8/0WPL#^$P,N_5C=Z8:+YY;$1J9?;:U(ATJ5]**I8!CX(9BR:C\@Y-
M$^/GL73E03O[V*JR"P$-5*3NG)=(,!7/LU;,N*1K8RS#8BF>SE*.@)H.6=?L
MMOJQC)*^"=IP!;V'=!L8JK]^^#A%F%TL<M[_,?F"T_&-I'<G4'(>R$_$.G$<
MG&,0@V+6\:(M+X*;)F5M]Z(Z.6WHCX,&&\&'B@>'9^/;J3>K97NPR>=J1KE4
MK>"X;+OKI.(0DD"-3=R8>U&=G(+TQT$# _0]?KZ8ID\PPQ=G4[Q53V5T44G&
MS*SRIA:8"Q:D1?JM0'*=((K29/O8#NGD5*,GZ??<H7CAT[]'TMH9WH,P1B^E
MB,#0U XAF T#!?0KJ;4WY(D%WZ7]:+>WG0SUC03<( _IU61:(SISW+QO 6:G
MC6(YZU+U,[&@O60E%!V"U*7D)C< ]Z(Z&2WIGX,&V4<_3<;X=9D=]>/%.%_5
MX68G=""-E;5=NR9LS!=5&/VQBM;+P$63Q/W-<$Y.)7J0>H,,H)<P_NTC.>2O
M<5%R=5V+7URLE=B!E)%66T^QQ#/C(6KKC+"<-TESW0SGY'2A!ZG?U05WL.UP
M9?'>V;%,LA8"(2M:DI8JQ5G$(@F9P)R%]W<ZK6RW&;:^Y61H[EF@=ZGVCUS8
M_JK.=(<TOX#19=KC<-$/^\;US8=;US?'K+_=%]NQ"W)[D>%:A:Y(0A@-Q9$'
MJH.+ :6G8\2!"RYYH?>HT.U!G)T5L7Z/X_GB:G$/5;GYMP\C<RN.-7$[;XJG
MDRRE %K8$*T),2+W,H)3* 9;(.TCD+U[%-Q]1F_"Z=!7@$NILR&+-G R;A&\
M"U[$DFS"H+C,@WOA[2.H_?>:#0_I351=OMZH--#FKTB3R!] XXLP+B+DZ&J%
M'0[N!]A96+<ZNL"-KBM[R&S[LPX374>,:Q*4V:$JJ(PM02L1?8ZD:\9YG@+]
MF1AT@GNX(/?^6!]Z8B.A=OB0';H@C16R9*5-D#ZX$B06S64!C7F[: _XK+<^
M<^M_@'DM2ZU=IZZK+\C,GF(:PF&=0-IA:41JOS):W]<-RD*G70;E-=9"<^.,
MB0*CMX&KN%T=^A37X8KT,TRGBSE"#13CSK,;$7W_&M:(LS:C5YB$E5RCYE#0
M9TA*&! Y);V=N/N6L\-!3<\\&]*.L)R> _7R;9)_'UX7W^QT8F]_VJ%'=T><
M:^(%!U&*X$($T#XI3P8B)_FF)'URD0\Z0NY#H >8C \]LYEP.YQ$7ENG5(V5
M.*^##]$E5[3-(1MNK4CWB?@@$W/K4U<I<)-RSP\=8I?V\^9FI.V__C5J@R^)
M)S!D *.&"&1F9"$C8HQ6E_N_GIU [!\I^['*#>L$L-K8\LWX4I++/UE_\]OK
M^D"D;3<'R=)B5"XWC@7O!"N.D]/N:IO#+A&T_=Y^^&WS#&&::G+G:_R"H\GB
M/'@SIJ,BX6PV($.@IG<6EE2-E/DZ!YB,0Z:D2AZ3<Q*;7!T\@.NX$P^/H!AW
M[Z'[XZ5!FM/ZHG_&^0]_I-'%HOSY\H.\JL#.#C(9D)8E$PW38 WS( KCKA3G
MU6*Z29O<Q^X@3UZAFC'6($?JQ^W"(-A7*%U0(I9ZV:I"O6S5D?G(H5ZUD4>K
MM+*YR?RW;O >X\ZC%<63YOP<5XO^,9W0'JH+_5] RU0=U:%ISV2 (= WI20J
M)Z7U35JW/ 3L^)K3@M#N.K,[&\?5EAM!B\L.:8N@Q0!D3@;IPS%"6:9% $:.
MH6+16)N$RD[$8^O/%JA_-HWJ@[$&J9WW"V50LO?"I,02.4:$#B4+ C(K)6>3
M4Q%V?9;\,<ZS/YON[,I$@V9U#QB$VP_UJ&,)/G FHTU5)(KYY!,3B#R5H(7D
M35( ]P5\PC;243AL4O^X&^Y!"<JJXCE+L*BG %Z'4W(6;>2<QR2,:;)K[0KT
M,73M&"IPH-[MQ%^3VLF'/\B!T$H%#)&AE[6H2]:2#)[H'[3-*Y421OU8$80_
MC5[US%./>U<-J5S7JN\47'GY]2?XUV3Z:@2SRW)VGRP$CHJ!38LQ:I9<$!(2
M0/U2I-+>K>G:QG!N7WA:=\$[<CCJT:AZ*GWS7E[,2( S<E'^ZV*X'(6Q*'\6
M(DJT@:0G!*T%4J!E+&9E88Y@BNXV%GGWO.S->([=<N+Q].+.1+O#^6EP3&Z"
M57\YQ=6@KBX 6W:E>!#AXS2EZ(7/#CIR.!F/HC5%.V,C[>$Q.<>T2H(%<G"9
M5S$".*]E;-+DYI&TY8&V%(^C++MPT*.2U"WWI\DB/6O5@\DE2:Y -0UKS^+:
M<#UZ'IF 4%PB$?#2I7[TUD./;Q[W+/!)']+J\0JV GF)TW/\;7@.<359WJL0
M3;9,1U\+4W4=V$&&M\Q1I (I"Q$Z,+?^W%,B[R"9]?S9_2=.XX>+Z=DPP>C-
M.*V*Q#)**[)GA3NRI\F18H!UUDJ4)>D8C(I=$DDV/OR4F#Q<>L>-[=\T4)>3
MNF4,G$X1ED'*.J,@L1A*9 Z4!&/(?W+^R('^=8Q_6ON_%8_'5;EKH#_#^>I[
MZP*WI8>P(]['\1>:\=]=SWHC[[C7Y!MA&R42'4^:%4WVD49#7V$)M IM9*$C
MET.;J4I/0M<>\#:>JJKMPEG/AM$O,+^<Z?)Q"AG/8?K;JJY:UW(DRPTM7@K:
MU.E\C[S:W'3*"QVS#,)UL(ZVO^%)770?3LRD=ZDVR"-=U-+?6?L2FN!01#2!
M25H=K59PYJN35><1ZQ)<$= DO>\>3*>I(GV3T?>><-F-*5]E/V].CEXU@"3'
M6UG,+/-@:P\W,OZX(;?<1ADY)Q==^B[[Q$YO/4W%:"S]XV<OW#E6R4W(Q=K
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M1@,"7)OYZT?@_8&[H6/1OHN$>\[ >349SR[.<7H9[$NRY"P2L$)6$-.(@04
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M2286%&J60K I6FD\-BE :+*:YZ^7CT]R@VJ7GV#Z&YF8!/U#14F4X.QG D^
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MYJ7.[X[@?=9%:^*J]07F8_#.4W%&(Z2!U_T0977D-(\VF"@A\43KUES5@\]
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MJ=KE(()G,8.PP3'IO%&ZSR$X!I:O3JU&(^:A8@TJT.MC&=X_RF].\,1YG1;
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M]@BFLU*>L63?H1>#0MG7Z0O5W-O>-5=_\R/9@*_^\;]_FB\"J3$I\8V^WXO
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M4^4X>;=H+WP/T\W<HAZHFC:<[H1UHH;3@VE[0@\&R'PZC9"%"6^5!/0>08G
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M<XAJ#M6LIX.4HQ,W2;;D [0S.N!I[3*#M$'7GNX2HO46'(G#FB2LCQ/ERSS
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MHP1ZI U1@%6^SDP,'H(+!9BVM9,-)N_;C 5[.1VC#J+PT(Y1A\C_F72,RIR
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MU?%86C87<?, WJN4+C]>7H0-7HVPK-'+%7ZHWU&=LD9_#W]>KH\)X/5]\K
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M_!>GFSM@O>*-JQ:C./XSC4)OG.;F^\SO'5\ 8W;:WY/;<@=:9%.RP1UA6MG
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M OMNA/!C9CXG-M92R0[:X'1B%=PJK;2P"M"&5CP91D!((%(Q2;PKQY^:HDF
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M%14B>6\NUAU$5:%/79"N1#]_>/<$K!K%$@TXO:165C(;M03MG0TE%D)%5#E
MI(UHN#^@JF2< S[=?Y__ZLUO;IZ(5^.MW=.WUKB76\(9HS2U5GMK9-8,E&*9
M18.K7- YND:\/@6@I4LQ>^Q9^CH<37J#SR>#J0TP%^/\A XL-9 X)SH6FQ:
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MHT([[YK<)EGU['WEK;6<.NA%=7[EQ[>7>XDFG9:2$E \H7,@!'&LI%A9IU.
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M2-P&G2.64B R!$X<QS^2L]E9*[26G1@13R)[(=I3EZ$.;,]-JLAI'K1ED9'
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M(-HH %4R+*&C(L[/N\/[6H0U[O"^CK2WV.$=C9N4F3-$)5E:[@5%G)6.""%
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M<&O(S:W.@ D9Q,B#$L6Z(+H4UMYZ]W0[VG>Q</?(S$>>1,X1$@9=N[VJIEG
M>F]LU)+'%.*0HOH;B,Q&&'EK/+:+A281[]-%VB#)\RS'>F(_@(N*UB&-,G"T
MPI@AM]:_C7BL#6FC[=3]V/#SADO&#-.RSB>>0*E,0:*7$D%&:V3Q65K6_]Z)
MXVQV;U9'&TE+!R6;S?U<0X#]M]E]/QX']S/O0\*DS>Y2,!TSHX13L$2?AJ H
M)?IZF:K DC":J+KL^AQ7LWL?Y]C%]A,VN[/H)<V+$:S#"(H[ \%+FC=#23$Y
MJ[Q+/5SB")K==V)L8+/[+N:>H-G=!1=#S IL-O5TERK@K%9@'#+'LM;/MK^/
ML=E]'R);6&S*9O<D+).Z&$*#55M5TVB-X>"9RK&@#SYW.7E]#,WN8S[D)@;?
MM1]E^;_KCX#7^<__\_]02P,$%     @ AH164HO2:\9UG   (JX  !,   !J
M;FHM,C R,3 Q,#-?9S$N:G!G[+H).%3Q^S=\;-F39)>ID+)-]I),FSU)A:Q3
M)%N64@S&3"G93244,2))TB1DB1F[)!2RC!ACB:PSENDPVWOZ_;?W^3W/];S_
M][VN__M<SW4]7^ZYN.:<\_W>W_N^/_?G<\[A#G,G@!TV%M86  \O#W 9^@&X
MR\#V$U=#O'P 'P :/-Q1X!3 R_-W_/WD_3OX^?Y^"O#S\_%O$]BV[1\F*"P$
MF>"V;4*B0L(B?P?TEYBHB-C??_Y>Y%].Y17@XQ,0$=PF*/+_>G ; 4DA7@7>
M-WP\^P!>21X^21YN*P"#UBCPC^7Q /\Z>'CY^ 6V"4++$(4.J-H!+9^/#UJT
M +1BZ-L8Z'N 7U)@YU[=$]ND'*X([KNQ2^_NHQ="*B?+FZ3/?Z>IZGO=C!46
MD9&5DU=0VZ]^X*"&@:&1\>$C)J=.FUM86EG;7+CHZ.1\R<75^ZK/-5\__X"P
M6[?#(U"14??NQSV(3TA,>IS^)",SZ^FS[(+"ET6OBE^7O/E045GUL;JFMJZY
MI;6MO>-SYY>^_H$?@T/#(V3JY-3TS*_9N=_S]-6U]0W&'W!SZZ]?/  ?S[^-
M_Z%?DI!?O']C(/C7+Q[>B+\'2/(+[-7=MO.$@^"5&U+[].X*[3KYZ$5YD["*
M_GF:M-?-[R(RJ@94-?I?U_[AV7_.L=C_3Y[]NV/_X1<9$./C@8+')PD@ #:K
M(.D \+^K$7*PUV&@AO/B"E,*?:&?LP/M3.M(@6\$V9[ .7TTV]V77Y/\.;+X
M/N_5/"-*W5@GCU7[]JB[ZQF8",X098>I.*V:(]I$<^O [D0C7\V9:..:NW ?
MY\D-\VZC3<1C& .*RL/2VK&+5U<O;7]UQZ07Q/Y9#.("IWLG\1PI(Q(K"WD<
MTP'[R 6:L:/1+:Z]240I,+HU^S8Q/F9W$1F5?C9M;&S,.#;VR%5^[Q+5L M<
MH 7+:<&N1Y#$2;2*"BXPE3$**DY)M,"3E;?7TH>:$; YHGK?TOBEM!<OYAW&
M3LSN>^#7U6[UDT_'XJ:Q"/#[-:&7"XQP 8X(CAF$(2OS6K*?8*_F\JZX]U]-
MY^PL\VY5:&DI''Z\-.W6EF6M_JR09U3\_L]:I6DW$,D%!'S8+XE[YJ,HBUT2
MBU'!9F9SY JR/74TZ(QY85N(G%G0^M#VCB]I^N7A*U?4<^2MM[, B08_0BJ'
MGT.A5"G?8WKXP\HI2]]IL..T=L)DMYD;03B0*$6,O+Y\QF_9X5ZG.E+#O&?&
MYW+^*Z5#$4N6T(SZ8"X-SN@(&9&B4A9!4]_2^7'9ZAI:;D,N/2FPS,;_T,YK
M(8\U;R6J/<*_/VL3ZW+<K)UPD%V(N Z/(U5(I*!Y)G )4=>J;D328:VVA7[P
M(E=SU1ON\GM3Y),_QTGI%VO(32@?EM]<:</2SL%&;1GF=*>[KSD44@4I3JM>
M<%+;XJC4)!>(WWJRII-Z-/9XK;5+UP3O6:-IS5TZSOZ?N4 LJ5N\=XF/J>[N
M]N6#I7I;C<MNQ;UW/_4G[$DKN&-&+R#>9M>00E DG]S %J0@41ZM7T>?;>4"
MBE;.+68[*_!?')0G27ZY-!O+&J-MV]#5:H\<GD8BTKA ,!< #_0NYE[QI]LS
M.MF/6 >-6_[4)FG[7@"Q;TVKHPX]BBVU>6R[CZ2ZW>B%E^S7\UT/)6I>$YXB
MKF/! V<H%2%W.3+H:)KS@W7*3K0AO;TJ*.@=ZD[O/NLK@:&)6LZ2K^6N-ZM[
MO=VF8'BAZ\8*4A9S$/2=H#0C=["\Z(;-N?"6.K7VXIN?I_X\:I./>1.=V>BX
MH76 KZB Z$AS9NU*YDAB0?4?^*5NYEF4QN@)SN!C^T7X=K]^_:Z8.DM;OX$N
MULW-$)TH+:2QEV9:/.,#M%,-'BA-CNQ+V/OJ>Y9QW:31K&8XH9L+"/.Y3&$L
M>ZN_CO3T:G[M5?;$N +,X*15^$@_XP>HS;3 ?.U@%'TW]"[R,S+*TD.E';-^
MP%:VO4JYH30:EIL<SQ\S[7/9[+IS;YX@NQX[\8)4552VTMH[7,$X0ZO$2E#K
M,L55+H'QI?7&)D.9;2XOT@Z>L_RLV3,M)C1N\_Z<1,T! A[KA1A]RAE0P"42
MI5AV8&#8!#*1N"W7B^Y\/WB9/U\EM'J']=U?I\\>"U^V?Y;Q(^=+9<CH*&.,
M_0:-G$S$7@X9F6H:&A>CO?IDA(,GU4>^M88Q<@=LY%MU3^W3$],[U+.2,?"X
M*.FU('G=N1M?+KO4.44@\TVJIY!\[<F"$Q36'LK.^FW[TIW[@PAFW_TC0O;_
MM!-=JT33GP=?=KKHX_U8]K<)L$IY0*D::I%(0E:&I'*!:Q+;_>N^8O;1Q&36
M IUEP\O+7B;K%<(?+^R]=OA&[N>&K:$2YYGQ'/J?24I3+ZA)Z,"+L !04SW-
M-'!RNK_,(%J8(-"0D6T>&*):[7P^?;7]GE^[Q61C,/^=&$HSA78.1[XW@>S
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M7N8%+E!&*AB'0!6F+J=7G&D((DX:;TDO2A$28(Z\UH:)ZBF6IND30$2^<"7
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M07C9S^1C*B[A@['JB\]Z*)I'P_"3"YZ)YL NAW^Q2-^E""8,O9==Q9$GLS3
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M650<_+RBHOP%<:%QV8+01DHBPD!SZD&T;5E-I-M![VME\;592A#0EQR+)_*
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MOT5T[@XDH[4GRS3;MBX-K%>K\&O1CFQ20T[-'Y,XM<$OD?3U0^=$4??NRUQ
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MS%S)^[G^<$2H(D[J;8&EYF:(BH1Z-VG-?=<< /-C!:^O+$B)\$/4^:281)"
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M'PA/&RD LV^>Y9!>-)'<1D_+^R'\(.EP?GJLGI7$3N%"L0JE1OT20>/XU.W
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MG'/K/J>Q&Y=FTA]NBBPODC:\N'Z> W]JC!B4#K-;X(W4$H3:.60/;VH:EIW
MM=062]B]0C\CF$F^*KZ^G+I4(8-"*"]-[M#XWN.KE=&9XS^S?Y5JX!Q^M5&K
ML<D'7.81RAWHJ<$.!/_M1$O2HQ^_ISHZG^:2@HPC2U M=GNWEC]HN#?A2N%:
M&?VDYX'AUD)<8A20'CG@![V5[=E"G='11DG_ZS1PCDO9*LLK0F1>_8N$M2GP
M#<1'I28[GAFR-FZ]K2*=;?5;K8A22D+@!SN0O%\(Z"2&2M-(U5.@JN*]?F.^
MA0SM/\91;'WVCP=@W-2;C'F,,87$.Q@+DP@Z^1COQ.VDT85L@&@BENHR1.QH
M?]R-!6<\USY"GNAFJ%2VIT7X*6_=C-(D,WQ^8@+OPQ B(8TVG?7 IGQ]Q_:I
M $(TFE8Q0,N9P/X];I]>=9O^FB94P1A '('9A7B^G+UC"NDV\'EQKH+CY\M%
M VKBP&<=3T \E0G(PI@0^9(Q4I04""_T;=_7YX=_EUY\MJF@2+@\37FZ0(T]
M(G=:+AI["R0 EZ9X$A")A5US)QL^WW ?7C7A#GRC()5)7?"RXP$,R@G0G;HB
M;+GBB0(=>(7-^]0ONSG1\[.!(MF@W(??Y?I()SW4W0W .4,NOM59UK74K8I6
MG^YZL!W)#@]*,1,*F)\TVI&WCFC23W@EB#JU=%@7:2$AE;FM8Q3[YH\(F;_(
MW[) \S>I("3,PUS8X<C_B,)CB#M\CQ\PAB$-J!@&KY1!\8@CB4?9T=R5T*NP
M[(JB_I%&9:A]K=CE8/ .T L'?K4O@J;0;B.#^5Z"E*BNX1:B5W2.V\?!"^\T
M?@A,@64;MF?\7E0#\46VVL96%BQM*=P^01^8'])=@5Y4CM@2P!/SVES16L0^
MI^@5E[&2W4"'ZQ?D8P"? ,&'-(3!1#R]^-]&T?^*!JNB!L"T@OB@G<"DJ7OB
M]>,A,G-#W>&GL%2C-+I#.C0^>H,$P=/SN[?8_&6/MTY5/3P>Z.W!*/=:DEK)
MU%WEEEG#\]K98(9VU=(5[)M\[P=Z^U;+AWPURA8'OCJ,]5NHG*=>5"<+P>D:
MIIYD2']0]B;\1)\$B SWVTW2>E"-R:9:+V,'R/]8H1I,^;<+9R+"K7&N=XMX
MBAS%XK%!?Z]!X#6Q5B'ZI#CN74CN#FNQ0'.]X$Z'<@HE*\S&3CO$2-5,.$!2
MX2P$B0OO%'0Y1_DXVN32E?'E\:^FJ\"G\7W -1TC<!JN/>_N,^E^7E5/58LW
MLLE6)]OFVB-/-CCZ/"[P>4:K$SFR4/ZU:+RJIYZ6TV1;92HSM%?6A6#)]2Y>
MYS$-A@I%ZN;0)H7/K+!Q=>:@2<D-7NBRYMZ!UYJV)+N0BN[8:"W:IM\+R2ZH
M[^U&!NW$/-E&?VU16R8Q!(B]IVQO*AG9U89#'N4@]K5WSB+2I*_'I63(GRYO
MK1_%4.JQV_:[JR.+Z XI6G3B(C#>^[OV$C1ALJ[XA>S[ %0]=GT7WU9=0ZKK
M)!G1?^>X)%@"B<)WYDOA5M?=K\+$^V]NJ;M.,0$\]M1=&O*.NX'W?=$,06XF
M(,4F>ASR_,!A<9ZB*K:.79AX_@@EZ$Y)6#@N-U0IGD9M:Q4"7H#G+H!$642D
M'"5(L_'3S"&B.D4QTNG;V"G#&ZFM19'O3BE<W.5;#U@R4ENIQ?) [=6SB]ZW
MU+KY&Z-IAY3$_ES=OX?KT=3\1L!+IJ1!KO@/LL C\ NL0*_-:1$H"MURSN^&
MZY%D-BNB#0_Z6ZEYN9]W^H5BC-D^;3C57X<@C@:7'CJBF#VI(0@R?7^CU*EY
MH'%N8Y6EO47N2LRI$_,3VQZ^M,.CA%<J0GW,N.V[+!:-[UHPQ"3.*(P^R;P,
M4J;Y4( $K;C(9WENN$CS[M)[#4I7V8/M\N6 (43N/@M 5A&_64?Y06-.:<"!
M6V]B]<J0NY-;MV=SPXL'V9H/GV2<YV0_(O<>$'N$,^!*_>\KI.ER1DO!!?^9
MVNEM,[[7[5J+3>ND"IC6"]K%EQ%-+9S9@+H/W_+BBCCS.=[:<BRP!Q_G!NR7
M1NZ4=U9&O#YKWLV**#]8"'OMT.!Q"L*9%)2D#E/#MQNX#%C:MZ4,=PX?ZA_4
MRQ!0N#Y3Q\_5C%XY1C:D%^T$35XD^Q%1GU[(7=K^/76')7[<+IUIP60^U_0:
MO"'I&-W\4^7Z%%:3-4F/@37/*!6D@CUR!:DQ%WN!J(>QB*E]>V,9_.@[J9@O
M2XB+''%'8;. GHW^!9&$%IR9Z2VVN^"^ 8R$/PPP9P+N]]"W U[1)1:8@.,F
M)]G?!CI%C45/(!Z;0NCM2GOF9BQD N/+-OZKUFO_58,8_,W /03O#V$"CH5W
MY:%:<_-,_14A+33.PM]0Q[VIJ((#VXK5%G=4M5^^I%F5;\[4[(4AUXMRGQ]Y
MQ/+AW1NM"\:_U!TAG"B?LFZ+1(]%3&SKMKW-",WOYS65)46_:424;#?OSYN'
M :480JN0(["'H,1E<)2J5?[5%@]&HR"4DPF(@*_L2?PV#]FE,J0$+,42T_UM
M2=DM/G^^*_.Z<"7E'OTZG%K'FD['7_^CUU>2ML]DZ"L]PY_;]%,KII00@B@6
M, 7=BR>G*]:GG0]B++>D?89L=<[R_ YPUO-)JI(,F6V5 %?QF$HX%'^!'.R:
MX CA*4(][NH%O\;/C3=VK9/3VB6$B[#GX-[J,]L<;%/-JRKHH=_#\4>OE\ED
MU^Q718YT.^9:;<ZR-$053^R_LU!Z>(!'[+150&B0]-"5>*4$WZXW219':XL2
M;N@<,>$/^(6=XB#[HCHPB'0SH,L7@S1=I;$,ZR^WC3-MK;M!;0^^GKFW&''@
MG.OT=-/^"=CVS8I= 8C(!. 6_+@G'[1CJY"/WZ%A])<(;WY,> 9&U ^KI?7N
M=[#RS.;=QY;$@VZS+8=]VU&BT>YO7#QT-F@L[-3UQG;VEOG'D$-M#ZF7:&X_
MS([!#$<P(Y70Q&O6+@YRZTFR[CX*;T)>^GA.7BOX64'&,HZ4_3V@!51GV:7-
M>L+Y!PTK0VGI@??X/915''J$ZU*_).OH%UQ-'[N@S'D&I-8[ T[ 2V??>NXT
MEM]J:[HT/VS<OSE;L@HU3M"6MB^RY)51[7/.WI"=JYV,IIZ,]OA[G*G987HN
MXS %L0#IFH;=\@V[</;^<_8O4<'S>C@=3\K/!]^B>.*E 6KMKU,8JMUWU @D
M(;2SK7U.8%-KX&S3ZN"ZB9ELAFB<[Q!273[;ZE[VT%_<$KK]?RB-G2./TDHL
M.T=IQTO #"O?97CU3[B7+U4M]?&8GO]M&;(5:Z9$*GL2^K=^(6^MLUBI[O3L
M%&8<V+DV.;IWX^QA[+FU09 O,.; IS>(KV*J+6QJ+!OUP?T,/M%>:/'%FSV&
MT.?5\U0S(0+XZ?@!Y@3CEQT3P!9-!SK\V4(D$S;%G=J!E7C<UFLL46EZ[!%"
M<YQ2GM). /&N%0N,5YL8$TP-K*W[P=-Z@AGGURW?*61:<DJGE$#J.D/>BZBT
MEM6!A(J4;>_K. ;\+>TJ5_Q+N1P<PXZD6"D#V,;;? A]*6+=Q>K9:E9=4[>0
M==/"MQV(\(C#9XP+SYA>B1^\LH-*PJBP<-V^,UPLL[]Q=2&Z>) W5N9Q?\9Y
M*;"BP%!*)"X1-T(D"V[>2H[4&F.@(K9IYFFU&9)FZ!T(>H;%=:*MMO^?]J
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M:E>[,J*GH3-O/O2($JBAX7&KJBIPD5OZ<LG1\I(8P")[F8/#M?*7@-, &=6
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MMCCS?_QHJO]/K5(KQ:@IXQ$P88K<0.SK?%\-S<99?LP_/_2F^?(-,M&B5[S
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M3>IM)>+P=DDFX?@@SE59Q3&]=DVG^@$.ZR8_'VSSL:17#N=L);[&3NR#-7Z
MOV&4Z7%FB@$HXE64).Q(]L&QP10@OQQ" %K.<'(XQ&A5^@9&<C_<CI.]X:)Z
MYMH[/@Y]\B%AMFVNQQMF>HPQ8,-\QV#J 1.POD9 )1: .C8XG"5_8C03Q&U?
MO5L5#9F*+ACRS/KVHZ_FS1^,@P('8 &(_OU?7^;]_[?_S49$450L>R')( X,
MCU^Q.L6-8+?>?F&QFSAE$T(^XS-[S,6UV:U.066_Y&*F;I^[350#C.7&AVXS
M 3EA0XCUT$86F[?^>@#GZ?K1$V(KF.NK>L'>ZFV.G65+I.[2QVF!I,[@MYH-
MW!]M3P>>:2P(=]$O-_-@ A(3&!.0'3 3L#T_PN)+LD@*-&@CG@DP1S !&G00
M$Y"UUO,.O8K<=4D _3Z,9!Q-9 +D$2Q!7P6S9P+.[V*)]UB/*:SPQ4*:?#8<
M"$Q &D. B$K"J-)+[,9,[#S\HH/HB7>*[^FX]F:TY@'Z<^_H'%$P$8"\SMT_
M035@,;%N"A>CSTV-";A"0(\?T+1Z*ILT^Q]*ZP4_]; Y8S J7Q(=.:F&:H>>
M?_[+J=@E)4^G?K5!+Z>HJ,!Q)6R=I2K@E^$8X>N7O[TKG8T!W,V&LL>H#!!0
M/"[06"WN&6A&IZDC].H'/R0TEG"Y=^N%IW(()+>9 ZBZHP_'GL3(KP+Y,4IK
M9D8LR?8-*CTST[< 3(V,1L=I"'QVP1Z[E5C7.L%%M+TO\.Q/$^M#G>GZ.(8)
M38N(^]2,]>,%=R=A^!.[4JME;/6T, .O!"O*,V[5YG9F6,D=MP&$B=A2NR4/
MY[]W^CV5U^P3%/%.3%2T;N:UU8-K[ 1]9:UZ?EO=M#3<E[UYXLU!<0JD(PPK
M8R8/[T0)Z-G%-Z5R#D&'K5O/ODT8O_-:[7EE%NUSB?&/Y1!\@LYEKEKZ2Q,$
M]<P<8PQ2]V9.G6A*QA+X^/NK[8C3W07PUT/3?A5D8S_E[$O'7WOEG4S2=*B)
MA0X HD7,85LD3_)^ZQ!<+P!8U[>^0C6"%A+*4DWT@WCF5) 6;8VU'X;;EF:%
M;\RZ&LSKY[^("5,XZWBLBJH"GY[2VE!=! G33I! G4A^"E=?,>\M15R;&N&$
ME%&7RE<;X9JB*XE+RQR)%W3$)0%[$HJ7LTIS.\MCG9XML*T&Y#,!\<M$:T:J
M6#R"^(IEJX0U^S[(MF( B'ST(Q,P9 -! 8E66A/'R,:47>IQ2A !TK,5<V#;
M6CWG;_0TW"AWIBXQR[,MEU\FFZWSG8SQ-:[?>:G5OXL51T; Q,TZ/X2?\D%K
MA5I\GL&!3C:O,WIP,'Z>%P-D? 81;]EP+%BNYS_41\:;N"T85PPFF0DTCI8V
M-XSX)"O[*I^83+,=D 8</GM=NU?TG-KDW]PT%50RS'YQ4) %(3?H.28N)%L@
MEW^V7[$\;EU?S<;8+H,,VLTC]@=/?GST^\*[94XOIULQT6?-H;CU!NH]FB']
M+0-(R>_E?;F*X<,2+4KTD>GU0.'>#X,E X)B#T]PHO, 0<\6:.F9VNXW0 OE
MLG(DK?@MABY,D9YL)D\IP\.?_9%"R;BT-S1_C!6\U&0P_N!#'C0_@#;I&FC<
MF/D)$ UY1WER;E@K4&_6Q;6NX2,VL\\S*.1!TI[FX2N];V)_W@W6':^E19 "
M\)#.CU7+%!1)MXLA;=VGZGM KCOT[$7BM02P6_?=8-. 96P*BB7B[F)34?P(
M[\%DL+O *.RZ5EKH=#-&*J 1C Z2S0U9LOS5T'T>%R%]PH*W(2OA$&R6=,S)
M#HD@.LXZ]RV"U\\2@!*3*Q ^^0\C;6KE7WQT)GKH+ROHZ)JE[6\\,L2SB#F?
M^Q;GN%;,4@E('LK3[Q@9DDC&R\"[W _4JX<A2DF?':=L1S*"_7=A\]23++)!
MOO,#YD':<Z"$+T2ACFC%MX4\F.=O"+2_[M/4^C%!V4]SD6?]1/+U6QMLYSA*
M'UQD'*T@\ 9TBB&DVSBH?#1+G)GP1$2V*W35L"'!*K!$T2J4-P=;J*[6D$&+
M87\Q'7P.<$!.Z:! 2%H=" DS6=]Y88;,FNH[WP(R2N9785@*^%MRK\7-[<JS
MAVR/9I[_Z;C[[^8Y1"1N>)#X>D&\9C). 1CN<;.><,T&:4%K,O3G-V^)9]6*
MCC+7;4.*U98'*0&@*2X&*V[22IT1I'(R:AK-L))]P01X2H,.[$(@*N"U&8D\
MKX^563>K+ 3S]1I";.@;P(R0:K_G'@^_V+]R#T:J/TI[DS_S_/<\<1Q1ST?G
M8X7<*_5,P*)# W&:_(*RB*:9_]#3<.EE!)9N-@0<&H5,-O9C#)\[Y*N)*\AE
M99Y' ZN1"WNTW,%CB(D^3R:@E!MBGO:E%HH_I9_PMB"5*K#Q&_;KF/%WG[0R
MB3O^>C\Q,ZUHW:V_14BHP=]_=Z/8JYM8SB8YHC1.LZQT7B%?"_Q3O75?5*6D
M_Y#4BR0.Q1B=R$PU#H88JD/K0-U=A GH3)AF E+1?V]]&4-\U3538@)F6)33
MSD"_%Z9.1X(6D ?Y7<#C_F:*1'27Z.A]/:FS6E,(T?+FYZ\N+"5.61PG/- >
MCS'K&FJ+6H (K.",L(EM?F_FIYS8@S0K&\1+,P"'"6ZY2>YL)HN/"PJ[BM6)
M36GJJ!M$9/(CNN/4V:LW7/UPR49J,=PW/E_FXI0.[9!M6,B?/X3U0CV9KRGK
M>4I_NL/+/F@YVB93@7FEG!@*;+BHOE+V]2Q"NW?A34@Q ?/W!!))_P/TIWDI
M=(=-&.E[%LD%OXM.-U'W IV:=1G0>/%3;75="&X4%P]_P[&#=B<!$]O4R@S0
MA.C(?IMZQZ,X\)X5S^WBF+I,'7_,^T4TY^](I:;D!JSXBF-DX*_!6G\QY[CK
M'6:[FH6*WD>GGXJ*F\1<)F"X6:]=#'!&]U1( 2<KNG##2F4))E+EM(NDQW';
MF=,6XXU'HB_.?%UX,GE>YLPR*,A80^QO3VT87YW#DP5/CE3K;['WP>LPHZ<;
MXX.EM3]_FK*UC60%2RV:%B@6LG.KC06T\;Q-3("82P%7LHDQH=W$GR'&BEMJ
M%Y;,Q^*';20\1N]?L+ LA97\O36;">#T9@)>V>%]&*+'6&"MOV.X3B=V+?AT
M0A+"6!+QA9[;J;[.83N-@0+?)GAT?<;&GQ;,K]D\\3.FYH!'./@I8B^JV@5Z
MAPGH#N/W!R>YC]@5D$0C1GV4%)0?\CW=YO)< :]MYR_.@ 00O@@)FAOK6TI@
M>LT%UXEV?9$.B5T-Z=_[!PRMPQDL=A(IP?NI"+6YG[JJMO,'[].-X(7=I@2\
MI-TD!N)>E$)3+S>-WE/\/)BKY_'IWB./(H&)6.-KAW?_=S:1_EV&%=;61?Y
M+P+ARQ@R3E NAI#6.JAF[?HJ,(#QG6I+SQR0'<#<A0X6%BU30C(>F"7&D29<
MZY*($Y57F_TZP?<')B,5YV>0183UPUIZ^$I',5Y9_YST[!9PN)N+]9;/DH,(
M.9]F=(Q1S7(7#2W&6@E#YA 3 .9E O)8(!J*VTFD7?I^A EXB:65L7A;)J@
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MP>X+W-L4P-3P)C966RD>&KB^;[+#*]C+6D,GYFYLI$4.M(#H@WL!D^9#;J-
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M/;UTHPR/O25BB1_23^F,'CH3^>Y6)W[_=F7FEK!@TAJA:@CKCGKFI&"JK6-
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MIA\SH=YF <5H%I [9<L"LC580*(U:@#^RYX%;+2\0F]81N^SA!!<<3LT7;H
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M0"@R?]:P;$:*J7E\[KU).\J8O 2FXE'*PP\^R@]<<%LA>-B<^[0I8:NW^N!
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MO7)4]E2P;K,,:KZ'3P1C(YS[*R'W.6'!/<SPEF$#]5;><HW&WC3K/<$+Y8<
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MA2@#Y-DZQLM6[=*JV*T!_H#B;4NK.,OW]?>]/&6$KK7;3-RZ7*JVK\%0HF.
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MW,P8I&8)_63AJK;?4/VI:Y7Z'@W'GKW-7N-Q\\:L;#X[TB%\[UG6^=8V9#?
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MZ'IWE!6[[!Z?#$L>.3QN^F"#:)-$_912)?1V%B30#D)ZT4T9>4AIY#A;5K)
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MK<\YH'W/#JH(VIY9_J^^+8I"!%F@N;= "K,Y&+)WIIB"8AY68H&.;K- O-G
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M-_PQ]W7!QUQSSYU1'18<R %TQ?1SW\_PP5M $H%AN.9;T:K/E$\V#CF759M
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M,Q([E?ICR^"2@?TOD^#UGLR>#.N.NF#?Q[]<3R(WK$6E7_N'ZW *+4F=9&1
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M?B5%+[I[\YS^\;:Y&5MNLOOL= GY G$;\RK@837L^\/7_; S4[ZA!^HVO>?
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M32!"(50\2S#Z%G9PB\FK-,(YN[S#RYO=X-0YV%WNV2L3>1O@\CNE=R2V6V:
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MP2H+(W([]I+C6D2?V%EWE_S(L<SB@@EQB9O;N]DD7<JWN_]*2UOW?6KO4Y0
MPY.$^1VXWG(!:4I-_@8/@M"4VZ$Z:V3+@<(6FE[\\D2FT\2TTL?+)UIE,R7:
M7RG(/U1(J??!/&( \RV8UR=89JI/@-37#@P4FE<&]83]9J+7C[<M)2LH.&OV
M.M\J_(KF^S_!ZU'X>\#C##=[;)1>:*>PU/$A[*.Q@_AR]^ME(="6+0X=[?Z=
MA[\TZCOO YI-9N;R;;^-;WQV7NK*^(V9:T 3 X,S-[TUQT*WH:>Q9G&N@_L
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MZ7%$*J1ZI#,ASN]B0K56QEG<(4H/DJ9$3OQ=,4FWHFXOM"F'QQ,GE2/0U-*
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MA>'\'LNG3D7H%*LWN=.*@O786AJ<\[R#&3J%B.]$71M$*E"AI/5$. >XXL]
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M76FUQ;(91<NNNBYB/[M@BC\S[#+$]#]_^5HJ5CFU>E7MQ?N3&PK3I3UHCW7
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M5F;84/8!X#8.:Q] OXMNQ?CL<O[C-Q6U<?J5=^K"S))].MYGL.3I^X!<XCX
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M!'P-HA)T0<;3$*8R_<9XNPHJD/&L_G3K\4J022/<<YU>R3WD\S9QPB;.,<.
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M35@/ESN(D.CTM\S]S9MJE'.[4>;J_BYIN;2B"GF@\\^> Z;S#'0_>F;**\V
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M)'E6R0.^KNXYU#ZYM /SIUU%(QX]OCK=8E+7:[Q43PUKJ_R KCDSL>3TRW)
M.J<2I)TD+RY/_A(.MJYYW8'0)&T=Q?(^(X@%V3KWYD,3@A''J57/)PD11B=4
MMZWE/QP2N9#-=>W$PGA>79[_"\^I_+:O]7,>;;::6H>0(U;&ZE0LM?$1HZ %
M,<4<+;0,NXOX^&4YHV$)WP1/:5<.P-88=6^XSW\X4(XZ&]^UW:0D[4+*6"QI
MW7+I&E))S'#EV,G:HV>2P'U(58HT_JU\]&ZC?_605S*>;#8W=>L\97LCA2@L
M:L$H:]< 7U(1 E\^TYU!#PK>M>T-97]!]53%+JRYA)GWEM,U(I%F]L1;:.2
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M4L\\^^GG9(-@7X;)MWPK\9.5BXXG_/9> JQ)[=2B&)B*0>8DI%?BSR*Z'U'
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MOO;&OCQU(-ZW9!E&L1S\ ]D SO PDQ/\V""S!Q73:H< '\&#2%OSH35';Y7
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M> 0 )WX.V:'OMRADP3P?]!!=)XP05D*WL92YB3RO^8IG'?8L#>W^,84_>0F
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M&<$Z C1NM-O J4A8IXV7_Q=5K+6%KD>MJ;G(,<G@-=[/HC-O'MQO])ML(AS
M=9>9..+&:WL9:@0\[R03YS26*WSIBB2B6,0Z":><L%FTE^L?NVTUY=0S>_('
M]('5,Y94W9B&DO0Q-NAJ<\9FM^2LHN\OU\\R/L7[+)J,N1_LTX=KT:Y5U@/5
ME!*227OO#K^T6J?,^<2>FT.NF_[[M>K%'E<S7S40;\0N2A+29<:6S(6LAXHU
MAFK*RF.=R_8X#ENV/1%V5:(Q4#X$^6%D2$<[0!'_'E&$#W_"\Q+-BSI!W>@8
M/.H#.\SP)OT.PO%/25\EWZ"&UY;5TPH^N]MK#E_].=M475DUD P:,*2?8O70
M<#6942@K3)'/UN\U[VK+'S;Z.*KZV .35+V !LM;^8B<SR=3;LMR%!@-%!+Q
MSR&&)+78E'[*KLFP\KRFDEZ'RD)MV)?8V4.1J5^_H3U90M^5QFHWP PM9BI*
M@#+QQ55U"!4>2AKDC4&Y!>\=?"?PZI&/^&73RF]5^[I-B4+%)T 2>Q,:-TP^
M+Q&7=734TVX'+T\]47@_G0?/,]WH(-C7)J 0HI87+&K^O"^H2A@O<VD9KK8.
M'M-$]5!D"<;%U&G2 .[YVF+]\(/.8?RLRYSAAS:^Z@'E'$IL8>(B=_Q$Z6\V
MB!OGB06O#"'M.33Y6',0G 3O$1MW;*W(G^YZ._,=>?,JUD ]^,OAF4MIKFGE
M/Y'VALRBH 2;62H$2L!,Z;5EPO-]["_+Z=H-_+3I.W5"T3R&IJEM?7+-@0VJ
MQJT:D;!1C;_J# P ,'%#W,L^Q/\ZZ^PHQ/)AS9KNR-.-$RG:#B+QGY0/6O(\
M>4T^,?QJCKA>IB:ZX5*LU&\5/(V:64]0G+^>';AD:Z>_&ZJA^4K'35'/\-:'
MG#]EDTH.^'X6/WH0)VC2CI-"YI&"2\CFBA"%LFFO.'"4V'!PAMFU2;?%PZ('
M50_=:_OMC1-F[6-<FC#8[X/6!1Q(4$G7#F++U=G^.R/-%I[[+[T?;/J:H1 Y
M)_OXZ*W4,&IWN&T'5B00]Q2S'ZWK@^;_P0!7 &@P>-+1.V.J&\LL+HRSI55*
MG6YZD/P6<=^LC>.LIPQ)76S0FA5=Z@Z\56!D&W;8"RW>:D3-?!%HH:MTYVWC
MW6NZT>M?U/@WFYG=A,6B 9+2]<(:BZ*M*X%FKD<1VI,;P?5#M>516-OVJ]%5
M/JJH=)=41%]W@6FAI(M:D)'6^HI$B^I@\N_WL;N#<7_W/0UZ.8HGR0;U+<,P
M/TLXIKE +'V/"DMF@RB&T#_ZYAMT43_,]OMAG*O2UM\#T>%_9'?]!*%SMFR0
MG_DVIX96%/WM^]@_,!:_"=T1(-/D./4%(1=)@AT_'Y*I*I$.DR8?71W,POR(
MO;Z^;A$NUTUE[2_R!Z;D\]EE/K+YNLQWGF=,Q'[>BB%$I\4SBYK]Z8<9=ZG!
M251#(F[-7;YIF=.3BH[9,]@*DU+YG:_RY0629P]K!BBDA(@\=E9.Z=#M++B_
M66?'S($^3)K*ID$YS4<@!8DA/6Q0;*XTT)MK '@7 2M=QV6PQ":!<UM$U'CP
MIM6\<EVH^,WF6,2XPR.YDQ?)/$B>E0.BP""= VK:;K)!/FK #9P[+@%[K#F$
MB!%"G6*60V 8 M J/87TF1UJYAMVAC@&TO8B,/G.=;^/4'7.R89(>#Y(/9$D
MC6ES9H.\RPPZNJ&U[IF)$"T$'<J  J/HX[]02A@!I^:L\L14^=+&EZ,<C+6L
M5S4B6^J#^K3,*W#\GWP0L^)_T<&N!50HU<D<"-=OJ?TZZ[(L_C0[3$G[\,CW
M2XD@\M;ICR+S6OVBP9Z.-6=-<O.J='T&J5JQ-1L'E]3"/[H:NL'!!\V.<!D\
M#9(C4'0THBN<D'$]KA(CT^;-&+Z^0"V74AH)_L^K1-'0]OJ5P?L7'&5D*"JM
M:<2F<-T]>$)(;_+ HL\U9U/GU)#'VMV6^@>\5TGI<WNK]70:XUMXK5E=<8^Y
MU^S$=@LS6-$;=_0,$$GH[]_@=UH@POKK$):2)Z-\C9W],YR%X]U2$L^BY DM
M3O1+-Y.Z=)N?;-#R[^NH9,S<KWOVR/#<L[[O3[!77&Y*B-Q<GM0XX+Z+PS%*
MA3KJ1C_VU:4W%NS"MAHRB1O<OV>%V:!DC_3"GYHS+PCUMSQD7CSM^ZT[_K[(
M-?+$8JQBZ;R"0G#@U3=W&^Z6-D?$*A8K_O_WLQJLA%'!%*M(B!XIQ^D6U2]:
M.1#/W?V *M#9&'\]ZWA,9_2:0LBZ9;N48,25_4$B7&-#L-.,>QP]G6<-P [U
M1)*C>_K)>H-@UXY" #W17I?J,U \J+K?*]48\O;;M^*H1X;G>22TMV8X]+28
M:DB+9;YGR:'D@0!*';E=YAS@^=ZP?'F U!\ZEWM'(=Z,;]I0@F^D\1-??*=8
MKT)4SXU'Z3)5-?;9]=B*7TD&'SR-57\TX[T*57)R2XPJ@I-P2E]9:NAI+!_Z
MH)F<P6EJ7=P!AJ??3Q5WK<SLQ@.;]PX3TK[\ NU6//U>2"73WC!?0KBH?K84
MS^[!F*R-^&8SL9R/#/6FUN@OY&LCZ!'(Q5F+HS;N-RN-;==3Z[GZVM\PS2EP
M6@C5[PMLNFT;P\_IMUT>:W")>,%?\"7),ZT+/'W_+L[3,]4X0##]\V9^H(''
MX_2*ZO8.4EK:YFU8V 1G'9RG3;Z $4<2-&;].-"<<"&88ZT&K  $- 8K#@VA
MU!,J7E:H/"!J8,6N9ZDD@[>&W.X_>(V9::,50*NM>L#QY)!.M7C#]CIA3.DP
MY( G3?_MSC[:PX&U'['S5JL3=$?4+>:+9B<"3IPC16PD^N*RC&SJXC5J8>2V
MK'Q+8K+J:>3:7/TKH]>.%\Y=L-V,NM)ZM71M6>8D,SD()XR>  N@E9Q13L +
M/\&GV_QE,FQ0>W#(_>D.EF*6UZ3!9-!#W-D4A]UGO0(BVM.?U@T^YS$D%/^L
MLW8Q;2=97X.@LQ^_HLTV>]83LF&DAX5$S$];0O3JGWNAI'#[:\.^!96&(1B2
MH)AK>.U[/ITL,U7>1 A7ZA=%47@7MBX(&P6%_\UY<C 0OP_8O15)XHGVK6V"
M2B[I.EH1P\]HVURM' AH\JD^-*IH=^_U6H_914CP+@W"3&>!4#K / $OAGP7
MY"? 0$_X-AN2UH2=J)=F*C^_B?+W33F?*WI8),KFP0'AQ3_VHLTZ=*3#;U>!
M'RQQU@!48,=*R)LE/(+8=E%U>)>NSM0</_3\9KG$AF)1K-8-:JY.W\K [9;K
MY3MR^!(]"J K@=S\$1&[:28338>B._<RL'0=)-R$682R(V*39L]1M%Z>H1ID
MDQ"P*_7521;I[L&UZ4?GK4G&T L03\E3MT9:U3DVV0;%39 VIX/;_5T9QE2Y
MA/D.[[Q]XZL,(FKUZ QT/K7/V3UIE9^J17O=&FT#S%/Y-E;UGL<19T33[\7E
M<A_=?]WX0KJ) OU/17[K8?0 FH>)#1RL1IIW9*%??6MZT,"[X&()G7Y=M;82
M\4B/RT&:Y]L !4][Q:Q*W!"&B[%!AU!@_PFKRE]J"TE#$?6O>WM/FQW%5$:Z
MXBB"+-YI2@>!WS $_CXAS"GI<)"^F_BE@ZS-4S+.J,4#]B'%&NN!_],2._(L
MP-;^1E8T41=[U*8JNG-5AFLK#DU[[\V,7FP3G1EH__8,\2Y^G9];]7%TGLP%
M5R<VZ(C[7X9KR/,,2E'=8(-25G:XNZ&;EV8QS=!M(1AX!OV#=?X'^A)ZXF9%
M3.!.-1#PWFLB5RK:H2%VPF+X0^;U+&_^K]-79;]^_.;RZ<)/^Q$3@\Z;;YN,
MM:;?FU.A.A5MGP];GK/QWKINL5$PS09IHOX>9/_W;7(@8_1%QHV_WVJ^8 'Q
M$#:H=V<%3#%)FM+KPM:>B219"?=5($<ZT=ST@SG[0UR5X;:8(\VR"C:QHI$'
M5$1?:_*<6#QW/1D^8:""LJ8>B>1P=T% A:BD[[B,[W"5I;!!,>L[^OI7_]A7
M3??XW@WNG7FEW'DWL7FAL2#G?IZ\V'C]TJ36KGI-N.T-,AMD^W@F,"/7KY]J
M7^URW.N/&NM$/_42*TIP'X;@@F>#9$>3,6U2K8K38IL,<T+,;O'MR3!DTZL=
M'C%&D@_SW/NDM6_V0;L\>]D9-$SHGQ)/CC@> X6% PM. +;M]B;74RIL5I9K
M1^S/AP'.+1\ ZZ]DIA##$)1+?/QMHO[AMW SS9T]!R/P]#_E*^N".UHJ4\/T
MR3^%/ RA"M*+FGXY5SD*Q.;4UT;7F9*S._N=YFR=6(<&J!I]*B3PODH%N>S^
M5LRF*\Z\*(\>(#H3WL;Z,-]2L(O-UL)23'!QQ^-]ZF64*>'M/;MB+L8[[4RN
M>M(;+,54+<Z_XP2<Q ;Q*C]B@TJN%.,/)#&'YNZB1??,C*QHLPK]Z^ ];*:?
M-X9P@S&6R3HT0S4.-$KK;.5-<9.X/#$1?S2(K,E BW#0:L0EAJ7);9@04M3!
M\HIXYEV.-)[N[#D9V=,6E!KI+_[?_N#_K3^Y^%ID==NN*TQIT4>K"K'G\8N4
MU_!O:6]M6G(*LCMG>;-NTP?E=\B7PLWJ!]#IUN9T/]%YSO3F9.J/XBAGT#[]
MG%GT!?(@%WH47C8+R_GO$SJ^1TWG6GF*H$#YLJP #I7J*BYM_<92I<0YN<F8
M^]A_@#Q!;%Z Y;^R9M;';M(CF9;]3>9LT#[/A?<<TR*%5I1ONMHJ1[G:WGG)
M6*U"LU*:%^S9;:0,I9@(QMX>ZDT!LMLNY'<\C,V<B)63B3^ DUV!%=AM$H%J
M:H0@< X<!5$C\08*"!,3*XDNP8MF0]M_!L9F"U1*]QZ7[<R5?A2*^1QD:OM<
M*NZ2&"$Q-#;@UG83SFK>@F5NM6GQD:-^%\?$]?15:%A[OQ7&E$'@OZZ-;4S'
M:_09S(\V@A6#OXD-FGNRLS'EUH,]BO.$QLV*CI8;G(%G9;Z$W"/'A>E)@[S7
MO DETOO,KAGK-;V4W20W\68<T_B2:O;/N6O&2LM^B;J9\=N8:,=76,' ,GY[
MJA,BMEO%A[JF?%_YBV3!@]O!=T8S-R<.T-8.-_0F[42*+-&M]!QG'N8T!56/
M]Q66I?>H\O;;69KK5X2UE$]4F/_YT/230?_/='H;RXWR!8I)>. ,M -[S&?V
M#%5^O0%#:BB%!)"L!+P'5,O@'XP^SK9I=*4W6YLR)-Y>/J8C?5J.&'.F#N.1
M-(7M%'?4ZJ#[Q;KJUE(0N"AB*L+O)E5ZK"XA@"055ZS@(F65X_'SP,C/CS.#
M?"^2M=(VG\[QLWYU!7QV\5JK3PUA/*QHLE QXG0_TV2BY/<48PS_8.3)I0*.
M]KEQ] #"<*>KL(;%7<],U,(.S_X<>.?\\]#VG\74NQL:39'1+P_^,@Y;3.D*
M9X.<U3K>U7=:<'XX_2D+L2-XW"F>*%L[Y^>VIHU1RXML#SL.%I@>PS]Z'ZLT
MJ/^E@I_30,+?_WF)AS[8.&I"AR#33"D;7>:2IUI'Q.UJZC]7C;LEM.6VPPRT
MK@EWM=A1\@V^N&HHKZR_NLE#JF <BZ3),_.A'DJP!*P,2I^N^QMZN/E>$%':
MMATM OADM935,^2R2H"(=9J*\9R'%+)LS2U+[T[5;X_ZFAF9T0Q-WVK6(2K]
M+&L8RF=P&JCJ)_>L-GU,DD %QEG7 TG4'CN@,,]G8H6W[LVTD]-2!C%7ZE'_
M_GV*#[[(GV"M2Y"3=O9B00Q/9C*&D(FM%6><@57AVZ O7?=3<-'HHZQ>EAJ.
M^APFI (Q]PN>U?5:EW'1Y0_7APZK9 <NAKXY<"'O3<E'$TV31!PA!5LS_NX>
M&3QIV?^%)=7 Q+).HGR@Q\H-SD%?(H8ME$Q"CRV[:"]AJ3OR/[VLQ8QD'()!
MZ0GQE:R)H<L'[";4O9H-\YT=K.1''_UZ9QP&?ZWRP9KU+:6J$1MT<NRC(G<G
M6AQU:&@#Y4\]K37:[%7B25*\9PB.TS"=?#8<N-B?_OG M*KQ0M^4:$#MK2.#
M+$F\(1OTMC"10S"K_\88GTGZ]QSKWX*80WZP0;_/DG$,Y1T,RRSO7U_[?Z*=
M_^O!_WKP_WM0N&PRX<;/N)+@5J'7K=_D87IWM6?J=;I-)9?2G"N>,_Q)5N)
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MA;=7AF\((\/1C?$<W.Q1O)C'J-B@-P:S0?J:&C3MBC] 8SA6!3UA_W&U9B*
M(*W&XI/R#*??AL\>Q43":@(Q1U8##VUL#TH*"JTD,/.*Q&^.(^ +'AH=6AN0
M[I.=Z!NZ*7-:^+K!-5$R[*>/TYH"$9P 4:!?R?$RD<G!E"*Q-RD;M$=O/ SE
M[%T]LX86Y_M."+>=,EDNQ4JA),5GJ2%1XBL?+T-I/A%64]Q?_,,WI)!&Z,:N
MSVS0Y#+S _@/^&]R4% ?D3K(@ID4_F2#UAJQ6 [*P5/W[=)^4M M^4ML$/@]
M( HG9L?!CB&]EO;FLFII5=^[E?Y1%9CHYRN.1ZB>%VTSN:ADU/4[EPO(X<"3
M+=+&TQVK8^C)7#FJ5J? D^6M]B?;8O\7>V\>U.3S]0M&$1$!$=E!B,HFNR*;
M;!&1340$$62-BNQ"1 4"A$11]DU 0$!!-D$0(ON>R!84!&3-%P*$A!U9$I;P
M0$(8G)I[Z\[O_=74U-1[;[U3=?_H/YZJ?KK[].D^YWRZ3Y^3GLF7S3TT=</C
M"0/?#)^X>/WK6OX%(Q;/5O#G9.0@]%0>?4J/8K_OW_/P %0UZM9"?\"0HXS$
M.CHA#"GN:2TV8L[LLY ;\1F)TW(MM6!F*&JVGWDD9YC:CS">9-VK1<CZ'R[*
M J"=;@JGD]ABF\W)O2$D7 4EK-O,YXI5/;4\G\SU;,VT;"8L)#9Q*O:Y9$P&
M[").J.DX9SW+"%+D;S1!# O@;D>M19-[4&<0!J,8*<=0="?O'_OJJ=MEZGBK
M59%+.M&2I P,/1CO-X,"Y+%M.=P3H5D&A^"MD9KP(\5BZ)?'ZE)&C,;LYV\0
M4@U3C^&TBV"A:(4J33E+-.,G1X10"-B&X(8;V/E=85SV\&!B'GY]A"EE(%O8
MXBZ72._[$\*0&R!"WVP1CZ!:59F<"$5*>70N &L+%!%/)#4,_KE953D*RXV\
MG7&$0^%F%2*9JW<S3N-7T"S>@0Q^S>2FQ+]V^HL+W-*]6MR:J*-?.%V8Q_#7
M;,-RQF9HGP&<!CR?_#EUNE06-4>\8;#0IKUY)O=0<N#0\! F.]LTH5<?UNQ)
M[A>&X^\P->J;3G?)E".W<G;/U!-@SX?BK&P,$Z,@U<05.F4]N)<JT3E>UK85
M:TI%UH1B%ZD30@<@=?YY7N:X?6"'<"9W!.H44A/>\/-B50]YWUES>"^);X.Z
M[;K3&6I+V:') )84;(\/^#L2;)I/KYITV*]TU<LSC?T&,7#./<8SWE:!BSWK
M%U]2HEZ2>.VB,.4LA WB91&G<KS:+#%B]!DXV2Q'>/E9M^!^H?<7 N0^?LDI
M(?UOB QJ>L+**"2**-K\L-Q!@UA16Y]ITE4N'B2$FM6BJ\> =JO:#I6C*3H,
M(U[%,[&H];E&AD%K&7'GWKT^@&9J.R>2H&/@5@SK0/Y0M05PLSI4[\)-^W^
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MARI04[!H(_]APDO0CV#<1;]]#<WY]_S@<S;+L/_5%\0CGA@EH*@4%R"D<Z7
M3.=R'?VYIC4'\5D:R+9['-:I/(:]1@6/J_[-Q6( S)"_NM,-.BK5J/5=)3],
MKNILLGHP[O^->0C028(QA^:&7 ^I]C4%8Q$[CJ:!7W\:471SQ=3K.?.K1R4=
M4>E@T?+Y%?LG";+R;5WC /02/8)M$7%0*6N*EYH+ZEE'? D=U(L_ +VIHGT
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M<[IX&8N$WQ-_>8K5K_M9UGQ*DZ[<B]S;.N\&S2IMC!>,5[KH6@Q/X#);_'G
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M+VT6[QE)B[-XCE SLH5^Z_6>QR;+G.#I#O*"H^LQ0@Q;"A:'/>$ O&YE7AA
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M"SXJ7AHK+I5QI[F%=@MTIE<70[WP,4R>)3T=O,]Z36HCQN%^F%36;>)CKN3
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M[ 0\BQ9)U?HC?AI D96C1:K.<@LAC')6U7\_3WY0*VEO=/SXZ8P?*_(C3!9
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MDQ]QG()O17$=ZIQ7L"_&^VC9G#O8YA$E]+;Y=:LFQ,]U]Z0UUR3;D^4; G=
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M)?0%:4+*FU#VC_W># /<(H$MA+&PH"EBX1++,[EY(W@GFELA5IW.&?7^HC>
M:IAL>K;J3G7[*=R:ZF'O6.5WV$-KFLCW*^\K7P-.*X.&Y'8@B22U:RF1H4Z+
MJ (R$5(_L3)C.//!EJ*X-@^KUG"WY:P3(<93#7ENRV:G@)_%F=U[\T?N73P'
MM""A"630NQ;N"!QP ,NDG9@3L-(YRD@M4=&5!;%A<1."JW!E^4C'M O36S:-
M?=5*=-A\-=GDMA;RU'?"]X<)2*P$=ATO@74.HR8J41/F$E@11@);LRQ6(2^0
M?Z==K>>0,,LTIJ[OS27:<T0#3:@V(X:;\'^)2@A[@-9@$1&Z65-P26Q$&T%'
MB+^*!QH"L2"X7/CV>^.B!.:[6<B>FD>[_(=3".$T[I58/IPG$&LOL1 <)29C
MU  A#[9U>1J7-[T '2OF\R("?(0M%8'=\;&L/>PL RN'&W?<"DZXPT4V#Q-0
M2%J4,FB@F0%$$C-60FRX $>)C+?@F1"%"@B(Q634T7$^@T>2NOBFE8].9T\>
M/'EA=OI!WD[0'G[_0%W\^!*O1ZS0!G&!-#3WL,=Q_DEN28U-DM#&)ODA-Z?X
ML4>4J'1[EN5#@W>\I<S>BVK;EQ]-G\*12Z&=ZH.HMRE-J.+;0:.@%_(AY.+?
MY(V*UUNL%9K4UQ./IPOA11VTS//G.,S4+_[,OU_TAQ+?Y5.O+Q_-:HN-W4)^
MB#JI/#+*UER887)"#X.O>71$CIJG&6IXN8,9J*S0]3#PH?H.,Y]S/7JA#8G#
M=$V9C)7_,*^89(!FGD*U2Q!OY7HKCQ 8$R&9O(OL"61ZS..NOY]2]RGS*?Q)
M2^G^@)>B1TJUU:/&=HT!1NR,9<8:H$6'^C=/C6\-7N,BV$N<U31-I Y8;#_X
M [O.[YL$MNXR64Y95I3>UF+\K.&,O[1U[&CH"14?I?LGT\BO3>\K9].8]Z!1
MW;+_YKN#/UG83)HZTNHL0Q=IAJ'+DI,X,?-DY=%O1V8#C%\99484<+OUPN./
M!D^%]^0?<^(LBLBM &@21FLC@J;.7=B<PA(38D #R'@X"[<6;[JZ[5VPI5F4
MXRNUZ!F;N\:P>\W'HGIWCF%FW4QEEM%\ &+I<==;(*VS[L=8()N200T6H/ ;
M>5[-N[C*;=HUJ[\@%CR.O!_L,/I=5%LPMV>J($ZE(4+A9J5V.ZG\/_QI$ 4T
M>8"9Q&@ WJ#H]BR+#I2\>#1W-L0<K'HL@47@\L38I'UG2F-B$P_U1&T:BLNC
M[OXF[YAA4/GD1L(+!YE&41V*><V*,(C2%1MC0K3 >18Y%5 2[W<O=^<=;XF%
MZSQ?$AHKG33(QP2.;-J?Y)(A<\M5QC)JXN,O^Q_',F"_KHO70%FUZLLS"*B2
M@194#"HAP#?=$(PI'P/.=(4#N@4QNYZEOL.5NR2OCLB4KEW5G1NZ=T9K+T#I
M$JI8\6.@QXA@)[N#H6:G**IEEWV4P)XU<+ "S'&*8)7;&9SG"&?Q88:GN>L8
MMZ>@5Z'3\N<?+S!EH2I:K/#W! HTFEFHP'!GVBBTT:+RL<&Y$+TAZIT:@(+5
MGE03E;A.^UFN<=1]RXC\OA)JAIF=^^>G5Q-HW!Z@Q80:+(')HKE="4)4N3 2
MG:J[D4LHWUP+E/5,R L/8EC:ST(%5E^=C=\?;;@@6ZBR[R6J9/0:_?[56D<8
MWI#- (V<VTGT0+XY3PZBM3F(AOR5=D\U^QH_,//-N,6@G5P%[CQ6AN&_16!;
M7E-U>W&#953+':W2NBI]^OPW!O<O3W!SQ\J"+ULY?1S%&VK_X,ZVZ;3(TBRX
M!)(ZAJY8PW<&V8<I)/:.:^_Q+[UFF)UF&SC=RI6N1'A!&[]5N J:1& $0Q$?
M*#C6Q[)0 5I/0NE/S_0I6O$:^*N8;['0XU]S^GG1T(=E4N_7/$I?HQT02T7_
MJV&ITEF&%&&GT.)SLS[A(W(;^)J)2EB](-S.S9Z^%E7>-5%J\Y88<TFMGD&U
MC/(RKTTVW9WB.>;[+?]_S!;L.W;O2ZV8R'8;=:,1W3Z;;P_+Z.6[1U]LO+1S
M?=[M]*-Z/OJ-&MJU65G3-&O:B250W[,+$G+:K-CR&AR6WQO(L>D,,<OL(.QM
M? ':/^JIQ+WSM-[??GP.4B>72\[>.;"UW6FPQ\ T[B*CXM81N6E&.Q&T21SJ
M(NGB7?E =HC1 "V<I(,3$4QP%1/65Y0:<N=^C]N_[7FLN7RR,<\KK4%ZY^[-
M'[W2QE'E4.DG<3T9(,XY%:DV2^,6 JV&$+C36"%$GMI[<8_XHWA0(!UD,<R;
M<9R*)T7T%1>.UB_NQOW>EP$#^_A_NLDE'L-E\DM$]R]+8)DT>?$N#$(*:8I8
MZ\',QOH\Y_YL?HTA1^2Y#"I&;C^3M\OUF(]9?156)N=)5LFL8"VAJT1+E""!
MG5Z2Q>MQ\85#N@BN=_%H6S2NY:GY5$&D24GX&YCU3?=MN3 9@AS,M_H_LGLU
MT.(/,(F$/UN6+XP'PUD<9?8/E-)E(.4$.C($\9*[2=>X_J;/LG_.@ZU!P<YK
MJPW7/S1Z]H(8F@M<>>,/=D"Y>1.\)W E?"A1&A#K$P;H!4V\P0EBUF!GB"+X
M((R)4=KQ;4#/4:-N-MIU,NB-%Y+9^ZK;8_1&@(W@"93?-+%"%?2.[]?%"K^X
MC([<N1"K3V)C_$'P!LN6K('KZ:!\.3K<_+SRKP.;;2-&\L;5CTBW5[]1G5PO
M[_WGN=_0=\=]%;>@5C=OQ?GT=7F00_ NO$X*VV^7\0"RDVY7E-BNH8*X9U(\
M>?L:H\EF9O'IWM]GH7$%8H5+@M5TB,=8HTY"BE&X\3E/&GP&>HV[[JZS7JZ
ML*T[.GY7]R6I@N#;JLE=MT=&2JRN_5#Z=Y_"H.M0L,G@,EE B[(&[E)KB-G-
M-X3-0Y>K,I5LVJ-'%$>L72>S'HX9&7^T[?QK2O;3Z748,E2"]T"4HY#!=<1F
MD[B':[". PTD>NM0"(C&5GE68YHW>";3H_*[TC??D8\C';=1'?M53*U_?>>V
MF5O2&IBZ6 EH><4GK2'L U$<!-S.L8;01UN+C[1H1\CBMQ0>;$S54?0[LVP8
M_LG[?7W+!N(VH\V[8#MDTY?AG@-049CQ'%7FRTA@J;6B"B"<E@85I@+@!-!Z
MG2<[_4IT3U3()W/Z&@[<B _!WBUQ&KLS5G=X1DL',R.!C:(AVL'RI,OQ$\ :
M-C9% FO0?<T]T\5/Z-?[B#2)*&W]\E*(W-R8^I5>F>I?EKW030EWLEPT:M)+
M<"-]?&DJDR6Z1U@5@:I;>8.5P^_EOARWN(Y7+AV-*(JC3R\_A<L;^GTNPROU
M'IK,A77O@9U8U_OO\DWN\P1-?84J2:P*3JD CW-F4U*!2!Q!)QB_MRX0*Q\Q
MA%ZWW<XUZO[A=WA!F:;O(<T29WUJV^H?WR?:SAB=_*T)H>B6/[1%GV?+)B6*
M%<&'R_R"3PT0B&&8U-_W:\$:#!,CFWG\.2U>(S#RQTF]QJV-G U;X]B6];F'
MDY6ARI-X!0H1U&44:-*U (1Q*:Y#NRS4T+TK 04TUOY#.R@!_*I8][$0NQ.Y
MUVZGN*Q8^O6KES@I&5Z5@H;>SS44RT]5X:6AUS@.B]\C$> ,&ZT$)CGF+2X=
M!E,F(LH_+M68A]&*^#NCV$VGN$D6A49.)Z<?+5B?\RYL$"70F,7PF87GO*0N
MM+IX"S[@,W(?_@SO9_FC&W&LOVM6#QVDU YPG!?/<:IK>ISES>/>MM0:;MW]
M.6I! O/I_^\DU[45$ @?FDU%SU"G(85DQ;W>;DM,N4++JM'T!%0#9TETJY%
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M>G;UA8.;+K2M2<ZQ/O(D8S4,=@&VZ837K?^UWJ?_UPXYR<A_ 5!+ P04
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M36H2 N"F9I/*+5Y]"4OFL,NCV+D=#USR7;Q4KXR,)>E.8*";@XC4/0%@<T4
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M5UDWX83\KR;2ZEZQ3:.J9$QZ@H=,OK7WX^5JKAA^\$Q^?V#T\]LJ[\.&:?A
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MK-\!TDZ#C#10%,>L(JU!.H95H$D&VKB4VJ%Y&K(="@DHH+L,?-RTM^;"R;'
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M;UN569A3?=%(9_S;34VZX@(:3N(2(&T)%#XFLQVHT$;,3="/T)_&7=D[56?
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M56;,@%_)QS<2&![7SBX8#J.8$N[F&_WG<6_,!\I@#2L3EH]TXK_\VF5^G&=
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MYWRP<3VI'?=K'?C5J4L )*$9M?P>#U6F'5W/=#=[Q,SZ7TFX"Y[Y#OZ2=A0
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MZFXSD4G7,]+%HDN)G#?(1(\C.6.%I3X<?6/.D1)O 2L+WZ<.IIZ!3C.*QGA
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MR09B>5;TJ^ <M"#4]ZGYK(!#347SX[@3%=+Z1UN$3\Q4.@JBA$,N\&WJ:.F
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MB/-CY57&D5I-93ML-;O,@BHE1<0T[+',D"9$U*7.4M@$?$@OZ-X!:7S/:NI
MA78<_UIQQ*XE"[O)I)UO2:^WZURECX9=K?'F!/<HG=N;:_1?MV_&?_F0U\L6
MXGAQRPFF^&#H7@EA$/M:D/B^]A-6%+H@(3Z+0,4ESN&A"<\I9Q\[UR%+I<VW
M[C9IA1CEM:=K D"$W;]1E0X4HM?@$\+,@W!+&/:W &GZ!CD/#>EV<)ZB:''<
MVPO@M"CN,>3, [1RT0P$#6V\IC"Z")+(X=;N)N[J7&R7/8[KU5[P_F?FO'9/
MGM HV"8"Q?$ ][V%<,8:%GQ!069LV,:Z"<M6I&-_W^^?YH*R"*0N[&T&^Q'4
M^/D'3!V;7Y$\CYWIQ7+5$%KL9CO[#[+!X!/;E_!M-YHN.(Z-&IKG2)-:5O/2
MW%_(0A&(\\6AJ8-9-GW%'Y.K%-I#@OP-\T(BIKOV) CO.<XP_X6 %XIYD*7&
MS<!L@1HIJ@+=G!"F7_.-T02,NA]&N7,>;O4HAK+9UWX6.A_9*;13UMK?,\.&
M?T>#9K##U?R?8CK\8Z/#!ZDA]"1V.($R*HC9:L=P&&T Y3C\S#T-1)D*<G16
MO6;"H]YG75-AGE\GZFAJ/_3F#VI_*'OJ.WG%Y0C[!-PQL@6IN8F<&]R'G#!W
MMEEHSON3'"6HQ&_\B%\+;!SU96BNKVM(47SZ>IM@4YF+<E&T_X\="*877Y\=
M<:]L"JCZK^ FU?;): 6\!Z/6A6&5,8:-5-5B/L7H,?%*9J2(L>4J*>AR[WC:
M\(G:Q8LG_+\^<AA0K ^\>;3W'"JUW@)NP4F U'Q<14=3L@RKEON:$U#@C=X0
MO$<"VX!;>[3FV5>#)^419EWTBIPQ41DW6Y/%+VD?%=T3_#^[!Q7G1 C#HFTT
M;&R]&-3)U&99<8D(CJ,D\6<91C>ON<K338VD0I_Z+89ZG:S-Y&[I;'EVM?MY
M;-_(>8';"\YAMQ4K/REIWT(RW_X'I,$^#7?N[D!2@=D!B^QBHL87H77*EJ^A
MR$>N3DX:E.!UW_2ON$6\&J%:*>:>-1C&?_@V_I9E#VG&)9NT:]7YL[=!RK!H
M4C'\.4^:89;Q^-=NJX02RJ4M?:^"14TUJZMW#-OI'CU^R:"GMM8N4^W+NF/"
M@^5_)U8<QMH=Q^#D9E 6.^N%%.)]A^&XHI4QQ//%/.#C/E@''.C0AF_>6T7'
MD!><.GG >A[P.Y801"-QTD[S@&84UP!MT6DIQST!;HGY9^'\FLSP7^;<28T'
M6<9#X,_MI,Y5#A5Q;@!YXA;^( \HS4/JEVTR(;6?>111SQK?'+EX(GRW8VZ#
M*@]($Y*!WR$LI$ORN*7<1-[[M51EH#CRQK"8'ML*;AJ5Y*#'1J/.IF1(/*MX
M8A^$KTFY6[7^HE/E.G&IR)1>9B$'.\I:X0&/1F-!1@XB0A-)R(2CT\&)5YQ=
MR-@79GC 84N"5_^<JNH51U2@T#[FF:'+)Z?N7B[0>G*\,N'5U)B;1F"K%&->
M4M]0Z.7M71IZ.YM_?2,5V9>R1O_4=SZ,GF?C$983T(B%CB#\M-FQZ:[C=[#)
MD-JQ@AB9@0SY@(%CRE7WPR#R-1"W@D:*02-"?P*(JQ(04I5$JWD ]!([AM"?
MJ@ZN$,<8H2;?0,YIO*TEFBE>;0SCL9P-X _T_SM]K-K#HHY(S3K)+<+Z=0R5
M]8]I-[>?/)1EE77HW=OT/2J*F^^T*6T]6:WZ\#>I38D=!(N@$/J[Z,$#+K0@
M9/))7STV!5*(7< H%]VF= 6^4)#-N9NW8#O]O1+SZ6;H<L*;N2T%T2VG3Q1J
M;>FZ[=#I[WMO&7L5$2P<6?BFF,Z3FUA)D+I,7#$E1B)\\Y@IFJLF>_S_^ $^
MDC3WK0D"0N,G&.9Q!E@J$:/#$,J@V=8=WT10KX62GG:$>&RXZS]EI*LOW0*?
M>W#NF-!LW.7[[>'^> 3V!54@-486*X[1VM@10Y0%+Y'E\4H1=C25NAL&HU$8
M=6Q<L)'TMXJ"C\GJBJ<I]S^<L9N,N;[EFS_P\*MP%MCP HG@F" BY#<Z&,T#
M)-S>($M9^HE^/1^+I>;#BE K4]IH>&;<J)$H-V0WUK&!*-C,F#I:_3JJ\]8J
M>?BLGW/"Q32515^!MX/J3;)!,NZ3N 1B:3]'.HY:E6($;^2X(XF_@'=E9"5<
M*[3LM=A+"Q@.F%7HN\0LCM>*"H])W_%A>OSJ[:*MFZ3<D!(K4 B%L&5"T>.X
MYMJ.@4583(Z&34V.&".*&248FLXG_AQ7>Q(6-$/TLIG/M%[@?%_,K-*>6$ F
M_NDLP/;]>V'X<QG_N@1:8!FGB2LVZ&846Q'1'E^ER0<95;#=;NP8$;[3\06/
MI'*Z+GGMZE%!_E2VSA/R2_N)K__X;*4./TL!EJA'#I1BHN"6<'ON%M-5+.XA
M^D^@!&]%%C,1CC!Q$@*!70^XE,;1A<T-8/]+</4 $DAU&0-_"R=U'D"=(*[H
MD3> LV<0L=^5AGNPM'H>"2E-Q ^N4! 2N,W]\-U$3@?I)UF$/'$WBXO/FI19
M"6HQ6M%#;.N6O_(!B4_N(<[S?WB0@MX!;<9RB.U9W"2E+#CI+)12_PWQ!%(4
MVSB#X$#I"W"Z@M2!1X1.^HZJ?UGT[P Q<*+B,:R(1/!Z[H<GB7HKI^"R_[RH
MU^26PWJ$3^";0LJ>U*$X5MG7\J)<\;'VB=WU]\(B'CU['.+UPC@B>[!8ZEYN
M@&98D]1]5JFQ^Q6![*6:%6=8C,*LHN#>D!I),<2-]>H<$Z;1[6NN,N-6#X*"
MQTC"T]8G>TA:SBK[2[+%C^V_1WLK>138A=.^PB[G8Q8V!:S=2B.-H_DO)\!&
M"/42>,:L2L9Z8Z5GE!PR?!@A- 5*^'X:%Q^1";YQ.Y2>E*Z?+FY[\&-,99BW
MTC97NPC7M0U(B,S6PH=VX<.0)(P"2S>-OIEJ<MT]<_0K1I]CUE.GL2$YPD.K
MQL5EH$WS6*M2NTS!+'W3I-Q#^8U\@OAAVCRD7X@4:)K1</A[L$*!LP?'>ID!
M2P7$$K09OU?ODH$Y0E\&;M0[:/@E:MO<?I5[#(-JV<4K?-+U>Q$CBU+8OJ%H
M%HU;C=G%L68HO!^-)PA6=6,40_GMWY5!#Z@_.DV5:]- 6MOZ!GG/'9:3=3IE
M,FU6+N>%]F$&_Q[0I*DX6 S)]ZW\:P'@;D%<7>?X>^^?>?%7C@$2)E]2UV#X
MJ?$B40Z<2"0A=?RG]\J/1!W2KXP5$YU_NJ>1&_.717E*F*,<P0,T-6AH[FT6
M<?4/O]\$<B(2Y"NJ-/(,DI6_GX%7KBQSXK<1EWXA:1F%=*_)^AO1^T"&=FG#
MA^<;B6QY0_+OIXX_(@CW04H;=L&1L(D'#)0&(S&L3C:>60UH,%K1TN(!.*V5
M0[ +,PD^/, #^I_#5Y%0)A_'ZHK][<ZY?VU_52(T2%58ZDV$F(-F.):^+V[5
MP&]Q5)8\<;OD;XOF*C<05PR\P5AP]>#?B@-\&EL<]9] 1G4K6*D%OT(<0FIB
M;@79%;KD)"EJNMS7VFXK%?P;XU)F&+$I9<D3R77,L#WCLYONNU[_\Q5*GX<B
MRAT7-%![2])M/_.UND9.O!W.VW&Q]0;G!?<5/I"],30)%E-C9C2@JQ#Y*.](
M0S<L?WUUS0,"J?;K.![$1C,ESP>&69<7BAG.S[W>^9$P#E[:VSHNG:+>LT=,
M'(7U&7V=2VXAW=X=-WN$'0(-CV?;CZ6*&B60..[C/SDVUYXY)X=_2-%[6^\Q
MHG3BZ[AXJ;+VYYT N^6_P?G_)7 66=L=)0SD:7(3,!LA/UIA+,P7VDKSZ:GS
M"\AWA;!CK)2 I:)JS_+:.^\*JC4^>P_)ID5N#O-1^]#B]_V7<LD>^_J\H1^L
M!L6G;^ZW^VB6"GEKZG1F'2#,7 IQ2;E>N^'65^$?F J$O1A"MK0 E5\\0 :/
M4'.A'W#?V:IXT\DJ5YQ#+]GKTYX7KPY)K01Z%+R]Y/^'3LM._JYW^;!H"/L/
M",5*XCZNWX821/3&+KP_>R\F8<Q(I&"2U&0$M([1K5VEO\U,:IY1]TPYHS[P
M*YV_NJ[LQ<[3_'1?DFI&P<&7[:\:GSD7++77'7-QT]?5RM09LDHQPWO<.^MT
M^,5.(6L-Y91]^G_7](Z+C<A,G1#31:XI_](\>RZ?WJKJ7^'G-$$>,;R7]1K'
M[5)<Z4@D+U@BA%46^[L<OV@IZ[ADR\G^TX9/ [*$JM&% Q@U!,@Z?!"4;2%;
MSZSM*?XIG)L1UL])#<0M+8"K)['5.\/A0QOM5Y?L$;#9CW2?'OZW?9X)'&<3
M$MI:(6,=W"0%W.H)O44,^0_LGZ.9:SZFP$E/1S(AG?,$- QM1DZZ!,[T@+L0
MN85[3KSW#Q?I(MXB=4^8!V2LE"%6<$?BL],/)]4_3&3L U>P.49L>5,CKGS%
MRGPB;L'*X5]634@>L^=DEF,;L5PUXEMDN: NL6__VB1IJ#_?Y([]YU ^)DS\
MB]TL1RKJKW:^ +F%*HY<0 N\C1'0& "TLMBN>N^1L)::I4%I-#UB0I:;M)V>
M26S8I;&L$Q4Q$Q55U3W27T2UUC_8\)J8.9:'?>F;%<\Q'QO=.&V>)\>\'NWQ
M\N>-Y-KA7TJ7"WPSAK\U-$IL2JO6_;5_\PL!J7WH-)P\Z(T= F'Q_<QD\!QJ
M4,:ZLX0@@C>HKJR&IL;1 OB+M9G=S:".V8A*>;^C_4A0;'ALLN:WHFC=.P+$
MM;]XL-."?QP]&,#*9?;/!C#88RW$Q_@]G1RM)WYED!-AAZ^J-J*4K!;F7 ]O
MSJ1'>+_1#/'S3E?VO*MOM>6>\.I^N:7E1O0MHAA!-/0HEH^C"'F,S8M,7_G8
MU?@$<K>,:NA4J5\4.6>Y[ZB0C:*I0N-HU*@P1MKUUS(/$"/(A'HURD!1#->9
M;BA\?U59Q&'J.H%^(=F3QC=MOJU8+#W:D/W?B/W_$&+_DVG_1^0N@<@X;@1I
M>]$+F &L3BB&*3RV/+M,^G7#K) FG&/?8_#XH$J3AZ30B3.!%%(Y@P<8OY_<
M9&\G=YNH95)P?6XYR>[BR%03%'=O?#%%KBB&TIB7?Z7,P=G6O-;.G?I+;QJ$
M@K4YLB@X&6P:A380.:YHQB][2 ?-5>(!"62&"A:J@6_Q@/@X"O&W/)F!&&=!
M>Y'(.9AGR@,>[0*I"+Q.I.;ID) YC_40&<>PJ\@7,B!U-\B\!C:^P%(?@;_]
MX"T\X/TUA#Q/_V-/"'Q*3B6#TQMPD"QV16,J\3\T'RQ-C>'%%21QA$!./-BT
M:QRWRI\%"Z)@FQ5:XBH:5K%=NWN8!^3CF.8P?R$/4+#F[,Z Q1 @M"+3 CC"
M]K!A*A2/1V:PWX\'\"& I8YF;@CMAV].\H!(A "G8T*?U,?Q@+@3(&4?#YCN
MYQSA 3=_\H#F3AZPX>F__,F@3A*4@YR-4.6D?%@=+01^/8NL$J'<'^+^R3QD
M,G5X?D4-+8F02J]R),K=<?E+##)'LI9U&1ICFW'4F>0X>"?>O =O'O(\-&K(
M;V.P[&ECJ]=R^M7:-T-)-7HK[CM+[&1R+NAVA]PN-"->FQ@" [GGT[\6Q;8Q
M>GR+#IM0LV=[3OC-KZ76>-?_)+60F!3LY=[A 3[H(4<:&%F!BQP560J0&OHY
M@JZ.71T_FNQT_DY']=9/&VQ^U&_X*POTSV.4 [U0%^LL&-"W [=6)F9[\I*M
M.@ZQT3=#'S186.<%*C51K\Q=804Z'M4[-1E<Y-JYV"SW&_L7+O@G3R-"@W,(
MLQXQ',(S;B( DH9%$BH^J(7\6]B((X;FI/T'.T(S)2%C.*H?YL?"A["T34P2
ME^\3#UB'>%03S[2,0/T/G/A7@?./$T)!<6M/D>Z[BG@:B?@VM,5Q'!(O?Q7G
M?QD[4JAH[+0!2$7(QL1!6*T#">JOF\@,'7#!ND..-<611,/V/S[!S<EV/,"R
M),SQ3VNM1\IGE!FA$5V1.LMF>PR%+H\+O^<&'.C,:EQFU.='2!?[:3R)<=NX
M8$-*8O+?WAE@/I98[:*J=C0_L.RPG<^69=M+$>2XAXI-@UC9KF;W;5]DNW*'
M \.;"]X$!"W5(^IMZLVJ_G_50V[_Y^T_\^&D_UOMO\B2;XFWT8JP-*&#C#)%
M)>$VU6MYYTDQ6M(35U/>T0P.[[%SOO)9[J"MFGCF!3G'HNW .ANY;L=<O"\W
M$T81.C$[&%D)&%/HZ*>F(3#:L[:V"V]:,M@:7*AB=3IE)VE$E,\Q3Z3II\PV
M-4R_'E^M'R"&?2-,)[/5"4,W3.%W[*UPIYLL<T+I5&+VD]!P!]MG90:Y>==<
M;"7]2\K+;@X?%:648).)%?:S=/8NEY\LM#+&<!I&U_7F9[J:'ZUY6-'[>3O@
M^6#S;9-DV?-WVPR_I\TI/[BJ-_8<>Q$'A(K#&_8QB$VI@VB*F:I<11DD_'R$
M$U+%Z'UR=L UJ:BPJBL]E,:'Z=4OM:C>;%QP,RCWK1F6FH*3#,8-9<%BYNPK
MA![8[.Z(FS=:E@J='],F$F?;%:S\[F[;A]K>:O'94,7*W"9$*FT?^C%&D5D5
M;>%'91O%NVU@7GY0Y*UT+PKG,S22$[&)E>7PI;8O],>!X^.Z!X4%HG:UA\Y3
M2-#698Y,(RL.>FO^'D00I3*@D2P;6K\E.'5_)^>(0+?+78'JJD;_MT-\VA^-
M;HI:\./DUQX@L-A3@#\'%;"O@Q2].D?P.F93J,SX7855JS3_[3;43M/:G*3A
M$HGMR9E7E??$9YNVMH69B1BDA<#B)6P!O%!/O1)>J)OL@8L:46* +=>@^;%V
M\S&S%]1W&R0POSH=K*MKVRHML1>C^D0OXS87$PY4J;S'6A'^OW;./1RJ=8_C
M(S%(!F%H9,3L36AJ#H^A,)YRJ=.QI8L[XY);8DK9V)B1D9%+=A0[8B:;;!(E
M]VHF3(8*V=,.TS'&3'LKUS42"V,YRWF>\\=^ZL_SUSG[C_??=_W6^_S6\WX^
M:WW?928+ ,D L9-(UG0@)&X@C@(#]#.]Q3OK'Z7\>*A^1M.FFX"I3##+HEO,
M=)[2=*PE*T(.*9AUUN*VAATINF#.73#S;==*73,AE#A_#G_S=-Y3[C^V%BU<
M.4/!.WL*ID:ZMU UUNNHAE,<#+S[2/:-=B\='OZ&:* )1@&/O$ F_J;)?O_I
MDYC^ [\FJ0,+?DJRWE)P9[CAI$VAQ(0;X+X$ Q*]&%('0SN7MU/N4E]O(.3C
M[<U[?,^YJH\)/U0LK0Y SOI6'U4IL?H+QB%-<JN67PFUR>/QADV7Y^JKCU1<
MW=:'R]7V<.S#E:>I?9Y@*G)$U>. .TJ %;\?EX.0T"A'3>8A!F^]M4>Z2JUV
MN,4=UQ2/;V^9C-S*-&4C<,#V'T@\)MT #9NKUEF.HMW%"W%6>Y-[Z0$MS3>J
MW]5Y)KYO:XRS78@U<FW]<8ORM0A$^D5R.0T(H(P8BZRK +[(NFS-3*8##-,A
MRVH>32V*H]SLKO#A?-2R9W:C_7.A6^.>-9S.@V-Q*PJA"]IM<_ =2;W$\[!@
M7F8K=X#7I3F\5??,2YAOG=I^BR]]GZZ=$'2]1R]KS+C]E)->1+@*JT#A!$B4
M?A*-SR)9 8FE(AXW@,BU;D'WA]7DZ'&2@R_5UL7,&07A6F^8&R?%F;4,>_;H
M[@#R9T.ER-/@.$RQ>M0!;*-!^YXVH+C;_4H)A[MRJ<8V?=+W)V'4V\)>!J-@
MQ/4/I_%G? +2ELO4<S":HCWBR. ]B]%M@&J+3K6$.Q]3\S'P;_P0F\RY96=T
MZ]N$!=.)ZB.AR><GKV.T6:@.JA'TFB3/U@"KNP,5P3)I1/>J3JMDKX?5O/*'
MCJ(:?:\?GO+UE>[?,4GA#4?N=L5=#K!NKX]DZPW%RHZ*W0*'W?E-:U%XROQ\
MO8YIS!UGBX4C,X<JS-*/:2(0A>3;),"G@4%"+<YO1A2,I9;? 2Z%%+'Y!D*@
MY4>>?A EK?K]C=$00;]0CNULX!M$L!$0LD?^W6:FT;1MM.!\.6'@"@>X/,5L
M0F?4L??-Y#:Y35RP&T;OL2;]7MBO4'?NP/Y4QNXL%JH!4J<*8-JG\09UF0R.
MDH-]8H+_L%KI>A6E\EU@3/D"SS"U<4Q_3WM+G\?D<S;I%C76)=6%8T6#.4S?
M)T5W_39["S2Z@5#^C$E,B8%17;+,F 0<[MU]53HWBY\HP]=Y=':_\^^Z]U1.
M,+USTHAS[$^6("]%?B54@OTBF"P/@\H7OG$/0'[%3-+^]&KU/V,%%A$*3$*>
MZS_!,\%#;?'I20F1:V_ XPHM.M:P&59N+C[9O2MR\WA/@6WXM1>JF45.>2-
M5H-Q+;/Z%Q9J$#LB#ZGT;WX>DA*Y,401:F9H[;M 63#8+PWE]BP_+ZEBI,<?
M/%86(@T:NY!L/N;'VW[_9E6E0@C]E<,I==>=REB+%=J#^'PZ;?/Z@ =9P)]
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M'#_\^X-_73@?$-5MN0D-43+DS'L4[]SXP)JWJ-7PRW%37%/79J5V]_.#<E0
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MD)J<$5!C:IJEN)Q1=EDWKNVR.U5WJ_V-,F[*A_,EN&%#9$TM&DP,7OQ./J
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M)^PAWM!]P4P!WT*4AVJ2M[@<9A'B*GG'AC?*;JPO.)>9__I[XTGI-;]^X-7
M9EHTC@\<U)W@ UQE=S % RW3Y-  N?6WIQ3"SJ0)F_^H;0S'0Y\/D""4D1<@
MOM3T]O7;7SH>?)&8N_E9 Q &'!MLQ?]U@+^L*"\;A<X>5&^Z$1_00 8^H!IR
ML9 >'[C/+OE3T?_##5_0"D(HPSRXZ*E[9 5[%ZLT+?#Y[ #U"FTLP*3^Y$4'
MC12[=MW,W\=Q6S]N:NP..YOQ]?5;HG6S4>>+KGT*N2/#FW1HC*L5UO(NRM0_
MZ!E]_9]6?/CA^7^2]0 BB@I_.?#I0I?Z9X=#47#&[T%E/AR]ES5$[#;A VO
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MAC[U:BNG!\?FC5N)Y6)._'=B/;D\AV9JS?9;X!PX0%DJ^?$KCJ)+.8=94;1
M,<D;05/$$P(^J &[8 '2LZ?EQNOVHE EAK)3<)-Z)FK@N7;&]7\\\XMV64U%
M(1>&"_C &>&[*&10ZV$RZ@3T!_@%$",/SEGU4I:B7&@*W)46=&C4]U+Q]WD*
MS92%#<W@#>QM1VN%"?5/?X@1A.7*9R*XZ7&0E\E#JV6;DM!?G\!&.^PD0D23
MUC"V'URZ,HC%5T!*W 0:_&U%BX65QDY&4QHQ72C.X0.BS?ZNDGA [*,L;(&]
MD0_"*#P_"?3*] KB'.$#[RO&TSAZ*H;(W9)([GYT22QP\,85]9ZUZ$<<2<0,
M\?TAB0[7X[OD^E_)U[I1V#F&&:YA9_"*B,KPCB:P/+O=E:@<23D )_F7C$2R
M@U9)'O=C[?>]DLSHOJA5N]7']9(IIGXTTOVW9B( "R)J*'D6&D152Z0L.M9M
M1W.NP@P&PN&&I=C?>8\H?J1$B@PEB#QB8ICJ!!<W(G)]T3L9+9!"6AQU0%^\
MA.CVDMK=D;.CJFIU9C=VQV7.Q0/>2A0TFVTAS3EPMG.#^RF^AO(!7J8LPV3N
M'@+!])8Q/IX/K*UR"*D,L;#?(AZZL5!J?3#KS6N'D>I7VA+)2]@R4ZX\B3[(
MG)Z87Q]I."YRC1M::$/WU+>NH]2RVF\&+[D%>SAF.AZPS7V;HNVSMZC,R-O?
MB'[QZ37+A'_?UR!WS _'(]9I:"8>X@,EX(S'X ])(H[X$;NP)3(;:><%\H%#
M8_4CU\#)R#_'V+IUFR-C4",JH(8[MD<G48\\G-;ZCX>$UL8@HJA_Z[)8-DB+
M)(JR-E576?@_3[A-*).()0J.0]>?@-_9Y'K]E<4$</(RBI_K*3M^Z\>#D_OC
M4!\'-?(3]=OVY/[9=:&#\"9=+JD'90(<W=]D),U]^D?NGP=F8 ?W#\\I!U^@
M6>=7*9'B2S=<D:&P.A=L&$0-\/T*ZN\/Q/3RZ[_ %_[C5@[9A%<$3KI![;P[
MDJBC'QIXIU,WPGZ$1I]O,X9]U!C/TW=GP?'(@4@29+^PY[$:^@E;E1O"[1E0
MT<NG/.[Y_NJ/7)-2L&$[-Z^"??./#*9(:B(E>3/2 _[E+-8SP67./SD80P'
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M?$94AE?#6/=:2\6JNV(.$3NLSW[N?#':9K+[8'<6RW28<8YF,8AY:24D<!P
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M*$_>U9L7YY<Z[NB?ON#K^D.W&/[?! !02P,$%     @ AH164LS9AZ[7F
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MC%)8\<LX!4Q_N_OJ8==%-BJ,?., \D78FB(+W!NG-I(M/DA7!@]-PYI%O(<
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MR"'7D5#5 3\)R7+.K[?L>JQ!CWET:P"!3.Z@$O!8$2W#'#SN3:%6>/M7]-<
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M'WAE4TD<DM7SK<TQ9WNM'XY5UU9ZL6Z.)\":?V^FD*.):?%H390YHTA?J02
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MG#B,@+]SB-@G*B]N/WE1.2ZAW@':VKY0DG$ 4=48#,4<89Y$"I.^1VJF)1Q
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MWZ3%F - ('F$B(TOW WN"&G(YMK6L3S7.JW@Y=%.=#5.</>+ZZNGXVBZ]$N
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M56RM?^BB@XO/ V-%';102TO3'_%(QJ^?$Z;#8S]M'IHH_54 R?9+_'PX 3;
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MVF%N@?-!5'U&/8: Q4'\T=(HF<39OY:LE^9L1^PI@KM7'C6+I87IGLJ_%[G
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MYA'KJ95<)W@4IH%M<CCSFX^TXER,YV)(YV%\R<R^0R@KQ<7K>3G1+2?,D><
M<JJ):6<(5U_I%OJ8EX*Z[;0E 0[RWRH6O[ONJR?2U8 $\*Z[X%VCD6.>@;S(
MI'YIH>3,9@.>?NN/%W_KO$45H VC.J.'0 @,7#R ##L=0%I@OC#Q >@.G^PM
M722]Y@H2B^T## 9L;H143L6-63(%6TBH1TI# 1(E"\572^A;Q[!#=G3^']V)
M3'>MP(50ZO.Y!-V=+9Z5O*_[-$12H-PX8U^FV@:HHEP2?VDHYTNH&Q&LAG\8
MNO"GB_UQ.ME)9*XK)1&\*]A7%]._C0]MGD%O<UN&C:HQF@JF543I/0XH3Z#_
M[5>>+CW2<,*=+/3FLXV6P_T4_MR-1NAB)O4S>4CL,J.Z6W:QZ%<,<O)/\0&D
M^_@-7*DEG)WR ;TC+K;!@;-U5I.XK\+<XY1?USR :*:MFR0R,9V@]]C_[>-+
M10J47&=^GO)YIZH16/NC.=2INU[3Q?,;J6N8&$>7#*%9> F5P(ZBN0"C@>R?
M)M\G2UNG B1#1[)?:_Q*MHM+(F<FOEMOMWH-)W\$8WS*&I&P3:#?(>I;7*VL
M@-.MVP\@'VX7$-#OK1&L*)E_'0;F6G!\]$@!Q:*7J4R^O2NXMF3ID4-]@.DA
M&#Z@RV!KNWG1,["&N"U^GQ88&U,;&33@=S/<T7NA2.+%,"+_T)6Z TC/<[M!
MC]LZ!6Y_5\Y.1>WX#H/P:Y=&>M+M,/ 5]FK^#N5LWE:XQ0&$Y5$.(?27M3$R
MKOW__7KY+^(21C-ESA1 #B!N>':=U&X]^I7Z"?^73INVJ8O;.Z_X]^]?; MS
M2G_%J_IPT%2K&<J/$'/4].K]^'!"KA9?9'(^V03*96)3-6HB.-,\:3'3\'GC
M/<P;OXBCVC&>^:'&4V&BFWY:G$E/FB,]\UZ;/$CE7AS.MC%@[9X^@'C9K0YO
M_7N,LP,P**FDO5Y<@V@)CI^NN5A\O.+,W]$%#/*]>G;;,9)R>\$?G\=VO8YC
M32#'MVF=ZS2JNHW'.W^<7/KW,&9$(S-C>]/<0Z%"08O&?P0P3AXH==*NV%RA
MIS?DC/XLWEW[ TVF*"3;*RME2185-.;L??P)E2\IW5MU*6><^,_.'1(VT>6T
M-QU&4Z!K-),'7WXLBT==30A%]S?(MYXZ#&\0CYOL%@#F:%;HSYC&@ H&EC*\
M<@1'<A#];7RDM%SC$LL!Y.W]9%.Q"1%NHA=VOAXM]O[AZ=*HPF.XM:;5 TBD
M'BYKZQM:\17%3L!S-U B_GDQO:410Q9UWVNB]R6>QJ+^$/ZW[SI4*.\$:FZT
M[ORBM=W)%^/G_?S>9B+N1-0%ML>)J8G'+0_YZQ7_')_',7FT:"'HL34^]< $
MHZ%VY?.(S8+C52X"Q<GR8ZNO[Y^'O+_U8#<_ZR^4!K+YWG"8NUI*32 1E]+<
M N4+F;_?[5&FLZ#9YE0V$ES)ZU(V>L5Z*@P[<%6)%(3C;W75L[I9O+G&G#:8
MVT/P_*GZ4_ @'4@8O"!L_330V_));O[N'UA"F,/B>^;;8(-P(XIA>B")G\]7
M.S?EZ=?+%A8;$D]SQ9_]<@N6MX=>?V"[\:>-D74 "< N!%%UYF(KR$8DX]&:
MY(RX+O(^,T!S<1RASG&>]W'@Y7J6B:?H>O0 C'R[8'Z%FM'60.8?:CT)A)'F
MJ</""&>.26R)/HMHO^N'>X_E6B6?'ODV1Y(T)^:'I5?8]C.9&1NB._+?I1"C
MSB&/8"'$ A%UR3]#J;*_10O,82&X[1'CW4=/1,=;RTML[:[_Z(E2/VS@[;L7
M_>O=_ZLOMI0CBP>E)<GP.+5.Q K?P[EKDXTC=FW36CSKL^?]B9?:7L^WVD \
M3^&D<(02!!GL#%*H@#QKX!Q- ;&,#.Q=S5^F#?QP5#%UN/8,U=#OV+,<+71V
MB!11;S=)GN->Z[1.HMK;+RB1\@!79F"](TZ^8D\2/O@2SDTTJ%6URP3N="MB
M,K:7DT;GH79@FIC@"(W_V<_G7O>$G$/@^0+@ABG;L3\?*+Q\^R,CV#!(D?&K
MYP R(G+^QA'J#6WH$"[I "+>K8AZ0MG:&< G&^ITS^V/_!X=W*=WQ$NEB]QU
M30EZ>H7EUGU([9T,*_,B7!G2-7HW]6C_+G%EU)I^$R/\:[,S9VSGYA_?1.3(
M>5*GJ?:IVXU3O[VQ3Q\?0#3V,$HJA\ JJ32\=KHH$?)?$QH/E1UL)8/,S]"Z
M_9FT2%1(:- *(HZ2E=)H04M>6I\('GTU^C%"]_*?Y!76$;DF] 1Z%-_$WPM=
M&"%^A0FC.8 %O.T[E,I7Z,.UOAOJ=UOCZ1/G?^D+?LR^P<7TV.AFO()Y8Y,/
M(/5Q QV(1!Q;YUWMK(J+E[\:9<S^_OS]%$]\0X*K8=RS^Q]M(F3W#-7(>-7Q
M%64KOC/V:?1L#,G"D[&*#1Z? G0&.D?B5B6UM=I;GU0S3ZMMM[0S-Z8:G#%O
M?936,(!"#EUDD;"SM4H\5^;8Z,B9^HMVYR\^9EMAY.PQO@<^P]+!%S;H9F:\
M%VP#WRK]:3@W4M=FI6Y_^[:D@M04?2[XKU8Q[.WNUQ'6/,)*8M^MFV4JN?0"
MC_:RRI\BU@@.3.\0IJ5L& \HI-&%>]%JS+&AM7&[.5386R#H!D4^ZWG05Z_C
M3P;LU$?#N#_6"#QGO#YADGZUZFO%$*%I(!0:-H%(A]7%)E0QYQ=,A\87.OYM
MS+I/OY%-NPP,$JO2> 9)\'BQA=*R^,8Z8N 1P^(R'UO'@?J!AL::\J$&_Q12
MME;*;2.AD^A4]!=,8Q-^<Y5,PC,% GE-28AXZ3.=_@K$N1C'>]&WII/A,F$O
M']YK:$F0:VW+XQR)%>OQ/)W,LG'+;N4 0C^> B+R%+2I9?,#S01U'RBE'$$(
M ]\=@5*5U>?,DYTYFP^<+<I,3UX1U:"&WY5A'4FX'W^VJD>4!"6[X+XD46<9
M"?MJ3S'-.IL4L T9 L053 KS I#G3]S <!F^DTG\NXM\^Q)3K[EQO<+?*TWH
MRFRJPF75ZWJ[5R*@7;]LU?H]*9]P1QJY#!7Z?:$)3L9-AC*I/6OLW;MVXX(%
MVUPZ*XNB%"Q=4HP"I78#_. (/P\DT(R8'PL:<72E#>QA[^S,KS5QL86M73@'
M[)OF]*/;GG=]]-OJ:R1=[KB]?^:Y"J%E) (%3+XI4+]4YC\$/X[FH5\&\E8L
MG08<J57^M?!*W\=KQ2I+2]]PBPOQ>.7)!OV4" [[S BEK?]ZI?S?%26=(4-U
M<ED_G@<!X(<-91HF@U-4YVNUI*XR'TAJ4TY_\'#M@3(K&ZI]C]O%->;58%RF
MWS34U;6$)XV,5%PV9C,K?;V4QEWY)@,.X::? 6NV"M-KC7*@^2"7OQ/3^E-,
M_&'$V!04IJ'FYD/#EC.2/",188O/KCUXIAWU[QE4Z,9YTQA*I]V+\#/HK?/S
M8T]RW)?A17^Z!'?U[PX"JD(C737PQ]6UA4=V.K9$9^C9U2!98_^W/ZH&P%(G
M*2('$&Y#T:]?UV&\FAN=O2P<%_;7K]-;Q%C+DP5?$ W.>XS<41C2M$;,S%O=
MC/AP]ES?'>+(8<;6OO]^8!6#_ULR_OPGC:\HRHL/>U:(A\Y"SD(_<->+$I4F
M]7O^6]YG1/2@#2@Y?2!^>N,$NJ6!C!VSV<:DTK:I$"7QJQ9LB<@3OW^=^"9@
M=B+*&/WMWQ85#*&RFY?1@M(1Z\?$3RYXX84;-V[,Y3Y$/?,5//&GUO\2#'G$
M17DU[&[6&+[W[PS9-(7N3%X<_!N:ULE.DJA1<)A4G=RPG/8K553IK'Q87?8W
M6/;$M^-_I%6)DIRBA+ SX4VN9'CEDP)D=]5:DV%_-#!\EJ@<:@![_+S[?+!O
M^Y;\!#T_;A_JXDN[WK*Y3@ID7R]@^??4X(CWX_%8YAE?!#G1M-@W.TFEE#&=
MW:)CSIO7>F/$B^G$GS>Z&T5,3 <+EVR! Q1-8T RL!,;9TR17?3&"0;SV!Q
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MR:]1<D)NV_B.U_-C06,^W,P!XM<X]OZ7M\\B_;-K]I_G[Z*[])14XR@Y0I[
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M:)#M+N=&6%RDZF'HB-DZQW7][SSJ(=6/PP1^IS==(N4B'Y!I>\[) ()_2BZ
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MF_/1J?]Q0$(A6$O6J44P.17ETHN#O]M_[HP&15[L^[K^OJL^>@)[G>?UQFW
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M"$6W@M[PGL+<-CI*!9%=5ESA&/U=W+T8\M0C6#JEYAT$$FQ5K_L&2/]1/U/
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MPNS#\I(-"0&YL_VEMR[47@\?:EUR/6K TH?N- <N#W*T38A&'939S'2PYTE
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MFD41]C!%T6J!DM''RUMXS2J!T#.A@F%-#8?J>V]O6OW>&_2^.6?U8T1/A#M
M(,I!HECT0&&&^*-.M,,>GTP#E_U]:Q#H)L:;>9,KOMFLZ<+ 01!<*#=::EK-
M\T3$Y+UENOGURYFJVV=-Z)+TU #THMEGN=I)CKCV;S4:+",KP@&_E'*$$QKX
M_MC2C]=+ #O?)3>$^:"OU]Q(&;_J2^(Q]7Z!>X+U]S,- O$,PVV*)''*/:L]
MJ@L#$J!I?&;2H.%]TK(/;;[?5+9.QW].3D2C. @Q[3-C@B+8P@:_PL59C<W
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MF*9$AL=_(VHBVF_B1#I"NFV 58MESFQ)D3%[5NWC>8?/!^0PH.C6B/ *7M6
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MT\)4 ..UV.0DZ"&%H8X&SY,$7R(# 6(T.7$#OBS'!O^N__A324U<N998[$-
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MB/J47GG_1:TQ153P30MGU>VN>XKYBV+-#<0>>?J=?!&ARVY]0_VPYT?+RTB
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MK;+\V#R*YB8-8,'^3!0&2ZQ$9[>LFA=&QK5+'KD8V2\CLTBA$[0#'OYMR>L
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MV#C<.69Q"M_;=5Q%NC=:K3#AX<.-#?]2S/WI;[7D:_>,*<L F6N54E%*55(
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M P#))B0@ID6N5_!2-<X]BFMD&M*[,L,_H!.LDR J]?'WJ;'KI\*7+DSPT14
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MIL4@1R)KQUT&.)]KT$\\+1FS:4H?(V3V><5B)-W5T=NB#KW161PG7U2!GC)
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MG.$1T)J2/K8KJ@U"&*"))M#G\\3K03/,ZD);&)JR(&\ WGA^$=A](B0)5?D
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M]2U!PM,&^TT:[Y/NI47Y@KF_2AA,;K%?T7E3\MM"85(2)F0P''5.OXLK\N"
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M'SQGIJ32Y377O<O@9^ &Y6YT?!&=7QW0Q$$ A^:38[M,%8Q*H=#J,L&$N:T
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M_:I:>+4&I3./]_Z0U7'Q$(2VCM]B@0Y!J%+&E"M4!5HF W1_>P;O2"N$>98
MQJ@'G$GUJIHB-QJ#JGW7_#]AEJ<5NBUQ;_!GZ"L1V]RE<_?X=\\ZZN5&PWBJ
ME)!B-=AO2H1'69#:B17+Y"O>T:"_3:?^$D7A6WK\YB Z#'$?,6V/X]]D C^.
M2OHH6A#B,Q!.S%_I$7VRS;W:O$/+\7W0%3[LU)2K,2'T6^O'ZNO?I*._/<[T
M:E?"S(%'\T3/P&QL&&DY->P#OK=>SY3\#NK'9),=SNJ3KY8"Y]&;BY9-$G^_
M(UH&$6;G;W'N!# +?R"02UR!,AO)';0[ZNBJZZ415-@=$OPYVK)A')>U !\H
MW#CKLJQ]O[,_RR<3.)"\P\F>\!@*7$3@33L@XO1^Q&<#N@CPYH.?>9[#>#&%
MHTRD1/^*;W&/][U*\Q)@\<8[V$CSG@G;H0*3WS!U"<I(C$"R(; K5M.E=&Y=
M?'[X()T'6#'-,!^CPB9]9BS3WS_Z=G54WU<C=,E$P9>PG/8F%IVW9/9W7@B!
MN4B7 ++)"4QE"R"^08"*:2=E50,N& FY@33^0NIN+7\T0+OL>_CT0T-",.QK
M*L*[P%'"[([@J0=1SY$SZOY&(P86'P<+(U-,&]"U7^[63<_-5M9</_=.Z\R)
MORR+MU=G--(6_FC)"'<>6C;$OVHF--77Q=Q/5OP9_.D]N\2E>!#B(IAX+2AE
MGKN>GPES,99[A%#<S7A?SS+ U/G;6&"UML]M_9:@>G_YGTDY7<_?8*5R3[PI
M O=\979^;,R<#BVKB*EY2-O%2%-RXT@A23D&O?#P:3:.(\8]'#[K6>H'GM*I
M6>?.3'AY7L,))U?Q=>Y'N<Q [R[;C8(YGI>"O]NS5,*"J]]']QN=6OER0N")
M "\(?A2! <-98$[_=#BF2H'UFM/R9$E:C1I<F_X3*D@5?8I#"9D5^M5 G5?)
M8.^OSA>WCQP;GIWC^515Z%@TN])[AOV63,WA"E5D$B,YV;,-Z/62C8BZL0$S
M.'P''!37]7CS$Y>%A<43@M-"ZK.GOY-84_=\B\!=YPZ9KEQ($^^PRROX@ WB
M6 N&SG%^R=&/O#T.=0&9']3*"6?=Y'G1Y?%.]M4"N-9^4V&>&^$#20(W:?96
MN=\D<?8@GM=@/,O6)9T@9$3B>><PX\:11_@3?,/575'>GB9?7T<E7&AW&&=;
M75<IC.;^G_(_Y;]75-EP5MU!"0A.@W/*J715@ $R)2Z_$NR<WW!Z%CX2N/GA
M7=J/)RI]E^)AEA1C! :#K(WHU(28 C(+W]QQ8L5ON$*%9" W><?>E-BHAM*F
MDC-'*J;ZOR#T?JX,Q'PX=?!Q"^6H;PR;QBW_-LY<O+7<>U_>J@\==6CL:K68
MT7:ZK;1\[;%B:EY)79GSC//5KSFX=<_T\[(?7T>K$H?PWE3Q%/)?X)-7+3$H
MZ1&4=>JZ>:6AU.BKE5.K8[_?'->E6!\@XF$?26 \?S<R5:]LTE -9CE)M8AT
MR RI7M^YJT4[EAJ>X1:MNONN"?,#UWR[9S)-<5I9=P>P_SU]4."--[%,#+P@
M*5Q.Z?NDF=M%W\U8-<)Y4T50Y&. R9!X&L(/P155\\XBJ!B:;^YAF";S^M5+
MBJ#K6;PFH#E/%=[HE$+7:$/%@90@J\V@8Z_WGQI.$.E?4)UZJIN?V_B#EQ3R
M'S<HT=Q%]U6: *1X"NGM\].-GVZ7LJ^=@GSKTVRGQ4] L(O(Z74.-R;?G,;W
M1%P&OYAS=;J"K)[,!E>%YB*)#U?BLQXV(S9C/EF O=_V]$F%[8JES<IL_ U/
M)I\"H)@73L-!$Z$TA0RQTN1W ;HE)S6O&^VE0!P(:.P2FNM\5 OMQ9[( Z(\
MJ3CP[)Y.W(&]&7,EX*(\.>PK#Q.#VF_NXYWEJ=#I?;M<A\.@R#IHAHBU3<?6
ML;S:]Y/%*X=]\1#1R!F^;0%DY<E#8_!7.-<_6/L?"D6UU>JM7H>?(8Z^\[(,
MZE2Z;(AVSPH]M&^ 76)>DDW'H$4\D^<[( WV<=1IXLFX.^,]2/GLX2/-@C6&
M4X.(BW?L,U*(3Q+]-JY678<X]#W]J4NU\N?"ZPI9AZ/,WTT6%]+WE-!LA_EC
M89=T'6I2;$:UCVI4E=P=_NUL+J, M?54$-PMVSB(!8)(=7@P9G:;H/EL7K35
M=.'-0*#O>1F_)U=[::A3N1'#D[_0K AL*[+)JL.=#XG/]S8ED?-E10M)L@7R
M7[E6F\3HSF(,D-\596B)H:X6,>+B^W>?;?&VX;Y,5D$8V/:AW*CK@>4*C(?4
M*YOM6UHB"*BM&[3APC8N6CZ$R26F]7&I1!^DE(%V!55_7+%=UUYB_#RA-S5J
M^'UFU-8(N\Q,VRR (*DNK'0C>#OQX 39BZ,PHX]6] KKD;"C6V[N:VU:)J8A
MXQ&HP3I7\,]:L[_X3^:R 4]0H^8DA!+\[4L2GUE!YUL65VV#[/W<RKO%;3ZS
MA<FJO9=>_'_R@%A1:VO=6.72N#;/)VQ3K$Y6U/*+TR;)6C]^1() 9LH?X>'P
M.031=8@)07@,9XEC9,/8L>ZY$W='K' #T<[FM8'/.CAX9].#VY.:!4:/53VY
MJ''E;0B'ZM0]WZ^&*)_>GU:>!VW/"S2BNBZ:\BT\;=,K3UYM>HGTJ9I?;*Y_
M.D#J),<#JA0=0,<*# L!,DLB0RUN)"VAD4(N%R3^+CQ_N&-X<2IYD !] VZ8
MI$H;X6A.RQL=D)JFF/NCE3WN4/'(@FFOYNQ&0/VA>VH$AXW2E261R96@'G#:
MO!C:AU_R-^P:,$1BLR')UCV\21DTQ[9U]QFZ^'=T'U=8$#B=WFZO#FTCKL1?
M-'1XY=)->9S?&'OP%$5Y8DK]1'^"@XK5O1MIOOB0+$+9MJ:2,V@MY72O,*@X
M_ (,"AS@R@P"2$B<20WNKN5.2I73WL>_+]]MIIG-"CV6 Q5]KK9+5MT[?:?L
M5DG96'*J79^JXFKF@:53@_]XV&FS?JOP/[-[#U0*DX=_,"?0OQ75<L"4U(OG
M;+<2Z<5;Q4&$PC)X_4(RW^8K[17N7*9+B,C4EI9_.?TD><FG<GWTH^O;TMNG
MK9^45"/+O5Z6__I@?:=464(]+]Q_I&B/AVS*A&#/M6GG9P!3<A\ US[^\!,,
MNN C=G'\T?RE#R?!!1;7;-B*/2;7,C#\,VS8(8(\]C7\)%4 >%X"I)CELI1^
M?JO)EHG4\)GEY\'GIY?/_:+VV'L25?%-/4/3.[V-<Q<!?OP?^RL3G94^AQ[/
M4C(+Y++DN&\^PR^&>2I+VR^],UVX:?7&Q+9V9?-T^!S_4BN"\$?\+[(R>#+%
M\:>SRLB/W*;2>;^4E7HT@0#= 8^]$OT+W0QCXO03B;V/E7*QT)F8W4'A[JH@
M21<_LOS 6+7R"4^^N\\T^/N=0]*2%,U9*Z".%:J?'MV[(G%$]BBJ/?1=ROGO
M(:Z=4I;=NT\56KHW)W&-ON<.A16':JM/=%!@O,:*O\)2"(K-B+@_.O',S/M^
M*?K_K6RK!I/C:46&_/0!Q+%M0S7J ](S29-,W[\E#%">_]<DQ7NQ9W<LY.\M
MF-XSZX@U5:0$P']#.!%NB'A-DC N8/8N]$].2N><5/TKXXF*8,X_+K3ODR=:
MB]U8I,]I5<!YX5.(QHR>[5E_W".D8)OFQM<$H;5"'YU4NR'S:.1>R,E+-SG6
M^!R_2UP \0]'JD;7M%K;VE=%NF5/W/7\8[J7,S"X"H_HH9^X]\4N^X/)K[/J
MOK*9;3\1Q1%P"YLI!+803+2'I($;ORU-1L/D F&*Q#4/.776.<1NFN65 X]O
MF7 F43P)_5/6$_&*'RIG;8RP7(JR@V;?P\=CQF[%KC:W$;;FWX[3709#'_3J
M]5B(IGU:T?VU>S=K6E/QO;6QZ*IL\'_T5RO[9GHOF M2'V8*?*V>112MC1VO
MOQ8,B7H$4M?ANREW),  3GI9X:4CNL@ \;:R5< L21\SXLZ'']V_#3]<2+";
M$Y7(LEOT.!T;\BM=Q..%*B&?WVC4X.R':<"[DUS"PVOXYU[]LQ?F[U<4HEF\
M%.JD>7_\"!GTACS]2V. EG:H:6Y;IDB4U<X!W+-\?WO:G[P/)!)%JZC*N'G]
M+EG1VR*.%DJ!:KD3G(&=]*BF@5YV+<M(7M'.O"6)\+!GD0\"M"\84DK_7!K;
M,0VW>>?E*'OV_F=;::66!Y->C?Y]R,]H7D/E2'G<_C/UUA B W0WF0&R:I;6
M"QZYL"%5MB0=84--TD9#LQ%U0X23)!YR,"D6R,9,%@2\VRRZ,[(2NNAJHB](
MU;@X@\_<XN+<;<+J$EB(.^1$XOW(IO;F]+NLU44E/]I=',U-?X?M&BPD'N/D
MC.7< 4L&*^G&5^B-;QOH/[:HA)5.DY] E#_0S##23V-PS:?3+(R$12L?6U"&
MMUJJ)O/&":N%R8#PKL#_Z$Q!2?SS &L .A[YN0GSM4V9>B4T"O%H>;ZS0*;I
MM7I/65@JX79HK?:1<]^O<)_%>!D'-I%?T#[0)>']#!"G=D8:6G3/)J!X3<##
M6/;89*BNX&Q'<=JH_CV6X8=FW%S@H2!"/L4-=HO6"->!,JMY]J/[2<N\/->2
M;P_[VKD]OR[_4RMJH(TE7 %[C.60GR78UE6EYXG?6N5Y<"L#](8!DF. 9I'&
MRR,'\TG2(1;QP:Z]?&-=XZ[K\Z\0^M!#\W5JMA;"CW\F#K="B" ]9(#PX![U
MR#_KXMZ>'XL=G0,,IX1NSQQ1V$Q[^-1"R/&YE\+!DHC]G@:8WXCKZGF?;A-!
M.S.?K+N"U**D+OONR5=^HP_?Y<\^;IRW$[$V?G"?.8'^K\452=& G4S!0=)N
MMJ"<U/(TDOJTQQ^"[-;OFR6S'KUX^XHW7DJ@^DJ8ME;NZ:_6&><KGX WZXAO
MZ:+S,0S0@N(O GE#DGI*X3T^[%LIK[3+(_6NU',,D &&I4A[;7Q-(<M7TM'#
M*_R^X^O%K,=9OO57#2KN=CQ<?OR N;KUR;M03$9JFPX@C!^P @.2U-X0EMF0
M!XL']L%9NL8G9.[@UX\>N1?M_[*PILMM]?ZJ>9I/V57SP4MY3WD_3^4!!M?\
MA[-3<5MY(R7-R"H&B,50'U!E@@1$$![-\9N@++@N"4L_UFB#5Q<^/$Q8[>2<
M"F\X.$?1HP\7G*>]@Y\PPFORF'LU9@NNS[BD7[/_[/W*,%6O8L]FG8MS#[R
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MD[7<Q;N]S< DTX,MB3CQ36M2!?D14;PWP+X3#@&6(I3*\)K)$Q-7-*K#E,Z
M#%[G&[2<#0J2R9NM6 H88-V6-\C8>R7"<D !4P6<VQ'"$&QZ@31S-3OX.%JV
M 75\'O#SU>85Q^DY"X86KT-\"AQDYT[E]\6J;,G.]D<<%'J!>E]-\Z4P5[<%
MXDE('&)S%F\U.TN.'8:%E, ']"#3K;S%@'?'F -8 %K6(.BG]W8H] R[7<=@
M6JN1?Y_4V:>I[JCA_T)L.Z" !KI7$W!&-Q54+#CS#.E:$35>!7R8C0]Z,11W
MJ=.=TF&6ZDW_DF%.&Y[82]/O;-:>3]).>94PVC-AD5+VMCBD,,<+<ID+M2R,
M0V4T0)+1PE13$L3)2[= ?C)P3[]J,'O9ZES_;YK#Y":<S[.\+2"IIP_!=UIU
M(@C1K X;ZJ;Z_/AS#,D?DT)7>X<L%IN'91\<9Q)+Q#7DX(*QR"V6?RU0%)AH
M# 84JW.Q"/XU2*-W+^&H%6K]3-5DS*[^=_A=+0X)BS61O?SQA%3$@/;)-@J_
MYF(&(!^T"?:DN,.'AW#()"??M^UTCC-S&[>NO[$T67K]]LFY NZS)E&0J524
M% ;<>OVYT%'\Y?(B[O(SH%U4%]4&+_G:EI86]^JC(J6G6;G>T-\QRC',>\M5
M)/BN@0U]IJ>'E-*@<%B_A^Q; ^NW)3FI%**10ZOW_KT<6]0$5!";_OXHWR9T
M/7\GKZ97T8,$J)#OQ%KW^&78I#FGF<A#//!2C-*^!=Q'^TS;CA=].I$J8'K$
M?CF10*#HFA+%<2._#,Z5'KA*D<0H^>KNT*R96X@G@9=8LR1,]UWXPO/H,<2Z
M5+_[>%I:ZJLET<<!6Z-S8,5*6'6S_ &^._U8Z;-<\@2W3FI^N6)MD"\#-#MD
MAG@\5&&@D:R"FAGJC/TW!U+\A6CL&Z@P9(&;5FC?81\AI6Y@7=KG8YLN/I0:
M57-V_^ N9^NK0VUH.I*/:@^),4 41DY,OS;,K'">TQCK^[MHWXM/M=^\<<XX
ME-OERHE'F4;R9=_OF5P1I2[AQ9RE#4--I42I#O6T>Q/HT.0#\&C!,:^'78NO
MB+<1'7G^H[YK#%",B=6R'E.W[_S3_T\>M/&S,_/M \P4N0"E"C- N-(4]4"#
M,@]B?=Z#V][L3GNC/P2W*?1+&P>_4+_!P 75'@:(F$+'G%KHRN7%64FND=6B
M]ZZ/^A?"HV=1.&,XV'ZW- ZP-4U8M_-W'$<\M+8@?:7VXC74)W!^CX1'\[7W
M^_K0'1AC$?L-SD6W?QW0E]F3;(]D1;(F'_+3N7R)[!"?[5ED._SHN%K7C"NR
MC-DB-\PW7NI,N ^I=#9_WY VI3=/*KFE?<R]YX<KIY['+=*$OD[GWJOP<CAT
M,(>*FJF@[#;A(PP0YAS:8\!J:H-L2ESI?-*B;27@=Y;7N3LKOE/G@UZ93]^6
MW.47&=9BC[-=:<:B5)N,'MPYM8 ;MA%1@U\A]H?A?R%?M*A\8+7VL8Y;=O$7
M/J&NH0WI3,7M3T[]>V= HDOSC9H86V"-*.Y ;,A_GWNG+H-P>(HGAW+C\HNX
M/Y,P!-& C+(N;"8>GSD(U"LXG5*_H*BXGD_?HIO*NL5T+D=*?C%?)Y:)BZ_^
M:ML;^T%U/E%VNO-(&$?R[ORL^,)[P(9B&EG4J4.,"L^&OMT %7&??!?UP;0V
MYQ03JZ*T4(0''%HY;C$?DS\2QY.S=OU6B&2WV(I<]_(%/^J=11SM_B93R[!W
M,?^'4E+) -5NIT(6#&CY5"E<1.Z/K #6.=7$H;D<Q;_%D/T9;?@-^S5.JC#8
MZ:D-V:FAQC>"5]>YM=$:V<RC-D5=4B:A^@SN=YB@^$>ZPN*OM=U.0>,R*9QQ
MQ_MNXTY/P;-+YG]JV5&E#)_]0\>_T%]SJZ PD!E^.O<;<8(NY3$LBI:*]@>G
MN>H1=5 +T!GA]KGC@"(6S1>)O#5\?J-*;KZG.:RM-$)M0LA(83_;T8L@N]#?
M+1650Y'5#F:A3!O#WA"WR>',,'X&D_Q?V'O/J":CK5TTBHB(B'2I4:2H-*4J
M(A$1:2(BTDM$I L1$0@2$A4! 2$* H)"E"(B)720%NDB36HH4A)Z"22 X86T
M&[]SS[AG[[//=\;XRK_[8PWXP0CO.]>:3UEKKAFR=CLFPH6'D8>EF\$*?'10
M]-/3XG3#%*GK.\W4$./2Z;CHP_)#LF4P+;AADU[(NIOWQ3>IE!WF81,R^X'^
M-F)19M3K<=*#@5-L9R@"I%*>H^+TSH1=:A!L&R\DR1>%\+9E];@&^'LD*KY4
M$2$)G_N4Y;I)<I6XQ;7M:XA8I#U!MN*$4?Z3*G\K@_%3%P'+&:'!M#\GR5^9
MEZ1@#HT>=TO[0F4MYNVO/3.).E\;G!Q1IF0*GN$#-,=P?AL\"%]&+O,@P@@@
M8>GFP"GR1GNUM"39(CZ(MNSOVC"L#%.(M2E)M'TD$Q9DXAXOE7T]429/I?L[
MN/2Q;0KR-Z0B(W4MA":-N,'(5WUPKT[O -GF4Z'#V(U6N<GN<^KZ^TX\/Y"X
MZ_V&L4)7&X)XP\;C;K+#MH^MG<@.BJKH*248>I,>&+;:)VI"Y$GB&45Y];@R
M$A_4]Y5+07P^T4Z@N[@60-)>''LGLNKQ5&W&I^WI\0GJ30!&N[EL<\9;%(T0
M_+R*=I<0$4G\[2B;J)^$[WJ3ILYL>V+]']Y41?JR4[BS=J8:.$G&MSBR0+,;
M;;8AE\(1[^^FL4 _IHN0^O@5+%VR(T!M@BY2:<N8P+W,2)4RC3_'P0*AP;VX
MLP5[U2V'?21%HU'="RS09D[J$DH6R+/LBZ><822;H^8OX(;8!H&VM?7K'P[C
M!BP K6G"CV&D#MT0P,I*I%XC%U6]2VA9;YCO>-_1J/1R#_R$/H'%PP"MVC8W
MP)!B<'M?H&J,DHP"#")7'XVE\^WNX9N!I)<IX(CS*I>Z4B"(653SXA3@'AVE
M$/_PJZ-1.E23VY%2NN?,1I--;T;POQ<&A 1[.7J3$]E$($A7G?6:/:QI+N!H
M=")\H3HU&%E38PD<WM5JG&//YK=E2M<,^X]7\C9:\EVNX8P2U%#;=MBHU;V^
M%L2U4EVQR$=3NOVT/%D<#_@'4MYU-FK6Z7;"P'SJ]*%JX/??2"3--/^O)-&X
M]_=^Q4IC2!.*?RFWG H33'NZO:5,@#+RH/OQ$]-DX]0/2](Z\>]"KVY^_\CV
MSCF[C/WXQ<;3@U8S/S=1[DTLT-PR,F]I2FCX,3#RPG;\%9YI/+T4'O_WM?,9
M]X5WU=F/RUZ#SQ\R6Z;)MUF@,=QMQI=&Z67JGG9; Q>Q/9H\7^_K>MQ(U I>
MUM%2?6SE%AOM3(T-N\SXY=Q'2T@!$@\@A<.;?"1N=O[>8Z0WJJQDRE-L6\!B
MP"RAJGP6!?;*5*(4 ([MZ>G+>\.,J%+/+Y6MM:CQR%IG$ZJ^^._V+Q1UI>R
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ME[!YTY+<@<KEWI3?,P>T W[XN\63I0CV$B#U9WN:?S<EV?+>=6.\FOIV /(
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MKK-%MT<Z+"ASR$/U_94P[A4MAVX7V43C[#A3/RVXP)+3#\]GR;J-MZT1+[I
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M9X@V7SCB8MMBYZ0BKUMY4D+S\=KZWF?\[[_W)S+U7BDN@H&SL!8()]V+D?I
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M[(W)*FM$3KP+-/NE2O6S^4<QY;C^_TT 4$L#!!0    ( (:$5E(__F ;-6@
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MV;%SMNDNZR#8; MZDT9&F?8DSDO0NUOJDJ<%_=-=P8HR?\]M?<.K4?Y4Y\A
MS_>'L\7CCV[6F)VUS,2&?N5;=')IYP%T>QX Z27.'X SSA"JCZ)CF,=5#0;"
MCFO;1MN[OO[,-F)J!X@[GXNU53W#9U9T\5"I8B7EEJR!?ADVA G1]6'T\B,@
MN5T%6R%=ANJO-H)$:&<80KI#-0:HWG(BC5EPO.NL2'%4_-&][<J1(Z.Q<N<
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M]*=24!6(2+%0>Y\SY*V[*OZRU--SKT@6G[F+Q*VG*2F_ 0\1+_R(<>=AL9%
M\K+KOIF72$,_86^#WH71478,]1^Y$]L>TIV0],RV*]XV1PH<ZI12K;Z;:N7I
MO%\\=W_\\% ?9BLI"'5C0@1U,9('!-FLFDW(X_;7]LJXY7K2G43QJ"I%XP<#
M)V<]=YR5'\UQR'81:P6BA.36AI!L%1@+!#N'+/CF2$BNLAO[).,N,6%A_&
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M^;K?NCG[V[OOGXP;)KW\[_<976!QWW*28$S/)]40YHTV[C+UH[SL$TBU00]
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M0+H+=3!ULI<J;B\&_=0MSG3I2XLU"/$/"=3HT!LZMU72)+"\_0!_=&!TTL.
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MI7\G"Z',?\;22!;,%N_"&0J<Z!)NRC'*W+H!3(=9)Y ;W\32Y\ >_@/LW'@
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MH7W)-RSLK]'MP^Z.7_:\L]E;^=:^OO1FW9I/W5[$JHVY\-\ZJ\*<!L:F"<)
MK%D2'0D<+PQ M]:F_>EN:7^9" Y5DAW/H=]H(P7==^?Z8;Q_53<O2Z9O\4<L
M>!?4) 692B<*U7L6[!@#(523VP/>$QZT$JS=M46R2/W#ZG<;YQM!()#9!U#!
M'T&@/ZIIA4=/N9Y_EK91G_ILU55M:'4^?^P%XL3 TQ:-8FQ&-B;Y:0Q:S^^G
M)YAZBS@RU)2(HQKO@E[!RJJ6-ET.Z.^G-J8%B+QV/YU(UG&S^;(B,<O^PT4N
M9I)\J?V'[_AXW%/B6!_9/I2L"DA[Y$^;"D*QAF1TV.@QL<MFR!5/Y45K0R'G
MS$3D-_V;!,X8O@#A;4WF5W0Y<2EV*F4E'%8^AZ_^)2%SNS]]%V16&7#E!ZU$
M1>Q<=-I,;:+Q@1$QOKK*J&-L\:D8WL 6<#GN)=;NU.(U:MN'+:?P=<<!74V2
M38/?@KNX48,2@1[I)OH&?UA1I\+!Y:[)X4.QZC\&.CS5A<;-'\Q!1RI2*A[/
M.E98EL7_K(2IWHAQ"LV9RIJ5NY%;89J56I+Y/;UDR--Z8GEKI7S[#$(;%KQW
MHSL>'")YLC%8V?(2524ALU[P^L?9]-ZV$[,'SJXY=,A.ZWK!- *;F.(- ,L5
M]NDQB@(E$0EBBF@A.P2JU?HP!/RX-$&E)4ZAH%TI0QI5G^4S-P^)@)7--<5&
MX43JN6AU9,YPA3J:*#ZR+@7-;6>49RIH\U4[XXN50/!79O$!WH/<6X)\L1&0
M<@P>%BFIT*?K7VR0/]\HVT-QQ/;5&Y,F[ /TMQ1=KJJ-G?M4]O[X@X))FV6S
M;\= GT_/%X84G^Q]=\O^F_UR7?O;5J*I9,G84F5C:D5IA0-W:3RJ,3H[%Z_B
M+>?N;:U(J9L<W6G8%D-((5G);7 F<Y HIO+LRW*]NE(R^"4*=2".9RPE0/O(
MRG&I&<VD6>G:= ARO^) /9S:OG?>; >' C>W50 +"04R?_2YMUDCB]'GJN(0
M#OC*[[Q#7/1PE/0H_SDED:^5(C7) N7./C 'P(J:0EII@G(:3+&@CWCL]3[I
M9*M1]839N.>S3U<)Y\K.&NMVS91WR)RM$[1ZG0,XD.!A2-5IG #2Y,5R"18C
MF/*LH:'AG5;8Z 0WWN4 Z,#4%9>'7%_5H(J")D_R'G7%2%P<>__M%KQ@+CY^
MUG^]S,]W50+YU:)%JW UK^V4'EC6W%)M+/>L-7U-_TDC;JAX%^2.9L7O)NU&
M$:#\#A4:C%2E:L.%&P;#U7@HERA8X=(09&]A>9'3]S2"57;\1EV3U :.:@H=
MU61EOEBG);NIE6BP8&8(4Y"GM;YL4$7YOD"KMU[VS& .2>A)!E16BR>4]SOH
ML_ PTI[Q7I>/YM5F#6_IP[BEB],L$K(FYC4:%:BM,T_LTK3G7-)[=K[,&$6_
M%V@ZV:AI1BO3,/[9> @I SRGBI,2(ZG^)*,P<J^N'FE;#MO["[C[*9I--NZ[
MB<Y9$4='N?=_ELK&N9 ^51><'U)0]9KL96QJW;)1,<]J]%U8*CU?+_>8.SAV
M16_"?0S]OJKNAX?JK$<$0T[HIGW^S+\+0?ZY3IM/LI^4W<_)^LD&*3^!5/A2
M)*C3]/N IR=-E*R2B;4\,S_Z3$F7<0GYZ$$T]/9XE>%1^0\ 8_OFC@PCC2E.
M1%ZAQ;ZB+ L.^E9@^XH\!.;JZF^BRZ4XPX]Y$,:/I5K.:%*4MTV01HQ\?1D"
MC9/,1Q\X&GNM]Z/7C O52?I\TTIWN>3=57\0VP9XR8&UWNUCR;@6?UPXK&)?
M"3JC$I-WAMJ6"5^]>'#Z9?G[%-R%LE0/!<ZCPO0)%&1]:X\UR\HF@N,"<I?
MY00*'X:Y,5M%);S&R&TSX@9)A, 7LGH(BSF.H(#-_TD'N,*?F3W$"E]\[$@X
MJ;6]!?:J-F; MCW7I?O3VCH7+2%"70_Z=$+H83*(E?N-ZI#:E_!4\C19M<7.
MR+7$H:_BY]WG6R^!;ZUBZ;DU'A%JIN#RV+]9/1WPA--$28.9-38""]K/ONLR
M])&/,MX:&8QK7CDBC6.%2!?XJ T90C&F2:)>00[!*_.^^UDD\*!EH"%: FW\
M@:%_KK;'#[/371C9+#4Z4 )3K#BZM?TTU:A@_K;6JOJ!L_''@GP7[H2?>B[1
M!&(T9E2#1]KI,8#G-A1YO@J(I"[>'"]^M2ZA[2@9B-97Z[F:^7%9/)-7P*ZU
M\N-]?]GN$:+!V;&O9<\BS-HTF(MLW=MBH.2([&P@%C\Z.S";^!IC96^::_M<
M[*5&E;&,C4G4YM-]LID.J<?$0O!,=6ILQ I6[RS>7J:\L;H'PY=3R%=$&NU]
MPG;F"^?$XT-/ IS9;T6T4'-;X/L0T^:#S^#<B&#%,0S_POYVJPCU>^X>?X2=
MJ;S ,1729F@XA8N0Y %""O?.G]2U5%20Z@42.G>-L'%G^#Z;M;)YL[4=V$R2
MF0S2YE9$4V$M 8?;K4OJ,N=%Q*+4$/[F;CQ#C:7.MZPNA4T<UA24/[ 9+H10
M;9]N2RZIRX[=[[9E21<I&(0X#U80I94-N/G1KF.Q:5Q=FK0O,D)LW3?W+I"K
M=RI"%)H//6/<_NR7'BWYM@";G=WU0=0Q^XB98<MYR$*7)T%+"*'8,GF6MC^W
M9 3 D&9JCXGY% UN&8XMG.E2M[GW(?)-'END[-O2FB-=-YS9/V2P')]C$7P(
M:VIB%](NR5?96URL[A1^,9UXTZJ3\:>9A2^(_^3K+\-^#L627#5 BF?>8CZ-
M\WJO,L5A8 )Y?LNV5Z?3X04VE[^Y(VV$I^W,!8E]P@1 6C5"8$%L$6E8VR.+
M=;<CA+7%Q!5FA^UO\OSQQ+%KZ=VF9]3-J6A5LDI:GEL9L-*J89W0T%6R^E/
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M_14+*! 8$DZA**HTE"D=^]>1<UGCG9U*8@@0N7=!)#WW75#+S;]VF7%^)DI
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M+<AV]?GC=%/G?P@4_.=LJ-V1_P502P,$%     @ AH164H&$?EZ]30  #VH
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M-&T3#'6B#Q8<,I I87-+Y:I7B[YV@+V1E;!%YP^E'B;#DO38YIW"6V>4*1\
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M'2R$O"PK^@QZM?V;>X(W6"DYA%4)!^'_\_]^^7\30?[(/P!02P,$%     @
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MG8^361KXCI.DN2<$!!N82V(#X/6Q5#;@OY:,XOW1AIJK0F#V]YI]I.2@U4K
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M/]H"MAXT##\M$W/0S?J87CNJIIGX'EMB9^3,>'G1#F#>+"0=PB'P'6]$(39
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M*PBJ0)>1(GCK9WD^S\<JUJC;<)??SZ6FL6LN^HNC/@/IFVDRV3=>/Q=04/F
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M#I8Y0!;TPPR=M@^!;:>W&5<MNW?I59617Z@?N%K%^!B\*]D@PE^TL,<ID?M
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M3XLJWNF_-O3F7&JX9X)1"5T+UX?@PKM;QTR&MVM-3'5&QB;-R^XAT:S2\)3
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MEZ%X,:*=-R*MLCUW6_BK[^;RN1W>OF1MTZN8;ZY\6VHN#0'I4:P29^5!K?C
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MOMSD;+K0,^67V5QS^659SC.Z* F=BOO9YYF:1_-2#:P>^G"3EV(NBG*2!")
M,?.@'Z8A1#(@D/B$0X(CBGF,$RK$I%RJ/!$Y_/FN%;J2K ^Q?K! L3Q@=O6<
MV6+.5O/HTW3?Y*CF13V3XG<Y>1+%,VEN4+IIEZ-6]]\KFX/BD<Q%H]OO?X<#
M/_DC$)6.__9NA<=@IL-8$D9(#%,OB"#"+((8BP2&(0]2)G"$/3YYWIK)1FC
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M8A0'O@BM*FK9#3^VB6(E/5@37Z^):P4NEBF!I 2K'0];!]7*0J8.:U^X]^[
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MY/5;O$163OIQ (ZXV0=N',Q1/B[XNJM[XDI[9OO+S9>[YDV+2!+2D'M0ICR
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M>_0M)=6+L*D2%2J>>@)<"6O'%@?1->.*LQ ;K(9;(Z+&ZM,2JP_'L+*FB5-
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M%*F)7Y\9AA A%$), P\20F7"4N9SDCC9^UZ-.387X<1FK18<_%*+;KD_9&*
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M$V@]+2,,7%K?C#Q?R:8]<^SPYK1FY!Z =TG<+L4;E-][P'5[&NACB(Z'@>U
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M$$GN0^+[1._!2HY)P!-L=7*U?YBQ,=]*RBIS 6@Y._E6!U UXZ[SL>J9GKK
M9,T^QU%P23 '1AJ40XYKNTT3)ZYV<(!=S[5)D. XC6+HAXBK;S_2+! BB),H
MB (OH(BA,TY=K:?=85:KGY17^@? 9D]/L[R)=W\44ZZGW[(1OYISV:PHP9O/
MLU+4=:/\X$?P!N'D(@S]"\_SZM\6=9Z4[DE1_RW>_IME[/P>.U&4^)@C!K%
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M*$&0\ !+Q)0?3*PJ_#N3;&SST/K^GTE1I>)H5:5S]V//-;OM7NV QAQP'W<
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M)W2=%3@^/DJW*<%@\_GRY.;SJJ%@4TR4?)](Y5)[82)AB)A.:61430XDA$'
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ME4J1EPD64$@[9I*I$A)F:\U*Q%..,"]D,F!HKZ<83E_%\2?VMB*":D2V_72
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MZ(U0#!=""Z<:ULM%F9JO9DQ+CT/H%V[#>2=M/'!?@-1 JPNHE=G]L:L.>+\
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MB7%?+Z3MP]CD4;*$YXK: :0BUX;,J)TJKS0D4A8Z*5+-)?>;+>PIP=0HK54
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M3YU3O_S! XL0VJ+/3F^7M7%"MZN5>2\TP=^2,\;R+(6I$@3BHA#&DT,*BK1
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M&%\MR1BD66:X V<Y5SF6B2I]R,)YY:FQQUYP\,!FGKW4W/%V8Y H*$:FE Z
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MJB75/JV$^I?SHLK1F@@U#<WGCY8?;4;0\YQ8/\)NUEXXW"+39"-H[^"D@,?
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MTG^#[7=SRB:YH9'MG$HAR*U&H*LUZ*AMRSZ[US6J@TKW*U!KW\WB@/H@R\8
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MCF*HW_H )IAG21J+E*=6##"VH'.CDEI,0%LY@3;[@-INMMHLOS,"EV!K#LS
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M"[TGQB'$61R$8:@R%#LU9AU5VKDQVLWVX8$63\9.6#_6SGC3R%OO8(")PBV
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M_]?/ZZ4)!RT_K'_\92-^;$[*6) I$80IE)$4^J4-8X@Q2:!*48*E4C205EW
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ME7#- UD,XQAC;=:PD":.04J=I\_M[6]B<FH)026B:XA2%[O^=_UL1$9^PUW
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M2[I>+DTV8;[2Q"I+UPR)X5.("*.Q" 64')GRA-I.92J*8:(7FY21! 6Q4U6
M<2=PRKCC\81--2=VB\\D2(^\)#5B5X=JM!:@_7='CYO]R83NE-Q>F!+GI>IJ
M.'TN8,.%F719NQJSP\7N^@<.6P*UA6^VN>5;6?_WPTJ;_NOM:E-^D5SF/TSB
MS()&DD8T4##&5#OR A-(DEC!, K2(*4R5$GDMMK9##N_A:V5]B^O6OG_;(XL
MTT9T4.QD=R-,JTFPXT9OP$[52J$6$[QJ!:X0;64&7RXCZLQW+A#YI#:K<2=E
M,1<D#@G+Z5Y?D45#C$W<*X@9S;(L@$0@<SB)!9!21&"01#PF/ A4ZK0/TS?8
M["RT]>H>ZH&^-]'%1_I4Y;?6L45T=6RQ _/0\.(P\%XDPK@7=<P@XS$@X\89
M.^.]<*CQ6//+T<83]PSH08VBH.KY\-9T>(V"-N.)1S*+10KCA#.(F<0F/3?1
MT-)48I[)6-]OVX+ZY!!SXPOT2Q0\;QH<!0[ME4_#V,\,?L 9F0].X3*D__29
M]\R^_?350$V45N?T(KDUG>Z%H*_G].D;IVLYW2OXLX[3_5<.S6(IM*VUR7]H
M ZS<%-5+\%9N:+Z\9655J&TA@Q2%2<8A4P1#C(VE)$4(:<*XH%)AQ!Q; ET>
M='[[L>_S%5WQ?%?1MXI!/HM-;CJMO%QS4RY.@IT=Y1?8D=ES+RS82PMJ<<'O
MK< >]U3LT?&;1G)QU(E31FQ1.$X/L;[3W=C2?F#%9RC5.)+JN,3^--#G8GU?
MT._-PH@%CA@6&8PC+"&FI@Y5RK@VQ1*5*$052H6M 68_[-R,LE9R@-(;8(1O
MCHEVSE U\MM;(@Z3<-E\&P?:T4G)%M4!AIX#O/;&WS@P3V00^H3;R5YT1ZW'
MAG1XV&1VI;N"75MSP-W#[,\WA<G3KEQU_O2AV</]0C>'!:N5C"5"2,*846)V
M6S$DIA [H4$J>1)BDB1N1JCER/.S1"O! 6\DWVU\@\(4V2O_H(^.6^"V4Q!&
MIC-WE$".LA3B2&KT]4H+4\)0J%*2!DRZ1$Q'F( IUMW+\ ^NV6X[$W;.P CX
MCKSXUM"V(H-69F"$'K.FNR-2/KT#VZ$G=1$<\3CT$UQO=W<6/FW- ];J49LG
MIGINOM(N^699)7LM,I*J( U"J*KX;"9B2/7R %&6)$$L9!)+J[ZAEP::&S'5
MLE9=O!IIS5;H7EY[.[47WLN&OR_01F:;B?"RM^1]X3:1[3X8/R=#W0:4'M.\
M]_;)C'$;);KFM]7U \MUR7OS%&W-KPMS./)M7O+ENMP6G?I/6&8R032" 3%]
M+G@F(,N2&&(D&-&F=Y(HZ69L6XPZ/T.[$;HTK_AKTU11EG78]V_2.$"/#SD'
MMR9YP;$HE\4,V%EXGE$=F6\;:<%.7+"7%_P^3FTM>X"\%M*R&';:JEGV.!R5
MR'*XU=V0>Z>4-#6VS*Z]L1"_2*-1OLRKM>NW5:'_?;_*_[LZD_A:KJ3*-^5G
MJ=](O;)*1BF6(H(X$0AJ$R^%E$<4\C3$611G.)'$UM"[1I"Y&8([74QZ3^V7
M%L_4N0';CD+55:Q1Z<8TV.%.UL]5<WC9FIQJ9D9FO_VDF&/5E4?[Y6!2NKI4
M5[W>3<KG22?%WF2=:G(F,FG'G20GN]<'LCUV\56/G\QN]@%"UZ[V\KR!S3,V
M#[+XL/HARXUYD3^M]9)*1;Y\^K5JEET5F*SRM%%,F:(J@R$7J3:Y8P$SCJKS
M84&8IH'"<>C43<-RX+FM8I7<8"^X21L"C>A@+WM3F]7Q)*OU;-@9XF-@//)Z
MY M>]Q8=CEAY[=EA._:T33P<$3GJZN%ZO[N=_J;JW5E^6#TK:GE0-IJ9'F"*
M8A@BTZ]<,5.W-L$P,59YS*22U*JDM^V <V.L1F83!7M>D-7>;+/"^;+-[!N]
ML?=]&N ^' +G4GA[&);VIJYO3"<R:3LOY:;%MJJH_(L?.]4%EAY[U.HQD]F=
M+DIU[4NG^P:6OLQ7\DZ]*:3(-^\IK_HW?9&FF$&^NG^]+HKU'_HO;ZA^'4SS
M,,DBPE*2PC3$#.(8"\CB.(8D23F)M369AD['G-R&GQM#[R0%K!45\$96QS*8
M;M-@9T:.!^[(!&X$-U'R6G30RFZ*Q;6 [\0';RX![EXK<Q!N7NMFNDDP;0W-
M0>@<U=,<]I0KG&73B*&0#W)55AG'YFQ75=23E@_OE^L__EV*>_DW/;[YX6NI
MUB9%C2]I6>8JKXN\W"I-*MJ37]"0<)5&$F(9:A:4*H19' F(HPRA- ZI8E8I
M 2/)-S>:O/UN#N*:#_I>RV]J3+Q::B7^##JA+W/*^N[-AP%NM\=Y=?#.7V:V
M)G'BGZG6'DY]913Y\PTP"@*C(:A4O %&R=UO6:4I.%3U!E"CK(EO>G;\_4^#
M]_B 1Q&G#R/XQ_=DM&&$8896@E_=FY/L;R7;?-./:*K0!0G!,HX"B#'B$"?8
M=!>+*10ACD(69FD4.+4D/CW,W'A[?Z[?R'D#C*0#2_V=P=72CKT:K;'MU4%
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M@6/K\FDD=_D*)VI__NS4['HO,7B5KT!9 7 ^B>I%WX)(R"3)0@HIXT2_!2B
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MT$X;@B06&&(24$@P32 +(Y$)RK0EYO25GQMH;M]Z(R?H".IX:NHBM';?O0_
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M[5LA5\(X;>6NY7PFB<K"3$+,A/XC$C&D2GM:2M&88D73A%C5XKA:DKDQ4D]
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M"_UT$_7=USALTW]C043 ,ZBB((48,02)4!+&*&$X#1*.0K<H;-]H<Z/\G;!
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M2]X,G @[ IT"WI'9\_DY\5UGZ*IS]%X1LQ&W4P70:C:,,L!HX[.^SG5X^JW
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M.TSRD[=-9H-W"=TVNCNOZYOBV&[W_?*AV*0/97WU;_(7*5EQ=<&24\P"7ZX
M$8EBB"(OA(03#\J%P$->(AQ):&;YC!JCSHWDRL[T="?U O!:;I56]UA+#E;R
M!]/L1ITYT#.*K2,[MD=$@7K=!O5#"]1&:/"Y"]0>^8D&(-E-1M09>.+,0P,L
MCM,,36[NQU ?LYRG]^LJHYN^[,[T6KV0OV:;][R05ZF3K*OB=\[N2__P]H+M
M^=_59GL"N'0=[B01<F'BJRQM@7UIYLJ?XM!Q&(FXI^G3'5W2N3%AK2AH- 6M
ML_)VAVH5$K33%N "U/JVKUKLCM<!WK0.V,U(=+S71(]X9S'Y(Y/U*\^[,<^/
M/B<VUX;QA)UT/1D=\\,U:/P!S=:M(M\LO\N]4^D2_XUG]SE^_*'L]?(HQDFP
M$Q%,81PY/D0.%3#V*88TC##C)$JXT%IS.D>9VWK1EL_H@*L;RVYBMH;0R*1J
M HXV VHIW\%>\OX6<\F_';)6]P"3,(Z6C@U;Z%W<]Z1J@U7ZP ><KR6M-+VL
M@D1^S"[!,":!W#0'F$/LN2%T*0ZH$%'L(JTJ]-W#S.U;;Z0$C9BF9T8GL=0]
M$1J*T.CG/0?@C- (K!L$NX<T)T>:^ BF2]OC Y;.J\V/3[[C9_4<E3&TJY-*
M&<:$Q1S&.$P@PCZ&B8@PC$CB$2)_#!.ME.ES \SMDZ]E+!/Q])W<)Z&[[/L?
M"LC(7W@;"[V2L'K Z'O_AP(TD?>_#90EWW^7YAV^_Y.W3>;[[Q*Z[?OOO*YG
M=[$G4O!_/<FY_J#*)JJ$]#IU#1')4X1Q"1:3NY38#Z41XS%(B4-=/X@$9D8A
M-&='FAV5;04%I:1U 81>V8+GX=6S9JR -C;=]</+O*_7)2RL-O$Z.]BT';LN
MZ7S4GNOB#?UXXBO_ZXJ6*<ZJ;TF>K>6/E%=U!//K'_)]X)_6[2OJ'I]W*D=P
MR0+A$1P)Z$0Q5EG*'DP\A&'HNH+YF">1,#H['"3-W/A&*@-VLH)]=>0D@4HA
MU2]O[[):)VEA**T,B6G8?.J1UV2S-#+!C3U!QDQH!5B;;#E,H$D9U0IVAZQK
MYZ%]^C\]I!0S7GM(HE (EWLQC"*YU40^B2!F80@#YE'A<Q(Z2(MFCQ\]-\YL
MI#/I=+0'U>5-9G\ 1G<@58+U""H[ ,&DV5-?,"9K]:0+BF&KIU-Z=S9ZVKMA
MPC9/IP3=;_)T\HJ>V\;&C5[9 W)?B'TWP="AE$+$(P8)IX[J/1U['$?$,#9L
M__%S(Y^M=/U,KP/L-#>"O1$9>_>G#8;YAN^DSE9W>?LC3+NU.ZG=T7[N]%7F
MIL(5W?"5I.":^K'K,I'$$?0I0A#):88)D4:#$Z'8CW#"&75T387]1\_M:VVD
MTU\E#Z"Z;"KT!V#DC[,1K(>I< ""OJG0'XR)3(6++X21A7!:W0X+X>"&R2R$
MTX*V+80S5YB'OE0=<;_PS8^,5=6C>+LHFN \B$*&H<">W*8DB0>Q*N0>.F%
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M>^+I6I*/TV13!"B@/HJE#>=3B,*(JMK?$62^2T+DA,(G2-MI/4"0N?&S_Y]
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M> &+(9:V>E45D@0,0\?'B/LX"DF0&'F!3H\S-_9OQ%3A^8V@X,]25--"Q6>
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M0G!-[^]'95=4VLQ/94G(KWSSQSKG>)7^+V=5E*\:K\GPKDWZV(]4X9Y$$EE
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M1;(UT9S(#TDL@8'<P10B-XI@S'@,G<!)0E=:EW%D5$;JW$!SXZ9:3K 55">
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M+H\],:RK<0^IYD:'IYOOUHH=5"G0*%O5NV.HC0G7,[DFG\:1J7SR&;3057D
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M/T<Q[0PPLVEXZ0P[J5ED@,.AT6)R:T]/@:H\(IE-OGH_L'QFGMWG^*'VQ-'
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M;/H-M,:=U&]@@L2AW\#H7DM%,YJ0\M)?>B.4>Z+^#5O&/$"4"@2C,/$A0J&
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M$40Y9:P@19KF5F1\OJE)4JRV%OS0V/M'MVQQ"VS/;P*$0VQ@+MR"U5+<)BE
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M+((DR@H88ZPP*I(H$4X)]9;M3BU*-O9M-&J>P<9N\*NQU7$#W!9Y6_H*CN?
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MSF4!98HR/:DP^28%E9 QEHF""9(ETG;SXE0CT^."C9U@8ZC]4O5)),_O(H3
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MH->,\>0C%NZ'W%-NO7^<<+7]_G*,F$>&RD_S]73]]>?I#'\[W_C8WECMC<R
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MPW#Q?%*TQTFV"UA<:W_S_A-)<?7F?%V[*M8SB4F)VG N/>14B)M:]1)4\D
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M<YCFG_[\C/,5TF;]9OT)ES>D--%%%A%" !9X(ND8 2YA@I1):AR+Y:6)T3F
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MQ*1%B%)GT#J)@(6QV.:NP#WT' 0G\TS@-(3,^T'00;<@M66\Q&*!*2M!!:[
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M%)9G(>'YFIR!V:]X%G%)CB*FS(L K/>'5!02(C(&+ M-+$DGXR$#,O8]>V0
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M3M*W-H^)"H$IZ11%H=K4P<GDR*O@(<H@2TP%/6]RQ^@IQ!Z&U^=XFM)<=1W
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M9)V5*(&E)$D,*D-T/(#1@GPBJ94I33<X/*"ECPCV0.WNP,JAHNX(+3-G?:'
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M\ 5):)-C, JT%+GV"FF@L%]!4"6$0G>?%XW&7S9[6N[HD>XTX!OG:7D?)'2
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M9U?8^ND2S"K+5XE^:CVORJIM-V^O:O[R-US-EWFF6& FUX7N1F?R"PJ"E[Q
ML5(*Y9$%C(>X]7O2,8T7U0)>)]=*!W9LXTQ<9\H?&N-"7@.7&G12=(Q8KI5H
MJ0!SY'3*F%)V31J)MU(SS:C!EO;K>*%W@)RG3QK_OC/FO3?4GY=7Q*@ORGL6
M!"1;%Y*@X^"$2N"Y29:G$G-J\N!Z,,73C&EJ?X.V5MZYU.C]1*PNTCQ<7)_)
ML,@_ST.<7VQ$$R[O*X#&+=#;]VN;5.<=Q?LI2O,P9V64R,"4C: TN7314'20
M9=$ZJV+RTTE__9?FW7WV@Z7HZ]?A@C2!?WQ"W-J+\;"7Z*ZCX\$<Y>ML452E
M).E)/BK4 =S<@O<B @^R.(S,E#;&M1U+G903'(O-G24MTV*@ T]BQRAYFY50
M=4"NQLJ%LB1<IPRDC'XS18"7)O/OCM@ T1Z%$X-EV,:'?337)?YNWH.,=&A$
M"F!1!O)UK(: '$$7E;U6)29LN<'R/#8^[*7LH1L?]I%\!PC:MG_ Q\1YE@)<
MS0:0C#QXD3,(Y[WR=+8X\RW <SX;'_92\H"-#_M(O /0O#B/(&/47DL%3&:2
M32H20JK/.)B-#8;%(OZ;;:7L] H<38M=(7++W )K+,]>)! &R=>EPP3>220,
M66LR(W9<DW>R,QTHLI?J]QDHLH\>.L#4"U,JO.!<,5$@8A1D_[&6ON3J2+B,
M06"*N4E]YEF.#=E+[<.W4.ZC@P[0]/+NPQB55ZAKAXG-%(Z3C#:CYQ)G1KN4
MO?%MNCC/= OE,9@:3Q,]P.J^:>E^X_D<5T34IV\_XU>\V-AT4G]*.I"?X%)M
MUZ@K,H@?$AIZX7WR23=Y%AM&WK3E;)VZ9PTTV\76U.VY_&<<WA:V<IUL(6!E
MCQ09&1<A&J;!I6"--L8GVQ:X0ZCL),,V(E!V87%TG?4%R4T[W7HC,WYS'^2<
MM&9"D%\1Z3ZP@D.,04)DFNG,0N2A22;M!9HZ@=OX6-B%NB/5TBW&Q.W0.\VE
MY2Q"P3I8KZ@$H9[4:'EBD<NDW<DP)GKP_:;%V"%JZ19C\G9)6E&^,*8@UN%$
MRN4$42$%^<A$RMQ@P+:/T<]IZL3MFP1CAZBE"XS=5_14U_?:LS!6)8\9LJD%
MT)'7S=DU)F?":*E1A-BDA_\Y*=/N]NTTD#A28QT$N8\Y>!,N\>-R-?^OC7QN
MSI$RQ?@L:_ET'=&NHX? HP:A>3%"&&E8HXS<]TB;>IG"<<I_$4M':Z(#;.V:
M;R&$4C*2(5:9D7_).;C %8B2O&91FF0:]D+T-9=D;*4/G#"RAP:ZN!E?7ZWG
M"URO']38WTP@R%SI0LXCSX7.&\8Z%I)!RD5@#!BM;[+*;0<]TVYN[?2.'$-W
M'1BS;6S47Z[P-G$NA"@A90-:%UOK_A@X*R1P'FQ2AL2GF]BU[U(VK8D;1?\#
M,'6X,B;N^7I%QGG];Q@N+C_=V&=NLXNE*)""DQM19T<&5@)8P5/!["AR&=*L
M_.R#^P/"$4I;CB7!'HS+%BN].20L&8=":- E>^*CUC$I,KR%3&YQF061F^3H
M=Q$T"$'FO]L--X;V.D7A[:,P<ZI$9D$',M%*< ?194T6VP2)AL(>TZ3L>C=)
M$]NR450^ $<'R+\#)&UZ&>^[&!\T#]W89TD13&*YML$F1?PP1ORX"$D[<@NT
M1/7TAANQE_0%POI#U2$ V-99.I8V>D'7FUW,6*S[C2A>Y@'K8ZRU$)0VD&)A
MTI.HO&I2DO@B5=.^^;3$U2AZZ !4#SR*.S?CY[N).=Q'[0(YD#S4-FQ'CD+T
M5D%,+*5DK7>\B;UZD:I!H++_S9RQ\?38%2COBXFO>V[ON@U5",74$X9>B#J
MV-2S:T 8+RABTH&C:HO,7:3U4C=[- X&%/<?H90N$JQ;]P*]6VQ6]*ROF\!?
MW;=]STA617*O@&M6^_VM(R^72]!*.VMRC%(U&>2W'YF] ' <F Q9FC>.QCHU
M?'?</? U'K*8I!,^& [&Z@C*Y 0N. %&.)Y\D:6T:<P\@-9>RK]/C\P1=-<!
M/&_JW&^7KF[E^-?EY=N[9L17ZQM?Y\$/; [I0R&X)&Q0F$#IXD%5M$7K%)
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MDC(]8([2[HMHV5O4W8'EU_#Y=MQL9*ED%S1$J0/%E)Z!EUY!IM]Z[:66I='
MD.T$]02<_17](FX.E/K4DYGE_X>KY9OEU9=-PO,KKB[G=)[^N(JDC/FFEYW8
M)/;(-*_S%<X7Y+>PV_4S=4UJ-K7ELW;S;5J/K0O M?,\2ZFXY]]Q?(ZEH2=
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M0I/C0SY/*%:#+R4%DV)R(0V!PO:/'X:$,THWCB#%J8&@'WG \C9%HED*%K,
M(7-]0!$.7*Z^CV/,<6,P#RMIV_[QPX!P1NG&$:0X-1#DXZ>T>QZ$$;80Y3Q&
M7I-E@F0B);!:E:7J#CT_L'AIZ^</@\(9I1S'D./46- _N&?>[VV2)"DKA-(4
M&RNY*=VV$&TN(#/'HCPJ%0<E'E_XCF&8.*/DXUCRG!H7\@?U,'%VQX/PQ@LI
M$=#D2%YP)&P;1E#WQK)HO)<X*.NTX_.'=<N=40)R##E.C07U@V9/,*WN,B<:
M2:]6 ?.J#IUDY "QZ" $DA9WUN:GZ_5V19<[OV,8)LXH%3F6/*?&!>GP/C:Z
MXP ]&N%J&;=/FS&D# (GH\?KJVL24CLY[/EZVZ</P\(9Y2./E^'4*%!TX]T;
M.'7;]Q6Y-1@L UMD3:EZ#I$%#LD@YA*Y]VE0I_WVCQ^&@[/*0AXMQ>F!\+ Q
M7-WES31G,=@Z.EEXH-O0D4ATW5_L./E @CD]J/IY^\</ \)9I1^/EN+40) _
MV(<LW.9*K%1%4F0,DF4*BVR=)E)2!.0B(7IF#1\$A.T?/PP(9Y1['$&*'0#A
MH5&[C8\]76/94D"<K*(XR)&C0W2[VN:CZL8(8G'@G(5M'S\,"&>5>CQ:BM,#
M03^,@M1]1,R2B(I#,-J *F@@(@:P3H>80B*F!F48=GS^,"B<4?)Q##E.C07Q
MJ#E<W[J\63,G0B%K5M<I*5WM6O5[HPT\96+BV03"'6'#UH\?AH0SRCV.(,7)
M@: >LF#N!@DY1QHU 0K/"93 6L&=!+BL0BY9:>&' 6'KQP\#PADE'$>08@=3
M)M]??L)5%<X?==G49O#SK;]#)HV%*('<W%0+^@L$9@509!10Y.2X;#++=B=%
MP^8XG4>*<ESQ=X"CN]4]K[\]6'.V65RVF<G)A=>9<0>Y! 2%9!^C)7:$89J"
M:^U"CBW0]!VZ>IH9>/S0VS&5T!.F[B=)UZ50UXN9UC>G+\D0<]*RVELZ?4X2
M3U):,!J=(KML2C1-@?4"<=,.,AT5#;N0-I9J.H#;;\O51C67=\QMX?)V.H*T
M9-KIE"II>"T_H1@P<+KJHPXNVHPZ-ME4L0>-G8!O-( L3Z.M#H#X)JQ6W^:+
MC[_C%V(2\[70=K-'UP)'9PR8>IJ5#B1&SPO$XE5 I4N6339][TGGM(!LAI?E
MZ937 38?;A/Y0/_-YB9QJ%)&%R%OFL QUUVTO@Z08L4RSR.F)M9P&S$]C?T]
MWJ,[6MP=0N;&^'LC>!0:0104%."4!,%2%"606VN=4"(UB0BVDS.M<3I>S=_!
MS0$R[P Y?^!BOEQMDBRWXR:<):\@<=#>U+GG3$+P.4,6+B47E%/9M0#-,TKZ
MPLLAZGVZ NPH67< EL>F]^>[#<+(HQ6:.;!D:(D-.D:NU )A.E!&,_KGT_$>
M+=:EW-'3TS3RL=?L'";T[K#S;D&?C.O+W\,E_E@*IKJ<^C=<I:JICS@+SGAR
MT1R@*L1<2AI"8 5J74CP3#$Z..T1]1TJ>UJB<B N7L3:F$KJ (&WNQ;?+#]_
M)B;FX>*W\ 57;ZY65=PSSWW6T7%"!6.@A+,0!0N@E;=,"DX,-5F=]S)9/65/
MQ\'8B&KH"%154C.%S$IK$'CB=4I3)C/OD(%//-)W.\E8$ZOUD(B>@K-Q ;.W
MB ^'Q_(R7(P.CUN$*Y^8MUZ!+W$SZM/49R<+!5G):$0THLD^PBVT].0IC0^6
M0P3>F4GY=;E(-UP@8N'.:7"^9LPLW;8>JTM9A,K!\)!E:@V;>W)ZVO0R/G(.
M%/O!X/F*J[AL[FC_<5D7X3UPX*2.F<*0>AQB!&5L!L=UJOM+3.:&"<M.L$OW
M)1)[6B33VL4^2CT=V*W'G/T4$EXGYF?%B"*E1\BN#J3BE@X3L@C<!Q53\<Z&
M$\#LGJ">=M*T -6!HN\ 0C\M5SC_N+B^N-.W'_]*G\+B(];3\6$5%NN+C9;X
MC#S )&N/:2ET/)1C$J*C&#19GWE)*+EKDG :2%]/NV[& 5@+Q8R&M__G?SV3
M,W']K\U?;?ZF_E>_8_F_ZK__^?N[1Y__'XO_^"$M/U]_\NOE:K7\<[[XN/XU
MK%:AYCO>XF687ZP?$[V>?_YR\>3!]UFEY@L?]K_N:7M*]<UG/D/$073B7Y>X
MR)C_[^,M^Y95\SZCY[K4@4&*0O60 T1+A\:JZ+7)2+]N9M>?DW-,O2[A&=?K
M]^7N#?D]>62WS\S7?U"NPT^)R9N$$+#6(+NZNR4X KD(,1&[B2*- 06\0[]O
M^@SCD6I_6,[;1,@=7%K5PKXO;^B+Y_7JG5_,+[_]$OZ:?[[Z?'=.WX0O]#>7
MWV:2!487L 0OZE =56N7A18@HF**)R2#W.8=?P\BI\\YCH2ZYAKJ 'T/$QT^
MU9H:7FGU1+K&VC:E,C#GM>;6:?5TN>MX!GF?C%+3]./(V#E4OAU XSN9]E1D
MYM$Q*(G0KG(AJ3!;($I><9Y**$W0,L*#1].4Y-C&9SPM=(2IA\>B*)\+*@5>
M:5M'CB-=U<)#-$4:[I"'IY-9ITUH-TU+-D+/H?(>,279(LQZ]?'C"C]2%/E+
MN+QISEF66Y[?QXOYQ\WWK,>(PO;]KO&"M*.X;!O#R61B]"'5ZML"JECR=KQ-
M( E#TFO+=6[R&#5N#+?MM+S^=B/M;W?,&C0LFUR@9CS(UM:$JL0(*7OM1(PN
M/)T+.KZA>DY6ET'>/KAXR68=J87.;KS[\_L[?@G?:GZ- MK?5O-%FG\)%^\6
MO])I_? G7GS%7Y:+RT_K6?36(WH/R1D/2G@!'ND6*&A41.>,,[8UY/:F>OK*
MR['@\P(RV^KRW(#[?S"L/ORYG%EIBD)+SDD.@J)?PR#4\AL5.6*QB2?>M IJ
M'V*GS5/T M-#-'>6Z"2XX4Q*ALP%!!=J+T],= 99#)!4XMDEY%XWR3D?1NZT
MV9"N$+JW]LX1HS\MKU:S%(OC)GEP+E*XEY.K["JHHT]CD4)ZV[R^:S"UTZ9;
M>D+HWKH[2X#.O^(L*!1>.@-!D3-S+58E''AK"Z_I"=ZF'N,@:J?-Z'0%T'UU
M=UX ?57H:^_X9(6X%,R"2_6FL#Q 5)E<;_J.6!/MTC3I0CN4X&D+U?J Z>$:
M[+ 4Y-V"?HD?PE]X2-;QX7]];!YQ)R4C90;O/G]+&L@D)V/A"7RV=<=LS!"2
M9,"2T(I[Z3,V.88OT'2L2=KRT1](DJ_I9_XUDR&85)@"(S;5OB)!-,0^N0.9
M.9\"?SK9N1F_=T1-FXT9"QU/[<IH:NCRA>/!F=UT@!YI0VX^8T1+LHVJ$]@3
M@=$HGQ-8KVMW5^00A(T@>)2RW@HZ-IE(T-">_)$^8;ZZJ 4FR\]?EHOK2_'N
M"W_\ZPLNUO@:%UCFU^W ]SA/Z+,1$D$CLKJVF5>_+D-QCFYL+('$U$(<1]#<
MKS7:!UO/6O-/I,0.7/)[5N]Z>N_XK/6\OV-:+FJ-U$:I3WCU/BOR)"V0XUA7
MN^0ZT$PZ2";S@,KYHDM;P.Y/]+1IXO:(;:S&KB#[]H8 8O+5>HV7ZU>+_/,\
MQ%K2-[^YU>[9S"Q(7NK$A9 U*&_(4RG!0/32!,N<E;))8<J!]$Z;+6X/U';*
MZP&C5Y\_A]6W!Y?&F^7B<K[XB'0*B;D'9\]PG0(">5J*K@OOZ12BA*0C1<3,
M2RZ;A!A#"9PV(]P,A2W4TW?:XK?5\NM\31]5EJL'?WQX*=7PSQXQ4-F'BQ,$
M,$FKK"FTA6)+;7#2 F)(M:M.9Z-Y8"HU*9IM&,#<E!7N<':OC\D5G93W7W!U
M7:=V)PV5F%2($6SMD%9<!(@2$R3A9"A!6YF:5+<<3G*_X<L^R'HV$?,T*NS@
MFKWA]"<D186+9ZS.@DVI!$<"Y!%!&2,AQE @<2N-Y#HFWJ3$[SMT30N[4\%C
M.RI'T55'T+MNA7W.3BG.!\P&9-UQ28Z* 6=\!FYL-%F+2'_2$GH[Z)HV_)T8
M>F/HJA_H[9#BC M5HBL)A*FA4BH"G#(6,A,*>4Y9MID[]3)9TX:STP)O#$UU
M,+[J-F(_1(K.&R,<ER!0I%I*4R JB2 "RD)R('O?J#O\8)K[S10>XQR>2HD=
MV,E;5F]<CEVGT',=K&26K+^J98B*041.]X J*9:8='ZZQGE<:+Y,WM3]("="
MRPZ4CJBZG@!Y[8CLXLIX9F-R'$ID=4P/*W0M,$_\!>],D4R7)HGJ8>1-/0]@
M8D".I[J. +F+G<2=(/H#6%W9"9'7T9H%O-'&VV2)UT8C!%ZD:^JQ M-"< QE
M=>!-[G2*8S;>D(A\K)6"G Y3S)F<8F.]5C9XU69-19=8:^4%CB'\"3%4!PC5
M1YNKS:OA_[N,ZU?I\GTAS=H-9U\N\!)?I52GWM%!_,?%,E8GXC(L/L[C!?Z\
M_+,^&]R<I&?G:A;0%LVR@6B0G(EB-'A9ZGB/Y+PMK@C]I!!GZURG=A3V^RIW
M""@[TN;$FX*'%&^\"5_F]?PLU^N92=KF7"=(9$6LQ3J8-DD#Q7/AT4>3GLZ/
MVCZ ;+^OG;8)HP7Z6LJ][V?A6N 65O/U<K$L#_XX7-;YLU>$U&]5$F&1-S^X
M^+:^$]6-D$9Y0!Z-BA&?FMM(YB2/TLGR7)<D,+)R*M _'),UR2A#T29[9YML
M)VSP*%W/YKT>GI=@OGJLC%?WRKC1P9U0.#<N&3JBZ).KBR3H$@C% C=&QSI9
M4+@TP%*.0DS/K\[#H?/0?IY>1QT$S]>,UOO@)Q+RMK#O-9;E"A\8C[?TB_7E
M/,U*8D7%I"!GXE=)E<$5\K-E2+(XSU/23=YHCJ!Y&M1.A*ZMX5)[59\GJF]R
M8K-8AXW9Z,!@W5]'MH(XY0J<LT*J*#C&)OT+AY,\32[S;#%]B*+/$]*_S!?+
MVC1[NY&!=/#X4W[\SZLZ-A8O/RWI;[[2CVSZ7V>6PM;LZC)(KA(HG24XC0R,
MMDGD&.FT-VP9/ F/TV3$SO;0G 1*'>1SM\?0VT2T-;R^4P\KUEKO(UA9V],+
MCQ 24Z"MCKQ8NC';O'Z-1/\TJ;D^3L<4$.C@?AF2/7IU6_AXIX='/SQ#M!XS
M7:F^#NU2'@MX7Q^V,\N66>NPS;#N$6B?-IR=!'.#<-\. &>"^:=OY9NDV)S^
MPZK7>;B8)>&X8-J =C'5 6">9&X]1&Z#0UF*:;-D=0SBIRV#.!?4CPJ!,WB<
M^1TOZMJV#\O;\)]^ZOUBX_HM-C]P6\LTX[DDJYT"IAFY>(:$[H.TP!Q7:)EB
M9 =&>KH93-2T;]U38GI:_9X!L!^]?GF9O#=U":'/M;3)0+"1@R@IYXC.%F03
MO3HV>_,^!W >JJ,S<2?>8KY*&Q&_O_R$JQFC@\2]+W7LLJZ/O>0[1;KLBZA#
MS) YUF9ZS &T3OMB?B[.PC$*WA_#_AK#B\TJAOSAI%#>4>URL^UU%E)]:?,,
M)*OE!:QH<*&0>R1)U,2[CFW6@AU/^K2##\\%Z".J_TQL]^9 O\K_<76;W'1)
M9UV7CF:ZJ$ I3O=3] *"+):A)N?(-"E2.(38:3<$GPNHCU)QMS#>)N>9U5CW
M*#LPO+:=:"?!2[2 'AT6)4S )FWEPTF<=N=POY ]6IVC/;2TF2Z)G[\L5V'U
M[3;'DG!=*]3J6M6R7/T95GF<B2_[?-&8<RH/Y>\$97?9^1 ILH*$B2(N[A$B
M5P$<E\;59 #]_TS*[N[:EQ],/_S.N*[[L4S!N9B\!FTV"3V.) %E0:.-FD)2
M'TR;[O/]:>VW#F\?+#WK.6^LM ZNZF=L52G>_-G-@V>5 OW[6IN+?-/?LOZ1
MS-SR&][VNZQG/BEI?)U2G!6"2B*"5]Q"1+ICD#@OHM'&N[%8F'B83&NT[6B"
M.['JSQKT?WPB5;X.:\P/?^#-<EU5X8UA48/0=1FIY[5A@@";0QVS+:WB6O8%
M_]W,3#S:YFP.PDAPZ/%(_+9:DEM_^>VWB["HA5:UM.I+C49G4GGR\BF*P!(T
MB1HSW:@Z02FLSG!,5K&F0QZ^3^+$ W*FAN\XJIOX)>T95X]>!G\GE1)IGXB[
MM_@5+Y8;_FY>;>;_A7F6DR["N0RRL#IKR"H(P;-: 8CTNYA2=M\)TD8@8]J7
MME,A\=3ZZM%>/K\S*L^KKU@%_2JEU56X6,^*MBP+4Z 6I((R)-A06?71)M31
MRN*;Y&H/(W?:M[;)[>CX*NT1N(^[O&>Q1,VX36!$%* DW1-19P2=I4K16Y=Y
MDZ3#=^B:]C5L<B@>H:0>,7>3,5Y\K 46CU*.MWTQ025O8F&08K1U^H\%'XCA
M+!DS+)408]/!3<-)G?9):W)DCJO*WIS.?R[RG*0VCU>7=P.K?@RK!?&[GH40
M-5<Q$(8<G<(:[#D6)?B4HHK"&6^'U!WN]:73OD9-ZE".IHLN+>*F3*<DY84O
M9,B%KATCY G[8A$2D> +F7S-FPX)>TS.(*SY<\?:B"KIS7IM.+CKG@[6I%A$
M!))2C:M"KKN)#(2"I00T+/B#S-6C;QF60F?G#IJ1Q=V717H@I'\LE_G/^<7%
MIM/R=DK477S_Z/>SH!D65Q1)S]>A>12\1\,=,!N<3=XI;)X /XSR89C].[[[
MG$#3TU>3/CFK#WC^ON\J'(E6I !92%W+9BC0JAV=%HTLPFENY)Y9Q'V^?A@P
MS_X=YE0*FAZ*+Q_!%QW<K+*+,BA@6:C:!*-K"6"DH(K"*Z5=S>"?SKH>':+P
MO^/S2PM=3@_:'<?SV\O#(V<^V\)=1A"2BRK33(ZS(2=(2&4=<9_MD-:F_;]Y
M&/[^;H\N+=0R/?9>/F0W$5HQ3DN3(.;$ZE!2$IY4&@0FGID(A?FF^S"VT#0,
M@G_'EY.CM-,EWJZE]BM>SI1$'W744-+_S]Z;-;>5).F"?V5LWOUV[(O9O"B5
MF54:RY(TDK++^@D6BX>$;A+0!4!5JG_]>(#@(A(DL9S ":AOFI5*!*%S?/G"
MPSW"E\A!9?1 [FX&7<CC8)))K7QCH-T2LQO"?MX+D7WUT4%7G^VK9.*=K.V3
M+10MZCE!C.!*(-,<I$^R%N:9UNDT]\C9#5<_XW7&H3HYVFB=HIIA,Z5W7E[5
M0@[R$C;5]ZOYG[,%IOGG64W"H*_>9+8-4MIP\%L'K',8AO-3%#WD4GSPY)C5
MDQ4*! I$K\F:!9YB*"%SUN3&LV'1PX.JMO*$Q'_[*UU<98J,7EW6OO3+][@@
M%=10Z=/\M[_"Y72V_OH'7%TM9LL/\XN+WZ]/ 28H2J05*<!*'T"I3(&4S I(
MDLE%D;5L,_*[-6,=EU/L@=*'QK8K.'1PY/X$_Q.CF=4E2) 6>=USZF0;)X )
M[3 E95-H<@OX!#WC@K$OT,R'U^#!0/R*B^D\?UR%Q:HE',D:+# L<?D!EU<7
M]3!VW:_S>ASG^S4-].WW\^7TN@34!,$3V@PQU<1W\L$A%LG :E43E5R*;=+#
MAR%_W,J'<P1[2WST:Z2W<_V>N%ULX3FKA(%8I= TV5H?Y2!P0G$0,NOH!%?9
MCKXFGB!^W&**GV=%#(&-?M?#K[@/SZ%XSX10X%6=4F\M!R_(J32(3E+87F(Z
MY1ZQ%_'CEG2<XWIHAXU^#HSW8OTCKE87N&[M\L_IZ@M]OVKJ:O6E=C>OYT_*
M!<:B2E"R*:"\C!!-DF"]D(9;S5QL<J4Q*!?C5H_\/ ME4+1TOV(^W':N^T$(
M?X2O2WQ77GW]>C%-(5[@=>]G^NB/Z>5TM6D_@\XD@;7/NL$,JD1&OJ6V8&F3
MM<5K)_"4^\HQO(Q;\'*.J^=DR.E^#4TBLU$+S:&$>NG*DP-?M";D<B:=E-G[
M)D5<QYP@-;M3.D<L[Z7!(T^0?IOEUM=/;\.BYO%]&V;$Y:.G#7A=]#RE)[@&
M,L'HB-I SD92.$@[>K3"@%,J9)5SUK[MS.[AKX'HH:\)DM/5_0S.3]443S#D
MQ+0WY.Q;4?O2)@A1&HA!HW=><]=F0OG3)/5[];(/,AZ:F8%4T,'YPQ_D\WY>
MZV.]CR]?_34E:QE+BMHPR-K4^4["0G0A@,00R#-&8J%)O+2-F'$!-)2BYP-+
MO4/D_#J_I/U](@L3WBH)Z#V"$H%#3)456WA**08;F]PA;R=G7/0<K^87<'.
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M\5Q7F]:"Z-7\5_R&%_.OK]+J*BRFX>+]]9O7!59S<O_G_WF_I.6N$*M-#NB
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M3>@>?O/F@^7[,,T36U1TWL5Z+45<!DZ^2B@14LQ)9EVT+2?:V)^E<R>0^I\
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M]6+^'1<3S)S93$O/"(H?53$%?(@!6'3,!FUU-.9$6_MV"GN]P#\Q,H?07Y?
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MZ"\&<F0Z:ZX03S4,]05*>_/ CD;+BW@<4G5=8O-V'UD^/*VZ&UL\B4P6&;D
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M[P!!+S9*S"[:J$L 6:^+E/89/ 8+!9DS4L4869,KD3-M6KF7^O=M6KF/+CK
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M&)\8=]T,*.ET6T?]5&0;G#\Z58:#EL&&4COSX.3/T?Q2&YY]41R\=76R:S:
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M! @U>8">Z<1'S32D('CM-23!F^A!*H'*%VV,+YT@JJW.38/J4[=7A5';XAH
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MKH"?7K[?/'NW]F!?;O8,B->C__G;=%POLN:OIW]YNTA_6>\AE!B+I8-3R**
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M97-X9F]R;3$P>&LN:'1M4$L! A0#%     @ A8164FL"S' / P  %@@  !X
M             ( !LR0  &5X,C,M<'=C8V]N<V5N='AF;W)M,3!X:W@R+FAT
M;5!+ 0(4 Q0    ( (6$5E*T31*"MS4  ,PS @ >              "  ?XG
M  !E>#,Q+6IJ97AC97-S<&QA;G@R,#(P<F5S="YH=&U02P$"% ,4    " "%
MA%92))7"!S$(  "&)@  '@              @ 'Q70  97@S,3$M,S R8V5R
M=&]F8V5O>&9O<FTQ,'@N:'1M4$L! A0#%     @ A8164G3LX5TO"   BB8
M !X              ( !7F8  &5X,S$R+3,P,F-E<G1O9F-F;WAF;W)M,3!X
M+FAT;5!+ 0(4 Q0    ( (6$5E(+2O'R9@4  '<;   >              "
M <EN  !E>#,R,2TY,#9C97)T;V9C96]X9F]R;3$P>"YH=&U02P$"% ,4
M" "%A%92,/ %1%P%  !6%P  '@              @ %K=   97@S,C(M.3 V
M8V5R=&]F8V9O>&9O<FTQ,'@N:'1M4$L! A0#%     @ A8164B$QH]]F; 8
MJ6U2 !               ( ! WH  &IN:BTR,#(Q,#$P,RYH=&U02P$"% ,4
M    " "&A%92R@;TF,8G   8P@$ $               @ &7Y@8 :FYJ+3(P
M,C$P,3 S+GAS9%!+ 0(4 Q0    ( (:$5E(C-]#,+#0  )PX @ 4
M      "  8L.!P!J;FHM,C R,3 Q,#-?8V%L+GAM;%!+ 0(4 Q0    ( (:$
M5E*N)WD#7OX  %KW"@ 4              "  >E"!P!J;FHM,C R,3 Q,#-?
M9&5F+GAM;%!+ 0(4 Q0    ( (:$5E*+TFO&=9P  "*N   3
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M2P$"% ,4    " "&A%9284A0FPU+   18@  $P              @ $%TPH
M:FYJ+3(P,C$P,3 S7V<S+FIP9U!+ 0(4 Q0    ( (:$5E*7C5,?8T,  ,A9
M   3              "  4,>"P!J;FHM,C R,3 Q,#-?9S0N:G!G4$L! A0#
M%     @ AH164LS9AZ[7F   OJL  !,              ( !UV$+ &IN:BTR
M,#(Q,#$P,U]G-2YJ<&=02P$"% ,4    " "&A%92O5*+*WN%  "9E@  $P
M            @ '?^@L :FYJ+3(P,C$P,3 S7V<V+FIP9U!+ 0(4 Q0    (
M (:$5E(__F ;-6@  %Z?   3              "  8N # !J;FHM,C R,3 Q
M,#-?9S<N:G!G4$L! A0#%     @ AH164H&$?EZ]30  #VH  !,
M     ( !\>@, &IN:BTR,#(Q,#$P,U]G."YJ<&=02P$"% ,4    " "&A%92
M"Y,8;IU@  "O@@  $P              @ '?-@T :FYJ+3(P,C$P,3 S7V<Y
M+FIP9U!+ 0(4 Q0    ( (:$5E)YRT :HQ " .>>%0 4              "
M :V7#0!J;FHM,C R,3 Q,#-?;&%B+GAM;%!+ 0(4 Q0    ( (:$5E)V1PT2
MS4L! ' G#P 4              "  8*H#P!J;FHM,C R,3 Q,#-?<')E+GAM
7;%!+!08     &  8 &4&  "!]!     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
